ID AKT1_HUMAN Reviewed; 480 AA. AC P31749; B2RAM5; B7Z5R1; Q9BWB6; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 2. DT 28-JAN-2026, entry version 272. DE RecName: Full=RAC-alpha serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; DE AltName: Full=Protein kinase B; DE Short=PKB; DE AltName: Full=Protein kinase B alpha; DE Short=PKB alpha; DE AltName: Full=Proto-oncogene c-Akt; DE AltName: Full=RAC-PK-alpha; GN Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY. RX PubMed=1851997; DOI=10.1073/pnas.88.10.4171; RA Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.; RT "Molecular cloning and identification of a serine/threonine protein kinase RT of the second-messenger subfamily."; RL Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11508278; DOI=10.1007/s001250100577; RA Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B., RA Permutt M.A.; RT "Isolation and characterization of the human AKT1 gene, identification of RT 13 single nucleotide polymorphisms (SNPs), and their lack of association RT with Type II diabetes."; RL Diabetologia 44:910-913(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Adrenal gland; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-480 (ISOFORM 1), FUNCTION, CATALYTIC RP ACTIVITY, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin; RX PubMed=1718748; DOI=10.1111/j.1432-1033.1991.tb16305.x; RA Coffer P.J., Woodgett J.R.; RT "Molecular cloning and characterisation of a novel putative protein-serine RT kinase related to the cAMP-dependent and protein kinase C families."; RL Eur. J. Biochem. 201:475-481(1991). RN [8] RP ERRATUM OF PUBMED:1718748, AND SEQUENCE REVISION. RX PubMed=1533586; RA Coffer P.J., Woodgett J.R.; RL Eur. J. Biochem. 205:1217-1218(1992). RN [9] RP FUNCTION IN PHOSPHORYLATION OF CREB1. RX PubMed=9829964; DOI=10.1074/jbc.273.49.32377; RA Du K., Montminy M.; RT "CREB is a regulatory target for the protein kinase Akt/PKB."; RL J. Biol. Chem. 273:32377-32379(1998). RN [10] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-473. RX PubMed=9736715; DOI=10.1073/pnas.95.19.11211; RA Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.; RT "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase RT kinase 3 and protein kinase B/AKT by the integrin-linked kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998). RN [11] RP MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND RP SER-473. RX PubMed=8978681; DOI=10.1002/j.1460-2075.1996.tb01045.x; RA Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P., RA Hemmings B.A.; RT "Mechanism of activation of protein kinase B by insulin and IGF-1."; RL EMBO J. 15:6541-6551(1996). RN [12] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1. RX PubMed=9512493; DOI=10.1042/bj3310299; RA Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.; RT "Activation of protein kinase B beta and gamma isoforms by insulin in vivo RT and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison RT with protein kinase B alpha."; RL Biochem. J. 331:299-308(1998). RN [13] RP FUNCTION IN PHOSPHORYLATION OF FOXO1. RX PubMed=10358075; DOI=10.1074/jbc.274.24.17179; RA Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.; RT "Phosphorylation of the transcription factor forkhead family member FKHR by RT protein kinase B."; RL J. Biol. Chem. 274:17179-17183(1999). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP FUNCTION IN PHOSPHORYLATION OF BAD, AND INTERACTION WITH BAD AND PKN2. RX PubMed=10926925; DOI=10.1074/jbc.m001753200; RA Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.; RT "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis RT factor-induced protein kinase C-related kinase 2 (PRK2) cleavage."; RL J. Biol. Chem. 275:34451-34458(2000). RN [16] RP INTERACTION WITH MTCP1; TCL1A AND TCL1B. RX PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3; RA Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.; RT "The protooncogene TCL1 is an Akt kinase coactivator."; RL Mol. Cell 6:395-407(2000). RN [17] RP INTERACTION WITH TCL1A. RX PubMed=10716693; DOI=10.1073/pnas.97.7.3028; RA Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., RA Russo G., Tsichlis P., Croce C.M.; RT "Tcl1 enhances Akt kinase activity and mediates its nuclear RT translocation."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000). RN [18] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5, AND INTERACTION WITH MAP3K5. RX PubMed=11154276; DOI=10.1128/mcb.21.3.893-901.2001; RA Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V.; RT "Akt phosphorylates and negatively regulates apoptosis signal-regulating RT kinase 1."; RL Mol. Cell. Biol. 21:893-901(2001). RN [19] RP INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION. RX PubMed=11598301; DOI=10.1126/science.1062030; RA Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M., RA Hemmings B.A.; RT "Carboxyl-terminal modulator protein (CTMP), a negative regulator of RT PKB/Akt and v-Akt at the plasma membrane."; RL Science 294:374-380(2001). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TBC1D4. RX PubMed=11994271; DOI=10.1074/jbc.c200198200; RA Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., RA Lienhard G.E.; RT "A method to identify serine kinase substrates. Akt phosphorylates a novel RT adipocyte protein with a Rab GTPase-activating protein (GAP) domain."; RL J. Biol. Chem. 277:22115-22118(2002). RN [21] RP INTERACTION WITH CDKN1B, AND FUNCTION. RX PubMed=12042314; DOI=10.1074/jbc.m203668200; RA Fujita N., Sato S., Katayama K., Tsuruo T.; RT "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and RT cytoplasmic localization."; RL J. Biol. Chem. 277:28706-28713(2002). RN [22] RP PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474. RX PubMed=12149249; DOI=10.1074/jbc.m203387200; RA Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.; RT "Direct identification of tyrosine 474 as a regulatory phosphorylation site RT for the Akt protein kinase."; RL J. Biol. Chem. 277:38021-38028(2002). RN [23] RP FUNCTION IN PHOSPHORYLATION OF TSC2. RX PubMed=12150915; DOI=10.1016/s1097-2765(02)00568-3; RA Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.; RT "Identification of the tuberous sclerosis complex-2 tumor suppressor gene RT product tuberin as a target of the phosphoinositide 3-kinase/akt pathway."; RL Mol. Cell 10:151-162(2002). RN [24] RP INTERACTION WITH TCL1A. RX PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002; RA Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F., RA Roumestand C., Stern M.H., Noguchi M.; RT "Identification of Akt association and oligomerization domains of the Akt RT kinase coactivator TCL1."; RL Mol. Cell. Biol. 22:1513-1525(2002). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=12172553; DOI=10.1038/ncb839; RA Inoki K., Li Y., Zhu T., Wu J., Guan K.L.; RT "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR RT signalling."; RL Nat. Cell Biol. 4:648-657(2002). RN [26] RP INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND SER-473. RX PubMed=12244301; DOI=10.1038/nm759; RA Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J., RA Arteaga C.L.; RT "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at RT threonine 157 and modulation of its cellular localization."; RL Nat. Med. 8:1145-1152(2002). RN [27] RP FUNCTION IN PARTICIPATION IN KIT SIGNALING. RX PubMed=12878163; DOI=10.1016/s0014-4827(03)00206-4; RA Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.; RT "Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent RT phosphorylation site mediating interaction with c-Crk."; RL Exp. Cell Res. 288:110-118(2003). RN [28] RP INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473. RX PubMed=14761976; DOI=10.1074/jbc.m312175200; RA Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.; RT "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt RT activity and mediates cellular invasion."; RL J. Biol. Chem. 279:16441-16451(2004). RN [29] RP PHOSPHORYLATION AT SER-473. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [30] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [31] RP PHOSPHORYLATION AT SER-473. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [32] RP INTERACTION WITH AKTIP. RX PubMed=14749367; DOI=10.1128/mcb.24.4.1493-1504.2004; RA Remy I., Michnick S.W.; RT "Regulation of apoptosis by the Ft1 protein, a new modulator of protein RT kinase B/Akt."; RL Mol. Cell. Biol. 24:1493-1504(2004). RN [33] RP INTERACTION WITH AGAP2. RX PubMed=15118108; DOI=10.1073/pnas.0400921101; RA Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.; RT "PIKE-A is amplified in human cancers and prevents apoptosis by up- RT regulating Akt."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004). RN [34] RP PHOSPHORYLATION AT SER-473 IN RESPONSE TO FLT3 SIGNALING. RX PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422; RA Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., RA Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., RA Serve H.; RT "Constitutive activation of Akt by Flt3 internal tandem duplications is RT necessary for increased survival, proliferation, and myeloid RT transformation."; RL Cancer Res. 65:9643-9650(2005). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001; RA Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K., RA Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.; RT "Akt/PKB regulates actin organization and cell motility via Girdin/APE."; RL Dev. Cell 9:389-402(2005). RN [36] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15861136; DOI=10.1038/sj.emboj.7600648; RA Cartlidge R.A., Knebel A., Peggie M., Alexandrov A., Phizicky E.M., RA Cohen P.; RT "The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK RT in vitro and in cells."; RL EMBO J. 24:1696-1705(2005). RN [37] RP PHOSPHORYLATION AT THR-308, AND PHOSPHORYLATION AT SER-473 BY MTOR. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [38] RP PHOSPHORYLATION AT SER-473. RX PubMed=17013611; DOI=10.1007/s00401-006-0128-y; RA Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E., RA Simon M., Knobbe C., Bluemcke I., Becker A.J.; RT "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene RT mutations in epilepsy-associated Taylor-type focal cortical dysplasias."; RL Acta Neuropathol. 112:715-725(2006). RN [39] RP INTERACTION WITH WDFY2, AND SUBCELLULAR LOCATION. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [40] RP FUNCTION, AND INTERACTION WITH RARA. RX PubMed=16417524; DOI=10.1042/bj20051794; RA Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., RA Brown P.H., Kurie J.M.; RT "Akt phosphorylates and suppresses the transactivation of retinoic acid RT receptor alpha."; RL Biochem. J. 395:653-662(2006). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [42] RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=16540465; DOI=10.1074/jbc.m601384200; RA Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.; RT "Kinetic mechanism of AKT/PKB enzyme family."; RL J. Biol. Chem. 281:13949-13956(2006). RN [43] RP FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=16982699; DOI=10.1128/mcb.00201-06; RA Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., RA Hemmings B.A., Fernandez A., Lamb N.J.; RT "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle RT exit through p21 binding."; RL Mol. Cell. Biol. 26:8267-8280(2006). RN [44] RP INTERACTION WITH STK4/MST1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17932490; DOI=10.1038/sj.emboj.7601872; RA Cinar B., Fang P.K., Lutchman M., Di Vizio D., Adam R.M., Pavlova N., RA Rubin M.A., Yelick P.C., Freeman M.R.; RT "The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct RT inhibitors of Akt1."; RL EMBO J. 26:4523-4534(2007). RN [45] RP FUNCTION, AND INTERACTION WITH STK4/MST1. RX PubMed=17726016; DOI=10.1074/jbc.m704542200; RA Jang S.W., Yang S.J., Srinivasan S., Ye K.; RT "Akt phosphorylates MstI and prevents its proteolytic activation, blocking RT FOXO3 phosphorylation and nuclear translocation."; RL J. Biol. Chem. 282:30836-30844(2007). RN [46] RP FUNCTION IN PHOSPHORYLATION OF PROHIBITIN. RX PubMed=18507042; RA Han E.K., Mcgonigal T., Butler C., Giranda V.L., Luo Y.; RT "Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is RT an Akt substrate both in vitro and in cells."; RL Anticancer Res. 28:957-963(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND SER-129, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP UBIQUITINATION BY TTC3. RX PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007; RA Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N., RA Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., RA Obata T., Noguchi M.; RT "The E3 ligase TTC3 facilitates ubiquitination and degradation of RT phosphorylated Akt."; RL Dev. Cell 17:800-810(2009). RN [49] RP FUNCTION IN PHOSPHORYLATION OF SRPK2, AND INTERACTION WITH SRPK2. RX PubMed=19592491; DOI=10.1074/jbc.m109.026237; RA Jang S.W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K.; RT "Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle RT and cell death in neurons."; RL J. Biol. Chem. 284:24512-24525(2009). RN [50] RP FUNCTION. RX PubMed=19934221; DOI=10.1242/jcs.053728; RA Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L., Webb D.J.; RT "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin RT dynamics and thereby regulate cell migration."; RL J. Cell Sci. 122:4535-4546(2009). RN [51] RP UBIQUITINATION, INTERACTION WITH TRAF6, MUTAGENESIS OF LYS-8 AND LYS-14, RP AND CHARACTERIZATION OF VARIANT BREAST CANCER LYS-17. RX PubMed=19713527; DOI=10.1126/science.1175065; RA Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B., RA Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.; RT "The E3 ligase TRAF6 regulates Akt ubiquitination and activation."; RL Science 325:1134-1138(2009). RN [52] RP FUNCTION, AND INTERACTION WITH STK3/MST2. RX PubMed=20086174; DOI=10.1158/0008-5472.can-09-3147; RA Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.; RT "Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, RT Raf-1, and Akt."; RL Cancer Res. 70:1195-1203(2010). RN [53] RP RETRACTED PAPER. RX PubMed=19940129; DOI=10.1074/jbc.m109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RT "Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic RT signaling through phosphorylation of threonine 120."; RL J. Biol. Chem. 285:3815-3824(2010). RN [54] RP RETRACTION NOTICE OF PUBMED:19940129. RX PubMed=27825096; DOI=10.1074/jbc.a109.059675; RA Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., RA Cheng J.Q.; RL J. Biol. Chem. 291:22858-22858(2016). RN [55] RP FUNCTION, AND INTERACTION WITH CLK2. RX PubMed=20682768; DOI=10.1074/jbc.m110.122044; RA Nam S.Y., Seo H.H., Park H.S., An S., Kim J.Y., Yang K.H., Kim C.S., RA Jeong M., Jin Y.W.; RT "Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls RT cell survival after ionizing radiation."; RL J. Biol. Chem. 285:31157-31163(2010). RN [56] RP FUNCTION IN PHOSPHORYLATION OF PALLD. RX PubMed=20471940; DOI=10.1016/j.molcel.2010.02.031; RA Chin Y.R., Toker A.; RT "The actin-bundling protein palladin is an Akt1-specific substrate that RT regulates breast cancer cell migration."; RL Mol. Cell 38:333-344(2010). RN [57] RP RETRACTED PAPER. RX PubMed=20231902; DOI=10.1371/journal.pone.0009616; RA Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.; RT "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1- RT Akt pathway."; RL PLoS ONE 5:E9616-E9616(2010). RN [58] RP CAUTION, AND RETRACTION NOTICE OF PUBMED:20231902. RX PubMed=37490513; DOI=10.1371/journal.pone.0289329; RG PLOS ONE Editors; RT "Retraction: Regulation of Proapoptotic Mammalian ste20-Like Kinase MST2 by RT the IGF1-Akt Pathway."; RL PLoS ONE 18:e0289329-e0289329(2023). RN [59] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-176; THR-308 AND RP SER-473, MUTAGENESIS OF TYR-176, INTERACTION WITH TNK2, AND TISSUE RP SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [60] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [61] RP INTERACTION WITH TRIM13, AND UBIQUITINATION. RX PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001; RA Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., RA Kim H.S., Jeong M., An S., Jin Y.W.; RT "Ret finger protein 2 enhances ionizing radiation-induced apoptosis via RT degradation of AKT and MDM2."; RL Eur. J. Cell Biol. 90:420-431(2011). RN [62] RP INTERACTION WITH PPP2R5B, AND DEPHOSPHORYLATION. RX PubMed=21329884; DOI=10.1016/j.molcel.2011.02.007; RA Rodgers J.T., Vogel R.O., Puigserver P.; RT "Clk2 and B56-beta mediate insulin-regulated assembly of the PP2A RT phosphatase holoenzyme complex on Akt."; RL Mol. Cell 41:471-479(2011). RN [63] RP INTERACTION WITH FAM168A. RX PubMed=23251525; DOI=10.1371/journal.pone.0051413; RA Peng B., Gu Y., Xiong Y., Zheng G., He Z.; RT "Microarray-assisted pathway analysis identifies MT1X & NFkappaB as RT mediators of TCRP1-associated resistance to cisplatin in oral squamous cell RT carcinoma."; RL PLoS ONE 7:E51413-E51413(2012). RN [64] RP PROTEOLYTIC CLEAVAGE. RX PubMed=23152800; DOI=10.1371/journal.pone.0048770; RA Sen T., Sen N., Noordhuis M.G., Ravi R., Wu T.C., Ha P.K., Sidransky D., RA Hoque M.O.; RT "OGDHL is a modifier of AKT-dependent signaling and NF-kappaB function."; RL PLoS ONE 7:e48770-e48770(2012). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [66] RP INTERACTION WITH FAM83B. RX PubMed=23676467; DOI=10.18632/oncotarget.1027; RA Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A., RA Jackson M.W.; RT "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to RT promote epithelial cell transformation and resistance to targeted RT therapies."; RL Oncotarget 4:729-738(2013). RN [67] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [68] RP REVIEW ON FUNCTION. RX PubMed=11882383; DOI=10.1016/s0898-6568(01)00271-6; RA Nicholson K.M., Anderson N.G.; RT "The protein kinase B/Akt signalling pathway in human malignancy."; RL Cell. Signal. 14:381-395(2002). RN [69] RP PHOSPHORYLATION AT SER-473. RX PubMed=20978158; DOI=10.1158/1535-7163.mct-10-0730; RA Kunoh T., Noda T., Koseki K., Sekigawa M., Takagi M., Shin-ya K., RA Goshima N., Iemura S., Natsume T., Wada S., Mukai Y., Ohta S., Sasaki R., RA Mizukami T.; RT "A novel human dynactin-associated protein, dynAP, promotes activation of RT Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of RT human cancer cells."; RL Mol. Cancer Ther. 9:2934-2942(2010). RN [70] RP REVIEW ON FUNCTION. RX PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004; RA Hers I., Vincent E.E., Tavare J.M.; RT "Akt signalling in health and disease."; RL Cell. Signal. 23:1515-1527(2011). RN [71] RP REVIEW ON FUNCTION. RX PubMed=21432781; DOI=10.14670/hh-26.651; RA Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.; RT "Akt1 and Akt2: differentiating the aktion."; RL Histol. Histopathol. 26:651-662(2011). RN [72] RP PHOSPHORYLATION AT THR-308 AND SER-473. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [73] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-14 AND LYS-20, DEACETYLATION AT RP LYS-14 AND LYS-20, AND MUTAGENESIS OF LYS-14; GLU-17 AND LYS-20. RX PubMed=21775285; DOI=10.1126/scisignal.2001465; RA Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., RA Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.; RT "The deacetylase SIRT1 promotes membrane localization and activation of Akt RT and PDK1 during tumorigenesis and cardiac hypertrophy."; RL Sci. Signal. 4:RA46-RA46(2011). RN [74] RP UBIQUITINATION AT LYS-284. RX PubMed=22410793; DOI=10.1038/cr.2012.38; RA Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K., Kim J., RA An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y., Jin Y.W., RA Lee J.H., An S.; RT "Akt is negatively regulated by the MULAN E3 ligase."; RL Cell Res. 22:873-885(2012). RN [75] RP GLYCOSYLATION AT SER-126; SER-129; THR-305 AND THR-312, SUBCELLULAR RP LOCATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-305 AND THR-312. RX PubMed=22629392; DOI=10.1371/journal.pone.0037427; RA Wang S., Huang X., Sun D., Xin X., Pan Q., Peng S., Liang Z., Luo C., RA Yang Y., Jiang H., Huang M., Chai W., Ding J., Geng M.; RT "Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates RT Akt signaling."; RL PLoS ONE 7:E37427-E37427(2012). RN [76] RP PHOSPHORYLATION AT SER-473, AND DEPHOSPHORYLATION BY CPPED1. RX PubMed=23799035; DOI=10.1371/journal.pone.0065679; RA Zhuo D.X., Zhang X.W., Jin B., Zhang Z., Xie B.S., Wu C.L., Gong K., RA Mao Z.B.; RT "CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell RT apoptosis, and suppresses tumor growth of bladder cancer by directly RT dephosphorylating Akt at Ser473 site."; RL PLoS ONE 8:E65679-E65679(2013). RN [77] RP FUNCTION. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [78] RP INTERACTION WITH SYAP1. RX PubMed=23300339; DOI=10.1126/scisignal.2003295; RA Yao Y., Suraokar M., Darnay B.G., Hollier B.G., Shaiken T.E., Asano T., RA Chen C.H., Chang B.H., Lu Y., Mills G.B., Sarbassov D., Mani S.A., RA Abbruzzese J.L., Reddy S.A.; RT "BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress RT expression of FoxC2 and stimulate adipocyte differentiation."; RL Sci. Signal. 6:RA2-RA2(2013). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-448 AND THR-450, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP PHOSPHORYLATION AT SER-477 AND THR-479, AND MUTAGENESIS OF 76-ARG--LEU-78 RP AND 273-ARG--LEU-275. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26440888; DOI=10.1016/j.celrep.2015.09.007; RA Seo G.J., Yang A., Tan B., Kim S., Liang Q., Choi Y., Yuan W., Feng P., RA Park H.S., Jung J.U.; RT "Akt kinase-mediated checkpoint of cGAS DNA sensing pathway."; RL Cell Rep. 13:440-449(2015). RN [82] RP INTERACTION WITH KIF14. RX PubMed=24784001; DOI=10.1016/j.neo.2014.03.008; RA Singel S.M., Cornelius C., Zaganjor E., Batten K., Sarode V.R., RA Buckley D.L., Peng Y., John G.B., Li H.C., Sadeghi N., Wright W.E., Lum L., RA Corson T.W., Shay J.W.; RT "KIF14 promotes AKT phosphorylation and contributes to chemoresistance in RT triple-negative breast cancer."; RL Neoplasia 16:247-256(2014). RN [83] RP PHOSPHORYLATION AT SER-473, DEPHOSPHORYLATION, AND INTERACTION WITH PHLPP1 RP AND FKBP5. RX PubMed=28147277; DOI=10.1016/j.celrep.2017.01.009; RA Yu J., Qin B., Wu F., Qin S., Nowsheen S., Shan S., Zayas J., Pei H., RA Lou Z., Wang L.; RT "Regulation of serine-threonine kinase Akt activation by NAD+-dependent RT deacetylase SIRT7."; RL Cell Rep. 18:1229-1240(2017). RN [84] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29343641; DOI=10.1073/pnas.1705954115; RA Choppara S., Malonia S.K., Sankaran G., Green M.R., Santra M.K.; RT "Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:998-1003(2018). RN [85] RP FUNCTION. RX PubMed=30504268; DOI=10.15252/embj.201899435; RA Marchi S., Corricelli M., Branchini A., Vitto V.A.M., Missiroli S., RA Morciano G., Perrone M., Ferrarese M., Giorgi C., Pinotti M., Galluzzi L., RA Kroemer G., Pinton P.; RT "Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels RT and tumor growth."; RL EMBO J. 38:0-0(2019). RN [86] RP FUNCTION. RX PubMed=31204173; DOI=10.1016/j.devcel.2019.05.022; RA Walia V., Cuenca A., Vetter M., Insinna C., Perera S., Lu Q., Ritt D.A., RA Semler E., Specht S., Stauffer J., Morrison D.K., Lorentzen E., RA Westlake C.J.; RT "Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis."; RL Dev. Cell 50:229-246(2019). RN [87] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [88] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32322062; DOI=10.1038/s41586-020-2183-2; RA Xu D., Wang Z., Xia Y., Shao F., Xia W., Wei Y., Li X., Qian X., Lee J.H., RA Du L., Zheng Y., Lv G., Leu J.S., Wang H., Xing D., Liang T., Hung M.C., RA Lu Z.; RT "The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis."; RL Nature 580:530-535(2020). RN [89] RP INTERACTION WITH TMEM175, AND FUNCTION. RX PubMed=32228865; DOI=10.7554/elife.53430; RA Oh S., Paknejad N., Hite R.K.; RT "Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175."; RL Elife 9:0-0(2020). RN [90] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-179. RX PubMed=33594058; DOI=10.1038/s41467-021-21206-3; RA Li T., Wang X., Ju E., da Silva S.R., Chen L., Zhang X., Wei S., Gao S.J.; RT "RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 RT for ubiquitination and degradation."; RL Nat. Commun. 12:1055-1055(2021). RN [91] RP INTERACTION WITH SLC9D1, PHOSPHORYLATION AT THR-308 AND SER-473, AND RP SUBCELLULAR LOCATION. RX PubMed=40285646; DOI=10.1002/advs.202504187; RA Li X., Han M., Zhu H., Pan Y., Su C., Liu Y., Liao Z., Zhang B., Chen X.; RT "m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by RT Facilitating the Membrane Translocation and Activation of AKT."; RL Adv. Sci. 12:e2504187-e2504187(2025). RN [92] RP X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-123, FUNCTION, INTERACTION WITH RP PTDINS(3,4,5)P3 AND PTDINS(3,4)P2, MUTAGENESIS OF LYS-14; ARG-25 AND RP ARG-86, AND CHARACTERIZATION OF VARIANT CWS6 CYS-25. RX PubMed=12176338; DOI=10.1016/s0960-9822(02)00972-7; RA Thomas C.C., Deak M., Alessi D.R., van Aalten D.M.; RT "High-resolution structure of the pleckstrin homology domain of protein RT kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate."; RL Curr. Biol. 12:1256-1262(2002). RN [93] RP X-RAY CRYSTALLOGRAPHY (0.98 ANGSTROMS) OF 1-121, FUNCTION, AND INTERACTION RP WITH PTDINS(1,3,4,5)P4. RX PubMed=12964941; DOI=10.1042/bj20031229; RA Milburn C.C., Deak M., Kelly S.M., Price N.C., Alessi D.R., RA Van Aalten D.M.; RT "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin RT homology domain of protein kinase B induces a conformational change."; RL Biochem. J. 375:531-538(2003). RN [94] {ECO:0007744|PDB:3CQU, ECO:0007744|PDB:3CQW} RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=18456494; DOI=10.1016/j.bmcl.2008.04.034; RA Lippa B., Pan G., Corbett M., Li C., Kauffman G.S., Pandit J., Robinson S., RA Wei L., Kozina E., Marr E.S., Borzillo G., Knauth E., Barbacci-Tobin E.G., RA Vincent P., Troutman M., Baker D., Rajamohan F., Kakar S., Clark T., RA Morris J.; RT "Synthesis and structure based optimization of novel Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 18:3359-3363(2008). RN [95] {ECO:0007744|PDB:3OCB} RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=20810279; DOI=10.1016/j.bmcl.2010.08.053; RA Blake J.F., Kallan N.C., Xiao D., Xu R., Bencsik J.R., Skelton N.J., RA Spencer K.L., Mitchell I.S., Woessner R.D., Gloor S.L., Risom T., RA Gross S.D., Martinson M., Morales T.H., Vigers G.P., Brandhuber B.J.; RT "Discovery of pyrrolopyrimidine inhibitors of Akt."; RL Bioorg. Med. Chem. Lett. 20:5607-5612(2010). RN [96] {ECO:0007744|PDB:3MV5, ECO:0007744|PDB:3MVH} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 144-480, PHOSPHORYLATION AT RP THR-308, AND ACTIVITY REGULATION. RX PubMed=20481595; DOI=10.1021/jm1003842; RA Freeman-Cook K.D., Autry C., Borzillo G., Gordon D., Barbacci-Tobin E., RA Bernardo V., Briere D., Clark T., Corbett M., Jakubczak J., Kakar S., RA Knauth E., Lippa B., Luzzio M.J., Mansour M., Martinelli G., Marx M., RA Nelson K., Pandit J., Rajamohan F., Robinson S., Subramanyam C., Wei L., RA Wythes M., Morris J.; RT "Design of selective, ATP-competitive inhibitors of Akt."; RL J. Med. Chem. 53:4615-4622(2010). RN [97] {ECO:0007744|PDB:3O96} RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-443, AND DISULFIDE BOND. RX PubMed=20886116; DOI=10.1371/journal.pone.0012913; RA Wu W.I., Voegtli W.C., Sturgis H.L., Dizon F.P., Vigers G.P., RA Brandhuber B.J.; RT "Crystal structure of human AKT1 with an allosteric inhibitor reveals a new RT mode of kinase inhibition."; RL PLoS ONE 5:E12913-E12913(2010). RN [98] {ECO:0007744|PDB:3QKK, ECO:0007744|PDB:3QKL} RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 144-480, AND ACTIVITY REGULATION. RX PubMed=21392984; DOI=10.1016/j.bmcl.2011.02.073; RA Kallan N.C., Spencer K.L., Blake J.F., Xu R., Heizer J., Bencsik J.R., RA Mitchell I.S., Gloor S.L., Martinson M., Risom T., Gross S.D., RA Morales T.H., Wu W.I., Vigers G.P., Brandhuber B.J., Skelton N.J.; RT "Discovery and SAR of spirochromane Akt inhibitors."; RL Bioorg. Med. Chem. Lett. 21:2410-2414(2011). RN [99] RP VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST CANCER RP LYS-17. RX PubMed=17611497; DOI=10.1038/nature05933; RA Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., RA Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., RA Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., RA Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., RA Thomas J.E.; RT "A transforming mutation in the pleckstrin homology domain of AKT1 in RT cancer."; RL Nature 448:439-444(2007). RN [100] RP CHARACTERIZATION OF VARIANT PROTEUSS LYS-17. RX PubMed=18954143; DOI=10.1021/bi801683k; RA Landgraf K.E., Pilling C., Falke J.J.; RT "Molecular mechanism of an oncogenic mutation that alters membrane RT targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH RT domain."; RL Biochemistry 47:12260-12269(2008). RN [101] RP VARIANT PROTEUSS LYS-17. RX PubMed=21793738; DOI=10.1056/nejmoa1104017; RA Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., RA Turner J., Cannons J.L., Bick D., Blakemore L., Blumhorst C., Brockmann K., RA Calder P., Cherman N., Deardorff M.A., Everman D.B., Golas G., RA Greenstein R.M., Kato B.M., Keppler-Noreuil K.M., Kuznetsov S.A., RA Miyamoto R.T., Newman K., Ng D., O'Brien K., Rothenberg S., RA Schwartzentruber D.J., Singhal V., Tirabosco R., Upton J., Wientroub S., RA Zackai E.H., Hoag K., Whitewood-Neal T., Robey P.G., Schwartzberg P.L., RA Darling T.N., Tosi L.L., Mullikin J.C., Biesecker L.G.; RT "A mosaic activating mutation in AKT1 associated with the Proteus RT syndrome."; RL N. Engl. J. Med. 365:611-619(2011). RN [102] RP VARIANTS CWS6 CYS-25 AND PRO-435. RX PubMed=23246288; DOI=10.1016/j.ajhg.2012.10.021; RA Orloff M.S., He X., Peterson C., Chen F., Chen J.L., Mester J.L., Eng C.; RT "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."; RL Am. J. Hum. Genet. 92:76-80(2013). CC -!- FUNCTION: AKT1 is one of 3 closely related serine/threonine-protein CC kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate CC many processes including metabolism, proliferation, cell survival, CC growth and angiogenesis (PubMed:11882383, PubMed:15526160, CC PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). CC This is mediated through serine and/or threonine phosphorylation of a CC range of downstream substrates (PubMed:11882383, PubMed:15526160, CC PubMed:21432781, PubMed:21620960, PubMed:29343641, PubMed:31204173). CC Over 100 substrate candidates have been reported so far, but for most CC of them, no isoform specificity has been reported (PubMed:11882383, CC PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible CC of the regulation of glucose uptake by mediating insulin-induced CC translocation of the SLC2A4/GLUT4 glucose transporter to the cell CC surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' CC negatively modulates its phosphatase activity preventing CC dephosphorylation of the insulin receptor and the attenuation of CC insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers CC the binding of this effector to inhibitory 14-3-3 proteins, which is CC required for insulin-stimulated glucose transport (PubMed:11994271). CC AKT also regulates the storage of glucose in the form of glycogen by CC phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in CC inhibition of its kinase activity (By similarity). Phosphorylation of CC GSK3 isoforms by AKT is also thought to be one mechanism by which cell CC proliferation is driven (By similarity). AKT also regulates cell CC survival via the phosphorylation of MAP3K5 (apoptosis signal-related CC kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 CC kinase activity stimulated by oxidative stress and thereby prevents CC apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein CC synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby CC activating the mTORC1 signaling pathway, and leading to both CC phosphorylation of 4E-BP1 and in activation of RPS6KB1 CC (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling CC pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 CC (PubMed:31548394, PubMed:33594058). AKT plays a role as key modulator CC of the AKT-mTOR signaling pathway controlling the tempo of the process CC of newborn neurons integration during adult neurogenesis, including CC correct neuron positioning, dendritic development and synapse formation CC (By similarity). Part of a positive feedback loop of mTORC2 signaling CC by mediating phosphorylation of MAPKAP1/SIN1, promoting mTORC2 CC activation (By similarity). AKT is involved in the phosphorylation of CC members of the FOXO factors (Forkhead family of transcription factors), CC leading to binding of 14-3-3 proteins and cytoplasmic localization CC (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', CC 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are CC phosphorylated on equivalent sites (PubMed:10358075). AKT has an CC important role in the regulation of NF-kappa-B-dependent gene CC transcription and positively regulates the activity of CREB1 (cyclic CC AMP (cAMP)-response element binding protein) (PubMed:9829964). The CC phosphorylation of CREB1 induces the binding of accessory proteins that CC are necessary for the transcription of pro-survival genes such as BCL2 CC and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate CC lyase (ACLY), thereby potentially regulating ACLY activity and fatty CC acid synthesis (By similarity). Activates the 3B isoform of cyclic CC nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', CC resulting in reduced cyclic AMP levels and inhibition of lipolysis (By CC similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in CC increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating CC protein DLC1 is another substrate and its phosphorylation is implicated CC in the regulation cell proliferation and cell growth (By similarity). CC Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate CC the effects of various growth factors such as platelet-derived growth CC factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like CC growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates CC the antiapoptotic effects of IGF1 (By similarity). Essential for the CC SPATA13-mediated regulation of cell migration and adhesion assembly and CC disassembly (PubMed:19934221). May be involved in the regulation of the CC placental development (By similarity). Phosphorylates STK4/MST1 at CC 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, CC nuclear translocation, autophosphorylation and ability to phosphorylate CC FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and CC 'Thr-384' leading to inhibition of its: cleavage, kinase activity, CC autophosphorylation at Thr-180, binding to RASSF1 and nuclear CC translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its CC kinase activity towards SRSF2 and ACIN1 and promotes its nuclear CC translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and CC negatively regulates its activity (PubMed:10576742). Phosphorylation of CC BAD stimulates its pro-apoptotic activity (PubMed:10926925). CC Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the CC interaction of KAT6A with PML and negatively regulates its acetylation CC activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin CC (PALLD), modulating cytoskeletal organization and cell motility CC (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an CC important role in cell metabolism and proliferation (PubMed:18507042). CC Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces CC its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). CC These recent findings indicate that the AKT1 isoform has a more CC specific role in cell motility and proliferation (PubMed:16139227). CC Phosphorylates CLK2 thereby controlling cell survival to ionizing CC radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing CC the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an CC atypical protein kinase activity using GTP as donor (PubMed:32322062). CC Also acts as an activator of TMEM175 potassium channel activity in CC response to growth factors: forms the lysoK(GF) complex together with CC TMEM175 and acts by promoting TMEM175 channel activation, independently CC of its protein kinase activity (PubMed:32228865). Acts as a regulator CC of mitochondrial calcium uptake by mediating phosphorylation of MICU1 CC in the mitochondrial intermembrane space, impairing MICU1 maturation CC (PubMed:30504268). Acts as an inhibitor of tRNA methylation by CC mediating phosphorylation of the N-terminus of METTL1, thereby CC inhibiting METTL1 methyltransferase activity (PubMed:15861136). In CC response to LPAR1 receptor pathway activation, phosphorylates CC Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which CC induces WDR44 binding to Rab11, thereby switching Rab11 vesicular CC function from preciliary trafficking to endocytic recycling CC (PubMed:31204173). {ECO:0000250|UniProtKB:P31750, CC ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:10358075, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10926925, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11994271, CC ECO:0000269|PubMed:12150915, ECO:0000269|PubMed:12172553, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12964941, CC ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:18507042, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20471940, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:30504268, CC ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:32322062, CC ECO:0000269|PubMed:33594058, ECO:0000269|PubMed:9829964, CC ECO:0000303|PubMed:11882383, ECO:0000303|PubMed:15526160, CC ECO:0000303|PubMed:21432781, ECO:0000303|PubMed:21620960}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:1851997, ECO:0000269|PubMed:26440888, CC ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:16139227, CC ECO:0000269|PubMed:1718748, ECO:0000269|PubMed:1851997}; CC -!- ACTIVITY REGULATION: Three specific sites, one in the kinase domain CC (Thr-308) and the two other ones in the C-terminal regulatory region CC (Ser-473 and Tyr-474), need to be phosphorylated for its full CC activation (PubMed:15262962, PubMed:20481595, PubMed:21392984, CC PubMed:9512493, PubMed:9736715). Inhibited by pyrrolopyrimidine CC inhibitors like aniline triazole and spiroindoline (PubMed:18456494, CC PubMed:20810279). {ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20810279, ECO:0000269|PubMed:21392984, CC ECO:0000269|PubMed:9512493, ECO:0000269|PubMed:9736715, CC ECO:0000305|PubMed:20810279}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.8 uM for ATP (for purified and in vitro activated AKT1) CC {ECO:0000269|PubMed:16540465}; CC KM=0.5 uM for peptide substrate (for purified and in vitro activated CC AKT1) {ECO:0000269|PubMed:16540465}; CC KM=143.3 uM for ATP (for recombinant myristoylated AKT1 expressed and CC immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465}; CC KM=2.9 uM for peptide substrate (for recombinant myristoylated AKT1 CC expressed and immunoprecipitated from Rat-1 cells) CC {ECO:0000269|PubMed:16540465}; CC -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20 CC (By similarity). Interacts (via the C-terminus) with CCDC88A (via its CC C-terminus). Interacts with GRB10; the interaction leads to GRB10 CC phosphorylation thus promoting YWHAE-binding (By similarity). Interacts CC with AGAP2 (isoform 2/PIKE-A); the interaction occurs in the presence CC of guanine nucleotides. Interacts with AKTIP. Interacts (via PH domain) CC with MTCP1, TCL1A and TCL1B. Interacts with CDKN1B; the interaction CC phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle CC progression. Interacts with MAP3K5 and TRAF6. Interacts with BAD, CC PPP2R5B, STK3 and STK4. Interacts (via PH domain) with SIRT1. Interacts CC with SRPK2 in a phosphorylation-dependent manner. Interacts with RAF1. CC Interacts with TRIM13; the interaction ubiquitinates AKT1 leading to CC its proteasomal degradation. Interacts with TNK2 and CLK2. Interacts CC (via the C-terminus) with THEM4 (via its C-terminus). Interacts with CC and phosphorylated by PDPK1. Interacts with PA2G4 (By similarity). CC Interacts with KIF14; the interaction is detected in the plasma CC membrane upon INS stimulation and promotes AKT1 phosphorylation CC (PubMed:24784001). Interacts with FAM83B; activates the PI3K/AKT CC signaling cascade (PubMed:23676467). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Forms a complex with WDFY2 and FOXO1 CC (By similarity). Interacts with FAM168A (PubMed:23251525). Interacts CC with SYAP1 (via phosphorylated form and BSD domain); this interaction CC is enhanced in a mTORC2-mediated manner in response to epidermal growth CC factor (EGF) stimulation and activates AKT1 (PubMed:23300339). CC Interacts with PKHM3 (By similarity). Interacts with FKBP5/FKBP51; CC promoting interaction between Akt/AKT1 and PHLPP1, thereby enhancing CC dephosphorylation and subsequent activation of Akt/AKT1 CC (PubMed:28147277). Interacts with TMEM175; leading to formation of the CC lysoK(GF) complex (PubMed:32228865). Acts as a negative regulator of CC the cGAS-STING pathway by mediating phosphorylation of CGAS during CC mitosis, leading to its inhibition (PubMed:26440888). Interacts with CC SLC9D1 (when phosphorylated); the interaction facilitates the membrane CC translocation and activation of AKT1 (PubMed:40285646). CC {ECO:0000250|UniProtKB:P31750, ECO:0000250|UniProtKB:P47196, CC ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10716693, CC ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:10983986, CC ECO:0000269|PubMed:11154276, ECO:0000269|PubMed:11598301, CC ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:12042314, CC ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:12244301, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:14749367, CC ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, CC ECO:0000269|PubMed:16139227, ECO:0000269|PubMed:16417524, CC ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17726016, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:19592491, CC ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20086174, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20682768, CC ECO:0000269|PubMed:21329884, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:22629392, CC ECO:0000269|PubMed:23251525, ECO:0000269|PubMed:23300339, CC ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:24784001, CC ECO:0000269|PubMed:26440888, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:32228865, ECO:0000269|PubMed:40285646}. CC -!- INTERACTION: CC P31749; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-296087, EBI-10173507; CC P31749; P31749: AKT1; NbExp=4; IntAct=EBI-296087, EBI-296087; CC P31749; P31751: AKT2; NbExp=3; IntAct=EBI-296087, EBI-296058; CC P31749; Q86V81: ALYREF; NbExp=5; IntAct=EBI-296087, EBI-347640; CC P31749; P32121: ARRB2; NbExp=5; IntAct=EBI-296087, EBI-714559; CC P31749; Q8IXJ9: ASXL1; NbExp=3; IntAct=EBI-296087, EBI-1646500; CC P31749; Q13315: ATM; NbExp=5; IntAct=EBI-296087, EBI-495465; CC P31749; P54253: ATXN1; NbExp=6; IntAct=EBI-296087, EBI-930964; CC P31749; Q99728: BARD1; NbExp=3; IntAct=EBI-296087, EBI-473181; CC P31749; O95999: BCL10; NbExp=5; IntAct=EBI-296087, EBI-958922; CC P31749; Q6W2J9: BCOR; NbExp=3; IntAct=EBI-296087, EBI-950027; CC P31749; P15056: BRAF; NbExp=4; IntAct=EBI-296087, EBI-365980; CC P31749; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-296087, EBI-935503; CC P31749; P62324: BTG1; NbExp=4; IntAct=EBI-296087, EBI-742279; CC P31749; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-296087, EBI-1383687; CC P31749; P20248: CCNA2; NbExp=2; IntAct=EBI-296087, EBI-457097; CC P31749; P30281: CCND3; NbExp=3; IntAct=EBI-296087, EBI-375013; CC P31749; Q16543: CDC37; NbExp=5; IntAct=EBI-296087, EBI-295634; CC P31749; P46527: CDKN1B; NbExp=4; IntAct=EBI-296087, EBI-519280; CC P31749; Q8TAP6: CEP76; NbExp=4; IntAct=EBI-296087, EBI-742887; CC P31749; Q92793: CREBBP; NbExp=3; IntAct=EBI-296087, EBI-81215; CC P31749; Q15438: CYTH1; NbExp=3; IntAct=EBI-296087, EBI-997830; CC P31749; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-296087, EBI-742054; CC P31749; P26358: DNMT1; NbExp=6; IntAct=EBI-296087, EBI-719459; CC P31749; P00533: EGFR; NbExp=4; IntAct=EBI-296087, EBI-297353; CC P31749; Q9UJM3: ERRFI1; NbExp=3; IntAct=EBI-296087, EBI-2941912; CC P31749; Q15910: EZH2; NbExp=3; IntAct=EBI-296087, EBI-530054; CC P31749; Q1W6H9: FAM110C; NbExp=2; IntAct=EBI-296087, EBI-3942563; CC P31749; Q00597: FANCC; NbExp=4; IntAct=EBI-296087, EBI-81625; CC P31749; Q9HB96: FANCE; NbExp=4; IntAct=EBI-296087, EBI-396803; CC P31749; Q969H0: FBXW7; NbExp=5; IntAct=EBI-296087, EBI-359574; CC P31749; Q12778: FOXO1; NbExp=2; IntAct=EBI-296087, EBI-1108782; CC P31749; O43524: FOXO3; NbExp=4; IntAct=EBI-296087, EBI-1644164; CC P31749; P06241: FYN; NbExp=3; IntAct=EBI-296087, EBI-515315; CC P31749; P22466: GAL; NbExp=3; IntAct=EBI-296087, EBI-6624768; CC P31749; P49841: GSK3B; NbExp=5; IntAct=EBI-296087, EBI-373586; CC P31749; P68431: H3C12; NbExp=4; IntAct=EBI-296087, EBI-79722; CC P31749; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-296087, EBI-25830912; CC P31749; P08238: HSP90AB1; NbExp=3; IntAct=EBI-296087, EBI-352572; CC P31749; P42858: HTT; NbExp=3; IntAct=EBI-296087, EBI-466029; CC P31749; P08476: INHBA; NbExp=3; IntAct=EBI-296087, EBI-8077140; CC P31749; Q8WZ60: KLHL6; NbExp=3; IntAct=EBI-296087, EBI-6426464; CC P31749; Q5S007: LRRK2; NbExp=6; IntAct=EBI-296087, EBI-5323863; CC P31749; Q99683: MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263; CC P31749; O15264: MAPK13; NbExp=4; IntAct=EBI-296087, EBI-2116951; CC P31749; Q8TD08: MAPK15; NbExp=3; IntAct=EBI-296087, EBI-1383794; CC P31749; Q9BPZ7: MAPKAP1; NbExp=3; IntAct=EBI-296087, EBI-749938; CC P31749; P10636: MAPT; NbExp=2; IntAct=EBI-296087, EBI-366182; CC P31749; Q07820: MCL1; NbExp=3; IntAct=EBI-296087, EBI-1003422; CC P31749; Q00987: MDM2; NbExp=6; IntAct=EBI-296087, EBI-389668; CC P31749; Q14696: MESD; NbExp=3; IntAct=EBI-296087, EBI-6165891; CC P31749; P42345: MTOR; NbExp=6; IntAct=EBI-296087, EBI-359260; CC P31749; P04198: MYCN; NbExp=3; IntAct=EBI-296087, EBI-878369; CC P31749; P25963: NFKBIA; NbExp=3; IntAct=EBI-296087, EBI-307386; CC P31749; Q9BZQ8: NIBAN1; NbExp=2; IntAct=EBI-296087, EBI-6916466; CC P31749; P04150: NR3C1; NbExp=5; IntAct=EBI-296087, EBI-493507; CC P31749; O15530: PDPK1; NbExp=5; IntAct=EBI-296087, EBI-717097; CC P31749; Q96S96: PEBP4; NbExp=2; IntAct=EBI-296087, EBI-8563667; CC P31749; P19174: PLCG1; NbExp=9; IntAct=EBI-296087, EBI-79387; CC P31749; Q03181: PPARD; NbExp=3; IntAct=EBI-296087, EBI-6426768; CC P31749; O60437: PPL; NbExp=2; IntAct=EBI-296087, EBI-368321; CC P31749; P62136: PPP1CA; NbExp=4; IntAct=EBI-296087, EBI-357253; CC P31749; P67775: PPP2CA; NbExp=4; IntAct=EBI-296087, EBI-712311; CC P31749; P30153: PPP2R1A; NbExp=3; IntAct=EBI-296087, EBI-302388; CC P31749; P54646: PRKAA2; NbExp=3; IntAct=EBI-296087, EBI-1383852; CC P31749; P17612: PRKACA; NbExp=3; IntAct=EBI-296087, EBI-476586; CC P31749; Q05513: PRKCZ; NbExp=2; IntAct=EBI-296087, EBI-295351; CC P31749; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-296087, EBI-743880; CC P31749; Q06124: PTPN11; NbExp=3; IntAct=EBI-296087, EBI-297779; CC P31749; P04049: RAF1; NbExp=3; IntAct=EBI-296087, EBI-365996; CC P31749; P10276: RARA; NbExp=3; IntAct=EBI-296087, EBI-413374; CC P31749; Q9NS23: RASSF1; NbExp=3; IntAct=EBI-296087, EBI-367363; CC P31749; Q6R327: RICTOR; NbExp=3; IntAct=EBI-296087, EBI-1387196; CC P31749; P15880: RPS2; NbExp=3; IntAct=EBI-296087, EBI-443446; CC P31749; P23443: RPS6KB1; NbExp=3; IntAct=EBI-296087, EBI-1775921; CC P31749; Q15047: SETDB1; NbExp=10; IntAct=EBI-296087, EBI-79691; CC P31749; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-296087, EBI-1802965; CC P31749; Q13309: SKP2; NbExp=4; IntAct=EBI-296087, EBI-456291; CC P31749; Q13485: SMAD4; NbExp=6; IntAct=EBI-296087, EBI-347263; CC P31749; Q8N3U4: STAG2; NbExp=3; IntAct=EBI-296087, EBI-1057252; CC P31749; Q14849: STARD3; NbExp=3; IntAct=EBI-296087, EBI-9819324; CC P31749; Q13043: STK4; NbExp=13; IntAct=EBI-296087, EBI-367376; CC P31749; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-296087, EBI-15687717; CC P31749; P56279: TCL1A; NbExp=8; IntAct=EBI-296087, EBI-749995; CC P31749; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-296087, EBI-750109; CC P31749; Q5T1C6: THEM4; NbExp=4; IntAct=EBI-296087, EBI-7684443; CC P31749; Q92547: TOPBP1; NbExp=2; IntAct=EBI-296087, EBI-308302; CC P31749; P53804: TTC3; NbExp=4; IntAct=EBI-296087, EBI-2681313; CC P31749; P10599: TXN; NbExp=3; IntAct=EBI-296087, EBI-594644; CC P31749; P08670: VIM; NbExp=29; IntAct=EBI-296087, EBI-353844; CC P31749; Q6GPH4: XAF1; NbExp=4; IntAct=EBI-296087, EBI-2815120; CC P31749; P17028: ZNF24; NbExp=3; IntAct=EBI-296087, EBI-707773; CC P31749; P29067: Arrb2; Xeno; NbExp=2; IntAct=EBI-296087, EBI-1636616; CC P31749; P06762: Hmox1; Xeno; NbExp=2; IntAct=EBI-296087, EBI-7410266; CC P31749; Q83730: m005R; Xeno; NbExp=3; IntAct=EBI-296087, EBI-6859930; CC P31749; P03165: X; Xeno; NbExp=3; IntAct=EBI-296087, EBI-7683985; CC P31749-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562306, EBI-12562315; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P31750}. Nucleus CC {ECO:0000269|PubMed:20333297}. Cell membrane CC {ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:40285646}. CC Mitochondrion intermembrane space {ECO:0000250|UniProtKB:P31750}. CC Note=Nucleus after activation by integrin-linked protein kinase 1 CC (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. CC Phosphorylation on Tyr-176 by TNK2 results in its localization to the CC cell membrane where it is targeted for further phosphorylations on Thr- CC 308 and Ser-473 leading to its activation and the activated form CC translocates to the nucleus. Colocalizes with WDFY2 in intracellular CC vesicles (PubMed:16792529). Also localizes to mitochondrial CC intermembrane space in response to rapamycin treatment (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:16792529}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P31749-1; Sequence=Displayed; CC Name=2; CC IsoId=P31749-2; Sequence=VSP_056180; CC -!- TISSUE SPECIFICITY: Expressed in prostate cancer and levels increase CC from the normal to the malignant state (at protein level). Expressed in CC all human cell types so far analyzed. The Tyr-176 phosphorylated form CC shows a significant increase in expression in breast cancers during the CC progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma CC in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node CC metastatic (LNMM) stages. {ECO:0000269|PubMed:1718748, CC ECO:0000269|PubMed:17932490, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5- CC trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase CC alpha (PIK3CA) activity results in its targeting to the plasma membrane CC (PubMed:12176338, PubMed:12964941). PI(3,4,5)P3 is also required for CC phosphorylation at Thr-308 and subsequent activation (By similarity). CC The PH domain mediates interaction with TNK2 and Tyr-176 is also CC essential for this interaction (PubMed:20333297). CC {ECO:0000250|UniProtKB:P47196, ECO:0000269|PubMed:12176338, CC ECO:0000269|PubMed:12964941, ECO:0000269|PubMed:20333297}. CC -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4. CC {ECO:0000269|PubMed:11598301}. CC -!- PTM: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating CC phosphorylation at Thr-308 via disrupting the interaction between AKT1 CC and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with CC phosphorylation at this site. {ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:17013611, CC ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:20978158, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for CC full activity (PubMed:12149249, PubMed:15047712, PubMed:15262962, CC PubMed:16266983, PubMed:18456494, PubMed:20481595, PubMed:20978158, CC PubMed:8978681, PubMed:9512493, PubMed:9736715). Phosphorylation of the CC activation loop at Thr-308 by PDPK1/PDK1 is a prerequisite for full CC activation (PubMed:9512493). Phosphorylation by mTORC2 in response to CC growth factors plays a key role in AKT1 activation: mTORC2 CC phosphorylates different sites depending on the context, such as Thr- CC 450, Ser-473, Ser-477 or Thr-479, thereby facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:15718470, CC PubMed:24670654). Phosphorylation at Ser-473 by mTORC2 promotes CC ubiquitination and degradation by the proteasome (By similarity). Also CC phosphorylated at Ser-477 and Thr-479 by CDK2, facilitating subsequent CC phosphorylation of the activation loop by PDPK1/PDK1 (PubMed:24670654). CC Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to CC the anionic plasma membrane phospholipid PA (PubMed:20333297). This CC phosphorylated form localizes to the cell membrane, where it is CC targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and CC Ser-473 leading to its activation (PubMed:20333297). Phosphorylated at CC Thr-308 and Ser-473 by IKBKE and TBK1 (PubMed:21464307). Ser-473 CC phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE- CC A) (PubMed:14761976). Ser-473 phosphorylation is enhanced in focal CC cortical dysplasias with Taylor-type balloon cells (PubMed:17013611). CC Ser-473 phosphorylation is enhanced by signaling through activated FLT3 CC (PubMed:16266983). Ser-473 is dephosphorylated by PHLPP CC (PubMed:28147277). Dephosphorylated at Thr-308 and Ser-473 by PP2A CC phosphatase (PubMed:21329884). The phosphorylated form of PPP2R5B is CC required for bridging AKT1 with PP2A phosphatase (PubMed:21329884). CC Ser-473 is dephosphorylated by CPPED1, leading to termination of CC signaling (PubMed:23799035). AIM2 acts as an inhibitor of AKT1 by CC inhibiting phosphorylation Ser-473: AIM2 acts both by inhibiting the CC activity of PRKDC/DNA-PK kinase and promoting dephosphorylation by PP2A CC phosphatase (By similarity). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:12149249, ECO:0000269|PubMed:14761976, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, CC ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:18456494, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20481595, CC ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21329884, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:23799035, CC ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28147277, CC ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9512493, CC ECO:0000269|PubMed:9736715}. CC -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked CC polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination CC is critical for phosphorylation and activation (PubMed:19713527). When CC ubiquitinated, it translocates to the plasma membrane, where it becomes CC phosphorylated (PubMed:20059950). When fully phosphorylated and CC translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination CC catalyzed by TTC3, leading to its degradation by the proteasome CC (PubMed:20059950). Also ubiquitinated by TRIM13 leading to its CC proteasomal degradation (PubMed:21333377). Phosphorylated, undergoes CC 'Lys-48'-linked polyubiquitination preferentially at Lys-284 catalyzed CC by MUL1, leading to its proteasomal degradation (PubMed:22410793). CC Ubiquitinated via 'Lys-48'-linked polyubiquitination by ZNRF1, leading CC to its degradation by the proteasome (By similarity). CC {ECO:0000250|UniProtKB:P31750, ECO:0000269|PubMed:19713527, CC ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:21333377, CC ECO:0000269|PubMed:22410793}. CC -!- PTM: Acetylated on Lys-14 and Lys-20 by the histone acetyltransferases CC EP300 and KAT2B. Acetylation results in reduced phosphorylation and CC inhibition of activity. Deacetylated at Lys-14 and Lys-20 by SIRT1. CC SIRT1-mediated deacetylation relieves the inhibition. CC {ECO:0000269|PubMed:21775285}. CC -!- PTM: Cleavage by caspase-3/CASP3 (By similarity). Cleaved at the CC caspase-3 consensus site Asp-462 during apoptosis, resulting in down- CC regulation of the AKT signaling pathway and decreased cell survival CC (PubMed:23152800). {ECO:0000250|UniProtKB:P31750, CC ECO:0000269|PubMed:23152800}. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:17611497}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- DISEASE: Note=Genetic variations in AKT1 may play a role in CC susceptibility to ovarian cancer. CC -!- DISEASE: Proteus syndrome (PROTEUSS) [MIM:176920]: A highly variable, CC severe disorder of asymmetric and disproportionate overgrowth of body CC parts, connective tissue nevi, epidermal nevi, dysregulated adipose CC tissue, and vascular malformations. Many features of Proteus syndrome CC overlap with other overgrowth syndromes. {ECO:0000269|PubMed:18954143, CC ECO:0000269|PubMed:21793738}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cowden syndrome 6 (CWS6) [MIM:615109]: A form of Cowden CC syndrome, a hamartomatous polyposis syndrome with age-related CC penetrance. Cowden syndrome is characterized by hamartomatous lesions CC affecting derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:12176338, ECO:0000269|PubMed:23246288}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. RAC subfamily. {ECO:0000305}. CC -!- CAUTION: PUBMED:20231902 has been retracted because there was evidence CC of data fabrication and/or falsification in multiple figure panels. CC {ECO:0000305|PubMed:20231902, ECO:0000305|PubMed:37490513}. CC -!- CAUTION: PUBMED:19940129 has been retracted because the same data were CC used to represent different experimental conditions. CC {ECO:0000305|PubMed:19940129, ECO:0000305|PubMed:27825096}. CC -!- CAUTION: In light of strong homologies in the primary amino acid CC sequence, the 3 AKT kinases were long surmised to play redundant and CC overlapping roles. More recent studies has brought into question the CC redundancy within AKT kinase isoforms and instead pointed to isoform CC specific functions in different cellular events and diseases. AKT1 is CC more specifically involved in cellular survival pathways, by inhibiting CC apoptotic processes; whereas AKT2 is more specific for the insulin CC receptor signaling pathway. Moreover, while AKT1 and AKT2 are often CC implicated in many aspects of cellular transformation, the 2 isoforms CC act in a complementary opposing manner. The role of AKT3 is less clear, CC though it appears to be predominantly expressed in brain. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/355/AKT1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63167; AAA36539.1; -; mRNA. DR EMBL; AF283830; AAL55732.1; -; Genomic_DNA. DR EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA. DR EMBL; AK299310; BAH12997.1; -; mRNA. DR EMBL; AK314256; BAG36922.1; -; mRNA. DR EMBL; AB451242; BAG70056.1; -; mRNA. DR EMBL; AB451367; BAG70181.1; -; mRNA. DR EMBL; AL583722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590327; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000479; AAH00479.1; -; mRNA. DR EMBL; BC084538; AAH84538.1; -; mRNA. DR EMBL; X61037; CAA43372.1; -; mRNA. DR CCDS; CCDS9994.1; -. [P31749-1] DR PIR; A39360; A39360. DR RefSeq; NP_001014431.1; NM_001014431.2. [P31749-1] DR RefSeq; NP_001014432.1; NM_001014432.2. [P31749-1] DR RefSeq; NP_001369359.1; NM_001382430.1. [P31749-1] DR RefSeq; NP_001369360.1; NM_001382431.1. [P31749-1] DR RefSeq; NP_001369361.1; NM_001382432.1. [P31749-1] DR RefSeq; NP_001369362.1; NM_001382433.1. [P31749-1] DR RefSeq; NP_005154.2; NM_005163.2. [P31749-1] DR RefSeq; XP_047287025.1; XM_047431069.1. [P31749-1] DR RefSeq; XP_047287026.1; XM_047431070.1. [P31749-1] DR RefSeq; XP_047287027.1; XM_047431071.1. [P31749-1] DR RefSeq; XP_047287028.1; XM_047431072.1. [P31749-1] DR RefSeq; XP_047287029.1; XM_047431073.1. [P31749-1] DR RefSeq; XP_047287030.1; XM_047431074.1. [P31749-1] DR RefSeq; XP_047287031.1; XM_047431075.1. [P31749-1] DR RefSeq; XP_054231528.1; XM_054375553.1. [P31749-1] DR RefSeq; XP_054231529.1; XM_054375554.1. [P31749-1] DR RefSeq; XP_054231530.1; XM_054375555.1. [P31749-1] DR RefSeq; XP_054231531.1; XM_054375556.1. [P31749-1] DR RefSeq; XP_054231532.1; XM_054375557.1. [P31749-1] DR RefSeq; XP_054231533.1; XM_054375558.1. [P31749-1] DR PDB; 1H10; X-ray; 1.40 A; A=1-123. DR PDB; 1UNP; X-ray; 1.65 A; A=1-121. DR PDB; 1UNQ; X-ray; 0.98 A; A=1-123. DR PDB; 1UNR; X-ray; 1.25 A; A=1-123. DR PDB; 2UVM; X-ray; 1.94 A; A=1-123. DR PDB; 2UZR; X-ray; 1.94 A; A=1-123. DR PDB; 2UZS; X-ray; 2.46 A; A=1-123. DR PDB; 3CQU; X-ray; 2.20 A; A=144-480. DR PDB; 3CQW; X-ray; 2.00 A; A=144-480. DR PDB; 3MV5; X-ray; 2.47 A; A=144-480. DR PDB; 3MVH; X-ray; 2.01 A; A=144-480. DR PDB; 3O96; X-ray; 2.70 A; A=2-443. DR PDB; 3OCB; X-ray; 2.70 A; A/B=144-480. DR PDB; 3OW4; X-ray; 2.60 A; A/B=144-480. DR PDB; 3QKK; X-ray; 2.30 A; A=144-480. DR PDB; 3QKL; X-ray; 1.90 A; A=144-480. DR PDB; 3QKM; X-ray; 2.20 A; A=144-480. DR PDB; 4EJN; X-ray; 2.19 A; A=2-446. DR PDB; 4EKK; X-ray; 2.80 A; A/B=144-480. DR PDB; 4EKL; X-ray; 2.00 A; A=144-480. DR PDB; 4GV1; X-ray; 1.49 A; A=144-480. DR PDB; 5KCV; X-ray; 2.70 A; A=2-446. DR PDB; 6BUU; X-ray; 2.40 A; A/B=144-480. DR PDB; 6CCY; X-ray; 2.18 A; A=144-466. DR PDB; 6HHF; X-ray; 2.90 A; A=2-446. DR PDB; 6HHG; X-ray; 2.30 A; A=2-446. DR PDB; 6HHH; X-ray; 2.70 A; A=2-446. DR PDB; 6HHI; X-ray; 2.70 A; A=2-446. DR PDB; 6HHJ; X-ray; 2.30 A; A=2-446. DR PDB; 6NPZ; X-ray; 2.12 A; A/B=123-480, A/B=144-480. DR PDB; 6S9W; X-ray; 2.30 A; A=2-446. DR PDB; 6S9X; X-ray; 2.60 A; A=2-446. DR PDB; 7APJ; X-ray; 2.05 A; A=1-119, A=136-445. DR PDB; 7MYX; X-ray; 1.39 A; A=1-121. DR PDB; 7NH4; X-ray; 2.30 A; A=2-446. DR PDB; 7NH5; X-ray; 1.90 A; A=2-446. DR PDB; 8JOW; X-ray; 1.40 A; B/D=466-477. DR PDB; 8UVY; X-ray; 2.11 A; A=2-446. DR PDB; 8UW2; X-ray; 2.20 A; A=2-446. DR PDB; 8UW7; X-ray; 1.97 A; A=2-446. DR PDB; 8UW9; X-ray; 1.90 A; A=2-446. DR PDB; 8ZPU; X-ray; 2.80 A; C/D=466-477. DR PDBsum; 1H10; -. DR PDBsum; 1UNP; -. DR PDBsum; 1UNQ; -. DR PDBsum; 1UNR; -. DR PDBsum; 2UVM; -. DR PDBsum; 2UZR; -. DR PDBsum; 2UZS; -. DR PDBsum; 3CQU; -. DR PDBsum; 3CQW; -. DR PDBsum; 3MV5; -. DR PDBsum; 3MVH; -. DR PDBsum; 3O96; -. DR PDBsum; 3OCB; -. DR PDBsum; 3OW4; -. DR PDBsum; 3QKK; -. DR PDBsum; 3QKL; -. DR PDBsum; 3QKM; -. DR PDBsum; 4EJN; -. DR PDBsum; 4EKK; -. DR PDBsum; 4EKL; -. DR PDBsum; 4GV1; -. DR PDBsum; 5KCV; -. DR PDBsum; 6BUU; -. DR PDBsum; 6CCY; -. DR PDBsum; 6HHF; -. DR PDBsum; 6HHG; -. DR PDBsum; 6HHH; -. DR PDBsum; 6HHI; -. DR PDBsum; 6HHJ; -. DR PDBsum; 6NPZ; -. DR PDBsum; 6S9W; -. DR PDBsum; 6S9X; -. DR PDBsum; 7APJ; -. DR PDBsum; 7MYX; -. DR PDBsum; 7NH4; -. DR PDBsum; 7NH5; -. DR PDBsum; 8JOW; -. DR PDBsum; 8UVY; -. DR PDBsum; 8UW2; -. DR PDBsum; 8UW7; -. DR PDBsum; 8UW9; -. DR PDBsum; 8ZPU; -. DR AlphaFoldDB; P31749; -. DR SMR; P31749; -. DR BioGRID; 106710; 600. DR CORUM; P31749; -. DR DIP; DIP-24269N; -. DR ELM; P31749; -. DR FunCoup; P31749; 3098. DR IntAct; P31749; 602. DR MINT; P31749; -. DR STRING; 9606.ENSP00000451828; -. DR BindingDB; P31749; -. DR ChEMBL; CHEMBL4282; -. DR DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE. DR DrugBank; DB07585; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. DR DrugBank; DB08568; A-674563. DR DrugBank; DB11648; Afuresertib. DR DrugBank; DB05971; Archexin. DR DrugBank; DB01169; Arsenic trioxide. DR DrugBank; DB00171; ATP. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12218; Capivasertib. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB12795; CMX-2043. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01645; Genistein. DR DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate. DR DrugBank; DB11743; Ipatasertib. DR DrugBank; DB15431; M-2698. DR DrugBank; DB14982; Miransertib. DR DrugBank; DB07584; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB02709; Resveratrol. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugCentral; P31749; -. DR GuidetoPHARMACOLOGY; 1479; -. DR TCDB; 8.A.104.1.10; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; P31749; 6 sites, 1 glycan. DR GlyGen; P31749; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; P31749; -. DR MetOSite; P31749; -. DR PhosphoSitePlus; P31749; -. DR BioMuta; AKT1; -. DR DMDM; 60391226; -. DR CPTAC; CPTAC-3162; -. DR CPTAC; CPTAC-3163; -. DR CPTAC; CPTAC-3164; -. DR CPTAC; CPTAC-3165; -. DR CPTAC; CPTAC-3166; -. DR CPTAC; CPTAC-3167; -. DR CPTAC; CPTAC-5758; -. DR CPTAC; CPTAC-5759; -. DR CPTAC; CPTAC-5805; -. DR CPTAC; CPTAC-5806; -. DR CPTAC; CPTAC-5807; -. DR CPTAC; CPTAC-5808; -. DR CPTAC; CPTAC-783; -. DR CPTAC; CPTAC-784; -. DR CPTAC; non-CPTAC-5328; -. DR CPTAC; non-CPTAC-5329; -. DR CPTAC; non-CPTAC-5332; -. DR CPTAC; non-CPTAC-5527; -. DR CPTAC; non-CPTAC-5528; -. DR CPTAC; non-CPTAC-5719; -. DR CPTAC; non-CPTAC-5720; -. DR jPOST; P31749; -. DR MassIVE; P31749; -. DR PaxDb; 9606-ENSP00000451828; -. DR PeptideAtlas; P31749; -. DR ProteomicsDB; 54800; -. [P31749-1] DR ProteomicsDB; 6712; -. DR Pumba; P31749; -. DR ABCD; P31749; 12 sequenced antibodies. DR Antibodypedia; 135; 5291 antibodies from 58 providers. DR CPTC; P31749; 6 antibodies. DR DNASU; 207; -. DR Ensembl; ENST00000349310.7; ENSP00000270202.4; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000402615.6; ENSP00000385326.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000407796.7; ENSP00000384293.2; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554581.5; ENSP00000451828.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000554848.5; ENSP00000451166.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000555528.5; ENSP00000450688.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000649815.2; ENSP00000497822.1; ENSG00000142208.20. [P31749-1] DR Ensembl; ENST00000683722.1; ENSP00000507879.1; ENSG00000142208.20. [P31749-1] DR GeneID; 207; -. DR KEGG; hsa:207; -. DR MANE-Select; ENST00000649815.2; ENSP00000497822.1; NM_001382430.1; NP_001369359.1. DR UCSC; uc001ypk.4; human. [P31749-1] DR AGR; HGNC:391; -. DR CIViC; 207; 18 evidence items across 19 molecular profiles. DR ClinPGx; PA24684; -. DR CTD; 207; -. DR DisGeNET; 207; -. DR GeneCards; AKT1; -. DR GeneReviews; AKT1; -. DR HGNC; HGNC:391; AKT1. DR HPA; ENSG00000142208; Low tissue specificity. DR MalaCards; AKT1; -. DR MIM; 114480; phenotype. DR MIM; 114500; phenotype. DR MIM; 164730; gene. DR MIM; 176920; phenotype. DR MIM; 615109; phenotype. DR OpenTargets; ENSG00000142208; -. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 2495; Meningioma. DR Orphanet; 744; Proteus syndrome. DR VEuPathDB; HostDB:ENSG00000142208; -. DR eggNOG; KOG0690; Eukaryota. DR GeneTree; ENSGT00940000158752; -. DR HOGENOM; CLU_000288_11_0_1; -. DR InParanoid; P31749; -. DR OMA; MDMEIYL; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P31749; 3 GO annotations based on evolutionary models. DR PhylomeDB; P31749; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P31749; -. DR Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol. DR Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-203615; eNOS activation. DR Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A. DR Reactome; R-HSA-354192; Integrin signaling. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma. DR Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9604323; Negative regulation of NOTCH4 signaling. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt). DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856532; Mechanical load activates signaling by PIEZO1 and integrins in osteocytes. DR SABIO-RK; P31749; -. DR SignaLink; P31749; -. DR SIGNOR; P31749; -. DR Agora; ENSG00000142208; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 207; 54 hits in 1212 CRISPR screens. DR ChiTaRS; AKT1; human. DR EvolutionaryTrace; P31749; -. DR GeneWiki; AKT1; -. DR GenomeRNAi; 207; -. DR Pharos; P31749; Tchem. DR PRO; PR:P31749; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P31749; protein. DR Bgee; ENSG00000142208; Expressed in stromal cell of endometrium and 189 other cell types or tissues. DR ExpressionAtlas; P31749; baseline and differential. DR GO; GO:0005938; C:cell cortex; NAS:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; NAS:BHF-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProt. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005758; C:mitochondrial intermembrane space; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0033011; C:perinuclear theca; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; IPI:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL. DR GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB. DR GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0099104; F:potassium channel activator activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; TAS:Reactome. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:1904841; F:TORC2 complex binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IEA:Ensembl. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0160213; P:beta-arrestin-dependent dopamine receptor signaling pathway; NAS:ParkinsonsUK-UCL. DR GO; GO:0030154; P:cell differentiation; TAS:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0036294; P:cellular response to decreased oxygen levels; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB. DR GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProtKB. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB. DR GO; GO:0140052; P:cellular response to oxidised low-density lipoprotein particle stimulus; IMP:BHF-UCL. DR GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl. DR GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl. DR GO; GO:0072752; P:cellular response to rapamycin; ISS:UniProt. DR GO; GO:0033554; P:cellular response to stress; TAS:Reactome. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IEA:Ensembl. DR GO; GO:0002430; P:complement receptor mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl. DR GO; GO:0010761; P:fibroblast migration; NAS:BHF-UCL. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW. DR GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0035655; P:interleukin-18-mediated signaling pathway; IDA:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:MGI. DR GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0022605; P:mammalian oogenesis stage; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB. DR GO; GO:0001893; P:maternal placenta development; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:BHF-UCL. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:1902018; P:negative regulation of cilium assembly; IDA:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IMP:BHF-UCL. DR GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL. DR GO; GO:2000402; P:negative regulation of lymphocyte migration; IMP:BHF-UCL. DR GO; GO:0016242; P:negative regulation of macroautophagy; NAS:ParkinsonsUK-UCL. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; TAS:Reactome. DR GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:BHF-UCL. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; ISS:UniProt. DR GO; GO:0150033; P:negative regulation of protein localization to lysosome; IDA:UniProtKB. DR GO; GO:1903318; P:negative regulation of protein maturation; ISS:UniProt. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:ARUK-UCL. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL. DR GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc. DR GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IDA:UniProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:1905786; P:positive regulation of anaphase-promoting complex-dependent catabolic process; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProt. DR GO; GO:0046326; P:positive regulation of D-glucose import; IMP:BHF-UCL. DR GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IDA:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:UniProtKB. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1905552; P:positive regulation of protein localization to endoplasmic reticulum; IDA:UniProt. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:BHF-UCL. DR GO; GO:0051247; P:positive regulation of protein metabolic process; ISS:BHF-UCL. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:0010765; P:positive regulation of sodium ion transport; IEA:Ensembl. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0005979; P:regulation of glycogen biosynthetic process; IMP:BHF-UCL. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW. DR GO; GO:0110002; P:regulation of tRNA methylation; IDA:UniProt. DR GO; GO:2000074; P:regulation of type B pancreatic cell development; TAS:Reactome. DR GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL. DR GO; GO:0032094; P:response to food; IEA:Ensembl. DR GO; GO:0070848; P:response to growth factor; IDA:UniProtKB. DR GO; GO:0060416; P:response to growth hormone; ISS:AgBase. DR GO; GO:0009408; P:response to heat; TAS:ProtInc. DR GO; GO:1990418; P:response to insulin-like growth factor stimulus; ISS:AgBase. DR GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0031929; P:TOR signaling; NAS:ParkinsonsUK-UCL. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR CDD; cd01241; PH_PKB; 1. DR CDD; cd05594; STKc_PKB_alpha; 1. DR DisProt; DP03300; -. DR FunFam; 1.10.510.10:FF:000033; Non-specific serine/threonine protein kinase; 1. DR FunFam; 2.30.29.30:FF:000027; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000838; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00412; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034676; Akt1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR039026; PH_PKB. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein; KW Disease variant; Disulfide bond; Glucose metabolism; Glycogen biosynthesis; KW Glycogen metabolism; Glycoprotein; Isopeptide bond; Kinase; Membrane; KW Mitochondrion; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Sugar transport; Transferase; KW Translation regulation; Transport; Ubl conjugation. FT CHAIN 1..480 FT /note="RAC-alpha serine/threonine-protein kinase" FT /id="PRO_0000085605" FT DOMAIN 5..108 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 150..408 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 409..480 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 113..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 450..480 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 274 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 14..19 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 23..25 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 53 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 86 FT /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate" FT /ligand_id="ChEBI:CHEBI:57895" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:12964941" FT BINDING 156..164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 462 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250|UniProtKB:P31750" FT MOD_RES 14 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 20 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21775285" FT MOD_RES 124 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 126 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 129 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 176 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:20333297" FT MOD_RES 308 FT /note="Phosphothreonine; by IKKE, PDPK1 and TBK1" FT /evidence="ECO:0000269|PubMed:15718470, FT ECO:0000269|PubMed:18456494, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20481595, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:40285646, ECO:0000269|PubMed:8978681, FT ECO:0000269|PubMed:9512493" FT MOD_RES 448 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 450 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 473 FT /note="Phosphoserine; by IKKE, MTOR, PRKDC and TBK1; FT alternate" FT /evidence="ECO:0000269|PubMed:14761976, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15262962, FT ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:16266983, FT ECO:0000269|PubMed:17013611, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20978158, ECO:0000269|PubMed:21464307, FT ECO:0000269|PubMed:23799035, ECO:0000269|PubMed:40285646, FT ECO:0000269|PubMed:8978681, ECO:0000269|PubMed:9736715" FT MOD_RES 474 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:12149249" FT MOD_RES 477 FT /note="Phosphoserine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT MOD_RES 479 FT /note="Phosphothreonine; by CDK2 and MTOR" FT /evidence="ECO:0000269|PubMed:24670654" FT CARBOHYD 126 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 129 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 305 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 312 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:22629392" FT CARBOHYD 473 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000250|UniProtKB:P31750" FT DISULFID 60..77 FT /evidence="ECO:0000269|PubMed:20886116" FT DISULFID 296..310 FT /evidence="ECO:0000250|UniProtKB:P31751" FT CROSSLNK 284 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22410793" FT VAR_SEQ 1..62 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056180" FT VARIANT 17 FT /note="E -> K (in PROTEUSS and breast cancer; also detected FT in colorectal and ovarian cancer; somatic mutation; results FT in increased phosphorylation at T-308 and higher basal FT ubiquitination; the mutant protein is more efficiently FT recruited to the plasma membrane; alters FT phosphatidylinositiol phosphates lipid specificity of the FT AKT1 PH domain; dbSNP:rs121434592)" FT /evidence="ECO:0000269|PubMed:17611497, FT ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527, FT ECO:0000269|PubMed:21793738" FT /id="VAR_055422" FT VARIANT 25 FT /note="R -> C (in CWS6; impairs interaction with FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2; dbSNP:rs397514644)" FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:23246288" FT /id="VAR_069791" FT VARIANT 167 FT /note="V -> A (in dbSNP:rs11555433)" FT /id="VAR_051617" FT VARIANT 435 FT /note="T -> P (in CWS6; dbSNP:rs397514645)" FT /evidence="ECO:0000269|PubMed:23246288" FT /id="VAR_069792" FT MUTAGEN 8 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation as well FT as IGF1-induced membrane recruitment. Decrease in FT ubiquitination and phosphorylation at T-308 as well as FT impaired association with the membrane; when associated FT with K-17." FT /evidence="ECO:0000269|PubMed:19713527" FT MUTAGEN 14 FT /note="K->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, loss of AKT activation, and loss of binding FT to PIP3 as well as IGF1-induced membrane recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 14 FT /note="K->R: Substantial reduction of ubiquitination, FT phosphorylation at T-308 and S-473, AKT activation, loss of FT binding to PIP3 as well as IGF1-induced membrane FT recruitment." FT /evidence="ECO:0000269|PubMed:12176338, FT ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285" FT MUTAGEN 17 FT /note="E->K: Loss of membrane localization; when associated FT with Q-20." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->Q: Substantial reduction of phosphorylation at T- FT 308 and S-473, reduced AKT activation, and reduced binding FT to PIP3 as well as IGF1-induced membrane recruitment. Loss FT of membrane localization; when associated with K-17." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 20 FT /note="K->R: Slight increase of phosphorylation at T-308 FT and S-473." FT /evidence="ECO:0000269|PubMed:21775285" FT MUTAGEN 25 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 76..78 FT /note="RCL->ACA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 86 FT /note="R->A: Impairs interaction with PtdIns(3,4,5)P3 and FT PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:12176338" FT MUTAGEN 176 FT /note="Y->F: Significant loss of interaction with TNK2. FT Loss of membrane localization. Significant reduction in FT phosphorylation on Ser-473." FT /evidence="ECO:0000269|PubMed:20333297" FT MUTAGEN 179 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:12172553, FT ECO:0000269|PubMed:33594058" FT MUTAGEN 273..275 FT /note="RDL->ADA: Abolished binding to cyclin-A, preventing FT phosphorylation by CDK2." FT /evidence="ECO:0000269|PubMed:24670654" FT MUTAGEN 305 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-312." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 305 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 308 FT /note="T->D: 5-fold activation and 18-fold activation; when FT associated with D-473." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 312 FT /note="T->A: Reduces O-GlcNAc levels; Reduces O-GlcNAc FT levels even more; when associated with A-305." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 312 FT /note="T->Y: Abolishes phosphorylation at Thr-308." FT /evidence="ECO:0000269|PubMed:22629392" FT MUTAGEN 473 FT /note="S->D: 7-fold activation and 25-fold activation; when FT associated with D-308." FT /evidence="ECO:0000269|PubMed:12244301, FT ECO:0000269|PubMed:8978681" FT MUTAGEN 474 FT /note="Y->F: 55% inhibition of activation." FT /evidence="ECO:0000269|PubMed:12149249" FT CONFLICT 173..174 FT /note="GR -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="L -> Q (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 212 FT /note="A -> R (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 246 FT /note="S -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 409 FT /note="A -> T (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="A -> P (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> A (in Ref. 7; CAA43372)" FT /evidence="ECO:0000305" FT CONFLICT 478 FT /note="G -> S (in Ref. 1; AAA36539, 2; AAL55732, 3; FT BAG36922 and 4; BAG70056/BAG70181)" FT /evidence="ECO:0000305" FT HELIX 2..4 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 6..15 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 22..30 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 33..40 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:7APJ" FT HELIX 45..48 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 67..69 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 72..79 FT /evidence="ECO:0007829|PDB:1UNQ" FT STRAND 82..89 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:1UNQ" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 150..158 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 160..169 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 170..172 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 175..182 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 183..188 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 213..218 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 235..242 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 247..268 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:4EJN" FT STRAND 288..290 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:3MVH" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 318..322 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 330..344 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 374..383 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:4GV1" FT TURN 396..398 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 399..403 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 406..408 FT /evidence="ECO:0007829|PDB:4GV1" FT HELIX 413..417 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:3MVH" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:7NH5" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:4GV1" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:4GV1" SQ SEQUENCE 480 AA; 55686 MW; 6EAFF4F8AD436714 CRC64; MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA // ID ANDR_HUMAN Reviewed; 920 AA. AC P10275; A0A0B4J1T2; A2RUN2; B1AKD7; C0JKD3; C0JKD4; E7EVX6; Q9UD95; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 16-MAR-2016, sequence version 3. DT 28-JAN-2026, entry version 308. DE RecName: Full=Androgen receptor; DE AltName: Full=Dihydrotestosterone receptor; DE AltName: Full=Nuclear receptor subfamily 3 group C member 4; GN Name=AR; Synonyms=DHTR, NR3C4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3216866; DOI=10.1210/mend-2-12-1265; RA Lubahn D.B., Joseph D.R., Sar M., Tan J., Higgs H.N., Larson R.E., RA French F.S., Wilson E.M.; RT "The human androgen receptor: complementary deoxyribonucleic acid cloning, RT sequence analysis and gene expression in prostate."; RL Mol. Endocrinol. 2:1265-1275(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=3174628; DOI=10.1073/pnas.85.19.7211; RA Chang C., Kokontis J., Liao S.; RT "Structural analysis of complementary DNA and amino acid sequences of human RT and rat androgen receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 85:7211-7215(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Prostate; RX PubMed=2911578; DOI=10.1073/pnas.86.1.327; RA Tilley W.D., Marcelli M., Wilson J.D., McPhaul M.J.; RT "Characterization and expression of a cDNA encoding the human androgen RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 86:327-331(1989). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT AIS MET-867. RX PubMed=2594783; DOI=10.1073/pnas.86.23.9534; RA Lubahn D.B., Brown T.R., Simental J.A., Higgs H.N., Migeon C.J., RA Wilson E.M., French F.S.; RT "Sequence of the intron/exon junctions of the coding region of the human RT androgen receptor gene and identification of a point mutation in a family RT with complete androgen insensitivity."; RL Proc. Natl. Acad. Sci. U.S.A. 86:9534-9538(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=2342476; DOI=10.1210/mend-4-3-417; RA Govindan M.V.; RT "Specific region in hormone binding domain is essential for hormone binding RT and trans-activation by human androgen receptor."; RL Mol. Endocrinol. 4:417-427(1990). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RP 1). RC TISSUE=Prostate; RX PubMed=2293020; DOI=10.1210/mend-4-8-1105; RA Marcelli M., Tilley W.D., Wilson C.M., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Definition of the human androgen receptor gene structure permits the RT identification of mutations that cause androgen resistance: premature RT termination of the receptor protein at amino acid residue 588 causes RT complete androgen resistance."; RL Mol. Endocrinol. 4:1105-1116(1990). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), TISSUE RP SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15634333; DOI=10.1111/j.1742-4658.2004.04395.x; RA Ahrens-Fath I., Politz O., Geserick C., Haendler B.; RT "Androgen receptor function is modulated by the tissue-specific AR45 RT variant."; RL FEBS J. 272:74-84(2005). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), VARIANT GLN-57, FUNCTION RP (ISOFORMS 3 AND 4), AND SUBCELLULAR LOCATION (ISOFORM 3). RX PubMed=19244107; DOI=10.1158/0008-5472.can-08-3795; RA Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., RA Melamed J., Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y.; RT "A novel androgen receptor splice variant is up-regulated during prostate RT cancer progression and promotes androgen depletion-resistant growth."; RL Cancer Res. 69:2305-2313(2009). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-539. RX PubMed=2917688; DOI=10.1016/0303-7207(89)90137-8; RA Faber P.W., Kuiper G.G.J.M., van Rooij H.C.J., van der Korput J.A.G.M., RA Brinkmann A.O., Trapman J.; RT "The N-terminal domain of the human androgen receptor is encoded by one, RT large exon."; RL Mol. Cell. Endocrinol. 61:257-262(1989). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 191-920 (ISOFORM 1). RX PubMed=3353726; DOI=10.1126/science.3353726; RA Chang C., Kokontis J., Liao S.; RT "Molecular cloning of human and rat complementary DNA encoding androgen RT receptors."; RL Science 240:324-326(1988). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 448-476. RC TISSUE=Blood; RA Lu J., Danielsen M.; RL Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 470-920 (ISOFORM 1). RX PubMed=3377788; DOI=10.1016/s0006-291x(88)81214-2; RA Trapman J., Klaassen P., Kuiper G.G.J.M., van der Korput J.A.G.M., RA Faber P.W., van Rooij H.C.J., Geurts van Kessel A., Voorhorst M.M., RA Mulder E., Brinkmann A.O.; RT "Cloning, structure and expression of a cDNA encoding the human androgen RT receptor."; RL Biochem. Biophys. Res. Commun. 153:241-248(1988). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 537-541; 587-591; 626-630; 722-726; RP 770-774; 814-817 AND 866-870. RX PubMed=2546571; DOI=10.1677/jme.0.002r001; RA Kuiper G.G., Faber P.W., van Rooij H.C., van der Korput J.A., RA Ris-Stalpers C., Klaassen P., Trapman J., Brinkmann A.O.; RT "Structural organization of the human androgen receptor gene."; RL J. Mol. Endocrinol. 2:R1-R4(1989). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 558-625 (ISOFORMS 1/2), AND VARIANT AIS RP HIS-616. RC TISSUE=Fibroblast; RX PubMed=8413310; DOI=10.1210/mend.7.7.8413310; RA Mowszowicz I., Lee H.-J., Chen H.-T., Mestayer C., Portois M.-C., RA Cabrol S., Mauvais-Jarvis P., Chang C.; RT "A point mutation in the second zinc finger of the DNA-binding domain of RT the androgen receptor gene causes complete androgen insensitivity in two RT siblings with receptor-positive androgen resistance."; RL Mol. Endocrinol. 7:861-869(1993). RN [18] RP NUCLEOTIDE SEQUENCE [MRNA] OF 560-625 (ISOFORMS 1/2). RX PubMed=3353727; DOI=10.1126/science.3353727; RA Lubahn D.B., Joseph D.R., Sullivan P.M., Willard H.F., French F.S., RA Wilson E.M.; RT "Cloning of human androgen receptor complementary DNA and localization to RT the X chromosome."; RL Science 240:327-330(1988). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 630-724, AND VARIANTS AIS ASN-696 AND RP HIS-696. RX PubMed=1775137; DOI=10.1210/mend-5-10-1562; RA Ris-Stalpers C., Trifiro M.A., Kuiper G.G.J.M., Jenster G., Romalo G., RA Sai T., van Rooij H.C.J., Kaufman M., Rosenfield R.L., Liao S., RA Schweikert H.-U., Trapman J., Pinsky L., Brinkmann A.O.; RT "Substitution of aspartic acid-686 by histidine or asparagine in the human RT androgen receptor leads to a functionally inactive protein with altered RT hormone-binding characteristics."; RL Mol. Endocrinol. 5:1562-1569(1991). RN [20] RP POLYMORPHISM OF POLY-GLN REGION. RX PubMed=1561105; DOI=10.1093/nar/20.6.1427-a; RA Sleddens H.F.B.M., Oostra B.A., Brinkmann A.O., Trapman J.; RT "Trinucleotide repeat polymorphism in the androgen receptor gene (AR)."; RL Nucleic Acids Res. 20:1427-1427(1992). RN [21] RP INTERACTION WITH NCOA4. RC TISSUE=Prostatic carcinoma; RX PubMed=8643607; DOI=10.1073/pnas.93.11.5517; RA Yeh S., Chang C.; RT "Cloning and characterization of a specific coactivator, ARA70, for the RT androgen receptor in human prostate cells."; RL Proc. Natl. Acad. Sci. U.S.A. 93:5517-5521(1996). RN [22] RP POLYMORPHISM OF POLY-GLN REGION. RX PubMed=9096391; DOI=10.1073/pnas.94.7.3320; RA Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., RA Talcott J., Hennekens C.H., Kantoff P.W.; RT "The CAG repeat within the androgen receptor gene and its relationship to RT prostate cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 94:3320-3323(1997). RN [23] RP ERRATUM OF PUBMED:9096391. RA Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., RA Talcott J., Hennekens C.H., Kantoff P.W.; RL Proc. Natl. Acad. Sci. U.S.A. 94:8272-8272(1997). RN [24] RP INTERACTION WITH PQBP1. RC TISSUE=Brain; RX PubMed=10332029; DOI=10.1093/hmg/8.6.977; RA Waragai M., Lammers C.-H., Takeuchi S., Imafuku I., Udagawa Y., RA Kanazawa I., Kawabata M., Mouradian M.M., Okazawa H.; RT "PQBP-1, a novel polyglutamine tract binding protein, inhibits RT transcription activation by Brn-2 and affects cell survival."; RL Hum. Mol. Genet. 8:977-987(1999). RN [25] RP INTERACTION WITH TGFB1I1. RX PubMed=10075738; DOI=10.1074/jbc.274.12.8316; RA Fujimoto N., Yeh S., Kang H.-Y., Inui S., Chang H.-C., Mizokami A., RA Chang C.; RT "Cloning and characterization of androgen receptor coactivator, ARA55, in RT human prostate."; RL J. Biol. Chem. 274:8316-8321(1999). RN [26] RP INTERACTION WITH UBE2I. RX PubMed=10383460; DOI=10.1074/jbc.274.27.19441; RA Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Jaenne O.A.; RT "Ubc9 interacts with the androgen receptor and activates receptor-dependent RT transcription."; RL J. Biol. Chem. 274:19441-19446(1999). RN [27] RP INTERACTION WITH RAN. RX PubMed=10400640; DOI=10.1074/jbc.274.29.20229; RA Hsiao P.-W., Lin D.-L., Nakao R., Chang C.; RT "The linkage of Kennedy's neuron disease to ARA24, the first identified RT androgen receptor polyglutamine region-associated coactivator."; RL J. Biol. Chem. 274:20229-20234(1999). RN [28] RP INTERACTION WITH SPDEF. RX PubMed=10625666; DOI=10.1074/jbc.275.2.1216; RA Oettgen P., Finger E., Sun Z., Akbarali Y., Thamrongsak U., Boltax J., RA Grall F., Dube A., Weiss A., Brown L., Quinn G., Kas K., Endress G., RA Kunsch C., Libermann T.A.; RT "PDEF, a novel prostate epithelium-specific ets transcription factor, RT interacts with the androgen receptor and activates prostate-specific RT antigen gene expression."; RL J. Biol. Chem. 275:1216-1225(2000). RN [29] RP INTERACTION WITH KAT7. RX PubMed=10930412; DOI=10.1074/jbc.m004838200; RA Sharma M., Zarnegar M., Li X., Lim B., Sun Z.; RT "Androgen receptor interacts with a novel MYST protein, HBO1."; RL J. Biol. Chem. 275:35200-35208(2000). RN [30] RP SUMOYLATION AT LYS-388 AND LYS-521. RX PubMed=11121022; DOI=10.1073/pnas.97.26.14145; RA Poukka H., Karvonen U., Jaenne O.A., Palvimo J.J.; RT "Covalent modification of the androgen receptor by small ubiquitin-like RT modifier 1 (SUMO-1)."; RL Proc. Natl. Acad. Sci. U.S.A. 97:14145-14150(2000). RN [31] RP INTERACTION WITH RANBP9. RX PubMed=12361945; DOI=10.1074/jbc.m209741200; RA Rao M.A., Cheng H., Quayle A.N., Nishitani H., Nelson C.C., Rennie P.S.; RT "RanBPM, a nuclear protein that interacts with and regulates RT transcriptional activity of androgen receptor and glucocorticoid RT receptor."; RL J. Biol. Chem. 277:48020-48027(2002). RN [32] RP INTERACTION WITH PRPF6. RX PubMed=12039962; DOI=10.1074/jbc.m203811200; RA Zhao Y., Goto K., Saitoh M., Yanase T., Nomura M., Okabe T., Takayanagi R., RA Nawata H.; RT "Activation function-1 domain of androgen receptor contributes to the RT interaction between subnuclear splicing factor compartment and nuclear RT receptor compartment. Identification of the p102 U5 small nuclear RT ribonucleoprotein particle-binding protein as a coactivator for the RT receptor."; RL J. Biol. Chem. 277:30031-30039(2002). RN [33] RP RETRACTED PAPER. RX PubMed=12415108; DOI=10.1073/pnas.192569699; RA Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.; RT "Estrogen receptor-interacting protein that modulates its nongenomic RT activity-crosstalk with Src/Erk phosphorylation cascade."; RL Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002). RN [34] RP RETRACTION NOTICE OF PUBMED:12415108. RX PubMed=19666546; DOI=10.1073/pnas.0908685106; RA Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.; RL Proc. Natl. Acad. Sci. U.S.A. 106:14180-14180(2009). RN [35] RP INTERACTION WITH ZMIZ1. RX PubMed=14609956; DOI=10.1093/emboj/cdg585; RA Sharma M., Li X., Wang Y., Zarnegar M., Huang C.-Y., Palvimo J.J., Lim B., RA Sun Z.; RT "hZimp10 is an androgen receptor co-activator and forms a complex with RT SUMO-1 at replication foci."; RL EMBO J. 22:6101-6114(2003). RN [36] RP INTERACTION WITH RACK1, AND SUBCELLULAR LOCATION. RX PubMed=12958311; DOI=10.1074/jbc.m306219200; RA Rigas A.C., Ozanne D.M., Neal D.E., Robson C.N.; RT "The scaffolding protein RACK1 interacts with androgen receptor and RT promotes cross-talk through a protein kinase C signaling pathway."; RL J. Biol. Chem. 278:46087-46093(2003). RN [37] RP FUNCTION, AND INTERACTION WITH RBAK. RX PubMed=14664718; DOI=10.1677/jme.0.0310583; RA Hofman K., Swinnen J.V., Claessens F., Verhoeven G., Heyns W.; RT "The retinoblastoma protein-associated transcription repressor RBaK RT interacts with the androgen receptor and enhances its transcriptional RT activity."; RL J. Mol. Endocrinol. 31:583-596(2003). RN [38] RP INTERACTION WITH EFCAB6. RX PubMed=12612053; RA Niki T., Takahashi-Niki K., Taira T., Iguchi-Ariga S.M.M., Ariga H.; RT "DJBP: a novel DJ-1-binding protein, negatively regulates the androgen RT receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes RT this inhibition by abrogation of this complex."; RL Mol. Cancer Res. 1:247-261(2003). RN [39] RP PHOSPHORYLATION BY PAK6. RX PubMed=14573606; DOI=10.1074/jbc.m311145200; RA Schrantz N., da Silva Correia J., Fowler B., Ge Q., Sun Z., Bokoch G.M.; RT "Mechanism of p21-activated kinase 6-mediated inhibition of androgen RT receptor signaling."; RL J. Biol. Chem. 279:1922-1931(2004). RN [40] RP INTERACTION WITH HIP1. RX PubMed=16027218; DOI=10.1083/jcb.200503106; RA Mills I.G., Gaughan L., Robson C., Ross T., McCracken S., Kelly J., RA Neal D.E.; RT "Huntingtin interacting protein 1 modulates the transcriptional activity of RT nuclear hormone receptors."; RL J. Cell Biol. 170:191-200(2005). RN [41] RP INTERACTION WITH ZMIZ2. RX PubMed=16051670; DOI=10.1210/me.2005-0097; RA Huang C.-Y., Beliakoff J., Li X., Lee J., Li X., Sharma M., Lim B., Sun Z.; RT "hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated RT transcription and interacts with SWI/SNF-like BAF complexes."; RL Mol. Endocrinol. 19:2915-2929(2005). RN [42] RP PHOSPHORYLATION AT TYR-225; TYR-269; TYR-309; TYR-348; TYR-359; TYR-364; RP TYR-365; TYR-395; TYR-535; TYR-552 AND TYR-916, MUTAGENESIS OF TYR-225; RP TYR-269; TYR-309; TYR-348; TYR-359; TYR-364; TYR-365; TYR-395; TYR-535; RP TYR-552 AND TYR-916, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=17045208; DOI=10.1016/j.ccr.2006.08.021; RA Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., Nesheiwat I., Kong X., RA Melamed J., Handratta V.D., Njar V.C., Brodie A.M., Yu L.-R., RA Veenstra T.D., Chen H., Qiu Y.; RT "Regulation of androgen receptor activity by tyrosine phosphorylation."; RL Cancer Cell 10:309-319(2006). RN [43] RP ERRATUM OF PUBMED:17045208. RA Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., Nesheiwat I., Kong X., RA Melamed J., Handratta V.D., Njar V.C., Brodie A.M., Yu L.-R., RA Veenstra T.D., Chen H., Qiu Y.; RL Cancer Cell 11:97-97(2007). RN [44] RP INTERACTION WITH MAK, AND SUBUNIT. RX PubMed=16951154; DOI=10.1158/0008-5472.can-06-1636; RA Ma A.H., Xia L., Desai S.J., Boucher D.L., Guan Y., Shih H.M., Shi X.B., RA deVere White R.W., Chen H.W., Tepper C.G., Kung H.J.; RT "Male germ cell-associated kinase, a male-specific kinase regulated by RT androgen, is a coactivator of androgen receptor in prostate cancer cells."; RL Cancer Res. 66:8439-8447(2006). RN [45] RP INTERACTION WITH PRMT2, AND SUBCELLULAR LOCATION. RX PubMed=17587566; DOI=10.1016/j.jsbmb.2007.05.006; RA Meyer R., Wolf S.S., Obendorf M.; RT "PRMT2, a member of the protein arginine methyltransferase family, is a RT coactivator of the androgen receptor."; RL J. Steroid Biochem. Mol. Biol. 107:1-14(2007). RN [46] RP INTERACTION WITH RREB1. RX PubMed=17550981; DOI=10.1210/me.2006-0503; RA Mukhopadhyay N.K., Cinar B., Mukhopadhyay L., Lutchman M., Ferdinand A.S., RA Kim J., Chung L.W.K., Adam R.M., Ray S.K., Leiter A.B., Richie J.P., RA Liu B.C.-S., Freeman M.R.; RT "The zinc finger protein Ras-responsive element binding protein-1 is a RT coregulator of the androgen receptor: implications for the role of the Ras RT pathway in enhancing androgenic signaling in prostate cancer."; RL Mol. Endocrinol. 21:2056-2070(2007). RN [47] RP INTERACTION WITH RANBP10. RX PubMed=18222118; DOI=10.1016/j.bbrc.2008.01.072; RA Harada N., Yokoyama T., Yamaji R., Nakano Y., Inui H.; RT "RanBP10 acts as a novel coactivator for the androgen receptor."; RL Biochem. Biophys. Res. Commun. 368:121-125(2008). RN [48] RP INTERACTION WITH TNK2, PHOSPHORYLATION AT TYR-269 AND TYR-365 BY TNK2, AND RP MUTAGENESIS OF TYR-269 AND TYR-365. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [49] RP INTERACTION WITH TRIM68. RX PubMed=18451177; DOI=10.1158/0008-5472.can-07-6059; RA Miyajima N., Maruyama S., Bohgaki M., Kano S., Shigemura M., Shinohara N., RA Nonomura K., Hatakeyama S.; RT "TRIM68 regulates ligand-dependent transcription of androgen receptor in RT prostate cancer cells."; RL Cancer Res. 68:3486-3494(2008). RN [50] RP INTERACTION WITH LPXN. RX PubMed=18451096; DOI=10.1210/me.2006-0546; RA Kaulfuss S., Grzmil M., Hemmerlein B., Thelen P., Schweyer S., Neesen J., RA Bubendorf L., Glass A.G., Jarry H., Auber B., Burfeind P.; RT "Leupaxin, a novel coactivator of the androgen receptor, is expressed in RT prostate cancer and plays a role in adhesion and invasion of prostate RT carcinoma cells."; RL Mol. Endocrinol. 22:1606-1621(2008). RN [51] RP FUNCTION, AND INTERACTION WITH ZIPK/DAPK3. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [52] RP INTERACTION WITH TRIM24. RX PubMed=19909775; DOI=10.1016/j.bbamcr.2009.11.001; RA Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N., Tanaka J., RA Imamura M., Hatakeyama S.; RT "TRIM24 mediates ligand-dependent activation of androgen receptor and is RT repressed by a bromodomain-containing protein, BRD7, in prostate cancer RT cells."; RL Biochim. Biophys. Acta 1793:1828-1836(2009). RN [53] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, POLYUBIQUITINATION AT RP LYS-846 AND LYS-848 BY RNF6, MUTAGENESIS OF LYS-846 AND LYS-848, RP INTERACTION WITH RNF14 AND RNF6, AND SUBCELLULAR LOCATION. RX PubMed=19345326; DOI=10.1016/j.ccr.2009.02.021; RA Xu K., Shimelis H., Linn D.E., Jiang R., Yang X., Sun F., Guo Z., Chen H., RA Li W., Chen H., Kong X., Melamed J., Fang S., Xiao Z., Veenstra T.D., RA Qiu Y.; RT "Regulation of androgen receptor transcriptional activity and specificity RT by RNF6-induced ubiquitination."; RL Cancer Cell 15:270-282(2009). RN [54] RP FUNCTION, AND INTERACTION WITH MACROD1. RX PubMed=19022849; DOI=10.1677/erc-08-0150; RA Yang J., Zhao Y.-L., Wu Z.-Q., Si Y.-L., Meng Y.G., Fu X.B., Mu Y.-M., RA Han W.-D.; RT "The single-macro domain protein LRP16 is an essential cofactor of androgen RT receptor."; RL Endocr. Relat. Cancer 16:139-153(2009). RN [55] RP FUNCTION IN AR KINASE, PHOSPHORYLATION AT SER-83 BY CDK9, MUTAGENESIS OF RP SER-83, AND INTERACTION WITH CDK9. RX PubMed=20980437; DOI=10.1210/me.2010-0238; RA Gordon V., Bhadel S., Wunderlich W., Zhang J., Ficarro S.B., Mollah S.A., RA Shabanowitz J., Hunt D.F., Xenarios I., Hahn W.C., Conaway M., Carey M.F., RA Gioeli D.; RT "CDK9 regulates AR promoter selectivity and cell growth through serine 81 RT phosphorylation."; RL Mol. Endocrinol. 24:2267-2280(2010). RN [56] RP UBIQUITINATION, DEUBIQUITINATION, AND INTERACTION WITH USP26. RX PubMed=20501646; DOI=10.1158/1541-7786.mcr-09-0424; RA Dirac A.M., Bernards R.; RT "The deubiquitinating enzyme USP26 is a regulator of androgen receptor RT signaling."; RL Mol. Cancer Res. 8:844-854(2010). RN [57] RP PHOSPHORYLATION AT TYR-269, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [58] RP PHOSPHORYLATION AT SER-651, AND INTERACTION WITH STK4/MST1. RX PubMed=21512132; DOI=10.1158/0008-5472.can-10-4532; RA Cinar B., Collak F.K., Lopez D., Akgul S., Mukhopadhyay N.K., RA Kilicarslan M., Gioeli D.G., Freeman M.R.; RT "MST1 is a multifunctional caspase-independent inhibitor of androgenic RT signaling."; RL Cancer Res. 71:4303-4313(2011). RN [59] RP FUNCTION, AND INTERACTION WITH NCOR1; NCOR2 AND ZBTB7A. RX PubMed=20812024; DOI=10.1007/s00018-010-0511-7; RA Cui J., Yang Y., Zhang C., Hu P., Kan W., Bai X., Liu X., Song H.; RT "FBI-1 functions as a novel AR co-repressor in prostate cancer cells."; RL Cell. Mol. Life Sci. 68:1091-1103(2011). RN [60] RP INTERACTION WITH CRY1. RX PubMed=22170608; DOI=10.1038/nature10700; RA Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W., RA Downes M., Evans R.M.; RT "Cryptochromes mediate rhythmic repression of the glucocorticoid RT receptor."; RL Nature 480:552-556(2011). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [62] RP PALMITOYLATION. RX PubMed=22031296; DOI=10.1091/mbc.e11-07-0638; RA Pedram A., Razandi M., Deschenes R.J., Levin E.R.; RT "DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors."; RL Mol. Biol. Cell 23:188-199(2012). RN [63] RP INTERACTION WITH RWDD1. RX PubMed=22406838; DOI=10.1016/j.mce.2012.02.020; RA Groetsch H., Kunert M., Mooslehner K.A., Gao Z., Struve D., Hughes I.A., RA Hiort O., Werner R.; RT "RWDD1 interacts with the ligand binding domain of the androgen receptor RT and acts as a coactivator of androgen-dependent transactivation."; RL Mol. Cell. Endocrinol. 358:53-62(2012). RN [64] RP INTERACTION WITH CCAR1 AND GATA2. RX PubMed=23887938; DOI=10.1093/nar/gkt644; RA Seo W.Y., Jeong B.C., Yu E.J., Kim H.J., Kim S.H., Lim J.E., Kwon G.Y., RA Lee H.M., Kim J.H.; RT "CCAR1 promotes chromatin loading of androgen receptor (AR) transcription RT complex by stabilizing the association between AR and GATA2."; RL Nucleic Acids Res. 41:8526-8536(2013). RN [65] RP INTERACTION WITH ARID4A. RX PubMed=23487765; DOI=10.1073/pnas.1218318110; RA Wu R.C., Jiang M., Beaudet A.L., Wu M.Y.; RT "ARID4A and ARID4B regulate male fertility, a functional link to the AR and RT RB pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 110:4616-4621(2013). RN [66] RP FUNCTIONAL CHARACTERIZATION OF ISOFORM 3. RX PubMed=25008967; DOI=10.1016/j.biocel.2014.06.013; RA Krause W.C., Shafi A.A., Nakka M., Weigel N.L.; RT "Androgen receptor and its splice variant, AR-V7, differentially regulate RT FOXA1 sensitive genes in LNCaP prostate cancer cells."; RL Int. J. Biochem. Cell Biol. 54:49-59(2014). RN [67] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96 AND SER-258, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 658-920. RX PubMed=10840043; DOI=10.1074/jbc.m004571200; RA Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., RA Otto N., Joschko S., Scholz P., Wegg A., Baesler S., Schaefer M., Egner U., RA Carrondo M.A.; RT "Structural evidence for ligand specificity in the binding domain of the RT human androgen receptor. Implications for pathogenic gene mutations."; RL J. Biol. Chem. 275:26164-26171(2000). RN [69] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 671-918. RX PubMed=11906285; DOI=10.1021/jm011072j; RA Matias P.M., Carrondo M.A., Coelho R., Thomaz M., Zhao X.Y., Wegg A., RA Crusius K., Egner U., Donner P.; RT "Structural basis for the glucocorticoid response in a mutant human RT androgen receptor (AR(ccr)) derived from an androgen-independent prostate RT cancer."; RL J. Med. Chem. 45:1439-1446(2002). RN [70] RP X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 672-920 IN COMPLEXES WITH RP N-TERMINAL MODULATING DOMAIN AND NCOA2, INTERACTION WITH NCOA1, AND RP CHARACTERIZATION OF VARIANT PROSTATE CANCER MET-731. RX PubMed=15525515; DOI=10.1016/j.molcel.2004.09.036; RA He B., Gampe R.T. Jr., Kole A.J., Hnat A.T., Stanley T.B., An G., RA Stewart E.L., Kalman R.I., Minges J.T., Wilson E.M.; RT "Structural basis for androgen receptor interdomain and coactivator RT interactions suggests a transition in nuclear receptor activation function RT dominance."; RL Mol. Cell 16:425-438(2004). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 670-920 IN COMPLEXES WITH RP DIHYDROTESTOSTERONE AND NCOA1; NCOA2; NCOA3 AND NCOA4, FUNCTION, RP INTERACTION WITH NCOA1; NCOA2; NCOA3 AND NCOA4, AND MUTAGENESIS OF LYS-721 RP AND GLU-898. RX PubMed=15563469; DOI=10.1074/jbc.m407046200; RA Estebanez-Perpina E., Moore J.M.R., Mar E., Delgado-Rodrigues E., RA Nguyen P., Baxter J.D., Buehrer B.M., Webb P., Fletterick R.J., Guy R.K.; RT "The molecular mechanisms of coactivator utilization in ligand-dependent RT transactivation by the androgen receptor."; RL J. Biol. Chem. 280:8060-8068(2005). RN [72] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 665-920 IN COMPLEXES WITH RP NONSTEROIDAL LIGANDS, MUTAGENESIS OF TRP-742, CHARACTERIZATION OF VARIANT RP PROSTATE CANCER ALA-878, AND CHARACTERIZATION OF VARIANT AIS THR-896. RX PubMed=16129672; DOI=10.1074/jbc.m507464200; RA Bohl C.E., Miller D.D., Chen J., Bell C.E., Dalton J.T.; RT "Structural basis for accommodation of nonsteroidal ligands in the androgen RT receptor."; RL J. Biol. Chem. 280:37747-37754(2005). RN [73] RP X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF 655-920 IN COMPLEXES WITH RP TESTOSTERONE; DIHYDROTESTOSTERONE AND TETRAHYDROGESTRINONE. RX PubMed=16641486; DOI=10.1110/ps.051905906; RA Pereira de Jesus-Tran K., Cote P.-L., Cantin L., Blanchet J., Labrie F., RA Breton R.; RT "Comparison of crystal structures of human androgen receptor ligand-binding RT domain complexed with various agonists reveals molecular determinants RT responsible for binding affinity."; RL Protein Sci. 15:987-999(2006). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 672-919 IN COMPLEX WITH NR0B2. RX PubMed=18007036; DOI=10.1107/s0907444907045702; RA Jouravel N., Sablin E., Arnold L.A., Guy R.K., Fletterick R.J.; RT "Interaction between the androgen receptor and a segment of its corepressor RT SHP."; RL Acta Crystallogr. D 63:1198-1200(2007). RN [75] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 671-919 OF MUTANT ALA-878 IN RP COMPLEX WITH THE ANTIANDROGEN CYPROTERONE ACETATE, CHARACTERIZATION OF RP VARIANT PROSTATE CANCER ALA-878, AND MUTAGENESIS OF LEU-702. RX PubMed=17311914; DOI=10.1074/jbc.m611711200; RA Bohl C.E., Wu Z., Miller D.D., Bell C.E., Dalton J.T.; RT "Crystal structure of the T877A human androgen receptor ligand-binding RT domain complexed to cyproterone acetate provides insight for ligand-induced RT conformational changes and structure-based drug design."; RL J. Biol. Chem. 282:13648-13655(2007). RN [76] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 663-919 OF WILD-TYPE AND MUTANT RP TYR-875 IN COMPLEX WITH TESTOSTERONE AND NCOA2, ACTIVATION BY THE RP N-TERMINAL MODULATING DOMAIN, INTERACTION WITH NCOA2 AND MAGEA11, FUNCTION, RP MUTAGENESIS OF LYS-721 AND GLU-898, AND CHARACTERIZATION OF VARIANT RP PROSTATE CANCER TYR-875. RX PubMed=17591767; DOI=10.1074/jbc.m703268200; RA Askew E.B., Gampe R.T. Jr., Stanley T.B., Faggart J.L., Wilson E.M.; RT "Modulation of androgen receptor activation function 2 by testosterone and RT dihydrotestosterone."; RL J. Biol. Chem. 282:25801-25816(2007). RN [77] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 655-920 IN COMPLEX WITH EM5744. RX PubMed=17711855; DOI=10.1074/jbc.m705524200; RA Cantin L., Faucher F., Couture J.-F., de Jesus-Tran K.P., Legrand P., RA Ciobanu L.C., Frechette Y., Labrecque R., Singh S.M., Labrie F., Breton R.; RT "Structural characterization of the human androgen receptor ligand-binding RT domain complexed with EM5744, a rationally designed steroidal ligand RT bearing a bulky chain directed toward helix 12."; RL J. Biol. Chem. 282:30910-30919(2007). RN [78] RP X-RAY CRYSTALLOGRAPHY (1.76 ANGSTROMS) OF 670-920 IN COMPLEXES WITH RP SYNTHETIC LIGANDS, FUNCTION, AND INTERACTION WITH NCOA2. RX PubMed=17911242; DOI=10.1073/pnas.0708036104; RA Estebanez-Perpina E., Arnold L.A., Nguyen P., Rodrigues E.D., Mar E., RA Bateman R., Pallai P., Shokat K.M., Baxter J.D., Guy R.K., Webb P., RA Fletterick R.J.; RT "A surface on the androgen receptor that allosterically regulates RT coactivator binding."; RL Proc. Natl. Acad. Sci. U.S.A. 104:16074-16079(2007). RN [79] {ECO:0007744|PDB:4OEA, ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, ECO:0007744|PDB:4OFU, ECO:0007744|PDB:4OGH, ECO:0007744|PDB:4OH5, ECO:0007744|PDB:4OHA, ECO:0007744|PDB:4OIL} RP X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 671-920 OF VARIANT PROSTATE RP CANCER ALA-878 AND WILD-TYPE IN COMPLEX WITH DIHYDROTESTOSTERONE AND BUD31 RP PEPTIDES, INTERACTION WITH BUD31, FUNCTION, SUBCELLULAR LOCATION, AND RP DOMAIN. RX PubMed=25091737; DOI=10.1016/j.molonc.2014.06.009; RA Hsu C.L., Liu J.S., Wu P.L., Guan H.H., Chen Y.L., Lin A.C., Ting H.J., RA Pang S.T., Yeh S.D., Ma W.L., Chen C.J., Wu W.G., Chang C.; RT "Identification of a new androgen receptor (AR) co-regulator BUD31 and RT related peptides to suppress wild-type and mutated AR-mediated prostate RT cancer growth via peptide screening and X-ray structure analysis."; RL Mol. Oncol. 8:1575-1587(2014). RN [80] RP VARIANT PAIS VAL-822, AND VARIANTS AIS ASN-665; TYR-733 AND ASN-815. RX PubMed=1458719; RA Pinsky L., Trifiro M.A., Kaufman M., Beitel L.K., Mhatre A., RA Kazemi-Esfarjani P., Sabbaghian N., Lumbroso R., Alvarado C., Vasiliou M., RA Gottlieb B.; RT "Androgen resistance due to mutation of the androgen receptor."; RL Clin. Invest. Med. 15:456-472(1992). RN [81] RP VARIANT PAIS TYR-807, AND VARIANT AIS LEU-857. RX PubMed=8339746; DOI=10.1007/bf02125442; RA Brown T.R., Scherer P.A., Chang Y.-T., Migeon C.J., Ghirri P., Murono K., RA Zhou Z.; RT "Molecular genetics of human androgen insensitivity."; RL Eur. J. Pediatr. 152 Suppl. 2:S62-S69(1993). RN [82] RP VARIANT AIS LYS-586. RX PubMed=8240973; DOI=10.1016/0960-0760(93)90178-y; RA Sultan C., Lumbroso S., Poujol N., Belon C., Boudon C., Lobaccaro J.-M.; RT "Mutations of androgen receptor gene in androgen insensitivity syndromes."; RL J. Steroid Biochem. Mol. Biol. 46:519-530(1993). RN [83] RP REVIEW ON VARIANTS. RX PubMed=7937057; RA Patterson M.N., Hughes I.A., Gottlieb B., Pinsky L.; RT "The androgen receptor gene mutations database."; RL Nucleic Acids Res. 22:3560-3562(1994). RN [84] RP VARIANTS AIS PHE-745 AND ARG-752. RX PubMed=7626493; DOI=10.1016/0960-0760(95)00090-m; RA Brinkmann A.O., Jenster G., Ris-Stalpers C., van der Korput J.A.G.M., RA Bruggenwirth H.T., Boehmer A.L.M., Trapman J.; RT "Androgen receptor mutations."; RL J. Steroid Biochem. Mol. Biol. 53:443-448(1995). RN [85] RP REVIEW ON VARIANTS. RX PubMed=9016528; DOI=10.1093/nar/25.1.158; RA Gottlieb B., Trifiro M.A., Lumbroso R., Vasiliou D.M., Pinsky L.; RT "The androgen receptor gene mutations database."; RL Nucleic Acids Res. 25:158-162(1997). RN [86] RP REVIEW ON VARIANTS. RX PubMed=22334387; DOI=10.1002/humu.22046; RA Gottlieb B., Beitel L.K., Nadarajah A., Paliouras M., Trifiro M.; RT "The androgen receptor gene mutations database: 2012 update."; RL Hum. Mutat. 33:887-894(2012). RN [87] RP VARIANT LNCAP ALA-878. RX PubMed=2260966; DOI=10.1016/s0006-291x(05)80067-1; RA Veldscholte J., Ris-Stalpers C., Kuiper G.G.J.M., Jenster G., RA Berrevoets C.A., Claassen E., van Rooij H.C.J., Trapman J., Brinkmann A.O., RA Mulder E.; RT "A mutation in the ligand binding domain of the androgen receptor of human RT LNCaP cells affects steroid binding characteristics and response to anti- RT androgens."; RL Biochem. Biophys. Res. Commun. 173:534-540(1990). RN [88] RP VARIANTS AIS CYS-775; GLN-832 AND MET-867. RX PubMed=2082179; DOI=10.1210/mend-4-12-1759; RA Brown T.R., Lubahn D.B., Wilson E.M., French F.S., Migeon C.J., RA Corfen J.L.; RT "Functional characterization of naturally occurring mutant androgen RT receptors from subjects with complete androgen insensitivity."; RL Mol. Endocrinol. 4:1759-1772(1990). RN [89] RP VARIANT CYS-775. RX PubMed=1856263; DOI=10.1210/jcem-73-2-318; RA Marcelli M., Tilley W.D., Zoppi S., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Androgen resistance associated with a mutation of the androgen receptor at RT amino acid 772 (Arg-->Cys) results from a combination of decreased RT messenger ribonucleic acid levels and impairment of receptor function."; RL J. Clin. Endocrinol. Metab. 73:318-325(1991). RN [90] RP VARIANTS AIS PRO-616 AND PRO-618. RX PubMed=1999491; DOI=10.1172/jci115076; RA Marcelli M., Zoppi S., Grino P.B., Griffin J.E., Wilson J.D., McPhaul M.J.; RT "A mutation in the DNA-binding domain of the androgen receptor gene causes RT complete testicular feminization in a patient with receptor-positive RT androgen resistance."; RL J. Clin. Invest. 87:1123-1126(1991). RN [91] RP VARIANT PAIS CYS-764. RX PubMed=2010552; DOI=10.1172/jci115147; RA McPhaul M.J., Marcelli M., Tilley W.D., Griffin J.E., RA Isidro-Gutierrez R.F., Wilson J.D.; RT "Molecular basis of androgen resistance in a family with a qualitative RT abnormality of the androgen receptor and responsive to high-dose androgen RT therapy."; RL J. Clin. Invest. 87:1413-1421(1991). RN [92] RP POLY-GLN REGION EXPANSION, AND INVOLVEMENT IN SPINAL AND BULBAR MUSCULAR RP ATROPHY. RX PubMed=2062380; DOI=10.1038/352077a0; RA la Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H.; RT "Androgen receptor gene mutations in X-linked spinal and bulbar muscular RT atrophy."; RL Nature 352:77-79(1991). RN [93] RP VARIANTS AIS CYS-775 AND HIS-775. RX PubMed=1609793; RA Prior L., Bordet S., Trifiro M.A., Mhatre A., Kaufman M., Pinsky L., RA Wrogemann K., Belsham D.D., Pereira F., Greenberg C.R., Trapman J., RA Brinkmann A.O., Chang C., Liao S.; RT "Replacement of arginine 773 by cysteine or histidine in the human androgen RT receptor causes complete androgen insensitivity with different receptor RT phenotypes."; RL Am. J. Hum. Genet. 51:143-155(1992). RN [94] RP VARIANTS PAIS LYS-609 AND LEU-867. RX PubMed=1424203; DOI=10.1111/j.1365-2265.1992.tb02313.x; RA Saunders P.T., Padayachi T., Tincello D.G., Shalet S.M., Wu F.C.; RT "Point mutations detected in the androgen receptor gene of three men with RT partial androgen insensitivity syndrome."; RL Clin. Endocrinol. (Oxf.) 37:214-220(1992). RN [95] RP VARIANT AIS THR-766. RX PubMed=1426313; DOI=10.1016/s0015-0282(16)55315-1; RA Sweet C.R., Behzadian M.A., McDonough P.G.; RT "A unique point mutation in the androgen receptor gene in a family with RT complete androgen insensitivity syndrome."; RL Fertil. Steril. 58:703-707(1992). RN [96] RP VARIANT AIS VAL-750. RX PubMed=1487249; DOI=10.1007/bf00220088; RA Jakubiczka S., Werder E.A., Wieacker P.; RT "Point mutation in the steroid-binding domain of the androgen receptor gene RT in a family with complete androgen insensitivity syndrome (CAIS)."; RL Hum. Genet. 90:311-312(1992). RN [97] RP VARIANTS AIS, AND VARIANTS PAIS. RX PubMed=1307250; DOI=10.1093/hmg/1.7.497; RA Batch J.A., Williams D.M., Davies H.R., Brown B.D., Evans B.A.J., RA Hughes I.A., Patterson M.N.; RT "Androgen receptor gene mutations identified by SSCP in fourteen subjects RT with androgen insensitivity syndrome."; RL Hum. Mol. Genet. 1:497-503(1992). RN [98] RP VARIANT AIS VAL-788. RX PubMed=1569163; DOI=10.1210/jcem.74.5.1569163; RA Nakao R., Haji M., Yanase T., Ogo A., Takayanagi R., Katsube T., RA Fukumaki Y., Nawata H.; RT "A single amino acid substitution (Met-786-->Val) in the steroid-binding RT domain of human androgen receptor leads to complete androgen insensitivity RT syndrome."; RL J. Clin. Endocrinol. Metab. 74:1152-1157(1992). RN [99] RP VARIANTS AIS ARG-742 AND CYS-835. RX PubMed=1464650; DOI=10.1210/jcem.75.6.1464650; RA Wilson C.M., Griffin J.E., Wilson J.D., Marcelli M., Zoppi S., RA McPhaul M.J.; RT "Immunoreactive androgen receptor expression in subjects with androgen RT resistance."; RL J. Clin. Endocrinol. Metab. 75:1474-1478(1992). RN [100] RP VARIANTS AIS, VARIANTS PAIS, VARIANTS AIS SER-767 AND HIS-905, AND VARIANTS RP PAIS LYS-855 AND MET-904. RX PubMed=1430233; DOI=10.1172/jci116093; RA McPhaul M.J., Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., RA Wilson J.D.; RT "Mutations in the ligand-binding domain of the androgen receptor gene RT cluster in two regions of the gene."; RL J. Clin. Invest. 90:2097-2101(1992). RN [101] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=1562539; DOI=10.1016/0960-0760(92)90401-4; RA Veldscholte J., Berrevoets C.A., Ris-Stalpers C., Kuiper G.G.J.M., RA Jenster G., Trapman J., Brinkmann A.O., Mulder E.; RT "The androgen receptor in LNCaP cells contains a mutation in the ligand RT binding domain which affects steroid binding characteristics and response RT to antiandrogens."; RL J. Steroid Biochem. Mol. Biol. 41:665-669(1992). RN [102] RP VARIANTS AIS TYR-560 AND ARG-577, AND VARIANTS PAIS GLY-598 AND PRO-618. RX PubMed=1316540; DOI=10.1210/mend.6.3.1316540; RA Zoppi S., Marcelli M., Deslypere J.-P., Griffin J.E., Wilson J.D., RA McPhaul M.J.; RT "Amino acid substitutions in the DNA-binding domain of the human androgen RT receptor are a frequent cause of receptor-binding positive androgen RT resistance."; RL Mol. Endocrinol. 6:409-415(1992). RN [103] RP VARIANTS AIS SER-706; VAL-750; PHE-760; HIS-775; CYS-856 AND GLY-865. RX PubMed=1480178; DOI=10.1210/mend.6.11.1480178; RA De Bellis A., Quigley C.A., Cariello N.F., el-Awady M.K., Sar M., RA Lane M.V., Wilson E.M., French F.S.; RT "Single base mutations in the human androgen receptor gene causing complete RT androgen insensitivity: rapid detection by a modified denaturing gradient RT gel electrophoresis technique."; RL Mol. Endocrinol. 6:1909-1920(1992). RN [104] RP VARIANT PAIS/BREAST CANCER GLN-608. RX PubMed=1303262; DOI=10.1038/ng1092-132; RA Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., RA Barrett-Lee P., Easton D.F., Ponder B.A., Stratton M.R.; RT "A germline mutation in the androgen receptor gene in two brothers with RT breast cancer and Reifenstein syndrome."; RL Nat. Genet. 2:132-134(1992). RN [105] RP VARIANT MET-731. RX PubMed=1631125; DOI=10.1073/pnas.89.14.6319; RA Newmark J.R., Hardy D.O., Tonb D.C., Carter B.S., Epstein J.I., RA Isaacs W.B., Brown T.R., Barrack E.R.; RT "Androgen receptor gene mutations in human prostate cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6319-6323(1992). RN [106] RP VARIANTS ARG-207 AND ASP-794. RX PubMed=8213813; RA Macke J.P., Hu N., Hu S., Bailey M., King V.L., Brown T., Hamer D., RA Nathans J.; RT "Sequence variation in the androgen receptor gene is not a common RT determinant of male sexual orientation."; RL Am. J. Hum. Genet. 53:844-852(1993). RN [107] RP VARIANT AIS PHE-582. RX PubMed=8224266; DOI=10.1016/s0015-0282(16)56281-5; RA Lumbroso S., Lobaccaro J.-M., Belon C., Martin D., Chaussain J.-L., RA Sultan C.; RT "A new mutation within the deoxyribonucleic acid-binding domain of the RT androgen receptor gene in a family with complete androgen insensitivity RT syndrome."; RL Fertil. Steril. 60:814-819(1993). RN [108] RP VARIANT AIS VAL-755. RX PubMed=8103398; DOI=10.1093/hmg/2.7.1041; RA Lobaccaro J.-M., Lumbroso S., Ktari R., Dumas R., Sultan C.; RT "An exonic point mutation creates a MaeIII site in the androgen receptor RT gene of a family with complete androgen insensitivity syndrome."; RL Hum. Mol. Genet. 2:1041-1043(1993). RN [109] RP VARIANT PAIS/BREAST CANCER LYS-609. RX PubMed=8281139; DOI=10.1093/hmg/2.11.1799; RA Lobaccaro J.-M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., RA Lesimple T., Namer M., Cutuli B.F., Pujol H., Sultan C.; RT "Androgen receptor gene mutation in male breast cancer."; RL Hum. Mol. Genet. 2:1799-1802(1993). RN [110] RP VARIANT AIS ARG-808. RX PubMed=8281140; DOI=10.1093/hmg/2.11.1809; RA Adeyemo O., Kallio P.J., Palvimo J.J., Kontula K., Jaenne O.A.; RT "A single-base substitution in exon 6 of the androgen receptor gene causing RT complete androgen insensitivity: the mutated receptor fails to RT transactivate but binds to DNA in vitro."; RL Hum. Mol. Genet. 2:1809-1812(1993). RN [111] RP VARIANT PAIS VAL-744. RX PubMed=8325932; DOI=10.1210/jcem.77.1.8325932; RA Nakao R., Yanase T., Sakai Y., Haji M., Nawata H.; RT "A single amino acid substitution (Gly743 --> Val) in the steroid-binding RT domain of the human androgen receptor leads to Reifenstein syndrome."; RL J. Clin. Endocrinol. Metab. 77:103-107(1993). RN [112] RP VARIANTS AIS LYS-682 AND THR-843, AND VARIANTS PAIS HIS-841 AND LEU-867. RX PubMed=8325950; DOI=10.1210/jcem.77.1.8325950; RA Hiort O., Huang Q., Sinnecker G.H., Sadeghi-Nejad A., Kruse K., Wolfe H.J., RA Yandell D.W.; RT "Single strand conformation polymorphism analysis of androgen receptor gene RT mutations in patients with androgen insensitivity syndromes: application RT for diagnosis, genetic counseling, and therapy."; RL J. Clin. Endocrinol. Metab. 77:262-266(1993). RN [113] RP INVOLVEMENT IN PAIS, INVOLVEMENT IN HYSP1, AND VARIANTS PAIS HIS-856 AND RP MET-870. RX PubMed=8097257; DOI=10.1136/jmg.30.3.198; RA Batch J.A., Evans B.A.J., Hughes I.A., Patterson M.N.; RT "Mutations of the androgen receptor gene identified in perineal RT hypospadias."; RL J. Med. Genet. 30:198-201(1993). RN [114] RP VARIANT AIS VAL-744. RX PubMed=8096390; DOI=10.1016/0960-0760(93)90081-7; RA Lobaccaro J.-M., Lumbroso S., Berta P., Chaussain J.-L., Sultan C.; RT "Complete androgen insensitivity syndrome associated with a de novo RT mutation of the androgen receptor gene detected by single strand RT conformation polymorphism."; RL J. Steroid Biochem. Mol. Biol. 44:211-216(1993). RN [115] RP VARIANTS HIS-702 AND ALA-878. RX PubMed=8274409; DOI=10.1016/0960-0760(93)90316-o; RA Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J.; RT "Androgen receptor gene mutations in human prostate cancer."; RL J. Steroid Biochem. Mol. Biol. 46:759-765(1993). RN [116] RP VARIANT AIS MET-867, AND VARIANT PAIS LEU-867. RX PubMed=8446106; DOI=10.1210/mend.7.1.8446106; RA Kazemi-Esfarjani P., Beitel L.K., Trifiro M.A., Kaufman M., Rennie P., RA Sheppard P., Matusik R., Pinsky L.; RT "Substitution of valine-865 by methionine or leucine in the human androgen RT receptor causes complete or partial androgen insensitivity, respectively RT with distinct androgen receptor phenotypes."; RL Mol. Endocrinol. 7:37-46(1993). RN [117] RP VARIANT PROSTATE CANCER MET-716. RX PubMed=8145761; DOI=10.1210/mend.7.12.8145761; RA Culig Z., Hobisch A., Cronauer M.V., Cato A.C.B., Hittmair A., Radmayr C., RA Eberle J., Bartsch G., Klocker H.; RT "Mutant androgen receptor detected in an advanced-stage prostatic carcinoma RT is activated by adrenal androgens and progesterone."; RL Mol. Endocrinol. 7:1541-1550(1993). RN [118] RP VARIANTS AIS PHE-582; VAL-744; VAL-755; GLU-768 AND CYS-856. RA Lobaccaro J.-M., Lumbroso S., Belon C., Chaussain J.L., Toublanc J.E., RA Leheup B., Sultan C.; RT "Androgen receptor (AR) gene mutations in 6 families with androgen RT insensitivity syndrome (Abstract #114)."; RL Pediatr. Res. Suppl. 33:S22-S22(1993). RN [119] RP VARIANTS PROSTATE CANCER LEU-342 AND GLU-799. RX PubMed=7511268; RA Castagnaro M., Yandell D.W., Dockhorn-Dworniczak B., Wolfe H.J., RA Poremba C.; RT "Androgen receptor gene mutations and p53 gene analysis in advanced RT prostate cancer."; RL Verh. Dtsch. Ges. Pathol. 77:119-123(1993). RN [120] RP POLY-GLN REGION CONTRACTION, AND INVOLVEMENT IN PROSTATE CANCER. RX PubMed=8292051; DOI=10.1006/bbrc.1994.1011; RA Schoenberg M.P., Hakimi J.M., Wang S., Bova G.S., Epstein J.I., RA Fischbeck K.H., Isaacs W.B., Walsh P.C., Barrack E.R.; RT "Microsatellite mutation (CAG24-->18) in the androgen receptor gene in RT human prostate cancer."; RL Biochem. Biophys. Res. Commun. 198:74-80(1994). RN [121] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=8187068; RA Gaddipati J.P., McLeod D.G., Heidenberg H.B., Sesterhenn I.A., Finger M.J., RA Moul J.W., Srivastava S.; RT "Frequent detection of codon 877 mutation in the androgen receptor gene in RT advanced prostate cancers."; RL Cancer Res. 54:2861-2864(1994). RN [122] RP VARIANT PAIS TRP-569. RX PubMed=7910529; DOI=10.1111/j.1365-2265.1994.tb03922.x; RA Lobaccaro J.-M., Belon C., Lumbroso S., Olewniczack G., Carre-Pigeon F., RA Job J.C., Chaussain J.L., Toublanc J.E., Sultan C.; RT "Molecular prenatal diagnosis of partial androgen insensitivity syndrome RT based on the Hind III polymorphism of the androgen receptor gene."; RL Clin. Endocrinol. (Oxf.) 40:297-302(1994). RN [123] RP VARIANT PAIS HIS-841. RX PubMed=7909256; DOI=10.1530/eje.0.1300327; RA Lumbroso S., Lobaccaro J.-M., Belon C., Amram S., Bachelard B., RA Garandeau P., Sultan C.; RT "Molecular prenatal exclusion of familial partial androgen insensitivity RT (Reifenstein syndrome)."; RL Eur. J. Endocrinol. 130:327-332(1994). RN [124] RP VARIANT PAIS HIS-841. RX PubMed=8205256; DOI=10.1530/eje.0.1300569; RA Imasaki K., Hasegawa T., Okabe T., Sakai Y., Haji M., Takayanagi R., RA Nawata H.; RT "Single amino acid substitution (840Arg-->His) in the hormone-binding RT domain of the androgen receptor leads to incomplete androgen insensitivity RT syndrome associated with a thermolabile androgen receptor."; RL Eur. J. Endocrinol. 130:569-574(1994). RN [125] RP VARIANT PAIS VAL-871. RX PubMed=8033918; DOI=10.1007/bf01956409; RA Hiort O., Klauber G., Cendron M., Sinnecker G.H., Keim L., Schwinger E., RA Wolfe H.J., Yandell D.W.; RT "Molecular characterization of the androgen receptor gene in boys with RT hypospadias."; RL Eur. J. Pediatr. 153:317-321(1994). RN [126] RP VARIANT PAIS ASP-691 DEL. RA Schwartz M., Skovby F., Mueller J., Nielsen O., Skakkebaek N.E.; RT "Partial androgen insensitivity (PAIS) in a large eskimo kindred caused by RT a delD690 mutation in the androgen receptor (AR) gene (Abstract #244)."; RL Horm. Res. 41:117-117(1994). RN [127] RP VARIANTS AIS PHE-583 DEL; ARG-616 DEL AND HIS-616. RX PubMed=8162033; DOI=10.1093/hmg/3.1.21; RA Beitel L.K., Prior L., Vasiliou D.M., Gottlieb B., Kaufman M., Lumbroso R., RA Alvarado C., McGillivray B., Trifiro M.A., Pinsky L.; RT "Complete androgen insensitivity due to mutations in the probable alpha- RT helical segments of the DNA-binding domain in the human androgen RT receptor."; RL Hum. Mol. Genet. 3:21-27(1994). RN [128] RP VARIANTS PAIS SER-583; TYR-605; ALA-709; LEU-755 AND HIS-772, AND VARIANT RP AIS TRP-780. RX PubMed=7981687; DOI=10.1093/hmg/3.7.1163; RA Hiort O., Wodtke A., Struve D., Zoellner A., Sinnecker G.H.; RT "Detection of point mutations in the androgen receptor gene using non- RT isotopic single strand conformation polymorphism analysis."; RL Hum. Mol. Genet. 3:1163-1166(1994). RN [129] RP VARIANT AIS PHE-602. RX PubMed=7981689; DOI=10.1093/hmg/3.7.1169; RA Baldazzi L., Baroncini C., Pirazzoli P., Balsamo A., Capelli M., RA Marchetti G., Bernardi F., Cacciari E.; RT "Two mutations causing complete androgen insensitivity: a frame-shift in RT the steroid binding domain and a Cys-->Phe substitution in the second zinc RT finger of the androgen receptor."; RL Hum. Mol. Genet. 3:1169-1170(1994). RN [130] RP VARIANTS PAIS ARG-617; HIS-841 AND MET-890. RX PubMed=8126121; DOI=10.1210/jcem.78.3.8126121; RA De Bellis A., Quigley C.A., Marschke K.B., el-Awady M.K., Lane M.V., RA Smith E.P., Sar M., Wilson E.M., French F.S.; RT "Characterization of mutant androgen receptors causing partial androgen RT insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 78:513-522(1994). RN [131] RP VARIANT AIS PHE-791. RX PubMed=7962294; DOI=10.1210/jcem.79.4.7962294; RA Tsukada T., Inoue M., Tachibana S., Nakai Y., Takebe H.; RT "An androgen receptor mutation causing androgen resistance in RT undervirilized male syndrome."; RL J. Clin. Endocrinol. Metab. 79:1202-1207(1994). RN [132] RP VARIANTS AIS CYS-841 AND HIS-841. RX PubMed=8040309; DOI=10.1172/jci117368; RA Beitel L.K., Kazemi-Esfarjani P., Kaufman M., Lumbroso R., DiGeorge A.M., RA Killinger D.W., Trifiro M.A., Pinsky L.; RT "Substitution of arginine-839 by cysteine or histidine in the androgen RT receptor causes different receptor phenotypes in cultured cells and RT coordinate degrees of clinical androgen resistance."; RL J. Clin. Invest. 94:546-554(1994). RN [133] RP VARIANTS AIS, AND VARIANTS PAIS. RX PubMed=7929841; DOI=10.1172/jci117507; RA Marcelli M., Zoppi S., Wilson C.M., Griffin J.E., McPhaul M.J.; RT "Amino acid substitutions in the hormone-binding domain of the human RT androgen receptor alter the stability of the hormone receptor complex."; RL J. Clin. Invest. 94:1642-1650(1994). RN [134] RP VARIANT AIS LYS-728. RX PubMed=7993455; DOI=10.1016/s0140-6736(94)92385-x; RA Yong E.L., Ng S.C., Roy A.C., Yun G., Ratnam S.S.; RT "Pregnancy after hormonal correction of severe spermatogenic defect due to RT mutation in androgen receptor gene."; RL Lancet 344:826-827(1994). RN [135] RP VARIANTS AIS HIS-616 AND LEU-765, AND VARIANTS PAIS VAL-743 AND THR-746. RX PubMed=7970939; DOI=10.1203/00006450-199408000-00015; RA Ris-Stalpers C., Hoogenboezem T., Sleddens H.F.B.M., RA Verleun-Mooijman M.C.T., Degenhart H.J., Drop S.L.S., Halley D.J.J., RA Oosterwijk J.C., Hodgins M.B., Trapman J., Brinkmann A.O.; RT "A practical approach to the detection of androgen receptor gene mutations RT and pedigree analysis in families with X-linked androgen insensitivity."; RL Pediatr. Res. 36:227-234(1994). RN [136] RP VARIANT AIS HIS-841. RX PubMed=8830623; DOI=10.1177/000456329503200508; RA Imai A., Ohno T., Iida K., Ohsuye K., Okano Y., Tamaya T.; RT "A frame-shift mutation of the androgen receptor gene in a patient with RT receptor-negative complete testicular feminization: comparison with a RT single base substitution in a receptor-reduced incomplete form."; RL Ann. Clin. Biochem. 32:482-486(1995). RN [137] RP VARIANTS PROSTATE CANCER. RX PubMed=7712463; RA Takahashi H., Furusato M., Allsbrook W.C. Jr., Nishii H., Wakui S., RA Barrett J.C., Boyd J.; RT "Prevalence of androgen receptor gene mutations in latent prostatic RT carcinomas from Japanese men."; RL Cancer Res. 55:1621-1624(1995). RN [138] RP VARIANT AIS VAL-882. RX PubMed=7641413; DOI=10.1111/j.1365-2265.1995.tb01895.x; RA Davies H.R., Hughes I.A., Patterson M.N.; RT "Genetic counselling in complete androgen insensitivity syndrome: RT trinucleotide repeat polymorphisms, single-strand conformation polymorphism RT and direct detection of two novel mutations in the androgen receptor RT gene."; RL Clin. Endocrinol. (Oxf.) 43:69-77(1995). RN [139] RP VARIANTS AIS SER-706 AND HIS-764, AND VARIANTS PAIS LEU-726; THR-738; RP HIS-775 AND GLU-799. RX PubMed=7671849; DOI=10.1210/edrv-16-3-271; RA Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., RA French F.S.; RT "Androgen receptor defects: historical, clinical, and molecular RT perspectives."; RL Endocr. Rev. 16:271-321(1995). RN [140] RP ERRATUM OF PUBMED:7671849. RA Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., RA French F.S.; RL Endocr. Rev. 16:546-546(1995). RN [141] RP VARIANTS AIS LEU-832 AND GLN-832. RX PubMed=7633398; DOI=10.1093/hmg/4.4.515; RA Shkolny D.L., Brown T.R., Punnett H.H., Kaufman M., Trifiro M.A., RA Pinsky L.; RT "Characterization of alternative amino acid substitutions at arginine 830 RT of the androgen receptor that cause complete androgen insensitivity in RT three families."; RL Hum. Mol. Genet. 4:515-521(1995). RN [142] RP VARIANT AIS PRO-678. RX PubMed=7537149; DOI=10.1002/humu.1380050104; RA Belsham D.D., Pereira F., Greenberg C.R., Liao S., Wrogemann K.; RT "Leu-676-Pro mutation of the androgen receptor causes complete androgen RT insensitivity syndrome in a large Hutterite kindred."; RL Hum. Mutat. 5:28-33(1995). RN [143] RP VARIANT PAIS CYS-764, AND VARIANTS AIS TRP-780; VAL-808 AND CYS-856. RX PubMed=7581399; DOI=10.1002/humu.1380060208; RA Murono K., Mendonca B.B., Arnhold I.J.P., Rigon A.C.M.M., Migeon C.J., RA Brown T.R.; RT "Human androgen insensitivity due to point mutations encoding amino acid RT substitutions in the androgen receptor steroid-binding domain."; RL Hum. Mutat. 6:152-162(1995). RN [144] RP VARIANT PROSTATE CANCER MET-731. RX PubMed=7591265; DOI=10.1002/ijc.2910630415; RA Peterziel H., Culig Z., Stober J., Hobisch A., Radmayr C., Bartsch G., RA Klocker H., Cato A.C.B.; RT "Mutant androgen receptors in prostatic tumors distinguish between amino- RT acid-sequence requirements for transactivation and ligand binding."; RL Int. J. Cancer 63:544-550(1995). RN [145] RP VARIANT VAL-569. RX PubMed=7673412; DOI=10.1210/jcem.80.9.7673412; RA Allera A., Herbst M.A., Griffin J.E., Wilson J.D., Schweikert H.-U., RA McPhaul M.J.; RT "Mutations of the androgen receptor coding sequence are infrequent in RT patients with isolated hypospadias."; RL J. Clin. Endocrinol. Metab. 80:2697-2699(1995). RN [146] RP INVOLVEMENT IN HPCX3, AND VARIANT HPCX3 LEU-727. RX PubMed=8530589; DOI=10.1210/jcem.80.12.8530589; RA Elo J.P., Kvist L., Leinonen K., Isomaa V., Henttu P., Lukkarinen O., RA Vihko P.; RT "Mutated human androgen receptor gene detected in a prostatic cancer RT patient is also activated by estradiol."; RL J. Clin. Endocrinol. Metab. 80:3494-3500(1995). RN [147] RP VARIANT PAIS THR-597. RX PubMed=7649358; DOI=10.1016/0303-7207(95)03554-k; RA Gast A., Neuschmid-Kaspar F., Klocker H., Cato A.C.B.; RT "A single amino acid exchange abolishes dimerization of the androgen RT receptor and causes Reifenstein syndrome."; RL Mol. Cell. Endocrinol. 111:93-98(1995). RN [148] RP VARIANTS PROSTATE CANCER. RX PubMed=7723794; DOI=10.1056/nejm199505253322101; RA Taplin M.-E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., RA Ogata G.K., Keer H.N., Balk S.P.; RT "Mutation of the androgen-receptor gene in metastatic androgen-independent RT prostate cancer."; RL N. Engl. J. Med. 332:1393-1398(1995). RN [149] RP VARIANTS AIS AND PAIS, VARIANTS PAIS ARG-687; VAL-688; PHE-713; MET-747; RP SER-757 AND SER-842, AND VARIANTS AIS GLU-689; MET-747 AND THR-899. RX PubMed=8723113; RX DOI=10.1002/(sici)1096-8628(19960503)63:1<218::aid-ajmg38>3.0.co;2-p; RA Hiort O., Sinnecker G.H., Holterhus P.M., Nitsche E.M., Kruse K.; RT "The clinical and molecular spectrum of androgen insensitivity syndromes."; RL Am. J. Med. Genet. 63:218-222(1996). RN [150] RP VARIANTS PROSTATE CANCER. RX PubMed=9816170; RA Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M.; RT "Mutations in the androgen receptor gene are associated with progression of RT human prostate cancer to androgen independence."; RL Clin. Cancer Res. 2:277-285(1996). RN [151] RP VARIANTS PAIS GLN-608; THR-611; LEU-755; HIS-841; THR-843 AND HIS-856, AND RP VARIANT AIS MET-867. RX PubMed=9039340; DOI=10.1046/j.1365-2265.1996.8600869.x; RA Weidemann W., Linck B., Haupt H., Mentrup B., Romalo G., Stockklauser K., RA Brinkmann A.O., Schweikert H.-U., Spindler K.D.; RT "Clinical and biochemical investigations and molecular analysis of subjects RT with mutations in the androgen receptor gene."; RL Clin. Endocrinol. (Oxf.) 45:733-739(1996). RN [152] RP VARIANT AIS CYS-856. RX PubMed=9001799; DOI=10.1111/j.1399-0004.1996.tb02626.x; RA Malmgren H., Gustavsson J., Tuvemo T., Dahl N.; RT "Rapid detection of a mutation hot-spot in the human androgen receptor."; RL Clin. Genet. 50:202-205(1996). RN [153] RP VARIANTS PAIS ILE-743; ILE-781; GLU-799; CYS-841; HIS-856 AND MET-870. RX PubMed=8824883; DOI=10.1093/hmg/5.2.265; RA Bevan C.L., Brown B.B., Davies H.R., Evans B.A.J., Hughes I.A., RA Patterson M.N.; RT "Functional analysis of six androgen receptor mutations identified in RT patients with partial androgen insensitivity syndrome."; RL Hum. Mol. Genet. 5:265-273(1996). RN [154] RP VARIANT PAIS ARG-910. RX PubMed=8550758; DOI=10.1210/jcem.81.1.8550758; RA Choong C.S., Sturm M.J., Strophair J.A., McCulloch R.K., Tilley W.D., RA Leedman P.J., Hurley D.M.; RT "Partial androgen insensitivity caused by an androgen receptor mutation at RT amino acid 907 (Gly-->Arg) that results in decreased ligand binding RT affinity and reduced androgen receptor messenger ribonucleic acid levels."; RL J. Clin. Endocrinol. Metab. 81:236-243(1996). RN [155] RP VARIANT AIS ARG-708. RX PubMed=8626869; DOI=10.1210/jcem.81.5.8626869; RA Lumbroso S., Lobaccaro J.-M., Georget V., Leger J., Poujol N., RA Terouanne B., Evain-Brion D., Czernichow P., Sultan C.; RT "A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene RT causes complete androgen resistance."; RL J. Clin. Endocrinol. Metab. 81:1984-1988(1996). RN [156] RP VARIANT AIS ILE-781. RX PubMed=8768864; DOI=10.1210/jcem.81.8.8768864; RA Rodien P., Mebarki F., Mowszowicz I., Chaussain J.L., Young J., Morel Y., RA Schaison G.; RT "Different phenotypes in a family with androgen insensitivity caused by the RT same M780I point mutation in the androgen receptor gene."; RL J. Clin. Endocrinol. Metab. 81:2994-2998(1996). RN [157] RP VARIANT PAIS LYS-2. RX PubMed=8823308; DOI=10.1172/jci118930; RA Choong C.S., Quigley C.A., French F.S., Wilson E.M.; RT "A novel missense mutation in the amino-terminal domain of the human RT androgen receptor gene in a family with partial androgen insensitivity RT syndrome causes reduced efficiency of protein translation."; RL J. Clin. Invest. 98:1423-1431(1996). RN [158] RP VARIANT AIS ASP-574. RX PubMed=8918984; DOI=10.1016/0960-0760(96)00095-7; RA Bruggenwirth H.T., Boehmer A.L.M., Verleun-Mooijman M.C.T., RA Hoogenboezem T., Kleijer W.J., Otten B.J., Trapman J., Brinkmann A.O.; RT "Molecular basis of androgen insensitivity."; RL J. Steroid Biochem. Mol. Biol. 58:569-575(1996). RN [159] RP VARIANT AIS SER-549. RX PubMed=8683794; DOI=10.1097/00005392-199608001-00077; RA Sutherland R.W., Wiener J.S., Hicks J.P., Marcelli M., Gonzales E.T. Jr., RA Roth D.R., Lamb D.J.; RT "Androgen receptor gene mutations are rarely associated with isolated RT penile hypospadias."; RL J. Urol. 156:828-831(1996). RN [160] RP VARIANT AIS PRO-617. RX PubMed=8647313; DOI=10.1016/0303-7207(95)03709-8; RA Lobaccaro J.-M., Poujol N., Chiche L., Lumbroso S., Brown T.R., Sultan C.; RT "Molecular modeling and in vitro investigations of the human androgen RT receptor DNA-binding domain: application for the study of two mutations."; RL Mol. Cell. Endocrinol. 116:137-147(1996). RN [161] RP VARIANT AIS PHE-580, AND VARIANT PAIS TYR-583. RX PubMed=8809734; DOI=10.1016/0303-7207(96)03812-9; RA Imasaki K., Okabe T., Murakami H., Tanaka Y., Haji M., Takayanagi R., RA Nawata H.; RT "Androgen insensitivity syndrome due to new mutations in the DNA-binding RT domain of the androgen receptor."; RL Mol. Cell. Endocrinol. 120:15-24(1996). RN [162] RP VARIANT PROSTATE CANCER GLU-799. RX PubMed=8628719; RX DOI=10.1002/(sici)1097-0045(199603)28:3<162::aid-pros3>3.0.co;2-h; RA Evans B.A.J., Harper M.E., Daniells C.E., Watts C.E., Matenhelia S., RA Green J., Griffiths K.; RT "Low incidence of androgen receptor gene mutations in human prostatic RT tumors using single strand conformation polymorphism analysis."; RL Prostate 28:162-171(1996). RN [163] RP VARIANT PROSTATE CANCER ALA-878. RX PubMed=8827083; RX DOI=10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5; RA Suzuki H., Akakura K., Komiya A., Aida S., Akimoto S., Shimazaki J.; RT "Codon 877 mutation in the androgen receptor gene in advanced prostate RT cancer: relation to antiandrogen withdrawal syndrome."; RL Prostate 29:153-158(1996). RN [164] RP VARIANT AIS HIS-856. RX PubMed=9106550; RA Boehmer A.L.M., Brinkmann A.O., Niermeijer M.F., Bakker L., Halley D.J.J., RA Drop S.L.S.; RT "Germ-line and somatic mosaicism in the androgen insensitivity syndrome: RT implications for genetic counseling."; RL Am. J. Hum. Genet. 60:1003-1006(1997). RN [165] RP VARIANT PROSTATE CANCER ALA-684. RX PubMed=9000575; RA Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., RA Trapman J., Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O.-P.; RT "Androgen receptor gene amplification: a possible molecular mechanism for RT androgen deprivation therapy failure in prostate cancer."; RL Cancer Res. 57:314-319(1997). RN [166] RP VARIANTS PAIS LYS-609 AND GLY-773. RX PubMed=9196614; DOI=10.1046/j.1365-2265.1997.1140927.x; RA Tincello D.G., Saunders P.T., Hodgins M.B., Simpson N.B., Edwards C.R., RA Hargreaves T.B., Wu F.C.; RT "Correlation of clinical, endocrine and molecular abnormalities with in RT vivo responses to high-dose testosterone in patients with partial androgen RT insensitivity syndrome."; RL Clin. Endocrinol. (Oxf.) 46:497-506(1997). RN [167] RP VARIANT AIS MET-890. RX PubMed=9160185; RA Essawi M., Gad Y.Z., el-Rouby O., Temtamy S.A., Sabour Y.A., el-Awady M.K.; RT "Molecular analysis of androgen resistance syndromes in Egyptian RT patients."; RL Dis. Markers 13:99-105(1997). RN [168] RP VARIANT AIS TRP-780. RX PubMed=9007482; DOI=10.1007/s004310050542; RA Sinnecker G.H., Hiort O., Nitsche E.M., Holterhus P.M., Kruse K.; RT "Functional assessment and clinical classification of androgen sensitivity RT in patients with mutations of the androgen receptor gene."; RL Eur. J. Pediatr. 156:7-14(1997). RN [169] RP VARIANTS AIS VAL-750; CYS-775; ILE-781 AND SER-795. RX PubMed=8990010; RX DOI=10.1002/(sici)1098-1004(1997)9:1<57::aid-humu10>3.0.co;2-o; RA Jakubiczka S., Nedel S., Werder E.A., Schleiermacher E., Theile U., RA Wolff G., Wieacker P.; RT "Mutations of the androgen receptor gene in patients with complete androgen RT insensitivity."; RL Hum. Mutat. 9:57-61(1997). RN [170] RP VARIANTS HIS-702 AND ARG-911. RX PubMed=9438000; DOI=10.1093/jjco/27.6.389; RA Watanabe M., Ushijima T., Shiraishi T., Yatani R., Shimazaki J., Kotake T., RA Sugimura T., Nagao M.; RT "Genetic alterations of androgen receptor gene in Japanese human prostate RT cancer."; RL Jpn. J. Clin. Oncol. 27:389-393(1997). RN [171] RP VARIANT PROSTATE CANCER GLN-630. RX PubMed=9184448; DOI=10.5980/jpnjurol1989.88.550; RA Wang C., Uchida T.; RT "Androgen receptor gene mutations in prostate cancer."; RL Nihon Hinyokika Gakkai Zasshi 88:550-556(1997). RN [172] RP VARIANTS AIS ARG-196 AND CYS-856. RX PubMed=9255042; DOI=10.1111/j.1447-0756.1997.tb00845.x; RA Komori S., Sakata K., Tanaka H., Shima H., Koyama K.; RT "DNA analysis of the androgen receptor gene in two cases with complete RT androgen insensitivity syndrome."; RL J. Obstet. Gynaecol. Res. 23:277-281(1997). RN [173] RP VARIANTS PAIS ALA-709 AND GLY-871. RX PubMed=9329414; DOI=10.1016/s0022-3476(97)80063-7; RA Albers N., Ulrichs C., Gluer S., Hiort O., Sinnecker G.H., Mildenberger H., RA Brodehl J.; RT "Etiologic classification of severe hypospadias: implications for prognosis RT and management."; RL J. Pediatr. 131:386-392(1997). RN [174] RP VARIANTS AIS ASN-733 AND THR-766. RX PubMed=9252933; RA Ko T.M., Yang Y.S., Wu M.Y., Kao C.H., Hsu P.M., Chuang S.M., Lee T.Y.; RT "Complete androgen insensitivity syndrome. Molecular characterization in RT two Chinese women."; RL J. Reprod. Med. 42:424-428(1997). RN [175] RP VARIANTS AIS ASP-751; PHE-763; THR-766; ASN-865 AND PHE-908. RX PubMed=9328206; DOI=10.1016/s0960-0760(97)00001-0; RA Bevan C.L., Hughes I.A., Patterson M.N.; RT "Wide variation in androgen receptor dysfunction in complete androgen RT insensitivity syndrome."; RL J. Steroid Biochem. Mol. Biol. 61:19-26(1997). RN [176] RP VARIANT PAIS GLY-704, AND VARIANT AIS LEU-917. RX PubMed=9302173; DOI=10.1097/00005392-199710000-00075; RA Radmayr C., Culig Z., Glatzl J., Neuschmid-Kaspar F., Bartsch G., RA Klocker H.; RT "Androgen receptor point mutations as the underlying molecular defect in 2 RT patients with androgen insensitivity syndrome."; RL J. Urol. 158:1553-1556(1997). RN [177] RP VARIANTS AIS CYS-572; GLN-753 AND CYS-775. RX PubMed=9544375; DOI=10.1007/s004040050206; RA Komori S., Kasumi H., Sakata K., Tanaka H., Hamada K., Koyama K.; RT "Molecular analysis of the androgen receptor gene in 4 patients with RT complete androgen insensitivity."; RL Arch. Gynecol. Obstet. 261:95-100(1998). RN [178] RP VARIANTS AIS HIS-616 AND GLN-753. RX PubMed=9698822; DOI=10.1590/s0100-879x1998000600008; RA Cabral D.F., Maciel-Guerra A.T., Hackel C.; RT "Mutations of androgen receptor gene in Brazilian patients with male RT pseudohermaphroditism."; RL Braz. J. Med. Biol. Res. 31:775-778(1998). RN [179] RP VARIANT ARG-216, AND CHARACTERIZATION OF VARIANT ARG-216. RX PubMed=9788719; DOI=10.1111/j.1399-0004.1998.tb04282.x; RA Wang Q., Ghadessy F.J., Yong E.L.; RT "Analysis of the transactivation domain of the androgen receptor in RT patients with male infertility."; RL Clin. Genet. 54:185-192(1998). RN [180] RP VARIANT AIS ASP-574. RX PubMed=9421404; DOI=10.1210/endo.139.1.5696; RA Brueggenwirth H.T., Boehmer A.L., Lobaccaro J.M., Chiche L., Sultan C., RA Trapman J., Brinkmann A.O.; RT "Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic RT acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu RT exerts differential effects on DNA binding."; RL Endocrinology 139:103-110(1998). RN [181] RP VARIANTS AIS PRO-257 AND ALA-821. RX PubMed=9610419; DOI=10.3109/09513599809024954; RA Tanaka H., Komori S., Sakata K., Shima H., Koyama K.; RT "One additional mutation at exon A amplifies thermolability of androgen RT receptor in a case with complete androgen insensitivity syndrome."; RL Gynecol. Endocrinol. 12:75-82(1998). RN [182] RP VARIANTS AIS THR-766; TYR-785 AND THR-896, AND VARIANT PAIS GLY-841. RX PubMed=9856504; DOI=10.1007/s004390050864; RA Lundberg Giwercman Y., Nikoshkov A., Lindsten K., Bystroem B., Pousette A., RA Chibalin A.V., Arvidsson S., Tiulpakov A., Semitcheva T.V., Peterkova V., RA Hagenfeldt K., Ritzen E.M., Wedell A.; RT "Functional characterisation of mutations in the ligand-binding domain of RT the androgen receptor gene in patients with androgen insensitivity RT syndrome."; RL Hum. Genet. 103:529-531(1998). RN [183] RP VARIANT AIS VAL-696. RX PubMed=9554754; RA Doerk T., Schnieders F., Jakubiczka S., Wieacker P., Schroeder-Kurth T., RA Schmidtke J.; RT "A new missense substitution at a mutational hot spot of the androgen RT receptor in siblings with complete androgen insensitivity syndrome."; RL Hum. Mutat. 11:337-339(1998). RN [184] RP VARIANT ASP-646. RX PubMed=9554755; RA Nordenskjoeld A., Soederhaell S.; RT "An androgen receptor gene mutation (A645D) in a boy with a normal RT phenotype."; RL Hum. Mutat. 11:339-339(1998). RN [185] RP VARIANT AIS LEU-893. RA Knoke I., Jakubiczka S., Rohrer T., Hanimann B., Werder E.A., Wieacker P.; RT "Single amino acid substitution in the hormone-binding domain of the RT androgen receptor in a family with complete androgen insensitivity syndrome RT (CAIS)."; RL Hum. Mutat. 12:220-220(1998). RN [186] RP VARIANT PAIS GLN-608. RX PubMed=9543136; DOI=10.1210/jcem.83.4.4704; RA Weidemann W., Peters B., Romalo G., Spindler K.D., Schweikert H.-U.; RT "Response to androgen treatment in a patient with partial androgen RT insensitivity and a mutation in the deoxyribonucleic acid-binding domain of RT the androgen receptor."; RL J. Clin. Endocrinol. Metab. 83:1173-1176(1998). RN [187] RP VARIANTS PAIS VAL-744 AND CYS-841. RX PubMed=9768671; DOI=10.1210/jcem.83.10.5201; RA Georget V., Terouanne B., Lumbroso S., Nicolas J.C., Sultan C.; RT "Trafficking of androgen receptor mutants fused to green fluorescent RT protein: a new investigation of partial androgen insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 83:3597-3603(1998). RN [188] RP VARIANT AIS GLU-799. RX PubMed=9851768; DOI=10.1210/jcem.83.12.5358; RA Wang Q., Ghadessy F.J., Trounson A., de Kretser D., McLachlan R., Ng S.C., RA Yong E.L.; RT "Azoospermia associated with a mutation in the ligand-binding domain of an RT androgen receptor displaying normal ligand binding, but defective trans- RT activation."; RL J. Clin. Endocrinol. Metab. 83:4303-4309(1998). RN [189] RP VARIANTS AIS, VARIANT AIS PHE-723, AND VARIANT PAIS HIS-734. RX PubMed=9627582; DOI=10.1016/s0022-3476(98)70387-7; RA Hiort O., Sinnecker G.H., Holterhus P.M., Nitsche E.M., Kruse K.; RT "Inherited and de novo androgen receptor gene mutations: investigation of RT single-case families."; RL J. Pediatr. 132:939-943(1998). RN [190] RP VARIANT PAIS THR-759. RX PubMed=9607727; DOI=10.1016/s0303-7207(97)00229-3; RA Yong E.L., Tut T.G., Ghadessy F.J., Prins G., Ratnam S.S.; RT "Partial androgen insensitivity and correlations with the predicted three RT dimensional structure of the androgen receptor ligand-binding domain."; RL Mol. Cell. Endocrinol. 137:41-50(1998). RN [191] RP VARIANT PAIS LEU-912. RX PubMed=10470409; DOI=10.1046/j.1439-0272.1999.00278.x; RA Knoke I., Jakubiczka S., Lehnert H., Wieacker P.; RT "A new point mutation of the androgen receptor gene in a patient with RT partial androgen resistance and severe oligozoospermia."; RL Andrologia 31:199-201(1999). RN [192] RP VARIANTS PROSTATE CANCER ALA-878 AND ASN-891. RX PubMed=10363963; RA Taplin M.-E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., RA Balk S.P.; RT "Selection for androgen receptor mutations in prostate cancers treated with RT androgen antagonist."; RL Cancer Res. 59:2511-2515(1999). RN [193] RP VARIANTS AIS ILE-685 AND VAL-709. RX PubMed=10425033; RX DOI=10.1002/(sici)1098-1004(1999)14:2<103::aid-humu2>3.0.co;2-a; RA Gottlieb B., Beitel L.K., Lumbroso R., Pinsky L., Trifiro M.; RT "Update of the androgen receptor gene mutations database."; RL Hum. Mutat. 14:103-114(1999). RN [194] RP VARIANT PAIS SER-841. RX PubMed=10502786; RX DOI=10.1002/(sici)1098-1004(199910)14:4<353::aid-humu16>3.0.co;2-7; RA Melo K.F.S., Latronico A.C., Costa E.M.F., Billerbeck A.E.C., RA Mendonca B.B., Arnhold I.J.P.; RT "A novel point mutation (R840S) in the androgen receptor in a Brazilian RT family with partial androgen insensitivity syndrome."; RL Hum. Mutat. 14:353-353(1999). RN [195] RP VARIANTS AIS ARG-392 AND ARG-445. RX PubMed=10571951; RX DOI=10.1002/(sici)1098-1004(199912)14:6<527::aid-humu12>3.0.co;2-x; RA Gottlieb B., Vasiliou D.M., Lumbroso R., Beitel L.K., Pinsky L., RA Trifiro M.A.; RT "Analysis of exon 1 mutations in the androgen receptor gene."; RL Hum. Mutat. 14:527-539(1999). RN [196] RP VARIANT PAIS GLN-608, AND VARIANT AIS LYS-682. RX PubMed=10221692; DOI=10.1093/humrep/14.3.664; RA Chen C.P., Chern S.R., Wang T.Y., Wang W., Wang K.L., Jeng C.J.; RT "Androgen receptor gene mutations in 46,XY females with germ cell RT tumours."; RL Hum. Reprod. 14:664-670(1999). RN [197] RP VARIANT AIS LEU-893. RX PubMed=10404311; DOI=10.1046/j.1442-2042.1999.00065.x; RA Kanayama H., Naroda T., Inoue Y., Kurokawa Y., Kagawa S.; RT "A case of complete testicular feminization: laparoscopic orchiectomy and RT analysis of androgen receptor gene mutation."; RL Int. J. Urol. 6:327-330(1999). RN [198] RP VARIANT PAIS ALA-773, AND VARIANT AIS GLY-872. RX PubMed=10022458; DOI=10.1210/jcem.84.2.5453; RA Shkolny D.L., Beitel L.K., Ginsberg J., Pekeles G., Arbour L., Pinsky L., RA Trifiro M.A.; RT "Discordant measures of androgen-binding kinetics in two mutant androgen RT receptors causing mild or partial androgen insensitivity, respectively."; RL J. Clin. Endocrinol. Metab. 84:805-810(1999). RN [199] RP VARIANT AIS VAL-887. RX PubMed=10359561; DOI=10.1172/jci4289; RA Ghadessy F.J., Lim J., Abdullah A.A., Panet-Raymond V., Choo C.K., RA Lumbroso R., Tut T.G., Gottlieb B., Pinsky L., Trifiro M.A., Yong E.L.; RT "Oligospermic infertility associated with an androgen receptor mutation RT that disrupts interdomain and coactivator (TIF2) interactions."; RL J. Clin. Invest. 103:1517-1525(1999). RN [200] RP VARIANT ALA-684. RX PubMed=10629558; RX DOI=10.1002/(sici)1096-9896(199912)189:4<559::aid-path471>3.0.co;2-y; RA Wallen M.J., Linja M., Kaartinen K., Schleutker J., Visakorpi T.; RT "Androgen receptor gene mutations in hormone-refractory prostate cancer."; RL J. Pathol. 189:559-563(1999). RN [201] RP VARIANTS HIS-702 AND ALA-878. RX PubMed=10569618; DOI=10.1016/s0022-5347(05)68158-x; RA Zhao X.Y., Boyle B., Krishnan A.V., Navone N.M., Peehl D.M., Feldman D.; RT "Two mutations identified in the androgen receptor of the new human RT prostate cancer cell line MDA PCa 2a."; RL J. Urol. 162:2192-2199(1999). RN [202] RP VARIANT PAIS THR-808. RX PubMed=10543676; DOI=10.1016/s0140-6736(99)03205-5; RA Ong Y.C., Wong H.B., Adaikan G., Yong E.L.; RT "Directed pharmacological therapy of ambiguous genitalia due to an androgen RT receptor gene mutation."; RL Lancet 354:1444-1445(1999). RN [203] RP VARIANT AIS LEU-893. RX PubMed=10221770; DOI=10.1016/s0303-7207(98)00237-8; RA Peters I., Weidemann W., Romalo G., Knorr D., Schweikert H.-U., RA Spindler K.D.; RT "An androgen receptor mutation in the direct vicinity of the proposed C- RT terminal alpha-helix of the ligand binding domain containing the AF-2 RT transcriptional activating function core is associated with complete RT androgen insensitivity."; RL Mol. Cell. Endocrinol. 148:47-53(1999). RN [204] RP VARIANT PROSTATE CANCER TYR-620. RX PubMed=10598582; DOI=10.1210/mend.13.12.0382; RA Nazareth L.V., Stenoien D.L., Bingman W.E. III, James A.J., Wu C., RA Zhang Y., Edwards D.P., Mancini M., Marcelli M., Lamb D.J., Weigel N.L.; RT "A C619Y mutation in the human androgen receptor causes inactivation and RT mislocalization of the receptor with concomitant sequestration of SRC-1."; RL Mol. Endocrinol. 13:2065-2075(1999). RN [205] RP ERRATUM OF PUBMED:10598582. RA Nazareth L.V., Stenoien D.L., Bingman W.E. III, James A.J., Wu C., RA Zhang Y., Edwards D.P., Mancini M., Marcelli M., Lamb D.J., Weigel N.L.; RL Mol. Endocrinol. 14:544-544(2000). RN [206] RP VARIANT AIS THR-597. RX PubMed=10590024; DOI=10.1203/00006450-199912000-00009; RA Holterhus P.M., Wiebel J., Sinnecker G.H., Bruggenwirth H.T., Sippell W.G., RA Brinkmann A.O., Kruse K., Hiort O.; RT "Clinical and molecular spectrum of somatic mosaicism in androgen RT insensitivity syndrome."; RL Pediatr. Res. 46:684-690(1999). RN [207] RP VARIANTS AIS PHE-813 AND GLN-832. RX PubMed=10458483; DOI=10.1620/tjem.187.263; RA Yaegashi N., Uehara S., Senoo M., Sato J., Fujiwara J., Funato T., RA Sasaki T., Yajima A.; RT "Point mutations in the steroid-binding domain of the androgen receptor RT gene of five Japanese patients with androgen insensitivity syndrome."; RL Tohoku J. Exp. Med. 187:263-272(1999). RN [208] RP VARIANTS THR-598 AND LEU-726. RX PubMed=10092153; DOI=10.1007/s002400050088; RA Nordenskjoeld A., Friedman E., Tapper-Persson M., Soederhaell C., RA Leviav A., Svensson J., Anvret M.; RT "Screening for mutations in candidate genes for hypospadias."; RL Urol. Res. 27:49-55(1999). RN [209] RP VARIANTS PROSTATE CANCER ALA-576; ARG-581; VAL-587; TYR-620; ALA-758 AND RP GLY-847. RX PubMed=10706109; RA Marcelli M., Ittmann M., Mariani S., Sutherland R.W., Nigam R., Murthy L., RA Zhao Y., DiConcini D., Puxeddu E., Esen A., Eastham J., Weigel N.L., RA Lamb D.J.; RT "Androgen receptor mutations in prostate cancer."; RL Cancer Res. 60:944-949(2000). RN [210] RP VARIANTS AIS AND PAIS, AND VARIANTS AIS SER-492; MET-701; CYS-704; THR-711; RP SER-724; ASP-725; PRO-769; PRO-792; LEU-857; PRO-866 AND ARG-918. RX PubMed=10690872; DOI=10.1210/jcem.85.2.6337; RA Ahmed S.F., Cheng A., Dovey L., Hawkins J.R., Martin H., Rowland J., RA Shimura N., Tait A.D., Hughes I.A.; RT "Phenotypic features, androgen receptor binding, and mutational analysis in RT 278 clinical cases reported as androgen insensitivity syndrome."; RL J. Clin. Endocrinol. Metab. 85:658-665(2000). RN [211] RP VARIANT AIS SER-392. RX PubMed=10946887; DOI=10.1210/jcem.85.8.6713; RA Hiort O., Holterhus P.M., Horter T., Schulze W., Kremke B., RA Bals-Pratsch M., Sinnecker G.H., Kruse K.; RT "Significance of mutations in the androgen receptor gene in males with RT idiopathic infertility."; RL J. Clin. Endocrinol. Metab. 85:2810-2815(2000). RN [212] RP VARIANTS PAIS THR-683 AND GLU-712, AND VARIANTS AIS GLU-744; VAL-828; RP ARG-875 AND TYR-880. RX PubMed=11587068; DOI=10.1007/s100380170021; RA Chavez B., Mendez J.P., Ulloa-Aguirre A., Larrea F., Vilchis F.; RT "Eight novel mutations of the androgen receptor gene in patients with RT androgen insensitivity syndrome."; RL J. Hum. Genet. 46:560-565(2001). RN [213] RP INVOLVEMENT IN ANDROGENETIC ALOPECIA, AND POLYMORPHISM OF POLY-GLY REGION. RX PubMed=11231320; DOI=10.1046/j.1523-1747.2001.01261.x; RA Ellis J.A., Stebbing M., Harrap S.B.; RT "Polymorphism of the androgen receptor gene is associated with male pattern RT baldness."; RL J. Invest. Dermatol. 116:452-455(2001). RN [214] RP VARIANT AIS TYR-706. RX PubMed=11744994; RA Sills E.S., Sholes T.E., Perloe M., Kaplan C.R., Davis J.G., Tucker M.J.; RT "Characterization of a novel receptor mutation A->T at exon 4 in complete RT androgen insensitivity syndrome and a carrier sibling via bidirectional RT polymorphism sequence analysis."; RL Int. J. Mol. Med. 9:45-48(2002). RN [215] RP VARIANT PAIS PHE-548. RX PubMed=11788616; DOI=10.1210/jcem.87.1.7923; RA Bouvattier C., Carel J.C., Lecointre C., David A., Sultan C., RA Bertrand A.M., Morel Y., Chaussain J.L.; RT "Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the RT AR gene."; RL J. Clin. Endocrinol. Metab. 87:29-32(2002). RN [216] RP INVOLVEMENT IN ANDROGENETIC ALOPECIA, AND POLYMORPHISM OF POLY-GLY REGION. RX PubMed=15902657; DOI=10.1086/431425; RA Hillmer A.M., Hanneken S., Ritzmann S., Becker T., Freudenberg J., RA Brockschmidt F.F., Flaquer A., Freudenberg-Hua Y., Jamra R.A., Metzen C., RA Heyn U., Schweiger N., Betz R.C., Blaumeiser B., Hampe J., Schreiber S., RA Schulze T.G., Hennies H.C., Schumacher J., Propping P., Ruzicka T., RA Cichon S., Wienker T.F., Kruse R., Noethen M.M.; RT "Genetic variation in the human androgen receptor gene is the major RT determinant of common early-onset androgenetic alopecia."; RL Am. J. Hum. Genet. 77:140-148(2005). RN [217] RP INVOLVEMENT IN SMAX1. RX PubMed=15851746; DOI=10.1212/01.wnl.0000158617.41819.f3; RA Echaniz-Laguna A., Rousso E., Anheim M., Cossee M., Tranchant C.; RT "A family with early-onset and rapidly progressive X-linked spinal and RT bulbar muscular atrophy."; RL Neurology 64:1458-1460(2005). RN [218] RP VARIANT AIS PHE-577. RX PubMed=14756668; DOI=10.1111/j.0009-9163.2004.00197.x; RA Hooper H.T., Figueiredo B.C., Pavan-Senn C.C., De Lacerda L., Sandrini R., RA Mengarelli J.K., Japp K., Karaviti L.P.; RT "Concordance of phenotypic expression and gender identity in a large RT kindred with a mutation in the androgen receptor."; RL Clin. Genet. 65:183-190(2004). RN [219] RP CHARACTERIZATION OF VARIANTS AIS ASN-696; CYS-764; HIS-775; GLU-799; RP HIS-856 AND PHE-908. RX PubMed=16595706; DOI=10.1677/jme.1.01885; RA Jaeaeskelaeinen J., Deeb A., Schwabe J.W., Mongan N.P., Martin H., RA Hughes I.A.; RT "Human androgen receptor gene ligand-binding-domain mutations leading to RT disrupted interaction between the N- and C-terminal domains."; RL J. Mol. Endocrinol. 36:361-368(2006). RN [220] RP VARIANT AIS LEU-892. RX PubMed=24737579; DOI=10.1111/j.2047-2927.2014.00215.x; RA Akcay T., Fernandez-Cancio M., Turan S., Gueran T., Audi L., Bereket A.; RT "AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children RT with a clinical diagnosis of androgen insensitivity."; RL Andrology 2:572-578(2014). RN [221] RP VARIANT ARG-216. RX PubMed=27535533; DOI=10.1038/nature19057; RG Exome Aggregation Consortium; RA Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., RA O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., RA Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J., RA Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M., RA Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N., RA Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P., RA Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A., RA Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G., RA Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M., RA Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C., RA Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M., RA McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M., RA Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P., RA Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G., RA Daly M.J., MacArthur D.G.; RT "Analysis of protein-coding genetic variation in 60,706 humans."; RL Nature 536:285-291(2016). RN [222] RP POLYMORPHISM. RX PubMed=33647767; DOI=10.1016/j.ebiom.2021.103246; RG Spanish Covid HGE, GEN-COVID Multicenter Study; RA Baldassarri M., Picchiotti N., Fava F., Fallerini C., Benetti E., Daga S., RA Valentino F., Doddato G., Furini S., Giliberti A., Tita R., Amitrano S., RA Bruttini M., Croci S., Meloni I., Pinto A.M., Iuso N., Gabbi C., RA Sciarra F., Venneri M.A., Gori M., Sanarico M., Crawley F.P., Pagotto U., RA Fanelli F., Mezzullo M., Dominguez-Garrido E., Planas-Serra L., RA Schlueter A., Colobran R., Soler-Palacin P., Lapunzina P., Tenorio J., RA Pujol A., Castagna M.G., Marcelli M., Isidori A.M., Renieri A., RA Frullanti E., Mari F.; RT "Shorter androgen receptor polyQ alleles protect against life-threatening RT COVID-19 disease in European males."; RL EBioMedicine 65:103246-103246(2021). CC -!- FUNCTION: Steroid hormone receptors are ligand-activated transcription CC factors that regulate eukaryotic gene expression and affect cellular CC proliferation and differentiation in target tissues (PubMed:19022849). CC Transcription factor activity is modulated by bound coactivator and CC corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the CC androgen response elements/ARE on target genes, negatively regulating CC androgen receptor signaling and androgen-induced cell proliferation CC (PubMed:20812024). Transcription activation is also down-regulated by CC NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. CC {ECO:0000269|PubMed:14664718, ECO:0000269|PubMed:15563469, CC ECO:0000269|PubMed:17591767, ECO:0000269|PubMed:17911242, CC ECO:0000269|PubMed:18084323, ECO:0000269|PubMed:19022849, CC ECO:0000269|PubMed:19345326, ECO:0000269|PubMed:20812024, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:25091737}. CC -!- FUNCTION: [Isoform 3]: Lacks the C-terminal ligand-binding domain and CC therefore constitutively regulates the transcription of a specific set CC of canonical AR-target genes, including PSA/KLK3 and TMPRSS2, CC independently of steroid hormones (PubMed:19244107, PubMed:25008967). CC However, some genes are differentially regulated by full-length AR CC (isoform 1) and isoform 3. Isoform 3-specific target genes may be CC regulated independently of FOXA1 expression (PubMed:25008967). CC {ECO:0000269|PubMed:19244107, ECO:0000269|PubMed:25008967}. CC -!- FUNCTION: [Isoform 4]: Lacks the C-terminal ligand-binding domain and CC may therefore constitutively activate the transcription of a specific CC set of genes independently of steroid hormones. CC {ECO:0000269|PubMed:19244107}. CC -!- ACTIVITY REGULATION: AIM-100 (4-amino-5,6-biaryl-furo[2,3-d]pyrimidine) CC suppresses TNK2-mediated phosphorylation at Tyr-269. Inhibits the CC binding of the Tyr-269 phosphorylated form to androgen-responsive CC enhancers (AREs) and its transcriptional activity. CC {ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Binds DNA as a homodimer. Part of a ternary complex containing CC AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the CC presence of androgen. The ligand binding domain interacts with CC KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with CC EFCAB6/DJBP, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1 and RREB1. CC Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its CC transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4. CC Interacts with MACROD1 (via macro domain) (PubMed:19022849). Interacts CC via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1, CC NCOA2, NCOA3 and MAGEA11. Interacts (via nuclear receptor DNA binding CC domain and nuclear receptor ligand binding domain) with NCOA4 CC (PubMed:15563469, PubMed:8643607). The AR N-terminal poly-Gln region CC binds Ran resulting in enhancement of AR-mediated transactivation. Ran- CC binding decreases as the poly-Gln length increases. Interacts with HIP1 CC (via coiled coil domain). Interacts (via ligand-binding domain) with CC TRIM68. Interacts with TNK2. Interacts with USP26. Interacts with RNF6. CC Interacts (regulated by RNF6 probably through polyubiquitination) with CC RNF14; regulates AR transcriptional activity. Interacts with PRMT2 and CC TRIM24. Interacts with RACK1. Interacts with RANBP10; this interaction CC enhances dihydrotestosterone-induced AR transcriptional activity. CC Interacts with PRPF6 in a hormone-independent way; this interaction CC enhances dihydrotestosterone-induced AR transcriptional activity. CC Interacts with STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with CC LPXN. Interacts with MAK. Part of a complex containing AR, MAK and CC NCOA3. Interacts with CRY1. Interacts with CCAR1 and GATA2. Interacts CC with ZNF318 (By similarity). Interacts with BUD31 (PubMed:25091737). CC Interacts with ARID4A (PubMed:23487765). Interacts with ARID4B (By CC similarity). Interacts (via NR LBD domain) with ZBTB7A; the interaction CC is direct and androgen-dependent (PubMed:20812024). Interacts with CC NCOR1 (PubMed:20812024). Interacts with NCOR2 (PubMed:20812024). CC Interacts with CRY2 in a ligand-dependent manner (By similarity). CC Interacts (via NR LBD domain) with RWDD1; the interaction is direct and CC may stimulate AR activity (PubMed:22406838). CC {ECO:0000250|UniProtKB:P15207, ECO:0000250|UniProtKB:P19091, CC ECO:0000269|PubMed:10075738, ECO:0000269|PubMed:10332029, CC ECO:0000269|PubMed:10383460, ECO:0000269|PubMed:10400640, CC ECO:0000269|PubMed:10625666, ECO:0000269|PubMed:10930412, CC ECO:0000269|PubMed:12039962, ECO:0000269|PubMed:12361945, CC ECO:0000269|PubMed:12612053, ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:14609956, ECO:0000269|PubMed:14664718, CC ECO:0000269|PubMed:15525515, ECO:0000269|PubMed:15563469, CC ECO:0000269|PubMed:16027218, ECO:0000269|PubMed:16051670, CC ECO:0000269|PubMed:16951154, ECO:0000269|PubMed:17311914, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:17550981, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:17591767, CC ECO:0000269|PubMed:17711855, ECO:0000269|PubMed:17911242, CC ECO:0000269|PubMed:18007036, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18222118, ECO:0000269|PubMed:18451096, CC ECO:0000269|PubMed:18451177, ECO:0000269|PubMed:19022849, CC ECO:0000269|PubMed:19345326, ECO:0000269|PubMed:19909775, CC ECO:0000269|PubMed:20501646, ECO:0000269|PubMed:20812024, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21512132, CC ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:22406838, CC ECO:0000269|PubMed:23487765, ECO:0000269|PubMed:23887938, CC ECO:0000269|PubMed:25091737, ECO:0000269|PubMed:8643607}. CC -!- INTERACTION: CC P10275; P00519: ABL1; NbExp=2; IntAct=EBI-608057, EBI-375543; CC P10275; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-608057, EBI-540797; CC P10275; P51451: BLK; NbExp=3; IntAct=EBI-608057, EBI-2105445; CC P10275; Q8WV28: BLNK; NbExp=2; IntAct=EBI-608057, EBI-2623522; CC P10275; O60885-1: BRD4; NbExp=6; IntAct=EBI-608057, EBI-9345088; CC P10275; P78543: BTG2; NbExp=4; IntAct=EBI-608057, EBI-1047576; CC P10275; Q14790: CASP8; NbExp=3; IntAct=EBI-608057, EBI-78060; CC P10275; P24385: CCND1; NbExp=4; IntAct=EBI-608057, EBI-375001; CC P10275; Q92793: CREBBP; NbExp=3; IntAct=EBI-608057, EBI-81215; CC P10275; O14595: CTDSP2; NbExp=3; IntAct=EBI-608057, EBI-2802973; CC P10275; P35222: CTNNB1; NbExp=15; IntAct=EBI-608057, EBI-491549; CC P10275; Q9UER7: DAXX; NbExp=5; IntAct=EBI-608057, EBI-77321; CC P10275; P20711: DDC; NbExp=2; IntAct=EBI-608057, EBI-1632155; CC P10275; P11308: ERG; NbExp=4; IntAct=EBI-608057, EBI-79704; CC P10275; P07332: FES; NbExp=3; IntAct=EBI-608057, EBI-1055635; CC P10275; P09769: FGR; NbExp=3; IntAct=EBI-608057, EBI-1383732; CC P10275; Q14192: FHL2; NbExp=2; IntAct=EBI-608057, EBI-701903; CC P10275; Q02790: FKBP4; NbExp=2; IntAct=EBI-608057, EBI-1047444; CC P10275; P55317: FOXA1; NbExp=4; IntAct=EBI-608057, EBI-3918034; CC P10275; O75593: FOXH1; NbExp=3; IntAct=EBI-608057, EBI-1759806; CC P10275; Q14451: GRB7; NbExp=3; IntAct=EBI-608057, EBI-970191; CC P10275; P06396: GSN; NbExp=2; IntAct=EBI-608057, EBI-351506; CC P10275; P56524: HDAC4; NbExp=4; IntAct=EBI-608057, EBI-308629; CC P10275; Q16665: HIF1A; NbExp=2; IntAct=EBI-608057, EBI-447269; CC P10275; Q16666: IFI16; NbExp=3; IntAct=EBI-608057, EBI-2867186; CC P10275; O15357: INPPL1; NbExp=3; IntAct=EBI-608057, EBI-1384248; CC P10275; Q15652: JMJD1C; NbExp=4; IntAct=EBI-608057, EBI-1224969; CC P10275; Q92993: KAT5; NbExp=2; IntAct=EBI-608057, EBI-399080; CC P10275; O95251: KAT7; NbExp=5; IntAct=EBI-608057, EBI-473199; CC P10275; Q9BY66: KDM5D; NbExp=2; IntAct=EBI-608057, EBI-1246860; CC P10275; Q9BY66-3: KDM5D; NbExp=2; IntAct=EBI-608057, EBI-12559887; CC P10275; Q03164: KMT2A; NbExp=4; IntAct=EBI-608057, EBI-591370; CC P10275; O14686: KMT2D; NbExp=3; IntAct=EBI-608057, EBI-996065; CC P10275; P06239: LCK; NbExp=7; IntAct=EBI-608057, EBI-1348; CC P10275; P07948: LYN; NbExp=5; IntAct=EBI-608057, EBI-79452; CC P10275; P20794: MAK; NbExp=5; IntAct=EBI-608057, EBI-3911321; CC P10275; P42679: MATK; NbExp=4; IntAct=EBI-608057, EBI-751664; CC P10275; Q00987: MDM2; NbExp=2; IntAct=EBI-608057, EBI-389668; CC P10275; Q15596: NCOA2; NbExp=4; IntAct=EBI-608057, EBI-81236; CC P10275; Q14686: NCOA6; NbExp=3; IntAct=EBI-608057, EBI-78670; CC P10275; O96028: NSD2; NbExp=5; IntAct=EBI-608057, EBI-2693298; CC P10275; Q99497: PARK7; NbExp=6; IntAct=EBI-608057, EBI-1164361; CC P10275; P27986: PIK3R1; NbExp=5; IntAct=EBI-608057, EBI-79464; CC P10275; O00459: PIK3R2; NbExp=14; IntAct=EBI-608057, EBI-346930; CC P10275; Q92569: PIK3R3; NbExp=37; IntAct=EBI-608057, EBI-79893; CC P10275; P19174: PLCG1; NbExp=22; IntAct=EBI-608057, EBI-79387; CC P10275; P16885: PLCG2; NbExp=6; IntAct=EBI-608057, EBI-617403; CC P10275; Q06830: PRDX1; NbExp=3; IntAct=EBI-608057, EBI-353193; CC P10275; P78527: PRKDC; NbExp=3; IntAct=EBI-608057, EBI-352053; CC P10275; Q06124: PTPN11; NbExp=12; IntAct=EBI-608057, EBI-297779; CC P10275; P20936: RASA1; NbExp=16; IntAct=EBI-608057, EBI-1026476; CC P10275; Q9UBS8: RNF14; NbExp=2; IntAct=EBI-608057, EBI-2130308; CC P10275; Q9Y252: RNF6; NbExp=10; IntAct=EBI-608057, EBI-2341483; CC P10275; O14796: SH2D1B; NbExp=3; IntAct=EBI-608057, EBI-3923013; CC P10275; Q9NP31: SH2D2A; NbExp=6; IntAct=EBI-608057, EBI-490630; CC P10275; P29353: SHC1; NbExp=14; IntAct=EBI-608057, EBI-78835; CC P10275; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-608057, EBI-9453524; CC P10275; Q5VZ18: SHE; NbExp=3; IntAct=EBI-608057, EBI-3956977; CC P10275; Q15797: SMAD1; NbExp=6; IntAct=EBI-608057, EBI-1567153; CC P10275; O14544: SOCS6; NbExp=4; IntAct=EBI-608057, EBI-3929549; CC P10275; P12931: SRC; NbExp=7; IntAct=EBI-608057, EBI-621482; CC P10275; Q9ULZ2: STAP1; NbExp=2; IntAct=EBI-608057, EBI-6083058; CC P10275; P63165: SUMO1; NbExp=7; IntAct=EBI-608057, EBI-80140; CC P10275; Q9HBL0: TNS1; NbExp=3; IntAct=EBI-608057, EBI-3389814; CC P10275; P07947: YES1; NbExp=5; IntAct=EBI-608057, EBI-515331; CC P10275; Q9R1E0: Foxo1; Xeno; NbExp=4; IntAct=EBI-608057, EBI-1371343; CC P10275; Q06986: Siah2; Xeno; NbExp=6; IntAct=EBI-608057, EBI-957413; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:15634333, ECO:0000269|PubMed:17587566, CC ECO:0000269|PubMed:19244107, ECO:0000269|PubMed:19345326, CC ECO:0000269|PubMed:25091737}. Cytoplasm {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:19244107}. CC Note=Detected at the promoter of target genes (PubMed:25091737). CC Predominantly cytoplasmic in unligated form but translocates to the CC nucleus upon ligand-binding. Can also translocate to the nucleus in CC unligated form in the presence of RACK1. {ECO:0000269|PubMed:12958311, CC ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:25091737}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=AR-B; CC IsoId=P10275-1; Sequence=Displayed; CC Name=2; Synonyms=AR-A, Variant AR45; CC IsoId=P10275-2; Sequence=VSP_036889, VSP_036890; CC Name=3; Synonyms=AR3, AR-V7 {ECO:0000303|PubMed:25008967}; CC IsoId=P10275-3; Sequence=VSP_058166, VSP_058168; CC Name=4; Synonyms=AR4; CC IsoId=P10275-4; Sequence=VSP_058167, VSP_058169; CC -!- TISSUE SPECIFICITY: [Isoform 2]: Mainly expressed in heart and skeletal CC muscle. {ECO:0000269|PubMed:15634333}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: Expressed in basal and stromal cells CC of the prostate (at protein level). {ECO:0000269|PubMed:19244107}. CC -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a CC DNA-binding domain and a C-terminal ligand-binding domain. In the CC presence of bound steroid the ligand-binding domain interacts with the CC N-terminal modulating domain, and thereby activates AR transcription CC factor activity. Agonist binding is required for dimerization and CC binding to target DNA. The transcription factor activity of the complex CC formed by ligand-activated AR and DNA is modulated by interactions with CC coactivator and corepressor proteins (PubMed:25091737). Interaction CC with RANBP9 is mediated by both the N-terminal domain and the DNA- CC binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA- CC binding domain. {ECO:0000269|PubMed:25091737}. CC -!- PTM: Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. CC Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked CC polyubiquitination by RNF6 modulates AR transcriptional activity and CC specificity. {ECO:0000269|PubMed:11121022, ECO:0000269|PubMed:19345326, CC ECO:0000269|PubMed:20501646}. CC -!- PTM: Phosphorylated in prostate cancer cells in response to several CC growth factors including EGF. Phosphorylation is induced by c-Src CC kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an CC increase in phosphorylation and Src kinase activity is associated with CC prostate cancer progression. Phosphorylation by TNK2 enhances the DNA- CC binding and transcriptional activity and may be responsible for CC androgen-independent progression of prostate cancer. Phosphorylation at CC Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. CC Phosphorylation by PAK6 leads to AR-mediated transcription inhibition. CC {ECO:0000269|PubMed:14573606, ECO:0000269|PubMed:17045208, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:20623637, CC ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21512132}. CC -!- PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required CC for plasma membrane targeting and for rapid intracellular signaling via CC ERK and AKT kinases and cAMP generation. {ECO:0000269|PubMed:22031296}. CC -!- POLYMORPHISM: The poly-Gln region of AR is highly polymorphic and the CC number of Gln varies in the population (from 17 to 26). A smaller size CC of the poly-Gln region may be associated with the development of CC prostate cancer. Long poly-Gln alleles (>23) may be associated with CC higher testosterone levels and severe clinical outcome in COVID-19 CC disease (PubMed:33647767). {ECO:0000269|PubMed:1561105, CC ECO:0000269|PubMed:2062380, ECO:0000269|PubMed:33647767, CC ECO:0000269|PubMed:8292051, ECO:0000269|PubMed:9096391}. CC -!- POLYMORPHISM: The poly-Gly region of AR is polymorphic and ranges from CC 24 to 31 Gly. A poly-Gly region shorter or equal to 23 may be CC associated with the development of androgenetic alopecia. CC {ECO:0000269|PubMed:11231320, ECO:0000269|PubMed:15902657}. CC -!- DISEASE: Androgen insensitivity syndrome (AIS) [MIM:300068]: An X- CC linked recessive form of pseudohermaphroditism due end-organ resistance CC to androgen. Affected males have female external genitalia, female CC breast development, blind vagina, absent uterus and female adnexa, and CC abdominal or inguinal testes, despite a normal 46,XY karyotype. CC {ECO:0000269|PubMed:10022458, ECO:0000269|PubMed:10221692, CC ECO:0000269|PubMed:10221770, ECO:0000269|PubMed:10359561, CC ECO:0000269|PubMed:10404311, ECO:0000269|PubMed:10425033, CC ECO:0000269|PubMed:10458483, ECO:0000269|PubMed:10571951, CC ECO:0000269|PubMed:10590024, ECO:0000269|PubMed:10690872, CC ECO:0000269|PubMed:10946887, ECO:0000269|PubMed:11587068, CC ECO:0000269|PubMed:11744994, ECO:0000269|PubMed:1307250, CC ECO:0000269|PubMed:1316540, ECO:0000269|PubMed:1426313, CC ECO:0000269|PubMed:1430233, ECO:0000269|PubMed:1458719, CC ECO:0000269|PubMed:1464650, ECO:0000269|PubMed:14756668, CC ECO:0000269|PubMed:1480178, ECO:0000269|PubMed:1487249, CC ECO:0000269|PubMed:1569163, ECO:0000269|PubMed:1609793, CC ECO:0000269|PubMed:16129672, ECO:0000269|PubMed:16595706, CC ECO:0000269|PubMed:1775137, ECO:0000269|PubMed:1999491, CC ECO:0000269|PubMed:2082179, ECO:0000269|PubMed:24737579, CC ECO:0000269|PubMed:2594783, ECO:0000269|PubMed:7537149, CC ECO:0000269|PubMed:7581399, ECO:0000269|PubMed:7626493, CC ECO:0000269|PubMed:7633398, ECO:0000269|PubMed:7641413, CC ECO:0000269|PubMed:7671849, ECO:0000269|PubMed:7929841, CC ECO:0000269|PubMed:7962294, ECO:0000269|PubMed:7970939, CC ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:7981689, CC ECO:0000269|PubMed:7993455, ECO:0000269|PubMed:8040309, CC ECO:0000269|PubMed:8096390, ECO:0000269|PubMed:8103398, CC ECO:0000269|PubMed:8162033, ECO:0000269|PubMed:8224266, CC ECO:0000269|PubMed:8240973, ECO:0000269|PubMed:8281140, CC ECO:0000269|PubMed:8325950, ECO:0000269|PubMed:8339746, CC ECO:0000269|PubMed:8413310, ECO:0000269|PubMed:8446106, CC ECO:0000269|PubMed:8626869, ECO:0000269|PubMed:8647313, CC ECO:0000269|PubMed:8683794, ECO:0000269|PubMed:8723113, CC ECO:0000269|PubMed:8768864, ECO:0000269|PubMed:8809734, CC ECO:0000269|PubMed:8830623, ECO:0000269|PubMed:8918984, CC ECO:0000269|PubMed:8990010, ECO:0000269|PubMed:9001799, CC ECO:0000269|PubMed:9007482, ECO:0000269|PubMed:9039340, CC ECO:0000269|PubMed:9106550, ECO:0000269|PubMed:9160185, CC ECO:0000269|PubMed:9252933, ECO:0000269|PubMed:9255042, CC ECO:0000269|PubMed:9302173, ECO:0000269|PubMed:9328206, CC ECO:0000269|PubMed:9421404, ECO:0000269|PubMed:9544375, CC ECO:0000269|PubMed:9554754, ECO:0000269|PubMed:9610419, CC ECO:0000269|PubMed:9627582, ECO:0000269|PubMed:9698822, CC ECO:0000269|PubMed:9851768, ECO:0000269|PubMed:9856504, CC ECO:0000269|Ref.118, ECO:0000269|Ref.185}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Spinal and bulbar muscular atrophy X-linked 1 (SMAX1) CC [MIM:313200]: An X-linked recessive form of spinal muscular atrophy. CC Spinal muscular atrophy refers to a group of neuromuscular disorders CC characterized by degeneration of the anterior horn cells of the spinal CC cord, leading to symmetrical muscle weakness and atrophy. SMAX1 occurs CC only in men. Age at onset is usually in the third to fifth decade of CC life, but earlier involvement has been reported. It is characterized by CC slowly progressive limb and bulbar muscle weakness with fasciculations, CC muscle atrophy, and gynecomastia. The disorder is clinically similar to CC classic forms of autosomal spinal muscular atrophy. CC {ECO:0000269|PubMed:15851746}. Note=The disease is caused by variants CC affecting the gene represented in this entry. Caused by trinucleotide CC CAG repeat expansion. In SMAX1 patients the number of Gln ranges from CC 38 to 62. Longer expansions result in earlier onset and more severe CC clinical manifestations of the disease. CC -!- DISEASE: Prostate cancer, hereditary, X-linked 3 (HPCX3) [MIM:301120]: CC A condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:8530589}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Note=Defects in AR may play a role in metastatic prostate CC cancer. The mutated receptor stimulates prostate growth and metastases CC development despite of androgen ablation. This treatment can reduce CC primary and metastatic lesions probably by inducing apoptosis of tumor CC cells when they express the wild-type receptor. CC {ECO:0000269|PubMed:10363963, ECO:0000269|PubMed:10569618, CC ECO:0000269|PubMed:1562539, ECO:0000269|PubMed:16129672, CC ECO:0000269|PubMed:17311914, ECO:0000269|PubMed:2260966, CC ECO:0000269|PubMed:25091737, ECO:0000269|PubMed:8187068, CC ECO:0000269|PubMed:8274409, ECO:0000269|PubMed:8827083}. CC -!- DISEASE: Androgen insensitivity, partial (PAIS) [MIM:312300]: A CC disorder that is characterized by hypospadias, hypogonadism, CC gynecomastia, genital ambiguity, normal XY karyotype, and a pedigree CC pattern consistent with X-linked recessive inheritance. Some patients CC present azoospermia or severe oligospermia without other clinical CC manifestations. {ECO:0000269|PubMed:10022458, CC ECO:0000269|PubMed:10221692, ECO:0000269|PubMed:10470409, CC ECO:0000269|PubMed:10502786, ECO:0000269|PubMed:10543676, CC ECO:0000269|PubMed:10690872, ECO:0000269|PubMed:11587068, CC ECO:0000269|PubMed:11788616, ECO:0000269|PubMed:1303262, CC ECO:0000269|PubMed:1307250, ECO:0000269|PubMed:1316540, CC ECO:0000269|PubMed:1424203, ECO:0000269|PubMed:1430233, CC ECO:0000269|PubMed:1458719, ECO:0000269|PubMed:14756668, CC ECO:0000269|PubMed:2010552, ECO:0000269|PubMed:7581399, CC ECO:0000269|PubMed:7649358, ECO:0000269|PubMed:7671849, CC ECO:0000269|PubMed:7909256, ECO:0000269|PubMed:7910529, CC ECO:0000269|PubMed:7929841, ECO:0000269|PubMed:7970939, CC ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:8033918, CC ECO:0000269|PubMed:8097257, ECO:0000269|PubMed:8126121, CC ECO:0000269|PubMed:8205256, ECO:0000269|PubMed:8281139, CC ECO:0000269|PubMed:8325932, ECO:0000269|PubMed:8325950, CC ECO:0000269|PubMed:8339746, ECO:0000269|PubMed:8446106, CC ECO:0000269|PubMed:8550758, ECO:0000269|PubMed:8723113, CC ECO:0000269|PubMed:8809734, ECO:0000269|PubMed:8823308, CC ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:9039340, CC ECO:0000269|PubMed:9196614, ECO:0000269|PubMed:9302173, CC ECO:0000269|PubMed:9329414, ECO:0000269|PubMed:9543136, CC ECO:0000269|PubMed:9607727, ECO:0000269|PubMed:9627582, CC ECO:0000269|PubMed:9768671, ECO:0000269|PubMed:9856504, CC ECO:0000269|Ref.126}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Hypospadias 1, X-linked (HYSP1) [MIM:300633]: A common CC malformation in which the urethra opens on the ventral side of the CC penis, due to developmental arrest of urethral fusion. The opening can CC be located glandular, penile, or even more posterior in the scrotum or CC perineum. Hypospadias is a feature of several syndromic disorders, CC including the androgen insensitivity syndrome and Opitz syndrome. CC {ECO:0000269|PubMed:8097257}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In the absence of ligand, steroid hormone receptors are CC thought to be weakly associated with nuclear components; hormone CC binding greatly increases receptor affinity. The hormone-receptor CC complex appears to recognize discrete DNA sequences upstream of CC transcriptional start sites. CC -!- MISCELLANEOUS: Transcriptional activity is enhanced by binding to CC RANBP9. CC -!- MISCELLANEOUS: The level of tyrosine phosphorylation may serve as a CC diagnostic tool to predict patient outcome in response to hormone- CC ablation therapy. Inhibition of tyrosine phosphorylation may be an CC effective intervention target for hormone-refractory prostate cancer. CC -!- MISCELLANEOUS: [Isoform 3]: Minor isoform up-regulated in prostate CC cancer cells. {ECO:0000269|PubMed:19244107}. CC -!- MISCELLANEOUS: [Isoform 4]: Minor isoform identified in prostate cancer CC cells. {ECO:0000269|PubMed:19244107}. CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3 CC subfamily. {ECO:0000305}. CC -!- CAUTION: Had previously been shown to interact with PELP1. However this CC paper was retracted as cell-based data was viewed as unreliable. CC {ECO:0000305|PubMed:12415108, ECO:0000305|PubMed:19666546}. CC -!- WEB RESOURCE: Name=Androgen receptor gene mutations database; CC URL="https://androgendb.mcgill.ca"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/685/AR"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Androgen receptor entry; CC URL="https://en.wikipedia.org/wiki/Androgen_receptor"; CC -!- WEB RESOURCE: Name=X-chromosome gene database, androgen receptor (AR); CC Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/AR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M20132; AAA51729.1; -; mRNA. DR EMBL; M23263; AAA51775.1; -; mRNA. DR EMBL; M27430; AAA51886.1; -; Genomic_DNA. DR EMBL; M27423; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27424; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27425; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27426; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27427; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27428; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M27429; AAA51886.1; JOINED; Genomic_DNA. DR EMBL; M34233; AAA51780.1; -; mRNA. DR EMBL; M21748; AAA51771.1; -; mRNA. DR EMBL; M35851; AAA51772.1; -; Genomic_DNA. DR EMBL; M35844; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35845; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35846; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35847; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35848; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35849; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; M35850; AAA51772.1; JOINED; Genomic_DNA. DR EMBL; AX453758; -; NOT_ANNOTATED_CDS; Unassigned_DNA. DR EMBL; FJ235916; ACN39559.1; -; mRNA. DR EMBL; FJ235917; ACN39560.1; -; mRNA. DR EMBL; AL049564; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL158016; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL356358; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471132; EAX05380.1; -; Genomic_DNA. DR EMBL; BC132975; AAI32976.1; -; mRNA. DR EMBL; L29496; AAA51770.1; -; mRNA. DR EMBL; U16371; AAB60346.1; -; Genomic_DNA. DR EMBL; M20260; AAA51774.1; -; mRNA. DR EMBL; S79366; AAB21256.2; -; Genomic_DNA. DR EMBL; S79368; AAB21257.2; -; Genomic_DNA. DR CCDS; CCDS14387.1; -. [P10275-1] DR CCDS; CCDS87754.1; -. [P10275-3] DR PIR; A39248; A39248. DR RefSeq; NP_000035.2; NM_000044.4. [P10275-1] DR RefSeq; NP_001011645.1; NM_001011645.3. [P10275-2] DR RefSeq; NP_001334990.1; NM_001348061.1. [P10275-3] DR RefSeq; NP_001334992.1; NM_001348063.1. [P10275-4] DR RefSeq; NP_001334993.1; NM_001348064.1. DR PDB; 1E3G; X-ray; 2.40 A; A=658-920. DR PDB; 1GS4; X-ray; 1.95 A; A=671-918. DR PDB; 1T5Z; X-ray; 2.30 A; A=670-920. DR PDB; 1T63; X-ray; 2.07 A; A=670-919. DR PDB; 1T65; X-ray; 1.66 A; A=670-920. DR PDB; 1XJ7; X-ray; 2.70 A; A=664-920. DR PDB; 1XOW; X-ray; 1.80 A; A=672-920, B=20-30. DR PDB; 1XQ3; X-ray; 2.25 A; A=672-920. DR PDB; 1Z95; X-ray; 1.80 A; A=673-918. DR PDB; 2AM9; X-ray; 1.64 A; A=655-920. DR PDB; 2AMA; X-ray; 1.90 A; A=655-920. DR PDB; 2AMB; X-ray; 1.75 A; A=655-920. DR PDB; 2AO6; X-ray; 1.89 A; A=672-920. DR PDB; 2AX6; X-ray; 1.50 A; A=665-920. DR PDB; 2AX7; X-ray; 1.90 A; A=665-920. DR PDB; 2AX8; X-ray; 1.70 A; A=665-920. DR PDB; 2AX9; X-ray; 1.65 A; A=665-920. DR PDB; 2AXA; X-ray; 1.80 A; A=665-920. DR PDB; 2HVC; X-ray; 2.10 A; A=670-919. DR PDB; 2OZ7; X-ray; 1.80 A; A=672-920. DR PDB; 2PIO; X-ray; 2.03 A; A=670-920. DR PDB; 2PIP; X-ray; 1.80 A; L=670-920. DR PDB; 2PIQ; X-ray; 2.40 A; A=670-920. DR PDB; 2PIR; X-ray; 2.10 A; A=670-920. DR PDB; 2PIT; X-ray; 1.76 A; A=670-920. DR PDB; 2PIU; X-ray; 2.12 A; A=670-920. DR PDB; 2PIV; X-ray; 1.95 A; A=670-920. DR PDB; 2PIW; X-ray; 2.58 A; A=670-920. DR PDB; 2PIX; X-ray; 2.40 A; A=670-920. DR PDB; 2PKL; X-ray; 2.49 A; A=670-920. DR PDB; 2PNU; X-ray; 1.65 A; A=655-920. DR PDB; 2Q7I; X-ray; 1.87 A; A=664-920, B=20-30. DR PDB; 2Q7J; X-ray; 1.90 A; A=664-920. DR PDB; 2Q7K; X-ray; 1.80 A; A=664-920, B=20-30. DR PDB; 2Q7L; X-ray; 1.92 A; A=664-920. DR PDB; 2YHD; X-ray; 2.20 A; A=672-920. DR PDB; 2YLO; X-ray; 2.50 A; A=665-920. DR PDB; 2YLP; X-ray; 2.30 A; A=665-920. DR PDB; 2YLQ; X-ray; 2.40 A; A=665-920. DR PDB; 2Z4J; X-ray; 2.60 A; A=672-919. DR PDB; 3B5R; X-ray; 1.80 A; A=672-920. DR PDB; 3B65; X-ray; 1.80 A; A=672-920. DR PDB; 3B66; X-ray; 1.65 A; A=672-920. DR PDB; 3B67; X-ray; 1.90 A; A=672-920. DR PDB; 3B68; X-ray; 1.90 A; A=672-920. DR PDB; 3BTR; X-ray; 2.60 A; B=622-636. DR PDB; 3L3X; X-ray; 1.55 A; A=671-919. DR PDB; 3L3Z; X-ray; 2.00 A; A=671-919. DR PDB; 3RLJ; X-ray; 1.90 A; A=672-918. DR PDB; 3RLL; X-ray; 1.70 A; A=672-918. DR PDB; 3V49; X-ray; 1.70 A; A=655-920, B=21-31. DR PDB; 3V4A; X-ray; 1.95 A; A=672-920, B=21-31. DR PDB; 3ZQT; X-ray; 2.29 A; A=665-920. DR PDB; 4HLW; X-ray; 2.50 A; A=665-920. DR PDB; 4K7A; X-ray; 2.44 A; A=671-919. DR PDB; 4OEA; X-ray; 2.12 A; A=671-920. DR PDB; 4OED; X-ray; 2.79 A; A=671-920. DR PDB; 4OEY; X-ray; 1.83 A; A=671-920. DR PDB; 4OEZ; X-ray; 1.80 A; A=671-920. DR PDB; 4OFR; X-ray; 2.26 A; A=671-920. DR PDB; 4OFU; X-ray; 2.12 A; A=671-920. DR PDB; 4OGH; X-ray; 2.98 A; A=671-920. DR PDB; 4OH5; X-ray; 2.00 A; A=671-920. DR PDB; 4OH6; X-ray; 3.56 A; A=671-920. DR PDB; 4OHA; X-ray; 1.42 A; A=671-920. DR PDB; 4OIL; X-ray; 2.51 A; A=671-920. DR PDB; 4OIU; X-ray; 3.01 A; A=671-920. DR PDB; 4OJ9; X-ray; 3.31 A; A=671-920. DR PDB; 4OJB; X-ray; 2.00 A; A=671-920. DR PDB; 4OK1; X-ray; 2.09 A; A=671-920. DR PDB; 4OKB; X-ray; 2.95 A; A=671-920. DR PDB; 4OKT; X-ray; 2.50 A; A=671-920. DR PDB; 4OKW; X-ray; 2.00 A; A=671-920. DR PDB; 4OKX; X-ray; 2.10 A; A=671-920. DR PDB; 4OLM; X-ray; 2.80 A; A=671-920. DR PDB; 4QL8; X-ray; 2.10 A; A=663-920. DR PDB; 5CJ6; X-ray; 2.07 A; A=642-920, B=21-30. DR PDB; 5JJM; X-ray; 2.15 A; A/B/C/D=669-920. DR PDB; 5T8E; X-ray; 2.71 A; A=672-920. DR PDB; 5T8J; X-ray; 2.70 A; A=672-920. DR PDB; 5V8Q; X-ray; 1.44 A; A=672-920. DR PDB; 5VO4; X-ray; 2.35 A; A=671-920. DR PDB; 7ZTX; X-ray; 1.89 A; A=672-920. DR PDB; 7ZTZ; X-ray; 1.40 A; A=672-920. DR PDB; 7ZU1; X-ray; 1.68 A; A=672-920. DR PDB; 7ZU2; X-ray; 1.74 A; A=672-920. DR PDB; 8E1A; X-ray; 1.20 A; A=665-920. DR PDB; 8FGY; X-ray; 2.20 A; A=663-920. DR PDB; 8FGZ; X-ray; 1.61 A; A=663-920. DR PDB; 8FH0; X-ray; 1.59 A; A=663-920. DR PDB; 8FH1; X-ray; 1.69 A; A=663-920. DR PDB; 8FH2; X-ray; 1.59 A; A=663-920. DR PDB; 8RM6; X-ray; 2.05 A; A/B=557-629. DR PDB; 8RM7; X-ray; 2.25 A; A/B=557-629. DR PDBsum; 1E3G; -. DR PDBsum; 1GS4; -. DR PDBsum; 1T5Z; -. DR PDBsum; 1T63; -. DR PDBsum; 1T65; -. DR PDBsum; 1XJ7; -. DR PDBsum; 1XOW; -. DR PDBsum; 1XQ3; -. DR PDBsum; 1Z95; -. DR PDBsum; 2AM9; -. DR PDBsum; 2AMA; -. DR PDBsum; 2AMB; -. DR PDBsum; 2AO6; -. DR PDBsum; 2AX6; -. DR PDBsum; 2AX7; -. DR PDBsum; 2AX8; -. DR PDBsum; 2AX9; -. DR PDBsum; 2AXA; -. DR PDBsum; 2HVC; -. DR PDBsum; 2OZ7; -. DR PDBsum; 2PIO; -. DR PDBsum; 2PIP; -. DR PDBsum; 2PIQ; -. DR PDBsum; 2PIR; -. DR PDBsum; 2PIT; -. DR PDBsum; 2PIU; -. DR PDBsum; 2PIV; -. DR PDBsum; 2PIW; -. DR PDBsum; 2PIX; -. DR PDBsum; 2PKL; -. DR PDBsum; 2PNU; -. DR PDBsum; 2Q7I; -. DR PDBsum; 2Q7J; -. DR PDBsum; 2Q7K; -. DR PDBsum; 2Q7L; -. DR PDBsum; 2YHD; -. DR PDBsum; 2YLO; -. DR PDBsum; 2YLP; -. DR PDBsum; 2YLQ; -. DR PDBsum; 2Z4J; -. DR PDBsum; 3B5R; -. DR PDBsum; 3B65; -. DR PDBsum; 3B66; -. DR PDBsum; 3B67; -. DR PDBsum; 3B68; -. DR PDBsum; 3BTR; -. DR PDBsum; 3L3X; -. DR PDBsum; 3L3Z; -. DR PDBsum; 3RLJ; -. DR PDBsum; 3RLL; -. DR PDBsum; 3V49; -. DR PDBsum; 3V4A; -. DR PDBsum; 3ZQT; -. DR PDBsum; 4HLW; -. DR PDBsum; 4K7A; -. DR PDBsum; 4OEA; -. DR PDBsum; 4OED; -. DR PDBsum; 4OEY; -. DR PDBsum; 4OEZ; -. DR PDBsum; 4OFR; -. DR PDBsum; 4OFU; -. DR PDBsum; 4OGH; -. DR PDBsum; 4OH5; -. DR PDBsum; 4OH6; -. DR PDBsum; 4OHA; -. DR PDBsum; 4OIL; -. DR PDBsum; 4OIU; -. DR PDBsum; 4OJ9; -. DR PDBsum; 4OJB; -. DR PDBsum; 4OK1; -. DR PDBsum; 4OKB; -. DR PDBsum; 4OKT; -. DR PDBsum; 4OKW; -. DR PDBsum; 4OKX; -. DR PDBsum; 4OLM; -. DR PDBsum; 4QL8; -. DR PDBsum; 5CJ6; -. DR PDBsum; 5JJM; -. DR PDBsum; 5T8E; -. DR PDBsum; 5T8J; -. DR PDBsum; 5V8Q; -. DR PDBsum; 5VO4; -. DR PDBsum; 7ZTX; -. DR PDBsum; 7ZTZ; -. DR PDBsum; 7ZU1; -. DR PDBsum; 7ZU2; -. DR PDBsum; 8E1A; -. DR PDBsum; 8FGY; -. DR PDBsum; 8FGZ; -. DR PDBsum; 8FH0; -. DR PDBsum; 8FH1; -. DR PDBsum; 8FH2; -. DR PDBsum; 8RM6; -. DR PDBsum; 8RM7; -. DR AlphaFoldDB; P10275; -. DR PCDDB; P10275; -. DR SMR; P10275; -. DR BioGRID; 106862; 954. DR CORUM; P10275; -. DR DIP; DIP-125N; -. DR ELM; P10275; -. DR FunCoup; P10275; 1131. DR IntAct; P10275; 312. DR MINT; P10275; -. DR STRING; 9606.ENSP00000363822; -. DR BindingDB; P10275; -. DR ChEMBL; CHEMBL1871; -. DR DrugBank; DB07422; (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide. DR DrugBank; DB07039; (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide. DR DrugBank; DB04709; (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE. DR DrugBank; DB07717; (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE. DR DrugBank; DB07454; (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE. DR DrugBank; DB02932; (R)-Bicalutamide. DR DrugBank; DB08035; 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE. DR DrugBank; DB01481; 1-Testosterone. DR DrugBank; DB05107; 16-Bromoepiandrosterone. DR DrugBank; DB08088; 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile. DR DrugBank; DB08461; 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL. DR DrugBank; DB08087; 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE. DR DrugBank; DB07421; 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile. DR DrugBank; DB01063; Acetophenazine. DR DrugBank; DB07423; Andarine. DR DrugBank; DB11901; Apalutamide. DR DrugBank; DB07352; Apigenin. DR DrugBank; DB01128; Bicalutamide. DR DrugBank; DB06973; Bisphenol A. DR DrugBank; DB07286; BMS-564929. DR DrugBank; DB01541; Boldenone. DR DrugBank; DB14639; Boldenone undecylenate. DR DrugBank; DB01564; Calusterone. DR DrugBank; DB13111; Chromanol. DR DrugBank; DB12499; Clascoterone. DR DrugBank; DB04839; Cyproterone acetate. DR DrugBank; DB01406; Danazol. DR DrugBank; DB12941; Darolutamide. DR DrugBank; DB09123; Dienogest. DR DrugBank; DB00255; Diethylstilbestrol. DR DrugBank; DB06133; Dimethylcurcumin. DR DrugBank; DB01395; Drospirenone. DR DrugBank; DB00858; Drostanolone. DR DrugBank; DB15488; Echinacoside. DR DrugBank; DB11219; Enzacamene. DR DrugBank; DB08899; Enzalutamide. DR DrugBank; DB19123; Enzalutamide d3. DR DrugBank; DB13155; Esculin. DR DrugBank; DB00655; Estrone. DR DrugBank; DB01493; Ethylestrenol. DR DrugBank; DB09086; Eugenol. DR DrugBank; DB07776; Flavone. DR DrugBank; DB00687; Fludrocortisone. DR DrugBank; DB02266; Flufenamic acid. DR DrugBank; DB01185; Fluoxymesterone. DR DrugBank; DB00623; Fluphenazine. DR DrugBank; DB00499; Flutamide. DR DrugBank; DB12415; Galeterone. DR DrugBank; DB11619; Gestrinone. DR DrugBank; DB12461; GLPG-0492. DR DrugBank; DB11064; Homosalate. DR DrugBank; DB01852; Kaempherol. DR DrugBank; DB01026; Ketoconazole. DR DrugBank; DB15647; Ketodarolutamide. DR DrugBank; DB00367; Levonorgestrel. DR DrugBank; DB08089; LGD-2226. DR DrugBank; DB05234; LGD2941. DR DrugBank; DB13934; Ligandrol. DR DrugBank; DB16221; Lonaprisan. DR DrugBank; DB11425; Luprostiol. DR DrugBank; DB06710; Methyltestosterone. DR DrugBank; DB02998; Metribolone. DR DrugBank; DB11429; Mibolerone. DR DrugBank; DB00648; Mitotane. DR DrugBank; DB16244; MK-0773. DR DrugBank; DB13169; Nandrolone. DR DrugBank; DB08804; Nandrolone decanoate. DR DrugBank; DB00984; Nandrolone phenpropionate. DR DrugBank; DB00665; Nilutamide. DR DrugBank; DB06713; Norelgestromin. DR DrugBank; DB00717; Norethisterone. DR DrugBank; DB09371; Norethynodrel. DR DrugBank; DB00957; Norgestimate. DR DrugBank; DB09389; Norgestrel. DR DrugBank; DB00621; Oxandrolone. DR DrugBank; DB01428; Oxybenzone. DR DrugBank; DB06412; Oxymetholone. DR DrugBank; DB01608; Periciazine. DR DrugBank; DB15221; PF-06260414. DR DrugBank; DB11447; Phenothiazine. DR DrugBank; DB01708; Prasterone. DR DrugBank; DB00396; Progesterone. DR DrugBank; DB13939; RAD-140. DR DrugBank; DB07419; S-23. DR DrugBank; DB07769; S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE. DR DrugBank; DB14583; Segesterone acetate. DR DrugBank; DB00421; Spironolactone. DR DrugBank; DB02901; Stanolone. DR DrugBank; DB13951; Stanolone acetate. DR DrugBank; DB06718; Stanozolol. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB00624; Testosterone. DR DrugBank; DB13943; Testosterone cypionate. DR DrugBank; DB13944; Testosterone enanthate. DR DrugBank; DB01420; Testosterone propionate. DR DrugBank; DB13946; Testosterone undecanoate. DR DrugBank; DB06870; Tetrahydrogestrinone. DR DrugBank; DB08604; Triclosan. DR DrugBank; DB08867; Ulipristal. DR DrugCentral; P10275; -. DR GuidetoPHARMACOLOGY; 628; -. DR SwissLipids; SLP:000001553; -. DR MoonDB; P10275; Predicted. DR GlyGen; P10275; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P10275; -. DR PhosphoSitePlus; P10275; -. DR SwissPalm; P10275; -. DR BioMuta; AR; -. DR DMDM; 113830; -. DR jPOST; P10275; -. DR MassIVE; P10275; -. DR PaxDb; 9606-ENSP00000363822; -. DR PeptideAtlas; P10275; -. DR ProteomicsDB; 18721; -. DR ProteomicsDB; 52590; -. [P10275-1] DR ProteomicsDB; 52591; -. [P10275-2] DR TopDownProteomics; P10275-1; -. [P10275-1] DR Antibodypedia; 3489; 2587 antibodies from 51 providers. DR DNASU; 367; -. DR Ensembl; ENST00000374690.9; ENSP00000363822.3; ENSG00000169083.19. [P10275-1] DR Ensembl; ENST00000504326.5; ENSP00000421155.1; ENSG00000169083.19. [P10275-3] DR Ensembl; ENST00000612452.5; ENSP00000484033.2; ENSG00000169083.19. [P10275-1] DR GeneID; 367; -. DR KEGG; hsa:367; -. DR MANE-Select; ENST00000374690.9; ENSP00000363822.3; NM_000044.6; NP_000035.2. DR UCSC; uc004dwv.3; human. [P10275-1] DR UCSC; uc011mpf.2; human. DR AGR; HGNC:644; -. DR CIViC; 367; 1 clinical assertion and 47 evidence items across 34 molecular profiles. DR ClinPGx; PA57; -. DR CTD; 367; -. DR DisGeNET; 367; -. DR GeneCards; AR; -. DR GeneReviews; AR; -. DR HGNC; HGNC:644; AR. DR HPA; ENSG00000169083; Tissue enhanced (liver). DR MalaCards; AR; -. DR MIM; 300068; phenotype. DR MIM; 300633; phenotype. DR MIM; 301120; phenotype. DR MIM; 312300; phenotype. DR MIM; 313200; phenotype. DR MIM; 313700; gene. DR OpenTargets; ENSG00000169083; -. DR Orphanet; 99429; Complete androgen insensitivity syndrome. DR Orphanet; 481; Kennedy disease. DR Orphanet; 95706; Non-syndromic posterior hypospadias. DR Orphanet; 90797; Partial androgen insensitivity syndrome. DR VEuPathDB; HostDB:ENSG00000169083; -. DR eggNOG; KOG3575; Eukaryota. DR GeneTree; ENSGT00940000155516; -. DR HOGENOM; CLU_007368_15_0_1; -. DR InParanoid; P10275; -. DR OMA; SHMEGYE; -. DR OrthoDB; 10032732at2759; -. DR PAN-GO; P10275; 5 GO annotations based on evolutionary models. DR PhylomeDB; P10275; -. DR PathwayCommons; P10275; -. DR Reactome; R-HSA-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand. DR Reactome; R-HSA-383280; Nuclear Receptor transcription pathway. DR Reactome; R-HSA-4090294; SUMOylation of intracellular receptors. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation. DR SignaLink; P10275; -. DR SIGNOR; P10275; -. DR Agora; ENSG00000169083; -. DR BioGRID-ORCS; 367; 14 hits in 805 CRISPR screens. DR CD-CODE; DFB52F78; Synthetic Condensate 000129. DR CD-CODE; EEE9EDCA; Synthetic Condensate 000155. DR ChiTaRS; AR; human. DR EvolutionaryTrace; P10275; -. DR GeneWiki; Androgen_receptor; -. DR GenomeRNAi; 367; -. DR Pharos; P10275; Tclin. DR PRO; PR:P10275; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P10275; protein. DR Bgee; ENSG00000169083; Expressed in seminal vesicle and 180 other cell types or tissues. DR ExpressionAtlas; P10275; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:CAFA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:Ensembl. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005497; F:androgen binding; IDA:UniProtKB. DR GO; GO:0051117; F:ATPase binding; IDA:MGI. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0034056; F:estrogen response element binding; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; IDA:DisProt. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt. DR GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB. DR GO; GO:0003707; F:nuclear steroid receptor activity; IDA:BHF-UCL. DR GO; GO:0070974; F:POU domain binding; IEA:Ensembl. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl. DR GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0001223; F:transcription coactivator binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0048645; P:animal organ formation; IEA:Ensembl. DR GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:ARUK-UCL. DR GO; GO:0071383; P:cellular response to steroid hormone stimulus; IMP:CAFA. DR GO; GO:0071394; P:cellular response to testosterone stimulus; IDA:ARUK-UCL. DR GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0030520; P:estrogen receptor signaling pathway; IDA:ARUK-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0030522; P:intracellular receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0060599; P:lateral sprouting involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl. DR GO; GO:0048808; P:male genitalia morphogenesis; IEA:Ensembl. DR GO; GO:0008584; P:male gonad development; IBA:GO_Central. DR GO; GO:0019102; P:male somatic sex determination; IEA:Ensembl. DR GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:DisProt. DR GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:CAFA. DR GO; GO:0045597; P:positive regulation of cell differentiation; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB. DR GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045726; P:positive regulation of integrin biosynthetic process; IDA:BHF-UCL. DR GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IDA:BHF-UCL. DR GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl. DR GO; GO:0060736; P:prostate gland growth; IEA:Ensembl. DR GO; GO:0060514; P:prostate induction; IEA:Ensembl. DR GO; GO:0048638; P:regulation of developmental growth; IEA:Ensembl. DR GO; GO:1903076; P:regulation of protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0003073; P:regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007338; P:single fertilization; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IBA:GO_Central. DR GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd07173; NR_DBD_AR; 1. DR CDD; cd07073; NR_LBD_AR; 1. DR DisProt; DP00492; -. DR FunFam; 3.30.50.10:FF:000024; Androgen receptor; 1. DR FunFam; 1.10.565.10:FF:000004; Androgen receptor variant; 1. DR Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1. DR Gene3D; 1.10.565.10; Retinoid X Receptor; 1. DR IDEAL; IID00020; -. DR InterPro; IPR001103; Andrgn_rcpt. DR InterPro; IPR035500; NHR-like_dom_sf. DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd. DR InterPro; IPR050200; Nuclear_hormone_rcpt_NR3. DR InterPro; IPR001628; Znf_hrmn_rcpt. DR InterPro; IPR013088; Znf_NHR/GATA. DR PANTHER; PTHR48092; KNIRPS-RELATED PROTEIN-RELATED; 1. DR Pfam; PF02166; Androgen_recep; 1. DR Pfam; PF00104; Hormone_recep; 1. DR Pfam; PF00105; zf-C4; 1. DR PRINTS; PR00521; ANDROGENR. DR PRINTS; PR00047; STROIDFINGER. DR SMART; SM00430; HOLI; 1. DR SMART; SM00399; ZnF_C4; 1. DR SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1. DR SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1. DR PROSITE; PS51843; NR_LBD; 1. DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1. DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Cytoplasm; Disease variant; KW DNA-binding; Isopeptide bond; Lipid-binding; Lipoprotein; Metal-binding; KW Neurodegeneration; Nucleus; Palmitate; Phosphoprotein; KW Proteomics identification; Pseudohermaphroditism; Receptor; KW Reference proteome; Steroid-binding; Transcription; KW Transcription regulation; Triplet repeat expansion; Ubl conjugation; Zinc; KW Zinc-finger. FT CHAIN 1..920 FT /note="Androgen receptor" FT /id="PRO_0000053704" FT DOMAIN 669..900 FT /note="NR LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189" FT DNA_BIND 560..632 FT /note="Nuclear receptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 560..580 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 596..620 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT REGION 1..587 FT /note="Interaction with ZNF318" FT /evidence="ECO:0000250|UniProtKB:P19091" FT REGION 1..559 FT /note="Modulating" FT REGION 36..167 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 195..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 552..919 FT /note="Interaction with LPXN" FT /evidence="ECO:0000269|PubMed:18451096" FT REGION 572..662 FT /note="Interaction with HIPK3" FT /evidence="ECO:0000250|UniProtKB:P15207" FT REGION 592..919 FT /note="Interaction with CCAR1" FT /evidence="ECO:0000269|PubMed:23887938" FT REGION 625..919 FT /note="Interaction with KAT7" FT /evidence="ECO:0000269|PubMed:10930412" FT COMPBIAS 44..91 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 195..217 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 218..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 706 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2AMB, FT ECO:0007744|PDB:2PIO, ECO:0007744|PDB:2PIP, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2PNU, FT ECO:0007744|PDB:2Q7I, ECO:0007744|PDB:2Q7J, FT ECO:0007744|PDB:2Q7K, ECO:0007744|PDB:2Q7L, FT ECO:0007744|PDB:2YHD, ECO:0007744|PDB:2YLO, FT ECO:0007744|PDB:2YLP, ECO:0007744|PDB:2YLQ, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT BINDING 753 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2PIO, FT ECO:0007744|PDB:2PIP, ECO:0007744|PDB:2PIQ, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2Q7I, FT ECO:0007744|PDB:2Q7J, ECO:0007744|PDB:2Q7K, FT ECO:0007744|PDB:2Q7L, ECO:0007744|PDB:2YHD, FT ECO:0007744|PDB:2YLO, ECO:0007744|PDB:2YLP, FT ECO:0007744|PDB:2YLQ, ECO:0007744|PDB:2Z4J, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT BINDING 878 FT /ligand="17beta-hydroxy-5alpha-androstan-3-one" FT /ligand_id="ChEBI:CHEBI:16330" FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:16641486, ECO:0000269|PubMed:17591767, FT ECO:0000269|PubMed:25091737, ECO:0007744|PDB:1T5Z, FT ECO:0007744|PDB:1T63, ECO:0007744|PDB:1T65, FT ECO:0007744|PDB:1XJ7, ECO:0007744|PDB:2AM9, FT ECO:0007744|PDB:2AMA, ECO:0007744|PDB:2PIO, FT ECO:0007744|PDB:2PIP, ECO:0007744|PDB:2PIQ, FT ECO:0007744|PDB:2PIR, ECO:0007744|PDB:2PIT, FT ECO:0007744|PDB:2PIU, ECO:0007744|PDB:2PIV, FT ECO:0007744|PDB:2PIW, ECO:0007744|PDB:2PIX, FT ECO:0007744|PDB:2PKL, ECO:0007744|PDB:2Q7I, FT ECO:0007744|PDB:2Q7J, ECO:0007744|PDB:2Q7K, FT ECO:0007744|PDB:2Q7L, ECO:0007744|PDB:2YHD, FT ECO:0007744|PDB:2YLO, ECO:0007744|PDB:2YLP, FT ECO:0007744|PDB:2YLQ, ECO:0007744|PDB:2Z4J, FT ECO:0007744|PDB:3L3X, ECO:0007744|PDB:3L3Z, FT ECO:0007744|PDB:3ZQT, ECO:0007744|PDB:4HLW, FT ECO:0007744|PDB:4K7A, ECO:0007744|PDB:4OEA, FT ECO:0007744|PDB:4OED, ECO:0007744|PDB:4OEY, FT ECO:0007744|PDB:4OEZ, ECO:0007744|PDB:4OFR, FT ECO:0007744|PDB:4OFU, ECO:0007744|PDB:5JJM" FT SITE 721 FT /note="Interaction with coactivator LXXL and FXXFY motifs" FT /evidence="ECO:0000269|PubMed:25091737" FT SITE 898 FT /note="Interaction with coactivator FXXLF and FXXFY motifs" FT /evidence="ECO:0000269|PubMed:25091737" FT MOD_RES 83 FT /note="Phosphoserine; by CDK9" FT /evidence="ECO:0000269|PubMed:20980437" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 225 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 258 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 269 FT /note="Phosphotyrosine; by CSK and TNK2" FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:20623637" FT MOD_RES 309 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 348 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 359 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 364 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 365 FT /note="Phosphotyrosine; by CSK and TNK2" FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MOD_RES 395 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 535 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 552 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT MOD_RES 651 FT /note="Phosphoserine; by STK4/MST1" FT /evidence="ECO:0000269|PubMed:21512132" FT MOD_RES 916 FT /note="Phosphotyrosine; by CSK" FT /evidence="ECO:0000269|PubMed:17045208" FT CROSSLNK 388 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11121022" FT CROSSLNK 521 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11121022" FT CROSSLNK 846 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19345326" FT CROSSLNK 848 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19345326" FT VAR_SEQ 1..532 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_036889" FT VAR_SEQ 533..539 FT /note="GPYGDMR -> MILWLHS (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_036890" FT VAR_SEQ 629..644 FT /note="ARKLKKLGNLKLQEEG -> EKFRVGNCKHLKMTRP (in isoform 3)" FT /id="VSP_058166" FT VAR_SEQ 630..648 FT /note="RKLKKLGNLKLQEEGEASS -> AVVVSERILRVFGVSEWLP (in FT isoform 4)" FT /id="VSP_058167" FT VAR_SEQ 645..920 FT /note="Missing (in isoform 3)" FT /id="VSP_058168" FT VAR_SEQ 649..920 FT /note="Missing (in isoform 4)" FT /id="VSP_058169" FT VARIANT 2 FT /note="E -> K (in PAIS; dbSNP:rs104894742)" FT /evidence="ECO:0000269|PubMed:8823308" FT /id="VAR_004679" FT VARIANT 54 FT /note="L -> S (in prostate cancer)" FT /id="VAR_004680" FT VARIANT 57 FT /note="L -> Q (in prostate cancer; dbSNP:rs78686797)" FT /evidence="ECO:0000269|PubMed:19244107" FT /id="VAR_004681" FT VARIANT 64 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009711" FT VARIANT 114 FT /note="Q -> H (in prostate cancer)" FT /id="VAR_009712" FT VARIANT 182 FT /note="K -> R (in prostate cancer)" FT /id="VAR_009713" FT VARIANT 196 FT /note="Q -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:9255042" FT /id="VAR_009224" FT VARIANT 207 FT /note="S -> R (in dbSNP:rs374549047)" FT /evidence="ECO:0000269|PubMed:8213813" FT /id="VAR_009714" FT VARIANT 216 FT /note="G -> R (20% lower transactivation capacity; FT dbSNP:rs199554641)" FT /evidence="ECO:0000269|PubMed:27535533, FT ECO:0000269|PubMed:9788719" FT /id="VAR_009715" FT VARIANT 257 FT /note="L -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:9610419" FT /id="VAR_009225" FT VARIANT 268 FT /note="M -> T (in prostate cancer)" FT /id="VAR_009716" FT VARIANT 271 FT /note="P -> S (in prostate cancer)" FT /id="VAR_009717" FT VARIANT 342 FT /note="P -> L (in prostate cancer; dbSNP:rs138454018)" FT /evidence="ECO:0000269|PubMed:7511268" FT /id="VAR_009718" FT VARIANT 392 FT /note="P -> R (in AIS; dbSNP:rs773996740)" FT /evidence="ECO:0000269|PubMed:10571951" FT /id="VAR_009226" FT VARIANT 392 FT /note="P -> S (in AIS; dbSNP:rs201934623)" FT /evidence="ECO:0000269|PubMed:10946887" FT /id="VAR_009227" FT VARIANT 445 FT /note="Q -> R (in AIS; uncertain significance; FT dbSNP:rs1355285524)" FT /evidence="ECO:0000269|PubMed:10571951" FT /id="VAR_009228" FT VARIANT 492 FT /note="G -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009719" FT VARIANT 529 FT /note="D -> G (in prostate cancer)" FT /id="VAR_009720" FT VARIANT 548 FT /note="L -> F (in PAIS; dbSNP:rs139524801)" FT /evidence="ECO:0000269|PubMed:11788616" FT /id="VAR_009721" FT VARIANT 549 FT /note="P -> S (in AIS; dbSNP:rs137852588)" FT /evidence="ECO:0000269|PubMed:8683794" FT /id="VAR_009722" FT VARIANT 560 FT /note="C -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009723" FT VARIANT 569 FT /note="G -> V (in a patient with isolated hypospadias)" FT /evidence="ECO:0000269|PubMed:7673412" FT /id="VAR_009725" FT VARIANT 569 FT /note="G -> W (in PAIS; dbSNP:rs1555982864)" FT /evidence="ECO:0000269|PubMed:7910529" FT /id="VAR_009726" FT VARIANT 572 FT /note="Y -> C (in AIS)" FT /evidence="ECO:0000269|PubMed:9544375" FT /id="VAR_009727" FT VARIANT 574 FT /note="A -> D (in AIS)" FT /evidence="ECO:0000269|PubMed:9421404" FT /id="VAR_009728" FT VARIANT 575 FT /note="L -> P (in prostate cancer)" FT /id="VAR_009729" FT VARIANT 576 FT /note="T -> A (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009730" FT VARIANT 577 FT /note="C -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:14756668" FT /id="VAR_009731" FT VARIANT 577 FT /note="C -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009732" FT VARIANT 580 FT /note="C -> F (in AIS; reduced transcription and DNA FT binding; dbSNP:rs137852586)" FT /evidence="ECO:0000269|PubMed:8809734" FT /id="VAR_009733" FT VARIANT 580 FT /note="C -> Y (in AIS; dbSNP:rs137852586)" FT /id="VAR_009734" FT VARIANT 581 FT /note="K -> R (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009735" FT VARIANT 582 FT /note="V -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:8224266, ECO:0000269|Ref.118" FT /id="VAR_009736" FT VARIANT 583 FT /note="F -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009737" FT VARIANT 583 FT /note="F -> Y (in PAIS; dbSNP:rs137852587)" FT /evidence="ECO:0000269|PubMed:8809734" FT /id="VAR_009738" FT VARIANT 583 FT /note="Missing (in AIS)" FT /evidence="ECO:0000269|PubMed:8162033" FT /id="VAR_009739" FT VARIANT 586 FT /note="R -> K (in AIS)" FT /evidence="ECO:0000269|PubMed:8240973" FT /id="VAR_009740" FT VARIANT 587 FT /note="A -> V (in prostate cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009741" FT VARIANT 588 FT /note="A -> S (in prostate cancer; somatic mutation)" FT /id="VAR_009742" FT VARIANT 597 FT /note="A -> T (in AIS; abolishes dimerization; FT dbSNP:rs137852569)" FT /evidence="ECO:0000269|PubMed:10590024, FT ECO:0000269|PubMed:7649358" FT /id="VAR_009743" FT VARIANT 598 FT /note="S -> G (in PAIS; normal androgen binding; does not FT activate transcription; impairs DNA binding; FT dbSNP:rs142280455)" FT /evidence="ECO:0000269|PubMed:1316540" FT /id="VAR_009744" FT VARIANT 598 FT /note="S -> T (in a patient with severe hypospadias)" FT /evidence="ECO:0000269|PubMed:10092153" FT /id="VAR_009745" FT VARIANT 602 FT /note="C -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:7981689" FT /id="VAR_009746" FT VARIANT 605 FT /note="D -> Y (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009747" FT VARIANT 608 FT /note="R -> Q (in PAIS and breast cancer; FT dbSNP:rs137852573)" FT /evidence="ECO:0000269|PubMed:10221692, FT ECO:0000269|PubMed:1303262, ECO:0000269|PubMed:9039340, FT ECO:0000269|PubMed:9543136" FT /id="VAR_004684" FT VARIANT 609 FT /note="R -> K (in PAIS and breast cancer; defective nuclear FT localization; dbSNP:rs137852576)" FT /evidence="ECO:0000269|PubMed:1424203, FT ECO:0000269|PubMed:8281139, ECO:0000269|PubMed:9196614" FT /id="VAR_004685" FT VARIANT 611 FT /note="N -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:9039340" FT /id="VAR_009748" FT VARIANT 612 FT /note="C -> Y (in AIS)" FT /id="VAR_009749" FT VARIANT 616 FT /note="R -> H (in AIS and PAIS; dbSNP:rs754201976)" FT /evidence="ECO:0000269|PubMed:7970939, FT ECO:0000269|PubMed:8162033, ECO:0000269|PubMed:8413310, FT ECO:0000269|PubMed:9698822" FT /id="VAR_009751" FT VARIANT 616 FT /note="R -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:1999491" FT /id="VAR_009752" FT VARIANT 616 FT /note="Missing (in AIS)" FT /evidence="ECO:0000269|PubMed:8162033" FT /id="VAR_009750" FT VARIANT 617 FT /note="L -> P (in AIS; dbSNP:rs1555990488)" FT /evidence="ECO:0000269|PubMed:8647313" FT /id="VAR_009753" FT VARIANT 617 FT /note="L -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8126121" FT /id="VAR_009754" FT VARIANT 618 FT /note="R -> P (in AIS and PAIS; loss of DNA-binding FT activity)" FT /evidence="ECO:0000269|PubMed:1316540, FT ECO:0000269|PubMed:1999491" FT /id="VAR_009755" FT VARIANT 620 FT /note="C -> Y (in prostate cancer; loss of DNA binding; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:10598582, FT ECO:0000269|PubMed:10706109" FT /id="VAR_009756" FT VARIANT 630 FT /note="R -> Q (in prostate cancer; dbSNP:rs868669253)" FT /evidence="ECO:0000269|PubMed:9184448" FT /id="VAR_009757" FT VARIANT 631 FT /note="K -> T (in prostate cancer)" FT /id="VAR_009758" FT VARIANT 646 FT /note="A -> D (in dbSNP:rs1800053)" FT /evidence="ECO:0000269|PubMed:9554755" FT /id="VAR_004686" FT VARIANT 648 FT /note="S -> N (in prostate cancer; dbSNP:rs137852584)" FT /id="VAR_009760" FT VARIANT 665 FT /note="I -> N (in AIS and PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004687" FT VARIANT 671 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009761" FT VARIANT 672 FT /note="P -> H (in PAIS)" FT /id="VAR_009762" FT VARIANT 673 FT /note="I -> T (in prostate cancer)" FT /id="VAR_009763" FT VARIANT 678 FT /note="L -> P (in AIS; dbSNP:rs137852579)" FT /evidence="ECO:0000269|PubMed:7537149" FT /id="VAR_004688" FT VARIANT 682 FT /note="E -> K (in AIS; dbSNP:rs1555995816)" FT /evidence="ECO:0000269|PubMed:10221692, FT ECO:0000269|PubMed:8325950" FT /id="VAR_009764" FT VARIANT 683 FT /note="P -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013474" FT VARIANT 684 FT /note="G -> A (found in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10629558, FT ECO:0000269|PubMed:9000575" FT /id="VAR_009765" FT VARIANT 685 FT /note="V -> I (in AIS; dbSNP:rs1555995822)" FT /evidence="ECO:0000269|PubMed:10425033" FT /id="VAR_009766" FT VARIANT 687 FT /note="C -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009767" FT VARIANT 688 FT /note="A -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009768" FT VARIANT 689 FT /note="G -> E (in AIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009769" FT VARIANT 691 FT /note="Missing (in PAIS)" FT /evidence="ECO:0000269|Ref.126" FT /id="VAR_009770" FT VARIANT 693 FT /note="Missing (in AIS)" FT /id="VAR_004689" FT VARIANT 696 FT /note="D -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:1775137" FT /id="VAR_004690" FT VARIANT 696 FT /note="D -> N (in AIS; almost complete loss of androgen FT binding and transcription activation; dbSNP:rs1555995840)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:1775137" FT /id="VAR_004691" FT VARIANT 696 FT /note="D -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:9554754" FT /id="VAR_004692" FT VARIANT 701 FT /note="L -> M (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009771" FT VARIANT 702 FT /note="L -> F (in AIS; dbSNP:rs1555995851)" FT /id="VAR_009772" FT VARIANT 702 FT /note="L -> H (found in prostate cancer; FT dbSNP:rs864622007)" FT /evidence="ECO:0000269|PubMed:10569618, FT ECO:0000269|PubMed:8274409, ECO:0000269|PubMed:9438000" FT /id="VAR_009773" FT VARIANT 703 FT /note="S -> A (in AIS)" FT /id="VAR_009774" FT VARIANT 704 FT /note="S -> C (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009775" FT VARIANT 704 FT /note="S -> G (in PAIS and AIS)" FT /evidence="ECO:0000269|PubMed:9302173" FT /id="VAR_004693" FT VARIANT 706 FT /note="N -> S (in AIS; dbSNP:rs925822435)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:7671849" FT /id="VAR_009776" FT VARIANT 706 FT /note="N -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:11744994" FT /id="VAR_013475" FT VARIANT 708 FT /note="L -> R (in AIS; dbSNP:rs137852585)" FT /evidence="ECO:0000269|PubMed:8626869" FT /id="VAR_004694" FT VARIANT 709 FT /note="G -> A (in PAIS)" FT /evidence="ECO:0000269|PubMed:7981687, FT ECO:0000269|PubMed:9329414" FT /id="VAR_009777" FT VARIANT 709 FT /note="G -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:10425033" FT /id="VAR_009778" FT VARIANT 711 FT /note="R -> T (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009779" FT VARIANT 712 FT /note="Q -> E (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013476" FT VARIANT 713 FT /note="L -> F (in PAIS; dbSNP:rs137852595)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009780" FT VARIANT 716 FT /note="V -> M (in prostate cancer; gain in function; FT dbSNP:rs1340026226)" FT /evidence="ECO:0000269|PubMed:8145761" FT /id="VAR_009781" FT VARIANT 718 FT /note="K -> E (in prostate cancer)" FT /id="VAR_009782" FT VARIANT 721 FT /note="K -> E (in prostate cancer; found in bone FT metastases)" FT /id="VAR_009783" FT VARIANT 722 FT /note="A -> T (in prostate cancer; somatic mutation; FT dbSNP:rs137852583)" FT /id="VAR_009784" FT VARIANT 723 FT /note="L -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:9627582" FT /id="VAR_009785" FT VARIANT 724 FT /note="P -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009786" FT VARIANT 725 FT /note="G -> D (in AIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009787" FT VARIANT 726 FT /note="F -> L (in a patient with severe hypospadias; FT dbSNP:rs1555996810)" FT /evidence="ECO:0000269|PubMed:10092153, FT ECO:0000269|PubMed:7671849" FT /id="VAR_009788" FT VARIANT 727 FT /note="R -> L (in HPCX3; dbSNP:rs137852593)" FT /evidence="ECO:0000269|PubMed:8530589" FT /id="VAR_009789" FT VARIANT 728 FT /note="N -> K (in AIS; dbSNP:rs768869912)" FT /evidence="ECO:0000269|PubMed:7993455" FT /id="VAR_009790" FT VARIANT 729 FT /note="L -> S (in PAIS)" FT /id="VAR_009791" FT VARIANT 731 FT /note="V -> M (in prostate cancer; increases transcription FT activation; dbSNP:rs137852571)" FT /evidence="ECO:0000269|PubMed:15525515, FT ECO:0000269|PubMed:1631125, ECO:0000269|PubMed:7591265" FT /id="VAR_004695" FT VARIANT 733 FT /note="D -> N (in AIS)" FT /evidence="ECO:0000269|PubMed:9252933" FT /id="VAR_004696" FT VARIANT 733 FT /note="D -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004697" FT VARIANT 734 FT /note="Q -> H (in PAIS)" FT /evidence="ECO:0000269|PubMed:9627582" FT /id="VAR_009792" FT VARIANT 738 FT /note="I -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:7671849" FT /id="VAR_009793" FT VARIANT 742 FT /note="W -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:1464650" FT /id="VAR_009794" FT VARIANT 743 FT /note="M -> I (in PAIS)" FT /evidence="ECO:0000269|PubMed:8824883" FT /id="VAR_004698" FT VARIANT 743 FT /note="M -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009795" FT VARIANT 744 FT /note="G -> E (in AIS; dbSNP:rs137852600)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013477" FT VARIANT 744 FT /note="G -> V (in PAIS and AIS; dbSNP:rs137852600)" FT /evidence="ECO:0000269|PubMed:8096390, FT ECO:0000269|PubMed:8325932, ECO:0000269|PubMed:9768671, FT ECO:0000269|Ref.118" FT /id="VAR_004699" FT VARIANT 745 FT /note="L -> F (in AIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:7626493" FT /id="VAR_009796" FT VARIANT 746 FT /note="M -> T (in PAIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009797" FT VARIANT 747 FT /note="V -> M (in PAIS and AIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009798" FT VARIANT 749 FT /note="A -> D (in PAIS)" FT /id="VAR_009799" FT VARIANT 749 FT /note="A -> T (in prostate cancer)" FT /id="VAR_009800" FT VARIANT 749 FT /note="A -> V (in prostate cancer)" FT /id="VAR_009801" FT VARIANT 750 FT /note="M -> I (in prostate cancer)" FT /id="VAR_009802" FT VARIANT 750 FT /note="M -> V (in PAIS and AIS; dbSNP:rs1085307685)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:1487249, ECO:0000269|PubMed:8990010" FT /id="VAR_004700" FT VARIANT 751 FT /note="G -> D (in AIS; loss of androgen binding)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004701" FT VARIANT 751 FT /note="G -> S (in prostate cancer)" FT /id="VAR_009803" FT VARIANT 752 FT /note="W -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:7626493" FT /id="VAR_009804" FT VARIANT 753 FT /note="R -> Q (in AIS; dbSNP:rs1057523747)" FT /evidence="ECO:0000269|PubMed:9544375, FT ECO:0000269|PubMed:9698822" FT /id="VAR_004702" FT VARIANT 755 FT /note="F -> L (in PAIS and prostate cancer)" FT /evidence="ECO:0000269|PubMed:7981687, FT ECO:0000269|PubMed:9039340" FT /id="VAR_009805" FT VARIANT 755 FT /note="F -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:8103398, ECO:0000269|Ref.118" FT /id="VAR_004703" FT VARIANT 756 FT /note="T -> A (in prostate cancer)" FT /id="VAR_009806" FT VARIANT 757 FT /note="N -> S (in PAIS; dbSNP:rs141425171)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009807" FT VARIANT 758 FT /note="V -> A (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009808" FT VARIANT 759 FT /note="N -> T (in PAIS; 50% reduction in transactivation)" FT /evidence="ECO:0000269|PubMed:9607727" FT /id="VAR_009809" FT VARIANT 760 FT /note="S -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:1480178" FT /id="VAR_009810" FT VARIANT 760 FT /note="S -> P (in prostate cancer)" FT /id="VAR_009811" FT VARIANT 763 FT /note="L -> F (in AIS; loss of androgen binding)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004704" FT VARIANT 764 FT /note="Y -> C (in PAIS and prostate cancer; partial loss of FT androgen binding; dbSNP:rs137852567)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:2010552, ECO:0000269|PubMed:7581399" FT /id="VAR_004705" FT VARIANT 764 FT /note="Y -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:7671849" FT /id="VAR_009812" FT VARIANT 765 FT /note="F -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:7970939" FT /id="VAR_009813" FT VARIANT 766 FT /note="A -> T (in AIS; loss of androgen binding; FT dbSNP:rs1555996863)" FT /evidence="ECO:0000269|PubMed:1426313, FT ECO:0000269|PubMed:9252933, ECO:0000269|PubMed:9328206, FT ECO:0000269|PubMed:9856504" FT /id="VAR_004707" FT VARIANT 766 FT /note="A -> V (in AIS)" FT /id="VAR_009814" FT VARIANT 767 FT /note="P -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009815" FT VARIANT 768 FT /note="D -> E (in AIS)" FT /evidence="ECO:0000269|Ref.118" FT /id="VAR_009816" FT VARIANT 769 FT /note="L -> P (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009817" FT VARIANT 772 FT /note="N -> H (in PAIS; dbSNP:rs886041352)" FT /evidence="ECO:0000269|PubMed:7981687" FT /id="VAR_009818" FT VARIANT 773 FT /note="E -> A (in PAIS)" FT /evidence="ECO:0000269|PubMed:10022458" FT /id="VAR_009819" FT VARIANT 773 FT /note="E -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9196614" FT /id="VAR_009820" FT VARIANT 775 FT /note="R -> C (in AIS; frequent mutation; loss of androgen FT binding; dbSNP:rs137852562)" FT /evidence="ECO:0000269|PubMed:1609793, FT ECO:0000269|PubMed:1856263, ECO:0000269|PubMed:2082179, FT ECO:0000269|PubMed:8990010, ECO:0000269|PubMed:9544375" FT /id="VAR_004709" FT VARIANT 775 FT /note="R -> H (in AIS and PAIS; almost complete loss of FT androgen binding; dbSNP:rs137852572)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:1609793, ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:7671849" FT /id="VAR_004708" FT VARIANT 780 FT /note="R -> W (in AIS)" FT /evidence="ECO:0000269|PubMed:7581399, FT ECO:0000269|PubMed:7981687, ECO:0000269|PubMed:9007482" FT /id="VAR_004710" FT VARIANT 781 FT /note="M -> I (in PAIS and AIS; dbSNP:rs137852589)" FT /evidence="ECO:0000269|PubMed:8768864, FT ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:8990010" FT /id="VAR_004711" FT VARIANT 783 FT /note="S -> N (in prostate cancer; somatic mutation)" FT /id="VAR_009821" FT VARIANT 785 FT /note="C -> Y (in AIS; loss of androgen binding and of FT transactivation)" FT /evidence="ECO:0000269|PubMed:9856504" FT /id="VAR_004712" FT VARIANT 788 FT /note="M -> V (in AIS; dbSNP:rs137852570)" FT /evidence="ECO:0000269|PubMed:1569163" FT /id="VAR_004713" FT VARIANT 789 FT /note="R -> S (in AIS; dbSNP:rs1254203917)" FT /id="VAR_009822" FT VARIANT 791 FT /note="L -> F (in AIS)" FT /evidence="ECO:0000269|PubMed:7962294" FT /id="VAR_009823" FT VARIANT 792 FT /note="S -> P (in prostate cancer and AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009824" FT VARIANT 794 FT /note="E -> D (in dbSNP:rs1414341563)" FT /evidence="ECO:0000269|PubMed:8213813" FT /id="VAR_009825" FT VARIANT 795 FT /note="F -> S (in AIS)" FT /evidence="ECO:0000269|PubMed:8990010" FT /id="VAR_004714" FT VARIANT 799 FT /note="Q -> E (in PAIS, AIS and prostate cancer; reduced FT transcription activation; dbSNP:rs137852591)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:7511268, ECO:0000269|PubMed:7671849, FT ECO:0000269|PubMed:8628719, ECO:0000269|PubMed:8824883, FT ECO:0000269|PubMed:9851768" FT /id="VAR_004715" FT VARIANT 807 FT /note="C -> Y (in PAIS; dbSNP:rs1064793480)" FT /evidence="ECO:0000269|PubMed:8339746" FT /id="VAR_009826" FT VARIANT 808 FT /note="M -> R (in AIS; loss of transactivation)" FT /evidence="ECO:0000269|PubMed:8281140" FT /id="VAR_004716" FT VARIANT 808 FT /note="M -> T (in PAIS; dbSNP:rs137852592)" FT /evidence="ECO:0000269|PubMed:10543676" FT /id="VAR_009827" FT VARIANT 808 FT /note="M -> V (in AIS; 25% androgen binding)" FT /evidence="ECO:0000269|PubMed:7581399" FT /id="VAR_004717" FT VARIANT 813 FT /note="L -> F (in AIS; dbSNP:rs1555997625)" FT /evidence="ECO:0000269|PubMed:10458483" FT /id="VAR_009828" FT VARIANT 815 FT /note="S -> N (in AIS and PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_004718" FT VARIANT 821 FT /note="G -> A (in AIS)" FT /evidence="ECO:0000269|PubMed:9610419" FT /id="VAR_009829" FT VARIANT 822 FT /note="L -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:1458719" FT /id="VAR_009830" FT VARIANT 828 FT /note="F -> V (in PAIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013478" FT VARIANT 831 FT /note="L -> P (in prostate cancer)" FT /id="VAR_009831" FT VARIANT 832 FT /note="R -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:7633398" FT /id="VAR_004719" FT VARIANT 832 FT /note="R -> Q (in AIS; loss of androgen binding; FT dbSNP:rs1386577803)" FT /evidence="ECO:0000269|PubMed:10458483, FT ECO:0000269|PubMed:2082179, ECO:0000269|PubMed:7633398" FT /id="VAR_004720" FT VARIANT 835 FT /note="Y -> C (in AIS; loss of androgen binding; FT dbSNP:rs1057521122)" FT /evidence="ECO:0000269|PubMed:1464650" FT /id="VAR_009832" FT VARIANT 841 FT /note="R -> C (in AIS; dbSNP:rs137852577)" FT /evidence="ECO:0000269|PubMed:8040309, FT ECO:0000269|PubMed:8824883, ECO:0000269|PubMed:9768671" FT /id="VAR_004721" FT VARIANT 841 FT /note="R -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9856504" FT /id="VAR_004722" FT VARIANT 841 FT /note="R -> H (in AIS; dbSNP:rs9332969)" FT /evidence="ECO:0000269|PubMed:7909256, FT ECO:0000269|PubMed:8040309, ECO:0000269|PubMed:8126121, FT ECO:0000269|PubMed:8205256, ECO:0000269|PubMed:8325950, FT ECO:0000269|PubMed:8830623, ECO:0000269|PubMed:9039340" FT /id="VAR_004723" FT VARIANT 841 FT /note="R -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:10502786" FT /id="VAR_009229" FT VARIANT 842 FT /note="I -> S (in PAIS)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009833" FT VARIANT 843 FT /note="I -> T (in AIS; dbSNP:rs9332970)" FT /evidence="ECO:0000269|PubMed:8325950, FT ECO:0000269|PubMed:9039340" FT /id="VAR_004724" FT VARIANT 847 FT /note="R -> G (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10706109" FT /id="VAR_009834" FT VARIANT 855 FT /note="R -> K (in PAIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009835" FT VARIANT 856 FT /note="R -> C (in AIS; dbSNP:rs886041132)" FT /evidence="ECO:0000269|PubMed:1480178, FT ECO:0000269|PubMed:7581399, ECO:0000269|PubMed:9001799, FT ECO:0000269|PubMed:9255042, ECO:0000269|Ref.118" FT /id="VAR_004725" FT VARIANT 856 FT /note="R -> H (in AIS; strongly reduced transcription FT activation; dbSNP:rs9332971)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:8097257, ECO:0000269|PubMed:8824883, FT ECO:0000269|PubMed:9039340, ECO:0000269|PubMed:9106550" FT /id="VAR_004726" FT VARIANT 857 FT /note="F -> L (in AIS; dbSNP:rs137852598)" FT /evidence="ECO:0000269|PubMed:10690872, FT ECO:0000269|PubMed:8339746" FT /id="VAR_009836" FT VARIANT 864 FT /note="L -> R (in AIS)" FT /id="VAR_009837" FT VARIANT 865 FT /note="D -> G (in AIS)" FT /evidence="ECO:0000269|PubMed:1480178" FT /id="VAR_009838" FT VARIANT 865 FT /note="D -> N (in AIS; loss of androgen binding; FT dbSNP:rs1555997810)" FT /evidence="ECO:0000269|PubMed:9328206" FT /id="VAR_004727" FT VARIANT 866 FT /note="S -> P (in AIS; dbSNP:rs137852597)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009839" FT VARIANT 867 FT /note="V -> E (in AIS)" FT /id="VAR_004728" FT VARIANT 867 FT /note="V -> L (in PAIS; dbSNP:rs137852564)" FT /evidence="ECO:0000269|PubMed:1424203, FT ECO:0000269|PubMed:8325950, ECO:0000269|PubMed:8446106" FT /id="VAR_004729" FT VARIANT 867 FT /note="V -> M (in AIS and prostate cancer; FT dbSNP:rs137852564)" FT /evidence="ECO:0000269|PubMed:2082179, FT ECO:0000269|PubMed:2594783, ECO:0000269|PubMed:8446106, FT ECO:0000269|PubMed:9039340" FT /id="VAR_004730" FT VARIANT 870 FT /note="I -> M (in PAIS; dbSNP:rs137852574)" FT /evidence="ECO:0000269|PubMed:8097257, FT ECO:0000269|PubMed:8824883" FT /id="VAR_004731" FT VARIANT 871 FT /note="A -> G (in PAIS)" FT /evidence="ECO:0000269|PubMed:9329414" FT /id="VAR_009840" FT VARIANT 871 FT /note="A -> V (in PAIS; dbSNP:rs143040492)" FT /evidence="ECO:0000269|PubMed:8033918" FT /id="VAR_009841" FT VARIANT 872 FT /note="R -> G (in AIS)" FT /evidence="ECO:0000269|PubMed:10022458" FT /id="VAR_009842" FT VARIANT 875 FT /note="H -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013479" FT VARIANT 875 FT /note="H -> Y (in prostate cancer; increases affinity for FT testosterone and androgen sensitivity; increased FT transcription activation; dbSNP:rs137852581)" FT /evidence="ECO:0000269|PubMed:17591767" FT /id="VAR_009843" FT VARIANT 878 FT /note="T -> A (found in prostate cancer; found in bone FT metastases; alters receptor specificity so that FT transcription is activated by antiandrogens such as FT cyproterone acetate; dbSNP:rs137852578)" FT /evidence="ECO:0000269|PubMed:10363963, FT ECO:0000269|PubMed:10569618, ECO:0000269|PubMed:1562539, FT ECO:0000269|PubMed:16129672, ECO:0000269|PubMed:17311914, FT ECO:0000269|PubMed:2260966, ECO:0000269|PubMed:25091737, FT ECO:0000269|PubMed:8187068, ECO:0000269|PubMed:8274409, FT ECO:0000269|PubMed:8827083" FT /id="VAR_004732" FT VARIANT 878 FT /note="T -> S (in prostate cancer; dbSNP:rs137852580)" FT /id="VAR_009844" FT VARIANT 880 FT /note="D -> Y (in AIS)" FT /evidence="ECO:0000269|PubMed:11587068" FT /id="VAR_013480" FT VARIANT 881 FT /note="L -> Q (in prostate cancer)" FT /id="VAR_009845" FT VARIANT 882 FT /note="L -> V (in AIS)" FT /evidence="ECO:0000269|PubMed:7641413" FT /id="VAR_009846" FT VARIANT 887 FT /note="M -> V (in AIS; dbSNP:rs755226547)" FT /evidence="ECO:0000269|PubMed:10359561" FT /id="VAR_009847" FT VARIANT 890 FT /note="V -> M (in AIS and PAIS; dbSNP:rs886041133)" FT /evidence="ECO:0000269|PubMed:8126121, FT ECO:0000269|PubMed:9160185" FT /id="VAR_009848" FT VARIANT 891 FT /note="D -> N (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:10363963" FT /id="VAR_009849" FT VARIANT 892 FT /note="F -> L (in prostate cancer and AIS)" FT /evidence="ECO:0000269|PubMed:24737579" FT /id="VAR_009850" FT VARIANT 893 FT /note="P -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:10221770, FT ECO:0000269|PubMed:10404311, ECO:0000269|Ref.185" FT /id="VAR_004733" FT VARIANT 896 FT /note="M -> T (in AIS; low androgen binding and FT transactivation)" FT /evidence="ECO:0000269|PubMed:16129672, FT ECO:0000269|PubMed:9856504" FT /id="VAR_004734" FT VARIANT 897 FT /note="A -> T (in prostate cancer)" FT /id="VAR_009851" FT VARIANT 899 FT /note="I -> T (in AIS; dbSNP:rs1555998105)" FT /evidence="ECO:0000269|PubMed:8723113" FT /id="VAR_009852" FT VARIANT 903 FT /note="Q -> R (in prostate cancer; dbSNP:rs137852582)" FT /id="VAR_009853" FT VARIANT 904 FT /note="V -> M (in PAIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009854" FT VARIANT 905 FT /note="P -> H (in AIS)" FT /evidence="ECO:0000269|PubMed:1430233" FT /id="VAR_009855" FT VARIANT 905 FT /note="P -> S (in AIS)" FT /id="VAR_009856" FT VARIANT 908 FT /note="L -> F (in AIS; almost complete loss of FT transcription activation)" FT /evidence="ECO:0000269|PubMed:16595706, FT ECO:0000269|PubMed:9328206" FT /id="VAR_004735" FT VARIANT 910 FT /note="G -> E (in prostate cancer)" FT /id="VAR_009857" FT VARIANT 910 FT /note="G -> R (in PAIS)" FT /evidence="ECO:0000269|PubMed:8550758" FT /id="VAR_009858" FT VARIANT 911 FT /note="K -> R (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:9438000" FT /id="VAR_009859" FT VARIANT 912 FT /note="V -> L (in PAIS)" FT /evidence="ECO:0000269|PubMed:10470409" FT /id="VAR_009860" FT VARIANT 914 FT /note="P -> S (in PAIS)" FT /id="VAR_004736" FT VARIANT 917 FT /note="F -> L (in AIS)" FT /evidence="ECO:0000269|PubMed:9302173" FT /id="VAR_009861" FT VARIANT 918 FT /note="H -> R (in AIS)" FT /evidence="ECO:0000269|PubMed:10690872" FT /id="VAR_009862" FT VARIANT 920 FT /note="Q -> R (in prostate cancer)" FT /id="VAR_009863" FT MUTAGEN 83 FT /note="S->A: Reduced cell growth." FT /evidence="ECO:0000269|PubMed:20980437" FT MUTAGEN 225 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 269 FT /note="Y->F: Decrease of CSK-induced phosphorylation and FT phosphorylation by TNK2. Complete loss of TNK2-dependent FT phosphorylation; when associated with F-365." FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MUTAGEN 309 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 348 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 359 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 364 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 365 FT /note="Y->F: Decrease of CSK-induced phosphorylation and FT phosphorylation by TNK2. Complete loss of TNK2-dependent FT phosphorylation; when associated with F-269." FT /evidence="ECO:0000269|PubMed:17045208, FT ECO:0000269|PubMed:17494760" FT MUTAGEN 395 FT /note="Y->F: Decrease of CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 535 FT /note="Y->F: Greatest decrease of CSK-induced FT phosphorylation and inhibition of transcriptional activity FT induced by EGF." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 552 FT /note="Y->F: Decrease in CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT MUTAGEN 702 FT /note="L->A: Alters receptor specificity, so that FT transcription is activated by the antiandrogen cyproterone FT acetate." FT /evidence="ECO:0000269|PubMed:17311914" FT MUTAGEN 721 FT /note="K->A: Loss of transcription activation in the FT presence of androgen and of interaction with NCOA2." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 742 FT /note="W->L: Strongly decreased transcription activation in FT the presence of androgen." FT /evidence="ECO:0000269|PubMed:16129672" FT MUTAGEN 846 FT /note="K->R: Prevents ubiquitination by RNF6. Prevents AR FT transcriptional activation by RNF14 in absence of hormone." FT /evidence="ECO:0000269|PubMed:19345326" FT MUTAGEN 848 FT /note="K->R: Partially prevents ubiquitination by RNF6." FT /evidence="ECO:0000269|PubMed:19345326" FT MUTAGEN 898 FT /note="E->A,Q: Reduced transcription activation in the FT presence of androgen." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 898 FT /note="E->K,R: Loss of transcription activation in the FT presence of androgen." FT /evidence="ECO:0000269|PubMed:15563469, FT ECO:0000269|PubMed:17591767" FT MUTAGEN 916 FT /note="Y->F: Decrease in CSK-induced phosphorylation." FT /evidence="ECO:0000269|PubMed:17045208" FT CONFLICT 168 FT /note="G -> A (in Ref. 5; AAA51780)" FT /evidence="ECO:0000305" FT CONFLICT 214 FT /note="A -> R (in Ref. 3 and 6; AAA51771/AAA51772)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="G -> E (in Ref. 2; AAA51775 and 13; AAA51770)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="E -> K (in Ref. 15; AAA51774)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="L -> P (in Ref. 19; AAB21256/AAB21257)" FT /evidence="ECO:0000305" FT CONFLICT 676 FT /note="N -> I (in Ref. 19; AAB21256/AAB21257)" FT /evidence="ECO:0000305" FT CONFLICT 811 FT /note="L -> M (in Ref. 5; AAA51780)" FT /evidence="ECO:0000305" FT HELIX 22..29 FT /evidence="ECO:0007829|PDB:3V49" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:1XJ7" FT HELIX 673..681 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 692..694 FT /evidence="ECO:0007829|PDB:5VO4" FT HELIX 698..721 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 726..728 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 731..758 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 761..766 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 769..771 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 773..778 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 782..797 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 802..813 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 815..818 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 825..844 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 850..883 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 885..888 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 894..902 FT /evidence="ECO:0007829|PDB:8E1A" FT HELIX 904..908 FT /evidence="ECO:0007829|PDB:8E1A" FT STRAND 911..914 FT /evidence="ECO:0007829|PDB:8E1A" SQ SEQUENCE 920 AA; 99188 MW; A73432C55D39AE06 CRC64; MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ QQQQQQQQQQ QQQQQQQQQQ ETSPRQQQQQ QGEDGSPQAH RRGPTGYLVL DEEQQPSQPQ SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSAA PSTLSLLGPT FPGLSSCSAD LKDILSEAST MQLLQQQQQE AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG KSTEDTAEYS PFKGGYTKGL EGESLGCSGS AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ SRDYYNFPLA LAGPPPPPPP PHPHARIKLE NPLDYGSAWA AAAAQCRYGD LASLHGAGAA GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP YGYTRPPQGL AGQESDFTAP DVWYPGGMVS RVPYPSPTCV KSEMGPWMDS YSGPYGDMRL ETARDHVLPI DYYFPPQKTC LICGDEASGC HYGALTCGSC KVFFKRAAEG KQKYLCASRN DCTIDKFRRK NCPSCRLRKC YEAGMTLGAR KLKKLGNLKL QEEGEASSTT SPTEETTQKL TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA LLSSLNELGE RQLVHVVKWA KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFTNVNS RMLYFAPDLV FNEYRMHKSR MYSQCVRMRH LSQEFGWLQI TPQEFLCMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD RIIACKRKNP TSCSRRFYQL TKLLDSVQPI ARELHQFTFD LLIKSHMVSV DFPEMMAEII SVQVPKILSG KVKPIYFHTQ // ID API5_HUMAN Reviewed; 524 AA. AC Q9BZZ5; B4DGR0; B4DRJ2; B4E283; D3DR21; G3V1C3; O15441; Q9Y4J7; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 19-OCT-2011, sequence version 3. DT 28-JAN-2026, entry version 178. DE RecName: Full=Apoptosis inhibitor 5 {ECO:0000305}; DE Short=API-5; DE AltName: Full=Antiapoptosis clone 11 protein; DE Short=AAC-11; DE AltName: Full=Cell migration-inducing gene 8 protein; DE AltName: Full=Fibroblast growth factor 2-interacting factor; DE Short=FIF; DE AltName: Full=Protein XAGL; GN Name=API5 {ECO:0000312|HGNC:HGNC:594}; ORFNames=MIG8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RX PubMed=9307294; RA Tewari M., Yu M., Ross B., Dean C., Giordano A., Rubin R.; RT "AAC-11, a novel cDNA that inhibits apoptosis after growth factor RT withdrawal."; RL Cancer Res. 57:4063-4069(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=10393420; DOI=10.1159/000015247; RA Gianfrancesco F., Esposito T., Ciccodicola A., D'Esposito M., RA Mazzarella R., D'Urso M., Forabosco A.; RT "Molecular cloning and fine mapping of API5L1, a novel human gene strongly RT related to an antiapoptotic gene."; RL Cytogenet. Cell Genet. 84:164-166(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF RP 72-524 (ISOFORM 1), IDENTIFICATION OF ISOFORM 3, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND INTERACTION WITH FGF2. RC TISSUE=Liver; RX PubMed=11075807; DOI=10.1210/mend.14.11.0556; RA Van den Berghe L., Laurell H., Huez I., Zanibellato C., Prats H., RA Bugler B.; RT "FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear RT putatively antiapoptotic factor, interacts specifically with FGF-2."; RL Mol. Endocrinol. 14:1709-1724(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Kim J.W.; RT "Identification of a human cell migration gene."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-276; VAL-300 AND RP SER-493. RG NIEHS SNPs program; RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 5 AND 6). RC TISSUE=Brain, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PROTEIN SEQUENCE OF 2-9; 26-36; 131-148; 161-169; 244-251 AND 427-436, RP CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Ovarian carcinoma; RA Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP NUCLEOTIDE SEQUENCE [MRNA] OF 384-524 (ISOFORM 3). RX PubMed=8889549; DOI=10.1101/gr.6.9.807; RA Hillier L.D., Lennon G., Becker M., Bonaldo M.F., Chiapelli B., Chissoe S., RA Dietrich N., DuBuque T., Favello A., Gish W., Hawkins M., Hultman M., RA Kucaba T., Lacy M., Le M., Le N., Mardis E., Moore B., Morris M., RA Parsons J., Prange C., Rifkin L., Rohlfing T., Schellenberg K., RA Bento Soares M., Tan F., Thierry-Meg J., Trevaskis E., Underwood K., RA Wohldman P., Waterston R., Wilson R., Marra M.; RT "Generation and analysis of 280,000 human expressed sequence tags."; RL Genome Res. 6:807-828(1996). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=10780674; DOI=10.1038/labinvest.3780063; RA Kim J.W., Cho H.S., Kim J.H., Hur S.Y., Kim T.E., Lee J.M., Kim I.K., RA Namkoong S.E.; RT "AAC-11 overexpression induces invasion and protects cervical cancer cells RT from apoptosis."; RL Lab. Invest. 80:587-594(2000). RN [14] RP TISSUE SPECIFICITY. RX PubMed=11557113; DOI=10.1016/s0169-5002(01)00213-6; RA Sasaki H., Moriyama S., Yukiue H., Kobayashi Y., Nakashima Y., Kaji M., RA Fukai I., Kiriyama M., Yamakawa Y., Fujii Y.; RT "Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in RT non-small cell lung cancer."; RL Lung Cancer 34:53-57(2001). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [16] RP FUNCTION. RX PubMed=17112319; DOI=10.1371/journal.pgen.0020196; RA Morris E.J., Michaud W.A., Ji J.Y., Moon N.S., Rocco J.W., Dyson N.J.; RT "Functional identification of Api5 as a suppressor of E2F-dependent RT apoptosis in vivo."; RL PLoS Genet. 2:E196-E196(2006). RN [17] RP TISSUE SPECIFICITY. RX PubMed=17827341; DOI=10.1189/jlb.0607425; RA Krejci P., Pejchalova K., Rosenbloom B.E., Rosenfelt F.P., Tran E.L., RA Laurell H., Wilcox W.R.; RT "The antiapoptotic protein Api5 and its partner, high molecular weight RT FGF2, are up-regulated in B cell chronic lymphoid leukemia."; RL J. Leukoc. Biol. 82:1363-1364(2007). RN [18] RP FUNCTION, INTERACTION WITH ACIN1, AND TISSUE SPECIFICITY. RX PubMed=19387494; DOI=10.1038/emboj.2009.106; RA Rigou P., Piddubnyak V., Faye A., Rain J.-C., Michel L., Calvo F., RA Poyet J.-L.; RT "The antiapoptotic protein AAC-11 interacts with and regulates Acinus- RT mediated DNA fragmentation."; RL EMBO J. 28:1576-1588(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-464, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-462 AND SER-464, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-399, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-464, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [25] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-500, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-498 OF WILD-TYPE AND MUTANT RP GLN-251, NUCLEAR LOCALIZATION SIGNAL, ACETYLATION AT LYS-251, REPEATS, AND RP SUBUNIT. RX PubMed=22334682; DOI=10.1074/jbc.m111.317594; RA Han B.G., Kim K.H., Lee S.J., Jeong K.C., Cho J.W., Noh K.H., Kim T.W., RA Kim S.J., Yoon H.J., Suh S.W., Lee S., Lee B.I.; RT "Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein RT interaction modules."; RL J. Biol. Chem. 287:10727-10737(2012). CC -!- FUNCTION: Antiapoptotic factor that may have a role in protein CC assembly. Negatively regulates ACIN1. By binding to ACIN1, it CC suppresses ACIN1 cleavage from CASP3 and ACIN1-mediated DNA CC fragmentation. Also known to efficiently suppress E2F1-induced CC apoptosis. Its depletion enhances the cytotoxic action of the CC chemotherapeutic drugs. {ECO:0000269|PubMed:10780674, CC ECO:0000269|PubMed:17112319, ECO:0000269|PubMed:19387494}. CC -!- SUBUNIT: Monomer. Interacts with FGF2 and ACIN1. CC {ECO:0000269|PubMed:11075807, ECO:0000269|PubMed:19387494, CC ECO:0000269|PubMed:22334682}. CC -!- INTERACTION: CC Q9BZZ5; Q9UKV3-3: ACIN1; NbExp=2; IntAct=EBI-1048422, EBI-6976596; CC Q9BZZ5; Q13838: DDX39B; NbExp=2; IntAct=EBI-1048422, EBI-348622; CC Q9BZZ5-2; Q9UBB4: ATXN10; NbExp=3; IntAct=EBI-10989614, EBI-702390; CC Q9BZZ5-2; A1A5D9: BICDL2; NbExp=3; IntAct=EBI-10989614, EBI-10171799; CC Q9BZZ5-2; P19404: NDUFV2; NbExp=3; IntAct=EBI-10989614, EBI-713665; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11075807}. Cytoplasm CC {ECO:0000269|PubMed:11075807}. Note=Mainly nuclear. Can also be CC cytoplasmic. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Additional isoforms seem to exist.; CC Name=4; CC IsoId=Q9BZZ5-4; Sequence=Displayed; CC Name=1; Synonyms=FIF-510; CC IsoId=Q9BZZ5-1; Sequence=VSP_041969, VSP_041972; CC Name=2; Synonyms=FIF-504; CC IsoId=Q9BZZ5-2; Sequence=VSP_041970, VSP_041971; CC Name=3; Synonyms=FIF C1; CC IsoId=Q9BZZ5-3; Sequence=VSP_039761, VSP_039762; CC Name=5; CC IsoId=Q9BZZ5-5; Sequence=VSP_043289, VSP_041970, VSP_041971; CC Name=6; CC IsoId=Q9BZZ5-6; Sequence=VSP_057412; CC -!- TISSUE SPECIFICITY: Expressed in all tissues tested, including heart, CC brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. CC Highest levels in heart, pancreas and placenta. Highly expressed in CC several cancers. Preferentially expressed in squamous cell carcinoma CC versus adenocarcinoma in non-small cell lung cancer. CC {ECO:0000269|PubMed:10780674, ECO:0000269|PubMed:11075807, CC ECO:0000269|PubMed:11557113, ECO:0000269|PubMed:17827341, CC ECO:0000269|PubMed:19387494}. CC -!- DOMAIN: Two regions, an N-terminal (aa 96-107) and a C-terminal (aa CC 274-311) are required for binding FGF2. CC -!- PTM: Acetylation at Lys-251 impairs antiapoptotic function. CC {ECO:0000269|PubMed:22334682}. CC -!- SIMILARITY: Belongs to the API5 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB86528.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAB86528.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U83857; AAB86528.1; ALT_SEQ; mRNA. DR EMBL; Y15906; CAA75867.1; -; mRNA. DR EMBL; AF229253; AAK00737.1; -; mRNA. DR EMBL; AF229254; AAK00738.1; -; mRNA. DR EMBL; AY311389; AAQ76714.1; -; mRNA. DR EMBL; BT007093; AAP35756.1; -; mRNA. DR EMBL; AY265973; AAO89077.1; -; Genomic_DNA. DR EMBL; AK294724; BAG57871.1; -; mRNA. DR EMBL; AK299288; BAG61304.1; -; mRNA. DR EMBL; AK304157; BAG65045.1; -; mRNA. DR EMBL; AC087276; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471064; EAW68098.1; -; Genomic_DNA. DR EMBL; CH471064; EAW68099.1; -; Genomic_DNA. DR EMBL; BC017709; AAH17709.1; -; mRNA. DR EMBL; W40304; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS31465.1; -. [Q9BZZ5-2] DR CCDS; CCDS44572.1; -. [Q9BZZ5-4] DR CCDS; CCDS44573.1; -. [Q9BZZ5-5] DR RefSeq; NP_001136402.1; NM_001142930.2. [Q9BZZ5-4] DR RefSeq; NP_001136403.1; NM_001142931.2. [Q9BZZ5-5] DR RefSeq; NP_001230676.1; NM_001243747.1. DR RefSeq; NP_006586.1; NM_006595.4. [Q9BZZ5-2] DR PDB; 3U0R; X-ray; 2.50 A; A=1-498. DR PDB; 3V6A; X-ray; 2.60 A; A=1-454. DR PDB; 6L4O; X-ray; 2.60 A; A=1-524. DR PDBsum; 3U0R; -. DR PDBsum; 3V6A; -. DR PDBsum; 6L4O; -. DR AlphaFoldDB; Q9BZZ5; -. DR SMR; Q9BZZ5; -. DR BioGRID; 114109; 198. DR CORUM; Q9BZZ5; -. DR FunCoup; Q9BZZ5; 5479. DR IntAct; Q9BZZ5; 47. DR MINT; Q9BZZ5; -. DR STRING; 9606.ENSP00000431391; -. DR GlyGen; Q9BZZ5; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BZZ5; -. DR PhosphoSitePlus; Q9BZZ5; -. DR SwissPalm; Q9BZZ5; -. DR BioMuta; API5; -. DR DMDM; 353526346; -. DR jPOST; Q9BZZ5; -. DR MassIVE; Q9BZZ5; -. DR PaxDb; 9606-ENSP00000431391; -. DR PeptideAtlas; Q9BZZ5; -. DR ProteomicsDB; 32325; -. DR ProteomicsDB; 79926; -. [Q9BZZ5-4] DR ProteomicsDB; 79927; -. [Q9BZZ5-1] DR ProteomicsDB; 79928; -. [Q9BZZ5-2] DR ProteomicsDB; 79929; -. [Q9BZZ5-3] DR ProteomicsDB; 79930; -. [Q9BZZ5-5] DR Pumba; Q9BZZ5; -. DR Antibodypedia; 13145; 290 antibodies from 33 providers. DR DNASU; 8539; -. DR Ensembl; ENST00000378852.7; ENSP00000368129.3; ENSG00000166181.14. [Q9BZZ5-2] DR Ensembl; ENST00000420461.6; ENSP00000402540.2; ENSG00000166181.14. [Q9BZZ5-5] DR Ensembl; ENST00000455725.6; ENSP00000399341.2; ENSG00000166181.14. [Q9BZZ5-6] DR Ensembl; ENST00000531273.6; ENSP00000431391.1; ENSG00000166181.14. [Q9BZZ5-4] DR Ensembl; ENST00000534600.5; ENSP00000434462.1; ENSG00000166181.14. [Q9BZZ5-1] DR GeneID; 8539; -. DR KEGG; hsa:8539; -. DR MANE-Select; ENST00000531273.6; ENSP00000431391.1; NM_001142930.2; NP_001136402.1. DR UCSC; uc001mxf.3; human. [Q9BZZ5-4] DR UCSC; uc010rfg.2; human. DR AGR; HGNC:594; -. DR ClinPGx; PA24881; -. DR CTD; 8539; -. DR DisGeNET; 8539; -. DR GeneCards; API5; -. DR HGNC; HGNC:594; API5. DR HPA; ENSG00000166181; Low tissue specificity. DR MIM; 609774; gene. DR OpenTargets; ENSG00000166181; -. DR VEuPathDB; HostDB:ENSG00000166181; -. DR eggNOG; KOG2213; Eukaryota. DR GeneTree; ENSGT00390000010991; -. DR HOGENOM; CLU_037809_1_0_1; -. DR InParanoid; Q9BZZ5; -. DR OMA; RCIKFLA; -. DR OrthoDB; 19224at2759; -. DR PAN-GO; Q9BZZ5; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BZZ5; -. DR PathwayCommons; Q9BZZ5; -. DR SignaLink; Q9BZZ5; -. DR Agora; ENSG00000166181; -. DR BioGRID-ORCS; 8539; 68 hits in 1156 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; API5; human. DR EvolutionaryTrace; Q9BZZ5; -. DR GeneWiki; API5; -. DR GenomeRNAi; 8539; -. DR Pharos; Q9BZZ5; Tbio. DR PRO; PR:Q9BZZ5; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q9BZZ5; protein. DR Bgee; ENSG00000166181; Expressed in islet of Langerhans and 218 other cell types or tissues. DR ExpressionAtlas; Q9BZZ5; baseline and differential. DR GO; GO:0005737; C:cytoplasm; NAS:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005681; C:spliceosomal complex; ISS:UniProtKB. DR GO; GO:0017134; F:fibroblast growth factor binding; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0044346; P:fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR DisProt; DP02894; -. [Q9BZZ5-2] DR FunFam; 1.25.10.10:FF:000092; apoptosis inhibitor 5 isoform X2; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR008383; API5. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR PANTHER; PTHR12758:SF19; APOPTOSIS INHIBITOR 5; 1. DR PANTHER; PTHR12758; APOPTOSIS INHIBITOR 5-RELATED; 1. DR Pfam; PF05918; API5; 1. DR SUPFAM; SSF48371; ARM repeat; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Direct protein sequencing; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.11" FT CHAIN 2..524 FT /note="Apoptosis inhibitor 5" FT /id="PRO_0000064634" FT REGION 2..360 FT /note="ARM-like and Heat-like helical repeats" FT REGION 370..391 FT /note="Leucine-zipper" FT REGION 452..524 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 454..475 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22334682" FT COMPBIAS 462..472 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 487..497 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 251 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22334682" FT MOD_RES 399 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 462 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 464 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O35841" FT MOD_RES 500 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT VAR_SEQ 1..23 FT /note="MPTVEELYRNYGILADATEQVGQ -> MKQRWRENGIGK (in isoform FT 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057412" FT VAR_SEQ 24..77 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043289" FT VAR_SEQ 427..431 FT /note="DLFHI -> AKESQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8889549" FT /id="VSP_039761" FT VAR_SEQ 432..510 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8889549" FT /id="VSP_039762" FT VAR_SEQ 498..510 FT /note="EQRGAFRGSRGGR -> GERFRLGTRNMRD (in isoform 1)" FT /evidence="ECO:0000303|PubMed:11075807" FT /id="VSP_041969" FT VAR_SEQ 499..504 FT /note="QRGAFR -> RSLQGK (in isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10393420, FT ECO:0000303|PubMed:11075807, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4, FT ECO:0000303|Ref.5" FT /id="VSP_041970" FT VAR_SEQ 505..524 FT /note="Missing (in isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10393420, FT ECO:0000303|PubMed:11075807, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4, FT ECO:0000303|Ref.5" FT /id="VSP_041971" FT VAR_SEQ 511..524 FT /note="Missing (in isoform 1)" FT /evidence="ECO:0000303|PubMed:11075807" FT /id="VSP_041972" FT VARIANT 276 FT /note="P -> S" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021519" FT VARIANT 300 FT /note="M -> V (in dbSNP:rs5743240)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021520" FT VARIANT 493 FT /note="G -> S (in dbSNP:rs2862934)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021521" FT CONFLICT 371..373 FT /note="KDF -> HES (in Ref. 1; AAB86528)" FT /evidence="ECO:0000305" FT HELIX 4..16 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 18..24 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 25..33 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 34..36 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 39..52 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 60..71 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 76..85 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 86..89 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 95..105 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 111..127 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 129..142 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 145..158 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 159..161 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 169..182 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 188..199 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 207..221 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:3V6A" FT HELIX 232..245 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 246..248 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 256..265 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 282..294 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 303..315 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 340..354 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 359..362 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 368..370 FT /evidence="ECO:0007829|PDB:3V6A" FT HELIX 371..395 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 402..404 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 406..427 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 430..432 FT /evidence="ECO:0007829|PDB:6L4O" SQ SEQUENCE 524 AA; 59005 MW; A2EA6BE4D8318BB9 CRC64; MPTVEELYRN YGILADATEQ VGQHKDAYQV ILDGVKGGTK EKRLAAQFIP KFFKHFPELA DSAINAQLDL CEDEDVSIRR QAIKELPQFA TGENLPRVAD ILTQLLQTDD SAEFNLVNNA LLSIFKMDAK GTLGGLFSQI LQGEDIVRER AIKFLSTKLK TLPDEVLTKE VEELILTESK KVLEDVTGEE FVLFMKILSG LKSLQTVSGR QQLVELVAEQ ADLEQTFNPS DPDCVDRLLQ CTRQAVPLFS KNVHSTRFVT YFCEQVLPNL GTLTTPVEGL DIQLEVLKLL AEMSSFCGDM EKLETNLRKL FDKLLEYMPL PPEEAENGEN AGNEEPKLQF SYVECLLYSF HQLGRKLPDF LTAKLNAEKL KDFKIRLQYF ARGLQVYIRQ LRLALQGKTG EALKTEENKI KVVALKITNN INVLIKDLFH IPPSYKSTVT LSWKPVQKVE IGQKRASEDT TSGSPPKKSS AGPKRDARQI YNPPSGKYSS NLGNFNYEQR GAFRGSRGGR GWGTRGNRSR GRLY // ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID ATR_HUMAN Reviewed; 2644 AA. AC Q13535; Q59HB2; Q7KYL3; Q93051; Q9BXK4; DT 29-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 3. DT 28-JAN-2026, entry version 219. DE RecName: Full=Serine/threonine-protein kinase ATR; DE EC=2.7.11.1 {ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; DE AltName: Full=Ataxia telangiectasia and Rad3-related protein; DE AltName: Full=FRAP-related protein 1; GN Name=ATR {ECO:0000303|PubMed:14729973, ECO:0000312|HGNC:HGNC:882}; GN Synonyms=FRP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8978690; DOI=10.1002/j.1460-2075.1996.tb01054.x; RA Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., RA Ford J.C., Hoekstra M., Carr A.M.; RT "The Schizosaccharomyces pombe rad3 checkpoint gene."; RL EMBO J. 15:6641-6651(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=T-cell; RX PubMed=8610130; DOI=10.1073/pnas.93.7.2850; RA Cimprich K.A., Shin T.B., Keith C.T., Schreiber S.L.; RT "cDNA cloning and gene mapping of a candidate human cell cycle checkpoint RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 93:2850-2855(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 433-526 (ISOFORMS 1 AND 2), AND RP TISSUE SPECIFICITY. RX PubMed=11470508; DOI=10.1016/s0378-1119(01)00543-1; RA Mannino J.L., Kim W.-J., Wernick M., Nguyen S.V., Braquet R., Adamson A.W., RA Den Z., Batzer M.A., Collins C.C., Brown K.D.; RT "Evidence for alternate splicing within the mRNA transcript encoding the RT DNA damage response kinase ATR."; RL Gene 272:35-43(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2155-2644 (ISOFORM 3). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=8843195; DOI=10.1101/gad.10.19.2423; RA Keegan K.S., Holtzman D.A., Plug A.W., Christenson E.R., Brainerd E.E., RA Flaggs G., Bentley N.J., Taylor E.M., Meyn M.S., Moss S.B., Carr A.M., RA Ashley T., Hoekstra M.F.; RT "The Atr and Atm protein kinases associate with different sites along RT meiotically pairing chromosomes."; RL Genes Dev. 10:2423-2437(1996). RN [6] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [7] RP FUNCTION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=9427750; DOI=10.1093/emboj/17.1.159; RA Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., RA Schreiber S.L., Friend S.H.; RT "Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA- RT damaging agents and defects in cell cycle checkpoints."; RL EMBO J. 17:159-169(1998). RN [8] RP FUNCTION, AND MUTAGENESIS OF ASP-2494. RX PubMed=9636169; DOI=10.1073/pnas.95.13.7445; RA Wright J.A., Keegan K.S., Herendeen D.R., Bentley N.J., Carr A.M., RA Hoekstra M.F., Concannon P.; RT "Protein kinase mutants of human ATR increase sensitivity to UV and RT ionizing radiation and abrogate cell cycle checkpoint control."; RL Proc. Natl. Acad. Sci. U.S.A. 95:7445-7450(1998). RN [9] RP INTERACTION WITH HDAC2, AND IDENTIFICATION IN A COMPLEX CONTAINING HDAC2 RP AND CHD4. RX PubMed=10545197; DOI=10.1021/bi991614n; RA Schmidt D.R., Schreiber S.L.; RT "Molecular association between ATR and two components of the nucleosome RT remodeling and deacetylating complex, HDAC2 and CHD4."; RL Biochemistry 38:14711-14717(1999). RN [10] RP FUNCTION, AND MUTAGENESIS OF LYS-2327 AND ASP-2475. RX PubMed=9925639; DOI=10.1101/gad.13.2.152; RA Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., RA Shieh S.-Y., Taya Y., Prives C., Abraham R.T.; RT "A role for ATR in the DNA damage-induced phosphorylation of p53."; RL Genes Dev. 13:152-157(1999). RN [11] RP COFACTOR, AND FUNCTION. RX PubMed=10608806; DOI=10.1074/jbc.274.53.37538; RA Kim S.-T., Lim D.-S., Canman C.E., Kastan M.B.; RT "Substrate specificities and identification of putative substrates of ATM RT kinase family members."; RL J. Biol. Chem. 274:37538-37543(1999). RN [12] RP FUNCTION, AUTOPHOSPHORYLATION, MUTAGENESIS OF ASP-2494, AND ACTIVITY RP REGULATION. RX PubMed=10597277; DOI=10.1038/sj.onc.1203077; RA Hall-Jackson C.A., Cross D.A.E., Morrice N., Smythe C.; RT "ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate RT specificity distinct from DNA-PK."; RL Oncogene 18:6707-6713(1999). RN [13] RP FUNCTION. RX PubMed=10859164; RA Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G., RA Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J.; RT "Chk1 is an essential kinase that is regulated by Atr and required for the RT G(2)/M DNA damage checkpoint."; RL Genes Dev. 14:1448-1459(2000). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-2327. RX PubMed=11114888; DOI=10.1101/gad.851000; RA Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., RA Elledge S.J., Abraham R.T.; RT "Functional interactions between BRCA1 and the checkpoint kinase ATR during RT genotoxic stress."; RL Genes Dev. 14:2989-3002(2000). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11673449; DOI=10.1074/jbc.c100569200; RA Ward I.M., Chen J.; RT "Histone H2AX is phosphorylated in an ATR-dependent manner in response to RT replicational stress."; RL J. Biol. Chem. 276:47759-47762(2001). RN [16] RP FUNCTION. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ATRIP. RX PubMed=11721054; DOI=10.1126/science.1065521; RA Cortez D., Guntuku S., Qin J., Elledge S.J.; RT "ATR and ATRIP: partners in checkpoint signaling."; RL Science 294:1713-1716(2001). RN [18] RP FUNCTION. RX PubMed=12526805; DOI=10.1016/s0092-8674(02)01113-3; RA Casper A.M., Nghiem P., Arlt M.F., Glover T.W.; RT "ATR regulates fragile site stability."; RL Cell 111:779-789(2002). RN [19] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11865061; DOI=10.1128/mcb.22.6.1834-1843.2002; RA Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J.; RT "Hypoxia links ATR and p53 through replication arrest."; RL Mol. Cell. Biol. 22:1834-1843(2002). RN [20] RP DNA-BINDING, AND MUTAGENESIS OF LYS-2327. RX PubMed=12011431; DOI=10.1073/pnas.102167799; RA Uensal-Kacmaz K., Makhov A.M., Griffith J.D., Sancar A.; RT "Preferential binding of ATR protein to UV-damaged DNA."; RL Proc. Natl. Acad. Sci. U.S.A. 99:6673-6678(2002). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=12814551; DOI=10.1016/s0960-9822(03)00376-2; RA Barr S.M., Leung C.G., Chang E.E., Cimprich K.A.; RT "ATR kinase activity regulates the intranuclear translocation of ATR and RT RPA following ionizing radiation."; RL Curr. Biol. 13:1047-1051(2003). RN [22] RP INTERACTION WITH CLSPN. RX PubMed=12766152; DOI=10.1074/jbc.m301136200; RA Chini C.C.S., Chen J.; RT "Human claspin is required for replication checkpoint control."; RL J. Biol. Chem. 278:30057-30062(2003). RN [23] RP FUNCTION, INTERACTION WITH MSH2, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [24] RP FUNCTION, DNA-BINDING, AND IDENTIFICATION IN A COMPLEX WITH RPA AND ATRIP. RX PubMed=12791985; DOI=10.1126/science.1083430; RA Zou L., Elledge S.J.; RT "Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes."; RL Science 300:1542-1548(2003). RN [25] RP INTERACTION WITH BCR-ABL. RX PubMed=15050919; DOI=10.1016/s1535-6108(04)00056-x; RA Dierov J., Dierova R., Carroll M.; RT "BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S RT phase checkpoint."; RL Cancer Cell 5:275-285(2004). RN [26] RP FUNCTION. RX PubMed=14742437; DOI=10.1074/jbc.c300554200; RA Ward I.M., Minn K., Chen J.; RT "UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation RT requires replication stress."; RL J. Biol. Chem. 279:9677-9680(2004). RN [27] RP DNA-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=14871897; DOI=10.1074/jbc.m314212200; RA Dart D.A., Adams K.E., Akerman I., Lakin N.D.; RT "Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S- RT phase."; RL J. Biol. Chem. 279:16433-16440(2004). RN [28] RP FUNCTION. RX PubMed=15314022; DOI=10.1101/gad.1196104; RA Andreassen P.R., D'Andrea A.D., Taniguchi T.; RT "ATR couples FANCD2 monoubiquitination to the DNA-damage response."; RL Genes Dev. 18:1958-1963(2004). RN [29] RP FUNCTION. RX PubMed=15496423; DOI=10.1093/hmg/ddh335; RA Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., RA O'Driscoll M.; RT "Seckel syndrome exhibits cellular features demonstrating defects in the RT ATR-signalling pathway."; RL Hum. Mol. Genet. 13:3127-3138(2004). RN [30] RP FUNCTION, SUBUNIT, IDENTIFICATION IN A COMPLEX WITH ATRIP AND RPA1, RP DNA-BINDING, AND ACTIVITY REGULATION. RX PubMed=14729973; DOI=10.1128/mcb.24.3.1292-1300.2003; RA Uensal-Kacmaz K., Sancar A.; RT "Quaternary structure of ATR and effects of ATRIP and replication protein A RT on its DNA binding and kinase activities."; RL Mol. Cell. Biol. 24:1292-1300(2004). RN [31] RP FUNCTION. RX PubMed=15210935; DOI=10.1073/pnas.0403410101; RA Cortez D., Glick G., Elledge S.J.; RT "Minichromosome maintenance proteins are direct targets of the ATM and ATR RT checkpoint kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10078-10083(2004). RN [32] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [33] RP INTERACTION WITH ATRIP. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [34] RP ACTIVITY REGULATION. RX PubMed=16530042; DOI=10.1016/j.cell.2005.12.041; RA Kumagai A., Lee J., Yoo H.Y., Dunphy W.G.; RT "TopBP1 activates the ATR-ATRIP complex."; RL Cell 124:943-955(2006). RN [35] RP INTERACTION WITH CEP164, AND SUBCELLULAR LOCATION. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [36] RP INVOLVEMENT IN SCKL1. RX PubMed=12640452; DOI=10.1038/ng1129; RA O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A.; RT "A splicing mutation affecting expression of ataxia-telangiectasia and RT Rad3-related protein (ATR) results in Seckel syndrome."; RL Nat. Genet. 33:497-501(2003). RN [37] RP FUNCTION IN DNA DAMAGE RESPONSE, AUTOPHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16260606; DOI=10.1128/mcb.25.22.9910-9919.2005; RA Zhang J., Bao S., Furumai R., Kucera K.S., Ali A., Dean N.M., Wang X.F.; RT "Protein phosphatase 5 is required for ATR-mediated checkpoint RT activation."; RL Mol. Cell. Biol. 25:9910-9919(2005). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428 AND THR-1989, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [41] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [42] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [43] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [45] RP FUNCTION IN DNA REPAIR, AND PHOSPHORYLATION AT SER-428. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [46] RP PHOSPHORYLATION AT THR-1989, AND MUTAGENESIS OF THR-1989. RX PubMed=21705319; DOI=10.1074/jbc.m111.248914; RA Nam E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., Cortez D.; RT "Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- RT mutated and Rad3-related (ATR) kinase."; RL J. Biol. Chem. 286:28707-28714(2011). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-428; SER-435 AND RP THR-1989, ACTIVITY REGULATION, AND INTERACTION WITH ATRIP AND TOPBP1. RX PubMed=21777809; DOI=10.1016/j.molcel.2011.06.019; RA Liu S., Shiotani B., Lahiri M., Marechal A., Tse A., Leung C.C., RA Glover J.N., Yang X.H., Zou L.; RT "ATR autophosphorylation as a molecular switch for checkpoint activation."; RL Mol. Cell 43:192-202(2011). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435; SER-436 AND THR-1989, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23273981; DOI=10.1016/j.molcel.2012.11.020; RA Peterson S.E., Li Y., Wu-Baer F., Chait B.T., Baer R., Yan H., RA Gottesman M.E., Gautier J.; RT "Activation of DSB processing requires phosphorylation of CtIP by ATR."; RL Mol. Cell 49:657-667(2013). RN [51] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25083873; DOI=10.1016/j.cell.2014.05.046; RA Kumar A., Mazzanti M., Mistrik M., Kosar M., Beznoussenko G.V., RA Mironov A.A., Garre M., Parazzoli D., Shivashankar G.V., Scita G., RA Bartek J., Foiani M.; RT "ATR mediates a checkpoint at the nuclear envelope in response to RT mechanical stress."; RL Cell 158:633-646(2014). RN [52] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND ACTIVITY RP REGULATION. RX PubMed=27723720; DOI=10.1038/ncb3415; RA Bass T.E., Luzwick J.W., Kavanaugh G., Carroll C., Dungrawala H., RA Glick G.G., Feldkamp M.D., Putney R., Chazin W.J., Cortez D.; RT "ETAA1 acts at stalled replication forks to maintain genome integrity."; RL Nat. Cell Biol. 18:1185-1195(2016). RN [53] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=27723717; DOI=10.1038/ncb3422; RA Haahr P., Hoffmann S., Tollenaere M.A., Ho T., Toledo L.I., Mann M., RA Bekker-Jensen S., Raeschle M., Mailand N.; RT "Activation of the ATR kinase by the RPA-binding protein ETAA1."; RL Nat. Cell Biol. 18:1196-1207(2016). RN [54] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=30139873; DOI=10.1126/science.aap9346; RA Saldivar J.C., Hamperl S., Bocek M.J., Chung M., Bass T.E., RA Cisneros-Soberanis F., Samejima K., Xie L., Paulson J.R., Earnshaw W.C., RA Cortez D., Meyer T., Cimprich K.A.; RT "An intrinsic S/G2 checkpoint enforced by ATR."; RL Science 361:806-810(2018). RN [55] RP FUNCTION, AND INTERACTION WITH UHRF2. RX PubMed=33848395; DOI=10.1111/gtc.12851; RA Hanaki S., Habara M., Shimada M.; RT "UV-induced activation of ATR is mediated by UHRF2."; RL Genes Cells 26:447-454(2021). RN [56] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37788673; DOI=10.1016/j.molcel.2023.09.003; RA Joo Y.K., Black E.M., Trier I., Haakma W., Zou L., Kabeche L.; RT "ATR promotes clearance of damaged DNA and damaged cells by rupturing RT micronuclei."; RL Mol. Cell 83:3642-3658(2023). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37832547; DOI=10.1016/j.molcel.2023.09.023; RA Kovacs M.T., Vallette M., Wiertsema P., Dingli F., Loew D., Nader G.P.F., RA Piel M., Ceccaldi R.; RT "DNA damage induces nuclear envelope rupture through ATR-mediated RT phosphorylation of lamin A/C."; RL Mol. Cell 83:3659-3668(2023). RN [58] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-64; TYR-90; ASN-297; ILE-316; MET-959; RP HIS-1087; GLY-1213; PRO-1488; ASN-1607; SER-1612; GLY-2002; ALA-2120; RP ASP-2132; ILE-2233; GLN-2425; ALA-2434; LYS-2438 AND GLN-2537. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [59] RP VARIANT FCTCS ARG-2144. RX PubMed=22341969; DOI=10.1016/j.ajhg.2012.01.007; RA Tanaka A., Weinel S., Nagy N., O'Driscoll M., Lai-Cheong J.E., RA Kulp-Shorten C.L., Knable A., Carpenter G., Fisher S.A., Hiragun M., RA Yanase Y., Hide M., Callen J., McGrath J.A.; RT "Germline mutation in ATR in autosomal- dominant oropharyngeal cancer RT syndrome."; RL Am. J. Hum. Genet. 90:511-517(2012). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon genotoxic stresses such as ionizing radiation (IR), CC ultraviolet light (UV), or DNA replication stalling, thereby acting as CC a DNA damage sensor (PubMed:10597277, PubMed:10608806, PubMed:10859164, CC PubMed:11721054, PubMed:12791985, PubMed:12814551, PubMed:14657349, CC PubMed:14729973, PubMed:14742437, PubMed:15210935, PubMed:15496423, CC PubMed:16260606, PubMed:21144835, PubMed:21777809, PubMed:23273981, CC PubMed:25083873, PubMed:27723717, PubMed:27723720, PubMed:30139873, CC PubMed:33848395, PubMed:37788673, PubMed:37832547, PubMed:9427750, CC PubMed:9636169). Recognizes the substrate consensus sequence [ST]-Q CC (PubMed:10597277, PubMed:10608806, PubMed:10859164, PubMed:11721054, CC PubMed:12791985, PubMed:12814551, PubMed:14657349, PubMed:14729973, CC PubMed:14742437, PubMed:15210935, PubMed:15496423, PubMed:16260606, CC PubMed:21144835, PubMed:23273981, PubMed:27723717, PubMed:27723720, CC PubMed:33848395, PubMed:9427750, PubMed:9636169). Phosphorylates BRCA1, CC CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively CC inhibit DNA replication and mitosis and promote DNA repair, CC recombination and apoptosis (PubMed:11114888, PubMed:11418864, CC PubMed:11865061, PubMed:21777809, PubMed:23273981, PubMed:25083873, CC PubMed:9925639). Phosphorylates 'Ser-139' of histone variant H2AX at CC sites of DNA damage, thereby regulating DNA damage response mechanism CC (PubMed:11673449). Required for FANCD2 ubiquitination CC (PubMed:15314022). Critical for maintenance of fragile site stability CC and efficient regulation of centrosome duplication (PubMed:12526805). CC Acts as a regulator of the S-G2 transition by restricting the activity CC of CDK1 during S-phase to prevent premature entry into G2 CC (PubMed:30139873). Acts as a regulator of the nuclear envelope CC integrity in response to DNA damage and stress (PubMed:25083873, CC PubMed:37788673, PubMed:37832547). Acts as a mechanical stress sensor CC at the nuclear envelope: relocalizes to the nuclear envelope in CC response to mechanical stress and mediates a checkpoint via CC phosphorylation of CHEK1 (PubMed:25083873). Also promotes nuclear CC envelope rupture in response to DNA damage by mediating phosphorylation CC of LMNA at 'Ser-282', leading to lamin disassembly (PubMed:37832547). CC Involved in the inflammatory response to genome instability and double- CC stranded DNA breaks: acts by localizing to micronuclei arising from CC genome instability and catalyzing phosphorylation of LMNA at 'Ser-395', CC priming LMNA for subsequent phosphorylation by CDK1 and micronuclei CC envelope rupture (PubMed:37788673). The rupture of micronuclear CC envelope triggers the cGAS-STING pathway thereby activating the type I CC interferon response and innate immunity (PubMed:37788673). Positively CC regulates the restart of stalled replication forks following activation CC by the KHDC3L-OOEP scaffold complex (By similarity). CC {ECO:0000250|UniProtKB:Q9JKK8, ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:10608806, ECO:0000269|PubMed:10859164, CC ECO:0000269|PubMed:11114888, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:11673449, ECO:0000269|PubMed:11721054, CC ECO:0000269|PubMed:11865061, ECO:0000269|PubMed:12526805, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14729973, CC ECO:0000269|PubMed:14742437, ECO:0000269|PubMed:15210935, CC ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15496423, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:21144835, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:23273981, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:33848395, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547, ECO:0000269|PubMed:9427750, CC ECO:0000269|PubMed:9636169, ECO:0000269|PubMed:9925639}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:10608806}; CC -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is CC directly stimulated by TOPBP1 (PubMed:16530042, PubMed:21777809). ATR CC kinase activity is also directly activated by ETAA1, independently of CC TOPBP1 (PubMed:27723717, PubMed:27723720, PubMed:30139873). Activated CC by DNA and inhibited by BCR-ABL oncogene (PubMed:10597277). Slightly CC activated by ATRIP (PubMed:14729973). Inhibited by caffeine, wortmannin CC and LY294002 (PubMed:9766667). {ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:16530042, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Forms a heterodimer with ATRIP, forming the ATR-ATRIP complex CC (PubMed:11721054, PubMed:12791985, PubMed:14729973, PubMed:15758953, CC PubMed:21777809). Present in a complex containing ATRIP and RPA-coated CC single-stranded DNA (PubMed:12791985, PubMed:14729973). Binds to DNA, CC and to UV-damaged DNA with higher affinity (PubMed:12791985). Interacts CC with MSH2 and HDAC2 (PubMed:14657349). Present in a complex containing CC CHD4 and HDAC2 (PubMed:10545197). Interacts with EEF1E1, the CC interaction is enhanced by UV irradiation (PubMed:15680327). Interacts CC with CLSPN and CEP164 (PubMed:12766152, PubMed:18283122). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with BCR-ABL after genotoxic stress CC (PubMed:15050919). Interacts with UHRF2; this interaction promotes ATR CC activation (PubMed:33848395). Interacts (when phosphorylated) with CC TOPBP1; interaction takes place when ATR is autophosphorylated at Thr- CC 1989, leading to ATR activation by TOPBP1 (PubMed:21705319, CC PubMed:21777809). {ECO:0000269|PubMed:10545197, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:12766152, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:14657349, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:15050919, CC ECO:0000269|PubMed:15680327, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:18283122, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650, CC ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:33848395}. CC -!- INTERACTION: CC Q13535; Q8WXE1: ATRIP; NbExp=5; IntAct=EBI-968983, EBI-747353; CC Q13535; Q99459: CDC5L; NbExp=3; IntAct=EBI-968983, EBI-374880; CC Q13535; P50750: CDK9; NbExp=3; IntAct=EBI-968983, EBI-1383449; CC Q13535; Q9BW66: CINP; NbExp=5; IntAct=EBI-968983, EBI-739784; CC Q13535; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-968983, EBI-81279; CC Q13535; O43156: TTI1; NbExp=2; IntAct=EBI-968983, EBI-1055680; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11114888, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:11865061, CC ECO:0000269|PubMed:12814551, ECO:0000269|PubMed:14871897, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:8843195}. Chromosome CC {ECO:0000269|PubMed:11673449}. Nucleus envelope CC {ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}. Note=Depending on the cell type, it can CC also be found in PML nuclear bodies (PubMed:12814551). Recruited to CC chromatin during S-phase (PubMed:14871897). Redistributes to discrete CC nuclear foci upon DNA damage, hypoxia or replication fork stalling CC (PubMed:27723720). Relocalizes to the nuclear envelope in response to CC mechanical stress or DNA damage (PubMed:25083873, PubMed:37832547). CC Also localizes to the micronuclear envelope in response to response to CC genome instability (PubMed:37788673). {ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723720, CC ECO:0000269|PubMed:37788673, ECO:0000269|PubMed:37832547}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q13535-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13535-2; Sequence=VSP_013305, VSP_013304; CC Name=3; CC IsoId=Q13535-3; Sequence=VSP_036907, VSP_036908; CC -!- TISSUE SPECIFICITY: Ubiquitous, with highest expression in testis. CC {ECO:0000269|PubMed:11470508, ECO:0000269|PubMed:8610130, CC ECO:0000269|PubMed:8843195}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Isoform 2 is found in pancreas, CC placenta and liver but not in heart, testis and ovary. CC {ECO:0000269|PubMed:11470508}. CC -!- PTM: Phosphorylated (PubMed:21144835). Autophosphorylation at Thr-1989 CC in response to DNA damage promotes interaction with TOPBP1 and CC activation of ATR (PubMed:21705319, PubMed:21777809). CC {ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:21705319, CC ECO:0000269|PubMed:21777809}. CC -!- DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal CC recessive disorder characterized by proportionate dwarfism of prenatal CC onset associated with low birth weight, growth retardation, severe CC microcephaly with a bird-headed like appearance, and intellectual CC disability. {ECO:0000269|PubMed:12640452}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) CC [MIM:614564]: A disease characterized by cutaneous telangiectases in CC infancy with patchy alopecia over areas of affected skin, thinning of CC the lateral eyebrows, and mild dental and nail anomalies. Affected CC individuals are at increased risk of developing oropharyngeal cancer, CC and other malignancies have been reported as well. CC {ECO:0000269|PubMed:22341969}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/728/ATR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y09077; CAA70298.1; -; mRNA. DR EMBL; U76308; AAC50929.1; -; mRNA. DR EMBL; U49844; AAC50405.1; -; mRNA. DR EMBL; AF325699; AAK26749.1; -; Genomic_DNA. DR EMBL; AB208847; BAD92084.1; -; mRNA. DR CCDS; CCDS3124.1; -. [Q13535-1] DR CCDS; CCDS93402.1; -. [Q13535-2] DR RefSeq; NP_001175.2; NM_001184.4. [Q13535-1] DR RefSeq; NP_001341508.1; NM_001354579.2. [Q13535-2] DR PDB; 5YZ0; EM; 4.70 A; A/B=1-2644. DR PDB; 9L40; EM; 2.87 A; A/B=1-2644. DR PDB; 9L43; EM; 3.83 A; A/B=1-2644. DR PDB; 9L45; EM; 3.95 A; A/B=1-2644. DR PDB; 9L46; EM; 6.29 A; A/B=1-2644. DR PDB; 9L4B; EM; 3.20 A; A/B=1-2644. DR PDB; 9L4C; EM; 4.06 A; A/B=1-2644. DR PDB; 9L4D; EM; 3.79 A; A/B=8-2644. DR PDB; 9L4F; EM; 6.22 A; A/B=1-2644. DR PDBsum; 5YZ0; -. DR PDBsum; 9L40; -. DR PDBsum; 9L43; -. DR PDBsum; 9L45; -. DR PDBsum; 9L46; -. DR PDBsum; 9L4B; -. DR PDBsum; 9L4C; -. DR PDBsum; 9L4D; -. DR PDBsum; 9L4F; -. DR AlphaFoldDB; Q13535; -. DR EMDB; EMD-62801; -. DR EMDB; EMD-62804; -. DR EMDB; EMD-62806; -. DR EMDB; EMD-62807; -. DR EMDB; EMD-62808; -. DR EMDB; EMD-62809; -. DR EMDB; EMD-62811; -. DR EMDB; EMD-62812; -. DR EMDB; EMD-6862; -. DR SMR; Q13535; -. DR BioGRID; 107027; 243. DR ComplexPortal; CPX-3622; ATR-ATRIP DNA damage-sensing kinase complex. DR CORUM; Q13535; -. DR DIP; DIP-35308N; -. DR FunCoup; Q13535; 3607. DR IntAct; Q13535; 96. DR MINT; Q13535; -. DR STRING; 9606.ENSP00000343741; -. DR BindingDB; Q13535; -. DR ChEMBL; CHEMBL5024; -. DR DrugBank; DB11794; Berzosertib. DR DrugBank; DB14917; Ceralasertib. DR DrugBank; DB19041; Elimusertib. DR GuidetoPHARMACOLOGY; 1935; -. DR CarbonylDB; Q13535; -. DR GlyGen; Q13535; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q13535; -. DR PhosphoSitePlus; Q13535; -. DR BioMuta; ATR; -. DR DMDM; 62286460; -. DR CPTAC; CPTAC-3214; -. DR CPTAC; CPTAC-3215; -. DR jPOST; Q13535; -. DR MassIVE; Q13535; -. DR PaxDb; 9606-ENSP00000343741; -. DR PeptideAtlas; Q13535; -. DR ProteomicsDB; 59521; -. [Q13535-1] DR ProteomicsDB; 59522; -. [Q13535-2] DR ProteomicsDB; 59523; -. [Q13535-3] DR Pumba; Q13535; -. DR Antibodypedia; 18078; 557 antibodies from 41 providers. DR CPTC; Q13535; 1 antibody. DR DNASU; 545; -. DR Ensembl; ENST00000350721.9; ENSP00000343741.4; ENSG00000175054.17. [Q13535-1] DR Ensembl; ENST00000661310.1; ENSP00000499589.1; ENSG00000175054.17. [Q13535-2] DR GeneID; 545; -. DR KEGG; hsa:545; -. DR MANE-Select; ENST00000350721.9; ENSP00000343741.4; NM_001184.4; NP_001175.2. DR UCSC; uc003eux.5; human. [Q13535-1] DR AGR; HGNC:882; -. DR CIViC; 545; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA74; -. DR CTD; 545; -. DR DisGeNET; 545; -. DR GeneCards; ATR; -. DR HGNC; HGNC:882; ATR. DR HPA; ENSG00000175054; Low tissue specificity. DR MalaCards; ATR; -. DR MIM; 210600; phenotype. DR MIM; 601215; gene. DR MIM; 614564; phenotype. DR OpenTargets; ENSG00000175054; -. DR Orphanet; 313846; Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome. DR Orphanet; 808; Seckel syndrome. DR VEuPathDB; HostDB:ENSG00000175054; -. DR eggNOG; KOG0890; Eukaryota. DR GeneTree; ENSGT00940000155714; -. DR HOGENOM; CLU_000178_2_1_1; -. DR InParanoid; Q13535; -. DR OMA; SMYIGWC; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13535; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13535; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13535; -. DR Reactome; R-HSA-1221632; Meiotic synapsis. DR Reactome; R-HSA-176187; Activation of ATR in response to replication stress. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6783310; Fanconi Anemia Pathway. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR SignaLink; Q13535; -. DR SIGNOR; Q13535; -. DR Agora; ENSG00000175054; -. DR BioGRID-ORCS; 545; 746 hits in 1209 CRISPR screens. DR CD-CODE; 804901D1; Nuclear speckle. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; D3B9EAFD; Synthetic Condensate 000362. DR ChiTaRS; ATR; human. DR GeneWiki; Ataxia_telangiectasia_and_Rad3_related; -. DR GenomeRNAi; 545; -. DR Pharos; Q13535; Tchem. DR PRO; PR:Q13535; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q13535; protein. DR Bgee; ENSG00000175054; Expressed in Brodmann (1909) area 23 and 205 other cell types or tissues. DR ExpressionAtlas; Q13535; baseline and differential. DR GO; GO:0070310; C:ATR-ATRIP complex; IPI:ComplexPortal. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:MGI. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:MGI. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IMP:BHF-UCL. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IBA:GO_Central. DR GO; GO:0006260; P:DNA replication; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProt. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IC:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0036297; P:interstrand cross-link repair; TAS:Reactome. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; IDA:UniProt. DR GO; GO:0008156; P:negative regulation of DNA replication; IMP:UniProtKB. DR GO; GO:0051081; P:nuclear membrane disassembly; IDA:UniProtKB. DR GO; GO:0006139; P:nucleobase-containing compound metabolic process; NAS:ComplexPortal. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0031297; P:replication fork processing; ISS:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl. DR GO; GO:0009612; P:response to mechanical stimulus; IDA:UniProtKB. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd00892; PIKKc_ATR; 1. DR FunFam; 1.10.1070.11:FF:000009; Putative serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.10.10:FF:000149; Serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.40.10:FF:000142; Serine/threonine-protein kinase ATR; 1. DR FunFam; 3.30.1010.10:FF:000011; serine/threonine-protein kinase ATR; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 2. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR056802; ATR-like_M-HEAT. DR InterPro; IPR056803; ATR-like_N-HEAT. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR021133; HEAT_type_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR InterPro; IPR012993; UME. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF69; SERINE_THREONINE-PROTEIN KINASE ATR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF25030; M-HEAT_ATR; 1. DR Pfam; PF25032; N-HEAT_ATR; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF08064; UME; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM00802; UME; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48452; TPR-like; 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50077; HEAT_REPEAT; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; Dwarfism; KW Intellectual disability; Kinase; Manganese; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..2644 FT /note="Serine/threonine-protein kinase ATR" FT /id="PRO_0000088844" FT REPEAT 799..835 FT /note="HEAT 1" FT REPEAT 1329..1365 FT /note="HEAT 2" FT DOMAIN 1640..2185 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2296..2604 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2612..2644 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 418..450 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2302..2308 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2472..2480 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2492..2516 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21777809, FT ECO:0007744|PubMed:23186163" FT MOD_RES 436 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1989 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:21705319, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 450 FT /note="E -> D (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013305" FT VAR_SEQ 451..514 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013304" FT VAR_SEQ 2588..2610 FT /note="AKTHVLDIEQRLQGVIKTRNRVT -> VSRRYSLIWAVVLISTNELDMQL FT (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036907" FT VAR_SEQ 2611..2644 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036908" FT VARIANT 64 FT /note="T -> A (in dbSNP:rs35306038)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041584" FT VARIANT 90 FT /note="H -> Y (in dbSNP:rs28897763)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041585" FT VARIANT 211 FT /note="M -> T (in dbSNP:rs2227928)" FT /id="VAR_050532" FT VARIANT 297 FT /note="K -> N (in dbSNP:rs2229033)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041586" FT VARIANT 316 FT /note="V -> I (in dbSNP:rs28897764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041587" FT VARIANT 959 FT /note="V -> M (in dbSNP:rs28910271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041588" FT VARIANT 1087 FT /note="Y -> H (in dbSNP:rs34253059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041589" FT VARIANT 1213 FT /note="S -> G (in dbSNP:rs34766606)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041590" FT VARIANT 1488 FT /note="A -> P (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041591" FT VARIANT 1526 FT /note="I -> V (in dbSNP:rs34124242)" FT /id="VAR_050533" FT VARIANT 1607 FT /note="S -> N (in dbSNP:rs55724025)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041592" FT VARIANT 1612 FT /note="N -> S (in dbSNP:rs55894265)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041593" FT VARIANT 2002 FT /note="A -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041594" FT VARIANT 2120 FT /note="G -> A (in dbSNP:rs35134774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041595" FT VARIANT 2132 FT /note="Y -> D (in dbSNP:rs28910273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041596" FT VARIANT 2144 FT /note="Q -> R (in FCTCS; dbSNP:rs387906797)" FT /evidence="ECO:0000269|PubMed:22341969" FT /id="VAR_067919" FT VARIANT 2233 FT /note="S -> I (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041597" FT VARIANT 2425 FT /note="R -> Q (in dbSNP:rs2229032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041598" FT VARIANT 2434 FT /note="P -> A (in dbSNP:rs33972295)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041599" FT VARIANT 2438 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs2108261462)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041600" FT VARIANT 2537 FT /note="E -> Q (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041601" FT MUTAGEN 1989 FT /note="T->A: Impaired autophosphorylation, leading to FT decreased activation of ATR." FT /evidence="ECO:0000269|PubMed:21705319" FT MUTAGEN 2327 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:11114888, FT ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639" FT MUTAGEN 2475 FT /note="D->A: Abolishes kinase activity; increases FT sensitivity to IR and impairs translocation to nuclear foci FT upon DNA damage." FT /evidence="ECO:0000269|PubMed:12814551, FT ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639" FT MUTAGEN 2494 FT /note="D->E: Abolishes kinase activity; reduces cell FT viability, augments sensitivity to IR and UV." FT /evidence="ECO:0000269|PubMed:10597277, FT ECO:0000269|PubMed:9636169" FT CONFLICT 92 FT /note="A -> R (in Ref. 1; CAA70298/AAC50929)" FT /evidence="ECO:0000305" SQ SEQUENCE 2644 AA; 301367 MW; 11BC22297FB9A802 CRC64; MGEHGLELAS MIPALRELGS ATPEEYNTVV QKPRQILCQF IDRILTDVNV VAVELVKKTD SQPTSVMLLD FIQHIMKSSP LMFVNVSGSH EAKGSCIEFS NWIITRLLRI AATPSCHLLH KKICEVICSL LFLFKSKSPA IFGVLTKELL QLFEDLVYLH RRNVMGHAVE WPVVMSRFLS QLDEHMGYLQ SAPLQLMSMQ NLEFIEVTLL MVLTRIIAIV FFRRQELLLW QIGCVLLEYG SPKIKSLAIS FLTELFQLGG LPAQPASTFF SSFLELLKHL VEMDTDQLKL YEEPLSKLIK TLFPFEAEAY RNIEPVYLNM LLEKLCVMFE DGVLMRLKSD LLKAALCHLL QYFLKFVPAG YESALQVRKV YVRNICKALL DVLGIEVDAE YLLGPLYAAL KMESMEIIEE IQCQTQQENL SSNSDGISPK RRRLSSSLNP SKRAPKQTEE IKHVDMNQKS ILWSALKQKA ESLQISLEYS GLKNPVIEML EGIAVVLQLT ALCTVHCSHQ NMNCRTFKDC QHKSKKKPSV VITWMSLDFY TKVLKSCRSL LESVQKLDLE ATIDKVVKIY DALIYMQVNS SFEDHILEDL CGMLSLPWIY SHSDDGCLKL TTFAANLLTL SCRISDSYSP QAQSRCVFLL TLFPRRIFLE WRTAVYNWAL QSSHEVIRAS CVSGFFILLQ QQNSCNRVPK ILIDKVKDDS DIVKKEFASI LGQLVCTLHG MFYLTSSLTE PFSEHGHVDL FCRNLKATSQ HECSSSQLKA SVCKPFLFLL KKKIPSPVKL AFIDNLHHLC KHLDFREDET DVKAVLGTLL NLMEDPDKDV RVAFSGNIKH ILESLDSEDG FIKELFVLRM KEAYTHAQIS RNNELKDTLI LTTGDIGRAA KGDLVPFALL HLLHCLLSKS ASVSGAAYTE IRALVAAKSV KLQSFFSQYK KPICQFLVES LHSSQMTALP NTPCQNADVR KQDVAHQREM ALNTLSEIAN VFDFPDLNRF LTRTLQVLLP DLAAKASPAA SALIRTLGKQ LNVNRREILI NNFKYIFSHL VCSCSKDELE RALHYLKNET EIELGSLLRQ DFQGLHNELL LRIGEHYQQV FNGLSILASF ASSDDPYQGP RDIISPELMA DYLQPKLLGI LAFFNMQLLS SSVGIEDKKM ALNSLMSLMK LMGPKHVSSV RVKMMTTLRT GLRFKDDFPE LCCRAWDCFV RCLDHACLGS LLSHVIVALL PLIHIQPKET AAIFHYLIIE NRDAVQDFLH EIYFLPDHPE LKKIKAVLQE YRKETSESTD LQTTLQLSMK AIQHENVDVR IHALTSLKET LYKNQEKLIK YATDSETVEP IISQLVTVLL KGCQDANSQA RLLCGECLGE LGAIDPGRLD FSTTETQGKD FTFVTGVEDS SFAYGLLMEL TRAYLAYADN SRAQDSAAYA IQELLSIYDC REMETNGPGH QLWRRFPEHV REILEPHLNT RYKSSQKSTD WSGVKKPIYL SKLGSNFAEW SASWAGYLIT KVRHDLASKI FTCCSIMMKH DFKVTIYLLP HILVYVLLGC NQEDQQEVYA EIMAVLKHDD QHTINTQDIA SDLCQLSTQT VFSMLDHLTQ WARHKFQALK AEKCPHSKSN RNKVDSMVST VDYEDYQSVT RFLDLIPQDT LAVASFRSKA YTRAVMHFES FITEKKQNIQ EHLGFLQKLY AAMHEPDGVA GVSAIRKAEP SLKEQILEHE SLGLLRDATA CYDRAIQLEP DQIIHYHGVV KSMLGLGQLS TVITQVNGVH ANRSEWTDEL NTYRVEAAWK LSQWDLVENY LAADGKSTTW SVRLGQLLLS AKKRDITAFY DSLKLVRAEQ IVPLSAASFE RGSYQRGYEY IVRLHMLCEL EHSIKPLFQH SPGDSSQEDS LNWVARLEMT QNSYRAKEPI LALRRALLSL NKRPDYNEMV GECWLQSARV ARKAGHHQTA YNALLNAGES RLAELYVERA KWLWSKGDVH QALIVLQKGV ELCFPENETP PEGKNMLIHG RAMLLVGRFM EETANFESNA IMKKYKDVTA CLPEWEDGHF YLAKYYDKLM PMVTDNKMEK QGDLIRYIVL HFGRSLQYGN QFIYQSMPRM LTLWLDYGTK AYEWEKAGRS DRVQMRNDLG KINKVITEHT NYLAPYQFLT AFSQLISRIC HSHDEVFVVL MEIIAKVFLA YPQQAMWMMT AVSKSSYPMR VNRCKEILNK AIHMKKSLEK FVGDATRLTD KLLELCNKPV DGSSSTLSMS THFKMLKKLV EEATFSEILI PLQSVMIPTL PSILGTHANH ASHEPFPGHW AYIAGFDDMV EILASLQKPK KISLKGSDGK FYIMMCKPKD DLRKDCRLME FNSLINKCLR KDAESRRREL HIRTYAVIPL NDECGIIEWV NNTAGLRPIL TKLYKEKGVY MTGKELRQCM LPKSAALSEK LKVFREFLLP RHPPIFHEWF LRTFPDPTSW YSSRSAYCRS TAVMSMVGYI LGLGDRHGEN ILFDSLTGEC VHVDFNCLFN KGETFEVPEI VPFRLTHNMV NGMGPMGTEG LFRRACEVTM RLMRDQREPL MSVLKTFLHD PLVEWSKPVK GHSKAPLNET GEVVNEKAKT HVLDIEQRLQ GVIKTRNRVT GLPLSIEGHV HYLIQEATDE NLLCQMYLGW TPYM // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID BARD1_HUMAN Reviewed; 777 AA. AC Q99728; F6MDH7; F6MDH8; F6MDH9; O43574; Q53SS5; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 239. DE RecName: Full=BRCA1-associated RING domain protein 1; DE Short=BARD-1; DE EC=2.3.2.27 {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:20351172}; DE AltName: Full=RING-type E3 ubiquitin transferase BARD1 {ECO:0000305}; GN Name=BARD1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=B-cell; RX PubMed=8944023; DOI=10.1038/ng1296-430; RA Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., RA Yang M.-C.W., Hwang L.-Y., Bowcock A.M., Baer R.; RT "Identification of a RING protein that can interact in vivo with the BRCA1 RT gene product."; RL Nat. Genet. 14:430-440(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-24; GLU-153; SER-378; RP MET-507; SER-557; HIS-564; CYS-658; LEU-695 AND ASN-761. RX PubMed=9425226; DOI=10.1093/hmg/7.2.195; RA Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A., Massa H.F., RA Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S., Trask B.J., Baer R., RA Bowcock A.M.; RT "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary RT breast, ovarian and uterine cancers."; RL Hum. Mol. Genet. 7:195-202(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND RP ALTERNATIVE SPLICING. RX PubMed=18089818; DOI=10.1158/0008-5472.can-07-2370; RA Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E., Bertoni F., RA Zeillinger R., Irminger-Finger I.; RT "Oncogenic BARD1 isoforms expressed in gynecological cancers."; RL Cancer Res. 67:11876-11885(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP DOMAINS. RX PubMed=10026184; DOI=10.1074/jbc.274.9.5659; RA Meza J.E., Brzovic P.S., King M.-C., Klevit R.E.; RT "Mapping the functional domains of BRCA1. Interaction of the ring finger RT domains of BRCA1 and BARD1."; RL J. Biol. Chem. 274:5659-5665(1999). RN [7] RP POSSIBLE FUNCTION. RX PubMed=10477523; DOI=10.1126/science.285.5433.1576; RA Kleiman F.E., Manley J.L.; RT "Functional interaction of BRCA1-associated BARD1 with polyadenylation RT factor CstF-50."; RL Science 285:1576-1579(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=12890688; DOI=10.1074/jbc.c300249200; RA Wu-Baer F., Lagrazon K., Yuan W., Baer R.; RT "The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an RT unconventional linkage involving lysine residue K6 of ubiquitin."; RL J. Biol. Chem. 278:34743-34746(2003). RN [9] RP FUNCTION, AND INTERACTION WITH BRCA1. RX PubMed=14976165; DOI=10.1093/hmg/ddh095; RA Morris J.R., Solomon E.; RT "BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, RT dependent on K6 of ubiquitin, in cells during DNA replication and repair."; RL Hum. Mol. Genet. 13:807-817(2004). RN [10] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=17643122; DOI=10.1038/nsmb1277; RA Kim H., Huang J., Chen J.; RT "CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage RT response."; RL Nat. Struct. Mol. Biol. 14:710-715(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-394, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=19261749; DOI=10.1101/gad.1770309; RA Wang B., Hurov K., Hofmann K., Elledge S.J.; RT "NBA1, a new player in the Brca1 A complex, is required for DNA damage RT resistance and checkpoint control."; RL Genes Dev. 23:729-739(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=20351172; DOI=10.1128/mcb.01056-09; RA Wu-Baer F., Ludwig T., Baer R.; RT "The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 RT tumor suppressor and inhibits its enzymatic function."; RL Mol. Cell. Biol. 30:2787-2798(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND THR-299, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-170, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-160; LYS-170; LYS-423 AND RP LYS-548, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP STRUCTURE BY NMR OF 26-140 IN COMPLEX WITH BRCA1 AND ZINC IONS, AND RP SUBUNIT. RX PubMed=11573085; DOI=10.1038/nsb1001-833; RA Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E.; RT "Structure of a BRCA1-BARD1 heterodimeric RING-RING complex."; RL Nat. Struct. Biol. 8:833-837(2001). RN [20] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 568-777. RX PubMed=17550235; DOI=10.1021/bi700323t; RA Birrane G., Varma A.K., Soni A., Ladias J.A.; RT "Crystal structure of the BARD1 BRCT domains."; RL Biochemistry 46:7706-7712(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 569-777, INTERACTION WITH CSTF1, RP DOMAIN STRUCTURE, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18842000; DOI=10.1021/bi801115g; RA Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I., RA Kleiman F.E., Tainer J.A., Glover J.N.; RT "The BARD1 C-terminal domain structure and interactions with RT polyadenylation factor CstF-50."; RL Biochemistry 47:11446-11456(2008). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 425-555, IDENTIFICATION BY MASS RP SPECTROMETRY, DOMAINS ANK REPEATS, AND DOMAIN STRUCTURE. RX PubMed=18480049; DOI=10.1074/jbc.m802333200; RA Fox D. III, Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E., RA Klevit R.E.; RT "Crystal structure of the BARD1 ankyrin repeat domain and its functional RT consequences."; RL J. Biol. Chem. 283:21179-21186(2008). CC -!- FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer CC specifically mediates the formation of 'Lys-6'-linked polyubiquitin CC chains and coordinates a diverse range of cellular pathways such as DNA CC damage repair, ubiquitination and transcriptional regulation to CC maintain genomic stability. Plays a central role in the control of the CC cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 CC ligase activity that is required for its tumor suppressor function. CC Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing CC and RNAP II stability by inhibiting pre-mRNA 3' cleavage. CC {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:20351172}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12890688, CC ECO:0000269|PubMed:20351172}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homo- and heterodimer. Heterodimer (RING-type zinc finger) CC with BRCA1. Heterodimer (via ANK repeats and BRCT domains) with CC CSTF1/CSTF-50. Component of the BRCA1-A complex, at least composed of CC the BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36, BABAM2 and CC BABAM1/NBA1. Interacts with UBXN1. {ECO:0000269|PubMed:11573085, CC ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:17643122, ECO:0000269|PubMed:18842000, CC ECO:0000269|PubMed:19261749, ECO:0000269|PubMed:20351172}. CC -!- INTERACTION: CC Q99728; P31749: AKT1; NbExp=3; IntAct=EBI-473181, EBI-296087; CC Q99728; Q9Y2T1: AXIN2; NbExp=3; IntAct=EBI-473181, EBI-4400025; CC Q99728; P38398: BRCA1; NbExp=20; IntAct=EBI-473181, EBI-349905; CC Q99728; P38398-1: BRCA1; NbExp=3; IntAct=EBI-473181, EBI-21498346; CC Q99728; Q9P2H0: CEP126; NbExp=2; IntAct=EBI-473181, EBI-473176; CC Q99728; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-473181, EBI-739624; CC Q99728; Q12873: CHD3; NbExp=2; IntAct=EBI-473181, EBI-523590; CC Q99728; Q05048: CSTF1; NbExp=4; IntAct=EBI-473181, EBI-1789619; CC Q99728; P33240: CSTF2; NbExp=8; IntAct=EBI-473181, EBI-711360; CC Q99728; O00471: EXOC5; NbExp=3; IntAct=EBI-473181, EBI-949824; CC Q99728; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-473181, EBI-10175124; CC Q99728; Q9Y2X7: GIT1; NbExp=2; IntAct=EBI-473181, EBI-466061; CC Q99728; Q08379: GOLGA2; NbExp=6; IntAct=EBI-473181, EBI-618309; CC Q99728; O75031: HSF2BP; NbExp=3; IntAct=EBI-473181, EBI-7116203; CC Q99728; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-473181, EBI-11522367; CC Q99728; O95251: KAT7; NbExp=2; IntAct=EBI-473181, EBI-473199; CC Q99728; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-473181, EBI-14069005; CC Q99728; Q6A162: KRT40; NbExp=3; IntAct=EBI-473181, EBI-10171697; CC Q99728; O95751: LDOC1; NbExp=7; IntAct=EBI-473181, EBI-740738; CC Q99728; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-473181, EBI-11522433; CC Q99728; O95453: PARN; NbExp=4; IntAct=EBI-473181, EBI-372832; CC Q99728; Q15276: RABEP1; NbExp=3; IntAct=EBI-473181, EBI-447043; CC Q99728; O14776: TCERG1; NbExp=2; IntAct=EBI-473181, EBI-473271; CC Q99728; Q13077: TRAF1; NbExp=3; IntAct=EBI-473181, EBI-359224; CC Q99728; Q8N720: ZNF655; NbExp=3; IntAct=EBI-473181, EBI-625509; CC Q99728-1; Q13526: PIN1; NbExp=4; IntAct=EBI-21498323, EBI-714158; CC -!- SUBCELLULAR LOCATION: Nucleus. Note=During S phase of the cell cycle, CC colocalizes with BRCA1 into discrete subnuclear foci. Can translocate CC to the cytoplasm. Localizes at sites of DNA damage at double-strand CC breaks (DSBs); recruitment to DNA damage sites is mediated by the CC BRCA1-A complex. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=FL; CC IsoId=Q99728-1; Sequence=Displayed; CC Name=alpha; CC IsoId=Q99728-2; Sequence=VSP_055876; CC Name=beta; CC IsoId=Q99728-3; Sequence=VSP_055874, VSP_055875; CC Name=gamma; CC IsoId=Q99728-4; Sequence=VSP_055877, VSP_055878; CC -!- PTM: Processed during apoptosis. The homodimer is more susceptible to CC proteolytic cleavage than the BARD1/BRCA1 heterodimer. CC -!- CAUTION: It is uncertain whether Met-1 or Met-26 is the initiator. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/756/BARD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U76638; AAB38316.1; -; mRNA. DR EMBL; AF038042; AAB99978.1; -; Genomic_DNA. DR EMBL; AF038034; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038035; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038036; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038037; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038038; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038039; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038040; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038041; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; JF790280; AEF57471.1; -; mRNA. DR EMBL; JF790281; AEF57472.1; -; mRNA. DR EMBL; JF790282; AEF57473.1; -; mRNA. DR EMBL; AC016708; AAX93130.1; -; Genomic_DNA. DR EMBL; BC126426; AAI26427.1; -; mRNA. DR CCDS; CCDS2397.1; -. [Q99728-1] DR CCDS; CCDS74646.1; -. [Q99728-2] DR RefSeq; NP_000456.2; NM_000465.4. [Q99728-1] DR RefSeq; NP_001269472.1; NM_001282543.2. [Q99728-2] DR PDB; 1JM7; NMR; -; B=26-140. DR PDB; 2NTE; X-ray; 1.90 A; A/B=568-777. DR PDB; 2R1Z; X-ray; 2.10 A; A/B=569-777. DR PDB; 3C5R; X-ray; 2.00 A; A/B=425-555. DR PDB; 3FA2; X-ray; 2.20 A; A/B=566-777. DR PDB; 6M14; X-ray; 1.88 A; A/B=568-777. DR PDB; 7E8I; EM; 3.10 A; K=425-777. DR PDB; 7JZV; EM; 3.90 A; B=26-140. DR PDB; 7LYB; EM; 3.28 A; N=26-122. DR PDB; 7LYC; EM; 2.94 A; N=415-777. DR PDB; 8GRQ; EM; 3.87 A; M=26-117. DR PDBsum; 1JM7; -. DR PDBsum; 2NTE; -. DR PDBsum; 2R1Z; -. DR PDBsum; 3C5R; -. DR PDBsum; 3FA2; -. DR PDBsum; 6M14; -. DR PDBsum; 7E8I; -. DR PDBsum; 7JZV; -. DR PDBsum; 7LYB; -. DR PDBsum; 7LYC; -. DR PDBsum; 8GRQ; -. DR AlphaFoldDB; Q99728; -. DR EMDB; EMD-22581; -. DR EMDB; EMD-23591; -. DR EMDB; EMD-23592; -. DR EMDB; EMD-31020; -. DR EMDB; EMD-34212; -. DR EMDB; EMD-6340; -. DR EMDB; EMD-6400; -. DR SMR; Q99728; -. DR BioGRID; 107056; 331. DR ComplexPortal; CPX-715; BRCA1-BARD1 complex. DR ComplexPortal; CPX-955; BRCC E3 ubiquitin ligase complex. DR CORUM; Q99728; -. DR DIP; DIP-5972N; -. DR FunCoup; Q99728; 1110. DR IntAct; Q99728; 68. DR MINT; Q99728; -. DR STRING; 9606.ENSP00000260947; -. DR BindingDB; Q99728; -. DR GlyGen; Q99728; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q99728; -. DR PhosphoSitePlus; Q99728; -. DR BioMuta; BARD1; -. DR DMDM; 116241265; -. DR jPOST; Q99728; -. DR MassIVE; Q99728; -. DR PaxDb; 9606-ENSP00000260947; -. DR PeptideAtlas; Q99728; -. DR ProteomicsDB; 78442; -. [Q99728-1] DR Pumba; Q99728; -. DR Antibodypedia; 20039; 288 antibodies from 35 providers. DR DNASU; 580; -. DR Ensembl; ENST00000260947.9; ENSP00000260947.4; ENSG00000138376.12. [Q99728-1] DR Ensembl; ENST00000617164.5; ENSP00000480470.1; ENSG00000138376.12. [Q99728-2] DR Ensembl; ENST00000620057.4; ENSP00000481988.1; ENSG00000138376.12. [Q99728-4] DR GeneID; 580; -. DR KEGG; hsa:580; -. DR MANE-Select; ENST00000260947.9; ENSP00000260947.4; NM_000465.4; NP_000456.2. DR UCSC; uc002veu.4; human. [Q99728-1] DR AGR; HGNC:952; -. DR CIViC; 580; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25256; -. DR CTD; 580; -. DR DisGeNET; 580; -. DR GeneCards; BARD1; -. DR HGNC; HGNC:952; BARD1. DR HPA; ENSG00000138376; Low tissue specificity. DR MalaCards; BARD1; -. DR MIM; 601593; gene. DR OpenTargets; ENSG00000138376; -. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR VEuPathDB; HostDB:ENSG00000138376; -. DR eggNOG; KOG0504; Eukaryota. DR eggNOG; KOG4362; Eukaryota. DR GeneTree; ENSGT00940000156532; -. DR HOGENOM; CLU_021642_0_0_1; -. DR InParanoid; Q99728; -. DR OMA; LGQCEHV; -. DR OrthoDB; 2384350at2759; -. DR PAN-GO; Q99728; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99728; -. DR BRENDA; 2.3.2.27; 2681. DR PathwayCommons; Q99728; -. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5689901; Metalloprotease DUBs. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9663199; Defective DNA double strand break response due to BRCA1 loss of function. DR Reactome; R-HSA-9699150; Defective DNA double strand break response due to BARD1 loss of function. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q99728; -. DR SIGNOR; Q99728; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000138376; -. DR BioGRID-ORCS; 580; 517 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BARD1; human. DR EvolutionaryTrace; Q99728; -. DR GeneWiki; BARD1; -. DR GenomeRNAi; 580; -. DR Pharos; Q99728; Tbio. DR PRO; PR:Q99728; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q99728; protein. DR Bgee; ENSG00000138376; Expressed in secondary oocyte and 204 other cell types or tissues. DR ExpressionAtlas; Q99728; baseline and differential. DR GO; GO:0070531; C:BRCA1-A complex; IDA:UniProtKB. DR GO; GO:0070532; C:BRCA1-B complex; IPI:ComplexPortal. DR GO; GO:0031436; C:BRCA1-BARD1 complex; IDA:UniProtKB. DR GO; GO:0070533; C:BRCA1-C complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0000152; C:nuclear ubiquitin ligase complex; IDA:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000151; C:ubiquitin ligase complex; NAS:UniProtKB. DR GO; GO:0140863; F:histone H2AK127 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0140864; F:histone H2AK129 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0019900; F:kinase binding; NAS:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; IDA:MGI. DR GO; GO:0061649; F:ubiquitin-modified histone reader activity; TAS:ARUK-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; NAS:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:ComplexPortal. DR GO; GO:0006338; P:chromatin remodeling; TAS:ARUK-UCL. DR GO; GO:0006974; P:DNA damage response; NAS:UniProtKB. DR GO; GO:0006281; P:DNA repair; NAS:ComplexPortal. DR GO; GO:0110025; P:DNA strand resection involved in replication fork processing; NAS:ComplexPortal. DR GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; NAS:ComplexPortal. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045786; P:negative regulation of cell cycle; NAS:ComplexPortal. DR GO; GO:0031441; P:negative regulation of mRNA 3'-end processing; NAS:UniProtKB. DR GO; GO:0046826; P:negative regulation of protein export from nucleus; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045732; P:positive regulation of protein catabolic process; NAS:UniProtKB. DR GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB. DR GO; GO:2000001; P:regulation of DNA damage checkpoint; NAS:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0042325; P:regulation of phosphorylation; IMP:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ARUK-UCL. DR GO; GO:0001894; P:tissue homeostasis; TAS:UniProtKB. DR CDD; cd17734; BRCT_Bard1_rpt1; 1. DR CDD; cd17720; BRCT_Bard1_rpt2; 1. DR CDD; cd16496; RING-HC_BARD1; 1. DR FunFam; 1.25.40.20:FF:000032; BCL-6 corepressor isoform X1; 1. DR FunFam; 3.30.40.10:FF:000349; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000013; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000019; BRCA1 associated RING domain 1; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 2. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR039503; BARD1_Znf-RING. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR24171; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 39-RELATED; 1. DR PANTHER; PTHR24171:SF8; BRCA1-ASSOCIATED RING DOMAIN PROTEIN 1; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF14835; zf-RING_6; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 3. DR SMART; SM00292; BRCT; 2. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 3. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; DNA damage; DNA repair; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Transferase; KW Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..777 FT /note="BRCA1-associated RING domain protein 1" FT /id="PRO_0000055819" FT REPEAT 427..459 FT /note="ANK 1" FT REPEAT 460..492 FT /note="ANK 2" FT REPEAT 493..525 FT /note="ANK 3" FT REPEAT 526..546 FT /note="ANK 4; degenerate" FT DOMAIN 560..653 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 667..777 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT ZN_FING 50..87 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 26..119 FT /note="Interaction with BRCA1" FT REGION 167..211 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 356..404 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 554..558 FT /note="Flexible linker" FT COMPBIAS 197..209 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 389..404 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 186 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 299 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 391 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 394 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CROSSLNK 160 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 423 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 548 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..24 FT /note="MPDNRQPRNRQPRIRSGNEPRSAP -> MVAVPGPTVAPRSTAWRSCCAARV FT (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055874" FT VAR_SEQ 25..121 FT /note="Missing (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055875" FT VAR_SEQ 54..72 FT /note="Missing (in isoform alpha)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055876" FT VAR_SEQ 122..127 FT /note="DLKEDK -> GRHTFC (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055877" FT VAR_SEQ 128..777 FT /note="Missing (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055878" FT VARIANT 24 FT /note="P -> S (in dbSNP:rs1048108)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010354" FT VARIANT 153 FT /note="K -> E (in dbSNP:rs753377280)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010355" FT VARIANT 186 FT /note="S -> G (in dbSNP:rs16852741)" FT /id="VAR_038371" FT VARIANT 241 FT /note="S -> C (in dbSNP:rs3738885)" FT /id="VAR_020109" FT VARIANT 378 FT /note="R -> S (in dbSNP:rs2229571)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_024611" FT VARIANT 507 FT /note="V -> M (in dbSNP:rs2070094)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010356" FT VARIANT 557 FT /note="C -> S (in dbSNP:rs28997576)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010357" FT VARIANT 564 FT /note="Q -> H (in an ovarian clear cell adenocarcinoma; FT dbSNP:rs1168537193)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010358" FT VARIANT 645 FT /note="C -> R (in dbSNP:rs2228456)" FT /id="VAR_038372" FT VARIANT 658 FT /note="R -> C (in dbSNP:rs3738888)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010359" FT VARIANT 695 FT /note="V -> L (in a breast cancer sample; somatic mutation; FT dbSNP:rs111367604)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010360" FT VARIANT 728 FT /note="S -> F (in dbSNP:rs13389423)" FT /id="VAR_028309" FT VARIANT 761 FT /note="S -> N (in an uterine cancer sample; somatic FT mutation; dbSNP:rs142155101)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010361" FT CONFLICT 85 FT /note="V -> A (in Ref. 3; AEF57473)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="R -> Q (in Ref. 1; AAB38316 and 3; AEF57471/ FT AEF57472)" FT /evidence="ECO:0000305" FT HELIX 35..45 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 51..53 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 58..61 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 64..67 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 72..75 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 78..81 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 99..115 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 431..438 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 441..449 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 459..461 FT /evidence="ECO:0007829|PDB:7LYC" FT HELIX 464..470 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 474..482 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 497..503 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 507..515 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 530..533 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 537..543 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 571..576 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 579..591 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:2NTE" FT STRAND 606..613 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 618..625 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 634..642 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 648..651 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 656..665 FT /evidence="ECO:0007829|PDB:6M14" FT TURN 671..674 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 676..679 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 684..686 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 688..697 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 701..705 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 712..716 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 729..731 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 735..739 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 741..744 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 748..752 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 755..759 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 760..769 FT /evidence="ECO:0007829|PDB:6M14" SQ SEQUENCE 777 AA; 86648 MW; 95E2D904046B5646 CRC64; MPDNRQPRNR QPRIRSGNEP RSAPAMEPDG RGAWAHSRAA LDRLEKLLRC SRCTNILREP VCLGGCEHIF CSNCVSDCIG TGCPVCYTPA WIQDLKINRQ LDSMIQLCSK LRNLLHDNEL SDLKEDKPRK SLFNDAGNKK NSIKMWFSPR SKKVRYVVSK ASVQTQPAIK KDASAQQDSY EFVSPSPPAD VSERAKKASA RSGKKQKKKT LAEINQKWNL EAEKEDGEFD SKEESKQKLV SFCSQPSVIS SPQINGEIDL LASGSLTESE CFGSLTEVSL PLAEQIESPD TKSRNEVVTP EKVCKNYLTS KKSLPLENNG KRGHHNRLSS PISKRCRTSI LSTSGDFVKQ TVPSENIPLP ECSSPPSCKR KVGGTSGRKN SNMSDEFISL SPGTPPSTLS SSSYRRVMSS PSAMKLLPNM AVKRNHRGET LLHIASIKGD IPSVEYLLQN GSDPNVKDHA GWTPLHEACN HGHLKVVELL LQHKALVNTT GYQNDSPLHD AAKNGHVDIV KLLLSYGASR NAVNIFGLRP VDYTDDESMK SLLLLPEKNE SSSASHCSVM NTGQRRDGPL VLIGSGLSSE QQKMLSELAV ILKAKKYTEF DSTVTHVVVP GDAVQSTLKC MLGILNGCWI LKFEWVKACL RRKVCEQEEK YEIPEGPRRS RLNREQLLPK LFDGCYFYLW GTFKHHPKDN LIKLVTAGGG QILSRKPKPD SDVTQTINTV AYHARPDSDQ RFCTQYIIYE DLCNYHPERV RQGKVWKAPS SWFIDCVMSF ELLPLDS // ID BAX_HUMAN Reviewed; 192 AA. AC Q07812; A8K4W1; P55269; Q07814; Q07815; Q8WZ49; Q9NR76; Q9NYG7; Q9UCZ6; AC Q9UCZ7; Q9UQD6; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 246. DE RecName: Full=Apoptosis regulator BAX; DE AltName: Full=Bcl-2-like protein 4; DE Short=Bcl2-L-4; GN Name=BAX; Synonyms=BCL2L4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), FUNCTION, RP SUBUNIT, AND SUBCELLULAR LOCATION. RC TISSUE=B-cell; RX PubMed=8358790; DOI=10.1016/0092-8674(93)90509-o; RA Oltvai Z.N., Milliman C.L., Korsmeyer S.J.; RT "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that RT accelerates programmed cell death."; RL Cell 74:609-619(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA). RX PubMed=7607685; DOI=10.1016/0888-7543(95)80180-t; RA Apte S.S., Mattei M.-G., Olsen B.R.; RT "Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of RT a novel alternatively spliced transcript, BAX delta."; RL Genomics 26:592-594(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EPSILON). RC TISSUE=Brain; RX PubMed=9920818; DOI=10.1006/bbrc.1998.0130; RA Shi B., Triebe D., Kajiji S., Iwata K.K., Bruskin A., Mahajna J.; RT "Identification and characterization of baxepsilon, a novel bax variant RT missing the BH2 and the transmembrane domains."; RL Biochem. Biophys. Res. Commun. 254:779-785(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND SIGMA), FUNCTION, RP INTERACTION WITH BCL2A1 AND BCL2L1, AND TISSUE SPECIFICITY. RX PubMed=10772918; DOI=10.1006/bbrc.2000.2537; RA Schmitt E., Paquet C., Beauchemin M., Dever-Bertrand J., Bertrand R.; RT "Characterization of Bax-sigma, a cell death-inducing isoform of Bax."; RL Biochem. Biophys. Res. Commun. 270:868-879(2000). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSI), AND TISSUE SPECIFICITY. RX PubMed=11912183; DOI=10.1093/hmg/11.6.675; RA Cartron P.F., Oliver L., Martin S., Moreau C., LeCabellec M.T., RA Jezequel P., Meflah K., Vallette F.M.; RT "The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, RT is correlated with an increased survival of glioblastoma multiforme RT patients."; RL Hum. Mol. Genet. 11:675-687(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA). RC TISSUE=Ovarian carcinoma; RA Perez R.P., Sanville H.; RT "Bax mRNA splice variant lacking exons 2 and 3."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-77 AND 98-118, AND VARIANTS ARG-67 AND RP VAL-108. RX PubMed=7475270; RA Meijerink J.P.P., Smetsers T.F.C.M., Sloetjes A.W., Linders E.H.P., RA Mensink E.J.B.M.; RT "Bax mutations in cell lines derived from hematological malignancies."; RL Leukemia 9:1828-1832(1995). RN [12] RP MUTAGENESIS, AND FUNCTION OF BH3 MOTIF. RX PubMed=8521816; DOI=10.1002/j.1460-2075.1995.tb00246.x; RA Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J., RA Elangovan B., Chinnadurai G., Lutz R.J.; RT "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death RT and protein binding functions."; RL EMBO J. 14:5589-5596(1995). RN [13] RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-184. RX PubMed=10228148; DOI=10.1093/emboj/18.9.2330; RA Nechushtan A., Smith C.L., Hsu Y.-T., Youle R.J.; RT "Conformation of the Bax C-terminus regulates subcellular location and cell RT death."; RL EMBO J. 18:2330-2341(1999). RN [14] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=11060313; DOI=10.1074/jbc.m008955200; RA Tan K.O., Tan K.M.L., Chan S.-L., Yee K.S.Y., Bevort M., Ang K.C., Yu V.C.; RT "MAP-1, a novel proapoptotic protein containing a BH3-like motif that RT associates with Bax through its Bcl-2 homology domains."; RL J. Biol. Chem. 276:2802-2807(2001). RN [15] RP INTERACTION WITH SH3GLB1. RX PubMed=11259440; DOI=10.1074/jbc.m101527200; RA Cuddeback S.M., Yamaguchi H., Komatsu K., Miyashita T., Yamada M., Wu C., RA Singh S., Wang H.-G.; RT "Molecular cloning and characterization of Bif-1. A novel Src homology 3 RT domain-containing protein that associates with Bax."; RL J. Biol. Chem. 276:20559-20565(2001). RN [16] RP INTERACTION WITH ADENOVIRUS PROTEIN E1B 19K. RX PubMed=11462023; DOI=10.1128/jvi.75.16.7506-7516.2001; RA Sundararajan R., White E.; RT "E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha- RT mediated apoptosis."; RL J. Virol. 75:7506-7516(2001). RN [17] RP INTERACTION WITH HUMANIN. RX PubMed=12732850; DOI=10.1038/nature01627; RA Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., RA Reed J.C.; RT "Humanin peptide suppresses apoptosis by interfering with Bax activation."; RL Nature 423:456-461(2003). RN [18] RP INTERACTION WITH SFN AND YWHAZ, AND SUBCELLULAR LOCATION. RX PubMed=15071501; DOI=10.1038/sj.emboj.7600194; RA Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., RA Yoshioka K., Masuyama N., Gotoh Y.; RT "JNK promotes Bax translocation to mitochondria through phosphorylation of RT 14-3-3 proteins."; RL EMBO J. 23:1889-1899(2004). RN [19] RP INTERACTION WITH NOL3. RX PubMed=15004034; DOI=10.1074/jbc.m400695200; RA Gustafsson A.B., Tsai J.G., Logue S.E., Crow M.T., Gottlieb R.A.; RT "Apoptosis repressor with caspase recruitment domain protects against cell RT death by interfering with Bax activation."; RL J. Biol. Chem. 279:21233-21238(2004). RN [20] RP INTERACTION WITH HHV-5 PROTEIN UL37. RX PubMed=15004026; DOI=10.1074/jbc.m308408200; RA Poncet D., Larochette N., Pauleau A.L., Boya P., Jalil A.A., Cartron P.F., RA Vallette F., Schnebelen C., Bartle L.M., Skaletskaya A., Boutolleau D., RA Martinou J.C., Goldmacher V.S., Kroemer G., Zamzami N.; RT "An anti-apoptotic viral protein that recruits Bax to mitochondria."; RL J. Biol. Chem. 279:22605-22614(2004). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CLU. RX PubMed=16113678; DOI=10.1038/ncb1291; RA Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.; RT "Clusterin inhibits apoptosis by interacting with activated Bax."; RL Nat. Cell Biol. 7:909-915(2005). RN [22] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=16199525; DOI=10.1073/pnas.0503524102; RA Tan K.O., Fu N.Y., Sukumaran S.K., Chan S.L., Kang J.H., Poon K.L., RA Chen B.S., Yu V.C.; RT "MAP-1 is a mitochondrial effector of Bax."; RL Proc. Natl. Acad. Sci. U.S.A. 102:14623-14628(2005). RN [23] RP INTERACTION WITH FAIM2/LFG2. RX PubMed=16964429; RA Reimers K., Choi C.Y., Mau-Thek E., Vogt P.M.; RT "Sequence analysis shows that Lifeguard belongs to a new evolutionarily RT conserved cytoprotective family."; RL Int. J. Mol. Med. 18:729-734(2006). RN [24] RP INTERACTION WITH GIMAP3 AND GIMAP5. RX PubMed=16509771; DOI=10.1371/journal.pbio.0040103; RA Nitta T., Nasreen M., Seike T., Goji A., Ohigashi I., Miyazaki T., Ohta T., RA Kanno M., Takahama Y.; RT "IAN family critically regulates survival and development of T RT lymphocytes."; RL PLoS Biol. 4:593-605(2006). RN [25] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [26] RP INTERACTION WITH RNF144B. RX PubMed=20300062; DOI=10.1038/emboj.2010.39; RA Benard G., Neutzner A., Peng G., Wang C., Livak F., Youle R.J., RA Karbowski M.; RT "IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax RT and apoptosis activation."; RL EMBO J. 29:1458-1471(2010). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [28] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2L1. RX PubMed=21458670; DOI=10.1016/j.cell.2011.02.034; RA Edlich F., Banerjee S., Suzuki M., Cleland M.M., Arnoult D., Wang C., RA Neutzner A., Tjandra N., Youle R.J.; RT "Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol."; RL Cell 145:104-116(2011). RN [29] RP INTERACTION WITH BCL2L10. RX PubMed=23235460; DOI=10.1038/cddis.2012.178; RA Rautureau G.J., Yabal M., Yang H., Huang D.C., Kvansakul M., Hinds M.G.; RT "The restricted binding repertoire of Bcl-B leaves Bim as the universal RT BH3-only prosurvival Bcl-2 protein antagonist."; RL Cell Death Dis. 3:e443-e443(2012). RN [30] RP INTERACTION WITH RTL10/BOP. RX PubMed=23055042; DOI=10.1007/s13238-012-2069-7; RA Zhang X., Weng C., Li Y., Wang X., Jiang C., Li X., Xu Y., Chen Q., Pan L., RA Tang H.; RT "Human Bop is a novel BH3-only member of the Bcl-2 protein family."; RL Protein Cell 3:790-801(2012). RN [31] RP FUNCTION, INTERACTION WITH IRF3 AND BCL2, AND SUBCELLULAR LOCATION. RX PubMed=25609812; DOI=10.1128/jvi.02959-14; RA Wei B., Cui Y., Huang Y., Liu H., Li L., Li M., Ruan K.C., Zhou Q., RA Wang C.; RT "Tom70 mediates Sendai virus-induced apoptosis on mitochondria."; RL J. Virol. 89:3804-3818(2015). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [33] RP INTERACTION WITH ENTEROVIRUS 71 PROTEIN 2B, AND SUBCELLULAR LOCATION. RX PubMed=27558414; DOI=10.1128/jvi.01499-16; RA Cong H., Du N., Yang Y., Song L., Zhang W., Tien P.; RT "Enterovirus 71 2B induces cell apoptosis by directly inducing the RT conformational activation of the proapoptotic protein Bax."; RL J. Virol. 90:9862-9877(2016). RN [34] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=29531808; DOI=10.1038/s41420-017-0006-5; RA Kuriyama S., Tsuji T., Sakuma T., Yamamoto T., Tanaka M.; RT "PLEKHN1 promotes apoptosis by enhancing Bax-Bak hetero-oligomerization RT through interaction with Bid in human colon cancer."; RL Cell. Death. Discov. 4:11-11(2018). RN [35] RP FORMATION OF FIBERS WITH HUMANIN, AND MUTAGENESIS OF 172-THR--GLY-192 AND RP SER-184. RX PubMed=31690630; DOI=10.1074/jbc.ra119.011297; RA Morris D.L., Kastner D.W., Johnson S., Strub M.P., He Y., Bleck C.K.E., RA Lee D.Y., Tjandra N.; RT "Humanin induces conformational changes in the apoptosis regulator BAX and RT sequesters it into fibers, preventing mitochondrial outer-membrane RT permeabilization."; RL J. Biol. Chem. 294:19055-19065(2019). RN [36] RP FUNCTION, DEUBIQUITINATION BY USP12, MUTAGENESIS OF LYS-128; LYS-189 AND RP LYS-190, SUBCELLULAR LOCATION, AND UBIQUITINATION AT LYS-128 AND LYS-190. RX PubMed=36361894; DOI=10.3390/ijms232113107; RA Choi H.S., Lim E.S., Baek K.H.; RT "Deubiquitinating Enzyme USP12 Regulates the Pro-Apoptosis Protein Bax."; RL Int. J. Mol. Sci. 23:0-0(2022). RN [37] RP STRUCTURE BY NMR, SUBCELLULAR LOCATION, AND SUBUNIT. RX PubMed=11106734; DOI=10.1016/s0092-8674(00)00167-7; RA Suzuki M., Youle R.J., Tjandra N.; RT "Structure of Bax: coregulation of dimer formation and intracellular RT localization."; RL Cell 103:645-654(2000). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-19 IN COMPLEX WITH ANTIBODY RP FRAGMENT. RX PubMed=16946732; DOI=10.1038/sj.cdd.4402025; RA Peyerl F.W., Dai S., Murphy G.A., Crawford F., White J., Marrack P., RA Kappler J.W.; RT "Elucidation of some Bax conformational changes through crystallization of RT an antibody-peptide complex."; RL Cell Death Differ. 14:447-452(2007). RN [39] RP STRUCTURE BY NMR IN COMPLEX WITH BCL2L11, FUNCTION, SUBUNIT, MUTAGENESIS OF RP LYS-21, AND INTERACTION WITH BCL2L11. RX PubMed=18948948; DOI=10.1038/nature07396; RA Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., RA Tu H.C., Kim H., Cheng E.H., Tjandra N., Walensky L.D.; RT "BAX activation is initiated at a novel interaction site."; RL Nature 455:1076-1081(2008). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 48-81 IN COMPLEXES WITH BCL2L1 RP AND MCL1, INTERACTION WITH MCL1; BCL2; BCL2L1 AND BCL2L2, FUNCTION, AND RP MUTAGENESIS OF MET-74. RX PubMed=21199865; DOI=10.1074/jbc.m110.161281; RA Czabotar P.E., Lee E.F., Thompson G.V., Wardak A.Z., Fairlie W.D., RA Colman P.M.; RT "Mutation to Bax beyond the BH3 domain disrupts interactions with pro- RT survival proteins and promotes apoptosis."; RL J. Biol. Chem. 286:7123-7131(2011). RN [41] RP VARIANTS GLU-11; ARG-67 AND VAL-108. RX PubMed=9531611; RA Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W., Sloetjes A.W., RA de Witte T., Waksman G., Korsmeyer S.J.; RT "Hematopoietic malignancies demonstrate loss-of-function mutations of RT BAX."; RL Blood 91:2991-2997(1998). RN [42] RP INTERACTION WITH XRCC6. RX PubMed=15023334; DOI=10.1016/s1097-2765(04)00094-2; RA Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., RA Miller C., Frye R., Ploegh H., Kessler B.M., Sinclair D.A.; RT "Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax- RT mediated apoptosis."; RL Mol. Cell 13:627-638(2004). RN [43] RP UBIQUITINATION. RX PubMed=18362350; DOI=10.1073/pnas.0706700105; RA Amsel A.D., Rathaus M., Kronman N., Cohen H.Y.; RT "Regulation of the proapoptotic factor Bax by Ku70-dependent RT deubiquitylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:5117-5122(2008). CC -!- FUNCTION: Plays a role in the mitochondrial apoptotic process CC (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, CC PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, CC PubMed:36361894, PubMed:8358790, PubMed:8521816). Under normal CC conditions, BAX is largely cytosolic via constant retrotranslocation CC from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which CC avoids accumulation of toxic BAX levels at the mitochondrial outer CC membrane (MOM) (PubMed:21458670). Under stress conditions, undergoes a CC conformation change that causes translocation to the mitochondrion CC membrane, leading to the release of cytochrome c that then triggers CC apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, CC PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, CC PubMed:25609812, PubMed:8358790, PubMed:8521816). Promotes activation CC of CASP3, and thereby apoptosis (PubMed:10772918, PubMed:11060313, CC PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, CC PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16199525, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:21199865, CC ECO:0000269|PubMed:21458670, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:36361894, ECO:0000269|PubMed:8358790, CC ECO:0000269|PubMed:8521816}. CC -!- SUBUNIT: Homodimer. Forms higher oligomers under stress conditions. CC Forms heterooligomers with BAK (PubMed:29531808). Interacts with CC BCL2L11. Interaction with BCL2L11 promotes BAX oligomerization and CC association with mitochondrial membranes, with subsequent release of CC cytochrome c. Forms heterodimers with BCL2, BCL2L1 isoform Bcl-X(L), CC BCL2L2, MCL1 and A1 (PubMed:25609812). Interacts with SH3GLB1. CC Interacts with humanin; forms fibers with humanin which results in BAX CC conformational changes and sequestering of BAX into the fibers, CC preventing BAX activation (PubMed:12732850, PubMed:31690630). Interacts CC with SFN and YWHAZ; the interaction occurs in the cytoplasm. Under CC stress conditions, JNK-mediated phosphorylation of SFN and YWHAZ, CC releases BAX to mitochondria. Interacts with RNF144B, which regulates CC the ubiquitin-dependent stability of BAX. Interacts with CLU under CC stress conditions that cause a conformation change leading to BAX CC oligomerization and association with mitochondria. Does not interact CC with CLU in unstressed cells. Interacts with FAIM2/LFG2. Interacts with CC RTL10/BOP. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD CC domain); inhibits BAX activation and translocation and consequently CC cytochrome c release from mitochondria. Interacts with GIMAP3/IAN4 and CC GIMAP5/IAN5; this interaction is increased, when cells initiate CC apoptosis upon IL2 withdrawal (PubMed:16509771). Interacts with IRF3; CC the interaction is direct, increases upon Sendai virus infection and CC mediates the formation of the apoptosis complex CC TOMM70:HSP90AA1:IRF3:BAX (PubMed:25609812). Interacts with MOAP1, CC facilitating BAX-dependent mitochondrial outer membrane CC permeabilization and apoptosis (PubMed:11060313, PubMed:16199525). CC Interacts with BCL2L10/BCL-B (PubMed:23235460). Interacts with non- CC acetylated XRCC6/Ku70; this interaction leads to BAX sequestration in CC the cytosol, away from the mitochondria, preventing BAX-mediated CC apoptosis (PubMed:15023334). {ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440, CC ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026, CC ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15023334, CC ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:16113678, CC ECO:0000269|PubMed:16199525, ECO:0000269|PubMed:16509771, CC ECO:0000269|PubMed:16946732, ECO:0000269|PubMed:16964429, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:20300062, CC ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:23055042, CC ECO:0000269|PubMed:23235460, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:29531808, ECO:0000269|PubMed:31690630, CC ECO:0000269|PubMed:8358790}. CC -!- SUBUNIT: [Isoform Sigma]: Interacts with BCL2A1 and BCL2L1 isoform Bcl- CC X(L). {ECO:0000269|PubMed:10772918}. CC -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E1B 19K CC protein; this interaction blocks BAX oligomerization (PubMed:11462023). CC {ECO:0000269|PubMed:11462023}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein vMIA/UL37. {ECO:0000269|PubMed:15004026}. CC -!- SUBUNIT: (Microbial infection) Interacts with enterovirus protein 2B; CC this interaction activates BAX-induced apoptosis. CC {ECO:0000269|PubMed:27558414}. CC -!- INTERACTION: CC Q07812; Q16611: BAK1; NbExp=6; IntAct=EBI-516580, EBI-519866; CC Q07812; Q07812: BAX; NbExp=29; IntAct=EBI-516580, EBI-516580; CC Q07812; P10415: BCL2; NbExp=16; IntAct=EBI-516580, EBI-77694; CC Q07812; Q07817-1: BCL2L1; NbExp=24; IntAct=EBI-516580, EBI-287195; CC Q07812; Q9HD36: BCL2L10; NbExp=3; IntAct=EBI-516580, EBI-2126349; CC Q07812; O43521: BCL2L11; NbExp=22; IntAct=EBI-516580, EBI-526406; CC Q07812; Q9HB09: BCL2L12; NbExp=3; IntAct=EBI-516580, EBI-3940897; CC Q07812; Q92843: BCL2L2; NbExp=8; IntAct=EBI-516580, EBI-707714; CC Q07812; P55957: BID; NbExp=17; IntAct=EBI-516580, EBI-519672; CC Q07812; O75460: ERN1; NbExp=2; IntAct=EBI-516580, EBI-371750; CC Q07812; O75031: HSF2BP; NbExp=3; IntAct=EBI-516580, EBI-7116203; CC Q07812; P22001: KCNA3; NbExp=2; IntAct=EBI-516580, EBI-8627664; CC Q07812; Q07820: MCL1; NbExp=11; IntAct=EBI-516580, EBI-1003422; CC Q07812; Q8IVG9: MT-RNR2; NbExp=5; IntAct=EBI-516580, EBI-8643752; CC Q07812; Q9ULZ3: PYCARD; NbExp=7; IntAct=EBI-516580, EBI-751215; CC Q07812; Q7Z419: RNF144B; NbExp=5; IntAct=EBI-516580, EBI-2129982; CC Q07812; Q7L3V2: RTL10; NbExp=2; IntAct=EBI-516580, EBI-10697720; CC Q07812; Q9Y371-1: SH3GLB1; NbExp=2; IntAct=EBI-516580, EBI-5291808; CC Q07812; P37840: SNCA; NbExp=4; IntAct=EBI-516580, EBI-985879; CC Q07812; Q9P2Y5: UVRAG; NbExp=6; IntAct=EBI-516580, EBI-2952704; CC Q07812; P12956: XRCC6; NbExp=2; IntAct=EBI-516580, EBI-353208; CC Q07812; P70444: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-783400; CC Q07812; PRO_0000223236 [P70444]: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-2128640; CC Q07812; Q99MI6: Gimap3; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572304; CC Q07812; Q8BWF2: Gimap5; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572348; CC Q07812; P97287: Mcl1; Xeno; NbExp=2; IntAct=EBI-516580, EBI-707292; CC Q07812; P17361: OPG035; Xeno; NbExp=3; IntAct=EBI-516580, EBI-7115640; CC Q07812; P49334: TOM22; Xeno; NbExp=3; IntAct=EBI-516580, EBI-12527; CC Q07812; P23644: TOM40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12539; CC Q07812; P24391: tom40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-1791540; CC Q07812; P07213: TOM70; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12551; CC Q07812; P16778: UL37; Xeno; NbExp=2; IntAct=EBI-516580, EBI-16026491; CC Q07812; PRO_0000037647 [P26662]; Xeno; NbExp=3; IntAct=EBI-516580, EBI-9099462; CC -!- SUBCELLULAR LOCATION: [Isoform Alpha]: Mitochondrion outer membrane CC {ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:29531808}; Single-pass CC membrane protein {ECO:0000255}. Cytoplasm {ECO:0000269|PubMed:27558414, CC ECO:0000269|PubMed:29531808}. Nucleus {ECO:0000269|PubMed:36361894}. CC Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress CC conditions, undergoes a conformation change that causes release from CC JNK-phosphorylated 14-3-3 proteins and translocation to the CC mitochondrion membrane. Upon Sendai virus infection, recruited to the CC mitochondrion through interaction with IRF3 (PubMed:25609812). CC {ECO:0000269|PubMed:25609812}. CC -!- SUBCELLULAR LOCATION: [Isoform Beta]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Gamma]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Delta]: Cytoplasm {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Name=Alpha; CC IsoId=Q07812-1; Sequence=Displayed; CC Name=Beta; CC IsoId=Q07812-2, Q07814-1; CC Sequence=VSP_031237; CC Name=Gamma; CC IsoId=Q07812-3, Q07815-1; CC Sequence=VSP_031234, VSP_031236; CC Name=Delta; CC IsoId=Q07812-4, P55269-1; CC Sequence=VSP_031235; CC Name=Epsilon; CC IsoId=Q07812-5; Sequence=VSP_031240; CC Name=Zeta; CC IsoId=Q07812-6; Sequence=VSP_031239; CC Name=Psi; CC IsoId=Q07812-7; Sequence=VSP_031238; CC Name=Sigma; CC IsoId=Q07812-8; Sequence=VSP_037475; CC -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues. Isoform Psi CC is found in glial tumors. Isoform Alpha is expressed in spleen, breast, CC ovary, testis, colon and brain, and at low levels in skin and lung. CC Isoform Sigma is expressed in spleen, breast, ovary, testis, lung, CC colon, brain and at low levels in skin. Isoform Alpha and isoform Sigma CC are expressed in pro-myelocytic leukemia, histiocytic lymphoma, CC Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast CC adenocarcinoma, ovary adenocarcinoma, prostate carcinoma, prostate CC adenocarcinoma, lung carcinoma, epidermoid carcinoma, small cell lung CC carcinoma and colon adenocarcinoma cell lines. CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11912183}. CC -!- DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX for CC their pro-apoptotic activity and for their interaction with anti- CC apoptotic members of the Bcl-2 family. {ECO:0000269|PubMed:8521816}. CC -!- PTM: Ubiquitinated in the absence of XRCC6/Ku70 (PubMed:18362350). CC Ubiquitination promotes protein degradation (PubMed:18362350). CC Ubiquitinated on Lys-128 and Lys-190. 'Lys-63'-linked polyubiquitin CC chains on Lys-128 are removed by USP12. {ECO:0000269|PubMed:18362350, CC ECO:0000269|PubMed:36361894}. CC -!- SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/128/BAX"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L22473; AAA03619.1; -; mRNA. DR EMBL; L22474; AAA03620.1; -; mRNA. DR EMBL; L22475; AAA03621.1; -; mRNA. DR EMBL; U19599; AAC50142.1; -; mRNA. DR EMBL; AF007826; AAD22706.1; -; mRNA. DR EMBL; AF247393; AAF71267.1; -; mRNA. DR EMBL; AJ417988; CAD10744.1; -; mRNA. DR EMBL; AF250190; AAF82094.1; -; mRNA. DR EMBL; AK291076; BAF83765.1; -; mRNA. DR EMBL; AY217036; AAO22992.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52418.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52417.1; -; Genomic_DNA. DR EMBL; BC014175; AAH14175.1; -; mRNA. DR CCDS; CCDS12742.1; -. [Q07812-1] DR CCDS; CCDS12743.1; -. [Q07812-4] DR CCDS; CCDS12744.1; -. [Q07812-2] DR CCDS; CCDS12745.2; -. [Q07812-8] DR PIR; A47538; A47538. DR PIR; B47538; B47538. DR PIR; C47538; C47538. DR PIR; I38921; I38921. DR PIR; JC7255; JC7255. DR RefSeq; NP_001278357.1; NM_001291428.1. DR RefSeq; NP_001278360.1; NM_001291431.2. [Q07812-6] DR RefSeq; NP_004315.1; NM_004324.4. [Q07812-2] DR RefSeq; NP_620116.1; NM_138761.4. [Q07812-1] DR RefSeq; NP_620118.1; NM_138763.4. [Q07812-4] DR RefSeq; NP_620119.2; NM_138764.5. [Q07812-8] DR PDB; 1F16; NMR; -; A=1-192. DR PDB; 2G5B; X-ray; 2.30 A; I/J/K/L=13-19. DR PDB; 2K7W; NMR; -; A=1-192. DR PDB; 2LR1; NMR; -; A=1-192. DR PDB; 3PK1; X-ray; 2.49 A; B/D=48-81. DR PDB; 3PL7; X-ray; 2.61 A; C=48-81. DR PDB; 4BD2; X-ray; 2.21 A; A=1-171. DR PDB; 4BD6; X-ray; 2.49 A; A=1-171, C=48-81. DR PDB; 4BD7; X-ray; 2.80 A; A/B/C/D=1-171. DR PDB; 4BD8; X-ray; 2.22 A; A/B/C/D=1-171. DR PDB; 4BDU; X-ray; 3.00 A; A/B/C/D=53-128. DR PDB; 4S0O; X-ray; 1.90 A; A/B=1-192. DR PDB; 4S0P; X-ray; 3.25 A; A/B=1-192. DR PDB; 4UF2; X-ray; 3.00 A; B=50-77. DR PDB; 4ZIE; X-ray; 1.80 A; A=1-166. DR PDB; 4ZIF; X-ray; 2.40 A; A=1-166. DR PDB; 4ZIG; X-ray; 2.20 A; A=1-166. DR PDB; 4ZIH; X-ray; 2.50 A; A=1-164. DR PDB; 4ZII; X-ray; 2.19 A; A=1-170. DR PDB; 5W5X; X-ray; 2.50 A; A=1-192. DR PDB; 5W5Z; X-ray; 2.00 A; A=32-192. DR PDB; 5W60; X-ray; 1.80 A; A=1-192. DR PDB; 5W61; X-ray; 2.30 A; A=1-192. DR PDB; 6EB6; X-ray; 2.02 A; A=1-192. DR PDB; 6L8V; NMR; -; A/B=53-128. DR PDB; 6L95; NMR; -; A/B=166-192. DR PDB; 6TRR; X-ray; 2.12 A; B=50-77. DR PDB; 6XY6; X-ray; 2.91 A; B/D/F/H/J/L/N/P=50-77. DR PDB; 7ADT; X-ray; 2.21 A; C/U=50-77. DR PDB; 8G1T; X-ray; 2.09 A; A/B/C/D/E/F/G/H=53-128. DR PDB; 8SPE; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d=53-128. DR PDB; 8SPF; X-ray; 2.20 A; A/B/C/D/E/F=53-128. DR PDB; 8SPZ; X-ray; 2.40 A; A/B/C/D=53-128. DR PDB; 8SRX; X-ray; 2.09 A; B/D=53-128. DR PDB; 8SRY; X-ray; 2.40 A; B/D=53-128. DR PDB; 8SVK; X-ray; 2.25 A; A/B/C/D=53-128. DR PDB; 9IXU; EM; 3.19 A; A/B/C/D/E/F/G/H=1-192. DR PDBsum; 1F16; -. DR PDBsum; 2G5B; -. DR PDBsum; 2K7W; -. DR PDBsum; 2LR1; -. DR PDBsum; 3PK1; -. DR PDBsum; 3PL7; -. DR PDBsum; 4BD2; -. DR PDBsum; 4BD6; -. DR PDBsum; 4BD7; -. DR PDBsum; 4BD8; -. DR PDBsum; 4BDU; -. DR PDBsum; 4S0O; -. DR PDBsum; 4S0P; -. DR PDBsum; 4UF2; -. DR PDBsum; 4ZIE; -. DR PDBsum; 4ZIF; -. DR PDBsum; 4ZIG; -. DR PDBsum; 4ZIH; -. DR PDBsum; 4ZII; -. DR PDBsum; 5W5X; -. DR PDBsum; 5W5Z; -. DR PDBsum; 5W60; -. DR PDBsum; 5W61; -. DR PDBsum; 6EB6; -. DR PDBsum; 6L8V; -. DR PDBsum; 6L95; -. DR PDBsum; 6TRR; -. DR PDBsum; 6XY6; -. DR PDBsum; 7ADT; -. DR PDBsum; 8G1T; -. DR PDBsum; 8SPE; -. DR PDBsum; 8SPF; -. DR PDBsum; 8SPZ; -. DR PDBsum; 8SRX; -. DR PDBsum; 8SRY; -. DR PDBsum; 8SVK; -. DR PDBsum; 9IXU; -. DR AlphaFoldDB; Q07812; -. DR BMRB; Q07812; -. DR EMDB; EMD-60977; -. DR SASBDB; Q07812; -. DR SMR; Q07812; -. DR BioGRID; 107057; 150. DR ComplexPortal; CPX-1988; BAX oligomer. DR CORUM; Q07812; -. DR DIP; DIP-232N; -. DR FunCoup; Q07812; 1141. DR IntAct; Q07812; 87. DR MINT; Q07812; -. DR STRING; 9606.ENSP00000293288; -. DR BindingDB; Q07812; -. DR ChEMBL; CHEMBL5318; -. DR DrugBank; DB12756; TAK-901. DR DrugBank; DB16447; Thymoquinone. DR TCDB; 1.A.21.1.2; the bcl-2 (bcl-2) family. DR GlyGen; Q07812; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q07812; -. DR MetOSite; Q07812; -. DR PhosphoSitePlus; Q07812; -. DR SwissPalm; Q07812; -. DR BioMuta; BAX; -. DR DMDM; 728945; -. DR jPOST; Q07812; -. DR MassIVE; Q07812; -. DR PaxDb; 9606-ENSP00000293288; -. DR PeptideAtlas; Q07812; -. DR ProteomicsDB; 58529; -. [Q07812-1] DR ProteomicsDB; 58530; -. [Q07812-2] DR ProteomicsDB; 58531; -. [Q07812-3] DR ProteomicsDB; 58532; -. [Q07812-4] DR ProteomicsDB; 58533; -. [Q07812-5] DR ProteomicsDB; 58534; -. [Q07812-6] DR ProteomicsDB; 58535; -. [Q07812-7] DR ProteomicsDB; 58536; -. [Q07812-8] DR Pumba; Q07812; -. DR TopDownProteomics; Q07812-1; -. [Q07812-1] DR TopDownProteomics; Q07812-2; -. [Q07812-2] DR TopDownProteomics; Q07812-5; -. [Q07812-5] DR TopDownProteomics; Q07812-6; -. [Q07812-6] DR TopDownProteomics; Q07812-8; -. [Q07812-8] DR ABCD; Q07812; 22 sequenced antibodies. DR Antibodypedia; 3777; 2176 antibodies from 53 providers. DR CPTC; Q07812; 1 antibody. DR DNASU; 581; -. DR Ensembl; ENST00000293288.12; ENSP00000293288.8; ENSG00000087088.22. [Q07812-2] DR Ensembl; ENST00000345358.12; ENSP00000263262.9; ENSG00000087088.22. [Q07812-1] DR Ensembl; ENST00000354470.7; ENSP00000346461.3; ENSG00000087088.22. [Q07812-4] DR Ensembl; ENST00000356483.8; ENSP00000348871.4; ENSG00000087088.22. [Q07812-5] DR Ensembl; ENST00000415969.6; ENSP00000389971.2; ENSG00000087088.22. [Q07812-8] DR Ensembl; ENST00000515540.5; ENSP00000426328.1; ENSG00000087088.22. [Q07812-3] DR GeneID; 581; -. DR KEGG; hsa:581; -. DR MANE-Select; ENST00000345358.12; ENSP00000263262.9; NM_138761.4; NP_620116.1. DR UCSC; uc002plf.2; human. [Q07812-1] DR AGR; HGNC:959; -. DR CIViC; 581; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25269; -. DR CTD; 581; -. DR DisGeNET; 581; -. DR GeneCards; BAX; -. DR HGNC; HGNC:959; BAX. DR HPA; ENSG00000087088; Low tissue specificity. DR MalaCards; BAX; -. DR MIM; 600040; gene. DR OpenTargets; ENSG00000087088; -. DR VEuPathDB; HostDB:ENSG00000087088; -. DR eggNOG; KOG4728; Eukaryota. DR GeneTree; ENSGT01130000278292; -. DR HOGENOM; CLU_3279262_0_0_1; -. DR InParanoid; Q07812; -. DR OMA; QCCGDSE; -. DR OrthoDB; 6080198at2759; -. DR PAN-GO; Q07812; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q07812; -. DR PathwayCommons; Q07812; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-114294; Activation, translocation and oligomerization of BAX. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q07812; -. DR SIGNOR; Q07812; -. DR Agora; ENSG00000087088; -. DR BioGRID-ORCS; 581; 32 hits in 1176 CRISPR screens. DR ChiTaRS; BAX; human. DR EvolutionaryTrace; Q07812; -. DR GeneWiki; Bcl-2-associated_X_protein; -. DR GenomeRNAi; 581; -. DR Pharos; Q07812; Tchem. DR PRO; PR:Q07812; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q07812; protein. DR Bgee; ENSG00000087088; Expressed in mucosa of transverse colon and 168 other cell types or tissues. DR ExpressionAtlas; Q07812; baseline and differential. DR GO; GO:0097145; C:BAK complex; IDA:ARUK-UCL. DR GO; GO:0097144; C:BAX complex; IDA:UniProtKB. DR GO; GO:0097136; C:Bcl-2 family protein complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:HGNC-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB. DR GO; GO:0005757; C:mitochondrial permeability transition pore complex; IDA:HGNC-UCL. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:AgBase. DR GO; GO:0005634; C:nucleus; IDA:AgBase. DR GO; GO:0046930; C:pore complex; IDA:BHF-UCL. DR GO; GO:0051434; F:BH3 domain binding; IDA:UniProtKB. DR GO; GO:0015267; F:channel activity; IDA:BHF-UCL. DR GO; GO:0030544; F:Hsp70 protein binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0008289; F:lipid binding; IDA:HGNC-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:HGNC-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IDA:HGNC-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:DIBU. DR GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060057; P:apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0001783; P:B cell apoptotic process; IDA:HGNC-UCL. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0002358; P:B cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0002352; P:B cell negative selection; IEA:Ensembl. DR GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0060402; P:calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; TAS:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IEA:Ensembl. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl. DR GO; GO:0045136; P:development of secondary sexual characteristics; IEA:Ensembl. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0032469; P:endoplasmic reticulum calcium ion homeostasis; TAS:UniProtKB. DR GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IDA:HGNC-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IMP:HGNC-UCL. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IBA:GO_Central. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IC:BHF-UCL. DR GO; GO:0009566; P:fertilization; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:HGNC-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; TAS:ParkinsonsUK-UCL. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IDA:HGNC-UCL. DR GO; GO:0008053; P:mitochondrial fusion; IDA:HGNC-UCL. DR GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0002262; P:myeloid cell homeostasis; IEA:Ensembl. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0032471; P:negative regulation of endoplasmic reticulum calcium ion concentration; IEA:Ensembl. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0010917; P:negative regulation of mitochondrial membrane potential; IDA:UniProtKB. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0002904; P:positive regulation of B cell apoptotic process; IEA:Ensembl. DR GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0048087; P:positive regulation of developmental pigmentation; IEA:Ensembl. DR GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL. DR GO; GO:1902110; P:positive regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:2000673; P:positive regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:HGNC-UCL. DR GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:2000243; P:positive regulation of reproductive process; IEA:Ensembl. DR GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0051204; P:protein insertion into mitochondrial membrane; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl. DR GO; GO:0033599; P:regulation of mammary gland epithelial cell proliferation; IEA:Ensembl. DR GO; GO:1902445; P:regulation of mitochondrial membrane permeability involved in programmed necrotic cell death; IEA:Ensembl. DR GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:HGNC-UCL. DR GO; GO:0006808; P:regulation of nitrogen utilization; IEA:Ensembl. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0032976; P:release of matrix enzymes from mitochondria; IDA:HGNC-UCL. DR GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:0048678; P:response to axon injury; IEA:Ensembl. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IDA:HGNC-UCL. DR GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl. DR GO; GO:0046666; P:retinal cell programmed cell death; IEA:Ensembl. DR GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl. DR GO; GO:0048515; P:spermatid differentiation; IEA:Ensembl. DR GO; GO:0097435; P:supramolecular fiber organization; IDA:UniProtKB. DR GO; GO:0001777; P:T cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR CDD; cd06845; Bcl-2_like; 1. DR DisProt; DP02540; -. DR FunFam; 1.10.437.10:FF:000004; apoptosis regulator BAX isoform X2; 1. DR Gene3D; 1.10.437.10; Blc2-like; 1. DR InterPro; IPR036834; Bcl-2-like_sf. DR InterPro; IPR046371; Bcl-2_BH1-3. DR InterPro; IPR026298; Bcl-2_fam. DR InterPro; IPR002475; Bcl2-like. DR InterPro; IPR020717; Bcl2_BH1_motif_CS. DR InterPro; IPR020726; Bcl2_BH2_motif_CS. DR InterPro; IPR020728; Bcl2_BH3_motif_CS. DR PANTHER; PTHR11256:SF42; APOPTOSIS REGULATOR BAX; 1. DR PANTHER; PTHR11256; BCL-2 RELATED; 1. DR Pfam; PF00452; Bcl-2; 1. DR PRINTS; PR01862; BCL2FAMILY. DR SMART; SM00337; BCL; 1. DR SUPFAM; SSF56854; Bcl-2 inhibitors of programmed cell death; 1. DR PROSITE; PS50062; BCL2_FAMILY; 1. DR PROSITE; PS01080; BH1; 1. DR PROSITE; PS01258; BH2; 1. DR PROSITE; PS01259; BH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Host-virus interaction; Isopeptide bond; Membrane; Mitochondrion; KW Mitochondrion outer membrane; Nucleus; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix; Tumor suppressor; KW Ubl conjugation. FT CHAIN 1..192 FT /note="Apoptosis regulator BAX" FT /id="PRO_0000143053" FT TRANSMEM 172..192 FT /note="Helical" FT /evidence="ECO:0000255" FT MOTIF 59..73 FT /note="BH3" FT /evidence="ECO:0000269|PubMed:8521816" FT MOTIF 98..118 FT /note="BH1" FT MOTIF 150..165 FT /note="BH2" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:25944712" FT CROSSLNK 128 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT CROSSLNK 190 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT VAR_SEQ 1..78 FT /note="Missing (in isoform Zeta)" FT /evidence="ECO:0000303|Ref.6" FT /id="VSP_031239" FT VAR_SEQ 1..19 FT /note="Missing (in isoform Psi)" FT /evidence="ECO:0000303|PubMed:11912183" FT /id="VSP_031238" FT VAR_SEQ 12..41 FT /note="GPTSSEQIMKTGALLLQGFIQDRAGRMGGE -> VSSRIEQGEWGGRHPSWP FT WTRCLRMRPPRS (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031234" FT VAR_SEQ 30..78 FT /note="Missing (in isoform Delta)" FT /evidence="ECO:0000303|PubMed:7607685" FT /id="VSP_031235" FT VAR_SEQ 42..192 FT /note="Missing (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031236" FT VAR_SEQ 125..192 FT /note="LCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIF FT VAGVLTASLTIWKKMG -> GVKWRDLGSLQPLPPGFKRFTCLSIPRSWDYRPCAPRCR FT N (in isoform Epsilon)" FT /evidence="ECO:0000303|PubMed:9920818" FT /id="VSP_031240" FT VAR_SEQ 159..192 FT /note="DGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG -> VRLLKPPHPHHRAL FT TTAPAPPSLPPATPLGPWAFWSRSQWCPLPIFRSSDVVYNAFSLRV (in isoform FT Beta)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031237" FT VAR_SEQ 159..171 FT /note="Missing (in isoform Sigma)" FT /evidence="ECO:0000303|PubMed:10772918" FT /id="VSP_037475" FT VARIANT 11 FT /note="G -> E (in a plasmacytoma cell line; FT dbSNP:rs555248599)" FT /evidence="ECO:0000269|PubMed:9531611" FT /id="VAR_013575" FT VARIANT 39 FT /note="G -> R (in dbSNP:rs36017265)" FT /id="VAR_047053" FT VARIANT 67 FT /note="G -> R (in a T-cell acute lymphoblastic leukemia FT cell line; loss of heterodimerization with Bcl-2 or Bcl- FT X(L); dbSNP:rs398122513)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_007809" FT VARIANT 108 FT /note="G -> V (in a Burkitt lymphoma; loss of FT homodimerization)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_013576" FT MUTAGEN 21 FT /note="K->E: Reduces interaction with BCL2L11, FT homooligomerization and triggering of apoptosis." FT /evidence="ECO:0000269|PubMed:18948948" FT MUTAGEN 74 FT /note="M->D,E: Strongly reduced interaction with MCL1, FT BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release FT and subsequent apoptosis triggered by etoposide." FT /evidence="ECO:0000269|PubMed:21199865" FT MUTAGEN 128 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 172..192 FT /note="Missing: Enhanced fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:31690630" FT MUTAGEN 184 FT /note="S->D,E,H,K: Constitutive cytoplasmic location." FT /evidence="ECO:0000269|PubMed:10228148" FT MUTAGEN 184 FT /note="S->V: Constitutive mitochondrial location. Enhanced FT fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:10228148, FT ECO:0000269|PubMed:31690630" FT MUTAGEN 189 FT /note="K->R: No loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 190 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT TURN 2..4 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 10..14 FT /evidence="ECO:0007829|PDB:1F16" FT HELIX 16..34 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 43..45 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 54..71 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 74..82 FT /evidence="ECO:0007829|PDB:4ZIE" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 88..99 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 107..147 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 149..154 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 159..164 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 167..169 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 170..187 FT /evidence="ECO:0007829|PDB:5W60" SQ SEQUENCE 192 AA; 21184 MW; 6C0CDB0A7DEE4994 CRC64; MDGSGEQPRG GGPTSSEQIM KTGALLLQGF IQDRAGRMGG EAPELALDPV PQDASTKKLS ECLKRIGDEL DSNMELQRMI AAVDTDSPRE VFFRVAADMF SDGNFNWGRV VALFYFASKL VLKALCTKVP ELIRTIMGWT LDFLRERLLG WIQDQGGWDG LLSYFGTPTW QTVTIFVAGV LTASLTIWKK MG // ID BIRC5_HUMAN Reviewed; 142 AA. AC O15392; A2SUH6; B2R4R1; Q2I3N8; Q4VGX0; Q53F61; Q5MGC6; Q6FHL2; Q75SP2; AC Q9P2W8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2012, sequence version 3. DT 28-JAN-2026, entry version 252. DE RecName: Full=Baculoviral IAP repeat-containing protein 5; DE AltName: Full=Apoptosis inhibitor 4; DE AltName: Full=Apoptosis inhibitor survivin; GN Name=BIRC5; Synonyms=API4, IAP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=9256286; DOI=10.1038/nm0897-917; RA Ambrosini G., Adida C., Altieri D.C.; RT "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma."; RL Nat. Med. 3:917-921(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10626797; RA Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.; RT "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the RT apoptosis inhibitor survivin with different antiapoptotic properties."; RL Cancer Res. 59:6097-6102(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RX PubMed=11084331; DOI=10.1016/s0960-9822(00)00769-7; RA Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., RA Choo K.H.; RT "Survivin and the inner centromere protein INCENP show similar cell-cycle RT localization and gene knockout phenotype."; RL Curr. Biol. 10:1319-1328(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY. RC TISSUE=Myeloid leukemia cell; RX PubMed=14741722; DOI=10.1016/j.bbrc.2003.12.178; RA Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., RA Inuzuka M.; RT "Identification of a novel splice variant of the human anti-apoptosis gene RT survivin."; RL Biochem. Biophys. Res. Commun. 314:902-907(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY. RC TISSUE=Mammary cancer; RX PubMed=16329164; DOI=10.1080/10425170500226490; RA Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S.; RT "Molecular cloning and bioinformatics analysis of a novel spliced variant RT of survivin from human breast cancer cells."; RL DNA Seq. 16:321-328(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Neuroblastoma; RA Kageyama H., Islam A., Takayasu H., Nakagawara A.; RT "An isoform of survivin (survivin-beta) which has 23 amino acids insertion RT into the BIR domain."; RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7). RA Caldas H., Honsey L.E., Altura R.A.; RT "Survivin 2 alpha: a novel survivin splice variant expressed in human RT malignancies."; RL Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6). RC TISSUE=Myeloid leukemia cell; RA Vietri M.T., Cioffi M., Sessa M., Sica V., Molinari A.M.; RT "Identification of a novel survivin splicing variant 3alpha in acute RT myeloid leukemia."; RL Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-129. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [14] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Mammary gland, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [16] RP FUNCTION. RX PubMed=9859993; DOI=10.1038/25141; RA Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., RA Altieri D.C.; RT "Control of apoptosis and mitotic spindle checkpoint by survivin."; RL Nature 396:580-584(1998). RN [17] RP PHOSPHORYLATION AT THR-34. RX PubMed=11069302; DOI=10.1073/pnas.240390697; RA O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., RA Tognin S., Marchisio P.C., Altieri D.C.; RT "Regulation of apoptosis at cell division by p34cdc2 phosphorylation of RT survivin."; RL Proc. Natl. Acad. Sci. U.S.A. 97:13103-13107(2000). RN [18] RP FUNCTION IN APOPTOSIS SUPPRESSION, INTERACTION WITH LAMTOR5/HBXIP, RP MUTAGENESIS OF THR-34, AND SUBCELLULAR LOCATION. RX PubMed=12773388; DOI=10.1093/emboj/cdg263; RA Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., RA Reed J.C.; RT "HBXIP functions as a cofactor of survivin in apoptosis suppression."; RL EMBO J. 22:2729-2740(2003). RN [19] RP INTERACTION WITH INCENP, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-117, RP AND MUTAGENESIS OF THR-117. RX PubMed=14610074; DOI=10.1074/jbc.m311299200; RA Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.; RT "Aurora-B phosphorylation in vitro identifies a residue of survivin that is RT essential for its localization and binding to inner centromere protein RT (INCENP) in vivo."; RL J. Biol. Chem. 279:5655-5660(2004). RN [20] RP INTERACTION WITH CDCA8. RX PubMed=15249581; DOI=10.1083/jcb.200404001; RA Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R., RA Nigg E.A., Gerloff D.L., Earnshaw W.C.; RT "Borealin: a novel chromosomal passenger required for stability of the RT bipolar mitotic spindle."; RL J. Cell Biol. 166:179-191(2004). RN [21] RP SUBCELLULAR LOCATION, AND INTERACTION WITH BIRC2/C-IAP1. RX PubMed=15665297; DOI=10.1158/0008-5472.210.65.1; RA Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.; RT "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle."; RL Cancer Res. 65:210-218(2005). RN [22] RP REVIEW ON FUNCTION. RX PubMed=16344111; DOI=10.1016/s0074-7696(05)47002-3; RA Wheatley S.P., McNeish I.A.; RT "Survivin: a protein with dual roles in mitosis and apoptosis."; RL Int. Rev. Cytol. 247:35-88(2005). RN [23] RP FUNCTION, INTERACTION WITH USP9X, SUBCELLULAR LOCATION, UBIQUITINATION, AND RP MUTAGENESIS OF LYS-23; LYS-62; LYS-78 AND LYS-79. RX PubMed=16322459; DOI=10.1126/science.1120160; RA Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.; RT "Chromosome alignment and segregation regulated by ubiquitination of RT survivin."; RL Science 310:1499-1504(2005). RN [24] RP MUTAGENESIS OF ASP-70; ASP-71 AND 70-ASP--ASP-71. RX PubMed=16762323; DOI=10.1016/j.bbrc.2006.05.131; RA Cao L., Yan X., Wu Y., Hu H., Li Q., Zhou T., Jiang S., Yu L.; RT "Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin RT with Aurora B and causes multinucleation in HeLa cells."; RL Biochem. Biophys. Res. Commun. 346:400-407(2006). RN [25] RP INTERACTION WITH CDCA8. RX PubMed=16239925; DOI=10.1038/sj.embor.7400562; RA Vader G., Kauw J.J.W., Medema R.H., Lens S.M.A.; RT "Survivin mediates targeting of the chromosomal passenger complex to the RT centromere and midbody."; RL EMBO Rep. 7:85-92(2006). RN [26] RP INTERACTION WITH CDCA8. RX PubMed=16427043; DOI=10.1016/j.yexcr.2005.12.015; RA Chang J.-L., Chen T.-H., Wang C.-F., Chiang Y.-H., Huang Y.-L., Wong F.-H., RA Chou C.-K., Chen C.-M.; RT "Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein RT and its nuclear accumulation is linked to poor prognosis for human gastric RT cancer."; RL Exp. Cell Res. 312:962-973(2006). RN [27] RP INTERACTION WITH EVI5. RX PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032; RA Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.; RT "EVI5 protein associates with the INCENP-aurora B kinase-survivin RT chromosomal passenger complex and is involved in the completion of RT cytokinesis."; RL Exp. Cell Res. 312:2325-2335(2006). RN [28] RP FUNCTION, AND INTERACTION WITH CDCA8. RX PubMed=16291752; DOI=10.1074/jbc.m508773200; RA Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., RA Wheatley S.P.; RT "Molecular analysis of survivin isoforms: evidence that alternatively RT spliced variants do not play a role in mitosis."; RL J. Biol. Chem. 281:1286-1295(2006). RN [29] RP INTERACTION WITH CDCA8. RX PubMed=16436504; DOI=10.1091/mbc.e05-08-0727; RA Lens S.M.A., Rodriguez J.A., Vader G., Span S.W., Giaccone G., Medema R.H.; RT "Uncoupling the central spindle-associated function of the chromosomal RT passenger complex from its role at centromeres."; RL Mol. Biol. Cell 17:1897-1909(2006). RN [30] RP INTERACTION WITH BIRC6/BRUCE. RX PubMed=18329369; DOI=10.1016/j.cell.2008.01.012; RA Pohl C., Jentsch S.; RT "Final stages of cytokinesis and midbody ring formation are controlled by RT BRUCE."; RL Cell 132:832-845(2008). RN [31] RP INDUCTION. RX PubMed=17993464; DOI=10.1074/jbc.m704035200; RA Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.; RT "Cartilage oligomeric matrix protein protects cells against death by RT elevating members of the IAP family of survival proteins."; RL J. Biol. Chem. 283:648-659(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-34, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [33] RP FUNCTION, INTERACTION WITH RAN; AURKB AND CDCA8, SUBCELLULAR LOCATION, RP DEVELOPMENTAL STAGE, AND MUTAGENESIS OF GLU-65. RX PubMed=18591255; DOI=10.1128/mcb.02039-07; RA Xia F., Canovas P.M., Guadagno T.M., Altieri D.C.; RT "A survivin-ran complex regulates spindle formation in tumor cells."; RL Mol. Cell. Biol. 28:5299-5311(2008). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21364656; DOI=10.1038/cddis.2010.25; RA Knauer S.K., Heinrich U.R., Bier C., Habtemichael N., Docter D., RA Helling K., Mann W.J., Stauber R.H.; RT "An otoprotective role for the apoptosis inhibitor protein survivin."; RL Cell Death Dis. 1:E51-E51(2010). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3 AND XPO1/CRM1, RP ACETYLATION AT LYS-23; LYS-90; LYS-110; LYS-112; LYS-115; LYS-121 AND RP LYS-129, MUTAGENESIS OF LYS-129, AND CHARACTERIZATION OF VARIANT GLU-129. RX PubMed=20826784; DOI=10.1074/jbc.m110.152777; RA Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., RA Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.; RT "Acetylation directs survivin nuclear localization to repress STAT3 RT oncogenic activity."; RL J. Biol. Chem. 285:36129-36137(2010). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20627126; DOI=10.1016/j.mcn.2010.07.003; RA Habtemichael N., Heinrich U.R., Knauer S.K., Schmidtmann I., Bier C., RA Docter D., Brochhausen C., Helling K., Brieger J., Stauber R.H., Mann W.J.; RT "Expression analysis suggests a potential cytoprotective role of Birc5 in RT the inner ear."; RL Mol. Cell. Neurosci. 45:297-305(2010). RN [37] RP FUNCTION, HISTONE-BINDING, AND MUTAGENESIS OF ARG-18; TRP-25; CYS-33; RP CYS-57 AND TRP-67. RX PubMed=20929775; DOI=10.1126/science.1194498; RA Yamagishi Y., Honda T., Tanno Y., Watanabe Y.; RT "Two histone marks establish the inner centromere and chromosome bi- RT orientation."; RL Science 330:239-243(2010). RN [38] RP PHOSPHORYLATION AT THR-48, AND MUTAGENESIS OF THR-48. RX PubMed=21252625; DOI=10.4161/cc.10.3.14758; RA Barrett R.M., Colnaghi R., Wheatley S.P.; RT "Threonine 48 in the BIR domain of survivin is critical to its mitotic and RT anti-apoptotic activities and can be phosphorylated by CK2 in vitro."; RL Cell Cycle 10:538-548(2011). RN [39] RP INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [40] RP FUNCTION, SUBUNIT, AND INTERACTION WITH XIAP/BIRC4 AND DIABLO/SMAC. RX PubMed=21536684; DOI=10.1074/jbc.m111.237586; RA Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., RA Kopantzev E.P., Shakhparonov M.I.; RT "Survivin monomer plays an essential role in apoptosis regulation."; RL J. Biol. Chem. 286:23296-23307(2011). RN [41] RP PHOSPHORYLATION AT THR-34 BY CDK15. RX PubMed=24866247; DOI=10.1016/j.bbrc.2014.05.070; RA Park M.H., Kim S.Y., Kim Y.J., Chung Y.H.; RT "ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing RT phosphorylation of survivin Thr34."; RL Biochem. Biophys. Res. Commun. 450:129-134(2014). RN [42] RP UBIQUITINATION. RX PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046; RA Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.; RT "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin RT to maintain genome integrity."; RL Mol. Cell 54:805-819(2014). RN [43] RP FUNCTION, INTERACTION WITH FBXL7, AND MUTAGENESIS OF 90-LYS-LYS-91 AND RP GLU-126. RX PubMed=25778398; DOI=10.1074/jbc.m114.629931; RA Liu Y., Lear T., Iannone O., Shiva S., Corey C., Rajbhandari S., Jerome J., RA Chen B.B., Mallampalli R.K.; RT "The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by RT Mediating the Ubiquitylation and Proteasomal Degradation of Survivin."; RL J. Biol. Chem. 290:11843-11852(2015). RN [44] RP SUBUNIT, AND PHOSPHORYLATION AT SER-20. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [45] RP FUNCTION, AND INTERACTION WITH FBXL7. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [46] RP INTERACTION WITH EPSTEIN-BARR VIRUS EBNA1 (MICROBIAL INFECTION). RX PubMed=28077791; DOI=10.18632/oncotarget.14540; RA Dheekollu J., Malecka K., Wiedmer A., Delecluse H.J., Chiang A.K., RA Altieri D.C., Messick T.E., Lieberman P.M.; RT "Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal RT latency."; RL Oncotarget 8:7248-7264(2017). RN [47] RP DEUBIQUITINATION BY USP35 AND USP38. RX PubMed=34438346; DOI=10.1016/j.bbrc.2021.08.050; RA Wang W., Lin H., Zheng E., Hou Z., Liu Y., Huang W., Chen D., Feng J., RA Li J., Li L.; RT "Regulation of survivin protein stability by USP35 is evolutionarily RT conserved."; RL Biochem. Biophys. Res. Commun. 574:48-55(2021). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF ISOFORM 1. RX PubMed=10949039; DOI=10.1016/s1097-2765(05)00020-1; RA Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., RA Margolis R.L.; RT "Crystal structure of human survivin reveals a bow tie-shaped dimer with RT two unusual alpha-helical extensions."; RL Mol. Cell 6:183-189(2000). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF ISOFORM 1. RX PubMed=10876248; DOI=10.1038/76838; RA Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P.; RT "Structure of the human anti-apoptotic protein survivin reveals a dimeric RT arrangement."; RL Nat. Struct. Biol. 7:602-608(2000). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, RP AND INTERACTION WITH CDCA8 AND INCENP. RX PubMed=17956729; DOI=10.1016/j.cell.2007.07.045; RA Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.; RT "Structure of a Survivin-Borealin-INCENP core complex reveals how RT chromosomal passengers travel together."; RL Cell 131:271-285(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS). RX PubMed=19530738; DOI=10.1021/bi900530v; RA Bourhis E., Lingel A., Phung Q., Fairbrother W.J., Cochran A.G.; RT "Phosphorylation of a borealin dimerization domain is required for proper RT chromosome segregation."; RL Biochemistry 48:6783-6793(2009). CC -!- FUNCTION: Multitasking protein that has dual roles in promoting cell CC proliferation and preventing apoptosis (PubMed:20627126, CC PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). CC Component of a chromosome passage protein complex (CPC) which is CC essential for chromosome alignment and segregation during mitosis and CC cytokinesis (PubMed:16322459). Acts as an important regulator of the CC localization of this complex; directs CPC movement to different CC locations from the inner centromere during prometaphase to midbody CC during cytokinesis and participates in the organization of the center CC spindle by associating with polymerized microtubules (PubMed:20826784). CC Involved in the recruitment of CPC to centromeres during early mitosis CC via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) CC during mitosis (PubMed:20929775). The complex with RAN plays a role in CC mitotic spindle formation by serving as a physical scaffold to help CC deliver the RAN effector molecule TPX2 to microtubules CC (PubMed:18591255). May counteract a default induction of apoptosis in CC G2/M phase (PubMed:9859993). The acetylated form represses STAT3 CC transactivation of target gene promoters (PubMed:20826784). May play a CC role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 CC (PubMed:21536684). Essential for the maintenance of mitochondrial CC integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do CC not appear to play vital roles in mitosis (PubMed:12773388, CC PubMed:16291752). Isoform 3 shows a marked reduction in its anti- CC apoptotic effects when compared with the displayed wild-type isoform CC (PubMed:10626797). {ECO:0000269|PubMed:10626797, CC ECO:0000269|PubMed:12773388, ECO:0000269|PubMed:16291752, CC ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:20929775, ECO:0000269|PubMed:21364656, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735, ECO:0000269|PubMed:9859993}. CC -!- SUBUNIT: Monomer or homodimer. Exists as a homodimer in the apo state CC and as a monomer in the CPC-bound state. The monomer protects cells CC against apoptosis more efficiently than the dimer. Only the dimeric CC form is capable of enhancing tubulin stability in cells. When CC phosphorylated, interacts with LAMTOR5/HBXIP; the resulting complex CC binds pro-CASP9, as well as active CASP9, but much less efficiently. CC Component of the chromosomal passenger complex (CPC) composed of at CC least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in the CC complex forms a triple-helix bundle-based subcomplex with INCENP and CC CDCA8 (PubMed:17956729). Interacts with JTB. Interacts (via BIR domain) CC with histone H3 phosphorylated at 'Thr-3' (H3pT3). Interacts with EVI5. CC Interacts with GTP-bound RAN in both the S and M phases of the cell CC cycle. Interacts with USP9X. Interacts with tubulin. Interacts with CC BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The CC monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The CC monomeric form interacts with XIAP/BIRC4. Both the dimeric and CC monomeric form can interact with DIABLO/SMAC. Interacts with CC BIRC6/bruce. Interacts with FBXL7; this interaction facilitates the CC polyubiquitination and subsequent proteasomal degradation of BIRC5 by CC the SCF(FBXL7) E3 ubiquitin-protein ligase complex (PubMed:25778398, CC PubMed:28218735). {ECO:0000269|PubMed:12773388, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:15249581, CC ECO:0000269|PubMed:15665297, ECO:0000269|PubMed:16239925, CC ECO:0000269|PubMed:16291752, ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:16427043, ECO:0000269|PubMed:16436504, CC ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729, CC ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus (EBV) CC EBNA1; this interaction is probably important for EBV episome CC maintenance in Burkitt's lymphoma cells. {ECO:0000269|PubMed:28077791}. CC -!- INTERACTION: CC O15392; Q92870-2: APBB2; NbExp=3; IntAct=EBI-518823, EBI-21535880; CC O15392; P05067: APP; NbExp=3; IntAct=EBI-518823, EBI-77613; CC O15392; P05067-2: APP; NbExp=3; IntAct=EBI-518823, EBI-17264467; CC O15392; O14965: AURKA; NbExp=2; IntAct=EBI-518823, EBI-448680; CC O15392; Q96GD4: AURKB; NbExp=13; IntAct=EBI-518823, EBI-624291; CC O15392; Q9UQB9: AURKC; NbExp=10; IntAct=EBI-518823, EBI-3926851; CC O15392; Q14457: BECN1; NbExp=3; IntAct=EBI-518823, EBI-949378; CC O15392; O15392: BIRC5; NbExp=2; IntAct=EBI-518823, EBI-518823; CC O15392; Q15834: CCDC85B; NbExp=3; IntAct=EBI-518823, EBI-739674; CC O15392; Q53HL2: CDCA8; NbExp=21; IntAct=EBI-518823, EBI-979174; CC O15392; P06493: CDK1; NbExp=6; IntAct=EBI-518823, EBI-444308; CC O15392; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-518823, EBI-25840379; CC O15392; Q9NR28: DIABLO; NbExp=2; IntAct=EBI-518823, EBI-517508; CC O15392; Q86XJ1: GAS2L3; NbExp=4; IntAct=EBI-518823, EBI-9248152; CC O15392; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-518823, EBI-11110431; CC O15392; P42858: HTT; NbExp=15; IntAct=EBI-518823, EBI-466029; CC O15392; Q9NQS7: INCENP; NbExp=11; IntAct=EBI-518823, EBI-307907; CC O15392; O43504: LAMTOR5; NbExp=3; IntAct=EBI-518823, EBI-713382; CC O15392; Q96CV9: OPTN; NbExp=3; IntAct=EBI-518823, EBI-748974; CC O15392; Q7Z412: PEX26; NbExp=3; IntAct=EBI-518823, EBI-752057; CC O15392; Q9BXM7: PINK1; NbExp=3; IntAct=EBI-518823, EBI-2846068; CC O15392; P62826: RAN; NbExp=7; IntAct=EBI-518823, EBI-286642; CC O15392; P37840: SNCA; NbExp=3; IntAct=EBI-518823, EBI-985879; CC O15392; Q13148: TARDBP; NbExp=6; IntAct=EBI-518823, EBI-372899; CC O15392; P09936: UCHL1; NbExp=3; IntAct=EBI-518823, EBI-714860; CC O15392; O14980: XPO1; NbExp=2; IntAct=EBI-518823, EBI-355867; CC O15392-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518838, EBI-624291; CC O15392-1; O15392-1: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518838; CC O15392-1; O15392-2: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518842; CC O15392-1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518838, EBI-979174; CC O15392-2; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518842, EBI-624291; CC O15392-2; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518842, EBI-979174; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21364656}. Nucleus CC {ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:21364656}. Chromosome {ECO:0000269|PubMed:14610074}. CC Chromosome, centromere {ECO:0000269|PubMed:11084331, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:16322459}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:11084331}. Chromosome, CC centromere, kinetochore {ECO:0000269|PubMed:11084331}. Midbody CC {ECO:0000269|PubMed:15665297}. Note=Localizes at the centromeres from CC prophase to metaphase, at the spindle midzone during anaphase and a the CC midbody during telophase and cytokinesis. Accumulates in the nucleus CC upon treatment with leptomycin B (LMB), a XPO1/CRM1 nuclear export CC inhibitor (By similarity). Localizes on chromosome arms and inner CC centromeres from prophase through metaphase. Localizes to kinetochores CC in metaphase, distributes to the midzone microtubules in anaphase and CC at telophase, localizes exclusively to the midbody (PubMed:11084331). CC Colocalizes with AURKB at mitotic chromosomes (PubMed:14610074). CC Acetylation at Lys-129 directs its localization to the nucleus by CC enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated CC nuclear export (PubMed:20826784). {ECO:0000250|UniProtKB:E3SCZ8, CC ECO:0000269|PubMed:11084331, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:20826784}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Alpha; CC IsoId=O15392-1; Sequence=Displayed; CC Name=2; Synonyms=2B, Beta; CC IsoId=O15392-2; Sequence=VSP_002454; CC Name=3; Synonyms=DeltaEx3; CC IsoId=O15392-3; Sequence=VSP_020338; CC Name=4; Synonyms=3B; CC IsoId=O15392-4; Sequence=VSP_020342; CC Name=5; Synonyms=SI; CC IsoId=O15392-5; Sequence=VSP_020341; CC Name=6; Synonyms=3 alpha; CC IsoId=O15392-6; Sequence=VSP_020339; CC Name=7; Synonyms=2 alpha; CC IsoId=O15392-7; Sequence=VSP_020340; CC -!- TISSUE SPECIFICITY: Expressed only in fetal kidney and liver, and to CC lesser extent, lung and brain (PubMed:10626797). Abundantly expressed CC in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in CC high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed CC in various renal cell carcinoma cell lines (PubMed:10626797). Expressed CC in cochlea including the organ of Corti, the lateral wall, the CC interdental cells of the Limbus as well as in Schwann cells and cells CC of the cochlear nerve and the spiral ganglions (at protein level). Not CC expressed in cells of the inner and outer sulcus or the Reissner's CC membrane (at protein level) (PubMed:20627126, PubMed:21364656). CC {ECO:0000269|PubMed:10626797, ECO:0000269|PubMed:14741722, CC ECO:0000269|PubMed:16329164, ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:21364656}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent and peaks at CC mitosis. {ECO:0000269|PubMed:18591255}. CC -!- INDUCTION: Up-regulated by COMP. {ECO:0000269|PubMed:17993464}. CC -!- DOMAIN: The BIR repeat is necessary and sufficient for LAMTOR5 binding. CC {ECO:0000269|PubMed:12773388}. CC -!- PTM: Ubiquitinated by the Cul9-RING ubiquitin-protein ligase complex, CC leading to its degradation. Ubiquitination is required for centrosomal CC targeting. Deubiquitinated by USP35 or USP38; leading to stabilization CC (PubMed:34438346). {ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:24793696, ECO:0000269|PubMed:34438346}. CC -!- PTM: In vitro phosphorylation at Thr-117 by AURKB prevents interaction CC with INCENP and localization to mitotic chromosomes (PubMed:14610074). CC Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti- CC apoptotic activities (PubMed:21252625). Phosphorylation at Thr-34 by CC CDK15 is critical for its anti-apoptotic activity (PubMed:24866247). CC Phosphorylation at Ser-20 by AURKC is critical for regulation of proper CC chromosome alignment and segregation, and possibly cytokinesis. CC {ECO:0000269|PubMed:11069302, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:21252625, ECO:0000269|PubMed:24866247, CC ECO:0000269|PubMed:27332895}. CC -!- PTM: Acetylation at Lys-129 by CBP results in its homodimerization, CC while deacetylation promotes the formation of monomers which CC heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The CC acetylated form represses STAT3 transactivation. The dynamic CC equilibrium between its acetylation and deacetylation at Lys-129 CC determines its interaction with XPO1/CRM1, its subsequent subcellular CC localization, and its ability to inhibit STAT3 transactivation. CC {ECO:0000269|PubMed:20826784}. CC -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U75285; AAC51660.1; -; Genomic_DNA. DR EMBL; AF077350; AAD34226.1; -; mRNA. DR EMBL; AB154416; BAD11155.1; -; mRNA. DR EMBL; AY830084; AAW22624.1; -; mRNA. DR EMBL; AB028869; BAA93676.1; -; mRNA. DR EMBL; AY927772; AAY15202.1; -; mRNA. DR EMBL; DQ227257; ABB76601.1; -; mRNA. DR EMBL; DQ310375; ABC42341.1; -; mRNA. DR EMBL; DQ310376; ABC42342.1; -; mRNA. DR EMBL; DQ310377; ABC42343.1; -; mRNA. DR EMBL; DQ310378; ABC42344.1; -; mRNA. DR EMBL; DQ310379; ABC42345.1; -; mRNA. DR EMBL; CR541740; CAG46540.1; -; mRNA. DR EMBL; AK223428; BAD97148.1; -; mRNA. DR EMBL; AK311917; BAG34858.1; -; mRNA. DR EMBL; AY795969; AAV40840.1; -; Genomic_DNA. DR EMBL; AC087645; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89514.1; -; Genomic_DNA. DR EMBL; BC008718; AAH08718.1; -; mRNA. DR EMBL; BC034148; AAH34148.1; -; mRNA. DR EMBL; BC065497; AAH65497.1; -; mRNA. DR CCDS; CCDS11755.1; -. [O15392-1] DR CCDS; CCDS32751.1; -. [O15392-3] DR CCDS; CCDS32752.1; -. [O15392-2] DR RefSeq; NP_001012270.1; NM_001012270.2. [O15392-3] DR RefSeq; NP_001012271.1; NM_001012271.1. DR RefSeq; NP_001159.2; NM_001168.2. DR PDB; 1E31; X-ray; 2.71 A; A/B=1-142. DR PDB; 1F3H; X-ray; 2.58 A; A/B=1-142. DR PDB; 1XOX; NMR; -; A/B=1-117. DR PDB; 2QFA; X-ray; 1.40 A; A=1-142. DR PDB; 2RAW; X-ray; 2.40 A; A=1-142. DR PDB; 2RAX; X-ray; 3.30 A; A/E/X=1-120. DR PDB; 3UEC; X-ray; 2.18 A; A=1-142. DR PDB; 3UED; X-ray; 2.70 A; A/C=1-142. DR PDB; 3UEE; X-ray; 2.61 A; A/C=1-142. DR PDB; 3UEF; X-ray; 2.45 A; A/C=1-142. DR PDB; 3UEG; X-ray; 2.80 A; A/B=1-142. DR PDB; 3UEH; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UEI; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIG; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UIH; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UII; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UIJ; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIK; X-ray; 2.70 A; A/B=1-142. DR PDB; 4A0I; X-ray; 2.60 A; A/B=1-142. DR PDB; 4A0J; X-ray; 2.80 A; A/B=1-142. DR PDB; 4A0N; X-ray; 2.74 A; A=1-142. DR PDB; 6SHO; X-ray; 3.20 A; A/B=1-142. DR PDB; 6YIE; X-ray; 3.49 A; A/D=1-142. DR PDB; 6YIF; X-ray; 1.81 A; A=1-142. DR PDB; 6YIH; X-ray; 2.55 A; A=1-142. DR PDB; 7LBK; X-ray; 2.70 A; A/B=1-142. DR PDB; 7LBO; X-ray; 2.50 A; A/B=1-142. DR PDB; 7LBP; X-ray; 2.60 A; A/C=1-142. DR PDB; 7LBQ; X-ray; 2.69 A; A=1-142. DR PDB; 8RUP; EM; 2.42 A; K=1-142. DR PDBsum; 1E31; -. DR PDBsum; 1F3H; -. DR PDBsum; 1XOX; -. DR PDBsum; 2QFA; -. DR PDBsum; 2RAW; -. DR PDBsum; 2RAX; -. DR PDBsum; 3UEC; -. DR PDBsum; 3UED; -. DR PDBsum; 3UEE; -. DR PDBsum; 3UEF; -. DR PDBsum; 3UEG; -. DR PDBsum; 3UEH; -. DR PDBsum; 3UEI; -. DR PDBsum; 3UIG; -. DR PDBsum; 3UIH; -. DR PDBsum; 3UII; -. DR PDBsum; 3UIJ; -. DR PDBsum; 3UIK; -. DR PDBsum; 4A0I; -. DR PDBsum; 4A0J; -. DR PDBsum; 4A0N; -. DR PDBsum; 6SHO; -. DR PDBsum; 6YIE; -. DR PDBsum; 6YIF; -. DR PDBsum; 6YIH; -. DR PDBsum; 7LBK; -. DR PDBsum; 7LBO; -. DR PDBsum; 7LBP; -. DR PDBsum; 7LBQ; -. DR PDBsum; 8RUP; -. DR AlphaFoldDB; O15392; -. DR BMRB; O15392; -. DR EMDB; EMD-19513; -. DR SASBDB; O15392; -. DR SMR; O15392; -. DR BioGRID; 106829; 111. DR ComplexPortal; CPX-111; Survivin homodimer complex. DR ComplexPortal; CPX-116; Chromosomal passenger complex. DR CORUM; O15392; -. DR DIP; DIP-34662N; -. DR ELM; O15392; -. DR FunCoup; O15392; 1567. DR IntAct; O15392; 57. DR MINT; O15392; -. DR STRING; 9606.ENSP00000301633; -. DR BindingDB; O15392; -. DR ChEMBL; CHEMBL5989; -. DR DrugBank; DB16095; APG-1387. DR DrugBank; DB04115; Berberine. DR DrugBank; DB12085; LCL-161. DR DrugBank; DB05141; LY2181308. DR DrugBank; DB00206; Reserpine. DR DrugBank; DB16305; Xevinapant. DR DrugCentral; O15392; -. DR GuidetoPHARMACOLOGY; 2795; -. DR MEROPS; I32.005; -. DR iPTMnet; O15392; -. DR PhosphoSitePlus; O15392; -. DR BioMuta; BIRC5; -. DR jPOST; O15392; -. DR MassIVE; O15392; -. DR PeptideAtlas; O15392; -. DR ProteomicsDB; 48627; -. [O15392-1] DR ProteomicsDB; 48628; -. [O15392-2] DR ProteomicsDB; 48629; -. [O15392-3] DR ProteomicsDB; 48630; -. [O15392-4] DR ProteomicsDB; 48631; -. [O15392-5] DR ProteomicsDB; 48632; -. [O15392-6] DR ProteomicsDB; 48633; -. [O15392-7] DR Pumba; O15392; -. DR ABCD; O15392; 5 sequenced antibodies. DR Antibodypedia; 1073; 1831 antibodies from 53 providers. DR DNASU; 332; -. DR Ensembl; ENST00000374948.6; ENSP00000364086.1; ENSG00000089685.16. [O15392-3] DR Ensembl; ENST00000590449.1; ENSP00000465868.1; ENSG00000089685.16. [O15392-7] DR Ensembl; ENST00000590925.6; ENSP00000467336.1; ENSG00000089685.16. [O15392-4] DR Ensembl; ENST00000592734.5; ENSP00000466617.1; ENSG00000089685.16. [O15392-6] DR GeneID; 332; -. DR KEGG; hsa:332; -. DR UCSC; uc002jvh.4; human. [O15392-1] DR AGR; HGNC:593; -. DR CIViC; 332; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA25362; -. DR CTD; 332; -. DR DisGeNET; 332; -. DR GeneCards; BIRC5; -. DR HGNC; HGNC:593; BIRC5. DR HPA; ENSG00000089685; Tissue enhanced (bone marrow, lymphoid tissue, testis). DR MIM; 603352; gene. DR OpenTargets; ENSG00000089685; -. DR VEuPathDB; HostDB:ENSG00000089685; -. DR GeneTree; ENSGT00510000047537; -. DR HOGENOM; CLU_1869818_0_0_1; -. DR InParanoid; O15392; -. DR OrthoDB; 2196114at2759; -. DR PAN-GO; O15392; 6 GO annotations based on evolutionary models. DR PathwayCommons; O15392; -. DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-68877; Mitotic Prometaphase. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation. DR SignaLink; O15392; -. DR SIGNOR; O15392; -. DR Agora; ENSG00000089685; -. DR BioGRID-ORCS; 332; 826 hits in 1161 CRISPR screens. DR CD-CODE; 3F4CB227; Synthetic Condensate 000322. DR CD-CODE; 45F3D8EC; Synthetic Condensate 000342. DR CD-CODE; 7230F6EA; Synthetic Condensate 000328. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BIRC5; human. DR EvolutionaryTrace; O15392; -. DR GeneWiki; Survivin; -. DR GenomeRNAi; 332; -. DR Pharos; O15392; Tchem. DR PRO; PR:O15392; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O15392; protein. DR Bgee; ENSG00000089685; Expressed in ventricular zone and 127 other cell types or tissues. DR ExpressionAtlas; O15392; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IPI:UniProtKB. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0031021; C:interphase microtubule organizing center; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:1990713; C:survivin complex; IPI:ComplexPortal. DR GO; GO:0050897; F:cobalt ion binding; NAS:UniProtKB. DR GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW. DR GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IMP:UniProtKB. DR GO; GO:0050000; P:chromosome localization; IMP:UniProtKB. DR GO; GO:0007059; P:chromosome segregation; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; NAS:ComplexPortal. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal. DR GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal. DR GO; GO:0031503; P:protein-containing complex localization; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IEP:UniProtKB. DR CDD; cd00022; BIR; 1. DR DisProt; DP03719; -. DR FunFam; 1.10.1170.10:FF:000009; Baculoviral IAP repeat-containing protein 5; 1. DR Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1. DR IDEAL; IID00186; -. DR InterPro; IPR051190; Baculoviral_IAP. DR InterPro; IPR001370; BIR_rpt. DR PANTHER; PTHR46771:SF3; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; 1. DR PANTHER; PTHR46771; DETERIN; 1. DR Pfam; PF00653; BIR; 1. DR SMART; SM00238; BIR; 1. DR SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1. DR PROSITE; PS50143; BIR_REPEAT_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell cycle; KW Cell division; Centromere; Chromosome; Chromosome partition; Cytoplasm; KW Cytoskeleton; Host-virus interaction; Kinetochore; Metal-binding; KW Microtubule; Mitosis; Nucleus; Phosphoprotein; Protease inhibitor; KW Proteomics identification; Reference proteome; Repressor; KW Thiol protease inhibitor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc. FT CHAIN 1..142 FT /note="Baculoviral IAP repeat-containing protein 5" FT /id="PRO_0000122356" FT REPEAT 18..88 FT /note="BIR" FT BINDING 57 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 60 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 77 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 84 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT SITE 126 FT /note="Interaction with FBXL7" FT /evidence="ECO:0000269|PubMed:25778398" FT MOD_RES 20 FT /note="Phosphoserine; by AURKC" FT /evidence="ECO:0000269|PubMed:27332895" FT MOD_RES 23 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 34 FT /note="Phosphothreonine; by CDK1 and CDK15" FT /evidence="ECO:0000269|PubMed:11069302, FT ECO:0000269|PubMed:24866247, ECO:0007744|PubMed:18691976" FT MOD_RES 48 FT /note="Phosphothreonine; by CK2; in vitro" FT /evidence="ECO:0000269|PubMed:21252625" FT MOD_RES 90 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 110 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 112 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 115 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 117 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:14610074" FT MOD_RES 121 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 129 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MQRKPTIRRKNLRKLRRKCAVPSSSWLPWIEASGRSCL FT VPEWLHHFQGLFPGATSLPVGPLAMS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10626797" FT /id="VSP_020338" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MRELC (in isoform 6)" FT /evidence="ECO:0000303|Ref.8" FT /id="VSP_020339" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> M (in isoform 7)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_020340" FT VAR_SEQ 74 FT /note="I -> IGPGTVAYACNTSTLGGRGGRITR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10626797, ECO:0000303|Ref.6" FT /id="VSP_002454" FT VAR_SEQ 105..142 FT /note="DRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD -> VRETLPPPRS FT FIR (in isoform 5)" FT /evidence="ECO:0000303|PubMed:16329164" FT /id="VSP_020341" FT VAR_SEQ 114..142 FT /note="AKETNNKKKEFEETAKKVRRAIEQLAAMD -> ERALLAE (in isoform FT 4)" FT /evidence="ECO:0000303|PubMed:14741722" FT /id="VSP_020342" FT VARIANT 129 FT /note="K -> E (loss of acetylation; localization primarily FT within the cytoplasm; increased likelihood of existing as FT monomer; stronger binding to XPO1/CRM1; dbSNP:rs2071214)" FT /evidence="ECO:0000269|PubMed:16625196, FT ECO:0000269|PubMed:20826784" FT /id="VAR_021071" FT MUTAGEN 18 FT /note="R->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 23 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-62; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 25 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 33 FT /note="C->R: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 34 FT /note="T->A: Loss of LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 34 FT /note="T->E: Higher affinity for LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 48 FT /note="T->A,E: Localizes normally during mitosis but cannot FT support cell proliferation. Increased affinity for FT CDCA8/borealin." FT /evidence="ECO:0000269|PubMed:21252625" FT MUTAGEN 57 FT /note="C->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 62 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 65 FT /note="E->A: Almost abolishes RAN-binding. Does not disrupt FT binding to AURKB or CDCA8. Disrupts mitotic spindle FT assembly. Does not disrupt nuclear export." FT /evidence="ECO:0000269|PubMed:18591255" FT MUTAGEN 67 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 70 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-71." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 71 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-70." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 78 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 79 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-78." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 84 FT /note="C->A: Loss of cytoprotection." FT MUTAGEN 90..91 FT /note="KK->RR: Loss of FBXL7 mediated polyubiquitination." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 117 FT /note="T->A: Prevents phosphorylation by AURKB. Still able FT to localize correctly but prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 117 FT /note="T->E: Mimics phosphorylation. Disrupts subcellular FT localization during mitosis and prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 126 FT /note="E->A: Loss of FBXL7 binding." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 129 FT /note="K->A,Q: Mimics acetylation. Localization primarily FT within the nucleus." FT /evidence="ECO:0000269|PubMed:20826784" FT MUTAGEN 129 FT /note="K->R: Loss of acetylation. Localization primarily FT within the cytoplasm." FT /evidence="ECO:0000269|PubMed:20826784" FT CONFLICT 57..58 FT /note="CF -> WV (in Ref. 5; AAW22624)" FT /evidence="ECO:0000305" FT CONFLICT 58 FT /note="F -> L (in Ref. 11; BAD97148)" FT /evidence="ECO:0000305" FT CONFLICT 128 FT /note="A -> V (in Ref. 9; CAG46540)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 11..13 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 15..20 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 35..40 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 43..45 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 49..51 FT /evidence="ECO:0007829|PDB:3UIG" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 73..80 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:1F3H" FT HELIX 85..88 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 98..139 FT /evidence="ECO:0007829|PDB:2QFA" SQ SEQUENCE 142 AA; 16389 MW; 9E7CADCDF2822286 CRC64; MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK KKEFEETAKK VRRAIEQLAA MD // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID CADH1_HUMAN Reviewed; 882 AA. AC P12830; A8K1U7; Q13799; Q14216; Q15855; Q16194; Q4PJ14; Q9UII8; DT 01-OCT-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1993, sequence version 3. DT 28-JAN-2026, entry version 271. DE RecName: Full=Cadherin-1 {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=CAM 120/80; DE AltName: Full=Epithelial cadherin {ECO:0000305}; DE Short=E-cadherin {ECO:0000312|HGNC:HGNC:1748}; DE AltName: Full=Uvomorulin {ECO:0000303|PubMed:8459805}; DE AltName: CD_antigen=CD324; DE Contains: DE RecName: Full=E-Cad/CTF1; DE Contains: DE RecName: Full=E-Cad/CTF2; DE Contains: DE RecName: Full=E-Cad/CTF3; DE Flags: Precursor; GN Name=CDH1 {ECO:0000312|HGNC:HGNC:1748}; GN Synonyms=CDHE, UVO {ECO:0000312|HGNC:HGNC:1748}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=8459805; DOI=10.1007/bf00996219; RA Bussemakers M.J.G., Mees S.G.M., van Bokhoven A., Debruyne F.M.J., RA Schalken J.A.; RT "Molecular cloning and characterization of the human E-cadherin cDNA."; RL Mol. Biol. Rep. 17:123-128(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT 274-GLY--PRO-277 DEL. RX PubMed=8127895; DOI=10.1073/pnas.91.5.1858; RA Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., RA Sugimura T., Hirohashi S.; RT "E-cadherin gene mutations in human gastric carcinoma cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1858-1862(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=8185635; DOI=10.1006/bbrc.1994.1656; RA Rimm D.L., Morrow J.S.; RT "Molecular cloning of human E-cadherin suggests a novel subdivision of the RT cadherin superfamily."; RL Biochem. Biophys. Res. Commun. 200:1754-1761(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 586-591, RP PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION. RC TISSUE=Epidermal carcinoma; RX PubMed=10597309; DOI=10.1038/sj.onc.1203191; RA Ito K., Okamoto I., Araki N., Kawano Y., Nakao M., Fujiyama S., Tomita K., RA Mimori T., Saya H.; RT "Calcium influx triggers the sequential proteolysis of extracellular and RT cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from RT cell-cell contacts."; RL Oncogene 18:7080-7090(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Shibamoto S., Fukudome Y., Yanagihara K.; RT "Mutant E-cadherin."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hippocampus, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-478; THR-617; MET-832 RP AND LYS-880. RG NIEHS SNPs program; RL Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RX PubMed=8093045; DOI=10.1006/bbrc.1994.2321; RA Bussemakers M.J.G., Giroldi L.A., van Bokhoven A., Schalken J.A.; RT "Transcriptional regulation of the human E-cadherin gene in human prostate RT cancer cell lines: characterization of the human E-cadherin gene RT promoter."; RL Biochem. Biophys. Res. Commun. 203:1284-1290(1994). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16. RC TISSUE=Placenta; RX PubMed=7543680; DOI=10.1073/pnas.92.16.7416; RA Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S.; RT "Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in RT human carcinomas."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7416-7419(1995). RN [12] RP INTERACTION WITH CTNNB1 AND PKP2. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [13] RP INTERACTION WITH PIP5K1C. RX PubMed=17261850; DOI=10.1083/jcb.200606023; RA Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G., RA Anderson R.A.; RT "Type I gamma phosphatidylinositol phosphate kinase modulates adherens RT junction and E-cadherin trafficking via a direct interaction with mu 1B RT adaptin."; RL J. Cell Biol. 176:343-353(2007). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 56-882. RC TISSUE=Placenta; RX PubMed=7601454; DOI=10.1016/0888-7543(95)80212-5; RA Berx G., Staes K., van Hengel J., Molemans F., Bussemakers M.J.G., RA van Bokhoven A., van Roy F.; RT "Cloning and characterization of the human invasion suppressor gene E- RT cadherin (CDH1)."; RL Genomics 26:281-289(1995). RN [15] RP PROTEIN SEQUENCE OF 155-174, AND FUNCTION AS L.MONOCYTOGENES RECEPTOR RP (MICROBIAL INFECTION). RX PubMed=8601315; DOI=10.1016/s0092-8674(00)81070-3; RA Mengaud J., Ohayon H., Gounon P., Mege R.M., Cossart P.; RT "E-cadherin is the receptor for internalin, a surface protein required for RT entry of L. monocytogenes into epithelial cells."; RL Cell 84:923-932(1996). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 172-311 (ISOFORM 1/2), AND TISSUE RP SPECIFICITY. RC TISSUE=Liver; RX PubMed=3263290; DOI=10.1111/j.1432-0436.1988.tb00593.x; RA Mansouri A., Spurr N., Goodfellow P.N., Kemler R.; RT "Characterization and chromosomal localization of the gene encoding the RT human cell adhesion molecule uvomorulin."; RL Differentiation 38:67-71(1988). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 265-392 (ISOFORM 1). RC TISSUE=Liver; RA Frixen U.H.; RL Submitted (MAR-1990) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-476, AND VARIANTS ALA-370 AND RP ASP-473. RX PubMed=8033105; RA Becker K.-F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., RA Hoefler H.; RT "E-cadherin gene mutations provide clues to diffuse type gastric RT carcinomas."; RL Cancer Res. 54:3845-3852(1994). RN [19] RP PROTEIN SEQUENCE OF 701-714 AND 732-742, PROTEOLYTIC PROCESSING BY RP GAMMA-SECRETASE/PS1 AND A MEMBRANE-BOUND METALLOPROTEINASE, AND MUTAGENESIS RP OF 759-GLY--GLY-761. RX PubMed=11953314; DOI=10.1093/emboj/21.8.1948; RA Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., RA Baki L., Wen P., Efthimiopoulos S., Shao Z., Wisniewski T., Robakis N.K.; RT "A presenilin-1/gamma-secretase cleavage releases the E-cadherin RT intracellular domain and regulates disassembly of adherens junctions."; RL EMBO J. 21:1948-1956(2002). RN [20] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION). RX PubMed=23532847; DOI=10.1074/jbc.m113.459875; RA Sumitomo T., Nakata M., Higashino M., Terao Y., Kawabata S.; RT "Group A streptococcal cysteine protease cleaves epithelial junctions and RT contributes to bacterial translocation."; RL J. Biol. Chem. 288:13317-13324(2013). RN [21] RP DOMAIN CATENIN-BINDING. RX PubMed=2349235; DOI=10.1073/pnas.87.11.4246; RA Ozawa M., Ringwald M., Kemler R.; RT "Uvomorulin-catenin complex formation is regulated by a specific domain in RT the cytoplasmic region of the cell adhesion molecule."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4246-4250(1990). RN [22] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [23] RP FUNCTION AS L.MONOCYTOGENES RECEPTOR (MICROBIAL INFECTION), AND MUTAGENESIS RP OF PRO-170. RX PubMed=10406800; DOI=10.1093/emboj/18.14.3956; RA Lecuit M., Dramsi S., Gottardi C., Fedor-Chaiken M., Gumbiner B., RA Cossart P.; RT "A single amino acid in E-cadherin responsible for host specificity towards RT the human pathogen Listeria monocytogenes."; RL EMBO J. 18:3956-3963(1999). RN [24] RP PROTEOLYTIC PROCESSING. RX PubMed=11076937; DOI=10.1074/jbc.m006102200; RA Steinhusen U., Weiske J., Badock V., Tauber R., Bommert K., Huber O.; RT "Cleavage and shedding of E-cadherin after induction of apoptosis."; RL J. Biol. Chem. 276:4972-4980(2001). RN [25] RP INTERACTION WITH PSEN1. RX PubMed=11226248; DOI=10.1073/pnas.041603398; RA Baki L., Marambaud P., Efthimiopoulos S., Georgakopoulos A., Wen P., RA Cui W., Shioi J., Koo E., Ozawa M., Friedrich V.L., Robakis N.K.; RT "Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 RT association, and regulates stability and function of the cadherin/catenin RT adhesion complex."; RL Proc. Natl. Acad. Sci. U.S.A. 98:2381-2386(2001). RN [26] RP INTERCHAIN DISULFIDE BOND. RX PubMed=11856755; DOI=10.1074/jbc.m200916200; RA Makagiansar I.T., Nguyen P.D., Ikesue A., Kuczera K., Dentler W., RA Urbauer J.L., Galeva N., Alterman M., Siahaan T.J.; RT "Disulfide bond formation promotes the cis- and trans-dimerization of the RT E-cadherin-derived first repeat."; RL J. Biol. Chem. 277:16002-16010(2002). RN [27] RP FUNCTION. RX PubMed=11976333; DOI=10.1074/jbc.m201984200; RA Meigs T.E., Fedor-Chaiken M., Kaplan D.D., Brackenbury R., Casey P.J.; RT "Galpha12 and Galpha13 negatively regulate the adhesive functions of RT cadherin."; RL J. Biol. Chem. 277:24594-24600(2002). RN [28] RP INTERACTION WITH DLGAP5, AND SUBCELLULAR LOCATION. RX PubMed=14699157; DOI=10.1074/jbc.m309843200; RA Laprise P., Viel A., Rivard N.; RT "Human homolog of disc-large is required for adherens junction assembly and RT differentiation of human intestinal epithelial cells."; RL J. Biol. Chem. 279:10157-10166(2004). RN [29] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [30] RP INTERACTION WITH CTNND1. RX PubMed=15240885; DOI=10.1073/pnas.0401366101; RA Krakstad B.F., Ardawatia V.V., Aragay A.M.; RT "A role for Galpha12/Galpha13 in p120ctn regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10314-10319(2004). RN [31] RP INTERACTION WITH PSEN1 AND CTNNB1, AND MUTAGENESIS OF 759-GLY--GLY-761. RX PubMed=16126725; DOI=10.1074/jbc.m507503200; RA Serban G., Kouchi Z., Baki L., Georgakopoulos A., Litterst C.M., Shioi J., RA Robakis N.K.; RT "Cadherins mediate both the association between PS1 and beta-catenin and RT the effects of PS1 on beta-catenin stability."; RL J. Biol. Chem. 280:36007-36012(2005). RN [32] RP SUBCELLULAR LOCATION. RX PubMed=15689490; DOI=10.1091/mbc.e04-10-0867; RA Lock J.G., Stow J.L.; RT "Rab11 in recycling endosomes regulates the sorting and basolateral RT transport of E-cadherin."; RL Mol. Biol. Cell 16:1744-1755(2005). RN [33] RP FUNCTION OF E-CAD/CTF2. RX PubMed=16417575; DOI=10.1111/j.1471-4159.2005.03616.x; RA Agiostratidou G., Muros R.M., Shioi J., Marambaud P., Robakis N.K.; RT "The cytoplasmic sequence of E-cadherin promotes non-amyloidogenic RT degradation of A beta precursors."; RL J. Neurochem. 96:1182-1188(2006). RN [34] RP INDUCTION. RX PubMed=17893710; DOI=10.1038/cr.2007.79; RA Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q., Mu Y.-M.; RT "Induction of the LRP16 gene by estrogen promotes the invasive growth of RT Ishikawa human endometrial cancer cells through the downregulation of E- RT cadherin."; RL Cell Res. 17:869-880(2007). RN [35] RP INVOLVEMENT IN LBC. RX PubMed=17660459; DOI=10.1136/jmg.2007.051268; RA Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., RA Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., RA Collins L., Schnitt S., Garber J.E., Huntsman D.; RT "Germline E-cadherin mutations in familial lobular breast cancer."; RL J. Med. Genet. 44:726-731(2007). RN [36] RP SUBCELLULAR LOCATION. RX PubMed=18343367; DOI=10.1016/j.yexcr.2008.01.031; RA Kanno M., Isa Y., Aoyama Y., Yamamoto Y., Nagai M., Ozawa M., Kitajima Y.; RT "P120-catenin is a novel desmoglein 3 interacting partner: identification RT of the p120-catenin association site of desmoglein 3."; RL Exp. Cell Res. 314:1683-1692(2008). RN [37] RP GLYCOSYLATION AT ASN-558; ASN-570; ASN-622 AND ASN-637, AND MUTAGENESIS OF RP ASN-637. RX PubMed=18491227; DOI=10.1007/s10719-008-9133-9; RA Zhou F., Su J., Fu L., Yang Y., Zhang L., Wang L., Zhao H., Zhang D., RA Li Z., Zha X.; RT "Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded RT incorrectly and arrested in endoplasmic reticulum, then sequentially RT degraded by ERAD."; RL Glycoconj. J. 25:727-740(2008). RN [38] RP INTERACTION WITH LIMA1. RX PubMed=18093941; DOI=10.1073/pnas.0710504105; RA Abe K., Takeichi M.; RT "EPLIN mediates linkage of the cadherin catenin complex to F-actin and RT stabilizes the circumferential actin belt."; RL Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008). RN [39] RP REVIEW ON CADHERINS. RX PubMed=20066110; DOI=10.1101/cshperspect.a003053; RA Shapiro L., Weis W.I.; RT "Structure and biochemistry of cadherins and catenins."; RL Cold Spring Harb. Perspect. Biol. 1:A3053-A3053(2009). RN [40] RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=19403558; DOI=10.1093/hmg/ddp194; RA Pinho S.S., Reis C.A., Paredes J., Magalhaes A.M., Ferreira A.C., RA Figueiredo J., Xiaogang W., Carneiro F., Gaertner F., Seruca R.; RT "The role of N-acetylglucosaminyltransferase III and V in the post- RT transcriptional modifications of E-cadherin."; RL Hum. Mol. Genet. 18:2599-2608(2009). RN [41] RP INTERACTION WITH TBC1D2. RX PubMed=20116244; DOI=10.1016/j.cub.2009.12.053; RA Frasa M.A., Maximiano F.C., Smolarczyk K., Francis R.E., Betson M.E., RA Lozano E., Goldenring J., Seabra M.C., Rak A., Ahmadian M.R., Braga V.M.; RT "Armus is a Rac1 effector that inactivates Rab7 and regulates E-cadherin RT degradation."; RL Curr. Biol. 20:198-208(2010). RN [42] RP SUBCELLULAR LOCATION, AND INTERACTION WITH DDR1. RX PubMed=20432435; DOI=10.1002/jcp.22134; RA Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C., RA Wang H.M., Wang C.Z.; RT "DDR1 regulates the stabilization of cell surface E-cadherin and E- RT cadherin-mediated cell aggregation."; RL J. Cell. Physiol. 224:387-397(2010). RN [43] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [44] RP SUBCELLULAR LOCATION. RX PubMed=20859650; DOI=10.1007/s00018-010-0531-3; RA Gosavi P., Kundu S.T., Khapare N., Sehgal L., Karkhanis M.S., Dalal S.N.; RT "E-cadherin and plakoglobin recruit plakophilin3 to the cell border to RT initiate desmosome assembly."; RL Cell. Mol. Life Sci. 68:1439-1454(2011). RN [45] RP UBIQUITINATION BY CBLL1. RX PubMed=21283129; DOI=10.1038/cr.2011.17; RA Zhou W.J., Geng Z.H., Chi S., Zhang W., Niu X.F., Lan S.J., Ma L., Yang X., RA Wang L.J., Ding Y.Q., Geng J.G.; RT "Slit-Robo signaling induces malignant transformation through Hakai- RT mediated E-cadherin degradation during colorectal epithelial cell RT carcinogenesis."; RL Cell Res. 21:609-626(2011). RN [46] RP UBIQUITINATION BY A SKP2-CONTAINING SCF COMPLEX, AND PHOSPHORYLATION BY RP CSNK1A1. RX PubMed=22770219; DOI=10.1016/j.cell.2012.05.038; RA Inuzuka H., Gao D., Finley L.W., Yang W., Wan L., Fukushima H., Chin Y.R., RA Zhai B., Shaik S., Lau A.W., Wang Z., Gygi S.P., Nakayama K., RA Teruya-Feldstein J., Toker A., Haigis M.C., Pandolfi P.P., Wei W.; RT "Acetylation-dependent regulation of Skp2 function."; RL Cell 150:179-193(2012). RN [47] RP PHOSPHORYLATION AT TYR-753; TYR-754 AND TYR-755, AND MUTAGENESIS OF RP TYR-754. RX PubMed=22252131; DOI=10.1038/emboj.2011.496; RA Mukherjee M., Chow S.Y., Yusoff P., Seetharaman J., Ng C., Sinniah S., RA Koh X.W., Asgar N.F., Li D., Yim D., Jackson R.A., Yew J., Qian J., Iyu A., RA Lim Y.P., Zhou X., Sze S.K., Guy G.R., Sivaraman J.; RT "Structure of a novel phosphotyrosine-binding domain in Hakai that targets RT E-cadherin."; RL EMBO J. 31:1308-1319(2012). RN [48] RP INTERACTION WITH DSG3, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-770 AND SER-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [50] RP IDENTIFICATION IN A COMPLEX WITH PKP3 AND RAP1A, INTERACTION WITH PKP3 AND RP RAP1A, AND SUBCELLULAR LOCATION. RX PubMed=25208567; DOI=10.1091/mbc.e14-05-0968; RA Todorovic V., Koetsier J.L., Godsel L.M., Green K.J.; RT "Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens RT junction maturation."; RL Mol. Biol. Cell 25:3749-3764(2014). RN [51] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=27760340; DOI=10.1016/j.immuni.2016.09.014; RA Cronan M.R., Beerman R.W., Rosenberg A.F., Saelens J.W., Johnson M.G., RA Oehlers S.H., Sisk D.M., Jurcic Smith K.L., Medvitz N.A., Miller S.E., RA Trinh L.A., Fraser S.E., Madden J.F., Turner J., Stout J.E., Lee S., RA Tobin D.M.; RT "Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma RT Formation and Promotes Infection."; RL Immunity 45:861-876(2016). RN [52] RP SUBCELLULAR LOCATION. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [53] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-175. RX PubMed=29999492; DOI=10.7554/elife.37629; RA Shafraz O., Ruebsam M., Stahley S.N., Caldara A.L., Kowalczyk A.P., RA Niessen C.M., Sivasankar S.; RT "E-cadherin binds to desmoglein to facilitate desmosome assembly."; RL Elife 7:0-0(2018). RN [54] RP INTERACTION WITH SPEF1. RX PubMed=31473225; DOI=10.1053/j.gastro.2019.08.031; RA Tapia R., Perez-Yepez E.A., Carlino M.J., Karandikar U.C., Kralicek S.E., RA Estes M.K., Hecht G.A.; RT "Sperm Flagellar 1 Binds Actin in Intestinal Epithelial Cells and RT Contributes to Formation of Filopodia and Lamellipodia."; RL Gastroenterology 157:1544-1555(2019). RN [55] RP INDUCTION. RX PubMed=31835537; DOI=10.3390/ijms20246221; RA Uttagomol J., Ahmad U.S., Rehman A., Huang Y., Laly A.C., Kang A., RA Soetaert J., Chance R., Teh M.T., Connelly J.T., Wan H.; RT "Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and RT Phospho-YAP in Keratinocyte Responses to Mechanical Forces."; RL Int. J. Mol. Sci. 20:0-0(2019). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=33596089; DOI=10.1091/mbc.e20-12-0775; RA Raya-Sandino A., Luissint A.C., Kusters D.H.M., Narayanan V., Flemming S., RA Garcia-Hernandez V., Godsel L.M., Green K.J., Hagen S.J., Conway D.E., RA Parkos C.A., Nusrat A.; RT "Regulation of intestinal epithelial intercellular adhesion and barrier RT function by desmosomal cadherin desmocollin-2."; RL Mol. Biol. Cell 32:753-768(2021). RN [57] RP SUBCELLULAR LOCATION. RX PubMed=36309486; DOI=10.1038/s41419-022-05326-2; RA Myo Min K.K., Rojas-Canales D., Penko D., DeNichilo M., Cockshell M.P., RA Ffrench C.B., Thompson E.J., Asplund O., Drogemuller C.J., Prasad R.B., RA Groop L., Grey S.T., Thomas H.E., Loudovaris T., Kay T.W., Mahoney M.G., RA Jessup C.F., Coates P.T., Bonder C.S.; RT "Desmoglein-2 is important for islet function and beta-cell survival."; RL Cell Death Dis. 13:911-911(2022). RN [58] {ECO:0007744|PDB:1O6S} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), SUBUNIT (MICROBIAL RP INFECTION), AND MUTAGENESIS OF TRP-156 AND PRO-170. RX PubMed=12526809; DOI=10.1016/s0092-8674(02)01136-4; RA Schubert W.-D., Urbanke C., Ziehm T., Beier V., Machner M.P., Domann E., RA Wehland J., Chakraborty T., Heinz D.W.; RT "Structure of internalin, a major invasion protein of Listeria RT monocytogenes, in complex with its human receptor E-cadherin."; RL Cell 111:825-836(2002). RN [59] RP REVIEW ON VARIANTS. RX PubMed=9744472; RX DOI=10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d; RA Berx G., Becker K.-F., Hoefler H., van Roy F.; RT "Mutations of the human E-cadherin (CDH1) gene."; RL Hum. Mutat. 12:226-237(1998). RN [60] {ECO:0007744|PDB:2OMV, ECO:0007744|PDB:2OMY} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, FUNCTION (MICROBIAL INFECTION), AND SUBUNIT RP (MICROBIAL INFECTION). RX PubMed=17540170; DOI=10.1016/j.cell.2007.03.049; RA Wollert T., Pasche B., Rochon M., Deppenmeier S., van den Heuvel J., RA Gruber A.D., Heinz D.W., Lengeling A., Schubert W.D.; RT "Extending the host range of Listeria monocytogenes by rational protein RT design."; RL Cell 129:891-902(2007). RN [61] {ECO:0007744|PDB:2OMU, ECO:0007744|PDB:2OMZ} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 156-255 IN COMPLEX WITH RP L.MONOCYTOGENES INLA, AND SUBUNIT (MICROBIAL INFECTION). RX PubMed=17715295; DOI=10.1073/pnas.0702199104; RA Wollert T., Heinz D.W., Schubert W.D.; RT "Thermodynamically reengineering the listerial invasion complex InlA/E- RT cadherin."; RL Proc. Natl. Acad. Sci. U.S.A. 104:13960-13965(2007). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 155-367, AND CALCIUM-BINDING RP SITES. RX PubMed=17850815; DOI=10.1016/j.jmb.2007.08.011; RA Parisini E., Higgins J.M., Liu J.H., Brenner M.B., Wang J.H.; RT "The crystal structure of human E-cadherin domains 1 and 2, and comparison RT with other cadherins in the context of adhesion mechanism."; RL J. Mol. Biol. 373:401-411(2007). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 155-253 IN COMPLEX WITH KLRG1. RX PubMed=19604491; DOI=10.1016/j.immuni.2009.04.019; RA Li Y., Hofmann M., Wang Q., Teng L., Chlewicki L.K., Pircher H., RA Mariuzza R.A.; RT "Structure of natural killer cell receptor KLRG1 bound to E-cadherin RT reveals basis for MHC-independent missing self recognition."; RL Immunity 31:35-46(2009). RN [64] RP VARIANT LOBULAR BREAST CARCINOMA SER-315. RX PubMed=7961105; DOI=10.1111/j.1349-7006.1994.tb02902.x; RA Kanai Y., Oda T., Tsuda H., Ochiai A., Hirohashi S.; RT "Point mutation of the E-cadherin gene in invasive lobular carcinoma of the RT breast."; RL Jpn. J. Cancer Res. 85:1035-1039(1994). RN [65] RP VARIANTS THR-617 AND VAL-711, AND VARIANT OVARIAN CANCER GLY-838. RX PubMed=8075649; DOI=10.1038/ng0594-98; RA Risinger J.I., Berchuck A., Kohler M.F., Boyd J.; RT "Mutations of the E-cadherin gene in human gynecologic cancers."; RL Nat. Genet. 7:98-102(1994). RN [66] RP VARIANT PRO-193. RX PubMed=8797891; DOI=10.1111/j.1349-7006.1996.tb02109.x; RA Muta H., Noguchi M., Kanai Y., Ochiai A., Nawata H., Hirohashi S.; RT "E-cadherin gene mutations in signet ring cell carcinoma of the stomach."; RL Jpn. J. Cancer Res. 87:843-848(1996). RN [67] RP VARIANTS ASP-400 DEL AND 418-ASP--PHE-423 DEL. RX PubMed=9045944; DOI=10.1111/j.1349-7006.1996.tb03125.x; RA Tamura G., Sakata K., Nishizuka S., Maesawa C., Suzuki Y., Iwaya T., RA Terashima M., Saito K., Satodate R.; RT "Inactivation of the E-cadherin gene in primary gastric carcinomas and RT gastric carcinoma cell lines."; RL Jpn. J. Cancer Res. 87:1153-1159(1996). RN [68] RP VARIANT THYROID CANCER THR-592. RX PubMed=8985087; RX DOI=10.1002/(sici)1097-0215(19970106)70:1<32::aid-ijc5>3.0.co;2-7; RA Soares P., Berx G., van Roy F., Sobrinho-Simoes M.; RT "E-cadherin gene alterations are rare events in thyroid tumors."; RL Int. J. Cancer 70:32-38(1997). RN [69] RP VARIANT DGLBC ASP-336, AND VARIANT ILE-470. RX PubMed=9537325; DOI=10.1038/32918; RA Guilford P.J., Hopkins J.B.W., Harraway J., McLeod M., McLeod N., RA Harawira P., Taite H., Scoular R., Miller A., Reeve A.E.; RT "E-cadherin germline mutations in familial gastric cancer."; RL Nature 392:402-405(1998). RN [70] RP VARIANTS DGLBC GLY-244 AND ALA-487. RX PubMed=10319582; DOI=10.1007/s100380050137; RA Yoon K.-A., Ku J.-L., Yang H.-K., Kim W.H., Park S.Y., Park J.-G.; RT "Germline mutations of E-cadherin gene in Korean familial gastric cancer RT patients."; RL J. Hum. Genet. 44:177-180(1999). RN [71] RP VARIANT ALA-340. RX PubMed=10896919; DOI=10.1136/gut.47.2.262; RA Kim H.C., Wheeler J.M.D., Kim J.C., Ilyas M., Beck N.E., Kim B.S., RA Park K.C., Bodmer W.F.; RT "The E-cadherin gene (CDH1) variants T340A and L599V in gastric and RT colorectal cancer patients in Korea."; RL Gut 47:262-267(2000). RN [72] RP VARIANT ALA-270. RX PubMed=11705864; RA Ikonen T., Matikainen M., Mononen N., Hyytinen E.R., Helin H.J., RA Tommola S., Tammela T.L., Pukkala E., Schleutker J., Kallioniemi O.-P., RA Koivisto P.A.; RT "Association of E-cadherin germ-line alterations with prostate cancer."; RL Clin. Cancer Res. 7:3465-3471(2001). RN [73] RP VARIANT THR-592. RX PubMed=11562785; DOI=10.3892/ijmm.8.4.439; RA Salahshor S., Hou H., Diep C.B., Loukola A., Zhang H., Liu T., Chen J., RA Iselius L., Rubio C., Lothe R.A., Aaltonen L., Sun X.F., Lindmark G., RA Lindblom A.; RT "A germline E-cadherin mutation in a family with gastric and colon RT cancer."; RL Int. J. Mol. Med. 8:439-443(2001). RN [74] RP VARIANT ALA-340. RX PubMed=11968083; DOI=10.1002/humu.10068; RA Oliveira C., Bordin M.C., Grehan N., Huntsman D., Suriano G., Machado J.C., RA Kiviluoto T., Aaltonen L., Jackson C.E., Seruca R., Caldas C.; RT "Screening E-cadherin in gastric cancer families reveals germline mutations RT only in hereditary diffuse gastric cancer kindred."; RL Hum. Mutat. 19:510-517(2002). RN [75] RP VARIANT DGLBC MET-832. RX PubMed=12216071; DOI=10.1002/ijc.10633; RA Yabuta T., Shinmura K., Tani M., Yamaguchi S., Yoshimura K., Katai H., RA Nakajima T., Mochiki E., Tsujinaka T., Takami M., Hirose K., Yamaguchi A., RA Takenoshita S., Yokota J.; RT "E-cadherin gene variants in gastric cancer families whose probands are RT diagnosed with diffuse gastric cancer."; RL Int. J. Cancer 101:434-441(2002). RN [76] RP VARIANTS THR-617 AND VAL-634, AND CHARACTERIZATION OF VARIANTS ALA-340; RP THR-617 AND VAL-634. RX PubMed=12588804; DOI=10.1093/hmg/ddg048; RA Suriano G., Oliveira C., Ferreira P., Machado J.C., Bordin M.C., RA De Wever O., Bruyneel E.A., Moguilevsky N., Grehan N., Porter T.R., RA Richards F.M., Hruban R.H., Roviello F., Huntsman D., Mareel M., RA Carneiro F., Caldas C., Seruca R.; RT "Identification of CDH1 germline missense mutations associated with RT functional inactivation of the E-cadherin protein in young gastric cancer RT probands."; RL Hum. Mol. Genet. 12:575-582(2003). RN [77] RP VARIANTS ILE-282 AND ASN-777. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [78] RP INVOLVEMENT IN BCDS1, VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, RP CHARACTERIZATION OF VARIANTS BCDS1 TYR-254; VAL-257 AND VAL-454 DEL, AND RP SUBCELLULAR LOCATION. RX PubMed=28301459; DOI=10.1038/gim.2017.11; RA Ghoumid J., Stichelbout M., Jourdain A.S., Frenois F., Lejeune-Dumoulin S., RA Alex-Cordier M.P., Lebrun M., Guerreschi P., Duquennoy-Martinot V., RA Vinchon M., Ferri J., Jung M., Vicaire S., Vanlerberghe C., Escande F., RA Petit F., Manouvrier-Hanu S.; RT "Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to RT mutations in CDH1 and CTNND1."; RL Genet. Med. 19:1013-1021(2017). CC -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins CC (PubMed:11976333). They preferentially interact with themselves in a CC homophilic manner in connecting cells; cadherins may thus contribute to CC the sorting of heterogeneous cell types. CDH1 is involved in mechanisms CC regulating cell-cell adhesions, mobility and proliferation of CC epithelial cells (PubMed:11976333). Promotes organization of radial CC actin fiber structure and cellular response to contractile forces, via CC its interaction with AMOTL2 which facilitates anchoring of radial actin CC fibers to CDH1 junction complexes at the cell membrane (By similarity). CC Plays a role in the early stages of desmosome cell-cell junction CC formation via facilitating the recruitment of DSG2 and DSP to desmosome CC plaques (PubMed:29999492). Has a potent invasive suppressor role. It is CC a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, CC ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, CC ECO:0000269|PubMed:29999492}. CC -!- FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta CC precursors. Has a strong inhibitory effect on APP C99 and C83 CC production. {ECO:0000269|PubMed:16417575}. CC -!- FUNCTION: (Microbial infection) Serves as a receptor for Listeria CC monocytogenes; internalin A (InlA) binds to this protein and promotes CC uptake of the bacteria. {ECO:0000269|PubMed:10406800, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:8601315}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11856755). Component of an CC E-cadherin/ catenin adhesion complex composed of at least E- CC cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and CC potentially alpha-catenin/CTNNA1; the complex is located to adherens CC junctions (PubMed:16126725, PubMed:7982500). Found in a complex CC composed of CDH1, RAP1A and PKP3; PKP3 acts as a scaffold protein CC within the complex, the complex is required for CDH1 localization to CC mature desmosome cell junctions (PubMed:25208567). Interacts with the CC TRPV4 and CTNNB1 complex (By similarity). Interacts with CTNND1 CC (PubMed:15240885). The stable association of CTNNA1 is controversial as CC CTNNA1 was shown not to bind to F-actin when assembled in the complex CC (By similarity). Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1 (By similarity). CC Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of CC cadherin-based adherens junctions (CAJs) (PubMed:11226248, CC PubMed:16126725). Interacts with AJAP1 and DLGAP5 (PubMed:14595118, CC PubMed:14699157). Interacts with TBC1D2 (PubMed:20116244). Interacts CC with LIMA1 (PubMed:18093941). Interacts with CAV1. Interacts with CC PIP5K1C (PubMed:17261850). Interacts with RAB8B (By similarity). CC Interacts with RAPGEF2 (By similarity). Interacts with DDR1; this CC stabilizes CDH1 at the cell surface and inhibits its internalization CC (PubMed:20432435). Interacts with KLRG1 (PubMed:19604491). Forms a CC ternary complex composed of ADAM10, CADH1 and EPHA4; within the CC complex, CADH1 is cleaved by ADAM10 which disrupts adherens junctions CC (By similarity). Interacts with SPEF1 (PubMed:31473225). Interacts with CC CTNNB1 and PKP2 (PubMed:11790773). Interacts with AMOTL2; the CC interaction may facilitate binding of radial actin fibers to cell CC junction complexes (By similarity). Interacts with DSG3; the CC interaction is required for CDH1 localization to developing adherens CC junctions (PubMed:22294297). {ECO:0000250, CC ECO:0000250|UniProtKB:F1PAA9, ECO:0000250|UniProtKB:P09803, CC ECO:0000250|UniProtKB:Q9R0T4, ECO:0000269|PubMed:11226248, CC ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:11856755, CC ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:14595118, CC ECO:0000269|PubMed:14699157, ECO:0000269|PubMed:15240885, CC ECO:0000269|PubMed:16126725, ECO:0000269|PubMed:17261850, CC ECO:0000269|PubMed:18093941, ECO:0000269|PubMed:19604491, CC ECO:0000269|PubMed:20116244, ECO:0000269|PubMed:20432435, CC ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:25208567, CC ECO:0000269|PubMed:31473225, ECO:0000269|PubMed:7982500}. CC -!- SUBUNIT: (Microbial infection) Interacts with L.monocytogenes InlA CC (PubMed:12526809, PubMed:17540170, PubMed:17715295). The formation of CC the complex between InlA and cadherin-1 is calcium-dependent CC (PubMed:12526809). {ECO:0000269|PubMed:12526809, CC ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295}. CC -!- INTERACTION: CC P12830; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-727477, EBI-10176008; CC P12830; P30260: CDC27; NbExp=2; IntAct=EBI-727477, EBI-994813; CC P12830; P12830: CDH1; NbExp=8; IntAct=EBI-727477, EBI-727477; CC P12830; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-727477, EBI-21670927; CC P12830; P35221: CTNNA1; NbExp=8; IntAct=EBI-727477, EBI-701918; CC P12830; P35222: CTNNB1; NbExp=23; IntAct=EBI-727477, EBI-491549; CC P12830; O60716: CTNND1; NbExp=9; IntAct=EBI-727477, EBI-701927; CC P12830; P49184: DNASE1L1; NbExp=3; IntAct=EBI-727477, EBI-20894690; CC P12830; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-727477, EBI-1054039; CC P12830; P00533: EGFR; NbExp=4; IntAct=EBI-727477, EBI-297353; CC P12830; P16422: EPCAM; NbExp=3; IntAct=EBI-727477, EBI-1171184; CC P12830; P11362: FGFR1; NbExp=3; IntAct=EBI-727477, EBI-1028277; CC P12830; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-727477, EBI-10975491; CC P12830; Q9UHB6: LIMA1; NbExp=2; IntAct=EBI-727477, EBI-351479; CC P12830; P43356: MAGEA2B; NbExp=3; IntAct=EBI-727477, EBI-5650739; CC P12830; Q7Z434: MAVS; NbExp=3; IntAct=EBI-727477, EBI-995373; CC P12830; P08581: MET; NbExp=2; IntAct=EBI-727477, EBI-1039152; CC P12830; Q8NCR3: MFI; NbExp=3; IntAct=EBI-727477, EBI-744790; CC P12830; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-727477, EBI-25834188; CC P12830; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-727477, EBI-3446748; CC P12830; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-727477, EBI-11750983; CC P12830; Q8N323: NXPE1; NbExp=3; IntAct=EBI-727477, EBI-25834085; CC P12830; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-727477, EBI-473160; CC P12830; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-727477, EBI-2557132; CC P12830; P62136: PPP1CA; NbExp=2; IntAct=EBI-727477, EBI-357253; CC P12830; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-727477, EBI-2860740; CC P12830; P17612: PRKACA; NbExp=3; IntAct=EBI-727477, EBI-476586; CC P12830; Q15139: PRKD1; NbExp=7; IntAct=EBI-727477, EBI-1181072; CC P12830; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-727477, EBI-709652; CC P12830; P49768: PSEN1; NbExp=2; IntAct=EBI-727477, EBI-297277; CC P12830; P50454: SERPINH1; NbExp=3; IntAct=EBI-727477, EBI-350723; CC P12830; Q02978: SLC25A11; NbExp=3; IntAct=EBI-727477, EBI-359174; CC P12830; P12931: SRC; NbExp=2; IntAct=EBI-727477, EBI-621482; CC P12830; P48775: TDO2; NbExp=3; IntAct=EBI-727477, EBI-743494; CC P12830; P37173: TGFBR2; NbExp=3; IntAct=EBI-727477, EBI-296151; CC P12830; Q9BT49: THAP7; NbExp=3; IntAct=EBI-727477, EBI-741350; CC P12830; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-727477, EBI-1220488; CC P12830; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-727477, EBI-1037322; CC P12830; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-727477, EBI-25830993; CC P12830; Q9BQ29; NbExp=3; IntAct=EBI-727477, EBI-22013570; CC P12830; A0A0S2C3P2: cagA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-55025805; CC P12830; Q9JIY2: Cbll1; Xeno; NbExp=21; IntAct=EBI-727477, EBI-7644904; CC P12830; P0DJM0: inlA; Xeno; NbExp=3; IntAct=EBI-727477, EBI-1035388; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:18343367, ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:27760340, ECO:0000269|PubMed:28169360}. Cell CC membrane {ECO:0000269|PubMed:19403558, ECO:0000269|PubMed:20859650, CC ECO:0000269|PubMed:28301459, ECO:0000269|PubMed:36309486}; Single-pass CC type I membrane protein. Endosome {ECO:0000269|PubMed:15689490}. Golgi CC apparatus, trans-Golgi network {ECO:0000269|PubMed:15689490}. Cytoplasm CC {ECO:0000269|PubMed:22294297}. Cell junction, desmosome CC {ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492, CC ECO:0000269|PubMed:33596089}. Note=Colocalizes with DLGAP5 at sites of CC cell-cell contact in intestinal epithelial cells. Anchored to actin CC microfilaments through association with alpha-, beta- and gamma- CC catenin. Sequential proteolysis induced by apoptosis or calcium influx, CC results in translocation from sites of cell-cell contact to the CC cytoplasm. Colocalizes with RAB11A endosomes during its transport from CC the Golgi apparatus to the plasma membrane. Recruited to desmosomes at CC the initial assembly phase and also accumulates progressively at mature CC desmosome cell-cell junctions (PubMed:25208567, PubMed:29999492). CC Localizes to cell-cell contacts as keratinocyte differentiation CC progresses (By similarity). {ECO:0000250|UniProtKB:P09803, CC ECO:0000269|PubMed:25208567, ECO:0000269|PubMed:29999492}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P12830-1; Sequence=Displayed; CC Name=2; CC IsoId=P12830-2; Sequence=VSP_055586; CC -!- TISSUE SPECIFICITY: Expressed in granuloma macrophages (at protein CC level) (PubMed:27760340). Expressed in the skin (at protein level) CC (PubMed:22294297). Expressed in the liver (PubMed:3263290). CC {ECO:0000269|PubMed:22294297, ECO:0000269|PubMed:27760340, CC ECO:0000269|PubMed:3263290}. CC -!- INDUCTION: Induced in the hours following cyclic mechanical strain in CC keratinocytes (PubMed:31835537). Expression is repressed by MACROD1 CC (PubMed:17893710). {ECO:0000269|PubMed:17893710, CC ECO:0000269|PubMed:31835537}. CC -!- DOMAIN: Three calcium ions are usually bound at the interface of each CC cadherin domain and strengthen the connections, imparting a strong CC curvature to the full-length ectodomain. {ECO:0000269|PubMed:2349235}. CC -!- PTM: During apoptosis or with calcium influx, cleaved by a membrane- CC bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 CC (PubMed:10597309, PubMed:11076937, PubMed:11953314). Processing by the CC metalloproteinase, induced by calcium influx, causes disruption of CC cell-cell adhesion and the subsequent release of beta-catenin into the CC cytoplasm (PubMed:10597309). The residual membrane-tethered cleavage CC product is rapidly degraded via an intracellular proteolytic pathway CC (PubMed:10597309). Cleavage by caspase-3 releases the cytoplasmic tail CC resulting in disintegration of the actin microfilament system CC (PubMed:11076937). The gamma-secretase-mediated cleavage promotes CC disassembly of adherens junctions (PubMed:11953314). During development CC of the cochlear organ of Corti, cleavage by ADAM10 at adherens CC junctions promotes pillar cell separation (By similarity). CC {ECO:0000250|UniProtKB:P09803, ECO:0000269|PubMed:10597309, CC ECO:0000269|PubMed:11076937, ECO:0000269|PubMed:11953314}. CC -!- PTM: N-glycosylation at Asn-637 is essential for expression, folding CC and trafficking. Addition of bisecting N-acetylglucosamine by MGAT3 CC modulates its cell membrane location (PubMed:19403558). CC {ECO:0000269|PubMed:18491227, ECO:0000269|PubMed:19403558}. CC -!- PTM: Ubiquitinated by a SCF complex containing SKP2, which requires CC prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, CC requires prior phosphorylation at Tyr-754. CC {ECO:0000269|PubMed:21283129, ECO:0000269|PubMed:22252131, CC ECO:0000269|PubMed:22770219}. CC -!- PTM: O-glycosylated. O-manosylated by TMTC1, TMTC2, TMTC3 or TMTC4. CC Thr-285 and Thr-509 are O-mannosylated by TMTC2 or TMTC4 but not TMTC1 CC or TMTC3. {ECO:0000250|UniProtKB:P09803}. CC -!- PTM: (Microbial infection) Cleaved by S.pyogenes SpeB protease; leading CC to its degradation (PubMed:23532847). Degradation by SpeB promotes CC bacterial translocation across the host epithelial barrier CC (PubMed:23532847). {ECO:0000269|PubMed:23532847}. CC -!- DISEASE: Diffuse gastric and lobular breast cancer syndrome (DGLBC) CC [MIM:137215]: A cancer predisposition syndrome with increased CC susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a CC malignant disease characterized by poorly differentiated infiltrating CC lesions resulting in thickening of the stomach. Malignant tumors start CC in the stomach, can spread to the esophagus or the small intestine, and CC can extend through the stomach wall to nearby lymph nodes and organs. CC It also can metastasize to other parts of the body. In addition to CC gastric cancer, most female mutation carriers develop lobular carcinoma CC of the breast. {ECO:0000269|PubMed:10319582, CC ECO:0000269|PubMed:12216071, ECO:0000269|PubMed:9537325}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. Heterozygous CDH1 germline mutations are CC responsible for familial cases of diffuse gastric cancer. Somatic CC mutations has also been found in patients with sporadic diffuse gastric CC cancer and lobular breast cancer. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:8075649}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Breast cancer, lobular (LBC) [MIM:137215]: A type of breast CC cancer that begins in the milk-producing glands (lobules) of the CC breast. {ECO:0000269|PubMed:17660459}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Blepharocheilodontic syndrome 1 (BCDS1) [MIM:119580]: A form CC of blepharocheilodontic syndrome, a rare autosomal dominant disorder. CC It is characterized by lower eyelid ectropion, upper eyelid CC distichiasis, euryblepharon, bilateral cleft lip and palate, and CC features of ectodermal dysplasia, including hair anomalies, conical CC teeth and tooth agenesis. An additional rare manifestation is CC imperforate anus. There is considerable phenotypic variability among CC affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: May play a role in blister formation in Pemphigus CC vulgaris patients, expression is lost at sites of cell-cell contact CC between the basal and suprabasal layers in blisters and immediately CC adjacent to blisters. {ECO:0000269|PubMed:22294297}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA61259.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/166/CDH1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=E-cadherin entry; CC URL="https://en.wikipedia.org/wiki/E-cadherin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z13009; CAA78353.1; -; mRNA. DR EMBL; Z18923; CAA79356.1; -; mRNA. DR EMBL; L08599; AAA61259.1; ALT_FRAME; mRNA. DR EMBL; AB025105; BAA88956.1; -; mRNA. DR EMBL; AK290012; BAF82701.1; -; mRNA. DR EMBL; AK312551; BAG35448.1; -; mRNA. DR EMBL; DQ090940; AAY68225.1; -; Genomic_DNA. DR EMBL; AC099314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471092; EAW83243.1; -; Genomic_DNA. DR EMBL; CH471092; EAW83244.1; -; Genomic_DNA. DR EMBL; L34545; AAA21764.1; -; Genomic_DNA. DR EMBL; D49685; BAA08537.1; -; Genomic_DNA. DR EMBL; Z35402; CAA84586.1; -; Genomic_DNA. DR EMBL; Z35403; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35404; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35405; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35406; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35407; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35408; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35409; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35410; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35411; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35412; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35413; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35414; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; Z35415; CAA84586.1; JOINED; Genomic_DNA. DR EMBL; X12790; CAA31279.1; -; mRNA. DR EMBL; X52279; CAA36522.1; -; mRNA. DR EMBL; S72492; AAD14108.1; -; Genomic_DNA. DR EMBL; S72397; AAD14108.1; JOINED; Genomic_DNA. DR EMBL; S72491; AAD14108.1; JOINED; Genomic_DNA. DR CCDS; CCDS10869.1; -. [P12830-1] DR CCDS; CCDS82005.1; -. [P12830-2] DR PIR; S37654; IJHUCE. DR RefSeq; NP_001304113.1; NM_001317184.2. [P12830-2] DR RefSeq; NP_001304114.1; NM_001317185.1. DR RefSeq; NP_001304115.1; NM_001317186.1. DR RefSeq; NP_004351.1; NM_004360.5. [P12830-1] DR PDB; 1O6S; X-ray; 1.80 A; B=156-255. DR PDB; 2O72; X-ray; 2.00 A; A=155-367. DR PDB; 2OMT; X-ray; 2.00 A; B=156-255. DR PDB; 2OMU; X-ray; 1.80 A; B=156-255. DR PDB; 2OMV; X-ray; 1.90 A; B=156-255. DR PDB; 2OMX; X-ray; 1.70 A; B=156-258. DR PDB; 2OMY; X-ray; 1.70 A; B=156-254. DR PDB; 2OMZ; X-ray; 1.60 A; B=156-254. DR PDB; 3FF7; X-ray; 1.80 A; A/B=155-253. DR PDB; 3FF8; X-ray; 2.00 A; A/B=155-254. DR PDB; 3L6X; X-ray; 2.40 A; B=756-773. DR PDB; 3L6Y; X-ray; 3.00 A; B/D/F=756-773. DR PDB; 4ZT1; X-ray; 1.92 A; A/B=157-367. DR PDB; 4ZTE; X-ray; 2.13 A; A/B=157-367. DR PDB; 6CXY; X-ray; 2.20 A; C=155-371. DR PDB; 6OLE; EM; 3.10 A; y=693-730. DR PDB; 6OLF; EM; 3.90 A; y=693-730. DR PDB; 6OLG; EM; 3.40 A; A=693-730. DR PDB; 6VEL; X-ray; 2.65 A; C=155-371. DR PDB; 7STZ; X-ray; 2.95 A; C/D=155-698. DR PDB; 8H62; X-ray; 1.91 A; B=155-367. DR PDBsum; 1O6S; -. DR PDBsum; 2O72; -. DR PDBsum; 2OMT; -. DR PDBsum; 2OMU; -. DR PDBsum; 2OMV; -. DR PDBsum; 2OMX; -. DR PDBsum; 2OMY; -. DR PDBsum; 2OMZ; -. DR PDBsum; 3FF7; -. DR PDBsum; 3FF8; -. DR PDBsum; 3L6X; -. DR PDBsum; 3L6Y; -. DR PDBsum; 4ZT1; -. DR PDBsum; 4ZTE; -. DR PDBsum; 6CXY; -. DR PDBsum; 6OLE; -. DR PDBsum; 6OLF; -. DR PDBsum; 6OLG; -. DR PDBsum; 6VEL; -. DR PDBsum; 7STZ; -. DR PDBsum; 8H62; -. DR AlphaFoldDB; P12830; -. DR EMDB; EMD-25883; -. DR EMDB; EMD-25884; -. DR EMDB; EMD-25886; -. DR EMDB; EMD-25892; -. DR SMR; P12830; -. DR BioGRID; 107434; 777. DR CORUM; P12830; -. DR DIP; DIP-477N; -. DR ELM; P12830; -. DR FunCoup; P12830; 811. DR IntAct; P12830; 146. DR MINT; P12830; -. DR STRING; 9606.ENSP00000261769; -. DR BindingDB; P12830; -. DR ChEMBL; CHEMBL2321609; -. DR TCDB; 8.A.204.1.1; the cadhesin (cdh) family. DR UniLectin; P12830; -. DR GlyCosmos; P12830; 13 sites, No reported glycans. DR GlyGen; P12830; 16 sites, 2 O-linked glycans (3 sites). DR iPTMnet; P12830; -. DR PhosphoSitePlus; P12830; -. DR SwissPalm; P12830; -. DR BioMuta; CDH1; -. DR DMDM; 399166; -. DR CPTAC; CPTAC-1599; -. DR CPTAC; CPTAC-5772; -. DR CPTAC; CPTAC-5773; -. DR CPTAC; non-CPTAC-5366; -. DR CPTAC; non-CPTAC-5367; -. DR CPTAC; non-CPTAC-5370; -. DR CPTAC; non-CPTAC-5541; -. DR CPTAC; non-CPTAC-5542; -. DR jPOST; P12830; -. DR MassIVE; P12830; -. DR PaxDb; 9606-ENSP00000261769; -. DR PeptideAtlas; P12830; -. DR ProteomicsDB; 52879; -. [P12830-1] DR ProteomicsDB; 84533; -. DR Pumba; P12830; -. DR TopDownProteomics; P12830-2; -. [P12830-2] DR ABCD; P12830; 29 sequenced antibodies. DR Antibodypedia; 1347; 3254 antibodies from 63 providers. DR CPTC; P12830; 4 antibodies. DR DNASU; 999; -. DR Ensembl; ENST00000261769.10; ENSP00000261769.4; ENSG00000039068.21. [P12830-1] DR Ensembl; ENST00000422392.6; ENSP00000414946.2; ENSG00000039068.21. [P12830-2] DR GeneID; 999; -. DR KEGG; hsa:999; -. DR MANE-Select; ENST00000261769.10; ENSP00000261769.4; NM_004360.5; NP_004351.1. DR UCSC; uc002ewg.2; human. [P12830-1] DR AGR; HGNC:1748; -. DR CIViC; 999; 4 evidence items across 4 molecular profiles. DR ClinPGx; PA26282; -. DR CTD; 999; -. DR DisGeNET; 999; -. DR GeneCards; CDH1; -. DR GeneReviews; CDH1; -. DR HGNC; HGNC:1748; CDH1. DR HPA; ENSG00000039068; Tissue enhanced (parathyroid). DR MalaCards; CDH1; -. DR MIM; 119580; phenotype. DR MIM; 137215; phenotype. DR MIM; 167000; phenotype. DR MIM; 192090; gene. DR MIM; 608089; phenotype. DR OpenTargets; ENSG00000039068; -. DR Orphanet; 1997; Blepharo-cheilo-odontic syndrome. DR Orphanet; 199306; Cleft lip/palate. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 26106; Hereditary diffuse gastric cancer. DR VEuPathDB; HostDB:ENSG00000039068; -. DR eggNOG; KOG3594; Eukaryota. DR GeneTree; ENSGT00940000157175; -. DR HOGENOM; CLU_005284_2_1_1; -. DR InParanoid; P12830; -. DR OrthoDB; 6079678at2759; -. DR PAN-GO; P12830; 8 GO annotations based on evolutionary models. DR PhylomeDB; P12830; -. DR PathwayCommons; P12830; -. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9764562; Regulation of CDH1 mRNA translation by microRNAs. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR Reactome; R-HSA-9926550; Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P12830; -. DR SIGNOR; P12830; -. DR Agora; ENSG00000039068; -. DR BioGRID-ORCS; 999; 47 hits in 1173 CRISPR screens. DR ChiTaRS; CDH1; human. DR EvolutionaryTrace; P12830; -. DR GeneWiki; CDH1_(gene); -. DR GenomeRNAi; 999; -. DR Pharos; P12830; Tbio. DR PRO; PR:P12830; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P12830; protein. DR Bgee; ENSG00000039068; Expressed in jejunal mucosa and 158 other cell types or tissues. DR ExpressionAtlas; P12830; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0043296; C:apical junction complex; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0030057; C:desmosome; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0016600; C:flotillin complex; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005802; C:trans-Golgi network; IMP:BHF-UCL. DR GO; GO:0030506; F:ankyrin binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0098631; F:cell adhesion mediator activity; IDA:UniProt. DR GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0032794; F:GTPase activating protein binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl. DR GO; GO:0034332; P:adherens junction organization; IMP:UniProtKB. DR GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000902; P:cell morphogenesis; IBA:GO_Central. DR GO; GO:0098609; P:cell-cell adhesion; IDA:BHF-UCL. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:0007043; P:cell-cell junction assembly; IBA:GO_Central. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0071285; P:cellular response to lithium ion; IDA:UniProtKB. DR GO; GO:0002159; P:desmosome assembly; IMP:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; NAS:UniProtKB. DR GO; GO:0030517; P:negative regulation of axon extension; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:ARUK-UCL. DR GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0031175; P:neuron projection development; IEA:Ensembl. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL. DR GO; GO:1903829; P:positive regulation of protein localization; IMP:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0099576; P:regulation of protein catabolic process at postsynapse, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0071503; P:response to heparin; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd00031; CA_like; 1. DR CDD; cd11304; Cadherin_repeat; 3. DR FunFam; 2.60.40.60:FF:000011; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000191; Cadherin 1; 1. DR FunFam; 2.60.40.60:FF:000019; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000022; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000027; Cadherin 2; 1. DR FunFam; 4.10.900.10:FF:000001; Cadherin 2; 1. DR FunFam; 2.60.40.60:FF:000031; Cadherin 3; 1. DR Gene3D; 2.60.40.60; Cadherins; 6. DR Gene3D; 4.10.900.10; TCF3-CBD (Catenin binding domain); 1. DR InterPro; IPR039808; Cadherin. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR020894; Cadherin_CS. DR InterPro; IPR014868; Cadherin_pro_dom. DR InterPro; IPR000233; Cadherin_Y-type_LIR. DR InterPro; IPR027397; Catenin-bd_sf. DR PANTHER; PTHR24027:SF319; CADHERIN-1; 1. DR PANTHER; PTHR24027; CADHERIN-23; 1. DR Pfam; PF01049; CADH_Y-type_LIR; 1. DR Pfam; PF00028; Cadherin; 5. DR Pfam; PF08758; Cadherin_pro; 1. DR PRINTS; PR00205; CADHERIN. DR SMART; SM00112; CA; 4. DR SMART; SM01055; Cadherin_pro; 1. DR SUPFAM; SSF49313; Cadherin-like; 6. DR PROSITE; PS00232; CADHERIN_1; 3. DR PROSITE; PS50268; CADHERIN_2; 5. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell junction; KW Cell membrane; Cleavage on pair of basic residues; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Endosome; Glycoprotein; Golgi apparatus; Membrane; KW Metal-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix; KW Ubl conjugation. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..154 FT /evidence="ECO:0000255" FT /id="PRO_0000003715" FT CHAIN 155..882 FT /note="Cadherin-1" FT /id="PRO_0000003716" FT CHAIN 701..882 FT /note="E-Cad/CTF1" FT /id="PRO_0000236067" FT CHAIN 732..882 FT /note="E-Cad/CTF2" FT /id="PRO_0000236068" FT CHAIN 751..882 FT /note="E-Cad/CTF3" FT /id="PRO_0000236069" FT TOPO_DOM 155..709 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 710..730 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 731..882 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 155..262 FT /note="Cadherin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 263..375 FT /note="Cadherin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 376..486 FT /note="Cadherin 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 487..593 FT /note="Cadherin 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 594..697 FT /note="Cadherin 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT REGION 747..767 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 758..769 FT /note="Required for binding CTNND1 and PSEN1" FT REGION 811..882 FT /note="Required for binding alpha, beta and gamma catenins" FT COMPBIAS 755..767 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 257 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 288 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT SITE 364..365 FT /note="Cleavage; by S.pyogenes SpeB" FT /evidence="ECO:0000269|PubMed:23532847" FT SITE 700..701 FT /note="Cleavage; by a metalloproteinase" FT SITE 731..732 FT /note="Cleavage; by gamma-secretase/PS1" FT SITE 750..751 FT /note="Cleavage; by caspase-3" FT MOD_RES 753 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 754 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 755 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:22252131" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 793 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 838 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 840 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT MOD_RES 846 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 280 FT /note="O-linked (Man...) serine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 285 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 358 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 470 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 472 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 509 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 570 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 576 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 578 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 580 FT /note="O-linked (Man...) threonine" FT /evidence="ECO:0000250|UniProtKB:P09803" FT CARBOHYD 622 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT CARBOHYD 637 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18491227" FT DISULFID 163 FT /note="Interchain" FT VAR_SEQ 380..440 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_055586" FT VARIANT 72 FT /note="D -> N (in dbSNP:rs35606263)" FT /id="VAR_048500" FT VARIANT 123 FT /note="H -> Y (in a gastric cancer sample; FT dbSNP:rs1555514482)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001306" FT VARIANT 193 FT /note="T -> P (in a diffuse gastric cancer sample; FT dbSNP:rs1597891014)" FT /evidence="ECO:0000269|PubMed:8797891" FT /id="VAR_001307" FT VARIANT 244 FT /note="D -> G (in DGLBC; likely benign; FT dbSNP:rs1064794231)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008712" FT VARIANT 254 FT /note="D -> Y (in BCDS1; abolishes protein abundance; loss FT of cell membrane localization; dbSNP:rs1555515445)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079392" FT VARIANT 257 FT /note="D -> V (in BCDS1; slightly decreases protein FT abundance; loss of cell membrane localization; FT dbSNP:rs1555515446)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079393" FT VARIANT 270 FT /note="S -> A (in dbSNP:rs587776399)" FT /evidence="ECO:0000269|PubMed:11705864" FT /id="VAR_013970" FT VARIANT 274..277 FT /note="Missing (found in gastric carcinoma cell lines)" FT /evidence="ECO:0000269|PubMed:8127895" FT /id="VAR_001308" FT VARIANT 282 FT /note="M -> I (in a breast cancer sample; somatic mutation; FT dbSNP:rs200932258)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033026" FT VARIANT 315 FT /note="N -> S (in lobular breast carcinoma)" FT /evidence="ECO:0000269|PubMed:7961105" FT /id="VAR_001309" FT VARIANT 336 FT /note="E -> D (in DGLBC; likely pathogenic; FT dbSNP:rs267606712)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001310" FT VARIANT 340 FT /note="T -> A (found in gastric and colorectal cancer FT samples; cells exhibited decreased aggregation increased FT invasiveness and non-uniform migration in vitro compared to FT cells transfected with wild-type sequence; FT dbSNP:rs116093741)" FT /evidence="ECO:0000269|PubMed:10896919, FT ECO:0000269|PubMed:11968083, ECO:0000269|PubMed:12588804" FT /id="VAR_013971" FT VARIANT 370 FT /note="D -> A (in a diffuse gastric cancer sample; FT dbSNP:rs2152132676)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001311" FT VARIANT 393 FT /note="I -> N (in dbSNP:rs34466743)" FT /id="VAR_048501" FT VARIANT 400 FT /note="Missing (in a gastric carcinoma sample; loss of FT heterozygosity)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001312" FT VARIANT 418..423 FT /note="Missing (in a gastric carcinoma sample)" FT /evidence="ECO:0000269|PubMed:9045944" FT /id="VAR_001313" FT VARIANT 454 FT /note="Missing (in BCDS1; decreases protein abundance; loss FT of cell membrane localization)" FT /evidence="ECO:0000269|PubMed:28301459" FT /id="VAR_079394" FT VARIANT 463 FT /note="E -> Q (in a gastric carcinoma sample; FT dbSNP:rs1960961009)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001314" FT VARIANT 470 FT /note="T -> I (in dbSNP:rs370864592)" FT /evidence="ECO:0000269|PubMed:9537325" FT /id="VAR_001315" FT VARIANT 473 FT /note="V -> D (in a diffuse gastric cancer sample; FT dbSNP:rs2152134881)" FT /evidence="ECO:0000269|PubMed:8033105" FT /id="VAR_001317" FT VARIANT 473 FT /note="V -> I (in dbSNP:rs36087757)" FT /id="VAR_048502" FT VARIANT 478 FT /note="L -> P (in dbSNP:rs35520415)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023357" FT VARIANT 487 FT /note="V -> A (in DGLBC; dbSNP:rs1960965342)" FT /evidence="ECO:0000269|PubMed:10319582" FT /id="VAR_008713" FT VARIANT 592 FT /note="A -> T (in dbSNP:rs35187787)" FT /evidence="ECO:0000269|PubMed:11562785, FT ECO:0000269|PubMed:8985087" FT /id="VAR_001318" FT VARIANT 598 FT /note="R -> Q (in a gastric cancer sample; FT dbSNP:rs780759537)" FT /evidence="ECO:0000269|PubMed:9744472" FT /id="VAR_001319" FT VARIANT 617 FT /note="A -> T (detected in an endometrial cancer sample; FT loss of heterozygosity; cells exhibited an intermediate FT phenotype concerning aggregation invasiveness and migration FT in vitro compared to cells transfected with wild-type FT sequence; dbSNP:rs33935154)" FT /evidence="ECO:0000269|PubMed:12588804, FT ECO:0000269|PubMed:8075649, ECO:0000269|Ref.7" FT /id="VAR_001320" FT VARIANT 630 FT /note="L -> V (in dbSNP:rs2276331)" FT /id="VAR_021868" FT VARIANT 634 FT /note="A -> V (found in a gastric cancer sample; cells FT exhibited decreased aggregation increased invasiveness and FT non-uniform migration in vitro compared to cells FT transfected with wild-type sequence; dbSNP:rs121964878)" FT /evidence="ECO:0000269|PubMed:12588804" FT /id="VAR_055431" FT VARIANT 695 FT /note="C -> R (in dbSNP:rs9282655)" FT /id="VAR_021869" FT VARIANT 711 FT /note="L -> V (detected in an endometrial cancer sample; FT dbSNP:rs121964871)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001321" FT VARIANT 777 FT /note="D -> N (in dbSNP:rs372989292)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033027" FT VARIANT 832 FT /note="V -> M (in DGLBC; benign; dbSNP:rs35572355)" FT /evidence="ECO:0000269|PubMed:12216071, ECO:0000269|Ref.7" FT /id="VAR_023358" FT VARIANT 838 FT /note="S -> G (in an ovarian carcinoma sample; somatic FT mutation; loss of heterozygosity; dbSNP:rs121964872)" FT /evidence="ECO:0000269|PubMed:8075649" FT /id="VAR_001322" FT VARIANT 880 FT /note="E -> K (in dbSNP:rs34507583)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_023359" FT MUTAGEN 156 FT /note="W->A,S: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 156 FT /note="W->D: Protein is partially unfolded, no longer binds FT L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->A,E,V: No longer binds L.monocytogenes InlA." FT /evidence="ECO:0000269|PubMed:12526809" FT MUTAGEN 170 FT /note="P->E: No longer adheres to L.monocytogenes InlA FT coated beads, nor do cells take up InlA coated beads." FT /evidence="ECO:0000269|PubMed:10406800" FT MUTAGEN 175 FT /note="L->D: Reduces localization to desmosome cell-cell FT junctions. Also reduces the localization of DSG2 and DSP to FT desmosome cell-cell junctions." FT /evidence="ECO:0000269|PubMed:29999492" FT MUTAGEN 637 FT /note="N->Q: CDH1 becomes a substrate for ERAD and is FT retro-translocated from ER to cytoplasm." FT /evidence="ECO:0000269|PubMed:18491227" FT MUTAGEN 754 FT /note="Y->F: Abolishes binding to CBLL1." FT /evidence="ECO:0000269|PubMed:22252131" FT MUTAGEN 759..761 FT /note="GGG->AAA: Binds to CTNNB1 but abolishes interaction FT of CTNNB1 with PSEN1. Abolishes gamma-secretase cleavage." FT /evidence="ECO:0000269|PubMed:11953314, FT ECO:0000269|PubMed:16126725" FT CONFLICT 10 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 29 FT /note="H -> L (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 47 FT /note="E -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 70..71 FT /note="SL -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 483 FT /note="A -> G (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 530 FT /note="A -> R (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 543 FT /note="S -> F (in Ref. 2; CAA79356)" FT /evidence="ECO:0000305" FT CONFLICT 615 FT /note="I -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 634..636 FT /note="ASA -> RVP (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="R -> P (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT CONFLICT 882 FT /note="D -> H (in Ref. 3; AAA61259)" FT /evidence="ECO:0000305" FT STRAND 163..166 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 169..177 FT /evidence="ECO:0007829|PDB:2OMZ" FT HELIX 181..184 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 189..195 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 213..216 FT /evidence="ECO:0007829|PDB:2OMZ" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:2OMZ" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 265..272 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 292..294 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 301..309 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 316..319 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 321..323 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 325..328 FT /evidence="ECO:0007829|PDB:8H62" FT TURN 335..337 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 340..348 FT /evidence="ECO:0007829|PDB:8H62" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 356..366 FT /evidence="ECO:0007829|PDB:8H62" FT STRAND 374..384 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 394..396 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 410..417 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 423..428 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 429..432 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 433..440 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 444..446 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 448..460 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 470..477 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 485..498 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 522..527 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 533..535 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 537..539 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 541..544 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 557..568 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 576..586 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 594..596 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 599..607 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 610..615 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 622..625 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 627..633 FT /evidence="ECO:0007829|PDB:7STZ" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 638..644 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 648..656 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 660..673 FT /evidence="ECO:0007829|PDB:7STZ" FT STRAND 675..691 FT /evidence="ECO:0007829|PDB:7STZ" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:3L6X" SQ SEQUENCE 882 AA; 97456 MW; E427118043A13C67 CRC64; MGPWSRSLSA LLLLLQVSSW LCQEPEPCHP GFDAESYTFT VPRRHLERGR VLGRVNFEDC TGRQRTAYFS LDTRFKVGTD GVITVKRPLR FHNPQIHFLV YAWDSTYRKF STKVTLNTVG HHHRPPPHQA SVSGIQAELL TFPNSSPGLR RQKRDWVIPP ISCPENEKGP FPKNLVQIKS NKDKEGKVFY SITGQGADTP PVGVFIIERE TGWLKVTEPL DRERIATYTL FSHAVSSNGN AVEDPMEILI TVTDQNDNKP EFTQEVFKGS VMEGALPGTS VMEVTATDAD DDVNTYNAAI AYTILSQDPE LPDKNMFTIN RNTGVISVVT TGLDRESFPT YTLVVQAADL QGEGLSTTAT AVITVTDTND NPPIFNPTTY KGQVPENEAN VVITTLKVTD ADAPNTPAWE AVYTILNDDG GQFVVTTNPV NNDGILKTAK GLDFEAKQQY ILHVAVTNVV PFEVSLTTST ATVTVDVLDV NEAPIFVPPE KRVEVSEDFG VGQEITSYTA QEPDTFMEQK ITYRIWRDTA NWLEINPDTG AISTRAELDR EDFEHVKNST YTALIIATDN GSPVATGTGT LLLILSDVND NAPIPEPRTI FFCERNPKPQ VINIIDADLP PNTSPFTAEL THGASANWTI QYNDPTQESI ILKPKMALEV GDYKINLKLM DNQNKDQVTT LEVSVCDCEG AAGVCRKAQP VEAGLQIPAI LGILGGILAL LILILLLLLF LRRRAVVKEP LLPPEDDTRD NVYYYDEEGG GEEDQDFDLS QLHRGLDARP EVTRNDVAPT LMSVPRYLPR PANPDEIGNF IDENLKAADT DPTAPPYDSL LVFDYEGSGS EAASLSSLNS SESDKDQDYD YLNEWGNRFK KLADMYGGGE DD // ID CASPA_HUMAN Reviewed; 521 AA. AC Q92851; Q68HC0; Q6KF62; Q6KF63; Q8IUP5; Q8WYQ8; Q99845; Q9Y2U6; Q9Y2U7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 3. DT 28-JAN-2026, entry version 241. DE RecName: Full=Caspase-10; DE Short=CASP-10; DE EC=3.4.22.63 {ECO:0000269|PubMed:16916640}; DE AltName: Full=Apoptotic protease Mch-4; DE AltName: Full=FAS-associated death domain protein interleukin-1B-converting enzyme 2; DE Short=FLICE2; DE AltName: Full=ICE-like apoptotic protease 4; DE Contains: DE RecName: Full=Caspase-10 subunit p23/17; DE Contains: DE RecName: Full=Caspase-10 subunit p12; DE Flags: Precursor; GN Name=CASP10; Synonyms=MCH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND VARIANT ILE-479 (ISOFORM B). RC TISSUE=T-cell; RX PubMed=8755496; DOI=10.1073/pnas.93.15.7464; RA Fernandes-Alnemri T., Armstrong R.C., Krebs J.F., Srinivasula S.M., RA Wang L., Bullrich F., Fritz L.C., Trapani J.A., Tomaselli K.J., Litwack G., RA Alnemri E.S.; RT "In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic RT cysteine protease containing two FADD-like domains."; RL Proc. Natl. Acad. Sci. U.S.A. 93:7464-7469(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A). RX PubMed=9045686; DOI=10.1074/jbc.272.10.6578; RA Vincenz C., Dixit V.M.; RT "Fas-associated death domain protein interleukin-1beta-converting enzyme 2 RT (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55- RT mediated death signaling."; RL J. Biol. Chem. 272:6578-6583(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS C AND D), VARIANT ILE-410, AND VARIANT RP ILE-522 (ISOFORM D). RC TISSUE=Spleen, and Thymus; RX PubMed=10187817; DOI=10.1074/jbc.274.15.10301; RA Ng P.W., Porter A.G., Janicke R.U.; RT "Molecular cloning and characterization of two novel pro-apoptotic isoforms RT of caspase-10."; RL J. Biol. Chem. 274:10301-10308(1999). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS A AND B), RP AND VARIANT ILE-479 (ISOFORM B). RX PubMed=11161814; DOI=10.1006/geno.2000.6392; RA Hadano S., Yanagisawa Y., Skaug J., Fichter K., Nasir J., Martindale D., RA Koop B.F., Scherer S.W., Nicholson D.W., Rouleau G.A., Ikeda J.-E., RA Hayden M.R.; RT "Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and RT ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical RT region at chromosome 2q33-q34: candidate genes for ALS2."; RL Genomics 71:200-213(2001). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), AND VARIANT ILE-455 (ISOFORM RP 6). RC TISSUE=Blood; RA Vonarbourg C., Fischer A., Rieux-Laucat F.; RT "A novel human caspase 10 isoform participating in Fas-induced apoptosis."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), AND FUNCTION (ISOFORM 7). RX PubMed=17822854; DOI=10.1016/j.bbagen.2007.07.010; RA Wang H., Wang P., Sun X., Luo Y., Wang X., Ma D., Wu J.; RT "Cloning and characterization of a novel caspase-10 isoform that activates RT NF-kappa B activity."; RL Biochim. Biophys. Acta 1770:1528-1537(2007). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-239; ILE-410; SER-444; RP CYS-446 AND ILE-522 (ISOFORM 2). RG NIEHS SNPs program; RL Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM D). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC PROCESSING. RX PubMed=8962078; DOI=10.1073/pnas.93.25.14486; RA Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E.S.; RT "Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease RT Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like RT cysteine proteases."; RL Proc. Natl. Acad. Sci. U.S.A. 93:14486-14491(1996). RN [12] RP FUNCTION, SELF-ASSOCIATION, INTERACTION WITH FADD, INTERACTION WITH CASP8, RP IDENTIFICATION IN A COMPLEX WITH FAS; FADD AND CASP8, AND MUTAGENESIS OF RP CYS-401. RX PubMed=11717445; DOI=10.1073/pnas.241358198; RA Wang J., Chun H.J., Wong W., Spencer D.M., Lenardo M.J.; RT "Caspase-10 is an initiator caspase in death receptor signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 98:13884-13888(2001). RN [13] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). RN [14] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=15069192; DOI=10.1073/pnas.0307459101; RA McDonald E.R. III, El-Deiry W.S.; RT "Suppression of caspase-8- and -10-associated RING proteins results in RT sensitization to death ligands and inhibition of tumor cell growth."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6170-6175(2004). RN [15] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=16916640; DOI=10.1016/j.molcel.2006.06.020; RA Denault J.B., Bekes M., Scott F.L., Sexton K.M., Bogyo M., Salvesen G.S.; RT "Engineered hybrid dimers: tracking the activation pathway of caspase-7."; RL Mol. Cell 23:523-533(2006). RN [16] RP INTERACTION WITH RIOK3. RX PubMed=19557502; DOI=10.1007/s11010-009-0180-8; RA Shan J., Wang P., Zhou J., Wu D., Shi H., Huo K.; RT "RIOK3 interacts with caspase-10 and negatively regulates the NF-kappaB RT signaling pathway."; RL Mol. Cell. Biochem. 332:113-120(2009). RN [17] RP VARIANT ALPS2A PHE-285, VARIANT ILE-410, AND ALTERNATIVE SPLICING (ISOFORMS RP B AND D). RX PubMed=10412980; DOI=10.1016/s0092-8674(00)80605-4; RA Wang J., Zheng L., Lobito A., Chan F.K., Dale J., Sneller M., Yao X., RA Puck J.M., Straus S.E., Lenardo M.J.; RT "Inherited human caspase 10 mutations underlie defective lymphocyte and RT dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type RT II."; RL Cell 98:47-58(1999). RN [18] RP VARIANT NHL VAL-414. RX PubMed=12010812; DOI=10.1182/blood.v99.11.4094; RA Shin M.S., Kim H.S., Kang C.S., Park W.S., Kim S.Y., Lee S.N., Lee J.H., RA Park J.Y., Jang J.J., Kim C.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.; RT "Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas."; RL Blood 99:4094-4099(2002). RN [19] RP VARIANT GASC THR-147, AND CHARACTERIZATION OF VARIANT GASC THR-147. RX PubMed=11973654; DOI=10.1038/sj.onc.1205394; RA Park W.S., Lee J.H., Shin M.S., Park J.Y., Kim H.S., Lee J.H., Kim Y.S., RA Lee S.N., Xiao W., Park C.H., Lee S.H., Yoo N.J., Lee J.Y.; RT "Inactivating mutations of the caspase-10 gene in gastric cancer."; RL Oncogene 21:2919-2925(2002). RN [20] RP VARIANTS LEU-406; ILE-410 AND CYS-446, AND CHARACTERIZATION OF VARIANTS RP LEU-406; ILE-410 AND CYS-446. RX PubMed=16446975; DOI=10.1007/s00439-006-0138-9; RA Zhu S., Hsu A.P., Vacek M.M., Zheng L., Schaeffer A.A., Dale J.K., RA Davis J., Fischer R.E., Straus S.E., Boruchov D., Saulsbury F.T., RA Lenardo M.J., Puck J.M.; RT "Genetic alterations in caspase-10 may be causative or protective in RT autoimmune lymphoproliferative syndrome."; RL Hum. Genet. 119:284-294(2006). RN [21] RP VARIANT ILE-522 (ISOFORM D), AND RISK FACTOR FOR CUTANEOUS MELANOMA. RX PubMed=18563783; DOI=10.1002/humu.20803; RA Li C., Zhao H., Hu Z., Liu Z., Wang L.-E., Gershenwald J.E., Prieto V.G., RA Lee J.E., Duvic M., Grimm E.A., Wei Q.; RT "Genetic variants and haplotypes of the caspase-8 and caspase-10 genes RT contribute to susceptibility to cutaneous melanoma."; RL Hum. Mutat. 29:1443-1451(2008). RN [22] RP VARIANTS CYS-21 AND PRO-285. RX PubMed=19900088; DOI=10.1080/00313020903041143; RA Kim M.S., Oh J.E., Min C.K., Lee S., Chung N.G., Yoo N.J., Lee S.H.; RT "Mutational analysis of CASP10 gene in acute leukaemias and multiple RT myelomas."; RL Pathology 41:484-487(2009). RN [23] RP VARIANT THR-14. RX PubMed=20025484; DOI=10.3109/00313020903434371; RA Oh J.E., Kim M.S., Ahn C.H., Kim S.S., Han J.Y., Lee S.H., Yoo N.J.; RT "Mutational analysis of CASP10 gene in colon, breast, lung and RT hepatocellular carcinomas."; RL Pathology 42:73-76(2010). RN [24] RP VARIANT LEU-406. RX PubMed=27378136; DOI=10.1016/j.imlet.2016.07.001; RA Tripodi S.I., Mazza C., Moratto D., Ramenghi U., Caorsi R., Gattorno M., RA Badolato R.; RT "Atypical presentation of autoimmune lymphoproliferative syndrome due to RT CASP10 mutation."; RL Immunol. Lett. 177:22-24(2016). RN [25] RP VARIANT LEU-406. RX PubMed=27535533; DOI=10.1038/nature19057; RG Exome Aggregation Consortium; RA Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., RA O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., RA Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J., RA Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M., RA Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N., RA Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P., RA Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A., RA Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G., RA Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M., RA Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C., RA Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M., RA McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M., RA Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P., RA Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G., RA Daly M.J., MacArthur D.G.; RT "Analysis of protein-coding genetic variation in 60,706 humans."; RL Nature 536:285-291(2016). CC -!- FUNCTION: Involved in the activation cascade of caspases responsible CC for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in CC a FADD dependent manner. May participate in the granzyme B apoptotic CC pathways. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CC CASP7, CASP8 and CASP9. Hydrolyzes the small- molecule substrates, Tyr- CC Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. CC {ECO:0000269|PubMed:11717445, ECO:0000269|PubMed:16916640}. CC -!- FUNCTION: Isoform 7 can enhance NF-kappaB activity but promotes only CC slight apoptosis. {ECO:0000269|PubMed:17822854}. CC -!- FUNCTION: Isoform C is proteolytically inactive. CC {ECO:0000269|PubMed:11717445}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Strict requirement for Asp at position P1 and has a preferred CC cleavage sequence of Leu-Gln-Thr-Asp-|-Gly.; EC=3.4.22.63; CC Evidence={ECO:0000269|PubMed:16916640}; CC -!- SUBUNIT: Heterotetramer that consists of two anti-parallel arranged CC heterodimers, each one formed by a 23/17 kDa (p23/17) (depending on the CC splicing events) and a 12 kDa (p12) subunit (By similarity). Self- CC associates. Interacts with FADD and CASP8. Found in a Fas signaling CC complex consisting of FAS, FADD, CASP8 and CASP10. Interacts with RFFL CC and RNF34; negatively regulate CASP10 through proteasomal degradation. CC Interacts with RIOK3. {ECO:0000250, ECO:0000269|PubMed:11717445, CC ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:19557502}. CC -!- INTERACTION: CC Q92851; Q14790: CASP8; NbExp=6; IntAct=EBI-495095, EBI-78060; CC Q92851; O15519: CFLAR; NbExp=3; IntAct=EBI-495095, EBI-514941; CC Q92851; Q13158: FADD; NbExp=4; IntAct=EBI-495095, EBI-494804; CC Q92851; O14730: RIOK3; NbExp=6; IntAct=EBI-495095, EBI-1047061; CC Q92851; Q13546: RIPK1; NbExp=2; IntAct=EBI-495095, EBI-358507; CC Q92851; P98170: XIAP; NbExp=3; IntAct=EBI-495095, EBI-517127; CC Q92851-4; PRO_0000004678 [O15519]: CFLAR; NbExp=3; IntAct=EBI-6621134, EBI-4478097; CC Q92851-4; P98170: XIAP; NbExp=3; IntAct=EBI-6621134, EBI-517127; CC Q92851-7; O14730: RIOK3; NbExp=3; IntAct=EBI-12737837, EBI-1047061; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=A; Synonyms=10-A; CC IsoId=Q92851-1; Sequence=Displayed; CC Name=B; Synonyms=10-B, 10-S; CC IsoId=Q92851-2; Sequence=VSP_000819, VSP_000820; CC Name=D; Synonyms=10-D, 10-L; CC IsoId=Q92851-4; Sequence=VSP_000820; CC Name=C; Synonyms=10-C; CC IsoId=Q92851-3; Sequence=VSP_000821, VSP_000822; CC Name=5; CC IsoId=Q92851-5; Sequence=VSP_000819; CC Name=6; CC IsoId=Q92851-6; Sequence=VSP_037229, VSP_000820; CC Name=7; Synonyms=10-G, 10g; CC IsoId=Q92851-7; Sequence=VSP_053333, VSP_053334; CC -!- TISSUE SPECIFICITY: Detectable in most tissues. Lowest expression is CC seen in brain, kidney, prostate, testis and colon. CC -!- PTM: Cleavage by granzyme B and autocatalytic activity generate the two CC active subunits. CC -!- DISEASE: Autoimmune lymphoproliferative syndrome 2A (ALPS2A) CC [MIM:603909]: A disorder of apoptosis that manifests in early childhood CC and results in the accumulation of autoreactive lymphocytes. It is CC characterized by non-malignant lymphadenopathy with hepatosplenomegaly, CC and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. CC {ECO:0000269|PubMed:10412980}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:12010812}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:11973654}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- MISCELLANEOUS: [Isoform B]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform C]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=CASP10base; Note=CASP10 mutation db; CC URL="https://databases.lovd.nl/shared/genes/CASP10"; CC -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome Database CC (ALPSbase); Note=Caspase-10 mutations causing ALPS type II; CC URL="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U60519; AAC50644.1; -; mRNA. DR EMBL; U86214; AAB46730.1; -; mRNA. DR EMBL; AF111344; AAD28402.1; -; mRNA. DR EMBL; AF111345; AAD28403.1; -; mRNA. DR EMBL; AB038979; BAB32553.1; -; Genomic_DNA. DR EMBL; AB038979; BAB32554.1; -; Genomic_DNA. DR EMBL; AJ487678; CAD32371.1; -; mRNA. DR EMBL; AJ487679; CAD32372.1; -; mRNA. DR EMBL; AY690601; AAU00989.1; -; mRNA. DR EMBL; EF050529; ABJ53426.1; -; Genomic_DNA. DR EMBL; AC007283; AAY24291.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70248.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70249.1; -; Genomic_DNA. DR EMBL; BC042844; AAH42844.1; -; mRNA. DR CCDS; CCDS2338.1; -. [Q92851-1] DR CCDS; CCDS2339.1; -. [Q92851-2] DR CCDS; CCDS2340.1; -. [Q92851-4] DR CCDS; CCDS56159.1; -. [Q92851-6] DR CCDS; CCDS56160.1; -. [Q92851-5] DR CCDS; CCDS77506.1; -. [Q92851-7] DR RefSeq; NP_001193453.1; NM_001206524.2. [Q92851-6] DR RefSeq; NP_001193471.1; NM_001206542.2. [Q92851-5] DR RefSeq; NP_001221.2; NM_001230.4. [Q92851-2] DR RefSeq; NP_001293012.1; NM_001306083.2. [Q92851-7] DR RefSeq; NP_116756.2; NM_032974.4. [Q92851-1] DR RefSeq; NP_116758.1; NM_032976.4. [Q92851-3] DR RefSeq; NP_116759.2; NM_032977.3. [Q92851-4] DR AlphaFoldDB; Q92851; -. DR SMR; Q92851; -. DR BioGRID; 107293; 98. DR CORUM; Q92851; -. DR FunCoup; Q92851; 364. DR IntAct; Q92851; 26. DR MINT; Q92851; -. DR STRING; 9606.ENSP00000286186; -. DR BindingDB; Q92851; -. DR ChEMBL; CHEMBL5037; -. DR MEROPS; C14.011; -. DR iPTMnet; Q92851; -. DR PhosphoSitePlus; Q92851; -. DR BioMuta; CASP10; -. DR DMDM; 12644463; -. DR CPTAC; CPTAC-1039; -. DR jPOST; Q92851; -. DR MassIVE; Q92851; -. DR PaxDb; 9606-ENSP00000286186; -. DR PeptideAtlas; Q92851; -. DR ProteomicsDB; 66146; -. DR ProteomicsDB; 75543; -. [Q92851-1] DR ProteomicsDB; 75544; -. [Q92851-2] DR ProteomicsDB; 75545; -. [Q92851-3] DR ProteomicsDB; 75546; -. [Q92851-4] DR ProteomicsDB; 75547; -. [Q92851-5] DR ProteomicsDB; 75548; -. [Q92851-6] DR Pumba; Q92851; -. DR Antibodypedia; 1700; 590 antibodies from 47 providers. DR DNASU; 843; -. DR Ensembl; ENST00000272879.9; ENSP00000272879.5; ENSG00000003400.17. [Q92851-1] DR Ensembl; ENST00000286186.11; ENSP00000286186.6; ENSG00000003400.17. [Q92851-4] DR Ensembl; ENST00000313728.12; ENSP00000314599.7; ENSG00000003400.17. [Q92851-6] DR Ensembl; ENST00000346817.10; ENSP00000237865.7; ENSG00000003400.17. [Q92851-2] DR Ensembl; ENST00000374650.8; ENSP00000363781.3; ENSG00000003400.17. [Q92851-7] DR Ensembl; ENST00000448480.1; ENSP00000396835.1; ENSG00000003400.17. [Q92851-5] DR Ensembl; ENST00000492363.6; ENSP00000512459.1; ENSG00000003400.17. [Q92851-3] DR GeneID; 843; -. DR KEGG; hsa:843; -. DR MANE-Select; ENST00000286186.11; ENSP00000286186.6; NM_032977.4; NP_116759.2. [Q92851-4] DR UCSC; uc002uxi.2; human. [Q92851-1] DR AGR; HGNC:1500; -. DR ClinPGx; PA26084; -. DR CTD; 843; -. DR DisGeNET; 843; -. DR GeneCards; CASP10; -. DR GeneReviews; CASP10; -. DR HGNC; HGNC:1500; CASP10. DR HPA; ENSG00000003400; Low tissue specificity. DR MalaCards; CASP10; -. DR MIM; 601762; gene. DR MIM; 603909; phenotype. DR MIM; 605027; phenotype. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000003400; -. DR Orphanet; 3261; Autoimmune lymphoproliferative syndrome. DR VEuPathDB; HostDB:ENSG00000003400; -. DR eggNOG; KOG3573; Eukaryota. DR GeneTree; ENSGT00940000160994; -. DR HOGENOM; CLU_088972_0_0_1; -. DR InParanoid; Q92851; -. DR OMA; CRDCISH; -. DR OrthoDB; 6114029at2759; -. DR PAN-GO; Q92851; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q92851; -. DR BioCyc; MetaCyc:HS00093-MONOMER; -. DR BRENDA; 3.4.22.63; 2681. DR PathwayCommons; Q92851; -. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-75157; FasL/ CD95L signaling. DR Reactome; R-HSA-75158; TRAIL signaling. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR SignaLink; Q92851; -. DR SIGNOR; Q92851; -. DR Agora; ENSG00000003400; -. DR BioGRID-ORCS; 843; 6 hits in 1156 CRISPR screens. DR ChiTaRS; CASP10; human. DR GeneWiki; Caspase_10; -. DR GenomeRNAi; 843; -. DR Pharos; Q92851; Tchem. DR PRO; PR:Q92851; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q92851; protein. DR Bgee; ENSG00000003400; Expressed in colonic epithelium and 126 other cell types or tissues. DR ExpressionAtlas; Q92851; baseline and differential. DR GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB. DR GO; GO:0035877; F:death effector domain binding; IPI:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IBA:GO_Central. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProt. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central. DR GO; GO:0051604; P:protein maturation; IDA:UniProt. DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW. DR CDD; cd00032; CASc; 1. DR CDD; cd08341; DED_Caspase_10_r1; 1. DR CDD; cd08814; DED_Caspase_10_r2; 1. DR FunFam; 1.10.533.10:FF:000038; Caspase 10; 1. DR FunFam; 1.10.533.10:FF:000070; Caspase 10; 1. DR FunFam; 3.40.50.1460:FF:000014; Caspase 10, apoptosis-related cysteine peptidase; 1. DR Gene3D; 3.40.50.1460; -; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 2. DR InterPro; IPR035701; CASP10_DED2. DR InterPro; IPR029030; Caspase-like_dom_sf. DR InterPro; IPR033139; Caspase_cys_AS. DR InterPro; IPR016129; Caspase_his_AS. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR011600; Pept_C14_caspase. DR InterPro; IPR002138; Pept_C14_p10. DR InterPro; IPR001309; Pept_C14_p20. DR InterPro; IPR015917; Pept_C14A. DR PANTHER; PTHR48169:SF7; CASPASE 10; 1. DR PANTHER; PTHR48169; DED DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF01335; DED; 2. DR Pfam; PF00656; Peptidase_C14; 1. DR PRINTS; PR00376; IL1BCENZYME. DR SMART; SM00115; CASc; 1. DR SMART; SM00031; DED; 2. DR SUPFAM; SSF52129; Caspase-like; 1. DR SUPFAM; SSF47986; DEATH domain; 2. DR PROSITE; PS01122; CASPASE_CYS; 1. DR PROSITE; PS01121; CASPASE_HIS; 1. DR PROSITE; PS50207; CASPASE_P10; 1. DR PROSITE; PS50208; CASPASE_P20; 1. DR PROSITE; PS50168; DED; 2. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; Direct protein sequencing; KW Disease variant; Hydrolase; Protease; Proteomics identification; KW Reference proteome; Repeat; Thiol protease; Zymogen. FT PROPEP 1..219 FT /id="PRO_0000004644" FT CHAIN 220..415 FT /note="Caspase-10 subunit p23/17" FT /id="PRO_0000004645" FT CHAIN 416..521 FT /note="Caspase-10 subunit p12" FT /id="PRO_0000004646" FT DOMAIN 19..97 FT /note="DED 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT DOMAIN 114..187 FT /note="DED 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 231..269 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 231..248 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 259..268 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 358 FT /evidence="ECO:0000250" FT ACT_SITE 401 FT /evidence="ECO:0000250" FT VAR_SEQ 229..271 FT /note="Missing (in isoform B and isoform 5)" FT /evidence="ECO:0000303|PubMed:8755496, ECO:0000303|Ref.5" FT /id="VSP_000819" FT VAR_SEQ 229..247 FT /note="QESWQNKHAGSNGNRATNG -> EGVFVFLNEGDRGNSPDDL (in FT isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053333" FT VAR_SEQ 241..307 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_037229" FT VAR_SEQ 241..273 FT /note="GNRATNGAPSLVSRGMQGASANTLNSETSTKRA -> EGSCVQDESEPQRPL FT CHCQQPQLYLPEGQTRNP (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000821" FT VAR_SEQ 248..521 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053334" FT VAR_SEQ 274..521 FT /note="Missing (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000822" FT VAR_SEQ 473..521 FT /note="MLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS -> FT HEDILSILTAVNDDVSRRVDKQGTKKQMPQPAFTLRKKLVFPVPLDALSL (in FT isoform B, isoform D and isoform 6)" FT /evidence="ECO:0000303|PubMed:10187817, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8755496, FT ECO:0000303|Ref.5" FT /id="VSP_000820" FT VARIANT 14 FT /note="K -> T (found in a colon cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:20025484" FT /id="VAR_065233" FT VARIANT 21 FT /note="R -> C (found in a multiple myeloma sample; somatic FT mutation; dbSNP:rs559979934)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065234" FT VARIANT 147 FT /note="M -> T (in GASC; somatic mutation; impairs CASP10- FT mediated apoptosis; dbSNP:rs121909776)" FT /evidence="ECO:0000269|PubMed:11973654" FT /id="VAR_037428" FT VARIANT 239 FT /note="S -> C (in dbSNP:rs41473647)" FT /id="VAR_055361" FT VARIANT 285 FT /note="L -> F (in ALPS2A; dbSNP:rs17860403)" FT /evidence="ECO:0000269|PubMed:10412980" FT /id="VAR_014071" FT VARIANT 285 FT /note="L -> P (found in a T-acute lymphoblastic leukemia FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065235" FT VARIANT 406 FT /note="I -> L (the mutant protein has defective apoptosis FT and exerts a dominant-negative effect when cotransfected FT with the wild-type protein; dbSNP:rs80358239)" FT /evidence="ECO:0000269|PubMed:16446975, FT ECO:0000269|PubMed:27378136, ECO:0000269|PubMed:27535533" FT /id="VAR_037429" FT VARIANT 410 FT /note="V -> I (does not interfere with apoptosis in a FT dominant negative manner; dbSNP:rs13010627)" FT /evidence="ECO:0000269|PubMed:10187817, FT ECO:0000269|PubMed:10412980, ECO:0000269|PubMed:16446975" FT /id="VAR_014072" FT VARIANT 414 FT /note="A -> V (in NHL; somatic mutation; dbSNP:rs28936699)" FT /evidence="ECO:0000269|PubMed:12010812" FT /id="VAR_037430" FT VARIANT 444 FT /note="P -> S (in dbSNP:rs41513147)" FT /id="VAR_055362" FT VARIANT 446 FT /note="Y -> C (risk factor for ALPS2A; does not interfere FT with apoptosis in a dominant negative manner; FT dbSNP:rs17860405)" FT /evidence="ECO:0000269|PubMed:16446975" FT /id="VAR_037431" FT MUTAGEN 401 FT /note="C->A: Abolishes proteolytic activity." FT /evidence="ECO:0000269|PubMed:11717445" FT CONFLICT 68 FT /note="E -> G (in Ref. 2; AAB46730)" FT /evidence="ECO:0000305" FT CONFLICT 268 FT /note="T -> A (in Ref. 3; AAD28403)" FT /evidence="ECO:0000305" FT VARIANT Q92851-2:479 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000269|PubMed:11161814, FT ECO:0000269|PubMed:8755496" FT /id="VAR_082802" FT VARIANT Q92851-4:522 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082803" FT VARIANT Q92851-6:455 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082804" SQ SEQUENCE 521 AA; 58951 MW; 840348AE602B8243 CRC64; MKSQGQHWYS SSDKNCKVSF REKLLIIDSN LGVQDVENLK FLCIGLVPNK KLEKSSSASD VFEHLLAEDL LSEEDPFFLA ELLYIIRQKK LLQHLNCTKE EVERLLPTRQ RVSLFRNLLY ELSEGIDSEN LKDMIFLLKD SLPKTEMTSL SFLAFLEKQG KIDEDNLTCL EDLCKTVVPK LLRNIEKYKR EKAIQIVTPP VDKEAESYQG EEELVSQTDV KTFLEALPQE SWQNKHAGSN GNRATNGAPS LVSRGMQGAS ANTLNSETST KRAAVYRMNR NHRGLCVIVN NHSFTSLKDR QGTHKDAEIL SHVFQWLGFT VHIHNNVTKV EMEMVLQKQK CNPAHADGDC FVFCILTHGR FGAVYSSDEA LIPIREIMSH FTALQCPRLA EKPKLFFIQA CQGEEIQPSV SIEADALNPE QAPTSLQDSI PAEADFLLGL ATVPGYVSFR HVEEGSWYIQ SLCNHLKKLV PRMLKFLEKT MEIRGRKRTV WGAKQISATS LPTAISAQTP RPPMRRWSSV S // ID CHK2_HUMAN Reviewed; 543 AA. AC O96017; A8K3Y9; B7ZBF3; B7ZBF4; B7ZBF5; Q6QA03; Q6QA04; Q6QA05; Q6QA06; AC Q6QA07; Q6QA08; Q6QA10; Q6QA11; Q6QA12; Q6QA13; Q9HBS5; Q9HCQ8; Q9UGF0; AC Q9UGF1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 256. DE RecName: Full=Serine/threonine-protein kinase Chk2 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:37943659}; DE AltName: Full=CHK2 checkpoint homolog; DE AltName: Full=Cds1 homolog; DE Short=Hucds1; DE Short=hCds1; DE AltName: Full=Checkpoint kinase 2; GN Name=CHEK2 {ECO:0000312|HGNC:HGNC:16627}; Synonyms=CDS1, CHK2, RAD53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF RP CDC25C, AND MUTAGENESIS OF ASP-347. RX PubMed=9836640; DOI=10.1126/science.282.5395.1893; RA Matsuoka S., Huang M., Elledge S.J.; RT "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase."; RL Science 282:1893-1897(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN MITOSIS. RX PubMed=9889122; DOI=10.1016/s0960-9822(99)80041-4; RA Blasina A., van de Weyer I., Laus M.C., Luyten W.H.M.L., Parker A.E., RA McGowan C.H.; RT "A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 RT phosphatase."; RL Curr. Biol. 9:1-10(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION IN PHOSPHORYLATION OF RP CDC25C. RX PubMed=10097108; DOI=10.1073/pnas.96.7.3745; RA Brown A.L., Lee C.-H., Schwarz J.K., Mitiku N., Piwnica-Worms H., RA Chung J.H.; RT "A human Cds1-related kinase that functions downstream of ATM protein in RT the cellular response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3745-3750(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 AND RP 12), AND SUBCELLULAR LOCATION. RC TISSUE=Mammary gland; RX PubMed=15361853; DOI=10.1038/sj.onc.1207928; RA Staalesen V., Falck J., Geisler S., Bartkova J., Boerresen-Dale A.-L., RA Lukas J., Lillehaug J.R., Bartek J., Lonning P.E.; RT "Alternative splicing and mutation status of CHEK2 in stage III breast RT cancer."; RL Oncogene 23:8535-8544(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9). RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon carcinoma; RA Shao R.-G., Zhang H., Yu Q., Pommier Y.; RT "Chk2/HuCds1 cell cycle checkpoint protein kinase from human colon RT carcinoma HT29 cells: regulation by autophosphorylation and DNA-dependent RT protein kinase and inhibition by cell cycle regulatory drugs."; RL Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12). RC TISSUE=T-cell; RA Ogawa A., Okabe-Nakamura A.; RT "An alternative spliced Chk2."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 13). RX PubMed=15498874; DOI=10.1073/pnas.0404089101; RA Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X., RA Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X., RA Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.; RT "Large-scale cDNA transfection screening for genes related to cancer RT development and progression."; RL Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-85; THR-157; MET-436; RP LYS-446; ILE-447; SER-448; LYS-501 AND VAL-512. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF BRCA1, AND INTERACTION WITH BRCA1. RX PubMed=10724175; DOI=10.1038/35004614; RA Lee J.S., Collins K.M., Brown A.L., Lee C.H., Chung J.H.; RT "hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage RT response."; RL Nature 404:201-204(2000). RN [15] RP PHOSPHORYLATION AT THR-68 BY ATM. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [16] RP PHOSPHORYLATION AT THR-383 AND THR-387, AND MUTAGENESIS OF THR-383 AND RP THR-387. RX PubMed=11390408; DOI=10.1074/jbc.m104414200; RA Lee C.H., Chung J.H.; RT "The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation RT events on hCds1 that is induced by ionizing radiation."; RL J. Biol. Chem. 276:30537-30541(2001). RN [17] RP FUNCTION IN INTRA S-PHASE CHECKPOINT, FUNCTION IN PHOSPHORYLATION OF RP CDC25A, INTERACTION WITH CDC25A, MUTAGENESIS OF ASP-347, CHARACTERIZATION RP OF VARIANT COLON CANCER TRP-145, AND CHARACTERIZATION OF VARIANT THR-157. RX PubMed=11298456; DOI=10.1038/35071124; RA Falck J., Mailand N., Syljuaasen R.G., Bartek J., Lukas J.; RT "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA RT synthesis."; RL Nature 410:842-847(2001). RN [18] RP INVOLVEMENT IN SUSCEPTIBILITY TO BC. RX PubMed=12094328; DOI=10.1086/341943; RA Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., RA Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., RA Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., Nevanlinna H.; RT "A CHEK2 genetic variant contributing to a substantial fraction of familial RT breast cancer."; RL Am. J. Hum. Genet. 71:432-438(2002). RN [19] RP HOMODIMERIZATION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF THR-68. RX PubMed=11901158; DOI=10.1074/jbc.m200822200; RA Ahn J.Y., Li X., Davis H.L., Canman C.E.; RT "Phosphorylation of threonine 68 promotes oligomerization and RT autophosphorylation of the Chk2 protein kinase via the forkhead-associated RT domain."; RL J. Biol. Chem. 277:19389-19395(2002). RN [20] RP FUNCTION IN APOPTOSIS, FUNCTION IN PHOSPHORYLATION OF PML, AND SUBCELLULAR RP LOCATION. RX PubMed=12402044; DOI=10.1038/ncb869; RA Yang S., Kuo C., Bisi J.E., Kim M.K.; RT "PML-dependent apoptosis after DNA damage is regulated by the checkpoint RT kinase hCds1/Chk2."; RL Nat. Cell Biol. 4:865-870(2002). RN [21] RP INTERACTION WITH TP53BP1. RX PubMed=12364621; DOI=10.1126/science.1076182; RA Wang B., Matsuoka S., Carpenter P.B., Elledge S.J.; RT "53BP1, a mediator of the DNA damage checkpoint."; RL Science 298:1435-1438(2002). RN [22] RP FUNCTION, INTERACTION WITH PML AND TP53, AND SUBCELLULAR LOCATION. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [23] RP FUNCTION IN TRANSCRIPTION REGULATION, FUNCTION IN APOPTOSIS, AND FUNCTION RP IN PHOSPHORYLATION OF E2F1. RX PubMed=12717439; DOI=10.1038/ncb974; RA Stevens C., Smith L., La Thangue N.B.; RT "Chk2 activates E2F-1 in response to DNA damage."; RL Nat. Cell Biol. 5:401-409(2003). RN [24] RP FUNCTION IN DNA DAMAGE RESPONSE, AND INTERACTION WITH MDC1. RX PubMed=12607004; DOI=10.1038/nature01447; RA Lou Z., Minter-Dykhouse K., Wu X., Chen J.; RT "MDC1 is coupled to activated CHK2 in mammalian DNA damage response RT pathways."; RL Nature 421:957-961(2003). RN [25] RP REVIEW ON PHOSPHORYLATION OF TP53 AND OTHER SUBSTRATES. RX PubMed=15279791; DOI=10.1016/j.dnarep.2004.03.033; RA Ahn J., Urist M., Prives C.; RT "The Chk2 protein kinase."; RL DNA Repair 3:1039-1047(2004). RN [26] RP ACTIVITY REGULATION, PHOSPHORYLATION AT THR-68 BY MAP3K20, AND MUTAGENESIS RP OF THR-68 AND ASP-368. RX PubMed=15342622; DOI=10.1074/jbc.m409961200; RA Tosti E., Waldbaum L., Warshaw G., Gross E.A., Ruggieri R.; RT "The stress kinase MRK contributes to regulation of DNA damage checkpoints RT through a p38gamma-independent pathway."; RL J. Biol. Chem. 279:47652-47660(2004). RN [27] RP FUNCTION IN TP53 ACTIVATION, AND FUNCTION IN PHOSPHORYLATION OF MDM4. RX PubMed=16163388; DOI=10.1038/sj.emboj.7600812; RA Chen L., Gilkes D.M., Pan Y., Lane W.S., Chen J.; RT "ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 RT activation after DNA damage."; RL EMBO J. 24:3411-3422(2005). RN [28] RP PHOSPHORYLATION AT THR-68, AND DEPHOSPHORYLATION AT THR-68 BY PPM1D. RX PubMed=16311512; DOI=10.1038/sj.cdd.4401801; RA Fujimoto H., Onishi N., Kato N., Takekawa M., Xu X.Z., Kosugi A., Kondo T., RA Imamura M., Oishi I., Yoda A., Minami Y.; RT "Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 RT phosphatase."; RL Cell Death Differ. 13:1170-1180(2006). RN [29] RP PHOSPHORYLATION AT SER-62; THR-68 AND SER-73, AND MUTAGENESIS OF SER-73. RX PubMed=16481012; DOI=10.1016/j.mrfmmm.2005.12.002; RA Bahassi el M., Myer D.L., McKenney R.J., Hennigan R.F., Stambrook P.J.; RT "Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its RT full activation by ATM and a downstream checkpoint in response to DNA RT damage."; RL Mutat. Res. 596:166-176(2006). RN [30] RP FUNCTION IN PHOSPHORYLATION OF RB1. RX PubMed=17380128; DOI=10.1038/sj.emboj.7601652; RA Inoue Y., Kitagawa M., Taya Y.; RT "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB RT and E2F-1 after DNA damage."; RL EMBO J. 26:2083-2093(2007). RN [31] RP FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-456, UBIQUITINATION, AND RP MUTAGENESIS OF SER-456. RX PubMed=17715138; DOI=10.1074/jbc.m704642200; RA Kass E.M., Ahn J., Tanaka T., Freed-Pastor W.A., Keezer S., Prives C.; RT "Stability of checkpoint kinase 2 is regulated via phosphorylation at RT serine 456."; RL J. Biol. Chem. 282:30311-30321(2007). RN [32] RP FUNCTION IN DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF FOXM1. RX PubMed=17101782; DOI=10.1128/mcb.01068-06; RA Tan Y., Raychaudhuri P., Costa R.H.; RT "Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate RT expression of DNA repair genes."; RL Mol. Cell. Biol. 27:1007-1016(2007). RN [33] RP FUNCTION IN PHOSPHORYLATION OF NEK6. RX PubMed=18728393; DOI=10.4161/cc.7.17.6551; RA Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I., RA Chung J.H., Yun J.; RT "Nek6 is involved in G2/M phase cell cycle arrest through DNA damage- RT induced phosphorylation."; RL Cell Cycle 7:2705-2709(2008). RN [34] RP FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-379, MUTAGENESIS OF SER-379, RP UBIQUITINATION, AND INTERACTION WITH CUL1. RX PubMed=18644861; DOI=10.1128/mcb.00821-08; RA Lovly C.M., Yan L., Ryan C.E., Takada S., Piwnica-Worms H.; RT "Regulation of Chk2 ubiquitination and signaling through RT autophosphorylation of serine 379."; RL Mol. Cell. Biol. 28:5874-5885(2008). RN [35] RP FUNCTION IN RAD51-MEDIATED DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF RP BRCA2. RX PubMed=18317453; DOI=10.1038/onc.2008.17; RA Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E., RA Stambrook P.J.; RT "The checkpoint kinases Chk1 and Chk2 regulate the functional associations RT between hBRCA2 and Rad51 in response to DNA damage."; RL Oncogene 27:3977-3985(2008). RN [36] RP PHOSPHORYLATION BY PLK4. RX PubMed=19164942; DOI=10.4161/cc.8.2.7355; RA Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.; RT "Polo-like kinase 4 phosphorylates Chk2."; RL Cell Cycle 8:327-329(2009). RN [37] RP FUNCTION IN PHOSPHORYLATION OF BRCA1, AND FUNCTION IN CHROMOSOMAL RP STABILITY. RX PubMed=20364141; DOI=10.1038/ncb2051; RA Stolz A., Ertych N., Kienitz A., Vogel C., Schneider V., Fritz B., RA Jacob R., Dittmar G., Weichert W., Petersen I., Bastians H.; RT "The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in RT human somatic cells."; RL Nat. Cell Biol. 12:492-499(2010). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [39] RP INVOLVEMENT IN SUSCEPTIBILITY TO BC, VARIANTS CYS-180 AND TYR-371, AND RP CHARACTERIZATION OF VARIANT TYR-371. RX PubMed=21618645; DOI=10.1002/humu.21538; RA Liu Y., Liao J., Xu Y., Chen W., Liu D., Ouyang T., Li J., Wang T., Fan Z., RA Fan T., Lin B., Xu X., Xie Y.; RT "A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk RT in Chinese women."; RL Hum. Mutat. 32:1000-1003(2011). RN [40] RP UBIQUITINATION BY RNF8. RX PubMed=22266820; DOI=10.1038/nsmb.2211; RA Feng L., Chen J.; RT "The E3 ligase RNF8 regulates KU80 removal and NHEJ repair."; RL Nat. Struct. Mol. Biol. 19:201-206(2012). RN [41] RP FUNCTION, AND INTERACTION WITH CCAR2 AND SIRT1. RX PubMed=25361978; DOI=10.1093/nar/gku1065; RA Magni M., Ruscica V., Buscemi G., Kim J.E., Nachimuthu B.T., Fontanella E., RA Delia D., Zannini L.; RT "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced RT apoptosis."; RL Nucleic Acids Res. 42:13150-13160(2014). RN [42] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=32001251; DOI=10.1016/j.jmb.2020.01.021; RA Hembram D.S.S., Negi H., Biswas P., Tripathi V., Bhushan L., Shet D., RA Kumar V., Das R.; RT "The Viral SUMO-Targeted Ubiquitin Ligase ICP0 is Phosphorylated and RT Activated by Host Kinase Chk2."; RL J. Mol. Biol. 432:1952-1977(2020). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37943659; DOI=10.1016/j.celrep.2023.113402; RA Liu J., Lu S., Zheng L., Guo Q., Cao L., Xiao Y., Chen D., Zou Y., Liu X., RA Deng C., Zhang S., Yang R., Wang Y., Zhang Y., Zhang N., Song X., Xing C., RA Wang Z., Cao L.; RT "ATM-CHK2-TRIM32 axis regulates ATG7 ubiquitination to initiate autophagy RT under oxidative stress."; RL Cell Rep. 42:113402-113402(2023). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 64-212. RX PubMed=12049740; DOI=10.1016/s1097-2765(02)00527-0; RA Li J., Williams B.L., Haire L.F., Goldberg M., Wilker E., Durocher D., RA Yaffe M.B., Jackson S.P., Smerdon S.J.; RT "Structural and functional versatility of the FHA domain in DNA-damage RT signaling by the tumor suppressor kinase Chk2."; RL Mol. Cell 9:1045-1054(2002). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 210-531 IN COMPLEX WITH ADP AND RP INHIBITOR, HOMODIMERIZATION, AND AUTOPHOSPHORYLATION. RX PubMed=16794575; DOI=10.1038/sj.emboj.7601209; RA Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D., RA Mittnacht S., Pearl L.H.; RT "Trans-activation of the DNA-damage signalling protein kinase Chk2 by T- RT loop exchange."; RL EMBO J. 25:3179-3190(2006). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 84-502 OF HOMODIMER. RX PubMed=19782031; DOI=10.1016/j.molcel.2009.09.007; RA Cai Z., Chehab N.H., Pavletich N.P.; RT "Structure and activation mechanism of the CHK2 DNA damage checkpoint RT kinase."; RL Mol. Cell 35:818-829(2009). RN [47] RP INTERACTION WITH CDKN2AIP. RX PubMed=24825908; DOI=10.1074/jbc.m114.547208; RA Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R.; RT "Collaborator of ARF (CARF) regulates proliferative fate of human cells by RT dose-dependent regulation of DNA damage signaling."; RL J. Biol. Chem. 289:18258-18269(2014). RN [48] RP VARIANT THR-157, AND VARIANT COLON CANCER TRP-145. RX PubMed=10617473; DOI=10.1126/science.286.5449.2528; RA Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C.R., RA Shannon K.E., Lubratovich M., Versalis S.J., Isselbacher K.J., RA Fraumeni J.F. Jr., Birch J.M., Li F.P., Garber J.E., Haber D.A.; RT "Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome."; RL Science 286:2528-2531(1999). RN [49] RP VARIANT THR-157. RX PubMed=11461078; DOI=10.1054/bjoc.2001.1858; RA Allinen M., Huusko P., Maentyniemi S., Launonen V., Winqvist R.; RT "Mutation analysis of the CHK2 gene in families with hereditary breast RT cancer."; RL Br. J. Cancer 85:209-212(2001). RN [50] RP VARIANT TPDS4 TRP-145. RX PubMed=11719428; RA Lee S.B., Kim S.H., Bell D.W., Wahrer D.C.R., Schiripo T.A., Jorczak M.M., RA Sgroi D.C., Garber J.E., Li F.P., Nichols K.E., Varley J.M., Godwin A.K., RA Shannon K.M., Harlow E., Haber D.A.; RT "Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni RT Syndrome."; RL Cancer Res. 61:8062-8067(2001). RN [51] RP VARIANT MULTIPLE CANCERS LYS-59. RX PubMed=12052256; DOI=10.1186/bcr435; RA Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H., RA Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V., RA Bergthorsson J.T.; RT "Mutation analysis of the CHK2 gene in breast carcinoma and other RT cancers."; RL Breast Cancer Res. 4:R4-R4(2002). RN [52] RP VARIANT BC GLY-117, AND VARIANTS GLN-137 AND HIS-180. RX PubMed=12454775; DOI=10.1038/sj.bjc.6600637; RA Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B., RA Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S., Eeles R.A.; RT "CHEK2 variants in susceptibility to breast cancer and evidence of RT retention of the wild type allele in tumours."; RL Br. J. Cancer 87:1445-1448(2002). RN [53] RP VARIANTS SER-17 AND LEU-85, AND INVOLVEMENT IN OSRC. RX PubMed=11746983; DOI=10.1002/gcc.1207; RA Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V., RA Tsukasaki K., Takeuchi S., Koeffler H.P.; RT "Mutations of the CHK2 gene are found in some osteosarcomas, but are rare RT in breast, lung, and ovarian tumors."; RL Genes Chromosomes Cancer 33:17-21(2002). RN [54] RP VARIANTS PROSTATE CANCER LYS-64; PRO-145; ARG-167; CYS-180; HIS-180; RP CYS-181; HIS-181; LYS-239; PHE-251; HIS-318; PRO-323; CYS-327 AND LYS-476, RP AND VARIANT THR-157. RX PubMed=12533788; DOI=10.1086/346094; RA Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., RA Qian C., Marks A.F., Slager S.L., Peterson B.J., Smith D.I., Cheville J.C., RA Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N., RA Liu W.; RT "Mutations in CHEK2 associated with prostate cancer risk."; RL Am. J. Hum. Genet. 72:270-280(2003). RN [55] RP VARIANT BC GLY-117, AND VARIANTS TRP-145 AND THR-157. RX PubMed=12610780; DOI=10.1086/373965; RA Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M., RA Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J., RA van den Ouweland A., Brady A., Cole T., Collins A., Cox H., Donaldson A., RA Eeles R., Evans G., Gregory H., Gray J., Houlston R., Lalloo F., RA Lucassen A., Mackay J., Mitchell G., Morrison P., Murday V., Narod S., RA Patterson J., Peretz T., Phelan C.M., Rogers M., Schofield A., Tonin P., RA Weber B., Weber W., Futreal P.A., Nathanson K.L., Weber B.L., Easton D.F., RA Stratton M.R., Rahman N.; RT "Variants in CHEK2 other than 1100delC do not make a major contribution to RT breast cancer susceptibility."; RL Am. J. Hum. Genet. 72:1023-1028(2003). RN [56] RP VARIANT THR-157. RX PubMed=14612911; DOI=10.1038/sj.bjc.6601425; RA Seppaelae E.H., Ikonen T., Mononen N., Autio V., Roekman A., RA Matikainen M.P., Tammela T.L.J., Schleutker J.; RT "CHEK2 variants associate with hereditary prostate cancer."; RL Br. J. Cancer 89:1966-1970(2003). RN [57] RP VARIANT THR-157. RX PubMed=15492928; DOI=10.1086/426403; RA Cybulski C., Gorski B., Huzarski T., Masojc B., Mierzejewski M., RA Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J., RA Zlowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Medrek K., RA Szymanska A., Szymanska J., Kurzawski G., Suchy J., Oszurek O., Witek A., RA Narod S.A., Lubinski J.; RT "CHEK2 is a multiorgan cancer susceptibility gene."; RL Am. J. Hum. Genet. 75:1131-1135(2004). RN [58] RP VARIANTS TRP-145 AND THR-157. RX PubMed=15535844; DOI=10.1186/bcr933; RA Friedrichsen D.M., Malone K.E., Doody D.R., Daling J.R., Ostrander E.A.; RT "Frequency of CHEK2 mutations in a population based, case-control study of RT breast cancer in young women."; RL Breast Cancer Res. 6:R629-R635(2004). RN [59] RP VARIANT THR-157. RX PubMed=15087378; DOI=10.1158/0008-5472.can-04-0341; RA Cybulski C., Huzarski T., Gorski B., Masojc B., Mierzejewski M., RA Debniak T., Gliniewicz B., Matyjasik J., Zlowocka E., Kurzawski G., RA Sikorski A., Posmyk M., Szwiec M., Czajka R., Narod S.A., Lubinski J.; RT "A novel founder CHEK2 mutation is associated with increased prostate RT cancer risk."; RL Cancer Res. 64:2677-2679(2004). RN [60] RP VARIANT THR-157. RX PubMed=15095295; DOI=10.1002/ijc.20073; RA Dufault M.R., Betz B., Wappenschmidt B., Hofmann W., Bandick K., Golla A., RA Pietschmann A., Nestle-Kraemling C., Rhiem K., Huettner C., von Lindern C., RA Dall P., Kiechle M., Untch M., Jonat W., Meindl A., Scherneck S., RA Niederacher D., Schmutzler R.K., Arnold N.; RT "Limited relevance of the CHEK2 gene in hereditary breast cancer."; RL Int. J. Cancer 110:320-325(2004). RN [61] RP VARIANT THR-157. RX PubMed=15239132; DOI=10.1002/ijc.20299; RA Kilpivaara O., Vahteristo P., Falck J., Syrjaekoski K., Eerola H., RA Easton D., Bartkova J., Lukas J., Heikkilae P., Aittomaeki K., Holli K., RA Blomqvist C., Kallioniemi O.-P., Bartek J., Nevanlinna H.; RT "CHEK2 variant I157T may be associated with increased breast cancer risk."; RL Int. J. Cancer 111:543-547(2004). RN [62] RP VARIANTS LEU-85 AND PHE-428. RX PubMed=15649950; DOI=10.1093/hmg/ddi052; RA Shaag A., Walsh T., Renbaum P., Kirchhoff T., Nafa K., Shiovitz S., RA Mandell J.B., Welcsh P., Lee M.K., Ellis N., Offit K., Levy-Lahad E., RA King M.-C.; RT "Functional and genomic approaches reveal an ancient CHEK2 allele RT associated with breast cancer in the Ashkenazi Jewish population."; RL Hum. Mol. Genet. 14:555-563(2005). RN [63] RP VARIANT THR-157. RX PubMed=15810020; DOI=10.1002/ijc.21022; RA Bogdanova N., Enbetaen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I., RA Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., Doerk T.; RT "Association of two mutations in the CHEK2 gene with breast cancer."; RL Int. J. Cancer 116:263-266(2005). RN [64] RP VARIANT BC GLY-117, AND VARIANTS GLN-137; TRP-145; THR-157 AND HIS-180. RX PubMed=15818573; DOI=10.1002/path.1764; RA van Puijenbroek M., van Asperen C.J., van Mil A., Devilee P., van Wezel T., RA Morreau H.; RT "Homozygosity for a CHEK2*1100delC mutation identified in familial RT colorectal cancer does not lead to a severe clinical phenotype."; RL J. Pathol. 206:198-204(2005). RN [65] RP VARIANT BC CYS-390, CHARACTERIZATION OF VARIANT BC CYS-390, AND FUNCTION. RX PubMed=25619829; DOI=10.1038/onc.2014.443; RA Wang N., Ding H., Liu C., Li X., Wei L., Yu J., Liu M., Ying M., Gao W., RA Jiang H., Wang Y.; RT "A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese RT breast cancer patients impairs its activity and is associated with RT increased breast cancer risk."; RL Oncogene 34:5198-5205(2015). CC -!- FUNCTION: Serine/threonine-protein kinase which is required for CC checkpoint-mediated cell cycle arrest, activation of DNA repair and CC apoptosis in response to the presence of DNA double-strand breaks. May CC also negatively regulate cell cycle progression during unperturbed cell CC cycles. Following activation, phosphorylates numerous effectors CC preferentially at the consensus sequence [L-X-R-X-X-S/T] CC (PubMed:37943659). Regulates cell cycle checkpoint arrest through CC phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their CC activity. Inhibition of CDC25 phosphatase activity leads to increased CC inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks CC cell cycle progression. May also phosphorylate NEK6 which is involved CC in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation CC of BRCA2, enhancing the association of RAD51 with chromatin which CC promotes DNA repair by homologous recombination. Also stimulates the CC transcription of genes involved in DNA repair (including BRCA2) through CC the phosphorylation and activation of the transcription factor FOXM1. CC Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and CC PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate CC inhibition by MDM2, leading to accumulation of active p53/TP53. CC Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also CC controls the transcription of pro-apoptotic genes through CC phosphorylation of the transcription factor E2F1. Tumor suppressor, it CC may also have a DNA damage-independent function in mitotic spindle CC assembly by phosphorylating BRCA1. Its absence may be a cause of the CC chromosomal instability observed in some cancer cells. Promotes the CC CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 CC inhibition (PubMed:25361978). Under oxidative stress, promotes ATG7 CC ubiquitination by phosphorylating the E3 ubiquitin ligase TRIM32 at CC 'Ser-55' leading to positive regulation of the autophagosme assembly CC (PubMed:37943659). {ECO:0000250|UniProtKB:Q9Z265, CC ECO:0000269|PubMed:10097108, ECO:0000269|PubMed:10724175, CC ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12402044, CC ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12717439, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:16163388, CC ECO:0000269|PubMed:17101782, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18317453, CC ECO:0000269|PubMed:18644861, ECO:0000269|PubMed:18728393, CC ECO:0000269|PubMed:20364141, ECO:0000269|PubMed:25361978, CC ECO:0000269|PubMed:25619829, ECO:0000269|PubMed:37943659, CC ECO:0000269|PubMed:9836640, ECO:0000269|PubMed:9889122}. CC -!- FUNCTION: (Microbial infection) Phosphorylates herpes simplex virus CC 1/HHV-1 protein ICP0 and thus activates its SUMO-targeted ubiquitin CC ligase activity. {ECO:0000269|PubMed:32001251}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:37943659}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Activated through phosphorylation at Thr-68 by ATM CC in response to DNA double-strand breaks. Activation is modulated by CC several mediators including MDC1 and TP53BP1. Induces homodimerization CC with exchange of the T-loop/activation segment between protomers and CC transphosphorylation of the protomers. The autophosphorylated kinase CC dimer is fully active. Negatively regulated by PPM1D through CC dephosphorylation of Thr-68. {ECO:0000269|PubMed:15342622}. CC -!- SUBUNIT: Homodimer. Homodimerization is part of the activation process CC but the dimer may dissociate following activation. Interacts with PML. CC Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts CC with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires CC ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1; CC modulates CHEK2 phosphorylation at Thr-68 in response to ionizing CC radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates CC its degradation in response to ionizing radiation. Interacts with CUL1; CC mediates CHEK2 ubiquitination and regulation. Interacts with CDKN2AIP. CC Interacts (via protein kinase domain) with CCAR2 (via N-terminus). CC Interacts with SIRT1. {ECO:0000269|PubMed:10724175, CC ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12364621, CC ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:16794575, ECO:0000269|PubMed:18644861, CC ECO:0000269|PubMed:24825908, ECO:0000269|PubMed:25361978}. CC -!- INTERACTION: CC O96017; Q9NY61: AATF; NbExp=4; IntAct=EBI-1180783, EBI-372428; CC O96017; P30304: CDC25A; NbExp=2; IntAct=EBI-1180783, EBI-747671; CC O96017; Q9UQ88-1: CDK11A; NbExp=2; IntAct=EBI-1180783, EBI-11579223; CC O96017; O96017: CHEK2; NbExp=6; IntAct=EBI-1180783, EBI-1180783; CC O96017; Q9Y248: GINS2; NbExp=2; IntAct=EBI-1180783, EBI-747491; CC O96017; Q13007: IL24; NbExp=3; IntAct=EBI-1180783, EBI-3915542; CC O96017; P52292: KPNA2; NbExp=7; IntAct=EBI-1180783, EBI-349938; CC O96017; Q96KN1: LRATD2; NbExp=3; IntAct=EBI-1180783, EBI-9057780; CC O96017; Q00987: MDM2; NbExp=6; IntAct=EBI-1180783, EBI-389668; CC O96017; P56645: PER3; NbExp=2; IntAct=EBI-1180783, EBI-2827813; CC O96017; P53350: PLK1; NbExp=7; IntAct=EBI-1180783, EBI-476768; CC O96017; O15355: PPM1G; NbExp=2; IntAct=EBI-1180783, EBI-725702; CC O96017; Q15172: PPP2R5A; NbExp=3; IntAct=EBI-1180783, EBI-641666; CC O96017; Q15173: PPP2R5B; NbExp=2; IntAct=EBI-1180783, EBI-1369497; CC O96017; Q13362-1: PPP2R5C; NbExp=3; IntAct=EBI-1180783, EBI-1266170; CC O96017; Q13362-2: PPP2R5C; NbExp=2; IntAct=EBI-1180783, EBI-1266173; CC O96017; Q13362-3: PPP2R5C; NbExp=4; IntAct=EBI-1180783, EBI-1266176; CC O96017; Q16537: PPP2R5E; NbExp=3; IntAct=EBI-1180783, EBI-968374; CC O96017; P06400: RB1; NbExp=3; IntAct=EBI-1180783, EBI-491274; CC O96017; Q5VTR2: RNF20; NbExp=3; IntAct=EBI-1180783, EBI-2372238; CC O96017; P04637: TP53; NbExp=3; IntAct=EBI-1180783, EBI-366083; CC O96017; Q93009: USP7; NbExp=2; IntAct=EBI-1180783, EBI-302474; CC O96017; P55072: VCP; NbExp=2; IntAct=EBI-1180783, EBI-355164; CC O96017; P18887: XRCC1; NbExp=8; IntAct=EBI-1180783, EBI-947466; CC O96017; PRO_0000037319 [P0C6X7]: rep; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-25487926; CC O96017; P06725: UL83; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-9545359; CC O96017; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-1180783, EBI-6904388; CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Note=Isoform 10 is present CC throughout the cell. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 12]: Nucleus. CC -!- SUBCELLULAR LOCATION: Nucleus, PML body. Nucleus, nucleoplasm. CC Note=Recruited into PML bodies together with TP53. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Name=1; CC IsoId=O96017-1; Sequence=Displayed; CC Name=2; Synonyms=ins2; CC IsoId=O96017-2; Sequence=VSP_014564, VSP_014567, VSP_014568; CC Name=3; Synonyms=del2-12; CC IsoId=O96017-3; Sequence=VSP_014559; CC Name=4; Synonyms=del2-3; CC IsoId=O96017-4; Sequence=VSP_014558; CC Name=5; Synonyms=del4; CC IsoId=O96017-5; Sequence=VSP_014565, VSP_014566; CC Name=6; Synonyms=sub3; CC IsoId=O96017-6; Sequence=VSP_014562, VSP_014563; CC Name=7; Synonyms=del9-12; CC IsoId=O96017-7; Sequence=VSP_014572, VSP_014573; CC Name=8; Synonyms=del7; CC IsoId=O96017-8; Sequence=VSP_014569, VSP_014570; CC Name=9; Synonyms=insx; CC IsoId=O96017-9; Sequence=VSP_014557; CC Name=10; Synonyms=iso2; CC IsoId=O96017-10; Sequence=VSP_014560, VSP_014561; CC Name=11; Synonyms=iso1; CC IsoId=O96017-11; Sequence=VSP_014556; CC Name=12; Synonyms=del9; CC IsoId=O96017-12; Sequence=VSP_014571; CC Name=13; CC IsoId=O96017-13; Sequence=VSP_045148; CC -!- TISSUE SPECIFICITY: High expression is found in testis, spleen, colon CC and peripheral blood leukocytes. Low expression is found in other CC tissues. CC -!- PTM: Phosphorylated. Phosphorylated at Ser-73 by PLK3 in response to CC DNA damage, promoting phosphorylation at Thr-68 by ATM and the G2/M CC transition checkpoint. Phosphorylation at Thr-68 induces CC homodimerization. Autophosphorylates at Thr-383 and Thr-387 in the T- CC loop/activation segment upon dimerization to become fully active and CC phosphorylate its substrates like for instance CDC25C. DNA damage- CC induced autophosphorylation at Ser-379 induces CUL1-mediated CC ubiquitination and regulates the pro-apoptotic function. CC Phosphorylation at Ser-456 also regulates ubiquitination. CC Phosphorylated by PLK4. {ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11390408, ECO:0000269|PubMed:15342622, CC ECO:0000269|PubMed:16311512, ECO:0000269|PubMed:16481012, CC ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18644861, CC ECO:0000269|PubMed:19164942}. CC -!- PTM: Ubiquitinated. CUL1-mediated ubiquitination regulates the pro- CC apoptotic function. Ubiquitination may also regulate protein stability. CC Ubiquitinated by RNF8 via 'Lys-48'-linked ubiquitination. CC -!- DISEASE: Tumor predisposition syndrome 4 (TPDS4) [MIM:609265]: A CC disorder characterized by an increased risk for developing various CC types of benign and/or malignant neoplasms that arise at an accelerated CC rate and in different organs. {ECO:0000269|PubMed:11719428}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:12533788}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating CC in bone-forming cells, affecting the ends of long bones. CC {ECO:0000269|PubMed:11746983}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy CC originating from breast epithelial tissue. Breast neoplasms can be CC distinguished by their histologic pattern. Invasive ductal carcinoma is CC by far the most common type. Breast cancer is etiologically and CC genetically heterogeneous. Important genetic factors have been CC indicated by familial occurrence and bilateral involvement. Mutations CC at more than one locus can be involved in different families or even in CC the same case. {ECO:0000269|PubMed:12094328, CC ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:12610780, CC ECO:0000269|PubMed:15818573, ECO:0000269|PubMed:21618645, CC ECO:0000269|PubMed:25619829}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Retains low level of catalytic activity. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 10]: Lacks enzymatic activity. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 12]: Lacks enzymatic activity. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CHK2 subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/312/CHEK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF086904; AAC83693.1; -; mRNA. DR EMBL; AJ131197; CAA10319.1; -; mRNA. DR EMBL; AF096279; AAD11784.1; -; mRNA. DR EMBL; AY551295; AAS58456.1; -; mRNA. DR EMBL; AY551296; AAS58457.1; -; mRNA. DR EMBL; AY551297; AAS58458.1; -; mRNA. DR EMBL; AY551298; AAS58459.1; -; mRNA. DR EMBL; AY551299; AAS58460.1; -; mRNA. DR EMBL; AY551300; AAS58461.1; -; mRNA. DR EMBL; AY551301; AAS58462.1; -; mRNA. DR EMBL; AY551302; AAS58463.1; -; mRNA. DR EMBL; AY551303; AAS58464.1; -; mRNA. DR EMBL; AY551304; AAS58465.1; -; mRNA. DR EMBL; AY551305; AAS58466.1; -; mRNA. DR EMBL; CR456418; CAG30304.1; -; mRNA. DR EMBL; AF174135; AAD48504.1; -; mRNA. DR EMBL; AB040105; BAB17231.1; -; mRNA. DR EMBL; AK290754; BAF83443.1; -; mRNA. DR EMBL; AF217975; AAG17218.1; -; mRNA. DR EMBL; AY800241; AAV41895.1; -; Genomic_DNA. DR EMBL; AL117330; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL121825; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471095; EAW59755.1; -; Genomic_DNA. DR EMBL; BC004207; AAH04207.1; -; mRNA. DR CCDS; CCDS13843.1; -. [O96017-1] DR CCDS; CCDS13844.1; -. [O96017-12] DR CCDS; CCDS33629.1; -. [O96017-9] DR RefSeq; NP_001005735.1; NM_001005735.3. [O96017-9] DR RefSeq; NP_001244316.1; NM_001257387.3. [O96017-13] DR RefSeq; NP_001424871.1; NM_001437942.1. [O96017-13] DR RefSeq; NP_009125.1; NM_007194.4. [O96017-1] DR RefSeq; NP_665861.1; NM_145862.3. [O96017-12] DR PDB; 1GXC; X-ray; 2.70 A; A/D/G/J=64-212. DR PDB; 2CN5; X-ray; 2.25 A; A=210-531. DR PDB; 2CN8; X-ray; 2.70 A; A=210-531. DR PDB; 2W0J; X-ray; 2.05 A; A=210-531. DR PDB; 2W7X; X-ray; 2.07 A; A=210-531. DR PDB; 2WTC; X-ray; 3.00 A; A=210-531. DR PDB; 2WTD; X-ray; 2.75 A; A=210-531. DR PDB; 2WTI; X-ray; 2.50 A; A=210-531. DR PDB; 2WTJ; X-ray; 2.10 A; A=210-531. DR PDB; 2XBJ; X-ray; 2.30 A; A=210-531. DR PDB; 2XK9; X-ray; 2.35 A; A=210-531. DR PDB; 2XM8; X-ray; 3.40 A; A=210-531. DR PDB; 2XM9; X-ray; 2.50 A; A=210-531. DR PDB; 2YCF; X-ray; 1.77 A; A=210-530. DR PDB; 2YCQ; X-ray; 2.05 A; A=210-531. DR PDB; 2YCR; X-ray; 2.20 A; A=210-531. DR PDB; 2YCS; X-ray; 2.35 A; A=210-531. DR PDB; 2YIQ; X-ray; 1.89 A; A=210-531. DR PDB; 2YIR; X-ray; 2.10 A; A=210-531. DR PDB; 2YIT; X-ray; 2.20 A; A=210-531. DR PDB; 3I6U; X-ray; 3.00 A; A/B=84-502. DR PDB; 3I6W; X-ray; 3.25 A; A/B/C/D/E/F/G/H=70-512. DR PDB; 3VA4; X-ray; 1.54 A; C=63-73. DR PDB; 4A9R; X-ray; 2.85 A; A=210-531. DR PDB; 4A9S; X-ray; 2.66 A; A=210-531. DR PDB; 4A9T; X-ray; 2.70 A; A=210-531. DR PDB; 4A9U; X-ray; 2.48 A; A=210-531. DR PDB; 4BDA; X-ray; 2.60 A; A=210-531. DR PDB; 4BDB; X-ray; 2.50 A; A=210-531. DR PDB; 4BDC; X-ray; 3.00 A; A=210-531. DR PDB; 4BDD; X-ray; 2.67 A; A=210-531. DR PDB; 4BDE; X-ray; 2.55 A; A=210-531. DR PDB; 4BDF; X-ray; 2.70 A; A=210-531. DR PDB; 4BDG; X-ray; 2.84 A; A=210-531. DR PDB; 4BDH; X-ray; 2.70 A; A=210-531. DR PDB; 4BDI; X-ray; 2.32 A; A=210-531. DR PDB; 4BDJ; X-ray; 3.01 A; A=210-531. DR PDB; 4BDK; X-ray; 3.30 A; A=210-531. DR PDBsum; 1GXC; -. DR PDBsum; 2CN5; -. DR PDBsum; 2CN8; -. DR PDBsum; 2W0J; -. DR PDBsum; 2W7X; -. DR PDBsum; 2WTC; -. DR PDBsum; 2WTD; -. DR PDBsum; 2WTI; -. DR PDBsum; 2WTJ; -. DR PDBsum; 2XBJ; -. DR PDBsum; 2XK9; -. DR PDBsum; 2XM8; -. DR PDBsum; 2XM9; -. DR PDBsum; 2YCF; -. DR PDBsum; 2YCQ; -. DR PDBsum; 2YCR; -. DR PDBsum; 2YCS; -. DR PDBsum; 2YIQ; -. DR PDBsum; 2YIR; -. DR PDBsum; 2YIT; -. DR PDBsum; 3I6U; -. DR PDBsum; 3I6W; -. DR PDBsum; 3VA4; -. DR PDBsum; 4A9R; -. DR PDBsum; 4A9S; -. DR PDBsum; 4A9T; -. DR PDBsum; 4A9U; -. DR PDBsum; 4BDA; -. DR PDBsum; 4BDB; -. DR PDBsum; 4BDC; -. DR PDBsum; 4BDD; -. DR PDBsum; 4BDE; -. DR PDBsum; 4BDF; -. DR PDBsum; 4BDG; -. DR PDBsum; 4BDH; -. DR PDBsum; 4BDI; -. DR PDBsum; 4BDJ; -. DR PDBsum; 4BDK; -. DR AlphaFoldDB; O96017; -. DR SMR; O96017; -. DR BioGRID; 116369; 255. DR CORUM; O96017; -. DR DIP; DIP-24270N; -. DR ELM; O96017; -. DR FunCoup; O96017; 2619. DR IntAct; O96017; 159. DR MINT; O96017; -. DR STRING; 9606.ENSP00000372023; -. DR BindingDB; O96017; -. DR ChEMBL; CHEMBL2527; -. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05786; Irofulven. DR DrugBank; DB05149; XL844. DR DrugCentral; O96017; -. DR GuidetoPHARMACOLOGY; 1988; -. DR GlyGen; O96017; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; O96017; -. DR MetOSite; O96017; -. DR PhosphoSitePlus; O96017; -. DR BioMuta; CHEK2; -. DR CPTAC; CPTAC-5892; -. DR CPTAC; CPTAC-5893; -. DR CPTAC; CPTAC-5894; -. DR jPOST; O96017; -. DR MassIVE; O96017; -. DR PaxDb; 9606-ENSP00000372023; -. DR PeptideAtlas; O96017; -. DR ProteomicsDB; 51198; -. [O96017-1] DR ProteomicsDB; 51199; -. [O96017-10] DR ProteomicsDB; 51200; -. [O96017-11] DR ProteomicsDB; 51201; -. [O96017-12] DR ProteomicsDB; 51202; -. [O96017-2] DR ProteomicsDB; 51203; -. [O96017-3] DR ProteomicsDB; 51204; -. [O96017-4] DR ProteomicsDB; 51205; -. [O96017-5] DR ProteomicsDB; 51206; -. [O96017-6] DR ProteomicsDB; 51207; -. [O96017-7] DR ProteomicsDB; 51208; -. [O96017-8] DR ProteomicsDB; 51209; -. [O96017-9] DR ProteomicsDB; 81589; -. DR Pumba; O96017; -. DR ABCD; O96017; 1 sequenced antibody. DR Antibodypedia; 278; 2028 antibodies from 51 providers. DR CPTC; O96017; 2 antibodies. DR DNASU; 11200; -. DR Ensembl; ENST00000348295.7; ENSP00000329012.5; ENSG00000183765.25. [O96017-12] DR Ensembl; ENST00000382580.6; ENSP00000372023.2; ENSG00000183765.25. [O96017-9] DR Ensembl; ENST00000403642.5; ENSP00000384919.1; ENSG00000183765.25. [O96017-4] DR Ensembl; ENST00000404276.6; ENSP00000385747.1; ENSG00000183765.25. [O96017-1] DR Ensembl; ENST00000405598.5; ENSP00000386087.1; ENSG00000183765.25. [O96017-1] DR Ensembl; ENST00000417588.5; ENSP00000412901.1; ENSG00000183765.25. [O96017-5] DR Ensembl; ENST00000425190.7; ENSP00000390244.2; ENSG00000183765.25. [O96017-13] DR Ensembl; ENST00000433728.5; ENSP00000404400.1; ENSG00000183765.25. [O96017-8] DR Ensembl; ENST00000439346.6; ENSP00000396903.2; ENSG00000183765.25. [O96017-5] DR Ensembl; ENST00000448511.5; ENSP00000404567.1; ENSG00000183765.25. [O96017-6] DR Ensembl; ENST00000649563.1; ENSP00000496928.1; ENSG00000183765.25. [O96017-13] DR Ensembl; ENST00000650281.1; ENSP00000497000.1; ENSG00000183765.25. [O96017-1] DR GeneID; 11200; -. DR KEGG; hsa:11200; -. DR MANE-Select; ENST00000404276.6; ENSP00000385747.1; NM_007194.4; NP_009125.1. DR UCSC; uc003adt.2; human. [O96017-1] DR AGR; HGNC:16627; -. DR CIViC; 11200; 9 evidence items across 6 molecular profiles. DR ClinPGx; PA404; -. DR CTD; 11200; -. DR DisGeNET; 11200; -. DR GeneCards; CHEK2; -. DR GeneReviews; CHEK2; -. DR HGNC; HGNC:16627; CHEK2. DR HPA; ENSG00000183765; Low tissue specificity. DR MalaCards; CHEK2; -. DR MIM; 114480; phenotype. DR MIM; 176807; phenotype. DR MIM; 259500; phenotype. DR MIM; 604373; gene. DR MIM; 609265; phenotype. DR OpenTargets; ENSG00000183765; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 668; Osteosarcoma. DR VEuPathDB; HostDB:ENSG00000183765; -. DR eggNOG; KOG0615; Eukaryota. DR GeneTree; ENSGT00800000124190; -. DR HOGENOM; CLU_070593_1_0_1; -. DR InParanoid; O96017; -. DR OMA; MLCAVQY; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; O96017; 4 GO annotations based on evolutionary models. DR PhylomeDB; O96017; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O96017; -. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69601; Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A. DR Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex. DR SignaLink; O96017; -. DR SIGNOR; O96017; -. DR Agora; ENSG00000183765; -. DR BioGRID-ORCS; 11200; 24 hits in 1201 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; CHEK2; human. DR EvolutionaryTrace; O96017; -. DR GeneWiki; CHEK2; -. DR GenomeRNAi; 11200; -. DR Pharos; O96017; Tchem. DR PRO; PR:O96017; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; O96017; protein. DR Bgee; ENSG00000183765; Expressed in primordial germ cell in gonad and 107 other cell types or tissues. DR ExpressionAtlas; O96017; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:1903926; P:cellular response to bisphenol A; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; TAS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:MGI. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0044773; P:mitotic DNA damage checkpoint signaling; IBA:GO_Central. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; IMP:UniProtKB. DR GO; GO:2000002; P:negative regulation of DNA damage checkpoint; IEA:Ensembl. DR GO; GO:2000210; P:positive regulation of anoikis; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0042176; P:regulation of protein catabolic process; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0090399; P:replicative senescence; NAS:BHF-UCL. DR GO; GO:1903416; P:response to glycoside; IEA:Ensembl. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:MGI. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR CDD; cd22666; FHA_CHK2; 1. DR CDD; cd14084; STKc_Chk2; 1. DR DisProt; DP01797; -. DR FunFam; 1.10.510.10:FF:000354; Serine/threonine-protein kinase Chk2; 1. DR FunFam; 2.60.200.20:FF:000011; Serine/threonine-protein kinase Chk2; 1. DR FunFam; 3.30.200.20:FF:000255; serine/threonine-protein kinase Chk2 isoform X1; 1. DR Gene3D; 2.60.200.20; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000253; FHA_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR PANTHER; PTHR44167; OVARIAN-SPECIFIC SERINE/THREONINE-PROTEIN KINASE LOK-RELATED; 1. DR PANTHER; PTHR44167:SF24; SERINE_THREONINE-PROTEIN KINASE CHK2; 1. DR Pfam; PF00498; FHA; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00240; FHA; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS50006; FHA_DOMAIN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell cycle; KW Cell division; Disease variant; DNA damage; DNA repair; KW Host-virus interaction; Kinase; Li-Fraumeni syndrome; Magnesium; KW Metal-binding; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Tumor suppressor; Ubl conjugation. FT CHAIN 1..543 FT /note="Serine/threonine-protein kinase Chk2" FT /id="PRO_0000085858" FT DOMAIN 113..175 FT /note="FHA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00086" FT DOMAIN 220..486 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..66 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 368..394 FT /note="T-loop/activation segment" FT REGION 506..538 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 8..22 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 23..62 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 506..517 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 523..534 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 347 FT /note="Proton acceptor" FT BINDING 227..234 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 249 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 302..308 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 351..352 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 62 FT /note="Phosphoserine; by PLK3" FT /evidence="ECO:0000269|PubMed:16481012" FT MOD_RES 68 FT /note="Phosphothreonine; by ATM and MAP3K20" FT /evidence="ECO:0000269|PubMed:10973490, FT ECO:0000269|PubMed:15342622, ECO:0000269|PubMed:16311512, FT ECO:0000269|PubMed:16481012" FT MOD_RES 73 FT /note="Phosphoserine; by PLK3" FT /evidence="ECO:0000269|PubMed:16481012" FT MOD_RES 379 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18644861" FT MOD_RES 383 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11390408" FT MOD_RES 387 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11390408" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17715138" FT VAR_SEQ 1..221 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:15498874" FT /id="VSP_045148" FT VAR_SEQ 75..392 FT /note="Missing (in isoform 11)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014556" FT VAR_SEQ 107..487 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014559" FT VAR_SEQ 107..197 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014558" FT VAR_SEQ 107 FT /note="E -> ETESGHVTQSDLELLLSSDPPASASQSAGIRGVRHHPRPVCSLK FT (in isoform 9)" FT /evidence="ECO:0000303|PubMed:15361853, FT ECO:0000303|PubMed:15461802" FT /id="VSP_014557" FT VAR_SEQ 131..147 FT /note="KRTDKYRTYSKKHFRIF -> EFRSYSFYLP (in isoform 10)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014560" FT VAR_SEQ 148..543 FT /note="Missing (in isoform 10)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014561" FT VAR_SEQ 150..165 FT /note="VGPKNSYIAYIEDHSG -> ENLSCPYRIWFNFCLF (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014562" FT VAR_SEQ 166..543 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014563" FT VAR_SEQ 198..224 FT /note="VFVFFDLTVDDQSVYPKALRDEYIMSK -> EKILKIYSLSRFSKIRRGAVA FT HVFNPS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014564" FT VAR_SEQ 199..203 FT /note="FVFFD -> VPVER (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014565" FT VAR_SEQ 204..543 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014566" FT VAR_SEQ 228..234 FT /note="SGACGEV -> GRGWQIT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014567" FT VAR_SEQ 235..543 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097108, FT ECO:0000303|PubMed:15361853" FT /id="VSP_014568" FT VAR_SEQ 283..289 FT /note="PCIIKIK -> DGRGRAV (in isoform 8)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014569" FT VAR_SEQ 290..543 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014570" FT VAR_SEQ 337..365 FT /note="Missing (in isoform 12)" FT /evidence="ECO:0000303|PubMed:15361853, ECO:0000303|Ref.7" FT /id="VSP_014571" FT VAR_SEQ 337..339 FT /note="YLH -> MKT (in isoform 7)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014572" FT VAR_SEQ 340..543 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:15361853" FT /id="VSP_014573" FT VARIANT 17 FT /note="A -> S (found in an osteogenic sarcoma sample; FT somatic mutation; might influence susceptibility to breast FT cancer; dbSNP:rs137853008)" FT /evidence="ECO:0000269|PubMed:11746983" FT /id="VAR_019101" FT VARIANT 59 FT /note="T -> K (in multiple cancers; dbSNP:rs149991239)" FT /evidence="ECO:0000269|PubMed:12052256" FT /id="VAR_026630" FT VARIANT 64 FT /note="E -> K (in prostate cancer; somatic mutation; FT dbSNP:rs141568342)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019107" FT VARIANT 85 FT /note="P -> L (found in an osteogenic sarcoma sample; FT somatic mutation; dbSNP:rs17883862)" FT /evidence="ECO:0000269|PubMed:11746983, FT ECO:0000269|PubMed:15649950, ECO:0000269|Ref.10" FT /id="VAR_019102" FT VARIANT 117 FT /note="R -> G (in BC; dbSNP:rs28909982)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15818573" FT /id="VAR_022461" FT VARIANT 137 FT /note="R -> Q (might influence susceptibility to breast FT cancer; dbSNP:rs368570187)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:15818573" FT /id="VAR_022462" FT VARIANT 145 FT /note="R -> P (in prostate cancer; somatic mutation; FT dbSNP:rs587781667)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019108" FT VARIANT 145 FT /note="R -> W (in TPDS4; loss of the ability to interact FT with and phosphorylate CDC25A and to promote CDC25A FT degradation in response to ionizing radiation; FT dbSNP:rs137853007)" FT /evidence="ECO:0000269|PubMed:10617473, FT ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11719428, FT ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15535844, FT ECO:0000269|PubMed:15818573" FT /id="VAR_008554" FT VARIANT 157 FT /note="I -> T (might influence susceptibility to different FT types of cancer; loss of the ability to interact with and FT phosphorylate CDC25A and to promote CDC25A degradation in FT response to ionizing radiation; dbSNP:rs17879961)" FT /evidence="ECO:0000269|PubMed:10617473, FT ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11461078, FT ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:12610780, FT ECO:0000269|PubMed:14612911, ECO:0000269|PubMed:15087378, FT ECO:0000269|PubMed:15095295, ECO:0000269|PubMed:15239132, FT ECO:0000269|PubMed:15492928, ECO:0000269|PubMed:15535844, FT ECO:0000269|PubMed:15810020, ECO:0000269|PubMed:15818573, FT ECO:0000269|Ref.10" FT /id="VAR_008555" FT VARIANT 167 FT /note="G -> R (in prostate cancer; somatic mutation; FT dbSNP:rs72552322)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019109" FT VARIANT 180 FT /note="R -> C (in prostate cancer; somatic mutation; FT dbSNP:rs77130927)" FT /evidence="ECO:0000269|PubMed:12533788, FT ECO:0000269|PubMed:21618645" FT /id="VAR_019103" FT VARIANT 180 FT /note="R -> H (in prostate cancer; somatic mutation; FT dbSNP:rs137853009)" FT /evidence="ECO:0000269|PubMed:12454775, FT ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:15818573" FT /id="VAR_019110" FT VARIANT 181 FT /note="R -> C (in prostate cancer; somatic mutation; FT dbSNP:rs137853010)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019104" FT VARIANT 181 FT /note="R -> H (in prostate cancer; somatic mutation; FT dbSNP:rs121908701)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019105" FT VARIANT 239 FT /note="E -> K (in prostate cancer; germline mutation; FT dbSNP:rs121908702)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019106" FT VARIANT 251 FT /note="I -> F (in prostate cancer; uncertain significance; FT dbSNP:rs587780189)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019111" FT VARIANT 318 FT /note="R -> H (in prostate cancer; uncertain significance; FT somatic mutation; dbSNP:rs143611747)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019112" FT VARIANT 323 FT /note="T -> P (in prostate cancer; somatic mutation; FT dbSNP:rs750984976)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019113" FT VARIANT 327 FT /note="Y -> C (in prostate cancer; uncertain significance; FT somatic mutation; dbSNP:rs587780194)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019114" FT VARIANT 347 FT /note="D -> N (in dbSNP:rs28909980)" FT /id="VAR_029154" FT VARIANT 371 FT /note="H -> Y (confers a moderate risk of breast cancer; FT partially reduces kinase activity; dbSNP:rs531398630)" FT /evidence="ECO:0000269|PubMed:21618645" FT /id="VAR_066012" FT VARIANT 390 FT /note="Y -> C (in BC; does not phosphorylate p53/TP53; FT dbSNP:rs200928781)" FT /evidence="ECO:0000269|PubMed:25619829" FT /id="VAR_073020" FT VARIANT 406 FT /note="R -> H (in dbSNP:rs200649225)" FT /id="VAR_024572" FT VARIANT 428 FT /note="S -> F (may increase breast cancer risk; FT dbSNP:rs137853011)" FT /evidence="ECO:0000269|PubMed:15649950" FT /id="VAR_022463" FT VARIANT 436 FT /note="L -> M (in dbSNP:rs17882922)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021117" FT VARIANT 446 FT /note="N -> K (in dbSNP:rs17880867)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021118" FT VARIANT 447 FT /note="F -> I (in dbSNP:rs17881473)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021119" FT VARIANT 448 FT /note="I -> S (in dbSNP:rs17886163)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021120" FT VARIANT 476 FT /note="T -> K (in prostate cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:12533788" FT /id="VAR_019115" FT VARIANT 500 FT /note="S -> C (in dbSNP:rs28909981)" FT /id="VAR_029155" FT VARIANT 501 FT /note="E -> K (in dbSNP:rs17883172)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021121" FT VARIANT 512 FT /note="L -> V (in dbSNP:rs17882942)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_021122" FT MUTAGEN 68 FT /note="T->A: Loss of activation and phosphorylation." FT /evidence="ECO:0000269|PubMed:11901158, FT ECO:0000269|PubMed:15342622" FT MUTAGEN 73 FT /note="S->A: Impaired activation, phosphorylation by ATM FT and G2/M transition checkpoint." FT /evidence="ECO:0000269|PubMed:16481012" FT MUTAGEN 347 FT /note="D->A: Loss of kinase activity and of the ability to FT phosphorylate CDC25A." FT /evidence="ECO:0000269|PubMed:11298456, FT ECO:0000269|PubMed:9836640" FT MUTAGEN 368 FT /note="D->N: Loss of autophosphorylation activity." FT /evidence="ECO:0000269|PubMed:15342622" FT MUTAGEN 379 FT /note="S->A: Abrogates autophosphorylation at Ser-379 and FT prevents ubiquitination." FT /evidence="ECO:0000269|PubMed:18644861" FT MUTAGEN 383 FT /note="T->A: Loss of phosphorylation in response to FT ionizing radiation." FT /evidence="ECO:0000269|PubMed:11390408" FT MUTAGEN 387 FT /note="T->A: Loss of phosphorylation in response to FT ionizing radiation." FT /evidence="ECO:0000269|PubMed:11390408" FT MUTAGEN 456 FT /note="S->A: Increased ubiquitination and degradation by FT the proteasome." FT /evidence="ECO:0000269|PubMed:17715138" FT STRAND 94..98 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 100..103 FT /evidence="ECO:0007829|PDB:3I6U" FT STRAND 106..108 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 128..132 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 135..138 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 154..162 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 187..193 FT /evidence="ECO:0007829|PDB:1GXC" FT STRAND 197..203 FT /evidence="ECO:0007829|PDB:1GXC" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:3I6U" FT HELIX 214..219 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 230..239 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 240..243 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 244..251 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 253..256 FT /evidence="ECO:0007829|PDB:3I6U" FT HELIX 270..279 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 288..302 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 307..309 FT /evidence="ECO:0007829|PDB:4BDD" FT HELIX 310..313 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2W7X" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 353..361 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4BDE" FT HELIX 379..385 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:2WTJ" FT HELIX 393..398 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 399..403 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 407..422 FT /evidence="ECO:0007829|PDB:2YCF" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:2CN5" FT HELIX 436..442 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 449..452 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 457..466 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 471..473 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:2YCF" FT HELIX 489..502 FT /evidence="ECO:0007829|PDB:2YCF" FT TURN 504..506 FT /evidence="ECO:0007829|PDB:2WTJ" SQ SEQUENCE 543 AA; 60915 MW; 28890ACF3C1F3408 CRC64; MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS QSSHSSSGTL SSLETVSTQE LYSIPEDQEP EDQEPEEPTP APWARLWALQ DGFANLECVN DNYWFGRDKS CEYCFDEPLL KRTDKYRTYS KKHFRIFREV GPKNSYIAYI EDHSGNGTFV NTELVGKGKR RPLNNNSEIA LSLSRNKVFV FFDLTVDDQS VYPKALRDEY IMSKTLGSGA CGEVKLAFER KTCKKVAIKI ISKRKFAIGS AREADPALNV ETEIEILKKL NHPCIIKIKN FFDAEDYYIV LELMEGGELF DKVVGNKRLK EATCKLYFYQ MLLAVQYLHE NGIIHRDLKP ENVLLSSQEE DCLIKITDFG HSKILGETSL MRTLCGTPTY LAPEVLVSVG TAGYNRAVDC WSLGVILFIC LSGYPPFSEH RTQVSLKDQI TSGKYNFIPE VWAEVSEKAL DLVKKLLVVD PKARFTTEEA LRHPWLQDED MKRKFQDLLS EENESTALPQ VLAQPSTSRK RPREGEAEGA ETTKRPAVCA AVL // ID DAPK3_HUMAN Reviewed; 454 AA. AC O43293; A0AVN4; B3KQE2; Q05JY4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1998, sequence version 1. DT 28-JAN-2026, entry version 218. DE RecName: Full=Death-associated protein kinase 3; DE Short=DAP kinase 3; DE EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; DE AltName: Full=DAP-like kinase; DE Short=Dlk; DE AltName: Full=MYPT1 kinase; DE AltName: Full=Zipper-interacting protein kinase; DE Short=ZIP-kinase; GN Name=DAPK3; Synonyms=ZIPK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9488481; DOI=10.1128/mcb.18.3.1642; RA Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.; RT "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis."; RL Mol. Cell. Biol. 18:1642-1651(1998). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR. RC TISSUE=Cervix carcinoma; RX PubMed=10356987; DOI=10.1016/s0014-5793(99)00550-5; RA Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.; RT "ZIP kinase identified as a novel myosin regulatory light chain kinase in RT HeLa cells."; RL FEBS Lett. 451:81-84(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE SPLICING, RP FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION RP WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Urinary bladder; RX PubMed=17126281; DOI=10.1016/j.abb.2006.09.026; RA Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.; RT "Novel ZIP kinase isoform lacks leucine zipper."; RL Arch. Biochem. Biophys. 456:194-203(2006). RN [6] RP FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11384979; DOI=10.1074/jbc.m102753200; RA Niiro N., Ikebe M.; RT "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle RT contraction via myosin light chain phosphorylation."; RL J. Biol. Chem. 276:29567-29574(2001). RN [7] RP FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11781833; DOI=10.1038/sj.onc.1205055; RA Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.; RT "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light RT chain and reorganization of actin filaments in nonmuscle cells."; RL Oncogene 20:8175-8183(2001). RN [8] {ECO:0000305} RP FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR. RX PubMed=12917339; DOI=10.1128/mcb.23.17.6174-6186.2003; RA Kawai T., Akira S., Reed J.C.; RT "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains."; RL Mol. Cell. Biol. 23:6174-6186(2003). RN [9] RP INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY. RX PubMed=15292222; DOI=10.1074/jbc.m403676200; RA Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.; RT "Identification and characterization of zipper-interacting protein kinase RT as the unique vascular smooth muscle myosin phosphatase-associated RT kinase."; RL J. Biol. Chem. 279:42055-42061(2004). RN [10] RP FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=15096528; DOI=10.1083/jcb.200309056; RA Komatsu S., Ikebe M.; RT "ZIP kinase is responsible for the phosphorylation of myosin II and RT necessary for cell motility in mammalian fibroblasts."; RL J. Cell Biol. 165:243-254(2004). RN [11] RP FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312; SER-318 RP AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR LOCATION. RX PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004; RA Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G., RA Kimchi A.; RT "Death-associated protein kinase phosphorylates ZIP kinase, forming a RT unique kinase hierarchy to activate its cell death functions."; RL Mol. Cell. Biol. 24:8611-8626(2004). RN [12] RP INTERACTION WITH STAT3. RX PubMed=16219639; DOI=10.1093/intimm/dxh331; RA Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y., RA Ishida M., Akira S., Matsuda T.; RT "Physical and functional interactions between STAT3 and ZIP kinase."; RL Int. Immunol. 17:1543-1552(2005). RN [13] RP INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION. RX PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x; RA Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.; RT "TCP10L is expressed specifically in spermatogenic cells and binds to death RT associated protein kinase-3."; RL Int. J. Androl. 28:163-170(2005). RN [14] RP PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND SER-311, RP ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-299; RP 299-THR-THR-300; VAL-427; VAL-434 AND LEU-441. RX PubMed=15611134; DOI=10.1074/jbc.m412538200; RA Graves P.R., Winkfield K.M., Haystead T.A.; RT "Regulation of zipper-interacting protein kinase activity in vitro and in RT vivo by multisite phosphorylation."; RL J. Biol. Chem. 280:9363-9374(2005). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615; RA Bialik S., Kimchi A.; RT "The death-associated protein kinases: structure, function, and beyond."; RL Annu. Rev. Biochem. 75:189-210(2006). RN [16] RP FUNCTION, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161; THR-225; RP THR-265 AND THR-299. RX PubMed=17158456; DOI=10.1074/jbc.m609990200; RA Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H., RA Loiselle D., Hosoya H., Haystead T.A.; RT "ROCK1 phosphorylates and activates zipper-interacting protein kinase."; RL J. Biol. Chem. 282:4884-4893(2007). RN [17] RP SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW. RX PubMed=17953487; DOI=10.1371/journal.pgen.0030180; RA Shoval Y., Pietrokovski S., Kimchi A.; RT "ZIPK: a unique case of murine-specific divergence of a conserved RT vertebrate gene."; RL PLoS Genet. 3:1884-1893(2007). RN [18] RP REVIEW ON FUNCTION. RX DOI=10.1002/sita.200600112; RA Scheidtmann K.H.; RT "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple RT functions."; RL Signal Transduct. 7:248-259(2007). RN [19] RP FUNCTION IN PHOSPHORYLATION OF RPL13A, AND CATALYTIC ACTIVITY. RX PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019; RA Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.; RT "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating RT inflammatory gene expression."; RL Mol. Cell 32:371-382(2008). RN [20] RP FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [21] RP FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112; ASN-161 RP AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION. RX PubMed=21487036; DOI=10.1158/0008-5472.can-10-3543; RA Brognard J., Zhang Y.W., Puto L.A., Hunter T.; RT "Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor- RT suppressing kinase."; RL Cancer Res. 71:3152-3161(2011). RN [22] RP PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 294-ARG-ARG-295. RX PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016; RA Weitzel D.H., Chambers J., Haystead T.A.; RT "Phosphorylation-dependent control of ZIPK nuclear import is species RT specific."; RL Cell. Signal. 23:297-303(2011). RN [23] RP FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1. RX PubMed=21169990; DOI=10.1038/emboj.2010.338; RA Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.; RT "Atg1-mediated myosin II activation regulates autophagosome formation RT during starvation-induced autophagy."; RL EMBO J. 30:636-651(2011). RN [24] RP FUNCTION, AND INTERACTION WITH NLK. RX PubMed=21454679; DOI=10.1074/jbc.m110.189829; RA Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R., RA Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.; RT "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta- RT catenin signaling through interaction with Nemo-like kinase and T-cell RT factor 4 (NLK/TCF4)."; RL J. Biol. Chem. 286:19170-19177(2011). RN [25] RP FUNCTION, AND INTERACTION WITH ATF4. RX PubMed=21408167; DOI=10.1371/journal.pone.0017344; RA Shoval Y., Berissi H., Kimchi A., Pietrokovski S.; RT "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene RT produces a ZIPk-like isoform."; RL PLoS ONE 6:E17344-E17344(2011). RN [26] RP FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH RP RHOD. RX PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046; RA Nehru V., Almeida F.N., Aspenstrom P.; RT "Interaction of RhoD and ZIP kinase modulates actin filament assembly and RT focal adhesion dynamics."; RL Biochem. Biophys. Res. Commun. 433:163-169(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP FUNCTION, INTERACTION WITH LUZP1, AND SUBCELLULAR LOCATION. RX PubMed=38009294; DOI=10.1111/febs.17017; RA Hyodo T., Asano-Inami E., Ito S., Sugiyama M., Nawa A., Rahman M.L., RA Hasan M.N., Mihara Y., Lam V.Q., Karnan S., Ota A., Tsuzuki S., RA Hamaguchi M., Hosokawa Y., Konishi H.; RT "Leucine zipper protein 1 (LUZP1) regulates the constriction velocity of RT the contractile ring during cytokinesis."; RL FEBS J. 291:927-944(2024). RN [29] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277. RA Kursula P., Vahokoski J., Wilmanns M.; RT "Crystal structure of human ZIP kinase."; RL Submitted (JUN-2006) to the PDB data bank. RN [30] {ECO:0007744|PDB:2J90} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH PYRIDONE-6, RP ACTIVITY REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50 AND THR-265. RX PubMed=18239682; DOI=10.1038/emboj.2008.8; RA Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A., RA Turk B.E., Pearl L.H., Knapp S.; RT "Activation segment dimerization: a mechanism for kinase RT autophosphorylation of non-consensus sites."; RL EMBO J. 27:704-714(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which is involved in the regulation CC of apoptosis, autophagy, transcription, translation and actin CC cytoskeleton reorganization. Involved in the regulation of smooth CC muscle contraction. Regulates both type I (caspase-dependent) apoptotic CC and type II (caspase-independent) autophagic cell deaths signal, CC depending on the cellular setting. Involved in regulation of CC starvation-induced autophagy. Regulates myosin phosphorylation in both CC smooth muscle and non-muscle cells. In smooth muscle, regulates myosin CC either directly by phosphorylating MYL12B and MYL9 or through CC inhibition of smooth muscle myosin phosphatase (SMPP1M) via CC phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to CC enhance muscle responsiveness to Ca(2+) and promote a contractile CC state. Phosphorylates MYL12B in non-muscle cells leading to CC reorganization of actin cytoskeleton. Isoform 2 can phosphorylate CC myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of CC actin stress fibers into thick bundles. Involved in actin filament CC focal adhesion dynamics. The function in both reorganization of actin CC cytoskeleton and focal adhesion dissolution is modulated by RhoD. CC Positively regulates canonical Wnt/beta-catenin signaling through CC interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon CC interferon-gamma activation which is causing RPL13A release from the CC ribosome, RPL13A association with the GAIT complex and its subsequent CC involvement in transcript-selective translation inhibition. Enhances CC transcription from AR-responsive promoters in a hormone- and kinase- CC dependent manner. Involved in regulation of cell cycle progression and CC cell proliferation. May be a tumor suppressor. CC {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120, CC ECO:0000269|PubMed:38009294}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10356987}; CC -!- ACTIVITY REGULATION: A sequential activation is proposed: CC autophosphorylation at consensus sites is leading to dimerization of CC the catalytic domain stabilized by phosphorylation at Ser-50 and CC activation segment exchange (producing an active confirmation of both CC kinase modules in trans) followed by phosphorylation at Thr-180 in the CC activation segment and at other regulatory sites (Probable). CC Phosphorylation at Thr-180, Thr-225 and Thr-265 is essential for CC activity. Oligomerization is required for full enzymatic activity. CC Inhibited by pyridone-6 (K00225), a potent, ATP-competitive inhibitor. CC {ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, CC ECO:0000269|PubMed:18239682, ECO:0000303|PubMed:18239682}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281}; CC KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281}; CC Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and CC homodimers are reported); monomeric in its kinase-inactive form. CC Homodimerization is required for activation segment autophosphorylation CC (Probable). Isoform 1 and isoform 2 interact with myosin and PPP1R12A; CC interaction of isoform 1 with PPP1R12A is inhibited by RhoA dominant CC negative form. Interacts with NLK, DAXX, STAT3, RHOD (GTP-bound form) CC and TCP10L. Interacts with PAWR; the interaction is reported CC conflictingly: according to PubMed:17953487 does not interact with CC PAWR. Interacts with ULK1; may be a substrate of ULK1. Interacts with CC LUZP1; the interaction is likely to occur throughout the cell cycle and CC reduces the LUZP1-mediated suppression of MYL9 phosphorylation CC (PubMed:38009294). {ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:15910542, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:18239682, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:23454120, ECO:0000269|PubMed:38009294, CC ECO:0000303|PubMed:18239682}. CC -!- INTERACTION: CC O43293; O43293: DAPK3; NbExp=3; IntAct=EBI-77293, EBI-77293; CC O43293; Q86V48: LUZP1; NbExp=3; IntAct=EBI-77293, EBI-350467; CC O43293; Q9UBE8: NLK; NbExp=3; IntAct=EBI-77293, EBI-366978; CC O43293; O14974: PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726; CC O43293; Q8TDR4: TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210; CC O43293-2; Q10728: Ppp1r12a; Xeno; NbExp=2; IntAct=EBI-9691390, EBI-918263; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}. Nucleus, PML CC body {ECO:0000250|UniProtKB:O54784}. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:O54784}. Chromosome, centromere CC {ECO:0000269|PubMed:38009294}. Cytoplasm {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17953487, CC ECO:0000269|PubMed:20854903}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:38009294}. Midbody {ECO:0000269|PubMed:38009294}. CC Note=Predominantly localizes to the cytoplasm but can shuttle between CC the nucleus and cytoplasm; cytoplasmic localization is promoted by CC phosphorylation at Thr-299 and involves Rho/Rock signaling. CC {ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=ZIPK-L; CC IsoId=O43293-1; Sequence=Displayed; CC Name=2; Synonyms=ZIPK-S; CC IsoId=O43293-2; Sequence=VSP_042059, VSP_042060; CC -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are CC expressed in the bladder smooth muscle. {ECO:0000269|PubMed:15292222, CC ECO:0000269|PubMed:17126281}. CC -!- PTM: The phosphorylation status is critical for kinase activity, CC oligomerization and intracellular localization. Phosphorylation at Thr- CC 180, Thr-225 and Thr-265 is essential for activity. The phosphorylated CC form is localized in the cytoplasm promoted by phosphorylation at Thr- CC 299; nuclear translocation or retention is maximal when it is not CC phosphorylated. Phosphorylation increases the trimeric form, and its CC dephosphorylation favors a kinase-inactive monomeric form. Both isoform CC 1 and isoform 2 can undergo autophosphorylation. CC {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:20854903}. CC -!- MISCELLANEOUS: [Isoform 2]: The internal splice site between exon 8 and CC the 3' UTR, which yields this truncated isoform, is non-canonical. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. DAP kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB007144; BAA24955.1; -; mRNA. DR EMBL; AB022341; BAA81746.1; -; mRNA. DR EMBL; AK074799; BAG52004.1; -; mRNA. DR EMBL; BC126430; AAI26431.1; -; mRNA. DR EMBL; BC126432; AAI26433.1; -; mRNA. DR EMBL; AB265224; BAF34614.1; -; mRNA. DR CCDS; CCDS12116.1; -. [O43293-1] DR RefSeq; NP_001339.1; NM_001348.3. [O43293-1] DR RefSeq; NP_001362587.1; NM_001375658.1. [O43293-1] DR PDB; 1YRP; X-ray; 3.10 A; A/B=1-277. DR PDB; 2J90; X-ray; 2.00 A; A/B=9-289. DR PDB; 3BHY; X-ray; 1.24 A; A=9-289. DR PDB; 3BQR; X-ray; 1.75 A; A=9-289. DR PDB; 5A6N; X-ray; 1.70 A; A/B=9-289. DR PDB; 5A6O; X-ray; 1.60 A; A/B=9-289. DR PDB; 5VJA; X-ray; 2.46 A; A/B/C/D=9-289. DR PDBsum; 1YRP; -. DR PDBsum; 2J90; -. DR PDBsum; 3BHY; -. DR PDBsum; 3BQR; -. DR PDBsum; 5A6N; -. DR PDBsum; 5A6O; -. DR PDBsum; 5VJA; -. DR AlphaFoldDB; O43293; -. DR SMR; O43293; -. DR BioGRID; 107983; 101. DR FunCoup; O43293; 2772. DR IntAct; O43293; 75. DR MINT; O43293; -. DR STRING; 9606.ENSP00000442973; -. DR BindingDB; O43293; -. DR ChEMBL; CHEMBL2468; -. DR DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB07125; 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O43293; -. DR GuidetoPHARMACOLOGY; 2004; -. DR GlyGen; O43293; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O43293; -. DR PhosphoSitePlus; O43293; -. DR BioMuta; DAPK3; -. DR CPTAC; CPTAC-3091; -. DR CPTAC; CPTAC-3092; -. DR jPOST; O43293; -. DR MassIVE; O43293; -. DR PaxDb; 9606-ENSP00000442973; -. DR PeptideAtlas; O43293; -. DR ProteomicsDB; 48863; -. [O43293-1] DR ProteomicsDB; 48864; -. [O43293-2] DR Pumba; O43293; -. DR Antibodypedia; 11137; 420 antibodies from 44 providers. DR DNASU; 1613; -. DR Ensembl; ENST00000301264.7; ENSP00000301264.3; ENSG00000167657.15. [O43293-1] DR Ensembl; ENST00000545797.7; ENSP00000442973.1; ENSG00000167657.15. [O43293-1] DR GeneID; 1613; -. DR KEGG; hsa:1613; -. DR MANE-Select; ENST00000545797.7; ENSP00000442973.1; NM_001348.3; NP_001339.1. DR UCSC; uc002lzc.2; human. [O43293-1] DR AGR; HGNC:2676; -. DR ClinPGx; PA27144; -. DR CTD; 1613; -. DR DisGeNET; 1613; -. DR GeneCards; DAPK3; -. DR HGNC; HGNC:2676; DAPK3. DR HPA; ENSG00000167657; Low tissue specificity. DR MIM; 603289; gene. DR OpenTargets; ENSG00000167657; -. DR VEuPathDB; HostDB:ENSG00000167657; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000161753; -. DR HOGENOM; CLU_000288_63_55_1; -. DR InParanoid; O43293; -. DR OMA; LWYKEEN; -. DR OrthoDB; 74764at2759; -. DR PAN-GO; O43293; 5 GO annotations based on evolutionary models. DR PhylomeDB; O43293; -. DR PathwayCommons; O43293; -. DR Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand. DR SABIO-RK; O43293; -. DR SignaLink; O43293; -. DR SIGNOR; O43293; -. DR Agora; ENSG00000167657; -. DR BioGRID-ORCS; 1613; 21 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; DAPK3; human. DR EvolutionaryTrace; O43293; -. DR GeneWiki; DAPK3; -. DR GenomeRNAi; 1613; -. DR Pharos; O43293; Tchem. DR PRO; PR:O43293; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O43293; protein. DR Bgee; ENSG00000167657; Expressed in apex of heart and 188 other cell types or tissues. DR ExpressionAtlas; O43293; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0005819; C:spindle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB. DR GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl. DR GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB. DR CDD; cd14105; STKc_DAPK; 1. DR FunFam; 3.30.200.20:FF:000110; Death-associated kinase 3, isoform CRA_a; 1. DR FunFam; 1.10.510.10:FF:000250; Death-associated protein kinase 3; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042870; DAPK3_STKc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24342:SF18; DEATH-ASSOCIATED PROTEIN KINASE 3; 1. DR PANTHER; PTHR24342; SERINE/THREONINE-PROTEIN KINASE 17; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding; KW Centromere; Chromatin regulator; Chromosome; Cytoplasm; Cytoskeleton; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Translation regulation; Tumor suppressor. FT CHAIN 1..454 FT /note="Death-associated protein kinase 3" FT /id="PRO_0000085914" FT DOMAIN 13..275 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 161..204 FT /note="Activation segment" FT /evidence="ECO:0000250|UniProtKB:O96017" FT REGION 427..441 FT /note="Leucine-zipper" FT /evidence="ECO:0000303|PubMed:9488481" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 19..27 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 42 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 94 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT BINDING 96 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT MOD_RES 50 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18239682" FT MOD_RES 180 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456" FT MOD_RES 225 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 265 FT /note="Phosphothreonine; by autocatalysis and ROCK1" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682" FT MOD_RES 299 FT /note="Phosphothreonine; by autocatalysis, DAPK1 and ROCK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, FT ECO:0000269|PubMed:20854903" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 309 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 311 FT /note="Phosphoserine; by autocatalysis and DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134" FT MOD_RES 312 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0007744|PubMed:23186163" FT MOD_RES 318 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 326 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT VAR_SEQ 313..322 FT /note="LPPNNSYADF -> ASPIVAPVDA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042059" FT VAR_SEQ 323..454 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042060" FT VARIANT 112 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040438" FT VARIANT 161 FT /note="D -> N (in an ovarian mucinous carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040439" FT VARIANT 216 FT /note="P -> S (in a lung neuroendocrine carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation, cell adhesion and cell FT survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040440" FT MUTAGEN 42 FT /note="K->A: Loss of kinase activity at low concentrations FT of ATP." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 161 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 180 FT /note="T->A: Greatly reduced kinase activity." FT /evidence="ECO:0000269|PubMed:21487036" FT MUTAGEN 225 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 265 FT /note="T->A: Loss of phosphorylation by ROCK1, FT catalytically inactive." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 294..295 FT /note="RR->AA: Cytoplasmic localization." FT /evidence="ECO:0000269|PubMed:20854903" FT MUTAGEN 299..300 FT /note="TT->AA: Predominantly nuclear localization." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 299 FT /note="T->A: Loss of phosphorylation by ROCK1." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 299 FT /note="T->D: Predominantly cytoplasmic localization; FT phosphomimetic." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 427 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-434 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 434 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-427 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 441 FT /note="L->A: Predominantly nuclear localization; when FT associated with A-427 and A-434." FT /evidence="ECO:0000269|PubMed:15611134" FT HELIX 9..12 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 13..21 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 23..32 FT /evidence="ECO:0007829|PDB:3BHY" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 49..51 FT /evidence="ECO:0007829|PDB:2J90" FT STRAND 53..56 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 58..70 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 113..132 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 145..148 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 150..154 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 171..175 FT /evidence="ECO:0007829|PDB:5A6N" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:5A6O" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 186..189 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 197..212 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 222..230 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 238..241 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 246..253 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 260..262 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 266..271 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 273..280 FT /evidence="ECO:0007829|PDB:3BHY" SQ SEQUENCE 454 AA; 52536 MW; 56773008A6A61CF0 CRC64; MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR // ID DEDD2_HUMAN Reviewed; 326 AA. AC Q8WXF8; Q8NBR2; Q8NES1; Q8TAA8; Q96D35; DT 10-MAY-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 1. DT 28-JAN-2026, entry version 176. DE RecName: Full=DNA-binding death effector domain-containing protein 2; DE AltName: Full=DED-containing protein FLAME-3; DE AltName: Full=FADD-like anti-apoptotic molecule 3; GN Name=DEDD2; Synonyms=FLAME3; ORFNames=PSEC0004; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION RP WITH CASP8. RX PubMed=11741985; DOI=10.1074/jbc.m110749200; RA Roth W., Stenner-Liewen F., Pawlowski K., Godzik A., Reed J.C.; RT "Identification and characterization of DEDD2, a death effector domain- RT containing protein."; RL J. Biol. Chem. 277:7501-7508(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INTERACTION WITH CASP8 AND GTF3C3. RX PubMed=11965497; DOI=10.1038/sj.cdd.4401038; RA Zhan Y., Hegde R., Srinivasula S.M., Fernandes-Alnemri T., Alnemri E.S.; RT "Death effector domain-containing proteins DEDD and FLAME-3 form nuclear RT complexes with the TFIIIC102 subunit of human transcription factor IIIC."; RL Cell Death Differ. 9:439-447(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=12235123; DOI=10.1083/jcb.200112124; RA Lee J.C., Schickling O., Stegh A.H., Oshima R.G., Dinsdale D., Cohen G.M., RA Peter M.E.; RT "DEDD regulates degradation of intermediate filaments during apoptosis."; RL J. Cell Biol. 158:1051-1066(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INTERACTION WITH CASP8 AND CASP10. RX PubMed=12527898; DOI=10.1038/sj.onc.1206099; RA Alcivar A., Hu S., Tang J., Yang X.; RT "DEDD and DEDD2 associate with caspase-8/10 and signal cell death."; RL Oncogene 22:291-297(2003). CC -!- FUNCTION: May play a critical role in death receptor-induced apoptosis CC and may target CASP8 and CASP10 to the nucleus. May regulate CC degradation of intermediate filaments during apoptosis. May play a role CC in the general transcription machinery in the nucleus and might be an CC important regulator of the activity of GTF3C3. CC -!- SUBUNIT: Interacts with CASP8, CASP10 and GTF3C3. Homodimerizes and CC heterodimerizes with DEDD. {ECO:0000269|PubMed:11741985, CC ECO:0000269|PubMed:11965497, ECO:0000269|PubMed:12527898}. CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:11965497}. CC Note=Nuclear, accumulated in subnuclear structures resembling nucleoli. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WXF8-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WXF8-2; Sequence=VSP_010312; CC -!- TISSUE SPECIFICITY: Expressed in most tissues. High levels were found CC in liver, kidney, heart, ovary, spleen, testes, skeletal muscle and CC peripheral blood leukocytes. Expression was absent or low in colon and CC small intestine. Expression is relatively high in the tumor cell lines CC chronic myologenous leukemia K-562 and the colorectal adenocarcinoma CC SW480. Expression is moderate in the cervical carcinoma HeLa, the CC Burkitt's lymphoma Raji, the lung carcinoma A-549, and the melanoma G- CC 361. In contrast, two leukemia cell lines, HL-60 (promyelocytic CC leukemia) and MOLT-4 (lymphoblastic leukemia), show relatively low CC levels. {ECO:0000269|PubMed:11741985, ECO:0000269|PubMed:11965497}. CC -!- DOMAIN: Interactions with CASP8 and CASP10 are mediated by the DED CC domain. CC -!- SEQUENCE CAUTION: CC Sequence=AAH13372.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF443591; AAL48220.1; -; mRNA. DR EMBL; AF457575; AAM10835.1; -; mRNA. DR EMBL; AY125488; AAM95240.1; -; mRNA. DR EMBL; AK075328; BAC11551.1; -; mRNA. DR EMBL; BC013372; AAH13372.2; ALT_FRAME; mRNA. DR EMBL; BC027930; AAH27930.1; -; mRNA. DR CCDS; CCDS12597.1; -. [Q8WXF8-1] DR CCDS; CCDS59391.1; -. [Q8WXF8-2] DR RefSeq; NP_001257543.1; NM_001270614.2. [Q8WXF8-1] DR RefSeq; NP_001257544.1; NM_001270615.2. [Q8WXF8-2] DR RefSeq; NP_579874.1; NM_133328.4. [Q8WXF8-1] DR RefSeq; XP_047294269.1; XM_047438313.1. [Q8WXF8-1] DR RefSeq; XP_054176029.1; XM_054320054.1. [Q8WXF8-1] DR AlphaFoldDB; Q8WXF8; -. DR SMR; Q8WXF8; -. DR BioGRID; 127838; 17. DR FunCoup; Q8WXF8; 1017. DR IntAct; Q8WXF8; 8. DR MINT; Q8WXF8; -. DR STRING; 9606.ENSP00000471512; -. DR iPTMnet; Q8WXF8; -. DR PhosphoSitePlus; Q8WXF8; -. DR BioMuta; DEDD2; -. DR DMDM; 47116024; -. DR MassIVE; Q8WXF8; -. DR PaxDb; 9606-ENSP00000470082; -. DR PeptideAtlas; Q8WXF8; -. DR ProteomicsDB; 75029; -. [Q8WXF8-1] DR ProteomicsDB; 75030; -. [Q8WXF8-2] DR Antibodypedia; 17411; 201 antibodies from 30 providers. DR DNASU; 162989; -. DR Ensembl; ENST00000336034.8; ENSP00000336972.4; ENSG00000160570.15. [Q8WXF8-2] DR Ensembl; ENST00000595337.5; ENSP00000470082.1; ENSG00000160570.15. [Q8WXF8-1] DR Ensembl; ENST00000596251.6; ENSP00000471512.1; ENSG00000160570.15. [Q8WXF8-1] DR GeneID; 162989; -. DR KEGG; hsa:162989; -. DR MANE-Select; ENST00000596251.6; ENSP00000471512.1; NM_133328.4; NP_579874.1. DR UCSC; uc002osu.3; human. [Q8WXF8-1] DR AGR; HGNC:24450; -. DR ClinPGx; PA134912744; -. DR CTD; 162989; -. DR DisGeNET; 162989; -. DR GeneCards; DEDD2; -. DR HGNC; HGNC:24450; DEDD2. DR HPA; ENSG00000160570; Low tissue specificity. DR OpenTargets; ENSG00000160570; -. DR VEuPathDB; HostDB:ENSG00000160570; -. DR eggNOG; ENOG502QQKR; Eukaryota. DR GeneTree; ENSGT00390000008714; -. DR HOGENOM; CLU_053869_0_0_1; -. DR InParanoid; Q8WXF8; -. DR OMA; GHPETHW; -. DR OrthoDB; 6422954at2759; -. DR PAN-GO; Q8WXF8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8WXF8; -. DR PathwayCommons; Q8WXF8; -. DR SignaLink; Q8WXF8; -. DR Agora; ENSG00000160570; -. DR BioGRID-ORCS; 162989; 13 hits in 1164 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; DEDD2; human. DR GenomeRNAi; 162989; -. DR Pharos; Q8WXF8; Tbio. DR PRO; PR:Q8WXF8; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8WXF8; protein. DR Bgee; ENSG00000160570; Expressed in granulocyte and 184 other cell types or tissues. DR ExpressionAtlas; Q8WXF8; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0003677; F:DNA binding; IBA:GO_Central. DR GO; GO:0030159; F:signaling receptor complex adaptor activity; NAS:UniProtKB. DR GO; GO:0030262; P:apoptotic nuclear changes; IDA:UniProtKB. DR GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR GO; GO:0016075; P:rRNA catabolic process; NAS:UniProtKB. DR FunFam; 1.10.533.10:FF:000023; DNA-binding death effector domain-containing protein 2; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR038856; DEDD/DEDD2. DR InterPro; IPR049341; TRADD-like_N. DR PANTHER; PTHR15205; DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR15205:SF1; DNA-BINDING DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; 1. DR Pfam; PF01335; DED; 1. DR Pfam; PF20694; TRADD-like_N; 1. DR SMART; SM00031; DED; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR PROSITE; PS50168; DED; 1. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; DNA-binding; Nucleus; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..326 FT /note="DNA-binding death effector domain-containing protein FT 2" FT /id="PRO_0000191277" FT DOMAIN 25..104 FT /note="DED" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 104..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 104..109 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOTIF 155..173 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 136..146 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 155..174 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 175..191 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 145..149 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12235123, FT ECO:0000303|PubMed:15489334" FT /id="VSP_010312" FT CONFLICT 27 FT /note="H -> N (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="A -> G (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 79 FT /note="D -> G (in Ref. 4; BAC11551)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="C -> R (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 230 FT /note="Missing (in Ref. 5; AAH13372)" FT /evidence="ECO:0000305" SQ SEQUENCE 326 AA; 36179 MW; 3F7B0B307CC870CD CRC64; MALSGSTPAP CWEEDECLDY YGMLSLHRMF EVVGGQLTEC ELELLAFLLD EAPGAAGGLA RARSGLELLL ELERRGQCDE SNLRLLGQLL RVLARHDLLP HLARKRRRPV SPERYSYGTS SSSKRTEGSC RRRRQSSSSA NSQQGQWETG SPPTKRQRRS RGRPSGGARR RRRGAPAAPQ QQSEPARPSS EGKVTCDIRL RVRAEYCEHG PALEQGVASR RPQALARQLD VFGQATAVLR SRDLGSVVCD IKFSELSYLD AFWGDYLSGA LLQALRGVFL TEALREAVGR EAVRLLVSVD EADYEAGRRR LLLMEEEGGR RPTEAS // ID DYRK2_HUMAN Reviewed; 601 AA. AC Q92630; B2R9V9; Q9BRB5; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 12-JUN-2007, sequence version 3. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 2; DE EC=2.7.12.1 {ECO:0000269|PubMed:22998443}; GN Name=DYRK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP PHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=9748265; DOI=10.1074/jbc.273.40.25893; RA Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F.J., Joost H.-G.; RT "Sequence characteristics, subcellular localization, and substrate RT specificity of DYRK-related kinases, a novel family of dual specificity RT protein kinases."; RL J. Biol. Chem. 273:25893-25902(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Muscle, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 320-528 (ISOFORMS 1/2). RC TISSUE=Placenta; RA Becker W., Joost H.-G.; RL Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases. RN [6] RP FUNCTION. RX PubMed=11311121; DOI=10.1042/bj3550609; RA Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G.; RT "The kinase DYRK phosphorylates protein-synthesis initiation factor RT eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at RT Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming RT kinase."; RL Biochem. J. 355:609-615(2001). RN [7] RP INDUCTION IN CANCER. RX PubMed=12874018; RA Miller C.T., Aggarwal S., Lin T.K., Dagenais S.L., Contreras J.I., RA Orringer M.B., Glover T.W., Beer D.G., Lin L.; RT "Amplification and overexpression of the dual-specificity tyrosine-(Y)- RT phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung RT adenocarcinomas."; RL Cancer Res. 63:4136-4143(2003). RN [8] RP FUNCTION. RX PubMed=12588975; DOI=10.1128/mcb.23.5.1546-1557.2003; RA Wang X., Li W., Parra J.L., Beugnet A., Proud C.G.; RT "The C terminus of initiation factor 4E-binding protein 1 contains multiple RT regulatory features that influence its function and phosphorylation."; RL Mol. Cell. Biol. 23:1546-1557(2003). RN [9] RP FUNCTION. RX PubMed=14593110; DOI=10.1074/jbc.m301769200; RA Skurat A.V., Dietrich A.D.; RT "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family RT protein kinases."; RL J. Biol. Chem. 279:2490-2498(2004). RN [10] RP INTERACTION WITH CCNL2. RX PubMed=14623875; DOI=10.1074/jbc.m310794200; RA de Graaf K., Hekerman P., Spelten O., Herrmann A., Packman L.C., Bussow K., RA Muller-Newen G., Becker W.; RT "Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich RT domain: phosphorylation by DYRK1A and colocalization with splicing RT factors."; RL J. Biol. Chem. 279:4612-4624(2004). RN [11] RP FUNCTION. RX PubMed=15910284; DOI=10.1042/bj20050733; RA Auld G.C., Campbell D.G., Morrice N., Cohen P.; RT "Identification of calcium-regulated heat-stable protein of 24 kDa RT (CRHSP24) as a physiological substrate for PKB and RSK using KESTREL."; RL Biochem. J. 389:775-783(2005). RN [12] RP FUNCTION AS CRMP4/DPYSL3 KINASE, AND ACTIVITY REGULATION BY PURVALANOL. RX PubMed=16611631; DOI=10.1074/jbc.m513344200; RA Cole A.R., Causeret F., Yadirgi G., Hastie C.J., McLauchlan H., RA McManus E.J., Hernandez F., Eickholt B.J., Nikolic M., Sutherland C.; RT "Distinct priming kinases contribute to differential regulation of RT collapsin response mediator proteins by glycogen synthase kinase-3 in RT vivo."; RL J. Biol. Chem. 281:16591-16598(2006). RN [13] RP FUNCTION, AND INTERACTION WITH NFATC1. RX PubMed=16511445; DOI=10.1038/nature04631; RA Gwack Y., Sharma S., Nardone J., Tanasa B., Iuga A., Srikanth S., RA Okamura H., Bolton D., Feske S., Hogan P.G., Rao A.; RT "A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as RT regulators of NFAT."; RL Nature 441:646-650(2006). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [15] RP FUNCTION IN APOPTOSIS AS P53/TP53 KINASE, SUBCELLULAR LOCATION, RP PHOSPHORYLATION BY ATM, AND GENE FAMILY. RX PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021; RA Yoshida K.; RT "Role for DYRK family kinases on regulation of apoptosis."; RL Biochem. Pharmacol. 76:1389-1394(2008). RN [16] RP FUNCTION, AND PHOSPHORYLATION AT THR-381 AND SER-449. RX PubMed=18455992; DOI=10.1016/j.cell.2008.02.047; RA Varjosalo M., Bjorklund M., Cheng F., Syvanen H., Kivioja T., Kilpinen S., RA Sun Z., Kallioniemi O., Stunnenberg H.G., He W.W., Ojala P., Taipale J.; RT "Application of active and kinase-deficient kinome collection for RT identification of kinases regulating hedgehog signaling."; RL Cell 133:537-548(2008). RN [17] RP SUBCELLULAR LOCATION. RX PubMed=18539531; DOI=10.1016/j.molmed.2008.05.003; RA Yoshida K.; RT "Nuclear trafficking of pro-apoptotic kinases in response to DNA damage."; RL Trends Mol. Med. 14:305-313(2008). RN [18] RP ACTIVITY REGULATION BY HARMINE. RX PubMed=19796173; DOI=10.1111/j.1742-4658.2009.07346.x; RA Goeckler N., Jofre G., Papadopoulos C., Soppa U., Tejedor F.J., Becker W.; RT "Harmine specifically inhibits protein kinase DYRK1A and interferes with RT neurite formation."; RL FEBS J. 276:6324-6337(2009). RN [19] RP FUNCTION IN E3 LIGASE REGULATION, FUNCTION AS KATNA1 KINASE, AND RP INTERACTION WITH EDVP COMPLEX. RX PubMed=19287380; DOI=10.1038/ncb1848; RA Maddika S., Chen J.; RT "Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 RT ligase."; RL Nat. Cell Biol. 11:409-419(2009). RN [20] RP ACTIVITY REGULATION BY ACRIDINE ANALOGS. RX PubMed=20836251; DOI=10.1016/j.bmcl.2010.04.150; RA Cuny G.D., Robin M., Ulyanova N.P., Patnaik D., Pique V., Casano G., RA Liu J.-F., Lin X., Xian J., Glicksman M.A., Stein R.L., Higgins J.M.G.; RT "Structure-activity relationship study of acridine analogs as haspin and RT DYRK2 kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 20:3491-3494(2010). RN [21] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-106 AND SER-442 BY ATM, RP UBIQUITINATION BY MDM2, INTERACTION WITH MDM2, MUTAGENESIS OF THR-106; RP SER-442 AND 189-LYS--ARG-191, NUCLEAR LOCALIZATION SIGNAL, AND INDUCTION BY RP DNA DAMAGE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [22] RP FUNCTION. RX PubMed=22307329; DOI=10.1172/jci60818; RA Taira N., Mimoto R., Kurata M., Yamaguchi T., Kitagawa M., Miki Y., RA Yoshida K.; RT "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle RT progression in human cancer cells."; RL J. Clin. Invest. 122:859-872(2012). RN [23] RP FUNCTION, AND UBIQUITINATION BY SIAH2. RX PubMed=22878263; DOI=10.1093/jmcb/mjs047; RA Perez M., Garcia-Limones C., Zapico I., Marina A., Schmitz M.L., Munoz E., RA Calzado M.A.; RT "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic RT signaling pathways."; RL J. Mol. Cell Biol. 4:316-330(2012). RN [24] RP FUNCTION, AND MUTAGENESIS OF LYS-251. RX PubMed=23362280; DOI=10.1074/jbc.m112.416792; RA Jung H.Y., Wang X., Jun S., Park J.I.; RT "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT RT degradation."; RL J. Biol. Chem. 288:7252-7262(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 146-552 IN COMPLEX WITH RP INDIRUBIN. RG Structural genomics consortium (SGC); RT "Crystal structure of dual-specificity tyrosine phosphorylation regulated RT kinase 2 (DYRK2) in complex with an indirubin ligand."; RL Submitted (JAN-2010) to the PDB data bank. RN [27] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 146-540 IN COMPLEX WITH RP LEUCETTAMINE DERIVATIVE, PHOSPHORYLATION AT TYR-382, AUTOPHOSPHORYLATION, RP ACTIVITY REGULATION, AND CATALYTIC ACTIVITY. RX PubMed=22998443; DOI=10.1021/jm301034u; RA Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M., Burgy G., RA Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F., Oberholzer A.E., RA Pearl L.H., Carreaux F., Bazureau J.P., Knapp S., Meijer L.; RT "Selectivity, cocrystal structures, and neuroprotective properties of RT leucettines, a family of protein kinase inhibitors derived from the marine RT sponge alkaloid leucettamine B."; RL J. Med. Chem. 55:9312-9330(2012). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF 146-552. RX PubMed=23665168; DOI=10.1016/j.str.2013.03.012; RA Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P., RA Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S., RA Elkins J.M.; RT "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase RT activation and substrate recognition."; RL Structure 21:986-996(2013). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-98; LEU-198; ASN-245; SER-295; GLN-451 RP AND TYR-455. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase involved in the regulation of CC the mitotic cell cycle, cell proliferation, apoptosis, organization of CC the cytoskeleton and neurite outgrowth. Functions in part via its role CC in ubiquitin-dependent proteasomal protein degradation. Functions CC downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby CC contributes to the induction of apoptosis in response to DNA damage. CC Phosphorylates NFATC1, and thereby inhibits its accumulation in the CC nucleus and its transcription factor activity. Phosphorylates EIF2B5 at CC 'Ser-544', enabling its subsequent phosphorylation and inhibition by CC GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CC CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May CC play a general role in the priming of GSK3 substrates. Inactivates GYS1 CC by phosphorylation at 'Ser-641', and potentially also a second CC phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP CC E3 ligase complex formation and is required for the phosphorylation and CC subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', CC promoting TERT ubiquitination by the EDVP complex. Phosphorylates CC SIAH2, and thereby increases its ubiquitin ligase activity. Promotes CC the proteasomal degradation of MYC and JUN, and thereby regulates CC progress through the mitotic cell cycle and cell proliferation. CC Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a CC role in smoothened and sonic hedgehog signaling. Plays a role in CC cytoskeleton organization and neurite outgrowth via its phosphorylation CC of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, CC EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, CC TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and CC histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). CC {ECO:0000269|PubMed:11311121, ECO:0000269|PubMed:12588975, CC ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:15910284, CC ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:16611631, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:18455992, CC ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19287380, CC ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:22878263, CC ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:9748265}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:9748265}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:9748265}; CC -!- ACTIVITY REGULATION: Activated by autophosphorylation on the second CC tyrosine residue in the Tyr-X-Tyr motif in the activation loop. CC Inhibited by acridine analogs, purvalanol, and barely by harmine. CC Inhibited by leucettine and leucettine derivatives. CC {ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:19796173, CC ECO:0000269|PubMed:20836251, ECO:0000269|PubMed:22998443}. CC -!- SUBUNIT: Component of an E3 ligase complex containing DYRK2, EDD/UBR5, CC DDB1 and DCAF1 (EDVP complex). Interacts directly with EDD/UBR5, DDB1 CC and DCAF1. Interacts with SIAH2 and MDM2. Interacts with MAP3K10 and CC NFATC1. May also interact with CCNL2. {ECO:0000269|PubMed:14623875, CC ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:19287380, CC ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:22998443, CC ECO:0000269|Ref.26}. CC -!- INTERACTION: CC Q92630; Q9NR20: DYRK4; NbExp=3; IntAct=EBI-749432, EBI-3914009; CC Q92630; Q13422: IKZF1; NbExp=3; IntAct=EBI-749432, EBI-745305; CC Q92630; Q9BQD3: KXD1; NbExp=3; IntAct=EBI-749432, EBI-739657; CC Q92630; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-749432, EBI-741037; CC Q92630; P23497: SP100; NbExp=3; IntAct=EBI-749432, EBI-751145; CC Q92630; O43379: WDR62; NbExp=3; IntAct=EBI-749432, EBI-714790; CC Q92630; P62258: YWHAE; NbExp=2; IntAct=EBI-749432, EBI-356498; CC Q92630; Q96C00: ZBTB9; NbExp=3; IntAct=EBI-749432, EBI-395708; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates into the CC nucleus following DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q92630-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92630-2; Sequence=VSP_026115; CC -!- TISSUE SPECIFICITY: Testis, after the onset of spermatogenesis. CC {ECO:0000269|PubMed:9748265}. CC -!- INDUCTION: Accumulates in nucleus upon DNA damage. Induced in both CC esophageal and lung adenocarcinomas. {ECO:0000269|PubMed:12874018, CC ECO:0000269|PubMed:19965871}. CC -!- PTM: Autophosphorylates cotranslationally on the second tyrosine CC residue in the Tyr-X-Tyr motif in the activation loop, but once mature, CC does not have any protein tyrosine kinase activity. Phosphorylated at CC Thr-106 and Ser-442 by ATM in response to genotoxic stress. CC {ECO:0000269|PubMed:19965871}. CC -!- PTM: Under normal conditions, polyubiquitinated in the nucleus by MDM2, CC leading to its proteasomal degradation. Phosphorylation on Thr-106 and CC Ser-442 by ATM in response to genotoxic stress disrupts MDM2 binding CC and prevents MDM2-mediated ubiquitination and subsequent proteasomal CC degradation. Polyubiquitinated by SIAH2, leading to its proteasomal CC degradation. Polyubiquitinated by SIAH2 occurs under normal conditions, CC and is enhanced in response to hypoxia. {ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:22878263}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MNB/DYRK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA73885.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y13493; CAA73885.1; ALT_INIT; mRNA. DR EMBL; AK313937; BAG36656.1; -; mRNA. DR EMBL; CH471054; EAW97176.1; -; Genomic_DNA. DR EMBL; BC005809; AAH05809.1; -; mRNA. DR EMBL; BC006375; AAH06375.1; -; mRNA. DR EMBL; Y09216; CAA70418.1; -; mRNA. DR CCDS; CCDS8978.1; -. [Q92630-1] DR CCDS; CCDS8979.1; -. [Q92630-2] DR RefSeq; NP_003574.1; NM_003583.4. [Q92630-2] DR RefSeq; NP_006473.2; NM_006482.3. [Q92630-1] DR RefSeq; XP_016875521.1; XM_017020032.2. [Q92630-2] DR PDB; 3K2L; X-ray; 2.36 A; A=146-552. DR PDB; 3KVW; X-ray; 2.28 A; A=146-552. DR PDB; 4AZF; X-ray; 2.55 A; A=146-540. DR PDB; 5LXC; X-ray; 2.15 A; A/B=146-552. DR PDB; 5LXD; X-ray; 2.58 A; A/B=146-552. DR PDB; 5ZTN; X-ray; 2.50 A; A/B=146-552. DR PDB; 6HDP; X-ray; 2.30 A; A=146-552. DR PDB; 6HDR; X-ray; 2.20 A; A=146-552. DR PDB; 6K0J; X-ray; 2.35 A; A=212-536. DR PDB; 7AKF; X-ray; 2.60 A; A=146-552. DR PDB; 7AKH; X-ray; 2.85 A; A=146-552. DR PDB; 7DG4; X-ray; 2.58 A; A=215-538. DR PDB; 7DH3; X-ray; 2.33 A; A=213-538. DR PDB; 7DH9; X-ray; 2.19 A; A=215-538. DR PDB; 7DHC; X-ray; 2.59 A; A=215-538. DR PDB; 7DHH; X-ray; 2.49 A; A=215-538. DR PDB; 7DHK; X-ray; 2.34 A; A=215-538. DR PDB; 7DHN; X-ray; 2.38 A; A=215-538. DR PDB; 7DHO; X-ray; 3.29 A; A=215-538. DR PDB; 7DHV; X-ray; 2.68 A; A=212-538. DR PDB; 7DJO; X-ray; 2.50 A; A=215-538. DR PDB; 7DL6; X-ray; 2.65 A; A=215-538. DR PDB; 7EJV; X-ray; 2.50 A; A=151-537, B=153-543. DR PDB; 8HLT; X-ray; 2.80 A; A/B=145-537. DR PDBsum; 3K2L; -. DR PDBsum; 3KVW; -. DR PDBsum; 4AZF; -. DR PDBsum; 5LXC; -. DR PDBsum; 5LXD; -. DR PDBsum; 5ZTN; -. DR PDBsum; 6HDP; -. DR PDBsum; 6HDR; -. DR PDBsum; 6K0J; -. DR PDBsum; 7AKF; -. DR PDBsum; 7AKH; -. DR PDBsum; 7DG4; -. DR PDBsum; 7DH3; -. DR PDBsum; 7DH9; -. DR PDBsum; 7DHC; -. DR PDBsum; 7DHH; -. DR PDBsum; 7DHK; -. DR PDBsum; 7DHN; -. DR PDBsum; 7DHO; -. DR PDBsum; 7DHV; -. DR PDBsum; 7DJO; -. DR PDBsum; 7DL6; -. DR PDBsum; 7EJV; -. DR PDBsum; 8HLT; -. DR AlphaFoldDB; Q92630; -. DR SMR; Q92630; -. DR BioGRID; 114023; 171. DR CORUM; Q92630; -. DR FunCoup; Q92630; 2020. DR IntAct; Q92630; 253. DR MINT; Q92630; -. DR STRING; 9606.ENSP00000342105; -. DR BindingDB; Q92630; -. DR ChEMBL; CHEMBL4376; -. DR DrugBank; DB04719; DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE. DR DrugBank; DB07919; Harmine. DR DrugCentral; Q92630; -. DR GuidetoPHARMACOLOGY; 2011; -. DR GlyGen; Q92630; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q92630; -. DR PhosphoSitePlus; Q92630; -. DR BioMuta; DYRK2; -. DR DMDM; 148887370; -. DR CPTAC; non-CPTAC-5645; -. DR CPTAC; non-CPTAC-5646; -. DR jPOST; Q92630; -. DR MassIVE; Q92630; -. DR PaxDb; 9606-ENSP00000342105; -. DR PeptideAtlas; Q92630; -. DR ProteomicsDB; 75387; -. [Q92630-1] DR ProteomicsDB; 75388; -. [Q92630-2] DR Antibodypedia; 16684; 343 antibodies from 37 providers. DR DNASU; 8445; -. DR Ensembl; ENST00000344096.4; ENSP00000342105.4; ENSG00000127334.12. [Q92630-1] DR Ensembl; ENST00000393555.3; ENSP00000377186.3; ENSG00000127334.12. [Q92630-2] DR GeneID; 8445; -. DR KEGG; hsa:8445; -. DR MANE-Select; ENST00000344096.4; ENSP00000342105.4; NM_006482.3; NP_006473.2. DR UCSC; uc001str.5; human. [Q92630-1] DR AGR; HGNC:3093; -. DR ClinPGx; PA27550; -. DR CTD; 8445; -. DR DisGeNET; 8445; -. DR GeneCards; DYRK2; -. DR HGNC; HGNC:3093; DYRK2. DR HPA; ENSG00000127334; Low tissue specificity. DR MIM; 603496; gene. DR OpenTargets; ENSG00000127334; -. DR VEuPathDB; HostDB:ENSG00000127334; -. DR eggNOG; KOG0667; Eukaryota. DR GeneTree; ENSGT00940000158113; -. DR HOGENOM; CLU_000288_5_13_1; -. DR InParanoid; Q92630; -. DR OMA; HTVGGNK; -. DR OrthoDB; 9332038at2759; -. DR PAN-GO; Q92630; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q92630; -. DR BRENDA; 2.7.12.1; 2681. DR PathwayCommons; Q92630; -. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR SignaLink; Q92630; -. DR SIGNOR; Q92630; -. DR Agora; ENSG00000127334; -. DR BioGRID-ORCS; 8445; 16 hits in 1188 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; DYRK2; human. DR EvolutionaryTrace; Q92630; -. DR GeneWiki; DYRK2; -. DR GenomeRNAi; 8445; -. DR Pharos; Q92630; Tchem. DR PRO; PR:Q92630; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q92630; protein. DR Bgee; ENSG00000127334; Expressed in jejunal mucosa and 205 other cell types or tissues. DR ExpressionAtlas; Q92630; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005856; C:cytoskeleton; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IEP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IMP:UniProtKB. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0007224; P:smoothened signaling pathway; IMP:UniProtKB. DR CDD; cd14224; PKc_DYRK2_3; 1. DR FunFam; 3.30.10.30:FF:000001; Dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR FunFam; 1.10.510.10:FF:000112; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR FunFam; 3.30.200.20:FF:000127; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR Gene3D; 3.30.10.30; DYRK; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042521; DYRK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050494; Ser_Thr_dual-spec_kinase. DR PANTHER; PTHR24058; DUAL SPECIFICITY PROTEIN KINASE; 1. DR PANTHER; PTHR24058:SF51; DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cytoplasm; KW Kinase; Magnesium; Manganese; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..601 FT /note="Dual specificity tyrosine-phosphorylation-regulated FT kinase 2" FT /id="PRO_0000085936" FT DOMAIN 222..535 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..24 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 189..191 FT /note="Nuclear localization signal" FT /evidence="ECO:0000305|PubMed:19965871" FT ACT_SITE 348 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 228..236 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 251 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 106 FT /note="Phosphothreonine; by ATM" FT /evidence="ECO:0000269|PubMed:19965871" FT MOD_RES 381 FT /note="Phosphothreonine; by MAP3K10" FT /evidence="ECO:0000269|PubMed:18455992" FT MOD_RES 382 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22998443" FT MOD_RES 442 FT /note="Phosphoserine; by ATM" FT /evidence="ECO:0000269|PubMed:19965871" FT MOD_RES 449 FT /note="Phosphoserine; by MAP3K10" FT /evidence="ECO:0000269|PubMed:18455992" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_026115" FT VARIANT 98 FT /note="S -> G (in dbSNP:rs35139851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040458" FT VARIANT 198 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs1384093596)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040459" FT VARIANT 245 FT /note="H -> N (in dbSNP:rs34166200)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040460" FT VARIANT 295 FT /note="N -> S (in dbSNP:rs56293072)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040461" FT VARIANT 451 FT /note="R -> Q (in dbSNP:rs35688869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040462" FT VARIANT 455 FT /note="F -> Y (in dbSNP:rs55774594)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040463" FT MUTAGEN 106 FT /note="T->A: Impaired ATM-mediated phosphorylation, reduced FT affinity with MDM2 and altered MDM2-triggered FT ubiquitination." FT /evidence="ECO:0000269|PubMed:19965871" FT MUTAGEN 189..191 FT /note="KKR->NNN: Impaired nuclear translocation." FT /evidence="ECO:0000269|PubMed:19965871" FT MUTAGEN 251 FT /note="K->R: Abolishes protein serine/threonine kinase FT activity." FT /evidence="ECO:0000269|PubMed:23362280" FT MUTAGEN 442 FT /note="S->A: Impaired ATM-mediated phosphorylation, reduced FT affinity with MDM2 and altered MDM2-triggered FT ubiquitination." FT /evidence="ECO:0000269|PubMed:19965871" FT CONFLICT 37 FT /note="A -> P (in Ref. 1; CAA73885)" FT /evidence="ECO:0000305" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:6HDR" FT HELIX 156..163 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 169..174 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:3K2L" FT HELIX 198..202 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3K2L" FT TURN 219..221 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 222..231 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 242..245 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 257..274 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:7AKH" FT STRAND 287..292 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 297..301 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 308..314 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 322..341 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 354..358 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:8HLT" FT HELIX 375..377 FT /evidence="ECO:0007829|PDB:7DHK" FT HELIX 386..388 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 391..395 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 427..438 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 443..447 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 452..455 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:6HDP" FT STRAND 465..469 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 471..473 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 475..478 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 496..499 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 500..502 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 506..515 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 526..529 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5LXC" SQ SEQUENCE 601 AA; 66652 MW; A7BEE25CDF944436 CRC64; MLTRKPSAAA PAAYPTGRGG DSAVRQLQAS PGLGAGATRS GVGTGPPSPI ALPPLRASNA AAAAHTIGGS KHTMNDHLHV GSHAHGQIQV QQLFEDNSNK RTVLTTQPNG LTTVGKTGLP VVPERQLDSI HRRQGSSTSL KSMEGMGKVK ATPMTPEQAM KQYMQKLTAF EHHEIFSYPE IYFLGLNAKK RQGMTGGPNN GGYDDDQGSY VQVPHDHVAY RYEVLKVIGK GSFGQVVKAY DHKVHQHVAL KMVRNEKRFH RQAAEEIRIL EHLRKQDKDN TMNVIHMLEN FTFRNHICMT FELLSMNLYE LIKKNKFQGF SLPLVRKFAH SILQCLDALH KNRIIHCDLK PENILLKQQG RSGIKVIDFG SSCYEHQRVY TYIQSRFYRA PEVILGARYG MPIDMWSLGC ILAELLTGYP LLPGEDEGDQ LACMIELLGM PSQKLLDASK RAKNFVSSKG YPRYCTVTTL SDGSVVLNGG RSRRGKLRGP PESREWGNAL KGCDDPLFLD FLKQCLEWDP AVRMTPGQAL RHPWLRRRLP KPPTGEKTSV KRITESTGAI TSISKLPPPS SSASKLRTNL AQMTDANGNI QQRTVLPKLV S // ID E2AK2_HUMAN Reviewed; 551 AA. AC P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4; DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase; DE EC=2.7.11.1; DE AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2; DE Short=eIF-2A protein kinase 2; DE AltName: Full=Interferon-inducible RNA-dependent protein kinase; DE AltName: Full=P1/eIF-2A protein kinase; DE AltName: Full=Protein kinase RNA-activated; DE Short=PKR; DE Short=Protein kinase R {ECO:0000303|PubMed:11438532}; DE AltName: Full=Tyrosine-protein kinase EIF2AK2; DE EC=2.7.10.2; DE AltName: Full=p68 kinase; GN Name=EIF2AK2; Synonyms=PKR, PRKR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND RP 309-325, AND INDUCTION. RX PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n; RA Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G., RA Hovanessian A.G.; RT "Molecular cloning and characterization of the human double-stranded RNA- RT activated protein kinase induced by interferon."; RL Cell 62:379-390(1990). RN [2] RP SEQUENCE REVISION. RA Meurs E.; RL Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5; RA Thomis D.C., Doohan J.P., Samuel C.E.; RT "Mechanism of interferon action: cDNA structure, expression, and regulation RT of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from RT human cells."; RL Virology 188:33-46(1992). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RX PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9; RA Kuhen K.L., Shen X., Samuel C.E.; RT "Mechanism of interferon action sequence of the human interferon-inducible RT RNA-dependent protein kinase (PKR) deduced from genomic clones."; RL Gene 178:191-193(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8812437; DOI=10.1006/geno.1996.0446; RA Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G., RA Tanaka H., Samuel C.E.; RT "Structural organization of the human gene (PKR) encoding an interferon- RT inducible RNA-dependent protein kinase (PKR) and differences from its mouse RT homolog."; RL Genomics 36:197-201(1996). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9726442; DOI=10.1089/jir.1998.18.609; RA Xu Z., Williams B.R.; RT "Genomic features of human PKR: alternative splicing and a polymorphic CGG RT repeat in the 5'-untranslated region."; RL J. Interferon Cytokine Res. 18:609-616(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Prostatic carcinoma; RA Bienvenut W.V., Gao M., Leug H.; RL Submitted (JUN-2009) to UniProtKB. RN [14] RP INTERACTION WITH DNAJC3. RX PubMed=8576172; DOI=10.1074/jbc.271.3.1702; RA Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.; RT "The P58 cellular inhibitor complexes with the interferon-induced, double- RT stranded RNA-dependent protein kinase, PKR, to regulate its RT autophosphorylation and activity."; RL J. Biol. Chem. 271:1702-1707(1996). RN [15] RP INTERACTION WITH HIV-1 TAT. RX PubMed=9079663; DOI=10.1074/jbc.272.13.8388; RA Brand S.R., Kobayashi R., Mathews M.B.; RT "The Tat protein of human immunodeficiency virus type 1 is a substrate and RT inhibitor of the interferon-induced, virally activated protein kinase, RT PKR."; RL J. Biol. Chem. 272:8388-8395(1997). RN [16] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9143277; DOI=10.1006/viro.1997.8493; RA Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., RA Polyak S.J., Gretch D.R., Katze M.G.; RT "Evidence that hepatitis C virus resistance to interferon is mediated RT through repression of the PKR protein kinase by the nonstructural 5A RT protein."; RL Virology 230:217-227(1997). RN [17] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9710605; DOI=10.1128/mcb.18.9.5208; RA Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M., RA Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.; RT "Control of PKR protein kinase by hepatitis C virus nonstructural 5A RT protein: molecular mechanisms of kinase regulation."; RL Mol. Cell. Biol. 18:5208-5218(1998). RN [18] RP INTERACTION WITH INFLUENZA A NS1 PROTEIN. RX PubMed=9781815; DOI=10.1089/jir.1998.18.757; RA Tan S.L., Katze M.G.; RT "Biochemical and genetic evidence for complex formation between the RT influenza A virus NS1 protein and the interferon-induced PKR protein RT kinase."; RL J. Interferon Cytokine Res. 18:757-766(1998). RN [19] RP INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION). RX PubMed=10390359; DOI=10.1126/science.285.5424.107; RA Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.; RT "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 RT protein."; RL Science 285:107-110(1999). RN [20] RP FUNCTION, AND INTERACTION WITH IKBKB. RX PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000; RA Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.; RT "PKR stimulates NF-kappaB irrespective of its kinase function by RT interacting with the IkappaB kinase complex."; RL Mol. Cell. Biol. 20:4532-4542(2000). RN [21] RP INTERACTION WITH TARBP2. RX PubMed=11438532; DOI=10.1074/jbc.m103584200; RA Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S., RA Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F., RA Gatignol A.; RT "Two dimerization domains in the trans-activation response RNA-binding RT protein (TRBP) individually reverse the protein kinase R inhibition of HIV- RT 1 long terminal repeat expression."; RL J. Biol. Chem. 276:33899-33905(2001). RN [22] RP PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND RP THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255; RP THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN. RX PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001; RA Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C., RA Mathews M.B.; RT "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple RT competition with autophosphorylation sites in the RNA-binding domain."; RL J. Virol. 75:1265-1273(2001). RN [23] RP MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT RP THR-446 AND THR-451. RX PubMed=11337501; DOI=10.1074/jbc.m102108200; RA Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E., RA Mathews M.B., Ozato K., Hinnebusch A.G.; RT "Binding of double-stranded RNA to protein kinase PKR is required for RT dimerization and promotes critical autophosphorylation events in the RT activation loop."; RL J. Biol. Chem. 276:24946-24958(2001). RN [24] RP INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION). RX PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001; RA Burysek L., Pitha P.M.; RT "Latently expressed human herpesvirus 8-encoded interferon regulatory RT factor 2 inhibits double-stranded RNA-activated protein kinase."; RL J. Virol. 75:2345-2352(2001). RN [25] RP FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION). RX PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002; RA Cassady K.A., Gross M.; RT "The herpes simplex virus type 1 U(S)11 protein interacts with protein RT kinase R in infected cells and requires a 30-amino-acid sequence adjacent RT to a kinase substrate domain."; RL J. Virol. 76:2029-2035(2002). RN [26] RP INTERACTION WITH NPM1, AND ACTIVITY REGULATION. RX PubMed=12882984; DOI=10.1074/jbc.m301392200; RA Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., RA Faulkner G.R., Speckhart A., Bagby G.C.; RT "Nucleophosmin interacts with and inhibits the catalytic function of RT eukaryotic initiation factor 2 kinase PKR."; RL J. Biol. Chem. 278:41709-41717(2003). RN [27] RP FUNCTION, AND INTERACTION WITH MAP2K6. RX PubMed=15229216; DOI=10.1074/jbc.m406554200; RA Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.; RT "Protein kinase R (PKR) interacts with and activates mitogen-activated RT protein kinase kinase 6 (MKK6) in response to double-stranded RNA RT stimulation."; RL J. Biol. Chem. 279:37670-37676(2004). RN [28] RP IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70. RX PubMed=15299030; DOI=10.1074/jbc.m403884200; RA Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.; RT "The Fanconi anemia proteins functionally interact with the protein kinase RT regulated by RNA (PKR)."; RL J. Biol. Chem. 279:43910-43919(2004). RN [29] RP FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR RP LOCATION. RX PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004; RA Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H., RA Alcami J., Esteban M.; RT "TRAF family proteins link PKR with NF-kappa B activation."; RL Mol. Cell. Biol. 24:4502-4512(2004). RN [30] RP INHIBITION BY VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=15207627; DOI=10.1016/j.virol.2004.03.012; RA Langland J.O., Jacobs B.L.; RT "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains RT of E3L."; RL Virology 324:419-429(2004). RN [31] RP REVIEW. RX PubMed=17158706; DOI=10.1128/mmbr.00027-06; RA Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., RA Esteban M.; RT "Impact of protein kinase PKR in cell biology: from antiviral to RT antiproliferative action."; RL Microbiol. Mol. Biol. Rev. 70:1032-1060(2006). RN [32] RP INTERACTION WITH HCMV TRS1 (MICROBIAL INFECTION). RX PubMed=16987971; DOI=10.1128/jvi.00957-06; RA Hakki M., Marshall E.E., De Niro K.L., Geballe A.P.; RT "Binding and nuclear relocalization of protein kinase R by human RT cytomegalovirus TRS1."; RL J. Virol. 80:11817-11826(2006). RN [33] RP PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293. RX PubMed=16373505; DOI=10.1073/pnas.0508207103; RA Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.; RT "Tyrosine phosphorylation acts as a molecular switch to full-scale RT activation of the eIF2alpha RNA-dependent protein kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006). RN [34] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=16951545; DOI=10.1016/s1016-8478(23)17385-7; RA Liang Y., Kang C.B., Yoon H.S.; RT "Molecular and structural characterization of the domain 2 of hepatitis C RT virus non-structural protein 5A."; RL Mol. Cells 22:13-20(2006). RN [35] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195; RA Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.; RT "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b RT during interferon or combined interferon-ribavirin therapy."; RL World J. Gastroenterol. 13:1195-1203(2007). RN [36] RP INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION). RX PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010; RA Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.; RT "Mapping of the interacting domains of hepatitis C virus core protein and RT the double-stranded RNA-activated protein kinase PKR."; RL Virus Res. 125:79-87(2007). RN [37] RP INTERACTION WITH ADAR. RX PubMed=17079286; DOI=10.1128/jvi.01527-06; RA Nie Y., Hammond G.L., Yang J.H.; RT "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus RT infection."; RL J. Virol. 81:917-923(2007). RN [38] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003; RA Cole J.L.; RT "Activation of PKR: an open and shut case?"; RL Trends Biochem. Sci. 32:57-62(2007). RN [39] RP FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION. RX PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112; RA Cardin E., Larose L.; RT "Nck-1 interacts with PKR and modulates its activation by dsRNA."; RL Biochem. Biophys. Res. Commun. 377:231-235(2008). RN [40] RP INTERACTION WITH DUS2L, AND ACTIVITY REGULATION. RX PubMed=18096616; DOI=10.1093/nar/gkm1129; RA Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V., RA Patel R.C.; RT "Interaction of human tRNA-dihydrouridine synthase-2 with interferon- RT induced protein kinase PKR."; RL Nucleic Acids Res. 36:998-1008(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP MUTAGENESIS OF ASP-486, AND INTERACTION WITH VACCINIA VIRUS PROTEIN K3 RP (MICROBIAL INFECTION). RX PubMed=18971339; DOI=10.1073/pnas.0805524105; RA Seo E.J., Liu F., Kawagishi-Kobayashi M., Ung T.L., Cao C., Dar A.C., RA Sicheri F., Dever T.E.; RT "Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 105:16894-16899(2008). RN [43] RP FUNCTION. RX PubMed=19507191; DOI=10.1002/jcp.21848; RA Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J., RA Martinelli G., Cocco L., Martelli A.M.; RT "PKR activity is required for acute leukemic cell maintenance and growth: a RT role for PKR-mediated phosphatase activity to regulate GSK-3 RT phosphorylation."; RL J. Cell. Physiol. 221:232-241(2009). RN [44] RP FUNCTION, AND INTERACTION WITH DHX9. RX PubMed=19229320; DOI=10.1371/journal.ppat.1000311; RA Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.; RT "An antiviral response directed by PKR phosphorylation of the RNA helicase RT A."; RL PLoS Pathog. 5:E1000311-E1000311(2009). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [46] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007; RA Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.; RT "PKR protein kinase is activated by hepatitis C virus and inhibits viral RT replication through translational control."; RL Virus Res. 142:51-56(2009). RN [47] RP FUNCTION. RX PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008; RA Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.; RT "A role for protein kinase PKR in the mediation of Epstein-Barr virus RT latent membrane protein-1-induced IL-6 and IL-10 expression."; RL Cytokine 50:210-219(2010). RN [48] RP FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN RP KINASE. RX PubMed=20395957; DOI=10.1038/embor.2010.45; RA Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.; RT "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers RT Cdc2 polyubiquitination and G2 arrest under genotoxic stresses."; RL EMBO Rep. 11:393-399(2010). RN [49] RP FUNCTION. RX PubMed=21123651; DOI=10.1101/gad.1965010; RA Harashima A., Guettouche T., Barber G.N.; RT "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase RT PKR constitutes a novel mechanism of translational regulation and cellular RT defense."; RL Genes Dev. 24:2640-2653(2010). RN [50] RP INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=20519500; DOI=10.1074/jbc.m109.077321; RA Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.; RT "Respiratory syncytial virus limits alpha subunit of eukaryotic translation RT initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and RT viral replication."; RL J. Biol. Chem. 285:24023-24031(2010). RN [51] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x; RA Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N., RA Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.; RT "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus RT replication but may be not essential in interferon treatment."; RL Liver Int. 30:311-318(2010). RN [52] RP FUNCTION, AND PHOSPHORYLATION AT THR-451. RX PubMed=20685959; DOI=10.1091/mbc.e10-06-0481; RA Yang X., Nath A., Opperman M.J., Chan C.; RT "The double-stranded RNA-dependent protein kinase differentially regulates RT insulin receptor substrates 1 and 2 in HepG2 cells."; RL Mol. Biol. Cell 21:3449-3458(2010). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x; RA Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.; RT "Modulation of tau phosphorylation by the kinase PKR: implications in RT Alzheimer's disease."; RL Brain Pathol. 21:189-200(2011). RN [56] RP REVIEW. RX PubMed=21924887; DOI=10.1016/j.coi.2011.08.009; RA Pfaller C.K., Li Z., George C.X., Samuel C.E.; RT "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old RT players as modulators of the interferon response."; RL Curr. Opin. Immunol. 23:573-582(2011). RN [57] RP REVIEW. RX PubMed=21166592; DOI=10.1089/jir.2010.0099; RA Pindel A., Sadler A.; RT "The role of protein kinase R in the interferon response."; RL J. Interferon Cytokine Res. 31:59-70(2011). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION. RX PubMed=21072047; DOI=10.1038/leu.2010.264; RA Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I., RA Martelli A.M., Follo M.Y., Cocco L.; RT "Multiple forms of PKR present in the nuclei of acute leukemia cells RT represent an active kinase that is responsive to stress."; RL Leukemia 25:236-245(2011). RN [59] RP FUNCTION IN HBV RESTRICTION. RX PubMed=21710204; DOI=10.1007/s10059-011-1059-6; RA Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.; RT "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus RT replication."; RL Mol. Cells 32:167-172(2011). RN [60] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [61] RP REVIEW. RX PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010; RA Lacy-Hulbert A., Stuart L.M.; RT "Penetration resistance: PKR's other talent."; RL Immunity 36:695-696(2012). RN [62] RP FUNCTION. RX PubMed=22948139; DOI=10.1074/jbc.m112.390039; RA McAllister C.S., Taghavi N., Samuel C.E.; RT "Protein kinase PKR amplification of interferon beta induction occurs RT through initiation factor eIF-2alpha-mediated translational control."; RL J. Biol. Chem. 287:36384-36392(2012). RN [63] RP FUNCTION, AND INTERACTION WITH STAT3. RX PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013; RA Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., RA Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O., RA Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.; RT "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity."; RL Mol. Cell 48:667-680(2012). RN [64] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [65] RP FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND RP AUTOPHOSPHORYLATION. RX PubMed=22801494; DOI=10.1038/nature11290; RA Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., RA Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., RA Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., RA Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.; RT "Novel role of PKR in inflammasome activation and HMGB1 release."; RL Nature 488:670-674(2012). RN [66] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [67] RP REVIEW. RX PubMed=23092889; DOI=10.1126/scisignal.2003511; RA Kang R., Tang D.; RT "PKR-dependent inflammatory signals."; RL Sci. Signal. 5:PE47-PE47(2012). RN [68] RP FUNCTION. RX PubMed=22381929; DOI=10.1016/j.virol.2012.01.029; RA Taghavi N., Samuel C.E.; RT "Protein kinase PKR catalytic activity is required for the PKR-dependent RT activation of mitogen-activated protein kinases and amplification of RT interferon beta induction following virus infection."; RL Virology 427:208-216(2012). RN [69] RP REVIEW. RX PubMed=23202496; DOI=10.3390/v4112598; RA Dabo S., Meurs E.F.; RT "dsRNA-dependent protein kinase PKR and its role in stress, signaling and RT HCV infection."; RL Viruses 4:2598-2635(2012). RN [70] RP TISSUE SPECIFICITY. RX PubMed=23403623; DOI=10.1182/blood-2012-09-456400; RA Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.; RT "PKR regulates proliferation, differentiation and survival of murine RT hematopoietic stem/progenitor cells."; RL Blood 121:3364-3374(2013). RN [71] RP REVIEW. RX PubMed=23354059; DOI=10.1007/s00018-012-1252-6; RA Donnelly N., Gorman A.M., Gupta S., Samali A.; RT "The eIF2alpha kinases: their structures and functions."; RL Cell. Mol. Life Sci. 70:3493-3511(2013). RN [72] RP FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [73] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [74] RP INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND RP ACTIVITY REGULATION. RX PubMed=23325696; DOI=10.1128/jvi.02506-12; RA Kalveram B., Ikegami T.; RT "Toscana virus NSs protein promotes degradation of double-stranded RNA- RT dependent protein kinase."; RL J. Virol. 87:3710-3718(2013). RN [75] RP FUNCTION IN MV RESTRICTION. RX PubMed=23115276; DOI=10.1128/jvi.02270-12; RA Okonski K.M., Samuel C.E.; RT "Stress granule formation induced by measles virus is protein kinase PKR RT dependent and impaired by RNA adenosine deaminase ADAR1."; RL J. Virol. 87:756-766(2013). RN [76] RP FUNCTION. RX PubMed=23372823; DOI=10.1371/journal.pone.0055108; RA Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.; RT "Protein kinase regulated by dsRNA downregulates the interferon production RT in dengue virus- and dsrna-stimulated human lung epithelial cells."; RL PLoS ONE 8:E55108-E55108(2013). RN [77] RP FUNCTION IN HCV RESTRICTION. RX PubMed=23399035; DOI=10.1016/j.virol.2013.01.015; RA Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W., RA Wang R.Y.; RT "The modulation of hepatitis C virus 1a replication by PKR is dependent on RT NF-kB mediated interferon beta response in Huh7.5.1 cells."; RL Virology 438:28-36(2013). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [79] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=25740987; DOI=10.1128/jvi.03288-14; RA Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.; RT "Mutational analysis of vaccinia virus E3 protein: the biological functions RT do not correlate with its biochemical capacity to bind double-stranded RT RNA."; RL J. Virol. 89:5382-5394(2015). RN [80] RP INTERACTION WITH MBIP AND MOCS2B, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=26705305; DOI=10.1093/jmcb/mjv070; RA Suganuma T., Swanson S.K., Florens L., Washburn M.P., Workman J.L.; RT "Moco biosynthesis and the ATAC acetyltransferase engage translation RT initiation by inhibiting latent PKR activity."; RL J. Mol. Cell Biol. 8:44-50(2016). RN [81] RP MUTAGENESIS OF PHE-489; THR-496; ILE-502; LYS-510 AND GLN-516, RP CHARACTERIZATION OF VARIANT VAL-506, AND INTERACTION WITH HCMV TRS1 RP (MICROBIAL INFECTION). RX PubMed=27780231; DOI=10.1371/journal.ppat.1005966; RA Carpentier K.S., Esparo N.M., Child S.J., Geballe A.P.; RT "A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated RT Viral Antagonists."; RL PLoS Pathog. 12:e1005966-e1005966(2016). RN [82] RP INTERACTION WITH HUMAN HERPES VIRUS 8 PROTEIN KTA/ORF57 (MICROBIAL RP INFECTION). RX PubMed=29084250; DOI=10.1371/journal.ppat.1006677; RA Sharma N.R., Majerciak V., Kruhlak M.J., Zheng Z.M.; RT "KSHV inhibits stress granule formation by viral ORF57 blocking PKR RT activation."; RL PLoS Pathog. 13:e1006677-e1006677(2017). RN [83] {ECO:0007744|PDB:1QU6} RP STRUCTURE BY NMR OF 1-170, AND DOMAIN. RX PubMed=9736623; DOI=10.1093/emboj/17.18.5458; RA Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.; RT "Structure of the double-stranded RNA-binding domain of the protein kinase RT PKR reveals the molecular basis of its dsRNA-mediated activation."; RL EMBO J. 17:5458-5465(1998). RN [84] {ECO:0007744|PDB:2A19, ECO:0007744|PDB:2A1A} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 258-550 IN COMPLEX WITH RP EIF2S1/EIF-2ALPHA, PHOSPHORYLATION AT THR-446, DOMAIN, SUBUNIT, COFACTOR, RP AND INTERACTION WITH EIF2S1/EIF-2ALPHA. RX PubMed=16179258; DOI=10.1016/j.cell.2005.06.044; RA Dar A.C., Dever T.E., Sicheri F.; RT "Higher-order substrate recognition of eIF2alpha by the RNA-dependent RT protein kinase PKR."; RL Cell 122:887-900(2005). RN [85] {ECO:0007744|PDB:6D3K, ECO:0007744|PDB:6D3L} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 229-551, AND SUBUNIT. RX PubMed=31246429; DOI=10.1021/acs.biochem.9b00161; RA Mayo C.B., Erlandsen H., Mouser D.J., Feinstein A.G., Robinson V.L., RA May E.R., Cole J.L.; RT "Structural Basis of Protein Kinase R Autophosphorylation."; RL Biochemistry 58:2967-2977(2019). RN [86] RP INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97; RP SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF RP VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [87] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [88] RP VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS RP DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33236446; DOI=10.1002/ana.25973; RA Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J., RA Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H., RA Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E., RA Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B., RA Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P., RA Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.; RT "EIF2AK2 Missense Variants Associated with Early Onset Generalized RT Dystonia."; RL Ann. Neurol. 89:485-497(2021). RN [89] RP VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33866603; DOI=10.1002/ana.26081; RA Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.; RT "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated RT Dystonia."; RL Ann. Neurol. 89:1257-1258(2021). RN [90] RP VARIANT DYT33 ARG-130. RX PubMed=35146068; DOI=10.1002/mdc3.13371; RA Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P., RA Maroofian R., Houlden H.; RT "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia RT Partially Responsive to DBS."; RL Mov. Disord. Clin. Pract. 9:268-271(2022). CC -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase CC that phosphorylates the alpha subunit of eukaryotic translation CC initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the CC innate immune response to viral infection (PubMed:18835251, CC PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, CC PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral CC replication via the integrated stress response (ISR): EIF2S1/eIF-2- CC alpha phosphorylation in response to viral infection converts CC EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting CC to a shutdown of cellular and viral protein synthesis, while CC concomitantly initiating the preferential translation of ISR-specific CC mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, CC PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its CC antiviral activity on a wide range of DNA and RNA viruses including CC hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) CC and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, CC PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, CC PubMed:23399035). Also involved in the regulation of signal CC transduction, apoptosis, cell proliferation and differentiation: CC phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, CC ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, CC PubMed:19229320, PubMed:22214662). In addition to serine/threonine- CC protein kinase activity, also has tyrosine-protein kinase activity and CC phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its CC ubiquitination and proteasomal degradation (PubMed:20395957). Either as CC an adapter protein and/or via its kinase activity, can regulate various CC signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling CC pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) CC involved in the expression of genes encoding pro-inflammatory cytokines CC and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates CC the NF-kappa-B pathway via interaction with IKBKB and TRAF family of CC proteins and activates the p38 MAP kinase pathway via interaction with CC MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as CC both a positive and negative regulator of the insulin signaling pathway CC (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the CC inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at CC 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A CC which activates FOXO1, which in turn up-regulates the expression of CC insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate CC NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 CC and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the CC regulation of the cytoskeleton by binding to gelsolin (GSN), CC sequestering the protein in an inactive conformation away from actin CC (By similarity). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, CC ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, CC ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, CC ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, CC ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, CC ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, CC ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, CC ECO:0000269|PubMed:32197074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:16179258, ECO:0000303|PubMed:31246429}; CC -!- ACTIVITY REGULATION: Initially produced in an inactive form and is CC activated by binding to viral dsRNA, which causes dimerization and CC autophosphorylation in the activation loop and stimulation of function. CC ISGylation can activate it in the absence of viral infection. Can also CC be activated by heparin, pro-inflammatory stimuli, growth factors, CC cytokines, oxidative stress and the cellular protein PRKRA. Activity is CC markedly stimulated by manganese ions. Activation is blocked by the CC viral components HIV-1 Tat protein and large amounts of HIV-1 trans- CC activation response (TAR) RNA element as well as by the cellular CC proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana CC virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its CC proteasomal degradation. Inhibited by vaccinia virus protein E3, CC probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: Homodimer (PubMed:16179258, PubMed:31246429). Interacts with CC STRBP (By similarity). Interacts with DNAJC3. Forms a complex with CC FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts CC with IRS1 (By similarity). The inactive form interacts with NCK1 and CC GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 CC domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). CC Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 CC and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). CC Interacts with DHX9 (via N-terminus) and this interaction is dependent CC upon activation of the kinase. Interacts with EIF2S1/EIF-2ALPHA; this CC interaction induces a conformational change in EIF2S1 and its CC phosphorylation by EIF2AK2 (PubMed:16179258). Interacts with MBIP; the CC interaction is direct and leads to inhibition of EIF2AK2 self- CC activating autophosphorylation (PubMed:26705305). Interacts with the CC molybdopterin synthase complex subunit MOCS2B; the interaction is CC direct and enhances the interaction between EIF2AK2 and MBIP CC (PubMed:26705305). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10390359, ECO:0000269|PubMed:10848580, CC ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:15299030, ECO:0000269|PubMed:16179258, CC ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18096616, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19229320, CC ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:25740987, ECO:0000269|PubMed:26705305, CC ECO:0000269|PubMed:31246429, ECO:0000269|PubMed:8576172, CC ECO:0000269|PubMed:9079663, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9781815}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) TRS1; this interaction retains EIF2AK2 to the nucleus and CC prevents its activation. {ECO:0000269|PubMed:16987971, CC ECO:0000269|PubMed:27780231}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein K3 CC (K3L); this interaction inhibits EIF2AK2. CC {ECO:0000269|PubMed:18971339}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex CC virus 1 (HHV-1) protein US11 in an RNA-dependent manner. CC {ECO:0000269|PubMed:11836380}. CC -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana CC virus (TOS) NSS. {ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v- CC IRF2; this interaction inhibits EIF2AK2 activation. CC {ECO:0000269|PubMed:11160738}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3. CC {ECO:0000269|PubMed:25740987}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with CC Hepatitis C virus (HCV) mature core protein (via N-terminus); this CC interaction induces the autophosphorylation of EIF2AK2. CC {ECO:0000269|PubMed:17267064}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC non-structural protein 5A (NS5A); this interaction leads to disruption CC of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545, CC ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9710605}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks CC its inhibitory effect on protein synthesis and cell growth. CC {ECO:0000269|PubMed:9143277}. CC -!- SUBUNIT: (Microbial infection) Interacts with human respiratory CC syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 CC phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation CC shutoff. {ECO:0000269|PubMed:20519500}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 8 CC protein MTA/ORF57; this interaction inhibits stress granule formation. CC {ECO:0000269|PubMed:29084250}. CC -!- INTERACTION: CC P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366; CC P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308; CC P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456; CC P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193; CC P19525; Q08211: DHX9; NbExp=4; IntAct=EBI-640775, EBI-352022; CC P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506; CC P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038; CC P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775; CC P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162; CC P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243; CC P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088; CC P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820; CC P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230; CC P19525; P06748: NPM1; NbExp=4; IntAct=EBI-640775, EBI-78579; CC P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955; CC P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172; CC P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938; CC P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581; CC P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615; CC P19525; Q9UL40: ZNF346; NbExp=4; IntAct=EBI-640775, EBI-2462313; CC P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793; CC P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856; CC P19525; P20639: OPG041; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942; CC P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681; CC P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177; CC P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883; CC P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269; CC P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867, CC ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:26705305}. Nucleus {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear CC localization is elevated in acute leukemia, myelodysplastic syndrome CC (MDS), melanoma, breast, colon, prostate and lung cancer patient CC samples or cell lines as well as neurocytes from advanced Creutzfeldt- CC Jakob disease patients. {ECO:0000269|PubMed:21072047}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P19525-1; Sequence=Displayed; CC Name=2; CC IsoId=P19525-2; Sequence=VSP_046177; CC -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow CC compared to non-hematopoietic tissues such as small intestine, liver, CC or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer CC disease (AD) brain. Elevated levels seen in breast and colon CC carcinomas, and which correlates with tumor progression and CC invasiveness or risk of progression. {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:23403623}. CC -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}. CC -!- DOMAIN: Contains 2 dsRNA-binding domain (DRBM) (PubMed:9736623). The N- CC terminus contains the catalytic domain dimerization. The C-terminus CC binds EIF2S1/EIF2-alpha (PubMed:16179258). CC {ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:9736623}. CC -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues. CC Autophosphorylation of Thr-451 is dependent on Thr-446 and is CC stimulated by dsRNA binding and dimerization. Autophosphorylation CC apparently leads to the activation of the kinase. Tyrosine CC autophosphorylation is essential for efficient dsRNA-binding, CC dimerization, and kinase activation. Autophosphorylation is inhibited CC by the concerted action of ATAC complex subunit MBIP and molybdopterin CC synthase complex subunit MOCS2B (PubMed:26705305). CC {ECO:0000269|PubMed:11152499, ECO:0000269|PubMed:11337501, CC ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:16373505, CC ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. CC -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic CC neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal CC dominant disorder characterized by global developmental delay apparent CC in early childhood, cognitive impairment, ataxia, poor or absent speech CC with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, CC and abnormal involuntary movements. Affected individuals also exhibit CC neurological regression in the setting of febrile illness or infection. CC Many patients have seizures. Brain imaging shows diffuse white matter CC abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a CC disorder defined by the presence of sustained involuntary muscle CC contraction, often leading to abnormal postures. DYT33 is a slowly CC progressive form characterized by onset of focal or generalized CC dystonia in the first decades of life. Disease manifestations are CC variable. Some patients show ambulation difficulties, dysarthria, or CC dysphagia. Some affected individuals may manifest motor delay, lower CC limb spasticity, and mild developmental delay with intellectual CC disability. DYT33 penetrance is incomplete. Inheritance can be CC autosomal dominant or recessive. {ECO:0000269|PubMed:33236446, CC ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41866/EIF2AK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M35663; AAA36409.1; -; mRNA. DR EMBL; M85294; AAA18253.1; -; mRNA. DR EMBL; U50648; AAC50768.1; -; Genomic_DNA. DR EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; AF167472; AAF13156.1; -; Genomic_DNA. DR EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AY302136; AAP57628.1; -; mRNA. DR EMBL; AK290655; BAF83344.1; -; mRNA. DR EMBL; AK313818; BAG36554.1; -; mRNA. DR EMBL; AY228338; AAO38055.1; -; Genomic_DNA. DR EMBL; AC007899; AAY24317.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00407.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00408.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00409.1; -; Genomic_DNA. DR EMBL; BC093676; AAH93676.1; -; mRNA. DR EMBL; BC101475; AAI01476.1; -; mRNA. DR CCDS; CCDS1786.1; -. [P19525-1] DR CCDS; CCDS46259.1; -. [P19525-2] DR PIR; JC5225; JC5225. DR RefSeq; NP_001129123.1; NM_001135651.3. [P19525-1] DR RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2] DR RefSeq; NP_002750.1; NM_002759.4. [P19525-1] DR RefSeq; XP_011531289.1; XM_011532987.3. [P19525-1] DR RefSeq; XP_054198993.1; XM_054343018.1. [P19525-1] DR PDB; 1QU6; NMR; -; A=1-170. DR PDB; 2A19; X-ray; 2.50 A; B/C=258-550. DR PDB; 2A1A; X-ray; 2.80 A; B=258-550. DR PDB; 3UIU; X-ray; 2.90 A; A/B=254-551. DR PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551. DR PDB; 6D3L; X-ray; 3.10 A; A=229-551. DR PDB; 7OBK; X-ray; 1.80 A; B=541-551. DR PDB; 7OBL; X-ray; 1.80 A; B=541-551. DR PDB; 8BI7; X-ray; 1.40 A; B=541-551. DR PDB; 8I9J; EM; 6.39 A; A=1-170. DR PDB; 8IZN; EM; 6.67 A; A=1-170. DR PDBsum; 1QU6; -. DR PDBsum; 2A19; -. DR PDBsum; 2A1A; -. DR PDBsum; 3UIU; -. DR PDBsum; 6D3K; -. DR PDBsum; 6D3L; -. DR PDBsum; 7OBK; -. DR PDBsum; 7OBL; -. DR PDBsum; 8BI7; -. DR PDBsum; 8I9J; -. DR PDBsum; 8IZN; -. DR AlphaFoldDB; P19525; -. DR BMRB; P19525; -. DR EMDB; EMD-35274; -. DR EMDB; EMD-35866; -. DR SMR; P19525; -. DR BioGRID; 111596; 395. DR DIP; DIP-2657N; -. DR FunCoup; P19525; 998. DR IntAct; P19525; 176. DR MINT; P19525; -. DR STRING; 9606.ENSP00000233057; -. DR BindingDB; P19525; -. DR ChEMBL; CHEMBL5785; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07995; H-89. DR DrugBank; DB00328; Indomethacin. DR DrugCentral; P19525; -. DR GuidetoPHARMACOLOGY; 2016; -. DR GlyGen; P19525; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P19525; -. DR PhosphoSitePlus; P19525; -. DR SwissPalm; P19525; -. DR BioMuta; EIF2AK2; -. DR DMDM; 125527; -. DR jPOST; P19525; -. DR MassIVE; P19525; -. DR PaxDb; 9606-ENSP00000233057; -. DR PeptideAtlas; P19525; -. DR ProteomicsDB; 19391; -. DR ProteomicsDB; 53670; -. [P19525-1] DR Pumba; P19525; -. DR TopDownProteomics; P19525-1; -. [P19525-1] DR Antibodypedia; 3548; 1196 antibodies from 44 providers. DR DNASU; 5610; -. DR Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.20. [P19525-2] DR Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.20. [P19525-1] DR GeneID; 5610; -. DR KEGG; hsa:5610; -. DR MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1. DR UCSC; uc010fab.3; human. [P19525-1] DR AGR; HGNC:9437; -. DR ClinPGx; PA33779; -. DR CTD; 5610; -. DR DisGeNET; 5610; -. DR GeneCards; EIF2AK2; -. DR HGNC; HGNC:9437; EIF2AK2. DR HPA; ENSG00000055332; Low tissue specificity. DR MalaCards; EIF2AK2; -. DR MIM; 176871; gene. DR MIM; 618877; phenotype. DR MIM; 619687; phenotype. DR OpenTargets; ENSG00000055332; -. DR Orphanet; 256; Early-onset generalized limb-onset dystonia. DR VEuPathDB; HostDB:ENSG00000055332; -. DR eggNOG; KOG1033; Eukaryota. DR GeneTree; ENSGT00940000160736; -. DR HOGENOM; CLU_023682_1_0_1; -. DR InParanoid; P19525; -. DR OMA; KIACEMM; -. DR OrthoDB; 341578at2759; -. DR PAN-GO; P19525; 2 GO annotations based on evolutionary models. DR PhylomeDB; P19525; -. DR PathwayCommons; P19525; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-169131; Inhibition of PKR. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9833109; Evasion by RSV of host interferon responses. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SignaLink; P19525; -. DR SIGNOR; P19525; -. DR Agora; ENSG00000055332; -. DR BioGRID-ORCS; 5610; 13 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; EIF2AK2; human. DR EvolutionaryTrace; P19525; -. DR GeneWiki; Protein_kinase_R; -. DR GenomeRNAi; 5610; -. DR Pharos; P19525; Tchem. DR PRO; PR:P19525; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P19525; protein. DR Bgee; ENSG00000055332; Expressed in endometrium epithelium and 211 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005840; C:ribosome; TAS:AgBase. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:UniProt. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProt. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB. DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB. DR GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IMP:UniProtKB. DR GO; GO:0006412; P:translation; IEA:Ensembl. DR CDD; cd19903; DSRM_EIF2AK2_rpt1; 1. DR CDD; cd19904; DSRM_EIF2AK2_rpt2; 1. DR CDD; cd14047; STKc_EIF2AK2_PKR; 1. DR DisProt; DP03944; -. DR FunFam; 3.30.160.20:FF:000045; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.160.20:FF:000062; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.200.20:FF:000536; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 1.10.510.10:FF:000251; eukaryotic translation initiation factor 2-alpha kinase 3; 1. DR Gene3D; 3.30.160.20; -; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00443; -. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR014720; dsRBD_dom. DR InterPro; IPR044452; EIF2AK2_DSRM_1. DR InterPro; IPR044453; EIF2AK2_DSRM_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF163; INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00035; dsrm; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00358; DSRM; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54768; dsRNA-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50137; DS_RBD; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Antiviral defense; KW ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant; KW Dystonia; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Kinase; Magnesium; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Tyrosine-protein kinase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..551 FT /note="Interferon-induced, double-stranded RNA-activated FT protein kinase" FT /id="PRO_0000085945" FT DOMAIN 9..77 FT /note="DRBM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 100..167 FT /note="DRBM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 267..538 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 331..343 FT /note="1" FT REPEAT 345..357 FT /note="2" FT REGION 2..180 FT /note="(Microbial infection) Interaction with HCV NS5A" FT /evidence="ECO:0000269|PubMed:17267064" FT REGION 202..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 266..551 FT /note="Interaction with TRAF5" FT /evidence="ECO:0000269|PubMed:15121867" FT REGION 266..362 FT /note="Dimerization" FT /evidence="ECO:0000269|PubMed:16179258" FT REGION 331..357 FT /note="2 X 13 AA approximate repeats" FT REGION 379..496 FT /note="Interaction with EIF2S1/EIF-2ALPHA" FT /evidence="ECO:0000269|PubMed:16179258" FT COMPBIAS 202..215 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 414 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 273..281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 296 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 432 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000305|PubMed:16179258, FT ECO:0000305|PubMed:31246429" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT MOD_RES 83 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11152499, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 88 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 89 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 90 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 101 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 242 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 255 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 258 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 293 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 446 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:16179258" FT MOD_RES 451 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:20685959" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 542 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 69 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT VAR_SEQ 263..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_046177" FT VARIANT 11 FT /note="M -> L (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084260" FT VARIANT 32 FT /note="N -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084261" FT VARIANT 32 FT /note="N -> T (in DYT33; uncertain significance; gain-of- FT function variant resulting in increased levels of FT phosphorylated EIF2AK2 and EIF2A in patient cells compared FT to controls)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086715" FT VARIANT 97 FT /note="S -> F (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084262" FT VARIANT 109 FT /note="A -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084263" FT VARIANT 109 FT /note="A -> V (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084264" FT VARIANT 114 FT /note="L -> Q (found in a patient with dysmorphic facies, FT syndactyly, congenital microcephaly and global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084265" FT VARIANT 130 FT /note="G -> R (in DYT33; gain-of-function variant resulting FT in increased levels of phosphorylated EIF2AK2 and EIF2A in FT patient cells compared to controls)" FT /evidence="ECO:0000269|PubMed:33236446, FT ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068" FT /id="VAR_086716" FT VARIANT 133 FT /note="Y -> F (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084266" FT VARIANT 138 FT /note="G -> A (in DYT33; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086717" FT VARIANT 325 FT /note="G -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084267" FT VARIANT 428 FT /note="V -> E (in dbSNP:rs56219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040474" FT VARIANT 439 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040475" FT VARIANT 461 FT /note="S -> C (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084268" FT VARIANT 506 FT /note="I -> V (no effect on PKR inhibition by HCMV protein FT TRS1; dbSNP:rs34821155)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:27780231" FT /id="VAR_040476" FT MUTAGEN 59..60 FT /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but FT no effect on dsRNA binding." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 60 FT /note="K->A: Impairs dsRNA binding but not dimerization or FT activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 67 FT /note="A->E: Significant loss of activity; loss of dsRNA FT binding and dimerization." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 83 FT /note="S->A: No effect on enzymatic activity; when FT associated with A-88; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 88 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 89 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 90 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-89." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 149..150 FT /note="TK->AA: In FL-PKR-2AII; no effect on activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 242 FT /note="S->A: Moderate loss of activity; when associated FT with A-255 and A-258." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 244..296 FT /note="Missing: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 255 FT /note="T->A: Moderate loss of activity; when associated FT with A-242 and A-255." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 258 FT /note="T->A: Moderate loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 296 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 446 FT /note="T->A: Significant loss of activity and impairs FT autophosphorylation of T-451." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 451 FT /note="T->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 486 FT /note="D->V: 15-fold decrease in K3L binding affinity and FT thus resistance of mutated PKR to K3L inhibition." FT /evidence="ECO:0000269|PubMed:18971339" FT MUTAGEN 489 FT /note="F->S: Loss of PKR inhibition by HCMV protein TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 496 FT /note="T->K: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 502 FT /note="I->T: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 510 FT /note="K->R: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 516 FT /note="Q->E: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT CONFLICT 102 FT /note="I -> M (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 224 FT /note="S -> R (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 512 FT /note="K -> E (in Ref. 6; AAF13156)" FT /evidence="ECO:0000305" FT STRAND 5..7 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 26..32 FT /evidence="ECO:0007829|PDB:1QU6" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 41..50 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 61..76 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 102..111 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 115..123 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 125..138 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 144..149 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 150..167 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 261..266 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 267..274 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:2A19" FT TURN 287..289 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 303..305 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 306..314 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 323..332 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 358..366 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 388..407 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:2A1A" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 420..424 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 433..435 FT /evidence="ECO:0007829|PDB:6D3L" FT STRAND 437..440 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 468..482 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 488..499 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:3UIU" FT HELIX 509..518 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 523..525 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 529..539 FT /evidence="ECO:0007829|PDB:2A19" SQ SEQUENCE 551 AA; 62094 MW; 815AD83ACAB45DA3 CRC64; MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK KSPEKNERHT C // ID EPHA2_HUMAN Reviewed; 976 AA. AC P29317; B5A968; Q8N3Z2; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=Ephrin type-A receptor 2; DE EC=2.7.10.1; DE AltName: Full=Epithelial cell kinase; DE AltName: Full=Tyrosine-protein kinase receptor ECK; DE Flags: Precursor; GN Name=EPHA2; Synonyms=ECK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND RP AUTOPHOSPHORYLATION. RC TISSUE=Epithelium; RX PubMed=2174105; DOI=10.1128/mcb.10.12.6316-6324.1990; RA Lindberg R.A., Hunter T.; RT "cDNA cloning and characterization of eck, an epithelial cell receptor RT protein-tyrosine kinase in the eph/elk family of protein kinases."; RL Mol. Cell. Biol. 10:6316-6324(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [7] RP FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL MIGRATION, RP PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND SUBCELLULAR RP LOCATION. RX PubMed=10655584; DOI=10.1038/35000008; RA Miao H., Burnett E., Kinch M., Simon E., Wang B.; RT "Activation of EphA2 kinase suppresses integrin function and causes focal- RT adhesion-kinase dephosphorylation."; RL Nat. Cell Biol. 2:62-69(2000). RN [8] RP ONCOGENICITY. RX PubMed=11280802; RA Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.; RT "EphA2 overexpression causes tumorigenesis of mammary epithelial cells."; RL Cancer Res. 61:2301-2306(2001). RN [9] RP INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1. RX PubMed=12167657; DOI=10.1074/jbc.m207127200; RA Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.; RT "Regulation of the EphA2 kinase by the low molecular weight tyrosine RT phosphatase induces transformation."; RL J. Biol. Chem. 277:39274-39279(2002). RN [10] RP FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND MUTAGENESIS RP OF LYS-646. RX PubMed=16236711; DOI=10.1074/jbc.m503786200; RA Tanaka M., Kamata R., Sakai R.; RT "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates RT paracellular permeability."; RL J. Biol. Chem. 280:42375-42382(2005). RN [11] RP TISSUE SPECIFICITY. RX PubMed=17332925; RA Liu D.-P., Wang Y., Koeffler H.P., Xie D.; RT "Ephrin-A1 is a negative regulator in glioma through down-regulation of RT EphA2 and FAK."; RL Int. J. Oncol. 30:865-871(2007). RN [12] RP INTERACTION WITH INPPL1. RX PubMed=17135240; DOI=10.1074/jbc.m608509200; RA Zhuang G., Hunter S., Hwang Y., Chen J.; RT "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via RT phosphatidylinositol 3-Kinase-dependent Rac1 activation."; RL J. Biol. Chem. 282:2683-2694(2007). RN [13] RP FUNCTION IN APOPTOSIS, AND INDUCTION BY UV. RX PubMed=18339848; DOI=10.1158/0008-5472.can-07-2372; RA Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.; RT "EphA2 is an essential mediator of UV radiation-induced apoptosis."; RL Cancer Res. 68:1691-1696(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND THR-647, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=18794797; DOI=10.1038/onc.2008.328; RA Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.; RT "Soluble monomeric EphrinA1 is released from tumor cells and is a RT functional ligand for the EphA2 receptor."; RL Oncogene 27:7260-7273(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND SER-901, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS OF RP ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB. RX PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009; RA Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., RA Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.; RT "EphA2 mediates ligand-dependent inhibition and ligand-independent RT promotion of cell migration and invasion via a reciprocal regulatory loop RT with Akt."; RL Cancer Cell 16:9-20(2009). RN [18] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [19] RP UBIQUITINATION BY STUB1. RX PubMed=19567782; DOI=10.1158/1541-7786.mcr-08-0582; RA Annamalai B., Liu X., Gopal U., Isaacs J.S.; RT "Hsp90 is an essential regulator of EphA2 receptor stability and signaling: RT implications for cancer cell migration and metastasis."; RL Mol. Cancer Res. 7:1021-1032(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647 AND RP SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND ELMO2. RX PubMed=20679435; DOI=10.1083/jcb.201005141; RA Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S., RA Negishi M., Katoh H.; RT "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent RT mechanism."; RL J. Cell Biol. 190:461-477(2010). RN [22] RP FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR RP LOCATION. RX PubMed=20861311; DOI=10.1091/mbc.e10-03-0242; RA Lin S., Gordon K., Kaplan N., Getsios S.; RT "Ligand targeting of EphA2 enhances keratinocyte adhesion and RT differentiation via desmoglein 1."; RL Mol. Biol. Cell 21:3902-3914(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP SUBCELLULAR LOCATION. RX PubMed=20223987; DOI=10.1126/science.1181729; RA Salaita K., Nair P.M., Petit R.S., Neve R.M., Das D., Gray J.W., RA Groves J.T.; RT "Restriction of receptor movement alters cellular response: physical force RT sensing by EphA2."; RL Science 327:1380-1385(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [27] RP INTERACTION WITH ANKS1A. RX PubMed=22332920; DOI=10.1021/bi300141h; RA Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M., Leone M.; RT "Solution structure of the first Sam domain of Odin and binding studies RT with the EphA2 receptor."; RL Biochemistry 51:2136-2145(2012). RN [28] RP INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL INFECTION). RX PubMed=22635007; DOI=10.1038/nm.2805; RA Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J., RA Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A., Myoung J., RA Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.; RT "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's RT sarcoma-associated herpesvirus."; RL Nat. Med. 18:961-966(2012). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897 AND RP SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [30] RP FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930, DEPHOSPHORYLATION RP AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1. RX PubMed=23358419; DOI=10.1128/mcb.01708-12; RA Lee H., Bennett A.M.; RT "Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate RT screen identifies EphA2 as a target for LAR in cell migration."; RL Mol. Cell. Biol. 33:1430-1441(2013). RN [31] RP INTERACTION WITH CEMIP. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [32] RP PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [33] RP PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND RP FUNCTION. RX PubMed=27385333; DOI=10.1091/mbc.e16-01-0048; RA Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M., RA Pasquale E.B.; RT "Protein kinase A can block EphA2 receptor-mediated cell repulsion by RT increasing EphA2 S897 phosphorylation."; RL Mol. Biol. Cell 27:2757-2770(2016). RN [34] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292383; DOI=10.1038/s41564-017-0080-8; RA Zhang H., Li Y., Wang H.B., Zhang A., Chen M.L., Fang Z.X., Dong X.D., RA Li S.B., Du Y., Xiong D., He J.Y., Li M.Z., Liu Y.M., Zhou A.J., Zhong Q., RA Zeng Y.X., Kieff E., Zhang Z., Gewurz B.E., Zhao B., Zeng M.S.; RT "Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus RT entry."; RL Nat. Microbiol. 3:1-8(2018). RN [35] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292384; DOI=10.1038/s41564-017-0081-7; RA Chen J., Sathiyamoorthy K., Zhang X., Schaller S., Perez White B.E., RA Jardetzky T.S., Longnecker R.; RT "Ephrin receptor A2 is a functional entry receptor for Epstein-Barr RT virus."; RL Nat. Microbiol. 3:172-180(2018). RN [36] RP INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION. RX PubMed=34067457; DOI=10.3390/cells10061290; RA Moon B., Yang S., Kim K., Lee J., Jeong D., Park D.; RT "EphA2 Interacts with Tim-4 through Association between Its FN3 Domain and RT the IgV Domain of Tim-4."; RL Cells 10:0-0(2021). RN [37] RP FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS RP PROTEINS GH AND GL (MICROBIAL INFECTION). RX PubMed=37146061; DOI=10.1371/journal.ppat.1011304; RA Dong X.D., Li Y., Li Y., Sun C., Liu S.X., Duan H., Cui R., Zhong Q., RA Mou Y.G., Wen L., Yang B., Zeng M.S., Luo M.H., Zhang H.; RT "EphA2 is a functional entry receptor for HCMV infection of glioblastoma RT cells."; RL PLoS Pathog. 19:e1011304-e1011304(2023). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [39] RP STRUCTURE BY NMR OF 902-976. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin type-A RT receptor 2 precursor (EC 2.7.10.1)."; RL Submitted (JAN-2008) to the PDB data bank. RN [40] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY CRYSTALLOGRAPHY RP (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1, SUBUNIT, DISULFIDE BOND, RP AND MUTAGENESIS OF ARG-103. RX PubMed=19525919; DOI=10.1038/embor.2009.91; RA Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M., RA Rajashankar K.R., Wang B., Nikolov D.B.; RT "Ligand recognition by A-class Eph receptors: crystal structures of the RT EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex."; RL EMBO Rep. 10:722-728(2009). RN [41] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND. RG Structural genomics consortium (SGC); RT "Ephrin A1 bound to the ligand binding domain of the human ephrin A2 RT (EPHA2) receptor protein kinase."; RL Submitted (FEB-2009) to the PDB data bank. RN [42] RP STRUCTURE BY NMR OF 523-563. RA Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.; RT "Left-handed dimer of EPHA2 transmembrane domain helix packing diversity RT among receptor tyrosine kinases."; RL Submitted (AUG-2009) to the PDB data bank. RN [43] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH EFNA1, AND RP SUBUNIT. RX PubMed=20505120; DOI=10.1073/pnas.1004148107; RA Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L., RA Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., Dhe-Paganon S.; RT "Architecture of Eph receptor clusters."; RL Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010). RN [44] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND RP HIS-876. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [45] RP VARIANT CTRCT6 TRP-948. RX PubMed=19005574; RA Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X., RA Hejtmancik J.F.; RT "The EPHA2 gene is associated with cataracts linked to chromosome 1p."; RL Mol. Vis. 14:2042-2055(2008). RN [46] RP VARIANT CTRCT6 ILE-940. RX PubMed=19306328; DOI=10.1002/humu.20995; RA Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E., RA Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J., Zhang X.; RT "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal RT dominant congenital cataract."; RL Hum. Mutat. 30:E603-E611(2009). RN [47] RP VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6 GLN-721. RX PubMed=19649315; DOI=10.1371/journal.pgen.1000584; RA Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H., RA Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P., RA Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J., RA Elston R.C., Iyengar S.K., Wang B.; RT "EPHA2 is associated with age-related cortical cataract in mice and RT humans."; RL PLoS Genet. 5:E1000584-E1000584(2009). RN [48] RP CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948. RX PubMed=22570727; DOI=10.1371/journal.pone.0036564; RA Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.; RT "Human cataract mutations in EPHA2 SAM domain alter receptor stability and RT function."; RL PLoS ONE 7:E36564-E36564(2012). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Activated by the ligand ephrin- CC A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation CC and differentiation of cells. Regulates cell adhesion and CC differentiation through DSG1/desmoglein-1 and inhibition of the CC ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also CC participate in UV radiation-induced apoptosis and have a ligand- CC independent stimulatory effect on chemotactic cell migration. During CC development, may function in distinctive aspects of pattern formation CC and subsequently in development of several fetal tissues. Involved for CC instance in angiogenesis, in early hindbrain development and epithelial CC proliferation and branching morphogenesis during mammary gland CC development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens CC fiber cells shape and interactions and be important for lens CC transparency development and maintenance. With ephrin-A2/EFNA2 may play CC a role in bone remodeling through regulation of osteoclastogenesis and CC osteoblastogenesis. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- FUNCTION: Acts as a receptor for human cytomegalovirus (HCMV) to CC mediate viral entry and fusion in glioblastoma cells. CC {ECO:0000269|PubMed:37146061}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:2174105}; CC -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated form) CC with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); CC critical for the EFNA1-induced activation of RAC1 which stimulates cell CC migration (By similarity). Interacts with INPPL1; regulates activated CC EPHA2 endocytosis and degradation. Interacts (inactivated form) with CC PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; CC regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 CC and ELMO2; mediates ligand-independent activation of RAC1 which CC stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 CC and may regulate tight junctions. Interacts with ACP1. Interacts (via CC SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP. CC Interacts with NCK1; may regulate EPHA2 activity in cell migration and CC adhesion. Interacts with TIMD4 (PubMed:34067457). CC {ECO:0000250|UniProtKB:Q03145, ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711, CC ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919, CC ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:34067457}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV- CC 8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC triggers EPHA2 phosphorylation and endocytosis, allowing virus entry. CC {ECO:0000269|PubMed:22635007}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) glycoprotein L/gL and glycoprotein H/gH heterodimer. CC {ECO:0000269|PubMed:37146061}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus/HHV-4 CC glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC facilitates virus internalization and fusion. CC {ECO:0000269|PubMed:29292383, ECO:0000269|PubMed:29292384}. CC -!- INTERACTION: CC P29317; P30530: AXL; NbExp=2; IntAct=EBI-702104, EBI-2850927; CC P29317; P35222: CTNNB1; NbExp=2; IntAct=EBI-702104, EBI-491549; CC P29317; P20827: EFNA1; NbExp=9; IntAct=EBI-702104, EBI-715194; CC P29317; P52803: EFNA5; NbExp=8; IntAct=EBI-702104, EBI-1753674; CC P29317; P98172: EFNB1; NbExp=3; IntAct=EBI-702104, EBI-538287; CC P29317; P29320: EPHA3; NbExp=3; IntAct=EBI-702104, EBI-1641575; CC P29317; P54756: EPHA5; NbExp=3; IntAct=EBI-702104, EBI-1383718; CC P29317; Q9UF33: EPHA6; NbExp=4; IntAct=EBI-702104, EBI-3950019; CC P29317; Q15375: EPHA7; NbExp=7; IntAct=EBI-702104, EBI-1383428; CC P29317; P08238: HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572; CC P29317; O15357-1: INPPL1; NbExp=3; IntAct=EBI-702104, EBI-15963021; CC P29317; P29376: LTK; NbExp=3; IntAct=EBI-702104, EBI-6596163; CC P29317; Q05397: PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142; CC P29317; Q06124: PTPN11; NbExp=3; IntAct=EBI-702104, EBI-297779; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20223987, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:34067457}; Single-pass CC type I membrane protein {ECO:0000255}. Cell projection, ruffle membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell projection, lamellipodium membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell junction, focal adhesion CC {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-cell CC contacts but also at the leading edge of migrating cells CC (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane CC to the cytoplasmic and perinuclear regions in cancer cells CC (PubMed:18794797). {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311, CC ECO:0000269|PubMed:26158630}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29317-1; Sequence=Displayed; CC Name=2; CC IsoId=P29317-2; Sequence=VSP_056014, VSP_056015; CC -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and glioma CC cell lines (at protein level). Expressed most highly in tissues that CC contain a high proportion of epithelial cells, e.g. skin, intestine, CC lung, and ovary. {ECO:0000269|PubMed:17332925}. CC -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent, MAPK- CC dependent mechanism. {ECO:0000269|PubMed:18339848}. CC -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding and CC activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are CC required for binding VAV2 and VAV3 while phosphorylated residues Tyr- CC 735 and Tyr-930 are required for binding PI3-kinase p85 subunit CC (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical CC for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which CC transduce downstream signaling to activate RAC1 GTPase and cell CC migration. Dephosphorylation of Tyr-930 by PTPRF prevents the CC interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB; CC serum-induced phosphorylation which targets EPHA2 to the cell leading CC edge and stimulates cell migration. Phosphorylation by PKB is inhibited CC by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal CC regulatory loop. Phosphorylated at Ser-897 in response to TNF by CC RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell CC migration (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks CC cell retraction induced by EPHA2 kinase activity (PubMed:27385333). CC Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808, CC ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630, CC ECO:0000269|PubMed:27385333}. CC -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the CC HSP90 chaperone and regulates the receptor stability and activity CC through proteasomal degradation. ANKS1A prevents ubiquitination and CC degradation (By similarity). {ECO:0000250}. CC -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An CC opacification of the crystalline lens of the eye that frequently CC results in visual impairment or blindness. Opacities vary in CC morphology, are often confined to a portion of the lens, and may be CC static or progressive. CTRCT6 includes posterior polar and age-related CC cortical cataracts, among others. Posterior polar cataract is a CC subcapsular opacity, usually disk-shaped, located at the back of the CC lens. Age-related cortical cataract is a developmental punctate opacity CC restricted to the cortex. The cataract is white or cerulean, increases CC in number with age, but rarely affects vision. CC {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328, CC ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Overexpressed in several cancer types and promotes CC malignancy. {ECO:0000269|PubMed:19573808}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40462/EPHA2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M59371; AAA53375.1; -; mRNA. DR EMBL; EU826606; ACF47642.1; -; mRNA. DR EMBL; AL451042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471167; EAW51769.1; -; Genomic_DNA. DR EMBL; BC037166; AAH37166.1; -; mRNA. DR CCDS; CCDS169.1; -. [P29317-1] DR PIR; A36355; A36355. DR RefSeq; NP_004422.2; NM_004431.4. [P29317-1] DR PDB; 1MQB; X-ray; 2.30 A; A/B=596-900. DR PDB; 2E8N; NMR; -; A=902-976. DR PDB; 2K9Y; NMR; -; A/B=523-563. DR PDB; 2KSO; NMR; -; A=908-972. DR PDB; 2X10; X-ray; 3.00 A; A=27-534. DR PDB; 2X11; X-ray; 4.83 A; A=27-534. DR PDB; 3C8X; X-ray; 1.95 A; A=23-202. DR PDB; 3CZU; X-ray; 2.65 A; A=23-202. DR PDB; 3FL7; X-ray; 2.50 A; A=23-531. DR PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201. DR PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201. DR PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971. DR PDB; 3MBW; X-ray; 2.81 A; A=23-326. DR PDB; 3MX0; X-ray; 3.51 A; A/C=27-435. DR PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202. DR PDB; 4P2K; X-ray; 1.50 A; A=590-876. DR PDB; 4PDO; X-ray; 2.10 A; A/B=590-876. DR PDB; 4TRL; X-ray; 2.45 A; A=590-876. DR PDB; 5EK7; X-ray; 1.90 A; A/B=583-876. DR PDB; 5I9U; X-ray; 1.89 A; A=596-900. DR PDB; 5I9V; X-ray; 1.46 A; A=596-900. DR PDB; 5I9W; X-ray; 1.36 A; A=596-900. DR PDB; 5I9X; X-ray; 1.43 A; A=596-900. DR PDB; 5I9Y; X-ray; 1.23 A; A=596-900. DR PDB; 5I9Z; X-ray; 1.70 A; A=596-900. DR PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900. DR PDB; 5IA1; X-ray; 2.04 A; A=596-900. DR PDB; 5IA2; X-ray; 1.62 A; A=596-900. DR PDB; 5IA3; X-ray; 1.79 A; A=596-900. DR PDB; 5IA4; X-ray; 1.80 A; A=596-900. DR PDB; 5IA5; X-ray; 1.78 A; A=596-900. DR PDB; 5NJZ; X-ray; 1.77 A; A=596-900. DR PDB; 5NK0; X-ray; 1.60 A; A=596-900. DR PDB; 5NK1; X-ray; 1.55 A; A=596-900. DR PDB; 5NK2; X-ray; 1.65 A; A=596-900. DR PDB; 5NK3; X-ray; 1.59 A; A=596-900. DR PDB; 5NK4; X-ray; 1.45 A; A=596-900. DR PDB; 5NK5; X-ray; 1.33 A; A=596-900. DR PDB; 5NK6; X-ray; 1.27 A; A=596-900. DR PDB; 5NK7; X-ray; 1.89 A; A=596-900. DR PDB; 5NK8; X-ray; 1.76 A; A=596-900. DR PDB; 5NK9; X-ray; 1.59 A; A=596-900. DR PDB; 5NKA; X-ray; 1.38 A; A=596-900. DR PDB; 5NKB; X-ray; 1.50 A; A=596-900. DR PDB; 5NKC; X-ray; 1.45 A; A=596-900. DR PDB; 5NKD; X-ray; 1.41 A; A=596-900. DR PDB; 5NKE; X-ray; 1.39 A; A=596-900. DR PDB; 5NKF; X-ray; 1.10 A; A=596-900. DR PDB; 5NKG; X-ray; 1.10 A; A=596-900. DR PDB; 5NKH; X-ray; 1.29 A; A=596-900. DR PDB; 5NKI; X-ray; 1.68 A; A=596-900. DR PDB; 5NZ9; NMR; -; A=945-969. DR PDB; 6B9L; X-ray; 3.20 A; A/B/C/D=27-200. DR PDB; 6F7M; NMR; -; A=945-969. DR PDB; 6F7N; NMR; -; A=951-963. DR PDB; 6FNF; X-ray; 1.56 A; A=596-900. DR PDB; 6FNG; X-ray; 1.04 A; A=596-900. DR PDB; 6FNH; X-ray; 1.38 A; A/B/C=596-900. DR PDB; 6HES; X-ray; 1.13 A; A=596-900. DR PDB; 6HET; X-ray; 1.21 A; A=596-900. DR PDB; 6HEU; X-ray; 1.72 A; A=596-900. DR PDB; 6HEV; X-ray; 1.28 A; A=596-900. DR PDB; 6HEW; X-ray; 1.27 A; A=596-900. DR PDB; 6HEX; X-ray; 1.41 A; A=596-900. DR PDB; 6HEY; X-ray; 1.37 A; A=596-900. DR PDB; 6NJZ; X-ray; 1.90 A; A/B=28-200. DR PDB; 6NK0; X-ray; 1.53 A; A/B=28-200. DR PDB; 6NK1; X-ray; 1.55 A; A/B=28-200. DR PDB; 6NK2; X-ray; 2.20 A; A/B=28-200. DR PDB; 6NKP; X-ray; 2.03 A; A/B=28-200. DR PDB; 6Q7B; X-ray; 1.01 A; A=596-900. DR PDB; 6Q7C; X-ray; 1.05 A; A=596-900. DR PDB; 6Q7D; X-ray; 0.98 A; A=596-900. DR PDB; 6Q7E; X-ray; 1.06 A; A=596-900. DR PDB; 6Q7F; X-ray; 1.20 A; A=596-900. DR PDB; 6Q7G; X-ray; 1.05 A; A=596-900. DR PDB; 6RW2; X-ray; 2.26 A; A=27-201. DR PDB; 7B7N; X-ray; 2.69 A; E=23-202. DR PDB; 7CZE; X-ray; 3.00 A; I/J/K/L=26-200. DR PDB; 7CZF; X-ray; 3.20 A; A/D=28-206. DR PDB; 7KJA; X-ray; 1.75 A; A/B=590-976. DR PDB; 7KJB; X-ray; 2.80 A; A=590-976. DR PDB; 7KJC; X-ray; 2.30 A; A/B=590-976. DR PDB; 8BIN; X-ray; 1.50 A; A=596-900. DR PDB; 8BIO; X-ray; 1.60 A; A=596-900. DR PDB; 8BK0; X-ray; 1.70 A; A=596-900. DR PDB; 8BM8; X-ray; 1.68 A; A=596-900. DR PDB; 8BOC; X-ray; 1.90 A; A=596-900. DR PDB; 8BOD; X-ray; 1.50 A; A=596-900. DR PDB; 8BOF; X-ray; 1.82 A; A=596-900. DR PDB; 8BOG; X-ray; 1.47 A; A=596-900. DR PDB; 8BOH; X-ray; 1.42 A; A=596-900. DR PDB; 8BOI; X-ray; 1.63 A; A=596-900. DR PDB; 8BOK; X-ray; 2.02 A; A=596-900. DR PDB; 8BOM; X-ray; 1.12 A; A=596-900. DR PDB; 8QQY; X-ray; 1.80 A; A=596-900. DR PDB; 8T9B; X-ray; 4.20 A; I/J/K/L=436-529. DR PDB; 8TRS; X-ray; 1.90 A; D=199-326. DR PDB; 8TRT; X-ray; 3.00 A; D/E=199-326. DR PDB; 8TRV; X-ray; 3.25 A; A/B=23-326. DR PDB; 8TV1; X-ray; 2.60 A; C=23-326. DR PDB; 8TV5; X-ray; 4.60 A; C/F=23-326. DR PDB; 8XPV; X-ray; 1.55 A; A=596-900. DR PDBsum; 1MQB; -. DR PDBsum; 2E8N; -. DR PDBsum; 2K9Y; -. DR PDBsum; 2KSO; -. DR PDBsum; 2X10; -. DR PDBsum; 2X11; -. DR PDBsum; 3C8X; -. DR PDBsum; 3CZU; -. DR PDBsum; 3FL7; -. DR PDBsum; 3HEI; -. DR PDBsum; 3HPN; -. DR PDBsum; 3KKA; -. DR PDBsum; 3MBW; -. DR PDBsum; 3MX0; -. DR PDBsum; 3SKJ; -. DR PDBsum; 4P2K; -. DR PDBsum; 4PDO; -. DR PDBsum; 4TRL; -. DR PDBsum; 5EK7; -. DR PDBsum; 5I9U; -. DR PDBsum; 5I9V; -. DR PDBsum; 5I9W; -. DR PDBsum; 5I9X; -. DR PDBsum; 5I9Y; -. DR PDBsum; 5I9Z; -. DR PDBsum; 5IA0; -. DR PDBsum; 5IA1; -. DR PDBsum; 5IA2; -. DR PDBsum; 5IA3; -. DR PDBsum; 5IA4; -. DR PDBsum; 5IA5; -. DR PDBsum; 5NJZ; -. DR PDBsum; 5NK0; -. DR PDBsum; 5NK1; -. DR PDBsum; 5NK2; -. DR PDBsum; 5NK3; -. DR PDBsum; 5NK4; -. DR PDBsum; 5NK5; -. DR PDBsum; 5NK6; -. DR PDBsum; 5NK7; -. DR PDBsum; 5NK8; -. DR PDBsum; 5NK9; -. DR PDBsum; 5NKA; -. DR PDBsum; 5NKB; -. DR PDBsum; 5NKC; -. DR PDBsum; 5NKD; -. DR PDBsum; 5NKE; -. DR PDBsum; 5NKF; -. DR PDBsum; 5NKG; -. DR PDBsum; 5NKH; -. DR PDBsum; 5NKI; -. DR PDBsum; 5NZ9; -. DR PDBsum; 6B9L; -. DR PDBsum; 6F7M; -. DR PDBsum; 6F7N; -. DR PDBsum; 6FNF; -. DR PDBsum; 6FNG; -. DR PDBsum; 6FNH; -. DR PDBsum; 6HES; -. DR PDBsum; 6HET; -. DR PDBsum; 6HEU; -. DR PDBsum; 6HEV; -. DR PDBsum; 6HEW; -. DR PDBsum; 6HEX; -. DR PDBsum; 6HEY; -. DR PDBsum; 6NJZ; -. DR PDBsum; 6NK0; -. DR PDBsum; 6NK1; -. DR PDBsum; 6NK2; -. DR PDBsum; 6NKP; -. DR PDBsum; 6Q7B; -. DR PDBsum; 6Q7C; -. DR PDBsum; 6Q7D; -. DR PDBsum; 6Q7E; -. DR PDBsum; 6Q7F; -. DR PDBsum; 6Q7G; -. DR PDBsum; 6RW2; -. DR PDBsum; 7B7N; -. DR PDBsum; 7CZE; -. DR PDBsum; 7CZF; -. DR PDBsum; 7KJA; -. DR PDBsum; 7KJB; -. DR PDBsum; 7KJC; -. DR PDBsum; 8BIN; -. DR PDBsum; 8BIO; -. DR PDBsum; 8BK0; -. DR PDBsum; 8BM8; -. DR PDBsum; 8BOC; -. DR PDBsum; 8BOD; -. DR PDBsum; 8BOF; -. DR PDBsum; 8BOG; -. DR PDBsum; 8BOH; -. DR PDBsum; 8BOI; -. DR PDBsum; 8BOK; -. DR PDBsum; 8BOM; -. DR PDBsum; 8QQY; -. DR PDBsum; 8T9B; -. DR PDBsum; 8TRS; -. DR PDBsum; 8TRT; -. DR PDBsum; 8TRV; -. DR PDBsum; 8TV1; -. DR PDBsum; 8TV5; -. DR PDBsum; 8XPV; -. DR AlphaFoldDB; P29317; -. DR BMRB; P29317; -. DR SMR; P29317; -. DR BioGRID; 108288; 748. DR CORUM; P29317; -. DR DIP; DIP-96N; -. DR FunCoup; P29317; 946. DR IntAct; P29317; 207. DR MINT; P29317; -. DR STRING; 9606.ENSP00000351209; -. DR BindingDB; P29317; -. DR ChEMBL; CHEMBL2068; -. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB08896; Regorafenib. DR DrugCentral; P29317; -. DR GuidetoPHARMACOLOGY; 1822; -. DR GlyConnect; 777; 3 N-Linked glycans (1 site). DR GlyCosmos; P29317; 2 sites, 4 glycans. DR GlyGen; P29317; 4 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P29317; -. DR PhosphoSitePlus; P29317; -. DR SwissPalm; P29317; -. DR BioMuta; EPHA2; -. DR DMDM; 229462861; -. DR CPTAC; CPTAC-1784; -. DR CPTAC; CPTAC-2783; -. DR CPTAC; CPTAC-3201; -. DR jPOST; P29317; -. DR MassIVE; P29317; -. DR PaxDb; 9606-ENSP00000351209; -. DR PeptideAtlas; P29317; -. DR ProteomicsDB; 54535; -. [P29317-1] DR Pumba; P29317; -. DR ABCD; P29317; 32 sequenced antibodies. DR Antibodypedia; 4183; 1411 antibodies from 48 providers. DR DNASU; 1969; -. DR Ensembl; ENST00000358432.8; ENSP00000351209.5; ENSG00000142627.14. [P29317-1] DR GeneID; 1969; -. DR KEGG; hsa:1969; -. DR MANE-Select; ENST00000358432.8; ENSP00000351209.5; NM_004431.5; NP_004422.2. DR UCSC; uc001aya.2; human. [P29317-1] DR AGR; HGNC:3386; -. DR ClinPGx; PA27818; -. DR CTD; 1969; -. DR DisGeNET; 1969; -. DR GeneCards; EPHA2; -. DR HGNC; HGNC:3386; EPHA2. DR HPA; ENSG00000142627; Tissue enhanced (esophagus). DR MalaCards; EPHA2; -. DR MIM; 116600; phenotype. DR MIM; 176946; gene. DR OpenTargets; ENSG00000142627; -. DR Orphanet; 98991; Early-onset nuclear cataract. DR Orphanet; 98993; Early-onset posterior polar cataract. DR Orphanet; 441447; Early-onset posterior subcapsular cataract. DR Orphanet; 98994; Total early-onset cataract. DR VEuPathDB; HostDB:ENSG00000142627; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160786; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; P29317; -. DR OMA; CLECPVH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29317; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29317; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29317; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9013408; RHOG GTPase cycle. DR Reactome; R-HSA-9013420; RHOU GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR Reactome; R-HSA-9013424; RHOV GTPase cycle. DR Reactome; R-HSA-9696264; RND3 GTPase cycle. DR Reactome; R-HSA-9696270; RND2 GTPase cycle. DR Reactome; R-HSA-9696273; RND1 GTPase cycle. DR SignaLink; P29317; -. DR SIGNOR; P29317; -. DR Agora; ENSG00000142627; -. DR BioGRID-ORCS; 1969; 20 hits in 1214 CRISPR screens. DR ChiTaRS; EPHA2; human. DR EvolutionaryTrace; P29317; -. DR GeneWiki; EPH_receptor_A2; -. DR GenomeRNAi; 1969; -. DR Pharos; P29317; Tclin. DR PRO; PR:P29317; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29317; protein. DR Bgee; ENSG00000142627; Expressed in lower esophagus mucosa and 143 other cell types or tissues. DR ExpressionAtlas; P29317; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell. DR GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070160; C:tight junction; IDA:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IPI:ARUK-UCL. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl. DR GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0046849; P:bone remodeling; ISS:UniProtKB. DR GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB. DR GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0048870; P:cell motility; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB. DR GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB. DR GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl. DR GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0060035; P:notochord cell development; IEA:Ensembl. DR GO; GO:0014028; P:notochord formation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB. DR GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB. DR GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IMP:ARUK-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB. DR GO; GO:0070848; P:response to growth factor; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd10480; EphR_LBD_A2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05063; PTKc_EphR_A2; 1. DR CDD; cd09543; SAM_EPH-A2; 1. DR DisProt; DP03145; -. DR FunFam; 1.10.150.50:FF:000029; Ephrin type-A receptor 1; 1. DR FunFam; 1.20.5.510:FF:000004; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.120.260:FF:000023; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.10:FF:000724; ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.1770:FF:000002; ephrin type-A receptor 2; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.510; Single helix bin; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034263; EphA2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF20; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Apoptosis; ATP-binding; KW Cataract; Cell adhesion; Cell junction; Cell membrane; Cell projection; KW Differentiation; Disease variant; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..976 FT /note="Ephrin type-A receptor 2" FT /id="PRO_0000016800" FT TOPO_DOM 24..537 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 538..558 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 559..976 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 28..206 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 438..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 613..875 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 904..968 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 1..206 FT /note="Mediates interaction with CLDN4" FT /evidence="ECO:0000269|PubMed:16236711" FT REGION 606..906 FT /note="Mediates interaction with ARHGEF16 and ELMO2" FT /evidence="ECO:0000269|PubMed:20679435" FT REGION 886..976 FT /note="Negatively regulates interaction with ARHGEF16" FT /evidence="ECO:0000269|PubMed:20679435" FT MOTIF 974..976 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 739 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 619..627 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 646 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 570 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 575 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 579 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 594 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 628 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 647 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 735 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 772 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 869 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 892 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 897 FT /note="Phosphoserine; by PKB/AKT1, RPS6KA1, RPS6KA3 AND FT PKA" FT /evidence="ECO:0000269|PubMed:19573808, FT ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:23186163" FT MOD_RES 901 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 921 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 930 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23358419" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 435 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 70..188 FT DISULFID 105..115 FT VAR_SEQ 477..497 FT /note="GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAGDRLVT (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056014" FT VAR_SEQ 498..976 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056015" FT VARIANT 99 FT /note="K -> N (in dbSNP:rs1058372)" FT /id="VAR_055989" FT VARIANT 391 FT /note="G -> R (in dbSNP:rs34192549)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042121" FT VARIANT 511 FT /note="T -> M (in dbSNP:rs55747232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042122" FT VARIANT 568 FT /note="R -> H (in dbSNP:rs56198600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042123" FT VARIANT 631 FT /note="M -> T (in dbSNP:rs34021505)" FT /id="VAR_055990" FT VARIANT 721 FT /note="R -> Q (in CTRCT6; retained in the cytoplasm and FT constitutively active it alters EPHA2 signaling; FT dbSNP:rs116506614)" FT /evidence="ECO:0000269|PubMed:19649315" FT /id="VAR_062532" FT VARIANT 777 FT /note="G -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs922655349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042124" FT VARIANT 876 FT /note="R -> H (in dbSNP:rs35903225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042125" FT VARIANT 940 FT /note="T -> I (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853200)" FT /evidence="ECO:0000269|PubMed:19306328, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058907" FT VARIANT 948 FT /note="G -> W (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853199)" FT /evidence="ECO:0000269|PubMed:19005574, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058908" FT MUTAGEN 103 FT /note="R->E: Significantly reduced response to EFNA1." FT /evidence="ECO:0000269|PubMed:19525919" FT MUTAGEN 646 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16236711" FT MUTAGEN 739 FT /note="D->N: Increases serum-induced chemotaxis. Loss of FT EFNA1-dependent regulation of cell migration." FT /evidence="ECO:0000269|PubMed:19573808" FT MUTAGEN 897 FT /note="S->A,D: Loss of serum-induced phosphorylation by FT PKB. Loss of serum-induced chemotaxis." FT /evidence="ECO:0000269|PubMed:19573808" FT CONFLICT 94..99 FT /note="IFIELK -> NNFELN (in Ref. 1; AAA53375)" FT /evidence="ECO:0000305" FT STRAND 28..33 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 34..37 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:6NK0" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:6NK1" FT STRAND 53..57 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 92..103 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 105..107 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:3HEI" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 119..128 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 136..138 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 140..145 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 148..151 FT /evidence="ECO:0007829|PDB:6RW2" FT HELIX 153..157 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 164..170 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 175..199 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:8TRS" FT HELIX 221..224 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 225..227 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:3MBW" FT STRAND 244..247 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 253..257 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 272..275 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 284..287 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 295..298 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 335..338 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 343..348 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 384..387 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 389..392 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 394..400 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 407..415 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 427..433 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 453..457 FT /evidence="ECO:0007829|PDB:3FL7" FT TURN 460..465 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 483..493 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 502..510 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 522..525 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 536..556 FT /evidence="ECO:0007829|PDB:2K9Y" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:2K9Y" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:5EK7" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:4PDO" FT TURN 601..604 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 610..612 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 613..622 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 625..632 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:5NKH" FT STRAND 641..648 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 654..669 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 678..682 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 684..693 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 700..706 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:6Q7E" FT HELIX 713..732 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 753..755 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 762..766 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 770..772 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 776..778 FT /evidence="ECO:0007829|PDB:5NKH" FT HELIX 781..783 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 786..791 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 796..811 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 823..831 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 844..853 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 858..860 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 864..876 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 878..881 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 882..884 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 889..892 FT /evidence="ECO:0007829|PDB:8QQY" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 919..921 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 922..927 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 933..936 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 952..969 FT /evidence="ECO:0007829|PDB:7KJA" SQ SEQUENCE 976 AA; 108266 MW; 845D7E1BBCCAACCC CRC64; MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY SLLGLKDQVN TVGIPI // ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID ERN1_HUMAN Reviewed; 977 AA. AC O75460; A1L457; A8K8N8; A8MXS7; Q59EE2; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-2008, sequence version 2. DT 28-JAN-2026, entry version 226. DE RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1 {ECO:0000305}; DE AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1 {ECO:0000303|PubMed:9637683}; DE AltName: Full=Inositol-requiring protein 1 {ECO:0000303|PubMed:9637683}; DE Short=hIRE1p {ECO:0000303|PubMed:9637683}; DE AltName: Full=Ire1-alpha {ECO:0000303|PubMed:11779464}; DE Short=IRE1a {ECO:0000303|PubMed:11779464}; DE Includes: DE RecName: Full=Serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; DE Includes: DE RecName: Full=Endoribonuclease; DE EC=3.1.26.- {ECO:0000269|PubMed:21317875, ECO:0000305|PubMed:30118681}; DE Flags: Precursor; GN Name=ERN1 {ECO:0000312|HGNC:HGNC:3449}; GN Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, RP GLYCOSYLATION, AND MUTAGENESIS OF LYS-599. RC TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1}; RX PubMed=9637683; DOI=10.1101/gad.12.12.1812; RA Tirasophon W., Welihinda A.A., Kaufman R.J.; RT "A stress response pathway from the endoplasmic reticulum to the nucleus RT requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in RT mammalian cells."; RL Genes Dev. 12:1812-1824(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Endothelial cell; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2). RC TISSUE=Brain, and Leukocyte; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0; RA Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.; RT "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress RT to produce a highly active transcription factor."; RL Cell 107:881-891(2001). RN [8] RP INTERACTION WITH TAOK3 AND TRAF2. RX PubMed=11278723; DOI=10.1074/jbc.m010677200; RA Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.; RT "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, RT through tumor necrosis factor receptor-associated factor 2-dependent RT mechanism in response to the ER stress."; RL J. Biol. Chem. 276:13935-13940(2001). RN [9] {ECO:0000305} RP FUNCTION, AND MUTAGENESIS OF LYS-599. RX PubMed=11175748; DOI=10.1038/35055065; RA Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C., RA Kimata Y., Tsuru A., Kohno K.; RT "Translational control by the ER transmembrane kinase/ribonuclease IRE1 RT under ER stress."; RL Nat. Cell Biol. 3:158-164(2001). RN [10] {ECO:0000305} RP FUNCTION, HOMODIMERIZATION, ACTIVITY REGULATION, INTERACTION WITH HSPA5, RP AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=12637535; DOI=10.1074/jbc.m300418200; RA Liu C.Y., Xu Z., Kaufman R.J.; RT "Structure and intermolecular interactions of the luminal dimerization RT domain of human IRE1alpha."; RL J. Biol. Chem. 278:17680-17687(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP FUNCTION, AND INTERACTION WITH TMBIM6. RX PubMed=19328063; DOI=10.1016/j.molcel.2009.02.017; RA Lisbona F., Rojas-Rivera D., Thielen P., Zamorano S., Todd D., Martinon F., RA Glavic A., Kress C., Lin J.H., Walter P., Reed J.C., Glimcher L.H., RA Hetz C.; RT "BAX inhibitor-1 is a negative regulator of the ER stress sensor RT IRE1alpha."; RL Mol. Cell 33:679-691(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP ADP-RIBOSYLATION BY PARP16. RX PubMed=23103912; DOI=10.1038/ncb2593; RA Jwa M., Chang P.; RT "PARP16 is a tail-anchored endoplasmic reticulum protein required for the RT PERK-and IRE1alpha-mediated unfolded protein response."; RL Nat. Cell Biol. 14:1223-1230(2012). RN [15] RP SUBUNIT, AND INTERACTION WITH DNAJB9 AND HSPA5. RX PubMed=29198525; DOI=10.1016/j.cell.2017.10.040; RA Amin-Wetzel N., Saunders R.A., Kamphuis M.J., Rato C., Preissler S., RA Harding H.P., Ron D.; RT "A J-Protein co-chaperone recruits bip to monomerize IRE1 and repress the RT unfolded protein response."; RL Cell 171:1625-1637(2017). RN [16] RP INTERACTION WITH RNF13. RX PubMed=23378536; DOI=10.1074/jbc.m112.368829; RA Arshad M., Ye Z., Gu X., Wong C.K., Liu Y., Li D., Zhou L., Zhang Y., RA Bay W.P., Yu V.C., Li P.; RT "RNF13, a RING finger protein, mediates endoplasmic reticulum stress- RT induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun RT NH2-terminal kinase pathway."; RL J. Biol. Chem. 288:8726-8736(2013). RN [17] RP INTERACTION WITH LACC1. RX PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105; RA Huang C., Hedl M., Ranjan K., Abraham C.; RT "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes RT in human macrophages and LACC1 risk variants modulate these outcomes."; RL Cell Rep. 29:4525-4539(2019). RN [18] RP FUNCTION. RX PubMed=21884936; DOI=10.1016/j.cell.2011.07.021; RA Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.; RT "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional RT secretion pathway."; RL Cell 146:746-760(2011). RN [19] RP FUNCTION, INTERACTION WITH PDIA6, SUBUNIT, AND MUTAGENESIS OF CYS-148. RX PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004; RA Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.; RT "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling RT via disulfide-dependent association."; RL Mol. Cell 53:562-576(2014). RN [20] RP FUNCTION, INTERACTION WITH DDRGK1, AND PHOSPHORYLATION. RX PubMed=28128204; DOI=10.1038/ncomms14186; RA Liu J., Wang Y., Song L., Zeng L., Yi W., Liu T., Chen H., Wang M., Ju Z., RA Cong Y.S.; RT "A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via RT regulation of IRE1alpha stability."; RL Nat. Commun. 8:14186-14186(2017). RN [21] RP FUNCTION. RX PubMed=28067262; DOI=10.1038/srep39887; RA Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.; RT "Sec16A is critical for both conventional and unconventional secretion of RT CFTR."; RL Sci. Rep. 7:39887-39887(2017). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND PHOSPHORYLATION AT SER-724 AND RP SER-729. RX PubMed=30118681; DOI=10.1016/j.molcel.2018.06.038; RA Chang T.K., Lawrence D.A., Lu M., Tan J., Harnoss J.M., Marsters S.A., RA Liu P., Sandoval W., Martin S.E., Ashkenazi A.; RT "Coordination between Two Branches of the Unfolded Protein Response RT Determines Apoptotic Cell Fate."; RL Mol. Cell 71:629-636.e5(2018). RN [23] RP INTERACTION WITH P4HB, AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=32149426; DOI=10.15252/embj.2019103841; RA Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L., RA Wang C.C., Wang L.; RT "Phosphorylation switches protein disulfide isomerase activity to maintain RT proteostasis and attenuate ER stress."; RL EMBO J. 39:e103841-e103841(2020). RN [24] RP FUNCTION, INTERACTION WITH MANF AND HSPA5, INDUCTION, AND PHOSPHORYLATION RP AT SER-724. RX PubMed=36739529; DOI=10.1016/j.celrep.2023.112066; RA Kovaleva V., Yu L.Y., Ivanova L., Shpironok O., Nam J., Eesmaa A., RA Kumpula E.P., Sakson S., Toots U., Ustav M., Huiskonen J.T., RA Voutilainen M.H., Lindholm P., Karelson M., Saarma M.; RT "MANF regulates neuronal survival and UPR through its ER-located receptor RT IRE1alpha."; RL Cell Rep. 42:112066-112066(2023). RN [25] {ECO:0007744|PDB:2HZ6} RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390, SUBUNIT, AND MUTAGENESIS RP OF GLN-105; ASP-123 AND TRP-125. RX PubMed=16973740; DOI=10.1073/pnas.0606480103; RA Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z., Kaufman R.J.; RT "The crystal structure of human IRE1 luminal domain reveals a conserved RT dimerization interface required for activation of the unfolded protein RT response."; RL Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006). RN [26] {ECO:0007744|PDB:3P23} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 547-977 IN COMPLEX WITH ADP, RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, AND RP COFACTOR. RX PubMed=21317875; DOI=10.1038/emboj.2011.18; RA Ali M.M., Bagratuni T., Davenport E.L., Nowak P.R., Silva-Santisteban M.C., RA Hardcastle A., McAndrews C., Rowlands M.G., Morgan G.J., Aherne W., RA Collins I., Davies F.E., Pearl L.H.; RT "Structure of the Ire1 autophosphorylation complex and implications for the RT unfolded protein response."; RL EMBO J. 30:894-905(2011). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635; RP SER-700; PHE-769 AND LEU-830. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase and endoribonuclease that CC acts as a key sensor for the endoplasmic reticulum unfolded protein CC response (UPR) (PubMed:11175748, PubMed:11779464, PubMed:12637535, CC PubMed:19328063, PubMed:21317875, PubMed:28128204, PubMed:30118681, CC PubMed:36739529, PubMed:9637683). In unstressed cells, the endoplasmic CC reticulum luminal domain is maintained in its inactive monomeric state CC by binding to the endoplasmic reticulum chaperone HSPA5/BiP CC (PubMed:21317875). Accumulation of misfolded proteins in the CC endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal CC domain to homodimerize, promoting autophosphorylation of the kinase CC domain and subsequent activation of the endoribonuclease activity CC (PubMed:21317875). The endoribonuclease activity is specific for XBP1 CC mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464, CC PubMed:21317875, PubMed:24508390). The resulting spliced transcript of CC XBP1 encodes a transcriptional activator protein that up-regulates CC expression of UPR target genes (PubMed:11779464, PubMed:21317875, CC PubMed:24508390). Acts as an upstream signal for ER stress-induced CC GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CC CFTR to cell membrane by modulating the expression and localization of CC SEC16A (PubMed:21884936, PubMed:28067262). CC {ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:11779464, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:21884936, CC ECO:0000269|PubMed:28067262, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:30118681, ECO:0000269|PubMed:36739529, CC ECO:0000269|PubMed:9637683, ECO:0000305|PubMed:24508390}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- ACTIVITY REGULATION: The kinase domain is activated by trans- CC autophosphorylation following homodimerization (PubMed:12637535, CC PubMed:9637683). Kinase activity is required for activation of the CC endoribonuclease domain (PubMed:12637535, PubMed:9637683). CC Endoribonuclease activity is specifically inhibited by hydroxy-aryl- CC aldehydes (HAA) (By similarity). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:9637683}. CC -!- SUBUNIT: Monomer (PubMed:16973740, PubMed:29198525). Homodimer; CC disulfide-linked; homodimerization takes place in response to CC endoplasmic reticulum stress and promotes activation of the kinase and CC endoribonuclease activities (PubMed:12637535, PubMed:16973740, CC PubMed:21317875, PubMed:24508390, PubMed:30118681). Dimer formation is CC driven by hydrophobic interactions within the N-terminal luminal CC domains and stabilized by disulfide bridges (PubMed:12637535). CC Interacts (via the luminal region) with DNAJB9/ERdj4; interaction takes CC place in unstressed cells and promotes recruitment of HSPA5/BiP CC (PubMed:29198525). Interacts (via the luminal region) with HSPA5/BiP; CC HSPA5/BiP is a negative regulator of the unfolded protein response CC (UPR) that prevents homodimerization of ERN1/IRE1 and subsequent CC activation of the protein (PubMed:12637535, PubMed:29198525, CC PubMed:36739529). Interaction with HSPA5 also competitively inhibits CC ERN1 interaction with MANF (PubMed:36739529). Interacts with PDIA6, a CC negative regulator of the UPR; the interaction is direct and disrupts CC homodimerization (PubMed:24508390). Interacts with DAB2IP (via PH CC domain); the interaction occurs in a endoplasmic reticulum stress- CC induced dependent manner and is required for subsequent recruitment of CC TRAF2 to ERN1/IRE1 (By similarity). Interacts with TAOK3 and TRAF2 CC (PubMed:11278723). Interacts with RNF13 (PubMed:23378536). Interacts CC with LACC1 (PubMed:31875558). Interacts (when unphosphorylated) with CC DDRGK1; interaction is dependent on UFM1 and takes place in response to CC endoplasmic reticulum stress, regulating ERN1/IRE1-alpha stability CC (PubMed:28128204). Interacts (via N-terminus) with P4HB/PDIA1; the CC interaction is enhanced by phosphorylation of P4HB by FAM20C in CC response to endoplasmic reticulum stress and results in attenuation of CC ERN1 activity (PubMed:32149426). Interacts with TMBIM6; this CC interaction inhibits ERN1 activity (PubMed:19328063). Interacts (via CC luminal domain) with MANF (via C-terminus); the interaction is CC decreased in the presence of increasing concentrations of Ca(2+) CC (PubMed:36739529). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:12637535, CC ECO:0000269|PubMed:16973740, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:23378536, CC ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:29198525, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:31875558, ECO:0000269|PubMed:32149426, CC ECO:0000269|PubMed:36739529}. CC -!- INTERACTION: CC O75460; Q07812: BAX; NbExp=2; IntAct=EBI-371750, EBI-516580; CC O75460; O75460: ERN1; NbExp=2; IntAct=EBI-371750, EBI-371750; CC O75460; P11021: HSPA5; NbExp=3; IntAct=EBI-371750, EBI-354921; CC O75460; Q86TM6: SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849; CC O75460; Q9H2K8: TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100; CC O75460; Q12933: TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744; CC O75460; Q969M3: YIPF5; NbExp=3; IntAct=EBI-371750, EBI-2124787; CC O75460; O08734: Bak1; Xeno; NbExp=2; IntAct=EBI-371750, EBI-822441; CC O75460; Q07813: Bax; Xeno; NbExp=2; IntAct=EBI-371750, EBI-700711; CC O75460; P20029: Hspa5; Xeno; NbExp=2; IntAct=EBI-371750, EBI-772325; CC O75460-1; O75460-1: ERN1; NbExp=5; IntAct=EBI-15600828, EBI-15600828; CC O75460-1; P11021: HSPA5; NbExp=4; IntAct=EBI-15600828, EBI-354921; CC O75460-1; Q13438: OS9; NbExp=2; IntAct=EBI-15600828, EBI-725454; CC O75460-1; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-15600828, EBI-358766; CC O75460-1; Q86TM6: SYVN1; NbExp=3; IntAct=EBI-15600828, EBI-947849; CC O75460-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-25852368, EBI-18899653; CC O75460-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-25852368, EBI-8466265; CC O75460-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25852368, EBI-5280499; CC O75460-2; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-25852368, EBI-540797; CC O75460-2; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-25852368, EBI-9089489; CC O75460-2; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-25852368, EBI-742750; CC O75460-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-25852368, EBI-12300031; CC O75460-2; P38936: CDKN1A; NbExp=3; IntAct=EBI-25852368, EBI-375077; CC O75460-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-25852368, EBI-11526226; CC O75460-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-25852368, EBI-23669343; CC O75460-2; O77932: DXO; NbExp=3; IntAct=EBI-25852368, EBI-372173; CC O75460-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-618189; CC O75460-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-9088619; CC O75460-2; P52655: GTF2A1; NbExp=3; IntAct=EBI-25852368, EBI-389518; CC O75460-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-25852368, EBI-6509505; CC O75460-2; Q92615: LARP4B; NbExp=3; IntAct=EBI-25852368, EBI-1052558; CC O75460-2; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-25852368, EBI-2802743; CC O75460-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-25852368, EBI-25830200; CC O75460-2; Q8N2H9-4: PELI3; NbExp=3; IntAct=EBI-25852368, EBI-25852006; CC O75460-2; O15534: PER1; NbExp=3; IntAct=EBI-25852368, EBI-2557276; CC O75460-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-25852368, EBI-21503705; CC O75460-2; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-25852368, EBI-26412802; CC O75460-2; Q14181: POLA2; NbExp=3; IntAct=EBI-25852368, EBI-712752; CC O75460-2; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-25852368, EBI-13292283; CC O75460-2; O14544: SOCS6; NbExp=3; IntAct=EBI-25852368, EBI-3929549; CC O75460-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-25852368, EBI-3923692; CC O75460-2; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-25852368, EBI-9089156; CC O75460-2; P49459: UBE2A; NbExp=3; IntAct=EBI-25852368, EBI-2339348; CC O75460-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-25852368, EBI-10316321; CC O75460-2; Q9BYN7-2: ZNF341; NbExp=3; IntAct=EBI-25852368, EBI-16435478; CC O75460-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-25852368, EBI-18036029; CC O75460-2; Q9BRT8: ZNG1A; NbExp=3; IntAct=EBI-25852368, EBI-1054417; CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:9637683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O75460-1; Sequence=Displayed; CC Name=2; CC IsoId=O75460-2; Sequence=VSP_034582, VSP_034583; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed in CC pancreatic tissue. {ECO:0000269|PubMed:9637683}. CC -!- INDUCTION: Induced by the ER stressor tunicamycin. CC {ECO:0000269|PubMed:36739529}. CC -!- PTM: Autophosphorylated following homodimerization. Autophosphorylation CC promotes activation of the endoribonuclease domain (PubMed:12637535, CC PubMed:21317875, PubMed:28128204, PubMed:9637683). In response to ER CC stress, phosphorylated at Ser-724, Ser-729 and possibly Ser-726; CC phosphorylation promotes oligomerization and endoribonuclease activity CC (PubMed:30118681). Dephosphorylated at Ser-724, Ser-729 and possibly CC Ser-726 by RPAP2 to abort failed ER-stress adaptation and trigger CC apoptosis (PubMed:30118681). Phosphorylated at Ser-724; in response to CC the ER stressor tunicamycin (PubMed:36739529). CC {ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875, CC ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:36739529, ECO:0000269|PubMed:9637683}. CC -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases both CC kinase and endonuclease activities. {ECO:0000269|PubMed:23103912}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059198; AAC25991.1; -; mRNA. DR EMBL; AK292403; BAF85092.1; -; mRNA. DR EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB209869; BAD93106.1; -; mRNA. DR EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471109; EAW94214.1; -; Genomic_DNA. DR EMBL; BC130405; AAI30406.1; -; mRNA. DR EMBL; BC130407; AAI30408.1; -; mRNA. DR EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS45762.1; -. [O75460-1] DR RefSeq; NP_001424.3; NM_001433.5. [O75460-1] DR PDB; 2HZ6; X-ray; 3.10 A; A=24-390. DR PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977. DR PDB; 4U6R; X-ray; 2.50 A; A=547-977. DR PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966. DR PDB; 4YZC; X-ray; 2.49 A; A/B=562-966. DR PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966. DR PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977. DR PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977. DR PDB; 5HGI; X-ray; 2.58 A; A=547-977. DR PDB; 6HV0; X-ray; 2.73 A; A=562-977. DR PDB; 6HX1; X-ray; 2.14 A; A=562-964. DR PDB; 6SHC; X-ray; 3.55 A; A=24-390. DR PDB; 6URC; X-ray; 2.20 A; A/B=547-977. DR PDB; 6W39; X-ray; 1.74 A; A/B=547-977. DR PDB; 6W3A; X-ray; 2.61 A; A/B=547-977. DR PDB; 6W3B; X-ray; 2.57 A; A=547-977. DR PDB; 6W3C; X-ray; 2.30 A; A/B/C/D=547-977. DR PDB; 6W3E; X-ray; 2.74 A; A/B=547-977. DR PDB; 6W3K; X-ray; 2.08 A; A=547-977. DR PDB; 6XDB; X-ray; 2.45 A; A=547-977. DR PDB; 6XDD; X-ray; 2.40 A; A/B=547-977. DR PDB; 6XDF; X-ray; 2.54 A; A/B=547-977. DR PDB; 7BMK; X-ray; 1.85 A; A/B=547-977. DR PDB; 8UVL; X-ray; 2.43 A; A=547-977. DR PDBsum; 2HZ6; -. DR PDBsum; 3P23; -. DR PDBsum; 4U6R; -. DR PDBsum; 4YZ9; -. DR PDBsum; 4YZC; -. DR PDBsum; 4YZD; -. DR PDBsum; 4Z7G; -. DR PDBsum; 4Z7H; -. DR PDBsum; 5HGI; -. DR PDBsum; 6HV0; -. DR PDBsum; 6HX1; -. DR PDBsum; 6SHC; -. DR PDBsum; 6URC; -. DR PDBsum; 6W39; -. DR PDBsum; 6W3A; -. DR PDBsum; 6W3B; -. DR PDBsum; 6W3C; -. DR PDBsum; 6W3E; -. DR PDBsum; 6W3K; -. DR PDBsum; 6XDB; -. DR PDBsum; 6XDD; -. DR PDBsum; 6XDF; -. DR PDBsum; 7BMK; -. DR PDBsum; 8UVL; -. DR AlphaFoldDB; O75460; -. DR SMR; O75460; -. DR BioGRID; 108391; 71. DR CORUM; O75460; -. DR DIP; DIP-31711N; -. DR FunCoup; O75460; 1464. DR IntAct; O75460; 74. DR MINT; O75460; -. DR STRING; 9606.ENSP00000401445; -. DR BindingDB; O75460; -. DR ChEMBL; CHEMBL1163101; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07382; N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine. DR DrugCentral; O75460; -. DR GuidetoPHARMACOLOGY; 2020; -. DR TCDB; 8.A.104.1.9; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; O75460; 1 site, No reported glycans. DR GlyGen; O75460; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75460; -. DR PhosphoSitePlus; O75460; -. DR BioMuta; ERN1; -. DR CPTAC; CPTAC-3100; -. DR CPTAC; CPTAC-3101; -. DR jPOST; O75460; -. DR MassIVE; O75460; -. DR PaxDb; 9606-ENSP00000401445; -. DR PeptideAtlas; O75460; -. DR ProteomicsDB; 50021; -. [O75460-1] DR Pumba; O75460; -. DR Antibodypedia; 4011; 736 antibodies from 44 providers. DR DNASU; 2081; -. DR Ensembl; ENST00000433197.4; ENSP00000401445.2; ENSG00000178607.17. [O75460-1] DR Ensembl; ENST00000606895.2; ENSP00000475519.1; ENSG00000178607.17. [O75460-2] DR GeneID; 2081; -. DR KEGG; hsa:2081; -. DR MANE-Select; ENST00000433197.4; ENSP00000401445.2; NM_001433.5; NP_001424.3. DR UCSC; uc002jdz.3; human. [O75460-1] DR AGR; HGNC:3449; -. DR ClinPGx; PA27861; -. DR CTD; 2081; -. DR DisGeNET; 2081; -. DR GeneCards; ERN1; -. DR HGNC; HGNC:3449; ERN1. DR HPA; ENSG00000178607; Tissue enhanced (adrenal gland, pancreas). DR MIM; 604033; gene. DR OpenTargets; ENSG00000178607; -. DR VEuPathDB; HostDB:ENSG00000178607; -. DR eggNOG; KOG1027; Eukaryota. DR GeneTree; ENSGT00940000159761; -. DR HOGENOM; CLU_004875_1_1_1; -. DR InParanoid; O75460; -. DR OMA; NYWVERF; -. DR OrthoDB; 63989at2759; -. DR PAN-GO; O75460; 6 GO annotations based on evolutionary models. DR PhylomeDB; O75460; -. DR PathwayCommons; O75460; -. DR Reactome; R-HSA-381070; IRE1alpha activates chaperones. DR SignaLink; O75460; -. DR SIGNOR; O75460; -. DR Agora; ENSG00000178607; -. DR BioGRID-ORCS; 2081; 13 hits in 1188 CRISPR screens. DR ChiTaRS; ERN1; human. DR EvolutionaryTrace; O75460; -. DR GeneWiki; ERN1; -. DR GenomeRNAi; 2081; -. DR Pharos; O75460; Tchem. DR PRO; PR:O75460; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O75460; protein. DR Bgee; ENSG00000178607; Expressed in parotid gland and 159 other cell types or tissues. DR GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB. DR GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL. DR GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL. DR GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl. DR GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; IDA:UniProtKB. DR GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; IDA:ParkinsonsUK-UCL. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:ParkinsonsUK-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:UniProtKB. DR GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB. DR GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:ParkinsonsUK-UCL. DR GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL. DR CDD; cd09769; Luminal_IRE1; 1. DR CDD; cd10422; RNase_Ire1; 1. DR CDD; cd13982; STKc_IRE1; 1. DR FunFam; 2.130.10.10:FF:000225; Endoplasmic reticulum to nucleus-signaling 1; 1. DR FunFam; 3.30.200.20:FF:000077; Putative Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.20.1440.180:FF:000001; Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.10.510.10:FF:000215; serine/threonine-protein kinase/endoribonuclease IRE1 isoform X1; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR045133; IRE1/2-like. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR018391; PQQ_b-propeller_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR011047; Quinoprotein_ADH-like_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR13954; IRE1-RELATED; 1. DR PANTHER; PTHR13954:SF17; SERINE_THREONINE-PROTEIN KINASE_ENDORIBONUCLEASE IRE1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR SMART; SM00564; PQQ; 5. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50998; Quinoprotein alcohol dehydrogenase-like; 1. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis; KW ATP-binding; Disulfide bond; Endoplasmic reticulum; Glycoprotein; KW Hydrolase; Kinase; Magnesium; Membrane; Metal-binding; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Unfolded protein response. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..977 FT /note="Serine/threonine-protein kinase/endoribonuclease FT IRE1" FT /id="PRO_0000024327" FT TOPO_DOM 19..443 FT /note="Lumenal" FT /evidence="ECO:0000255" FT TRANSMEM 444..464 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 465..977 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 571..832 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 835..963 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT REGION 410..434 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 491..559 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 906..907 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT COMPBIAS 410..419 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 513..552 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 688 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 577..585 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 599 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683, FT ECO:0007744|PDB:3P23" FT BINDING 643..645 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 690..693 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 711 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT SITE 892 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681, FT ECO:0000269|PubMed:36739529" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681" FT MOD_RES 973 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 176 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..70 FT /note="IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEE FT -> VSDRGAWGGGQLATAGSGPGQRRGAGAGVRAGSATAAARCPVSPAVGGSGRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034582" FT VAR_SEQ 71..977 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034583" FT VARIANT 244 FT /note="N -> S (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs1397145500)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040488" FT VARIANT 418 FT /note="V -> M (in dbSNP:rs55869215)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040489" FT VARIANT 474 FT /note="L -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs186305118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040490" FT VARIANT 635 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs146710304)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040491" FT VARIANT 700 FT /note="N -> S (in dbSNP:rs918253870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040492" FT VARIANT 769 FT /note="S -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040493" FT VARIANT 830 FT /note="P -> L (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs1279653488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040494" FT MUTAGEN 105 FT /note="Q->E: Impaired ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 109 FT /note="C->S: No effect on dimerization. No effect on FT interaction with P4HB; when associated with S-148 and S- FT 332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 123 FT /note="D->P: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 125 FT /note="W->A: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 148 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-332. Abolishes interaction with PDIA6. FT Prolonged splicing of XBP1, probably due to prolonged FT activation of PDIA6. Inhibits formation of oxidized FT multimeric forms of ERN1 in response to ER stress. No FT effect on interaction with P4HB; when associated with S-109 FT and S-332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426" FT MUTAGEN 332 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-148. No effect on interaction with P4HB; FT when associated with S-109 and S-148." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 599 FT /note="K->A: Loss of autophosphorylation and of FT endoribonuclease activity. Inhibition of growth arrest." FT /evidence="ECO:0000269|PubMed:11175748, FT ECO:0000269|PubMed:9637683" FT CONFLICT 190..191 FT /note="DV -> EG (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 768 FT /note="I -> V (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 816 FT /note="D -> G (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 824..825 FT /note="KH -> ND (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 880 FT /note="V -> D (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="M -> T (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 924 FT /note="S -> T (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT STRAND 32..37 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 120..128 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 154..164 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 168..172 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 176..182 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 205..209 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 216..221 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 226..231 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 247..264 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 273..279 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 297..300 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 359..361 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 569..578 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 581..583 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 585..591 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 594..601 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 603..605 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 606..619 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 628..633 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 645..648 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 649..654 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 658..661 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 665..681 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 701..703 FT /evidence="ECO:0007829|PDB:6W3E" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 711..716 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HV0" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:6HV0" FT TURN 732..736 FT /evidence="ECO:0007829|PDB:6HV0" FT HELIX 740..743 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 744..746 FT /evidence="ECO:0007829|PDB:6XDF" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 778..780 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 781..787 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 793..795 FT /evidence="ECO:0007829|PDB:4YZC" FT HELIX 800..812 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 817..819 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 823..827 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 830..832 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 835..848 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 849..851 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 854..856 FT /evidence="ECO:0007829|PDB:4YZ9" FT HELIX 857..863 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 880..884 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 887..890 FT /evidence="ECO:0007829|PDB:6W3K" FT HELIX 897..909 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 911..913 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 916..922 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 927..936 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 940..947 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 948..951 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 952..954 FT /evidence="ECO:0007829|PDB:3P23" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 958..960 FT /evidence="ECO:0007829|PDB:6W39" SQ SEQUENCE 977 AA; 109735 MW; A2DF808CCE015536 CRC64; MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY YFHEPPEPQP PVTPDAL // ID FABP6_HUMAN Reviewed; 128 AA. AC P51161; Q07DR7; Q8TBI3; Q9UGI7; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 2. DT 28-JAN-2026, entry version 205. DE RecName: Full=Gastrotropin; DE Short=GT; DE AltName: Full=Fatty acid-binding protein 6; DE AltName: Full=Ileal lipid-binding protein; DE Short=ILBP; DE AltName: Full=Intestinal 15 kDa protein; DE Short=I-15P; DE AltName: Full=Intestinal bile acid-binding protein; DE Short=I-BABP; GN Name=FABP6; Synonyms=ILBP, ILLBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Ileum; RX PubMed=7619861; DOI=10.1016/0005-2760(95)00098-w; RA Oelkers P., Dawson P.A.; RT "Cloning and chromosomal localization of the human ileal lipid-binding RT protein."; RL Biochim. Biophys. Acta 1257:199-202(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BILE ACID-BINDING, AND TISSUE RP SPECIFICITY. RC TISSUE=Ileum; RX PubMed=7588781; DOI=10.1111/j.1432-1033.1995.406_2.x; RA Fujita M., Fujii H., Kanda T., Sato E., Hatakeyama K., Ono T.; RT "Molecular cloning, expression, and characterization of a human intestinal RT 15-kDa protein."; RL Eur. J. Biochem. 233:406-413(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), ALTERNATIVE RP PROMOTER USAGE, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=17909007; DOI=10.1158/0008-5472.can-06-3690; RA Fang C., Dean J., Smith J.W.; RT "A novel variant of ileal bile acid binding protein is up-regulated through RT nuclear factor-kappaB activation in colorectal adenocarcinoma."; RL Cancer Res. 67:9039-9046(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS RP HIS-33 AND TYR-55. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19 (ISOFORM 1). RA Barley N.F., Shaw-Smith C.J., Chakravarty P., Howard A., Legon S., RA Walters J.R.; RT "The human ileal bile acid binding protein gene: promoter sequence and RT effects of CDX2 on expression."; RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP BILE ACID-BINDING. RX PubMed=11461829; DOI=10.1016/s1357-2725(01)00070-x; RA Zimmerman A.W., van Moerkerk H.T., Veerkamp J.H.; RT "Ligand specificity and conformational stability of human fatty acid- RT binding proteins."; RL Int. J. Biochem. Cell Biol. 33:865-876(2001). RN [8] RP STRUCTURE BY NMR IN COMPLEX WITH TAUROCHOLATE, AND DOMAIN. RX PubMed=12486725; DOI=10.1002/prot.10289; RA Kurz M., Brachvogel V., Matter H., Stengelin S., Thuering H., Kramer W.; RT "Insights into the bile acid transportation system: the human ileal lipid- RT binding protein-cholyltaurine complex and its comparison with homologous RT structures."; RL Proteins 50:312-328(2003). RN [9] RP STRUCTURE BY NMR IN COMPLEX WITH GLYCOCHOLATE AND GLYCOCHENODEOXYCHOLATE, RP AND DOMAIN. RX PubMed=26613247; DOI=10.1111/febs.13610; RA Horvath G., Bencsura A., Simon A., Tochtrop G.P., DeKoster G.T., RA Covey D.F., Cistola D.P., Toke O.; RT "Structural determinants of ligand binding in the ternary complex of human RT ileal bile acid binding protein with glycocholate and RT glycochenodeoxycholate obtained from solution NMR."; RL FEBS J. 283:541-555(2016). RN [10] RP VARIANT MET-79. RX PubMed=19744871; DOI=10.1016/j.ymgme.2009.08.001; RA Fisher E., Grallert H., Klapper M., Pfaefflin A., Schrezenmeir J., RA Illig T., Boeing H., Doering F.; RT "Evidence for the Thr79Met polymorphism of the ileal fatty acid binding RT protein (FABP6) to be associated with type 2 diabetes in obese RT individuals."; RL Mol. Genet. Metab. 98:400-405(2009). CC -!- FUNCTION: Binds to bile acids and is involved in enterohepatic bile CC acid metabolism. Required for efficient apical to basolateral transport CC of conjugated bile acids in ileal enterocytes (By similarity). In vitro CC binds to bile acids in the order: deoxycholic acid > cholic acid > CC chenodeoxycholic acid and respective BA conjugation modifies affinities CC in the order taurine-conjugated > glycine-conjugated > unconjugated CC bile acids. Stimulates gastric acid and pepsinogen secretion (By CC similarity). {ECO:0000250|UniProtKB:P10289, CC ECO:0000250|UniProtKB:P51162, ECO:0000269|PubMed:12486725, CC ECO:0000269|PubMed:7588781}. CC -!- FUNCTION: [Isoform 2]: Essential for the survival of colon cancer cells CC to bile acid-induced apoptosis. {ECO:0000269|PubMed:17909007}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm CC {ECO:0000250|UniProtKB:P80020}. Membrane; Peripheral membrane protein CC {ECO:0000250|UniProtKB:P50119}; Cytoplasmic side CC {ECO:0000250|UniProtKB:P50119}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000269|PubMed:17909007}. Note=Localized close to nucleus on the CC apical side of both normal and neoplastic cells. CC {ECO:0000269|PubMed:17909007}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage; Named isoforms=2; CC Name=1; CC IsoId=P51161-1; Sequence=Displayed; CC Name=2; Synonyms=IBABP-L; CC IsoId=P51161-2; Sequence=VSP_038039; CC -!- TISSUE SPECIFICITY: Isoform 1 is expressed in the jejunum, ileum, cecum CC and ascending colon intestine. Isoform 2 is xpressed in the CC gallbladder, duodenum, jejunum, ileum, cecum, ascending, transverse and CC descending colon, sigmoid colon and rectum. Isoform 2 is expressed in CC colorectal adenocarcinomas and their adjacent normal mucosa (at protein CC level). {ECO:0000269|PubMed:17909007, ECO:0000269|PubMed:7588781, CC ECO:0000269|PubMed:7619861}. CC -!- INDUCTION: Isoform 1 is up-regulated by chenodeoxycholic acid (CDCA) CC via the FXR transcription pathway. Isoform 2 is up-regulated by NF- CC kappa-B and in all stages of colorectal adenocarcinoma. Isoform 1 is CC not up-regulated in all stages of colorectal adenocarcinoma. CC {ECO:0000269|PubMed:17909007}. CC -!- DOMAIN: Forms a beta-barrel structure that accommodates the hydrophobic CC ligand in its interior. Can bind at least two ligands per molecule, CC however, the stoichiometry is debated. {ECO:0000305|PubMed:12486725, CC ECO:0000305|PubMed:26613247}. CC -!- SIMILARITY: Belongs to the calycin superfamily. Fatty-acid binding CC protein (FABP) family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH22489.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U19869; AAB82751.1; -; mRNA. DR EMBL; X90908; CAA62415.1; -; mRNA. DR EMBL; DQ132786; ABA12611.1; -; mRNA. DR EMBL; AC008609; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC112191; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC022489; AAH22489.1; ALT_INIT; mRNA. DR EMBL; AJ250902; CAB65728.1; -; Genomic_DNA. DR CCDS; CCDS43393.1; -. [P51161-2] DR CCDS; CCDS4349.1; -. [P51161-1] DR PIR; S63983; S63983. DR RefSeq; NP_001035532.1; NM_001040442.1. [P51161-2] DR RefSeq; NP_001124430.1; NM_001130958.2. [P51161-2] DR RefSeq; NP_001436.1; NM_001445.3. [P51161-1] DR PDB; 1O1U; NMR; -; A=2-128. DR PDB; 1O1V; NMR; -; A=2-128. DR PDB; 2MM3; NMR; -; A=2-128. DR PDB; 5L8I; X-ray; 1.88 A; A/B/C=1-128. DR PDB; 5L8N; X-ray; 2.12 A; A/B/C=1-128. DR PDB; 5L8O; X-ray; 2.39 A; A/B/C=1-128. DR PDBsum; 1O1U; -. DR PDBsum; 1O1V; -. DR PDBsum; 2MM3; -. DR PDBsum; 5L8I; -. DR PDBsum; 5L8N; -. DR PDBsum; 5L8O; -. DR AlphaFoldDB; P51161; -. DR BMRB; P51161; -. DR SMR; P51161; -. DR BioGRID; 108470; 6. DR FunCoup; P51161; 1163. DR IntAct; P51161; 2. DR STRING; 9606.ENSP00000377549; -. DR BindingDB; P51161; -. DR ChEMBL; CHEMBL4523235; -. DR DrugBank; DB02659; Cholic Acid. DR DrugBank; DB02691; Glycocholic acid. DR DrugBank; DB04348; Taurocholic acid. DR SwissLipids; SLP:000001518; -. DR iPTMnet; P51161; -. DR PhosphoSitePlus; P51161; -. DR BioMuta; FABP6; -. DR DMDM; 1708457; -. DR jPOST; P51161; -. DR MassIVE; P51161; -. DR PaxDb; 9606-ENSP00000377549; -. DR PeptideAtlas; P51161; -. DR ProteomicsDB; 56292; -. [P51161-1] DR ProteomicsDB; 56293; -. [P51161-2] DR Antibodypedia; 1989; 238 antibodies from 31 providers. DR DNASU; 2172; -. DR Ensembl; ENST00000393980.8; ENSP00000377549.4; ENSG00000170231.17. [P51161-2] DR Ensembl; ENST00000402432.4; ENSP00000385433.4; ENSG00000170231.17. [P51161-1] DR GeneID; 2172; -. DR KEGG; hsa:2172; -. DR MANE-Select; ENST00000402432.4; ENSP00000385433.4; NM_001445.3; NP_001436.1. DR UCSC; uc003lxx.2; human. [P51161-1] DR AGR; HGNC:3561; -. DR ClinPGx; PA27962; -. DR CTD; 2172; -. DR DisGeNET; 2172; -. DR GeneCards; FABP6; -. DR HGNC; HGNC:3561; FABP6. DR HPA; ENSG00000170231; Tissue enriched (intestine). DR MIM; 600422; gene. DR OpenTargets; ENSG00000170231; -. DR VEuPathDB; HostDB:ENSG00000170231; -. DR eggNOG; KOG4015; Eukaryota. DR GeneTree; ENSGT00940000157139; -. DR HOGENOM; CLU_113772_4_0_1; -. DR InParanoid; P51161; -. DR OrthoDB; 10016075at2759; -. DR PAN-GO; P51161; 4 GO annotations based on evolutionary models. DR PhylomeDB; P51161; -. DR PathwayCommons; P51161; -. DR Reactome; R-HSA-159418; Recycling of bile acids and salts. DR Reactome; R-HSA-163560; Triglyceride catabolism. DR Reactome; R-HSA-9623433; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis. DR SIGNOR; P51161; -. DR Agora; ENSG00000170231; -. DR BioGRID-ORCS; 2172; 6 hits in 1149 CRISPR screens. DR ChiTaRS; FABP6; human. DR EvolutionaryTrace; P51161; -. DR GeneWiki; FABP6; -. DR GenomeRNAi; 2172; -. DR Pharos; P51161; Tbio. DR PRO; PR:P51161; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P51161; protein. DR Bgee; ENSG00000170231; Expressed in ileal mucosa and 137 other cell types or tissues. DR ExpressionAtlas; P51161; baseline and differential. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005504; F:fatty acid binding; IBA:GO_Central. DR GO; GO:0008289; F:lipid binding; TAS:ProtInc. DR GO; GO:0015908; P:fatty acid transport; IBA:GO_Central. DR GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd19446; FABP6; 1. DR FunFam; 2.40.128.20:FF:000006; Fatty acid-binding protein, liver; 1. DR Gene3D; 2.40.128.20; -; 1. DR InterPro; IPR012674; Calycin. DR InterPro; IPR000463; Fatty_acid-bd. DR InterPro; IPR031259; ILBP. DR PANTHER; PTHR11955; FATTY ACID BINDING PROTEIN; 1. DR Pfam; PF14651; Lipocalin_7; 1. DR PRINTS; PR00178; FATTYACIDBP. DR SUPFAM; SSF50814; Lipocalins; 1. DR PROSITE; PS00214; FABP; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; Cytoplasm; KW Lipid transport; Lipid-binding; Membrane; Proteomics identification; KW Reference proteome; Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P10289" FT CHAIN 2..128 FT /note="Gastrotropin" FT /id="PRO_0000067380" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P10289" FT VAR_SEQ 1 FT /note="M -> MKTVTMMMVVEMQALTQVLRAVLSACTWVSRKGDLQRMKQTHKGKPP FT SSM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17909007" FT /id="VSP_038039" FT VARIANT 33 FT /note="R -> H (in dbSNP:rs17856662)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_039578" FT VARIANT 55 FT /note="S -> Y (in dbSNP:rs17852045)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_039579" FT VARIANT 79 FT /note="T -> M (probable risk factor for type 2 diabetes FT obese individuals; dbSNP:rs1130435)" FT /evidence="ECO:0000269|PubMed:19744871" FT /id="VAR_039580" FT STRAND 5..14 FT /evidence="ECO:0007829|PDB:5L8I" FT HELIX 15..22 FT /evidence="ECO:0007829|PDB:5L8I" FT HELIX 26..33 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 37..44 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 47..54 FT /evidence="ECO:0007829|PDB:5L8I" FT TURN 55..57 FT /evidence="ECO:0007829|PDB:5L8O" FT STRAND 59..65 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 68..72 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:5L8N" FT STRAND 80..83 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 98..104 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 106..115 FT /evidence="ECO:0007829|PDB:5L8I" FT STRAND 118..127 FT /evidence="ECO:0007829|PDB:5L8I" SQ SEQUENCE 128 AA; 14371 MW; 173CBC5DBEDADDE1 CRC64; MAFTGKFEME SEKNYDEFMK LLGISSDVIE KARNFKIVTE VQQDGQDFTW SQHYSGGHTM TNKFTVGKES NIQTMGGKTF KATVQMEGGK LVVNFPNYHQ TSEIVGDKLV EVSTIGGVTY ERVSKRLA // ID FGFR2_HUMAN Reviewed; 821 AA. AC P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300; Q14301; AC Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; AC Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; AC Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; AC Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Fibroblast growth factor receptor 2; DE Short=FGFR-2; DE EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; DE AltName: Full=K-sam; DE Short=KGFR; DE AltName: Full=Keratinocyte growth factor receptor; DE AltName: CD_antigen=CD332; DE Flags: Precursor; GN Name=FGFR2; Synonyms=BEK, KGFR, KSAM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Neonatal brain stem; RX PubMed=1697263; DOI=10.1002/j.1460-2075.1990.tb07454.x; RA Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G., Ruta M., RA Burgess W.H., Jaye M., Schlessinger J.; RT "Cloning and expression of two distinct high-affinity receptors cross- RT reacting with acidic and basic fibroblast growth factors."; RL EMBO J. 9:2685-2692(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10). RX PubMed=2172978; DOI=10.1073/pnas.87.20.8180; RA Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C., RA Torriglia A., Courtois Y., Breathnach R.; RT "Related fibroblast growth factor receptor genes exist in the human RT genome."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11). RX PubMed=1647213; DOI=10.1016/0167-4781(91)90015-e; RA Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.; RT "Two cDNAs encoding novel human FGF receptor."; RL Biochim. Biophys. Acta 1089:244-246(1991). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Stomach cancer; RX PubMed=2377625; DOI=10.1073/pnas.87.15.5983; RA Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K., Sakamoto H., RA Katoh O., Yoshida T., Sugimura T., Terada M.; RT "K-sam, an amplified gene in stomach cancer, is a member of the heparin- RT binding growth factor receptor genes."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 8; 9 AND 16). RX PubMed=1313574; DOI=10.1073/pnas.89.7.2960; RA Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y., RA Sugimura T., Terada M.; RT "K-sam gene encodes secreted as well as transmembrane receptor tyrosine RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 16), DOMAIN, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=1400433; DOI=10.1016/s0021-9258(19)36821-8; RA Dell K.R., Williams L.T.; RT "A novel form of fibroblast growth factor receptor 2. Alternative splicing RT of the third immunoglobulin-like domain confers ligand binding RT specificity."; RL J. Biol. Chem. 267:21225-21229(1992). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 13 AND 16), SUBUNIT, DOMAIN, AND RP VARIANT ARG-613. RC TISSUE=Mammary gland; RX PubMed=1309608; DOI=10.1073/pnas.89.1.246; RA Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H., RA Chan A.M.-L., Aaronson S.A.; RT "Determination of ligand-binding specificity by alternative splicing: two RT distinct growth factor receptors encoded by a single gene."; RL Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 13). RC TISSUE=Cornea, and Mammary gland; RX PubMed=7866434; RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RT "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and RT their receptors in human breast cells and tissues: alternative receptors."; RL Cell. Mol. Biol. Res. 40:337-350(1994). RN [9] RP ERRATUM OF PUBMED:7866434. RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RL Cell. Mol. Biol. Res. 40:707-707(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342. RC TISSUE=Blood; RA Steinberger D., Mueller U.; RL Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-613. RX PubMed=10626794; RA Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H., RA Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.; RT "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology- RT mediated recombination, generating preferential expression of specific RT messenger RNAs."; RL Cancer Res. 59:6080-6086(1999). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 7; 8 AND 12). RX PubMed=11856867; DOI=10.1159/000048802; RA Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G., Jabs E.W.; RT "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and RT variations."; RL Cytogenet. Cell Genet. 94:121-126(2001). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3). RA Lind D.L., Cox D.R.; RT "Sequence and polymorphisms in fibroblast growth factor receptor 2 (FGFR2) RT gene in humans."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17). RA Jang J.; RT "Identification of a novel variant of FGFR2."; RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186. RG NIEHS SNPs program; RL Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 15). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427. RX PubMed=10712195; DOI=10.1086/302831; RA Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A., RA Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A., RA Wilkie A.O.M., Jabs E.W.; RT "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome RT and Pfeiffer syndrome."; RL Am. J. Hum. Genet. 66:768-777(2000). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821 (ISOFORMS RP 5; 8 AND 12). RX PubMed=10196476; DOI=10.1016/s0378-1119(99)00047-5; RA Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.; RT "Genomic organization of the human fibroblast growth factor receptor 2 RT (FGFR2) gene and comparative analysis of the human FGFR gene family."; RL Gene 230:69-79(1999). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS TRP-252 AND RP ARG-253. RX PubMed=7668257; RA Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S., Dufresne C., RA Cohen M.M. Jr., Jabs E.W.; RT "Analysis of phenotypic features and FGFR2 mutations in Apert syndrome."; RL Am. J. Hum. Genet. 57:321-328(1995). RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259. RX PubMed=8676562; RA Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F., RA Yamazaki Y., Ohtani H.; RT "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth RT factor receptor 2 and rapid mutational analysis in Apert syndrome."; RL Rinsho Byori 44:435-438(1996). RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318. RX PubMed=8673103; DOI=10.1038/ng0596-48; RA Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P., Stenman G., RA Wilkie A.O.M.; RT "Exclusive paternal origin of new mutations in Apert syndrome."; RL Nat. Genet. 13:48-53(1996). RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289; RP ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354. RX PubMed=7581378; DOI=10.1093/hmg/4.8.1387; RA Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K., Losken H.W., RA Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.; RT "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common RT point mutation shared with Jackson-Weiss syndrome."; RL Hum. Mol. Genet. 4:1387-1390(1995). RN [25] RP FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN. RX PubMed=8961926; DOI=10.1021/bi961942c; RA Gray T.E., Eisenstein M., Yayon A., Givol D.; RT "Asparagine-344 is a key residue for ligand binding in keratinocyte growth RT factor receptor."; RL Biochemistry 35:15640-15645(1996). RN [26] RP INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND FUNCTION RP IN CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [27] RP INVOLVEMENT IN SCS, AND VARIANT SCS 269-VAL-VAL-270 DEL. RX PubMed=9585583; DOI=10.1086/301855; RA Paznekas W.A., Cunningham M.L., Howard T.D., Korf B.R., Lipson M.H., RA Grix A.W., Feingold M., Goldberg R., Borochowitz Z., Aleck K., Mulliken J., RA Yin M., Jabs E.W.; RT "Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR RT mutations."; RL Am. J. Hum. Genet. 62:1370-1380(1998). RN [28] RP FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION AND RP APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4. RX PubMed=12529371; DOI=10.1074/jbc.m205875200; RA Lu Y., Pan Z.-Z., Devaux Y., Ray P.; RT "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte RT growth factor receptor and participates in keratinocyte growth factor- RT mediated inhibition of oxidant-induced cell death."; RL J. Biol. Chem. 278:10374-10380(2003). RN [29] RP FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL, RP INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT APRS RP TRP-252. RX PubMed=15190072; DOI=10.1074/jbc.m402469200; RA Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.; RT "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast RT growth factor receptor-2 activation supports osteoblast differentiation."; RL J. Biol. Chem. 279:36259-36267(2004). RN [30] RP FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS, RP MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION WITH RP PLCG1. RX PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031; RA Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.; RT "Tyrosine 769 of the keratinocyte growth factor receptor is required for RT receptor signaling but not endocytosis."; RL Biochem. Biophys. Res. Commun. 327:523-532(2005). RN [31] RP INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22 AND RP FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [32] RP FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1, SUBCELLULAR RP LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657, UBIQUITINATION, AND RP CHARACTERIZATION OF VARIANT PS PHE-278. RX PubMed=16844695; DOI=10.1074/jbc.m600448200; RA Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.; RT "Intracellular retention, degradation, and signaling of glycosylation- RT deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F."; RL J. Biol. Chem. 281:27292-27305(2006). RN [33] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION OF RP FRS2 AND ACTIVATION OF MAP KINASES. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [34] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18374639; DOI=10.1016/j.bone.2008.02.009; RA Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.; RT "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt RT signaling and osteoblast survival."; RL Bone 42:1032-1039(2008). RN [36] RP FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2, RP CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656 RP AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004; RA Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.; RT "Novel phosphotyrosine targets of FGFR2IIIb signaling."; RL Cell. Signal. 21:1370-1378(2009). RN [37] RP FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND RP PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2, RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769. RX PubMed=19103595; DOI=10.1074/jbc.m803998200; RA Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.; RT "Aberrant receptor internalization and enhanced FRS2-dependent signaling RT contribute to the transforming activity of the fibroblast growth factor RT receptor 2 IIIb C3 isoform."; RL J. Biol. Chem. 284:6227-6240(2009). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [39] RP FUNCTION, AND UBIQUITINATION. RX PubMed=21596750; DOI=10.1074/jbc.m110.197525; RA Severe N., Miraoui H., Marie P.J.; RT "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic RT differentiation in human mesenchymal stromal cells in part by decreased RT Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast RT growth factor receptor 2 ubiquitination."; RL J. Biol. Chem. 286:24443-24450(2011). RN [40] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [41] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND ROLE IN RP DISEASE. RX PubMed=19387476; DOI=10.1038/jid.2009.97; RA Katoh M.; RT "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer RT pathologies."; RL J. Invest. Dermatol. 129:1861-1867(2009). RN [42] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2. RX PubMed=10830168; DOI=10.1016/s0092-8674(00)80851-x; RA Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.; RT "Crystal structures of two FGF-FGFR complexes reveal the determinants of RT ligand-receptor specificity."; RL Cell 101:413-424(2000). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1 AND RP HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN. RX PubMed=11069186; DOI=10.1038/35039551; RA Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.; RT "Crystal structure of fibroblast growth factor receptor ectodomain bound to RT ligand and heparin."; RL Nature 407:1029-1034(2000). RN [46] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1. RX PubMed=10618369; DOI=10.1073/pnas.97.1.49; RA Stauber D.J., DiGabriele A.D., Hendrickson W.A.; RT "Structural interactions of fibroblast growth factor receptor with its RT ligands."; RL Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS TRP-252 RP AND ARG-253 IN COMPLEX WITH FGF2. RX PubMed=11390973; DOI=10.1073/pnas.121183798; RA Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., RA Mohammadi M.; RT "Structural basis for fibroblast growth factor receptor 2 activation in RT Apert syndrome."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH FGF10. RX PubMed=12591959; DOI=10.1073/pnas.0436500100; RA Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I., Ron D., RA Aaronson S.A., Mohammadi M.; RT "Structural basis by which alternative splicing confers specificity in RT fibroblast growth factor receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH FGF8, RP FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE BONDS. RX PubMed=16384934; DOI=10.1101/gad.1365406; RA Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., RA Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.; RT "Structural basis by which alternative splicing modulates the organizer RT activity of FGF8 in the brain."; RL Genes Dev. 20:185-198(2006). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP RP ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ACTIVITY REGULATION, RP PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF ASN-549 AND RP GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526, CHARACTERIZATION OF RP VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS PS GLY-565 AND ARG-641, RP AND CHARACTERIZATION OF VARIANT CRANIOSYNOSTOSIS ASN-659. RX PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028; RA Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., RA Mohammadi M.; RT "A molecular brake in the kinase hinge region regulates the activity of RT receptor tyrosine kinases."; RL Mol. Cell 27:717-730(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADD1 THR-628 RP IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND RP AUTOPHOSPHORYLATION. RX PubMed=18056630; DOI=10.1073/pnas.0709905104; RA Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.; RT "Structural basis for reduced FGFR2 activity in LADD syndrome: Implications RT for FGFR autoinhibition and activation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007). RN [52] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP, RP ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION, AND RP PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND TYR-769. RX PubMed=19060208; DOI=10.1073/pnas.0807752105; RA Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., RA Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.; RT "A crystallographic snapshot of tyrosine trans-phosphorylation in action."; RL Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH RP INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ACTIVITY RP REGULATION. RX PubMed=21454610; DOI=10.1074/jbc.m110.213736; RA Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J., RA Chen C.R., Chan T.C., France D.S., Ashwell M.A.; RT "A novel mode of protein kinase inhibition exploiting hydrophobic motifs of RT autoinhibited kinases: discovery of ATP-independent inhibitors of RT fibroblast growth factor receptor."; RL J. Biol. Chem. 286:20677-20687(2011). RN [54] RP VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354. RX PubMed=7987400; DOI=10.1038/ng0994-98; RA Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M., Malcolm S.; RT "Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon RT syndrome."; RL Nat. Genet. 8:98-103(1994). RN [55] RP VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344. RX PubMed=7874170; DOI=10.1038/ng1194-275; RA Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J., RA Charnas L.R., Jackson C.E., Jaye M.; RT "Jackson-Weiss and Crouzon syndromes are allelic with mutations in RT fibroblast growth factor receptor 2."; RL Nat. Genet. 8:275-279(1994). RN [56] RP VARIANTS CS PRO-267; PHE-278 AND ARG-290. RX PubMed=7655462; DOI=10.1093/hmg/4.6.1077; RA Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J., RA Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M., RA Reardon W., Malcolm S.; RT "Mutations in the third immunoglobulin domain of the fibroblast growth RT factor receptor-2 gene in Crouzon syndrome."; RL Hum. Mol. Genet. 4:1077-1082(1995). RN [57] RP VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342. RX PubMed=8528214; DOI=10.1093/hmg/4.7.1229; RA Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., RA Jabs E.W.; RT "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic RT heterogeneity and phenotypic variability."; RL Hum. Mol. Genet. 4:1229-1233(1995). RN [58] RP VARIANT PS ALA-321. RX PubMed=7719333; DOI=10.1038/ng0295-108; RA Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M., Renier D.; RT "FGFR2 mutations in Pfeiffer syndrome."; RL Nat. Genet. 9:108-108(1995). RN [59] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=7719344; DOI=10.1038/ng0295-165; RA Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., RA Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P., RA Malcolm S., Winter R.M., Reardon W.; RT "Apert syndrome results from localized mutations of FGFR2 and is allelic RT with Crouzon syndrome."; RL Nat. Genet. 9:165-172(1995). RN [60] RP VARIANTS PS PRO-341; ARG-342 AND TYR-342. RX PubMed=7719345; DOI=10.1038/ng0295-173; RA Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R., Jones B.M., RA Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., RA Wilkie A.O.M.; RT "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon RT syndrome phenotypes."; RL Nat. Genet. 9:173-176(1995). RN [61] RP VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278; ARG-342; RP SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289. RX PubMed=8644708; RA Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., RA Graham J.M. Jr., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., RA Jabs E.W.; RT "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer RT syndromes: evidence for missense changes, insertions, and a deletion due to RT alternative RNA splicing."; RL Am. J. Hum. Genet. 58:491-498(1996). RN [62] RP VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384. RX PubMed=8946174; DOI=10.1159/000472215; RA Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M., Hayward R., RA Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S., Winter R.M.; RT "Spectrum of craniosynostosis phenotypes associated with novel mutations at RT the fibroblast growth factor receptor 2 locus."; RL Eur. J. Hum. Genet. 4:283-291(1996). RN [63] RP VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL. RX PubMed=8956050; RX DOI=10.1002/(sici)1098-1004(1996)8:4<386::aid-humu18>3.0.co;2-z; RA Steinberger D., Mulliken J.B., Mueller U.; RT "Crouzon syndrome: previously unrecognized deletion, duplication, and point RT mutation within FGFR2 gene."; RL Hum. Mutat. 8:386-390(1996). RN [64] RP VARIANTS BSTVS CYS-372 AND CYS-375. RX PubMed=8696350; DOI=10.1038/ng0896-492; RA Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W., Bamshad M.J., RA Carey J.C., Hall B.D., Stevenson R., Orlow S.J., Cohen M.M. Jr., Jabs E.W.; RT "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis RT gyrata syndrome."; RL Nat. Genet. 13:492-494(1996). RN [65] RP VARIANT PS CYS-290. RX PubMed=9150725; DOI=10.1007/s004390050413; RA Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.; RT "Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 RT (FGFR2) gene is associated with Pfeiffer syndrome."; RL Hum. Genet. 99:602-606(1997). RN [66] RP VARIANT JWS SER-342. RX PubMed=9385368; DOI=10.1007/s004390050584; RA Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F., RA Battaglia P.A.; RT "Jackson-Weiss syndrome: identification of two novel FGFR2 missense RT mutations shared with Crouzon and Pfeiffer craniosynostotic disorders."; RL Hum. Genet. 101:47-50(1997). RN [67] RP VARIANT LEU-252, VARIANT APRS PHE-252, AND VARIANT PS 252-SER-PRO-253 RP DELINS PHE-SER. RX PubMed=9002682; DOI=10.1093/hmg/6.1.137; RA Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M., RA Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G., RA Gagnon D.M., Jabs E.W., Wilkie A.O.M.; RT "Genotype-phenotype correlation for nucleotide substitutions in the IgII- RT IgIII linker of FGFR2."; RL Hum. Mol. Genet. 6:137-143(1997). RN [68] RP VARIANT CS GLU-292. RX PubMed=9152842; DOI=10.1136/jmg.34.5.420; RA Steinberger D., Collmann H., Schmalenberger B., Mueller U.; RT "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with RT Crouzon phenotype and plagiocephaly."; RL J. Med. Genet. 34:420-422(1997). RN [69] RP VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342, RP VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278. RX PubMed=9677057; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<237::aid-ajmg5>3.3.co;2-5; RA Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G., Zatz M., RA Alonso N., Brunoni D., Ribeiro S.F.M.; RT "Description of a new mutation and characterization of FGFR1, FGFR2, and RT FGFR3 mutations among Brazilian patients with syndromic craniosynostoses."; RL Am. J. Med. Genet. 78:237-241(1998). RN [70] RP VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314. RX PubMed=9521581; DOI=10.1007/s004390050668; RA Steinberger D., Vriend G., Mulliken J.B., Mueller U.; RT "The mutations in FGFR2-associated craniosynostoses are clustered in five RT structural elements of immunoglobulin-like domain III of the receptor."; RL Hum. Genet. 102:145-150(1998). RN [71] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=9452027; DOI=10.1002/humu.1380110106; RA Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.; RT "Two common mutations 934C to G and 937C to G of fibroblast growth factor RT receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome."; RL Hum. Mutat. Suppl. 1:S18-S19(1998). RN [72] RP VARIANT PS CYS-351. RX PubMed=9693549; DOI=10.1097/00001665-199805000-00004; RA Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J., Hesseling-Janssen A.L.W., RA van den Ouweland A.M.W.; RT "Pfeiffer's syndrome resulting from an S351C mutation in the fibroblast RT growth factor receptor-2 gene."; RL J. Craniofac. Surg. 9:207-209(1998). RN [73] RP VARIANT PS TRP-252. RX PubMed=9719378; DOI=10.1136/jmg.35.8.677; RA Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.; RT "Presence of the Apert canonical S252W FGFR2 mutation in a patient without RT severe syndactyly."; RL J. Med. Genet. 35:677-679(1998). RN [74] RP VARIANT CS SER-362. RX PubMed=10574673; DOI=10.1597/1545-1569_1999_036_0533_anfgmi_2.3.co_2; RA Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.; RT "A novel FGFR2 gene mutation in Crouzon syndrome associated with apparent RT nonpenetrance."; RL Cleft Palate Craniofac. J. 36:533-541(1999). RN [75] RP VARIANTS PS CYS-340 AND GLY-342. RX PubMed=10394936; DOI=10.1007/s004390050979; RA Cornejo-Roldan L.R., Roessler E., Muenke M.; RT "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer RT syndrome."; RL Hum. Genet. 104:425-431(1999). RN [76] RP VARIANT PS ASP-273 DEL. RX PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x; RA Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A., RA Capra V., Silengo M.; RT "Pfeiffer syndrome type 2 associated with a single amino acid deletion in RT the FGFR2 gene."; RL Clin. Genet. 58:81-83(2000). RN [77] RP VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276; PHE-278; RP TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354 AND PHE-359, RP AND VARIANT PS SER-342. RX PubMed=11173845; DOI=10.1159/000056833; RA Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.; RT "Clustering of FGFR2 gene mutations in patients with Pfeiffer and Crouzon RT syndromes (FGFR2-associated craniosynostoses)."; RL Cytogenet. Cell Genet. 91:134-137(2000). RN [78] RP VARIANT SER-315. RX PubMed=10951518; DOI=10.1038/sj.ejhg.5200499; RA Johnson D., Wall S.A., Mann S., Wilkie A.O.M.; RT "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction RT leading to craniosynostosis?"; RL Eur. J. Hum. Genet. 8:571-577(2000). RN [79] RP VARIANTS ABS2 ARG-342; SER-342 AND CYS-351. RX PubMed=10633130; DOI=10.1136/jmg.37.1.26; RA Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G., RA Nelson I., Malcolm S., Ades L., Sillence D., Kumar D., RA DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M., RA Winter R.M.; RT "Evidence for digenic inheritance in some cases of Antley-Bixler RT syndrome?"; RL J. Med. Genet. 37:26-32(2000). RN [80] RP VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342. RX PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x; RA Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.; RT "Mutation analysis of Crouzon syndrome and identification of one novel RT mutation in Taiwanese patients."; RL Pediatr. Int. 43:263-266(2001). RN [81] RP VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; RP PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678, VARIANTS PS RP PHE-172; 252-SER-PRO-253 DELINS PHE-SER; CYS-290; CYS-340; PRO-341; RP ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS RP TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT RP CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315. RX PubMed=11781872; DOI=10.1086/338758; RA Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J., Reich E.W., RA Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S., RA McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M., Wilkie A.O.M.; RT "Genomic screening of fibroblast growth-factor receptor 2 reveals a wide RT spectrum of mutations in patients with syndromic craniosynostosis."; RL Am. J. Hum. Genet. 70:472-486(2002). RN [82] RP VARIANT BSTVS CYS-375. RX PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x; RA Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.; RT "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson RT cutis gyrata syndrome."; RL Clin. Genet. 61:218-221(2002). RN [83] RP VARIANT FSPC GLU-526. RX PubMed=16061565; DOI=10.1136/jmg.2004.027888; RA McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R., RA Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.; RT "Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 RT tyrosine kinase domain."; RL J. Med. Genet. 42:656-662(2005). RN [84] RP VARIANTS LADD1 THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [85] RP VARIANT [LARGE SCALE ANALYSIS] CYS-203. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [86] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272; ASN-283; RP CYS-290 AND THR-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [87] RP VARIANTS BBDS1 ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT BBDS1 RP ARG-391. RX PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005; RA Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N., Estrada K.D., RA Lyons K.M., Deixler H., Robinson H., Chitayat D., Curry C.J., Lachman R.S., RA Wilcox W.R., Krakow D.; RT "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has RT deficient canonical FGF signaling."; RL Am. J. Hum. Genet. 90:550-557(2012). RN [88] RP VARIANT LEU-57. RX PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336; RA Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L., Edvardson S., RA Rein A.J., Elpeleg O., Katsanis N.; RT "A human laterality disorder caused by a homozygous deleterious mutation in RT MMP21."; RL J. Med. Genet. 52:840-847(2015). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation, migration and CC apoptosis, and in the regulation of embryonic development. Required for CC normal embryonic patterning, trophoblast function, limb bud CC development, lung morphogenesis, osteogenesis and skin development. CC Plays an essential role in the regulation of osteoblast CC differentiation, proliferation and apoptosis, and is required for CC normal skeleton development. Promotes cell proliferation in CC keratinocytes and immature osteoblasts, but promotes apoptosis in CC differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand CC binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC FGFR2 signaling is down-regulated by ubiquitination, internalization CC and degradation. Mutations that lead to constitutive kinase activation CC or impair normal FGFR2 maturation, internalization and degradation lead CC to aberrant signaling. Over-expressed FGFR2 promotes activation of CC STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ CC 069; these compounds maintain the kinase in an inactive conformation CC and inhibit autophosphorylation. {ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:21454610}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts CC predominantly with FGF1 and FGF2, but can also interact with FGF3, CC FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). CC Ligand specificity is determined by tissue-specific expression of CC isoforms, and differences in the third Ig-like domain are crucial for CC ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but CC low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, CC and has much higher affinity for FGF7 than isoform 1 (in vitro). CC Affinity for fibroblast growth factors (FGFs) is increased by heparan CC sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB CC increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 CC and PAK4. Interacts with FLRT2 (By similarity). CC {ECO:0000250|UniProtKB:P21803, ECO:0000269|PubMed:10618369, CC ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11069186, CC ECO:0000269|PubMed:11390973, ECO:0000269|PubMed:12529371, CC ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19060208, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:21454610, CC ECO:0000269|PubMed:8663044, ECO:0000269|PubMed:8961926}. CC -!- INTERACTION: CC P21802; P06734: FCER2; NbExp=2; IntAct=EBI-1028658, EBI-10199985; CC P21802; P05230: FGF1; NbExp=3; IntAct=EBI-1028658, EBI-698068; CC P21802; PRO_0000008908 [P05230]: FGF1; NbExp=5; IntAct=EBI-1028658, EBI-6880860; CC P21802; O15520: FGF10; NbExp=2; IntAct=EBI-1028658, EBI-1035684; CC P21802; P09038: FGF2; NbExp=5; IntAct=EBI-1028658, EBI-977447; CC P21802; P09038-2: FGF2; NbExp=2; IntAct=EBI-1028658, EBI-11122080; CC P21802; P11362: FGFR1; NbExp=3; IntAct=EBI-1028658, EBI-1028277; CC P21802; P62993: GRB2; NbExp=6; IntAct=EBI-1028658, EBI-401755; CC P21802; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-1028658, EBI-6358090; CC P21802-1; P05230-1: FGF1; NbExp=2; IntAct=EBI-15489960, EBI-15489950; CC P21802-1; P09038: FGF2; NbExp=2; IntAct=EBI-15489960, EBI-977447; CC P21802-1; P21802-1: FGFR2; NbExp=3; IntAct=EBI-15489960, EBI-15489960; CC P21802-1; P19174: PLCG1; NbExp=9; IntAct=EBI-15489960, EBI-79387; CC P21802-3; P21781: FGF7; NbExp=2; IntAct=EBI-6354683, EBI-3937699; CC P21802-3; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-6354683, EBI-6358090; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on CC osteoblast plasma membrane lipid rafts. After ligand binding, the CC activated receptor is rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 13]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Name=1; Synonyms=BEK, FGFR2IIIc; CC IsoId=P21802-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P21802-2; Sequence=VSP_002978; CC Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR; CC IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972; CC Name=4; Synonyms=K-sam; CC IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002975, CC VSP_002976; CC Name=5; Synonyms=K-sam-I, BEK, IgIIIc; CC IsoId=P21802-5; Sequence=VSP_002975; CC Name=6; Synonyms=K-sam-IIC2; CC IsoId=P21802-6; Sequence=VSP_002975, VSP_002984; CC Name=7; Synonyms=K-sam-IIC3; CC IsoId=P21802-8; Sequence=VSP_002975, VSP_002978; CC Name=8; Synonyms=K-sam-IV, Soluble KGFR; CC IsoId=P21802-14; Sequence=VSP_002965, VSP_002966; CC Name=9; Synonyms=K-sam-III; CC IsoId=P21802-15; Sequence=VSP_002968; CC Name=10; Synonyms=TK14; CC IsoId=P21802-16; Sequence=VSP_002967, VSP_002975; CC Name=11; CC IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002978; CC Name=12; Synonyms=K-sam-IIC1, KGFR, IgIIIb; CC IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002975; CC Name=13; Synonyms=Soluble KGFR; CC IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002973, VSP_002974; CC Name=14; CC IsoId=P21802-20; Sequence=VSP_019608, VSP_019609; CC Name=15; CC IsoId=P21802-21; Sequence=VSP_002964, VSP_041915; CC Name=16; CC IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002978; CC Name=17; CC IsoId=P21802-23; Sequence=VSP_041914; CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC Alternative splicing events affecting the third Ig-like domain are CC crucial for ligand selectivity. {ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:8961926}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on several tyrosine residues. CC Autophosphorylation occurs in trans between the two FGFR molecules CC present in the dimer. Phosphorylation at Tyr-769 is essential for CC interaction with PLCG1. {ECO:0000269|PubMed:15629145, CC ECO:0000269|PubMed:19060208}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17311277}. CC -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after CC autophosphorylation, leading to internalization and degradation. CC Subject to degradation both in lysosomes and by the proteasome. CC {ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:21596750}. CC -!- DISEASE: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant CC syndrome characterized by craniosynostosis, hypertelorism, exophthalmos CC and external strabismus, parrot-beaked nose, short upper lip, CC hypoplastic maxilla, and a relative mandibular prognathism. CC {ECO:0000269|PubMed:10574673, ECO:0000269|PubMed:11173845, CC ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:17803937, ECO:0000269|PubMed:7581378, CC ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:7874170, CC ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:8946174, CC ECO:0000269|PubMed:8956050, ECO:0000269|PubMed:9152842, CC ECO:0000269|PubMed:9521581, ECO:0000269|PubMed:9677057, CC ECO:0000269|Ref.10}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal CC dominant craniosynostosis syndrome characterized by craniofacial CC abnormalities and abnormality of the feet: broad great toes with medial CC deviation and tarsal-metatarsal coalescence. CC {ECO:0000269|PubMed:7874170, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Apert syndrome (APRS) [MIM:101200]: A syndrome characterized CC by facio-cranio-synostosis, osseous and membranous syndactyly of the CC four extremities, and midface hypoplasia. The craniosynostosis is CC bicoronal and results in acrocephaly of brachysphenocephalic type. CC Syndactyly of the fingers and toes may be total (mitten hands and sock CC feet) or partial affecting the second, third, and fourth digits. CC Intellectual deficit is frequent and often severe, usually being CC associated with cerebral malformations. {ECO:0000269|PubMed:11390973, CC ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, CC ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9452027, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized CC by the association of craniosynostosis, broad and deviated thumbs and CC big toes, and partial syndactyly of the fingers and toes. Three CC subtypes are known: mild autosomal dominant form (type 1); cloverleaf CC skull, elbow ankylosis, early death, sporadic (type 2); CC craniosynostosis, early demise, sporadic (type 3). CC {ECO:0000269|PubMed:10394936, ECO:0000269|PubMed:10945669, CC ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:7719333, ECO:0000269|PubMed:7719345, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9002682, CC ECO:0000269|PubMed:9150725, ECO:0000269|PubMed:9693549, CC ECO:0000269|PubMed:9719378}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An CC autosomal dominant disease characterized by craniofacial anomalies, CC particularly craniosynostosis, and ear defects, cutis gyrata, CC acanthosis nigricans, anogenital anomalies, skin tags, and prominent CC umbilical stump. The skin furrows have a corrugated appearance and are CC widespread. Cutis gyrata variably affects the scalp, forehead, face, CC preauricular area, neck, trunk, hands, and feet. CC {ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An CC autosomal dominant craniosynostosis syndrome characterized by CC scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and CC mild intellectual disability. Scaphocephaly is the most common of the CC craniosynostosis conditions and is characterized by a long, narrow CC head. It is due to premature fusion of the sagittal suture or from CC external deformation. {ECO:0000269|PubMed:16061565, CC ECO:0000269|PubMed:17803937}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 1 (LADD1) CC [MIM:149730]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574, CC ECO:0000269|PubMed:18056630}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Antley-Bixler syndrome, without genital anomalies or CC disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome CC characterized by craniosynostosis, radiohumeral synostosis present from CC the perinatal period, midface hypoplasia, choanal stenosis or atresia, CC femoral bowing and multiple joint contractures. Arachnodactyly and/or CC camptodactyly have also been reported. {ECO:0000269|PubMed:10633130}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Bent bone dysplasia syndrome 1 (BBDS1) [MIM:614592]: A CC perinatal lethal skeletal dysplasia characterized by poor CC mineralization of the calvarium, craniosynostosis, dysmorphic facial CC features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, CC and bent long bones. Dysmorphic facial features included low-set ears, CC hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and CC micrognathia. {ECO:0000269|PubMed:22387015}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Saethre-Chotzen syndrome (SCS) [MIM:101400]: A CC craniosynostosis syndrome characterized by coronal synostosis, CC brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, CC broad halluces, and clinodactyly. {ECO:0000269|PubMed:9585583}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89296.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89297.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89298.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89299.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89300.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89301.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAG57383.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40570/FGFR2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52832; CAA37014.1; -; mRNA. DR EMBL; M55614; AAA61188.1; -; mRNA. DR EMBL; X56191; CAA39654.1; -; mRNA. DR EMBL; M35718; AAA36152.1; -; mRNA. DR EMBL; M87770; AAA59470.1; -; mRNA. DR EMBL; M87771; AAA59471.1; -; mRNA. DR EMBL; M87772; AAA59472.1; -; mRNA. DR EMBL; M97193; AAA52449.1; -; mRNA. DR EMBL; U11814; AAA68514.1; -; mRNA. DR EMBL; M80634; AAA36147.1; -; mRNA. DR EMBL; Z71929; CAA96492.1; -; mRNA. DR EMBL; AB030073; BAA89296.1; ALT_SEQ; mRNA. DR EMBL; AB030074; BAA89297.1; ALT_SEQ; mRNA. DR EMBL; AB030075; BAA89298.1; ALT_SEQ; mRNA. DR EMBL; AB030076; BAA89299.1; ALT_SEQ; mRNA. DR EMBL; AB030077; BAA89300.1; ALT_SEQ; mRNA. DR EMBL; AB030078; BAA89301.1; ALT_SEQ; mRNA. DR EMBL; AF360695; AAK94205.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94206.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94207.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94208.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94209.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA. DR EMBL; AF487553; AAM74056.1; -; Genomic_DNA. DR EMBL; AB084153; BAC45037.1; -; mRNA. DR EMBL; DQ493927; ABE96832.1; -; Genomic_DNA. DR EMBL; AK294026; BAG57383.1; ALT_INIT; mRNA. DR EMBL; AC009988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039243; AAH39243.2; -; mRNA. DR EMBL; AF169399; AAF43273.1; -; Genomic_DNA. DR EMBL; AF169399; AAF43274.1; -; Genomic_DNA. DR EMBL; AF097353; AAD31560.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097353; AAD31561.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097340; AAD31562.1; -; Genomic_DNA. DR EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097354; AAD31565.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31567.1; -; Genomic_DNA. DR EMBL; S82438; AAD14392.1; -; Genomic_DNA. DR EMBL; Y17131; CAA76643.1; -; Genomic_DNA. DR EMBL; L49237; AAC41933.1; -; Genomic_DNA. DR EMBL; L49242; AAC41934.1; -; Genomic_DNA. DR EMBL; L49238; AAC41935.1; -; Genomic_DNA. DR EMBL; L49239; AAC41936.1; -; Genomic_DNA. DR EMBL; L49240; AAC41937.1; -; Genomic_DNA. DR EMBL; L49241; AAC41938.1; -; Genomic_DNA. DR CCDS; CCDS31298.1; -. [P21802-1] DR CCDS; CCDS44485.1; -. [P21802-20] DR CCDS; CCDS44486.1; -. [P21802-23] DR CCDS; CCDS44487.1; -. [P21802-15] DR CCDS; CCDS44488.1; -. [P21802-22] DR CCDS; CCDS44489.1; -. [P21802-17] DR CCDS; CCDS53584.1; -. [P21802-21] DR CCDS; CCDS7620.2; -. [P21802-3] DR CCDS; CCDS81515.1; -. [P21802-5] DR PIR; A35969; A35969. DR PIR; A42691; TVHUF2. DR PIR; A45081; A45081. DR PIR; C42691; C42691. DR PIR; S16236; S16236. DR RefSeq; NP_000132.3; NM_000141.5. [P21802-1] DR RefSeq; NP_001138385.1; NM_001144913.1. [P21802-17] DR RefSeq; NP_001138386.1; NM_001144914.1. [P21802-23] DR RefSeq; NP_001138387.1; NM_001144915.2. [P21802-21] DR RefSeq; NP_001138388.1; NM_001144916.1. DR RefSeq; NP_001138389.1; NM_001144917.2. [P21802-15] DR RefSeq; NP_001138390.1; NM_001144918.2. [P21802-20] DR RefSeq; NP_001138391.1; NM_001144919.2. [P21802-22] DR RefSeq; NP_001307583.1; NM_001320654.1. DR RefSeq; NP_001307587.1; NM_001320658.2. [P21802-5] DR RefSeq; NP_001428016.1; NM_001441087.1. [P21802-18] DR RefSeq; NP_075259.4; NM_022970.4. [P21802-3] DR RefSeq; NP_075418.1; NM_023029.2. DR PDB; 1DJS; X-ray; 2.40 A; A=153-362. DR PDB; 1E0O; X-ray; 2.80 A; B/D=148-366. DR PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366. DR PDB; 1GJO; X-ray; 2.40 A; A=456-768. DR PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366. DR PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366. DR PDB; 1NUN; X-ray; 2.90 A; B=140-368. DR PDB; 1OEC; X-ray; 2.40 A; A=456-768. DR PDB; 1WVZ; NMR; -; A=147-249. DR PDB; 2FDB; X-ray; 2.28 A; P/R=149-368. DR PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768. DR PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778. DR PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768. DR PDB; 2PWL; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PY3; X-ray; 2.30 A; A/B=458-768. DR PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZP; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZR; X-ray; 3.00 A; A/B=458-768. DR PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768. DR PDB; 3B2T; X-ray; 1.80 A; A/B=458-766. DR PDB; 3CAF; X-ray; 1.96 A; A=150-249. DR PDB; 3CLY; X-ray; 2.00 A; A=458-778. DR PDB; 3CU1; X-ray; 2.60 A; A/C=150-249. DR PDB; 3DAR; X-ray; 2.20 A; A/B=146-249. DR PDB; 3EUU; X-ray; 2.34 A; A/B=150-249. DR PDB; 3OJ2; X-ray; 2.20 A; C/D=140-313. DR PDB; 3OJM; X-ray; 2.10 A; B=140-313. DR PDB; 3RI1; X-ray; 2.10 A; A/B=458-768. DR PDB; 4J23; X-ray; 3.88 A; A=147-366. DR PDB; 4J95; X-ray; 2.38 A; A/B/C/D=458-768. DR PDB; 4J96; X-ray; 2.30 A; A/B=458-768. DR PDB; 4J97; X-ray; 2.55 A; A/B/C/D=458-768. DR PDB; 4J98; X-ray; 2.31 A; A/B=458-768. DR PDB; 4J99; X-ray; 1.85 A; A/B/C/D=458-768. DR PDB; 4WV1; X-ray; 2.36 A; C/F=153-251. DR PDB; 5EG3; X-ray; 2.61 A; A=458-778. DR PDB; 5UGL; X-ray; 1.86 A; A/B=458-768. DR PDB; 5UGX; X-ray; 2.35 A; A/B=458-768. DR PDB; 5UHN; X-ray; 2.91 A; A/B=458-768. DR PDB; 5UI0; X-ray; 2.05 A; A/B=458-768. DR PDB; 6AGX; X-ray; 2.95 A; A/B/C/D=467-764. DR PDB; 6LVK; X-ray; 2.29 A; A/B=459-768. DR PDB; 6LVL; X-ray; 2.98 A; A/B=459-768. DR PDB; 6V6Q; X-ray; 2.46 A; A/B/C/D=413-821. DR PDB; 7KIA; X-ray; 2.22 A; A/B=461-768. DR PDB; 7KIE; X-ray; 2.47 A; A/B=461-768. DR PDB; 7OZY; X-ray; 2.28 A; AAA/BBB=465-763. DR PDB; 8E1X; X-ray; 2.68 A; A/B=459-768. DR PDB; 8H75; X-ray; 3.75 A; A/B/C/D=459-768. DR PDB; 8STG; X-ray; 3.79 A; A/B=458-769. DR PDB; 8SWE; X-ray; 2.24 A; A/B=458-768. DR PDB; 8U1F; X-ray; 3.33 A; A/B=458-768. DR PDB; 8W2X; X-ray; 2.98 A; A/B=458-768. DR PDB; 8W38; X-ray; 2.60 A; A/B/C/D=458-768. DR PDB; 8W3B; X-ray; 2.23 A; A/B/C/D=458-768. DR PDB; 8W3D; X-ray; 2.04 A; A/B/C/D=458-768. DR PDB; 9U3N; X-ray; 3.25 A; A/B=458-768. DR PDBsum; 1DJS; -. DR PDBsum; 1E0O; -. DR PDBsum; 1EV2; -. DR PDBsum; 1GJO; -. DR PDBsum; 1II4; -. DR PDBsum; 1IIL; -. DR PDBsum; 1NUN; -. DR PDBsum; 1OEC; -. DR PDBsum; 1WVZ; -. DR PDBsum; 2FDB; -. DR PDBsum; 2PSQ; -. DR PDBsum; 2PVF; -. DR PDBsum; 2PVY; -. DR PDBsum; 2PWL; -. DR PDBsum; 2PY3; -. DR PDBsum; 2PZ5; -. DR PDBsum; 2PZP; -. DR PDBsum; 2PZR; -. DR PDBsum; 2Q0B; -. DR PDBsum; 3B2T; -. DR PDBsum; 3CAF; -. DR PDBsum; 3CLY; -. DR PDBsum; 3CU1; -. DR PDBsum; 3DAR; -. DR PDBsum; 3EUU; -. DR PDBsum; 3OJ2; -. DR PDBsum; 3OJM; -. DR PDBsum; 3RI1; -. DR PDBsum; 4J23; -. DR PDBsum; 4J95; -. DR PDBsum; 4J96; -. DR PDBsum; 4J97; -. DR PDBsum; 4J98; -. DR PDBsum; 4J99; -. DR PDBsum; 4WV1; -. DR PDBsum; 5EG3; -. DR PDBsum; 5UGL; -. DR PDBsum; 5UGX; -. DR PDBsum; 5UHN; -. DR PDBsum; 5UI0; -. DR PDBsum; 6AGX; -. DR PDBsum; 6LVK; -. DR PDBsum; 6LVL; -. DR PDBsum; 6V6Q; -. DR PDBsum; 7KIA; -. DR PDBsum; 7KIE; -. DR PDBsum; 7OZY; -. DR PDBsum; 8E1X; -. DR PDBsum; 8H75; -. DR PDBsum; 8STG; -. DR PDBsum; 8SWE; -. DR PDBsum; 8U1F; -. DR PDBsum; 8W2X; -. DR PDBsum; 8W38; -. DR PDBsum; 8W3B; -. DR PDBsum; 8W3D; -. DR PDBsum; 9U3N; -. DR AlphaFoldDB; P21802; -. DR BMRB; P21802; -. DR SMR; P21802; -. DR BioGRID; 108554; 241. DR CORUM; P21802; -. DR DIP; DIP-3788N; -. DR FunCoup; P21802; 1763. DR IntAct; P21802; 206. DR MINT; P21802; -. DR STRING; 9606.ENSP00000410294; -. DR BindingDB; P21802; -. DR ChEMBL; CHEMBL4142; -. DR DrugBank; DB02058; 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. DR DrugBank; DB02491; 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB13022; LY-2874455. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB00039; Palifermin. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB01901; Sucrosofate. DR DrugCentral; P21802; -. DR GuidetoPHARMACOLOGY; 1809; -. DR GlyConnect; 1997; 1 N-Linked glycan (1 site). DR GlyCosmos; P21802; 9 sites, 2 glycans. DR GlyGen; P21802; 9 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P21802; -. DR PhosphoSitePlus; P21802; -. DR BioMuta; FGFR2; -. DR DMDM; 120049; -. DR CPTAC; CPTAC-3175; -. DR jPOST; P21802; -. DR MassIVE; P21802; -. DR PaxDb; 9606-ENSP00000410294; -. DR PeptideAtlas; P21802; -. DR ProteomicsDB; 53905; -. [P21802-1] DR ProteomicsDB; 53910; -. [P21802-14] DR ProteomicsDB; 53911; -. [P21802-15] DR ProteomicsDB; 53912; -. [P21802-16] DR ProteomicsDB; 53913; -. [P21802-17] DR ProteomicsDB; 53914; -. [P21802-18] DR ProteomicsDB; 53915; -. [P21802-19] DR ProteomicsDB; 53916; -. [P21802-2] DR ProteomicsDB; 53917; -. [P21802-20] DR ProteomicsDB; 53918; -. [P21802-21] DR ProteomicsDB; 53919; -. [P21802-22] DR ProteomicsDB; 53920; -. [P21802-23] DR ProteomicsDB; 53921; -. [P21802-3] DR ProteomicsDB; 53922; -. [P21802-4] DR ProteomicsDB; 53923; -. [P21802-5] DR ProteomicsDB; 53924; -. [P21802-6] DR ProteomicsDB; 53926; -. [P21802-8] DR TopDownProteomics; P21802-8; -. [P21802-8] DR ABCD; P21802; 5 sequenced antibodies. DR Antibodypedia; 4393; 1424 antibodies from 47 providers. DR DNASU; 2263; -. DR Ensembl; ENST00000346997.6; ENSP00000263451.5; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000351936.11; ENSP00000309878.10; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000356226.8; ENSP00000348559.4; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000357555.9; ENSP00000350166.5; ENSG00000066468.25. [P21802-21] DR Ensembl; ENST00000358487.10; ENSP00000351276.6; ENSG00000066468.25. [P21802-1] DR Ensembl; ENST00000359354.6; ENSP00000352309.2; ENSG00000066468.25. [P21802-14] DR Ensembl; ENST00000360144.7; ENSP00000353262.3; ENSG00000066468.25. [P21802-22] DR Ensembl; ENST00000369056.5; ENSP00000358052.1; ENSG00000066468.25. [P21802-17] DR Ensembl; ENST00000369060.8; ENSP00000358056.4; ENSG00000066468.25. [P21802-15] DR Ensembl; ENST00000369061.8; ENSP00000358057.4; ENSG00000066468.25. [P21802-23] DR Ensembl; ENST00000457416.7; ENSP00000410294.2; ENSG00000066468.25. [P21802-3] DR Ensembl; ENST00000682550.1; ENSP00000507633.1; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000683211.1; ENSP00000508257.1; ENSG00000066468.25. [P21802-5] DR GeneID; 2263; -. DR KEGG; hsa:2263; -. DR MANE-Select; ENST00000358487.10; ENSP00000351276.6; NM_000141.5; NP_000132.3. DR UCSC; uc010qtl.3; human. [P21802-1] DR AGR; HGNC:3689; -. DR CIViC; 2263; 42 evidence items across 27 molecular profiles. DR ClinPGx; PA28128; -. DR CTD; 2263; -. DR DisGeNET; 2263; -. DR GeneCards; FGFR2; -. DR GeneReviews; FGFR2; -. DR HGNC; HGNC:3689; FGFR2. DR HPA; ENSG00000066468; Tissue enriched (brain). DR MalaCards; FGFR2; -. DR MIM; 101200; phenotype. DR MIM; 101400; phenotype. DR MIM; 101600; phenotype. DR MIM; 123150; phenotype. DR MIM; 123500; phenotype. DR MIM; 123790; phenotype. DR MIM; 149730; phenotype. DR MIM; 176943; gene. DR MIM; 207410; phenotype. DR MIM; 609579; phenotype. DR MIM; 614592; phenotype. DR OpenTargets; ENSG00000066468; -. DR Orphanet; 596008; Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis. DR Orphanet; 87; Apert syndrome. DR Orphanet; 207; Crouzon syndrome. DR Orphanet; 1555; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome. DR Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type. DR Orphanet; 313855; FGFR2-related bent bone dysplasia. DR Orphanet; 1540; Jackson-Weiss syndrome. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 93258; Pfeiffer syndrome type 1. DR Orphanet; 93259; Pfeiffer syndrome type 2. DR Orphanet; 93260; Pfeiffer syndrome type 3. DR Orphanet; 794; Saethre-Chotzen syndrome. DR VEuPathDB; HostDB:ENSG00000066468; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000155447; -. DR HOGENOM; CLU_000288_74_2_1; -. DR InParanoid; P21802; -. DR OMA; PANCTSE; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P21802; 7 GO annotations based on evolutionary models. DR PhylomeDB; P21802; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P21802; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-190375; FGFR2c ligand binding and activation. DR Reactome; R-HSA-190377; FGFR2b ligand binding and activation. DR Reactome; R-HSA-2023837; Signaling by FGFR2 amplification mutants. DR Reactome; R-HSA-2033519; Activated point mutants of FGFR2. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851708; Signaling by FGFR2 IIIa TM. DR Reactome; R-HSA-8853333; Signaling by FGFR2 fusions. DR SignaLink; P21802; -. DR SIGNOR; P21802; -. DR Agora; ENSG00000066468; -. DR BioGRID-ORCS; 2263; 24 hits in 1187 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR2; human. DR EvolutionaryTrace; P21802; -. DR GeneWiki; Fibroblast_growth_factor_receptor_2; -. DR GenomeRNAi; 2263; -. DR Pharos; P21802; Tclin. DR PRO; PR:P21802; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P21802; protein. DR Bgee; ENSG00000066468; Expressed in C1 segment of cervical spinal cord and 202 other cell types or tissues. DR ExpressionAtlas; P21802; baseline and differential. DR GO; GO:0005938; C:cell cortex; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0009887; P:animal organ morphogenesis; ISS:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0060348; P:bone development; ISS:UniProtKB. DR GO; GO:0030282; P:bone mineralization; ISS:UniProtKB. DR GO; GO:0060349; P:bone morphogenesis; ISS:UniProtKB. DR GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISS:UniProtKB. DR GO; GO:0060442; P:branching involved in prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060445; P:branching involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0060449; P:bud elongation involved in lung branching; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl. DR GO; GO:0048565; P:digestive tract development; ISS:UniProtKB. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL. DR GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB. DR GO; GO:0048568; P:embryonic organ development; ISS:UniProtKB. DR GO; GO:0048562; P:embryonic organ morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; IEA:Ensembl. DR GO; GO:0048730; P:epidermis morphogenesis; ISS:UniProtKB. DR GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; ISS:UniProtKB. DR GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell; ISS:UniProtKB. DR GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; ISS:UniProtKB. DR GO; GO:0022612; P:gland morphogenesis; ISS:UniProtKB. DR GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0032808; P:lacrimal gland development; ISS:UniProtKB. DR GO; GO:0060601; P:lateral sprouting from an epithelium; ISS:UniProtKB. DR GO; GO:0060174; P:limb bud formation; ISS:UniProtKB. DR GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB. DR GO; GO:0030324; P:lung development; ISS:UniProtKB. DR GO; GO:0060463; P:lung lobe morphogenesis; ISS:UniProtKB. DR GO; GO:0060484; P:lung-associated mesenchyme development; ISS:UniProtKB. DR GO; GO:0060615; P:mammary gland bud formation; ISS:UniProtKB. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:UniProtKB. DR GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB. DR GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; ISS:UniProtKB. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; ISS:UniProtKB. DR GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl. DR GO; GO:0030901; P:midbrain development; ISS:UniProtKB. DR GO; GO:0016331; P:morphogenesis of embryonic epithelium; ISS:UniProtKB. DR GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0042476; P:odontogenesis; ISS:UniProtKB. DR GO; GO:0021769; P:orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035265; P:organ growth; ISS:UniProtKB. DR GO; GO:0030916; P:otic vesicle formation; ISS:UniProtKB. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; ISS:UniProtKB. DR GO; GO:0060523; P:prostate epithelial cord elongation; ISS:UniProtKB. DR GO; GO:0060512; P:prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0060688; P:regulation of morphogenesis of a branching structure; ISS:UniProtKB. DR GO; GO:0045667; P:regulation of osteoblast differentiation; TAS:UniProtKB. DR GO; GO:0033688; P:regulation of osteoblast proliferation; TAS:UniProtKB. DR GO; GO:0051150; P:regulation of smooth muscle cell differentiation; ISS:UniProtKB. DR GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0048608; P:reproductive structure development; ISS:UniProtKB. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB. DR GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISS:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB. DR GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:UniProtKB. DR GO; GO:0021847; P:ventricular zone neuroblast division; ISS:UniProtKB. DR CDD; cd04973; IgI_1_FGFR; 1. DR CDD; cd05857; IgI_2_FGFR; 1. DR CDD; cd05858; IgI_3_FGFR2; 1. DR CDD; cd05101; PTKc_FGFR2; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000252; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00546; -. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF130; FIBROBLAST GROWTH FACTOR RECEPTOR 2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Craniosynostosis; Cytoplasmic vesicle; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Glycoprotein; Golgi apparatus; Heparin-binding; KW Immunoglobulin domain; Intellectual disability; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..821 FT /note="Fibroblast growth factor receptor 2" FT /id="PRO_0000016783" FT TOPO_DOM 22..377 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 378..398 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 399..821 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 25..125 FT /note="Ig-like C2-type 1" FT DOMAIN 154..247 FT /note="Ig-like C2-type 2" FT DOMAIN 256..358 FT /note="Ig-like C2-type 3" FT DOMAIN 481..770 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 131..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 161..178 FT /note="Heparin-binding" FT COMPBIAS 131..144 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 626 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028, FT ECO:0000269|PubMed:19060208" FT BINDING 487..495 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 517 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 565..567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 571 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT MOD_RES 466 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 586 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 656 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 657 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 769 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19060208" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT CARBOHYD 83 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 228 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 331 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..107 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 179..231 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT DISULFID 278..342 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT VAR_SEQ 37..152 FT /note="EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLI FT GEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSEN FT SNNKR -> G (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019608" FT VAR_SEQ 37..125 FT /note="Missing (in isoform 4, isoform 15 and isoform 16)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:2377625" FT /id="VSP_002964" FT VAR_SEQ 250..361 FT /note="Missing (in isoform 17)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_041914" FT VAR_SEQ 250..254 FT /note="ERSPH -> GSQGL (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002965" FT VAR_SEQ 255..821 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002966" FT VAR_SEQ 313 FT /note="K -> KVTK (in isoform 10)" FT /evidence="ECO:0000303|PubMed:2172978" FT /id="VSP_002967" FT VAR_SEQ 314..429 FT /note="Missing (in isoform 9)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002968" FT VAR_SEQ 314..330 FT /note="AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002969" FT VAR_SEQ 334..335 FT /note="FE -> EA (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002970" FT VAR_SEQ 341..353 FT /note="TCLAGNSIGISFH -> ICKVSNYIGQANQ (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002971" FT VAR_SEQ 361 FT /note="P -> PKQQ (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002972" FT VAR_SEQ 362..365 FT /note="APGR -> GRRC (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002973" FT VAR_SEQ 366..821 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002974" FT VAR_SEQ 428..429 FT /note="Missing (in isoform 4, isoform 5, isoform 6, isoform FT 7, isoform 10 and isoform 12)" FT /evidence="ECO:0000303|PubMed:1313574, FT ECO:0000303|PubMed:2172978, ECO:0000303|PubMed:2377625" FT /id="VSP_002975" FT VAR_SEQ 429..430 FT /note="Missing (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019609" FT VAR_SEQ 761..821 FT /note="LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQY FT PHINGSVKT -> PPNPSLMSIFRK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2377625" FT /id="VSP_002976" FT VAR_SEQ 768..821 FT /note="EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSV FT KT -> I (in isoform 2, isoform 7, isoform 11 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:1647213" FT /id="VSP_002978" FT VAR_SEQ 769..821 FT /note="YLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVK FT T -> EKKVSGAVDCHKPPCNPSHLPCVLAVDQ (in isoform 15)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041915" FT VAR_SEQ 778..821 FT /note="QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT -> PYSP FT CYPDPR (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_002984" FT VARIANT 6 FT /note="R -> P (in dbSNP:rs3750819)" FT /evidence="ECO:0000269|Ref.15" FT /id="VAR_017258" FT VARIANT 57 FT /note="S -> L (in dbSNP:rs56226109)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26429889" FT /id="VAR_042204" FT VARIANT 105 FT /note="Y -> C (in CS; dbSNP:rs1434545235)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8946174" FT /id="VAR_004112" FT VARIANT 172 FT /note="A -> F (in PS; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017259" FT VARIANT 186 FT /note="M -> T (in dbSNP:rs755793)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.15" FT /id="VAR_017260" FT VARIANT 203 FT /note="R -> C (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation; dbSNP:rs2134829270)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_036380" FT VARIANT 252..253 FT /note="SP -> FS (in PS; dbSNP:rs281865420)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:9002682" FT /id="VAR_004116" FT VARIANT 252 FT /note="S -> F (in APRS; requires 2 nucleotide FT substitutions; dbSNP:rs121918498)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004114" FT VARIANT 252 FT /note="S -> L (in dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004113" FT VARIANT 252 FT /note="S -> W (in APRS and PS; common mutation; FT dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:7668257, FT ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, FT ECO:0000269|PubMed:9677057, ECO:0000269|PubMed:9719378" FT /id="VAR_004115" FT VARIANT 253 FT /note="P -> R (in APRS; common mutation; dbSNP:rs77543610)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, FT ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057" FT /id="VAR_004117" FT VARIANT 263 FT /note="P -> L (in CS; dbSNP:rs779326224)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017261" FT VARIANT 267 FT /note="S -> P (in CS; dbSNP:rs121918505)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7655462" FT /id="VAR_004118" FT VARIANT 268 FT /note="T -> TG (in CS)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004119" FT VARIANT 269..270 FT /note="Missing (in SCS)" FT /evidence="ECO:0000269|PubMed:9585583" FT /id="VAR_075856" FT VARIANT 272 FT /note="G -> V (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042205" FT VARIANT 273 FT /note="Missing (in PS; type 2; dbSNP:rs121918503)" FT /evidence="ECO:0000269|PubMed:10945669" FT /id="VAR_017262" FT VARIANT 276 FT /note="F -> V (in CS; dbSNP:rs1057519036)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:9521581" FT /id="VAR_004120" FT VARIANT 278 FT /note="C -> F (in CS, JWS and PS; forms disulfide-linked FT dimers with constitutive kinase activity, is retained in an FT intracellular compartment and not detected at the cell FT surface; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695, FT ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004121" FT VARIANT 278 FT /note="C -> Y (in CS; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017263" FT VARIANT 281 FT /note="Y -> C (in CS; dbSNP:rs1057519038)" FT /evidence="ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017264" FT VARIANT 283 FT /note="D -> N (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2134313441)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042206" FT VARIANT 287..289 FT /note="Missing (in CS)" FT /id="VAR_004122" FT VARIANT 288 FT /note="I -> S (in CS)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017265" FT VARIANT 289 FT /note="Q -> P (in CS and JWS; dbSNP:rs121918497)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:8644708" FT /id="VAR_004123" FT VARIANT 290 FT /note="W -> C (in PS; severe; also in a lung squamous cell FT carcinoma sample; somatic mutation; dbSNP:rs121918499)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9150725" FT /id="VAR_004124" FT VARIANT 290 FT /note="W -> G (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:8528214" FT /id="VAR_017266" FT VARIANT 290 FT /note="W -> R (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:7655462" FT /id="VAR_004125" FT VARIANT 292 FT /note="K -> E (in CS; dbSNP:rs121918500)" FT /evidence="ECO:0000269|PubMed:9152842" FT /id="VAR_004126" FT VARIANT 301 FT /note="Y -> C (in CS; dbSNP:rs1554930684)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004127" FT VARIANT 314 FT /note="A -> S (in craniosynostosis; dbSNP:rs1358919643)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004128" FT VARIANT 315 FT /note="A -> S (in a non-syndromic craniosynostosis patient FT with abnormal intrauterine history; confers predisposition FT to craniosynostosis; dbSNP:rs121918504)" FT /evidence="ECO:0000269|PubMed:10951518, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017267" FT VARIANT 321 FT /note="D -> A (in PS; dbSNP:rs121918510)" FT /evidence="ECO:0000269|PubMed:7719333" FT /id="VAR_004129" FT VARIANT 328 FT /note="Y -> C (in CS; dbSNP:rs121918493)" FT /evidence="ECO:0000269|PubMed:7874170" FT /id="VAR_004130" FT VARIANT 331 FT /note="N -> I (in CS; dbSNP:rs2134258264)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004131" FT VARIANT 337 FT /note="A -> ANA (in CS)" FT /id="VAR_004132" FT VARIANT 337 FT /note="A -> P (in CS; dbSNP:rs387906676)" FT /evidence="ECO:0000269|PubMed:9677057" FT /id="VAR_017268" FT VARIANT 338 FT /note="G -> E (in CS; dbSNP:rs1057519044)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004133" FT VARIANT 338 FT /note="G -> R (in CS; dbSNP:rs1057519043)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:9677057" FT /id="VAR_015011" FT VARIANT 340 FT /note="Y -> C (in PS; dbSNP:rs1554928884)" FT /evidence="ECO:0000269|PubMed:10394936, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017269" FT VARIANT 340 FT /note="Y -> H (in CS; dbSNP:rs121918489)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7987400" FT /id="VAR_004134" FT VARIANT 341 FT /note="T -> P (in PS and CS; dbSNP:rs121918495)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345" FT /id="VAR_004135" FT VARIANT 342 FT /note="C -> F (in CS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004136" FT VARIANT 342 FT /note="C -> G (in PS; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10394936" FT /id="VAR_017270" FT VARIANT 342 FT /note="C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004137" FT VARIANT 342 FT /note="C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, FT ECO:0000269|Ref.10" FT /id="VAR_004138" FT VARIANT 342 FT /note="C -> W (in CS; dbSNP:rs121918496)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8528214" FT /id="VAR_017271" FT VARIANT 342 FT /note="C -> Y (in CS and PS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004139" FT VARIANT 344 FT /note="A -> G (in CS and JWS; dbSNP:rs121918492)" FT /evidence="ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004140" FT VARIANT 344 FT /note="A -> P (in CS and PS; dbSNP:rs2134256250)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004141" FT VARIANT 347 FT /note="S -> C (in CS; dbSNP:rs121918494)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004142" FT VARIANT 351 FT /note="S -> C (in CS, PS and ABS2; dbSNP:rs121918502)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:8946174, ECO:0000269|PubMed:9693549" FT /id="VAR_004143" FT VARIANT 354 FT /note="S -> C (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214" FT /id="VAR_004144" FT VARIANT 354 FT /note="S -> Y (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017272" FT VARIANT 356..358 FT /note="Missing (in CS)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004145" FT VARIANT 359 FT /note="V -> F (in CS and PS; dbSNP:rs1274989878)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:8644708" FT /id="VAR_004146" FT VARIANT 362 FT /note="A -> S (in CS)" FT /evidence="ECO:0000269|PubMed:10574673" FT /id="VAR_017273" FT VARIANT 372 FT /note="S -> C (in BSTVS; dbSNP:rs121913477)" FT /evidence="ECO:0000269|PubMed:8696350" FT /id="VAR_017274" FT VARIANT 375 FT /note="Y -> C (in PS and BSTVS; dbSNP:rs121913478)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350" FT /id="VAR_017275" FT VARIANT 381 FT /note="Y -> D (in BBDS1; dbSNP:rs387906678)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067977" FT VARIANT 384 FT /note="G -> R (in CS; dbSNP:rs1554927408)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004147" FT VARIANT 391 FT /note="M -> R (in BBDS1; the mutation selectively reduces FT plasma-membrane levels of the protein and markedly FT diminishes the receptor's responsiveness to extracellular FT FGF; dbSNP:rs387906677)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067978" FT VARIANT 526 FT /note="K -> E (in FSPC; constitutive kinase activity; FT dbSNP:rs121918507)" FT /evidence="ECO:0000269|PubMed:16061565, FT ECO:0000269|PubMed:17803937" FT /id="VAR_023788" FT VARIANT 549 FT /note="N -> H (in CS; constitutive kinase activity; FT dbSNP:rs1057519045)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017276" FT VARIANT 565 FT /note="E -> G (in PS; constitutive kinase activity; FT dbSNP:rs121918506)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017277" FT VARIANT 612 FT /note="R -> T (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1846839725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046071" FT VARIANT 613 FT /note="G -> R (in dbSNP:rs2133933864)" FT /evidence="ECO:0000269|PubMed:10626794, FT ECO:0000269|PubMed:1309608" FT /id="VAR_015012" FT VARIANT 628 FT /note="A -> T (in LADD1; strongly reduced kinase activity; FT dbSNP:rs121918509)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029884" FT VARIANT 641 FT /note="K -> R (in PS; constitutive kinase activity; FT dbSNP:rs1057519047)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017278" FT VARIANT 648 FT /note="A -> T (in LADD1; dbSNP:rs121918508)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029885" FT VARIANT 649..650 FT /note="RD -> S (in LADD1)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029886" FT VARIANT 659 FT /note="K -> N (in craniosynostosis; constitutive kinase FT activity; dbSNP:rs1589722765)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017279" FT VARIANT 663 FT /note="G -> E (in PS; dbSNP:rs2133825396)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017280" FT VARIANT 678 FT /note="R -> G (in CS; dbSNP:rs1845559552)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017281" FT MUTAGEN 265 FT /note="N->Q: Reduced N-glycosylation. Reduced expression at FT the cell surface." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 549 FT /note="N->T: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 565 FT /note="E->A: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 656..657 FT /note="Missing: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 769 FT /note="Y->F: Increases fibroblast proliferation. Decreases FT phosphorylation of PLCG1 and FRS2. Decreases activation of FT MAP kinases." FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19103595" FT CONFLICT 246 FT /note="L -> P (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT CONFLICT 310 FT /note="K -> N (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT STRAND 152..157 FT /evidence="ECO:0007829|PDB:3CAF" FT TURN 159..162 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 166..170 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 175..178 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 181..185 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 188..193 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4WV1" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 211..213 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 215..218 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 238..249 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 287..293 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:3OJ2" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 315..319 FT /evidence="ECO:0007829|PDB:2FDB" FT HELIX 321..323 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:3OJM" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 338..346 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 349..360 FT /evidence="ECO:0007829|PDB:3OJM" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:5UI0" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 481..489 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 490..492 FT /evidence="ECO:0007829|PDB:8W3D" FT STRAND 494..500 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 504..506 FT /evidence="ECO:0007829|PDB:3CLY" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 525..541 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 550..554 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 556..558 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 561..565 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 568..571 FT /evidence="ECO:0007829|PDB:1OEC" FT HELIX 572..577 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 585..588 FT /evidence="ECO:0007829|PDB:4J99" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:8W3D" FT HELIX 594..596 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 600..619 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 629..631 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 632..634 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 636..638 FT /evidence="ECO:0007829|PDB:2PVY" FT STRAND 640..642 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5UGL" FT TURN 652..654 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 655..658 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 659..662 FT /evidence="ECO:0007829|PDB:2PZR" FT STRAND 664..666 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 667..669 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 672..677 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 682..697 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 709..718 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 726..728 FT /evidence="ECO:0007829|PDB:2PZ5" FT HELIX 730..739 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 744..746 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 750..764 FT /evidence="ECO:0007829|PDB:2PVF" FT CONFLICT P21802-16:315 FT /note="T -> L (in Ref. 2; AAA61188)" FT /evidence="ECO:0000305" SQ SEQUENCE 821 AA; 92025 MW; 6CD5001C960ED82F CRC64; MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T // ID FGFR3_HUMAN Reviewed; 806 AA. AC P22607; D3DVP9; D3DVQ0; Q14308; Q16294; Q16608; Q59FL9; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1991, sequence version 1. DT 28-JAN-2026, entry version 271. DE RecName: Full=Fibroblast growth factor receptor 3; DE Short=FGFR-3; DE EC=2.7.10.1; DE AltName: CD_antigen=CD333; DE Flags: Precursor; GN Name=FGFR3; Synonyms=JTK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1847508; DOI=10.1073/pnas.88.4.1095; RA Keegan K., Johnson D.E., Williams L.T., Hayman M.J.; RT "Isolation of an additional member of the fibroblast growth factor receptor RT family, FGFR-3."; RL Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND RP FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION. RC TISSUE=Squamous cell carcinoma; RX PubMed=11703096; DOI=10.1006/mcbr.2001.0306; RA Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H., RA Kurokawa-Seo M.; RT "Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane RT domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs."; RL Mol. Cell Biol. Res. Commun. 4:365-373(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384; THR-441; RP THR-717 AND PHE-726. RG NIEHS SNPs program; RL Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=1664411; DOI=10.1016/0888-7543(91)90041-c; RA Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F., RA Housman D.E., Wasmuth J.J.; RT "A gene encoding a fibroblast growth factor receptor isolated from the RT Huntington disease gene region of human chromosome 4."; RL Genomics 11:1133-1142(1991). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 614-681. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2). RC TISSUE=Colon tumor; RX PubMed=7923141; RA Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.; RT "Identification of a novel variant form of fibroblast growth factor RT receptor 3 (FGFR3 IIIb) in human colonic epithelium."; RL Cancer Res. 54:5206-5211(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2). RC TISSUE=Keratinocyte; RX PubMed=7495869; DOI=10.1016/0167-4781(95)00156-b; RA Scotet E., Houssaint E.; RT "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is RT not strictly tissue-specific."; RL Biochim. Biophys. Acta 1264:238-242(1995). RN [11] RP INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL RP PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [12] RP INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF RP VARIANT SADDAN MET-650. RX PubMed=10053006; DOI=10.1086/302275; RA Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., RA McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J., RA Donoghue D.J., Thompson L.M., Francomano C.A.; RT "A novel skeletal dysplasia with developmental delay and acanthosis RT nigricans is caused by a Lys650Met mutation in the fibroblast growth factor RT receptor 3 gene."; RL Am. J. Hum. Genet. 64:722-731(1999). RN [13] RP FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF SIGNALING RP PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION, AUTOPHOSPHORYLATION, RP AND CHARACTERIZATION OF VARIANT ACH ARG-380. RX PubMed=10611230; DOI=10.1128/mcb.20.2.516-522.2000; RA Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.; RT "The transmembrane mutation G380R in fibroblast growth factor receptor 3 RT uncouples ligand-mediated receptor activation from down-regulation."; RL Mol. Cell. Biol. 20:516-522(2000). RN [14] RP FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF PIK3R1; RP PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT TYR-724, RP MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND CHARACTERIZATION RP OF VARIANT GLU-650. RX PubMed=11294897; DOI=10.1091/mbc.12.4.931; RA Hart K.C., Robertson S.C., Donoghue D.J.; RT "Identification of tyrosine residues in constitutively activated fibroblast RT growth factor receptor 3 involved in mitogenesis, Stat activation, and RT phosphatidylinositol 3-kinase activation."; RL Mol. Biol. Cell 12:931-942(2001). RN [15] RP UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF RP LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION OF RP VARIANT TD2 GLU-650. RX PubMed=12297284; DOI=10.1016/s0014-5793(02)03255-6; RA Monsonego-Ornan E., Adar R., Rom E., Yayon A.; RT "FGF receptors ubiquitylation: dependence on tyrosine kinase activity and RT role in downregulation."; RL FEBS Lett. 528:83-89(2002). RN [16] RP FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL RP PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF RP VARIANT GLU-650, AND AUTOPHOSPHORYLATION. RX PubMed=14534538; DOI=10.1038/sj.onc.1206798; RA Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.; RT "The phosphotyrosine phosphatase SHP2 is a critical mediator of RT transformation induced by the oncogenic fibroblast growth factor receptor RT 3."; RL Oncogene 22:6909-6918(2003). RN [17] RP INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND RP FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [18] RP INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND MAP RP KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508, AND RP SUBCELLULAR LOCATION. RX PubMed=16410555; DOI=10.1242/jcs.02740; RA Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.; RT "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and RT modulate fibroblast growth factor receptor signaling."; RL J. Cell Sci. 119:380-387(2006). RN [19] RP FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION OF RP PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR LOCATION, RP PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380; GLU-650 AND RP MET-650. RX PubMed=17561467; DOI=10.1016/j.bone.2006.11.030; RA Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y., RA Tanaka H.; RT "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic RT dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via RT PLCgamma-activated STAT1."; RL Bone 41:273-281(2007). RN [20] RP FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION, RP SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND CHARACTERIZATION OF VARIANTS RP CYS-248; CYS-373 AND MET-650. RX PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x; RA Bonaventure J., Horne W.C., Baron R.; RT "The localization of FGFR3 mutations causing thanatophoric dysplasia type I RT differentially affects phosphorylation, processing and ubiquitylation of RT the receptor."; RL FEBS J. 274:3078-3093(2007). RN [21] RP FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT GLU-650, RP ACTIVITY REGULATION, AND CATALYTIC ACTIVITY. RX PubMed=17145761; DOI=10.1074/jbc.m606144200; RA Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H., RA Thompson L.M., Wilcox W.R.; RT "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated RT activation of Erk MAP kinase in chondrocytes by preventing Shp2 association RT with the Frs2 and Gab1 adaptor proteins."; RL J. Biol. Chem. 282:2929-2936(2007). RN [22] RP INTERACTION WITH FGF19; FGF21 AND KLB. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [23] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [24] RP FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE MAP RP KINASE SIGNALING PATHWAY. RX PubMed=19088846; DOI=10.1371/journal.pone.0003961; RA Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A., RA Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.; RT "Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal RT dysplasia undermines dominant role of STAT1 in FGFR3 signaling in RT cartilage."; RL PLoS ONE 3:E3961-E3961(2008). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT RP TYR-760. RX PubMed=19286672; DOI=10.1093/hmg/ddp116; RA Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D., RA Wilcox W.R., Thompson L.M.; RT "A novel interaction between fibroblast growth factor receptor 3 and the RT p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation RT of ERK by p85 in multiple myeloma cells."; RL Hum. Mol. Genet. 18:1951-1961(2009). RN [27] RP REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN DISEASE. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [28] RP REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN; ROLE RP IN DISEASE; UBIQUITINATION AND DEGRADATION. RX PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012; RA L'Hote C.G., Knowles M.A.; RT "Cell responses to FGFR3 signalling: growth, differentiation and RT apoptosis."; RL Exp. Cell Res. 304:417-431(2005). RN [29] RP REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE. RX PubMed=19066716; DOI=10.1007/s00774-008-0009-7; RA Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.; RT "FGFR3-related dwarfism and cell signaling."; RL J. Bone Miner. Metab. 27:9-15(2009). RN [30] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1, RP ACTIVITY REGULATION, AND DOMAIN. RX PubMed=14732692; DOI=10.1073/pnas.0307287101; RA Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., RA Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.; RT "Insights into the molecular basis for fibroblast growth factor receptor RT autoinhibition and ligand-binding promiscuity."; RL Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004). RN [33] RP VARIANT ACH ARG-380. RX PubMed=8078586; DOI=10.1038/371252a0; RA Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M., RA Maroteaux P., le Merrer M., Munnich A.; RT "Mutations in the gene encoding fibroblast growth factor receptor-3 in RT achondroplasia."; RL Nature 371:252-254(1994). RN [34] RP VARIANT ACH ARG-380. RX PubMed=7847369; RA Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A., RA Machado M., Kaitila I., McIntosh I., Francomano C.A.; RT "Achondroplasia is defined by recurrent G380R mutations of FGFR3."; RL Am. J. Hum. Genet. 56:368-373(1995). RN [35] RP VARIANT ACH CYS-375. RX PubMed=7758520; DOI=10.1007/bf01954274; RA Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A., RA Gitzelmann R., Steinmann B.; RT "A glycine 375-to-cysteine substitution in the transmembrane domain of the RT fibroblast growth factor receptor-3 in a newborn with achondroplasia."; RL Eur. J. Pediatr. 154:215-219(1995). RN [36] RP VARIANT TD1 CYS-249. RX PubMed=8589699; DOI=10.1093/hmg/4.11.2175; RA Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R., Wasmuth J.J.; RT "Another mutation that results in the substitution of an unpaired cysteine RT residue in the extracellular domain of FGFR3 in thanatophoric dysplasia RT type I."; RL Hum. Mol. Genet. 4:2175-2177(1995). RN [37] RP VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650. RX PubMed=7773297; DOI=10.1038/ng0395-321; RA Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J., RA Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.; RT "Thanatophoric dysplasia (types I and II) caused by distinct mutations in RT fibroblast growth factor receptor 3."; RL Nat. Genet. 9:321-328(1995). RN [38] RP VARIANT HYPOCHONDROPLASIA LYS-540. RX PubMed=7670477; DOI=10.1038/ng0795-357; RA Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I., RA Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.; RT "A recurrent mutation in the tyrosine kinase domain of fibroblast growth RT factor receptor 3 causes hypochondroplasia."; RL Nat. Genet. 10:357-359(1995). RN [39] RP VARIANT CAN GLU-391. RX PubMed=7493034; DOI=10.1038/ng1295-462; RA Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.; RT "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in RT Crouzon syndrome with acanthosis nigricans."; RL Nat. Genet. 11:462-464(1995). RN [40] RP CHARACTERIZATION OF VARIANT ACH ARG-380. RX PubMed=8599935; DOI=10.1002/j.1460-2075.1996.tb00384.x; RA Webster M.K., Donoghue D.J.; RT "Constitutive activation of fibroblast growth factor receptor 3 by the RT transmembrane domain point mutation found in achondroplasia."; RL EMBO J. 15:520-527(1996). RN [41] RP VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373. RX PubMed=8845844; DOI=10.1093/hmg/5.4.509; RA Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L., RA le Merrer M., Munnich A., Bonaventure J.; RT "Missense FGFR3 mutations create cysteine residues in thanatophoric RT dwarfism type I (TD1)."; RL Hum. Mol. Genet. 5:509-512(1996). RN [42] RP CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT RP GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648. RX PubMed=8754806; DOI=10.1128/mcb.16.8.4081; RA Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.; RT "Profound ligand-independent kinase activation of fibroblast growth factor RT receptor 3 by the activation loop mutation responsible for a lethal RT skeletal dysplasia, thanatophoric dysplasia type II."; RL Mol. Cell. Biol. 16:4081-4087(1996). RN [43] RP VARIANT MNKS ARG-250. RX PubMed=9042914; RA Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K., Whitaker L.A., RA Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J., RA Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A., RA Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M. Jr., Bellus G.A., RA Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.; RT "A unique point mutation in the fibroblast growth factor receptor 3 gene RT (FGFR3) defines a new craniosynostosis syndrome."; RL Am. J. Hum. Genet. 60:555-564(1997). RN [44] RP INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND MET-650. RX PubMed=9207791; DOI=10.1038/ng0797-260; RA Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M., RA Bergsagel P.L.; RT "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is RT associated with increased expression and activating mutations of fibroblast RT growth factor receptor 3."; RL Nat. Genet. 16:260-264(1997). RN [45] RP VARIANT TD1 CYS-370. RX PubMed=9790257; DOI=10.1507/endocrj.45.suppl_s171; RA Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A., RA Nimura A., Horikawa R., Tanaka T.; RT "G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric RT dysplasia."; RL Endocr. J. 45:S171-S174(1998). RN [46] RP VARIANT HYPOCHONDROPLASIA VAL-538. RX PubMed=10215410; RX DOI=10.1002/(sici)1098-1004(1998)11:4<333::aid-humu18>3.0.co;2-g; RA Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E., RA Anvret M.; RT "A novel missense mutation Ile538Val in the fibroblast growth factor RT receptor 3 in hypochondroplasia."; RL Hum. Mutat. 11:333-333(1998). RN [47] RP VARIANT HYPOCHONDROPLASIA THR-540. RX PubMed=9452043; DOI=10.1002/humu.1380110122; RA Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M., Bakker E.; RT "Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine RT kinase domain causing hypochondroplasia."; RL Hum. Mutat. Suppl. 1:S62-S65(1998). RN [48] RP VARIANT TD1 MET-650. RX PubMed=10671061; RA Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.; RT "Lys650Met substitution in the tyrosine kinase domain of the fibroblast RT growth factor receptor gene causes thanatophoric dysplasia type I."; RL Hum. Mutat. 12:362-363(1998). RN [49] RP VARIANT ARG-250. RX PubMed=9525367; DOI=10.1016/s0140-6736(98)24012-8; RA Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J., RA Mulley J.C.; RT "Deafness due to Pro250Arg mutation of FGFR3."; RL Lancet 351:877-878(1998). RN [50] RP VARIANTS TD1 CYS-248; CYS-249 AND CYS-373. RX PubMed=10360402; RX DOI=10.1002/(sici)1096-8628(19990611)84:5<476::aid-ajmg12>3.3.co;2-o; RA Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B., RA Wilcox W.R.; RT "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by RT FGFR3 mutations."; RL Am. J. Med. Genet. 84:476-480(1999). RN [51] RP VARIANT MNKS ARG-250. RX PubMed=9950359; RA Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J., RA Renier D.; RT "Sex related expressivity of the phenotype in coronal craniosynostosis RT caused by the recurrent P250R FGFR3 mutation."; RL J. Med. Genet. 36:9-13(1999). RN [52] RP VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA RP CYS-248; CYS-249; CYS-370 AND GLU-650. RX PubMed=10471491; DOI=10.1038/12615; RA Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S., Bourdin J., RA Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.; RT "Frequent activating mutations of FGFR3 in human bladder and cervix RT carcinomas."; RL Nat. Genet. 23:18-20(1999). RN [53] RP VARIANT HYPOCHONDROPLASIA GLN-650. RX PubMed=11055896; DOI=10.1086/316892; RA Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T., RA Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J., RA Francomano C.A.; RT "Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor RT kinase activation and the severity of the skeletal dysplasia phenotype."; RL Am. J. Hum. Genet. 67:1411-1421(2000). RN [54] RP VARIANT HYPOCHONDROPLASIA SER-540. RX PubMed=10777366; DOI=10.1136/jmg.37.3.220; RA Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G., De Paepe A.; RT "Clinical and radiographic features of a family with hypochondroplasia RT owing to a novel asn540ser mutation in the fibroblast growth factor RT receptor 3 gene."; RL J. Med. Genet. 37:220-224(2000). RN [55] RP VARIANT MNKS ARG-250. RX PubMed=11746040; DOI=10.1002/ajmg.10049; RA Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.; RT "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel RT shoulder with and without Pro250Arg mutation in the FGFR3 gene."; RL Am. J. Med. Genet. 104:112-119(2001). RN [56] RP INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248. RX PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x; RA Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T., RA Neri A.; RT "Analysis of FGFR3 gene mutations in multiple myeloma patients with RT t(4;14)."; RL Br. J. Haematol. 114:362-364(2001). RN [57] RP VARIANT COLORECTAL CANCER LYS-322. RX PubMed=11325814; RA Jang J.-H., Shin K.-H., Park J.-G.; RT "Mutations in fibroblast growth factor receptor 2 and fibroblast growth RT factor receptor 3 genes associated with human gastric and colorectal RT cancers."; RL Cancer Res. 61:3541-3543(2001). RN [58] RP VARIANT BLC CANCER GLN-650. RX PubMed=11314002; DOI=10.1038/sj.onc.1204110; RA Sibley K., Cuthbert-Heavens D., Knowles M.A.; RT "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional RT cell carcinoma."; RL Oncogene 20:686-691(2001). RN [59] RP VARIANT HYPOCHONDROPLASIA SER-540. RX PubMed=12707965; DOI=10.1002/ajmg.a.10238; RA Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V., Francois C., RA Huet F., Couailler J.-F., Campos-Xavier A.B., Bonaventure J., Le Merrer M.; RT "Hypochondroplasia and stature within normal limits: another family with an RT Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene."; RL Am. J. Med. Genet. A 119:81-84(2003). RN [60] RP VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650 AND RP MET-650. RX PubMed=15772091; DOI=10.1093/hmg/ddi127; RA Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., RA Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., RA Radvanyi F.; RT "Activating mutations of the tyrosine kinase receptor FGFR3 are associated RT with benign skin tumors in mice and humans."; RL Hum. Mol. Genet. 14:1153-1160(2005). RN [61] RP VARIANT CATSHLS HIS-621. RX PubMed=17033969; DOI=10.1086/508433; RA Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A., RA Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C., RA Bamshad M.J.; RT "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing RT loss (CATSHL) syndrome."; RL Am. J. Hum. Genet. 79:935-941(2006). RN [62] RP VARIANTS KNEN CYS-248; CYS-370 AND ARG-380. RX PubMed=16841094; DOI=10.1172/jci28163; RA Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H., RA Hofstaedter F., Zwarthoff E.C., Hartmann A.; RT "Mosaicism of activating FGFR3 mutations in human skin causes epidermal RT nevi."; RL J. Clin. Invest. 116:2201-2207(2006). RN [63] RP VARIANT LADD2 ASN-513, AND INVOLVEMENT IN LADD2. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [64] RP VARIANT CAN GLU-391. RX PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x; RA Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.; RT "Crouzon with acanthosis nigricans. Further delineation of the syndrome."; RL Clin. Genet. 72:405-410(2007). RN [65] RP VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646 RP AND GLU-650. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [66] RP VARIANT TGCT GLU-650. RX PubMed=19855393; DOI=10.1038/ng.470; RA Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., RA McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E., Wilkie A.O.; RT "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for RT congenital disorders and testicular tumors."; RL Nat. Genet. 41:1247-1252(2009). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation and apoptosis. Plays CC an essential role in the regulation of chondrocyte differentiation, CC proliferation and apoptosis, and is required for normal skeleton CC development. Regulates both osteogenesis and postnatal bone CC mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but CC can also promote cancer cell proliferation. Required for normal CC development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. CC Ligand binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC Plays a role in the regulation of vitamin D metabolism. Mutations that CC lead to constitutive kinase activation or impair normal FGFR3 CC maturation, internalization and degradation lead to aberrant signaling. CC Over-expressed or constitutively activated FGFR3 promotes activation of CC PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its CC capacity to bind FGF1 and FGF2 and hence may interfere with FGF CC signaling. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897, CC ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538, CC ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, CC ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, CC ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17145761}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by SU5402. CC {ECO:0000269|PubMed:14732692, ECO:0000269|PubMed:17145761, CC ECO:0000269|PubMed:17509076}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1, CC FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19, FGF20 and CC FGF23 (in vitro). Interacts with KLB. Affinity for fibroblast growth CC factors (FGFs) is increased by heparan sulfate glycosaminoglycans that CC function as coreceptors. Likewise, KLB increases the affinity for FGF19 CC and FGF21. Interacts with PIK3R1, PLCG1, SOCS1 and SOCS3. Isoform 3 CC forms disulfide-linked dimers. {ECO:0000269|PubMed:10611230, CC ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14732692, CC ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, CC ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:17623664, CC ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:8663044}. CC -!- INTERACTION: CC P22607; Q6H8Q1-8: ABLIM2; NbExp=3; IntAct=EBI-348399, EBI-16436655; CC P22607; Q8NC06-3: ACBD4; NbExp=3; IntAct=EBI-348399, EBI-12811089; CC P22607; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-348399, EBI-10173507; CC P22607; Q8N302-2: AGGF1; NbExp=3; IntAct=EBI-348399, EBI-25838028; CC P22607; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-348399, EBI-528269; CC P22607; P55008: AIF1; NbExp=3; IntAct=EBI-348399, EBI-9031341; CC P22607; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-348399, EBI-11022349; CC P22607; Q9NQ31: AKIP1; NbExp=3; IntAct=EBI-348399, EBI-517035; CC P22607; P53677-2: AP3M2; NbExp=3; IntAct=EBI-348399, EBI-12177015; CC P22607; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-348399, EBI-18172597; CC P22607; Q9Y2Y0: ARL2BP; NbExp=3; IntAct=EBI-348399, EBI-3449344; CC P22607; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-348399, EBI-5280499; CC P22607; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-348399, EBI-10254793; CC P22607; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-348399, EBI-9089489; CC P22607; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-348399, EBI-718459; CC P22607; Q9ULK2-2: ATXN7L1; NbExp=3; IntAct=EBI-348399, EBI-21568482; CC P22607; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-348399, EBI-10693257; CC P22607; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-348399, EBI-742750; CC P22607; Q9UQB8-6: BAIAP2; NbExp=3; IntAct=EBI-348399, EBI-9092016; CC P22607; Q16520: BATF; NbExp=3; IntAct=EBI-348399, EBI-749503; CC P22607; P54687-4: BCAT1; NbExp=3; IntAct=EBI-348399, EBI-25834445; CC P22607; Q00994: BEX3; NbExp=3; IntAct=EBI-348399, EBI-741753; CC P22607; Q5H9J7: BEX5; NbExp=3; IntAct=EBI-348399, EBI-10243741; CC P22607; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-348399, EBI-2548012; CC P22607; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-348399, EBI-5666615; CC P22607; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-348399, EBI-23662416; CC P22607; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-348399, EBI-10693038; CC P22607; Q6P5X5: C22orf39; NbExp=3; IntAct=EBI-348399, EBI-7317823; CC P22607; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-348399, EBI-18036948; CC P22607; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-348399, EBI-751596; CC P22607; P20807-4: CAPN3; NbExp=3; IntAct=EBI-348399, EBI-11532021; CC P22607; O00257-3: CBX4; NbExp=3; IntAct=EBI-348399, EBI-4392727; CC P22607; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-348399, EBI-744556; CC P22607; Q6ZP82-1: CCDC141; NbExp=3; IntAct=EBI-348399, EBI-49119542; CC P22607; Q5M9N0-2: CCDC158; NbExp=3; IntAct=EBI-348399, EBI-21796846; CC P22607; Q16543: CDC37; NbExp=4; IntAct=EBI-348399, EBI-295634; CC P22607; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-348399, EBI-9091443; CC P22607; P24941: CDK2; NbExp=3; IntAct=EBI-348399, EBI-375096; CC P22607; O14519: CDK2AP1; NbExp=3; IntAct=EBI-348399, EBI-1052532; CC P22607; P38936: CDKN1A; NbExp=3; IntAct=EBI-348399, EBI-375077; CC P22607; O95674: CDS2; NbExp=4; IntAct=EBI-348399, EBI-3913685; CC P22607; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-348399, EBI-1003700; CC P22607; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-348399, EBI-12950757; CC P22607; Q86XR8: CEP57; NbExp=3; IntAct=EBI-348399, EBI-308614; CC P22607; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-348399, EBI-11953200; CC P22607; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-348399, EBI-749253; CC P22607; Q9H2A9: CHST8; NbExp=3; IntAct=EBI-348399, EBI-21642354; CC P22607; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-348399, EBI-744045; CC P22607; Q3SX64: CIMAP1D; NbExp=3; IntAct=EBI-348399, EBI-6660184; CC P22607; Q96BR5: COA7; NbExp=3; IntAct=EBI-348399, EBI-6269632; CC P22607; P02458-1: COL2A1; NbExp=3; IntAct=EBI-348399, EBI-12375799; CC P22607; P21964-2: COMT; NbExp=3; IntAct=EBI-348399, EBI-10200977; CC P22607; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-348399, EBI-10260134; CC P22607; Q03060-25: CREM; NbExp=3; IntAct=EBI-348399, EBI-12884642; CC P22607; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-348399, EBI-12024320; CC P22607; O60759: CYTIP; NbExp=3; IntAct=EBI-348399, EBI-997814; CC P22607; Q9UJU6: DBNL; NbExp=3; IntAct=EBI-348399, EBI-751783; CC P22607; Q6ZN54-2: DEF8; NbExp=3; IntAct=EBI-348399, EBI-12346463; CC P22607; Q8NDP9: DKFZp547K2416; NbExp=3; IntAct=EBI-348399, EBI-25842538; CC P22607; O60479: DLX3; NbExp=3; IntAct=EBI-348399, EBI-3908248; CC P22607; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-348399, EBI-11526226; CC P22607; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-348399, EBI-2795449; CC P22607; Q92782-2: DPF1; NbExp=3; IntAct=EBI-348399, EBI-23669343; CC P22607; Q7Z7J5: DPPA2; NbExp=3; IntAct=EBI-348399, EBI-741400; CC P22607; Q14117: DPYS; NbExp=3; IntAct=EBI-348399, EBI-12275416; CC P22607; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-348399, EBI-724653; CC P22607; Q9BVC3: DSCC1; NbExp=3; IntAct=EBI-348399, EBI-11143782; CC P22607; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-348399, EBI-3443946; CC P22607; O14641: DVL2; NbExp=3; IntAct=EBI-348399, EBI-740850; CC P22607; A0AVK6: E2F8; NbExp=3; IntAct=EBI-348399, EBI-7779316; CC P22607; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-348399, EBI-10248874; CC P22607; Q6UXG2-3: ELAPOR1; NbExp=3; IntAct=EBI-348399, EBI-12920100; CC P22607; O00472: ELL2; NbExp=3; IntAct=EBI-348399, EBI-395274; CC P22607; O43768-8: ENSA; NbExp=3; IntAct=EBI-348399, EBI-25853109; CC P22607; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-348399, EBI-10213520; CC P22607; Q15910-2: EZH2; NbExp=3; IntAct=EBI-348399, EBI-10699473; CC P22607; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-348399, EBI-11793142; CC P22607; A1KXE4-2: FAM168B; NbExp=3; IntAct=EBI-348399, EBI-12193763; CC P22607; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-348399, EBI-9917523; CC P22607; Q86UY5: FAM83A; NbExp=3; IntAct=EBI-348399, EBI-1384254; CC P22607; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-348399, EBI-8468186; CC P22607; Q8TC84: FANK1; NbExp=3; IntAct=EBI-348399, EBI-21975404; CC P22607; Q9UBX5: FBLN5; NbExp=3; IntAct=EBI-348399, EBI-947897; CC P22607; Q9Y3I1: FBXO7; NbExp=3; IntAct=EBI-348399, EBI-1161222; CC P22607; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-348399, EBI-11958845; CC P22607; P05230: FGF1; NbExp=3; IntAct=EBI-348399, EBI-698068; CC P22607; P22607: FGFR3; NbExp=4; IntAct=EBI-348399, EBI-348399; CC P22607; P15407: FOSL1; NbExp=3; IntAct=EBI-348399, EBI-744510; CC P22607; P15408: FOSL2; NbExp=3; IntAct=EBI-348399, EBI-3893419; CC P22607; P55318: FOXA3; NbExp=3; IntAct=EBI-348399, EBI-3910364; CC P22607; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-618189; CC P22607; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-9088619; CC P22607; P15976-2: GATA1; NbExp=3; IntAct=EBI-348399, EBI-9090198; CC P22607; P23769-2: GATA2; NbExp=3; IntAct=EBI-348399, EBI-21856389; CC P22607; P23771: GATA3; NbExp=3; IntAct=EBI-348399, EBI-6664760; CC P22607; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-348399, EBI-12143817; CC P22607; Q7Z5G4: GOLGA7; NbExp=3; IntAct=EBI-348399, EBI-4403685; CC P22607; Q9NWQ4-1: GPATCH2L; NbExp=3; IntAct=EBI-348399, EBI-11959863; CC P22607; P52655: GTF2A1; NbExp=3; IntAct=EBI-348399, EBI-389518; CC P22607; Q15486: GUSBP1; NbExp=4; IntAct=EBI-348399, EBI-712457; CC P22607; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-348399, EBI-2514791; CC P22607; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-348399, EBI-2558143; CC P22607; Q99075: HBEGF; NbExp=3; IntAct=EBI-348399, EBI-7211558; CC P22607; A8K0U2: hCG_2001421; NbExp=3; IntAct=EBI-348399, EBI-25843825; CC P22607; Q5T447-2: HECTD3; NbExp=3; IntAct=EBI-348399, EBI-25854793; CC P22607; Q8IV36: HID1; NbExp=3; IntAct=EBI-348399, EBI-743438; CC P22607; Q4VB01: HOXB1; NbExp=3; IntAct=EBI-348399, EBI-17494170; CC P22607; P09629: HOXB7; NbExp=3; IntAct=EBI-348399, EBI-1248457; CC P22607; O43248: HOXC11; NbExp=3; IntAct=EBI-348399, EBI-2652631; CC P22607; Q53T59: HS1BP3; NbExp=3; IntAct=EBI-348399, EBI-11335623; CC P22607; Q53GQ0: HSD17B12; NbExp=4; IntAct=EBI-348399, EBI-2963255; CC P22607; P14060: HSD3B1; NbExp=3; IntAct=EBI-348399, EBI-17426018; CC P22607; P08238: HSP90AB1; NbExp=4; IntAct=EBI-348399, EBI-352572; CC P22607; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-348399, EBI-25835621; CC P22607; P10809: HSPD1; NbExp=3; IntAct=EBI-348399, EBI-352528; CC P22607; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-348399, EBI-12141931; CC P22607; P41134: ID1; NbExp=3; IntAct=EBI-348399, EBI-1215527; CC P22607; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-348399, EBI-11742277; CC P22607; P22692: IGFBP4; NbExp=3; IntAct=EBI-348399, EBI-2831948; CC P22607; Q9NP60: IL1RAPL2; NbExp=3; IntAct=EBI-348399, EBI-20865879; CC P22607; Q9NZH6: IL37; NbExp=3; IntAct=EBI-348399, EBI-3862125; CC P22607; Q9NXX0: ILF3; NbExp=3; IntAct=EBI-348399, EBI-743980; CC P22607; Q86VI3: IQGAP3; NbExp=3; IntAct=EBI-348399, EBI-1237354; CC P22607; Q8NA54: IQUB; NbExp=3; IntAct=EBI-348399, EBI-10220600; CC P22607; Q86U28: ISCA2; NbExp=3; IntAct=EBI-348399, EBI-10258659; CC P22607; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-348399, EBI-712105; CC P22607; P05412: JUN; NbExp=3; IntAct=EBI-348399, EBI-852823; CC P22607; P17275: JUNB; NbExp=3; IntAct=EBI-348399, EBI-748062; CC P22607; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-348399, EBI-743960; CC P22607; Q7Z7F0-4: KHDC4; NbExp=3; IntAct=EBI-348399, EBI-9089060; CC P22607; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-348399, EBI-14069005; CC P22607; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-348399, EBI-2554344; CC P22607; Q6P597: KLC3; NbExp=3; IntAct=EBI-348399, EBI-1643885; CC P22607; P57682: KLF3; NbExp=3; IntAct=EBI-348399, EBI-8472267; CC P22607; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-348399, EBI-714379; CC P22607; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-348399, EBI-8524663; CC P22607; P08727: KRT19; NbExp=3; IntAct=EBI-348399, EBI-742756; CC P22607; Q14525: KRT33B; NbExp=3; IntAct=EBI-348399, EBI-1049638; CC P22607; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-348399, EBI-1048945; CC P22607; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-348399, EBI-10241353; CC P22607; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-348399, EBI-10261141; CC P22607; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-348399, EBI-715385; CC P22607; O43504: LAMTOR5; NbExp=3; IntAct=EBI-348399, EBI-713382; CC P22607; Q14847-2: LASP1; NbExp=3; IntAct=EBI-348399, EBI-9088686; CC P22607; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-348399, EBI-25835523; CC P22607; Q68G74: LHX8; NbExp=3; IntAct=EBI-348399, EBI-8474075; CC P22607; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-348399, EBI-10264791; CC P22607; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-348399, EBI-2510853; CC P22607; Q96JB6: LOXL4; NbExp=3; IntAct=EBI-348399, EBI-749562; CC P22607; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-348399, EBI-741355; CC P22607; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-348399, EBI-21916939; CC P22607; P27338: MAOB; NbExp=3; IntAct=EBI-348399, EBI-3911344; CC P22607; Q9GZQ8: MAP1LC3B; NbExp=3; IntAct=EBI-348399, EBI-373144; CC P22607; Q15759: MAPK11; NbExp=3; IntAct=EBI-348399, EBI-298304; CC P22607; Q9NS73-5: MBIP; NbExp=3; IntAct=EBI-348399, EBI-10182361; CC P22607; P33993-2: MCM7; NbExp=3; IntAct=EBI-348399, EBI-11741465; CC P22607; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-348399, EBI-348259; CC P22607; Q9HAF1: MEAF6; NbExp=3; IntAct=EBI-348399, EBI-399266; CC P22607; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-348399, EBI-25851300; CC P22607; Q53S70: MGC4677; NbExp=3; IntAct=EBI-348399, EBI-10242717; CC P22607; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-348399, EBI-2801965; CC P22607; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-348399, EBI-25835557; CC P22607; Q00013: MPP1; NbExp=3; IntAct=EBI-348399, EBI-711788; CC P22607; Q8TCY5: MRAP; NbExp=3; IntAct=EBI-348399, EBI-9538727; CC P22607; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-348399, EBI-25835707; CC P22607; O60783: MRPS14; NbExp=3; IntAct=EBI-348399, EBI-1045956; CC P22607; Q96H12: MSANTD3; NbExp=3; IntAct=EBI-348399, EBI-8466227; CC P22607; P01106: MYC; NbExp=3; IntAct=EBI-348399, EBI-447544; CC P22607; Q9NPC6: MYOZ2; NbExp=3; IntAct=EBI-348399, EBI-746712; CC P22607; P41271-2: NBL1; NbExp=3; IntAct=EBI-348399, EBI-12135485; CC P22607; P14598: NCF1; NbExp=3; IntAct=EBI-348399, EBI-395044; CC P22607; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-348399, EBI-928842; CC P22607; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-348399, EBI-25852289; CC P22607; Q16621: NFE2; NbExp=3; IntAct=EBI-348399, EBI-726369; CC P22607; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-348399, EBI-718372; CC P22607; Q99743: NPAS2; NbExp=3; IntAct=EBI-348399, EBI-3932727; CC P22607; Q14995: NR1D2; NbExp=3; IntAct=EBI-348399, EBI-6144053; CC P22607; F1D8P7: NR1H2; NbExp=3; IntAct=EBI-348399, EBI-10177172; CC P22607; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-348399, EBI-2802743; CC P22607; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-348399, EBI-22002759; CC P22607; Q96MF7: NSMCE2; NbExp=3; IntAct=EBI-348399, EBI-2557388; CC P22607; Q4KMX9: OBSCN; NbExp=3; IntAct=EBI-348399, EBI-10490715; CC P22607; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-348399, EBI-8466445; CC P22607; Q5BJF6-2: ODF2; NbExp=3; IntAct=EBI-348399, EBI-9090919; CC P22607; O43482: OIP5; NbExp=3; IntAct=EBI-348399, EBI-536879; CC P22607; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-348399, EBI-25830200; CC P22607; Q8IVL6-2: P3H3; NbExp=3; IntAct=EBI-348399, EBI-12149899; CC P22607; Q9H8K7: PAAT; NbExp=3; IntAct=EBI-348399, EBI-714785; CC P22607; Q8N3R9: PALS1; NbExp=3; IntAct=EBI-348399, EBI-2513978; CC P22607; Q495U3: PANX2; NbExp=3; IntAct=EBI-348399, EBI-17242559; CC P22607; Q9NR21-5: PARP11; NbExp=3; IntAct=EBI-348399, EBI-17159452; CC P22607; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-348399, EBI-22012354; CC P22607; Q5VU43-8: PDE4DIP; NbExp=3; IntAct=EBI-348399, EBI-25837868; CC P22607; Q13956: PDE6H; NbExp=3; IntAct=EBI-348399, EBI-10231995; CC P22607; O15534: PER1; NbExp=3; IntAct=EBI-348399, EBI-2557276; CC P22607; O15212: PFDN6; NbExp=3; IntAct=EBI-348399, EBI-356973; CC P22607; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-348399, EBI-722852; CC P22607; P14618: PKM; NbExp=3; IntAct=EBI-348399, EBI-353408; CC P22607; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-348399, EBI-311059; CC P22607; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-348399, EBI-12891828; CC P22607; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-348399, EBI-26412802; CC P22607; Q96T60: PNKP; NbExp=3; IntAct=EBI-348399, EBI-1045072; CC P22607; P19388: POLR2E; NbExp=3; IntAct=EBI-348399, EBI-395189; CC P22607; Q07869: PPARA; NbExp=3; IntAct=EBI-348399, EBI-78615; CC P22607; Q9UNP9: PPIE; NbExp=3; IntAct=EBI-348399, EBI-591818; CC P22607; O60927: PPP1R11; NbExp=3; IntAct=EBI-348399, EBI-1048104; CC P22607; O60237-2: PPP1R12B; NbExp=3; IntAct=EBI-348399, EBI-10700351; CC P22607; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-348399, EBI-710402; CC P22607; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-348399, EBI-25835994; CC P22607; O43741: PRKAB2; NbExp=3; IntAct=EBI-348399, EBI-1053424; CC P22607; O60260-5: PRKN; NbExp=3; IntAct=EBI-348399, EBI-21251460; CC P22607; Q86UA1: PRPF39; NbExp=3; IntAct=EBI-348399, EBI-2803203; CC P22607; P62333: PSMC6; NbExp=3; IntAct=EBI-348399, EBI-357669; CC P22607; Q06323: PSME1; NbExp=3; IntAct=EBI-348399, EBI-712149; CC P22607; P06454-2: PTMA; NbExp=3; IntAct=EBI-348399, EBI-10194874; CC P22607; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-348399, EBI-25835884; CC P22607; Q9UNT1-2: RABL2B; NbExp=3; IntAct=EBI-348399, EBI-12256104; CC P22607; Q15311: RALBP1; NbExp=3; IntAct=EBI-348399, EBI-749285; CC P22607; Q9HD47-3: RANGRF; NbExp=3; IntAct=EBI-348399, EBI-9089733; CC P22607; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-348399, EBI-438710; CC P22607; Q9NWB1-5: RBFOX1; NbExp=3; IntAct=EBI-348399, EBI-12123390; CC P22607; Q9BWF3: RBM4; NbExp=3; IntAct=EBI-348399, EBI-2856454; CC P22607; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-348399, EBI-12068216; CC P22607; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-348399, EBI-1504830; CC P22607; Q04206: RELA; NbExp=3; IntAct=EBI-348399, EBI-73886; CC P22607; P47804-3: RGR; NbExp=3; IntAct=EBI-348399, EBI-25834767; CC P22607; Q15382: RHEB; NbExp=3; IntAct=EBI-348399, EBI-1055287; CC P22607; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-348399, EBI-21890191; CC P22607; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-348399, EBI-749039; CC P22607; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-348399, EBI-751555; CC P22607; P62899: RPL31; NbExp=3; IntAct=EBI-348399, EBI-1053664; CC P22607; P62244: RPS15A; NbExp=3; IntAct=EBI-348399, EBI-347895; CC P22607; P62701: RPS4X; NbExp=3; IntAct=EBI-348399, EBI-354303; CC P22607; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-348399, EBI-10248967; CC P22607; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-348399, EBI-25837959; CC P22607; Q86SQ7-2: SDCCAG8; NbExp=3; IntAct=EBI-348399, EBI-10696955; CC P22607; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-348399, EBI-9089805; CC P22607; Q13435: SF3B2; NbExp=3; IntAct=EBI-348399, EBI-749111; CC P22607; O60902-3: SHOX2; NbExp=3; IntAct=EBI-348399, EBI-9092164; CC P22607; Q9NSD5-3: SLC6A13; NbExp=3; IntAct=EBI-348399, EBI-25831241; CC P22607; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-348399, EBI-13292283; CC P22607; Q12824: SMARCB1; NbExp=3; IntAct=EBI-348399, EBI-358419; CC P22607; Q13573: SNW1; NbExp=3; IntAct=EBI-348399, EBI-632715; CC P22607; O14544: SOCS6; NbExp=3; IntAct=EBI-348399, EBI-3929549; CC P22607; Q02086-2: SP2; NbExp=3; IntAct=EBI-348399, EBI-9088579; CC P22607; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-348399, EBI-10696971; CC P22607; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-348399, EBI-12041693; CC P22607; Q496A3: SPATS1; NbExp=3; IntAct=EBI-348399, EBI-3923692; CC P22607; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-348399, EBI-7082156; CC P22607; Q9C004: SPRY4; NbExp=3; IntAct=EBI-348399, EBI-354861; CC P22607; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-348399, EBI-12408727; CC P22607; Q99469: STAC; NbExp=3; IntAct=EBI-348399, EBI-2652799; CC P22607; Q92783-2: STAM; NbExp=3; IntAct=EBI-348399, EBI-12025738; CC P22607; O75886: STAM2; NbExp=3; IntAct=EBI-348399, EBI-373258; CC P22607; Q13586: STIM1; NbExp=4; IntAct=EBI-348399, EBI-448878; CC P22607; Q8N4C7: STX19; NbExp=3; IntAct=EBI-348399, EBI-8484990; CC P22607; Q15814: TBCC; NbExp=3; IntAct=EBI-348399, EBI-15695297; CC P22607; O15273: TCAP; NbExp=3; IntAct=EBI-348399, EBI-954089; CC P22607; Q86WV5: TEN1; NbExp=3; IntAct=EBI-348399, EBI-2562799; CC P22607; Q96A09: TENT5B; NbExp=3; IntAct=EBI-348399, EBI-752030; CC P22607; P54274-2: TERF1; NbExp=3; IntAct=EBI-348399, EBI-711018; CC P22607; Q6N021: TET2; NbExp=3; IntAct=EBI-348399, EBI-310727; CC P22607; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-348399, EBI-12090309; CC P22607; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-348399, EBI-12833746; CC P22607; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-348399, EBI-17438286; CC P22607; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-348399, EBI-7684443; CC P22607; O60830: TIMM17B; NbExp=3; IntAct=EBI-348399, EBI-2372529; CC P22607; Q9BZW5-2: TM6SF1; NbExp=3; IntAct=EBI-348399, EBI-25852210; CC P22607; Q96B77: TMEM186; NbExp=3; IntAct=EBI-348399, EBI-9089409; CC P22607; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-348399, EBI-25830583; CC P22607; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-348399, EBI-10242677; CC P22607; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-348399, EBI-1390168; CC P22607; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-348399, EBI-9089156; CC P22607; Q71RG4-4: TMUB2; NbExp=3; IntAct=EBI-348399, EBI-25831574; CC P22607; P50616: TOB1; NbExp=3; IntAct=EBI-348399, EBI-723281; CC P22607; Q9H496: TOR1AIP2; NbExp=3; IntAct=EBI-348399, EBI-2510146; CC P22607; P36406: TRIM23; NbExp=3; IntAct=EBI-348399, EBI-740098; CC P22607; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-348399, EBI-17716262; CC P22607; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-348399, EBI-11525489; CC P22607; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-348399, EBI-739485; CC P22607; Q99598: TSNAX; NbExp=3; IntAct=EBI-348399, EBI-21353855; CC P22607; O60636: TSPAN2; NbExp=3; IntAct=EBI-348399, EBI-3914288; CC P22607; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-348399, EBI-8656864; CC P22607; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-348399, EBI-10964469; CC P22607; P49459: UBE2A; NbExp=3; IntAct=EBI-348399, EBI-2339348; CC P22607; Q13404: UBE2V1; NbExp=3; IntAct=EBI-348399, EBI-1050671; CC P22607; P11441: UBL4A; NbExp=3; IntAct=EBI-348399, EBI-356983; CC P22607; Q9HA47-2: UCK1; NbExp=3; IntAct=EBI-348399, EBI-16434682; CC P22607; P22415: USF1; NbExp=3; IntAct=EBI-348399, EBI-1054489; CC P22607; Q495M9: USH1G; NbExp=3; IntAct=EBI-348399, EBI-8601749; CC P22607; Q9H270: VPS11; NbExp=3; IntAct=EBI-348399, EBI-373380; CC P22607; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-348399, EBI-2850578; CC P22607; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-348399, EBI-25835297; CC P22607; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-348399, EBI-10316321; CC P22607; Q8TBZ3-3: WDR20; NbExp=3; IntAct=EBI-348399, EBI-9089370; CC P22607; O00755: WNT7A; NbExp=3; IntAct=EBI-348399, EBI-727198; CC P22607; P19544-6: WT1; NbExp=3; IntAct=EBI-348399, EBI-11745701; CC P22607; O43829: ZBTB14; NbExp=3; IntAct=EBI-348399, EBI-10176632; CC P22607; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-348399, EBI-14104088; CC P22607; Q9NP64: ZCCHC17; NbExp=3; IntAct=EBI-348399, EBI-746345; CC P22607; Q8WUU4: ZNF296; NbExp=3; IntAct=EBI-348399, EBI-8834821; CC P22607; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-348399, EBI-25835852; CC P22607; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-348399, EBI-8489702; CC P22607; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-348399, EBI-745520; CC P22607; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-348399, EBI-18036029; CC P22607; B7Z3E8; NbExp=3; IntAct=EBI-348399, EBI-25831617; CC P22607; Q7L8T7; NbExp=3; IntAct=EBI-348399, EBI-25831943; CC P22607; Q7Z637; NbExp=3; IntAct=EBI-348399, EBI-25831475; CC P22607; Q86V28; NbExp=3; IntAct=EBI-348399, EBI-10259496; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The CC activated receptor is rapidly internalized and degraded. Detected in CC intracellular vesicles after internalization of the autophosphorylated CC receptor. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane {ECO:0000250}; Single- CC pass type I membrane protein {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane {ECO:0000250}; Single- CC pass type I membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=IIIc; CC IsoId=P22607-1; Sequence=Displayed; CC Name=2; Synonyms=IIIb; CC IsoId=P22607-2; Sequence=VSP_002988; CC Name=3; Synonyms=FGFR3deltaTM; CC IsoId=P22607-3; Sequence=VSP_002989; CC Name=4; CC IsoId=P22607-4; Sequence=VSP_040945; CC -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very low or CC no expression in spleen, heart, and muscle. In 20- to 22-week old CC fetuses it is expressed at high level in kidney, lung, small intestine CC and brain, and to a lower degree in spleen, liver, and muscle. Isoform CC 2 is detected in epithelial cells. Isoform 1 is not detected in CC epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic CC cells. {ECO:0000269|PubMed:1664411}. CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC {ECO:0000269|PubMed:14732692}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on tyrosine residues. Autophosphorylation CC occurs in trans between the two FGFR molecules present in the dimer. CC Phosphorylation at Tyr-724 is essential for stimulation of cell CC proliferation and activation of PIK3R1, STAT1 and MAP kinase signaling. CC Phosphorylation at Tyr-760 is required for interaction with PIK3R1 and CC PLCG1. {ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:19286672}. CC -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding and CC autophosphorylation, leading to receptor internalization and CC degradation. Subject to both proteasomal and lysosomal degradation. CC {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17509076}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:16410555, CC ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17509076}. CC -!- DISEASE: Achondroplasia (ACH) [MIM:100800]: A frequent form of short- CC limb dwarfism. It is characterized by a long, narrow trunk, short CC extremities, particularly in the proximal (rhizomelic) segments, a CC large head with frontal bossing, hypoplasia of the midface and a CC trident configuration of the hands. ACH is an autosomal dominant CC disease. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:12297284, CC ECO:0000269|PubMed:7758520, ECO:0000269|PubMed:7847369, CC ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]: CC Classic Crouzon disease which is caused by mutations in the FGFR2 gene CC is characterized by craniosynostosis (premature fusion of the skull CC sutures), and facial hypoplasia. Crouzon syndrome with acanthosis CC nigricans (a skin disorder characterized by pigmentation anomalies), CC CAN, is considered to be an independent disorder from classic Crouzon CC syndrome. CAN is characterized by additional more severe physical CC manifestation, such as Chiari malformation, hydrocephalus, and atresia CC or stenosis of the choanas, and is caused by a specific mutation (Ala- CC 391 to Glu) in the transmembrane domain of FGFR3. It is proposed to CC have an autosomal dominant mode of inheritance. CC {ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Thanatophoric dysplasia 1 (TD1) [MIM:187600]: A neonatal CC lethal skeletal dysplasia. Affected individuals manifest severe CC shortening of the limbs with macrocephaly, narrow thorax, short ribs, CC and curved femurs. {ECO:0000269|PubMed:10360402, CC ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:7773297, CC ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844, CC ECO:0000269|PubMed:9790257}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Thanatophoric dysplasia 2 (TD2) [MIM:187601]: A neonatal CC lethal skeletal dysplasia causing severe shortening of the limbs, CC narrow thorax and short ribs. Patients with thanatophoric dysplasia CC type 2 have straight femurs and cloverleaf skull. CC {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:7773297, CC ECO:0000269|PubMed:8754806}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hypochondroplasia (HCH) [MIM:146000]: Autosomal dominant CC disease and is characterized by disproportionate short stature. It CC resembles achondroplasia, but with a less severe phenotype. CC {ECO:0000269|PubMed:10215410, ECO:0000269|PubMed:10777366, CC ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:12707965, CC ECO:0000269|PubMed:7670477, ECO:0000269|PubMed:9452043}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC {ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11314002}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. Somatic mutations can constitutively CC activate FGFR3. CC -!- DISEASE: Cervical cancer (CERCA) [MIM:603956]: A malignant neoplasm of CC the cervix, typically originating from a dysplastic or premalignant CC lesion previously present at the active squamocolumnar junction. The CC transformation from mild dysplastic to invasive carcinoma generally CC occurs slowly within several years, although the rate of this process CC varies widely. Carcinoma in situ is particularly known to precede CC invasive cervical cancer in most cases. Cervical cancer is strongly CC associated with infection by oncogenic types of human papillomavirus. CC {ECO:0000269|PubMed:10471491}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Camptodactyly, tall stature, and hearing loss syndrome CC (CATSHLS) [MIM:610474]: An autosomal dominant syndrome characterized by CC permanent and irreducible flexion of one or more fingers of the hand CC and/or feet, tall stature, scoliosis and/or a pectus excavatum, and CC hearing loss. Affected individuals have developmental delay and/or CC intellectual disability, and several of these have microcephaly. CC Radiographic findings included tall vertebral bodies with irregular CC borders and broad femoral metaphyses with long tubular shafts. On CC audiological exam, each tested member have bilateral sensorineural CC hearing loss and absent otoacoustic emissions. The hearing loss was CC congenital or developed in early infancy, progressed variably in early CC childhood, and range from mild to severe. Computed tomography and CC magnetic resonance imaging reveal that the brain, middle ear, and inner CC ear are structurally normal. {ECO:0000269|PubMed:17033969}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of CC plasma cells usually arising in the bone marrow and characterized by CC diffuse involvement of the skeletal system, hyperglobulinemia, Bence- CC Jones proteinuria and anemia. Complications of multiple myeloma are CC bone pain, hypercalcemia, renal failure and spinal cord compression. CC The aberrant antibodies that are produced lead to impaired humoral CC immunity and patients have a high prevalence of infection. Amyloidosis CC may develop in some patients. Multiple myeloma is part of a spectrum of CC diseases ranging from monoclonal gammopathy of unknown significance CC (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:11529856, CC ECO:0000269|PubMed:9207791}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. A chromosomal aberration CC involving FGFR3 is found in multiple myeloma. Translocation CC t(4;14)(p16.3;q32.3) with the IgH locus. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 2 (LADD2) CC [MIM:620192]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]: CC Epidermal nevi of the common, non-organoid and non-epidermolytic type CC are benign skin lesions and may vary in their extent from a single CC (usually linear) lesion to widespread and systematized involvement. CC They may be present at birth or develop early during childhood. CC {ECO:0000269|PubMed:16841094}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Muenke syndrome (MNKS) [MIM:602849]: A condition characterized CC by premature closure of coronal suture of skull during development CC (coronal craniosynostosis), which affects the shape of the head and CC face. It may be uni- or bilateral. When bilateral, it is characterized CC by a skull with a small antero-posterior diameter (brachycephaly), CC often with a decrease in the depth of the orbits and hypoplasia of the CC maxillae. Unilateral closure of the coronal sutures leads to flattening CC of the orbit on the involved side (plagiocephaly). The intellect is CC normal. In addition to coronal craniosynostosis some affected CC individuals show skeletal abnormalities of hands and feet, CC sensorineural hearing loss, intellectual disability and respiratory CC insufficiency. {ECO:0000269|PubMed:11746040, CC ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9950359}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:15772091}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:19855393}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Achondroplasia, severe, with developmental delay and CC acanthosis nigricans (SADDAN) [MIM:616482]: A severe form of CC achondroplasia associated with developmental delay and acanthosis CC nigricans. Patients manifest short-limb dwarfism, with a long, narrow CC trunk, short extremities, particularly in the proximal (rhizomelic) CC segments, a large head with frontal bossing, hypoplasia of the midface CC and a trident configuration of the hands. Acanthosis nigricans is a CC skin condition characterized by brown-pigmented, velvety verrucosities CC in body folds and creases. {ECO:0000269|PubMed:10053006}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92678.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/99/FGFR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M58051; AAA52450.1; -; mRNA. DR EMBL; AF245114; AAF63380.1; -; mRNA. DR EMBL; AB209441; BAD92678.1; ALT_INIT; mRNA. DR EMBL; AY768549; AAU89726.1; -; Genomic_DNA. DR EMBL; AC016773; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471131; EAW82564.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82565.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82566.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82567.1; -; Genomic_DNA. DR EMBL; M64347; AAA58470.1; -; mRNA. DR EMBL; M59374; AAA63209.1; -; mRNA. DR EMBL; S76733; AAB33323.1; -; Genomic_DNA. DR EMBL; X84939; CAA59334.1; -; mRNA. DR EMBL; U22410; AAA67781.1; -; Genomic_DNA. DR CCDS; CCDS3353.1; -. [P22607-1] DR CCDS; CCDS3354.1; -. [P22607-3] DR CCDS; CCDS54706.1; -. [P22607-2] DR PIR; A38576; TVHUF3. DR RefSeq; NP_000133.1; NM_000142.5. [P22607-1] DR RefSeq; NP_001156685.1; NM_001163213.2. [P22607-2] DR RefSeq; NP_075254.1; NM_022965.4. [P22607-3] DR RefSeq; XP_047305780.1; XM_047449824.1. [P22607-1] DR PDB; 1RY7; X-ray; 3.20 A; B=33-365. DR PDB; 2LZL; NMR; -; A/B=357-399. DR PDB; 4K33; X-ray; 2.34 A; A=449-759. DR PDB; 6LVM; X-ray; 2.53 A; A=472-759. DR PDB; 6PNX; X-ray; 2.20 A; A/B=451-759. DR PDB; 7DHL; X-ray; 2.57 A; A=472-759. DR PDB; 7YSU; EM; 3.20 A; C/E=148-358. DR PDB; 8UDT; X-ray; 2.83 A; A/B/C=454-756. DR PDB; 8UDU; X-ray; 1.74 A; A/B=454-756. DR PDB; 8UDV; X-ray; 2.35 A; A/B/C=454-756. DR PDB; 9CD7; X-ray; 2.53 A; A/B/C=448-759. DR PDB; 9D1X; X-ray; 1.60 A; A=455-756. DR PDB; 9KFU; X-ray; 1.40 A; A=448-756. DR PDBsum; 1RY7; -. DR PDBsum; 2LZL; -. DR PDBsum; 4K33; -. DR PDBsum; 6LVM; -. DR PDBsum; 6PNX; -. DR PDBsum; 7DHL; -. DR PDBsum; 7YSU; -. DR PDBsum; 8UDT; -. DR PDBsum; 8UDU; -. DR PDBsum; 8UDV; -. DR PDBsum; 9CD7; -. DR PDBsum; 9D1X; -. DR PDBsum; 9KFU; -. DR AlphaFoldDB; P22607; -. DR BMRB; P22607; -. DR EMDB; EMD-34082; -. DR SASBDB; P22607; -. DR SMR; P22607; -. DR BioGRID; 108552; 357. DR DIP; DIP-4016N; -. DR FunCoup; P22607; 1466. DR IntAct; P22607; 608. DR MINT; P22607; -. DR STRING; 9606.ENSP00000339824; -. DR BindingDB; P22607; -. DR ChEMBL; CHEMBL2742; -. DR DrugBank; DB08577; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB11865; Brivanib alaninate. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05014; XL999. DR DrugCentral; P22607; -. DR GuidetoPHARMACOLOGY; 1810; -. DR GlyCosmos; P22607; 6 sites, No reported glycans. DR GlyGen; P22607; 10 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P22607; -. DR PhosphoSitePlus; P22607; -. DR BioMuta; FGFR3; -. DR DMDM; 120050; -. DR CPTAC; CPTAC-3180; -. DR CPTAC; CPTAC-3181; -. DR jPOST; P22607; -. DR MassIVE; P22607; -. DR PaxDb; 9606-ENSP00000339824; -. DR PeptideAtlas; P22607; -. DR ProteomicsDB; 54005; -. [P22607-1] DR ProteomicsDB; 54006; -. [P22607-2] DR ProteomicsDB; 54007; -. [P22607-3] DR ProteomicsDB; 54008; -. [P22607-4] DR ABCD; P22607; 3 sequenced antibodies. DR Antibodypedia; 3787; 779 antibodies from 45 providers. DR DNASU; 2261; -. DR Ensembl; ENST00000340107.9; ENSP00000339824.4; ENSG00000068078.21. [P22607-2] DR Ensembl; ENST00000352904.6; ENSP00000231803.1; ENSG00000068078.21. [P22607-3] DR Ensembl; ENST00000440486.8; ENSP00000414914.2; ENSG00000068078.21. [P22607-1] DR GeneID; 2261; -. DR KEGG; hsa:2261; -. DR MANE-Select; ENST00000440486.8; ENSP00000414914.2; NM_000142.5; NP_000133.1. DR UCSC; uc003gdr.3; human. [P22607-1] DR AGR; HGNC:3690; -. DR CIViC; 2261; 3 clinical assertions and 139 evidence items across 97 molecular profiles. DR ClinPGx; PA28129; -. DR CTD; 2261; -. DR DisGeNET; 2261; -. DR GeneCards; FGFR3; -. DR GeneReviews; FGFR3; -. DR HGNC; HGNC:3690; FGFR3. DR HPA; ENSG00000068078; Tissue enhanced (brain, esophagus, skin). DR MalaCards; FGFR3; -. DR MIM; 100800; phenotype. DR MIM; 109800; phenotype. DR MIM; 134934; gene. DR MIM; 146000; phenotype. DR MIM; 162900; phenotype. DR MIM; 182000; phenotype. DR MIM; 187600; phenotype. DR MIM; 187601; phenotype. DR MIM; 254500; phenotype. DR MIM; 273300; phenotype. DR MIM; 602849; phenotype. DR MIM; 603956; phenotype. DR MIM; 610474; phenotype. DR MIM; 612247; phenotype. DR MIM; 616482; phenotype. DR MIM; 620192; phenotype. DR OpenTargets; ENSG00000068078; -. DR Orphanet; 15; Achondroplasia. DR Orphanet; 85164; Camptodactyly-tall stature-scoliosis-hearing loss syndrome. DR Orphanet; 93262; Crouzon syndrome-acanthosis nigricans syndrome. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 429; Hypochondroplasia. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 53271; Muenke syndrome. DR Orphanet; 35099; Non-syndromic bicoronal craniosynostosis. DR Orphanet; 794; Saethre-Chotzen syndrome. DR Orphanet; 85165; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome. DR Orphanet; 1860; Thanatophoric dysplasia type 1. DR Orphanet; 93274; Thanatophoric dysplasia type 2. DR VEuPathDB; HostDB:ENSG00000068078; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000159880; -. DR HOGENOM; CLU_000288_74_3_1; -. DR InParanoid; P22607; -. DR OMA; RPANCTH; -. DR OrthoDB; 6019866at2759; -. DR PAN-GO; P22607; 8 GO annotations based on evolutionary models. DR PhylomeDB; P22607; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P22607; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1839130; Signaling by activated point mutants of FGFR3. DR Reactome; R-HSA-190371; FGFR3b ligand binding and activation. [P22607-2] DR Reactome; R-HSA-190372; FGFR3c ligand binding and activation. [P22607-1] DR Reactome; R-HSA-2033515; t(4;14) translocations of FGFR3. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer. DR SignaLink; P22607; -. DR SIGNOR; P22607; -. DR Agora; ENSG00000068078; -. DR BioGRID-ORCS; 2261; 15 hits in 1201 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR3; human. DR EvolutionaryTrace; P22607; -. DR GeneWiki; Fibroblast_growth_factor_receptor_3; -. DR GenomeRNAi; 2261; -. DR Pharos; P22607; Tclin. DR PRO; PR:P22607; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P22607; protein. DR Bgee; ENSG00000068078; Expressed in upper leg skin and 181 other cell types or tissues. DR ExpressionAtlas; P22607; baseline and differential. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0030133; C:transport vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0070977; P:bone maturation; ISS:BHF-UCL. DR GO; GO:0030282; P:bone mineralization; ISS:BHF-UCL. DR GO; GO:0060349; P:bone morphogenesis; ISS:BHF-UCL. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; TAS:UniProtKB. DR GO; GO:0035988; P:chondrocyte proliferation; TAS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; TAS:UniProtKB. DR GO; GO:0001958; P:endochondral ossification; TAS:UniProtKB. DR GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; TAS:ProtInc. DR GO; GO:0048640; P:negative regulation of developmental growth; ISS:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; TAS:ProtInc. DR CDD; cd05857; IgI_2_FGFR; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000423; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 6.10.250.1740; -; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF505; FIBROBLAST GROWTH FACTOR RECEPTOR 3; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF21165; FGFR3_TM; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Chromosomal rearrangement; Craniosynostosis; Cytoplasmic vesicle; Deafness; KW Disease variant; Disulfide bond; Dwarfism; Ectodermal dysplasia; KW Endoplasmic reticulum; Glycoprotein; Immunoglobulin domain; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..22 FT CHAIN 23..806 FT /note="Fibroblast growth factor receptor 3" FT /id="PRO_0000016785" FT TOPO_DOM 23..375 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 376..396 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 397..806 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 24..126 FT /note="Ig-like C2-type 1" FT DOMAIN 151..244 FT /note="Ig-like C2-type 2" FT DOMAIN 253..355 FT /note="Ig-like C2-type 3" FT DOMAIN 472..761 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 126..153 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 765..806 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 132..145 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 771..787 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 617 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 478..486 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 508 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61851" FT MOD_RES 445 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61851" FT MOD_RES 647 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:8754806" FT MOD_RES 648 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:8754806" FT MOD_RES 724 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11294897" FT MOD_RES 760 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19286672" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 225 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 262 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 294 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 328 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..109 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 176..228 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 275..339 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..422 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11703096" FT /id="VSP_002989" FT VAR_SEQ 311..358 FT /note="TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLP -> FT SWISESVEADVRLRLANVSERDGGEYLCRATNFIGVAEKAFWLSVHGPRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:7495869" FT /id="VSP_002988" FT VAR_SEQ 654..806 FT /note="GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFK FT LLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLS FT APFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT -> LVLWGPALGDLHA FT GGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVHDHAGVLACRALPEAHLQAAGGGPG FT PCPYRDVHRRVPGPVGAFRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADVK FT GHWSPTM (in isoform 4)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_040945" FT VARIANT 65 FT /note="G -> R (in dbSNP:rs2305178)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022167" FT VARIANT 79 FT /note="T -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042207" FT VARIANT 228 FT /note="C -> R (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042208" FT VARIANT 248 FT /note="R -> C (in KERSEB, BLC, keratinocytic non- FT epidermolytic nevus and TD1; severe and lethal; also found FT as somatic mutation in one patient with multiple myeloma; FT constitutive dimerization and kinase activation; FT dbSNP:rs121913482)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11529856, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:7773297, FT ECO:0000269|PubMed:8845844" FT /id="VAR_004148" FT VARIANT 249 FT /note="S -> C (in KERSEB, BLC, cervical cancer and TD1; FT dbSNP:rs121913483)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844" FT /id="VAR_004149" FT VARIANT 250 FT /note="P -> R (in MNKS; also some individuals with FT autosomal dominant congenital sensorineural deafness FT without craniosynostosis; dbSNP:rs4647924)" FT /evidence="ECO:0000269|PubMed:11746040, FT ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9525367, FT ECO:0000269|PubMed:9950359" FT /id="VAR_004150" FT VARIANT 322 FT /note="E -> K (in colorectal cancer; dbSNP:rs121913111)" FT /evidence="ECO:0000269|PubMed:11325814" FT /id="VAR_018388" FT VARIANT 338 FT /note="T -> M" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042209" FT VARIANT 370 FT /note="G -> C (in KERSEB, BLC, keratinocytic non- FT epidermolytic nevus and TD1; dbSNP:rs121913479)" FT /evidence="ECO:0000269|PubMed:10471491, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9790257" FT /id="VAR_004151" FT VARIANT 371 FT /note="S -> C (in KERSEB and TD1; dbSNP:rs121913484)" FT /evidence="ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:7773297" FT /id="VAR_004152" FT VARIANT 373 FT /note="Y -> C (in KERSEB and TD1; disulfide-linked dimer FT with constitutive kinase activation; dbSNP:rs121913485)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076, FT ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9207791" FT /id="VAR_004153" FT VARIANT 375 FT /note="G -> C (in ACH; dbSNP:rs75790268)" FT /evidence="ECO:0000269|PubMed:7758520" FT /id="VAR_004154" FT VARIANT 380 FT /note="G -> R (in keratinocytic non-epidermolytic nevus and FT ACH; very common mutation; constitutively activated kinase FT with impaired internalization and degradation, resulting in FT prolonged FGFR3 signaling; dbSNP:rs28931614)" FT /evidence="ECO:0000269|PubMed:10611230, FT ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369, FT ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935" FT /id="VAR_004155" FT VARIANT 384 FT /note="F -> L (in dbSNP:rs17881656)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_022168" FT VARIANT 391 FT /note="A -> E (in CAN; dbSNP:rs28931615)" FT /evidence="ECO:0000269|PubMed:17935505, FT ECO:0000269|PubMed:7493034" FT /id="VAR_004156" FT VARIANT 441 FT /note="A -> T (in dbSNP:rs17884368)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022169" FT VARIANT 513 FT /note="D -> N (in LADD2; uncertain significance; FT dbSNP:rs121913112)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029887" FT VARIANT 538 FT /note="I -> V (in hypochondroplasia; dbSNP:rs80053154)" FT /evidence="ECO:0000269|PubMed:10215410" FT /id="VAR_004157" FT VARIANT 540 FT /note="N -> K (in hypochondroplasia; dbSNP:rs28933068)" FT /evidence="ECO:0000269|PubMed:7670477" FT /id="VAR_004158" FT VARIANT 540 FT /note="N -> S (in hypochondroplasia; mild; FT dbSNP:rs77722678)" FT /evidence="ECO:0000269|PubMed:10777366, FT ECO:0000269|PubMed:12707965" FT /id="VAR_018389" FT VARIANT 540 FT /note="N -> T (in hypochondroplasia; dbSNP:rs77722678)" FT /evidence="ECO:0000269|PubMed:9452043" FT /id="VAR_004159" FT VARIANT 621 FT /note="R -> H (in CATSHLS; dbSNP:rs121913113)" FT /evidence="ECO:0000269|PubMed:17033969" FT /id="VAR_029108" FT VARIANT 646 FT /note="D -> N (in dbSNP:rs1721881918)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042210" FT VARIANT 650 FT /note="K -> E (in KERSEB, TD2, TGCT and BLC; bladder FT transitional cell carcinoma; somatic mutation; FT constitutively activated kinase with impaired FT internalization and degradation, resulting in prolonged FT FGFR3 signaling; dbSNP:rs78311289)" FT /evidence="ECO:0000269|PubMed:10471491, FT ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284, FT ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393, FT ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806, FT ECO:0000269|PubMed:9207791" FT /id="VAR_004160" FT VARIANT 650 FT /note="K -> M (in KERSEB, ACH, TD1 and SADDAN; FT constitutively activated kinase with impaired FT internalization and degradation, resulting in prolonged FT FGFR3 signaling; dbSNP:rs121913105)" FT /evidence="ECO:0000269|PubMed:10053006, FT ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, FT ECO:0000269|PubMed:9207791" FT /id="VAR_004161" FT VARIANT 650 FT /note="K -> Q (in hypochondroplasia and BLC; in FT hypochondroplasia the form is milder than that seen in FT individuals with the K-540 or M-650 mutations; FT constitutively activated kinase; dbSNP:rs78311289)" FT /evidence="ECO:0000269|PubMed:11055896, FT ECO:0000269|PubMed:11314002, ECO:0000269|PubMed:8754806" FT /id="VAR_018390" FT VARIANT 717 FT /note="A -> T (in dbSNP:rs17882190)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022170" FT VARIANT 726 FT /note="I -> F (in dbSNP:rs17880763)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022171" FT MUTAGEN 508 FT /note="K->A: Loss of kinase activity. Abolishes FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12297284, FT ECO:0000269|PubMed:16410555" FT MUTAGEN 577 FT /note="Y->F: Minor effect on kinase activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 650 FT /note="K->D: Constitutively activated kinase." FT MUTAGEN 650 FT /note="K->L: Constitutively activated kinase." FT MUTAGEN 724 FT /note="Y->F: Strongly reduced kinase activity. Strongly FT reduced mitogen activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 760 FT /note="Y->F: Minor effect on kinase activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 770 FT /note="Y->F: Minor effect on kinase activity. Increased FT mitogen activity." FT /evidence="ECO:0000269|PubMed:11294897" FT CONFLICT 395 FT /note="L -> V (in Ref. 7; AAA58470)" FT /evidence="ECO:0000305" FT CONFLICT 421 FT /note="R -> RQ (in Ref. 3; BAD92678)" FT /evidence="ECO:0000305" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:7YSU" FT HELIX 156..158 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 163..167 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 172..175 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 185..187 FT /evidence="ECO:0007829|PDB:1RY7" FT TURN 208..211 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:1RY7" FT HELIX 220..222 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 226..232 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 235..246 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 263..268 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 271..273 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 283..289 FT /evidence="ECO:0007829|PDB:1RY7" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 302..304 FT /evidence="ECO:0007829|PDB:1RY7" FT TURN 319..321 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 331..333 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 335..345 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 348..357 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 369..372 FT /evidence="ECO:0007829|PDB:2LZL" FT HELIX 374..398 FT /evidence="ECO:0007829|PDB:2LZL" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 480..492 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8UDT" FT STRAND 502..508 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 516..532 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 541..545 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 547..550 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 552..556 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 563..568 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 591..610 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 620..622 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 631..633 FT /evidence="ECO:0007829|PDB:8UDU" FT TURN 643..645 FT /evidence="ECO:0007829|PDB:6LVM" FT STRAND 646..649 FT /evidence="ECO:0007829|PDB:4K33" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:8UDV" FT HELIX 658..660 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 663..668 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 673..688 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 700..708 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 721..730 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 741..756 FT /evidence="ECO:0007829|PDB:8UDU" SQ SEQUENCE 806 AA; 87710 MW; BC5EA75EA46F447E CRC64; MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS SSSGDDSVFA HDLLPPAPPS SGGSRT // ID FOXA1_HUMAN Reviewed; 472 AA. AC P55317; B2R9H6; B7ZAP5; Q9H2A0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 219. DE RecName: Full=Hepatocyte nuclear factor 3-alpha; DE Short=HNF-3-alpha; DE Short=HNF-3A; DE AltName: Full=Forkhead box protein A1; DE AltName: Full=Transcription factor 3A; DE Short=TCF-3A; GN Name=FOXA1; Synonyms=HNF3A, TCF3A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-72; MET-124 INS RP AND ARG-185. RC TISSUE=Lung; RX PubMed=8652662; DOI=10.1016/0167-4781(96)00058-9; RA Bingle C.D., Gowan S.; RT "Molecular cloning of the forkhead transcription factor HNF-3 alpha from a RT human pulmonary adenocarcinoma cell line."; RL Biochim. Biophys. Acta 1307:17-20(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-72; THR-83; MET-124 RP INS; ARG-185 AND ASN-448. RX PubMed=10899756; DOI=10.1159/000022943; RA Navas M.A., Vaisse C., Boger S., Heimesaat M., Kollee L.A., Stoffel M.; RT "The human HNF-3 genes: cloning, partial sequence and mutation screening in RT patients with impaired glucose homeostasis."; RL Hum. Hered. 50:370-381(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Yu L., Takeda J.; RT "Genetic variation in the HNF-3alpha gene."; RL Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Mammary gland, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12234996; RA Lin L., Miller C.T., Contreras J.I., Prescott M.S., Dagenais S.L., Wu R., RA Yee J., Orringer M.B., Misek D.E., Hanash S.M., Glover T.W., Beer D.G.; RT "The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on RT chromosome band 14q13 is amplified and overexpressed in esophageal and lung RT adenocarcinomas."; RL Cancer Res. 62:5273-5279(2002). RN [9] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15987773; DOI=10.1242/dev.01917; RA Gao N., Ishii K., Mirosevich J., Kuwajima S., Oppenheimer S.R., RA Roberts R.L., Jiang M., Yu X., Shappell S.B., Caprioli R.M., Stoffel M., RA Hayward S.W., Matusik R.J.; RT "Forkhead box A1 regulates prostate ductal morphogenesis and promotes RT epithelial cell maturation."; RL Development 132:3431-3443(2005). RN [10] RP FUNCTION. RX PubMed=16087863; DOI=10.1073/pnas.0505575102; RA Laganiere J., Deblois G., Lefebvre C., Bataille A.R., Robert F., RA Giguere V.; RT "Location analysis of estrogen receptor alpha target promoters reveals that RT FOXA1 defines a domain of the estrogen response."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11651-11656(2005). RN [11] RP FUNCTION IN CELL CYCLE REGULATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=16331276; DOI=10.1038/sj.onc.1209170; RA Williamson E.A., Wolf I., O'Kelly J., Bose S., Tanosaki S., Koeffler H.P.; RT "BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle- RT dependent kinase inhibitor p27(Kip1)."; RL Oncogene 25:1391-1399(2006). RN [12] RP INTERACTION WITH NKX2-1. RX PubMed=17220277; DOI=10.1128/mcb.01133-06; RA Minoo P., Hu L., Xing Y., Zhu N.L., Chen H., Li M., Borok Z., Li C.; RT "Physical and functional interactions between homeodomain NKX2.1 and winged RT helix/forkhead FOXA1 in lung epithelial cells."; RL Mol. Cell. Biol. 27:2155-2165(2007). RN [13] RP FUNCTION IN CELL TYPE-SPECIFIC TRANSCRIPTION, AND DIFFERENTIAL RECRUITMENT RP TO CHROMATIN. RX PubMed=18358809; DOI=10.1016/j.cell.2008.01.018; RA Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., RA Carroll J.S., Liu X.S., Brown M.; RT "FoxA1 translates epigenetic signatures into enhancer-driven lineage- RT specific transcription."; RL Cell 132:958-970(2008). RN [14] RP FUNCTION IN REGULATION OF APOPTOSIS. RX PubMed=19127412; DOI=10.1007/s12192-008-0095-4; RA Song L., Wei X., Zhang B., Luo X., Liu J., Feng Y., Xiao X.; RT "Role of Foxa1 in regulation of bcl2 expression during oxidative-stress- RT induced apoptosis in A549 type II pneumocytes."; RL Cell Stress Chaperones 14:417-425(2009). RN [15] RP INTERACTION WITH FOXA2. RX PubMed=19919681; DOI=10.1186/gb-2009-10-11-r129; RA Motallebipour M., Ameur A., Reddy Bysani M.S., Patra K., Wallerman O., RA Mangion J., Barker M.A., McKernan K.J., Komorowski J., Wadelius C.; RT "Differential binding and co-binding pattern of FOXA1 and FOXA3 and their RT relation to H3K4me3 in HepG2 cells revealed by ChIP-seq."; RL Genome Biol. 10:R129.0-R129.0(2009). RN [16] RP FUNCTION IN ESR1-MEDIATED TRANSCRIPTION REPRESSION, DIFFERENTIAL RP RECRUITMENT TO CHROMATIN, AND INTERACTION WITH HDAC7. RX PubMed=19917725; DOI=10.1128/mcb.00907-09; RA Malik S., Jiang S., Garee J.P., Verdin E., Lee A.V., O'Malley B.W., RA Zhang M., Belaguli N.S., Oesterreich S.; RT "Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM."; RL Mol. Cell. Biol. 30:399-412(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307 AND SER-331, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Transcription factor that is involved in embryonic CC development, establishment of tissue-specific gene expression and CC regulation of gene expression in differentiated tissues. Is thought to CC act as a 'pioneer' factor opening the compacted chromatin for other CC proteins through interactions with nucleosomal core histones and CC thereby replacing linker histones at target enhancer and/or promoter CC sites. Binds DNA with the consensus sequence 5'- CC [AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). Proposed to play CC a role in translating the epigenetic signatures into cell type-specific CC enhancer-driven transcriptional programs. Its differential recruitment CC to chromatin is dependent on distribution of histone H3 methylated at CC 'Lys-5' (H3K4me2) in estrogen-regulated genes. Involved in the CC development of multiple endoderm-derived organ systems such as liver, CC pancreas, lung and prostate; FOXA1 and FOXA2 seem to have at least in CC part redundant roles (By similarity). Modulates the transcriptional CC activity of nuclear hormone receptors. Is involved in ESR1-mediated CC transcription; required for ESR1 binding to the NKX2-1 promoter in CC breast cancer cells; binds to the RPRM promoter and is required for the CC estrogen-induced repression of RPRM. Involved in regulation of CC apoptosis by inhibiting the expression of BCL2. Involved in cell cycle CC regulation by activating expression of CDKN1B, alone or in conjunction CC with BRCA1. Originally described as a transcription activator for a CC number of liver genes such as AFP, albumin, tyrosine aminotransferase, CC PEPCK, etc. Interacts with the cis-acting regulatory regions of these CC genes. Involved in glucose homeostasis. {ECO:0000250, CC ECO:0000269|PubMed:16087863, ECO:0000269|PubMed:16331276, CC ECO:0000269|PubMed:18358809, ECO:0000269|PubMed:19127412, CC ECO:0000269|PubMed:19917725}. CC -!- SUBUNIT: Binds DNA as a monomer (By similarity). Interacts with FOXA2. CC Interacts with NKX2-1. Interacts with HDAC7. Interacts with the histone CC H3-H4 heterodimer. Associates with nucleosomes containing histone H2A. CC Interacts with AR. Interacts with NR0B2 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC P55317; P10275: AR; NbExp=4; IntAct=EBI-3918034, EBI-608057; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00089, CC ECO:0000269|PubMed:15987773, ECO:0000269|PubMed:16331276}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P55317-1; Sequence=Displayed; CC Name=2; CC IsoId=P55317-2; Sequence=VSP_055094; CC -!- TISSUE SPECIFICITY: Highly expressed in prostate and ESR1-positive CC breast tumors. Overexpressed in esophageal and lung adenocarcinomas. CC {ECO:0000269|PubMed:12234996, ECO:0000269|PubMed:15987773, CC ECO:0000269|PubMed:16331276}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Hepatocyte nuclear factors entry; CC URL="https://en.wikipedia.org/wiki/Hepatocyte_nuclear_factors"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44403/FOXA1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39840; AAB06493.1; -; mRNA. DR EMBL; AF176112; AAD51979.1; -; Genomic_DNA. DR EMBL; AF176111; AAD51979.1; JOINED; Genomic_DNA. DR EMBL; AF303743; AAG40847.1; -; Genomic_DNA. DR EMBL; AF303742; AAG40847.1; JOINED; Genomic_DNA. DR EMBL; AK313785; BAG36523.1; -; mRNA. DR EMBL; AK316360; BAH14731.1; -; mRNA. DR EMBL; AL121790; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471078; EAW65844.1; -; Genomic_DNA. DR EMBL; BC033890; AAH33890.1; -; mRNA. DR CCDS; CCDS9665.1; -. [P55317-1] DR PIR; S70357; S70357. DR RefSeq; NP_004487.2; NM_004496.3. [P55317-1] DR PDB; 7VOX; X-ray; 2.10 A; A/B/C/H=168-264. DR PDB; 8VFY; EM; 2.89 A; O=1-472. DR PDB; 8VFZ; EM; 4.10 A; O/P=1-472. DR PDB; 8VG1; EM; 2.48 A; O=1-472. DR PDB; 8VG2; EM; 3.04 A; O=1-472. DR PDBsum; 7VOX; -. DR PDBsum; 8VFY; -. DR PDBsum; 8VFZ; -. DR PDBsum; 8VG1; -. DR PDBsum; 8VG2; -. DR AlphaFoldDB; P55317; -. DR EMDB; EMD-43194; -. DR EMDB; EMD-43195; -. DR EMDB; EMD-43197; -. DR EMDB; EMD-43198; -. DR SMR; P55317; -. DR BioGRID; 109411; 523. DR CORUM; P55317; -. DR DIP; DIP-57138N; -. DR ELM; P55317; -. DR FunCoup; P55317; 4980. DR IntAct; P55317; 54. DR MINT; P55317; -. DR STRING; 9606.ENSP00000250448; -. DR GlyGen; P55317; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; P55317; -. DR PhosphoSitePlus; P55317; -. DR SwissPalm; P55317; -. DR BioMuta; FOXA1; -. DR DMDM; 296434509; -. DR jPOST; P55317; -. DR MassIVE; P55317; -. DR PaxDb; 9606-ENSP00000250448; -. DR PeptideAtlas; P55317; -. DR ProteomicsDB; 56845; -. [P55317-1] DR ProteomicsDB; 7076; -. DR Pumba; P55317; -. DR Antibodypedia; 23304; 1517 antibodies from 44 providers. DR DNASU; 3169; -. DR Ensembl; ENST00000250448.5; ENSP00000250448.3; ENSG00000129514.8. [P55317-1] DR GeneID; 3169; -. DR KEGG; hsa:3169; -. DR MANE-Select; ENST00000250448.5; ENSP00000250448.3; NM_004496.5; NP_004487.2. DR UCSC; uc001wuf.5; human. [P55317-1] DR AGR; HGNC:5021; -. DR ClinPGx; PA201090; -. DR CTD; 3169; -. DR DisGeNET; 3169; -. DR GeneCards; FOXA1; -. DR HGNC; HGNC:5021; FOXA1. DR HPA; ENSG00000129514; Tissue enhanced (prostate, stomach). DR MalaCards; FOXA1; -. DR MIM; 602294; gene. DR OpenTargets; ENSG00000129514; -. DR VEuPathDB; HostDB:ENSG00000129514; -. DR eggNOG; KOG3563; Eukaryota. DR GeneTree; ENSGT00940000162043; -. DR HOGENOM; CLU_027910_4_1_1; -. DR InParanoid; P55317; -. DR OMA; WSSYYTD; -. DR OrthoDB; 5954824at2759; -. DR PAN-GO; P55317; 5 GO annotations based on evolutionary models. DR PhylomeDB; P55317; -. DR PathwayCommons; P55317; -. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR SignaLink; P55317; -. DR SIGNOR; P55317; -. DR Agora; ENSG00000129514; -. DR BioGRID-ORCS; 3169; 64 hits in 1194 CRISPR screens. DR ChiTaRS; FOXA1; human. DR GeneWiki; FOXA1; -. DR GenomeRNAi; 3169; -. DR Pharos; P55317; Tbio. DR PRO; PR:P55317; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P55317; protein. DR Bgee; ENSG00000129514; Expressed in endometrium epithelium and 106 other cell types or tissues. DR ExpressionAtlas; P55317; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005902; C:microvillus; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0019904; F:protein domain specific binding; IEA:InterPro. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0061144; P:alveolar secondary septum development; IEA:Ensembl. DR GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0071542; P:dopaminergic neuron differentiation; TAS:ParkinsonsUK-UCL. DR GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl. DR GO; GO:0060743; P:epithelial cell maturation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060739; P:mesenchymal-epithelial cell signaling involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IC:BHF-UCL. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:1904340; P:positive regulation of dopaminergic neuron differentiation; IEA:Ensembl. DR GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IC:BHF-UCL. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl. DR GO; GO:0060741; P:prostate gland stromal morphogenesis; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:1902691; P:respiratory basal cell differentiation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:UniProtKB. DR GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR CDD; cd20038; FH_FOXA1; 1. DR FunFam; 1.10.10.10:FF:000042; hepatocyte nuclear factor 3-beta; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR InterPro; IPR013638; Fork-head_N. DR InterPro; IPR001766; Fork_head_dom. DR InterPro; IPR018533; Forkhead_box_C. DR InterPro; IPR050211; FOX_domain-containing. DR InterPro; IPR018122; TF_fork_head_CS_1. DR InterPro; IPR030456; TF_fork_head_CS_2. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR PANTHER; PTHR11829; FORKHEAD BOX PROTEIN; 1. DR PANTHER; PTHR11829:SF195; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; 1. DR Pfam; PF00250; Forkhead; 1. DR Pfam; PF08430; Forkhead_N; 1. DR Pfam; PF09354; HNF_C; 1. DR PRINTS; PR00053; FORKHEAD. DR SMART; SM00339; FH; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS00657; FORK_HEAD_1; 1. DR PROSITE; PS00658; FORK_HEAD_2; 1. DR PROSITE; PS50039; FORK_HEAD_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Chromatin regulator; KW Developmental protein; DNA-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation. FT CHAIN 1..472 FT /note="Hepatocyte nuclear factor 3-alpha" FT /id="PRO_0000091792" FT DNA_BIND 169..260 FT /note="Fork-head" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00089" FT REGION 269..392 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 273..289 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 322..332 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 351..366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 331 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..33 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055094" FT VARIANT 72 FT /note="G -> A" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015183" FT VARIANT 83 FT /note="A -> T (in dbSNP:rs7144658)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013457" FT VARIANT 87 FT /note="G -> E (in dbSNP:rs35220193)" FT /id="VAR_055835" FT VARIANT 124 FT /note="M -> MM" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015184" FT VARIANT 185 FT /note="Q -> R" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015185" FT VARIANT 448 FT /note="S -> N (in dbSNP:rs33984772)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013458" FT HELIX 175..184 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 193..203 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 205..208 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 211..224 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 228..231 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 248..250 FT /evidence="ECO:0007829|PDB:7VOX" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8VG1" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8VFY" SQ SEQUENCE 472 AA; 49148 MW; B2489523459EEB4C CRC64; MLGTVKMEGH ETSDWNSYYA DTQEAYSSVP VSNMNSGLGS MNSMNTYMTM NTMTTSGNMT PASFNMSYAN PGLGAGLSPG AVAGMPGGSA GAMNSMTAAG VTAMGTALSP SGMGAMGAQQ AASMNGLGPY AAAMNPCMSP MAYAPSNLGR SRAGGGGDAK TFKRSYPHAK PPYSYISLIT MAIQQAPSKM LTLSEIYQWI MDLFPYYRQN QQRWQNSIRH SLSFNDCFVK VARSPDKPGK GSYWTLHPDS GNMFENGCYL RRQKRFKCEK QPGAGGGGGS GSGGSGAKGG PESRKDPSGA SNPSADSPLH RGVHGKTGQL EGAPAPGPAA SPQTLDHSGA TATGGASELK TPASSTAPPI SSGPGALASV PASHPAHGLA PHESQLHLKG DPHYSFNHPF SINNLMSSSE QQHKLDFKAY EQALQYSPYG STLPASLPLG SASVTTRSPI EPSALEPAYY QGVYSRPVLN TS // ID GPER1_HUMAN Reviewed; 375 AA. AC Q99527; A8K6C5; B5BUJ1; O00143; O43494; Q13631; Q6FHL1; Q96F42; Q99981; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 28-JAN-2026, entry version 209. DE RecName: Full=G-protein coupled estrogen receptor 1 {ECO:0000305}; DE AltName: Full=Chemoattractant receptor-like 2; DE AltName: Full=Flow-induced endothelial G-protein coupled receptor 1; DE Short=FEG-1; DE AltName: Full=G protein-coupled estrogen receptor 1; DE AltName: Full=G-protein coupled receptor 30 {ECO:0000303|PubMed:17379646, ECO:0000303|PubMed:18566127}; DE AltName: Full=GPCR-Br; DE AltName: Full=IL8-related receptor DRY12; DE AltName: Full=Lymphocyte-derived G-protein coupled receptor; DE Short=LYGPR; DE AltName: Full=Membrane estrogen receptor; DE Short=mER; GN Name=GPER1 {ECO:0000312|HGNC:HGNC:4485}; GN Synonyms=CEPR, CMKRL2, DRY12, GPER, GPR30 {ECO:0000303|PubMed:17379646, GN ECO:0000303|PubMed:18566127}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8920907; DOI=10.1006/bbrc.1996.1654; RA Owman C.S.O., Blay P., Nilsson C., Lolait S.J.; RT "Cloning of human cDNA encoding a novel heptahelix receptor expressed in RT Burkitt's lymphoma and widely distributed in brain and peripheral RT tissues."; RL Biochem. Biophys. Res. Commun. 228:285-292(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9070864; DOI=10.1006/bbrc.1997.6161; RA Feng Y., Gregor P.; RT "Cloning of a novel member of the G protein-coupled receptor family related RT to peptide receptors."; RL Biochem. Biophys. Res. Commun. 231:651-654(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9398636; DOI=10.1006/bbrc.1997.7734; RA Takada Y., Kato C., Kondo S., Korenaga R., Ando J.; RT "Cloning of cDNAs encoding G protein-coupled receptor expressed in human RT endothelial cells exposed to fluid shear stress."; RL Biochem. Biophys. Res. Commun. 240:737-741(1997). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9141481; DOI=10.1016/s0014-5793(97)00278-0; RA Kvingedal A.M., Smeland E.B.; RT "A novel putative G-protein-coupled receptor expressed in lung, heart and RT lymphoid tissue."; RL FEBS Lett. 407:59-62(1997). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9367686; DOI=10.1006/geno.1997.4972; RA Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J.; RT "Identification of a gene (GPR30) with homology to the G-protein-coupled RT receptor superfamily associated with estrogen receptor expression in breast RT cancer."; RL Genomics 45:607-617(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9479505; DOI=10.1006/geno.1998.5095; RA O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H.Q., RA Kolakowski L.F. Jr., George S.R.; RT "Discovery of three novel G-protein-coupled receptor genes."; RL Genomics 47:310-313(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Liver; RA McCoy R.L., Perlmutter D.H.; RT "Cloning of novel IL8-related receptors from human hepatic tissue."; RL Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-16. RC TISSUE=Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP FUNCTION. RX PubMed=11043579; DOI=10.1210/mend.14.10.0532; RA Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Jr.; RT "Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein- RT coupled receptor homolog, GPR30, and occurs via trans-activation of the RT epidermal growth factor receptor through release of HB-EGF."; RL Mol. Endocrinol. 14:1649-1660(2000). RN [15] RP INDUCTION. RX PubMed=12027886; DOI=10.1046/j.1432-1033.2002.02912.x; RA Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., Ylikomi T.; RT "Progestin upregulates G-protein-coupled receptor 30 in breast cancer RT cells."; RL Eur. J. Biochem. 269:2485-2490(2002). RN [16] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15539556; DOI=10.1210/en.2004-1064; RA Thomas P., Pang Y., Filardo E.J., Dong J.; RT "Identity of an estrogen membrane receptor coupled to a G protein in human RT breast cancer cells."; RL Endocrinology 146:624-632(2005). RN [17] RP FUNCTION, ESTROGEN-BINDING, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR RP LOCATION. RX PubMed=15705806; DOI=10.1126/science.1106943; RA Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R.; RT "A transmembrane intracellular estrogen receptor mediates rapid cell RT signaling."; RL Science 307:1625-1630(2005). RN [18] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=16645038; DOI=10.1210/me.2005-0525; RA Pedram A., Razandi M., Levin E.R.; RT "Nature of functional estrogen receptors at the plasma membrane."; RL Mol. Endocrinol. 20:1996-2009(2006). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=17379646; DOI=10.1210/en.2006-1605; RA Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P.; RT "Activation of the novel estrogen receptor G protein-coupled receptor 30 RT (GPR30) at the plasma membrane."; RL Endocrinology 148:3236-3245(2007). RN [20] RP ABSENCE OF ESTROGEN-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=18566127; DOI=10.1210/en.2008-0269; RA Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., RA Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H.; RT "G protein-coupled receptor 30 localizes to the endoplasmic reticulum and RT is not activated by estradiol."; RL Endocrinology 149:4846-4856(2008). RN [21] RP FUNCTION. RX PubMed=19179659; DOI=10.1161/circresaha.108.190892; RA Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., RA Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., RA Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., RA Resta T.C., Prossnitz E.R., Barton M.; RT "Regulatory role of G protein-coupled estrogen receptor for vascular RT function and obesity."; RL Circ. Res. 104:288-291(2009). RN [22] RP FUNCTION. RX PubMed=19342448; DOI=10.1210/me.2008-0262; RA Quinn J.A., Graeber C.T., Frackelton A.R. Jr., Kim M., Schwarzbauer J.E., RA Filardo E.J.; RT "Coordinate regulation of estrogen-mediated fibronectin matrix assembly and RT epidermal growth factor receptor transactivation by the G protein-coupled RT receptor, GPR30."; RL Mol. Endocrinol. 23:1052-1064(2009). RN [23] RP INTERACTION WITH EGFR AND ESR1, AND INDUCTION. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [24] RP FUNCTION, INTERACTION WITH EGFR, ASSOCIATION WITH CHROMATIN, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [25] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20203690; DOI=10.1038/cdd.2010.20; RA Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., RA Lau K.M.; RT "Activation of GPR30 inhibits the growth of prostate cancer cells through RT sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, RT and induction of G(2) cell-cycle arrest."; RL Cell Death Differ. 17:1511-1523(2010). RN [26] RP ESTROGEN-BINDING, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=19931550; DOI=10.1016/j.steroids.2009.11.005; RA Thomas P., Alyea R., Pang Y., Peyton C., Dong J., Berg A.H.; RT "Conserved estrogen binding and signaling functions of the G protein- RT coupled estrogen receptor 1 (GPER) in mammals and fish."; RL Steroids 75:595-602(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, AND TISSUE SPECIFICITY. RX PubMed=21427217; DOI=10.1210/en.2010-0979; RA Maiti K., Paul J.W., Read M., Chan E.C., Riley S.C., Nahar P., Smith R.; RT "G-1-activated membrane estrogen receptors mediate increased contractility RT of the human myometrium."; RL Endocrinology 152:2448-2455(2011). RN [28] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=21242460; DOI=10.1161/hypertensionaha.110.161653; RA Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., RA Chorazyczewski J., Feldman R.D.; RT "GPR30 expression is required for the mineralocorticoid receptor- RT independent rapid vascular effects of aldosterone."; RL Hypertension 57:442-451(2011). RN [29] RP SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=21540189; DOI=10.1074/jbc.m111.224071; RA Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.; RT "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the RT cell surface occurs via a trans-Golgi-proteasome pathway."; RL J. Biol. Chem. 286:22441-22455(2011). RN [30] RP FUNCTION, INTERACTION WITH KRT7 AND KRT8, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=21149639; DOI=10.1124/mol.110.069500; RA Sanden C., Broselid S., Cornmark L., Andersson K., Daszkiewicz-Nilsson J., RA Martensson U.E., Olde B., Leeb-Lundberg L.M.; RT "G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 RT localizes in the plasma membrane and traffics intracellularly on RT cytokeratin intermediate filaments."; RL Mol. Pharmacol. 79:400-410(2011). RN [31] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21354433; DOI=10.1016/j.steroids.2011.02.018; RA Cheng S.B., Graeber C.T., Quinn J.A., Filardo E.J.; RT "Retrograde transport of the transmembrane estrogen receptor, G-protein- RT coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the RT nucleus."; RL Steroids 76:892-896(2011). RN [32] RP FUNCTION. RX PubMed=23135268; DOI=10.1074/jbc.m112.417303; RA Santolla M.F., Lappano R., De Marco P., Pupo M., Vivacqua A., Sisci D., RA Abonante S., Iacopetta D., Cappello A.R., Dolce V., Maggiolini M.; RT "G protein-coupled estrogen receptor mediates the up-regulation of fatty RT acid synthase induced by 17beta-estradiol in cancer cells and cancer- RT associated fibroblasts."; RL J. Biol. Chem. 287:43234-43245(2012). RN [33] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=23285008; DOI=10.1371/journal.pone.0052357; RA Chakrabarti S., Davidge S.T.; RT "G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial RT inflammation."; RL PLoS ONE 7:E52357-E52357(2012). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP ALDOSTERONE-BINDING, AND FUNCTION. RX PubMed=23283935; DOI=10.1152/ajpcell.00203.2012; RA Gros R., Ding Q., Liu B., Chorazyczewski J., Feldman R.D.; RT "Aldosterone mediates its rapid effects in vascular endothelial cells RT through GPER activation."; RL Am. J. Physiol. 304:C532-C540(2013). RN [36] RP FUNCTION, INTERACTION WITH RAMP3, AND SUBCELLULAR LOCATION. RX PubMed=23674134; DOI=10.1530/jme-13-0021; RA Lenhart P.M., Broselid S., Barrick C.J., Leeb-Lundberg L.M., Caron K.M.; RT "G-protein-coupled receptor 30 interacts with receptor activity-modifying RT protein 3 and confers sex-dependent cardioprotection."; RL J. Mol. Endocrinol. 51:191-202(2013). RN [37] RP REVIEW. RX PubMed=22521564; DOI=10.1016/j.steroids.2012.04.001; RA Barton M.; RT "Position paper: The membrane estrogen receptor GPER--Clues and RT questions."; RL Steroids 77:935-942(2012). RN [38] RP REVIEW. RX PubMed=22495674; DOI=10.1210/en.2012-1061; RA Filardo E.J., Thomas P.; RT "Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism RT of action and role in female reproductive cancer, renal and vascular RT physiology."; RL Endocrinology 153:2953-2962(2012). CC -!- FUNCTION: G-protein coupled estrogen receptor that binds to 17-beta- CC estradiol (E2) with high affinity, leading to rapid and transient CC activation of numerous intracellular signaling pathways. Stimulates CC cAMP production, calcium mobilization and tyrosine kinase Src inducing CC the release of heparin-bound epidermal growth factor (HB-EGF) and CC subsequent transactivation of the epidermal growth factor receptor CC (EGFR), activating downstream signaling pathways such as PI3K/Akt and CC ERK/MAPK. Mediates pleiotropic functions among others in the CC cardiovascular, endocrine, reproductive, immune and central nervous CC systems. Has a role in cardioprotection by reducing cardiac hypertrophy CC and perivascular fibrosis in a RAMP3-dependent manner. Regulates CC arterial blood pressure by stimulating vasodilation and reducing CC vascular smooth muscle and microvascular endothelial cell CC proliferation. Plays a role in blood glucose homeostasis contributing CC to the insulin secretion response by pancreatic beta cells. Triggers CC mitochondrial apoptosis during pachytene spermatocyte differentiation. CC Stimulates uterine epithelial cell proliferation. Enhances uterine CC contractility in response to oxytocin. Contributes to thymic atrophy by CC inducing apoptosis. Attenuates TNF-mediated endothelial expression of CC leukocyte adhesion molecules. Promotes neuritogenesis in developing CC hippocampal neurons. Plays a role in acute neuroprotection against CC NMDA-induced excitotoxic neuronal death. Increases firing activity and CC intracellular calcium oscillations in luteinizing hormone-releasing CC hormone (LHRH) neurons. Inhibits early osteoblast proliferation at CC growth plate during skeletal development. Inhibits mature adipocyte CC differentiation and lipid accumulation. Involved in the recruitment of CC beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also CC functions as a receptor for aldosterone mediating rapid regulation of CC vascular contractibility through the PI3K/ERK signaling pathway. CC Involved in cancer progression regulation. Stimulates cancer-associated CC fibroblast (CAF) proliferation by a rapid genomic response through the CC EGFR/ERK transduction pathway. Associated with EGFR, may act as a CC transcription factor activating growth regulatory genes (c-fos, cyclin CC D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix CC assembly in breast cancer cells. {ECO:0000269|PubMed:11043579, CC ECO:0000269|PubMed:15539556, ECO:0000269|PubMed:15705806, CC ECO:0000269|PubMed:19179659, ECO:0000269|PubMed:19342448, CC ECO:0000269|PubMed:20203690, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:21242460, CC ECO:0000269|PubMed:21427217, ECO:0000269|PubMed:23135268, CC ECO:0000269|PubMed:23283935, ECO:0000269|PubMed:23285008, CC ECO:0000269|PubMed:23674134}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=Binds 17-beta-estradiol (E2) in plasma membranes with high CC affinity (Kd is 3.3 nM) and displays rapid kinetics of association CC and dissociation. {ECO:0000269|PubMed:15539556, CC ECO:0000269|PubMed:15705806, ECO:0000269|PubMed:19931550}; CC -!- SUBUNIT: Homodimer (Probable). Heterodimer; heterodimerizes with other CC G-protein-coupled receptor (GPCRs) like CRHR1, HTR1A and PAQR8. CC Interacts (via C-terminus tail motif) with DLG4 (via N-terminus tandem CC pair of PDZ domains); the interaction is direct and induces the CC increase of GPER1 protein levels residing at the plasma membrane CC surface in a estradiol-independent manner (By similarity). Interacts CC with RAMP3; the interaction confers proper subcellular localization and CC function in cardioprotection. Interacts with KRT7 and KRT8. Interacts CC with EGFR; the interaction increases after agonist-induced stimulation CC in cancer-associated fibroblasts (CAF). Interacts with EGFR and ESR1. CC {ECO:0000250, ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:21149639, ECO:0000269|PubMed:23674134, ECO:0000305}. CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}. Cytoplasm, CC perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Multi-pass CC membrane protein. Basolateral cell membrane; Multi-pass membrane CC protein. Cytoplasmic vesicle membrane; Multi-pass membrane protein. CC Early endosome. Recycling endosome. Golgi apparatus membrane CC {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Golgi CC apparatus, trans-Golgi network. Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:18566127}; Multi-pass membrane protein. Cell CC projection, dendrite {ECO:0000250}. Cell projection, dendritic spine CC membrane {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Postsynaptic density {ECO:0000250}. CC Mitochondrion membrane {ECO:0000250}; Multi-pass membrane protein CC {ECO:0000250}. Note=Colocalized with BSN to the active zone of CC presynaptic density. Colocalized with DLG4/PSD95 and neurabin-2 PPP1R9B CC in neuronal synaptosomes (By similarity). Endocytosed in a agonist- and CC arrestin-independent manner. Colocalized with RAMP3 and clathrin-coated CC pits at the plasma membrane. Colocalized with transferrin receptor at CC the plasma membrane and perinuclear region. Accumulated and colocalized CC with RAB11 proteins in recycling endosomes and trans-Golgi network CC (TGN), but does neither recycle back to the cell surface nor traffics CC to late endosome or lysosome. Colocalized with calnexin in the CC endoplasmic reticulum. Traffics to intracellular sites via cytokeratin CC intermediate filaments like KRT7 and KRT8 after constitutive CC endocytosis in epithelial cells. Colocalized with EGFR in the nucleus CC of agonist-induced cancer-associated fibroblasts (CAF). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in placenta, endothelial and epithelial CC cells, non laboring and laboring term myometrium, fibroblasts and CC cancer-associated fibroblasts (CAF), prostate cancer cells and invasive CC adenocarcinoma (at protein level). Ubiquitously expressed, but is most CC abundant in placenta. In brain regions, expressed as a 2.8 kb CC transcript in basal forebrain, frontal cortex, thalamus, hippocampus, CC caudate and putamen. {ECO:0000269|PubMed:20203690, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:21149639, CC ECO:0000269|PubMed:21354433, ECO:0000269|PubMed:21427217, CC ECO:0000269|PubMed:23285008}. CC -!- INDUCTION: Up-regulated by EGF and TGF-alpha in endometrial, ovarian CC and breast tumor cells. Up-regulated by progestin and by phorbol 12- CC myristate 13-acetate (PMA) in breast cancer cell lines. CC {ECO:0000269|PubMed:12027886, ECO:0000269|PubMed:19749156}. CC -!- PTM: Ubiquitinated; ubiquitination occurs at the plasma membrane and CC leads to proteasome-mediated degradation. CC {ECO:0000269|PubMed:21540189}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:21427217}. CC -!- MISCELLANEOUS: Does not bind estradiol according to PubMed:18566127 and CC PubMed:16645038. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC {ECO:0000255|PROSITE-ProRule:PRU00521}. CC -!- CAUTION: Data is conflicting regarding whether it fulfills the criteria CC of a membrane-bound estrogen receptor (PubMed:15705806, CC PubMed:17379646). Other reports suggest that it is not CC (PubMed:16645038, PubMed:18566127). {ECO:0000305|PubMed:15705806, CC ECO:0000305|PubMed:16645038, ECO:0000305|PubMed:17379646, CC ECO:0000305|PubMed:18566127}. CC -!- CAUTION: Data is conflicting regarding whether it is localized either CC at the cell membrane (PM) (PubMed:15539556, PubMed:21149639, CC PubMed:21354433, PubMed:21427217, PubMed:21540189, PubMed:23674134). CC Other reports suggest that it localizes at the endoplasmic reticulum CC (ER) (PubMed:15705806, PubMed:18566127). {ECO:0000305|PubMed:15539556, CC ECO:0000305|PubMed:15705806, ECO:0000305|PubMed:18566127, CC ECO:0000305|PubMed:21149639, ECO:0000305|PubMed:21354433, CC ECO:0000305|PubMed:21427217, ECO:0000305|PubMed:21540189, CC ECO:0000305|PubMed:23674134}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44344/GPER"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y08162; CAA69354.1; -; mRNA. DR EMBL; U77827; AAC51173.1; -; Genomic_DNA. DR EMBL; AF015257; AAC51904.1; -; mRNA. DR EMBL; X98510; CAA67133.1; -; mRNA. DR EMBL; U63917; AAB88017.1; -; mRNA. DR EMBL; AF027956; AAC52027.1; -; Genomic_DNA. DR EMBL; U58828; AAB02736.1; -; mRNA. DR EMBL; CR541741; CAG46541.1; -; mRNA. DR EMBL; AK291590; BAF84279.1; -; mRNA. DR EMBL; AB451427; BAG70241.1; -; mRNA. DR EMBL; CH236953; EAL23938.1; -; Genomic_DNA. DR EMBL; CH471144; EAW87194.1; -; Genomic_DNA. DR EMBL; BC011634; AAH11634.1; -; mRNA. DR CCDS; CCDS5322.1; -. DR PIR; G02670; G02670. DR PIR; JC5069; JC5069. DR RefSeq; NP_001035055.1; NM_001039966.2. DR RefSeq; NP_001091671.1; NM_001098201.3. DR RefSeq; NP_001496.1; NM_001505.3. DR PDB; 8XOF; EM; 2.60 A; R=1-375. DR PDB; 8XOG; EM; 2.90 A; R=1-375. DR PDB; 8XOH; EM; 3.20 A; R=1-375. DR PDB; 8XOI; EM; 3.20 A; R=1-375. DR PDB; 8XOJ; EM; 3.10 A; R=1-375. DR PDBsum; 8XOF; -. DR PDBsum; 8XOG; -. DR PDBsum; 8XOH; -. DR PDBsum; 8XOI; -. DR PDBsum; 8XOJ; -. DR AlphaFoldDB; Q99527; -. DR EMDB; EMD-38527; -. DR EMDB; EMD-38528; -. DR EMDB; EMD-38529; -. DR EMDB; EMD-38530; -. DR EMDB; EMD-38531; -. DR SMR; Q99527; -. DR BioGRID; 109110; 4. DR CORUM; Q99527; -. DR FunCoup; Q99527; 533. DR IntAct; Q99527; 1. DR STRING; 9606.ENSP00000380281; -. DR BindingDB; Q99527; -. DR ChEMBL; CHEMBL5872; -. DR DrugBank; DB00783; Estradiol. DR DrugBank; DB13952; Estradiol acetate. DR DrugBank; DB13953; Estradiol benzoate. DR DrugBank; DB13954; Estradiol cypionate. DR DrugBank; DB13955; Estradiol dienanthate. DR DrugBank; DB13956; Estradiol valerate. DR DrugBank; DB01645; Genistein. DR DrugBank; DB18091; LNS-8801. DR DrugBank; DB05939; MK-0354. DR DrugCentral; Q99527; -. DR GuidetoPHARMACOLOGY; 221; -. DR TCDB; 9.A.14.13.19; the g-protein-coupled receptor (gpcr) family. DR GlyCosmos; Q99527; 3 sites, No reported glycans. DR GlyGen; Q99527; 3 sites. DR iPTMnet; Q99527; -. DR PhosphoSitePlus; Q99527; -. DR BioMuta; GPER1; -. DR DMDM; 3023539; -. DR MassIVE; Q99527; -. DR PaxDb; 9606-ENSP00000380281; -. DR PeptideAtlas; Q99527; -. DR Antibodypedia; 10887; 427 antibodies from 34 providers. DR DNASU; 2852; -. DR Ensembl; ENST00000297469.3; ENSP00000297469.3; ENSG00000164850.17. DR Ensembl; ENST00000397088.4; ENSP00000380277.3; ENSG00000164850.17. DR Ensembl; ENST00000397092.5; ENSP00000380281.1; ENSG00000164850.17. DR Ensembl; ENST00000401670.1; ENSP00000385151.1; ENSG00000164850.17. DR GeneID; 2852; -. DR KEGG; hsa:2852; -. DR MANE-Select; ENST00000397088.4; ENSP00000380277.3; NM_001098201.3; NP_001091671.1. DR UCSC; uc003sjz.1; human. DR AGR; HGNC:4485; -. DR ClinPGx; PA28873; -. DR CTD; 2852; -. DR DisGeNET; 2852; -. DR GeneCards; GPER1; -. DR HGNC; HGNC:4485; GPER1. DR HPA; ENSG00000164850; Tissue enhanced (stomach). DR MIM; 601805; gene. DR OpenTargets; ENSG00000164850; -. DR VEuPathDB; HostDB:ENSG00000164850; -. DR eggNOG; ENOG502QU56; Eukaryota. DR GeneTree; ENSGT00940000154307; -. DR HOGENOM; CLU_009579_8_3_1; -. DR InParanoid; Q99527; -. DR OMA; FRTKQHA; -. DR OrthoDB; 5957382at2759; -. DR PAN-GO; Q99527; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99527; -. DR PathwayCommons; Q99527; -. DR Reactome; R-HSA-375276; Peptide ligand-binding receptors. DR Reactome; R-HSA-418594; G alpha (i) signalling events. DR Reactome; R-HSA-9634597; GPER1 signaling. DR SignaLink; Q99527; -. DR SIGNOR; Q99527; -. DR Agora; ENSG00000164850; -. DR BioGRID-ORCS; 2852; 13 hits in 1132 CRISPR screens. DR GeneWiki; GPR30; -. DR GenomeRNAi; 2852; -. DR Pharos; Q99527; Tchem. DR PRO; PR:Q99527; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q99527; protein. DR Bgee; ENSG00000164850; Expressed in body of stomach and 131 other cell types or tissues. DR ExpressionAtlas; Q99527; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043198; C:dendritic shaft; ISS:UniProtKB. DR GO; GO:0044327; C:dendritic spine head; ISS:UniProtKB. DR GO; GO:0032591; C:dendritic spine membrane; ISS:UniProtKB. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0045095; C:keratin filament; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; ISS:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB. DR GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; ISS:UniProtKB. DR GO; GO:0055037; C:recycling endosome; IDA:UniProtKB. DR GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0038054; F:G protein-coupled estrogen receptor activity; ISS:UniProtKB. DR GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc. DR GO; GO:0030284; F:nuclear estrogen receptor activity; IDA:UniProtKB. DR GO; GO:0005496; F:steroid binding; IDA:UniProtKB. DR GO; GO:1990239; F:steroid hormone binding; IDA:UniProtKB. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030263; P:apoptotic chromosome condensation; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB. DR GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; ISS:UniProtKB. DR GO; GO:0071375; P:cellular response to peptide hormone stimulus; IDA:UniProtKB. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:AgBase. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0010948; P:negative regulation of cell cycle process; IMP:AgBase. DR GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:AgBase. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:AgBase. DR GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB. DR GO; GO:0002695; P:negative regulation of leukocyte activation; IDA:UniProtKB. DR GO; GO:0051055; P:negative regulation of lipid biosynthetic process; ISS:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:AgBase. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:AgBase. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0019228; P:neuronal action potential; ISS:UniProtKB. DR GO; GO:0030264; P:nuclear fragmentation involved in apoptotic nuclear change; ISS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:2000724; P:positive regulation of cardiac vascular smooth muscle cell differentiation; IMP:AgBase. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; ISS:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:UniProtKB. DR GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:AgBase. DR GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB. DR GO; GO:0001956; P:positive regulation of neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:UniProtKB. DR GO; GO:0043401; P:steroid hormone receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042311; P:vasodilation; ISS:UniProtKB. DR CDD; cd14989; 7tmA_GPER1; 1. DR FunFam; 1.20.1070.10:FF:000093; G-protein coupled estrogen receptor 1; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR047143; GPER1-like. DR PANTHER; PTHR24226:SF2; G-PROTEIN COUPLED ESTROGEN RECEPTOR 1; 1. DR PANTHER; PTHR24226; G-PROTEIN COUPLED RECEPTOR 182 AND ESTROGEN RECEPTOR 1; 1. DR Pfam; PF00001; 7tm_1; 1. DR PRINTS; PR00237; GPCRRHODOPSN. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell cycle; Cell membrane; KW Cell projection; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; KW Differentiation; Disulfide bond; Endoplasmic reticulum; Endosome; KW G-protein coupled receptor; Glycoprotein; Golgi apparatus; Immunity; KW Inflammatory response; Innate immunity; Membrane; Mitochondrion; KW Neurogenesis; Nucleus; Postsynaptic cell membrane; KW Proteomics identification; Receptor; Reference proteome; Synapse; KW Transducer; Transmembrane; Transmembrane helix; Ubl conjugation. FT CHAIN 1..375 FT /note="G-protein coupled estrogen receptor 1" FT /id="PRO_0000069310" FT TOPO_DOM 1..62 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 63..84 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 85..96 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 97..120 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 121..132 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 133..153 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 154..175 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 176..194 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 195..220 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 221..236 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 237..259 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 260..280 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 281..306 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 307..327 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 328..375 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT CARBOHYD 25 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 44 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 130..207 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VARIANT 16 FT /note="P -> L (in dbSNP:rs11544331)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851" FT /id="VAR_033319" FT CONFLICT 20..21 FT /note="QP -> HA (in Ref. 6; AAC52027)" FT /evidence="ECO:0000305" FT CONFLICT 32..49 FT /note="Missing (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 104 FT /note="A -> G (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 140..146 FT /note="NMYSSVF -> QHVQAASS (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="G -> A (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 184 FT /note="A -> S (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 312 FT /note="A -> T (in Ref. 2; AAC51173)" FT /evidence="ECO:0000305" FT CONFLICT 320 FT /note="N -> T (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 355 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT CONFLICT 358 FT /note="A -> V (in Ref. 7; AAB02736)" FT /evidence="ECO:0000305" FT HELIX 53..86 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 88..90 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 93..115 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 121..124 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 127..160 FT /evidence="ECO:0007829|PDB:8XOG" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 171..199 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 212..222 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 224..245 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 255..284 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 303..324 FT /evidence="ECO:0007829|PDB:8XOG" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:8XOG" FT HELIX 329..341 FT /evidence="ECO:0007829|PDB:8XOG" SQ SEQUENCE 375 AA; 42248 MW; 0A54EED8A698F075 CRC64; MDVTSQARGV GLEMYPGTAQ PAAPNTTSPE LNLSHPLLGT ALANGTGELS EHQQYVIGLF LSCLYTIFLF PIGFVGNILI LVVNISFREK MTIPDLYFIN LAVADLILVA DSLIEVFNLH ERYYDIAVLC TFMSLFLQVN MYSSVFFLTW MSFDRYIALA RAMRCSLFRT KHHARLSCGL IWMASVSATL VPFTAVHLQH TDEACFCFAD VREVQWLEVT LGFIVPFAII GLCYSLIVRV LVRAHRHRGL RPRRQKALRM ILAVVLVFFV CWLPENVFIS VHLLQRTQPG AAPCKQSFRH AHPLTGHIVN LAAFSNSCLN PLIYSFLGET FRDKLRLYIE QKTNLPALNR FCHAALKAVI PDSTEQSDVR FSSAV // ID GSDME_HUMAN Reviewed; 496 AA. AC O60443; A4D156; B2RAX9; B3KT05; O14590; Q08AQ8; Q9UBV3; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 2. DT 28-JAN-2026, entry version 177. DE RecName: Full=Gasdermin-E {ECO:0000303|PubMed:28459430}; DE AltName: Full=Inversely correlated with estrogen receptor expression 1 {ECO:0000303|PubMed:9523727}; DE Short=ICERE-1 {ECO:0000303|PubMed:9523727}; DE AltName: Full=Non-syndromic hearing impairment protein 5 {ECO:0000303|PubMed:9771715}; DE Contains: DE RecName: Full=Gasdermin-E, N-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-NT {ECO:0000303|PubMed:28459430}; DE Contains: DE RecName: Full=Gasdermin-E, C-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-CT {ECO:0000303|PubMed:28459430}; GN Name=GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810}; GN Synonyms=DFNA5 {ECO:0000303|PubMed:9771715}, GN ICERE1 {ECO:0000303|PubMed:9523727}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INVOLVEMENT RP IN DFNA5. RC TISSUE=Cochlea; RX PubMed=9771715; DOI=10.1038/2503; RA Van Laer L., Huizing E.H., Verstreken M., van Zuijlen D., Wauters J.G., RA Bossuyt P.J., Van de Heyning P., McGuirt W.T., Smith R.J.H., Willems P.J., RA Legan P.K., Richardson G.P., Van Camp G.; RT "Nonsyndromic hearing impairment is associated with a mutation in DFNA5."; RL Nat. Genet. 20:194-197(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Van Laer L., Van Camp G.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Mei G., Yu W., Gibbs R.A.; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-142. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 5-496 (ISOFORM 1). RC TISSUE=Mammary gland; RX PubMed=9523727; DOI=10.1046/j.1432-1327.1998.2520169.x; RA Thompson D.A., Weigel R.J.; RT "Characterization of a gene that is inversely correlated with estrogen RT receptor expression (ICERE-1) in breast carcinomas."; RL Eur. J. Biochem. 252:169-177(1998). RN [10] RP SEQUENCE REVISION TO C-TERMINUS. RA Thompson D.A.; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION IN TP53-MEDIATED CELLULAR RESPONSE. RX PubMed=16897187; DOI=10.1007/s10038-006-0004-6; RA Masuda Y., Futamura M., Kamino H., Nakamura Y., Kitamura N., Ohnishi S., RA Miyamoto Y., Ichikawa H., Ohta T., Ohki M., Kiyono T., Egami H., Baba H., RA Arakawa H.; RT "The potential role of DFNA5, a hearing impairment gene, in p53-mediated RT cellular response to DNA damage."; RL J. Hum. Genet. 51:652-664(2006). RN [12] RP INVOLVEMENT IN CRC. RX PubMed=18223688; DOI=10.1038/sj.onc.1211021; RA Kim M.S., Chang X., Yamashita K., Nagpal J.K., Baek J.H., Wu G., Trink B., RA Ratovitski E.A., Mori M., Sidransky D.; RT "Aberrant promoter methylation and tumor suppressive activity of the DFNA5 RT gene in colorectal carcinoma."; RL Oncogene 27:3624-3634(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP FUNCTION. RX PubMed=21522185; DOI=10.1038/ejhg.2011.63; RA Op de Beeck K., Van Camp G., Thys S., Cools N., Callebaut I., Vrijens K., RA Van Nassauw L., Van Tendeloo V.F., Timmermans J.P., Van Laer L.; RT "The DFNA5 gene, responsible for hearing loss and involved in cancer, RT encodes a novel apoptosis-inducing protein."; RL Eur. J. Hum. Genet. 19:965-973(2011). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP INVOLVEMENT IN DFNA5. RX PubMed=19911014; DOI=10.1038/jhg.2009.114; RA Park H.J., Cho H.J., Baek J.I., Ben-Yosef T., Kwon T.J., Griffith A.J., RA Kim U.K.; RT "Evidence for a founder mutation causing DFNA5 hearing loss in East RT Asians."; RL J. Hum. Genet. 55:59-62(2010). RN [18] RP INVOLVEMENT IN DFNA5. RX PubMed=24506266; DOI=10.1111/ahg.12053; RA Nishio A., Noguchi Y., Sato T., Naruse T.K., Kimura A., Takagi A., RA Kitamura K.; RT "A DFNA5 mutation identified in Japanese families with autosomal dominant RT hereditary hearing loss."; RL Ann. Hum. Genet. 78:83-91(2014). RN [19] RP INVOLVEMENT IN DFNA5. RX PubMed=26236191; DOI=10.3389/fncel.2015.00231; RA Van Rossom S., Op de Beeck K., Hristovska V., Winderickx J., Van Camp G.; RT "The deafness gene DFNA5 induces programmed cell death through mitochondria RT and MAPK-related pathways."; RL Front. Cell. Neurosci. 9:231-231(2015). RN [20] RP FUNCTION, AND MUTAGENESIS OF ILE-313; PHE-388 AND ALA-392. RX PubMed=27281216; DOI=10.1038/nature18590; RA Ding J., Wang K., Liu W., She Y., Sun Q., Shi J., Sun H., Wang D.C., RA Shao F.; RT "Pore-forming activity and structural autoinhibition of the gasdermin RT family."; RL Nature 535:111-116(2016). RN [21] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF ASP-267 AND ASP-270. RX PubMed=28459430; DOI=10.1038/nature22393; RA Wang Y., Gao W., Shi X., Ding J., Liu W., He H., Wang K., Shao F.; RT "Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a RT gasdermin."; RL Nature 547:99-103(2017). RN [22] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-2; LYS-39; LYS-40; RP LYS-41 AND ASP-270. RX PubMed=28045099; DOI=10.1038/ncomms14128; RA Rogers C., Fernandes-Alnemri T., Mayes L., Alnemri D., Cingolani G., RA Alnemri E.S.; RT "Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to RT secondary necrotic/pyroptotic cell death."; RL Nat. Commun. 8:14128-14128(2017). RN [23] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY GZMB, RP DOMAIN, MUTAGENESIS OF PHE-2 AND ASP-270, VARIANTS TYR-14; VAL-18; ASP-24; RP CYS-44; ILE-48; THR-137; GLU-199; LEU-212 AND ASN-217, AND CHARACTERIZATION RP OF VARIANTS TYR-14; VAL-18; ASP-24; CYS-44; ILE-48; THR-137; GLU-199; RP LEU-212 AND ASN-217. RX PubMed=32188940; DOI=10.1038/s41586-020-2071-9; RA Zhang Z., Zhang Y., Xia S., Kong Q., Li S., Liu X., Junqueira C., RA Meza-Sosa K.F., Mok T.M.Y., Ansara J., Sengupta S., Yao Y., Wu H., RA Lieberman J.; RT "Gasdermin E suppresses tumour growth by activating anti-tumour immunity."; RL Nature 579:415-420(2020). RN [24] RP SUCCINATION AT CYS-45; CYS-156; CYS-168; CYS-180; CYS-235; CYS-371; RP CYS-417; CYS-408 AND CYS-489. RX PubMed=32820063; DOI=10.1126/science.abb9818; RA Humphries F., Shmuel-Galia L., Ketelut-Carneiro N., Li S., Wang B., RA Nemmara V.V., Wilson R., Jiang Z., Khalighinejad F., Muneeruddin K., RA Shaffer S.A., Dutta R., Ionete C., Pesiridis S., Yang S., Thompson P.R., RA Fitzgerald K.A.; RT "Succination inactivates gasdermin D and blocks pyroptosis."; RL Science 369:1633-1637(2020). RN [25] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, AND CLEAVAGE BY RP GZMB. RX PubMed=31953257; DOI=10.1126/sciimmunol.aax7969; RA Liu Y., Fang Y., Chen X., Wang Z., Liang X., Zhang T., Liu M., Zhou N., RA Lv J., Tang K., Xie J., Gao Y., Cheng F., Zhou Y., Zhang Z., Hu Y., RA Zhang X., Gao Q., Zhang Y., Huang B.; RT "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers RT cytokine release syndrome."; RL Sci. Immunol. 5:0-0(2020). RN [26] RP FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-270. RX PubMed=33852854; DOI=10.1016/j.celrep.2021.108998; RA Zhou B., Abbott D.W.; RT "Gasdermin E permits interleukin-1 beta release in distinct sublytic and RT pyroptotic phases."; RL Cell Rep. 35:108998-108998(2021). RN [27] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=35972780; DOI=10.7554/elife.73792; RA Zhao Z., Li Q., Ashraf U., Yang M., Zhu W., Gu J., Chen Z., Gu C., Si Y., RA Cao S., Ye J.; RT "Zika virus causes placental pyroptosis and associated adverse fetal RT outcomes by activating GSDME."; RL Elife 11:0-0(2022). RN [28] RP FUNCTION, ACTIVITY REGULATION, AND ACTIVITY REGULATION (MICROBIAL RP INFECTION). RX PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033; RG COVID Human Genetic Effort; RA Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., RA Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., RA Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., RA Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., RA Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., RA Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.; RT "Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung RT epithelial cells."; RL Mol. Cell 82:2385-2400(2022). RN [29] RP FUNCTION, AND UBIQUITINATION AT LYS-120 AND LYS-189. RX PubMed=36607699; DOI=10.1158/0008-5472.can-22-1812; RA Ren Y., Feng M., Hao X., Liu X., Li J., Li P., Gao J., Qi Q., Du L., RA Wang C., Wang Q., Wang Y.; RT "USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer."; RL Cancer Res. 83:1074-1093(2023). RN [30] RP PALMITOYLATION. RX PubMed=38599239; DOI=10.1038/s41586-024-07373-5; RA Du G., Healy L.B., David L., Walker C., El-Baba T.J., Lutomski C.A., RA Goh B., Gu B., Pi X., Devant P., Fontana P., Dong Y., Ma X., Miao R., RA Balasubramanian A., Puthenveetil R., Banerjee A., Luo H.R., Kagan J.C., RA Oh S.F., Robinson C.V., Lieberman J., Wu H.; RT "ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D."; RL Nature 0:0-0(2024). CC -!- FUNCTION: [Gasdermin-E]: Precursor of a pore-forming protein that CC converts non-inflammatory apoptosis to pyroptosis (PubMed:27281216, CC PubMed:28459430, PubMed:33852854, PubMed:35594856, PubMed:36607699). CC This form constitutes the precursor of the pore-forming protein: upon CC cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) CC binds to membranes and forms pores, triggering pyroptosis CC (PubMed:28459430). {ECO:0000269|PubMed:27281216, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856, ECO:0000269|PubMed:36607699}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: Pore-forming protein produced by CC cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory CC apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, CC respectively (PubMed:27281216, PubMed:28459430, PubMed:32188940, CC PubMed:33852854, PubMed:35594856). After cleavage, moves to the plasma CC membrane, homooligomerizes within the membrane and forms pores of 10-15 CC nanometers (nm) of inner diameter, allowing the release of mature CC interleukins (IL1B and IL16) and triggering pyroptosis CC (PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). CC Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, CC such as phosphatidylinositol (4,5)-bisphosphate (PubMed:28459430). CC Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or CC danger signals, such as chemotherapy drugs, to pyroptosis CC (PubMed:27281216, PubMed:28459430, PubMed:32188940). Mediates secondary CC necrosis downstream of the mitochondrial apoptotic pathway and CASP3 CC activation as well as in response to viral agents (PubMed:28045099). CC Exhibits bactericidal activity (PubMed:27281216). Cleavage by GZMB CC promotes tumor suppressor activity by triggering robust anti-tumor CC immunity (PubMed:21522185, PubMed:32188940). Suppresses tumors by CC mediating granzyme-mediated pyroptosis in target cells of natural CC killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target CC cells from NK-cells, triggers pyroptosis of tumor cells and tumor CC suppression (PubMed:31953257, PubMed:32188940). May play a role in the CC p53/TP53-regulated cellular response to DNA damage (PubMed:16897187). CC {ECO:0000269|PubMed:16897187, ECO:0000269|PubMed:21522185, CC ECO:0000269|PubMed:27281216, ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: (Microbial infection) Pore-forming CC protein, which promotes maternal placental pyroptosis in response to CC Zika virus infection, contributing to adverse fetal outcomes. CC {ECO:0000269|PubMed:35972780}. CC -!- ACTIVITY REGULATION: [Gasdermin-E]: The full-length protein before CC cleavage is inactive: intramolecular interactions between N- and C- CC terminal domains mediate autoinhibition in the absence of activation CC signal (PubMed:28045099, PubMed:28459430). The intrinsic pyroptosis- CC inducing activity is carried by the released N-terminal moiety CC (Gasdermin-E, N-terminal) following cleavage by CASP3 or granzyme B CC (GZMB) (PubMed:28459430, PubMed:31953257, PubMed:32188940, CC PubMed:35594856). Activated by NLRP1 in the absence of GSDMD CC expression: NLRP1 cleaves and activates CASP8, promoting downstream CC activation of CASP3 and subsequent activation of GSDME CC (PubMed:33852854, PubMed:35594856). {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- ACTIVITY REGULATION: (Microbial infection) Activated upon human CC coronavirus SARS-CoV-2 infection, leading to lung epithelial cell death CC (PubMed:35594856). Activation takes place in response to (1) activation CC of NLRP1 and (2) inactivation of GSDMD following NLRP1 and GSDMD CC cleavage by the SARS-CoV-2 3C-like proteinase nsp5 (PubMed:35594856). CC {ECO:0000269|PubMed:35594856}. CC -!- SUBUNIT: [Gasdermin-E, N-terminal]: Homooligomer; homooligomeric ring- CC shaped pore complex containing 27-28 subunits when inserted in the CC membrane. {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- INTERACTION: CC O60443; Q96CG3: TIFA; NbExp=3; IntAct=EBI-719315, EBI-740711; CC -!- SUBCELLULAR LOCATION: [Gasdermin-E, N-terminal]: Cell membrane CC {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430}; Multi-pass CC membrane protein {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- SUBCELLULAR LOCATION: [Gasdermin-E]: Cytoplasm, cytosol CC {ECO:0000269|PubMed:28045099}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O60443-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O60443-2; Sequence=VSP_004190; CC Name=3; CC IsoId=O60443-3; Sequence=VSP_044276; CC -!- TISSUE SPECIFICITY: Expressed in cochlea (PubMed:9771715). Low level of CC expression in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas, with highest expression in placenta CC (PubMed:9771715). {ECO:0000269|PubMed:9771715}. CC -!- DOMAIN: Intramolecular interactions between N- and C-terminal domains CC may be important for autoinhibition in the absence of activation CC signal. The intrinsic pyroptosis-inducing activity is carried by the N- CC terminal domain, that is released upon cleavage by CASP3 or granzyme B CC (GZMB). {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: Cleavage at Asp-270 by CASP3 (mature and uncleaved precursor CC forms) or granzyme B (GZMB) relieves autoinhibition and is sufficient CC to initiate pyroptosis. {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: [Gasdermin-E]: Succination by the Krebs cycle intermediate CC fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits CC processing by caspases, and ability to initiate pyroptosis CC (PubMed:32820063). Succination modification is catalyzed by a non- CC enzymatic reaction caused by an accumulation of fumarate CC (PubMed:32820063). {ECO:0000269|PubMed:32820063}. CC -!- PTM: [Gasdermin-E]: Ubiquitinated at Lys-120 and Lys-189 via 'Lys-48'- CC linked polyubiquitin chains, leading to proteasomal degradation. CC Deubiquitinated by USP48, leading to increased stability. CC {ECO:0000269|PubMed:36607699}. CC -!- PTM: Palmitoylated. {ECO:0000269|PubMed:38599239}. CC -!- DISEASE: Deafness, autosomal dominant, 5 (DFNA5) [MIM:600994]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:19911014, ECO:0000269|PubMed:24506266, CC ECO:0000269|PubMed:26236191, ECO:0000269|PubMed:9771715}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Is a tumor suppressor gene with an important role in CC colorectal cancer (CRC). {ECO:0000303|PubMed:18223688}. CC -!- SIMILARITY: Belongs to the gasdermin family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB83938.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=AAC39635.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF073308; AAC69324.1; -; mRNA. DR EMBL; AF075171; AAC69326.1; -; mRNA. DR EMBL; AF131765; AAD20039.1; -; mRNA. DR EMBL; AK094714; BAG52917.1; -; mRNA. DR EMBL; AK314402; BAG37026.1; -; mRNA. DR EMBL; AC003093; AAB83938.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH236948; EAL24246.1; -; Genomic_DNA. DR EMBL; CH471073; EAW93813.1; -; Genomic_DNA. DR EMBL; BC125065; AAI25066.1; -; mRNA. DR EMBL; AF007790; AAC39635.2; ALT_INIT; mRNA. DR CCDS; CCDS47563.1; -. [O60443-3] DR CCDS; CCDS5389.1; -. [O60443-1] DR RefSeq; NP_001120925.1; NM_001127453.2. [O60443-1] DR RefSeq; NP_001120926.1; NM_001127454.2. [O60443-3] DR RefSeq; NP_001424988.1; NM_001438059.1. [O60443-3] DR RefSeq; NP_004394.1; NM_004403.3. [O60443-1] DR RefSeq; XP_024302438.1; XM_024446670.2. [O60443-1] DR RefSeq; XP_054213373.1; XM_054357398.1. [O60443-1] DR AlphaFoldDB; O60443; -. DR BioGRID; 108049; 65. DR FunCoup; O60443; 518. DR IntAct; O60443; 158. DR MINT; O60443; -. DR STRING; 9606.ENSP00000339587; -. DR TCDB; 1.C.123.1.5; the pore-forming gasdermin (gasdermin) family. DR GlyGen; O60443; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O60443; -. DR PhosphoSitePlus; O60443; -. DR SwissPalm; O60443; -. DR BioMuta; GSDME; -. DR jPOST; O60443; -. DR MassIVE; O60443; -. DR PaxDb; 9606-ENSP00000339587; -. DR PeptideAtlas; O60443; -. DR ProteomicsDB; 3659; -. DR ProteomicsDB; 49403; -. [O60443-1] DR ProteomicsDB; 49404; -. [O60443-2] DR Antibodypedia; 1157; 225 antibodies from 32 providers. DR DNASU; 1687; -. DR Ensembl; ENST00000342947.9; ENSP00000339587.3; ENSG00000105928.17. [O60443-1] DR Ensembl; ENST00000409970.6; ENSP00000387119.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000419307.6; ENSP00000401332.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000645220.1; ENSP00000494186.1; ENSG00000105928.17. [O60443-1] DR GeneID; 1687; -. DR KEGG; hsa:1687; -. DR MANE-Select; ENST00000645220.1; ENSP00000494186.1; NM_001127453.2; NP_001120925.1. DR UCSC; uc003sxa.2; human. [O60443-1] DR AGR; HGNC:2810; -. DR ClinPGx; PA27281; -. DR CTD; 1687; -. DR DisGeNET; 1687; -. DR GeneCards; GSDME; -. DR GeneReviews; GSDME; -. DR HGNC; HGNC:2810; GSDME. DR HPA; ENSG00000105928; Low tissue specificity. DR MalaCards; GSDME; -. DR MIM; 600994; phenotype. DR MIM; 608798; gene. DR OpenTargets; ENSG00000105928; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000105928; -. DR eggNOG; ENOG502QRAB; Eukaryota. DR GeneTree; ENSGT00940000155880; -. DR HOGENOM; CLU_042999_0_0_1; -. DR InParanoid; O60443; -. DR OMA; EMTNDCL; -. DR OrthoDB; 8815334at2759; -. DR PAN-GO; O60443; 2 GO annotations based on evolutionary models. DR PhylomeDB; O60443; -. DR PathwayCommons; O60443; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand. DR Reactome; R-HSA-9710421; Defective pyroptosis. DR SignaLink; O60443; -. DR Agora; ENSG00000105928; -. DR BioGRID-ORCS; 1687; 9 hits in 1147 CRISPR screens. DR ChiTaRS; DFNA5; human. DR GeneWiki; DFNA5; -. DR GenomeRNAi; 1687; -. DR Pharos; O60443; Tbio. DR PRO; PR:O60443; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; O60443; protein. DR Bgee; ENSG00000105928; Expressed in germinal epithelium of ovary and 190 other cell types or tissues. DR ExpressionAtlas; O60443; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:1901612; F:cardiolipin binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0022829; F:wide pore channel activity; IDA:UniProt. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0042491; P:inner ear auditory receptor cell differentiation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0002839; P:positive regulation of immune response to tumor cell; IDA:UniProt. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0012501; P:programmed cell death; IMP:UniProtKB. DR GO; GO:0141201; P:pyroptotic cell death; IDA:UniProt. DR GO; GO:0070269; P:pyroptotic inflammatory response; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc. DR InterPro; IPR040460; Gasdermin_pore. DR InterPro; IPR041263; Gasdermin_PUB. DR InterPro; IPR042377; GSDME. DR PANTHER; PTHR15207:SF1; GASDERMIN-E; 1. DR PANTHER; PTHR15207; NONSYNDROMIC HEARING IMPAIRMENT PROTEIN; 1. DR Pfam; PF04598; Gasdermin; 1. DR Pfam; PF17708; Gasdermin_C; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Deafness; Isopeptide bond; KW Lipoprotein; Membrane; Necrosis; Non-syndromic deafness; Palmitate; KW Proteomics identification; Reference proteome; Transmembrane; KW Transmembrane beta strand; Tumor suppressor; Ubl conjugation. FT CHAIN 1..496 FT /note="Gasdermin-E" FT /id="PRO_0000148178" FT CHAIN 1..270 FT /note="Gasdermin-E, N-terminal" FT /evidence="ECO:0000269|PubMed:27281216, FT ECO:0000305|PubMed:28459430, ECO:0000305|PubMed:32188940" FT /id="PRO_0000442786" FT CHAIN 271..496 FT /note="Gasdermin-E, C-terminal" FT /evidence="ECO:0000305|PubMed:28459430" FT /id="PRO_0000442787" FT REGION 1..56 FT /note="Membrane targeting domain" FT /evidence="ECO:0000269|PubMed:28045099" FT SITE 270..271 FT /note="Cleavage; by CASP3 or granzyme B" FT /evidence="ECO:0000269|PubMed:28459430, FT ECO:0000269|PubMed:32188940" FT MOD_RES 45 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 156 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 168 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 180 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 235 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 371 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 408 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 417 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 489 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT CROSSLNK 120 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT CROSSLNK 189 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT VAR_SEQ 1..395 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3" FT /id="VSP_004190" FT VAR_SEQ 1..164 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044276" FT VARIANT 14 FT /note="D -> Y (in a breast carcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083903" FT VARIANT 18 FT /note="D -> V (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083904" FT VARIANT 24 FT /note="N -> D (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083905" FT VARIANT 44 FT /note="W -> C (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083906" FT VARIANT 48 FT /note="R -> I (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083907" FT VARIANT 137 FT /note="I -> T (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083908" FT VARIANT 142 FT /note="P -> T (in dbSNP:rs754554)" FT /evidence="ECO:0000269|PubMed:12690205" FT /id="VAR_030824" FT VARIANT 174 FT /note="M -> T (in dbSNP:rs876306)" FT /id="VAR_053102" FT VARIANT 199 FT /note="G -> E (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083909" FT VARIANT 207 FT /note="V -> M (in dbSNP:rs12540919)" FT /id="VAR_030825" FT VARIANT 212 FT /note="P -> L (in a melanoma sample; somatic mutation; FT reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083910" FT VARIANT 217 FT /note="I -> N (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083911" FT MUTAGEN 2 FT /note="F->A: No effect on plasma membrane targeting. FT Decreases induction of necrotic activity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-40." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:32188940" FT MUTAGEN 39 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-40 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 40 FT /note="K->A: No effect on plasma membrane targeting. No FT effect on induction of cytotoxivity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-2 or A-39 and A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 41 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-39 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 267 FT /note="D->A: Abolishes cleavage by CASP3. Abolishes FT pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28459430" FT MUTAGEN 270 FT /note="D->A,E: Abolishes cleavage by CASP3 or granzyme B. FT Abolishes pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:32188940, FT ECO:0000269|PubMed:33852854" FT MUTAGEN 313 FT /note="I->D: No spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 388 FT /note="F->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 392 FT /note="A->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" SQ SEQUENCE 496 AA; 54555 MW; A407C9AC31AA716B CRC64; MFAKATRNFL REVDADGDLI AVSNLNDSDK LQLLSLVTKK KRFWCWQRPK YQFLSLTLGD VLIEDQFPSP VVVESDFVKY EGKFANHVSG TLETALGKVK LNLGGSSRVE SQSSFGTLRK QEVDLQQLIR DSAERTINLR NPVLQQVLEG RNEVLCVLTQ KITTMQKCVI SEHMQVEEKC GGIVGIQTKT VQVSATEDGN VTKDSNVVLE IPAATTIAYG VIELYVKLDG QFEFCLLRGK QGGFENKKRI DSVYLDPLVF REFAFIDMPD AAHGISSQDG PLSVLKQATL LLERNFHPFA ELPEPQQTAL SDIFQAVLFD DELLMVLEPV CDDLVSGLSP TVAVLGELKP RQQQDLVAFL QLVGCSLQGG CPGPEDAGSK QLFMTAYFLV SALAEMPDSA AALLGTCCKL QIIPTLCHLL RALSDDGVSD LEDPTLTPLK DTERFGIVQR LFASADISLE RLKSSVKAVI LKDSKVFPLL LCITLNGLCA LGREHS // ID IRF1_HUMAN Reviewed; 325 AA. AC P10914; Q96GG7; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 16-APR-2002, sequence version 2. DT 28-JAN-2026, entry version 213. DE RecName: Full=Interferon regulatory factor 1; DE Short=IRF-1; GN Name=IRF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2726461; DOI=10.1093/nar/17.8.3292; RA Maruyama M., Fujita T., Taniguchi T.; RT "Sequence of a cDNA coding for human IRF-1."; RL Nucleic Acids Res. 17:3292-3292(1989). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=3409321; DOI=10.1016/s0092-8674(88)91307-4; RA Miyamoto M., Fujita T., Kimura Y., Maruyama M., Harada H., Sudo Y., RA Miyata T., Taniguchi T.; RT "Regulated expression of a gene encoding a nuclear factor, IRF-1, that RT specifically binds to IFN-beta gene regulatory elements."; RL Cell 54:903-913(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=1382447; DOI=10.1089/dna.1992.11.605; RA Cha Y., Sims S.H., Romine M.F., Kaufmann M., Deisseroth A.B.; RT "Human interferon regulatory factor 1: intron-exon organization."; RL DNA Cell Biol. 11:605-611(1992). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION. RX PubMed=7687740; DOI=10.1128/mcb.13.8.4531-4538.1993; RA Tanaka N., Kawakami T., Taniguchi T.; RT "Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and RT IRF-2, regulators of cell growth and the interferon system."; RL Mol. Cell. Biol. 13:4531-4538(1993). RN [7] RP INVOLVEMENT IN LEUKEMIAS. RX PubMed=8438156; DOI=10.1126/science.8438156; RA Willman C.L., Sever C.E., Pallavicini M.G., Harada H., Tanaka N., RA Slovak M.L., Yamamoto H., Harada K., Meeker T.C., List A.F., Taniguchi T.; RT "Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and RT preleukemic myelodysplasia."; RL Science 259:968-971(1993). RN [8] RP INDUCTION. RX PubMed=7507207; DOI=10.1128/mcb.14.2.1500-1509.1994; RA Harada H., Takahashi E., Itoh S., Harada K., Hori T.A., Taniguchi T.; RT "Structure and regulation of the human interferon regulatory factor 1 (IRF- RT 1) and IRF-2 genes: implications for a gene network in the interferon RT system."; RL Mol. Cell. Biol. 14:1500-1509(1994). RN [9] RP PHOSPHORYLATION. RX PubMed=10094406; DOI=10.1023/a:1006850009017; RA Lin R., Hiscott J.; RT "A role for casein kinase II phosphorylation in the regulation of IRF-1 RT transcriptional activity."; RL Mol. Cell. Biochem. 191:169-180(1999). RN [10] RP REVIEW ON FUNCTION. RX PubMed=11244049; DOI=10.1146/annurev.immunol.19.1.623; RA Taniguchi T., Ogasawara K., Takaoka A., Tanaka N.; RT "IRF family of transcription factors as regulators of host defense."; RL Annu. Rev. Immunol. 19:623-655(2001). RN [11] RP REVIEW ON FUNCTION. RX PubMed=11846971; DOI=10.1089/107999002753452610; RA Kroeger A., Koester M., Schroeder K., Hauser H., Mueller P.P.; RT "Activities of IRF-1."; RL J. Interferon Cytokine Res. 22:5-14(2002). RN [12] RP REVIEW ON FUNCTION. RX PubMed=11846974; DOI=10.1089/107999002753452647; RA Romeo G., Fiorucci G., Chiantore M.V., Percario Z.A., Vannucchi S., RA Affabris E.; RT "IRF-1 as a negative regulator of cell proliferation."; RL J. Interferon Cytokine Res. 22:39-47(2002). RN [13] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=15226432; DOI=10.1128/mcb.24.14.6298-6310.2004; RA Oshima S., Nakamura T., Namiki S., Okada E., Tsuchiya K., Okamoto R., RA Yamazaki M., Yokota T., Aida M., Yamaguchi Y., Kanai T., Handa H., RA Watanabe M.; RT "Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate RT gene expression and production of interleukin-7 in human intestinal RT epithelial cells."; RL Mol. Cell. Biol. 24:6298-6310(2004). RN [14] RP FUNCTION, AND INTERACTION WITH EP300. RX PubMed=15509808; DOI=10.1128/mcb.24.22.10083-10098.2004; RA Dornan D., Eckert M., Wallace M., Shimizu H., Ramsay E., Hupp T.R., RA Ball K.L.; RT "Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent RT acetylation of p53."; RL Mol. Cell. Biol. 24:10083-10098(2004). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16932750; DOI=10.1038/nri1900; RA Honda K., Taniguchi T.; RT "IRFs: master regulators of signalling by Toll-like receptors and cytosolic RT pattern-recognition receptors."; RL Nat. Rev. Immunol. 6:644-658(2006). RN [16] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=17516545; DOI=10.1002/jcp.21128; RA Su Z.Z., Sarkar D., Emdad L., Barral P.M., Fisher P.B.; RT "Central role of interferon regulatory factor-1 (IRF-1) in controlling RT retinoic acid inducible gene-I (RIG-I) expression."; RL J. Cell. Physiol. 213:502-510(2007). RN [17] RP FUNCTION. RX PubMed=18084608; DOI=10.1593/neo.07640; RA Maratheftis C.I., Giannouli S., Spachidou M.P., Panayotou G., RA Voulgarelis M.; RT "RNA interference of interferon regulatory factor-1 gene expression in THP- RT 1 cell line leads to Toll-like receptor-4 overexpression/activation as well RT as up-modulation of annexin-II."; RL Neoplasia 9:1012-1020(2007). RN [18] RP SUMOYLATION AT LYS-275 AND LYS-299, UBIQUITINATION AT LYS-275 AND LYS-299, RP FUNCTION, INDUCTION BY IFN, AND MUTAGENESIS OF LYS-275 AND LYS-299. RX PubMed=17942705; DOI=10.1073/pnas.0609852104; RA Park J., Kim K., Lee E.-J., Seo Y.-J., Lim S.-N., Park K., Rho S.B., RA Lee S.-H., Lee J.-H.; RT "Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1- RT mediated apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 104:17028-17033(2007). RN [19] RP FUNCTION. RX PubMed=18497060; DOI=10.1007/978-0-387-69080-3_35; RA Bowie M.L., Ibarra C., Seewalt V.L.; RT "IRF-1 promotes apoptosis in p53-damaged basal-type human mammary RT epithelial cells: a model for early basal-type mammary carcinogenesis."; RL Adv. Exp. Med. Biol. 617:367-374(2008). RN [20] RP FUNCTION. RX PubMed=18641303; DOI=10.4049/jimmunol.181.3.1673; RA Fragale A., Gabriele L., Stellacci E., Borghi P., Perrotti E., Ilari R., RA Lanciotti A., Remoli A.L., Venditti M., Belardelli F., Battistini A.; RT "IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell RT differentiation by repressing Foxp3 expression."; RL J. Immunol. 181:1673-1682(2008). RN [21] RP FUNCTION, AND INDUCTION BY HIV AND IFN. RX PubMed=19404407; DOI=10.1371/journal.pone.0005397; RA Huang Y., Walstrom A., Zhang L., Zhao Y., Cui M., Ye L., Zheng J.C.; RT "Type I interferons and interferon regulatory factors regulate TNF-related RT apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages."; RL PLoS ONE 4:E5397-E5397(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20049431; DOI=10.1007/s00262-009-0804-6; RA Savitsky D., Tamura T., Yanai H., Taniguchi T.; RT "Regulation of immunity and oncogenesis by the IRF transcription factor RT family."; RL Cancer Immunol. Immunother. 59:489-510(2010). RN [23] RP FUNCTION, AND INDUCTION BY IFN. RX PubMed=19851330; DOI=10.1038/cdd.2009.156; RA Gao J., Senthil M., Ren B., Yan J., Xing Q., Yu J., Zhang L., Yim J.H.; RT "IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial RT apoptotic pathway in IRF-1-induced apoptosis in cancer cells."; RL Cell Death Differ. 17:699-709(2010). RN [24] RP FUNCTION, AND INDUCTION BY HPV16 E5. RX PubMed=21389130; DOI=10.1128/jvi.02114-10; RA Muto V., Stellacci E., Lamberti A.G., Perrotti E., Carrabba A., Matera G., RA Sgarbanti M., Battistini A., Liberto M.C., Foca A.; RT "Human papillomavirus type 16 E5 protein induces expression of beta RT interferon through interferon regulatory factor 1 in human keratinocytes."; RL J. Virol. 85:5070-5080(2011). RN [25] RP FUNCTION. RX PubMed=22200613; DOI=10.1016/j.canlet.2011.12.027; RA Armstrong M.J., Stang M.T., Liu Y., Gao J., Ren B., Zuckerbraun B.S., RA Mahidhara R.S., Xing Q., Pizzoferrato E., Yim J.H.; RT "Interferon regulatory factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent RT cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in RT cancer cells."; RL Cancer Lett. 319:56-65(2012). RN [26] RP FUNCTION, INDUCTION BY N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, ACETYLATION AT RP LYS-78, AND MUTAGENESIS OF LYS-78. RX PubMed=22367195; DOI=10.1074/jbc.m111.313429; RA Qi H., Zhu H., Lou M., Fan Y., Liu H., Shen J., Li Z., Lv X., Shan J., RA Zhu L., Chin Y.E., Shao J.; RT "Interferon regulatory factor 1 transactivates the expression of human DNA RT polymerase eta in response to the carcinogen N-methyl-N'-nitro-N- RT nitrosoguanidine."; RL J. Biol. Chem. 287:12622-12633(2012). RN [27] RP FUNCTION. RX PubMed=32385160; DOI=10.1073/pnas.1921484117; RA Somerville T.D.D., Xu Y., Wu X.S., Maia-Silva D., Hur S.K., RA de Almeida L.M.N., Preall J.B., Koo P.K., Vakoc C.R.; RT "ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell RT identity in pancreatic cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 117:11471-11482(2020). RN [28] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SPOP. RX PubMed=37622993; DOI=10.7554/elife.89951; RA Schwartz I., Vunjak M., Budroni V., Cantoran Garcia A., Mastrovito M., RA Soderholm A., Hinterndorfer M., de Almeida M., Hacker K., Wang J., RA Froussios K., Jude J., Decker T., Zuber J., Versteeg G.A.; RT "SPOP targets the immune transcription factor IRF1 for proteasomal RT degradation."; RL Elife 12:0-0(2023). RN [29] RP VARIANT GASC LEU-8, AND CHARACTERIZATION OF VARIANT GASC LEU-8. RX PubMed=9679752; RX DOI=10.1002/(sici)1097-0215(19980812)77:4<522::aid-ijc8>3.0.co;2-w; RA Nozawa H., Oda E., Ueda S., Tamura G., Maesawa C., Muto T., Taniguchi T., RA Tanaka N.; RT "Functionally inactivating point mutation in the tumor-suppressor IRF-1 RT gene identified in human gastric cancer."; RL Int. J. Cancer 77:522-527(1998). RN [30] RP VARIANT GASC ARG-11. RX PubMed=10395927; DOI=10.1016/s0167-4781(99)00078-0; RA Eason D.D., Shepherd A.T., Blanck G.; RT "Interferon regulatory factor 1 tryptophan 11 to arginine point mutation RT abolishes DNA binding."; RL Biochim. Biophys. Acta 1446:140-144(1999). RN [31] RP VARIANT IMD117 129-ARG--PRO-325 DEL, CHARACTERIZATION OF VARIANT IMD117 RP 129-ARG--PRO-325 DEL, INVOLVEMENT IN IMD117, MUTAGENESIS OF ALA-67, AND RP FUNCTION. RX PubMed=36736301; DOI=10.1016/j.cell.2022.12.038; RA Rosain J., Neehus A.L., Manry J., Yang R., Le Pen J., Daher W., Liu Z., RA Chan Y.H., Tahuil N., Tuerel O., Bourgey M., Ogishi M., Doisne J.M., RA Izquierdo H.M., Shirasaki T., Le Voyer T., Guerin A., Bastard P., RA Moncada-Velez M., Han J.E., Khan T., Rapaport F., Hong S.H., Cheung A., RA Haake K., Mindt B.C., Perez L., Philippot Q., Lee D., Zhang P., Rinchai D., RA Al Ali F., Ahmad Ata M.M., Rahman M., Peel J.N., Heissel S., Molina H., RA Kendir-Demirkol Y., Bailey R., Zhao S., Bohlen J., Mancini M., RA Seeleuthner Y., Roelens M., Lorenzo L., Soudee C., Paz M.E.J., RA Gonzalez M.L., Jeljeli M., Soulier J., Romana S., L'Honneur A.S., RA Materna M., Martinez-Barricarte R., Pochon M., Oleaga-Quintas C., RA Michev A., Migaud M., Levy R., Alyanakian M.A., Rozenberg F., Croft C.A., RA Vogt G., Emile J.F., Kremer L., Ma C.S., Fritz J.H., Lemon S.M., RA Spaan A.N., Manel N., Abel L., MacDonald M.R., Boisson-Dupuis S., Marr N., RA Tangye S.G., Di Santo J.P., Zhang Q., Zhang S.Y., Rice C.M., Beziat V., RA Lachmann N., Langlais D., Casanova J.L., Gros P., Bustamante J.; RT "Human IRF1 governs macrophagic IFN-gamma immunity to mycobacteria."; RL Cell 186:621-645(2023). CC -!- FUNCTION: Transcriptional regulator which displays a remarkable CC functional diversity in the regulation of cellular responses CC (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, CC PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195, CC PubMed:32385160). Regulates transcription of IFN and IFN-inducible CC genes, host response to viral and bacterial infections, regulation of CC many genes expressed during hematopoiesis, inflammation, immune CC responses and cell proliferation and differentiation, regulation of the CC cell cycle and induction of growth arrest and programmed cell death CC following DNA damage (PubMed:15226432, PubMed:15509808, CC PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, CC PubMed:19851330, PubMed:22367195, PubMed:7687740). Stimulates both CC innate and acquired immune responses through the activation of specific CC target genes and can act as a transcriptional activator and repressor CC regulating target genes by binding to an interferon-stimulated response CC element (ISRE) in their promoters (PubMed:15226432, PubMed:15509808, CC PubMed:17516545, PubMed:17942705, PubMed:18497060, PubMed:19404407, CC PubMed:19851330, PubMed:21389130, PubMed:22367195). Has an essentail CC role in IFNG-dependent immunity to mycobacteria (PubMed:36736301). CC Competes with the transcriptional repressor ZBED2 for binding to a CC common consensus sequence in gene promoters (PubMed:32385160). Its CC target genes for transcriptional activation activity include: genes CC involved in anti-viral response, such as IFN-alpha/beta, RIGI, CC TNFSF10/TRAIL, ZBP1, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; CC antibacterial response, such as GBP2, GBP5 and NOS2/INOS; anti- CC proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, CC such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as CC IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and CC DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, CC PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II CC expression, such as CIITA; metabolic enzymes, such as ACOD1/IRG1 CC (PubMed:15226432, PubMed:15509808, PubMed:17516545, PubMed:17942705, CC PubMed:18497060, PubMed:19404407, PubMed:19851330, PubMed:22367195). CC Represses genes involved in anti-proliferative response, such as CC BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune CC response, such as FOXP3, IL4, ANXA2 and TLR4 (PubMed:18641303, CC PubMed:22200613). Stimulates p53/TP53-dependent transcription through CC enhanced recruitment of EP300 leading to increased acetylation of CC p53/TP53 (PubMed:15509808, PubMed:18084608). Plays an important role in CC immune response directly affecting NK maturation and activity, CC macrophage production of IL12, Th1 development and maturation of CD8+ CC T-cells (PubMed:11244049, PubMed:11846971, PubMed:11846974, CC PubMed:16932750). Also implicated in the differentiation and maturation CC of dendritic cells and in the suppression of regulatory T (Treg) cells CC development (PubMed:11244049, PubMed:11846971, PubMed:11846974, CC PubMed:16932750). Acts as a tumor suppressor and plays a role not only CC in antagonism of tumor cell growth but also in stimulating an immune CC response against tumor cells (PubMed:20049431). CC {ECO:0000269|PubMed:15226432, ECO:0000269|PubMed:15509808, CC ECO:0000269|PubMed:17516545, ECO:0000269|PubMed:17942705, CC ECO:0000269|PubMed:18084608, ECO:0000269|PubMed:18497060, CC ECO:0000269|PubMed:18641303, ECO:0000269|PubMed:19404407, CC ECO:0000269|PubMed:19851330, ECO:0000269|PubMed:21389130, CC ECO:0000269|PubMed:22200613, ECO:0000269|PubMed:22367195, CC ECO:0000269|PubMed:32385160, ECO:0000269|PubMed:36736301, CC ECO:0000269|PubMed:7687740, ECO:0000303|PubMed:11244049, CC ECO:0000303|PubMed:11846971, ECO:0000303|PubMed:11846974, CC ECO:0000303|PubMed:16932750, ECO:0000303|PubMed:20049431}. CC -!- ACTIVITY REGULATION: Activated by MYD88. CC {ECO:0000250|UniProtKB:P15314}. CC -!- SUBUNIT: Monomer (By similarity). Homodimer (By similarity). Interacts CC with EP300 (PubMed:15509808). Interacts with MYD88 (By similarity). CC Interacts with PIAS3 (By similarity). Interacts with SPOP CC (PubMed:37622993). {ECO:0000250|UniProtKB:P15314, CC ECO:0000269|PubMed:15509808, ECO:0000269|PubMed:37622993}. CC -!- INTERACTION: CC P10914; Q14653: IRF3; NbExp=5; IntAct=EBI-1055781, EBI-2650369; CC P10914; Q16236: NFE2L2; NbExp=3; IntAct=EBI-1055781, EBI-2007911; CC P10914; P63165: SUMO1; NbExp=2; IntAct=EBI-1055781, EBI-80140; CC P10914; P03129: E7; Xeno; NbExp=4; IntAct=EBI-1055781, EBI-866453; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:37622993}. Cytoplasm CC {ECO:0000250|UniProtKB:P15314}. Note=MYD88-associated IRF1 migrates CC into the nucleus more efficiently than non-MYD88-associated IRF1. CC {ECO:0000250|UniProtKB:P15314}. CC -!- INDUCTION: By viruses and IFN (PubMed:7507207). Induced by HPV16 E5 CC (PubMed:21389130). Induced by HIV (PubMed:19404407). By interferon CC (IFN) (PubMed:15226432, PubMed:17516545, PubMed:17942705, CC PubMed:19404407, PubMed:19851330, PubMed:32385160). Induced by N- CC methyl-N'-nitro-N-nitrosoguanidine (PubMed:22367195). CC {ECO:0000269|PubMed:15226432, ECO:0000269|PubMed:17516545, CC ECO:0000269|PubMed:17942705, ECO:0000269|PubMed:19404407, CC ECO:0000269|PubMed:19851330, ECO:0000269|PubMed:21389130, CC ECO:0000269|PubMed:22367195, ECO:0000269|PubMed:32385160, CC ECO:0000269|PubMed:7507207}. CC -!- PTM: Phosphorylated by CK2 and this positively regulates its activity. CC {ECO:0000269|PubMed:10094406}. CC -!- PTM: Sumoylation represses the transcriptional activity and displays CC enhanced resistance to protein degradation (PubMed:17942705). CC Sumoylated by UBE2I/UBC9 and SUMO1 (By similarity). Inactivates the CC tumor suppressor activity (PubMed:17942705). Elevated levels in tumor CC cells (PubMed:17942705). Major site is Lys-275 (PubMed:17942705). CC Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 CC in tumor cells and appears to compete with ubiquitination on C-terminal CC sites (PubMed:17942705). {ECO:0000250|UniProtKB:P15314, CC ECO:0000269|PubMed:17942705}. CC -!- PTM: Ubiquitinated in a SPOP-depedent manner (PubMed:37622993). Appears CC to compete with sumoylation on C-terminal sites. CC {ECO:0000269|PubMed:17942705, ECO:0000269|PubMed:37622993}. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:10395927, CC ECO:0000269|PubMed:9679752}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Immunodeficiency 117 (IMD117) [MIM:620668]: An autosomal CC recessive immunologic disorder characterized by increased CC susceptibility to disseminated mycobacterial infection apparent in CC early childhood, after exposure to weakly virulent mycobacteria. CC Affected individuals develop mycobacterial disease after BCG (bacille CC Calmette-Guerin) vaccination. Immunologic workup shows impaired CC development of myeloid and lymphoid cell subsets that secrete and CC respond to gamma-interferon. {ECO:0000269|PubMed:36736301}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Deletion or rearrangement of IRF1 are found in CC preleukemic myelodysplastic syndrome (MDS) and acute myelogenous CC leukemia (AML). CC -!- SIMILARITY: Belongs to the IRF family. {ECO:0000255|PROSITE- CC ProRule:PRU00840}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40990/IRF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X14454; CAA32624.1; -; mRNA. DR EMBL; L05072; AAA36043.1; -; Genomic_DNA. DR EMBL; BT019756; AAV38561.1; -; mRNA. DR EMBL; BC009483; AAH09483.1; -; mRNA. DR CCDS; CCDS4155.1; -. DR PIR; B31595; B31595. DR PIR; I52998; I52998. DR RefSeq; NP_002189.1; NM_002198.3. DR AlphaFoldDB; P10914; -. DR SMR; P10914; -. DR BioGRID; 109867; 69. DR CORUM; P10914; -. DR DIP; DIP-40988N; -. DR FunCoup; P10914; 2329. DR IntAct; P10914; 33. DR MINT; P10914; -. DR STRING; 9606.ENSP00000245414; -. DR iPTMnet; P10914; -. DR PhosphoSitePlus; P10914; -. DR BioMuta; IRF1; -. DR DMDM; 20178295; -. DR jPOST; P10914; -. DR MassIVE; P10914; -. DR PaxDb; 9606-ENSP00000245414; -. DR PeptideAtlas; P10914; -. DR ProteomicsDB; 52676; -. DR Antibodypedia; 3180; 485 antibodies from 38 providers. DR DNASU; 3659; -. DR Ensembl; ENST00000245414.9; ENSP00000245414.4; ENSG00000125347.16. DR Ensembl; ENST00000405885.6; ENSP00000384406.1; ENSG00000125347.16. DR GeneID; 3659; -. DR KEGG; hsa:3659; -. DR MANE-Select; ENST00000245414.9; ENSP00000245414.4; NM_002198.3; NP_002189.1. DR AGR; HGNC:6116; -. DR ClinPGx; PA29915; -. DR CTD; 3659; -. DR DisGeNET; 3659; -. DR GeneCards; IRF1; -. DR HGNC; HGNC:6116; IRF1. DR HPA; ENSG00000125347; Tissue enhanced (bone). DR MalaCards; IRF1; -. DR MIM; 147575; gene. DR MIM; 613659; phenotype. DR MIM; 620668; phenotype. DR OpenTargets; ENSG00000125347; -. DR Orphanet; 699615; Severe mendelian susceptibility to mycobacterial diseases due to complete IRF1 deficiency. DR VEuPathDB; HostDB:ENSG00000125347; -. DR eggNOG; ENOG502QVVN; Eukaryota. DR GeneTree; ENSGT00940000156288; -. DR HOGENOM; CLU_056386_1_0_1; -. DR InParanoid; P10914; -. DR OMA; HSGYTIH; -. DR OrthoDB; 6538197at2759; -. DR PAN-GO; P10914; 5 GO annotations based on evolutionary models. DR PhylomeDB; P10914; -. DR PathwayCommons; P10914; -. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR SignaLink; P10914; -. DR SIGNOR; P10914; -. DR Agora; ENSG00000125347; -. DR BioGRID-ORCS; 3659; 25 hits in 1185 CRISPR screens. DR ChiTaRS; IRF1; human. DR GeneWiki; IRF1; -. DR GenomeRNAi; 3659; -. DR Pharos; P10914; Tbio. DR PRO; PR:P10914; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P10914; protein. DR Bgee; ENSG00000125347; Expressed in granulocyte and 182 other cell types or tissues. DR ExpressionAtlas; P10914; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003677; F:DNA binding; TAS:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0043374; P:CD8-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0035458; P:cellular response to interferon-beta; IDA:BHF-UCL. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0002376; P:immune system process; IBA:GO_Central. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; ISS:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IMP:UniProtKB. DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0032481; P:positive regulation of type I interferon production; ISS:UniProtKB. DR GO; GO:0002819; P:regulation of adaptive immune response; TAS:UniProtKB. DR GO; GO:2000564; P:regulation of CD8-positive, alpha-beta T cell proliferation; ISS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0045088; P:regulation of innate immune response; TAS:UniProtKB. DR GO; GO:0034124; P:regulation of MyD88-dependent toll-like receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:MGI. DR GO; GO:0034138; P:toll-like receptor 3 signaling pathway; IDA:MGI. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; ISS:UniProtKB. DR CDD; cd00103; IRF; 1. DR FunFam; 1.10.10.10:FF:000065; Interferon regulatory factor; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR InterPro; IPR019817; Interferon_reg_fac_CS. DR InterPro; IPR001346; Interferon_reg_fact_DNA-bd_dom. DR InterPro; IPR017431; IRF1/IRF2. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR PANTHER; PTHR11949; INTERFERON REGULATORY FACTOR; 1. DR PANTHER; PTHR11949:SF3; INTERFERON REGULATORY FACTOR 1; 1. DR Pfam; PF00605; IRF; 1. DR PIRSF; PIRSF038196; IFN_RF1/2; 1. DR PRINTS; PR00267; INTFRNREGFCT. DR SMART; SM00348; IRF; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS00601; IRF_1; 1. DR PROSITE; PS51507; IRF_2; 1. PE 1: Evidence at protein level; KW Acetylation; Activator; Antiviral defense; Cytoplasm; Disease variant; KW DNA-binding; Immunity; Innate immunity; Isopeptide bond; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repressor; KW Transcription; Transcription regulation; Tumor suppressor; Ubl conjugation. FT CHAIN 1..325 FT /note="Interferon regulatory factor 1" FT /id="PRO_0000154545" FT DNA_BIND 5..113 FT /note="IRF tryptophan pentad repeat" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00840" FT REGION 92..165 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 141..157 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 78 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22367195" FT CROSSLNK 275 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT CROSSLNK 299 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT VARIANT 8 FT /note="M -> L (in GASC; somatic mutation; produces a FT protein with markedly reduced transcriptional activity but FT unaltered DNA-binding activity; dbSNP:rs121912469)" FT /evidence="ECO:0000269|PubMed:9679752" FT /id="VAR_065134" FT VARIANT 11 FT /note="W -> R (in GASC; the mutation abolishes DNA binding FT and transactivating activities; dbSNP:rs121912470)" FT /evidence="ECO:0000269|PubMed:10395927" FT /id="VAR_065135" FT VARIANT 129..325 FT /note="Missing (in IMD117; likely pathogenic; lack of a FT detectable protein in homozygous patient cells; no effect FT on nuclear localization; no effect on DNA binding; loss of FT transcriptional activity)" FT /evidence="ECO:0000269|PubMed:36736301" FT /id="VAR_089208" FT MUTAGEN 67 FT /note="A->P: No effect on transcriptional activity." FT /evidence="ECO:0000269|PubMed:36736301" FT MUTAGEN 78 FT /note="K->R: Loss of acetylation. Partial loss of DNA- FT binding and transcriptional activity." FT /evidence="ECO:0000269|PubMed:22367195" FT MUTAGEN 275 FT /note="K->R: Some loss of sumoylation. Partial inhibition FT of acetylation and activity. Abolishes sumoylation, FT diminished ubiquitination, higher resistance to FT degradation, and increased apoptotic activity; when FT associated with R-299." FT /evidence="ECO:0000269|PubMed:17942705" FT MUTAGEN 299 FT /note="K->R: Large loss of sumoylation. Abolishes FT sumoylation, diminished ubiquitination, higher resistance FT to degradation, and increased apoptotic activity; when FT associated with R-275." FT /evidence="ECO:0000269|PubMed:17942705" FT CONFLICT 5 FT /note="R -> W (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 34..35 FT /note="FQ -> LE (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 220 FT /note="T -> I (in Ref. 1; no nucleotide entry and 2; no FT nucleotide entry)" FT /evidence="ECO:0000305" SQ SEQUENCE 325 AA; 36502 MW; 2E06245A212D1541 CRC64; MPITRMRMRP WLEMQINSNQ IPGLIWINKE EMIFQIPWKH AAKHGWDINK DACLFRSWAI HTGRYKAGEK EPDPKTWKAN FRCAMNSLPD IEEVKDQSRN KGSSAVRVYR MLPPLTKNQR KERKSKSSRD AKSKAKRKSC GDSSPDTFSD GLSSSTLPDD HSSYTVPGYM QDLEVEQALT PALSPCAVSS TLPDWHIPVE VVPDSTSDLY NFQVSPMPST SEATTDEDEE GKLPEDIMKL LEQSEWQPTN VDGKGYLLNE PGVQPTSVYG DFSCKEEPEI DSPGGDIGLS LQRVFTDLKN MDATWLDSLL TPVRLPSIQA IPCAP // ID KPCA_HUMAN Reviewed; 672 AA. AC P17252; B5BU22; Q15137; Q32M72; Q96RE4; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 4. DT 28-JAN-2026, entry version 258. DE RecName: Full=Protein kinase C alpha type; DE Short=PKC-A; DE Short=PKC-alpha; DE EC=2.7.11.13 {ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; GN Name=PRKCA; Synonyms=PKCA, PRKACA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568. RC TISSUE=Blood; RX PubMed=2336401; DOI=10.1093/nar/18.8.2183; RA Finkenzeller G., Marme D., Hug H.; RT "Sequence of human protein kinase C alpha."; RL Nucleic Acids Res. 18:2183-2183(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-445. RX PubMed=1714454; DOI=10.1016/s0021-9258(18)98596-0; RA McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.; RT "Phorbol diester-induced alterations in the expression of protein kinase C RT isozymes and their mRNAs. Analysis in wild-type and phorbol diester- RT resistant HL-60 cell clones."; RL J. Biol. Chem. 266:15135-15143(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RA Haridasse V., Hackenbruck J., Glazer R.I.; RT "Homo sapiens protein kinase C alpha 5-flanking sequence."; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-19. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [9] RP FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION. RX PubMed=9738012; DOI=10.1074/jbc.273.39.25436; RA Ruvolo P.P., Deng X., Carr B.K., May W.S.; RT "A functional role for mitochondrial protein kinase Calpha in Bcl2 RT phosphorylation and suppression of apoptosis."; RL J. Biol. Chem. 273:25436-25442(1998). RN [10] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9830023; DOI=10.1074/jbc.273.49.32787; RA St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.; RT "Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a RT murine macrophage cell line."; RL J. Biol. Chem. 273:32787-32792(1998). RN [11] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9873035; DOI=10.1074/jbc.274.2.939; RA Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.; RT "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory RT feedback loop in hepatocytes. A role for protein kinase calpha in post- RT transcriptional regulation of ikappabalpha resynthesis."; RL J. Biol. Chem. 274:939-947(1999). RN [12] RP FUNCTION IN APOPTOSIS. RX PubMed=9927633; DOI=10.1124/mol.55.2.396; RA Shen L., Dean N.M., Glazer R.I.; RT "Induction of p53-dependent, insulin-like growth factor-binding protein-3- RT mediated apoptosis in glioblastoma multiforme cells by a protein kinase RT Calpha antisense oligonucleotide."; RL Mol. Pharmacol. 55:396-402(1999). RN [13] RP FUNCTION IN CELL CYCLE PROGRESSION. RX PubMed=10848585; DOI=10.1128/mcb.20.13.4580-4590.2000; RA Besson A., Yong V.W.; RT "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle RT progression."; RL Mol. Cell. Biol. 20:4580-4590(2000). RN [14] RP FUNCTION IN ANGIOGENESIS. RX PubMed=11909826; DOI=10.1161/01.res.0000012503.30315.e8; RA Wang A., Nomura M., Patan S., Ware J.A.; RT "Inhibition of protein kinase Calpha prevents endothelial cell migration RT and vascular tube formation in vitro and myocardial neovascularization in RT vivo."; RL Circ. Res. 90:609-616(2002). RN [15] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [16] RP FUNCTION IN PLATELET AGGREGATION. RX PubMed=12724315; DOI=10.1074/jbc.m212407200; RA Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H., Kita T., RA Horiuchi H.; RT "Direct demonstration of involvement of protein kinase Calpha in the Ca2+- RT induced platelet aggregation."; RL J. Biol. Chem. 278:26374-26379(2003). RN [17] RP FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT. RX PubMed=12832403; DOI=10.1074/jbc.m306325200; RA Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.; RT "Identification of a functionally critical protein kinase C phosphorylation RT residue of cardiac troponin T."; RL J. Biol. Chem. 278:35135-35144(2003). RN [18] RP FUNCTION IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [19] RP FUNCTION IN PHOSPHORYLATION OF TRPC1. RX PubMed=15016832; DOI=10.1074/jbc.m313975200; RA Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C., Tiruppathi C., RA Malik A.B.; RT "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates RT store-operated Ca2+ entry in endothelial cells."; RL J. Biol. Chem. 279:20941-20949(2004). RN [20] RP INTERACTION WITH PICK1. RX PubMed=15247289; DOI=10.1074/jbc.m404499200; RA Dev K.K., Nakanishi S., Henley J.M.; RT "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and RT GluR2 as interacting ligands."; RL J. Biol. Chem. 279:41393-41397(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4. RX PubMed=15504744; DOI=10.1074/jbc.m411045200; RA Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T., RA Stallcup W.B.; RT "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates RT polarized membrane distribution and cell motility."; RL J. Biol. Chem. 279:55262-55270(2004). RN [22] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [24] RP INTERACTION WITH TRIM41. RX PubMed=17893151; DOI=10.1074/jbc.m703320200; RA Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.; RT "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin RT ligase."; RL J. Biol. Chem. 282:33776-33787(2007). RN [25] RP FUNCTION IN ANGIOGENESIS. RX PubMed=18056764; DOI=10.1093/cvr/cvm085; RA Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.; RT "Protein kinase C alpha promotes angiogenic activity of human endothelial RT cells via induction of vascular endothelial growth factor."; RL Cardiovasc. Res. 78:349-355(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [29] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [30] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [34] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-657, AND MUTAGENESIS RP OF LYS-368. RX PubMed=21806543; DOI=10.1042/bj20110678; RA Cameron A.J., Linch M.D., Saurin A.T., Escribano C., Parker P.J.; RT "mTORC2 targets AGC kinases through Sin1-dependent recruitment."; RL Biochem. J. 439:287-297(2011). RN [35] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [36] RP FUNCTION IN PHOSPHORYLATION OF EIF4G1. RX PubMed=21576361; DOI=10.1128/mcb.05589-11; RA Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.; RT "Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) RT by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1."; RL Mol. Cell. Biol. 31:2947-2959(2011). RN [37] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272; RA Nakashima S.; RT "Protein kinase C alpha (PKC alpha): regulation and biological function."; RL J. Biochem. 132:669-675(2002). RN [38] RP REVIEW ON FUNCTION. RX PubMed=19969380; DOI=10.1016/j.tips.2009.10.006; RA Konopatskaya O., Poole A.W.; RT "Protein kinase Calpha: disease regulator and therapeutic target."; RL Trends Pharmacol. Sci. 31:8-14(2010). RN [39] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [40] RP FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND SER-657, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [44] RP INTERACTION WITH PARD3. RX PubMed=27925688; DOI=10.1002/humu.23153; RA Chen X., An Y., Gao Y., Guo L., Rui L., Xie H., Sun M., Lam Hung S., RA Sheng X., Zou J., Bao Y., Guan H., Niu B., Li Z., Finnell R.H., RA Gusella J.F., Wu B.L., Zhang T.; RT "Rare deleterious PARD3 variants in the aPKC-binding region are implicated RT in the pathogenesis of human cranial neural tube defects via disrupting RT apical tight junction formation."; RL Hum. Mutat. 38:378-389(2017). RN [45] RP FUNCTION. RX PubMed=28028151; DOI=10.1084/jem.20160068; RA Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P., RA Wu Z.Y., Ding J., Hu R., Wei B., Wang H.; RT "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates RT experimental autoimmune encephalomyelitis."; RL J. Exp. Med. 214:209-226(2017). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH RP INHIBITOR. RX PubMed=19827831; DOI=10.1021/jm901108b; RA Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C., RA Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W., Beerli C., RA Weckbecker G., Evenou J.P., Zenke G., Cottens S.; RT "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- RT yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein RT kinase C isotypes."; RL J. Med. Chem. 52:6193-6196(2009). RN [48] RP STRUCTURE BY NMR OF 88-169. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second phorbol esters/diacylglycerol binding RT domain of human protein kinase C alpha type."; RL Submitted (APR-2008) to the PDB data bank. RN [49] RP VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in positive CC and negative regulation of cell proliferation, apoptosis, CC differentiation, migration and adhesion, tumorigenesis, cardiac CC hypertrophy, angiogenesis, platelet function and inflammation, by CC directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, CC or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. CC Involved in cell proliferation and cell growth arrest by positive and CC negative regulation of the cell cycle. Can promote cell growth by CC phosphorylating and activating RAF1, which mediates the activation of CC the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which CC facilitates active cyclin-dependent kinase (CDK) complex formation in CC glioma cells. In intestinal cells stimulated by the phorbol ester PMA, CC can trigger a cell cycle arrest program which is associated with the CC accumulation of the hyper-phosphorylated growth-suppressive form of RB1 CC and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti- CC apoptotic function in glioma cells and protects them from apoptosis by CC suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia CC cells mediates anti-apoptotic action by phosphorylating BCL2. During CC macrophage differentiation induced by macrophage colony-stimulating CC factor (CSF1), is translocated to the nucleus and is associated with CC macrophage development. After wounding, translocates from focal CC contacts to lamellipodia and participates in the modulation of CC desmosomal adhesion. Plays a role in cell motility by phosphorylating CC CSPG4, which induces association of CSPG4 with extensive lamellipodia CC at the cell periphery and polarization of the cell accompanied by CC increases in cell motility. During chemokine-induced CD4(+) T cell CC migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting CC in its dissociation from LRCH1 and the activation of GTPase CDC42 CC (PubMed:28028151). Is highly expressed in a number of cancer cells CC where it can act as a tumor promoter and is implicated in malignant CC phenotypes of several tumors such as gliomas and breast cancers. CC Negatively regulates myocardial contractility and positively regulates CC angiogenesis, platelet aggregation and thrombus formation in arteries. CC Mediates hypertrophic growth of neonatal cardiomyocytes, in part CC through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA CC treatment, is required to induce cardiomyocyte hypertrophy up to heart CC failure and death, by increasing protein synthesis, protein-DNA ratio CC and cell surface area. Regulates cardiomyocyte function by CC phosphorylating cardiac troponin T (TNNT2/CTNT), which induces CC significant reduction in actomyosin ATPase activity, myofilament CC calcium sensitivity and myocardial contractility. In angiogenesis, is CC required for full endothelial cell migration, adhesion to vitronectin CC (VTN), and vascular endothelial growth factor A (VEGFA)-dependent CC regulation of kinase activation and vascular tube formation. Involved CC in the stabilization of VEGFA mRNA at post-transcriptional level and CC mediates VEGFA-induced cell proliferation. In the regulation of CC calcium-induced platelet aggregation, mediates signals from the CC CD36/GP4 receptor for granule release, and activates the integrin CC heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. CC During response to lipopolysaccharides (LPS), may regulate selective CC LPS-induced macrophage functions involved in host defense and CC inflammation. But in some inflammatory responses, may negatively CC regulate NF-kappa-B-induced genes, through IL1A-dependent induction of CC NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O- CC tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which CC modulates EIF4G1 binding to MKNK1 and may be involved in the regulation CC of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of CC KIT activity. Phosphorylates ATF2 which promotes cooperation between CC ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser- CC 52' facilitating its ubiquitination and proteasomal degradation (By CC similarity). Phosphorylates KLHL3 in response to angiotensin II CC signaling, decreasing the interaction between KLHL3 and WNK4 CC (PubMed:25313067). Phosphorylates and activates LRRK1, which CC phosphorylates RAB proteins involved in intracellular trafficking CC (PubMed:36040231). {ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826, CC ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403, CC ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744, CC ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764, CC ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361, CC ECO:0000269|PubMed:21806543, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:28028151, CC ECO:0000269|PubMed:36040231, ECO:0000269|PubMed:9738012, CC ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035, CC ECO:0000269|PubMed:9927633}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P05696}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-497 CC (activation loop of the kinase domain), Thr-638 (turn motif) and Ser- CC 657 (hydrophobic region), need to be phosphorylated for its full CC activation. {ECO:0000269|PubMed:21806543}. CC -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex which CC also includes BMAL1 and RACK1 (By similarity). Interacts with CC ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744). CC Binds to CAVIN2 in the presence of phosphatidylserine (By similarity). CC Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289). CC Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3 CC (PubMed:27925688). Interacts with SOCS2 (By similarity). CC {ECO:0000250|UniProtKB:P05696, ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289, CC ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151, CC ECO:0000269|PubMed:27925688}. CC -!- INTERACTION: CC P17252; Q15027: ACAP1; NbExp=3; IntAct=EBI-1383528, EBI-751746; CC P17252; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1383528, EBI-25646567; CC P17252; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-1383528, EBI-5280499; CC P17252; Q13072: BAGE; NbExp=3; IntAct=EBI-1383528, EBI-25884811; CC P17252; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1383528, EBI-11524452; CC P17252; Q96A33: CCDC47; NbExp=3; IntAct=EBI-1383528, EBI-720151; CC P17252; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-1383528, EBI-17967022; CC P17252; P15169: CPN1; NbExp=3; IntAct=EBI-1383528, EBI-2116369; CC P17252; P43234: CTSO; NbExp=3; IntAct=EBI-1383528, EBI-2874283; CC P17252; O95424: DEXI; NbExp=3; IntAct=EBI-1383528, EBI-724515; CC P17252; P78352: DLG4; NbExp=2; IntAct=EBI-1383528, EBI-80389; CC P17252; O43598: DNPH1; NbExp=3; IntAct=EBI-1383528, EBI-748674; CC P17252; P21728: DRD1; NbExp=3; IntAct=EBI-1383528, EBI-6624459; CC P17252; P00533: EGFR; NbExp=3; IntAct=EBI-1383528, EBI-297353; CC P17252; P60228: EIF3E; NbExp=3; IntAct=EBI-1383528, EBI-347740; CC P17252; Q96J88-3: EPSTI1; NbExp=3; IntAct=EBI-1383528, EBI-25885343; CC P17252; Q8IVH2-2: FOXP4; NbExp=3; IntAct=EBI-1383528, EBI-25885364; CC P17252; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1383528, EBI-13213391; CC P17252; O14926: FSCN2; NbExp=3; IntAct=EBI-1383528, EBI-21017948; CC P17252; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-1383528, EBI-9088619; CC P17252; P19440-3: GGT1; NbExp=3; IntAct=EBI-1383528, EBI-21558069; CC P17252; Q9UJ42: GPR160; NbExp=3; IntAct=EBI-1383528, EBI-25885139; CC P17252; P62805: H4C9; NbExp=3; IntAct=EBI-1383528, EBI-302023; CC P17252; Q9UBN7: HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697; CC P17252; P52597: HNRNPF; NbExp=3; IntAct=EBI-1383528, EBI-352986; CC P17252; Q92826: HOXB13; NbExp=3; IntAct=EBI-1383528, EBI-11317274; CC P17252; Q02363: ID2; NbExp=3; IntAct=EBI-1383528, EBI-713450; CC P17252; Q96FT9-2: IFT43; NbExp=3; IntAct=EBI-1383528, EBI-11944538; CC P17252; P17936: IGFBP3; NbExp=3; IntAct=EBI-1383528, EBI-715709; CC P17252; P26951: IL3RA; NbExp=3; IntAct=EBI-1383528, EBI-1757512; CC P17252; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-1383528, EBI-9996449; CC P17252; Q9Y234: LIPT1; NbExp=4; IntAct=EBI-1383528, EBI-727376; CC P17252; P51884: LUM; NbExp=3; IntAct=EBI-1383528, EBI-725780; CC P17252; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-1383528, EBI-473834; CC P17252; P80192: MAP3K9; NbExp=3; IntAct=EBI-1383528, EBI-3951604; CC P17252; Q15759: MAPK11; NbExp=3; IntAct=EBI-1383528, EBI-298304; CC P17252; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-1383528, EBI-13288755; CC P17252; Q8N983-3: MRPL43; NbExp=3; IntAct=EBI-1383528, EBI-11109389; CC P17252; P49821: NDUFV1; NbExp=3; IntAct=EBI-1383528, EBI-748312; CC P17252; Q2M1J6: OXA1L; NbExp=3; IntAct=EBI-1383528, EBI-9978021; CC P17252; Q9BRX2: PELO; NbExp=3; IntAct=EBI-1383528, EBI-1043580; CC P17252; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-1383528, EBI-2803703; CC P17252; P11309-2: PIM1; NbExp=2; IntAct=EBI-1383528, EBI-1018633; CC P17252; Q6P1J6-2: PLB1; NbExp=3; IntAct=EBI-1383528, EBI-10694821; CC P17252; Q9UNA4: POLI; NbExp=3; IntAct=EBI-1383528, EBI-741774; CC P17252; Q02156: PRKCE; NbExp=2; IntAct=EBI-1383528, EBI-706254; CC P17252; P05129: PRKCG; NbExp=6; IntAct=EBI-1383528, EBI-949799; CC P17252; P07225: PROS1; NbExp=3; IntAct=EBI-1383528, EBI-2803380; CC P17252; Q3YEC7-3: RABL6; NbExp=3; IntAct=EBI-1383528, EBI-25885259; CC P17252; O94844: RHOBTB1; NbExp=3; IntAct=EBI-1383528, EBI-6426999; CC P17252; Q9NWS8-3: RMND1; NbExp=3; IntAct=EBI-1383528, EBI-25884400; CC P17252; Q9ULK6-3: RNF150; NbExp=3; IntAct=EBI-1383528, EBI-36513929; CC P17252; P18077: RPL35A; NbExp=3; IntAct=EBI-1383528, EBI-353383; CC P17252; Q14160: SCRIB; NbExp=3; IntAct=EBI-1383528, EBI-357345; CC P17252; P31431: SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237; CC P17252; Q99643: SDHC; NbExp=3; IntAct=EBI-1383528, EBI-1224539; CC P17252; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-1383528, EBI-745901; CC P17252; Q01105-2: SET; NbExp=3; IntAct=EBI-1383528, EBI-7481343; CC P17252; P37840: SNCA; NbExp=3; IntAct=EBI-1383528, EBI-985879; CC P17252; Q9Y5X0: SNX10; NbExp=3; IntAct=EBI-1383528, EBI-10329478; CC P17252; P56693: SOX10; NbExp=3; IntAct=EBI-1383528, EBI-1167533; CC P17252; Q9BRW5: SP2; NbExp=3; IntAct=EBI-1383528, EBI-25868254; CC P17252; O43761: SYNGR3; NbExp=3; IntAct=EBI-1383528, EBI-11321949; CC P17252; P15884: TCF4; NbExp=3; IntAct=EBI-1383528, EBI-533224; CC P17252; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-1383528, EBI-2821479; CC P17252; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-1383528, EBI-1390168; CC P17252; P0CG48: UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054; CC P17252; P13051-2: UNG; NbExp=3; IntAct=EBI-1383528, EBI-25834258; CC P17252; Q8NB14: USP38; NbExp=3; IntAct=EBI-1383528, EBI-2512509; CC P17252; O95498: VNN2; NbExp=3; IntAct=EBI-1383528, EBI-21494555; CC P17252; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-1383528, EBI-12040603; CC P17252; Q9BQ24: ZFYVE21; NbExp=3; IntAct=EBI-1383528, EBI-2849569; CC P17252; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-1383528, EBI-25835471; CC P17252; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1383528, EBI-12010736; CC P17252; O15535: ZSCAN9; NbExp=3; IntAct=EBI-1383528, EBI-751531; CC P17252; Q24008: inaD; Xeno; NbExp=2; IntAct=EBI-1383528, EBI-195326; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}. Cell CC membrane {ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:36040231}; CC Peripheral membrane protein {ECO:0000305|PubMed:23990668, CC ECO:0000305|PubMed:36040231}. Mitochondrion membrane CC {ECO:0000269|PubMed:9738012}; Peripheral membrane protein CC {ECO:0000305|PubMed:9738012}. Nucleus {ECO:0000250|UniProtKB:P20444}. CC -!- PTM: In response to growth factors, phosphorylated at Thr-631 and Ser- CC 657 by the mTORC2 complex, promoting autophosphorylation and activation CC of PRKCA. {ECO:0000269|PubMed:21806543}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52479; CAA36718.1; -; mRNA. DR EMBL; AB451258; BAG70072.1; -; mRNA. DR EMBL; AB451383; BAG70197.1; -; mRNA. DR EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89014.1; -; Genomic_DNA. DR EMBL; BC109273; AAI09274.1; -; mRNA. DR EMBL; BC109274; AAI09275.1; -; mRNA. DR EMBL; M22199; AAA60098.1; -; mRNA. DR EMBL; AF395829; AAK84184.1; -; Genomic_DNA. DR CCDS; CCDS11664.1; -. DR PIR; S09496; KIHUCA. DR RefSeq; NP_002728.2; NM_002737.3. DR PDB; 2ELI; NMR; -; A=93-169. DR PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672. DR PDB; 4DNL; X-ray; 1.90 A; A=155-293. DR PDB; 4RA4; X-ray; 2.63 A; A=318-672. DR PDB; 8U37; X-ray; 2.48 A; A=320-672. DR PDB; 8UAK; X-ray; 2.82 A; A=320-672. DR PDBsum; 2ELI; -. DR PDBsum; 3IW4; -. DR PDBsum; 4DNL; -. DR PDBsum; 4RA4; -. DR PDBsum; 8U37; -. DR PDBsum; 8UAK; -. DR AlphaFoldDB; P17252; -. DR BMRB; P17252; -. DR SMR; P17252; -. DR BioGRID; 111564; 342. DR CORUM; P17252; -. DR DIP; DIP-531N; -. DR FunCoup; P17252; 2547. DR IntAct; P17252; 209. DR MINT; P17252; -. DR STRING; 9606.ENSP00000408695; -. DR BindingDB; P17252; -. DR ChEMBL; CHEMBL299; -. DR DrugBank; DB12996; Acteoside. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB06451; Aprinocarsen. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB11752; Bryostatin 1. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB05013; Ingenol mebutate. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB06819; Phenylbutyric acid. DR DrugBank; DB00144; Phosphatidyl serine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P17252; -. DR GuidetoPHARMACOLOGY; 1482; -. DR GlyGen; P17252; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P17252; -. DR MetOSite; P17252; -. DR PhosphoSitePlus; P17252; -. DR SwissPalm; P17252; -. DR BioMuta; PRKCA; -. DR DMDM; 317373571; -. DR CPTAC; CPTAC-1615; -. DR CPTAC; CPTAC-3172; -. DR CPTAC; CPTAC-3173; -. DR jPOST; P17252; -. DR MassIVE; P17252; -. DR PaxDb; 9606-ENSP00000408695; -. DR PeptideAtlas; P17252; -. DR ProteomicsDB; 53464; -. DR Pumba; P17252; -. DR Antibodypedia; 1464; 1251 antibodies from 49 providers. DR DNASU; 5578; -. DR Ensembl; ENST00000413366.8; ENSP00000408695.3; ENSG00000154229.13. DR GeneID; 5578; -. DR KEGG; hsa:5578; -. DR MANE-Select; ENST00000413366.8; ENSP00000408695.3; NM_002737.3; NP_002728.2. DR UCSC; uc002jfp.2; human. DR AGR; HGNC:9393; -. DR ClinPGx; PA33759; -. DR CTD; 5578; -. DR DisGeNET; 5578; -. DR GeneCards; PRKCA; -. DR HGNC; HGNC:9393; PRKCA. DR HPA; ENSG00000154229; Tissue enhanced (brain). DR MalaCards; PRKCA; -. DR MIM; 176960; gene. DR OpenTargets; ENSG00000154229; -. DR VEuPathDB; HostDB:ENSG00000154229; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000156104; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P17252; -. DR OMA; VHEIKSH; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P17252; 3 GO annotations based on evolutionary models. DR PhylomeDB; P17252; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P17252; -. DR Reactome; R-HSA-111933; Calmodulin induced events. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-3000170; Syndecan interactions. DR Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion. DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9010642; ROBO receptors bind AKAP5. DR SABIO-RK; P17252; -. DR SignaLink; P17252; -. DR SIGNOR; P17252; -. DR Agora; ENSG00000154229; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5578; 13 hits in 1191 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCA; human. DR EvolutionaryTrace; P17252; -. DR GeneWiki; PKC_alpha; -. DR GenomeRNAi; 5578; -. DR Pharos; P17252; Tchem. DR PRO; PR:P17252; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P17252; protein. DR Bgee; ENSG00000154229; Expressed in CA1 field of hippocampus and 192 other cell types or tissues. DR ExpressionAtlas; P17252; baseline and differential. DR GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISS:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0019992; F:diacylglycerol binding; TAS:Reactome. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0005178; F:integrin binding; ISS:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; IEA:Ensembl. DR GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007611; P:learning or memory; IEA:Ensembl. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IEA:Ensembl. DR GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0110063; P:positive regulation of angiotensin-activated signaling pathway; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0045780; P:positive regulation of bone resorption; ISS:BHF-UCL. DR GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045921; P:positive regulation of exocytosis; IEA:Ensembl. DR GO; GO:0032024; P:positive regulation of insulin secretion; TAS:Reactome. DR GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl. DR GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl. DR GO; GO:1904627; P:response to phorbol 13-acetate 12-myristate; IEA:Ensembl. DR GO; GO:0000302; P:response to reactive oxygen species; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05615; STKc_cPKC_alpha; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000103; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034663; cPKC_alpha. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium; KW Cell adhesion; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase; KW Membrane; Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Proto-oncogene; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase; KW Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22814378" FT CHAIN 2..672 FT /note="Protein kinase C alpha type" FT /id="PRO_0000055679" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 339..597 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 598..668 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 463 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 195 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 245 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 345..353 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:21806543" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 10 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 226 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P05696" FT MOD_RES 494 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 495 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 497 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P04409, ECO:0000305" FT MOD_RES 501 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P05771" FT MOD_RES 628 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 631 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P20444" FT MOD_RES 638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 657 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000269|PubMed:21806543, FT ECO:0007744|PubMed:24275569" FT MOD_RES 658 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P20444" FT VARIANT 98 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042301" FT VARIANT 467 FT /note="D -> N (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042302" FT VARIANT 489 FT /note="M -> V (in dbSNP:rs34406842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042303" FT VARIANT 568 FT /note="V -> I (in dbSNP:rs6504459)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:2336401, FT ECO:0000269|Ref.4" FT /id="VAR_050558" FT MUTAGEN 368 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:21806543" FT CONFLICT 50 FT /note="C -> S (in Ref. 6; AAA60098)" FT /evidence="ECO:0000305" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 138..140 FT /evidence="ECO:0007829|PDB:2ELI" FT TURN 141..146 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 161..169 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 172..182 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 194..202 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 222..230 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 233..237 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 239..246 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 254..262 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 263..268 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 271..276 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 282..284 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 336..338 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 339..348 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 351..358 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 364..371 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 372..378 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 381..392 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 410..418 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:3IW4" FT HELIX 425..430 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 437..456 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 466..468 FT /evidence="ECO:0007829|PDB:4RA4" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 477..479 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 502..504 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 507..510 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 518..533 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 543..552 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 563..572 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 577..579 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 587..592 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 602..606 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 642..645 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 650..653 FT /evidence="ECO:0007829|PDB:8U37" SQ SEQUENCE 672 AA; 76750 MW; 9EB157789A062349 CRC64; MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN PQFVHPILQS AV // ID KPCB_HUMAN Reviewed; 671 AA. AC P05771; C5IFJ8; D3DWF5; O43744; P05127; Q15138; Q93060; Q9UE49; Q9UE50; AC Q9UEH8; Q9UJ30; Q9UJ33; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 4. DT 28-JAN-2026, entry version 270. DE RecName: Full=Protein kinase C beta type; DE Short=PKC-B; DE Short=PKC-beta; DE EC=2.7.11.13 {ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:25982116, ECO:0000269|PubMed:36040231}; GN Name=PRKCB; Synonyms=PKCB, PRKCB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-II). RX PubMed=3755548; DOI=10.1126/science.3755548; RA Coussens L., Parker P.J., Rhee L., Yang-Feng T.L., Chen E., RA Waterfield M.D., Francke U., Ullrich A.; RT "Multiple, distinct forms of bovine and human protein kinase C suggest RT diversity in cellular signaling pathways."; RL Science 233:859-866(1986). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II). RX PubMed=3666134; DOI=10.1016/0014-5793(87)80524-0; RA Kubo K., Ohno S., Suzuki K.; RT "Primary structures of human protein kinase C beta I and beta II differ RT only in their C-terminal sequences."; RL FEBS Lett. 223:138-142(1987). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2009) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10493829; DOI=10.1006/geno.1999.5927; RA Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J., RA Mason T., Crosby M.L., Barnstead M., Cronin L., Mays A.D., Cao Y., Xu R.X., RA Kang H.-L., Mitchell S., Eichler E.E., Harris P.C., Venter J.C., RA Adams M.D.; RT "Genome duplications and other features in 12 Mb of DNA sequence from human RT chromosome 16p and 16q."; RL Genomics 60:295-308(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-69. RX PubMed=7880442; DOI=10.1089/dna.1995.14.213; RA Mahajna J., King P., Parker P., Haley J.; RT "Autoregulation of cloned human protein kinase C beta and gamma gene RT promoters in U937 cells."; RL DNA Cell Biol. 14:213-222(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58. RX PubMed=1556124; DOI=10.1016/s0021-9258(18)42675-0; RA Niino Y.S., Ohno S., Suzuki K.; RT "Positive and negative regulation of the transcription of the human protein RT kinase C beta gene."; RL J. Biol. Chem. 267:6158-6163(1992). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RX PubMed=1400396; DOI=10.1016/s0021-9258(19)36758-4; RA Obeid L.M., Blobe G.C., Karolak L.A., Hannun Y.A.; RT "Cloning and characterization of the major promoter of the human protein RT kinase C beta gene. Regulation by phorbol esters."; RL J. Biol. Chem. 267:20804-20810(1992). RN [10] RP PROTEIN SEQUENCE OF 2-19, AND ACETYLATION AT ALA-2. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 97-176. RA Greenham J.A., Adams M.D., Doggett N.A., Mole S.E.; RT "The genomic structure of the human protein kinase C beta gene (PRKCB)."; RL Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 609-671. RC TISSUE=Fetal brain; RX PubMed=3677994; DOI=10.1089/dna.1987.6.389; RA Coussens L., Rhee L., Parker P.J., Ullrich A.; RT "Alternative splicing increases the diversity of the human protein kinase C RT family."; RL DNA 6:389-394(1987). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 622-671. RX PubMed=3658678; DOI=10.1093/nar/15.17.7179; RA Kubo K., Ohno S., Suzuki K.; RT "Nucleotide sequence of the 3' portion of a human gene for protein kinase C RT beta-I/beta-II."; RL Nucleic Acids Res. 15:7179-7180(1987). RN [14] RP FUNCTION IN PHOSPHORYLATION OF BTK. RX PubMed=11598012; DOI=10.1093/emboj/20.20.5692; RA Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M., RA Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N., RA Rawlings D.J.; RT "PKCbeta modulates antigen receptor signaling via regulation of Btk RT membrane localization."; RL EMBO J. 20:5692-5702(2001). RN [15] RP ACTIVITY REGULATION. RX PubMed=16103100; DOI=10.1158/0008-5472.can-05-0071; RA Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., RA Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L., Huss K.L., RA Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J., Musib L., RA Geeganage S., Thornton D.; RT "The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), RT suppresses signaling through the AKT pathway, induces apoptosis, and RT suppresses growth of human colon cancer and glioblastoma xenografts."; RL Cancer Res. 65:7462-7469(2005). RN [16] RP INTERACTION WITH PHLPP1 AND PHLPP2. RX PubMed=18162466; DOI=10.1074/jbc.m707319200; RA Gao T., Brognard J., Newton A.C.; RT "The phosphatase PHLPP controls the cellular levels of protein kinase C."; RL J. Biol. Chem. 283:6300-6311(2008). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [18] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-504, PHOSPHORYLATION [LARGE RP SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM BETA-II), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [20] RP FUNCTION IN HISTONE H3 PHOSPHORYLATION, CATALYTIC ACTIVITY, SUBCELLULAR RP LOCATION, AND INTERACTION WITH KDM1A; PKN1 AND AR. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [21] RP REVIEW ON FUNCTION. RX PubMed=12417015; DOI=10.1093/oxfordjournals.jbchem.a003273; RA Kawakami T., Kawakami Y., Kitaura J.; RT "Protein kinase C beta (PKC beta): normal functions and diseases."; RL J. Biochem. 132:677-682(2002). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20186491; DOI=10.1007/s11154-010-9134-4; RA Tabit C.E., Chung W.B., Hamburg N.M., Vita J.A.; RT "Endothelial dysfunction in diabetes mellitus: molecular mechanisms and RT clinical implications."; RL Rev. Endocr. Metab. Disord. 11:61-74(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; THR-17; SER-206; SER-311; RP THR-314 AND THR-642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM RP BETA-II), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [27] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25982116; DOI=10.1016/j.molcel.2015.04.015; RA Lee E.E., Ma J., Sacharidou A., Mi W., Salato V.K., Nguyen N., Jiang Y., RA Pascual J.M., North P.E., Shaul P.W., Mettlen M., Wang R.C.; RT "A protein kinase C phosphorylation motif in GLUT1 affects glucose RT transport and is mutated in GLUT1 deficiency syndrome."; RL Mol. Cell 58:845-853(2015). RN [28] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35027735; DOI=10.1038/s41556-021-00818-3; RA Zhang H.L., Hu B.X., Li Z.L., Du T., Shan J.L., Ye Z.P., Peng X.D., Li X., RA Huang Y., Zhu X.Y., Chen Y.H., Feng G.K., Yang D., Deng R., Zhu X.F.; RT "PKCbetaII phosphorylates ACSL4 to amplify lipid peroxidation to induce RT ferroptosis."; RL Nat. Cell Biol. 24:88-98(2022). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=40246981; DOI=10.1038/s41589-025-01888-2; RA Zhang H.L., Guo Y.Q., Liu S., Ye Z.P., Li L.C., Hu B.X., Li Z.L., RA Chen Y.H., Feng G.K., Shen H.Q., Deng R., Zhu X.F.; RT "Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis RT propagation."; RL Nat. Chem. Biol. 0:0-0(2025). RN [31] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 321-660 IN COMPLEX WITH INHIBITOR, RP AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661. RX PubMed=17115692; DOI=10.1021/bi061128h; RA Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., RA Grant S.; RT "Structure of the catalytic domain of human protein kinase C beta II RT complexed with a bisindolylmaleimide inhibitor."; RL Biochemistry 45:13970-13981(2006). RN [32] RP VARIANTS [LARGE SCALE ANALYSIS] MET-144; MET-496 AND HIS-588. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase involved in various cellular CC processes such as regulation of the B-cell receptor (BCR) signalosome, CC oxidative stress-induced apoptosis, androgen receptor-dependent CC transcription regulation, insulin signaling and endothelial cells CC proliferation. Plays a key role in B-cell activation by regulating BCR- CC induced NF-kappa-B activation. Mediates the activation of the canonical CC NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 CC at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CC CARD11/CARMA1 association with lipid rafts and recruitment of the CC BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK CC complex, resulting in nuclear translocation and activation of NFKB1. CC Plays a direct role in the negative feedback regulation of the BCR CC signaling, by down-modulating BTK function via direct phosphorylation CC of BTK at 'Ser-180', which results in the alteration of BTK plasma CC membrane localization and in turn inhibition of BTK activity CC (PubMed:11598012). Involved in apoptosis following oxidative damage: in CC case of oxidative conditions, specifically phosphorylates 'Ser-36' of CC isoform p66Shc of SHC1, leading to mitochondrial accumulation of CC p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts CC as a coactivator of androgen receptor (AR)-dependent transcription, by CC being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for CC epigenetic transcriptional activation that prevents demethylation of CC histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin CC signaling, may function downstream of IRS1 in muscle cells and mediate CC insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling CC cascade. Participates in the regulation of glucose transport in CC adipocytes by negatively modulating the insulin-stimulated CC translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates CC SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 CC (PubMed:25982116). Under high glucose in pancreatic beta-cells, is CC probably involved in the inhibition of the insulin gene transcription, CC via regulation of MYC expression. In endothelial cells, activation of CC PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced CC cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide CC synthase (NOS3/eNOS) regulation by insulin, which causes endothelial CC dysfunction. Also involved in triglyceride homeostasis (By similarity). CC Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, CC activating transcription (PubMed:19176525). Phosphorylates KLHL3 in CC response to angiotensin II signaling, decreasing the interaction CC between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates CC LRRK1, which phosphorylates RAB proteins involved in intracellular CC trafficking (PubMed:36040231). {ECO:0000250|UniProtKB:P68404, CC ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:19176525, CC ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, CC ECO:0000269|PubMed:25982116, ECO:0000269|PubMed:36040231}. CC -!- FUNCTION: [Isoform Beta-II]: Acts as an activator of ferroptosis by CC mediating phosphorylation and activation of ACSL4 (PubMed:35027735). CC Also stimulates ferroptosis propagation by catalyzing phosphorylation CC of FOXK1, thereby promoting LGALS13 secretion (PubMed:40246981). CC {ECO:0000269|PubMed:35027735, ECO:0000269|PubMed:40246981}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116, CC ECO:0000269|PubMed:36040231}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, CC ECO:0000269|PubMed:36040231}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:20228790}; CC -!- CATALYTIC ACTIVITY: [Isoform Beta-II]: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:40246981}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:40246981}; CC -!- CATALYTIC ACTIVITY: [Isoform Beta-II]: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:35027735}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:35027735}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P68403}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-500 CC (activation loop of the kinase domain), Thr-642 (turn motif) and Ser- CC 661 (hydrophobic region), need to be phosphorylated for its full CC activation. Specifically inhibited by enzastaurin (LY317615). CC {ECO:0000269|PubMed:16103100}. CC -!- SUBUNIT: Interacts with PDPK1/PDK1 (By similarity). Interacts in vitro CC with PRKCBP1. Interacts with PHLPP1 and PHLPP2; both proteins mediate CC its dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and AR. CC {ECO:0000250, ECO:0000269|PubMed:17115692, ECO:0000269|PubMed:18162466, CC ECO:0000269|PubMed:20228790}. CC -!- INTERACTION: CC P05771; Q8NEM2: SHCBP1; NbExp=3; IntAct=EBI-706216, EBI-744700; CC P05771; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-706216, EBI-717399; CC P05771-1; O60341-1: KDM1A; NbExp=2; IntAct=EBI-5774492, EBI-15599570; CC P05771-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-5774511, EBI-18899653; CC P05771-2; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-5774511, EBI-1383687; CC P05771-2; Q6ZQX7-4: LIAT1; NbExp=3; IntAct=EBI-5774511, EBI-25830459; CC P05771-2; O60346: PHLPP1; NbExp=5; IntAct=EBI-5774511, EBI-2511516; CC P05771-2; Q6ZVD8: PHLPP2; NbExp=2; IntAct=EBI-5774511, EBI-2511496; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus CC {ECO:0000269|PubMed:20228790}. Membrane {ECO:0000250}; Peripheral CC membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Beta-I; Synonyms=PRKCB1; CC IsoId=P05771-1; Sequence=Displayed; CC Name=Beta-II; Synonyms=PRKCB2; CC IsoId=P05771-2; Sequence=VSP_004738; CC -!- PTM: Phosphorylation on Thr-500 within the activation loop renders it CC competent to autophosphorylate. Subsequent autophosphorylation of Thr- CC 642 maintains catalytic competence, and autophosphorylation on Ser-661 CC appears to release the kinase into the cytosol. Autophosphorylation on CC other sites i.e. in the N-terminal and hinge regions have no effect on CC enzyme activity. Phosphorylation at Tyr-662 by SYK induces binding with CC GRB2 and contributes to the activation of MAPK/ERK signaling cascade CC (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M13975; AAA60095.1; -; mRNA. DR EMBL; X06318; CAA29634.1; -; mRNA. DR EMBL; X07109; CAA30130.1; -; mRNA. DR EMBL; FJ907246; ACS14045.1; -; Genomic_DNA. DR EMBL; AC130454; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC002299; AAB97933.1; -; Genomic_DNA. DR EMBL; AC002299; AAB97934.1; -; Genomic_DNA. DR EMBL; CH471145; EAW55797.1; -; Genomic_DNA. DR EMBL; CH471145; EAW55798.1; -; Genomic_DNA. DR EMBL; BC036472; AAH36472.1; -; mRNA. DR EMBL; X62532; CAA44393.1; -; Genomic_DNA. DR EMBL; S47311; AAD13852.1; -; Genomic_DNA. DR EMBL; D10022; BAA00912.1; -; Genomic_DNA. DR EMBL; AJ002799; CAA05725.1; -; Genomic_DNA. DR EMBL; AJ002800; CAA05725.1; JOINED; Genomic_DNA. DR EMBL; M18254; AAA60096.1; -; Genomic_DNA. DR EMBL; M18255; AAA60097.1; -; Genomic_DNA. DR EMBL; X05972; CAA29396.1; -; Genomic_DNA. DR EMBL; X05971; CAA29395.1; -; Genomic_DNA. DR CCDS; CCDS10618.1; -. [P05771-1] DR CCDS; CCDS10619.1; -. [P05771-2] DR PIR; B24664; KIHUC2. DR PIR; S00159; KIHUC1. DR RefSeq; NP_002729.2; NM_002738.6. [P05771-2] DR RefSeq; NP_997700.1; NM_212535.3. [P05771-1] DR PDB; 2I0E; X-ray; 2.60 A; A/B=321-671. DR PDB; 8SE1; X-ray; 3.32 A; A/B=2-668. DR PDB; 8SE2; X-ray; 2.95 A; A/B=2-671. DR PDB; 8SE3; X-ray; 2.60 A; A=2-671. DR PDB; 8SE4; X-ray; 2.68 A; A/B=2-671. DR PDB; 8SG2; NMR; -; B=641-662. DR PDBsum; 2I0E; -. DR PDBsum; 8SE1; -. DR PDBsum; 8SE2; -. DR PDBsum; 8SE3; -. DR PDBsum; 8SE4; -. DR PDBsum; 8SG2; -. DR AlphaFoldDB; P05771; -. DR SMR; P05771; -. DR BioGRID; 111565; 207. DR CORUM; P05771; -. DR DIP; DIP-34187N; -. DR FunCoup; P05771; 3545. DR IntAct; P05771; 155. DR MINT; P05771; -. DR STRING; 9606.ENSP00000496129; -. DR BindingDB; P05771; -. DR ChEMBL; CHEMBL3045; -. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB01738; Phosphorylcolamine. DR DrugBank; DB11829; Ruboxistaurin. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P05771; -. DR GuidetoPHARMACOLOGY; 1483; -. DR TCDB; 8.A.104.1.4; the 5'-amp-activated protein kinase (ampk) family. DR iPTMnet; P05771; -. DR MetOSite; P05771; -. DR PhosphoSitePlus; P05771; -. DR SwissPalm; P05771; -. DR BioMuta; PRKCB; -. DR DMDM; 20141488; -. DR CPTAC; CPTAC-1338; -. DR CPTAC; CPTAC-3051; -. DR CPTAC; CPTAC-3052; -. DR jPOST; P05771; -. DR MassIVE; P05771; -. DR PaxDb; 9606-ENSP00000305355; -. DR PeptideAtlas; P05771; -. DR ProteomicsDB; 51855; -. [P05771-1] DR ProteomicsDB; 51856; -. [P05771-2] DR Pumba; P05771; -. DR Antibodypedia; 3547; 873 antibodies from 46 providers. DR DNASU; 5579; -. DR Ensembl; ENST00000321728.12; ENSP00000318315.7; ENSG00000166501.15. [P05771-1] DR Ensembl; ENST00000643927.1; ENSP00000496129.1; ENSG00000166501.15. [P05771-2] DR GeneID; 5579; -. DR KEGG; hsa:5579; -. DR MANE-Select; ENST00000643927.1; ENSP00000496129.1; NM_002738.7; NP_002729.2. [P05771-2] DR UCSC; uc002dmd.4; human. [P05771-1] DR AGR; HGNC:9395; -. DR CIViC; 5579; 3 evidence items across 2 molecular profiles. DR ClinPGx; PA33761; -. DR CTD; 5579; -. DR DisGeNET; 5579; -. DR GeneCards; PRKCB; -. DR HGNC; HGNC:9395; PRKCB. DR HPA; ENSG00000166501; Tissue enhanced (brain, lymphoid tissue). DR MalaCards; PRKCB; -. DR MIM; 176970; gene. DR OpenTargets; ENSG00000166501; -. DR VEuPathDB; HostDB:ENSG00000166501; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000155217; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P05771; -. DR OMA; VVXQLKE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P05771; 3 GO annotations based on evolutionary models. DR PhylomeDB; P05771; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P05771; -. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells. DR SABIO-RK; P05771; -. DR SignaLink; P05771; -. DR SIGNOR; P05771; -. DR Agora; ENSG00000166501; -. DR BioGRID-ORCS; 5579; 18 hits in 1197 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCB; human. DR EvolutionaryTrace; P05771; -. DR GeneWiki; PRKCB1; -. DR GenomeRNAi; 5579; -. DR Pharos; P05771; Tchem. DR PRO; PR:P05771; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; P05771; protein. DR Bgee; ENSG00000166501; Expressed in middle temporal gyrus and 189 other cell types or tissues. DR ExpressionAtlas; P05771; baseline and differential. DR GO; GO:0044305; C:calyx of Held; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0099523; C:presynaptic cytosol; IEA:Ensembl. DR GO; GO:0008091; C:spectrin; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IMP:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0042113; P:B cell activation; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0006874; P:intracellular calcium ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0042953; P:lipoprotein transport; TAS:BHF-UCL. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:0010829; P:negative regulation of D-glucose transmembrane transport; ISS:UniProtKB. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0007207; P:phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0160020; P:positive regulation of ferroptosis; IDA:UniProtKB. DR GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl. DR GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0010827; P:regulation of D-glucose transmembrane transport; IDA:UniProtKB. DR GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05616; STKc_cPKC_beta; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034664; cPKC-beta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Adaptive immunity; Alternative splicing; KW Apoptosis; ATP-binding; Calcium; Chromatin regulator; Cytoplasm; KW Direct protein sequencing; Immunity; Kinase; Membrane; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801" FT CHAIN 2..671 FT /note="Protein kinase C beta type" FT /id="PRO_0000055684" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 342..600 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 601..671 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 311..330 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 614..635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 623..635 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 466 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 251 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P68403" FT BINDING 348..356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 371 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|PubMed:12665801" FT MOD_RES 11 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 16 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255" FT MOD_RES 17 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 206 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 250 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 311 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 314 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 324 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255" FT MOD_RES 500 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305|PubMed:17115692" FT MOD_RES 504 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 635 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P68403" FT MOD_RES 642 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17115692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 661 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17115692" FT MOD_RES 662 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P68404" FT VAR_SEQ 622..671 FT /note="RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV FT -> CGRNAENFDRFFTRHPPVLTPPDQEVIRNIDQSEFEGFSFVNSEFLKPEVKS (in FT isoform Beta-II)" FT /evidence="ECO:0000303|PubMed:3666134, FT ECO:0000303|PubMed:3755548" FT /id="VSP_004738" FT VARIANT 144 FT /note="V -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs764534677)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042304" FT VARIANT 496 FT /note="V -> M (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs1466858740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042305" FT VARIANT 588 FT /note="P -> H (in dbSNP:rs35631544)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042306" FT CONFLICT 69 FT /note="V -> G (in Ref. 7; CAA44393)" FT /evidence="ECO:0000305" FT STRAND 342..351 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 354..361 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 364..374 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 384..394 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 406..411 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 413..421 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 472..474 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 480..482 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 521..536 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 546..555 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 566..575 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 590..595 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 598..600 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 605..609 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 629..636 FT /evidence="ECO:0007829|PDB:2I0E" FT HELIX 646..651 FT /evidence="ECO:0007829|PDB:2I0E" FT TURN 654..657 FT /evidence="ECO:0007829|PDB:2I0E" FT STRAND 658..660 FT /evidence="ECO:0007829|PDB:8SG2" FT MOD_RES P05771-2:641 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES P05771-2:660 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" SQ SEQUENCE 671 AA; 76869 MW; 3937E7B667108C68 CRC64; MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR DVLIVLVRDA KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL SVEIWDWDLT SRNDFMGSLS FGISELQKAS VDGWFKLLSQ EEGEYFNVPV PPEGSEANEE LRQKFERAKI SQGTKVPEEK TTNTVSKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF SYTNPEFVIN V // ID KPCL_HUMAN Reviewed; 683 AA. AC P24723; B4DJN5; Q16246; Q8NE03; DT 01-MAR-1992, integrated into UniProtKB/Swiss-Prot. DT 15-DEC-2009, sequence version 4. DT 28-JAN-2026, entry version 232. DE RecName: Full=Protein kinase C eta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:34593629}; DE AltName: Full=PKC-L; DE AltName: Full=nPKC-eta; GN Name=PRKCH; Synonyms=PKCL, PRKCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=1986216; DOI=10.1128/mcb.11.1.126-133.1991; RA Bacher N., Zisman Y., Berent E., Livneh E.; RT "Isolation and characterization of PKC-L, a new member of the protein RT kinase C-related gene family specifically expressed in lung, skin, and RT heart."; RL Mol. Cell. Biol. 11:126-133(1991). RN [2] RP ERRATUM OF PUBMED:1986216, AND SEQUENCE REVISION. RX PubMed=1545821; DOI=10.1128/mcb.12.3.1404-.1992; RA Bacher N., Zisman Y., Berent E., Livneh E.; RL Mol. Cell. Biol. 12:1404-1404(1992). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 438-539 (ISOFORM 1). RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [8] RP FUNCTION. RX PubMed=11112424; DOI=10.1006/bbrc.2000.3903; RA Akkaraju G.R., Basu A.; RT "Overexpression of protein kinase C-eta attenuates caspase activation and RT tumor necrosis factor-alpha-induced cell death."; RL Biochem. Biophys. Res. Commun. 279:103-107(2000). RN [9] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=10806212; DOI=10.1074/jbc.m003203200; RA Hussaini I.M., Karns L.R., Vinton G., Carpenter J.E., Redpath G.T., RA Sando J.J., VandenBerg S.R.; RT "Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific RT proliferative response in astrocytic tumor cells."; RL J. Biol. Chem. 275:22348-22354(2000). RN [10] RP FUNCTION. RX PubMed=11772428; DOI=10.1093/neuonc/4.1.9; RA Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J., Shaffrey M.E., RA Vandenberg S.R.; RT "Protein kinase C-eta regulates resistance to UV- and gamma-irradiation- RT induced apoptosis in glioblastoma cells by preventing caspase-9 RT activation."; RL Neuro-oncol. 4:9-21(2002). RN [11] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=15489897; DOI=10.1038/sj.onc.1208093; RA Aeder S.E., Martin P.M., Soh J.W., Hussaini I.M.; RT "PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR RT signaling pathways."; RL Oncogene 23:9062-9069(2004). RN [12] RP INTERACTION WITH DGKQ. RX PubMed=15632189; DOI=10.1074/jbc.m409301200; RA van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.; RT "Translocation of diacylglycerol kinase theta from cytosol to plasma RT membrane in response to activation of G protein-coupled receptors and RT protein kinase C."; RL J. Biol. Chem. 280:9870-9878(2005). RN [13] RP FUNCTION. RX PubMed=17146445; DOI=10.1038/sj.onc.1210090; RA Uht R.M., Amos S., Martin P.M., Riggan A.E., Hussaini I.M.; RT "The protein kinase C-eta isoform induces proliferation in glioblastoma RT cell lines through an ERK/Elk-1 pathway."; RL Oncogene 26:2885-2893(2007). RN [14] RP FUNCTION IN B-CELL SIGNALING. RX PubMed=18780722; DOI=10.1093/intimm/dxn101; RA Oda A., Ono T., Yamamoto M., Goitsuka R., Kitamura D.; RT "PKC eta directs induction of IRF-4 expression and Ig kappa gene RT rearrangement in pre-BCR signaling pathway."; RL Int. Immunol. 20:1417-1426(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP INDUCTION. RX PubMed=19797084; DOI=10.1128/mcb.01044-09; RA Raveh-Amit H., Maissel A., Poller J., Marom L., Elroy-Stein O., Shapira M., RA Livneh E.; RT "Translational control of protein kinase Ceta by two upstream open reading RT frames."; RL Mol. Cell. Biol. 29:6140-6148(2009). RN [17] RP FUNCTION IN PHOSPHORYLATION OF OCLN. RX PubMed=19114660; DOI=10.1073/pnas.0802741106; RA Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., RA Desiderio D., Guntaka R., Rao R.; RT "PKC eta regulates occludin phosphorylation and epithelial tight junction RT integrity."; RL Proc. Natl. Acad. Sci. U.S.A. 106:61-66(2009). RN [18] RP FUNCTION. RX PubMed=20558593; DOI=10.1124/mol.110.064394; RA Lee H.K., Yeo S., Kim J.S., Lee J.G., Bae Y.S., Lee C., Baek S.H.; RT "Protein kinase C-eta and phospholipase D2 pathway regulates foam cell RT formation via regulator of G protein signaling 2."; RL Mol. Pharmacol. 78:478-485(2010). RN [19] RP FUNCTION. RX PubMed=21820409; DOI=10.1016/j.bbrc.2011.07.090; RA Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E.; RT "Protein kinase C? activates NF-?B in response to camptothecin-induced DNA RT damage."; RL Biochem. Biophys. Res. Commun. 412:313-317(2011). RN [20] RP REVIEW. RX PubMed=12473186; DOI=10.1093/oxfordjournals.jbchem.a003297; RA Kashiwagi M., Ohba M., Chida K., Kuroki T.; RT "Protein kinase C eta (PKC eta): its involvement in keratinocyte RT differentiation."; RL J. Biochem. 132:853-857(2002). RN [21] RP FUNCTION. RX PubMed=22304920; DOI=10.1016/j.cell.2012.01.016; RA Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L., Ideker T., RA Ronai Z.A.; RT "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while RT blocking its apoptotic function at mitochondria."; RL Cell 148:543-555(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-656, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH PRKCH UPSTREAM RP OPEN READING FRAME 2, AND PHOSPHORYLATION AT THR-656 AND SER-675. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [25] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-138, PHOSPHORYLATION AT SER-28 RP AND SER-32, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16973127; DOI=10.1016/j.bbrc.2006.08.160; RA Littler D.R., Walker J.R., She Y.-M., Finerty P.J. Jr., Newman E.M., RA Dhe-Paganon S.; RT "Structure of human protein kinase C eta (PKCeta) C2 domain and RT identification of phosphorylation sites."; RL Biochem. Biophys. Res. Commun. 349:1182-1189(2006). RN [26] RP ASSOCIATION OF VARIANT ILE-374 WITH ISCHSTR, AND CHARACTERIZATION OF RP VARIANT ILE-374. RX PubMed=17206144; DOI=10.1038/ng1945; RA Kubo M., Hata J., Ninomiya T., Matsuda K., Yonemoto K., Nakano T., RA Matsushita T., Yamazaki K., Ohnishi Y., Saito S., Kitazono T., Ibayashi S., RA Sueishi K., Iida M., Nakamura Y., Kiyohara Y.; RT "A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of RT cerebral infarction."; RL Nat. Genet. 39:212-217(2007). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-19; ARG-65; GLN-149; GLN-359; ILE-374; RP ALA-575; ILE-594 AND SER-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in the CC regulation of cell differentiation in keratinocytes and pre-B cell CC receptor, mediates regulation of epithelial tight junction integrity CC and foam cell formation, and is required for glioblastoma proliferation CC and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and CC activates the tyrosine kinase FYN, which in turn blocks epidermal CC growth factor receptor (EGFR) signaling and leads to keratinocyte CC growth arrest and differentiation. Associates with the cyclin CCNE1- CC CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 CC dephosphorylation and thereby G1 arrest in keratinocytes. In CC association with RALA activates actin depolymerization, which is CC necessary for keratinocyte differentiation. In the pre-B cell receptor CC signaling, functions downstream of BLNK by up-regulating IRF4, which in CC turn activates L chain gene rearrangement. Regulates epithelial tight CC junctions (TJs) by phosphorylating occludin (OCLN) on threonine CC residues, which is necessary for the assembly and maintenance of TJs. CC In association with PLD2 and via TLR4 signaling, is involved in CC lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell CC formation. Upon PMA stimulation, mediates glioblastoma cell CC proliferation by activating the mTOR pathway, the PI3K/AKT pathway and CC the ERK1-dependent phosphorylation of ELK1. Involved in the protection CC of glioblastoma cells from irradiation-induced apoptosis by preventing CC caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates CC NF-kappa-B upstream signaling by activating IKBKB, and confers CC protection against DNA damage-induced apoptosis. Promotes oncogenic CC functions of ATF2 in the nucleus while blocking its apoptotic function CC at mitochondria. Phosphorylates ATF2 which promotes its nuclear CC retention and transcriptional activity and negatively regulates its CC mitochondrial localization. {ECO:0000269|PubMed:10806212, CC ECO:0000269|PubMed:11112424, ECO:0000269|PubMed:11772428, CC ECO:0000269|PubMed:15489897, ECO:0000269|PubMed:17146445, CC ECO:0000269|PubMed:18780722, ECO:0000269|PubMed:19114660, CC ECO:0000269|PubMed:20558593, ECO:0000269|PubMed:21820409, CC ECO:0000269|PubMed:22304920}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-513 (activation loop of CC the kinase domain), Thr-656 (turn motif) and Ser-675 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Interacts with FYN (By similarity). Interacts with RALA (By CC similarity). Interacts with DGKQ (PubMed:15632189). Interacts with CC PRKCH upstream open reading frame 2; the interaction leads to CC inhibition of kinase activity (PubMed:34593629). CC {ECO:0000250|UniProtKB:P23298, ECO:0000269|PubMed:15632189, CC ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC P24723; Q16625-1: OCLN; NbExp=2; IntAct=EBI-2865850, EBI-16115673; CC P24723; Q28269: OCLN; Xeno; NbExp=2; IntAct=EBI-2865850, EBI-16222162; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P24723-1; Sequence=Displayed; CC Name=2; CC IsoId=P24723-2; Sequence=VSP_056572; CC -!- TISSUE SPECIFICITY: Most abundant in lung, less in heart and skin. CC {ECO:0000269|PubMed:1986216}. CC -!- INDUCTION: By stress conditions caused by amino acid starvation (at CC protein level). {ECO:0000269|PubMed:19797084}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an acute CC neurologic event leading to death of neural tissue of the brain and CC resulting in loss of motor, sensory and/or cognitive function. Ischemic CC strokes, resulting from vascular occlusion, is considered to be a CC highly complex disease consisting of a group of heterogeneous disorders CC with multiple genetic and environmental risk factors. CC {ECO:0000269|PubMed:17206144}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M55284; AAA60100.1; -; mRNA. DR EMBL; AK290183; BAF82872.1; -; mRNA. DR EMBL; AK296158; BAG58897.1; -; mRNA. DR EMBL; AL138996; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL355916; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL359220; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471061; EAW80800.1; -; Genomic_DNA. DR EMBL; CH471061; EAW80801.1; -; Genomic_DNA. DR EMBL; BC037268; AAH37268.1; -; mRNA. DR EMBL; S74620; AAB32724.1; -; mRNA. DR CCDS; CCDS9752.1; -. [P24723-1] DR PIR; A39666; A39666. DR RefSeq; NP_006246.2; NM_006255.4. [P24723-1] DR RefSeq; XP_024305429.1; XM_024449661.2. [P24723-2] DR RefSeq; XP_024305430.1; XM_024449662.2. [P24723-2] DR RefSeq; XP_054232364.1; XM_054376389.1. [P24723-2] DR RefSeq; XP_054232365.1; XM_054376390.1. [P24723-2] DR PDB; 2FK9; X-ray; 1.75 A; A=1-138. DR PDB; 3TXO; X-ray; 2.05 A; A=333-683. DR PDB; 8FP1; X-ray; 1.85 A; A=333-683. DR PDB; 8FP3; X-ray; 2.30 A; A=333-683. DR PDBsum; 2FK9; -. DR PDBsum; 3TXO; -. DR PDBsum; 8FP1; -. DR PDBsum; 8FP3; -. DR AlphaFoldDB; P24723; -. DR SMR; P24723; -. DR BioGRID; 111569; 31. DR DIP; DIP-44588N; -. DR FunCoup; P24723; 864. DR IntAct; P24723; 14. DR MINT; P24723; -. DR STRING; 9606.ENSP00000329127; -. DR BindingDB; P24723; -. DR ChEMBL; CHEMBL3616; -. DR DrugCentral; P24723; -. DR GuidetoPHARMACOLOGY; 1487; -. DR GlyGen; P24723; 3 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P24723; -. DR PhosphoSitePlus; P24723; -. DR BioMuta; PRKCH; -. DR DMDM; 281185512; -. DR CPTAC; CPTAC-3187; -. DR CPTAC; CPTAC-3188; -. DR jPOST; P24723; -. DR MassIVE; P24723; -. DR PaxDb; 9606-ENSP00000329127; -. DR PeptideAtlas; P24723; -. DR ProteomicsDB; 4395; -. DR ProteomicsDB; 54223; -. [P24723-1] DR Pumba; P24723; -. DR Antibodypedia; 24422; 309 antibodies from 34 providers. DR DNASU; 5583; -. DR Ensembl; ENST00000332981.11; ENSP00000329127.5; ENSG00000027075.18. [P24723-1] DR Ensembl; ENST00000555082.6; ENSP00000450981.1; ENSG00000027075.18. [P24723-2] DR GeneID; 5583; -. DR KEGG; hsa:5583; -. DR MANE-Select; ENST00000332981.11; ENSP00000329127.5; NM_006255.5; NP_006246.2. DR UCSC; uc001xfn.4; human. [P24723-1] DR AGR; HGNC:9403; -. DR ClinPGx; PA33767; -. DR CTD; 5583; -. DR DisGeNET; 5583; -. DR GeneCards; PRKCH; -. DR HGNC; HGNC:9403; PRKCH. DR HPA; ENSG00000027075; Low tissue specificity. DR MalaCards; PRKCH; -. DR MIM; 601367; phenotype. DR MIM; 605437; gene. DR OpenTargets; ENSG00000027075; -. DR VEuPathDB; HostDB:ENSG00000027075; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000158220; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; P24723; -. DR OMA; MTKNPNM; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P24723; 3 GO annotations based on evolutionary models. DR PhylomeDB; P24723; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P24723; -. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR SABIO-RK; P24723; -. DR SignaLink; P24723; -. DR SIGNOR; P24723; -. DR Agora; ENSG00000027075; -. DR BioGRID-ORCS; 5583; 14 hits in 1196 CRISPR screens. DR ChiTaRS; PRKCH; human. DR EvolutionaryTrace; P24723; -. DR GeneWiki; PRKCH; -. DR GenomeRNAi; 5583; -. DR Pharos; P24723; Tchem. DR PRO; PR:P24723; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P24723; protein. DR Bgee; ENSG00000027075; Expressed in parotid gland and 189 other cell types or tissues. DR ExpressionAtlas; P24723; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0004699; F:diacylglycerol-dependent, calcium-independent serine/threonine kinase activity; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0141212; P:phospholipase C/protein kinase C signal transduction; IEA:Ensembl. DR GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB. DR GO; GO:0045618; P:positive regulation of keratinocyte differentiation; ISS:UniProtKB. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; TAS:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20835; C1_nPKC_epsilon-like_rpt1; 1. DR CDD; cd20838; C1_nPKC_epsilon-like_rpt2; 1. DR CDD; cd04014; C2_PKC_epsilon; 1. DR CDD; cd05590; STKc_nPKC_eta; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 1.10.510.10:FF:000126; Protein kinase C epsilon; 1. DR FunFam; 2.60.40.150:FF:000056; Protein kinase C epsilon; 1. DR FunFam; 3.30.60.20:FF:000024; Protein kinase C epsilon; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034665; nPKC_eta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027431; PKC_eta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501107; Protein_kin_C_eta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Differentiation; Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..683 FT /note="Protein kinase C eta type" FT /id="PRO_0000055705" FT DOMAIN 1..118 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 355..614 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 615..683 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 171..222 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 245..295 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 320..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 479 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 361..369 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 28 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127, FT ECO:0007744|PubMed:23186163" FT MOD_RES 32 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127" FT MOD_RES 317 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P23298" FT MOD_RES 513 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305" FT MOD_RES 656 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:34593629, FT ECO:0007744|PubMed:24275569" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:34593629" FT VAR_SEQ 1..161 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056572" FT VARIANT 19 FT /note="A -> V (in dbSNP:rs55645551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042312" FT VARIANT 65 FT /note="K -> R (in dbSNP:rs55737090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042313" FT VARIANT 149 FT /note="R -> Q (in dbSNP:rs55848048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042314" FT VARIANT 359 FT /note="R -> Q (in dbSNP:rs55818778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042315" FT VARIANT 374 FT /note="V -> I (risk factor for ischemic stroke; increases FT autophosphorylation and kinase activity; dbSNP:rs2230500)" FT /evidence="ECO:0000269|PubMed:17206144, FT ECO:0000269|PubMed:17344846" FT /id="VAR_034604" FT VARIANT 497 FT /note="D -> Y (in dbSNP:rs11846991)" FT /id="VAR_060736" FT VARIANT 575 FT /note="T -> A (in a aLL TEL/AML1+ sample; somatic mutation; FT dbSNP:rs1378993559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042316" FT VARIANT 594 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042317" FT VARIANT 612 FT /note="P -> S (in dbSNP:rs34159231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042318" FT VARIANT 645 FT /note="D -> V (in dbSNP:rs35561533)" FT /id="VAR_042438" FT CONFLICT 96 FT /note="Missing (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 109 FT /note="L -> R (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 110 FT /note="R -> G (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="Q -> L (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 472 FT /note="D -> E (in Ref. 7; AAB32724)" FT /evidence="ECO:0000305" FT STRAND 8..20 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 26..30 FT /evidence="ECO:0007829|PDB:2FK9" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 43..49 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 67..79 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 81..88 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 105..112 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 116..123 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 129..137 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 355..364 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 367..374 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 380..387 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 388..393 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 397..409 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 419..424 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 426..434 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 441..448 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 453..472 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 493..495 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 523..526 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 534..549 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 559..568 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 600..602 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 603..605 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 606..609 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 619..623 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 660..662 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 663..665 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 668..671 FT /evidence="ECO:0007829|PDB:8FP1" SQ SEQUENCE 683 AA; 77828 MW; 0A29806CE31912F2 CRC64; MSSGTMKFNG YLRVRIGEAV GLQPTRWSLR HSLFKKGHQL LDPYLTVSVD QVRVGQTSTK QKTNKPTYNE EFCANVTDGG HLELAVFHET PLGYDHFVAN CTLQFQELLR TTGASDTFEG WVDLEPEGKV FVVITLTGSF TEATLQRDRI FKHFTRKRQR AMRRRVHQIN GHKFMATYLR QPTYCSHCRE FIWGVFGKQG YQCQVCTCVV HKRCHHLIVT ACTCQNNINK VDSKIAEQRF GINIPHKFSI HNYKVPTFCD HCGSLLWGIM RQGLQCKICK MNVHIRCQAN VAPNCGVNAV ELAKTLAGMG LQPGNISPTS KLVSRSTLRR QGKESSKEGN GIGVNSSNRL GIDNFEFIRV LGKGSFGKVM LARVKETGDL YAVKVLKKDV ILQDDDVECT MTEKRILSLA RNHPFLTQLF CCFQTPDRLF FVMEFVNGGD LMFHIQKSRR FDEARARFYA AEIISALMFL HDKGIIYRDL KLDNVLLDHE GHCKLADFGM CKEGICNGVT TATFCGTPDY IAPEILQEML YGPAVDWWAM GVLLYEMLCG HAPFEAENED DLFEAILNDE VVYPTWLHED ATGILKSFMT KNPTMRLGSL TQGGEHAILR HPFFKEIDWA QLNHRQIEPP FRPRIKSRED VSNFDPDFIK EEPVLTPIDE GHLPMINQDE FRNFSYVSPE LQP // ID KPCT_HUMAN Reviewed; 706 AA. AC Q04759; B4DF52; Q14DH6; Q3MJF1; Q64FY5; Q9H508; Q9H549; DT 01-OCT-1993, integrated into UniProtKB/Swiss-Prot. DT 27-MAR-2002, sequence version 3. DT 28-JAN-2026, entry version 247. DE RecName: Full=Protein kinase C theta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-theta; GN Name=PRKCQ; Synonyms=PRKCT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT RP LEU-330. RX PubMed=7686153; DOI=10.1016/s0021-9258(19)85228-6; RA Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.; RT "Molecular cloning and expression of a cDNA encoding a novel isoenzyme of RT protein kinase C (nPKC). A new member of the nPKC family expressed in RT skeletal muscle, megakaryoblastic cells, and platelets."; RL J. Biol. Chem. 268:14208-14214(1993). RN [2] RP ERRATUM OF PUBMED:7686153, AND SEQUENCE REVISION. RX PubMed=7983077; DOI=10.1016/s0021-9258(18)47426-1; RA Chang J.D., Xu Y., Raychowdhury M.K., Ware J.A.; RL J. Biol. Chem. 269:31322-31322(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=8444877; DOI=10.1016/s0021-9258(18)53494-3; RA Baier G., Telford D., Giampa L., Coggeshall K.M., Baier-Bitterlich G., RA Isakov N., Altman A.; RT "Molecular cloning and characterization of PKC theta, a novel member of the RT protein kinase C (PKC) gene family expressed predominantly in hematopoietic RT cells."; RL J. Biol. Chem. 268:4997-5004(1993). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-330. RA Li H., Ke R., Zhou G., Shen C., Zhong G., Lin L., Yang S.; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION IN ACTIVATION OF JUN. RX PubMed=8657160; DOI=10.1128/mcb.16.4.1842; RA Baier-Bitterlich G., Uberall F., Bauer B., Fresser F., Wachter H., RA Grunicke H., Utermann G., Altman A., Baier G.; RT "Protein kinase C-theta isoenzyme selective stimulation of the RT transcription factor complex AP-1 in T lymphocytes."; RL Mol. Cell. Biol. 16:1842-1850(1996). RN [9] RP INTERACTION WITH GLRX3. RX PubMed=10636891; DOI=10.1074/jbc.275.3.1902; RA Witte S., Villalba M., Bi K., Liu Y., Isakov N., Altman A.; RT "Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by RT PICOT, a novel protein kinase C-interacting protein with a thioredoxin RT homology domain."; RL J. Biol. Chem. 275:1902-1909(2000). RN [10] RP PHOSPHORYLATION AT TYR-90, AND MUTAGENESIS OF TYR-90; ALA-148 AND LYS-409. RX PubMed=10652356; DOI=10.1074/jbc.275.5.3603; RA Liu Y., Witte S., Liu Y.C., Doyle M., Elly C., Altman A.; RT "Regulation of protein kinase Ctheta function during T cell activation by RT Lck-mediated tyrosine phosphorylation."; RL J. Biol. Chem. 275:3603-3609(2000). RN [11] RP FUNCTION IN PHOSPHORYLATION OF BAD. RX PubMed=11342610; DOI=10.4049/jimmunol.166.10.5955; RA Villalba M., Bushway P., Altman A.; RT "Protein kinase C-theta mediates a selective T cell survival signal via RT phosphorylation of BAD."; RL J. Immunol. 166:5955-5963(2001). RN [12] RP PHOSPHORYLATION AT THR-538; SER-676 AND SER-695, AND MUTAGENESIS OF THR-538 RP AND SER-695. RX PubMed=11772397; DOI=10.1042/bj3610255; RA Liu Y., Graham C., Li A., Fisher R.J., Shaw S.; RT "Phosphorylation of the protein kinase C-theta activation loop and RT hydrophobic motif regulates its kinase activity, but only activation loop RT phosphorylation is critical to in vivo nuclear-factor-kappaB induction."; RL Biochem. J. 361:255-265(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF STK39/SPAK. RX PubMed=14988727; DOI=10.1038/sj.emboj.7600125; RA Li Y., Hu J., Vita R., Sun B., Tabata H., Altman A.; RT "SPAK kinase is a substrate and target of PKCtheta in T-cell receptor- RT induced AP-1 activation pathway."; RL EMBO J. 23:1112-1122(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF IRS1. RX PubMed=15364919; DOI=10.1074/jbc.c400186200; RA Li Y., Soos T.J., Li X., Wu J., Degennaro M., Sun X., Littman D.R., RA Birnbaum M.J., Polakiewicz R.D.; RT "Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 RT at Ser(1101)."; RL J. Biol. Chem. 279:45304-45307(2004). RN [15] RP INTERACTION WITH ECT2. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [16] RP FUNCTION, PHOSPHORYLATION AT THR-219; THR-538; SER-676 AND SER-695, AND RP MUTAGENESIS OF THR-219; THR-538; SER-676 AND SER-695. RX PubMed=16252004; DOI=10.1038/sj.emboj.7600856; RA Thuille N., Heit I., Fresser F., Krumbock N., Bauer B., Leuthaeusser S., RA Dammeier S., Graham C., Copeland T.D., Shaw S., Baier G.; RT "Critical role of novel Thr-219 autophosphorylation for the cellular RT function of PKCtheta in T lymphocytes."; RL EMBO J. 24:3869-3880(2005). RN [17] RP FUNCTION IN PHOSPHORYLATION OF CARD11, AND SUBUNIT. RX PubMed=16356855; DOI=10.1016/j.immuni.2005.09.014; RA Sommer K., Guo B., Pomerantz J.L., Bandaranayake A.D., Moreno-Garcia M.E., RA Ovechkina Y.L., Rawlings D.J.; RT "Phosphorylation of the CARMA1 linker controls NF-kappaB activation."; RL Immunity 23:561-574(2005). RN [18] RP FUNCTION IN ACTIVATION OF BCL-X(L)/BCL2L1. RX PubMed=16709830; DOI=10.4049/jimmunol.176.11.6709; RA Manicassamy S., Gupta S., Huang Z., Sun Z.; RT "Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by RT up-regulating Bcl-xL."; RL J. Immunol. 176:6709-6716(2006). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-348; SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CBLB. RX PubMed=19549985; DOI=10.1126/scisignal.2000046; RA Gruber T., Hermann-Kleiter N., Hinterleitner R., Fresser F., Schneider R., RA Gastl G., Penninger J.M., Baier G.; RT "PKC-theta modulates the strength of T cell responses by targeting Cbl-b RT for ubiquitination and degradation."; RL Sci. Signal. 2:RA30-RA30(2009). RN [22] RP FUNCTION, AND INTERACTION WITH CD28. RX PubMed=21964608; DOI=10.1038/ni.2120; RA Kong K.F., Yokosuka T., Canonigo-Balancio A.J., Isakov N., Saito T., RA Altman A.; RT "A motif in the V3 domain of the kinase PKC-theta determines its RT localization in the immunological synapse and functions in T cells via RT association with CD28."; RL Nat. Immunol. 12:1105-1112(2011). RN [23] RP REVIEW ON FUNCTION. RX PubMed=11861617; DOI=10.1146/annurev.immunol.20.100301.064807; RA Isakov N., Altman A.; RT "Protein kinase C(theta) in T cell activation."; RL Annu. Rev. Immunol. 20:761-794(2002). RN [24] RP REVIEW ON FUNCTION. RX PubMed=12473184; DOI=10.1093/oxfordjournals.jbchem.a003295; RA Altman A., Villalba M.; RT "Protein kinase C-theta (PKC theta): a key enzyme in T cell life and RT death."; RL J. Biochem. 132:841-846(2002). RN [25] RP REVIEW. RX PubMed=15282562; DOI=10.1038/ni1097; RA Spitaler M., Cantrell D.A.; RT "Protein kinase C and beyond."; RL Nat. Immunol. 5:785-790(2004). RN [26] RP REVIEW ON FUNCTION. RX PubMed=16978534; RA Manicassamy S., Gupta S., Sun Z.; RT "Selective function of PKC-theta in T cells."; RL Cell. Mol. Immunol. 3:263-270(2006). RN [27] RP REVIEW ON FUNCTION. RX PubMed=17544292; DOI=10.1016/j.phrs.2007.04.009; RA Hayashi K., Altman A.; RT "Protein kinase C theta (PKCtheta): a key player in T cell life and RT death."; RL Pharmacol. Res. 55:537-544(2007). RN [28] RP REVIEW ON FUNCTION. RX PubMed=18328786; DOI=10.1016/j.it.2008.01.005; RA Marsland B.J., Kopf M.; RT "T-cell fate and function: PKC-theta and beyond."; RL Trends Immunol. 29:179-185(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP REVIEW ON FUNCTION IN PLATELET ACTIVATION. RX PubMed=21944869; DOI=10.1016/j.febslet.2011.09.014; RA Cohen S., Braiman A., Shubinsky G., Isakov N.; RT "Protein kinase C-theta in platelet activation."; RL FEBS Lett. 585:3208-3215(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676; SER-685 AND SER-695, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A. RX PubMed=23509302; DOI=10.1073/pnas.1303392110; RA Lopez-Sanchez I., Garcia-Marcos M., Mittal Y., Aznar N., Farquhar M.G., RA Ghosh P.; RT "Protein kinase C-theta (PKCtheta) phosphorylates and inhibits the guanine RT exchange factor, GIV/Girdin."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5510-5515(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-695, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH PRKCH RP UPSTREAM OPEN READING FRAME 2. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [37] RP FUNCTION IN PHOSPHORYLATION OF LRRK1. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 362-706, AND PHOSPHORYLATION AT RP THR-538 AND SER-695. RX PubMed=15364937; DOI=10.1074/jbc.m409216200; RA Xu Z.B., Chaudhary D., Olland S., Wolfrom S., Czerwinski R., Malakian K., RA Lin L., Stahl M.L., Joseph-McCarthy D., Benander C., Fitz L., Greco R., RA Somers W.S., Mosyak L.; RT "Catalytic domain crystal structure of protein kinase C-theta (PKCtheta)."; RL J. Biol. Chem. 279:50401-50409(2004). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 361-706, AND PHOSPHORYLATION AT RP SER-676 AND SER-695. RA Stark W., Bitsch F., Berner A., Buelens F., Graff P., Depersin H., RA Fendrich G., Geiser M., Knecht R., Rahuel J., Rummel G., Schlaeppi J.M., RA Schmitz R., Strauss A., Wagner J.; RT "The crystal structure of the kinase domain of the protein kinase C theta RT in complex with Nvp-Xaa228."; RL Submitted (JAN-2007) to the PDB data bank. RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-240; VAL-306; LEU-330 AND ASN-354. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that mediates non-redundant CC functions in T-cell receptor (TCR) signaling, including T-cells CC activation, proliferation, differentiation and survival, by mediating CC activation of multiple transcription factors such as NF-kappa-B, JUN, CC NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required CC for the activation of NF-kappa-B and JUN, which in turn are essential CC for IL2 production, and participates in the calcium-dependent NFATC1 CC and NFATC2 transactivation (PubMed:21964608). Mediates the activation CC of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation CC of CARD11 on several serine residues, inducing CARD11 association with CC lipid rafts and recruitment of the BCL10-MALT1 complex, which then CC activates IKK complex, resulting in nuclear translocation and CC activation of NFKB1. May also play an indirect role in activation of CC the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway CC leading to JUN activation, acts by phosphorylating the mediator CC STK39/SPAK and may not act through MAP kinases signaling. Plays a CC critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by CC participating in the regulation of reduced inositol 1,4,5-trisphosphate CC generation and intracellular calcium mobilization. After costimulation CC of T-cells through CD28 can phosphorylate CBLB and is required for the CC ubiquitination and subsequent degradation of CBLB, which is a CC prerequisite for the activation of TCR. During T-cells differentiation, CC plays an important role in the development of T-helper 2 (Th2) cells CC following immune and inflammatory responses, and, in the development of CC inflammatory autoimmune diseases, is necessary for the activation of CC IL17-producing Th17 cells. May play a minor role in Th1 response. Upon CC TCR stimulation, mediates T-cell protective survival signal by CC phosphorylating BAD, thus protecting T-cells from BAD-induced CC apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF- CC kappa-B and JUN pathways. In platelets, regulates signal transduction CC downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, CC playing a positive role in 'outside-in' signaling and granule secretion CC signal transduction. May relay signals from the activated ITGA2B CC receptor by regulating the uncoupling of WASP and WIPF1, thereby CC permitting the regulation of actin filament nucleation and branching CC activity of the Arp2/3 complex. May mediate inhibitory effects of free CC fatty acids on insulin signaling by phosphorylating IRS1, which in turn CC blocks IRS1 tyrosine phosphorylation and downstream activation of the CC PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of CC phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at CC 'Ser-504' and 'Ser-532' and negatively regulates its ability to CC phosphorylate PKB/AKT1. Phosphorylates CCDC88A/GIV and inhibits its CC guanine nucleotide exchange factor activity (PubMed:23509302). CC Phosphorylates and activates LRRK1, which phosphorylates RAB proteins CC involved in intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11342610, ECO:0000269|PubMed:14988727, CC ECO:0000269|PubMed:15364919, ECO:0000269|PubMed:16252004, CC ECO:0000269|PubMed:16356855, ECO:0000269|PubMed:16709830, CC ECO:0000269|PubMed:19549985, ECO:0000269|PubMed:21964608, CC ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:8657160}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-538 (activation loop of CC the kinase domain), Ser-676 (turn motif) and Ser-695 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Part of a lipid raft complex composed at least of BCL10, CC CARD11, MALT1 and IKBKB (PubMed:16356855). Interacts with GLRX3 (via N- CC terminus) (PubMed:10636891). Interacts with ECT2 (PubMed:15254234). CC Interacts with CCDC88A/GIV; the interaction leads to phosphorylation of CC CCDC88A and inhibition of its guanine nucleotide exchange factor CC activity (PubMed:23509302). Interacts with PRKCH upstream open reading CC frame 2; the interaction leads to inhibition of kinase activity CC (PubMed:34593629). Interacts with CD28 (PubMed:21964608). CC {ECO:0000269|PubMed:10636891, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16356855, ECO:0000269|PubMed:21964608, CC ECO:0000269|PubMed:23509302, ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC Q04759; Q06187: BTK; NbExp=2; IntAct=EBI-374762, EBI-624835; CC Q04759; P06241: FYN; NbExp=7; IntAct=EBI-374762, EBI-515315; CC Q04759; O76003: GLRX3; NbExp=5; IntAct=EBI-374762, EBI-374781; CC Q04759; Q00613: HSF1; NbExp=2; IntAct=EBI-374762, EBI-719620; CC Q04759; P06239: LCK; NbExp=2; IntAct=EBI-374762, EBI-1348; CC Q04759; Q8IVH8: MAP4K3; NbExp=4; IntAct=EBI-374762, EBI-1758170; CC Q04759; Q05513: PRKCZ; NbExp=3; IntAct=EBI-374762, EBI-295351; CC Q04759; P35570: Irs1; Xeno; NbExp=2; IntAct=EBI-374762, EBI-520230; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane CC protein. Note=In resting T-cells, mostly localized in cytoplasm. In CC response to TCR stimulation, associates with lipid rafts and then CC localizes in the immunological synapse. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q04759-1; Sequence=Displayed; CC Name=2; CC IsoId=Q04759-2; Sequence=VSP_017294; CC Name=3; CC IsoId=Q04759-3; Sequence=VSP_054550; CC -!- TISSUE SPECIFICITY: Expressed in skeletal muscle, T-cells, CC megakaryoblastic cells and platelets. {ECO:0000269|PubMed:7686153}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- PTM: Autophosphorylation at Thr-219 is required for targeting to the CC TCR and cellular function of PRKCQ upon antigen receptor ligation. CC Following TCR stimulation, phosphorylated at Tyr-90 and Ser-685. CC {ECO:0000269|PubMed:10652356, ECO:0000269|PubMed:11772397, CC ECO:0000269|PubMed:15364937, ECO:0000269|PubMed:16252004, CC ECO:0000269|Ref.39}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L01087; AAA75571.1; -; mRNA. DR EMBL; L07032; AAA60101.1; -; mRNA. DR EMBL; AY702977; AAU29340.1; -; mRNA. DR EMBL; AK293935; BAG57313.1; -; mRNA. DR EMBL; AL158043; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL137145; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC101465; AAI01466.1; -; mRNA. DR EMBL; BC113359; AAI13360.1; -; mRNA. DR CCDS; CCDS55701.1; -. [Q04759-2] DR CCDS; CCDS60482.1; -. [Q04759-3] DR CCDS; CCDS7079.1; -. [Q04759-1] DR PIR; A45416; A45416. DR RefSeq; NP_001229342.1; NM_001242413.2. [Q04759-2] DR RefSeq; NP_001269573.1; NM_001282644.1. DR RefSeq; NP_001269574.1; NM_001282645.1. [Q04759-3] DR RefSeq; NP_001310194.1; NM_001323265.1. [Q04759-1] DR RefSeq; NP_001310195.1; NM_001323266.2. [Q04759-3] DR RefSeq; NP_006248.1; NM_006257.5. [Q04759-1] DR PDB; 1XJD; X-ray; 2.00 A; A=362-706. DR PDB; 2ENJ; NMR; -; A=1-125. DR PDB; 2ENN; NMR; -; A=144-213. DR PDB; 2ENZ; NMR; -; A=227-284. DR PDB; 2JED; X-ray; 2.32 A; A/B=361-706. DR PDB; 4Q9Z; X-ray; 2.60 A; A/B=374-706. DR PDB; 4RA5; X-ray; 2.61 A; A/B=374-706. DR PDB; 5F9E; X-ray; 2.00 A; A/B=361-706. DR PDBsum; 1XJD; -. DR PDBsum; 2ENJ; -. DR PDBsum; 2ENN; -. DR PDBsum; 2ENZ; -. DR PDBsum; 2JED; -. DR PDBsum; 4Q9Z; -. DR PDBsum; 4RA5; -. DR PDBsum; 5F9E; -. DR AlphaFoldDB; Q04759; -. DR SMR; Q04759; -. DR BioGRID; 111574; 62. DR CORUM; Q04759; -. DR FunCoup; Q04759; 797. DR IntAct; Q04759; 27. DR MINT; Q04759; -. DR STRING; 9606.ENSP00000263125; -. DR BindingDB; Q04759; -. DR ChEMBL; CHEMBL3920; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB04522; Dexfosfoserine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q04759; -. DR GuidetoPHARMACOLOGY; 1488; -. DR CarbonylDB; Q04759; -. DR GlyGen; Q04759; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q04759; -. DR PhosphoSitePlus; Q04759; -. DR BioMuta; PRKCQ; -. DR DMDM; 20141582; -. DR CPTAC; CPTAC-2825; -. DR CPTAC; non-CPTAC-2890; -. DR jPOST; Q04759; -. DR MassIVE; Q04759; -. DR PaxDb; 9606-ENSP00000263125; -. DR PeptideAtlas; Q04759; -. DR ProteomicsDB; 4008; -. DR ProteomicsDB; 58279; -. [Q04759-1] DR ProteomicsDB; 58280; -. [Q04759-2] DR Pumba; Q04759; -. DR Antibodypedia; 10940; 860 antibodies from 42 providers. DR DNASU; 5588; -. DR Ensembl; ENST00000263125.10; ENSP00000263125.5; ENSG00000065675.17. [Q04759-1] DR Ensembl; ENST00000397176.6; ENSP00000380361.2; ENSG00000065675.17. [Q04759-2] DR Ensembl; ENST00000539722.5; ENSP00000441752.1; ENSG00000065675.17. [Q04759-3] DR GeneID; 5588; -. DR KEGG; hsa:5588; -. DR MANE-Select; ENST00000263125.10; ENSP00000263125.5; NM_006257.5; NP_006248.1. DR UCSC; uc001ijj.3; human. [Q04759-1] DR AGR; HGNC:9410; -. DR ClinPGx; PA33773; -. DR CTD; 5588; -. DR DisGeNET; 5588; -. DR GeneCards; PRKCQ; -. DR HGNC; HGNC:9410; PRKCQ. DR HPA; ENSG00000065675; Group enriched (lymphoid tissue, skeletal muscle, tongue). DR MalaCards; PRKCQ; -. DR MIM; 600448; gene. DR OpenTargets; ENSG00000065675; -. DR VEuPathDB; HostDB:ENSG00000065675; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000157638; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; Q04759; -. DR OMA; EIWIELK; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q04759; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q04759; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q04759; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-373752; Netrin-1 signaling. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function. DR Reactome; R-HSA-9648002; RAS processing. DR SABIO-RK; Q04759; -. DR SignaLink; Q04759; -. DR SIGNOR; Q04759; -. DR Agora; ENSG00000065675; -. DR BioGRID-ORCS; 5588; 12 hits in 1187 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PRKCQ; human. DR EvolutionaryTrace; Q04759; -. DR GeneWiki; PRKCQ; -. DR GenomeRNAi; 5588; -. DR Pharos; Q04759; Tchem. DR PRO; PR:Q04759; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q04759; protein. DR Bgee; ENSG00000065675; Expressed in triceps brachii and 170 other cell types or tissues. DR ExpressionAtlas; Q04759; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:HPA. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0001772; C:immunological synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0035739; P:CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0006509; P:membrane protein ectodomain proteolysis; ISS:BHF-UCL. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0070233; P:negative regulation of T cell apoptotic process; IMP:UniProtKB. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl. DR GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB. DR GO; GO:0032743; P:positive regulation of interleukin-2 production; IEA:Ensembl. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:0050870; P:positive regulation of T cell activation; ISS:UniProtKB. DR GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:UniProtKB. DR GO; GO:2000570; P:positive regulation of T-helper 2 cell activation; ISS:UniProtKB. DR GO; GO:0032206; P:positive regulation of telomere maintenance; IMP:BHF-UCL. DR GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB. DR CDD; cd20834; C1_nPKC_theta-like_rpt1; 1. DR CDD; cd20837; C1_nPKC_theta-like_rpt2; 1. DR CDD; cd05619; STKc_nPKC_theta; 1. DR FunFam; 3.30.200.20:FF:000360; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 2.60.40.150:FF:000049; Protein kinase C delta type; 1. DR FunFam; 3.30.60.20:FF:000008; Protein kinase C theta; 1. DR FunFam; 1.10.510.10:FF:000150; Protein kinase C, theta; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034668; nPKC_theta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027264; PKC_theta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF21494; PKC_C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501105; Protein_kin_C_theta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Cytoplasm; KW Immunity; Inflammatory response; Kinase; Magnesium; Membrane; KW Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..706 FT /note="Protein kinase C theta type" FT /id="PRO_0000055708" FT DOMAIN 1..107 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 380..634 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 635..706 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 159..209 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 231..281 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 504 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 386..394 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 409 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 90 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0000269|PubMed:10652356" FT MOD_RES 219 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16252004" FT MOD_RES 348 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 538 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305|PubMed:11772397, FT ECO:0000305|PubMed:15364937, ECO:0000305|PubMed:16252004" FT MOD_RES 676 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004, ECO:0000269|Ref.39, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 685 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 695 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:15364937, ECO:0000269|PubMed:16252004, FT ECO:0000269|Ref.39, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 2..126 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054550" FT VAR_SEQ 550..612 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_017294" FT VARIANT 240 FT /note="K -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042319" FT VARIANT 306 FT /note="D -> V (in dbSNP:rs45590231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042320" FT VARIANT 330 FT /note="P -> L (in dbSNP:rs2236379)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7686153, ECO:0000269|Ref.4" FT /id="VAR_020401" FT VARIANT 354 FT /note="D -> N (in dbSNP:rs34524148)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042321" FT MUTAGEN 90 FT /note="Y->F: Loss of function in T-cells proliferation. No FT effect on kinase activity." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 148 FT /note="A->E: Constitutively active form." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 219 FT /note="T->A: Loss of transactivation of the IL2 promoter FT and translocation to the plasma membrane. No effect on FT kinase activity." FT /evidence="ECO:0000269|PubMed:16252004" FT MUTAGEN 409 FT /note="K->A,E: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10652356" FT MUTAGEN 538 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004" FT MUTAGEN 676 FT /note="S->A: Reduction in kinase activity." FT /evidence="ECO:0000269|PubMed:16252004" FT MUTAGEN 695 FT /note="S->A: Reduction in kinase activity." FT /evidence="ECO:0000269|PubMed:11772397, FT ECO:0000269|PubMed:16252004" FT CONFLICT 700 FT /note="G -> R (in Ref. 1; AAA75571 and 4; AAU29340)" FT /evidence="ECO:0000305" FT STRAND 5..13 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 28..39 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 42..52 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 69..75 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 83..89 FT /evidence="ECO:0007829|PDB:2ENJ" FT HELIX 90..98 FT /evidence="ECO:0007829|PDB:2ENJ" FT TURN 99..101 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 103..108 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 114..121 FT /evidence="ECO:0007829|PDB:2ENJ" FT STRAND 155..159 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 161..165 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 174..176 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 196..199 FT /evidence="ECO:0007829|PDB:2ENN" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:2ENN" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 246..248 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 255..257 FT /evidence="ECO:0007829|PDB:2ENZ" FT STRAND 259..265 FT /evidence="ECO:0007829|PDB:2ENZ" FT TURN 271..276 FT /evidence="ECO:0007829|PDB:2ENZ" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:2ENZ" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:5F9E" FT STRAND 380..388 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 390..399 FT /evidence="ECO:0007829|PDB:1XJD" FT TURN 400..402 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 405..412 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 413..418 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 422..435 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 444..449 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 451..459 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 463..465 FT /evidence="ECO:0007829|PDB:5F9E" FT HELIX 466..473 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 478..497 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 507..509 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:1XJD" FT STRAND 518..520 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 543..545 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 548..551 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 559..574 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 584..593 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 604..613 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 628..630 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 639..643 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:5F9E" FT HELIX 680..685 FT /evidence="ECO:0007829|PDB:5F9E" FT TURN 690..693 FT /evidence="ECO:0007829|PDB:1XJD" FT HELIX 699..706 FT /evidence="ECO:0007829|PDB:5F9E" SQ SEQUENCE 706 AA; 81865 MW; B3C53AB892D5210A CRC64; MSPFLRIGLS NFDCGSCQSC QGEAVNPYCA VLVKEYVESE NGQMYIQKKP TMYPPWDSTF DAHINKGRVM QIIVKGKNVD LISETTVELY SLAERCRKNN GKTEIWLELK PQGRMLMNAR YFLEMSDTKD MNEFETEGFF ALHQRRGAIK QAKVHHVKCH EFTATFFPQP TFCSVCHEFV WGLNKQGYQC RQCNAAIHKK CIDKVIAKCT GSAINSRETM FHKERFKIDM PHRFKVYNYK SPTFCEHCGT LLWGLARQGL KCDACGMNVH HRCQTKVANL CGINQKLMAE ALAMIESTQQ ARCLRDTEQI FREGPVEIGL PCSIKNEARP PCLPTPGKRE PQGISWESPL DEVDKMCHLP EPELNKERPS LQIKLKIEDF ILHKMLGKGS FGKVFLAEFK KTNQFFAIKA LKKDVVLMDD DVECTMVEKR VLSLAWEHPF LTHMFCTFQT KENLFFVMEY LNGGDLMYHI QSCHKFDLSR ATFYAAEIIL GLQFLHSKGI VYRDLKLDNI LLDKDGHIKI ADFGMCKENM LGDAKTNTFC GTPDYIAPEI LLGQKYNHSV DWWSFGVLLY EMLIGQSPFH GQDEEELFHS IRMDNPFYPR WLEKEAKDLL VKLFVREPEK RLGVRGDIRQ HPLFREINWE ELERKEIDPP FRPKVKSPFD CSNFDKEFLN EKPRLSFADR ALINSMDQNM FRNFSFMNPG MERLIS // ID KPCZ_HUMAN Reviewed; 592 AA. AC Q05513; A8K4N0; A8MU64; B7Z2J7; E9PCW2; Q15207; Q5SYT5; Q969S4; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 4. DT 28-JAN-2026, entry version 253. DE RecName: Full=Protein kinase C zeta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-zeta; GN Name=PRKCZ; Synonyms=PKC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Frontal cortex; RX PubMed=8224878; DOI=10.1016/0378-1119(93)90213-m; RA Barbee J.L., Loomis C.R., Deutscher S.L., Burns D.J.; RT "The cDNA sequence encoding human protein kinase C-zeta."; RL Gene 132:305-306(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 7-592. RC TISSUE=Hippocampus; RX PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x; RA Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.; RT "Activation and substrate specificity of the human protein kinase C alpha RT and zeta isoenzymes."; RL Eur. J. Biochem. 216:597-606(1993). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=7597083; DOI=10.1073/pnas.92.13.6072; RA Stuart R.O., Nigam S.K.; RT "Regulated assembly of tight junctions by protein kinase C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:6072-6076(1995). RN [8] RP FUNCTION IN ACTIVATION OF MAP2K1/MEK1 AND MAPK1/ERK2. RX PubMed=9447975; DOI=10.1128/mcb.18.2.790; RA Schoenwasser D.C., Marais R.M., Marshall C.J., Parker P.J.; RT "Activation of the mitogen-activated protein kinase/extracellular signal- RT regulated kinase pathway by conventional, novel, and atypical protein RT kinase C isotypes."; RL Mol. Cell. Biol. 18:790-798(1998). RN [9] RP INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION. RX PubMed=9566925; DOI=10.1128/mcb.18.5.3069; RA Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.; RT "Localization of atypical protein kinase C isoforms into lysosome-targeted RT endosomes through interaction with p62."; RL Mol. Cell. Biol. 18:3069-3080(1998). RN [10] RP PHOSPHORYLATION AT THR-410 BY PDPK1. RX PubMed=9768361; DOI=10.1016/s0960-9822(98)70444-0; RA Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S., RA Newton A.C., Schaffhausen B.S., Toker A.; RT "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1."; RL Curr. Biol. 8:1069-1077(1998). RN [11] RP INTERACTION WITH SQSTM1 AND IKBKB. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP FUNCTION IN ACTIVATION OF MAPK1/ERK2. RX PubMed=11035106; DOI=10.4049/jimmunol.165.8.4632; RA Monick M.M., Carter A.B., Flaherty D.M., Peterson M.W., Hunninghake G.W.; RT "Protein kinase C zeta plays a central role in activation of the p42/44 RT mitogen-activated protein kinase by endotoxin in alveolar macrophages."; RL J. Immunol. 165:4632-4639(2000). RN [13] RP INTERACTION WITH PARD6A; PARD6B AND PARD6G. RC TISSUE=Neuroblastoma; RX PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x; RA Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.; RT "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 RT as an adaptor that links the small GTPases Rac and Cdc42 to atypical RT protein kinase C."; RL Genes Cells 6:107-119(2001). RN [14] RP INTERACTION WITH PDPK1, AND PHOSPHORYLATION. RX PubMed=11781095; DOI=10.1021/bi010719z; RA Hodgkinson C.P., Sale G.J.; RT "Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by RT a C-terminal PRK2 fragment."; RL Biochemistry 41:561-569(2002). RN [15] RP FUNCTION IN ACTIVATION OF AKT3. RX PubMed=12162751; DOI=10.1021/bi026065r; RA Hodgkinson C.P., Sale E.M., Sale G.J.; RT "Characterization of PDK2 activity against protein kinase B gamma."; RL Biochemistry 41:10351-10359(2002). RN [16] RP INTERACTION WITH SQSTM1 AND PAWR. RX PubMed=11755531; DOI=10.1016/s0014-5793(01)03224-0; RA Chang S., Kim J.H., Shin J.; RT "p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4- RT induced PKCzeta inhibition."; RL FEBS Lett. 510:57-61(2002). RN [17] RP INTERACTION WITH PARD3. RX PubMed=12234671; DOI=10.1016/s0378-1119(02)00681-9; RA Gao L., Macara I.G., Joberty G.; RT "Multiple splice variants of Par3 and of a novel related gene, Par3L, RT produce proteins with different binding properties."; RL Gene 294:99-107(2002). RN [18] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [19] RP INTERACTION WITH SQSTM1 AND PARD6B, DOMAIN, AND MUTAGENESIS OF LYS-19; RP ASP-62 AND ASP-66. RX PubMed=12887891; DOI=10.1016/s1097-2765(03)00246-6; RA Wilson M.I., Gill D.J., Perisic O., Quinn M.T., Williams R.L.; RT "PB1 domain-mediated heterodimerization in NADPH oxidase and signaling RT complexes of atypical protein kinase C with Par6 and p62."; RL Mol. Cell 12:39-50(2003). RN [20] RP FUNCTION IN PHOSPHORYLATION OF MARK2 AND MARK3, AND CATALYTIC ACTIVITY. RX PubMed=15084291; DOI=10.1016/j.cub.2004.04.007; RA Hurov J.B., Watkins J.L., Piwnica-Worms H.; RT "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and RT activity."; RL Curr. Biol. 14:736-741(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF MARK2, AND CATALYTIC ACTIVITY. RX PubMed=15324659; DOI=10.1016/j.cub.2004.08.021; RA Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K., RA Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.; RT "aPKC acts upstream of PAR-1b in both the establishment and maintenance of RT mammalian epithelial polarity."; RL Curr. Biol. 14:1425-1435(2004). RN [22] RP PHOSPHORYLATION AT THR-410 BY PI3K. RX PubMed=15314172; DOI=10.1128/mcb.24.17.7643-7653.2004; RA Castoria G., Migliaccio A., Di Domenico M., Lombardi M., de Falco A., RA Varricchio L., Bilancio A., Barone M.V., Auricchio F.; RT "Role of atypical protein kinase C in estradiol-triggered G1/S progression RT of MCF-7 cells."; RL Mol. Cell. Biol. 24:7643-7653(2004). RN [23] RP INTERACTION WITH WDFY2. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [24] RP FUNCTION, INTERACTION WITH VAMP2, COMPLEX FORMATION WITH VAMP2 AND WDFY2, RP AND SUBCELLULAR LOCATION. RX PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x; RA Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.; RT "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase RT Czeta."; RL FEBS J. 274:1552-1566(2007). RN [25] RP INTERACTION WITH WWC1 AND DDR1. RX PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007; RA Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J., RA Ormandy C.J.; RT "KIBRA interacts with discoidin domain receptor 1 to modulate collagen- RT induced signalling."; RL Biochim. Biophys. Acta 1783:383-393(2008). RN [26] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [27] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [30] RP SUBCELLULAR LOCATION, SUBUNIT, AND PHOSPHORYLATION AT THR-410. RX PubMed=20332120; DOI=10.1242/jcs.059329; RA Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G., RA Chapon F., Dejana E.; RT "CCM1 regulates vascular-lumen organization by inducing endothelial RT polarity."; RL J. Cell Sci. 123:1073-1080(2010). RN [31] RP REVIEW ON FUNCTION. RX PubMed=12761192; DOI=10.1093/jb/mvg017; RA Hirai T., Chida K.; RT "Protein kinase Czeta (PKCzeta): activation mechanisms and cellular RT functions."; RL J. Biochem. 133:1-7(2003). RN [32] RP REVIEW ON FUNCTION. RX PubMed=16903823; DOI=10.1134/s0006297906070017; RA Liu L.Z., He A.B., Liu X.J., Li Y., Chang Y.S., Fang F.D.; RT "Protein kinase Czeta and glucose uptake."; RL Biochemistry (Mosc.) 71:701-706(2006). RN [33] RP REVIEW ON FUNCTION. RX PubMed=16322752; DOI=10.1038/sj.cdd.4401823; RA Moscat J., Rennert P., Diaz-Meco M.T.; RT "PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways."; RL Cell Death Differ. 13:702-711(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [37] RP INTERACTION WITH APPL1. RX PubMed=26583432; DOI=10.18632/oncotarget.6346; RA Song J., Mu Y., Li C., Bergh A., Miaczynska M., Heldin C.H., Landstroem M.; RT "APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta RT type I receptor intracellular domain."; RL Oncotarget 7:279-292(2016). RN [38] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [39] RP VARIANT [LARGE SCALE ANALYSIS] PHE-514. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-84 AND CYS-519. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium- and diacylglycerol-independent serine/threonine- CC protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) CC pathway and mitogen-activated protein (MAP) kinase cascade, and is CC involved in NF-kappa-B activation, mitogenic signaling, cell CC proliferation, cell polarity, inflammatory response and maintenance of CC long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment CC in macrophages, or following mitogenic stimuli, functions downstream of CC PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently CC of RAF1 activation. Required for insulin-dependent activation of AKT3, CC but may function as an adapter rather than a direct activator. Upon CC insulin treatment may act as a downstream effector of PI3K and CC contribute to the activation of translocation of the glucose CC transporter SLC2A4/GLUT4 and subsequent glucose transport in CC adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5- CC MAPK7/ERK5 independently of its kinase activity and can activate JUN CC promoter through MEF2C. Through binding with SQSTM1/p62, functions in CC interleukin-1 signaling and activation of NF-kappa-B with the specific CC adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation CC of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in CC turn leads to the degradation of NF-kappa-B inhibitors. In migrating CC astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CC CDC42 to function in the establishment of cell polarity along with the CC microtubule motor and dynein. In association with FEZ1, stimulates CC neuronal differentiation in PC12 cells. In the inflammatory response, CC is required for the T-helper 2 (Th2) differentiation process, including CC interleukin production, efficient activation of JAK1 and the subsequent CC phosphorylation and nuclear translocation of STAT6. May be involved in CC development of allergic airway inflammation (asthma), a process CC dependent on Th2 immune response. In the NF-kappa-B-mediated CC inflammatory response, can relieve SETD6-dependent repression of NF- CC kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. CC Phosphorylates VAMP2 in vitro (PubMed:17313651). Phosphorylates and CC activates LRRK1, which phosphorylates RAB proteins involved in CC intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11035106, ECO:0000269|PubMed:12162751, CC ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:9447975}. CC -!- FUNCTION: [Isoform 2]: Involved in late synaptic long term potention CC phase in CA1 hippocampal cells and long term memory maintenance. CC {ECO:0000250|UniProtKB:Q02956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- ACTIVITY REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an CC elevated basal enzymatic activity (that may be due to the interaction CC with SMG1 or SQSTM1) and are not regulated by diacylglycerol, CC phosphatidylserine, phorbol esters or calcium ions. Two specific sites, CC Thr-410 (activation loop of the kinase domain) and Thr-560 (turn CC motif), need to be phosphorylated for its full activation. CC Phosphatidylinositol 3,4,5-trisphosphate might be a physiological CC activator (By similarity). Isoform 2: Constitutively active (By CC similarity). {ECO:0000250|UniProtKB:Q02956}. CC -!- SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Forms another CC ternary complex with SQSTM1 and GABRR3. Forms a complex with SQSTM1 and CC MAP2K5 (By similarity). Interacts with PARD6A, PARD6B, PARD6G and CC SQSTM1. Part of a complex with PARD3, PARD6A or PARD6B or PARD6G and CC CDC42 or RAC1. Interacts with ADAP1/CENTA1. Forms a ternary complex CC composed of SQSTM1 and PAWR. Interacts directly with SQSTM1 (Probable). CC Interacts with IKBKB. Interacts (via the protein kinase domain) with CC WWC1. Forms a tripartite complex with WWC1 and DDR1, but predominantly CC in the absence of collagen. Component of the Par polarity complex, CC composed of at least phosphorylated PRKCZ, PARD3 and TIAM1. Interacts CC with PDPK1 (via N-terminal region). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). CC Forms a complex with WDFY2 and VAMP2 (PubMed:17313651). Interacts with CC APPL1 (PubMed:26583432). Interacts with WWC1, WWC2 and WWC3 CC (PubMed:24682284). {ECO:0000250|UniProtKB:P09217, CC ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:11260256, CC ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:12234671, ECO:0000269|PubMed:12887891, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:16792529, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:18190796, CC ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26583432, ECO:0000269|PubMed:9566925, ECO:0000305}. CC -!- INTERACTION: CC Q05513; Q15109: AGER; NbExp=6; IntAct=EBI-295351, EBI-1646426; CC Q05513; P31749: AKT1; NbExp=2; IntAct=EBI-295351, EBI-296087; CC Q05513; O95999: BCL10; NbExp=3; IntAct=EBI-295351, EBI-958922; CC Q05513; Q07021: C1QBP; NbExp=4; IntAct=EBI-295351, EBI-347528; CC Q05513; P08238: HSP90AB1; NbExp=2; IntAct=EBI-295351, EBI-352572; CC Q05513; P14598: NCF1; NbExp=3; IntAct=EBI-295351, EBI-395044; CC Q05513; P49757-1: NUMB; NbExp=4; IntAct=EBI-295351, EBI-7199607; CC Q05513; Q9NPB6: PARD6A; NbExp=10; IntAct=EBI-295351, EBI-81876; CC Q05513; Q9BYG5: PARD6B; NbExp=18; IntAct=EBI-295351, EBI-295391; CC Q05513; Q9BYG4: PARD6G; NbExp=9; IntAct=EBI-295351, EBI-295417; CC Q05513; P41743: PRKCI; NbExp=10; IntAct=EBI-295351, EBI-286199; CC Q05513; Q04759: PRKCQ; NbExp=3; IntAct=EBI-295351, EBI-374762; CC Q05513; P40337: VHL; NbExp=3; IntAct=EBI-295351, EBI-301246; CC Q05513; P16554: numb; Xeno; NbExp=2; IntAct=EBI-295351, EBI-429581; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:9566925}. Endosome {ECO:0000269|PubMed:9566925}. CC Cell junction {ECO:0000269|PubMed:7597083}. Membrane CC {ECO:0000250|UniProtKB:P09217}; Peripheral membrane protein CC {ECO:0000305}. Note=In the retina, localizes in the terminals of the CC rod bipolar cells (By similarity). Associates with endosomes CC (PubMed:9566925). Presence of KRIT1, CDH5 and RAP1B is required for its CC localization to the cell junction (PubMed:7597083). Colocalizes with CC VAMP2 and WDFY2 in intracellular vesicles (PubMed:17313651). CC Transiently translocates to the membrane of CA1 hippocampal cells in CC response to the induction of long term potentiation (By similarity). CC {ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:7597083, ECO:0000269|PubMed:9566925}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000250|UniProtKB:P09217}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q05513-1; Sequence=Displayed; CC Name=2; Synonyms=PKMzeta {ECO:0000250|UniProtKB:P09217}; CC IsoId=Q05513-2; Sequence=VSP_041904; CC Name=3; CC IsoId=Q05513-3; Sequence=VSP_046347; CC -!- TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent in lung, CC kidney and testis. CC -!- DOMAIN: The PB1 domain mediate mutually exclusive interactions with CC SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC {ECO:0000269|PubMed:12887891}. CC -!- PTM: CDH5 is required for its phosphorylation at Thr-410. CC Phosphorylated by protein kinase PDPK1; phosphorylation is inhibited by CC the apoptotic C-terminal cleavage product of PKN2. Phosphorylation at CC Thr-410 by PI3K activates the kinase. {ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:15314172, ECO:0000269|PubMed:20332120, CC ECO:0000269|PubMed:9768361}. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage. CC {ECO:0000250|UniProtKB:P09217}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC -!- CAUTION: Reported to phosphorylate STK11 leading to nuclear export of CC STK11, subsequent inhibition of PI3K/Akt signaling, and increased CC apoptosis in vein endothelial cells treated with the oxidant CC peroxynitrite (PubMed:18321849). However this paper was withdrawn by CC the authors due to concerns of image duplication in the figures. Its CC role in protein phosphorylation has been confirmed in other studies CC (PubMed:15084291, PubMed:15324659). {ECO:0000269|PubMed:15084291, CC ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:18321849, CC ECO:0000305|PubMed:31519760}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA78813.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L14283; AAA36488.1; -; mRNA. DR EMBL; BT007082; AAP35745.1; -; mRNA. DR EMBL; AK290995; BAF83684.1; -; mRNA. DR EMBL; AK294649; BAH11833.1; -; mRNA. DR EMBL; AK294782; BAH11883.1; -; mRNA. DR EMBL; AL162271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590822; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL645703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008058; AAH08058.1; -; mRNA. DR EMBL; BC014270; AAH14270.1; -; mRNA. DR EMBL; Z15108; CAA78813.1; ALT_INIT; mRNA. DR CCDS; CCDS37.1; -. [Q05513-1] DR CCDS; CCDS41229.1; -. [Q05513-2] DR CCDS; CCDS55563.1; -. [Q05513-3] DR PIR; JN0877; JN0877. DR RefSeq; NP_001028753.1; NM_001033581.3. [Q05513-2] DR RefSeq; NP_001028754.1; NM_001033582.3. [Q05513-2] DR RefSeq; NP_001229803.1; NM_001242874.3. [Q05513-3] DR RefSeq; NP_002735.3; NM_002744.4. [Q05513-1] DR RefSeq; XP_047281304.1; XM_047425348.1. [Q05513-2] DR RefSeq; XP_054193674.1; XM_054337699.1. [Q05513-2] DR AlphaFoldDB; Q05513; -. DR SMR; Q05513; -. DR BioGRID; 111576; 381. DR ComplexPortal; CPX-6195; PAR cell polarity complex, PARD6G-PRKCZ variant. DR ComplexPortal; CPX-6196; PAR cell polarity complex, PARD6B-PRKCZ variant. DR ComplexPortal; CPX-6197; PAR cell polarity complex, PARD6A-PRKCZ variant. DR CORUM; Q05513; -. DR ELM; Q05513; -. DR FunCoup; Q05513; 1725. DR IntAct; Q05513; 231. DR MINT; Q05513; -. DR STRING; 9606.ENSP00000367830; -. DR BindingDB; Q05513; -. DR ChEMBL; CHEMBL3438; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q05513; -. DR GuidetoPHARMACOLOGY; 1491; -. DR MoonDB; Q05513; Predicted. DR GlyGen; Q05513; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q05513; -. DR PhosphoSitePlus; Q05513; -. DR BioMuta; PRKCZ; -. DR DMDM; 68067736; -. DR jPOST; Q05513; -. DR MassIVE; Q05513; -. DR PaxDb; 9606-ENSP00000367830; -. DR PeptideAtlas; Q05513; -. DR ProteomicsDB; 19529; -. DR ProteomicsDB; 58330; -. [Q05513-1] DR ProteomicsDB; 58331; -. [Q05513-2] DR Pumba; Q05513; -. DR Antibodypedia; 3869; 858 antibodies from 46 providers. DR DNASU; 5590; -. DR Ensembl; ENST00000378567.8; ENSP00000367830.3; ENSG00000067606.18. [Q05513-1] DR Ensembl; ENST00000400921.6; ENSP00000383712.2; ENSG00000067606.18. [Q05513-2] DR Ensembl; ENST00000461106.6; ENSP00000426412.1; ENSG00000067606.18. [Q05513-3] DR GeneID; 5590; -. DR KEGG; hsa:5590; -. DR MANE-Select; ENST00000378567.8; ENSP00000367830.3; NM_002744.6; NP_002735.3. DR UCSC; uc001aiq.3; human. [Q05513-1] DR AGR; HGNC:9412; -. DR ClinPGx; PA33775; -. DR CTD; 5590; -. DR DisGeNET; 5590; -. DR GeneCards; PRKCZ; -. DR HGNC; HGNC:9412; PRKCZ. DR HPA; ENSG00000067606; Tissue enhanced (brain). DR MalaCards; PRKCZ; -. DR MIM; 176982; gene. DR OpenTargets; ENSG00000067606; -. DR Orphanet; 1606; 1p36 deletion syndrome. DR VEuPathDB; HostDB:ENSG00000067606; -. DR eggNOG; KOG0695; Eukaryota. DR GeneTree; ENSGT00940000153497; -. DR HOGENOM; CLU_000288_63_5_1; -. DR InParanoid; Q05513; -. DR OMA; DKMAGLC; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q05513; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q05513; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q05513; -. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR SignaLink; Q05513; -. DR SIGNOR; Q05513; -. DR Agora; ENSG00000067606; -. DR BioGRID-ORCS; 5590; 23 hits in 1195 CRISPR screens. DR ChiTaRS; PRKCZ; human. DR GeneWiki; Protein_kinase_M_zeta/Protein_kinase_C_zeta; -. DR GenomeRNAi; 5590; -. DR Pharos; Q05513; Tchem. DR PRO; PR:Q05513; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05513; protein. DR Bgee; ENSG00000067606; Expressed in right hemisphere of cerebellum and 168 other cell types or tissues. DR ExpressionAtlas; Q05513; baseline and differential. DR GO; GO:0045179; C:apical cortex; IEA:Ensembl. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0030054; C:cell junction; TAS:Reactome. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005814; C:centriole; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl. DR GO; GO:0005635; C:nuclear envelope; IEA:Ensembl. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0120157; C:PAR polarity complex; ISS:ComplexPortal. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0070160; C:tight junction; NAS:ComplexPortal. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0043560; F:insulin receptor substrate binding; IDA:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; ISS:ComplexPortal. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:UniProtKB. DR GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:UniProtKB. DR GO; GO:0032736; P:positive regulation of interleukin-13 production; ISS:UniProtKB. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0032754; P:positive regulation of interleukin-5 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB. DR GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB. DR GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd21095; C1_aPKC_zeta; 1. DR CDD; cd06404; PB1_aPKC; 1. DR CDD; cd05617; STKc_aPKC_zeta; 1. DR FunFam; 1.10.510.10:FF:000048; Protein kinase C; 1. DR FunFam; 3.10.20.90:FF:000071; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000070; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000012; Protein kinase C; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034662; aPKC_zeta. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR047314; C1_aPKC_zeta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR053793; PB1-like. DR InterPro; IPR034877; PB1_aPKC. DR InterPro; IPR000270; PB1_dom. DR InterPro; IPR012233; PKC. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00564; PB1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000554; PKC_zeta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00666; PB1; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54277; CAD & PB1 domains; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS51745; PB1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW Alternative promoter usage; Alternative splicing; ATP-binding; KW Cell junction; Cytoplasm; Endosome; Inflammatory response; Kinase; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..592 FT /note="Protein kinase C zeta type" FT /id="PRO_0000055701" FT DOMAIN 15..98 FT /note="PB1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01081" FT DOMAIN 252..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 519..590 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 130..180 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 79..145 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000250" FT ACT_SITE 376 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 258..266 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 410 FT /note="Phosphothreonine; by PDPK1 and PI3K" FT /evidence="ECO:0000269|PubMed:15314172, FT ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361" FT MOD_RES 560 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 591 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09217" FT VAR_SEQ 1..183 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041904" FT VAR_SEQ 1..112 FT /note="MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQ FT QHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGED FT K -> MLTPRTDE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046347" FT VARIANT 49 FT /note="R -> H (in dbSNP:rs35271800)" FT /id="VAR_050560" FT VARIANT 84 FT /note="R -> H (in dbSNP:rs56017162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042310" FT VARIANT 514 FT /note="S -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035467" FT VARIANT 519 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376894109)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042311" FT MUTAGEN 19 FT /note="K->A: No effect on interaction with SQSTM1 and FT PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 62 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 66 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT CONFLICT 6 FT /note="G -> D (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 198 FT /note="K -> R (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 262 FT /note="S -> T (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 281 FT /note="K -> R (in Ref. 3; BAH11883)" FT /evidence="ECO:0000305" FT CONFLICT 366 FT /note="F -> L (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 500 FT /note="R -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" SQ SEQUENCE 592 AA; 67660 MW; 88CCD0577E6A596C CRC64; MPSRTGPKME GSGGRVRLKA HYGGDIFITS VDAATTFEEL CEEVRDMCRL HQQHPLTLKW VDSEGDPCTV SSQMELEEAF RLARQCRDEG LIIHVFPSTP EQPGLPCPGE DKSIYRRGAR RWRKLYRANG HLFQAKRFNR RAYCGQCSER IWGLARQGYR CINCKLLVHK RCHGLVPLTC RKHMDSVMPS QEPPVDDKNE DADLPSEETD GIAYISSSRK HDSIKDDSED LKPVIDGMDG IKISQGLGLQ DFDLIRVIGR GSYAKVLLVR LKKNDQIYAM KVVKKELVHD DEDIDWVQTE KHVFEQASSN PFLVGLHSCF QTTSRLFLVI EYVNGGDLMF HMQRQRKLPE EHARFYAAEI CIALNFLHER GIIYRDLKLD NVLLDADGHI KLTDYGMCKE GLGPGDTTST FCGTPNYIAP EILRGEEYGF SVDWWALGVL MFEMMAGRSP FDIITDNPDM NTEDYLFQVI LEKPIRIPRF LSVKASHVLK GFLNKDPKER LGCRPQTGFS DIKSHAFFRS IDWDLLEKKQ ALPPFQPQIT DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE SV // ID LATS1_HUMAN Reviewed; 1130 AA. AC O95835; Q6PKD0; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase LATS1; DE EC=2.7.11.1 {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:39173637}; DE AltName: Full=Large tumor suppressor homolog 1; DE AltName: Full=WARTS protein kinase; DE Short=h-warts; GN Name=LATS1 {ECO:0000312|EMBL:AAD16882.1}; GN Synonyms=WARTS {ECO:0000312|EMBL:AAD50272.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD16882.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION, AND RP INTERACTION WITH CDK1. RC TISSUE=Fetal brain {ECO:0000312|EMBL:AAD16882.1}; RX PubMed=9988268; DOI=10.1038/5960; RA Tao W., Zhang S., Turenchalk G.S., Stewart R.A., St John M.A., Chen W., RA Xu T.; RT "Human homologue of the Drosophila melanogaster lats tumour suppressor RT modulates CDC2 activity."; RL Nat. Genet. 21:177-181(1999). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAD50272.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=10518011; DOI=10.1016/s0014-5793(99)01224-7; RA Nishiyama Y., Hirota T., Morisaki T., Hara T., Marumoto T., Iida S., RA Makino K., Yamamoto H., Hiraoka T., Kitamura N., Saya H.; RT "A human homolog of Drosophila warts tumor suppressor, h-warts, localized RT to mitotic apparatus and specifically phosphorylated during mitosis."; RL FEBS Lett. 459:159-165(1999). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAH02767.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Endometrium {ECO:0000312|EMBL:AAH02767.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH ZYX. RX PubMed=10831611; DOI=10.1083/jcb.149.5.1073; RA Hirota T., Morisaki T., Nishiyama Y., Marumoto T., Tada K., Hara T., RA Masuko N., Inagaki M., Hatakeyama K., Saya H.; RT "Zyxin, a regulator of actin filament assembly, targets the mitotic RT apparatus by interacting with h-warts/LATS1 tumor suppressor."; RL J. Cell Biol. 149:1073-1086(2000). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [6] {ECO:0000305} RP FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF RP LYS-734. RX PubMed=15122335; DOI=10.1038/sj.onc.1207623; RA Iida S., Hirota T., Morisaki T., Marumoto T., Hara T., Kuninaka S., RA Honda S., Kosai K., Kawasuji M., Pallas D.C., Saya H.; RT "Tumor suppressor WARTS ensures genomic integrity by regulating both RT mitotic progression and G1 tetraploidy checkpoint function."; RL Oncogene 23:5266-5274(2004). RN [7] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH LIMK1. RX PubMed=15220930; DOI=10.1038/ncb1140; RA Yang X., Yu K., Hao Y., Li D.-M., Stewart R.A., Insogna K.L., Xu T.; RT "LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1."; RL Nat. Cell Biol. 6:609-617(2004). RN [8] RP PHOSPHORYLATION AT SER-909 AND THR-1079. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-674, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [10] RP FUNCTION, INTERACTION WITH YAP1, AND MUTAGENESIS OF TYR-559. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-278 AND SER-464, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [17] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [18] RP FUNCTION, PHOSPHORYLATION AT SER-464, AND MUTAGENESIS OF SER-464. RX PubMed=19927127; DOI=10.1038/emboj.2009.342; RA Humbert N., Navaratnam N., Augert A., Da Costa M., Martien S., Wang J., RA Martinez D., Abbadie C., Carling D., de Launoit Y., Gil J., Bernard D.; RT "Regulation of ploidy and senescence by the AMPK-related kinase NUAK1."; RL EMBO J. 29:376-386(2010). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-464 AND SER-613, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [21] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [22] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [23] RP INTERACTION WITH STK3, AND PHOSPHORYLATION AT THR-1079. RX PubMed=28087714; DOI=10.1101/gad.284539.116; RA Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S., RA Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.; RT "DLG5 connects cell polarity and Hippo signaling protein networks by RT linking PAR-1 with MST1/2."; RL Genes Dev. 30:2696-2709(2016). RN [24] RP FUNCTION, AND INTERACTION WITH DCAF13; ESR1 AND DCAF1. RX PubMed=28068668; DOI=10.1038/nature20829; RA Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S., RA De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A., RA Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P., RA Bonamy G.M., Reddy V.A., Bentires-Alj M.; RT "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk RT with ERalpha."; RL Nature 541:541-545(2017). RN [25] RP INTERACTION WITH SCRIB. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-96; GLY-204; GLN-237; TRP-370; SER-531; RP LEU-641; ILE-669; PRO-806 AND SER-1000. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:10518011, CC PubMed:10831611, PubMed:18158288, PubMed:26437443, PubMed:28068668). CC The core of this pathway is composed of a kinase cascade wherein CC STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, CC phosphorylates and activates LATS1/2 in complex with its regulatory CC protein MOB1, which in turn phosphorylates and inactivates YAP1 CC oncoprotein and WWTR1/TAZ (PubMed:18158288, PubMed:26437443, CC PubMed:28068668). Phosphorylation of YAP1 by LATS1 inhibits its CC translocation into the nucleus to regulate cellular genes important for CC cell proliferation, cell death, and cell migration (PubMed:18158288, CC PubMed:26437443, PubMed:28068668). Acts as a tumor suppressor which CC plays a critical role in maintenance of ploidy through its actions in CC both mitotic progression and the G1 tetraploidy checkpoint CC (PubMed:15122335, PubMed:19927127). Negatively regulates G2/M CC transition by down-regulating CDK1 kinase activity (PubMed:9988268). CC Involved in the control of p53 expression (PubMed:15122335). Affects CC cytokinesis by regulating actin polymerization through negative CC modulation of LIMK1 (PubMed:15220930). May also play a role in CC endocrine function. Plays a role in mammary gland epithelial cell CC differentiation, both through the Hippo signaling pathway and the CC intracellular estrogen receptor signaling pathway by promoting the CC degradation of ESR1 (PubMed:28068668). Acts as an activator of the CC NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of NLRP3 CC following NLRP3 palmitoylation, promoting NLRP3 activation by NEK7 CC (PubMed:39173637). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:10831611, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:28068668, ECO:0000269|PubMed:39173637, CC ECO:0000269|PubMed:9988268}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Complexes with CDK1 in early mitosis (PubMed:9988268). LATS1- CC associated CDK1 has no mitotic cyclin partner and no apparent kinase CC activity (PubMed:9988268). Binds phosphorylated ZYX, locating this CC protein to the mitotic spindle and suggesting a role for actin CC regulatory proteins during mitosis (PubMed:10831611). Binds to and CC colocalizes with LIMK1 at the actomyosin contractile ring during CC cytokinesis (PubMed:15220930). Interacts (via PPxY motif 2) with YAP1 CC (via WW domains) (PubMed:18158288). Interacts with MOB1A and MOB1B CC (PubMed:19739119). Interacts with LIMD1, WTIP and AJUBA CC (PubMed:20303269). Interacts with ESR1, DCAF1 and DCAF13; probably CC recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and CC ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts CC with STK3/MST2; this interaction is inhibited in the presence of DLG5 CC (PubMed:28087714). Interacts with SCRIB in the presence of DLG5 CC (PubMed:28169360). Interacts with WWTR1/TAZ (By similarity). Interacts CC with WWC1, WWC2 and WWC3 (via their WW domains) (PubMed:24682284). CC {ECO:0000250|UniProtKB:Q8BYR2, ECO:0000269|PubMed:10831611, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:24682284, ECO:0000269|PubMed:28068668, CC ECO:0000269|PubMed:28087714, ECO:0000269|PubMed:28169360, CC ECO:0000269|PubMed:9988268}. CC -!- INTERACTION: CC O95835; P06493: CDK1; NbExp=3; IntAct=EBI-444209, EBI-444308; CC O95835; P24941: CDK2; NbExp=4; IntAct=EBI-444209, EBI-375096; CC O95835; Q9Y4B6: DCAF1; NbExp=4; IntAct=EBI-444209, EBI-1996353; CC O95835; P03372: ESR1; NbExp=2; IntAct=EBI-444209, EBI-78473; CC O95835; P53667: LIMK1; NbExp=5; IntAct=EBI-444209, EBI-444403; CC O95835; Q9H8S9: MOB1A; NbExp=9; IntAct=EBI-444209, EBI-748229; CC O95835; Q7L9L4: MOB1B; NbExp=9; IntAct=EBI-444209, EBI-2558745; CC O95835; P35240: NF2; NbExp=4; IntAct=EBI-444209, EBI-1014472; CC O95835; O60285: NUAK1; NbExp=2; IntAct=EBI-444209, EBI-1046789; CC O95835; O43255: SIAH2; NbExp=2; IntAct=EBI-444209, EBI-948141; CC O95835; Q13485: SMAD4; NbExp=7; IntAct=EBI-444209, EBI-347263; CC O95835; Q15831: STK11; NbExp=2; IntAct=EBI-444209, EBI-306838; CC O95835; Q9GZV5: WWTR1; NbExp=5; IntAct=EBI-444209, EBI-747743; CC O95835; P46937: YAP1; NbExp=10; IntAct=EBI-444209, EBI-1044059; CC O95835; Q15942: ZYX; NbExp=10; IntAct=EBI-444209, EBI-444225; CC O95835; P46662: Nf2; Xeno; NbExp=5; IntAct=EBI-444209, EBI-644586; CC O95835-2; O15145: ARPC3; NbExp=3; IntAct=EBI-17978514, EBI-351829; CC O95835-2; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-17978514, EBI-947187; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:10518011}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10518011}. Midbody CC {ECO:0000269|PubMed:10518011}. Cytoplasm, cytoskeleton, microtubule CC organizing center, spindle pole body {ECO:0000269|PubMed:10518011}. CC Note=Localizes to the centrosomes throughout interphase but migrates to CC the mitotic apparatus, including spindle pole bodies, mitotic spindle, CC and midbody, during mitosis. {ECO:0000269|PubMed:10518011}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:9988268}; CC IsoId=O95835-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=O95835-2; Sequence=VSP_051604, VSP_051605; CC -!- TISSUE SPECIFICITY: Expressed in all adult tissues examined except for CC lung and kidney. {ECO:0000269|PubMed:10518011}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase of the cell CC cycle (PubMed:10518011, PubMed:15122335, PubMed:9988268). CC Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in CC its activation (PubMed:15688006). Phosphorylated by MAP4Ks; in parallel CC to STK3/MST2 and resulting to its activation (PubMed:26437443). CC Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased CC protein level and is required to regulate cellular senescence and CC cellular ploidy (PubMed:19927127). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:9988268}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41127/LATS1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF104413; AAD16882.1; -; mRNA. DR EMBL; AF164041; AAD50272.1; -; mRNA. DR EMBL; BC002767; AAH02767.1; -; mRNA. DR CCDS; CCDS34551.1; -. [O95835-1] DR CCDS; CCDS59040.1; -. [O95835-2] DR RefSeq; NP_001257448.1; NM_001270519.2. [O95835-2] DR RefSeq; NP_004681.1; NM_004690.4. [O95835-1] DR RefSeq; XP_047275474.1; XM_047419518.1. [O95835-1] DR RefSeq; XP_054212722.1; XM_054356747.1. [O95835-1] DR PDB; 4ZRK; X-ray; 2.32 A; E/F/G/H=69-100. DR PDB; 5B5W; X-ray; 2.96 A; U=622-704. DR PDB; 5BRK; X-ray; 2.30 A; B=602-704. DR PDB; 7LWH; X-ray; 1.61 A; B=69-91. DR PDBsum; 4ZRK; -. DR PDBsum; 5B5W; -. DR PDBsum; 5BRK; -. DR PDBsum; 7LWH; -. DR AlphaFoldDB; O95835; -. DR SMR; O95835; -. DR BioGRID; 114563; 460. DR CORUM; O95835; -. DR DIP; DIP-31516N; -. DR FunCoup; O95835; 4799. DR IntAct; O95835; 114. DR MINT; O95835; -. DR STRING; 9606.ENSP00000437550; -. DR BindingDB; O95835; -. DR ChEMBL; CHEMBL6167; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O95835; -. DR GuidetoPHARMACOLOGY; 1515; -. DR MoonProt; O95835; -. DR GlyGen; O95835; 7 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; O95835; -. DR PhosphoSitePlus; O95835; -. DR BioMuta; LATS1; -. DR CPTAC; CPTAC-3110; -. DR CPTAC; CPTAC-3111; -. DR jPOST; O95835; -. DR MassIVE; O95835; -. DR PaxDb; 9606-ENSP00000437550; -. DR PeptideAtlas; O95835; -. DR ProteomicsDB; 51081; -. [O95835-1] DR ProteomicsDB; 51082; -. [O95835-2] DR Pumba; O95835; -. DR Antibodypedia; 33280; 394 antibodies from 32 providers. DR DNASU; 9113; -. DR Ensembl; ENST00000253339.9; ENSP00000253339.5; ENSG00000131023.14. [O95835-1] DR Ensembl; ENST00000392273.7; ENSP00000444678.1; ENSG00000131023.14. [O95835-2] DR Ensembl; ENST00000543571.6; ENSP00000437550.1; ENSG00000131023.14. [O95835-1] DR GeneID; 9113; -. DR KEGG; hsa:9113; -. DR MANE-Select; ENST00000543571.6; ENSP00000437550.1; NM_004690.4; NP_004681.1. DR UCSC; uc003qmu.2; human. [O95835-1] DR AGR; HGNC:6514; -. DR ClinPGx; PA30301; -. DR CTD; 9113; -. DR DisGeNET; 9113; -. DR GeneCards; LATS1; -. DR HGNC; HGNC:6514; LATS1. DR HPA; ENSG00000131023; Low tissue specificity. DR MalaCards; LATS1; -. DR MIM; 603473; gene. DR OpenTargets; ENSG00000131023; -. DR VEuPathDB; HostDB:ENSG00000131023; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000157684; -. DR HOGENOM; CLU_004885_0_0_1; -. DR InParanoid; O95835; -. DR OMA; NHHGSRQ; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; O95835; 7 GO annotations based on evolutionary models. DR PhylomeDB; O95835; -. DR PathwayCommons; O95835; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; O95835; -. DR SIGNOR; O95835; -. DR Agora; ENSG00000131023; -. DR BioGRID-ORCS; 9113; 25 hits in 1204 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS1; human. DR EvolutionaryTrace; O95835; -. DR GeneWiki; LATS1; -. DR GenomeRNAi; 9113; -. DR Pharos; O95835; Tchem. DR PRO; PR:O95835; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; O95835; protein. DR Bgee; ENSG00000131023; Expressed in germinal epithelium of ovary and 183 other cell types or tissues. DR ExpressionAtlas; O95835; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProt. DR GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; ISS:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; IMP:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IMP:ARUK-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB. DR GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0099151; P:regulation of postsynaptic density assembly; IEA:Ensembl. DR GO; GO:0043254; P:regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR GO; GO:2000058; P:regulation of ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0000819; P:sister chromatid segregation; IDA:UniProtKB. DR CDD; cd21778; MobB_LATS1; 1. DR CDD; cd05625; STKc_LATS1; 1. DR CDD; cd14397; UBA_LATS1; 1. DR DisProt; DP03124; -. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049761; LATS1-like_MobB. DR InterPro; IPR042706; LATS1_STKc. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF138; SERINE_THREONINE-PROTEIN KINASE LATS1; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cytoplasm; Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1130 FT /note="Serine/threonine-protein kinase LATS1" FT /id="PRO_0000086232" FT DOMAIN 100..141 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 705..1010 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1011..1090 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..71 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 149..276 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 294..321 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..405 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 432..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 515..631 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 526..655 FT /note="Interaction with YAP1" FT /evidence="ECO:0000269|PubMed:18158288" FT REGION 1104..1130 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 373..376 FT /note="PPxY motif 1" FT MOTIF 556..559 FT /note="PPxY motif 2" FT COMPBIAS 1..11 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19..30 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 46..64 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 235..268 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 300..312 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 381..405 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..447 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 454..482 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..609 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 621..630 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 828 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 711..719 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:15122335" FT MOD_RES 246 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 278 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 464 FT /note="Phosphoserine; by NUAK1 and NUAK2" FT /evidence="ECO:0000269|PubMed:19927127, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 613 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 909 FT /note="Phosphoserine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006" FT MOD_RES 1079 FT /note="Phosphothreonine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006, FT ECO:0000269|PubMed:28087714" FT VAR_SEQ 672..690 FT /note="GLSQDAQDQMRKMLCQKES -> KPFKMSIFILNHLFAWCLF (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051604" FT VAR_SEQ 691..1130 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051605" FT VARIANT 96 FT /note="R -> W (in dbSNP:rs55945045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040660" FT VARIANT 204 FT /note="S -> G (in dbSNP:rs34793526)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040661" FT VARIANT 237 FT /note="P -> Q (in dbSNP:rs56149740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040662" FT VARIANT 370 FT /note="R -> W (in dbSNP:rs56348064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040663" FT VARIANT 531 FT /note="P -> S (in dbSNP:rs55874734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040664" FT VARIANT 641 FT /note="F -> L (in dbSNP:rs35163691)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040665" FT VARIANT 669 FT /note="M -> I (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1390558952)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040666" FT VARIANT 806 FT /note="R -> P (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040667" FT VARIANT 1000 FT /note="G -> S (in dbSNP:rs56412005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040668" FT MUTAGEN 464 FT /note="S->A: Abolishes phosphorylation by NUAK1 and NUAK2." FT /evidence="ECO:0000269|PubMed:19927127" FT MUTAGEN 559 FT /note="Y->F: Loss of interaction with YAP1." FT /evidence="ECO:0000269|PubMed:18158288" FT MUTAGEN 734 FT /note="K->A: Loss of kinase activity, autophosphorylation, FT increased ploidy, prolonged duration of mitosis and lack of FT p53 expression." FT /evidence="ECO:0000269|PubMed:15122335" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 86..88 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 637..671 FT /evidence="ECO:0007829|PDB:5BRK" FT HELIX 675..697 FT /evidence="ECO:0007829|PDB:5BRK" SQ SEQUENCE 1130 AA; 126870 MW; 11CFBCD8FD87DCD8 CRC64; MKRSEKPEGY RQMRPKTFPA SNYTVSSRQM LQEIRESLRN LSKPSDAAKA EHNMSKMSTE DPRQVRNPPK FGTHHKALQE IRNSLLPFAN ETNSSRSTSE VNPQMLQDLQ AAGFDEDMVI QALQKTNNRS IEAAIEFISK MSYQDPRREQ MAAAAARPIN ASMKPGNVQQ SVNRKQSWKG SKESLVPQRH GPPLGESVAY HSESPNSQTD VGRPLSGSGI SAFVQAHPSN GQRVNPPPPP QVRSVTPPPP PRGQTPPPRG TTPPPPSWEP NSQTKRYSGN MEYVISRISP VPPGAWQEGY PPPPLNTSPM NPPNQGQRGI SSVPVGRQPI IMQSSSKFNF PSGRPGMQNG TGQTDFMIHQ NVVPAGTVNR QPPPPYPLTA ANGQSPSALQ TGGSAAPSSY TNGSIPQSMM VPNRNSHNME LYNISVPGLQ TNWPQSSSAP AQSSPSSGHE IPTWQPNIPV RSNSFNNPLG NRASHSANSQ PSATTVTAIT PAPIQQPVKS MRVLKPELQT ALAPTHPSWI PQPIQTVQPS PFPEGTASNV TVMPPVAEAP NYQGPPPPYP KHLLHQNPSV PPYESISKPS KEDQPSLPKE DESEKSYENV DSGDKEKKQI TTSPITVRKN KKDEERRESR IQSYSPQAFK FFMEQHVENV LKSHQQRLHR KKQLENEMMR VGLSQDAQDQ MRKMLCQKES NYIRLKRAKM DKSMFVKIKT LGIGAFGEVC LARKVDTKAL YATKTLRKKD VLLRNQVAHV KAERDILAEA DNEWVVRLYY SFQDKDNLYF VMDYIPGGDM MSLLIRMGIF PESLARFYIA ELTCAVESVH KMGFIHRDIK PDNILIDRDG HIKLTDFGLC TGFRWTHDSK YYQSGDHPRQ DSMDFSNEWG DPSSCRCGDR LKPLERRAAR QHQRCLAHSL VGTPNYIAPE VLLRTGYTQL CDWWSVGVIL FEMLVGQPPF LAQTPLETQM KVINWQTSLH IPPQAKLSPE ASDLIIKLCR GPEDRLGKNG ADEIKAHPFF KTIDFSSDLR QQSASYIPKI THPTDTSNFD PVDPDKLWSD DNEEENVNDT LNGWYKNGKH PEHAFYEFTF RRFFDDNGYP YNYPKPIEYE YINSQGSEQQ SDEDDQNTGS EIKNRDLVYV // ID LATS2_HUMAN Reviewed; 1088 AA. AC Q9NRM7; B1AM47; Q9P2X1; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 04-NOV-2008, sequence version 2. DT 28-JAN-2026, entry version 211. DE RecName: Full=Serine/threonine-protein kinase LATS2; DE EC=2.7.11.1 {ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; DE AltName: Full=Kinase phosphorylated during mitosis protein; DE AltName: Full=Large tumor suppressor homolog 2; DE AltName: Full=Serine/threonine-protein kinase kpm; DE AltName: Full=Warts-like kinase; GN Name=LATS2 {ECO:0000312|EMBL:BAA92381.1}; Synonyms=KPM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF80561.1} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-697. RC TISSUE=Myeloid {ECO:0000312|EMBL:AAF80561.1}; RX PubMed=10871863; DOI=10.1038/sj.onc.1203659; RA Hori T., Takaori-Kondo A., Kamikubo Y., Uchiyama T.; RT "Molecular cloning of a novel human protein kinase, kpm, that is homologous RT to warts/lats, a Drosophila tumor suppressor."; RL Oncogene 19:3101-3109(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:BAA92381.1} RP NUCLEOTIDE SEQUENCE [MRNA] OF 42-1088, TISSUE SPECIFICITY, AND VARIANT RP VAL-324. RC TISSUE=Testis {ECO:0000269|PubMed:10673337}; RX PubMed=10673337; DOI=10.1006/geno.1999.6065; RA Yabuta N., Fujii T., Copeland N.G., Gilbert D.J., Jenkins N.A., RA Nishiguchi H., Endo Y., Toji S., Tanaka H., Nishimune Y., Nojima H.; RT "Structure, expression, and chromosome mapping of LATS2, a mammalian RT homologue of the Drosophila tumor suppressor gene lats/warts."; RL Genomics 63:263-270(2000). RN [6] {ECO:0000305} RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-697 AND SER-872. RX PubMed=12853976; DOI=10.1038/sj.onc.1206603; RA Li Y., Pei J., Xia H., Ke H., Wang H., Tao W.; RT "Lats2, a putative tumor suppressor, inhibits G1/S transition."; RL Oncogene 22:4398-4405(2003). RN [7] {ECO:0000305} RP SUBCELLULAR LOCATION, INTERACTION WITH AURKA, MUTAGENESIS OF SER-83, AND RP PHOSPHORYLATION AT SER-83. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [8] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH AR. RX PubMed=15131260; DOI=10.1210/me.2004-0065; RA Powzaniuk M., McElwee-Witmer S., Vogel R.L., Hayami T., Rutledge S.J., RA Chen F., Harada S., Schmidt A., Rodan G.A., Freedman L.P., Bai C.; RT "The LATS2/KPM tumor suppressor is a negative regulator of the androgen RT receptor."; RL Mol. Endocrinol. 18:2011-2023(2004). RN [9] RP PHOSPHORYLATION. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [10] RP INTERACTION WITH AJUBA. RX PubMed=16413547; DOI=10.1016/j.febslet.2005.12.096; RA Abe Y., Ohsugi M., Haraguchi K., Fujimoto J., Yamamoto T.; RT "LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and RT spindle organization during mitosis."; RL FEBS Lett. 580:782-788(2006). RN [11] RP FUNCTION, AND INTERACTION WITH YAP1. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [14] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SNAI1, AND PHOSPHORYLATION RP AT THR-1041. RX PubMed=21952048; DOI=10.1038/emboj.2011.357; RA Zhang K., Rodriguez-Aznar E., Yabuta N., Owen R.J., Mingot J.M., Nojima H., RA Nieto M.A., Longmore G.D.; RT "Lats2 kinase potentiates Snail1 activity by promoting nuclear retention RT upon phosphorylation."; RL EMBO J. 31:29-43(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380 AND SER-576, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [19] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [20] RP FUNCTION, AND INTERACTION WITH AMOTL2. RX PubMed=26598551; DOI=10.15252/embr.201540809; RA Kim M., Kim M., Park S.J., Lee C., Lim D.S.; RT "Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition."; RL EMBO Rep. 17:64-78(2016). RN [21] RP PHOSPHORYLATION BY NUAK2. RX PubMed=32845958; DOI=10.1084/jem.20191561; RA Bonnard C., Navaratnam N., Ghosh K., Chan P.W., Tan T.T., Pomp O., RA Ng A.Y.J., Tohari S., Changede R., Carling D., Venkatesh B., Altunoglu U., RA Kayserili H., Reversade B.; RT "A loss-of-function NUAK2 mutation in humans causes anencephaly due to RT impaired Hippo-YAP signaling."; RL J. Exp. Med. 217:0-0(2020). RN [22] RP FUNCTION. RX PubMed=34404733; DOI=10.26508/lsa.202000953; RA Hwang D., Kim M., Kim S., Kwon M.R., Kang Y.S., Kim D., Kang H.C., RA Lim D.S.; RT "AMOTL2 mono-ubiquitination by WWP1 promotes contact inhibition by RT facilitating LATS activation."; RL Life. Sci Alliance 4:0-0(2021). RN [23] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-40; LEU-91; VAL-799; GLY-1014 AND RP PRO-1025. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:18158288, CC PubMed:26437443, PubMed:26598551, PubMed:34404733). The core of this CC pathway is composed of a kinase cascade wherein STK3/MST2 and CC STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates CC and activates LATS1/2 in complex with its regulatory protein MOB1, CC which in turn phosphorylates and inactivates YAP1 oncoprotein and CC WWTR1/TAZ (PubMed:26437443, PubMed:26598551, PubMed:34404733). CC Phosphorylation of YAP1 by LATS2 inhibits its translocation into the CC nucleus to regulate cellular genes important for cell proliferation, CC cell death, and cell migration (PubMed:26598551, PubMed:34404733). Also CC phosphorylates YAP1 in response to cell contact inhibition-driven WWP1 CC ubiquitination of AMOTL2, which results in LATS2 activation CC (PubMed:34404733). Acts as a tumor suppressor which plays a critical CC role in centrosome duplication, maintenance of mitotic fidelity and CC genomic stability (PubMed:10871863). Negatively regulates G1/S CC transition by down-regulating cyclin E/CDK2 kinase activity CC (PubMed:12853976). Negative regulator of the androgen receptor CC (PubMed:15131260). Phosphorylates SNAI1 in the nucleus leading to its CC nuclear retention and stabilization, which enhances its epithelial- CC mesenchymal transition and tumor cell invasion/migration activities CC (PubMed:21952048). This tumor-promoting activity is independent of its CC effects upon YAP1 or WWTR1/TAZ (PubMed:21952048). Acts as an activator CC of the NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of CC NLRP3 following NLRP3 palmitoylation, promoting NLRP3 activation by CC NEK7 (PubMed:39173637). {ECO:0000269|PubMed:10871863, CC ECO:0000269|PubMed:12853976, ECO:0000269|PubMed:15131260, CC ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:21952048, CC ECO:0000269|PubMed:26437443, ECO:0000269|PubMed:26598551, CC ECO:0000269|PubMed:34404733, ECO:0000269|PubMed:39173637}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Interacts with and is phosphorylated by AURKA. Binds to AR. CC Interacts with AJUBA during mitosis and this complex regulates CC organization of the spindle apparatus through recruitment of gamma- CC tubulin to the centrosome. Interacts (via PPxY motif) with YAP1 (via WW CC domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP CC and AJUBA. Interacts with SNAI1. Interacts with WWC1, WWC2 and WWC3 CC (via their WW domains) (PubMed:24682284). Interacts (via UBA domain) CC with ubiquitinated AMOTL2; the interaction promotes LATS2 CC phosphorylation of YAP1 (PubMed:26598551). CC {ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:16413547, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26598551}. CC -!- INTERACTION: CC Q9NRM7; Q96IF1: AJUBA; NbExp=7; IntAct=EBI-3506895, EBI-949782; CC Q9NRM7; Q9Y4B6: DCAF1; NbExp=2; IntAct=EBI-3506895, EBI-1996353; CC Q9NRM7; Q13643: FHL3; NbExp=4; IntAct=EBI-3506895, EBI-741101; CC Q9NRM7; Q9H8S9: MOB1A; NbExp=5; IntAct=EBI-3506895, EBI-748229; CC Q9NRM7; Q7L9L4: MOB1B; NbExp=7; IntAct=EBI-3506895, EBI-2558745; CC Q9NRM7; O43255: SIAH2; NbExp=6; IntAct=EBI-3506895, EBI-948141; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. CC Nucleus. Note=Colocalizes with AURKA at the centrosomes during CC interphase, early prophase and cytokinesis. Migrates to the spindle CC poles during mitosis, and to the midbody during cytokinesis. CC Translocates to the nucleus upon mitotic stress by nocodazole CC treatment. CC -!- TISSUE SPECIFICITY: Expressed at high levels in heart and skeletal CC muscle and at lower levels in all other tissues examined. CC {ECO:0000269|PubMed:10673337, ECO:0000269|PubMed:10871863}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase and the G1/S- CC phase of the cell cycle (PubMed:15147269, PubMed:21952048). CC Phosphorylated and activated by STK3/MST2 (PubMed:15688006). CC Phosphorylated by MAP4Ks; in parallel to STK3/MST2 and resulting to its CC activation (PubMed:26437443). Phosphorylation by NUAK2 may regulate its CC activity in phosphorylation and inactivation YAP1 (PubMed:32845958). CC {ECO:0000269|PubMed:15147269, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:32845958}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92381.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41128/LATS2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF207547; AAF80561.1; -; mRNA. DR EMBL; AK314235; BAG36905.1; -; mRNA. DR EMBL; AL161613; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL356285; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08286.1; -; Genomic_DNA. DR EMBL; AB028019; BAA92381.1; ALT_FRAME; mRNA. DR CCDS; CCDS9294.1; -. DR RefSeq; NP_055387.2; NM_014572.3. DR RefSeq; XP_005266399.1; XM_005266342.1. DR RefSeq; XP_047286222.1; XM_047430266.1. DR PDB; 4ZRI; X-ray; 2.70 A; C/D=68-99. DR PDBsum; 4ZRI; -. DR AlphaFoldDB; Q9NRM7; -. DR SMR; Q9NRM7; -. DR BioGRID; 117727; 297. DR CORUM; Q9NRM7; -. DR DIP; DIP-43883N; -. DR ELM; Q9NRM7; -. DR FunCoup; Q9NRM7; 1955. DR IntAct; Q9NRM7; 94. DR MINT; Q9NRM7; -. DR STRING; 9606.ENSP00000372035; -. DR BindingDB; Q9NRM7; -. DR ChEMBL; CHEMBL5907; -. DR DrugCentral; Q9NRM7; -. DR GuidetoPHARMACOLOGY; 1516; -. DR GlyCosmos; Q9NRM7; 1 site, 1 glycan. DR GlyGen; Q9NRM7; 9 sites, 1 O-linked glycan (8 sites). DR iPTMnet; Q9NRM7; -. DR PhosphoSitePlus; Q9NRM7; -. DR BioMuta; LATS2; -. DR DMDM; 212276441; -. DR jPOST; Q9NRM7; -. DR MassIVE; Q9NRM7; -. DR PaxDb; 9606-ENSP00000372035; -. DR PeptideAtlas; Q9NRM7; -. DR ProteomicsDB; 82392; -. DR Pumba; Q9NRM7; -. DR Antibodypedia; 22361; 321 antibodies from 32 providers. DR DNASU; 26524; -. DR Ensembl; ENST00000382592.5; ENSP00000372035.4; ENSG00000150457.10. DR GeneID; 26524; -. DR KEGG; hsa:26524; -. DR MANE-Select; ENST00000382592.5; ENSP00000372035.4; NM_014572.3; NP_055387.2. DR UCSC; uc001unr.6; human. DR AGR; HGNC:6515; -. DR ClinPGx; PA30302; -. DR CTD; 26524; -. DR DisGeNET; 26524; -. DR GeneCards; LATS2; -. DR HGNC; HGNC:6515; LATS2. DR HPA; ENSG00000150457; Low tissue specificity. DR MalaCards; LATS2; -. DR MIM; 604861; gene. DR OpenTargets; ENSG00000150457; -. DR VEuPathDB; HostDB:ENSG00000150457; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000159161; -. DR HOGENOM; CLU_004885_1_0_1; -. DR InParanoid; Q9NRM7; -. DR OMA; FNNHQQP; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; Q9NRM7; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRM7; -. DR PathwayCommons; Q9NRM7; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; Q9NRM7; -. DR SIGNOR; Q9NRM7; -. DR Agora; ENSG00000150457; -. DR BioGRID-ORCS; 26524; 32 hits in 1200 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS2; human. DR GeneWiki; LATS2; -. DR GenomeRNAi; 26524; -. DR Pharos; Q9NRM7; Tchem. DR PRO; PR:Q9NRM7; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; Q9NRM7; protein. DR Bgee; ENSG00000150457; Expressed in epithelial cell of pancreas and 196 other cell types or tissues. DR ExpressionAtlas; Q9NRM7; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:FlyBase. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0060243; P:negative regulation of cell growth involved in contact inhibition; IDA:UniProt. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; ISS:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR CDD; cd21777; MobB_LATS2; 1. DR CDD; cd05626; STKc_LATS2; 1. DR CDD; cd14398; UBA_LATS2; 1. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF149; SERINE_THREONINE-PROTEIN KINASE LATS2; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cytoplasm; KW Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1088 FT /note="Serine/threonine-protein kinase LATS2" FT /id="PRO_0000086234" FT DOMAIN 98..139 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 668..973 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 974..1052 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 24..49 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 101..141 FT /note="Interaction with ubiquitinated AMOTL2" FT /evidence="ECO:0000269|PubMed:26598551" FT REGION 271..323 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 383..428 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 454..483 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 543..592 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 994..1022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1056..1088 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 515..518 FT /note="PPxY motif" FT COMPBIAS 271..280 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 404..413 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 466..478 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 553..572 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 583..592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 791 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 674..682 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 697 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:10871863" FT MOD_RES 83 FT /note="Phosphoserine; by AURKA" FT /evidence="ECO:0000269|PubMed:15147269" FT MOD_RES 279 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 380 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 576 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21952048" FT VARIANT 40 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040669" FT VARIANT 91 FT /note="S -> L (in dbSNP:rs55842804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040670" FT VARIANT 324 FT /note="A -> V (in dbSNP:rs558614)" FT /evidence="ECO:0000269|PubMed:10673337" FT /id="VAR_019789" FT VARIANT 363 FT /note="G -> S (in dbSNP:rs2770928)" FT /id="VAR_047077" FT VARIANT 799 FT /note="I -> V (in dbSNP:rs35368391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040671" FT VARIANT 1014 FT /note="A -> G (in dbSNP:rs45523141)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040672" FT VARIANT 1025 FT /note="L -> P (in dbSNP:rs56116059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040673" FT MUTAGEN 83 FT /note="S->C: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 83 FT /note="S->E: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 697 FT /note="K->A: Loss of kinase activity, autophosphorylation FT and tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:10871863, FT ECO:0000269|PubMed:12853976" FT MUTAGEN 872 FT /note="S->A: Loss of tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:12853976" FT CONFLICT 59..61 FT /note="RQQ -> SSK (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 436 FT /note="T -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 711 FT /note="A -> V (in Ref. 1; AAF80561)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="C -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT HELIX 74..84 FT /evidence="ECO:0007829|PDB:4ZRI" FT HELIX 85..87 FT /evidence="ECO:0007829|PDB:4ZRI" SQ SEQUENCE 1088 AA; 120136 MW; 2866F6B75637AD36 CRC64; MRPKTFPATT YSGNSRQRLQ EIREGLKQPS KSSVQGLPAG PNSDTSLDAK VLGSKDATRQ QQQMRATPKF GPYQKALREI RYSLLPFANE SGTSAAAEVN RQMLQELVNA GCDQEMAGRA LKQTGSRSIE AALEYISKMG YLDPRNEQIV RVIKQTSPGK GLMPTPVTRR PSFEGTGDSF ASYHQLSGTP YEGPSFGADG PTALEEMPRP YVDYLFPGVG PHGPGHQHQH PPKGYGASVE AAGAHFPLQG AHYGRPHLLV PGEPLGYGVQ RSPSFQSKTP PETGGYASLP TKGQGGPPGA GLAFPPPAAG LYVPHPHHKQ AGPAAHQLHV LGSRSQVFAS DSPPQSLLTP SRNSLNVDLY ELGSTSVQQW PAATLARRDS LQKPGLEAPP RAHVAFRPDC PVPSRTNSFN SHQPRPGPPG KAEPSLPAPN TVTAVTAAHI LHPVKSVRVL RPEPQTAVGP SHPAWVPAPA PAPAPAPAPA AEGLDAKEEH ALALGGAGAF PLDVEYGGPD RRCPPPPYPK HLLLRSKSEQ YDLDSLCAGM EQSLRAGPNE PEGGDKSRKS AKGDKGGKDK KQIQTSPVPV RKNSRDEEKR ESRIKSYSPY AFKFFMEQHV ENVIKTYQQK VNRRLQLEQE MAKAGLCEAE QEQMRKILYQ KESNYNRLKR AKMDKSMFVK IKTLGIGAFG EVCLACKVDT HALYAMKTLR KKDVLNRNQV AHVKAERDIL AEADNEWVVK LYYSFQDKDS LYFVMDYIPG GDMMSLLIRM EVFPEHLARF YIAELTLAIE SVHKMGFIHR DIKPDNILID LDGHIKLTDF GLCTGFRWTH NSKYYQKGSH VRQDSMEPSD LWDDVSNCRC GDRLKTLEQR ARKQHQRCLA HSLVGTPNYI APEVLLRKGY TQLCDWWSVG VILFEMLVGQ PPFLAPTPTE TQLKVINWEN TLHIPAQVKL SPEARDLITK LCCSADHRLG RNGADDLKAH PFFSAIDFSS DIRKQPAPYV PTISHPMDTS NFDPVDEESP WNDASEGSTK AWDTLTSPNN KHPEHAFYEF TFRRFFDDNG YPFRCPKPSG AEASQAESSD LESSDLVDQT EGCQPVYV // ID LMTK1_HUMAN Reviewed; 1374 AA. AC Q6ZMQ8; O75136; Q6ZN31; Q86X28; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 05-SEP-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Serine/threonine-protein kinase LMTK1; DE EC=2.7.11.1; DE AltName: Full=Apoptosis-associated tyrosine kinase; DE Short=AATYK; DE AltName: Full=Brain apoptosis-associated tyrosine kinase; DE AltName: Full=CDK5-binding protein; DE AltName: Full=Lemur tyrosine kinase 1; DE AltName: Full=p35-binding protein; DE Short=p35BP; GN Name=AATK; Synonyms=AATYK, KIAA0641, LMR1, LMTK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT RP CYS-703. RC TISSUE=Cerebellum, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 49-1374 (ISOFORM 1), AND VARIANT RP CYS-703. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 786-1374 (ISOFORM 1), AND VARIANT RP SER-1266. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP ALTERNATIVE SPLICING (ISOFORM 2), INTERACTION WITH CDK5, AND RP PHOSPHORYLATION. RX PubMed=14521924; DOI=10.1016/j.bbrc.2003.08.143; RA Honma N., Asada A., Takeshita S., Enomoto M., Yamakawa E., Tsutsumi K., RA Saito T., Satoh T., Itoh H., Kaziro Y., Kishimoto T., Hisanaga S.; RT "Apoptosis-associated tyrosine kinase is a Cdk5 activator p35 binding RT protein."; RL Biochem. Biophys. Res. Commun. 310:398-404(2003). RN [6] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=10837911; DOI=10.1016/s0169-328x(00)00048-6; RA Raghunath M., Patti R., Bannerman P., Lee C.M., Baker S., Sutton L.N., RA Phillips P.C., Damodar Reddy C.; RT "A novel kinase, AATYK induces and promotes neuronal differentiation in a RT human neuroblastoma (SH-SY5Y) cell line."; RL Brain Res. Mol. Brain Res. 77:151-162(2000). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495 AND SER-1262, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [8] RP VARIANTS PHE-81; VAL-97; VAL-104; CYS-703; ARG-815; LEU-923; LYS-1160; RP SER-1192; SER-1266 AND THR-1332. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in neuronal differentiation. CC {ECO:0000269|PubMed:10837911}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with CDK5. {ECO:0000269|PubMed:14521924}. CC -!- INTERACTION: CC Q6ZMQ8; P62136: PPP1CA; NbExp=3; IntAct=EBI-2008380, EBI-357253; CC Q6ZMQ8; P36873: PPP1CC; NbExp=3; IntAct=EBI-2008380, EBI-356283; CC Q6ZMQ8; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-2008380, EBI-11139477; CC Q6ZMQ8-1; Q15078: CDK5R1; NbExp=2; IntAct=EBI-2008436, EBI-746189; CC Q6ZMQ8-2; Q15078: CDK5R1; NbExp=6; IntAct=EBI-2008441, EBI-746189; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:10837911}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:10837911}. Note=Predominantly perinuclear. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZMQ8-1; Sequence=Displayed; CC Name=2; Synonyms=hAATYKs-p35BP; CC IsoId=Q6ZMQ8-2; Sequence=VSP_020225, VSP_020226, VSP_020227, CC VSP_020228; CC Name=3; CC IsoId=Q6ZMQ8-3; Sequence=VSP_020226, VSP_020227, VSP_020228; CC -!- TISSUE SPECIFICITY: Expressed in brain. {ECO:0000269|PubMed:10837911}. CC -!- INDUCTION: Up-regulated during apoptosis. CC -!- PTM: Autophosphorylated. Phosphorylated by CDK5. CC {ECO:0000269|PubMed:14521924}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131395; BAD18544.1; -; mRNA. DR EMBL; AK131529; BAD18667.1; -; mRNA. DR EMBL; AB014541; BAA31616.2; -; mRNA. DR EMBL; BC047378; AAH47378.1; -; mRNA. DR CCDS; CCDS45807.1; -. [Q6ZMQ8-1] DR RefSeq; NP_001073864.2; NM_001080395.3. [Q6ZMQ8-1] DR RefSeq; NP_004911.2; NM_004920.2. DR AlphaFoldDB; Q6ZMQ8; -. DR SMR; Q6ZMQ8; -. DR BioGRID; 114984; 194. DR FunCoup; Q6ZMQ8; 75. DR IntAct; Q6ZMQ8; 190. DR MINT; Q6ZMQ8; -. DR STRING; 9606.ENSP00000324196; -. DR TCDB; 8.A.23.1.35; the basigin (basigin) family. DR GlyGen; Q6ZMQ8; 4 sites. DR iPTMnet; Q6ZMQ8; -. DR PhosphoSitePlus; Q6ZMQ8; -. DR SwissPalm; Q6ZMQ8; -. DR BioMuta; AATK; -. DR DMDM; 114149222; -. DR jPOST; Q6ZMQ8; -. DR MassIVE; Q6ZMQ8; -. DR PaxDb; 9606-ENSP00000324196; -. DR PeptideAtlas; Q6ZMQ8; -. DR ProteomicsDB; 67901; -. [Q6ZMQ8-1] DR ProteomicsDB; 67902; -. [Q6ZMQ8-2] DR ProteomicsDB; 67903; -. [Q6ZMQ8-3] DR Antibodypedia; 2104; 203 antibodies from 28 providers. DR DNASU; 9625; -. DR Ensembl; ENST00000326724.9; ENSP00000324196.4; ENSG00000181409.15. [Q6ZMQ8-1] DR Ensembl; ENST00000374792.6; ENSP00000363924.2; ENSG00000181409.15. [Q6ZMQ8-3] DR GeneID; 9625; -. DR KEGG; hsa:9625; -. DR MANE-Select; ENST00000326724.9; ENSP00000324196.4; NM_001080395.3; NP_001073864.2. DR UCSC; uc010dia.4; human. [Q6ZMQ8-1] DR AGR; HGNC:21; -. DR ClinPGx; PA24370; -. DR CTD; 9625; -. DR DisGeNET; 9625; -. DR GeneCards; AATK; -. DR HGNC; HGNC:21; AATK. DR HPA; ENSG00000181409; Tissue enhanced (brain, intestine). DR MIM; 605276; gene. DR OpenTargets; ENSG00000181409; -. DR VEuPathDB; HostDB:ENSG00000181409; -. DR eggNOG; ENOG502RCHK; Eukaryota. DR GeneTree; ENSGT00940000154244; -. DR HOGENOM; CLU_004618_1_0_1; -. DR InParanoid; Q6ZMQ8; -. DR OMA; WEPPDYY; -. DR PAN-GO; Q6ZMQ8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZMQ8; -. DR PathwayCommons; Q6ZMQ8; -. DR SignaLink; Q6ZMQ8; -. DR SIGNOR; Q6ZMQ8; -. DR Agora; ENSG00000181409; -. DR BioGRID-ORCS; 9625; 23 hits in 1182 CRISPR screens. DR GeneWiki; AATK; -. DR GenomeRNAi; 9625; -. DR Pharos; Q6ZMQ8; Tbio. DR PRO; PR:Q6ZMQ8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q6ZMQ8; protein. DR Bgee; ENSG00000181409; Expressed in sural nerve and 183 other cell types or tissues. DR ExpressionAtlas; Q6ZMQ8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-ARBA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IBA:GO_Central. DR CDD; cd05087; PTKc_Aatyk1; 1. DR FunFam; 1.10.510.10:FF:000347; Apoptosis associated tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000275; Apoptosis associated tyrosine kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042817; LMTK1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR24417; SERINE/THREONINE-PROTEIN KINASE LMTK1; 1. DR PANTHER; PTHR24417:SF0; SERINE_THREONINE-PROTEIN KINASE LMTK1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix. FT CHAIN 1..1374 FT /note="Serine/threonine-protein kinase LMTK1" FT /id="PRO_0000248300" FT TRANSMEM 32..52 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 125..395 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 542..622 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 667..731 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 765..1195 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1245..1302 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1320..1374 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 606..620 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 680..690 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 719..731 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 801..831 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 847..856 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 900..914 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 978..987 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1063..1073 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1138..1155 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1158..1173 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1272..1291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1321..1332 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1337..1352 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1353..1363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1365..1374 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 253 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 131..139 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 156 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1029 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1168 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1171 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1184 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1262 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..433 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020225" FT VAR_SEQ 468..503 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020226" FT VAR_SEQ 897..915 FT /note="VGTPDSLDSLDIPSSASDG -> WPQREESLPRLCLLLRPRG (in FT isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020227" FT VAR_SEQ 916..1374 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020228" FT VARIANT 81 FT /note="S -> F (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2060924369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032679" FT VARIANT 97 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032680" FT VARIANT 104 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs1337040042)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032681" FT VARIANT 118 FT /note="T -> M (in dbSNP:rs8082016)" FT /id="VAR_027267" FT VARIANT 703 FT /note="G -> C (in dbSNP:rs7503604)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9734811" FT /id="VAR_032682" FT VARIANT 815 FT /note="S -> R (in dbSNP:rs56032966)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032683" FT VARIANT 923 FT /note="S -> L (in dbSNP:rs56313973)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032684" FT VARIANT 1160 FT /note="E -> K (in dbSNP:rs55793641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032685" FT VARIANT 1192 FT /note="P -> S (in dbSNP:rs55856613)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032686" FT VARIANT 1266 FT /note="F -> S (in dbSNP:rs36000545)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032687" FT VARIANT 1332 FT /note="A -> T (in dbSNP:rs55713566)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032688" FT CONFLICT 49..63 FT /note="MLACLCCKKGGIGFK -> HQVKVQGCWGRWRWQ (in Ref. 2)" FT /evidence="ECO:0000305" FT CONFLICT 511 FT /note="A -> T (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 541 FT /note="A -> T (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="T -> I (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 786 FT /note="A -> V (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 790 FT /note="T -> A (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 1028 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1271 FT /note="P -> H (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1324 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1360 FT /note="K -> E (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" SQ SEQUENCE 1374 AA; 144569 MW; AD46BD688AF7103E CRC64; MSSSFFNPSF AFSSHFDPDG APLSELSWPS SLAVVAVSFS GLFAVIVLML ACLCCKKGGI GFKEFENAEG DEYAADLAQG SPATAAQNGP DVYVLPLTEV SLPMAKQPGR SVQLLKSTDV GRHSLLYLKE IGRGWFGKVF LGEVNSGISS AQVVVKELQA SASVQEQMQF LEEVQPYRAL KHSNLLQCLA QCAEVTPYLL VMEFCPLGDL KGYLRSCRVA ESMAPDPRTL QRMACEVACG VLHLHRNNFV HSDLALRNCL LTADLTVKIG DYGLAHCKYR EDYFVTADQL WVPLRWIAPE LVDEVHSNLL VVDQTKSGNV WSLGVTIWEL FELGTQPYPQ HSDQQVLAYT VREQQLKLPK PQLQLTLSDR WYEVMQFCWL QPEQRPTAEE VHLLLSYLCA KGATEAEEEF ERRWRSLRPG GGGVGPGPGA AGPMLGGVVE LAAASSFPLL EQFAGDGFHA DGDDVLTVTE TSRGLNFEYK WEAGRGAEAF PATLSPGRTA RLQELCAPDG APPGVVPVLS AHSPSLGSEY FIRLEEAAPA AGHDPDCAGC APSPPATADQ DDDSDGSTAA SLAMEPLLGH GPPVDVPWGR GDHYPRRSLA RDPLCPSRSP SPSAGPLSLA EGGAEDADWG VAAFCPAFFE DPLGTSPLGS SGAPPLPLTG EDELEEVGAR RAAQRGHWRS NVSANNNSGS RCPESWDPVS AGGHAEGCPS PKQTPRASPE PGYPGEPLLG LQAASAQEPG CCPGLPHLCS AQGLAPAPCL VTPSWTETAS SGGDHPQAEP KLATEAEGTT GPRLPLPSVP SPSQEGAPLP SEEASAPDAP DALPDSPTPA TGGEVSAIKL ASALNGSSSS PEVEAPSSED EDTAEATSGI FTDTSSDGLQ ARRPDVVPAF RSLQKQVGTP DSLDSLDIPS SASDGGYEVF SPSATGPSGG QPRALDSGYD TENYESPEFV LKEAQEGCEP QAFAELASEG EGPGPETRLS TSLSGLNEKN PYRDSAYFSD LEAEAEATSG PEKKCGGDRA PGPELGLPST GQPSEQVCLR PGVSGEAQGS GPGEVLPPLL QLEGSSPEPS TCPSGLVPEP PEPQGPAKVR PGPSPSCSQF FLLTPVPLRS EGNSSEFQGP PGLLSGPAPQ KRMGGPGTPR APLRLALPGL PAALEGRPEE EEEDSEDSDE SDEELRCYSV QEPSEDSEEE APAVPVVVAE SQSARNLRSL LKMPSLLSET FCEDLERKKK AVSFFDDVTV YLFDQESPTR ELGEPFPGAK ESPPTFLRGS PGSPSAPNRP QQADGSPNGS TAEEGGGFAW DDDFPLMTAK AAFAMALDPA APAPAAPTPT PAPFSRFTVS PAPTSRFSIT HVSDSDAESK RGPEAGAGGE SKEA // ID LOX12_HUMAN Reviewed; 663 AA. AC P18054; O95569; Q6ISF8; Q9UQM4; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 06-FEB-2007, sequence version 4. DT 28-JAN-2026, entry version 234. DE RecName: Full=Polyunsaturated fatty acid lipoxygenase ALOX12 {ECO:0000305}; DE EC=1.13.11.- {ECO:0000269|PubMed:17493578}; DE AltName: Full=Arachidonate (12S)-lipoxygenase {ECO:0000305|PubMed:17493578}; DE Short=12S-LOX; DE Short=12S-lipoxygenase {ECO:0000303|PubMed:23578768}; DE EC=1.13.11.31 {ECO:0000269|PubMed:17493578, ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:24282679, ECO:0000269|PubMed:8500694}; DE AltName: Full=Arachidonate (15S)-lipoxygenase {ECO:0000305|PubMed:17493578}; DE EC=1.13.11.33 {ECO:0000269|PubMed:17493578}; DE AltName: Full=Linoleate (13S)-lipoxygenase {ECO:0000250|UniProtKB:P39655}; DE AltName: Full=Lipoxin synthase 12-LO; DE EC=3.3.2.-; DE AltName: Full=Platelet-type lipoxygenase 12; GN Name=ALOX12 {ECO:0000312|HGNC:HGNC:429}; Synonyms=12LO, LOG12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322. RX PubMed=2244907; DOI=10.1016/0006-291x(90)91580-l; RA Yoshimoto T., Yamamoto Y., Arakawa T., Suzuki H., Yamamoto S., Yokoyama C., RA Tanabe T., Toh H.; RT "Molecular cloning and expression of human arachidonate 12-lipoxygenase."; RL Biochem. Biophys. Res. Commun. 172:1230-1235(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322. RX PubMed=2377602; DOI=10.1073/pnas.87.15.5638; RA Funk C.D., Furci L., Fitzgerald G.A.; RT "Molecular cloning, primary structure, and expression of the human RT platelet/erythroleukemia cell 12-lipoxygenase."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5638-5642(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-261. RX PubMed=2217179; DOI=10.1073/pnas.87.19.7477; RA Izumi T., Hoshiko S., Raadmark O., Samuelsson B.; RT "Cloning of the cDNA for human 12-lipoxygenase."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7477-7481(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-261; SER-322 AND RP HIS-430. RG SeattleSNPs variation discovery resource; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-261. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112. RX PubMed=1447217; DOI=10.1016/s0021-9258(18)35835-6; RA Yoshimoto T., Arakawa T., Hada T., Yamamoto S., Takahashi E.; RT "Structure and chromosomal localization of human arachidonate 12- RT lipoxygenase gene."; RL J. Biol. Chem. 267:24805-24809(1992). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45. RX PubMed=1570320; DOI=10.1073/pnas.89.9.3962; RA Funk C.D., Funk L.B., Fitzgerald G.A., Samuelsson B.; RT "Characterization of human 12-lipoxygenase genes."; RL Proc. Natl. Acad. Sci. U.S.A. 89:3962-3966(1992). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 340-427. RC TISSUE=Skin; RX PubMed=8304420; DOI=10.1152/ajpcell.1994.266.1.c243; RA Hussain H., Shornick L.P., Shannon V.R., Wilson J.D., Funk C.D., RA Pentland A.P., Holtzman M.J.; RT "Epidermis contains platelet-type 12-lipoxygenase that is overexpressed in RT germinal layer keratinocytes in psoriasis."; RL Am. J. Physiol. 266:C243-C253(1994). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 531-663. RA Persson A.E., Lundeberg J., Uhlen M.; RT "EU-IMAGE: full-insert length sequencing of human cDNA clones."; RL Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP CATALYTIC ACTIVITY, PATHWAY, SUBSTRATE SPECIFICITY, BIOPHYSICOCHEMICAL RP PROPERTIES, AND FUNCTION. RX PubMed=1851637; DOI=10.1016/0005-2760(91)90128-5; RA Hada T., Ueda N., Takahashi Y., Yamamoto S.; RT "Catalytic properties of human platelet 12-lipoxygenase as compared with RT the enzymes of other origins."; RL Biochim. Biophys. Acta 1083:89-93(1991). RN [12] RP FUNCTION IN LIPOXIN SYNTHESIS, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL RP PROPERTIES, AND REACTION MECHANISM. RX PubMed=8250832; DOI=10.1042/bj2960127; RA Romano M., Chen X.S., Takahashi Y., Yamamoto S., Funk C.D., Serhan C.N.; RT "Lipoxin synthase activity of human platelet 12-lipoxygenase."; RL Biochem. J. 296:127-133(1993). RN [13] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, RP AND FUNCTION. RX PubMed=8319693; DOI=10.1111/j.1432-1033.1993.tb17988.x; RA Chen X.S., Brash A.R., Funk C.D.; RT "Purification and characterization of recombinant histidine-tagged human RT platelet 12-lipoxygenase expressed in a baculovirus/insect cell system."; RL Eur. J. Biochem. 214:845-852(1993). RN [14] RP CATALYTIC ACTIVITY, MUTAGENESIS OF HIS-355; HIS-360; HIS-365; HIS-383; RP HIS-392; LYS-416; ALA-417; VAL-418 AND HIS-540, AND FUNCTION. RX PubMed=8500694; DOI=10.1096/fasebj.7.8.8500694; RA Chen X.S., Funk C.D.; RT "Structure-function properties of human platelet 12-lipoxygenase: chimeric RT enzyme and in vitro mutagenesis studies."; RL FASEB J. 7:694-701(1993). RN [15] RP SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND INDUCTION. RX PubMed=8912711; DOI=10.1006/excr.1996.0317; RA Hagmann W., Gao X., Timar J., Chen Y.Q., Strohmaier A.R., Fahrenkopf C., RA Kagawa D., Lee M., Zacharek A., Honn K.V.; RT "12-Lipoxygenase in A431 cells: genetic identity, modulation of expression, RT and intracellular localization."; RL Exp. Cell Res. 228:197-205(1996). RN [16] RP FUNCTION IN ANGIOGENESIS. RX PubMed=9751607; RA Nie D., Hillman G.G., Geddes T., Tang K., Pierson C., Grignon D.J., RA Honn K.V.; RT "Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates RT angiogenesis and tumor growth."; RL Cancer Res. 58:4047-4051(1998). RN [17] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16638750; DOI=10.1074/jbc.m601887200; RA Nie D., Krishnamoorthy S., Jin R., Tang K., Chen Y., Qiao Y., Zacharek A., RA Guo Y., Milanini J., Pages G., Honn K.V.; RT "Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate RT cancer cells."; RL J. Biol. Chem. 281:18601-18609(2006). RN [18] RP CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=17493578; DOI=10.1016/j.abb.2007.04.007; RA Prusakiewicz J.J., Turman M.V., Vila A., Ball H.L., Al-Mestarihi A.H., RA Di Marzo V., Marnett L.J.; RT "Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases RT and cyclooxygenases."; RL Arch. Biochem. Biophys. 464:260-268(2007). RN [19] RP CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=18311922; DOI=10.1021/bi702530z; RA Turman M.V., Kingsley P.J., Rouzer C.A., Cravatt B.F., Marnett L.J.; RT "Oxidative metabolism of a fatty acid amide hydrolase-regulated lipid, RT arachidonoyltaurine."; RL Biochemistry 47:3917-3925(2008). RN [20] RP INDUCTION BY UV. RX PubMed=18755188; DOI=10.1016/j.febslet.2008.08.017; RA Yoo H., Jeon B., Jeon M.S., Lee H., Kim T.Y.; RT "Reciprocal regulation of 12- and 15-lipoxygenases by UV-irradiation in RT human keratinocytes."; RL FEBS Lett. 582:3249-3253(2008). RN [21] RP FUNCTION IN CELL MIGRATION. RX PubMed=22237009; DOI=10.1016/j.yexcr.2011.12.017; RA Klampfl T., Bogner E., Bednar W., Mager L., Massudom D., Kalny I., RA Heinzle C., Berger W., Staettner S., Karner J., Klimpfinger M., RA Fuerstenberger G., Krieg P., Marian B.; RT "Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in RT colorectal cancer cells."; RL Exp. Cell Res. 318:768-778(2012). RN [22] RP FUNCTION IN APOPTOTIC PROCESS, AND TISSUE SPECIFICITY. RX PubMed=23578768; DOI=10.1016/j.yexcr.2013.04.001; RA Weisinger G., Grafi-Cohen M., Hirsh M., Knoll E., Sharon O., Many A., RA Limor R., Stern N.; RT "12S-Lipoxygenase is necessary for human vascular smooth muscle cell RT survival."; RL Exp. Cell Res. 319:1586-1593(2013). RN [23] RP CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=22984144; DOI=10.1194/jlr.m026385; RA Ikei K.N., Yeung J., Apopa P.L., Ceja J., Vesci J., Holman T.R., RA Holinstat M.; RT "Investigations of human platelet-type 12-lipoxygenase: role of RT lipoxygenase products in platelet activation."; RL J. Lipid Res. 53:2546-2559(2012). RN [24] RP CATALYTIC ACTIVITY, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=23504711; DOI=10.1096/fj.13-227728; RA Dalli J., Zhu M., Vlasenko N.A., Deng B., Haeggstroem J.Z., Petasis N.A., RA Serhan C.N.; RT "The novel 13S,14S-epoxy-maresin is converted by human macrophages to RT maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts RT macrophage phenotype."; RL FASEB J. 27:2573-2583(2013). RN [25] RP CATALYTIC ACTIVITY, FUNCTION, VARIANTS HIS-134; LYS-259; ARG-261 AND RP SER-322, AND CHARACTERIZATION OF VARIANTS HIS-134; LYS-259; ARG-261 AND RP SER-322. RX PubMed=24282679; DOI=10.1016/j.redox.2013.11.001; RA Horn T., Reddy Kakularam K., Anton M., Richter C., Reddanna P., Kuhn H.; RT "Functional characterization of genetic enzyme variations in human RT lipoxygenases."; RL Redox Biol. 1:566-577(2013). RN [26] RP CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=25036362; DOI=10.1371/journal.pone.0102362; RA Deng B., Wang C.W., Arnardottir H.H., Li Y., Cheng C.Y., Dalli J., RA Serhan C.N.; RT "Maresin biosynthesis and identification of maresin 2, a new anti- RT inflammatory and pro-resolving mediator from human macrophages."; RL PLoS ONE 9:E102362-E102362(2014). RN [27] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=32404334; DOI=10.1194/jlr.ra120000777; RA Perry S.C., Kalyanaraman C., Tourdot B.E., Conrad W.S., Akinkugbe O., RA Freedman J.C., Holinstat M., Jacobson M.P., Holman T.R.; RT "15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15- RT lipoxygenase-2 in biosynthesis of resolvin D5."; RL J. Lipid Res. 61:1087-1103(2020). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 172-662 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Crystal structure of the lipoxygenase domain of human arachidonate 12- RT lipoxygenase, 12s-type."; RL Submitted (FEB-2009) to the PDB data bank. RN [29] RP VARIANT ARG-261. RX PubMed=15308583; DOI=10.1093/carcin/bgh260; RA Goodman J.E., Bowman E.D., Chanock S.J., Alberg A.J., Harris C.C.; RT "Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms RT and colon cancer risk."; RL Carcinogenesis 25:2467-2472(2004). RN [30] RP VARIANT ARG-261, AND INVOLVEMENT IN COLORECTAL CANCER. RX PubMed=17151091; DOI=10.1093/carcin/bgl242; RA Tan W., Wu J., Zhang X., Guo Y., Liu J., Sun T., Zhang B., Zhao D., RA Yang M., Yu D., Lin D.; RT "Associations of functional polymorphisms in cyclooxygenase-2 and platelet RT 12-lipoxygenase with risk of occurrence and advanced disease status of RT colorectal cancer."; RL Carcinogenesis 28:1197-1201(2007). RN [31] RP VARIANT ARG-261, AND INVOLVEMENT IN ESOPHAGEAL CANCER. RX PubMed=17460548; DOI=10.1097/fpc.0b013e328010bda1; RA Guo Y., Zhang X., Tan W., Miao X., Sun T., Zhao D., Lin D.; RT "Platelet 12-lipoxygenase Arg261Gln polymorphism: functional RT characterization and association with risk of esophageal squamous cell RT carcinoma in combination with COX-2 polymorphisms."; RL Pharmacogenet. Genomics 17:197-205(2007). CC -!- FUNCTION: Catalyzes the regio and stereo-specific incorporation of CC molecular oxygen into free and esterified polyunsaturated fatty acids CC generating lipid hydroperoxides that can be further reduced to the CC corresponding hydroxy species (PubMed:17493578, PubMed:18311922, CC PubMed:1851637, PubMed:32404334, PubMed:8319693, PubMed:8500694). CC Mainly converts arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to the CC specific bioactive lipid (12S)-hydroperoxyeicosatetraenoate/(12S)-HPETE CC (PubMed:17493578, PubMed:22984144, PubMed:24282679, PubMed:8319693, CC PubMed:8500694). Through the production of bioactive lipids like (12S)- CC HPETE it regulates different biological processes including platelet CC activation (PubMed:8319693, PubMed:8500694). It can also catalyze the CC epoxidation of double bonds of polyunsaturated fatty acids such as CC (14S)-hydroperoxy-docosahexaenoate/(14S)-HPDHA resulting in the CC formation of (13S,14S)-epoxy-DHA (PubMed:23504711). Furthermore, it may CC participate in the sequential oxidations of DHA CC ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro- CC resolving mediators (SPMs) like resolvin D5 ((7S,17S)-diHPDHA) and CC (7S,14S)-diHPDHA, that actively down-regulate the immune response and CC have anti-aggregation properties with platelets (PubMed:32404334). An CC additional function involves a multistep process by which it transforms CC leukotriene A4/LTA4 into the bioactive lipids lipoxin A4/LXA4 and CC lipoxin B4/LXB4, both are vasoactive and LXA4 may regulate neutrophil CC function via occupancy of specific recognition sites (PubMed:8250832). CC Can also peroxidize linoleate ((9Z,12Z)-octadecadienoate) to (13S)- CC hydroperoxyoctadecadienoate/ (13S-HPODE) (By similarity). Due to its CC role in regulating both the expression of the vascular endothelial CC growth factor (VEGF, an angiogenic factor involved in the survival and CC metastasis of solid tumors) and the expression of integrin beta-1 CC (known to affect tumor cell migration and proliferation), it can be CC regarded as protumorigenic (PubMed:16638750, PubMed:22237009, CC PubMed:9751607). Important for cell survival, as it may play a role not CC only in proliferation but also in the prevention of apoptosis in CC vascular smooth muscle cells (PubMed:23578768). CC {ECO:0000250|UniProtKB:P39655, ECO:0000269|PubMed:16638750, CC ECO:0000269|PubMed:17493578, ECO:0000269|PubMed:18311922, CC ECO:0000269|PubMed:1851637, ECO:0000269|PubMed:22237009, CC ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:23504711, CC ECO:0000269|PubMed:23578768, ECO:0000269|PubMed:24282679, CC ECO:0000269|PubMed:32404334, ECO:0000269|PubMed:8250832, CC ECO:0000269|PubMed:8319693, ECO:0000269|PubMed:8500694, CC ECO:0000269|PubMed:9751607}. CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (12S)-hydroperoxy- CC (5Z,8Z,10E,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:10428, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57444; CC EC=1.13.11.31; Evidence={ECO:0000269|PubMed:17493578, CC ECO:0000269|PubMed:22984144, ECO:0000269|PubMed:24282679, CC ECO:0000269|PubMed:8319693, ECO:0000269|PubMed:8500694}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10429; CC Evidence={ECO:0000305|PubMed:17493578, ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (15S)-hydroperoxy- CC (5Z,8Z,11Z,13E)-eicosatetraenoate; Xref=Rhea:RHEA:16869, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57446; CC EC=1.13.11.33; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16870; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2 leukotriene A4 + O2 + 2 H2O = 2 lipoxin A4; CC Xref=Rhea:RHEA:48584, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:57463, ChEBI:CHEBI:67026; CC Evidence={ECO:0000269|PubMed:1851637, ECO:0000269|PubMed:8250832}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48585; CC Evidence={ECO:0000305|PubMed:8250832}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2 leukotriene A4 + O2 + 2 H2O = 2 lipoxin B4; CC Xref=Rhea:RHEA:48588, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:57463, ChEBI:CHEBI:67031; CC Evidence={ECO:0000269|PubMed:8250832}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48589; CC Evidence={ECO:0000305|PubMed:8250832}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14S)-hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate = CC (13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate + H2O; CC Xref=Rhea:RHEA:53532, ChEBI:CHEBI:15377, ChEBI:CHEBI:78048, CC ChEBI:CHEBI:131958; Evidence={ECO:0000269|PubMed:23504711}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53533; CC Evidence={ECO:0000305|PubMed:23504711}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-L-alanine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-alanine; CC Xref=Rhea:RHEA:50184, ChEBI:CHEBI:15379, ChEBI:CHEBI:132071, CC ChEBI:CHEBI:132077; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50185; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-L-alanine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-alanine; CC Xref=Rhea:RHEA:50172, ChEBI:CHEBI:15379, ChEBI:CHEBI:132071, CC ChEBI:CHEBI:132074; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50173; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-gamma-aminobutanoate + O2 = CC N-(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-gamma- CC aminobutanoate; Xref=Rhea:RHEA:50180, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:132072, ChEBI:CHEBI:132078; CC Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50181; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-gamma-aminobutanoate + O2 = CC N-(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-gamma- CC aminobutanoate; Xref=Rhea:RHEA:50176, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:132072, ChEBI:CHEBI:132075; CC Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50177; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-glycine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-glycine; CC Xref=Rhea:RHEA:50188, ChEBI:CHEBI:15379, ChEBI:CHEBI:59002, CC ChEBI:CHEBI:132076; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50189; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-glycine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-glycine; CC Xref=Rhea:RHEA:50168, ChEBI:CHEBI:15379, ChEBI:CHEBI:59002, CC ChEBI:CHEBI:132073; Evidence={ECO:0000269|PubMed:17493578}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50169; CC Evidence={ECO:0000305|PubMed:17493578}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-taurine + O2 = N-(12S)- CC hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-taurine; CC Xref=Rhea:RHEA:50160, ChEBI:CHEBI:15379, ChEBI:CHEBI:132060, CC ChEBI:CHEBI:132061; Evidence={ECO:0000269|PubMed:18311922}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50161; CC Evidence={ECO:0000305|PubMed:18311922}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-taurine + O2 = N-(15S)- CC hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-taurine; CC Xref=Rhea:RHEA:50156, ChEBI:CHEBI:15379, ChEBI:CHEBI:132060, CC ChEBI:CHEBI:132062; Evidence={ECO:0000269|PubMed:18311922}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50157; CC Evidence={ECO:0000305|PubMed:18311922}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 = (14S)- CC hydroperoxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:41332, ChEBI:CHEBI:15379, ChEBI:CHEBI:77016, CC ChEBI:CHEBI:78048; Evidence={ECO:0000269|PubMed:25036362, CC ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41333; CC Evidence={ECO:0000305|PubMed:25036362, ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(7S)-hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 CC = (7S,14S)-dihydroperoxy-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:64724, ChEBI:CHEBI:15379, ChEBI:CHEBI:156049, CC ChEBI:CHEBI:156082; Evidence={ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64725; CC Evidence={ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(7S)-hydroperoxy-(4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 CC = (7S,17S)-dihydroperoxy-(4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoate; CC Xref=Rhea:RHEA:64728, ChEBI:CHEBI:15379, ChEBI:CHEBI:140349, CC ChEBI:CHEBI:156049; Evidence={ECO:0000269|PubMed:32404334}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:64729; CC Evidence={ECO:0000305|PubMed:32404334}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 = (12S)- CC hydroperoxy-(5Z,8Z,10E,14Z,17Z)-eicosapentaenoate; CC Xref=Rhea:RHEA:48704, ChEBI:CHEBI:15379, ChEBI:CHEBI:58562, CC ChEBI:CHEBI:90772; Evidence={ECO:0000269|PubMed:22984144}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48705; CC Evidence={ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(8Z,11Z,14Z)-eicosatrienoate + O2 = (12S)-hydroperoxy- CC (8Z,10E,14Z)-eicosatrienoate; Xref=Rhea:RHEA:41328, CC ChEBI:CHEBI:15379, ChEBI:CHEBI:71589, ChEBI:CHEBI:78047; CC Evidence={ECO:0000269|PubMed:22984144}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41329; CC Evidence={ECO:0000305|PubMed:22984144}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z,12Z)-octadecadienoate + O2 = (13S)-hydroperoxy-(9Z,11E)- CC octadecadienoate; Xref=Rhea:RHEA:22780, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:30245, ChEBI:CHEBI:57466; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22781; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)-hydroperoxy- CC (5Z,8Z,10E)-eicosatrienoate; Xref=Rhea:RHEA:41324, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:78043, ChEBI:CHEBI:78046; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41325; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)- CC hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-eicosatrienoate; CC Xref=Rhea:RHEA:50276, ChEBI:CHEBI:15379, ChEBI:CHEBI:131965, CC ChEBI:CHEBI:132063; Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50277; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + O2 = (12S)- CC hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-eicosatrienoate; CC Xref=Rhea:RHEA:50284, ChEBI:CHEBI:15379, ChEBI:CHEBI:131964, CC ChEBI:CHEBI:132065; Evidence={ECO:0000250|UniProtKB:P39655}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50285; CC Evidence={ECO:0000250|UniProtKB:P39655}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Note=Binds 1 Fe cation per subunit.; CC -!- ACTIVITY REGULATION: Activated by EGF (PubMed:8912711). Arachidonic CC acid conversion is inhibited by (13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)- CC docosahexaenoate (13S,14S-epoxy-DHA) (PubMed:23504711). Arachidonate CC 12-lipoxygenase activity is decreased when PH decreases from 7.4 to 6 CC (By similarity). {ECO:0000250|UniProtKB:P39655, CC ECO:0000269|PubMed:23504711, ECO:0000269|PubMed:8912711}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=8 uM for arachidonate (at pH 7.0 and 37 degrees Celsius) CC {ECO:0000269|PubMed:1851637}; CC KM=10 uM for arachidonate (at pH 8.0 and 25 degrees Celsius) CC {ECO:0000269|PubMed:8319693}; CC KM=6.2 uM for arachidonate (at pH 7.4) {ECO:0000269|PubMed:8250832}; CC KM=9 uM for linoleate (at pH 8.0 and 25 degrees Celsius) CC {ECO:0000269|PubMed:8319693}; CC KM=7.9 uM for leukotriene A4 (at pH 7.4) CC {ECO:0000269|PubMed:8250832}; CC KM=3 uM for eicosa-5,8,11,14,17-pentaenoate (at pH 7.0 and 37 degrees CC Celsius) {ECO:0000269|PubMed:1851637}; CC KM=35 uM for eicosa-8,11,14-trienoate (at pH 7.0 and 37 degrees CC Celsius) {ECO:0000269|PubMed:1851637}; CC KM=14.3 uM for 5,6-epoxy-8,11,14-eicosatrienoate (at pH 7.4) CC {ECO:0000269|PubMed:8250832}; CC KM=9.5 uM for arachidonic acid {ECO:0000269|PubMed:17493578}; CC KM=10.1 uM for N-arachidonoylglycine {ECO:0000269|PubMed:17493578}; CC KM=15.7 uM for N-arachidonoyl-L-alanine CC {ECO:0000269|PubMed:17493578}; CC KM=10.9 uM for N-arachidonoyl-gamma-aminobutyric acid CC {ECO:0000269|PubMed:17493578}; CC KM=9.7 uM for arachidonic acid {ECO:0000269|PubMed:25036362}; CC KM=5.1 uM for docosahexaenoate {ECO:0000269|PubMed:25036362}; CC KM=12.6 uM for arachidonic acid (in presence of calcium dichloride) CC {ECO:0000269|PubMed:25036362}; CC KM=7.1 uM for docosahexaenoate (in presence of calcium dichloride) CC {ECO:0000269|PubMed:25036362}; CC Vmax=3 umol/min/mg enzyme with arachidonate as substrate (at pH 8.0 CC and 25 degrees Celsius) {ECO:0000269|PubMed:8319693}; CC Vmax=1.057 umol/min/mg enzyme with arachidonate as substrate (at pH CC 7.4) {ECO:0000269|PubMed:8250832}; CC Vmax=0.0375 umol/min/mg enzyme with linoleate as substrate (at pH 8.0 CC and 25 degrees Celsius) {ECO:0000269|PubMed:8319693}; CC Vmax=0.025 umol/min/mg enzyme with leukotriene A4 as substrate (at pH CC 7.4) {ECO:0000269|PubMed:8250832}; CC Vmax=0.985 umol/min/mg enzyme with 5,6-epoxy-8,11,14-eicosatrienoate CC as substrate (at pH 7.4) {ECO:0000269|PubMed:8250832}; CC pH dependence: CC Optimum pH is 7.5-8.0 (for arachidonate 12-lipoxygenase activity). CC {ECO:0000269|PubMed:8250832, ECO:0000269|PubMed:8319693}; CC -!- PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid CC biosynthesis. {ECO:0000269|PubMed:1851637}. CC -!- INTERACTION: CC P18054; P13647: KRT5; NbExp=7; IntAct=EBI-1633210, EBI-702187; CC P18054; P02545: LMNA; NbExp=4; IntAct=EBI-1633210, EBI-351935; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Membrane. Note=Membrane CC association is stimulated by EGF. CC -!- TISSUE SPECIFICITY: Expressed in vascular smooth muscle cells. CC {ECO:0000269|PubMed:23578768}. CC -!- INDUCTION: Down-regulated upon starvation, by UV-irradiation and 15- CC lipoxygenase metabolites. {ECO:0000269|PubMed:18755188, CC ECO:0000269|PubMed:8912711}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:17460548}. CC Note=Disease susceptibility may be associated with variants affecting CC the gene represented in this entry. Gln at position 261 may confer CC interindividual susceptibility to esophageal cancer (PubMed:17460548). CC {ECO:0000269|PubMed:17460548}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:17151091}. Note=Disease CC susceptibility may be associated with variants affecting the gene CC represented in this entry. Gln at position 261 may confer CC interindividual susceptibility to colorectal cancer (PubMed:17460548). CC {ECO:0000269|PubMed:17460548}. CC -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/620/ALOX12"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M62982; AAA51533.1; -; mRNA. DR EMBL; M35418; AAA60056.1; -; mRNA. DR EMBL; M58704; AAA59523.1; -; mRNA. DR EMBL; AY527817; AAS00094.1; -; Genomic_DNA. DR EMBL; AC040977; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC069557; AAH69557.1; -; mRNA. DR EMBL; D12638; BAA02162.1; -; Genomic_DNA. DR EMBL; M87004; AAA51587.1; -; Genomic_DNA. DR EMBL; S68587; AAD14020.1; -; mRNA. DR EMBL; AF143883; AAD32700.1; -; mRNA. DR CCDS; CCDS11084.1; -. DR PIR; A38283; A38283. DR RefSeq; NP_000688.2; NM_000697.3. DR PDB; 3D3L; X-ray; 2.60 A; A/B=172-663. DR PDB; 8GHB; EM; 2.76 A; A=2-663. DR PDB; 8GHC; EM; 2.30 A; A/B=2-663. DR PDB; 8GHD; EM; 2.20 A; A/B/C/D/E/F=2-663. DR PDB; 8GHE; EM; 2.05 A; A/B/C/D=2-663. DR PDBsum; 3D3L; -. DR PDBsum; 8GHB; -. DR PDBsum; 8GHC; -. DR PDBsum; 8GHD; -. DR PDBsum; 8GHE; -. DR AlphaFoldDB; P18054; -. DR EMDB; EMD-40039; -. DR EMDB; EMD-40040; -. DR EMDB; EMD-40041; -. DR EMDB; EMD-40042; -. DR SMR; P18054; -. DR BioGRID; 106740; 12. DR FunCoup; P18054; 201. DR IntAct; P18054; 5. DR MINT; P18054; -. DR STRING; 9606.ENSP00000251535; -. DR BindingDB; P18054; -. DR ChEMBL; CHEMBL3687; -. DR DrugCentral; P18054; -. DR GuidetoPHARMACOLOGY; 1387; -. DR SwissLipids; SLP:000000670; -. DR GlyGen; P18054; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P18054; -. DR PhosphoSitePlus; P18054; -. DR BioMuta; ALOX12; -. DR DMDM; 125987838; -. DR MassIVE; P18054; -. DR PaxDb; 9606-ENSP00000251535; -. DR PeptideAtlas; P18054; -. DR ProteomicsDB; 53540; -. DR ABCD; P18054; 3 sequenced antibodies. DR Antibodypedia; 2760; 241 antibodies from 29 providers. DR DNASU; 239; -. DR Ensembl; ENST00000251535.11; ENSP00000251535.6; ENSG00000108839.13. DR GeneID; 239; -. DR KEGG; hsa:239; -. DR MANE-Select; ENST00000251535.11; ENSP00000251535.6; NM_000697.3; NP_000688.2. DR UCSC; uc002gdx.4; human. DR AGR; HGNC:429; -. DR ClinPGx; PA45; -. DR CTD; 239; -. DR DisGeNET; 239; -. DR GeneCards; ALOX12; -. DR HGNC; HGNC:429; ALOX12. DR HPA; ENSG00000108839; Tissue enhanced (cervix, esophagus, vagina). DR MIM; 114500; phenotype. DR MIM; 133239; phenotype. DR MIM; 152391; gene. DR OpenTargets; ENSG00000108839; -. DR VEuPathDB; HostDB:ENSG00000108839; -. DR eggNOG; ENOG502QQSP; Eukaryota. DR GeneTree; ENSGT00940000155191; -. DR HOGENOM; CLU_004282_3_3_1; -. DR InParanoid; P18054; -. DR OMA; NNGQYDW; -. DR OrthoDB; 407298at2759; -. DR PAN-GO; P18054; 10 GO annotations based on evolutionary models. DR PhylomeDB; P18054; -. DR BioCyc; MetaCyc:HS03167-MONOMER; -. DR BRENDA; 1.13.11.31; 2681. DR PathwayCommons; P18054; -. DR Reactome; R-HSA-2142696; Synthesis of Hepoxilins (HX) and Trioxilins (TrX). DR Reactome; R-HSA-2142700; Biosynthesis of Lipoxins (LX). DR Reactome; R-HSA-2142712; Synthesis of 12-eicosatetraenoic acid derivatives. DR Reactome; R-HSA-9018677; Biosynthesis of DHA-derived SPMs. DR Reactome; R-HSA-9025106; Biosynthesis of DPAn-6 SPMs. DR Reactome; R-HSA-9026290; Biosynthesis of DPAn-3-derived maresins. DR SABIO-RK; P18054; -. DR SignaLink; P18054; -. DR UniPathway; UPA00881; -. DR Agora; ENSG00000108839; -. DR BioGRID-ORCS; 239; 9 hits in 1152 CRISPR screens. DR ChiTaRS; ALOX12; human. DR EvolutionaryTrace; P18054; -. DR GeneWiki; ALOX12; -. DR GenomeRNAi; 239; -. DR Pharos; P18054; Tchem. DR PRO; PR:P18054; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P18054; protein. DR Bgee; ENSG00000108839; Expressed in lower esophagus mucosa and 116 other cell types or tissues. DR ExpressionAtlas; P18054; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0042383; C:sarcolemma; IDA:UniProtKB. DR GO; GO:0004052; F:arachidonate 12(S)-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0050473; F:arachidonate 15-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0047977; F:hepoxilin-epoxide hydrolase activity; ISS:UniProtKB. DR GO; GO:0005506; F:iron ion binding; IEA:InterPro. DR GO; GO:0016165; F:linoleate 13S-lipoxygenase activity; IDA:UniProtKB. DR GO; GO:0019369; P:arachidonate metabolic process; IDA:UniProtKB. DR GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB. DR GO; GO:0019395; P:fatty acid oxidation; IDA:UniProtKB. DR GO; GO:0051122; P:hepoxilin biosynthetic process; ISS:UniProtKB. DR GO; GO:1901751; P:leukotriene A4 metabolic process; IDA:UniProtKB. DR GO; GO:0043651; P:linoleic acid metabolic process; IDA:UniProtKB. DR GO; GO:0006629; P:lipid metabolic process; IDA:UniProtKB. DR GO; GO:0034440; P:lipid oxidation; IBA:GO_Central. DR GO; GO:2001303; P:lipoxin A4 biosynthetic process; IDA:UniProtKB. DR GO; GO:2001306; P:lipoxin B4 biosynthetic process; IDA:UniProtKB. DR GO; GO:0019372; P:lipoxygenase pathway; IDA:UniProtKB. DR GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IMP:UniProtKB. DR GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB. DR GO; GO:0042554; P:superoxide anion generation; NAS:UniProtKB. DR GO; GO:0033559; P:unsaturated fatty acid metabolic process; IDA:UniProtKB. DR CDD; cd01753; PLAT_LOX; 1. DR FunFam; 3.10.450.60:FF:000004; Arachidonate 12-lipoxygenase, 12S-type; 1. DR FunFam; 1.20.245.10:FF:000001; Arachidonate 5-lipoxygenase a; 1. DR FunFam; 2.60.60.20:FF:000002; Arachidonate 5-lipoxygenase a; 1. DR Gene3D; 3.10.450.60; -; 1. DR Gene3D; 1.20.245.10; Lipoxygenase-1, Domain 5; 1. DR Gene3D; 2.60.60.20; PLAT/LH2 domain; 1. DR InterPro; IPR000907; LipOase. DR InterPro; IPR013819; LipOase_C. DR InterPro; IPR036226; LipOase_C_sf. DR InterPro; IPR020834; LipOase_CS. DR InterPro; IPR020833; LipOase_Fe_BS. DR InterPro; IPR001885; LipOase_mml. DR InterPro; IPR001024; PLAT/LH2_dom. DR InterPro; IPR036392; PLAT/LH2_dom_sf. DR InterPro; IPR042062; PLAT_LOX_verte. DR PANTHER; PTHR11771; LIPOXYGENASE; 1. DR Pfam; PF00305; Lipoxygenase; 1. DR Pfam; PF01477; PLAT; 1. DR PRINTS; PR00087; LIPOXYGENASE. DR PRINTS; PR00467; MAMLPOXGNASE. DR SMART; SM00308; LH2; 1. DR SUPFAM; SSF49723; Lipase/lipooxygenase domain (PLAT/LH2 domain); 1. DR SUPFAM; SSF48484; Lipoxigenase; 1. DR PROSITE; PS00711; LIPOXYGENASE_1; 1. DR PROSITE; PS00081; LIPOXYGENASE_2; 1. DR PROSITE; PS51393; LIPOXYGENASE_3; 1. DR PROSITE; PS50095; PLAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasm; Dioxygenase; Fatty acid metabolism; Hydrolase; KW Iron; Lipid metabolism; Membrane; Metal-binding; Oxidoreductase; KW Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..663 FT /note="Polyunsaturated fatty acid lipoxygenase ALOX12" FT /id="PRO_0000220682" FT DOMAIN 2..114 FT /note="PLAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00152" FT DOMAIN 115..663 FT /note="Lipoxygenase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT BINDING 360 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 365 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 540 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT BINDING 544 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT BINDING 663 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_note="catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00726" FT MOD_RES 246 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1LQ70" FT VARIANT 134 FT /note="D -> H (does not affect lipoxygenase activity; FT dbSNP:rs114985038)" FT /evidence="ECO:0000269|PubMed:24282679" FT /id="VAR_082032" FT VARIANT 259 FT /note="E -> K (does not affect lipoxygenase activity; FT dbSNP:rs4987104)" FT /evidence="ECO:0000269|PubMed:24282679" FT /id="VAR_030471" FT VARIANT 261 FT /note="Q -> R (does not affect lipoxygenase activity; FT dbSNP:rs1126667)" FT /evidence="ECO:0000269|PubMed:15308583, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17151091, FT ECO:0000269|PubMed:17460548, ECO:0000269|PubMed:2217179, FT ECO:0000269|PubMed:24282679, ECO:0000269|Ref.4" FT /id="VAR_018743" FT VARIANT 298 FT /note="A -> T" FT /id="VAR_004279" FT VARIANT 322 FT /note="N -> S (does not affect lipoxygenase activity; FT dbSNP:rs434473)" FT /evidence="ECO:0000269|PubMed:2244907, FT ECO:0000269|PubMed:2377602, ECO:0000269|PubMed:24282679, FT ECO:0000269|Ref.4" FT /id="VAR_018744" FT VARIANT 430 FT /note="R -> H (in dbSNP:rs11571342)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018745" FT MUTAGEN 355 FT /note="H->Q: No effect on arachidonate 12(S)-lipoxygenase FT activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 360 FT /note="H->Q,Y: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 365 FT /note="H->Q: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 383 FT /note="H->Q: Alteredarachidonate 12(S)-lipoxygenase FT activity and protein expression." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 392 FT /note="H->Q: No effect on arachidonate 12(S)-lipoxygenase FT activity." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 416 FT /note="K->Q: Reduced arachidonate 12(S)-lipoxygenase FT activity. No effect on the stereoselectivity of the FT oxygenation reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 417 FT /note="A->I: Reduced arachidonate 12(S)-lipoxygenase FT activity. Alters the stereoselectivity of the oxygenation FT reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 418 FT /note="V->M: No effect onarachidonate 12(S)-lipoxygenase FT activity. No effect on the stereoselectivity of the FT oxygenation reaction." FT /evidence="ECO:0000269|PubMed:8500694" FT MUTAGEN 540 FT /note="H->Q: Complete loss of arachidonate 12(S)- FT lipoxygenase activity." FT /evidence="ECO:0000269|PubMed:8500694" FT CONFLICT 189..192 FT /note="RVYT -> PCLH (in Ref. 1; AAA51533)" FT /evidence="ECO:0000305" FT CONFLICT 345 FT /note="S -> C (in Ref. 1; AAA51533)" FT /evidence="ECO:0000305" FT CONFLICT 389 FT /note="L -> P (in Ref. 2; AAA60056)" FT /evidence="ECO:0000305" FT STRAND 3..14 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 16..18 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 20..30 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 32..39 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 47..52 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 59..69 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 75..84 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 86..88 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 92..99 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 102..104 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 106..109 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 123..138 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 151..153 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 162..164 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 168..191 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 193..195 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 200..205 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 213..221 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 225..234 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 258..269 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 273..277 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 300..305 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 311..317 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:3D3L" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:8GHC" FT HELIX 337..357 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 358..364 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 365..378 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 390..393 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 396..406 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 414..417 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 419..423 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 424..434 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 438..441 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 443..449 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 459..482 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 486..490 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 493..503 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 504..508 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 510..514 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 522..536 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 538..544 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 547..551 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 554..556 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 561..563 FT /evidence="ECO:0007829|PDB:8GHB" FT STRAND 567..571 FT /evidence="ECO:0007829|PDB:3D3L" FT HELIX 574..580 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 584..598 FT /evidence="ECO:0007829|PDB:8GHE" FT HELIX 618..642 FT /evidence="ECO:0007829|PDB:8GHE" FT TURN 654..656 FT /evidence="ECO:0007829|PDB:8GHE" FT STRAND 657..660 FT /evidence="ECO:0007829|PDB:8GHE" SQ SEQUENCE 663 AA; 75694 MW; C4D6D5B320666A77 CRC64; MGRYRIRVAT GAWLFSGSYN RVQLWLVGTR GEAELELQLR PARGEEEEFD HDVAEDLGLL QFVRLRKHHW LVDDAWFCDR ITVQGPGACA EVAFPCYRWV QGEDILSLPE GTARLPGDNA LDMFQKHREK ELKDRQQIYC WATWKEGLPL TIAADRKDDL PPNMRFHEEK RLDFEWTLKA GALEMALKRV YTLLSSWNCL EDFDQIFWGQ KSALAEKVRQ CWQDDELFSY QFLNGANPML LRRSTSLPSR LVLPSGMEEL QAQLEKELQN GSLFEADFIL LDGIPANVIR GEKQYLAAPL VMLKMEPNGK LQPMVIQIQP PNPSSPTPTL FLPSDPPLAW LLAKSWVRNS DFQLHEIQYH LLNTHLVAEV IAVATMRCLP GLHPIFKFLI PHIRYTMEIN TRARTQLISD GGIFDKAVST GGGGHVQLLR RAAAQLTYCS LCPPDDLADR GLLGLPGALY AHDALRLWEI IARYVEGIVH LFYQRDDIVK GDPELQAWCR EITEVGLCQA QDRGFPVSFQ SQSQLCHFLT MCVFTCTAQH AAINQGQLDW YAWVPNAPCT MRMPPPTTKE DVTMATVMGS LPDVRQACLQ MAISWHLSRR QPDMVPLGHH KEKYFSGPKP KAVLNQFRTD LEKLEKEITA RNEQLDWPYE YLKPSCIENS VTI // ID M3K15_HUMAN Reviewed; 1313 AA. AC Q6ZN16; A2AI49; A2AI50; A6NJ61; Q5JPR4; Q6ZMV3; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 15; DE EC=2.7.11.25 {ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; DE AltName: Full=Apoptosis signal-regulating kinase 3; DE AltName: Full=MAPK/ERK kinase kinase 15; DE Short=MEK kinase 15; DE Short=MEKK 15; GN Name=MAP3K15; Synonyms=ASK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY. RX PubMed=20362554; DOI=10.1016/j.bbrc.2010.03.164; RA Kaji T., Yoshida S., Kawai K., Fuchigami Y., Watanabe W., Kubodera H., RA Kishimoto T.; RT "ASK3, a novel member of the apoptosis signal-regulating kinase family, is RT essential for stress-induced cell death in HeLa cells."; RL Biochem. Biophys. Res. Commun. 395:213-218(2010). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-994, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-681. RX PubMed=26732173; DOI=10.1038/srep18710; RA Maruyama J., Kobayashi Y., Umeda T., Vandewalle A., Takeda K., Ichijo H., RA Naguro I.; RT "Osmotic stress induces the phosphorylation of WNK4 Ser575 via the p38MAPK- RT MK pathway."; RL Sci. Rep. 6:18710-18710(2016). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] THR-192; ASN-199; HIS-226; SER-255; RP GLY-456; CYS-494; LEU-562; GLN-677; SER-838; LEU-993; HIS-1029; ARG-1247 RP AND GLU-1251. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as a component of the MAP CC kinase signal transduction pathway (PubMed:20362554, PubMed:26732173). CC Once activated, acts as an upstream activator of the p38 MAPK signal CC transduction cascade through the phosphorylation and activation of CC several MAP kinase kinases (PubMed:20362554, PubMed:26732173). May CC function in a signal transduction pathway that is activated by various CC cell stresses and leads to apoptosis (PubMed:20362554). Involved in CC phosphorylation of WNK4 in response to osmotic stress or hypotonic low- CC chloride stimulation via the p38 MAPK signal transduction cascade CC (PubMed:26732173). {ECO:0000269|PubMed:20362554, CC ECO:0000269|PubMed:26732173}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q99683}; CC -!- ACTIVITY REGULATION: Contains an N-terminal autoinhibitory domain. CC Activated by phosphorylation at Thr-812, inhibited by phosphorylation CC at Ser-924 and Ser-994 (By similarity). {ECO:0000250|UniProtKB:Q99683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZN16-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6ZN16-2; Sequence=VSP_021038; CC Name=3; CC IsoId=Q6ZN16-3; Sequence=VSP_021039, VSP_021040; CC -!- TISSUE SPECIFICITY: Isoform 2 and isoform 3 are widely expressed. CC Isoform 2 highest levels are observed in fetal brain, and isoform 3 CC highest levels in pancreas, peripheral blood leukocytes, fetal brain CC and spleen. {ECO:0000269|PubMed:20362554}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131412; BAD18559.1; -; mRNA. DR EMBL; AK131477; BAD18622.1; -; mRNA. DR EMBL; AL732326; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL732423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS35212.2; -. [Q6ZN16-1] DR RefSeq; NP_001001671.3; NM_001001671.4. [Q6ZN16-1] DR RefSeq; XP_011543813.1; XM_011545511.2. [Q6ZN16-2] DR RefSeq; XP_054183016.1; XM_054327041.1. [Q6ZN16-2] DR PDB; 6V0M; X-ray; 1.80 A; A/B/C=1241-1308. DR PDBsum; 6V0M; -. DR AlphaFoldDB; Q6ZN16; -. DR SMR; Q6ZN16; -. DR BioGRID; 133293; 23. DR FunCoup; Q6ZN16; 177. DR IntAct; Q6ZN16; 9. DR STRING; 9606.ENSP00000345629; -. DR BindingDB; Q6ZN16; -. DR ChEMBL; CHEMBL1163127; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q6ZN16; -. DR GlyGen; Q6ZN16; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN16; -. DR PhosphoSitePlus; Q6ZN16; -. DR BioMuta; MAP3K15; -. DR DMDM; 116248533; -. DR CPTAC; CPTAC-841; -. DR CPTAC; CPTAC-842; -. DR jPOST; Q6ZN16; -. DR MassIVE; Q6ZN16; -. DR PaxDb; 9606-ENSP00000345629; -. DR PeptideAtlas; Q6ZN16; -. DR ProteomicsDB; 67956; -. [Q6ZN16-1] DR ProteomicsDB; 67957; -. [Q6ZN16-2] DR ProteomicsDB; 67958; -. [Q6ZN16-3] DR Antibodypedia; 571; 146 antibodies from 26 providers. DR DNASU; 389840; -. DR Ensembl; ENST00000338883.9; ENSP00000345629.4; ENSG00000180815.16. [Q6ZN16-1] DR GeneID; 389840; -. DR KEGG; hsa:389840; -. DR MANE-Select; ENST00000338883.9; ENSP00000345629.4; NM_001001671.4; NP_001001671.3. DR UCSC; uc004czj.3; human. [Q6ZN16-1] DR AGR; HGNC:31689; -. DR ClinPGx; PA134935369; -. DR CTD; 389840; -. DR DisGeNET; 389840; -. DR GeneCards; MAP3K15; -. DR HGNC; HGNC:31689; MAP3K15. DR HPA; ENSG00000180815; Group enriched (adrenal gland, choroid plexus). DR MalaCards; MAP3K15; -. DR MIM; 300820; gene. DR OpenTargets; ENSG00000180815; -. DR VEuPathDB; HostDB:ENSG00000180815; -. DR eggNOG; KOG4279; Eukaryota. DR GeneTree; ENSGT00940000159562; -. DR HOGENOM; CLU_048342_0_0_1; -. DR InParanoid; Q6ZN16; -. DR OMA; CLCGRIC; -. DR OrthoDB; 275301at2759; -. DR PAN-GO; Q6ZN16; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN16; -. DR PathwayCommons; Q6ZN16; -. DR SignaLink; Q6ZN16; -. DR Agora; ENSG00000180815; -. DR BioGRID-ORCS; 389840; 3 hits in 297 CRISPR screens. DR CD-CODE; FBBE2A73; Synthetic Condensate 000275. DR ChiTaRS; MAP3K15; human. DR GenomeRNAi; 389840; -. DR Pharos; Q6ZN16; Tchem. DR PRO; PR:Q6ZN16; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q6ZN16; protein. DR Bgee; ENSG00000180815; Expressed in adrenal tissue and 80 other cell types or tissues. DR ExpressionAtlas; Q6ZN16; baseline and differential. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0007254; P:JNK cascade; IBA:GO_Central. DR GO; GO:0038066; P:p38MAPK cascade; IBA:GO_Central. DR CDD; cd06624; STKc_ASK; 1. DR FunFam; 1.10.510.10:FF:000054; Mitogen-activated protein kinase kinase kinase 5; 1. DR FunFam; 3.30.200.20:FF:000067; Mitogen-activated protein kinase kinase kinase 5; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046872; DRHyd-ASK. DR InterPro; IPR046873; HisK-N-like. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR043969; MAP3K_PH. DR InterPro; IPR025136; MAP3K_TRAF-bd. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11584:SF363; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 15; 1. DR PANTHER; PTHR11584; SERINE/THREONINE PROTEIN KINASE; 1. DR Pfam; PF19039; ASK_PH; 1. DR Pfam; PF20309; DRHyd-ASK; 1. DR Pfam; PF20302; HisK-N-like; 1. DR Pfam; PF13281; MAP3K_TRAF_bd; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Coiled coil; Kinase; KW Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1313 FT /note="Mitogen-activated protein kinase kinase kinase 15" FT /id="PRO_0000253481" FT DOMAIN 652..908 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..58 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 939..958 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1179..1225 FT /evidence="ECO:0000255" FT COMPBIAS 28..43 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 44..57 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 942..955 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 773 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 658..666 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 681 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 994 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..565 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021038" FT VAR_SEQ 1..525 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021039" FT VAR_SEQ 526..582 FT /note="GLRFPVLVIEPTKVYQPSYVSINNEAEERTVSLWHVSPTEMKQMHEWNFTAS FT SIKGI -> MACLTHRNETDARMEFYSLFHKGNKAGVQWHDLGSLQPLPPRFKRFSCLS FT LQSSWDY (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021040" FT VARIANT 192 FT /note="A -> T (in dbSNP:rs5909299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040716" FT VARIANT 199 FT /note="S -> N (in dbSNP:rs55916006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040717" FT VARIANT 226 FT /note="D -> H (in dbSNP:rs56338727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040718" FT VARIANT 255 FT /note="R -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040719" FT VARIANT 456 FT /note="S -> G (in dbSNP:rs56212339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040720" FT VARIANT 494 FT /note="R -> C (in dbSNP:rs41305349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040721" FT VARIANT 562 FT /note="S -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2063704764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040722" FT VARIANT 677 FT /note="R -> Q (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040723" FT VARIANT 838 FT /note="G -> S (in dbSNP:rs56381411)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040724" FT VARIANT 993 FT /note="S -> L (in dbSNP:rs56233219)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040725" FT VARIANT 1029 FT /note="N -> H (in dbSNP:rs55787622)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040726" FT VARIANT 1247 FT /note="W -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs2063287881)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040727" FT VARIANT 1251 FT /note="Q -> E (in dbSNP:rs15943)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040728" FT MUTAGEN 681 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:26732173" FT CONFLICT 793 FT /note="F -> L (in Ref. 1; BAD18622)" FT /evidence="ECO:0000305" FT HELIX 1241..1250 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1255..1263 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1268..1273 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1277..1282 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1287..1307 FT /evidence="ECO:0007829|PDB:6V0M" SQ SEQUENCE 1313 AA; 147437 MW; 60751706D6AEE3E9 CRC64; MESGGGNAPA GALGAASESP QCPPPPGVEG AAGPAEPDGA AEGAAGGSGE GESGGGPRRA LRAVYVRSES SQGGAAGGPE AGARQCLLRA CEAEGAHLTS VPFGELDFGE TAVLDAFYDA DVAVVDMSDV SRQPSLFYHL GVRESFDMAN NVILYHDTDA DTALSLKDMV TQKNTASSGN YYFIPYIVTP CADYFCCESD AQRRASEYMQ PNWDNILGPL CMPLVDRFIS LLKDIHVTSC VYYKETLLND IRKAREKYQG EELAKELARI KLRMDNTEVL TSDIIINLLL SYRDIQDYDA MVKLVETLEM LPTCDLADQH NIKFHYAFAL NRRNSTGDRE KALQIMLQVL QSCDHPGPDM FCLCGRIYKD IFLDSDCKDD TSRDSAIEWY RKGFELQSSL YSGINLAVLL IVAGQQFETS LELRKIGVRL NSLLGRKGSL EKMNNYWDVG QFFSVSMLAH DVGKAVQAAE RLFKLKPPVW YLRSLVQNLL LIRRFKKTII EHSPRQERLN FWLDIIFEAT NEVTNGLRFP VLVIEPTKVY QPSYVSINNE AEERTVSLWH VSPTEMKQMH EWNFTASSIK GISLSKFDER CCFLYVHDNS DDFQIYFSTE EQCSRFFSLV KEMITNTAGS TVELEGETDG DTLEYEYDHD ANGERVVLGK GTYGIVYAGR DLSNQVRIAI KEIPERDSRY SQPLHEEIAL HKYLKHRNIV QYLGSVSENG YIKIFMEQVP GGSLSALLRS KWGPMKEPTI KFYTKQILEG LKYLHENQIV HRDIKGDNVL VNTYSGVVKI SDFGTSKRLA GVNPCTETFT GTLQYMAPEI IDQGPRGYGA PADIWSLGCT IIEMATSKPP FHELGEPQAA MFKVGMFKIH PEIPEALSAE ARAFILSCFE PDPHKRATTA ELLREGFLRQ VNKGKKNRIA FKPSEGPRGV VLALPTQGEP MATSSSEHGS VSPDSDAQPD ALFERTRAPR HHLGHLLSVP DESSALEDRG LASSPEDRDQ GLFLLRKDSE RRAILYKILW EEQNQVASNL QECVAQSSEE LHLSVGHIKQ IIGILRDFIR SPEHRVMATT ISKLKVDLDF DSSSISQIHL VLFGFQDAVN KILRNHLIRP HWMFAMDNII RRAVQAAVTI LIPELRAHFE PTCETEGVDK DMDEAEEGYP PATGPGQEAQ PHQQHLSLQL GELRQETNRL LEHLVEKERE YQNLLRQTLE QKTQELYHLQ LKLKSNCITE NPAGPYGQRT DKELIDWLRL QGADAKTIEK IVEEGYTLSD ILNEITKEDL RYLRLRGGLL CRLWSAVSQY RRAQEASETK DKA // ID M3K9_HUMAN Reviewed; 1104 AA. AC P80192; A3KN85; Q0D2G7; Q6EH31; Q9H2N5; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 214. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 9; DE EC=2.7.11.25; DE AltName: Full=Mixed lineage kinase 1; GN Name=MAP3K9; Synonyms=MLK1, PRKE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-304; THR-305; SER-308 AND THR-312, AND MUTAGENESIS RP OF LYS-171; THR-304; THR-305; SER-308 AND THR-312. RX PubMed=15610029; DOI=10.1021/bi049866y; RA Durkin J.T., Holskin B.P., Kopec K.K., Reed M.S., Spais C.M., Steffy B.M., RA Gessner G., Angeles T.S., Pohl J., Ator M.A., Meyer S.L.; RT "Phosphoregulation of mixed-lineage kinase 1 activity by multiple RT phosphorylation in the activation loop."; RL Biochemistry 43:16348-16355(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 53-1104 (ISOFORM 2). RA McNee J.J., Dower S.K., Guesdon F.; RT "cDNA sequence and gene organisation of mixed lineage kinase 1."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 142-535, AND TISSUE SPECIFICITY. RC TISSUE=Colon epithelium; RX PubMed=8477742; DOI=10.1111/j.1432-1033.1993.tb17810.x; RA Dorow D.S., Devereux L., Dietzsch E., de Kretser T.; RT "Identification of a new family of human epithelial protein kinases RT containing two leucine/isoleucine-zipper domains."; RL Eur. J. Biochem. 213:701-710(1993). RN [5] RP ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND PHOSPHORYLATION OF RP MAP2K4/MKK4. RX PubMed=11325962; DOI=10.1074/jbc.m011601200; RA Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., RA Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L.; RT "Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase RT family."; RL J. Biol. Chem. 276:25302-25308(2001). RN [6] RP FUNCTION IN THE APOPTOSIS PATHWAY. RX PubMed=11416147; DOI=10.1128/mcb.21.14.4713-4724.2001; RA Xu Z., Maroney A.C., Dobrzanski P., Kukekov N.V., Greene L.A.; RT "The MLK family mediates c-Jun N-terminal kinase activation in neuronal RT apoptosis."; RL Mol. Cell. Biol. 21:4713-4724(2001). RN [7] RP ACTIVITY REGULATION. RX PubMed=11755341; DOI=10.1016/s0960-894x(01)00690-4; RA Murakata C., Kaneko M., Gessner G., Angeles T.S., Ator M.A., O'Kane T.M., RA McKenna B.A., Thomas B.A., Mathiasen J.R., Saporito M.S., RA Bozyczko-Coyne D., Hudkins R.L.; RT "Mixed lineage kinase activity of indolocarbazole analogues."; RL Bioorg. Med. Chem. Lett. 12:147-150(2002). RN [8] RP POSSIBLE ROLE IN ESOPHAGEAL CANCER. RX PubMed=18241037; DOI=10.1002/ijc.23397; RA Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M., RA Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W., Fan J.B.; RT "Genomic profiling of 766 cancer-related genes in archived esophageal RT normal and carcinoma tissues."; RL Int. J. Cancer 122:2249-2254(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 136-406. RX PubMed=18714982; DOI=10.1021/jm8005838; RA Hudkins R.L., Diebold J.L., Tao M., Josef K.A., Park C.H., Angeles T.S., RA Aimone L.D., Husten J., Ator M.A., Meyer S.L., Holskin B.P., Durkin J.T., RA Fedorov A.A., Fedorov E.V., Almo S.C., Mathiasen J.R., Bozyczko-Coyne D., RA Saporito M.S., Scott R.W., Mallamo J.P.; RT "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective RT dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed- RT lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- RT phenyltetrahydropyridine models."; RL J. Med. Chem. 51:5680-5689(2008). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-246; CYS-467; GLN-497 AND CYS-646. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. Plays an important role CC in the cascades of cellular responses evoked by changes in the CC environment. Once activated, acts as an upstream activator of the CC MKK/JNK signal transduction cascade through the phosphorylation of CC MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The CC MKK/JNK signaling pathway regulates stress response via activator CC protein-1 (JUN) and GATA4 transcription factors. Also plays a role in CC mitochondrial death signaling pathway, including the release cytochrome CC c, leading to apoptosis. {ECO:0000269|PubMed:11416147, CC ECO:0000269|PubMed:15610029}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Homodimerization via the leucine zipper domains is CC required for autophosphorylation of multiple sites in the activation CC loop and subsequent activation. Autophosphorylation at Thr-312 is the CC key step in activation of MAP3K9/MLK1 and is required for full CC phosphorylation. Autophosphorylation at Thr-304 and Ser-308 have been CC shown to be of secondary importance in the activation of MAP3K9/MLK1. CC CEP-1347 and many indolocarbazole analogs have been shown to act as CC inhibitors of MAP3K9/MLK1 activity. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:11755341, ECO:0000269|PubMed:15610029}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=62 uM for ATP {ECO:0000269|PubMed:11325962}; CC KM=7 uM for myelin basic protein (MBP) as substrate CC {ECO:0000269|PubMed:11325962}; CC -!- SUBUNIT: Homodimer. {ECO:0000250}. CC -!- INTERACTION: CC P80192; P08238: HSP90AB1; NbExp=2; IntAct=EBI-3951604, EBI-352572; CC P80192; Q92993: KAT5; NbExp=3; IntAct=EBI-3951604, EBI-399080; CC P80192; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-3951604, EBI-11742507; CC P80192; P17252: PRKCA; NbExp=3; IntAct=EBI-3951604, EBI-1383528; CC P80192; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-3951604, EBI-9090795; CC P80192; P62258: YWHAE; NbExp=3; IntAct=EBI-3951604, EBI-356498; CC P80192; P61981: YWHAG; NbExp=4; IntAct=EBI-3951604, EBI-359832; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P80192-1; Sequence=Displayed; CC Name=2; CC IsoId=P80192-4; Sequence=VSP_013765; CC -!- TISSUE SPECIFICITY: Expressed in epithelial tumor cell lines of CC colonic, breast and esophageal origin. {ECO:0000269|PubMed:8477742}. CC -!- PTM: Autophosphorylation on serine and threonine residues within the CC activation loop plays a role in enzyme activation. Thr-312 is likely to CC be the main autophosphorylation site. Autophosphorylation also occurs CC on Thr-304 and Ser-308. {ECO:0000269|PubMed:11325962, CC ECO:0000269|PubMed:15610029}. CC -!- DISEASE: Note=May play a role in esophageal cancer susceptibility CC and/or development. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAI11408.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY327900; AAQ23054.1; -; mRNA. DR EMBL; BC111407; AAI11408.1; ALT_INIT; mRNA. DR EMBL; BC133706; AAI33707.1; -; mRNA. DR EMBL; AF251442; AAG44591.1; -; mRNA. DR CCDS; CCDS32112.1; -. [P80192-4] DR CCDS; CCDS61488.1; -. [P80192-1] DR PIR; S32467; JU0229. DR RefSeq; NP_001271159.1; NM_001284230.2. [P80192-1] DR RefSeq; NP_149132.2; NM_033141.3. [P80192-4] DR PDB; 3DTC; X-ray; 2.60 A; A=136-406. DR PDB; 4UY9; X-ray; 2.81 A; A/B=135-456. DR PDBsum; 3DTC; -. DR PDBsum; 4UY9; -. DR AlphaFoldDB; P80192; -. DR SMR; P80192; -. DR BioGRID; 110439; 29. DR FunCoup; P80192; 485. DR IntAct; P80192; 32. DR STRING; 9606.ENSP00000451263; -. DR BindingDB; P80192; -. DR ChEMBL; CHEMBL2872; -. DR DrugBank; DB08703; 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P80192; -. DR GuidetoPHARMACOLOGY; 2084; -. DR GlyGen; P80192; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P80192; -. DR PhosphoSitePlus; P80192; -. DR BioMuta; MAP3K9; -. DR DMDM; 116242625; -. DR CPTAC; CPTAC-860; -. DR CPTAC; CPTAC-861; -. DR jPOST; P80192; -. DR MassIVE; P80192; -. DR PaxDb; 9606-ENSP00000451263; -. DR PeptideAtlas; P80192; -. DR ProteomicsDB; 57671; -. [P80192-1] DR ProteomicsDB; 57672; -. [P80192-4] DR Antibodypedia; 75; 343 antibodies from 33 providers. DR DNASU; 4293; -. DR Ensembl; ENST00000554752.7; ENSP00000451612.2; ENSG00000006432.17. [P80192-1] DR Ensembl; ENST00000555993.6; ENSP00000451263.2; ENSG00000006432.17. [P80192-4] DR GeneID; 4293; -. DR KEGG; hsa:4293; -. DR MANE-Select; ENST00000554752.7; ENSP00000451612.2; NM_001284230.2; NP_001271159.1. DR UCSC; uc001xml.5; human. [P80192-1] DR AGR; HGNC:6861; -. DR ClinPGx; PA30607; -. DR CTD; 4293; -. DR DisGeNET; 4293; -. DR GeneCards; MAP3K9; -. DR HGNC; HGNC:6861; MAP3K9. DR HPA; ENSG00000006432; Tissue enhanced (retina). DR MIM; 600136; gene. DR OpenTargets; ENSG00000006432; -. DR VEuPathDB; HostDB:ENSG00000006432; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000158243; -. DR InParanoid; P80192; -. DR OMA; GCGPYRE; -. DR OrthoDB; 339325at2759; -. DR PAN-GO; P80192; 1 GO annotation based on evolutionary models. DR PhylomeDB; P80192; -. DR PathwayCommons; P80192; -. DR SABIO-RK; P80192; -. DR SignaLink; P80192; -. DR SIGNOR; P80192; -. DR Agora; ENSG00000006432; -. DR BioGRID-ORCS; 4293; 8 hits in 1178 CRISPR screens. DR ChiTaRS; MAP3K9; human. DR EvolutionaryTrace; P80192; -. DR GeneWiki; MAP3K9; -. DR GenomeRNAi; 4293; -. DR Pharos; P80192; Tchem. DR PRO; PR:P80192; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P80192; protein. DR Bgee; ENSG00000006432; Expressed in buccal mucosa cell and 161 other cell types or tissues. DR ExpressionAtlas; P80192; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; NAS:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd12059; SH3_MLK1-3; 1. DR CDD; cd14145; STKc_MLK1; 1. DR DisProt; DP02571; -. DR FunFam; 1.10.510.10:FF:000076; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 2.30.30.40:FF:000079; Mitogen-activated protein kinase kinase kinase; 1. DR FunFam; 3.30.200.20:FF:000085; Mitogen-activated protein kinase kinase kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR035779; MLK1-3_SH3. DR InterPro; IPR016231; MLK1-4. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR PANTHER; PTHR44329:SF35; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF14604; SH3_9; 1. DR PIRSF; PIRSF000556; MAPKKK9_11; 1. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00326; SH3; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; SH3 domain; KW Stress response; Transcription; Transcription regulation; Transferase. FT CHAIN 1..1104 FT /note="Mitogen-activated protein kinase kinase kinase 9" FT /id="PRO_0000086258" FT DOMAIN 52..116 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 144..412 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 12..47 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 430..451 FT /note="Leucine-zipper 1" FT REGION 465..486 FT /note="Leucine-zipper 2" FT REGION 532..636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 675..742 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 781..819 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 890..1038 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..22 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..575 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..739 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 785..797 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 893..910 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 929..944 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1014..1038 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 268 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 150..158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 171 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 304 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 305 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 308 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 312 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15610029" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 675 FT /note="M -> MALLAASWVVPIDIE (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_013765" FT VARIANT 246 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040698" FT VARIANT 467 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs773256562)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040699" FT VARIANT 497 FT /note="R -> Q (in dbSNP:rs56196343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040700" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34322726)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040701" FT MUTAGEN 171 FT /note="K->A: Loss of kinase activity and threonine FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 304 FT /note="T->A: Reduces threonine phosphorylation. Impairs JNK FT activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 305 FT /note="T->A: Little effect on threonine phosphorylation. FT Mildly impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 308 FT /note="S->A: Impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT MUTAGEN 312 FT /note="T->A: Loss of threonine phosphorylation. Strongly FT impairs JNK activation." FT /evidence="ECO:0000269|PubMed:15610029" FT CONFLICT 356 FT /note="A -> R (in Ref. 4)" FT /evidence="ECO:0000305" FT CONFLICT 433 FT /note="M -> T (in Ref. 1; AAQ23054)" FT /evidence="ECO:0000305" FT CONFLICT 511..535 FT /note="KLKDGNRISLPSDFQHKFTVQASPT -> AQPVLPFPHGHSRCPGGTGSSWG FT GQ (in Ref. 4)" FT /evidence="ECO:0000305" FT STRAND 143..153 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 156..163 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 166..172 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 185..197 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 206..210 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 228..232 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 239..258 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 274..278 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:3DTC" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 299..301 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 313..315 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 318..323 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 328..344 FT /evidence="ECO:0007829|PDB:3DTC" FT TURN 348..351 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 354..362 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 376..385 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:3DTC" FT HELIX 410..412 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 418..439 FT /evidence="ECO:0007829|PDB:4UY9" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:4UY9" SQ SEQUENCE 1104 AA; 121895 MW; 0F059C867FCE7276 CRC64; MEPSRALLGC LASAAAAAPP GEDGAGAGAE EEEEEEEEAA AAVGPGELGC DAPLPYWTAV FEYEAAGEDE LTLRLGDVVE VLSKDSQVSG DEGWWTGQLN QRVGIFPSNY VTPRSAFSSR CQPGGEDPSC YPPIQLLEID FAELTLEEII GIGGFGKVYR AFWIGDEVAV KAARHDPDED ISQTIENVRQ EAKLFAMLKH PNIIALRGVC LKEPNLCLVM EFARGGPLNR VLSGKRIPPD ILVNWAVQIA RGMNYLHDEA IVPIIHRDLK SSNILILQKV ENGDLSNKIL KITDFGLARE WHRTTKMSAA GTYAWMAPEV IRASMFSKGS DVWSYGVLLW ELLTGEVPFR GIDGLAVAYG VAMNKLALPI PSTCPEPFAK LMEDCWNPDP HSRPSFTNIL DQLTTIEESG FFEMPKDSFH CLQDNWKHEI QEMFDQLRAK EKELRTWEEE LTRAALQQKN QEELLRRREQ ELAEREIDIL ERELNIIIHQ LCQEKPRVKK RKGKFRKSRL KLKDGNRISL PSDFQHKFTV QASPTMDKRK SLINSRSSPP ASPTIIPRLR AIQLTPGESS KTWGRSSVVP KEEGEEEEKR APKKKGRTWG PGTLGQKELA SGDEGSPQRR EKANGLSTPS ESPHFHLGLK SLVDGYKQWS SSAPNLVKGP RSSPALPGFT SLMEMEDEDS EGPGSGESRL QHSPSQSYLC IPFPRGEDGD GPSSDGIHEE PTPVNSATST PQLTPTNSLK RGGAHHRRCE VALLGCGAVL AATGLGFDLL EAGKCQLLPL EEPEPPAREE KKRREGLFQR SSRPRRSTSP PSRKLFKKEE PMLLLGDPSA SLTLLSLSSI SECNSTRSLL RSDSDEIVVY EMPVSPVEAP PLSPCTHNPL VNVRVERFKR DPNQSLTPTH VTLTTPSQPS SHRRTPSDGA LKPETLLASR SPSSNGLSPS PGAGMLKTPS PSRDPGEFPR LPDPNVVFPP TPRRWNTQQD STLERPKTLE FLPRPRPSAN RQRLDPWWFV SPSHARSTSP ANSSSTETPS NLDSCFASSS STVEERPGLP ALLPFQAGPL PPTERTLLDL DAEGQSQDST VPLCRAELNT HRPAPYEIQQ EFWS // ID MARK4_HUMAN Reviewed; 752 AA. AC Q96L34; Q8NG37; Q96JG7; Q96SQ2; Q9BYD8; DT 28-FEB-2003, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=MAP/microtubule affinity-regulating kinase 4 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942}; DE AltName: Full=MAP/microtubule affinity-regulating kinase-like 1 {ECO:0000303|PubMed:11326310}; GN Name=MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}; GN Synonyms=KIAA1860 {ECO:0000303|PubMed:11347906}, GN MARKL1 {ECO:0000303|PubMed:11326310}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=11326310; DOI=10.1038/sj.neo.7900132; RA Kato T., Satoh S., Okabe H., Kitahara O., Ono K., Kihara C., Tanaka T., RA Tsunoda T., Yamaoka Y., Nakamura Y., Furukawa Y.; RT "Isolation of a novel human gene, MARKL1, homologous to MARK3 and its RT involvement in hepatocellular carcinogenesis."; RL Neoplasia 3:4-9(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP COFACTOR, INTERACTION WITH GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=14594945; DOI=10.1074/jbc.m304528200; RA Trinczek B., Brajenovic M., Ebneth A., Drewes G.; RT "MARK4 is a novel microtubule-associated proteins/microtubule affinity- RT regulating kinase that binds to the cellular microtubule network and to RT centrosomes."; RL J. Biol. Chem. 279:5915-5923(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND CATALYTIC RP ACTIVITY. RX PubMed=15009667; DOI=10.1046/j.1471-4159.2003.02228.x; RA Schneider A., Laage R., von Ahsen O., Fischer A., Rossner M., Scheek S., RA Grunewald S., Kuner R., Weber D., Kruger C., Klaussner B., Gotz B., RA Hiemisch H., Newrzella D., Martin-Villalba A., Bach A., Schwaninger M.; RT "Identification of regulated genes during permanent focal cerebral RT ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4."; RL J. Neurochem. 88:1114-1126(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Beghini A., Magnani I., Roversi G., Piepoli T., DiTerlizzi S., Pollo B., RA Conti A.M.F., Cowell J.K., Finocchiaro G., Larizza L.; RT "Neural progenitor-restricted isoform of MARKL1 gene is upregulated by RT 19q13 amplification in human glioblastoma."; RL Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Thyroid; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP ACTIVITY REGULATION, PHOSPHORYLATION AT THR-214, AND MUTAGENESIS OF RP THR-214. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [8] RP INTERACTION WITH YWHAQ. RX PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200; RA Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M., RA Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B., RA Bouwmeester T., Acker-Palmer A.; RT "Transgenic mouse proteomics identifies new 14-3-3-associated proteins RT involved in cytoskeletal rearrangements and cell signaling."; RL Mol. Cell. Proteomics 5:2211-2227(2006). RN [9] RP UBIQUITINATION, DEUBIQUITINATION BY USP9X, AND INTERACTION WITH USP9X. RX PubMed=18254724; DOI=10.1042/bj20080067; RA Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M., Alessi D.R.; RT "Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)- RT linked polyubiquitin chains."; RL Biochem. J. 411:249-260(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF THR-214. RX PubMed=23184942; DOI=10.1074/jbc.c112.396903; RA Li L., Guan K.L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) is a negative regulator of the mammalian target of rapamycin RT complex 1 (mTORC1)."; RL J. Biol. Chem. 288:703-708(2013). RN [12] RP FUNCTION, INTERACTION WITH ODF2, AND SUBCELLULAR LOCATION. RX PubMed=23400999; DOI=10.1083/jcb.201206013; RA Kuhns S., Schmidt K.N., Reymann J., Gilbert D.F., Neuner A., Hub B., RA Carvalho R., Wiedemann P., Zentgraf H., Erfle H., Klingmuller U., RA Boutros M., Pereira G.; RT "The microtubule affinity regulating kinase MARK4 promotes axoneme RT extension during early ciliogenesis."; RL J. Cell Biol. 200:505-522(2013). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [15] RP FUNCTION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION. RX PubMed=25123532; DOI=10.1016/j.ejcb.2014.07.004; RA Rovina D., Fontana L., Monti L., Novielli C., Panini N., Sirchia S.M., RA Erba E., Magnani I., Larizza L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics."; RL Eur. J. Cell Biol. 93:355-365(2014). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NLRP3. RX PubMed=28656979; DOI=10.1038/ncomms15986; RA Li X., Thome S., Ma X., Amrute-Nayak M., Finigan A., Kitt L., Masters L., RA James J.R., Shi Y., Meng G., Mallat Z.; RT "MARK4 regulates NLRP3 positioning and inflammasome activation through a RT microtubule-dependent mechanism."; RL Nat. Commun. 8:15986-15986(2017). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-377 AND CYS-418. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:14594945, CC PubMed:15009667, PubMed:23184942, PubMed:23666762). Phosphorylates the CC microtubule-associated protein MAPT/TAU (PubMed:14594945, CC PubMed:23666762). Also phosphorylates the microtubule-associated CC proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the CC microtubule network, causing reorganization of microtubules into CC bundles (PubMed:14594945, PubMed:25123532). Required for the initiation CC of axoneme extension during cilium assembly (PubMed:23400999). CC Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in CC vitro (PubMed:23400999). Plays a role in cell cycle progression, CC specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal CC cell survival (PubMed:15009667). Plays a role in energy homeostasis by CC regulating satiety and metabolic rate (By similarity). Promotes CC adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and CC triggers apoptosis by activating the JNK1 pathway (By similarity). CC Phosphorylates mTORC1 complex member RPTOR and acts as a negative CC regulator of the mTORC1 complex, probably due to disruption of the CC interaction between phosphorylated RPTOR and the RRAGA/RRAGC CC heterodimer which is required for mTORC1 activation (PubMed:23184942). CC Involved in NLRP3 positioning along microtubules by mediating NLRP3 CC recruitment to microtubule organizing center (MTOC) upon inflammasome CC activation (PubMed:28656979). {ECO:0000250|UniProtKB:Q8CIP4, CC ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:25123532, CC ECO:0000269|PubMed:28656979}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14594945}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-214. CC {ECO:0000269|PubMed:14976552}. CC -!- SUBUNIT: Interacts with MAPT/TAU (PubMed:23666762). Interacts with CC gamma-tubulin (PubMed:14594945). Interacts with ODF2 (PubMed:23400999). CC Interacts with USP9X (PubMed:18254724). Interacts with YWHAQ CC (PubMed:16959763). Interacts with NLRP3; promoting NLRP3 recruitment to CC microtubule organizing center (MTOC) (PubMed:28656979). CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:16959763, CC ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28656979}. CC -!- INTERACTION: CC Q96L34; Q06481-5: APLP2; NbExp=3; IntAct=EBI-302319, EBI-25646567; CC Q96L34; P05067: APP; NbExp=3; IntAct=EBI-302319, EBI-77613; CC Q96L34; P60953: CDC42; NbExp=2; IntAct=EBI-302319, EBI-81752; CC Q96L34; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-302319, EBI-9087876; CC Q96L34; Q15323: KRT31; NbExp=3; IntAct=EBI-302319, EBI-948001; CC Q96L34; P07948: LYN; NbExp=3; IntAct=EBI-302319, EBI-79452; CC Q96L34; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-302319, EBI-295417; CC Q96L34; Q8ND90: PNMA1; NbExp=2; IntAct=EBI-302319, EBI-302345; CC Q96L34; P41743: PRKCI; NbExp=2; IntAct=EBI-302319, EBI-286199; CC Q96L34; Q15831: STK11; NbExp=2; IntAct=EBI-302319, EBI-306838; CC Q96L34; P23258: TUBG1; NbExp=4; IntAct=EBI-302319, EBI-302589; CC Q96L34; Q04917: YWHAH; NbExp=7; IntAct=EBI-302319, EBI-306940; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:14594945}. Cytoplasm, CC cytoskeleton, microtubule organizing center CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:28656979}. Cytoplasm, CC cytoskeleton, cilium basal body {ECO:0000269|PubMed:23400999}. CC Cytoplasm, cytoskeleton, cilium axoneme {ECO:0000269|PubMed:23400999}. CC Cytoplasm {ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Localized CC at the tips of neurite-like processes in differentiated neuroblast CC cells. Detected in the cytoplasm and neuropil of the hippocampus. CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:23666762}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=MARK4L; CC IsoId=Q96L34-1; Sequence=Displayed; CC Name=2; Synonyms=MARKL1S, MARK4S; CC IsoId=Q96L34-2; Sequence=VSP_004946; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoform 2 is brain-specific CC (PubMed:11326310). Expressed at highest levels in brain and testis. CC Also expressed in heart, lung, liver, muscle, kidney and spleen CC (PubMed:14594945). {ECO:0000269|PubMed:11326310, CC ECO:0000269|PubMed:14594945}. CC -!- DEVELOPMENTAL STAGE: Expressed at all stages of the mitotic cell cycle. CC {ECO:0000269|PubMed:25123532}. CC -!- PTM: Ubiquitinated with 'Lys-29'- and 'Lys-33'-linked polyubiquitins CC which appear to impede LKB1-mediated phosphorylation. Deubiquitinated CC by USP9X. {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18254724}. CC -!- PTM: Phosphorylated at Thr-214 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39 CC (PubMed:14976552). Phosphorylated throughout the cell cycle CC (PubMed:25123532). {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:25123532}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB47489.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55238.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/419/MARK4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB049127; BAB39380.1; -; mRNA. DR EMBL; AB088047; BAC03375.1; -; mRNA. DR EMBL; AY057448; AAL23683.1; -; mRNA. DR EMBL; AX305105; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AX305106; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AY120867; AAM55491.1; -; mRNA. DR EMBL; AB058763; BAB47489.1; ALT_INIT; mRNA. DR EMBL; AK027619; BAB55238.1; ALT_INIT; mRNA. DR EMBL; AK075272; BAC11510.1; -; mRNA. DR CCDS; CCDS12658.1; -. [Q96L34-2] DR CCDS; CCDS56097.1; -. [Q96L34-1] DR RefSeq; NP_001186796.1; NM_001199867.2. [Q96L34-1] DR RefSeq; NP_113605.2; NM_031417.3. [Q96L34-2] DR PDB; 5ES1; X-ray; 2.80 A; A=44-370. DR PDB; 8XFL; X-ray; 3.00 A; A/B=44-370. DR PDBsum; 5ES1; -. DR PDBsum; 8XFL; -. DR AlphaFoldDB; Q96L34; -. DR SMR; Q96L34; -. DR BioGRID; 121760; 74. DR FunCoup; Q96L34; 1008. DR IntAct; Q96L34; 50. DR MINT; Q96L34; -. DR STRING; 9606.ENSP00000262891; -. DR BindingDB; Q96L34; -. DR ChEMBL; CHEMBL5754; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96L34; -. DR GuidetoPHARMACOLOGY; 2100; -. DR GlyGen; Q96L34; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96L34; -. DR PhosphoSitePlus; Q96L34; -. DR BioMuta; MARK4; -. DR DMDM; 29840797; -. DR CPTAC; non-CPTAC-5644; -. DR jPOST; Q96L34; -. DR MassIVE; Q96L34; -. DR PaxDb; 9606-ENSP00000262891; -. DR PeptideAtlas; Q96L34; -. DR ProteomicsDB; 77145; -. [Q96L34-1] DR ProteomicsDB; 77146; -. [Q96L34-2] DR Pumba; Q96L34; -. DR Antibodypedia; 31285; 373 antibodies from 36 providers. DR DNASU; 57787; -. DR Ensembl; ENST00000262891.9; ENSP00000262891.3; ENSG00000007047.17. [Q96L34-1] DR Ensembl; ENST00000300843.8; ENSP00000300843.3; ENSG00000007047.17. [Q96L34-2] DR GeneID; 57787; -. DR KEGG; hsa:57787; -. DR MANE-Select; ENST00000262891.9; ENSP00000262891.3; NM_001199867.2; NP_001186796.1. DR UCSC; uc002pba.3; human. [Q96L34-1] DR AGR; HGNC:13538; -. DR ClinPGx; PA30641; -. DR CTD; 57787; -. DR DisGeNET; 57787; -. DR GeneCards; MARK4; -. DR HGNC; HGNC:13538; MARK4. DR HPA; ENSG00000007047; Low tissue specificity. DR MalaCards; MARK4; -. DR MIM; 606495; gene. DR OpenTargets; ENSG00000007047; -. DR VEuPathDB; HostDB:ENSG00000007047; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000159555; -. DR HOGENOM; CLU_000288_157_5_1; -. DR InParanoid; Q96L34; -. DR OMA; CHLPWDK; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q96L34; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96L34; -. DR PathwayCommons; Q96L34; -. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR SignaLink; Q96L34; -. DR SIGNOR; Q96L34; -. DR Agora; ENSG00000007047; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 57787; 12 hits in 1188 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; MARK4; human. DR EvolutionaryTrace; Q96L34; -. DR GeneWiki; MARK4; -. DR GenomeRNAi; 57787; -. DR Pharos; Q96L34; Tchem. DR PRO; PR:Q96L34; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96L34; protein. DR Bgee; ENSG00000007047; Expressed in cortical plate and 200 other cell types or tissues. DR ExpressionAtlas; Q96L34; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IMP:CACAO. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:ARUK-UCL. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:ARUK-UCL. DR GO; GO:0043005; C:neuron projection; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; NAS:UniProtKB. DR GO; GO:0008093; F:cytoskeletal anchor activity; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0043130; F:ubiquitin binding; NAS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0044782; P:cilium organization; IGI:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0001578; P:microtubule bundle formation; IEP:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; IDA:ARUK-UCL. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:ARUK-UCL. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0043068; P:positive regulation of programmed cell death; NAS:UniProtKB. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; IMP:ARUK-UCL. DR CDD; cd12197; MARK4_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14407; UBA_MARK3_4; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000009; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF28; MAP_MICROTUBULE AFFINITY-REGULATING KINASE 4; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cell projection; Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Kinase; Mitosis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..752 FT /note="MAP/microtubule affinity-regulating kinase 4" FT /id="PRO_0000086307" FT DOMAIN 59..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 324..368 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 703..752 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..36 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 385..614 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 391..406 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 544..553 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 181 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 88 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 214 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8CIP4" FT MOD_RES 543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 628..752 FT /note="ADEPERIGGPEVTSCHLPWDQTETAPRLLRFPWSVKLTSSRPPEALMAALRQ FT ATAAARCRCRQPQPFLLACLHGGAGGPEPLSHFEVEVCQLPRPGLRGVLFRRVAGTALA FT FRTLVTRISNDLEL -> TLDPSKRQNSNRCVSGASLPQGSKIRSQTNLRESGDLRSQV FT AIYLGIKRKPPPGCSDSPGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11326310, FT ECO:0000303|PubMed:11347906" FT /id="VSP_004946" FT VARIANT 377 FT /note="R -> Q (in dbSNP:rs35070611)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040766" FT VARIANT 418 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs780763668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040767" FT MUTAGEN 214 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 214 FT /note="T->E: Mimicks phosphorylation state, leading to FT increased activity. Decreases mTORC1 activity." FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:23184942" FT CONFLICT 70 FT /note="F -> S (in Ref. 1; BAB39380/BAC03375)" FT /evidence="ECO:0000305" FT CONFLICT 518 FT /note="P -> L (in Ref. 6; BAB55238)" FT /evidence="ECO:0000305" FT STRAND 59..67 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 69..78 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 79..81 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 84..91 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 97..111 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 121..126 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 143..150 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 155..174 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 186..189 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 195..197 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 219..221 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 224..228 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 235..251 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 261..270 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 281..290 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 295..297 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 308..311 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 332..339 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 367..369 FT /evidence="ECO:0007829|PDB:5ES1" SQ SEQUENCE 752 AA; 82520 MW; 4B430FFD2B150E7A CRC64; MSSRTVLAPG NDRNSDTHGT LGSGRSSDKG PSWSSRSLGA RCRNSIASCP EEQPHVGNYR LLRTIGKGNF AKVKLARHIL TGREVAIKII DKTQLNPSSL QKLFREVRIM KGLNHPNIVK LFEVIETEKT LYLVMEYASA GEVFDYLVSH GRMKEKEARA KFRQIVSAVH YCHQKNIVHR DLKAENLLLD AEANIKIADF GFSNEFTLGS KLDTFCGSPP YAAPELFQGK KYDGPEVDIW SLGVILYTLV SGSLPFDGHN LKELRERVLR GKYRVPFYMS TDCESILRRF LVLNPAKRCT LEQIMKDKWI NIGYEGEELK PYTEPEEDFG DTKRIEVMVG MGYTREEIKE SLTSQKYNEV TATYLLLGRK TEEGGDRGAP GLALARVRAP SDTTNGTSSS KGTSHSKGQR SSSSTYHRQR RHSDFCGPSP APLHPKRSPT STGEAELKEE RLPGRKASCS TAGSGSRGLP PSSPMVSSAH NPNKAEIPER RKDSTSTPNN LPPSMMTRRN TYVCTERPGA ERPSLLPNGK ENSSGTPRVP PASPSSHSLA PPSGERSRLA RGSTIRSTFH GGQVRDRRAG GGGGGGVQNG PPASPTLAHE AAPLPAGRPR PTTNLFTKLT SKLTRRVADE PERIGGPEVT SCHLPWDQTE TAPRLLRFPW SVKLTSSRPP EALMAALRQA TAAARCRCRQ PQPFLLACLH GGAGGPEPLS HFEVEVCQLP RPGLRGVLFR RVAGTALAFR TLVTRISNDL EL // ID MIEN1_HUMAN Reviewed; 115 AA. AC Q9BRT3; DT 12-DEC-2006, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2001, sequence version 1. DT 28-JAN-2026, entry version 164. DE RecName: Full=Migration and invasion enhancer 1; DE AltName: Full=HBV X-transactivated gene 4 protein; DE AltName: Full=HBV XAg-transactivated protein 4; DE AltName: Full=Protein C35; DE Flags: Precursor; GN Name=MIEN1; Synonyms=C17orf37, RDX12, XTP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP ISOPRENYLATION. RX PubMed=17121940; DOI=10.1158/1535-7163.mct-06-0389; RA Evans E.E., Henn A.D., Jonason A., Paris M.J., Schiffhauer L.M., RA Borrello M.A., Smith E.S., Sahasrabudhe D.M., Zauderer M.; RT "C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast RT cancer."; RL Mol. Cancer Ther. 5:2919-2930(2006). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Liu Y., Cheng J., Lu Y., Wang G., Zhang L., Chen J., Li L.; RT "Cloning and identification of human gene 4 transactivated by hepatitis B RT virus X antigen."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [6] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND ISOPRENYLATION AT RP CYS-112. RX PubMed=19503095; DOI=10.1038/onc.2009.145; RA Dasgupta S., Wasson L.M., Rauniyar N., Prokai L., Borejdo J., RA Vishwanatha J.K.; RT "Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of RT prostate cancer cells."; RL Oncogene 28:2860-2872(2009). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP FUNCTION, SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-112, AND MUTAGENESIS RP OF CYS-112 AND 112-CYS--LEU-115. RX PubMed=21628459; DOI=10.1074/jbc.m111.254599; RA Dasgupta S., Cushman I., Kpetemey M., Casey P.J., Vishwanatha J.K.; RT "Prenylated c17orf37 induces filopodia formation to promote cell migration RT and metastasis."; RL J. Biol. Chem. 286:25935-25946(2011). RN [9] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [10] RP STRUCTURE BY NMR, AND DISULFIDE BOND. RX PubMed=23284973; DOI=10.1371/journal.pone.0052292; RA Hsu C.H., Shen T.L., Chang C.F., Chang Y.Y., Huang L.Y.; RT "Solution structure of the oncogenic MIEN1 protein reveals a thioredoxin- RT like fold with a redox-active motif."; RL PLoS ONE 7:E52292-E52292(2012). CC -!- FUNCTION: Increases cell migration by inducing filopodia formation at CC the leading edge of migrating cells. Plays a role in regulation of CC apoptosis, possibly through control of CASP3. May be involved in a CC redox-related process. {ECO:0000269|PubMed:19503095, CC ECO:0000269|PubMed:21628459}. CC -!- SUBUNIT: Interacts with GPX1. {ECO:0000250}. CC -!- INTERACTION: CC Q9BRT3; Q03989: ARID5A; NbExp=3; IntAct=EBI-6137472, EBI-948603; CC Q9BRT3; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-6137472, EBI-742054; CC Q9BRT3; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-6137472, EBI-739467; CC Q9BRT3; Q8WUI4-6: HDAC7; NbExp=5; IntAct=EBI-6137472, EBI-12094670; CC Q9BRT3; Q14774: HLX; NbExp=3; IntAct=EBI-6137472, EBI-6678255; CC Q9BRT3; P26583: HMGB2; NbExp=6; IntAct=EBI-6137472, EBI-1057009; CC Q9BRT3; P78424: POU6F2; NbExp=3; IntAct=EBI-6137472, EBI-12029004; CC Q9BRT3; Q04864: REL; NbExp=3; IntAct=EBI-6137472, EBI-307352; CC Q9BRT3; Q04864-2: REL; NbExp=3; IntAct=EBI-6137472, EBI-10829018; CC Q9BRT3; Q15654: TRIP6; NbExp=3; IntAct=EBI-6137472, EBI-742327; CC Q9BRT3; O95231: VENTX; NbExp=3; IntAct=EBI-6137472, EBI-10191303; CC Q9BRT3; A0A0C4DGF1: ZBTB32; NbExp=5; IntAct=EBI-6137472, EBI-10188476; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane; Lipid-anchor; CC Cytoplasmic side. Note=Concentrates at the leading edge of migrating CC cells. Localizes outside membrane raft regions. CC -!- TISSUE SPECIFICITY: Among normal tissues, present only in Leydig cells. CC Strongly up-regulated in breast cancers and in brain cancer distant CC metastasis (at protein level). Up-regulated in prostate cancer cells CC and in the higher grades of prostate adenocarcinoma (at protein level). CC {ECO:0000269|PubMed:17121940, ECO:0000269|PubMed:19503095}. CC -!- PTM: Isoprenylation facilitates association with the plasma membrane CC and enhances the migratory phenotype of cells by inducing increased CC filopodia formation. {ECO:0000269|PubMed:17121940, CC ECO:0000269|PubMed:19503095, ECO:0000269|PubMed:21628459}. CC -!- SIMILARITY: Belongs to the SelWTH family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/52476/MIEN1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY508814; AAR92035.1; -; mRNA. DR EMBL; AF490253; AAO85461.1; -; mRNA. DR EMBL; AC079199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC006006; AAH06006.1; -; mRNA. DR CCDS; CCDS11344.1; -. DR RefSeq; NP_001317135.1; NM_001330206.1. DR RefSeq; NP_115715.3; NM_032339.4. DR PDB; 2LJK; NMR; -; A=1-115. DR PDBsum; 2LJK; -. DR AlphaFoldDB; Q9BRT3; -. DR BMRB; Q9BRT3; -. DR SMR; Q9BRT3; -. DR BioGRID; 124025; 19. DR FunCoup; Q9BRT3; 184. DR IntAct; Q9BRT3; 15. DR STRING; 9606.ENSP00000462998; -. DR iPTMnet; Q9BRT3; -. DR PhosphoSitePlus; Q9BRT3; -. DR SwissPalm; Q9BRT3; -. DR BioMuta; MIEN1; -. DR DMDM; 74732925; -. DR jPOST; Q9BRT3; -. DR MassIVE; Q9BRT3; -. DR PaxDb; 9606-ENSP00000377778; -. DR PeptideAtlas; Q9BRT3; -. DR ProteomicsDB; 78828; -. DR Pumba; Q9BRT3; -. DR Antibodypedia; 28368; 568 antibodies from 26 providers. DR DNASU; 84299; -. DR Ensembl; ENST00000394231.8; ENSP00000377778.3; ENSG00000141741.13. DR GeneID; 84299; -. DR KEGG; hsa:84299; -. DR MANE-Select; ENST00000394231.8; ENSP00000377778.3; NM_032339.5; NP_115715.3. DR UCSC; uc002hsq.4; human. DR AGR; HGNC:28230; -. DR ClinPGx; PA134947080; -. DR CTD; 84299; -. DR DisGeNET; 84299; -. DR GeneCards; MIEN1; -. DR HGNC; HGNC:28230; MIEN1. DR HPA; ENSG00000141741; Low tissue specificity. DR MIM; 611802; gene. DR OpenTargets; ENSG00000141741; -. DR VEuPathDB; HostDB:ENSG00000141741; -. DR eggNOG; ENOG502S3GR; Eukaryota. DR GeneTree; ENSGT00390000010440; -. DR HOGENOM; CLU_068510_4_0_1; -. DR InParanoid; Q9BRT3; -. DR OMA; AAPIKDC; -. DR OrthoDB; 5962009at2759; -. DR PAN-GO; Q9BRT3; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9BRT3; -. DR PathwayCommons; Q9BRT3; -. DR SignaLink; Q9BRT3; -. DR Agora; ENSG00000141741; -. DR BioGRID-ORCS; 84299; 45 hits in 1151 CRISPR screens. DR ChiTaRS; MIEN1; human. DR EvolutionaryTrace; Q9BRT3; -. DR GenomeRNAi; 84299; -. DR Pharos; Q9BRT3; Tbio. DR PRO; PR:Q9BRT3; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BRT3; protein. DR Bgee; ENSG00000141741; Expressed in mucosa of transverse colon and 184 other cell types or tissues. DR ExpressionAtlas; Q9BRT3; baseline and differential. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0051491; P:positive regulation of filopodium assembly; IDA:UniProtKB. DR FunFam; 3.40.30.10:FF:000131; migration and invasion enhancer 1; 1. DR Gene3D; 3.40.30.10; Glutaredoxin; 1. DR InterPro; IPR011893; Selenoprotein_Rdx-typ. DR InterPro; IPR051441; SelW_related. DR InterPro; IPR036249; Thioredoxin-like_sf. DR NCBIfam; TIGR02174; CXXU_selWTH; 1. DR PANTHER; PTHR15124:SF27; MIGRATION AND INVASION ENHANCER 1; 1. DR PANTHER; PTHR15124; SELENOPROTEIN W; 1. DR Pfam; PF10262; Rdx; 1. DR SUPFAM; SSF52833; Thioredoxin-like; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Apoptosis; Cell membrane; Cytoplasm; KW Disulfide bond; Lipoprotein; Membrane; Prenylation; KW Proteomics identification; Redox-active center; Reference proteome. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..112 FT /note="Migration and invasion enhancer 1" FT /id="PRO_0000265099" FT PROPEP 113..115 FT /note="Removed in mature form" FT /evidence="ECO:0000305" FT /id="PRO_0000396008" FT REGION 1..21 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..10 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT LIPID 112 FT /note="S-geranylgeranyl cysteine" FT /evidence="ECO:0000269|PubMed:19503095, FT ECO:0000269|PubMed:21628459" FT DISULFID 30..33 FT /note="Redox-active" FT /evidence="ECO:0000269|PubMed:23284973" FT MUTAGEN 112..115 FT /note="Missing: No effect on subcellular location. Low FT protein abundance, suggesting that stability is affected." FT /evidence="ECO:0000269|PubMed:21628459" FT MUTAGEN 112 FT /note="C->S: Abolishes prenylation. Predominantly cytosolic FT with little plasma membrane-associated expression. Reduces FT cell migration by affecting filopodia formation." FT /evidence="ECO:0000269|PubMed:21628459" FT STRAND 26..29 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 31..34 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 36..46 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 51..53 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 56..59 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:2LJK" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 77..80 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 86..90 FT /evidence="ECO:0007829|PDB:2LJK" FT HELIX 91..96 FT /evidence="ECO:0007829|PDB:2LJK" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:2LJK" SQ SEQUENCE 115 AA; 12403 MW; 5D8B911C0F23DDC1 CRC64; MSGEPGQTSV APPPEEVEPG SGVRIVVEYC EPCGFEATYL ELASAVKEQY PGIEIESRLG GTGAFEIEIN GQLVFSKLEN GGFPYEKDLI EAIRRASNGE TLEKITNSRP PCVIL // ID MINK1_HUMAN Reviewed; 1332 AA. AC Q8N4C8; D3DTK3; D3DTK4; Q5U8Z0; Q9P1X1; Q9P2R8; DT 28-MAR-2003, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 209. DE RecName: Full=Misshapen-like kinase 1; DE EC=2.7.11.1; DE AltName: Full=GCK family kinase MiNK; DE AltName: Full=MAPK/ERK kinase kinase kinase 6; DE Short=MEK kinase kinase 6; DE Short=MEKKK 6; DE AltName: Full=Misshapen/NIK-related kinase; DE AltName: Full=Mitogen-activated protein kinase kinase kinase kinase 6; GN Name=MINK1 {ECO:0000312|HGNC:HGNC:17565}; GN Synonyms=B55, MAP4K6 {ECO:0000250|UniProtKB:Q9JM52}, GN MINK {ECO:0000312|EMBL:BAA94838.1}, YSK2, ZC3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:AAH34673.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=10708748; DOI=10.1016/s0014-5793(00)01247-3; RA Dan I., Watanabe N.M., Kobayashi T., Yamashita-Suzuki K., Fukagaya Y., RA Kajikawa E., Kimura W.K., Nakashima T.M., Matsumoto K., Ninomiya-Tsuji J., RA Kusumi A.; RT "Molecular cloning of MINK, a novel member of mammalian GCK family kinases, RT which is up-regulated during postnatal mouse cerebral development."; RL FEBS Lett. 469:19-23(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH NCK1, TISSUE SPECIFICITY, ALTERNATIVE SPLICING, RP AUTOPHOSPHORYLATION, AND VARIANTS ALA-771 AND LEU-775. RX PubMed=15469942; DOI=10.1074/jbc.m404497200; RA Hu Y., Leo C., Yu S., Huang B.C., Wang H., Shen M., Luo Y., RA Daniel-Issakani S., Payan D.G., Xu X.; RT "Identification and functional characterization of a novel human RT misshapen/Nck interacting kinase-related kinase, hMINK beta."; RL J. Biol. Chem. 279:54387-54397(2004). RN [3] RP ERRATUM OF PUBMED:15469942. RA Hu Y., Leo C., Yu S., Huang B.C., Wang H., Shen M., Luo Y., RA Daniel-Issakani S., Payan D.G., Xu X.; RL J. Biol. Chem. 280:5128-5128(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS ALA-771 RP AND LEU-775. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, AND INDUCTION. RX PubMed=16337592; DOI=10.1016/j.molcel.2005.10.038; RA Nicke B., Bastien J., Khanna S.J., Warne P.H., Cowling V., Cook S.J., RA Peters G., Delpuech O., Schulze A., Berns K., Mullenders J., RA Beijersbergen R.L., Bernards R., Ganesan T.S., Downward J., Hancock D.C.; RT "Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth RT arrest in human ovarian surface epithelial cells."; RL Mol. Cell 20:673-685(2005). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [9] RP FUNCTION, INTERACTION WITH RAP2A, AND SUBCELLULAR LOCATION. RX PubMed=18930710; DOI=10.1016/j.bbrc.2008.10.038; RA Nonaka H., Takei K., Umikawa M., Oshiro M., Kuninaka K., Bayarjargal M., RA Asato T., Yamashiro Y., Uechi Y., Endo S., Suzuki T., Kariya K.; RT "MINK is a Rap2 effector for phosphorylation of the postsynaptic scaffold RT protein TANC1."; RL Biochem. Biophys. Res. Commun. 377:573-578(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-641; SER-763 AND SER-782, RP VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763; SER-777; SER-778 AND RP SER-782, VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, VARIANT [LARGE SCALE RP ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-778, VARIANT [LARGE SCALE RP ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP FUNCTION. RX PubMed=21690388; DOI=10.1073/pnas.1104128108; RA Kaneko S., Chen X., Lu P., Yao X., Wright T.G., Rajurkar M., Kariya K., RA Mao J., Ip Y.T., Xu L.; RT "Smad inhibition by the Ste20 kinase Misshapen."; RL Proc. Natl. Acad. Sci. U.S.A. 108:11127-11132(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-641; SER-701; SER-754; RP SER-763 AND SER-778, VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-509, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [23] RP FUNCTION. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] THR-514; ILE-863; VAL-1010 AND VAL-1200. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [25] RP VARIANT [LARGE SCALE ANALYSIS] LEU-775, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). CC -!- FUNCTION: Serine/threonine kinase which acts as a negative regulator of CC Ras-related Rap2-mediated signal transduction to control neuronal CC structure and AMPA receptor trafficking (PubMed:10708748, CC PubMed:16337592). Required for normal synaptic density, dendrite CC complexity, as well as surface AMPA receptor expression in hippocampal CC neurons (By similarity). Can activate the JNK and MAPK14/p38 pathways CC and mediates stimulation of the stress-activated protein kinase CC MAPK14/p38 MAPK downstream of the Raf/ERK pathway. Phosphorylates TANC1 CC upon stimulation by RAP2A, MBP and SMAD1 (PubMed:18930710, CC PubMed:21690388). Has an essential function in negative selection of CC thymocytes, perhaps by coupling NCK1 to activation of JNK1 (By CC similarity). Activator of the Hippo signaling pathway which plays a CC pivotal role in organ size control and tumor suppression by restricting CC proliferation and promoting apoptosis. MAP4Ks act in parallel to and CC are partially redundant with STK3/MST2 and STK4/MST2 in the CC phosphorylation and activation of LATS1/2, and establish MAP4Ks as CC components of the expanded Hippo pathway (PubMed:26437443). CC {ECO:0000250|UniProtKB:F1LP90, ECO:0000250|UniProtKB:Q9JM52, CC ECO:0000269|PubMed:10708748, ECO:0000269|PubMed:16337592, CC ECO:0000269|PubMed:18930710, ECO:0000269|PubMed:21690388, CC ECO:0000269|PubMed:26437443}. CC -!- FUNCTION: Isoform 4 can activate the JNK pathway. Involved in the CC regulation of actin cytoskeleton reorganization, cell-matrix adhesion, CC cell-cell adhesion and cell migration. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9JM52}; CC -!- SUBUNIT: Interacts with TANC1 (By similarity). Interacts with RAP2A. CC Isoform 4 interacts with NCK1. {ECO:0000250, CC ECO:0000269|PubMed:15469942, ECO:0000269|PubMed:18930710}. CC -!- INTERACTION: CC Q8N4C8; Q00613: HSF1; NbExp=2; IntAct=EBI-2133481, EBI-719620; CC Q8N4C8; O95819: MAP4K4; NbExp=3; IntAct=EBI-2133481, EBI-2511133; CC Q8N4C8; P10114: RAP2A; NbExp=3; IntAct=EBI-2133481, EBI-602366; CC Q8N4C8; P31947: SFN; NbExp=3; IntAct=EBI-2133481, EBI-476295; CC Q8N4C8; P62258: YWHAE; NbExp=3; IntAct=EBI-2133481, EBI-356498; CC Q8N4C8-4; Q5VY09: IER5; NbExp=2; IntAct=EBI-11475194, EBI-1774000; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15469942, CC ECO:0000269|PubMed:18930710}. Postsynaptic density {ECO:0000250}. Cell CC projection, axon {ECO:0000250}. Cell projection, dendrite CC {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Golgi apparatus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=3 {ECO:0000269|PubMed:10708748}; Synonyms=MINK-alpha; CC IsoId=Q8N4C8-1; Sequence=Displayed; CC Name=1 {ECO:0000269|PubMed:10708748}; Synonyms=MiNK-1, MINK-delta; CC IsoId=Q8N4C8-2; Sequence=VSP_007059; CC Name=2 {ECO:0000269|PubMed:10708748}; Synonyms=MiNK-2, MINK-gamma; CC IsoId=Q8N4C8-3; Sequence=VSP_007059, VSP_007060; CC Name=4; Synonyms=MINK-beta; CC IsoId=Q8N4C8-4; Sequence=VSP_041871; CC Name=5; Synonyms=MINK-eta; CC IsoId=Q8N4C8-5; Sequence=VSP_041871, VSP_007059; CC -!- TISSUE SPECIFICITY: Expressed in the brain, isoform 2 is more abundant CC than isoform 1. Isoform 3 is ubiquitously expressed. Isoform 1 is most CC abundant in the skeletal muscle. Isoform 4 is ubiquitously expressed CC with relative high levels in brain, skeletal muscle, pancreas and CC testis. {ECO:0000269|PubMed:15469942}. CC -!- INDUCTION: Activated after Ras induction via a mechanism involving CC reactive oxygen species. {ECO:0000269|PubMed:16337592}. CC -!- PTM: Autophosphorylated. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB041926; BAA94838.1; -; mRNA. DR EMBL; AB035698; BAA90753.1; -; mRNA. DR EMBL; AY775058; AAV41830.1; -; mRNA. DR EMBL; AC233723; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90401.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90403.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90399.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90400.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90402.1; -; Genomic_DNA. DR EMBL; BC034673; AAH34673.1; -; mRNA. DR CCDS; CCDS45588.1; -. [Q8N4C8-1] DR CCDS; CCDS45589.1; -. [Q8N4C8-3] DR CCDS; CCDS45590.1; -. [Q8N4C8-4] DR RefSeq; NP_001020108.1; NM_001024937.4. [Q8N4C8-4] DR RefSeq; NP_001308165.1; NM_001321236.1. DR RefSeq; NP_056531.1; NM_015716.5. [Q8N4C8-2] DR RefSeq; NP_722549.2; NM_153827.4. [Q8N4C8-1] DR RefSeq; NP_733763.1; NM_170663.5. [Q8N4C8-3] DR RefSeq; XP_047292132.1; XM_047436176.1. [Q8N4C8-5] DR AlphaFoldDB; Q8N4C8; -. DR SMR; Q8N4C8; -. DR BioGRID; 119075; 184. DR FunCoup; Q8N4C8; 2105. DR IntAct; Q8N4C8; 101. DR MINT; Q8N4C8; -. DR STRING; 9606.ENSP00000347427; -. DR BindingDB; Q8N4C8; -. DR ChEMBL; CHEMBL5518; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q8N4C8; -. DR GuidetoPHARMACOLOGY; 2103; -. DR GlyCosmos; Q8N4C8; 1 site, 1 glycan. DR GlyGen; Q8N4C8; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q8N4C8; -. DR PhosphoSitePlus; Q8N4C8; -. DR SwissPalm; Q8N4C8; -. DR BioMuta; MINK1; -. DR DMDM; 296437370; -. DR jPOST; Q8N4C8; -. DR MassIVE; Q8N4C8; -. DR PaxDb; 9606-ENSP00000347427; -. DR PeptideAtlas; Q8N4C8; -. DR ProteomicsDB; 71917; -. [Q8N4C8-1] DR ProteomicsDB; 71918; -. [Q8N4C8-2] DR ProteomicsDB; 71919; -. [Q8N4C8-3] DR ProteomicsDB; 71920; -. [Q8N4C8-4] DR ProteomicsDB; 71921; -. [Q8N4C8-5] DR Pumba; Q8N4C8; -. DR Antibodypedia; 5678; 234 antibodies from 32 providers. DR DNASU; 50488; -. DR Ensembl; ENST00000347992.11; ENSP00000269296.7; ENSG00000141503.18. [Q8N4C8-3] DR Ensembl; ENST00000355280.11; ENSP00000347427.6; ENSG00000141503.18. [Q8N4C8-1] DR Ensembl; ENST00000453408.7; ENSP00000406487.3; ENSG00000141503.18. [Q8N4C8-4] DR GeneID; 50488; -. DR KEGG; hsa:50488; -. DR MANE-Select; ENST00000355280.11; ENSP00000347427.6; NM_153827.5; NP_722549.2. DR UCSC; uc010vsl.3; human. [Q8N4C8-1] DR AGR; HGNC:17565; -. DR ClinPGx; PA134910641; -. DR CTD; 50488; -. DR DisGeNET; 50488; -. DR GeneCards; MINK1; -. DR HGNC; HGNC:17565; MINK1. DR HPA; ENSG00000141503; Low tissue specificity. DR MalaCards; MINK1; -. DR MIM; 609426; gene. DR OpenTargets; ENSG00000141503; -. DR VEuPathDB; HostDB:ENSG00000141503; -. DR eggNOG; KOG0587; Eukaryota. DR GeneTree; ENSGT00950000183196; -. DR InParanoid; Q8N4C8; -. DR OMA; QIPPGDR; -. DR OrthoDB; 8957712at2759; -. DR PAN-GO; Q8N4C8; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q8N4C8; -. DR PathwayCommons; Q8N4C8; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR SignaLink; Q8N4C8; -. DR SIGNOR; Q8N4C8; -. DR Agora; ENSG00000141503; -. DR BioGRID-ORCS; 50488; 16 hits in 1191 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; MINK1; human. DR GeneWiki; MINK1; -. DR GenomeRNAi; 50488; -. DR Pharos; Q8N4C8; Tchem. DR PRO; PR:Q8N4C8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q8N4C8; protein. DR Bgee; ENSG00000141503; Expressed in CA1 field of hippocampus and 208 other cell types or tissues. DR ExpressionAtlas; Q8N4C8; baseline and differential. DR GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0007268; P:chemical synaptic transmission; ISS:UniProtKB. DR GO; GO:0048813; P:dendrite morphogenesis; ISS:UniProtKB. DR GO; GO:0007254; P:JNK cascade; TAS:ProtInc. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central. DR GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB. DR GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IMP:CACAO. DR GO; GO:2000311; P:regulation of AMPA receptor activity; ISS:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0001952; P:regulation of cell-matrix adhesion; IMP:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR CDD; cd06636; STKc_MAP4K4_6_N; 1. DR FunFam; 1.10.510.10:FF:000003; TRAF2 and NCK-interacting protein kinase isoform 4; 1. DR FunFam; 3.30.200.20:FF:000006; TRAF2 and NCK-interacting protein kinase isoform 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051700; STE20_Ser-Thr_kinase. DR PANTHER; PTHR47096; MISSHAPEN LIKE KINASE 1; 1. DR PANTHER; PTHR47096:SF1; MISSHAPEN LIKE KINASE 1; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell projection; Cytoplasm; KW Golgi apparatus; Kinase; Methylation; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..1332 FT /note="Misshapen-like kinase 1" FT /id="PRO_0000086329" FT DOMAIN 25..289 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1019..1306 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT REGION 300..347 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 363..383 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..887 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..1332 FT /note="Mediates interaction with RAP2A" FT /evidence="ECO:0000269|PubMed:18930710" FT REGION 902..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 317..333 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 371..380 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 396..466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..497 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 518..528 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 547..561 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 670..682 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 716..729 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 736..748 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 804..821 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 828..841 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 915..929 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 153 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 31..39 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 54 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 324 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 501 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT MOD_RES 509 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 641 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 701 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 754 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 763 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 777 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 778 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 782 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976" FT MOD_RES 891 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JM52" FT VAR_SEQ 581..600 FT /note="Missing (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:15469942" FT /id="VSP_041871" FT VAR_SEQ 696..732 FT /note="Missing (in isoform 1, isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10708748" FT /id="VSP_007059" FT VAR_SEQ 800 FT /note="A -> ASYKRAIGE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10708748" FT /id="VSP_007060" FT VARIANT 514 FT /note="A -> T (in dbSNP:rs56131206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040799" FT VARIANT 771 FT /note="V -> A (in dbSNP:rs11556634)" FT /evidence="ECO:0000269|PubMed:15469942, FT ECO:0000269|PubMed:15489334" FT /id="VAR_046058" FT VARIANT 775 FT /note="P -> L (in dbSNP:rs11556635)" FT /evidence="ECO:0000269|PubMed:15469942, FT ECO:0000269|PubMed:15489334, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT /id="VAR_046059" FT VARIANT 863 FT /note="V -> I (in dbSNP:rs2302319)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046060" FT VARIANT 1010 FT /note="E -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046061" FT VARIANT 1200 FT /note="I -> V" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040800" SQ SEQUENCE 1332 AA; 149822 MW; 3E3B182CDDB3659C CRC64; MGDPAPARSL DDIDLSALRD PAGIFELVEV VGNGTYGQVY KGRHVKTGQL AAIKVMDVTE DEEEEIKQEI NMLKKYSHHR NIATYYGAFI KKSPPGNDDQ LWLVMEFCGA GSVTDLVKNT KGNALKEDCI AYICREILRG LAHLHAHKVI HRDIKGQNVL LTENAEVKLV DFGVSAQLDR TVGRRNTFIG TPYWMAPEVI ACDENPDATY DYRSDIWSLG ITAIEMAEGA PPLCDMHPMR ALFLIPRNPP PRLKSKKWSK KFIDFIDTCL IKTYLSRPPT EQLLKFPFIR DQPTERQVRI QLKDHIDRSR KKRGEKEETE YEYSGSEEED DSHGEEGEPS SIMNVPGEST LRREFLRLQQ ENKSNSEALK QQQQLQQQQQ RDPEAHIKHL LHQRQRRIEE QKEERRRVEE QQRREREQRK LQEKEQQRRL EDMQALRREE ERRQAEREQE YKRKQLEEQR QSERLQRQLQ QEHAYLKSLQ QQQQQQQLQK QQQQQLLPGD RKPLYHYGRG MNPADKPAWA REVEERTRMN KQQNSPLAKS KPGSTGPEPP IPQASPGPPG PLSQTPPMQR PVEPQEGPHK SLVAHRVPLK PYAAPVPRSQ SLQDQPTRNL AAFPASHDPD PAIPAPTATP SARGAVIRQN SDPTSEGPGP SPNPPAWVRP DNEAPPKVPQ RTSSIATALN TSGAGGSRPA QAVRARPRSN SAWQIYLQRR AERGTPKPPG PPAQPPGPPN ASSNPDLRRS DPGWERSDSV LPASHGHLPQ AGSLERNRVG VSSKPDSSPV LSPGNKAKPD DHRSRPGRPA DFVLLKERTL DEAPRPPKKA MDYSSSSEEV ESSEDDEEEG EGGPAEGSRD TPGGRSDGDT DSVSTMVVHD VEEITGTQPP YGGGTMVVQR TPEEERNLLH ADSNGYTNLP DVVQPSHSPT ENSKGQSPPS KDGSGDYQSR GLVKAPGKSS FTMFVDLGIY QPGGSGDSIP ITALVGGEGT RLDQLQYDVR KGSVVNVNPT NTRAHSETPE IRKYKKRFNS EILCAALWGV NLLVGTENGL MLLDRSGQGK VYGLIGRRRF QQMDVLEGLN LLITISGKRN KLRVYYLSWL RNKILHNDPE VEKKQGWTTV GDMEGCGHYR VVKYERIKFL VIALKSSVEV YAWAPKPYHK FMAFKSFADL PHRPLLVDLT VEEGQRLKVI YGSSAGFHAV DVDSGNSYDI YIPVHIQSQI TPHAIIFLPN TDGMEMLLCY EDEGVYVNTY GRIIKDVVLQ WGEMPTSVAY ICSNQIMGWG EKAIEIRSVE TGHLDGVFMH KRAQRLKFLC ERNDKVFFAS VRSGGSSQVY FMTLNRNCIM NW // ID MK09_HUMAN Reviewed; 424 AA. AC P45984; A8K0S3; B5BU66; B5M0B4; D3DWQ8; D3DWQ9; Q15708; Q15710; Q15711; AC Q8N5C5; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 24-JAN-2006, sequence version 2. DT 28-JAN-2026, entry version 240. DE RecName: Full=Mitogen-activated protein kinase 9; DE Short=MAP kinase 9; DE Short=MAPK 9; DE EC=2.7.11.24 {ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; DE AltName: Full=JNK-55; DE AltName: Full=Stress-activated protein kinase 1a; DE Short=SAPK1a; DE AltName: Full=Stress-activated protein kinase JNK2; DE AltName: Full=c-Jun N-terminal kinase 2; GN Name=MAPK9; Synonyms=JNK2, PRKM9, SAPK1A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=7969172; DOI=10.1128/mcb.14.12.8376-8384.1994; RA Sluss H.K., Barrett T., Derijard B., Davis R.J.; RT "Signal transduction by tumor necrosis factor mediated by JNK protein RT kinases."; RL Mol. Cell. Biol. 14:8376-8384(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=8001819; DOI=10.1101/gad.8.24.2996; RA Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., RA Davis R., Karin M.; RT "JNK2 contains a specificity-determining region responsible for efficient RT c-Jun binding and phosphorylation."; RL Genes Dev. 8:2996-3007(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND CATALYTIC ACTIVITY. RC TISSUE=Brain; RX PubMed=8654373; DOI=10.1002/j.1460-2075.1996.tb00636.x; RA Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., RA Davis R.J.; RT "Selective interaction of JNK protein kinase isoforms with transcription RT factors."; RL EMBO J. 15:2760-2770(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND CATALYTIC ACTIVITY. RX PubMed=21110917; DOI=10.5483/bmbrep.2010.43.11.738; RA Wang P., Xiong Y., Ma C., Shi T., Ma D.; RT "Molecular cloning and characterization of novel human JNK2 (MAPK9) RT transcript variants that show different stimulation activities on AP-1."; RL BMB Rep. 43:738-743(2010). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-2). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-268. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-2). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP INTERACTION WITH ATF7, AND FUNCTION. RX PubMed=10376527; DOI=10.1038/sj.onc.1202723; RA De Graeve F., Bahr A., Sabapathy K.T., Hauss C., Wagner E.F., Kedinger C., RA Chatton B.; RT "Role of the ATFa/JNK2 complex in Jun activation."; RL Oncogene 18:3491-3500(1999). RN [13] RP PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND MAP2K7, RP CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=11062067; DOI=10.1042/bj3520145; RA Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P.; RT "Synergistic activation of stress-activated protein kinase 1/c-Jun N- RT terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase RT kinase 4 (MKK4) and MKK7."; RL Biochem. J. 352:145-154(2000). RN [14] RP INTERACTION WITH SPAG9. RX PubMed=15693750; DOI=10.1042/bj20041577; RA Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C., RA Okumura K., Hasegawa A., Koyama K., Suri A.; RT "Characterization of a novel human sperm-associated antigen 9 (SPAG9) RT having structural homology with c-Jun N-terminal kinase-interacting RT protein."; RL Biochem. J. 389:73-82(2005). RN [15] RP FUNCTION IN PHOSPHORYLATION OF RRN3, AND CATALYTIC ACTIVITY. RX PubMed=15805466; DOI=10.1101/gad.333205; RA Mayer C., Bierhoff H., Grummt I.; RT "The nucleolus as a stress sensor: JNK2 inactivates the transcription RT factor TIF-IA and down-regulates rRNA synthesis."; RL Genes Dev. 19:933-941(2005). RN [16] RP INTERACTION WITH NFATC4, AND CATALYTIC ACTIVITY. RX PubMed=17875713; DOI=10.1158/0008-5472.can-06-4788; RA Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y., RA Bode A.M., Dong Z.; RT "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 RT induced cell transformation."; RL Cancer Res. 67:8725-8735(2007). RN [17] RP INTERACTION WITH BCL10, AND CATALYTIC ACTIVITY. RX PubMed=17189706; DOI=10.1016/j.immuni.2006.11.008; RA Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., Lin X.; RT "The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in RT the T cell receptor-signaling pathway."; RL Immunity 26:55-66(2007). RN [18] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND CATALYTIC ACTIVITY. RX PubMed=17525747; DOI=10.1038/sj.onc.1210526; RA Oleinik N.V., Krupenko N.I., Krupenko S.A.; RT "Cooperation between JNK1 and JNK2 in activation of p53 apoptotic RT pathway."; RL Oncogene 26:7222-7230(2007). RN [19] RP REVIEW ON FUNCTION. RX PubMed=19290929; DOI=10.1111/j.1600-065x.2008.00749.x; RA Blonska M., Lin X.; RT "CARMA1-mediated NF-kappaB and JNK activation in lymphocytes."; RL Immunol. Rev. 228:199-211(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNB1. RX PubMed=19675674; DOI=10.1371/journal.pone.0006640; RA Hu D., Bi X., Fang W., Han A., Yang W.; RT "GSK3beta is involved in JNK2-mediated beta-catenin inhibition."; RL PLoS ONE 4:E6640-E6640(2009). RN [22] RP FUNCTION. RX PubMed=20595622; DOI=10.1152/ajpgi.00265.2010; RA Samak G., Suzuki T., Bhargava A., Rao R.K.; RT "c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction RT disruption in the intestinal epithelium."; RL Am. J. Physiol. 299:G572-G584(2010). RN [23] RP FUNCTION IN PHOSPHORYLATION OF YAP1, AND CATALYTIC ACTIVITY. RX PubMed=21364637; DOI=10.1038/cddis.2010.7; RA Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A., Basu S.; RT "JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis."; RL Cell Death Dis. 1:E29-E29(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22441692; DOI=10.1038/embor.2012.37; RA Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D., RA Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T., Honma K., RA Fukada Y.; RT "JNK regulates the photic response of the mammalian circadian clock."; RL EMBO Rep. 13:455-461(2012). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=34048572; DOI=10.1093/nar/gkab415; RA Yu F., Wei J., Cui X., Yu C., Ni W., Bungert J., Wu L., He C., Qian Z.; RT "Post-translational modification of RNA m6A demethylase ALKBH5 regulates RT ROS-induced DNA damage response."; RL Nucleic Acids Res. 49:5779-5797(2021). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 7-362. RX PubMed=18801372; DOI=10.1016/j.jmb.2008.08.086; RA Shaw D., Wang S.M., Villasenor A.G., Tsing S., Walter D., Browner M.F., RA Barnett J., Kuglstatter A.; RT "The crystal structure of JNK2 reveals conformational flexibility in the RT MAP kinase insert and indicates its involvement in the regulation of RT catalytic activity."; RL J. Mol. Biol. 383:885-893(2008). RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] MET-13; ASN-56; THR-246 AND ILE-366. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [29] RP INTERACTION WITH MAPKBP1. RX PubMed=28089251; DOI=10.1016/j.ajhg.2016.12.011; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RT "Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent RT nephronophthisis."; RL Am. J. Hum. Genet. 100:323-333(2017). RN [30] RP ERRATUM OF PUBMED:28089251. RX PubMed=28157543; DOI=10.1016/j.ajhg.2017.01.025; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RL Am. J. Hum. Genet. 100:372-372(2017). CC -!- FUNCTION: Serine/threonine-protein kinase involved in various processes CC such as cell proliferation, differentiation, migration, transformation CC and programmed cell death (PubMed:10376527, PubMed:15805466, CC PubMed:17525747, PubMed:19675674, PubMed:20595622, PubMed:21364637, CC PubMed:22441692, PubMed:34048572). Extracellular stimuli such as pro- CC inflammatory cytokines or physical stress stimulate the stress- CC activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling CC pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and CC MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2 (PubMed:10376527, CC PubMed:15805466, PubMed:17525747, PubMed:19675674, PubMed:20595622, CC PubMed:21364637, PubMed:22441692, PubMed:34048572). In turn, MAPK9/JNK2 CC phosphorylates a number of transcription factors, primarily components CC of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional CC activity (PubMed:10376527). In response to oxidative or ribotoxic CC stresses, inhibits rRNA synthesis by phosphorylating and inactivating CC the RNA polymerase 1-specific transcription initiation factor RRN3 CC (PubMed:15805466). Promotes stressed cell apoptosis by phosphorylating CC key regulatory factors including TP53 and YAP1 (PubMed:17525747, CC PubMed:21364637). In T-cells, MAPK8 and MAPK9 are required for CC polarized differentiation of T-helper cells into Th1 cells CC (PubMed:19290929). Upon T-cell receptor (TCR) stimulation, is activated CC by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels CC (PubMed:19290929). Plays an important role in the osmotic stress- CC induced epithelial tight-junctions disruption (PubMed:20595622). When CC activated, promotes beta-catenin/CTNNB1 degradation and inhibits the CC canonical Wnt signaling pathway (PubMed:19675674). Also participates in CC neurite growth in spiral ganglion neurons (By similarity). CC Phosphorylates the CLOCK-BMAL1 heterodimer and plays a role in the CC regulation of the circadian clock (PubMed:22441692). Phosphorylates CC POU5F1, which results in the inhibition of POU5F1's transcriptional CC activity and enhances its proteasomal degradation (By similarity). CC Phosphorylates ALKBH5 in response to reactive oxygen species (ROS), CC promoting ALKBH5 sumoylation and inactivation (PubMed:34048572). CC {ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:20595622, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000303|PubMed:19290929}. CC -!- FUNCTION: MAPK9 isoforms display different binding patterns: alpha-1 CC and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind CC to ATF2. However, there is no correlation between binding and CC phosphorylation, which is achieved at about the same efficiency by all CC isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only CC weakly to it. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000269|PubMed:7969172, CC ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, CC ECO:0000269|PubMed:8654373}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:11062067}; CC -!- ACTIVITY REGULATION: Activated by threonine and tyrosine CC phosphorylation by either of two dual specificity kinases, MAP2K4 and CC MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while MAP2K7 CC phosphorylates Tyr-183 preferentially. Inhibited by dual specificity CC phosphatases, such as DUSP1. {ECO:0000269|PubMed:11062067}. CC -!- SUBUNIT: Interacts with MECOM (By similarity). Interacts with DCLK2 (By CC similarity). Binds to at least four scaffolding proteins, MAPK8IP1/JIP- CC 1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These CC proteins also bind other components of the JNK signaling pathway (By CC similarity). Interacts with NFATC4 (PubMed:17875713). Interacts with CC ATF7; the interaction does not phosphorylate ATF7 but acts as a docking CC site for ATF7-associated partners such as JUN (PubMed:10376527). CC Interacts with BCL10 (PubMed:17189706). Interacts with CTNNB1 and GSK3B CC (PubMed:19675674). Interacts with MAPKBP1 (PubMed:28089251). Interacts CC with POU5F1; phosphorylates POU5F1 at 'Ser-355'. Found in a complex CC with SH3RF1, RAC2, MAP3K7/TAK1, MAP2K7/MKK7, MAPK8IP1/JIP1 and CC MAPK8/JNK1 (By similarity). {ECO:0000250|UniProtKB:P49186, CC ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17875713, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:28089251}. CC -!- INTERACTION: CC P45984; P49407: ARRB1; NbExp=9; IntAct=EBI-713568, EBI-743313; CC P45984; P32121: ARRB2; NbExp=9; IntAct=EBI-713568, EBI-714559; CC P45984; P15336: ATF2; NbExp=9; IntAct=EBI-713568, EBI-1170906; CC P45984; P0C671: BNIP5; NbExp=4; IntAct=EBI-713568, EBI-12806802; CC P45984; O95561: C1orf105; NbExp=5; IntAct=EBI-713568, EBI-10191951; CC P45984; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-713568, EBI-946029; CC P45984; Q8N7E2: CBLL2; NbExp=3; IntAct=EBI-713568, EBI-12196065; CC P45984; Q13042: CDC16; NbExp=3; IntAct=EBI-713568, EBI-994830; CC P45984; Q9C0F1: CEP44; NbExp=9; IntAct=EBI-713568, EBI-744115; CC P45984; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-713568, EBI-10171858; CC P45984; O43602-2: DCX; NbExp=3; IntAct=EBI-713568, EBI-14148644; CC P45984; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-713568, EBI-2340258; CC P45984; Q9Y6W6: DUSP10; NbExp=5; IntAct=EBI-713568, EBI-3443946; CC P45984; Q9BY84: DUSP16; NbExp=8; IntAct=EBI-713568, EBI-3443956; CC P45984; Q13115: DUSP4; NbExp=4; IntAct=EBI-713568, EBI-6591081; CC P45984; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-713568, EBI-2349927; CC P45984; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-713568, EBI-744099; CC P45984; P14136: GFAP; NbExp=3; IntAct=EBI-713568, EBI-744302; CC P45984; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-713568, EBI-11163335; CC P45984; O15499: GSC2; NbExp=3; IntAct=EBI-713568, EBI-19954058; CC P45984; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-713568, EBI-8638439; CC P45984; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-713568, EBI-712105; CC P45984; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-713568, EBI-11959635; CC P45984; O00505: KPNA3; NbExp=3; IntAct=EBI-713568, EBI-358297; CC P45984; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-2686809; CC P45984; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-11985629; CC P45984; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-713568, EBI-12039345; CC P45984; Q8TBB1: LNX1; NbExp=7; IntAct=EBI-713568, EBI-739832; CC P45984; Q8N448: LNX2; NbExp=3; IntAct=EBI-713568, EBI-2340947; CC P45984; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-713568, EBI-1216080; CC P45984; P45985: MAP2K4; NbExp=3; IntAct=EBI-713568, EBI-447868; CC P45984; P45983: MAPK8; NbExp=5; IntAct=EBI-713568, EBI-286483; CC P45984; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-713568, EBI-348259; CC P45984; Q86YW9: MED12L; NbExp=3; IntAct=EBI-713568, EBI-3957138; CC P45984; P50221: MEOX1; NbExp=7; IntAct=EBI-713568, EBI-2864512; CC P45984; Q5VWP3-2: MLIP; NbExp=5; IntAct=EBI-713568, EBI-12320785; CC P45984; Q5HYW2: NHSL2; NbExp=5; IntAct=EBI-713568, EBI-2859639; CC P45984; Q02548: PAX5; NbExp=3; IntAct=EBI-713568, EBI-296331; CC P45984; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-713568, EBI-10302990; CC P45984; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-713568, EBI-79165; CC P45984; P78424: POU6F2; NbExp=3; IntAct=EBI-713568, EBI-12029004; CC P45984; P37231: PPARG; NbExp=3; IntAct=EBI-713568, EBI-781384; CC P45984; Q96S79: RASL10B; NbExp=4; IntAct=EBI-713568, EBI-3919507; CC P45984; Q2I0M5: RSPO4; NbExp=3; IntAct=EBI-713568, EBI-12821217; CC P45984; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-713568, EBI-3957636; CC P45984; O00560: SDCBP; NbExp=3; IntAct=EBI-713568, EBI-727004; CC P45984; Q15427: SF3B4; NbExp=7; IntAct=EBI-713568, EBI-348469; CC P45984; P34896: SHMT1; NbExp=7; IntAct=EBI-713568, EBI-715117; CC P45984; A2RU48: SMCO3; NbExp=6; IntAct=EBI-713568, EBI-10173195; CC P45984; P40763: STAT3; NbExp=2; IntAct=EBI-713568, EBI-518675; CC P45984; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-713568, EBI-3923210; CC P45984; Q8IYF3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-742397; CC P45984; Q8IYF3-3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-11523345; CC P45984; O43379: WDR62; NbExp=6; IntAct=EBI-713568, EBI-714790; CC P45984; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-713568, EBI-14104088; CC P45984; P52744: ZNF138; NbExp=3; IntAct=EBI-713568, EBI-10746567; CC P45984; Q9BR84: ZNF559; NbExp=3; IntAct=EBI-713568, EBI-746605; CC P45984; O43257: ZNHIT1; NbExp=3; IntAct=EBI-713568, EBI-347522; CC P45984-1; P40763: STAT3; NbExp=3; IntAct=EBI-713586, EBI-518675; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19675674}. Nucleus CC {ECO:0000269|PubMed:19675674}. Note=Colocalizes with POU5F1 in the CC nucleus. {ECO:0000250|UniProtKB:Q9WTU6}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=Alpha-2; CC IsoId=P45984-1; Sequence=Displayed; CC Name=Alpha-1; CC IsoId=P45984-2; Sequence=VSP_004835; CC Name=Beta-1; CC IsoId=P45984-3; Sequence=VSP_004834, VSP_004835; CC Name=Beta-2; CC IsoId=P45984-4; Sequence=VSP_004834; CC Name=5; CC IsoId=P45984-5; Sequence=VSP_041908, VSP_041909; CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4, CC which activates the enzyme. Autophosphorylated in vitro. CC {ECO:0000269|PubMed:11062067}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/426/JNK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L31951; AAA56831.1; -; mRNA. DR EMBL; U09759; AAA74740.1; -; mRNA. DR EMBL; U34821; AAC50606.1; -; mRNA. DR EMBL; U35002; AAC50608.1; -; mRNA. DR EMBL; U35003; AAC50609.1; -; mRNA. DR EMBL; EU927388; ACH57450.1; -; mRNA. DR EMBL; CR536580; CAG38817.1; -; mRNA. DR EMBL; AK289638; BAF82327.1; -; mRNA. DR EMBL; DQ066599; AAY46156.1; -; Genomic_DNA. DR EMBL; AB451302; BAG70116.1; -; mRNA. DR EMBL; AB451355; BAG70169.1; -; mRNA. DR EMBL; AC008610; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104115; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471165; EAW53759.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53757.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53758.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53762.1; -; Genomic_DNA. DR EMBL; BC032539; AAH32539.1; -; mRNA. DR CCDS; CCDS43409.1; -. [P45984-2] DR CCDS; CCDS43410.1; -. [P45984-3] DR CCDS; CCDS4453.1; -. [P45984-1] DR CCDS; CCDS4454.1; -. [P45984-4] DR CCDS; CCDS47356.1; -. [P45984-5] DR PIR; A55480; A55480. DR PIR; S71102; S71102. DR RefSeq; NP_001128516.1; NM_001135044.2. [P45984-5] DR RefSeq; NP_001295173.1; NM_001308244.1. DR RefSeq; NP_001351536.1; NM_001364607.2. [P45984-2] DR RefSeq; NP_001351537.1; NM_001364608.2. [P45984-1] DR RefSeq; NP_001351538.1; NM_001364609.2. [P45984-4] DR RefSeq; NP_001351539.1; NM_001364610.2. [P45984-5] DR RefSeq; NP_002743.3; NM_002752.4. [P45984-1] DR RefSeq; NP_620707.1; NM_139068.3. [P45984-2] DR RefSeq; NP_620708.1; NM_139069.3. [P45984-3] DR RefSeq; NP_620709.1; NM_139070.3. [P45984-4] DR PDB; 3E7O; X-ray; 2.14 A; A/B=7-362. DR PDB; 3NPC; X-ray; 2.35 A; A/B=1-364. DR PDB; 7CML; X-ray; 2.15 A; A/B=1-364. DR PDB; 7N8T; X-ray; 1.69 A; A=10-364. DR PDB; 8ELC; X-ray; 2.07 A; A=1-424. DR PDBsum; 3E7O; -. DR PDBsum; 3NPC; -. DR PDBsum; 7CML; -. DR PDBsum; 7N8T; -. DR PDBsum; 8ELC; -. DR AlphaFoldDB; P45984; -. DR SMR; P45984; -. DR BioGRID; 111587; 180. DR DIP; DIP-270N; -. DR ELM; P45984; -. DR FunCoup; P45984; 5816. DR IntAct; P45984; 118. DR MINT; P45984; -. DR STRING; 9606.ENSP00000394560; -. DR BindingDB; P45984; -. DR ChEMBL; CHEMBL4179; -. DR DrugBank; DB12432; CC-401. DR DrugBank; DB05660; D-JNKI-1. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15624; Halicin. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB07020; N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide. DR DrugBank; DB16995; NP-51. DR DrugBank; DB01782; Pyrazolanthrone. DR DrugBank; DB11798; Tanzisertib. DR DrugCentral; P45984; -. DR GuidetoPHARMACOLOGY; 1497; -. DR GlyConnect; 1515; 1 N-Linked glycan (1 site). DR GlyCosmos; P45984; 1 site, 1 glycan. DR GlyGen; P45984; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P45984; -. DR MetOSite; P45984; -. DR PhosphoSitePlus; P45984; -. DR BioMuta; MAPK9; -. DR DMDM; 85700366; -. DR REPRODUCTION-2DPAGE; P45984; -. DR CPTAC; CPTAC-3146; -. DR CPTAC; CPTAC-893; -. DR CPTAC; CPTAC-894; -. DR jPOST; P45984; -. DR MassIVE; P45984; -. DR PaxDb; 9606-ENSP00000394560; -. DR PeptideAtlas; P45984; -. DR ProteomicsDB; 55698; -. [P45984-1] DR ProteomicsDB; 55699; -. [P45984-2] DR ProteomicsDB; 55700; -. [P45984-3] DR ProteomicsDB; 55701; -. [P45984-4] DR ProteomicsDB; 55702; -. [P45984-5] DR Pumba; P45984; -. DR Antibodypedia; 4557; 913 antibodies from 47 providers. DR DNASU; 5601; -. DR Ensembl; ENST00000343111.10; ENSP00000345524.6; ENSG00000050748.19. [P45984-3] DR Ensembl; ENST00000393360.7; ENSP00000377028.3; ENSG00000050748.19. [P45984-2] DR Ensembl; ENST00000425491.6; ENSP00000397422.2; ENSG00000050748.19. [P45984-5] DR Ensembl; ENST00000452135.7; ENSP00000394560.2; ENSG00000050748.19. [P45984-1] DR Ensembl; ENST00000455781.5; ENSP00000389338.1; ENSG00000050748.19. [P45984-4] DR GeneID; 5601; -. DR KEGG; hsa:5601; -. DR MANE-Select; ENST00000452135.7; ENSP00000394560.2; NM_002752.5; NP_002743.3. DR UCSC; uc003mls.5; human. [P45984-1] DR AGR; HGNC:6886; -. DR ClinPGx; PA30630; -. DR CTD; 5601; -. DR DisGeNET; 5601; -. DR GeneCards; MAPK9; -. DR HGNC; HGNC:6886; MAPK9. DR HPA; ENSG00000050748; Low tissue specificity. DR MIM; 602896; gene. DR OpenTargets; ENSG00000050748; -. DR VEuPathDB; HostDB:ENSG00000050748; -. DR eggNOG; KOG0665; Eukaryota. DR GeneTree; ENSGT00940000158327; -. DR HOGENOM; CLU_000288_181_1_1; -. DR InParanoid; P45984; -. DR OMA; GCRNILR; -. DR OrthoDB; 192887at2759; -. DR PAN-GO; P45984; 4 GO annotations based on evolutionary models. DR PhylomeDB; P45984; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; P45984; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR SignaLink; P45984; -. DR SIGNOR; P45984; -. DR Agora; ENSG00000050748; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5601; 8 hits in 1191 CRISPR screens. DR ChiTaRS; MAPK9; human. DR EvolutionaryTrace; P45984; -. DR GeneWiki; Mitogen-activated_protein_kinase_9; -. DR GenomeRNAi; 5601; -. DR Pharos; P45984; Tchem. DR PRO; PR:P45984; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P45984; protein. DR Bgee; ENSG00000050748; Expressed in middle temporal gyrus and 214 other cell types or tissues. DR ExpressionAtlas; P45984; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0090594; P:inflammatory response to wounding; IDA:UniProt. DR GO; GO:0007254; P:JNK cascade; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IDA:UniProt. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL. DR GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl. DR GO; GO:0061833; P:protein localization to tricellular tight junction; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR CDD; cd07850; STKc_JNK; 1. DR FunFam; 1.10.510.10:FF:000009; Mitogen-activated protein kinase; 1. DR FunFam; 3.30.200.20:FF:000210; Mitogen-activated protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR008351; MAPK_JNK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01772; JNKMAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Biological rhythms; KW Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..424 FT /note="Mitogen-activated protein kinase 9" FT /id="PRO_0000186273" FT DOMAIN 26..321 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 368..424 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 183..185 FT /note="TXY" FT COMPBIAS 388..417 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 151 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 32..40 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 55 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 183 FT /note="Phosphothreonine; by MAP2K7" FT /evidence="ECO:0000269|PubMed:11062067" FT MOD_RES 185 FT /note="Phosphotyrosine; by MAP2K4" FT /evidence="ECO:0000269|PubMed:11062067" FT VAR_SEQ 216..230 FT /note="GELVKGCVIFQGTDH -> AEMVLHKVLFPGRDY (in isoform Beta- FT 1 and isoform Beta-2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_004834" FT VAR_SEQ 230..242 FT /note="HIDQWNKVIEQLG -> RILPRDLGPAMLS (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041908" FT VAR_SEQ 243..424 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041909" FT VAR_SEQ 378..424 FT /note="DAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR -> A FT QMQQ (in isoform Alpha-1 and isoform Beta-1)" FT /evidence="ECO:0000305" FT /id="VSP_004835" FT VARIANT 13 FT /note="V -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1762231480)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042260" FT VARIANT 56 FT /note="K -> N (in a head & Neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042261" FT VARIANT 246 FT /note="A -> T (in dbSNP:rs35421153)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042262" FT VARIANT 268 FT /note="G -> A (in dbSNP:rs35693958)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_025175" FT VARIANT 366 FT /note="R -> I (in dbSNP:rs55736180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042263" FT CONFLICT 51 FT /note="N -> S (in Ref. 1; AAA56831 and 3; AAC50606/ FT AAC50608/AAC50609)" FT /evidence="ECO:0000305" FT CONFLICT 377 FT /note="S -> P (in Ref. 2; AAA74740)" FT /evidence="ECO:0000305" FT TURN 6..8 FT /evidence="ECO:0007829|PDB:7CML" FT STRAND 11..23 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 38..45 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 46..49 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 50..59 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 60..62 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 64..79 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 88..92 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 125..144 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:3NPC" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 189..191 FT /evidence="ECO:0007829|PDB:7CML" FT HELIX 194..197 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 206..220 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 230..241 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 246..250 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 254..262 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 271..274 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 285..301 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 306..308 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 312..316 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 319..322 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 327..330 FT /evidence="ECO:0007829|PDB:8ELC" FT STRAND 342..344 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 349..361 FT /evidence="ECO:0007829|PDB:7N8T" SQ SEQUENCE 424 AA; 48139 MW; 9C15DA79981290AF CRC64; MSDSKCDSQF YSVQVADSTF TVLKRYQQLK PIGSGAQGIV CAAFDTVLGI NVAVKKLSRP FQNQTHAKRA YRELVLLKCV NHKNIISLLN VFTPQKTLEE FQDVYLVMEL MDANLCQVIH MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTACTNF MMTPYVVTRY YRAPEVILGM GYKENVDIWS VGCIMGELVK GCVIFQGTDH IDQWNKVIEQ LGTPSAEFMK KLQPTVRNYV ENRPKYPGIK FEELFPDWIF PSESERDKIK TSQARDLLSK MLVIDPDKRI SVDEALRHPY ITVWYDPAEA EAPPPQIYDA QLEEREHAIE EWKELIYKEV MDWEERSKNG VVKDQPSDAA VSSNATPSQS SSINDISSMS TEQTLASDTD SSLDASTGPL EGCR // ID MK14_HUMAN Reviewed; 360 AA. AC Q16539; A6ZJ92; A8K6P4; B0LPH0; B5TY32; O60776; Q13083; Q14084; Q8TDX0; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 28-JAN-2026, entry version 267. DE RecName: Full=Mitogen-activated protein kinase 14 {ECO:0000305}; DE Short=MAP kinase 14; DE Short=MAPK 14; DE EC=2.7.11.24 {ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:15284239, ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:7493921}; DE AltName: Full=Cytokine suppressive anti-inflammatory drug-binding protein; DE Short=CSAID-binding protein; DE Short=CSBP; DE AltName: Full=MAP kinase MXI2; DE AltName: Full=MAX-interacting protein 2; DE AltName: Full=Mitogen-activated protein kinase p38 alpha; DE Short=MAP kinase p38 alpha; DE AltName: Full=Stress-activated protein kinase 2a; DE Short=SAPK2a; GN Name=MAPK14 {ECO:0000312|HGNC:HGNC:6876}; GN Synonyms=CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS CSBP1 AND CSBP2), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Peripheral blood; RX PubMed=7997261; DOI=10.1038/372739a0; RA Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., RA McNulty D., Blumenthal M.J., Heys R.J., Landvatter S.W., Strickler J.E., RA McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., RA Adams J.L., Young P.R.; RT "A protein kinase involved in the regulation of inflammatory cytokine RT biosynthesis."; RL Nature 372:739-746(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=Liver; RX PubMed=7696354; DOI=10.1016/0167-4889(95)00002-a; RA Han J., Richter B., Li Z., Kravchenko V.V., Ulevitch R.J.; RT "Molecular cloning of human p38 MAP kinase."; RL Biochim. Biophys. Acta 1265:224-227(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MXI2). RX PubMed=7479834; DOI=10.1073/pnas.92.23.10531; RA Zervos A.S., Faccio L., Gatto J.P., Kyriakis J.M., Brent R.; RT "Mxi2, a mitogen-activated protein kinase that recognizes and RT phosphorylates Max protein."; RL Proc. Natl. Acad. Sci. U.S.A. 92:10531-10534(1995). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=B-cell; RX PubMed=10727080; DOI=10.3109/10425179909033952; RA Herbison C.E., Sayer D.C., Bellgard M., Allcock R.J.N., Christiansen F.T., RA Price P.; RT "Structure and polymorphism of two stress-activated protein kinase genes RT centromeric of the MHC: SAPK2a and SAPK4."; RL DNA Seq. 10:229-243(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EXIP), AND ACTIVITY REGULATION. RC TISSUE=Renal cell carcinoma; RX PubMed=11866441; DOI=10.1006/bbrc.2002.6529; RA Sudo T., Yagasaki Y., Hama H., Watanabe N., Osada H.; RT "Exip, a new alternative splicing variant of p38 alpha, can induce an RT earlier onset of apoptosis in HeLa cells."; RL Biochem. Biophys. Res. Commun. 291:838-843(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RX PubMed=19906316; DOI=10.1186/1471-2164-10-518; RA Wang P., Yu P., Gao P., Shi T., Ma D.; RT "Discovery of novel human transcript variants by analysis of intronic RT single-block EST with polyadenylation site."; RL BMC Genomics 10:518-518(2009). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP PROTEIN SEQUENCE OF 2-10. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [15] RP PROTEIN SEQUENCE OF 174-186. RX PubMed=7923354; DOI=10.1016/0092-8674(94)90278-x; RA Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., RA Saklatvala J.; RT "Interleukin-1 activates a novel protein kinase cascade that results in the RT phosphorylation of Hsp27."; RL Cell 78:1039-1049(1994). RN [16] RP PHOSPHORYLATION AT THR-180 AND TYR-182, ACTIVITY REGULATION, AND RP SUBCELLULAR LOCATION. RX PubMed=7535770; DOI=10.1074/jbc.270.13.7420; RA Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., RA Davis R.J.; RT "Pro-inflammatory cytokines and environmental stress cause p38 mitogen- RT activated protein kinase activation by dual phosphorylation on tyrosine and RT threonine."; RL J. Biol. Chem. 270:7420-7426(1995). RN [17] RP MUTAGENESIS OF ALA-34; LYS-53; ASP-168; THR-175; THR-180 AND TYR-182, AND RP CATALYTIC ACTIVITY. RX PubMed=7493921; DOI=10.1074/jbc.270.49.29043; RA Kumar S., McLaughlin M.M., McDonnell P.C., Lee J.C., Livi G.P., Young P.R.; RT "Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a RT hog1 deletion in yeast."; RL J. Biol. Chem. 270:29043-29046(1995). RN [18] RP PHOSPHORYLATION BY MAP2K3/MKK3 AND MAP2K6/MKK6, AND ACTIVITY REGULATION. RX PubMed=8622669; DOI=10.1128/mcb.16.3.1247; RA Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B., Davis R.J.; RT "MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen- RT activated protein kinase signal transduction pathway."; RL Mol. Cell. Biol. 16:1247-1255(1996). RN [19] RP FUNCTION IN ACTIVATION OF RPS6KA5/MSK1. RX PubMed=9687510; DOI=10.1093/emboj/17.15.4426; RA Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.; RT "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly RT activated by MAPK and SAPK2/p38, and may mediate activation of CREB."; RL EMBO J. 17:4426-4441(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF ATF2; ELK1 AND MBP, AND ACTIVITY REGULATION. RX PubMed=9430721; DOI=10.1074/jbc.273.3.1741; RA Enslen H., Raingeaud J., Davis R.J.; RT "Selective activation of p38 mitogen-activated protein (MAP) kinase RT isoforms by the MAP kinase kinases MKK3 and MKK6."; RL J. Biol. Chem. 273:1741-1748(1998). RN [21] RP INTERACTION WITH RPS6KA4, FUNCTION IN PHOSPHORYLATION OF RPS6KA4, AND RP SUBCELLULAR LOCATION. RX PubMed=9792677; DOI=10.1074/jbc.273.45.29661; RA Pierrat B., Correia J.D.S., Mary J.L., Tomas-Zuber M., Lesslauer W.; RT "RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under RT dominant control of p38alpha mitogen-activated protein kinase RT (p38alphaMAPK)."; RL J. Biol. Chem. 273:29661-29671(1998). RN [22] RP INTERACTION WITH DUSP10, AND ACTIVITY REGULATION. RX PubMed=10391943; DOI=10.1074/jbc.274.28.19949; RA Tanoue T., Moriguchi T., Nishida E.; RT "Molecular cloning and characterization of a novel dual specificity RT phosphatase, MKP-5."; RL J. Biol. Chem. 274:19949-19956(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF MEF2A. RX PubMed=9858528; DOI=10.1128/mcb.19.1.21; RA Zhao M., New L., Kravchenko V.V., Kato Y., Gram H., di Padova F., RA Olson E.N., Ulevitch R.J., Han J.-D.; RT "Regulation of the MEF2 family of transcription factors by p38."; RL Mol. Cell. Biol. 19:21-30(1999). RN [24] RP FUNCTION IN PHOSPHORYLATION OF MEF2A AND MEF2C. RX PubMed=10330143; DOI=10.1128/mcb.19.6.4028; RA Yang S.-H., Galanis A., Sharrocks A.D.; RT "Targeting of p38 mitogen-activated protein kinases to MEF2 transcription RT factors."; RL Mol. Cell. Biol. 19:4028-4038(1999). RN [25] RP FUNCTION. RC TISSUE=Hepatoma; RX PubMed=10943842; DOI=10.1016/s0092-8674(00)00027-1; RA Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M.; RT "Requirement for p38alpha in erythropoietin expression: a role for stress RT kinases in erythropoiesis."; RL Cell 102:221-231(2000). RN [26] RP FUNCTION (ISOFORM MXI2), COFACTOR, AND ACTIVITY REGULATION. RX PubMed=10838079; DOI=10.1016/s0014-5793(00)01598-2; RA Sanz V., Arozarena I., Crespo P.; RT "Distinct carboxy-termini confer divergent characteristics to the mitogen- RT activated protein kinase p38alpha and its splice isoform Mxi2."; RL FEBS Lett. 474:169-174(2000). RN [27] RP INTERACTION WITH CSNK2A1 AND CSNK2B, AND FUNCTION IN ACTIVATION OF CASEIN RP KINASE II. RX PubMed=10747897; DOI=10.1074/jbc.m000312200; RA Sayed M., Kim S.O., Salh B.S., Issinger O.G., Pelech S.L.; RT "Stress-induced activation of protein kinase CK2 by direct interaction with RT p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 275:16569-16573(2000). RN [28] RP INTERACTION WITH MA2PK6/MKK6, PHOSPHORYLATION BY MAP2K6/MKK6, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-54, AND CATALYTIC ACTIVITY. RX PubMed=11010976; DOI=10.1074/jbc.m007835200; RA Alonso G., Ambrosino C., Jones M., Nebreda A.R.; RT "Differential activation of p38 mitogen-activated protein kinase isoforms RT depending on signal strength."; RL J. Biol. Chem. 275:40641-40648(2000). RN [29] RP INTERACTION WITH DUSP1, AND ACTIVITY REGULATION. RX PubMed=11278799; DOI=10.1074/jbc.m010966200; RA Slack D.N., Seternes O.M., Gabrielsen M., Keyse S.M.; RT "Distinct binding determinants for ERK2/p38alpha and JNK map kinases RT mediate catalytic activation and substrate selectivity of map kinase RT phosphatase-1."; RL J. Biol. Chem. 276:16491-16500(2001). RN [30] RP INTERACTION WITH DUSP16, AND ACTIVITY REGULATION. RX PubMed=11359773; DOI=10.1074/jbc.m101981200; RA Tanoue T., Yamamoto T., Maeda R., Nishida E.; RT "A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 RT alpha and beta MAPKs."; RL J. Biol. Chem. 276:26629-26639(2001). RN [31] RP FUNCTION AS MKNK2 KINASE. RX PubMed=11154262; DOI=10.1128/mcb.21.3.743-754.2001; RA Scheper G.C., Morrice N.A., Kleijn M., Proud C.G.; RT "The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a RT eukaryotic initiation factor 4E kinase with high levels of basal activity RT in mammalian cells."; RL Mol. Cell. Biol. 21:743-754(2001). RN [32] RP INTERACTION WITH CDC25B AND CDC25C, AND FUNCTION IN PHOSPHORYLATION OF RP CDC25B AND CDC25C. RX PubMed=11333986; DOI=10.1038/35075107; RA Bulavin D.V., Higashimoto Y., Popoff I.J., Gaarde W.A., Basrur V., RA Potapova O., Appella E., Fornace A.J. Jr.; RT "Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 RT kinase."; RL Nature 411:102-107(2001). RN [33] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, ACTIVITY REGULATION, AND RP CATALYTIC ACTIVITY. RX PubMed=11847341; DOI=10.1126/science.1067289; RA Ge B., Gram H., Di Padova F., Huang B., New L., Ulevitch R.J., Luo Y., RA Han J.; RT "MAPKK-independent activation of p38alpha mediated by TAB1-dependent RT autophosphorylation of p38alpha."; RL Science 295:1291-1294(2002). RN [34] RP MUTAGENESIS OF TYR-69; ASP-176; ASP-177; ALA-320; PHE-327 AND TRP-337. RX PubMed=15284239; DOI=10.1074/jbc.m404595200; RA Diskin R., Askari N., Capone R., Engelberg D., Livnah O.; RT "Active mutants of the human p38alpha mitogen-activated protein kinase."; RL J. Biol. Chem. 279:47040-47049(2004). RN [35] RP FUNCTION IN PHOSPHORYLATION OF S100A9. RX PubMed=15905572; DOI=10.4049/jimmunol.174.11.7257; RA Lominadze G., Rane M.J., Merchant M., Cai J., Ward R.A., McLeish K.R.; RT "Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils."; RL J. Immunol. 174:7257-7267(2005). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [37] RP PHOSPHORYLATION AT TYR-323, AND ACTIVITY REGULATION. RX PubMed=15735648; DOI=10.1038/ni1177; RA Salvador J.M., Mittelstadt P.R., Guszczynski T., Copeland T.D., RA Yamaguchi H., Appella E., Fornace A.J. Jr., Ashwell J.D.; RT "Alternative p38 activation pathway mediated by T cell receptor-proximal RT tyrosine kinases."; RL Nat. Immunol. 6:390-395(2005). RN [38] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15735649; DOI=10.1038/ni1176; RA Salvador J.M., Mittelstadt P.R., Belova G.I., Fornace A.J. Jr., RA Ashwell J.D.; RT "The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 RT activation pathway."; RL Nat. Immunol. 6:396-402(2005). RN [39] RP INTERACTION WITH SUPT20H. RX PubMed=16751104; DOI=10.1016/j.cell.2006.03.048; RA Zohn I.E., Li Y., Skolnik E.Y., Anderson K.V., Han J., Niswander L.; RT "p38 and a p38-interacting protein are critical for downregulation of E- RT cadherin during mouse gastrulation."; RL Cell 125:957-969(2006). RN [40] RP FUNCTION IN STRESS-INDUCED INTERNALIZATION OF EGFR. RX PubMed=16932740; DOI=10.1038/sj.emboj.7601297; RA Zwang Y., Yarden Y.; RT "p38 MAP kinase mediates stress-induced internalization of EGFR: RT implications for cancer chemotherapy."; RL EMBO J. 25:4195-4206(2006). RN [41] RP FUNCTION IN PHOSPHORYLATION OF SIAH2, AND ACTIVITY REGULATION. RX PubMed=17003045; DOI=10.1074/jbc.m606568200; RA Khurana A., Nakayama K., Williams S., Davis R.J., Mustelin T., Ronai Z.; RT "Regulation of the ring finger E3 ligase Siah2 by p38 MAPK."; RL J. Biol. Chem. 281:35316-35326(2006). RN [42] RP INTERACTION WITH NP60. RX PubMed=16352664; DOI=10.1242/jcs.02699; RA Fu J., Yang Z., Wei J., Han J., Gu J.; RT "Nuclear protein NP60 regulates p38 MAPK activity."; RL J. Cell Sci. 119:115-123(2006). RN [43] RP FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=17724032; DOI=10.1074/jbc.m703857200; RA Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A., Chen G.; RT "p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin- RT proteasome pathways in regulating Ras transformation and stress response."; RL J. Biol. Chem. 282:31398-31408(2007). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [45] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [46] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-16, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [50] RP FUNCTION IN INHIBITION OF AUTOPHAGY. RX PubMed=19893488; DOI=10.1038/emboj.2009.321; RA Webber J.L., Tooze S.A.; RT "Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and RT p38IP."; RL EMBO J. 29:27-40(2010). RN [51] RP FUNCTION IN PHOSPHORYLATION OF TIAR. RX PubMed=20932473; DOI=10.1016/j.molcel.2010.09.018; RA Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S., van Vugt M.A., RA Wang X., Linding R., Ong S.E., Weaver D., Carr S.A., Yaffe M.B.; RT "DNA damage activates a spatially distinct late cytoplasmic cell-cycle RT checkpoint network controlled by MK2-mediated RNA stabilization."; RL Mol. Cell 40:34-49(2010). RN [52] RP INTERACTION WITH ADAM17, AND FUNCTION IN PHOSPHORYLATION OF ADAM17. RX PubMed=20188673; DOI=10.1016/j.molcel.2010.01.034; RA Xu P., Derynck R.; RT "Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase RT regulates EGF receptor-dependent cell proliferation."; RL Mol. Cell 37:551-566(2010). RN [53] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2; THR-180 AND TYR-182, CLEAVAGE OF INITIATOR METHIONINE RP [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE RP SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP IDENTIFICATION IN A COMPLEX WITH AKAP13; PKN1; ZAK AND MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [56] RP FUNCTION (MICROBIAL INFECTION). RC TISSUE=T-cell; RX PubMed=21586573; DOI=10.1074/jbc.m111.234062; RA Peng H., Wang X., Barnes P.F., Tang H., Townsend J.C., Samten B.; RT "The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa RT inhibits T cell interferon-gamma production through the p38 mitogen- RT activated protein kinase pathway."; RL J. Biol. Chem. 286:24508-24518(2011). RN [57] RP ACETYLATION AT LYS-53 AND LYS-152 BY KAT2B/PCAF AND EP300, AND RP DEACETYLATION BY HDAC3. RX PubMed=21444723; DOI=10.1128/mcb.01205-10; RA Pillai V.B., Sundaresan N.R., Samant S.A., Wolfgeher D., Trivedi C.M., RA Gupta M.P.; RT "Acetylation of a conserved lysine residue in the ATP binding pocket of p38 RT augments its kinase activity during hypertrophy of cardiomyocytes."; RL Mol. Cell. Biol. 31:2349-2363(2011). RN [58] RP INTERACTION WITH CDK5RAP3 AND PPM1D, AND DEPHOSPHORYLATION BY PPM1D. RX PubMed=21283629; DOI=10.1371/journal.pone.0016427; RA An H., Lu X., Liu D., Yarbrough W.G.; RT "LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating RT p38 association with the wild-type p53 induced phosphatase 1 (WIP1)."; RL PLoS ONE 6:E16427-E16427(2011). RN [59] RP REVIEW ON FUNCTION. RX PubMed=12452429; DOI=10.1515/bc.2002.173; RA Shi Y., Gaestel M.; RT "In the cellular garden of forking paths: how p38 MAPKs signal for RT downstream assistance."; RL Biol. Chem. 383:1519-1536(2002). RN [60] RP REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION. RX PubMed=20626350; DOI=10.1042/bj20100323; RA Cuadrado A., Nebreda A.R.; RT "Mechanisms and functions of p38 MAPK signalling."; RL Biochem. J. 429:403-417(2010). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [64] RP SUBCELLULAR LOCATION. RX PubMed=30878395; DOI=10.1016/j.yjmcc.2019.03.005; RA Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X., RA Sun L.; RT "MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 RT after myocardial infarction."; RL J. Mol. Cell. Cardiol. 129:281-292(2019). RN [65] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35857590; DOI=10.1126/science.abl6324; RA Robinson K.S., Toh G.A., Rozario P., Chua R., Bauernfried S., Sun Z., RA Firdaus M.J., Bayat S., Nadkarni R., Poh Z.S., Tham K.C., Harapas C.R., RA Lim C.K., Chu W., Tay C.W.S., Tan K.Y., Zhao T., Bonnard C., Sobota R., RA Connolly J.E., Common J., Masters S.L., Chen K.W., Ho L., Wu B., RA Hornung V., Zhong F.L.; RT "ZAKalpha-driven ribotoxic stress response activates the human NLRP1 RT inflammasome."; RL Science 377:328-335(2022). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS). RX PubMed=8910361; DOI=10.1074/jbc.271.44.27696; RA Wilson K.P., Fitzgibbon M.J., Caron P.R., Griffith J.P., Chen W., RA McCaffrey P.G., Chambers S.P., Su M.S.-S.; RT "Crystal structure of p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 271:27696-27700(1996). RN [67] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS). RX PubMed=9095200; DOI=10.1038/nsb0497-311; RA Tong L., Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Brown M.L., RA Pargellis C.A.; RT "A highly specific inhibitor of human p38 MAP kinase binds in the ATP RT pocket."; RL Nat. Struct. Biol. 4:311-316(1997). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS). RX PubMed=9753691; DOI=10.1016/s0969-2126(98)00113-0; RA Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., RA Abdel-Meguid S., Adams J.L., Goldsmith E.J.; RT "Structural basis of inhibitor selectivity in MAP kinases."; RL Structure 6:1117-1128(1998). RN [69] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS). RX PubMed=10633045; DOI=10.1021/jm990401t; RA Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., RA Kuyper L.F.; RT "Binding mode of the 4-anilinoquinazoline class of protein kinase RT inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to RT cyclin-dependent kinase 2 and p38 kinase."; RL J. Med. Chem. 43:133-138(2000). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=11896401; DOI=10.1038/nsb770; RA Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., RA Grob P.M., Hickey E.R., Moss N., Pav S., Regan J.; RT "Inhibition of p38 MAP kinase by utilizing a novel allosteric binding RT site."; RL Nat. Struct. Biol. 9:268-272(2002). RN [71] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=12482439; DOI=10.1016/s0960-894x(02)00752-7; RA Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., RA Hop C.E., Wang Z., Strauss J.R., Cameron P.M., Nichols E.A., O'Keefe S.J., RA O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., RA Doherty J.B.; RT "Design and synthesis of potent, orally bioavailable dihydroquinazolinone RT inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 13:277-280(2003). RN [72] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14561090; DOI=10.1021/jm0301787; RA Trejo A., Arzeno H., Browner M., Chanda S., Cheng S., Comer D.D., RA Dalrymple S.A., Dunten P., Lafargue J., Lovejoy B., Freire-Moar J., Lim J., RA Mcintosh J., Miller J., Papp E., Reuter D., Roberts R., Sanpablo F., RA Saunders J., Song K., Villasenor A., Warren S.D., Welch M., Weller P., RA Whiteley P.E., Zeng L., Goldstein D.M.; RT "Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase."; RL J. Med. Chem. 46:4702-4713(2003). RN [73] {ECO:0007744|PDB:1OUK, ECO:0007744|PDB:1OUY, ECO:0007744|PDB:1OVE} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR. RX PubMed=12897767; DOI=10.1038/nsb949; RA Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., RA Pikounis V.B., O'Keefe S.J., Scapin G.; RT "Structural basis for p38alpha MAP kinase quinazolinone and pyridol- RT pyrimidine inhibitor specificity."; RL Nat. Struct. Biol. 10:764-769(2003). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14726206; DOI=10.1016/j.bbapap.2003.09.009; RA Patel S.B., Cameron P.M., Frantz-Wattley B., O'Neill E., Becker J.W., RA Scapin G.; RT "Lattice stabilization and enhanced diffraction in human p38 alpha crystals RT by protein engineering."; RL Biochim. Biophys. Acta 1696:67-73(2004). RN [75] {ECO:0007744|PDB:2BAJ, ECO:0007744|PDB:2BAK, ECO:0007744|PDB:2BAL, ECO:0007744|PDB:2BAQ} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=16342939; DOI=10.1021/bi051714v; RA Sullivan J.E., Holdgate G.A., Campbell D., Timms D., Gerhardt S., Breed J., RA Breeze A.L., Bermingham A., Pauptit R.A., Norman R.A., Embrey K.J., RA Read J., VanScyoc W.S., Ward W.H.; RT "Prevention of MKK6-dependent activation by binding to p38alpha MAP RT kinase."; RL Biochemistry 44:16475-16490(2005). RN [76] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-359, AND ACTIVITY REGULATION. RX PubMed=15837335; DOI=10.1016/j.bmcl.2005.02.010; RA Tamayo N., Liao L., Goldberg M., Powers D., Tudor Y.Y., Yu V., Wong L.M., RA Henkle B., Middleton S., Syed R., Harvey T., Jang G., Hungate R., RA Dominguez C.; RT "Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 15:2409-2413(2005). RN [77] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=16169718; DOI=10.1016/j.bmcl.2005.08.038; RA Michelotti E.L., Moffett K.K., Nguyen D., Kelly M.J., Shetty R., Chai X., RA Northrop K., Namboodiri V., Campbell B., Flynn G.A., Fujimoto T., RA Hollinger F.P., Bukhtiyarova M., Springman E.B., Karpusas M.; RT "Two classes of p38alpha MAP kinase inhibitors having a common RT diphenylether core but exhibiting divergent binding modes."; RL Bioorg. Med. Chem. Lett. 15:5274-5279(2005). RN [78] {ECO:0007744|PDB:1W7H, ECO:0007744|PDB:1WBO} RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=15658854; DOI=10.1021/jm0495778; RA Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., RA Jhoti H.; RT "Fragment-based lead discovery using X-ray crystallography."; RL J. Med. Chem. 48:403-413(2005). RN [79] RP X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF 2-359 IN COMPLEX WITH MAPKAPK2. RX PubMed=17255097; DOI=10.1074/jbc.m611165200; RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RT "Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer."; RL J. Biol. Chem. 282:9733-9739(2007). RN [80] RP ERRATUM OF PUBMED:17255097. RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RL J. Biol. Chem. 282:14684-14684(2007). RN [81] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-51; ARG-322 AND GLY-343. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. MAPK14 is one of the CC four p38 MAPKs which play an important role in the cascades of cellular CC responses evoked by extracellular stimuli such as pro-inflammatory CC cytokines or physical stress leading to direct activation of CC transcription factors. Accordingly, p38 MAPKs phosphorylate a broad CC range of proteins and it has been estimated that they may have CC approximately 200 to 300 substrates each. Some of the targets are CC downstream kinases which are activated through phosphorylation and CC further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 CC can directly phosphorylate and activate transcription factors such as CC CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but CC can also phosphorylate histone H3 and the nucleosomal protein HMGN1 CC (PubMed:9687510, PubMed:9792677). RPS6KA5/MSK1 and RPS6KA4/MSK2 play CC important roles in the rapid induction of immediate-early genes in CC response to stress or mitogenic stimuli, either by inducing chromatin CC remodeling or by recruiting the transcription machinery CC (PubMed:9687510, PubMed:9792677). On the other hand, two other kinase CC targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of CC gene expression mostly at the post-transcriptional level, by CC phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating CC EEF2K, which is important for the elongation of mRNA during CC translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by CC p38 MAPKs, regulate protein synthesis by phosphorylating the initiation CC factor EIF4E2 (PubMed:11154262). MAPK14 also interacts with casein CC kinase II, leading to its activation through autophosphorylation and CC further phosphorylation of TP53/p53 (PubMed:10747897). In the CC cytoplasm, the p38 MAPK pathway is an important regulator of protein CC turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis CC whose proteasome-mediated degradation is regulated by p38 MAPK CC phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin CC ligase SIAH2, regulating its activity towards EGLN3 (PubMed:17003045). CC MAPK14 may also inhibit the lysosomal degradation pathway of autophagy CC by interfering with the intracellular trafficking of the transmembrane CC protein ATG9 (PubMed:19893488). Another function of MAPK14 is to CC regulate the endocytosis of membrane receptors by different mechanisms CC that impinge on the small GTPase RAB5A. In addition, clathrin-mediated CC EGFR internalization induced by inflammatory cytokines and UV CC irradiation depends on MAPK14-mediated phosphorylation of EGFR itself CC as well as of RAB5A effectors (PubMed:16932740). Ectodomain shedding of CC transmembrane proteins is regulated by p38 MAPKs as well. In response CC to inflammatory stimuli, p38 MAPKs phosphorylate the membrane- CC associated metalloprotease ADAM17 (PubMed:20188673). Such CC phosphorylation is required for ADAM17-mediated ectodomain shedding of CC TGF-alpha family ligands, which results in the activation of EGFR CC signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. CC FGFR1 can be translocated from the extracellular space into the cytosol CC and nucleus of target cells, and regulates processes such as rRNA CC synthesis and cell growth. FGFR1 translocation requires p38 MAPK CC activation. In the nucleus, many transcription factors are CC phosphorylated and activated by p38 MAPKs in response to different CC stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, CC DDIT3, TP53/p53 and MEF2C and MEF2A (PubMed:10330143, PubMed:9430721, CC PubMed:9858528). The p38 MAPKs are emerging as important modulators of CC gene expression by regulating chromatin modifiers and remodelers. The CC promoters of several genes involved in the inflammatory response, such CC as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of CC histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated CC myeloid cells. This phosphorylation enhances the accessibility of the CC cryptic NF-kappa-B-binding sites marking promoters for increased NF- CC kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required CC for binding to 14-3-3 proteins and leads to initiation of a G2 delay CC after ultraviolet radiation (PubMed:11333986). Phosphorylates TIAR CC following DNA damage, releasing TIAR from GADD45A mRNA and preventing CC mRNA degradation (PubMed:20932473). The p38 MAPKs may also have kinase- CC independent roles, which are thought to be due to the binding to CC targets in the absence of phosphorylation. Protein O-Glc-N-acylation CC catalyzed by the OGT is regulated by MAPK14, and, although OGT does not CC seem to be phosphorylated by MAPK14, their interaction increases upon CC MAPK14 activation induced by glucose deprivation. This interaction may CC regulate OGT activity by recruiting it to specific targets such as CC neurofilament H, stimulating its O-Glc-N-acylation. Required in mid- CC fetal development for the growth of embryo-derived blood vessels in the CC labyrinth layer of the placenta. Also plays an essential role in CC developmental and stress-induced erythropoiesis, through regulation of CC EPO gene expression (PubMed:10943842). Isoform MXI2 activation is CC stimulated by mitogens and oxidative stress and only poorly CC phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early CC onset of apoptosis. Phosphorylates S100A9 at 'Thr-113' CC (PubMed:15905572). Phosphorylates NLRP1 downstream of MAP3K20/ZAK in CC response to UV-B irradiation and ribosome collisions, promoting CC activation of the NLRP1 inflammasome and pyroptosis (PubMed:35857590). CC {ECO:0000269|PubMed:10330143, ECO:0000269|PubMed:10747897, CC ECO:0000269|PubMed:10943842, ECO:0000269|PubMed:11154262, CC ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:15905572, CC ECO:0000269|PubMed:16932740, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:19893488, CC ECO:0000269|PubMed:20188673, ECO:0000269|PubMed:20932473, CC ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:9430721, CC ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9792677, CC ECO:0000269|PubMed:9858528}. CC -!- FUNCTION: (Microbial infection) Activated by phosphorylation by CC M.tuberculosis EsxA in T-cells leading to inhibition of IFN-gamma CC production; phosphorylation is apparent within 15 minutes and is CC inhibited by kinase-specific inhibitors SB203580 and siRNA CC (PubMed:21586573). {ECO:0000269|PubMed:21586573}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10838079}; CC -!- ACTIVITY REGULATION: Activated by cell stresses such as DNA damage, CC heat shock, osmotic shock, anisomycin and sodium arsenite, as well as CC pro-inflammatory stimuli such as bacterial lipopolysaccharide (LPS) and CC interleukin-1. Activation occurs through dual phosphorylation of Thr- CC 180 and Tyr-182 by either of two dual specificity kinases, MAP2K3/MKK3 CC or MAP2K6/MKK6, and potentially also MAP2K4/MKK4, as well as by TAB1- CC mediated autophosphorylation. MAPK14 phosphorylated on both Thr-180 and CC Tyr-182 is 10-20-fold more active than MAPK14 phosphorylated only on CC Thr-180, whereas MAPK14 phosphorylated on Tyr-182 alone is inactive. CC whereas Thr-180 is necessary for catalysis, Tyr-182 may be required for CC auto-activation and substrate recognition. Phosphorylated at Tyr-323 by CC ZAP70 in an alternative activation pathway in response to TCR signaling CC in T-cells. This alternative pathway is inhibited by GADD45A. Inhibited CC by dual specificity phosphatases, such as DUSP1, DUSP10, and DUSP16. CC Specifically inhibited by the binding of pyridinyl-imidazole compounds, CC which are cytokine-suppressive anti-inflammatory drugs (CSAID). Isoform CC Mxi2 is 100-fold less sensitive to these agents than the other isoforms CC and is not inhibited by DUSP1. Isoform Exip is not activated by MAP2K6. CC SB203580 is an inhibitor of MAPK14. {ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10838079, ECO:0000269|PubMed:11278799, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:11866441, ECO:0000269|PubMed:11896401, CC ECO:0000269|PubMed:12482439, ECO:0000269|PubMed:14561090, CC ECO:0000269|PubMed:14726206, ECO:0000269|PubMed:15735648, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:15837335, CC ECO:0000269|PubMed:16169718, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:7535770, ECO:0000269|PubMed:8622669, CC ECO:0000269|PubMed:9430721}. CC -!- SUBUNIT: Component of a signaling complex containing at least AKAP13, CC PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13 interacts CC directly with PKN1, which in turn recruits MAPK14, MAP2K3 and ZAK CC (PubMed:21224381). Binds to a kinase interaction motif within the CC protein tyrosine phosphatase, PTPRR (By similarity). This interaction CC retains MAPK14 in the cytoplasm and prevents nuclear accumulation (By CC similarity). Interacts with SPAG9 and GADD45A (By similarity). CC Interacts with CDC25B, CDC25C, DUSP1, DUSP10, DUSP16, NP60, SUPT20H and CC TAB1. Interacts with casein kinase II subunits CSNK2A1 and CSNK2B. CC Interacts with PPM1D. Interacts with CDK5RAP3; recruits PPM1D to MAPK14 CC and may regulate its dephosphorylation (PubMed:21283629). Interacts CC with DUSP2; this interaction does not lead to catalytic activation of CC DUSP2 and dephosphorylation of MAPK14 (By similarity). CC {ECO:0000250|UniProtKB:P47811, ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10747897, ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:11278799, ECO:0000269|PubMed:11333986, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:12897767, ECO:0000269|PubMed:15658854, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:16342939, CC ECO:0000269|PubMed:16352664, ECO:0000269|PubMed:16751104, CC ECO:0000269|PubMed:17255097, ECO:0000269|PubMed:20188673, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21283629, CC ECO:0000269|PubMed:9792677}. CC -!- INTERACTION: CC Q16539; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-73946, EBI-9087876; CC Q16539; P28562: DUSP1; NbExp=4; IntAct=EBI-73946, EBI-975493; CC Q16539; Q9BY84: DUSP16; NbExp=4; IntAct=EBI-73946, EBI-3443956; CC Q16539; Q16829: DUSP7; NbExp=2; IntAct=EBI-73946, EBI-1265847; CC Q16539; Q99956: DUSP9; NbExp=6; IntAct=EBI-73946, EBI-3906678; CC Q16539; P68104: EEF1A1; NbExp=3; IntAct=EBI-73946, EBI-352162; CC Q16539; Q969H0: FBXW7; NbExp=5; IntAct=EBI-73946, EBI-359574; CC Q16539; P46734: MAP2K3; NbExp=7; IntAct=EBI-73946, EBI-602462; CC Q16539; P52564: MAP2K6; NbExp=3; IntAct=EBI-73946, EBI-448135; CC Q16539; P27361: MAPK3; NbExp=5; IntAct=EBI-73946, EBI-73995; CC Q16539; P49137: MAPKAPK2; NbExp=16; IntAct=EBI-73946, EBI-993299; CC Q16539; Q16644: MAPKAPK3; NbExp=16; IntAct=EBI-73946, EBI-1384657; CC Q16539; Q6PJG2: MIDEAS; NbExp=3; IntAct=EBI-73946, EBI-2795569; CC Q16539; Q9BUB5: MKNK1; NbExp=7; IntAct=EBI-73946, EBI-73837; CC Q16539; Q9HBH9: MKNK2; NbExp=5; IntAct=EBI-73946, EBI-2864341; CC Q16539; P35813: PPM1A; NbExp=2; IntAct=EBI-73946, EBI-989143; CC Q16539; Q15256: PTPRR; NbExp=4; IntAct=EBI-73946, EBI-2265659; CC Q16539; P06400: RB1; NbExp=4; IntAct=EBI-73946, EBI-491274; CC Q16539; O75676: RPS6KA4; NbExp=10; IntAct=EBI-73946, EBI-73933; CC Q16539; O75582: RPS6KA5; NbExp=4; IntAct=EBI-73946, EBI-73869; CC Q16539; Q8NEM7: SUPT20H; NbExp=5; IntAct=EBI-73946, EBI-946984; CC Q16539; Q15750: TAB1; NbExp=4; IntAct=EBI-73946, EBI-358643; CC Q16539; Q92574: TSC1; NbExp=2; IntAct=EBI-73946, EBI-1047085; CC Q16539; Q07352: ZFP36L1; NbExp=2; IntAct=EBI-73946, EBI-721823; CC Q16539; O43257: ZNHIT1; NbExp=7; IntAct=EBI-73946, EBI-347522; CC Q16539-1; P22736-1: NR4A1; NbExp=5; IntAct=EBI-15834191, EBI-16085263; CC Q16539-1; Q15256-1: PTPRR; NbExp=6; IntAct=EBI-15834191, EBI-16067395; CC Q16539-1; P54830-1: Ptpn5; Xeno; NbExp=6; IntAct=EBI-15834191, EBI-16067443; CC Q16539-3; P28482: MAPK1; NbExp=5; IntAct=EBI-6932370, EBI-959949; CC Q16539-3; P49790: NUP153; NbExp=2; IntAct=EBI-6932370, EBI-286779; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:7535770}. Nucleus CC {ECO:0000269|PubMed:30878395, ECO:0000269|PubMed:7535770}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=CSBP2; CC IsoId=Q16539-1; Sequence=Displayed; CC Name=CSBP1; CC IsoId=Q16539-2; Sequence=VSP_004842; CC Name=Mxi2; CC IsoId=Q16539-3; Sequence=VSP_004844; CC Name=Exip; Synonyms=Exon skip; CC IsoId=Q16539-4; Sequence=VSP_004843, VSP_004845; CC Name=5; CC IsoId=Q16539-5; Sequence=VSP_057194; CC -!- TISSUE SPECIFICITY: Brain, heart, placenta, pancreas and skeletal CC muscle. Expressed to a lesser extent in lung, liver and kidney. CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by the MAP2Ks CC MAP2K3/MKK3, MAP2K4/MKK4 and MAP2K6/MKK6 in response to inflammatory CC citokines, environmental stress or growth factors, which activates the CC enzyme. Dual phosphorylation can also be mediated by TAB1-mediated CC autophosphorylation. TCR engagement in T-cells also leads to Tyr-323 CC phosphorylation by ZAP70. Dephosphorylated and inactivated by DUPS1, CC DUSP10 and DUSP16. PPM1D also mediates dephosphorylation and CC inactivation of MAPK14 (PubMed:21283629). {ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:15735648, ECO:0000269|PubMed:17724032, CC ECO:0000269|PubMed:21283629, ECO:0000269|PubMed:7535770, CC ECO:0000269|PubMed:8622669}. CC -!- PTM: Acetylated at Lys-53 and Lys-152 by KAT2B and EP300. Acetylation CC at Lys-53 increases the affinity for ATP and enhances kinase activity. CC Lys-53 and Lys-152 are deacetylated by HDAC3. CC {ECO:0000269|PubMed:21444723}. CC -!- PTM: Ubiquitinated. Ubiquitination leads to degradation by the CC proteasome pathway. {ECO:0000269|PubMed:17724032}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=P38 mitogen-activated protein CC kinases entry; CC URL="https://en.wikipedia.org/wiki/P38_mitogen-activated_protein_kinases"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41292/MAPK14"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L35263; AAA57455.1; -; mRNA. DR EMBL; L35264; AAA57456.1; -; mRNA. DR EMBL; L35253; AAA74301.1; -; mRNA. DR EMBL; U19775; AAC50329.1; -; mRNA. DR EMBL; AF100544; AAF36770.1; -; mRNA. DR EMBL; AB074150; BAB85654.1; -; mRNA. DR EMBL; FJ032367; ACI00233.1; -; mRNA. DR EMBL; AK291709; BAF84398.1; -; mRNA. DR EMBL; BT006933; AAP35579.1; -; mRNA. DR EMBL; CR536505; CAG38743.1; -; mRNA. DR EMBL; EU332860; ABY87549.1; -; Genomic_DNA. DR EMBL; Z95152; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03869.1; -; Genomic_DNA. DR EMBL; BC000092; AAH00092.1; -; mRNA. DR EMBL; BC031574; AAH31574.1; -; mRNA. DR CCDS; CCDS4815.1; -. [Q16539-2] DR CCDS; CCDS4816.1; -. [Q16539-1] DR CCDS; CCDS4817.1; -. [Q16539-4] DR PIR; S53536; S53536. DR RefSeq; NP_001306.1; NM_001315.3. [Q16539-2] DR RefSeq; NP_620581.1; NM_139012.3. [Q16539-1] DR RefSeq; NP_620582.1; NM_139013.3. [Q16539-3] DR RefSeq; NP_620583.1; NM_139014.3. [Q16539-4] DR PDB; 1A9U; X-ray; 2.50 A; A=1-360. DR PDB; 1BL6; X-ray; 2.50 A; A=1-360. DR PDB; 1BL7; X-ray; 2.50 A; A=1-360. DR PDB; 1BMK; X-ray; 2.40 A; A=1-360. DR PDB; 1DI9; X-ray; 2.60 A; A=1-360. DR PDB; 1IAN; X-ray; 2.00 A; A=2-360. DR PDB; 1KV1; X-ray; 2.50 A; A=1-360. DR PDB; 1KV2; X-ray; 2.80 A; A=1-360. DR PDB; 1M7Q; X-ray; 2.40 A; A=1-360. DR PDB; 1OUK; X-ray; 2.50 A; A=1-360. DR PDB; 1OUY; X-ray; 2.50 A; A=1-360. DR PDB; 1OVE; X-ray; 2.10 A; A=1-360. DR PDB; 1OZ1; X-ray; 2.10 A; A=1-360. DR PDB; 1R39; X-ray; 2.30 A; A=1-360. DR PDB; 1R3C; X-ray; 2.00 A; A=1-360. DR PDB; 1W7H; X-ray; 2.21 A; A=2-360. DR PDB; 1W82; X-ray; 2.20 A; A=2-360. DR PDB; 1W83; X-ray; 2.50 A; A=2-360. DR PDB; 1W84; X-ray; 2.20 A; A=2-360. DR PDB; 1WBN; X-ray; 2.40 A; A=2-360. DR PDB; 1WBO; X-ray; 2.16 A; A=2-360. DR PDB; 1WBS; X-ray; 1.80 A; A=2-360. DR PDB; 1WBT; X-ray; 2.00 A; A=2-360. DR PDB; 1WBV; X-ray; 2.00 A; A=2-360. DR PDB; 1WBW; X-ray; 2.41 A; A=2-360. DR PDB; 1WFC; X-ray; 2.30 A; A=1-360. DR PDB; 1YQJ; X-ray; 2.00 A; A=2-360. DR PDB; 1ZYJ; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZ2; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZL; X-ray; 2.00 A; A=4-354. DR PDB; 2BAJ; X-ray; 2.25 A; A=2-360. DR PDB; 2BAK; X-ray; 2.20 A; A=2-360. DR PDB; 2BAL; X-ray; 2.10 A; A=2-360. DR PDB; 2BAQ; X-ray; 2.80 A; A=2-360. DR PDB; 2FSL; X-ray; 1.70 A; X=2-360. DR PDB; 2FSM; X-ray; 1.86 A; X=2-360. DR PDB; 2FSO; X-ray; 1.83 A; X=2-360. DR PDB; 2FST; X-ray; 1.45 A; X=2-360. DR PDB; 2GFS; X-ray; 1.75 A; A=2-360. DR PDB; 2I0H; X-ray; 2.00 A; A=1-360. DR PDB; 2LGC; NMR; -; A=2-354. DR PDB; 2NPQ; X-ray; 1.80 A; A=2-360. DR PDB; 2OKR; X-ray; 2.00 A; A/D=2-360. DR PDB; 2ONL; X-ray; 4.00 A; A/B=2-360. DR PDB; 2QD9; X-ray; 1.70 A; A=2-360. DR PDB; 2RG5; X-ray; 2.40 A; A=2-360. DR PDB; 2RG6; X-ray; 1.72 A; A=2-360. DR PDB; 2Y8O; X-ray; 1.95 A; A=1-360. DR PDB; 2YIS; X-ray; 2.00 A; A=2-360. DR PDB; 2YIW; X-ray; 2.00 A; A=2-360. DR PDB; 2YIX; X-ray; 2.30 A; A=4-354. DR PDB; 2ZAZ; X-ray; 1.80 A; A=1-360. DR PDB; 2ZB0; X-ray; 2.10 A; A=1-360. DR PDB; 2ZB1; X-ray; 2.50 A; A=1-360. DR PDB; 3BV2; X-ray; 2.40 A; A=2-360. DR PDB; 3BV3; X-ray; 2.59 A; A=2-360. DR PDB; 3BX5; X-ray; 2.40 A; A=2-360. DR PDB; 3C5U; X-ray; 2.80 A; A=2-360. DR PDB; 3CTQ; X-ray; 1.95 A; A=5-352. DR PDB; 3D7Z; X-ray; 2.10 A; A=1-360. DR PDB; 3D83; X-ray; 1.90 A; A=1-360. DR PDB; 3DS6; X-ray; 2.90 A; A/B/C/D=1-360. DR PDB; 3DT1; X-ray; 2.80 A; A=1-360. DR PDB; 3E92; X-ray; 2.00 A; A=1-360. DR PDB; 3E93; X-ray; 2.00 A; A=1-360. DR PDB; 3FC1; X-ray; 2.40 A; X=1-360. DR PDB; 3FI4; X-ray; 2.20 A; A=1-360. DR PDB; 3FKL; X-ray; 2.00 A; A=1-360. DR PDB; 3FKN; X-ray; 2.00 A; A=1-360. DR PDB; 3FKO; X-ray; 2.00 A; A=1-360. DR PDB; 3FL4; X-ray; 1.80 A; A=1-360. DR PDB; 3FLN; X-ray; 1.90 A; C=1-360. DR PDB; 3FLQ; X-ray; 1.90 A; A=1-360. DR PDB; 3FLS; X-ray; 2.30 A; A=1-360. DR PDB; 3FLW; X-ray; 2.10 A; A=1-360. DR PDB; 3FLY; X-ray; 1.80 A; A=1-360. DR PDB; 3FLZ; X-ray; 2.23 A; A=1-360. DR PDB; 3FMH; X-ray; 1.90 A; A=1-360. DR PDB; 3FMJ; X-ray; 2.00 A; A=1-360. DR PDB; 3FMK; X-ray; 1.70 A; A=1-360. DR PDB; 3FML; X-ray; 2.10 A; A=1-360. DR PDB; 3FMM; X-ray; 2.00 A; A=1-360. DR PDB; 3FMN; X-ray; 1.90 A; A=1-360. DR PDB; 3FSF; X-ray; 2.10 A; A=1-360. DR PDB; 3FSK; X-ray; 2.00 A; A=1-360. DR PDB; 3GC7; X-ray; 1.80 A; A=1-360. DR PDB; 3GCP; X-ray; 2.25 A; A=2-360. DR PDB; 3GCQ; X-ray; 2.00 A; A=2-360. DR PDB; 3GCS; X-ray; 2.10 A; A=2-360. DR PDB; 3GCU; X-ray; 2.10 A; A/B=2-360. DR PDB; 3GCV; X-ray; 2.30 A; A=2-360. DR PDB; 3GFE; X-ray; 2.10 A; A=1-360. DR PDB; 3GI3; X-ray; 2.40 A; A=1-360. DR PDB; 3HA8; X-ray; 2.48 A; A=1-360. DR PDB; 3HEC; X-ray; 2.50 A; A=5-352. DR PDB; 3HEG; X-ray; 2.20 A; A=5-352. DR PDB; 3HL7; X-ray; 1.88 A; A=1-360. DR PDB; 3HLL; X-ray; 1.95 A; A=1-360. DR PDB; 3HP2; X-ray; 2.15 A; A=1-360. DR PDB; 3HP5; X-ray; 2.30 A; A=1-360. DR PDB; 3HRB; X-ray; 2.20 A; A=2-360. DR PDB; 3HUB; X-ray; 2.25 A; A=2-360. DR PDB; 3HUC; X-ray; 1.80 A; A=2-360. DR PDB; 3HV3; X-ray; 2.00 A; A=2-360. DR PDB; 3HV4; X-ray; 2.60 A; A/B=2-360. DR PDB; 3HV5; X-ray; 2.25 A; A/B=2-360. DR PDB; 3HV6; X-ray; 1.95 A; A=2-360. DR PDB; 3HV7; X-ray; 2.40 A; A=2-360. DR PDB; 3HVC; X-ray; 2.10 A; A=1-360. DR PDB; 3IPH; X-ray; 2.10 A; A=1-360. DR PDB; 3ITZ; X-ray; 2.25 A; A=1-360. DR PDB; 3IW5; X-ray; 2.50 A; A=2-360. DR PDB; 3IW6; X-ray; 2.10 A; A=2-360. DR PDB; 3IW7; X-ray; 2.40 A; A=2-360. DR PDB; 3IW8; X-ray; 2.00 A; A=2-360. DR PDB; 3K3I; X-ray; 1.70 A; A=5-352. DR PDB; 3K3J; X-ray; 2.00 A; A=1-360. DR PDB; 3KF7; X-ray; 2.00 A; A=1-360. DR PDB; 3KQ7; X-ray; 1.80 A; A=1-360. DR PDB; 3L8S; X-ray; 2.35 A; A=2-360. DR PDB; 3L8X; X-ray; 2.15 A; A=2-360. DR PDB; 3LFA; X-ray; 2.10 A; A=2-360. DR PDB; 3LFB; X-ray; 2.60 A; A=2-360. DR PDB; 3LFC; X-ray; 2.80 A; A=2-360. DR PDB; 3LFD; X-ray; 3.40 A; A=2-360. DR PDB; 3LFE; X-ray; 2.30 A; A=2-360. DR PDB; 3LFF; X-ray; 1.50 A; A=2-360. DR PDB; 3LHJ; X-ray; 3.31 A; A=1-360. DR PDB; 3MGY; X-ray; 2.10 A; A=1-360. DR PDB; 3MH0; X-ray; 2.00 A; A=1-360. DR PDB; 3MH1; X-ray; 2.20 A; A=1-360. DR PDB; 3MH2; X-ray; 2.30 A; A=1-360. DR PDB; 3MH3; X-ray; 2.20 A; A=1-360. DR PDB; 3MPA; X-ray; 2.10 A; A=1-360. DR PDB; 3MPT; X-ray; 1.89 A; A=1-360. DR PDB; 3MVL; X-ray; 2.80 A; A/B=2-360. DR PDB; 3MVM; X-ray; 2.00 A; A/B=2-360. DR PDB; 3MW1; X-ray; 2.80 A; A=2-360. DR PDB; 3NEW; X-ray; 2.51 A; A=1-360. DR PDB; 3NNU; X-ray; 2.40 A; A=1-354. DR PDB; 3NNV; X-ray; 2.10 A; A=1-354. DR PDB; 3NNW; X-ray; 1.89 A; A=1-354. DR PDB; 3NNX; X-ray; 2.28 A; A=1-354. DR PDB; 3NWW; X-ray; 2.09 A; A=2-360. DR PDB; 3O8P; X-ray; 2.10 A; A=1-360. DR PDB; 3O8T; X-ray; 2.00 A; A=1-360. DR PDB; 3O8U; X-ray; 2.10 A; A=1-360. DR PDB; 3OBG; X-ray; 2.80 A; A=1-360. DR PDB; 3OBJ; X-ray; 2.40 A; A=1-360. DR PDB; 3OC1; X-ray; 2.59 A; A=1-360. DR PDB; 3OCG; X-ray; 2.21 A; A=2-360. DR PDB; 3OD6; X-ray; 2.68 A; X=1-360. DR PDB; 3ODY; X-ray; 2.20 A; X=1-360. DR PDB; 3ODZ; X-ray; 2.30 A; X=1-360. DR PDB; 3OEF; X-ray; 1.60 A; X=1-360. DR PDB; 3PG3; X-ray; 2.00 A; A=2-360. DR PDB; 3QUD; X-ray; 2.00 A; A=2-360. DR PDB; 3QUE; X-ray; 2.70 A; A=2-360. DR PDB; 3RIN; X-ray; 2.20 A; A=1-360. DR PDB; 3ROC; X-ray; 1.70 A; A=1-360. DR PDB; 3S3I; X-ray; 1.80 A; A=4-352. DR PDB; 3S4Q; X-ray; 2.27 A; A=2-360. DR PDB; 3U8W; X-ray; 2.15 A; A=1-360. DR PDB; 3UVP; X-ray; 2.40 A; A=2-360. DR PDB; 3UVQ; X-ray; 2.20 A; A=2-360. DR PDB; 3UVR; X-ray; 2.10 A; A=2-360. DR PDB; 3ZS5; X-ray; 1.60 A; A=2-360. DR PDB; 3ZSG; X-ray; 1.89 A; A=2-360. DR PDB; 3ZSH; X-ray; 2.05 A; A=2-360. DR PDB; 3ZSI; X-ray; 2.40 A; A=2-360. DR PDB; 3ZYA; X-ray; 1.90 A; A=1-360. DR PDB; 4A9Y; X-ray; 2.20 A; A=2-360. DR PDB; 4AA0; X-ray; 1.80 A; A=2-360. DR PDB; 4AA4; X-ray; 2.30 A; A=2-360. DR PDB; 4AA5; X-ray; 2.38 A; A=2-360. DR PDB; 4AAC; X-ray; 2.50 A; A=2-360. DR PDB; 4DLI; X-ray; 1.91 A; A=2-360. DR PDB; 4DLJ; X-ray; 2.60 A; A=2-360. DR PDB; 4E5A; X-ray; 1.87 A; X=1-360. DR PDB; 4E5B; X-ray; 2.00 A; A=1-360. DR PDB; 4E6A; X-ray; 2.09 A; A=1-360. DR PDB; 4E6C; X-ray; 2.39 A; A=1-360. DR PDB; 4E8A; X-ray; 2.70 A; A=1-360. DR PDB; 4EH2; X-ray; 2.00 A; A=2-360. DR PDB; 4EH3; X-ray; 2.40 A; A=2-360. DR PDB; 4EH4; X-ray; 2.50 A; A=2-360. DR PDB; 4EH5; X-ray; 2.00 A; A=2-360. DR PDB; 4EH6; X-ray; 2.10 A; A=2-360. DR PDB; 4EH7; X-ray; 2.10 A; A=2-360. DR PDB; 4EH8; X-ray; 2.20 A; A=2-360. DR PDB; 4EH9; X-ray; 2.10 A; A=2-360. DR PDB; 4EHV; X-ray; 1.60 A; A=2-360. DR PDB; 4EWQ; X-ray; 2.10 A; A=2-360. DR PDB; 4F9W; X-ray; 2.00 A; A=2-360. DR PDB; 4F9Y; X-ray; 1.85 A; A=2-360. DR PDB; 4FA2; X-ray; 2.00 A; A=2-360. DR PDB; 4GEO; X-ray; 1.66 A; A=2-360. DR PDB; 4KIN; X-ray; 1.97 A; A/B/C/D=2-360. DR PDB; 4KIP; X-ray; 2.27 A; A/B=2-360. DR PDB; 4KIQ; X-ray; 2.50 A; A/B/C/D=2-360. DR PDB; 4L8M; X-ray; 2.10 A; A=2-360. DR PDB; 4R3C; X-ray; 2.06 A; A=2-360. DR PDB; 4ZTH; X-ray; 2.15 A; A=2-360. DR PDB; 5ETA; X-ray; 2.80 A; A/B=1-360. DR PDB; 5ETC; X-ray; 2.42 A; A=1-360. DR PDB; 5ETF; X-ray; 2.40 A; A=1-360. DR PDB; 5ETI; X-ray; 2.80 A; A=1-360. DR PDB; 5ML5; X-ray; 1.90 A; A=1-360. DR PDB; 5MTX; X-ray; 1.80 A; A=1-360. DR PDB; 5MTY; X-ray; 2.31 A; A=1-360. DR PDB; 5MZ3; X-ray; 2.15 A; A=1-360. DR PDB; 5N63; X-ray; 2.40 A; A=1-360. DR PDB; 5N64; X-ray; 2.40 A; A=1-360. DR PDB; 5N65; X-ray; 2.00 A; A=1-360. DR PDB; 5N66; X-ray; 2.40 A; A=1-360. DR PDB; 5N67; X-ray; 1.90 A; A=1-360. DR PDB; 5N68; X-ray; 1.85 A; A=1-360. DR PDB; 5O8U; X-ray; 2.00 A; A=1-360. DR PDB; 5O8V; X-ray; 2.00 A; A=1-360. DR PDB; 5OMG; X-ray; 2.00 A; A=1-360. DR PDB; 5OMH; X-ray; 2.50 A; A=1-360. DR PDB; 5TBE; X-ray; 2.44 A; A=1-360. DR PDB; 5TCO; X-ray; 2.10 A; A=2-360. DR PDB; 5WJJ; X-ray; 1.60 A; A=1-360. DR PDB; 5XYX; X-ray; 2.61 A; A=1-360. DR PDB; 5XYY; X-ray; 1.70 A; A=1-360. DR PDB; 6ANL; X-ray; 2.00 A; A=1-360. DR PDB; 6HWT; X-ray; 1.70 A; A=2-360. DR PDB; 6HWU; X-ray; 2.30 A; A=2-360. DR PDB; 6HWV; X-ray; 1.70 A; A=2-360. DR PDB; 6M95; X-ray; 1.80 A; A=1-360. DR PDB; 6M9L; X-ray; 2.45 A; A=1-360. DR PDB; 6OHD; X-ray; 2.50 A; A=1-360. DR PDB; 6QDZ; X-ray; 1.73 A; A=1-360. DR PDB; 6QE1; X-ray; 1.85 A; A=1-360. DR PDB; 6QYX; X-ray; 1.66 A; A=1-166, A=197-360. DR PDB; 6RFO; X-ray; 1.70 A; A=167-196. DR PDB; 6SFI; X-ray; 1.60 A; A=1-360. DR PDB; 6SFJ; X-ray; 1.95 A; A=1-360. DR PDB; 6SFK; X-ray; 1.80 A; A=1-360. DR PDB; 6SFO; X-ray; 1.75 A; A=1-360. DR PDB; 6TCA; X-ray; 3.70 A; B/D/F/H=1-360. DR PDB; 6ZQS; X-ray; 1.95 A; A=1-360. DR PDB; 6ZWP; X-ray; 1.90 A; A=1-360. DR PDB; 8A8M; EM; 4.00 A; A=1-360. DR PDB; 8VXE; X-ray; 1.85 A; A=2-360. DR PDB; 8X3M; X-ray; 1.85 A; A=1-360. DR PDB; 8YD9; X-ray; 1.66 A; A=1-360. DR PDB; 9CJ1; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ2; X-ray; 2.83 A; A/B=1-360. DR PDB; 9CJ3; X-ray; 1.95 A; A=1-360. DR PDB; 9CJ4; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ5; X-ray; 3.30 A; A=1-360. DR PDB; 9MHB; X-ray; 1.65 A; A=2-360. DR PDB; 9NYT; X-ray; 2.16 A; A=1-360. DR PDB; 9O4L; X-ray; 2.27 A; A=1-360. DR PDBsum; 1A9U; -. DR PDBsum; 1BL6; -. DR PDBsum; 1BL7; -. DR PDBsum; 1BMK; -. DR PDBsum; 1DI9; -. DR PDBsum; 1IAN; -. DR PDBsum; 1KV1; -. DR PDBsum; 1KV2; -. DR PDBsum; 1M7Q; -. DR PDBsum; 1OUK; -. DR PDBsum; 1OUY; -. DR PDBsum; 1OVE; -. DR PDBsum; 1OZ1; -. DR PDBsum; 1R39; -. DR PDBsum; 1R3C; -. DR PDBsum; 1W7H; -. DR PDBsum; 1W82; -. DR PDBsum; 1W83; -. DR PDBsum; 1W84; -. DR PDBsum; 1WBN; -. DR PDBsum; 1WBO; -. DR PDBsum; 1WBS; -. DR PDBsum; 1WBT; -. DR PDBsum; 1WBV; -. DR PDBsum; 1WBW; -. DR PDBsum; 1WFC; -. DR PDBsum; 1YQJ; -. DR PDBsum; 1ZYJ; -. DR PDBsum; 1ZZ2; -. DR PDBsum; 1ZZL; -. DR PDBsum; 2BAJ; -. DR PDBsum; 2BAK; -. DR PDBsum; 2BAL; -. DR PDBsum; 2BAQ; -. DR PDBsum; 2FSL; -. DR PDBsum; 2FSM; -. DR PDBsum; 2FSO; -. DR PDBsum; 2FST; -. DR PDBsum; 2GFS; -. DR PDBsum; 2I0H; -. DR PDBsum; 2LGC; -. DR PDBsum; 2NPQ; -. DR PDBsum; 2OKR; -. DR PDBsum; 2ONL; -. DR PDBsum; 2QD9; -. DR PDBsum; 2RG5; -. DR PDBsum; 2RG6; -. DR PDBsum; 2Y8O; -. DR PDBsum; 2YIS; -. DR PDBsum; 2YIW; -. DR PDBsum; 2YIX; -. DR PDBsum; 2ZAZ; -. DR PDBsum; 2ZB0; -. DR PDBsum; 2ZB1; -. DR PDBsum; 3BV2; -. DR PDBsum; 3BV3; -. DR PDBsum; 3BX5; -. DR PDBsum; 3C5U; -. DR PDBsum; 3CTQ; -. DR PDBsum; 3D7Z; -. DR PDBsum; 3D83; -. DR PDBsum; 3DS6; -. DR PDBsum; 3DT1; -. DR PDBsum; 3E92; -. DR PDBsum; 3E93; -. DR PDBsum; 3FC1; -. DR PDBsum; 3FI4; -. DR PDBsum; 3FKL; -. DR PDBsum; 3FKN; -. DR PDBsum; 3FKO; -. DR PDBsum; 3FL4; -. DR PDBsum; 3FLN; -. DR PDBsum; 3FLQ; -. DR PDBsum; 3FLS; -. DR PDBsum; 3FLW; -. DR PDBsum; 3FLY; -. DR PDBsum; 3FLZ; -. DR PDBsum; 3FMH; -. DR PDBsum; 3FMJ; -. DR PDBsum; 3FMK; -. DR PDBsum; 3FML; -. DR PDBsum; 3FMM; -. DR PDBsum; 3FMN; -. DR PDBsum; 3FSF; -. DR PDBsum; 3FSK; -. DR PDBsum; 3GC7; -. DR PDBsum; 3GCP; -. DR PDBsum; 3GCQ; -. DR PDBsum; 3GCS; -. DR PDBsum; 3GCU; -. DR PDBsum; 3GCV; -. DR PDBsum; 3GFE; -. DR PDBsum; 3GI3; -. DR PDBsum; 3HA8; -. DR PDBsum; 3HEC; -. DR PDBsum; 3HEG; -. DR PDBsum; 3HL7; -. DR PDBsum; 3HLL; -. DR PDBsum; 3HP2; -. DR PDBsum; 3HP5; -. DR PDBsum; 3HRB; -. DR PDBsum; 3HUB; -. DR PDBsum; 3HUC; -. DR PDBsum; 3HV3; -. DR PDBsum; 3HV4; -. DR PDBsum; 3HV5; -. DR PDBsum; 3HV6; -. DR PDBsum; 3HV7; -. DR PDBsum; 3HVC; -. DR PDBsum; 3IPH; -. DR PDBsum; 3ITZ; -. DR PDBsum; 3IW5; -. DR PDBsum; 3IW6; -. DR PDBsum; 3IW7; -. DR PDBsum; 3IW8; -. DR PDBsum; 3K3I; -. DR PDBsum; 3K3J; -. DR PDBsum; 3KF7; -. DR PDBsum; 3KQ7; -. DR PDBsum; 3L8S; -. DR PDBsum; 3L8X; -. DR PDBsum; 3LFA; -. DR PDBsum; 3LFB; -. DR PDBsum; 3LFC; -. DR PDBsum; 3LFD; -. DR PDBsum; 3LFE; -. DR PDBsum; 3LFF; -. DR PDBsum; 3LHJ; -. DR PDBsum; 3MGY; -. DR PDBsum; 3MH0; -. DR PDBsum; 3MH1; -. DR PDBsum; 3MH2; -. DR PDBsum; 3MH3; -. DR PDBsum; 3MPA; -. DR PDBsum; 3MPT; -. DR PDBsum; 3MVL; -. DR PDBsum; 3MVM; -. DR PDBsum; 3MW1; -. DR PDBsum; 3NEW; -. DR PDBsum; 3NNU; -. DR PDBsum; 3NNV; -. DR PDBsum; 3NNW; -. DR PDBsum; 3NNX; -. DR PDBsum; 3NWW; -. DR PDBsum; 3O8P; -. DR PDBsum; 3O8T; -. DR PDBsum; 3O8U; -. DR PDBsum; 3OBG; -. DR PDBsum; 3OBJ; -. DR PDBsum; 3OC1; -. DR PDBsum; 3OCG; -. DR PDBsum; 3OD6; -. DR PDBsum; 3ODY; -. DR PDBsum; 3ODZ; -. DR PDBsum; 3OEF; -. DR PDBsum; 3PG3; -. DR PDBsum; 3QUD; -. DR PDBsum; 3QUE; -. DR PDBsum; 3RIN; -. DR PDBsum; 3ROC; -. DR PDBsum; 3S3I; -. DR PDBsum; 3S4Q; -. DR PDBsum; 3U8W; -. DR PDBsum; 3UVP; -. DR PDBsum; 3UVQ; -. DR PDBsum; 3UVR; -. DR PDBsum; 3ZS5; -. DR PDBsum; 3ZSG; -. DR PDBsum; 3ZSH; -. DR PDBsum; 3ZSI; -. DR PDBsum; 3ZYA; -. DR PDBsum; 4A9Y; -. DR PDBsum; 4AA0; -. DR PDBsum; 4AA4; -. DR PDBsum; 4AA5; -. DR PDBsum; 4AAC; -. DR PDBsum; 4DLI; -. DR PDBsum; 4DLJ; -. DR PDBsum; 4E5A; -. DR PDBsum; 4E5B; -. DR PDBsum; 4E6A; -. DR PDBsum; 4E6C; -. DR PDBsum; 4E8A; -. DR PDBsum; 4EH2; -. DR PDBsum; 4EH3; -. DR PDBsum; 4EH4; -. DR PDBsum; 4EH5; -. DR PDBsum; 4EH6; -. DR PDBsum; 4EH7; -. DR PDBsum; 4EH8; -. DR PDBsum; 4EH9; -. DR PDBsum; 4EHV; -. DR PDBsum; 4EWQ; -. DR PDBsum; 4F9W; -. DR PDBsum; 4F9Y; -. DR PDBsum; 4FA2; -. DR PDBsum; 4GEO; -. DR PDBsum; 4KIN; -. DR PDBsum; 4KIP; -. DR PDBsum; 4KIQ; -. DR PDBsum; 4L8M; -. DR PDBsum; 4R3C; -. DR PDBsum; 4ZTH; -. DR PDBsum; 5ETA; -. DR PDBsum; 5ETC; -. DR PDBsum; 5ETF; -. DR PDBsum; 5ETI; -. DR PDBsum; 5ML5; -. DR PDBsum; 5MTX; -. DR PDBsum; 5MTY; -. DR PDBsum; 5MZ3; -. DR PDBsum; 5N63; -. DR PDBsum; 5N64; -. DR PDBsum; 5N65; -. DR PDBsum; 5N66; -. DR PDBsum; 5N67; -. DR PDBsum; 5N68; -. DR PDBsum; 5O8U; -. DR PDBsum; 5O8V; -. DR PDBsum; 5OMG; -. DR PDBsum; 5OMH; -. DR PDBsum; 5TBE; -. DR PDBsum; 5TCO; -. DR PDBsum; 5WJJ; -. DR PDBsum; 5XYX; -. DR PDBsum; 5XYY; -. DR PDBsum; 6ANL; -. DR PDBsum; 6HWT; -. DR PDBsum; 6HWU; -. DR PDBsum; 6HWV; -. DR PDBsum; 6M95; -. DR PDBsum; 6M9L; -. DR PDBsum; 6OHD; -. DR PDBsum; 6QDZ; -. DR PDBsum; 6QE1; -. DR PDBsum; 6QYX; -. DR PDBsum; 6RFO; -. DR PDBsum; 6SFI; -. DR PDBsum; 6SFJ; -. DR PDBsum; 6SFK; -. DR PDBsum; 6SFO; -. DR PDBsum; 6TCA; -. DR PDBsum; 6ZQS; -. DR PDBsum; 6ZWP; -. DR PDBsum; 8A8M; -. DR PDBsum; 8VXE; -. DR PDBsum; 8X3M; -. DR PDBsum; 8YD9; -. DR PDBsum; 9CJ1; -. DR PDBsum; 9CJ2; -. DR PDBsum; 9CJ3; -. DR PDBsum; 9CJ4; -. DR PDBsum; 9CJ5; -. DR PDBsum; 9MHB; -. DR PDBsum; 9NYT; -. DR PDBsum; 9O4L; -. DR AlphaFoldDB; Q16539; -. DR BMRB; Q16539; -. DR EMDB; EMD-15233; -. DR SASBDB; Q16539; -. DR SMR; Q16539; -. DR BioGRID; 107819; 321. DR CORUM; Q16539; -. DR DIP; DIP-30987N; -. DR ELM; Q16539; -. DR FunCoup; Q16539; 4149. DR IntAct; Q16539; 185. DR MINT; Q16539; -. DR STRING; 9606.ENSP00000229795; -. DR BindingDB; Q16539; -. DR ChEMBL; CHEMBL260; -. DR DrugBank; DB02873; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One. DR DrugBank; DB01948; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One. DR DrugBank; DB02277; 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea. DR DrugBank; DB06882; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea. DR DrugBank; DB08097; 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE. DR DrugBank; DB08395; 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE. DR DrugBank; DB03110; 2-Chlorophenol. DR DrugBank; DB07942; 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine. DR DrugBank; DB08093; 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. DR DrugBank; DB08095; 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA. DR DrugBank; DB02195; 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine. DR DrugBank; DB02352; 3-(Benzyloxy)Pyridin-2-Amine. DR DrugBank; DB08730; 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE. DR DrugBank; DB08091; 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE. DR DrugBank; DB08092; 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide. DR DrugBank; DB04632; 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE. DR DrugBank; DB08522; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE. DR DrugBank; DB03980; 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole. DR DrugBank; DB07829; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE. DR DrugBank; DB02984; 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline. DR DrugBank; DB08521; 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine. DR DrugBank; DB07607; 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE. DR DrugBank; DB01761; 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine. DR DrugBank; DB07459; 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. DR DrugBank; DB07832; 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde. DR DrugBank; DB01988; 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine. DR DrugBank; DB08352; 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine. DR DrugBank; DB08096; 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM. DR DrugBank; DB08424; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE. DR DrugBank; DB08423; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12140; Dilmapimod. DR DrugBank; DB03044; Doramapimod. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB01953; Inhibitor of P38 Kinase. DR DrugBank; DB05157; KC706. DR DrugBank; DB12270; Losmapimod. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB08242; N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide. DR DrugBank; DB07833; N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide. DR DrugBank; DB08064; N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA. DR DrugBank; DB07834; N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide. DR DrugBank; DB01807; N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea. DR DrugBank; DB06991; N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide. DR DrugBank; DB08068; N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO. DR DrugBank; DB07811; N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide. DR DrugBank; DB08349; N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide. DR DrugBank; DB07307; N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide. DR DrugBank; DB08351; N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide. DR DrugBank; DB06940; N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. DR DrugBank; DB07138; Neflamapimod. DR DrugBank; DB07835; N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide. DR DrugBank; DB12017; Ozagrel. DR DrugBank; DB19169; Pamapimod. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07941; PH-797804. DR DrugBank; DB06518; R-1487. DR DrugBank; DB04338; SB220025. DR DrugBank; DB07943; SD-0006. DR DrugBank; DB05412; Talmapimod. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB04797; Triazolopyridine. DR DrugBank; DB05470; VX-702. DR DrugCentral; Q16539; -. DR GuidetoPHARMACOLOGY; 1499; -. DR GlyGen; Q16539; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q16539; -. DR MetOSite; Q16539; -. DR PhosphoSitePlus; Q16539; -. DR BioMuta; MAPK14; -. DR OGP; Q16539; -. DR CPTAC; CPTAC-1325; -. DR CPTAC; CPTAC-1355; -. DR CPTAC; CPTAC-1356; -. DR CPTAC; CPTAC-3005; -. DR CPTAC; CPTAC-3006; -. DR CPTAC; CPTAC-878; -. DR CPTAC; CPTAC-879; -. DR CPTAC; non-CPTAC-5408; -. DR CPTAC; non-CPTAC-5699; -. DR CPTAC; non-CPTAC-5700; -. DR CPTAC; non-CPTAC-5701; -. DR jPOST; Q16539; -. DR MassIVE; Q16539; -. DR PaxDb; 9606-ENSP00000229795; -. DR PeptideAtlas; Q16539; -. DR PRIDE; Q16539; -. DR ProteomicsDB; 60901; -. [Q16539-1] DR ProteomicsDB; 60902; -. [Q16539-2] DR ProteomicsDB; 60903; -. [Q16539-3] DR ProteomicsDB; 60904; -. [Q16539-4] DR Pumba; Q16539; -. DR ABCD; Q16539; 4 sequenced antibodies. DR Antibodypedia; 4142; 2328 antibodies from 55 providers. DR CPTC; Q16539; 3 antibodies. DR DNASU; 1432; -. DR Ensembl; ENST00000229794.9; ENSP00000229794.4; ENSG00000112062.14. [Q16539-1] DR Ensembl; ENST00000229795.8; ENSP00000229795.3; ENSG00000112062.14. [Q16539-2] DR Ensembl; ENST00000310795.8; ENSP00000308669.4; ENSG00000112062.14. [Q16539-4] DR GeneID; 1432; -. DR KEGG; hsa:1432; -. DR MANE-Select; ENST00000229794.9; ENSP00000229794.4; NM_139012.3; NP_620581.1. DR UCSC; uc003olp.4; human. [Q16539-1] DR AGR; HGNC:6876; -. DR ClinPGx; PA30621; -. DR CTD; 1432; -. DR DisGeNET; 1432; -. DR GeneCards; MAPK14; -. DR HGNC; HGNC:6876; MAPK14. DR HPA; ENSG00000112062; Low tissue specificity. DR MIM; 600289; gene. DR OpenTargets; ENSG00000112062; -. DR VEuPathDB; HostDB:ENSG00000112062; -. DR eggNOG; KOG0660; Eukaryota. DR GeneTree; ENSGT00940000155325; -. DR InParanoid; Q16539; -. DR OMA; NRYTDLN; -. DR OrthoDB; 9474812at2759; -. DR PAN-GO; Q16539; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q16539; -. DR BioCyc; MetaCyc:HS03507-MONOMER; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; Q16539; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1. DR Reactome; R-HSA-432142; Platelet sensitization by LDL. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR SignaLink; Q16539; -. DR SIGNOR; Q16539; -. DR Agora; ENSG00000112062; -. DR BioGRID-ORCS; 1432; 83 hits in 1217 CRISPR screens. DR ChiTaRS; MAPK14; human. DR EvolutionaryTrace; Q16539; -. DR GeneWiki; MAPK14; -. DR GenomeRNAi; 1432; -. DR Pharos; Q16539; Tchem. DR PRO; PR:Q16539; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q16539; protein. DR Bgee; ENSG00000112062; Expressed in buccal mucosa cell and 205 other cell types or tissues. DR ExpressionAtlas; Q16539; baseline and differential. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0034774; C:secretory granule lumen; TAS:Reactome. DR GO; GO:0000922; C:spindle pole; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc. DR GO; GO:0048273; F:mitogen-activated protein kinase p38 binding; IPI:UniProtKB. DR GO; GO:0051525; F:NFAT protein binding; ISS:BHF-UCL. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; TAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0060348; P:bone development; IEA:Ensembl. DR GO; GO:0001502; P:cartilage condensation; IEA:Ensembl. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007178; P:cell surface receptor protein serine/threonine kinase signaling pathway; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI. DR GO; GO:0071223; P:cellular response to lipoteichoic acid; IMP:UniProtKB. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0098586; P:cellular response to virus; IMP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0035331; P:negative regulation of hippo signaling; IMP:FlyBase. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0030316; P:osteoclast differentiation; ISS:BHF-UCL. DR GO; GO:0038066; P:p38MAPK cascade; IDA:UniProt. DR GO; GO:0001890; P:placenta development; IEA:Ensembl. DR GO; GO:0030168; P:platelet activation; TAS:Reactome. DR GO; GO:0090336; P:positive regulation of brown fat cell differentiation; IEA:Ensembl. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IMP:UniProtKB. DR GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome. DR GO; GO:0045663; P:positive regulation of myoblast differentiation; ISS:UniProtKB. DR GO; GO:1901741; P:positive regulation of myoblast fusion; ISS:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IDA:CACAO. DR GO; GO:0030278; P:regulation of ossification; IEA:Ensembl. DR GO; GO:0099179; P:regulation of synaptic membrane adhesion; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0002021; P:response to dietary excess; IEA:Ensembl. DR GO; GO:0032868; P:response to insulin; IEA:Ensembl. DR GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IMP:BHF-UCL. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl. DR GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB. DR GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IDA:UniProt. DR GO; GO:0090400; P:stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL. DR CDD; cd07877; STKc_p38alpha; 1. DR FunFam; 1.10.510.10:FF:000063; Mitogen-activated protein kinase 14; 1. DR FunFam; 3.30.200.20:FF:000769; Mitogen-activated protein kinase 14; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00280; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR038784; MAPK14. DR InterPro; IPR008352; MAPK_HOG-like. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01773; P38MAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:20068231" FT CHAIN 2..360 FT /note="Mitogen-activated protein kinase 14" FT /id="PRO_0000186291" FT DOMAIN 24..308 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOTIF 180..182 FT /note="TXY" FT ACT_SITE 168 FT /note="Proton acceptor" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 16 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 53 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 152 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 180 FT /note="Phosphothreonine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 182 FT /note="Phosphotyrosine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 263 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 323 FT /note="Phosphotyrosine; by ZAP70" FT /evidence="ECO:0000269|PubMed:15735648" FT VAR_SEQ 230..254 FT /note="DQLKLILRLVGTPGAELLKKISSES -> NQLQQIMRLTGTPPAYLINRMPS FT HE (in isoform CSBP1)" FT /evidence="ECO:0000303|PubMed:7997261" FT /id="VSP_004842" FT VAR_SEQ 255..360 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT YFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES -> V FT S (in isoform 5)" FT /evidence="ECO:0000303|PubMed:19906316" FT /id="VSP_057194" FT VAR_SEQ 255..307 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT Y -> LSTCWRRCLYWTQIRELQRPKPLHMPTLLSTTILMMNQWPILMISPLKAGTSL FT (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004843" FT VAR_SEQ 281..360 FT /note="AVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDL FT LIDEWKSLTYDEVISFVPPPLDQEEMES -> GKLTIYPHLMDIELVMI (in FT isoform Mxi2)" FT /evidence="ECO:0000303|PubMed:7479834" FT /id="VSP_004844" FT VAR_SEQ 308..360 FT /note="Missing (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004845" FT VARIANT 51 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042270" FT VARIANT 322 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1765837157)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042271" FT VARIANT 343 FT /note="D -> G (in dbSNP:rs45496794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042272" FT MUTAGEN 34 FT /note="A->V: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 53 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 54 FT /note="K->R: Impairs MAP2K6/MKK6-dependent FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:11010976" FT MUTAGEN 69 FT /note="Y->H: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 168 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 175 FT /note="T->A: No effect on either the kinase activity or FT tyrosine phosphorylation." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 176 FT /note="D->A: Emulation of the active state. Increase in FT activity; when associated with S-327 or L-327." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 177 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 180 FT /note="T->E: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 182 FT /note="Y->F: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 320 FT /note="A->T: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->L: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->S: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 337 FT /note="W->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT CONFLICT 67 FT /note="R -> G (in Ref. 7; BAF84398)" FT /evidence="ECO:0000305" FT STRAND 8..13 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 16..21 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 24..29 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 31..33 FT /evidence="ECO:0007829|PDB:6SFI" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:3BV2" FT STRAND 38..43 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 44..47 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 48..54 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 62..77 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 87..90 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 96..98 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3LFF" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:4GEO" FT TURN 116..119 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 124..143 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 153..155 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 156..158 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 160..162 FT /evidence="ECO:0007829|PDB:2RG6" FT STRAND 164..166 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:4GEO" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:1ZZL" FT TURN 176..179 FT /evidence="ECO:0007829|PDB:5XYY" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:3FMK" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 191..194 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:4EHV" FT HELIX 204..218 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 228..239 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 244..247 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 253..260 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 270..273 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 274..276 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 279..288 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 299..303 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 309..311 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:2FST" SQ SEQUENCE 360 AA; 41293 MW; 286C81D0487618B3 CRC64; MSQERPTFYR QELNKTIWEV PERYQNLSPV GSGAYGSVCA AFDTKTGLRV AVKKLSRPFQ SIIHAKRTYR ELRLLKHMKH ENVIGLLDVF TPARSLEEFN DVYLVTHLMG ADLNNIVKCQ KLTDDHVQFL IYQILRGLKY IHSADIIHRD LKPSNLAVNE DCELKILDFG LARHTDDEMT GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLTGR TLFPGTDHID QLKLILRLVG TPGAELLKKI SSESARNYIQ SLTQMPKMNF ANVFIGANPL AVDLLEKMLV LDSDKRITAA QALAHAYFAQ YHDPDDEPVA DPYDQSFESR DLLIDEWKSL TYDEVISFVP PPLDQEEMES // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MP2K4_HUMAN Reviewed; 399 AA. AC P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4; DE Short=MAP kinase kinase 4; DE Short=MAPKK 4; DE EC=2.7.12.2; DE AltName: Full=JNK-activating kinase 1; DE AltName: Full=MAPK/ERK kinase 4; DE Short=MEK 4; DE AltName: Full=SAPK/ERK kinase 1; DE Short=SEK1; DE AltName: Full=Stress-activated protein kinase kinase 1; DE Short=SAPK kinase 1; DE Short=SAPKK-1; DE Short=SAPKK1; DE AltName: Full=c-Jun N-terminal kinase kinase 1; DE Short=JNKK; GN Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=7839144; DOI=10.1126/science.7839144; RA Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., RA Davis R.J.; RT "Independent human MAP-kinase signal transduction pathways defined by MEK RT and MKK isoforms."; RL Science 267:682-685(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION. RX PubMed=7716521; DOI=10.1126/science.7716521; RA Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C., RA Mercurio F., Johnson G.L., Karin M.; RT "Identification of a dual specificity kinase that activates the Jun kinases RT and p38-Mpk2."; RL Science 268:286-290(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9622070; RA Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H., RA Kern S.E.; RT "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as RT a genetically targeted tumor suppressor gene."; RL Cancer Res. 58:2339-2342(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH RP MAP3K11/MLK3. RX PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x; RA Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., RA Lassam N.J.; RT "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6."; RL EMBO J. 15:7026-7035(1996). RN [12] RP CLEAVAGE BY ANTHRAX LETHAL FACTOR. RX PubMed=11104681; DOI=10.1042/bj3520739; RA Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.; RT "Susceptibility of mitogen-activated protein kinase kinase family members RT to proteolysis by anthrax lethal factor."; RL Biochem. J. 352:739-745(2000). RN [13] RP INTERACTION WITH ARRB2. RX PubMed=11090355; DOI=10.1126/science.290.5496.1574; RA McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T., RA Davis R.J., Lefkowitz R.J.; RT "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of RT JNK3."; RL Science 290:1574-1577(2000). RN [14] RP INTERACTION WITH MAPK8IP3/JIP3. RX PubMed=12189133; DOI=10.1074/jbc.m202004200; RA Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M., RA Yoshioka K., Ichijo H.; RT "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK RT signaling pathway. A new mode of regulation of the MAP kinase cascade."; RL J. Biol. Chem. 277:40703-40709(2002). RN [15] RP DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11 RP AND MAPK14. RX PubMed=12788955; DOI=10.1074/jbc.m304229200; RA Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.; RT "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and RT competes with similar docking sites in JNK substrates."; RL J. Biol. Chem. 278:32662-32672(2003). RN [16] RP DOMAIN. RX PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001; RA Takekawa M., Tatebayashi K., Saito H.; RT "Conserved docking site is essential for activation of mammalian MAP kinase RT kinases by specific MAP kinase kinase kinases."; RL Mol. Cell 18:295-306(2005). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP INTERACTION WITH ARRB1 AND ARRB2. RX PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035; RA Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C., RA Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.; RT "A scanning peptide array approach uncovers association sites within the RT JNK/beta arrestin signalling complex."; RL FEBS Lett. 583:3310-3316(2009). RN [20] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17496909; DOI=10.1038/sj.onc.1210392; RA Raman M., Chen W., Cobb M.H.; RT "Differential regulation and properties of MAPKs."; RL Oncogene 26:3100-3112(2007). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20801953; DOI=10.1093/jb/mvq098; RA Asaoka Y., Nishina H.; RT "Diverse physiological functions of MKK4 and MKK7 during early RT embryogenesis."; RL J. Biochem. 148:393-401(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP REVIEW ON REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008; RA Haeusgen W., Herdegen T., Waetzig V.; RT "The bottleneck of JNK signaling: molecular and functional characteristics RT of MKK4 and MKK7."; RL Eur. J. Cell Biol. 90:536-544(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399. RX PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071; RA Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.; RT "Crystal structures of MKK4 kinase domain reveal that substrate peptide RT binds to an allosteric site and induces an auto-inhibition state."; RL Biochem. Biophys. Res. Commun. 400:369-373(2010). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND RP THR-279. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Dual specificity protein kinase which acts as an essential CC component of the MAP kinase signal transduction pathway. Essential CC component of the stress-activated protein kinase/c-Jun N-terminal CC kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the CC only known kinase to directly activate the stress-activated protein CC kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. CC MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, CC but they differ in their preference for the phosphorylation site in the CC Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the CC Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of CC the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK CC activation at least in response to pro-inflammatory cytokines, while CC other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which CC synergistically phosphorylate JNKs. MAP2K4 is required for maintaining CC peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also CC involved in mitochondrial death signaling pathway, including the CC release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 CC exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 CC MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- ACTIVITY REGULATION: Activated in response to a variety of cellular CC stresses, including UV and gamma-irradiation, heat shock, CC hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory CC cytokines. Also activated by developmental cues. MAP2K4/MKK4 is CC activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1, CC MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK. CC {ECO:0000269|PubMed:9003778}. CC -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D CC domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11 CC and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like CC MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and CC MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355, CC ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955, CC ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}. CC -!- INTERACTION: CC P45985; Q13233: MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776; CC P45985; P45983: MAPK8; NbExp=4; IntAct=EBI-447868, EBI-286483; CC P45985; P45984: MAPK9; NbExp=3; IntAct=EBI-447868, EBI-713568; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P45985-1; Sequence=Displayed; CC Name=2; CC IsoId=P45985-2; Sequence=VSP_038838; CC -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle. CC It is also widely expressed in other tissues. CC -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking CC site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD CC sites bind to their specific upstream MAP kinase kinase kinases CC (MAP3Ks) and are essential for activation. CC -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site CC and is required for the binding to MAPK substrates. CC -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase CC kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/244/MAP2K4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36870; AAC41719.1; -; mRNA. DR EMBL; U17743; AAC50127.1; -; mRNA. DR EMBL; AF070090; AAC24130.1; -; Genomic_DNA. DR EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; CR536564; CAG38801.1; -; mRNA. DR EMBL; BT019676; AAV38482.1; -; mRNA. DR EMBL; AK131544; BAG54774.1; -; mRNA. DR EMBL; AK313053; BAG35884.1; -; mRNA. DR EMBL; DQ015703; AAY22176.1; -; Genomic_DNA. DR EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW89975.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89974.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89976.1; -; Genomic_DNA. DR EMBL; BC036032; AAH36032.1; -; mRNA. DR EMBL; BC060764; AAH60764.1; -; mRNA. DR CCDS; CCDS11162.1; -. [P45985-1] DR CCDS; CCDS62095.1; -. [P45985-2] DR PIR; I38901; I38901. DR RefSeq; NP_001268364.1; NM_001281435.2. [P45985-2] DR RefSeq; NP_003001.1; NM_003010.4. [P45985-1] DR PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399. DR PDB; 3ALO; X-ray; 2.60 A; A=80-399. DR PDB; 3VUT; X-ray; 3.50 A; A/B=80-399. DR PDB; 8YP5; X-ray; 2.50 A; A=80-399. DR PDBsum; 3ALN; -. DR PDBsum; 3ALO; -. DR PDBsum; 3VUT; -. DR PDBsum; 8YP5; -. DR AlphaFoldDB; P45985; -. DR SMR; P45985; -. DR BioGRID; 112315; 69. DR CORUM; P45985; -. DR FunCoup; P45985; 2185. DR IntAct; P45985; 26. DR MINT; P45985; -. DR STRING; 9606.ENSP00000410402; -. DR BindingDB; P45985; -. DR ChEMBL; CHEMBL2897; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB14904; Pimasertib. DR DrugCentral; P45985; -. DR GuidetoPHARMACOLOGY; 2065; -. DR GlyCosmos; P45985; 2 sites, 1 glycan. DR GlyGen; P45985; 4 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P45985; -. DR PhosphoSitePlus; P45985; -. DR BioMuta; MAP2K4; -. DR DMDM; 1170596; -. DR CPTAC; CPTAC-816; -. DR CPTAC; CPTAC-817; -. DR jPOST; P45985; -. DR MassIVE; P45985; -. DR PaxDb; 9606-ENSP00000410402; -. DR PeptideAtlas; P45985; -. DR ProteomicsDB; 55703; -. [P45985-1] DR ProteomicsDB; 55704; -. [P45985-2] DR Pumba; P45985; -. DR Antibodypedia; 3571; 1422 antibodies from 43 providers. DR CPTC; P45985; 1 antibody. DR DNASU; 6416; -. DR Ensembl; ENST00000353533.10; ENSP00000262445.5; ENSG00000065559.16. [P45985-1] DR Ensembl; ENST00000415385.7; ENSP00000410402.3; ENSG00000065559.16. [P45985-2] DR GeneID; 6416; -. DR KEGG; hsa:6416; -. DR MANE-Select; ENST00000353533.10; ENSP00000262445.5; NM_003010.4; NP_003001.1. DR UCSC; uc002gnj.5; human. [P45985-1] DR AGR; HGNC:6844; -. DR CIViC; 6416; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA30589; -. DR CTD; 6416; -. DR DisGeNET; 6416; -. DR GeneCards; MAP2K4; -. DR HGNC; HGNC:6844; MAP2K4. DR HPA; ENSG00000065559; Low tissue specificity. DR MalaCards; MAP2K4; -. DR MIM; 601335; gene. DR OpenTargets; ENSG00000065559; -. DR VEuPathDB; HostDB:ENSG00000065559; -. DR eggNOG; KOG1006; Eukaryota. DR GeneTree; ENSGT00940000154744; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; P45985; -. DR OMA; HILLEFC; -. DR OrthoDB; 10252354at2759; -. DR PAN-GO; P45985; 2 GO annotations based on evolutionary models. DR PhylomeDB; P45985; -. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; P45985; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5210891; Uptake and function of anthrax toxins. DR Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation. DR SABIO-RK; P45985; -. DR SignaLink; P45985; -. DR SIGNOR; P45985; -. DR Agora; ENSG00000065559; -. DR BioGRID-ORCS; 6416; 53 hits in 1202 CRISPR screens. DR ChiTaRS; MAP2K4; human. DR EvolutionaryTrace; P45985; -. DR GeneWiki; MAP2K4; -. DR GenomeRNAi; 6416; -. DR Pharos; P45985; Tchem. DR PRO; PR:P45985; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P45985; protein. DR Bgee; ENSG00000065559; Expressed in lateral nuclear group of thalamus and 204 other cell types or tissues. DR ExpressionAtlas; P45985; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008545; F:JUN kinase kinase activity; TAS:Reactome. DR GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0036481; P:intrinsic apoptotic signaling pathway in response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; TAS:Reactome. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0009611; P:response to wounding; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0034390; P:smooth muscle cell apoptotic process; IEA:Ensembl. DR CDD; cd06616; PKc_MKK4; 1. DR DisProt; DP01400; -. DR FunFam; 1.10.510.10:FF:000090; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR FunFam; 3.30.200.20:FF:000126; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR48013:SF15; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; 1. DR PANTHER; PTHR48013; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transferase; KW Tyrosine-protein kinase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..399 FT /note="Dual specificity mitogen-activated protein kinase FT kinase 4" FT /id="PRO_0000086381" FT DOMAIN 102..367 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 37..52 FT /note="D domain" FT REGION 364..387 FT /note="DVD domain" FT COMPBIAS 7..22 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 229 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 108..116 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 131 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 45..46 FT /note="Cleavage; by anthrax lethal factor" FT SITE 58..59 FT /note="Cleavage; by anthrax lethal factor" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 58 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 58 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 90 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 257 FT /note="Phosphoserine; by MAP3K" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES 261 FT /note="Phosphothreonine; by MAP3K" FT /evidence="ECO:0000269|PubMed:9003778" FT VAR_SEQ 39 FT /note="G -> GFQINFCEKAQS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038838" FT VARIANT 16 FT /note="S -> R (in dbSNP:rs17855590)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_062963" FT VARIANT 142 FT /note="Q -> L (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040818" FT VARIANT 154 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1567657403)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040819" FT VARIANT 234 FT /note="N -> I (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040820" FT VARIANT 251 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040821" FT VARIANT 279 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs753665559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040822" FT CONFLICT 118 FT /note="K -> R (in Ref. 4; CAG38801)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="E -> G (in Ref. 6; BAG35884)" FT /evidence="ECO:0000305" FT CONFLICT 356 FT /note="P -> L (in Ref. 10; AAH60764)" FT /evidence="ECO:0000305" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 112..121 FT /evidence="ECO:0007829|PDB:3ALN" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 127..134 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 139..153 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 164..169 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 171..178 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 202..223 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 243..245 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 255..259 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 267..270 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 287..302 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:3ALO" FT STRAND 316..321 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 338..347 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 358..361 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 365..372 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 377..387 FT /evidence="ECO:0007829|PDB:3ALN" SQ SEQUENCE 399 AA; 44288 MW; A472537F2F26770B CRC64; MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD // ID MP2K7_HUMAN Reviewed; 419 AA. AC O14733; B2R9S5; D6W659; O14648; O14816; O60452; O60453; Q1PG43; Q8IY10; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 2. DT 28-JAN-2026, entry version 226. DE RecName: Full=Dual specificity mitogen-activated protein kinase kinase 7; DE Short=MAP kinase kinase 7; DE Short=MAPKK 7; DE EC=2.7.12.2; DE AltName: Full=JNK-activating kinase 2; DE AltName: Full=MAPK/ERK kinase 7; DE Short=MEK 7; DE AltName: Full=Stress-activated protein kinase kinase 4; DE Short=SAPK kinase 4; DE Short=SAPKK-4; DE Short=SAPKK4; DE AltName: Full=c-Jun N-terminal kinase kinase 2; DE Short=JNK kinase 2; DE Short=JNKK 2; GN Name=MAP2K7; Synonyms=JNKK2, MEK7, MKK7, PRKMK7, SKK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY. RC TISSUE=Heart, and Skeletal muscle; RX PubMed=9372971; DOI=10.1128/mcb.17.12.7407; RA Wu Z., Wu J., Jacinto E., Karin M.; RT "Molecular cloning and characterization of human JNKK2, a novel jun NH2- RT terminal kinase-specific kinase."; RL Mol. Cell. Biol. 17:7407-7416(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND ACTIVITY REGULATION. RX PubMed=9312068; DOI=10.1074/jbc.272.40.24751; RA Lu X., Nemoto S., Lin A.; RT "Identification of c-Jun NH2-terminal protein kinase (JNK)-activating RT kinase 2 as an activator of JNK but not p38."; RL J. Biol. Chem. 272:24751-24754(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE RP SPECIFICITY, AND VARIANT PHE-259. RC TISSUE=Fetal kidney; RX PubMed=9535930; DOI=10.1074/jbc.273.15.9344; RA Foltz I.N., Gerl R.E., Wieler J.S., Luckach M., Salmon R.A., Schrader J.W.; RT "Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly RT conserved c-Jun N-terminal kinase/stress-activated protein kinase RT (JNK/SAPK) activated by environmental stresses and physiological stimuli."; RL J. Biol. Chem. 273:9344-9351(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), ACTIVITY REGULATION, AND TISSUE RP SPECIFICITY. RX PubMed=16442502; DOI=10.1016/j.bbrc.2005.12.223; RA Michael L., Swantek J., Robinson M.J.; RT "Cloning and expression of human mitogen-activated protein kinase kinase RT 7gamma1."; RL Biochem. Biophys. Res. Commun. 341:679-683(2006). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN PHOSPHORYLATION OF RP MAPK8/JNK1 AND MAPK9/JNK2. RA Yang J., New L., Yong J., Han J., Su B.; RT "Molecular cloning of human JNKK2 reveals a novel kinase module for c-Jun RT N-terminal kinase activation."; RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-260 (ISOFORMS 1/4). RX PubMed=9207092; DOI=10.1073/pnas.94.14.7337; RA Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., Davis R.J.; RT "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun RT NH2-terminal kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:7337-7342(1997). RN [10] RP INTERACTION WITH MAPK8IP1/JIP1 AND MAPK8IP2/JIP2. RX PubMed=10490659; DOI=10.1128/mcb.19.10.7245; RA Yasuda J., Whitmarsh A.J., Cavanagh J., Sharma M., Davis R.J.; RT "The JIP group of mitogen-activated protein kinase scaffold proteins."; RL Mol. Cell. Biol. 19:7245-7254(1999). RN [11] RP CLEAVAGE BY ANTHRAX LETHAL FACTOR. RX PubMed=11104681; DOI=10.1042/bj3520739; RA Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.; RT "Susceptibility of mitogen-activated protein kinase kinase family members RT to proteolysis by anthrax lethal factor."; RL Biochem. J. 352:739-745(2000). RN [12] RP INTERACTION WITH MAPK8IP3/JIP3. RX PubMed=12189133; DOI=10.1074/jbc.m202004200; RA Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M., RA Yoshioka K., Ichijo H.; RT "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK RT signaling pathway. A new mode of regulation of the MAP kinase cascade."; RL J. Biol. Chem. 277:40703-40709(2002). RN [13] RP DOMAIN. RX PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001; RA Takekawa M., Tatebayashi K., Saito H.; RT "Conserved docking site is essential for activation of mammalian MAP kinase RT kinases by specific MAP kinase kinase kinases."; RL Mol. Cell 18:295-306(2005). RN [14] RP INTERACTION WITH VRK2. RX PubMed=18286207; DOI=10.1371/journal.pone.0001660; RA Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.; RT "Modulation of interleukin-1 transcriptional response by the interaction RT between VRK2 and the JIP1 scaffold protein."; RL PLoS ONE 3:E1660-E1660(2008). RN [15] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17496909; DOI=10.1038/sj.onc.1210392; RA Raman M., Chen W., Cobb M.H.; RT "Differential regulation and properties of MAPKs."; RL Oncogene 26:3100-3112(2007). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [17] RP REVIEW ON FUNCTION. RX PubMed=20801953; DOI=10.1093/jb/mvq098; RA Asaoka Y., Nishina H.; RT "Diverse physiological functions of MKK4 and MKK7 during early RT embryogenesis."; RL J. Biochem. 148:393-401(2010). RN [18] RP INTERACTION WITH RASSF7. RX PubMed=21278800; DOI=10.1038/cdd.2010.137; RA Takahashi S., Ebihara A., Kajiho H., Kontani K., Nishina H., Katada T.; RT "RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the RT activity of phosphorylated-MKK7."; RL Cell Death Differ. 18:645-655(2011). RN [19] RP REVIEW ON REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008; RA Haeusgen W., Herdegen T., Waetzig V.; RT "The bottleneck of JNK signaling: molecular and functional characteristics RT of MKK4 and MKK7."; RL Eur. J. Cell Biol. 90:536-544(2011). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP FUNCTION. RX PubMed=28111074; DOI=10.1016/j.cell.2016.12.044; RA Huang Y.A., Zhou B., Wernig M., Suedhof T.C.; RT "ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and RT Abeta Secretion."; RL Cell 168:427-441(2017). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 101-405. RG RIKEN structural genomics initiative (RSGI); RT "Crystal structure of human mitogen-activated protein kinase kinase 7 RT activated mutant (s287d, t291d)."; RL Submitted (FEB-2009) to the PDB data bank. RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] SER-118; CYS-138; CYS-162; HIS-162 AND RP THR-195. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Dual specificity protein kinase which acts as an essential CC component of the MAP kinase signal transduction pathway. Essential CC component of the stress-activated protein kinase/c-Jun N-terminal CC kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the CC only known kinase to directly activate the stress-activated protein CC kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. CC MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, CC but they differ in their preference for the phosphorylation site in the CC Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of CC the Tyr residue and MAP2K7/MKK7 for the Thr residue. The CC monophosphorylation of JNKs on the Thr residue is sufficient to CC increase JNK activity indicating that MAP2K7/MKK7 is important to CC trigger JNK activity, while the additional phosphorylation of the Tyr CC residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific CC role in JNK signal transduction pathway activated by pro-inflammatory CC cytokines. The MKK/JNK signaling pathway is also involved in CC mitochondrial death signaling pathway, including the release cytochrome CC c, leading to apoptosis. Part of a non-canonical MAPK signaling CC pathway, composed of the upstream MAP3K12 kinase and downstream MAP CC kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated CC transcription of APP in response to APOE (PubMed:28111074). CC {ECO:0000269|PubMed:28111074, ECO:0000269|PubMed:9312068, CC ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930, CC ECO:0000269|Ref.5}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Activated by phosphorylation by specific MAP CC kinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3, MAP3K11/MLK3 CC and MAP3K12/DLK. {ECO:0000269|PubMed:16442502, CC ECO:0000269|PubMed:9312068}. CC -!- SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its D domain) CC with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3 (By CC similarity). Interacts (via its DVD domain) with MAP3Ks activators like CC MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity). Interacts with CC MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3 scaffold proteins. CC Interacts with RASSF7, the interaction promotes phosphorylation. Found CC in a complex with SH3RF1, RAC1, MAP3K11/MLK3, MAPK8IP1/JIP1 and CC MAPK8/JNK1. Found in a complex with SH3RF1, RAC2, MAP3K7/TAK1, CC MAPK8IP1/JIP1, MAPK8/JNK1 and MAPK9/JNK2 (By similarity). CC {ECO:0000250|UniProtKB:Q8CE90, ECO:0000269|PubMed:10490659, CC ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207, CC ECO:0000269|PubMed:21278800}. CC -!- INTERACTION: CC O14733; O15519-1: CFLAR; NbExp=2; IntAct=EBI-492605, EBI-4567563; CC O14733; O75293: GADD45B; NbExp=8; IntAct=EBI-492605, EBI-448187; CC O14733; P08238: HSP90AB1; NbExp=2; IntAct=EBI-492605, EBI-352572; CC O14733; Q5S007: LRRK2; NbExp=3; IntAct=EBI-492605, EBI-5323863; CC O14733; O43318: MAP3K7; NbExp=3; IntAct=EBI-492605, EBI-358684; CC O14733; Q9UQF2: MAPK8IP1; NbExp=5; IntAct=EBI-492605, EBI-78404; CC O14733; P62258: YWHAE; NbExp=2; IntAct=EBI-492605, EBI-356498; CC O14733-2; P45983: MAPK8; NbExp=3; IntAct=EBI-492627, EBI-286483; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=A; CC IsoId=O14733-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=O14733-2; Sequence=VSP_004883; CC Name=3; Synonyms=gamma1; CC IsoId=O14733-3; Sequence=VSP_022309; CC Name=4; CC IsoId=O14733-4; Sequence=VSP_022310; CC -!- TISSUE SPECIFICITY: Ubiquitous; with highest level of expression in CC skeletal muscle. Isoform 3 is found at low levels in placenta, fetal CC liver, and skeletal muscle. {ECO:0000269|PubMed:16442502, CC ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}. CC -!- DOMAIN: The DVD domain (residues 377-400) contains a conserved docking CC site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD CC sites bind to their specific upstream MAP kinase kinase kinases CC (MAP3Ks) and are essential for activation. CC {ECO:0000269|PubMed:15866172}. CC -!- DOMAIN: The D domain (residues 37-57) contains a conserved docking site CC and is required for the binding to MAPK substrates. CC {ECO:0000269|PubMed:15866172}. CC -!- PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAP kinase CC kinase kinases (MAP3Ks). {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be due to intron retention. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB97813.1; Type=Erroneous termination; Note=Extended C-terminus.; Evidence={ECO:0000305}; CC Sequence=AAB97813.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF014401; AAB88048.1; -; mRNA. DR EMBL; AF006689; AAB97813.1; ALT_SEQ; mRNA. DR EMBL; AF013588; AAC16272.1; -; mRNA. DR EMBL; AF013589; AAC16273.1; -; mRNA. DR EMBL; DQ445915; ABE03013.1; -; mRNA. DR EMBL; AF022805; AAC26142.1; -; mRNA. DR EMBL; AK313899; BAG36622.1; -; mRNA. DR EMBL; CH471139; EAW68964.1; -; Genomic_DNA. DR EMBL; CH471139; EAW68968.1; -; Genomic_DNA. DR EMBL; BC038295; AAH38295.1; -; mRNA. DR EMBL; AF003199; AAB63374.1; -; mRNA. DR CCDS; CCDS42491.1; -. [O14733-1] DR CCDS; CCDS74277.1; -. [O14733-3] DR CCDS; CCDS74278.1; -. [O14733-4] DR RefSeq; NP_001284484.1; NM_001297555.2. [O14733-3] DR RefSeq; NP_001284485.1; NM_001297556.2. [O14733-4] DR RefSeq; NP_660186.1; NM_145185.4. [O14733-1] DR PDB; 2DYL; X-ray; 2.45 A; A=101-405. DR PDB; 3WZU; X-ray; 3.01 A; A=103-419. DR PDB; 4UX9; X-ray; 2.34 A; F/G/H/I=37-48. DR PDB; 5B2K; X-ray; 2.75 A; A=103-419. DR PDB; 5B2L; X-ray; 2.10 A; A=103-419. DR PDB; 5B2M; X-ray; 3.06 A; A=103-419. DR PDB; 5Y8U; X-ray; 2.92 A; A=103-419. DR PDB; 5Y90; X-ray; 1.30 A; A=103-419. DR PDB; 5Z1D; X-ray; 2.28 A; A=102-419. DR PDB; 5Z1E; X-ray; 2.30 A; A=102-419. DR PDB; 6IB0; X-ray; 2.60 A; A=101-408. DR PDB; 6IB2; X-ray; 2.10 A; A=101-408. DR PDB; 6QFL; X-ray; 2.20 A; A=101-408. DR PDB; 6QFR; X-ray; 2.30 A; A=101-408. DR PDB; 6QFT; X-ray; 2.70 A; A=101-408. DR PDB; 6QG4; X-ray; 2.30 A; A=111-408. DR PDB; 6QG7; X-ray; 2.10 A; A=101-408. DR PDB; 6QHO; X-ray; 2.70 A; A=111-408. DR PDB; 6QHR; X-ray; 2.52 A; A=111-408. DR PDB; 6YFZ; X-ray; 1.90 A; A=100-405. DR PDB; 6YG0; X-ray; 2.00 A; A=100-405. DR PDB; 6YG1; X-ray; 2.22 A; A/B/C=60-405. DR PDB; 6YG2; X-ray; 2.00 A; A=100-405. DR PDB; 6YG3; X-ray; 2.05 A; A=100-405. DR PDB; 6YG4; X-ray; 2.30 A; A=100-405. DR PDB; 6YG5; X-ray; 2.40 A; A=100-405. DR PDB; 6YG6; X-ray; 2.15 A; A/B=100-405. DR PDB; 6YG7; X-ray; 2.20 A; A/B=100-405. DR PDB; 6YZ4; X-ray; 1.70 A; A=100-405. DR PDB; 7CBX; X-ray; 2.06 A; A=103-419. DR PDB; 7OVI; X-ray; 1.95 A; A=101-408. DR PDB; 7OVJ; X-ray; 2.35 A; A=101-408. DR PDB; 7OVK; X-ray; 2.05 A; A=101-408. DR PDB; 7OVL; X-ray; 2.90 A; A=101-408. DR PDB; 7OVM; X-ray; 2.90 A; A=101-408. DR PDB; 7OVN; X-ray; 2.90 A; A=101-408. DR PDB; 9HZ0; X-ray; 2.25 A; A=101-408. DR PDBsum; 2DYL; -. DR PDBsum; 3WZU; -. DR PDBsum; 4UX9; -. DR PDBsum; 5B2K; -. DR PDBsum; 5B2L; -. DR PDBsum; 5B2M; -. DR PDBsum; 5Y8U; -. DR PDBsum; 5Y90; -. DR PDBsum; 5Z1D; -. DR PDBsum; 5Z1E; -. DR PDBsum; 6IB0; -. DR PDBsum; 6IB2; -. DR PDBsum; 6QFL; -. DR PDBsum; 6QFR; -. DR PDBsum; 6QFT; -. DR PDBsum; 6QG4; -. DR PDBsum; 6QG7; -. DR PDBsum; 6QHO; -. DR PDBsum; 6QHR; -. DR PDBsum; 6YFZ; -. DR PDBsum; 6YG0; -. DR PDBsum; 6YG1; -. DR PDBsum; 6YG2; -. DR PDBsum; 6YG3; -. DR PDBsum; 6YG4; -. DR PDBsum; 6YG5; -. DR PDBsum; 6YG6; -. DR PDBsum; 6YG7; -. DR PDBsum; 6YZ4; -. DR PDBsum; 7CBX; -. DR PDBsum; 7OVI; -. DR PDBsum; 7OVJ; -. DR PDBsum; 7OVK; -. DR PDBsum; 7OVL; -. DR PDBsum; 7OVM; -. DR PDBsum; 7OVN; -. DR PDBsum; 9HZ0; -. DR AlphaFoldDB; O14733; -. DR SMR; O14733; -. DR BioGRID; 111595; 203. DR FunCoup; O14733; 4166. DR IntAct; O14733; 149. DR MINT; O14733; -. DR STRING; 9606.ENSP00000381070; -. DR BindingDB; O14733; -. DR ChEMBL; CHEMBL3530; -. DR DrugBank; DB14904; Pimasertib. DR DrugCentral; O14733; -. DR GuidetoPHARMACOLOGY; 2068; -. DR iPTMnet; O14733; -. DR MetOSite; O14733; -. DR PhosphoSitePlus; O14733; -. DR BioMuta; MAP2K7; -. DR CPTAC; CPTAC-3079; -. DR CPTAC; CPTAC-3080; -. DR CPTAC; CPTAC-822; -. DR CPTAC; CPTAC-823; -. DR jPOST; O14733; -. DR MassIVE; O14733; -. DR PaxDb; 9606-ENSP00000381070; -. DR PeptideAtlas; O14733; -. DR ProteomicsDB; 48192; -. [O14733-1] DR ProteomicsDB; 48193; -. [O14733-2] DR ProteomicsDB; 48194; -. [O14733-3] DR ProteomicsDB; 48195; -. [O14733-4] DR Pumba; O14733; -. DR Antibodypedia; 1176; 769 antibodies from 43 providers. DR DNASU; 5609; -. DR Ensembl; ENST00000397979.4; ENSP00000381066.3; ENSG00000076984.19. [O14733-1] DR Ensembl; ENST00000397981.7; ENSP00000381068.3; ENSG00000076984.19. [O14733-4] DR Ensembl; ENST00000397983.7; ENSP00000381070.2; ENSG00000076984.19. [O14733-3] DR GeneID; 5609; -. DR KEGG; hsa:5609; -. DR MANE-Select; ENST00000397979.4; ENSP00000381066.3; NM_145185.4; NP_660186.1. DR UCSC; uc002mit.4; human. [O14733-1] DR AGR; HGNC:6847; -. DR CIViC; 5609; 1 evidence item across 1 molecular profile. DR ClinPGx; PA284; -. DR CTD; 5609; -. DR DisGeNET; 5609; -. DR GeneCards; MAP2K7; -. DR HGNC; HGNC:6847; MAP2K7. DR HPA; ENSG00000076984; Low tissue specificity. DR MIM; 603014; gene. DR OpenTargets; ENSG00000076984; -. DR VEuPathDB; HostDB:ENSG00000076984; -. DR eggNOG; KOG0983; Eukaryota. DR GeneTree; ENSGT00940000158914; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; O14733; -. DR OMA; NVWICME; -. DR OrthoDB; 10252354at2759; -. DR PAN-GO; O14733; 2 GO annotations based on evolutionary models. DR PhylomeDB; O14733; -. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; O14733; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5210891; Uptake and function of anthrax toxins. DR SignaLink; O14733; -. DR SIGNOR; O14733; -. DR Agora; ENSG00000076984; -. DR BioGRID-ORCS; 5609; 92 hits in 1195 CRISPR screens. DR ChiTaRS; MAP2K7; human. DR EvolutionaryTrace; O14733; -. DR GeneWiki; MAP2K7; -. DR GenomeRNAi; 5609; -. DR Pharos; O14733; Tchem. DR PRO; PR:O14733; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O14733; protein. DR Bgee; ENSG00000076984; Expressed in buccal mucosa cell and 189 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0008545; F:JUN kinase kinase activity; ISS:ARUK-UCL. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0004707; F:MAP kinase activity; IEA:Ensembl. DR GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0019903; F:protein phosphatase binding; ISS:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0007254; P:JNK cascade; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl. DR GO; GO:0032206; P:positive regulation of telomere maintenance; IMP:BHF-UCL. DR GO; GO:2000671; P:regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0009408; P:response to heat; IDA:UniProtKB. DR GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB. DR GO; GO:0034612; P:response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0009411; P:response to UV; IDA:UniProtKB. DR GO; GO:0009611; P:response to wounding; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB. DR CDD; cd06618; PKc_MKK7; 1. DR DisProt; DP00841; -. DR FunFam; 3.30.200.20:FF:000040; Dual specificity mitogen-activated protein kinase kinase; 1. DR FunFam; 1.10.510.10:FF:000214; Dual specificity mitogen-activated protein kinase kinase 7; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR052468; Dual_spec_MAPK_kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR47238:SF2; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE HEMIPTEROUS; 1. DR PANTHER; PTHR47238; MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Coiled coil; Cytoplasm; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Stress response; KW Transferase; Tyrosine-protein kinase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..419 FT /note="Dual specificity mitogen-activated protein kinase FT kinase 7" FT /id="PRO_0000086388" FT DOMAIN 120..380 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 18..76 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 37..57 FT /note="D domain" FT /evidence="ECO:0000250" FT REGION 377..400 FT /note="DVD domain" FT COILED 2..30 FT /evidence="ECO:0000255" FT COMPBIAS 18..30 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 36..63 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 243 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 126..134 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 149 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 44..45 FT /note="Cleavage; by anthrax lethal factor" FT SITE 76..77 FT /note="Cleavage; by anthrax lethal factor" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 271 FT /note="Phosphoserine; by MAP3K" FT /evidence="ECO:0000250" FT MOD_RES 275 FT /note="Phosphothreonine; by MAP3K" FT /evidence="ECO:0000250" FT MOD_RES 411 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 42 FT /note="T -> IIVITLSPAPAPSQRAA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:16442502" FT /id="VSP_022309" FT VAR_SEQ 111 FT /note="Q -> QVPPSLWRGEGGGPARLDPSWERQWGAGGGGRAPGTLQPSLSSQ FT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9535930" FT /id="VSP_004883" FT VAR_SEQ 312 FT /note="L -> LPCPSPSQ (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_022310" FT VARIANT 118 FT /note="N -> S (in dbSNP:rs56316660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040825" FT VARIANT 138 FT /note="R -> C (in dbSNP:rs56106612)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040826" FT VARIANT 162 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1982759144)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040827" FT VARIANT 162 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040828" FT VARIANT 195 FT /note="A -> T (in dbSNP:rs55800262)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040829" FT VARIANT 259 FT /note="L -> F (in dbSNP:rs1053566)" FT /evidence="ECO:0000269|PubMed:9535930" FT /id="VAR_029890" FT CONFLICT 94 FT /note="Q -> H (in Ref. 2; AAB97813)" FT /evidence="ECO:0000305" FT CONFLICT 106 FT /note="L -> P (in Ref. 4; ABE03013)" FT /evidence="ECO:0000305" FT CONFLICT 133 FT /note="Q -> P (in Ref. 2; AAB97813)" FT /evidence="ECO:0000305" FT CONFLICT 142 FT /note="T -> N (in Ref. 1; AAB88048)" FT /evidence="ECO:0000305" FT CONFLICT 407 FT /note="S -> N (in Ref. 2; AAB97813)" FT /evidence="ECO:0000305" FT CONFLICT 415 FT /note="L -> LG (in Ref. 2; AAB97813)" FT /evidence="ECO:0000305" FT HELIX 87..100 FT /evidence="ECO:0007829|PDB:6YG1" FT STRAND 104..108 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 111..115 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 117..119 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 129..138 FT /evidence="ECO:0007829|PDB:5Y90" FT TURN 140..142 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 145..152 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 157..171 FT /evidence="ECO:0007829|PDB:5Y90" FT TURN 172..175 FT /evidence="ECO:0007829|PDB:6YFZ" FT STRAND 182..187 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 189..196 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 200..202 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 203..210 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 216..237 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 246..248 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 257..259 FT /evidence="ECO:0007829|PDB:5Y90" FT TURN 262..265 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 281..283 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 286..289 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 294..296 FT /evidence="ECO:0007829|PDB:6YZ4" FT HELIX 302..317 FT /evidence="ECO:0007829|PDB:5Y90" FT TURN 321..324 FT /evidence="ECO:0007829|PDB:6YZ4" FT HELIX 328..337 FT /evidence="ECO:0007829|PDB:5Y90" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 351..360 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 365..367 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 371..374 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 378..385 FT /evidence="ECO:0007829|PDB:5Y90" FT HELIX 390..401 FT /evidence="ECO:0007829|PDB:5Y90" SQ SEQUENCE 419 AA; 47485 MW; F1B22E050F54299A CRC64; MAASSLEQKL SRLEAKLKQE NREARRRIDL NLDISPQRPR PTLQLPLAND GGSRSPSSES SPQHPTPPAR PRHMLGLPST LFTPRSMESI EIDQKLQEIM KQTGYLTIGG QRYQAEINDL ENLGEMGSGT CGQVWKMRFR KTGHVIAVKQ MRRSGNKEEN KRILMDLDVV LKSHDCPYIV QCFGTFITNT DVFIAMELMG TCAEKLKKRM QGPIPERILG KMTVAIVKAL YYLKEKHGVI HRDVKPSNIL LDERGQIKLC DFGISGRLVD SKAKTRSAGC AAYMAPERID PPDPTKPDYD IRADVWSLGI SLVELATGQF PYKNCKTDFE VLTKVLQEEP PLLPGHMGFS GDFQSFVKDC LTKDHRKRPK YNKLLEHSFI KRYETLEVDV ASWFKDVMAK TESPRTSGVL SQPHLPFFR // ID MRCKB_HUMAN Reviewed; 1711 AA. AC Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5; DT 08-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 04-APR-2006, sequence version 2. DT 28-JAN-2026, entry version 213. DE RecName: Full=Serine/threonine-protein kinase MRCK beta; DE EC=2.7.11.1; DE AltName: Full=CDC42-binding protein kinase beta; DE Short=CDC42BP-beta; DE AltName: Full=DMPK-like beta; DE AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase beta; DE Short=MRCK beta; DE Short=Myotonic dystrophy protein kinase-like beta; GN Name=CDC42BPB {ECO:0000312|EMBL:AAD37506.1}; GN Synonyms=KIAA1124 {ECO:0000312|EMBL:BAA86438.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD37506.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Brain {ECO:0000312|EMBL:AAD37506.1}; RX PubMed=10198171; DOI=10.1006/geno.1999.5769; RA Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J.; RT "Cloning and chromosomal localization of human Cdc42-binding protein kinase RT beta."; RL Genomics 57:297-300(1999). RN [2] {ECO:0000312|EMBL:BAA86438.2} RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-1203. RC TISSUE=Brain {ECO:0000312|EMBL:BAA86438.2}; RX PubMed=10574461; DOI=10.1093/dnares/6.5.329; RA Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.; RT "Characterization of cDNA clones selected by the GeneMark analysis from RT size-fractionated cDNA libraries from human brain."; RL DNA Res. 6:329-336(1999). RN [3] {ECO:0000305} RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-1077. RG NIEHS SNPs program; RL Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH47871.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-1203. RC TISSUE=PNS {ECO:0000312|EMBL:AAH47871.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH LURAP1 RP AND MYO18A. RX PubMed=18854160; DOI=10.1016/j.cell.2008.09.018; RA Tan I., Yong J., Dong J.M., Lim L., Leung T.; RT "A tripartite complex containing MRCK modulates lamellar actomyosin RT retrograde flow."; RL Cell 135:123-136(2008). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=21240187; DOI=10.1038/emboj.2010.353; RA Huo L., Wen W., Wang R., Kam C., Xia J., Feng W., Zhang M.; RT "Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading edge RT controls cell migration."; RL EMBO J. 30:665-678(2011). RN [14] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ACTIVITY RP REGULATION. RX PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054; RA Tan I., Lai J., Yong J., Li S.F., Leung T.; RT "Chelerythrine perturbs lamellar actomyosin filaments by selective RT inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase."; RL FEBS Lett. 585:1260-1268(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690 AND SER-1693, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-423; SER-1680; SER-1682 AND RP SER-1686, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-671, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [19] RP INTERACTION WITH STRP1; STRN3 AND SIKE1. RX PubMed=25743393; DOI=10.1038/ncomms7449; RA Lant B., Yu B., Goudreault M., Holmyard D., Knight J.D., Xu P., Zhao L., RA Chin K., Wallace E., Zhen M., Gingras A.C., Derry W.B.; RT "CCM-3/STRIPAK promotes seamless tube extension through endocytic RT recycling."; RL Nat. Commun. 6:6449-6449(2015). RN [20] RP PROTEOLYTIC CLEAVAGE. RX PubMed=29162624; DOI=10.1083/jcb.201703044; RA Gagliardi P.A., Somale D., Puliafito A., Chiaverina G., di Blasio L., RA Oneto M., Bianchini P., Bussolino F., Primo L.; RT "MRCKalpha is activated by caspase cleavage to assemble an apical actin RT ring for epithelial cell extrusion."; RL J. Cell Biol. 217:231-249(2018). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 2-417 IN COMPLEXES WITH FASUDIL RP AND TPCA-1, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY. RX PubMed=21949762; DOI=10.1371/journal.pone.0024825; RA Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J., RA Mezna M., Pang L., Rushbrooke M., Turnbull A., Olson M.F.; RT "Co-crystal structures of inhibitors with MRCKbeta, a key regulator of RT tumor cell invasion."; RL PLoS ONE 6:E24825-E24825(2011). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-500; GLN-555; GLN-671; TRP-876; RP LYS-1315 AND TYR-1633. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP INVOLVEMENT IN CHOCNS, AND VARIANTS CHOCNS THR-142; TYR-175; MET-293; RP 764-ARG--THR-1711 DEL; CYS-867; PRO-871; PRO-876; TRP-876; GLN-1299 AND RP PRO-1350. RX PubMed=32031333; DOI=10.1002/ajmg.a.61505; RA Chilton I., Okur V., Vitiello G., Selicorni A., Mariani M., Goldenberg A., RA Husson T., Campion D., Lichtenbelt K.D., van Gassen K., Steinraths M., RA Rice J., Roeder E.R., Littlejohn R.O., Srour M., Sebire G., Accogli A., RA Heron D., Heide S., Nava C., Depienne C., Larson A., Niyazov D., Azage M., RA Hoganson G., Burton J., Rush E.T., Jenkins J.L., Saunders C.J., RA Thiffault I., Alaimo J.T., Fleischer J., Groepper D., Gripp K.W., RA Chung W.K.; RT "De novo heterozygous missense and loss-of-function variants in CDC42BPB RT are associated with a neurodevelopmental phenotype."; RL Am. J. Med. Genet. A 182:962-973(2020). CC -!- FUNCTION: Serine/threonine-protein kinase which is an important CC downstream effector of CDC42 and plays a role in the regulation of CC cytoskeleton reorganization and cell migration. Regulates actin CC cytoskeletal reorganization via phosphorylation of PPP1R12C and CC MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A CC and LURAP1, is involved in modulating lamellar actomyosin retrograde CC flow that is crucial to cell protrusion and migration CC (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In CC concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the CC lamellipodium resulting in its activation and subsequent CC phosphorylation of CFL1 which is important for lamellipodial F-actin CC regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715, CC ECO:0000269|PubMed:21949762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q5VT25}; CC -!- ACTIVITY REGULATION: Maintained in an inactive, closed conformation by CC an interaction between the kinase domain and the negative CC autoregulatory C-terminal coiled-coil region. Agonist binding to the CC phorbol ester binding site disrupts this, releasing the kinase domain CC to allow N-terminus-mediated dimerization and kinase activation by CC transautophosphorylation (By similarity). Inhibited by chelerythrine CC chloride. {ECO:0000250, ECO:0000269|PubMed:21457715}. CC -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions CC (PubMed:21949762). Interacts tightly with GTP-bound but not GDP-bound CC CDC42. Interacts with TJP1, when in the presence of catalytically CC active CDC42 (By similarity). Forms a tripartite complex with MYO18A CC and LURAP1 with the latter acting as an adapter connecting CDC42BPB and CC MYO18A. LURAP1 binding results in activation of CDC42BPB by abolition CC of its negative autoregulation (PubMed:18854160). Interacts with CC STRIP1, STRN3 and SIKE1 (PubMed:25743393). Interacts with CPNE4 (via CC VWFA domain). Interacts with LURAP1. Interacts (via AGC-kinase C- CC terminal domain) with FAM89B/LRAP25 (via LRR repeat). Forms a CC tripartite complex with FAM89B/LRAP25 and LIMK1 (By similarity). CC {ECO:0000250|UniProtKB:Q7TT49, ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21949762, CC ECO:0000269|PubMed:25743393}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane CC {ECO:0000269|PubMed:21240187}; Peripheral membrane protein CC {ECO:0000269|PubMed:21240187}; Cytoplasmic side CC {ECO:0000269|PubMed:21240187}. Cell junction CC {ECO:0000269|PubMed:21240187}. Cell projection, lamellipodium CC {ECO:0000250|UniProtKB:Q3UU96}. Note=Displays a dispersed punctate CC distribution and concentrates along the cell periphery, especially at CC the leading edge and cell-cell junction. This concentration is PH- CC domain dependent (By similarity). Detected at the leading edge of CC migrating cells. Localization at the leading edge of migrating cells CC requires interaction with catalytically active CDC42 (PubMed:21240187). CC Localizes in the lamellipodium in a FAM89B/LRAP25-dependent manner (By CC similarity). {ECO:0000250|UniProtKB:O54874, CC ECO:0000250|UniProtKB:Q3UU96, ECO:0000269|PubMed:21240187}. CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined, with high levels CC in heart, brain, placenta and lung. {ECO:0000269|PubMed:10198171}. CC -!- PTM: Proteolytically cleaved by caspases upon apoptosis induction. CC {ECO:0000269|PubMed:29162624}. CC -!- DISEASE: Chilton-Okur-Chung neurodevelopmental syndrome (CHOCNS) CC [MIM:619841]: A disorder characterized by developmental delay, CC intellectual disability, hypotonia, and structural brain abnormalities CC including cerebellar vermis hypoplasia and agenesis or hypoplasia of CC the corpus callosum. Most patients have behavioral abnormalities, CC including autism spectrum disorder, attention deficit and hyperactivity CC disorder, and aggression. About half of patients have dysmorphic facial CC features. Rare involvement of other organ systems may be present. CC {ECO:0000269|PubMed:32031333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. DMPK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47871.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAA86438.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF128625; AAD37506.1; -; mRNA. DR EMBL; AB032950; BAA86438.2; ALT_INIT; mRNA. DR EMBL; DQ355971; ABC67469.1; -; Genomic_DNA. DR EMBL; BC047871; AAH47871.1; ALT_SEQ; mRNA. DR EMBL; BC155541; AAI55542.1; -; mRNA. DR CCDS; CCDS9978.1; -. DR RefSeq; NP_006026.3; NM_006035.3. DR PDB; 3QFV; X-ray; 2.65 A; A/B=1-415. DR PDB; 3TKU; X-ray; 2.15 A; A/B=2-417. DR PDB; 4UAK; X-ray; 1.73 A; A=2-417. DR PDB; 4UAL; X-ray; 1.71 A; A=2-417. DR PDB; 5OTE; X-ray; 1.68 A; A=2-417. DR PDB; 5OTF; X-ray; 2.00 A; A=2-417. DR PDBsum; 3QFV; -. DR PDBsum; 3TKU; -. DR PDBsum; 4UAK; -. DR PDBsum; 4UAL; -. DR PDBsum; 5OTE; -. DR PDBsum; 5OTF; -. DR AlphaFoldDB; Q9Y5S2; -. DR SMR; Q9Y5S2; -. DR BioGRID; 114947; 127. DR FunCoup; Q9Y5S2; 1147. DR MINT; Q9Y5S2; -. DR STRING; 9606.ENSP00000355237; -. DR BindingDB; Q9Y5S2; -. DR ChEMBL; CHEMBL5052; -. DR DrugCentral; Q9Y5S2; -. DR GlyGen; Q9Y5S2; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9Y5S2; -. DR MetOSite; Q9Y5S2; -. DR PhosphoSitePlus; Q9Y5S2; -. DR SwissPalm; Q9Y5S2; -. DR BioMuta; CDC42BPB; -. DR DMDM; 92090617; -. DR CPTAC; CPTAC-2986; -. DR CPTAC; non-CPTAC-2985; -. DR CPTAC; non-CPTAC-5628; -. DR CPTAC; non-CPTAC-5629; -. DR jPOST; Q9Y5S2; -. DR MassIVE; Q9Y5S2; -. DR PaxDb; 9606-ENSP00000355237; -. DR PeptideAtlas; Q9Y5S2; -. DR ProteomicsDB; 86490; -. DR Pumba; Q9Y5S2; -. DR Antibodypedia; 14692; 175 antibodies from 28 providers. DR DNASU; 9578; -. DR Ensembl; ENST00000361246.7; ENSP00000355237.2; ENSG00000198752.12. DR GeneID; 9578; -. DR KEGG; hsa:9578; -. DR MANE-Select; ENST00000361246.7; ENSP00000355237.2; NM_006035.4; NP_006026.3. DR UCSC; uc001ymi.2; human. DR AGR; HGNC:1738; -. DR ClinPGx; PA26268; -. DR CTD; 9578; -. DR DisGeNET; 9578; -. DR GeneCards; CDC42BPB; -. DR HGNC; HGNC:1738; CDC42BPB. DR HPA; ENSG00000198752; Low tissue specificity. DR MalaCards; CDC42BPB; -. DR MIM; 614062; gene. DR MIM; 619841; phenotype. DR OpenTargets; ENSG00000198752; -. DR VEuPathDB; HostDB:ENSG00000198752; -. DR eggNOG; KOG0612; Eukaryota. DR GeneTree; ENSGT01030000234517; -. DR HOGENOM; CLU_000288_140_3_1; -. DR InParanoid; Q9Y5S2; -. DR OMA; ELEALKX; -. DR OrthoDB; 10047816at2759; -. DR PAN-GO; Q9Y5S2; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y5S2; -. DR PathwayCommons; Q9Y5S2; -. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013406; RHOQ GTPase cycle. DR Reactome; R-HSA-9013409; RHOJ GTPase cycle. DR SignaLink; Q9Y5S2; -. DR SIGNOR; Q9Y5S2; -. DR Agora; ENSG00000198752; -. DR BioGRID-ORCS; 9578; 15 hits in 1188 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CDC42BPB; human. DR EvolutionaryTrace; Q9Y5S2; -. DR GenomeRNAi; 9578; -. DR Pharos; Q9Y5S2; Tchem. DR PRO; PR:Q9Y5S2; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9Y5S2; protein. DR Bgee; ENSG00000198752; Expressed in stromal cell of endometrium and 186 other cell types or tissues. DR ExpressionAtlas; Q9Y5S2; baseline and differential. DR GO; GO:0042641; C:actomyosin; IDA:UniProtKB. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005856; C:cytoskeleton; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; TAS:ProtInc. DR GO; GO:0007163; P:establishment or maintenance of cell polarity; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20865; C1_MRCKbeta; 1. DR CDD; cd00132; CRIB; 1. DR CDD; cd01243; PH_MRCK; 1. DR CDD; cd05624; STKc_MRCK_beta; 1. DR FunFam; 2.30.29.30:FF:000140; CDC42 binding protein kinase beta; 1. DR FunFam; 1.10.510.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.20.5.340:FF:000010; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.60.20:FF:000005; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:001044; Serine/threonine-protein kinase MRCK beta; 1. DR FunFam; 3.30.200.20:FF:001209; Serine/threonine-protein kinase MRCK beta; 1. DR Gene3D; 1.20.5.340; -; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR031597; KELK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR057529; MRCK/ROCK_PH. DR InterPro; IPR042718; MRCKB_STKc. DR InterPro; IPR014930; Myotonic_dystrophy_kinase_coil. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050839; Rho-assoc_Ser/Thr_Kinase. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22988; MYOTONIC DYSTROPHY S/T KINASE-RELATED; 1. DR PANTHER; PTHR22988:SF34; SERINE_THREONINE-PROTEIN KINASE MRCK BETA; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF08826; DMPK_coil; 1. DR Pfam; PF15796; KELK; 1. DR Pfam; PF25346; PH_MRCK; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00285; PBD; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Disease variant; Intellectual disability; Kinase; KW Magnesium; Membrane; Metal-binding; Methylation; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..1711 FT /note="Serine/threonine-protein kinase MRCK beta" FT /id="PRO_0000086394" FT DOMAIN 76..342 FT /note="Protein kinase" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 343..413 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 1095..1214 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 1240..1513 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT DOMAIN 1583..1596 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT ZN_FING 1025..1075 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 461..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 969..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1611..1711 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 431..815 FT /evidence="ECO:0000255" FT COILED 878..939 FT /evidence="ECO:0000255" FT COMPBIAS 463..481 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1641..1650 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1664..1675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 200 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 82..90 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 105 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 221 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 233 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 239 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 423 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 671 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 954 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q7TT50" FT MOD_RES 1680 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1682 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1686 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT VARIANT 142 FT /note="A -> T (in CHOCNS; uncertain significance; FT dbSNP:rs1198710710)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087124" FT VARIANT 175 FT /note="D -> Y (in CHOCNS; uncertain significance; FT dbSNP:rs1595127294)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087125" FT VARIANT 293 FT /note="I -> M (in CHOCNS; uncertain significance; FT dbSNP:rs1016320330)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087126" FT VARIANT 500 FT /note="K -> E (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1158962067)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040834" FT VARIANT 555 FT /note="R -> Q (in dbSNP:rs36001612)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040835" FT VARIANT 671 FT /note="R -> Q (in dbSNP:rs55948035)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040836" FT VARIANT 764..1711 FT /note="Missing (in CHOCNS)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087127" FT VARIANT 867 FT /note="R -> C (in CHOCNS; dbSNP:rs1595472764)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087128" FT VARIANT 871 FT /note="L -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595472756)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087129" FT VARIANT 876 FT /note="R -> P (in CHOCNS; dbSNP:rs1595472739)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087130" FT VARIANT 876 FT /note="R -> W (in a colorectal adenocarcinoma sample and FT CHOCNS; somatic mutation; dbSNP:rs1595472741)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:32031333" FT /id="VAR_040837" FT VARIANT 1077 FT /note="I -> V (in dbSNP:rs34822377)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_025847" FT VARIANT 1203 FT /note="R -> K (in dbSNP:rs146298297)" FT /evidence="ECO:0000269|PubMed:10574461, FT ECO:0000269|PubMed:15489334" FT /id="VAR_070886" FT VARIANT 1299 FT /note="R -> Q (in CHOCNS; uncertain significance; FT dbSNP:rs1595450393)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087131" FT VARIANT 1315 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040838" FT VARIANT 1350 FT /note="R -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595450125)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087132" FT VARIANT 1633 FT /note="S -> Y (in dbSNP:rs56412851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040839" FT CONFLICT 1017 FT /note="A -> V (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT CONFLICT 1123 FT /note="D -> E (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT HELIX 3..20 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:3QFV" FT HELIX 27..41 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 44..47 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 50..69 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 73..75 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 86..95 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 101..108 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 109..114 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 115..118 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 121..130 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 133..135 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 146..153 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 161..167 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 168..170 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 174..193 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 203..205 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:5OTF" FT STRAND 227..229 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 231..235 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 245..250 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 255..258 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 261..276 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 286..294 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 296..299 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 311..318 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 324..326 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 334..337 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 347..349 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 362..365 FT /evidence="ECO:0007829|PDB:4UAK" FT HELIX 396..398 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 403..406 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:3QFV" SQ SEQUENCE 1711 AA; 194315 MW; 041A009E0273ABE0 CRC64; MSAKVRLKKL EQLLLDGPWR NESALSVETL LDVLVCLYTE CSHSALRRDK YVAEFLEWAK PFTQLVKEMQ LHREDFEIIK VIGRGAFGEV AVVKMKNTER IYAMKILNKW EMLKRAETAC FREERDVLVN GDCQWITALH YAFQDENHLY LVMDYYVGGD LLTLLSKFED KLPEDMARFY IGEMVLAIDS IHQLHYVHRD IKPDNVLLDV NGHIRLADFG SCLKMNDDGT VQSSVAVGTP DYISPEILQA MEDGMGKYGP ECDWWSLGVC MYEMLYGETP FYAESLVETY GKIMNHEERF QFPSHVTDVS EEAKDLIQRL ICSRERRLGQ NGIEDFKKHA FFEGLNWENI RNLEAPYIPD VSSPSDTSNF DVDDDVLRNT EILPPGSHTG FSGLHLPFIG FTFTTESCFS DRGSLKSIMQ SNTLTKDEDV QRDLEHSLQM EAYERRIRRL EQEKLELSRK LQESTQTVQS LHGSSRALSN SNRDKEIKKL NEEIERLKNK IADSNRLERQ LEDTVALRQE REDSTQRLRG LEKQHRVVRQ EKEELHKQLV EASERLKSQA KELKDAHQQR KLALQEFSEL NERMAELRAQ KQKVSRQLRD KEEEMEVATQ KVDAMRQEMR RAEKLRKELE AQLDDAVAEA SKERKLREHS ENFCKQMESE LEALKVKQGG RGAGATLEHQ QEISKIKSEL EKKVLFYEEE LVRREASHVL EVKNVKKEVH DSESHQLALQ KEILMLKDKL EKSKRERHNE MEEAVGTIKD KYERERAMLF DENKKLTAEN EKLCSFVDKL TAQNRQLEDE LQDLAAKKES VAHWEAQIAE IIQWVSDEKD ARGYLQALAS KMTEELEALR SSSLGSRTLD PLWKVRRSQK LDMSARLELQ SALEAEIRAK QLVQEELRKV KDANLTLESK LKDSEAKNRE LLEEMEILKK KMEEKFRADT GLKLPDFQDS IFEYFNTAPL AHDLTFRTSS ASEQETQAPK PEASPSMSVA ASEQQEDMAR PPQRPSAVPL PTTQALALAG PKPKAHQFSI KSFSSPTQCS HCTSLMVGLI RQGYACEVCS FACHVSCKDG APQVCPIPPE QSKRPLGVDV QRGIGTAYKG HVKVPKPTGV KKGWQRAYAV VCDCKLFLYD LPEGKSTQPG VIASQVLDLR DDEFSVSSVL ASDVIHATRR DIPCIFRVTA SLLGAPSKTS SLLILTENEN EKRKWVGILE GLQSILHKNR LRNQVVHVPL EAYDSSLPLI KAILTAAIVD ADRIAVGLEE GLYVIEVTRD VIVRAADCKK VHQIELAPRE KIVILLCGRN HHVHLYPWSS LDGAEGSFDI KLPETKGCQL MATATLKRNS GTCLFVAVKR LILCYEIQRT KPFHRKFNEI VAPGSVQCLA VLRDRLCVGY PSGFCLLSIQ GDGQPLNLVN PNDPSLAFLS QQSFDALCAV ELESEEYLLC FSHMGLYVDP QGRRARAQEL MWPAAPVACS CSPTHVTVYS EYGVDVFDVR TMEWVQTIGL RRIRPLNSEG TLNLLNCEPP RLIYFKSKFS GAVLNVPDTS DNSKKQMLRT RSKRRFVFKV PEEERLQQRR EMLRDPELRS KMISNPTNFN HVAHMGPGDG MQVLMDLPLS AVPPSQEERP GPAPTNLARQ PPSRNKPYIS WPSSGGSEPS VTVPLRSMSD PDQDFDKEPD SDSTKHSTPS NSSNPSGPPS PNSPHRSQLP LEGLEQPACD T // ID MSH2_HUMAN Reviewed; 934 AA. AC P43246; B4E2Z2; O75488; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=DNA mismatch repair protein Msh2; DE Short=hMSH2; DE AltName: Full=MutS protein homolog 2; GN Name=MSH2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8252616; DOI=10.1016/0092-8674(93)90546-3; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RT "The human mutator gene homolog MSH2 and its association with hereditary RT nonpolyposis colon cancer."; RL Cell 75:1027-1038(1993). RN [2] RP ERRATUM OF PUBMED:8252616. RX PubMed=8156592; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RL Cell 77:167-167(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYNCH1 LEU-622 AND RP TYR-639. RX PubMed=8261515; DOI=10.1016/0092-8674(93)90330-s; RA Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., RA Peltomaeki P., Sistonen P., Aaltonen L.A., Nystroem-Lahti M., Guan X.-Y., RA Zhang J., Meltzer P.S., Yu J.-W., Kao F.-T., Chen D.J., Cerosaletti K.M., RA Fournier R.E.K., Todd S., Lewis T., Leach R.J., Naylor S.L., RA Weissenbach J., Mecklin J.-P., Jaervinen H., Petersen G.M., Hamilton S.R., RA Green J., Jass J., Watson P., Lynch H.T., Trent J.M., de la Chapelle A., RA Kinzler K.W., Vogelstein B.; RT "Mutations of a mutS homolog in hereditary nonpolyposis colorectal RT cancer."; RL Cell 75:1215-1225(1993). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN MRTES. RX PubMed=7713503; DOI=10.1006/geno.1994.1661; RA Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R.S., Morrison P., RA Wirth L., Finan P.J., Burn J., Chapman P., Earabino C., Merchant E., RA Bishop D.T.; RT "Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds RT for msh2 mutations."; RL Genomics 24:516-526(1994). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-96. RX PubMed=7726159; RA Wijnen J., Vasen H., Khan P.M., Menko F.H., van der Klift H., RA van Leeuwen C., van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer A., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Fodde R.; RT "Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing RT gradient-gel electrophoresis."; RL Am. J. Hum. Genet. 56:1060-1066(1995). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-8; CYS-43; SER-127; RP ASP-322 AND PHE-390. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 375-425. RC TISSUE=Blood; RA Corvello C.M., Bevilacqua R.A.U., Rossi B.M., Simpson A.J.G.; RT "A novel germline mutation at exon 7 of the hMSH2 gene (417 del G) in a RT large HNPCC Brazilian kindred."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP DNA-BINDING. RX PubMed=7923193; RA Fishel R., Ewel A., Lescoe M.K.; RT "Purified human MSH2 protein binds to DNA containing mismatched RT nucleotides."; RL Cancer Res. 54:5539-5542(1994). RN [13] RP DNA-BINDING. RX PubMed=8769132; DOI=10.1006/bbrc.1996.1168; RA Whitehouse A., Taylor G.R., Deeble J., Phillips S.E., Meredith D.M., RA Markham A.F.; RT "A carboxy terminal domain of the hMSH-2 gene product is sufficient for RT binding specific mismatched oligonucleotides."; RL Biochem. Biophys. Res. Commun. 225:289-295(1996). RN [14] RP INTERACTION WITH MSH3 AND MSH6. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [15] RP INTERACTION WITH EXO1. RX PubMed=9788596; RA Schmutte C., Marinescu R.C., Sadoff M.M., Guerrette S., Overhauser J., RA Fishel R.; RT "Human exonuclease I interacts with the mismatch repair protein hMSH2."; RL Cancer Res. 58:4537-4542(1998). RN [16] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [17] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [18] RP FUNCTION, AND MUTAGENESIS OF LYS-675. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [19] RP MISMATCH-BINDING, AND CHARACTERIZATION OF VARIANT LYNCH1 PRO-524. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [20] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [21] RP IDENTIFICATION OF MSH2 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [22] RP INTERACTION WITH EXO1, AND TISSUE SPECIFICITY. RX PubMed=10856833; DOI=10.1016/s0921-8777(00)00012-4; RA Rasmussen L.J., Rasmussen M., Lee B.-I., Rasmussen A.K., Wilson D.M. III, RA Nielsen F.C., Bisgaard H.C.; RT "Identification of factors interacting with hMSH2 in the fetal liver RT utilizing the yeast two-hybrid system. In vivo interaction through the C- RT terminal domains of hEXO1 and hMSH2 and comparative expression analysis."; RL Mutat. Res. 460:41-52(2000). RN [23] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [24] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=11306449; RA Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaeki R., RA Salovaara R., Arola J., Butzow R., Jiricny J., Peltomaeki P., RA Nystroem-Lahti M.; RT "Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas RT in hereditary nonpolyposis colorectal cancer."; RL Cancer Res. 61:2813-2815(2001). RN [25] RP INTERACTION WITH EXO1. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [26] RP INTERACTION WITH EXO1. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [27] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [28] RP INVOLVEMENT IN MMRCS2. RX PubMed=12549480; DOI=10.1086/345297; RA Bougeard G., Charbonnier F., Moerman A., Martin C., Ruchoux M.M., RA Drouot N., Frebourg T.; RT "Early onset brain tumor and lymphoma in MSH2-deficient children."; RL Am. J. Hum. Genet. 72:213-216(2003). RN [29] RP INTERACTION WITH ATR, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [30] RP INTERACTION WITH EXO1. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [31] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [32] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [33] RP INVOLVEMENT IN MMRCS2. RX PubMed=16372347; DOI=10.1002/ajmg.a.31070; RA Mueller A., Schackert H.K., Lange B., Rueschoff J., Fuezesi L., Willert J., RA Burfeind P., Shah P., Becker H., Epplen J.T., Stemmler S.; RT "A novel MSH2 germline mutation in homozygous state in two brothers with RT colorectal cancers diagnosed at the age of 11 and 12 years."; RL Am. J. Med. Genet. A 140:195-199(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [35] RP FUNCTION. RX PubMed=17611581; DOI=10.1038/sj.jid.5700941; RA Seifert M., Scherer S.J., Edelmann W., Bohm M., Meineke V., Lobrich M., RA Tilgen W., Reichrath J.; RT "The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle RT arrest and apoptosis in melanoma cells."; RL J. Invest. Dermatol. 128:203-213(2008). RN [36] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-555, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-921, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [40] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-845; LYS-847; LYS-871 AND LYS-892, RP DEACETYLATION BY HDAC6, UBIQUITINATION AT LYS-845; LYS-847; LYS-871 AND RP LYS-892, AND MUTAGENESIS OF LYS-845; LYS-847; LYS-871 AND LYS-892. RX PubMed=24882211; DOI=10.1016/j.molcel.2014.04.028; RA Zhang M., Xiang S., Joo H.Y., Wang L., Williams K.A., Liu W., Hu C., RA Tong D., Haakenson J., Wang C., Zhang S., Pavlovicz R.E., Jones A., RA Schmidt K.H., Tang J., Dong H., Shan B., Fang B., Radhakrishnan R., RA Glazer P.M., Matthias P., Koomen J., Seto E., Bepler G., Nicosia S.V., RA Chen J., Li C., Gu L., Li G.M., Bai W., Wang H., Zhang X.; RT "HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of RT MutSalpha."; RL Mol. Cell 55:31-46(2014). RN [41] RP FUNCTION, IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND RP MCM8, AND SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [42] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-430, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [43] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; MET-44; VAL-45; SER-127; RP MET-145; ASP-161; ARG-162; ARG-164; PRO-173; ARG-187; PRO-187; VAL-272; RP TYR-333; LEU-519; ASN-603; PRO-636; ALA-674; VAL-688; PHE-697; RP 745-ILE-ILE-746 DEL; LYS-749; THR-834; GLY-886 AND GLU-923, RP CHARACTERIZATION OF VARIANTS ASP-322 AND ILE-722, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [44] RP REVIEW. RX PubMed=8036718; DOI=10.1016/0168-9525(94)90093-0; RA Jiricny J.; RT "Colon cancer and DNA repair: have mismatches met their match?"; RL Trends Genet. 10:164-168(1994). RN [45] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [46] RP REVIEW. RX PubMed=17080293; DOI=10.1007/s10735-006-9062-5; RA Seifert M., Reichrath J.; RT "The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell RT cycle control and apoptosis: implications for pathogenesis, progression and RT therapy of cancer."; RL J. Mol. Histol. 37:301-307(2006). RN [47] RP INTERACTION WITH SMARCAD1. RX PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031; RA Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T., RA Ohara O., Koga H.; RT "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of RT TSS."; RL J. Mol. Biol. 382:257-265(2008). RN [48] RP INTERACTION WITH SLX4. RX PubMed=19596235; DOI=10.1016/j.cell.2009.06.030; RA Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P., RA Elledge S.J., Harper J.W.; RT "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is RT required for DNA repair."; RL Cell 138:63-77(2009). RN [49] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=21642682; DOI=10.1001/jama.2011.743; RG French Cancer Genetics Network; RA Bonadona V., Bonaiti B., Olschwang S., Grandjouan S., Huiart L., Longy M., RA Guimbaud R., Buecher B., Bignon Y.J., Caron O., Colas C., Nogues C., RA Lejeune-Dumoulin S., Olivier-Faivre L., Polycarpe-Osaer F., Nguyen T.D., RA Desseigne F., Saurin J.C., Berthet P., Leroux D., Duffour J., RA Manouvrier S., Frebourg T., Sobol H., Lasset C., Bonaiti-Pellie C.; RT "Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 RT genes in Lynch syndrome."; RL JAMA 305:2304-2310(2011). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [51] RP VARIANT LYNCH1 ASN-596 DEL. RX PubMed=7874129; RA Mary J.-L., Bishop T., Kolodner R.D., Lipford J.R., Kane M.F., Weber W., RA Torhorst J., Mueller H., Spycher M., Scott R.J.; RT "Mutational analysis of the hMSH2 gene reveals a three base pair deletion RT in a family predisposed to colorectal cancer development."; RL Hum. Mol. Genet. 3:2067-2069(1994). RN [52] RP VARIANTS PHE-390 AND LYS-419. RX PubMed=8690195; DOI=10.1053/gast.1996.v111.pm8690195; RA Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., RA Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., RA Nomizu S., Konishi F., Utsunomiya J., Miyaki M.; RT "Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, RT familial polyposis, and sporadic colon cancer."; RL Gastroenterology 111:307-317(1996). RN [53] RP VARIANT ASP-322. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [54] RP VARIANT LYNCH1 ASN-596 DEL, AND VARIANT HIS-167. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [55] RP VARIANT LYNCH1 TYR-506. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [56] RP VARIANT LYNCH1 GLN-46. RX PubMed=8700523; RA Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., RA Morris R.G., White S., Bird C.C., Wyllie A.H.; RT "Microsatellite instability and the role of hMSH2 in sporadic colorectal RT cancer."; RL Oncogene 12:2641-2649(1996). RN [57] RP VARIANTS LYNCH1 THR-305; ASN-596 DEL AND THR-834. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [58] RP VARIANT LYNCH1 CYS-323. RX PubMed=9240418; DOI=10.1006/bbrc.1997.6942; RA Akiyama Y., Tsubouchi N., Yuasa Y.; RT "Frequent somatic mutations of hMSH3 with reference to microsatellite RT instability in hereditary nonpolyposis colorectal cancers."; RL Biochem. Biophys. Res. Commun. 236:248-252(1997). RN [59] RP VARIANTS LYNCH1 THR-110; ARG-639; LYS-647; HIS-656; THR-679; VAL-729 AND RP ILE-732. RX PubMed=9419403; RA Nakahara M., Yokozaki H., Yasui W., Dohi K., Tahara E.; RT "Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in RT Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Cancer Epidemiol. Biomarkers Prev. 6:1057-1064(1997). RN [60] RP VARIANT SER-596. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [61] RP VARIANT ASP-322. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [62] RP VARIANT LYNCH1 VAL-562. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [63] RP VARIANT LYNCH1 PHE-697, AND VARIANT ASP-322. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [64] RP VARIANT LYNCH1 265-VAL--GLN-314 DEL, AND VARIANTS GLY-641 AND VAL-770. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [65] RP VARIANT ARG-199. RX PubMed=9777949; DOI=10.1016/s0002-9440(10)65662-3; RA Leung S.Y., Chan T.L., Chung L.P., Chan A.S.Y., Fan Y.W., Hung K.N., RA Kwong W.K., Ho J.W.C., Yuen S.T.; RT "Microsatellite instability and mutation of DNA mismatch repair genes in RT gliomas."; RL Am. J. Pathol. 153:1181-1188(1998). RN [66] RP VARIANT CRC TYR-506, AND VARIANT LYNCH1 ILE-688. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [67] RP VARIANT ASP-322. RX PubMed=10023327; DOI=10.1016/s0959-8049(98)00217-2; RA Liu T., Stathopoulos P., Lindblom P., Rubio C., Wasteson Arver B., RA Iselius L., Holmberg E., Groenberg H., Lindblom A.; RT "MSH2 codon 322 Gly to Asp does not seem to confer an increased risk for RT colorectal cancer susceptibility."; RL Eur. J. Cancer 34:1981-1981(1998). RN [68] RP VARIANT LYNCH1 PHE-390. RX PubMed=9621522; DOI=10.1007/s100380050057; RA Okamura S., Koyama K., Miyoshi Y., Monden M., Takami M.; RT "Novel germline mutations of hMSH2 in a patient with hereditary RT nonpolyposis colorectal cancer 'HNPCC' and in a patient with six primary RT cancers."; RL J. Hum. Genet. 43:143-145(1998). RN [69] RP VARIANTS LYNCH1 SER-336 AND ASN-596 DEL. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [70] RP CHARACTERIZATION OF VARIANTS ASP-322; PHE-390; LYS-419; TYR-506; PRO-524; RP LEU-622 AND PHE-697. RX PubMed=10469597; DOI=10.1016/s0960-9822(99)80396-0; RA Drotschmann K., Clark A.B., Kunkel T.A.; RT "Mutator phenotypes of common polymorphisms and missense mutations in RT MSH2."; RL Curr. Biol. 9:907-910(1999). RN [71] RP VARIANTS LYNCH1 GLN-246; SER-596 AND THR-834, AND VARIANT ASP-322. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [72] RP VARIANT LYNCH1 PHE-390. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH1 PRO-636. RX PubMed=10528862; DOI=10.1136/jmg.36.10.792; RA Yuan Z.Q., Wong N., Foulkes W.D., Alpert L., Manganaro F., RA Andreutti-Zaugg C., Iggo R., Anthony K., Hsieh E., Redston M., Pinsky L., RA Trifiro M., Gordon P.H., Lasko D.; RT "A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC RT kindred: implications for clinical screening."; RL J. Med. Genet. 36:790-793(1999). RN [74] RP VARIANTS LYNCH1 ILE-688 AND GLU-845, AND VARIANT MET-8. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANT ASP-322. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANTS LYNCH1 ARG-692 AND ARG-697. RX PubMed=10612836; RX DOI=10.1002/(sici)1098-1004(200001)15:1<116::aid-humu24>3.0.co;2-q; RA Isidro G., Veiga I., Matos P., Almeida S., Bizarro S., Marshall B., RA Baptista M., Leite J., Regateiro F., Soares J., Castedo S., Boavida M.G.; RT "Four novel MSH2 / MLH1 gene mutations in Portuguese HNPCC families."; RL Hum. Mutat. 15:116-116(2000). RN [77] RP VARIANT LYNCH1 ASN-603, AND VARIANT ASP-322. RX PubMed=10829038; DOI=10.1200/jco.2000.18.11.2193; RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RT "Population-based molecular detection of hereditary nonpolyposis colorectal RT cancer."; RL J. Clin. Oncol. 18:2193-2200(2000). RN [78] RP ERRATUM OF PUBMED:10829038. RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RL J. Clin. Oncol. 18:3456-3456(2000). RN [79] RP VARIANTS GASTRIC CANCER PHE-17; GLU-824; ALA-868; GLY-870 AND GLY-873, AND RP VARIANTS LYNCH1 CYS-98; TYR-323; ILE-335; ARG-629 AND VAL-714. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [80] RP VARIANTS LYNCH1 ASP-161; VAL-216 AND ARG-554. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [81] RP CHARACTERIZATION OF VARIANTS ASP-322; LEU-622 AND TYR-639. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [82] RP VARIANT LYNCH1 VAL-813. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [83] RP VARIANTS LYNCH1 VAL-600 AND PHE-723. RX PubMed=11920458; DOI=10.1002/cncr.10332.abs; RA Furukawa T., Konishi F., Shitoh K., Kojima M., Nagai H., Tsukamoto T.; RT "Evaluation of screening strategy for detecting hereditary nonpolyposis RT colorectal carcinoma."; RL Cancer 94:911-920(2002). RN [84] RP VARIANTS LYNCH1 HIS-167; MET-393; PRO-524; ASN-596 DEL; LEU-622; SER-674 RP AND ARG-905, AND CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; MET-393; RP PRO-524; ASN-596 DEL; LEU-622; SER-674 AND ARG-905. RX PubMed=12124176; DOI=10.1016/s1535-6108(02)00073-9; RA Heinen C.D., Wilson T., Mazurek A., Berardini M., Butz C., Fishel R.; RT "HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch RT functions."; RL Cancer Cell 1:469-478(2002). RN [85] RP INVOLVEMENT IN MULTIPLE CAFE-AU-LAIT SPOTS WITH LEUKEMIA. RX PubMed=11809679; RA Whiteside D., McLeod R., Graham G., Steckley J.L., Booth K., RA Somerville M.J., Andrew S.E.; RT "A homozygous germ-line mutation in the human MSH2 gene predisposes to RT hematological malignancy and multiple cafe-au-lait spots."; RL Cancer Res. 62:359-362(2002). RN [86] RP VARIANT ASP-322. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [87] RP VARIANTS LYNCH1 MET-44; VAL-45; ASN-596 DEL; GLY-886 AND GLU-923. RX PubMed=12112654; DOI=10.1002/humu.10083; RA Bisgaard M.L., Jaeger A.C., Myrhoej T., Bernstein I., Nielsen F.C.; RT "Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype RT correlation between patients with and without identified mutation."; RL Hum. Mutat. 20:20-27(2002). RN [88] RP VARIANTS LYNCH1 ILE-102; ASP-163 AND ALA-564, AND VARIANT ASP-322. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [89] RP VARIANTS LYNCH1 HIS-167 AND SER-359. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [90] RP VARIANTS LYNCH1 LEU-92 DEL AND ALA-853, AND VARIANT ASP-322. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [91] RP VARIANTS LYNCH1 PRO-552; SER-583 AND PRO-636. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [92] RP VARIANTS CRC ILE-13 AND ILE-342, AND VARIANT ASP-322. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [93] RP VARIANT LYNCH1 SER-127. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [94] RP VARIANT LYNCH1 PRO-175. RX PubMed=12655568; DOI=10.1002/humu.9127; RA Bartosova Z., Fridrichova I., Bujalkova M., Wolf B., Ilencikova D., RA Krizan P., Hlavcak P., Palaj J., Lukac L., Lukacova M., Boeoer A., RA Haider R., Jiricny J., Nystroem-Lahti M., Marra G.; RT "Novel MLH1 and MSH2 germline mutations in the first HNPCC families RT identified in Slovakia."; RL Hum. Mutat. 21:449-449(2003). RN [95] RP VARIANTS LYNCH1 GLY-163 AND GLY-660. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [96] RP VARIANTS CRC SER-40; VAL-169; ARG-203; PHE-390; LYS-419; CYS-619 AND RP ARG-629, AND VARIANT MET-8. RX PubMed=12792735; RA Yamada K., Zhong X., Kanazawa S., Koike J., Tsujita K., Hemmi H.; RT "Oncogenic pathway of sporadic colorectal cancer with novel germline RT missense mutations in the hMSH2 gene."; RL Oncol. Rep. 10:859-866(2003). RN [97] RP VARIANT LYNCH1 THR-931. RX PubMed=15046096; RA Sun M.H., Cai Q., Fu G., Ren S., Mo S., Xu Y., Ding C., Zhang T., Zhu X., RA Xu X., Min D., Cai S., Luo D., Shi Y., Shi D.; RT "Gene symbol: hMSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 114:409-409(2004). RN [98] RP VARIANT LYNCH1 TYR-671. RX PubMed=15300854; DOI=10.1002/humu.9267; RA Sharp A., Pichert G., Lucassen A., Eccles D.; RT "RNA analysis reveals splicing mutations and loss of expression defects in RT MLH1 and BRCA1."; RL Hum. Mutat. 24:272-272(2004). RN [99] RP VARIANTS LYNCH1 LEU-440 DEL; TYR-506; ARG-629 AND ILE-688. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [100] RP VARIANT LYNCH1 ARG-839, AND VARIANT ARG-629. RX PubMed=15613555; DOI=10.1093/jjco/hyh121; RA Yuan Y., Huang Y.-Q., Cai S.-R., Song Y.-M., Zheng S., Zhang S.-Z.; RT "Genetic characterization of Chinese hereditary non-polyposis colorectal RT cancer by DHPLC and multiplex PCR."; RL Jpn. J. Clin. Oncol. 34:660-666(2004). RN [101] RP VARIANTS LYNCH1 LEU-349 AND ASN-596 DEL. RX PubMed=15342696; DOI=10.1136/jmg.2004.020651; RA Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., RA Westra J., Frebourg T., Espin E., Armengol M., Hamelin R., Yamamoto H., RA Hofstra R.M.W., Seruca R., Lindblom A., Peltomaeki P., Thibodeau S.N., RA Aaltonen L.A., Schwartz S. Jr.; RT "BRAF screening as a low-cost effective strategy for simplifying HNPCC RT genetic testing."; RL J. Med. Genet. 41:664-668(2004). RN [102] RP VARIANT LYNCH1 PHE-93. RX PubMed=15896463; DOI=10.1016/j.canlet.2004.09.051; RA Baudi F., Fersini G., Lavecchia A., Terracciano R., Leone F., Quaresima B., RA Faniello M.C., De Paola L., Doldo P., Cuda G., Costanzo F., Venuta S.; RT "A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC RT family from Southern Italy."; RL Cancer Lett. 223:285-291(2005). RN [103] RP VARIANTS LYNCH1 VAL-169; PHE-390; ALA-564 AND ARG-629, AND VARIANT CRC RP LYS-419. RX PubMed=15996210; DOI=10.1111/j.1399-0004.2005.00469.x; RA Lee S.-C., Guo J.-Y., Lim R., Soo R., Koay E., Salto-Tellez M., Leong A., RA Goh B.-C.; RT "Clinical and molecular characteristics of hereditary non-polyposis RT colorectal cancer families in Southeast Asia."; RL Clin. Genet. 68:137-145(2005). RN [104] RP VARIANT LYNCH1 TYR-283. RX PubMed=15870828; DOI=10.1038/sj.ejhg.5201421; RA Wehner M., Mangold E., Sengteller M., Friedrichs N., Aretz S., Friedl W., RA Propping P., Pagenstecher C.; RT "Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening RT in MSH2 and MLH1 genes."; RL Eur. J. Hum. Genet. 13:983-986(2005). RN [105] RP VARIANT LYNCH1 ARG-162. RX PubMed=15991316; RA Kohonen-Corish M.R.J., Otway R., Tetlow N., Hornby J., Doe W.F.; RT "Gene symbol: MSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 116:539-539(2005). RN [106] RP VARIANTS LYNCH1 THR-2; LEU-92 DEL; MET-145; PHE-390 AND ALA-853, AND RP VARIANT ASP-322. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [107] RP VARIANTS LYNCH1 PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; RP TYR-333; ASN-603; PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, RP VARIANTS VAL-272; THR-834 AND GLU-923, CHARACTERIZATION OF VARIANTS LYNCH1 RP PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; TYR-333; ASN-603; RP PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, AND CHARACTERIZATION OF RP VARIANTS VAL-272; THR-834 AND GLU-923. RX PubMed=17101317; DOI=10.1053/j.gastro.2006.08.044; RA Ollila S., Sarantaus L., Kariola R., Chan P., Hampel H., Holinski-Feder E., RA Macrae F., Kohonen-Corish M., Gerdes A.-M., Peltomaeki P., Mangold E., RA de la Chapelle A., Greenblatt M., Nystroem M.; RT "Pathogenicity of MSH2 missense mutations is typically associated with RT impaired repair capability of the mutated protein."; RL Gastroenterology 131:1408-1417(2006). RN [108] RP VARIANT LYNCH1 ALA-162. RX PubMed=17128465; RA Leonardis D.; RT "Gene symbol: msh2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 119:675-675(2006). RN [109] RP VARIANT LYNCH1 ARG-674. RX PubMed=18625694; DOI=10.1136/gut.2008.156695; RA Ramsoekh D., Wagner A., van Leerdam M.E., Dinjens W.N., Steyerberg E.W., RA Halley D.J., Kuipers E.J., Dooijes D.; RT "A high incidence of MSH6 mutations in Amsterdam criteria II-negative RT families tested in a diagnostic setting."; RL Gut 57:1539-1544(2008). RN [110] RP VARIANTS GLN-46; LYS-106; ASP-322; SER-596; LEU-670; ILE-779; SER-807; RP HIS-835 AND ARG-911. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [111] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; SER-127; ASP-161; ARG-162; RP ARG-164; PRO-173; PRO-187; VAL-272; TYR-333; ASN-603; PRO-636; ALA-674; RP PHE-697; 745-ILE-ILE-746 DEL; LYS-749; THR-834 AND GLU-923, AND RP CHARACTERIZATION OF VARIANT ASP-322. RX PubMed=18951462; DOI=10.1002/humu.20893; RA Ollila S., Dermadi Bebek D., Jiricny J., Nystroem M.; RT "Mechanisms of pathogenicity in human MSH2 missense mutants."; RL Hum. Mutat. 29:1355-1363(2008). RN [112] RP VARIANTS LYNCH1 LEU-92 DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; RP GLU-645; LEU-696; TYR-748 AND GLN-839, VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723, CHARACTERIZATION OF VARIANTS LYNCH1 LEU-92 RP DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; GLU-645; LEU-696; TYR-748 RP AND GLN-839, AND CHARACTERIZATION OF VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [113] RP CHARACTERIZATION OF VARIANTS LYNCH1 ARG-162; HIS-167 AND SER-359. RX PubMed=18781619; DOI=10.1002/humu.20875; RA Belvederesi L., Bianchi F., Galizia E., Loretelli C., Bracci R., RA Catalani R., Amati M., Cellerino R.; RT "MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a RT human expression system."; RL Hum. Mutat. 29:E296-E309(2008). RN [114] RP CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; THR-305: LEU-622; ARG-639; RP ARG-674; PHE-697 AND THR-834. RX PubMed=18822302; DOI=10.1016/j.mrfmmm.2008.08.015; RA Lutzen A., de Wind N., Georgijevic D., Nielsen F.C., Rasmussen L.J.; RT "Functional analysis of HNPCC-related missense mutations in MSH2."; RL Mutat. Res. 645:44-55(2008). RN [115] RP CHARACTERIZATION OF VARIANTS LYNCH1 MET-44; VAL-45; HIS-167; THR-305; RP PHE-390; ASN-596 DEL; ARG-639; ARG-674; PHE-697; PHE-723 AND GLY-886, AND RP CHARACTERIZATION OF VARIANTS ASP-165; HIS-177; VAL-272; LEU-385; LEU-519; RP ALA-675; GLU-759; VAL-805; GLY-843 AND LEU-860. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [116] RP CHARACTERIZATION OF VARIANTS SER-127; MET-145; GLN-205; ASP-322; PRO-328; RP ILE-367; GLU-487 AND ILE-909. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). RN [117] RP VARIANT LYNCH1 ARG-669. RX PubMed=22371642; DOI=10.3748/wjg.v18.i8.814; RA Zahary M.N., Kaur G., Abu Hassan M.R., Singh H., Naik V.R., Ankathil R.; RT "Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome RT patients."; RL World J. Gastroenterol. 18:814-820(2012). RN [118] RP VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839, AND CHARACTERIZATION RP OF VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 CC heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA CC mismatches thereby initiating DNA repair. When bound, heterodimers bend CC the DNA helix and shields approximately 20 base pairs. MutS alpha CC recognizes single base mismatches and dinucleotide insertion-deletion CC loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion CC loops up to 13 nucleotides long. After mismatch binding, MutS alpha or CC beta forms a ternary complex with the MutL alpha heterodimer, which is CC thought to be responsible for directing the downstream MMR events, CC including strand discrimination, excision, and resynthesis. Recruits CC DNA helicase MCM9 to chromatin which unwinds the mismatch containing CC DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. In melanocytes may CC modulate both UV-B-induced cell cycle regulation and apoptosis. CC {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:17611581, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:26300262, CC ECO:0000269|PubMed:9564049, ECO:0000269|PubMed:9822679, CC ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) or MSH2-MSH3 (MutS beta) CC (PubMed:8942985). Both heterodimers form a ternary complex with MutL CC alpha (MLH1-PMS1) (PubMed:10856833, PubMed:11427529, PubMed:11429708, CC PubMed:12414623, PubMed:14676842, PubMed:9788596). Interacts with MCM9; CC the interaction recruits MCM9 to chromatin (PubMed:26300262). Interacts CC with MCM8 (PubMed:26300262). Interacts with EXO1 (PubMed:10856833, CC PubMed:11427529, PubMed:11429708, PubMed:12414623, PubMed:14676842, CC PubMed:9788596). Part of the BRCA1-associated genome surveillance CC complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 CC and the RAD50-MRE11-NBS1 protein complex (PubMed:10783165). This CC association could be a dynamic process changing throughout the cell CC cycle and within subnuclear domains (PubMed:10783165). Interacts with CC ATR (PubMed:14657349). Interacts with SLX4/BTBD12; this interaction is CC direct and links MutS beta to SLX4, a subunit of different structure- CC specific endonucleases (PubMed:19596235). Interacts with SMARCAD1 CC (PubMed:18675275). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:18675275, ECO:0000269|PubMed:19596235, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:8942985, CC ECO:0000269|PubMed:9788596}. CC -!- INTERACTION: CC P43246; Q92624: APPBP2; NbExp=3; IntAct=EBI-355888, EBI-743771; CC P43246; Q9UQ84-1: EXO1; NbExp=3; IntAct=EBI-355888, EBI-944694; CC P43246; P09429: HMGB1; NbExp=2; IntAct=EBI-355888, EBI-389432; CC P43246; P20585: MSH3; NbExp=14; IntAct=EBI-355888, EBI-1164205; CC P43246; P52701: MSH6; NbExp=11; IntAct=EBI-355888, EBI-395529; CC P43246; Q8IY92: SLX4; NbExp=5; IntAct=EBI-355888, EBI-2370740; CC P43246; P39875: EXO1; Xeno; NbExp=2; IntAct=EBI-355888, EBI-6738; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24882211, CC ECO:0000269|PubMed:26300262}. Chromosome {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P43246-1; Sequence=Displayed; CC Name=2; CC IsoId=P43246-2; Sequence=VSP_045536; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. CC {ECO:0000269|PubMed:10856833}. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- PTM: Sequentially deacetylated and polyubiquitinated by HDAC6, leading CC to MSH2 degradation. {ECO:0000269|PubMed:24882211}. CC -!- DISEASE: Lynch syndrome 1 (LYNCH1) [MIM:120435]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10375096, ECO:0000269|PubMed:10386556, CC ECO:0000269|PubMed:10528862, ECO:0000269|PubMed:10573010, CC ECO:0000269|PubMed:10612836, ECO:0000269|PubMed:10777691, CC ECO:0000269|PubMed:10829038, ECO:0000269|PubMed:11726306, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:11920458, CC ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:12655568, CC ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14635101, CC ECO:0000269|PubMed:15046096, ECO:0000269|PubMed:15300854, CC ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15870828, CC ECO:0000269|PubMed:15896463, ECO:0000269|PubMed:15991316, CC ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:17128465, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18625694, CC ECO:0000269|PubMed:18781619, ECO:0000269|PubMed:18822302, CC ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22371642, CC ECO:0000269|PubMed:7874129, ECO:0000269|PubMed:8261515, CC ECO:0000269|PubMed:8700523, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9048925, CC ECO:0000269|PubMed:9240418, ECO:0000269|PubMed:9298827, CC ECO:0000269|PubMed:9311737, ECO:0000269|PubMed:9419403, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9621522, CC ECO:0000269|PubMed:9718327, ECO:0000269|PubMed:9889267}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:7713503}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000305|PubMed:11306449, CC ECO:0000305|PubMed:21642682}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 2 (MMRCS2) [MIM:619096]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:12549480, CC ECO:0000269|PubMed:16372347}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12792735, CC ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:15996210, CC ECO:0000269|PubMed:9559627}. Note=Disease susceptibility may be CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC27930.1; Type=Frameshift; Note=The frameshift is caused by a single nucleotide deletion which is found in a HNPCC kindred.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/340/MSH2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03911; AAA18643.1; -; mRNA. DR EMBL; U04045; AAA61870.1; -; mRNA. DR EMBL; U41221; AAA82080.1; ALT_SEQ; Genomic_DNA. DR EMBL; U41206; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41207; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41208; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41210; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41211; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41212; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41213; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41214; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41215; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41216; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41217; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41218; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41219; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41220; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; L47583; AAB59564.1; -; mRNA. DR EMBL; L47582; AAB59565.1; -; mRNA. DR EMBL; L47581; AAA76858.1; -; mRNA. DR EMBL; AY601851; AAS99351.1; -; Genomic_DNA. DR EMBL; AK304496; BAG65304.1; -; mRNA. DR EMBL; BX649122; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC079775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC021566; AAH21566.1; -; mRNA. DR EMBL; AF066081; AAC27930.1; ALT_FRAME; Genomic_DNA. DR CCDS; CCDS1834.1; -. [P43246-1] DR CCDS; CCDS58709.1; -. [P43246-2] DR PIR; I64819; I64819. DR RefSeq; NP_000242.1; NM_000251.3. [P43246-1] DR RefSeq; NP_001245210.1; NM_001258281.1. [P43246-2] DR RefSeq; NP_001393570.1; NM_001406641.1. [P43246-1] DR PDB; 2O8B; X-ray; 2.75 A; A=1-934. DR PDB; 2O8C; X-ray; 3.37 A; A=1-934. DR PDB; 2O8D; X-ray; 3.00 A; A=1-934. DR PDB; 2O8E; X-ray; 3.30 A; A=1-934. DR PDB; 2O8F; X-ray; 3.25 A; A=1-934. DR PDB; 3THW; X-ray; 3.09 A; A=1-934. DR PDB; 3THX; X-ray; 2.70 A; A=1-934. DR PDB; 3THY; X-ray; 2.89 A; A=1-934. DR PDB; 3THZ; X-ray; 4.30 A; A=1-934. DR PDB; 8AG6; EM; 2.80 A; A=1-934. DR PDB; 8OLX; EM; 3.10 A; A=1-934. DR PDB; 8OM5; EM; 3.52 A; A=1-934. DR PDB; 8OM9; EM; 3.32 A; A=1-934. DR PDB; 8OMA; EM; 3.29 A; A=1-934. DR PDB; 8OMO; EM; 3.43 A; A=1-934. DR PDB; 8OMQ; EM; 3.11 A; A=1-934. DR PDB; 8R7C; X-ray; 2.82 A; A/E=1-930. DR PDB; 8R7E; X-ray; 2.78 A; A/E=1-930. DR PDB; 8R7V; EM; 3.12 A; A=1-934. DR PDB; 8RAU; X-ray; 2.33 A; A=1-934. DR PDB; 8RAV; X-ray; 2.63 A; A=1-934. DR PDB; 8RAW; X-ray; 2.69 A; A=1-934. DR PDB; 8RAX; X-ray; 3.16 A; A=1-934. DR PDB; 8RAZ; X-ray; 2.84 A; A=1-934. DR PDB; 8RB0; X-ray; 2.67 A; A=1-934. DR PDB; 8RB1; X-ray; 2.08 A; A=1-934. DR PDB; 8RB2; X-ray; 2.53 A; A/E=1-934. DR PDB; 8RZ7; EM; 3.37 A; A=1-934. DR PDB; 8RZ8; EM; 3.06 A; A=1-934. DR PDB; 8RZ9; EM; 3.02 A; A=1-934. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 3THW; -. DR PDBsum; 3THX; -. DR PDBsum; 3THY; -. DR PDBsum; 3THZ; -. DR PDBsum; 8AG6; -. DR PDBsum; 8OLX; -. DR PDBsum; 8OM5; -. DR PDBsum; 8OM9; -. DR PDBsum; 8OMA; -. DR PDBsum; 8OMO; -. DR PDBsum; 8OMQ; -. DR PDBsum; 8R7C; -. DR PDBsum; 8R7E; -. DR PDBsum; 8R7V; -. DR PDBsum; 8RAU; -. DR PDBsum; 8RAV; -. DR PDBsum; 8RAW; -. DR PDBsum; 8RAX; -. DR PDBsum; 8RAZ; -. DR PDBsum; 8RB0; -. DR PDBsum; 8RB1; -. DR PDBsum; 8RB2; -. DR PDBsum; 8RZ7; -. DR PDBsum; 8RZ8; -. DR PDBsum; 8RZ9; -. DR AlphaFoldDB; P43246; -. DR EMDB; EMD-15417; -. DR EMDB; EMD-15518; -. DR EMDB; EMD-15519; -. DR EMDB; EMD-16964; -. DR EMDB; EMD-16969; -. DR EMDB; EMD-16971; -. DR EMDB; EMD-16972; -. DR EMDB; EMD-16973; -. DR EMDB; EMD-16974; -. DR EMDB; EMD-18992; -. DR EMDB; EMD-19605; -. DR EMDB; EMD-19606; -. DR EMDB; EMD-19607; -. DR SMR; P43246; -. DR BioGRID; 110573; 329. DR ComplexPortal; CPX-77; DNA mismatch repair MutSbeta complex. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P43246; -. DR DIP; DIP-35054N; -. DR FunCoup; P43246; 3266. DR IntAct; P43246; 111. DR MINT; P43246; -. DR STRING; 9606.ENSP00000233146; -. DR ChEMBL; CHEMBL4296019; -. DR GlyGen; P43246; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P43246; -. DR PhosphoSitePlus; P43246; -. DR SwissPalm; P43246; -. DR BioMuta; MSH2; -. DR DMDM; 1171032; -. DR jPOST; P43246; -. DR MassIVE; P43246; -. DR PaxDb; 9606-ENSP00000233146; -. DR PeptideAtlas; P43246; -. DR ProteomicsDB; 55601; -. [P43246-1] DR ProteomicsDB; 5866; -. DR Pumba; P43246; -. DR Antibodypedia; 4037; 803 antibodies from 50 providers. DR CPTC; P43246; 1 antibody. DR DNASU; 4436; -. DR Ensembl; ENST00000233146.7; ENSP00000233146.2; ENSG00000095002.17. [P43246-1] DR Ensembl; ENST00000543555.6; ENSP00000442697.1; ENSG00000095002.17. [P43246-2] DR GeneID; 4436; -. DR KEGG; hsa:4436; -. DR MANE-Select; ENST00000233146.7; ENSP00000233146.2; NM_000251.3; NP_000242.1. DR UCSC; uc002rvy.3; human. [P43246-1] DR AGR; HGNC:7325; -. DR CIViC; 4436; 8 evidence items across 9 molecular profiles. DR ClinPGx; PA31133; -. DR CTD; 4436; -. DR DisGeNET; 4436; -. DR GeneCards; MSH2; -. DR GeneReviews; MSH2; -. DR HGNC; HGNC:7325; MSH2. DR HPA; ENSG00000095002; Low tissue specificity. DR MalaCards; MSH2; -. DR MIM; 114500; phenotype. DR MIM; 120435; phenotype. DR MIM; 158320; phenotype. DR MIM; 608089; phenotype. DR MIM; 609309; gene. DR MIM; 619096; phenotype. DR OpenTargets; ENSG00000095002; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000095002; -. DR eggNOG; KOG0219; Eukaryota. DR GeneTree; ENSGT00550000074867; -. DR HOGENOM; CLU_002472_10_0_1; -. DR InParanoid; P43246; -. DR OMA; LVRFPQK; -. DR OrthoDB; 295033at2759; -. DR PAN-GO; P43246; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43246; -. DR PathwayCommons; P43246; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5632927; Defective Mismatch Repair Associated With MSH3. DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; P43246; -. DR SIGNOR; P43246; -. DR Agora; ENSG00000095002; -. DR BioGRID-ORCS; 4436; 27 hits in 1168 CRISPR screens. DR ChiTaRS; MSH2; human. DR EvolutionaryTrace; P43246; -. DR GeneWiki; MSH2; -. DR GenomeRNAi; 4436; -. DR Pharos; P43246; Tbio. DR PRO; PR:P43246; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P43246; protein. DR Bgee; ENSG00000095002; Expressed in secondary oocyte and 194 other cell types or tissues. DR ExpressionAtlas; P43246; baseline and differential. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0032302; C:MutSbeta complex; IDA:HGNC-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:Ensembl. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0032137; F:guanine/thymine mispair binding; IMP:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0019724; P:B cell mediated immunity; ISS:BHF-UCL. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006301; P:DNA damage tolerance; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0043570; P:maintenance of DNA repeat elements; IMP:HGNC-UCL. DR GO; GO:0008584; P:male gonad development; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0006312; P:mitotic recombination; IBA:GO_Central. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL. DR GO; GO:0006119; P:oxidative phosphorylation; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0010224; P:response to UV-B; ISS:BHF-UCL. DR GO; GO:0010165; P:response to X-ray; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IEA:Ensembl. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0002204; P:somatic recombination of immunoglobulin genes involved in immune response; IBA:GO_Central. DR CDD; cd03285; ABC_MSH2_euk; 1. DR FunFam; 1.10.1420.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000009; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000523; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00048; -. DR InterPro; IPR011184; DNA_mismatch_repair_Msh2. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR032642; Msh2_ATP-bd. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF35; DNA MISMATCH REPAIR PROTEIN MSH2; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR PIRSF; PIRSF005813; MSH2; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; KW Hereditary nonpolyposis colorectal cancer; Isopeptide bond; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..934 FT /note="DNA mismatch repair protein Msh2" FT /id="PRO_0000115183" FT REGION 601..671 FT /note="Interaction with EXO1" FT BINDING 669..676 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 555 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 567 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P43247" FT MOD_RES 845 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 847 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 871 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 892 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 921 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 430 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 845 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 847 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 871 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 892 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:17974005" FT /id="VSP_045536" FT VARIANT 2 FT /note="A -> T (in LYNCH1; likely benign; dbSNP:rs63750466)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_054511" FT VARIANT 5 FT /note="P -> Q (decreases protein levels; dbSNP:rs56170584)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079822" FT VARIANT 8 FT /note="T -> M (in dbSNP:rs17217716)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:12792735, ECO:0000269|Ref.9" FT /id="VAR_013171" FT VARIANT 13 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63749907)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043736" FT VARIANT 17 FT /note="V -> F (in gastric cancer; uncertain significance; FT cryptic acceptor splice site suppressed on ex vivo splicing FT assay; dbSNP:rs63750966)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043737" FT VARIANT 33 FT /note="T -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751107)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043738" FT VARIANT 40 FT /note="G -> S (in CRC; uncertain significance; FT dbSNP:rs63751260)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043739" FT VARIANT 43 FT /note="Y -> C (in dbSNP:rs17217723)" FT /evidence="ECO:0000269|Ref.9" FT /id="VAR_019233" FT VARIANT 44 FT /note="T -> M (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs587779085)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043740" FT VARIANT 45 FT /note="A -> V (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs63750285)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043741" FT VARIANT 46 FT /note="H -> Q (in LYNCH1; likely benign; dbSNP:rs33946261)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:8700523" FT /id="VAR_004470" FT VARIANT 55 FT /note="R -> G (decreases protein levels; FT dbSNP:rs587782354)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079823" FT VARIANT 92 FT /note="Missing (in LYNCH1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18561205" FT /id="VAR_043742" FT VARIANT 93 FT /note="L -> F (in LYNCH1; dbSNP:rs63751429)" FT /evidence="ECO:0000269|PubMed:15896463" FT /id="VAR_043743" FT VARIANT 96 FT /note="R -> H (in dbSNP:rs63750002)" FT /evidence="ECO:0000269|PubMed:7726159" FT /id="VAR_004471" FT VARIANT 98 FT /note="Y -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750887)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043744" FT VARIANT 102 FT /note="V -> I (in LYNCH1; likely benign; FT dbSNP:rs193922373)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043745" FT VARIANT 106 FT /note="R -> K (in dbSNP:rs41295286)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038026" FT VARIANT 110 FT /note="K -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043746" FT VARIANT 127 FT /note="N -> S (in LYNCH1; benign; presumed to enhance FT cancer risk considerably when associated with P-328; shows FT significantly decreased repair efficiency when associated FT with variant P-328; dbSNP:rs17217772)" FT /evidence="ECO:0000269|PubMed:12655564, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22581703, ECO:0000269|Ref.9" FT /id="VAR_019234" FT VARIANT 139 FT /note="N -> S (in LYNCH1; dbSNP:rs1553350676)" FT /id="VAR_004472" FT VARIANT 145 FT /note="I -> M (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750124)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_004473" FT VARIANT 161 FT /note="V -> D (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750126)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012936" FT VARIANT 162 FT /note="G -> A (in LYNCH1; dbSNP:rs63750773)" FT /evidence="ECO:0000269|PubMed:17128465" FT /id="VAR_054512" FT VARIANT 162 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; associated with an abnormal subcellular FT localization pattern; affects protein stability; loss of FT protein expression; dbSNP:rs63750624)" FT /evidence="ECO:0000269|PubMed:15991316, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043747" FT VARIANT 163 FT /note="V -> D (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043748" FT VARIANT 163 FT /note="V -> G (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022670" FT VARIANT 164 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750582)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043749" FT VARIANT 165 FT /note="Y -> D (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779163)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067284" FT VARIANT 167 FT /note="D -> H (in LYNCH1; benign; shows reduced mismatch FT binding; does not show a decreased expression level of the FT MutS alpha complex; not associated with an abnormal FT subcellular localization pattern; normal mismatch repair FT activity; dbSNP:rs63750255)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:8872463" FT /id="VAR_004474" FT VARIANT 169 FT /note="I -> V (in LYNCH1 and CRC; likely benign; FT dbSNP:rs63750716)" FT /evidence="ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043750" FT VARIANT 173 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750070)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043751" FT VARIANT 175 FT /note="L -> P (in LYNCH1; dbSNP:rs63751291)" FT /evidence="ECO:0000269|PubMed:12655568" FT /id="VAR_043752" FT VARIANT 177 FT /note="E -> H (in LYNCH1; uncertain significance; normal FT mismatch repair activity; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067285" FT VARIANT 187 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043753" FT VARIANT 187 FT /note="L -> R (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076352" FT VARIANT 198 FT /note="E -> G (in dbSNP:rs63750327)" FT /id="VAR_054513" FT VARIANT 199 FT /note="C -> R (in LYNCH1; also found in a patient with FT glioma; no effect on MSH2 splicing; dbSNP:rs63751110)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9777949" FT /id="VAR_012937" FT VARIANT 203 FT /note="G -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs587779973)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043754" FT VARIANT 205 FT /note="E -> Q (shows no defects; normal mismatch repair FT activity; dbSNP:rs63749984)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068705" FT VARIANT 216 FT /note="I -> V (in LYNCH1; uncertain significance; shows FT slightly reduced mismatch binding or release efficiency; FT dbSNP:rs63749936)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012938" FT VARIANT 246 FT /note="K -> Q (in LYNCH1; uncertain significance; FT dbSNP:rs63750881)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043755" FT VARIANT 265..314 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004475" FT VARIANT 272 FT /note="A -> V (in LYNCH1; benign; shows slightly reduced FT mismatch binding or release efficiency; results in partial FT MSH2 exon 5 skipping; normal mismatch repair activity; FT dbSNP:rs34136999)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043756" FT VARIANT 283 FT /note="D -> Y (in LYNCH1; dbSNP:rs63750381)" FT /evidence="ECO:0000269|PubMed:15870828" FT /id="VAR_043757" FT VARIANT 305 FT /note="A -> T (in LYNCH1; normal mismatch repair activity; FT dbSNP:rs63751454)" FT /evidence="ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004476" FT VARIANT 322 FT /note="G -> D (in dbSNP:rs4987188)" FT /evidence="ECO:0000269|PubMed:10023327, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703, FT ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:9087566, FT ECO:0000269|PubMed:9298827, ECO:0000269|Ref.9" FT /id="VAR_004477" FT VARIANT 323 FT /note="S -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:9240418" FT /id="VAR_012939" FT VARIANT 323 FT /note="S -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043758" FT VARIANT 328 FT /note="A -> P (shows significantly decreased repair FT efficiency when associated with variant S-127; presumed to FT enhance cancer risk considerably when associated with FT variant S-127; dbSNP:rs753237286)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068706" FT VARIANT 331 FT /note="N -> D (in LYNCH1; uncertain significance; no effect FT on MSH2 splicing; dbSNP:rs267607938)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054514" FT VARIANT 333 FT /note="C -> Y (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750828)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043759" FT VARIANT 335 FT /note="T -> I (in LYNCH1; uncertain significance; FT dbSNP:rs63750602)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043760" FT VARIANT 336 FT /note="P -> S (in LYNCH1; dbSNP:rs63751062)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043761" FT VARIANT 342 FT /note="V -> I (in CRC; uncertain significance; FT dbSNP:rs63749879)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043762" FT VARIANT 349 FT /note="P -> L (in LYNCH1; dbSNP:rs587779067)" FT /evidence="ECO:0000269|PubMed:15342696" FT /id="VAR_043763" FT VARIANT 359 FT /note="R -> S (in LYNCH1; shows a decreased expression FT level of the MutS alpha complex; associated with an FT abnormal subcellular localization pattern; FT dbSNP:rs63751617)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:18781619" FT /id="VAR_043764" FT VARIANT 367 FT /note="V -> I (shows no defects; normal mismatch repair FT activity; dbSNP:rs80285180)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068707" FT VARIANT 385 FT /note="P -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs564736113)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067286" FT VARIANT 390 FT /note="L -> F (in LYNCH1 and CRC; benign; may decrease FT mismatch repair activity; dbSNP:rs17224367)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:8690195, FT ECO:0000269|PubMed:9621522, ECO:0000269|Ref.9" FT /id="VAR_004478" FT VARIANT 393 FT /note="K -> M (in LYNCH1; dbSNP:rs1558478490)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_043765" FT VARIANT 419 FT /note="Q -> K (in CRC; likely benign; decreased mismatch FT repair activity; dbSNP:rs63750006)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15996210, FT ECO:0000269|PubMed:8690195" FT /id="VAR_012940" FT VARIANT 440 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043766" FT VARIANT 470 FT /note="V -> E (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607959)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054515" FT VARIANT 487 FT /note="D -> E (decreased mismatch repair activity; FT dbSNP:rs35107951)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068708" FT VARIANT 492 FT /note="M -> V (in LYNCH1)" FT /id="VAR_043767" FT VARIANT 506 FT /note="D -> Y (in LYNCH1 and CRC; sporadic early-onset CRC; FT decreased mismatch repair activity; dbSNP:rs63750492)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_012941" FT VARIANT 519 FT /note="F -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1371291280)" FT /evidence="ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614" FT /id="VAR_067287" FT VARIANT 524 FT /note="R -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751207)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:9889267" FT /id="VAR_004479" FT VARIANT 534 FT /note="R -> P (no effect on protein levels; FT dbSNP:rs587778523)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079824" FT VARIANT 552 FT /note="T -> P (in LYNCH1; dbSNP:rs63750838)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043768" FT VARIANT 554 FT /note="S -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751656)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012942" FT VARIANT 562 FT /note="E -> V (in LYNCH1; dbSNP:rs63750997)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004480" FT VARIANT 564 FT /note="T -> A (in LYNCH1; benign; dbSNP:rs55778204)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043769" FT VARIANT 583 FT /note="N -> S (in LYNCH1; dbSNP:rs201118107)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043770" FT VARIANT 596 FT /note="N -> S (in LYNCH1; uncertain significance; FT dbSNP:rs41295288)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8993976" FT /id="VAR_012943" FT VARIANT 596 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63749831)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:7874129, FT ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9311737" FT /id="VAR_004481" FT VARIANT 600 FT /note="A -> V (in LYNCH1; dbSNP:rs63751236)" FT /evidence="ECO:0000269|PubMed:11920458" FT /id="VAR_043771" FT VARIANT 603 FT /note="D -> N (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; affects protein stability; loss FT of protein expression; dbSNP:rs63750657)" FT /evidence="ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043772" FT VARIANT 610 FT /note="H -> N (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607980)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054516" FT VARIANT 619 FT /note="Y -> C (in CRC; uncertain significance; FT dbSNP:rs63749982)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043773" FT VARIANT 622 FT /note="P -> L (in LYNCH1; decreased mismatch repair FT activity; confers multiple biochemical defects; FT dbSNP:rs28929483)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:8261515" FT /id="VAR_004482" FT VARIANT 629 FT /note="Q -> R (in LYNCH1; benign; dbSNP:rs61756468)" FT /evidence="ECO:0000269|PubMed:12132870, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15996210" FT /id="VAR_043774" FT VARIANT 636 FT /note="A -> P (in LYNCH1; decreased mismatch binding FT activity; dbSNP:rs63750875)" FT /evidence="ECO:0000269|PubMed:10528862, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_012944" FT VARIANT 638 FT /note="R -> G (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607981)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054517" FT VARIANT 639 FT /note="H -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779116)" FT /evidence="ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9419403" FT /id="VAR_043775" FT VARIANT 639 FT /note="H -> Y (in LYNCH1; the equivalent substitution in FT yeast does not affect mismatch repair efficiency in vitro; FT dbSNP:rs28929484)" FT /evidence="ECO:0000269|PubMed:11555625, FT ECO:0000269|PubMed:8261515" FT /id="VAR_004483" FT VARIANT 641 FT /note="C -> G (in dbSNP:rs63749946)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004484" FT VARIANT 645 FT /note="Q -> E (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607982)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054518" FT VARIANT 647 FT /note="E -> K (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043776" FT VARIANT 656 FT /note="Y -> H (in LYNCH1; somatic mutation; FT dbSNP:rs1573567393)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043777" FT VARIANT 660 FT /note="D -> G (in LYNCH1; dbSNP:rs1085308057)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022671" FT VARIANT 669 FT /note="G -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751668)" FT /evidence="ECO:0000269|PubMed:22371642" FT /id="VAR_067761" FT VARIANT 670 FT /note="P -> L (in dbSNP:rs41294982)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038027" FT VARIANT 671 FT /note="N -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63751232)" FT /evidence="ECO:0000269|PubMed:15300854, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043778" FT VARIANT 674 FT /note="G -> A (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs267607996)" FT /evidence="ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_076353" FT VARIANT 674 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:18625694, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614" FT /id="VAR_067288" FT VARIANT 674 FT /note="G -> S (in LYNCH1; somatic mutation; FT dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004485" FT VARIANT 675 FT /note="K -> A (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; requires 2 nucleotide FT substitutions; dbSNP:rs587779128)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067289" FT VARIANT 679 FT /note="I -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043779" FT VARIANT 688 FT /note="M -> I (in LYNCH1; dbSNP:rs63750790)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:9559627" FT /id="VAR_012945" FT VARIANT 688 FT /note="M -> V (in LYNCH1; loss of protein expression; FT dbSNP:rs1573569964)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076354" FT VARIANT 692 FT /note="G -> R (in LYNCH1; dbSNP:rs63750232)" FT /evidence="ECO:0000269|PubMed:10612836" FT /id="VAR_009250" FT VARIANT 696 FT /note="P -> L (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607994)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054519" FT VARIANT 697 FT /note="C -> F (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; confers multiple FT biochemical defects; dbSNP:rs63750398)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9298827" FT /id="VAR_004486" FT VARIANT 697 FT /note="C -> R (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs63750961)" FT /evidence="ECO:0000269|PubMed:10612836, FT ECO:0000269|PubMed:18561205" FT /id="VAR_009251" FT VARIANT 714 FT /note="A -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63751224)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043780" FT VARIANT 722 FT /note="V -> I (in LYNCH1; dbSNP:rs587781996)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076355" FT VARIANT 723 FT /note="S -> F (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63750794)" FT /evidence="ECO:0000269|PubMed:11920458, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:22102614" FT /id="VAR_043781" FT VARIANT 729 FT /note="M -> V (in LYNCH1; somatic mutation; FT dbSNP:rs1558520059)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043782" FT VARIANT 732 FT /note="T -> I (in LYNCH1; somatic mutation; FT dbSNP:rs730881765)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043783" FT VARIANT 745..746 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043784" FT VARIANT 748 FT /note="D -> Y (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608007)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054520" FT VARIANT 749 FT /note="E -> K (in LYNCH1; decreased mismatch repair FT activity; no loss of protein expression; dbSNP:rs63751477)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043785" FT VARIANT 759 FT /note="G -> E (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; dbSNP:rs386833406)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067290" FT VARIANT 770 FT /note="I -> V (in dbSNP:rs63750684)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004487" FT VARIANT 779 FT /note="M -> I (in dbSNP:rs41295292)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038028" FT VARIANT 805 FT /note="L -> V (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs779182536)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067291" FT VARIANT 807 FT /note="T -> S (in dbSNP:rs41295294)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038029" FT VARIANT 813 FT /note="M -> I (no effect on protein levels; FT dbSNP:rs587781678)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079825" FT VARIANT 813 FT /note="M -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63749841)" FT /evidence="ECO:0000269|PubMed:12373605" FT /id="VAR_043786" FT VARIANT 824 FT /note="Q -> E (in gastric cancer; uncertain significance; FT dbSNP:rs63750623)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043787" FT VARIANT 834 FT /note="A -> T (in LYNCH1; likely benign; decreased mismatch FT repair activity; shows no functional defects in gel shift FT assay; dbSNP:rs63750757)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004488" FT VARIANT 835 FT /note="N -> H (in dbSNP:rs41295296)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038030" FT VARIANT 839 FT /note="H -> Q (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608016)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054521" FT VARIANT 839 FT /note="H -> R (in LYNCH1; decreases protein levels; FT dbSNP:rs63750027)" FT /evidence="ECO:0000269|PubMed:15613555, FT ECO:0000269|PubMed:28494185" FT /id="VAR_043788" FT VARIANT 843 FT /note="C -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1667495338)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067292" FT VARIANT 845 FT /note="K -> E (in LYNCH1; dbSNP:rs63750571)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_013172" FT VARIANT 853 FT /note="E -> A (in LYNCH1; uncertain significance; FT dbSNP:rs63750797)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043789" FT VARIANT 860 FT /note="S -> L (in LYNCH1; likely benign; normal mismatch FT repair activity; dbSNP:rs63750849)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067293" FT VARIANT 868 FT /note="P -> A (in gastric cancer; uncertain significance; FT dbSNP:rs63751400)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043790" FT VARIANT 870 FT /note="A -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750709)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043791" FT VARIANT 873 FT /note="C -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750795)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043792" FT VARIANT 886 FT /note="E -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750350)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043793" FT VARIANT 905 FT /note="T -> R (in LYNCH1; likely benign; FT dbSNP:rs267608022)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004489" FT VARIANT 909 FT /note="K -> I (found in a colorectal cancer sample; normal FT mismatch repair activity; dbSNP:rs34319539)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068709" FT VARIANT 911 FT /note="L -> R (in dbSNP:rs41295182)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038031" FT VARIANT 923 FT /note="V -> E (in LYNCH1; uncertain significance; FT dbSNP:rs146421227)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043794" FT VARIANT 931 FT /note="K -> T (in LYNCH1; dbSNP:rs267608023)" FT /evidence="ECO:0000269|PubMed:15046096" FT /id="VAR_043795" FT MUTAGEN 675 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH6 mutant R- FT 1140." FT /evidence="ECO:0000269|PubMed:9564049" FT MUTAGEN 845 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-847, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 847 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 871 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 892 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-871." FT /evidence="ECO:0000269|PubMed:24882211" FT CONFLICT 784 FT /note="F -> I (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT CONFLICT 836 FT /note="F -> S (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT HELIX 14..24 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 33..38 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 48..56 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 65..71 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 82..94 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 117..124 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 137..139 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 160..167 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 168..171 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 172..179 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 197..204 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 208..220 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 229..232 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:8OLX" FT HELIX 237..244 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:8OLX" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:2O8E" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 259..262 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 264..277 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 283..285 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 286..288 FT /evidence="ECO:0007829|PDB:8R7E" FT STRAND 289..293 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 304..309 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:8OMA" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 336..347 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 353..367 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 370..377 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 378..380 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 387..395 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 401..411 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 432..435 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 437..455 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 476..502 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 517..519 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 521..525 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 527..530 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 531..535 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 536..538 FT /evidence="ECO:0007829|PDB:8OMO" FT STRAND 540..544 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8OMQ" FT STRAND 549..552 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 556..563 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 568..585 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 589..613 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 631..637 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 640..644 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:8R7C" FT STRAND 653..658 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 659..661 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 664..668 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 671..674 FT /evidence="ECO:0007829|PDB:8OMO" FT HELIX 675..691 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 695..703 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 706..711 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 718..721 FT /evidence="ECO:0007829|PDB:8OMQ" FT HELIX 724..738 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 744..749 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 750..753 FT /evidence="ECO:0007829|PDB:8R7E" FT HELIX 756..772 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 777..783 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 785..792 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 797..807 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 810..820 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 827..833 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 838..850 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 851..855 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 875..892 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 896..898 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 901..917 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 921..928 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 934 AA; 104743 MW; 664A058C78242E05 CRC64; MAVQPKETLQ LESAAEVGFV RFFQGMPEKP TTTVRLFDRG DFYTAHGEDA LLAAREVFKT QGVIKYMGPA GAKNLQSVVL SKMNFESFVK DLLLVRQYRV EVYKNRAGNK ASKENDWYLA YKASPGNLSQ FEDILFGNND MSASIGVVGV KMSAVDGQRQ VGVGYVDSIQ RKLGLCEFPD NDQFSNLEAL LIQIGPKECV LPGGETAGDM GKLRQIIQRG GILITERKKA DFSTKDIYQD LNRLLKGKKG EQMNSAVLPE MENQVAVSSL SAVIKFLELL SDDSNFGQFE LTTFDFSQYM KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGQR LVNQWIKQPL MDKNRIEERL NLVEAFVEDA ELRQTLQEDL LRRFPDLNRL AKKFQRQAAN LQDCYRLYQG INQLPNVIQA LEKHEGKHQK LLLAVFVTPL TDLRSDFSKF QEMIETTLDM DQVENHEFLV KPSFDPNLSE LREIMNDLEK KMQSTLISAA RDLGLDPGKQ IKLDSSAQFG YYFRVTCKEE KVLRNNKNFS TVDIQKNGVK FTNSKLTSLN EEYTKNKTEY EEAQDAIVKE IVNISSGYVE PMQTLNDVLA QLDAVVSFAH VSNGAPVPYV RPAILEKGQG RIILKASRHA CVEVQDEIAF IPNDVYFEKD KQMFHIITGP NMGGKSTYIR QTGVIVLMAQ IGCFVPCESA EVSIVDCILA RVGAGDSQLK GVSTFMAEML ETASILRSAT KDSLIIIDEL GRGTSTYDGF GLAWAISEYI ATKIGAFCMF ATHFHELTAL ANQIPTVNNL HVTALTTEET LTMLYQVKKG VCDQSFGIHV AELANFPKHV IECAKQKALE LEEFQYIGES QGYDIMEPAA KKCYLEREQG EKIIQEFLSK VKQMPFTEMS EENITIKLKQ LKAEVIAKNN SFVNEIISRI KVTT // ID NDRG1_HUMAN Reviewed; 394 AA. AC Q92597; B3KR80; B7Z446; O15207; Q6IBG2; Q9NYR6; Q9UK29; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 219. DE RecName: Full=Protein NDRG1; DE AltName: Full=Differentiation-related gene 1 protein; DE Short=DRG-1; DE AltName: Full=N-myc downstream-regulated gene 1 protein; DE AltName: Full=Nickel-specific induction protein Cap43; DE AltName: Full=Reducing agents and tunicamycin-responsive protein; DE Short=RTP; DE AltName: Full=Rit42; GN Name=NDRG1; Synonyms=CAP43, DRG1, RTP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND TISSUE SPECIFICITY. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8939898; DOI=10.1074/jbc.271.47.29659; RA Kokame K., Kato H., Miyata T.; RT "Homocysteine-respondent genes in vascular endothelial cells identified by RT differential display analysis. GRP78/BiP and novel genes."; RL J. Biol. Chem. 271:29659-29665(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, SUBCELLULAR LOCATION, RP AND TISSUE SPECIFICITY. RX PubMed=9251681; RA van Belzen N., Dinjens W.N.M., Diesveld M.P.G., Groen N.A., RA van der Made A.C.J., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T.; RT "A novel gene which is up-regulated during colon epithelial cell RT differentiation and down-regulated in colorectal neoplasms."; RL Lab. Invest. 77:85-92(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION. RC TISSUE=Lung; RX PubMed=9605764; RA Zhou D., Salnikow K., Costa M.; RT "Cap43, a novel gene specifically induced by Ni2+ compounds."; RL Cancer Res. 58:2182-2189(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RX PubMed=10395947; DOI=10.1016/s0167-4889(99)00056-7; RA Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T.; RT "Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating RT and growth arrested cells."; RL Biochim. Biophys. Acta 1450:364-373(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1). RC TISSUE=Brain; RA Angelicheva D., Kalaydjieva L.; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 4-19; 54-70; 133-148; 199-212; 286-300; 307-322; RP 328-341 AND 364-388, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=9766676; RA Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., RA Lee S.W.; RT "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 RT and DNA damage."; RL Cancer Res. 58:4439-4444(1998). RN [13] RP INVOLVEMENT IN CMT4D. RX PubMed=10831399; DOI=10.1086/302978; RA Kalaydjieva L., Gresham D., Gooding R., Heather L., Baas F., de Jonge R., RA Blechschmidt K., Angelicheva D., Chandler D., Worsley P., Rosenthal A., RA King R.H.M., Thomas P.K.; RT "N-myc downstream-regulated gene 1 is mutated in hereditary motor and RT sensory neuropathy-Lom."; RL Am. J. Hum. Genet. 67:47-58(2000). RN [14] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=10860807; DOI=10.1006/bbrc.2000.2833; RA Agarwala K.L., Kokame K., Kato H., Miyata T.; RT "Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein."; RL Biochem. Biophys. Res. Commun. 272:641-647(2000). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12432451; DOI=10.1007/s00418-002-0460-9; RA Lachat P., Shaw P., Gebhard S., van Belzen N., Chaubert P., Bosman F.T.; RT "Expression of NDRG1, a differentiation-related gene, in human tissues."; RL Histochem. Cell Biol. 118:399-408(2002). RN [16] RP PHOSPHORYLATION AT THR-328; SER-330; THR-346; THR-356 AND THR-366. RX PubMed=15461589; DOI=10.1042/bj20041057; RA Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., RA Peggie M., Bain J., Bloomberg G.B., Grahammer F., Lang F., Wulff P., RA Kuhl D., Cohen P.; RT "Exploitation of KESTREL to identify NDRG family members as physiological RT substrates for SGK1 and GSK3."; RL Biochem. J. 384:477-488(2004). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15247272; DOI=10.1074/jbc.m400781200; RA Kim K.T., Ongusaha P.P., Hong Y.K., Kurdistani S.K., Nakamura M., Lu K.P., RA Lee S.W.; RT "Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint."; RL J. Biol. Chem. 279:38597-38602(2004). RN [18] RP FUNCTION. RX PubMed=15377670; DOI=10.1074/jbc.m400386200; RA Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., RA Jackson R.S. II, Wang M., Liang P.; RT "NDRG1 is necessary for p53-dependent apoptosis."; RL J. Biol. Chem. 279:48930-48940(2004). RN [19] RP INTERACTION WITH APOA1; APOA2; PRA1 AND RTN1, AND POSSIBLE FUNCTION. RX PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050; RA Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C., Watts G.F., RA Kremensky I., Kalaydjieva L.; RT "NDRG1 interacts with APO A-I and A-II and is a functional candidate for RT the HDL-C QTL on 8q24."; RL Biochem. Biophys. Res. Commun. 332:982-992(2005). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-330 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Prostate cancer; RX PubMed=17487921; DOI=10.1002/elps.200600782; RA Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.; RT "Toward a global characterization of the phosphoproteome in prostate cancer RT cells: identification of phosphoproteins in the LNCaP cell line."; RL Electrophoresis 28:2027-2034(2007). RN [23] RP SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=17316623; DOI=10.1016/j.febslet.2007.01.080; RA Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., RA Vorburger S.A., Weimann R., Candinas D., Stroka D.; RT "Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for RT its membrane localization in human hepatocellular carcinoma."; RL FEBS Lett. 581:989-994(2007). RN [24] RP INTERACTION WITH RAB4A, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17786215; DOI=10.1371/journal.pone.0000844; RA Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., RA Denmeade S.R., DeMarzo A.M., Carducci M.A.; RT "The N-Myc down regulated Gene1 (NDRG1) is a Rab4a effector involved in RT vesicular recycling of E-cadherin."; RL PLoS ONE 2:E844-E844(2007). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326; SER-330; SER-333; RP SER-336; SER-364 AND THR-375, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [27] RP PHOSPHORYLATION AT THR-346; THR-356 AND THR-366. RX PubMed=18787837; DOI=10.1007/s00424-008-0587-1; RA Inglis S.K., Gallacher M., Brown S.G., McTavish N., Getty J., Husband E.M., RA Murray J.T., Wilson S.M.; RT "SGK1 activity in Na+ absorbing airway epithelial cells monitored by RT assaying NDRG1-Thr346/356/366 phosphorylation."; RL Pflugers Arch. 457:1287-1301(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328 AND SER-330, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=21708134; DOI=10.1016/j.bbrc.2011.06.092; RA McCaig C., Potter L., Abramczyk O., Murray J.T.; RT "Phosphorylation of NDRG1 is temporally and spatially controlled during the RT cell cycle."; RL Biochem. Biophys. Res. Commun. 411:227-234(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-328; SER-330; SER-333; RP SER-336; SER-364; THR-366 AND THR-375, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328; SER-332 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Stress-responsive protein involved in hormone responses, cell CC growth, and differentiation. Acts as a tumor suppressor in many cell CC types. Necessary but not sufficient for p53/TP53-mediated caspase CC activation and apoptosis. Has a role in cell trafficking, notably of CC the Schwann cell, and is necessary for the maintenance and development CC of the peripheral nerve myelin sheath. Required for vesicular recycling CC of CDH1 and TF. May also function in lipid trafficking. Protects cells CC from spindle disruption damage. Functions in p53/TP53-dependent mitotic CC spindle checkpoint. Regulates microtubule dynamics and maintains CC euploidy. {ECO:0000269|PubMed:15247272, ECO:0000269|PubMed:15377670, CC ECO:0000269|PubMed:17786215, ECO:0000269|PubMed:9766676}. CC -!- SUBUNIT: Interacts with RAB4A (membrane-bound form); the interaction CC involves NDRG1 in vesicular recycling of CDH1. CC {ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:17786215}. CC -!- INTERACTION: CC Q92597; P05023: ATP1A1; NbExp=2; IntAct=EBI-716486, EBI-358778; CC Q92597; P27824: CANX; NbExp=2; IntAct=EBI-716486, EBI-355947; CC Q92597; Q9H6J7-2: CSTPP1; NbExp=3; IntAct=EBI-716486, EBI-13328871; CC Q92597; P35222: CTNNB1; NbExp=3; IntAct=EBI-716486, EBI-491549; CC Q92597; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-716486, EBI-3508943; CC Q92597; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-716486, EBI-6425864; CC Q92597; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-716486, EBI-1108377; CC Q92597; Q9H204: MED28; NbExp=3; IntAct=EBI-716486, EBI-514199; CC Q92597; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-716486, EBI-9092052; CC Q92597; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-716486, EBI-21535400; CC Q92597; Q8N488: RYBP; NbExp=3; IntAct=EBI-716486, EBI-752324; CC Q92597; O75446: SAP30; NbExp=3; IntAct=EBI-716486, EBI-632609; CC Q92597; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-716486, EBI-11959123; CC Q92597; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-716486, EBI-2510414; CC Q92597; Q6PID6: TTC33; NbExp=3; IntAct=EBI-716486, EBI-2555404; CC Q92597; P12956: XRCC6; NbExp=2; IntAct=EBI-716486, EBI-353208; CC Q92597; P61981: YWHAG; NbExp=3; IntAct=EBI-716486, EBI-359832; CC Q92597; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-716486, EBI-2682299; CC Q92597-3; Q9Y3D8: AK6; NbExp=3; IntAct=EBI-10278703, EBI-2896123; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome. Nucleus. Cell membrane. CC Note=Mainly cytoplasmic but differentially localized to other regions. CC Associates with the plasma membrane in intestinal epithelia and CC lactating mammary gland. Translocated to the nucleus in a p53/TP53- CC dependent manner. In prostate epithelium and placental chorion, located CC in both the cytoplasm and in the nucleus. No nuclear localization in CC colon epithelium cells. In intestinal mucosa, prostate and renal CC cortex, located predominantly adjacent to adherens junctions. CC Cytoplasmic with granular staining in proximal tubular cells of the CC kidney and salivary gland ducts. Recruits to the membrane of CC recycling/sorting and late endosomes via binding to CC phosphatidylinositol 4-phosphate. Associates with microtubules. CC Colocalizes with TUBG1 in the centrosome. Cytoplasmic location CC increased with hypoxia. Phosphorylated form found associated with CC centromeres during S-phase of mitosis and with the plasma membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q92597-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92597-2; Sequence=VSP_045038; CC Name=3; CC IsoId=Q92597-3; Sequence=VSP_045037; CC -!- TISSUE SPECIFICITY: Ubiquitous; expressed most prominently in placental CC membranes and prostate, kidney, small intestine, and ovary tissues. CC Also expressed in heart, brain, skeletal muscle, lung, liver and CC pancreas. Low levels in peripheral blood leukocytes and in tissues of CC the immune system. Expressed mainly in epithelial cells. Also found in CC Schwann cells of peripheral neurons. Reduced expression in CC adenocarcinomas compared to normal tissues. In colon, prostate and CC placental membranes, the cells that border the lumen show the highest CC expression. {ECO:0000269|PubMed:12432451, ECO:0000269|PubMed:8939898, CC ECO:0000269|PubMed:9251681, ECO:0000269|PubMed:9605764}. CC -!- INDUCTION: By homocysteine, 2-mercaptoethanol, tunicamycin in CC endothelial cells. Induced approximately 20-fold during in vitro CC differentiation of the colon carcinoma cell lines HT-29-D4 and Caco-2. CC Induced by oxidative stress in colon cancers. Decreased expression in CC colon adenomas and adenocarcinomas. Induced by nickel compounds in all CC tested cell lines. The primary signal for its induction is an elevation CC of free intracellular calcium ion caused by nickel ion exposure. CC Okadaic acid, a serine/threonine phosphatase inhibitor, induced its CC expression more rapidly and more efficiently than nickel. CC {ECO:0000269|PubMed:10395947, ECO:0000269|PubMed:17316623, CC ECO:0000269|PubMed:8939898, ECO:0000269|PubMed:9251681, CC ECO:0000269|PubMed:9605764, ECO:0000269|PubMed:9766676}. CC -!- PTM: Under stress conditions, phosphorylated in the C-terminal on many CC serine and threonine residues. Phosphorylated in vitro by PKA. CC Phosphorylation enhanced by increased intracellular cAMP levels. CC Homocysteine induces dephosphorylation. Phosphorylation by SGK1 is cell CC cycle dependent. {ECO:0000269|PubMed:10860807, CC ECO:0000269|PubMed:15461589, ECO:0000269|PubMed:18787837, CC ECO:0000269|PubMed:21708134}. CC -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, type 4D (CMT4D) CC [MIM:601455]: A recessive demyelinating form of Charcot-Marie-Tooth CC disease, a disorder of the peripheral nervous system, characterized by CC progressive weakness and atrophy, initially of the peroneal muscles and CC later of the distal muscles of the arms. Charcot-Marie-Tooth disease is CC classified in two main groups on the basis of electrophysiologic CC properties and histopathology: primary peripheral demyelinating CC neuropathies (designated CMT1 when they are dominantly inherited) and CC primary peripheral axonal neuropathies (CMT2). Demyelinating CC neuropathies are characterized by severely reduced nerve conduction CC velocities (less than 38 m/sec), segmental demyelination and CC remyelination with onion bulb formations on nerve biopsy, slowly CC progressive distal muscle atrophy and weakness, absent deep tendon CC reflexes, and hollow feet. By convention autosomal recessive forms of CC demyelinating Charcot-Marie-Tooth disease are designated CMT4. CC {ECO:0000269|PubMed:10831399}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the NDRG family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41512/NDRG1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D87953; BAA13505.1; -; mRNA. DR EMBL; X92845; CAA63430.1; -; mRNA. DR EMBL; AF004162; AAC13419.1; -; mRNA. DR EMBL; AF186190; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR456842; CAG33123.1; -; mRNA. DR EMBL; AK091147; BAG52292.1; -; mRNA. DR EMBL; AK126924; BAG54400.1; -; mRNA. DR EMBL; AK296794; BAH12432.1; -; mRNA. DR EMBL; AF192304; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW92164.1; -; Genomic_DNA. DR EMBL; BC003175; AAH03175.1; -; mRNA. DR EMBL; AF230380; AAF71305.1; -; mRNA. DR CCDS; CCDS34945.1; -. [Q92597-1] DR CCDS; CCDS59113.1; -. [Q92597-2] DR RefSeq; NP_001128714.1; NM_001135242.2. [Q92597-1] DR RefSeq; NP_001245361.1; NM_001258432.2. [Q92597-2] DR RefSeq; NP_001245362.1; NM_001258433.2. [Q92597-3] DR RefSeq; NP_001361774.1; NM_001374845.1. [Q92597-1] DR RefSeq; NP_001361775.1; NM_001374846.1. [Q92597-1] DR RefSeq; NP_001361776.1; NM_001374847.1. [Q92597-2] DR RefSeq; NP_006087.2; NM_006096.3. [Q92597-1] DR PDB; 6ZMM; X-ray; 2.96 A; A/B=31-319. DR PDBsum; 6ZMM; -. DR AlphaFoldDB; Q92597; -. DR SMR; Q92597; -. DR BioGRID; 115669; 247. DR FunCoup; Q92597; 1492. DR IntAct; Q92597; 165. DR MINT; Q92597; -. DR STRING; 9606.ENSP00000404854; -. DR ChEMBL; CHEMBL4295916; -. DR ESTHER; human-NDRG1; Ndr_family. DR MEROPS; S33.988; -. DR GlyGen; Q92597; 3 sites, 2 O-linked glycans (3 sites). DR iPTMnet; Q92597; -. DR MetOSite; Q92597; -. DR PhosphoSitePlus; Q92597; -. DR SwissPalm; Q92597; -. DR BioMuta; NDRG1; -. DR DMDM; 6166568; -. DR jPOST; Q92597; -. DR MassIVE; Q92597; -. DR PaxDb; 9606-ENSP00000404854; -. DR PeptideAtlas; Q92597; -. DR ProteomicsDB; 3585; -. DR ProteomicsDB; 6569; -. DR ProteomicsDB; 75343; -. [Q92597-1] DR Pumba; Q92597; -. DR TopDownProteomics; Q92597-1; -. [Q92597-1] DR Antibodypedia; 1521; 643 antibodies from 43 providers. DR DNASU; 10397; -. DR Ensembl; ENST00000323851.13; ENSP00000319977.8; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000414097.6; ENSP00000404854.2; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000522476.5; ENSP00000427894.1; ENSG00000104419.17. [Q92597-2] DR GeneID; 10397; -. DR KEGG; hsa:10397; -. DR MANE-Select; ENST00000323851.13; ENSP00000319977.8; NM_006096.4; NP_006087.2. DR UCSC; uc003yug.3; human. [Q92597-1] DR AGR; HGNC:7679; -. DR ClinPGx; PA31482; -. DR CTD; 10397; -. DR DisGeNET; 10397; -. DR GeneCards; NDRG1; -. DR GeneReviews; NDRG1; -. DR HGNC; HGNC:7679; NDRG1. DR HPA; ENSG00000104419; Low tissue specificity. DR MalaCards; NDRG1; -. DR MIM; 601455; phenotype. DR MIM; 605262; gene. DR OpenTargets; ENSG00000104419; -. DR Orphanet; 99950; Charcot-Marie-Tooth disease type 4D. DR VEuPathDB; HostDB:ENSG00000104419; -. DR eggNOG; KOG2931; Eukaryota. DR GeneTree; ENSGT00950000182872; -. DR HOGENOM; CLU_035361_1_0_1; -. DR InParanoid; Q92597; -. DR OMA; LVEKGEX; -. DR OrthoDB; 741027at2759; -. DR PAN-GO; Q92597; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q92597; -. DR PathwayCommons; Q92597; -. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR SignaLink; Q92597; -. DR SIGNOR; Q92597; -. DR Agora; ENSG00000104419; -. DR BioGRID-ORCS; 10397; 11 hits in 1163 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; NDRG1; human. DR GeneWiki; NDRG1; -. DR GenomeRNAi; 10397; -. DR Pharos; Q92597; Tbio. DR PRO; PR:Q92597; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q92597; protein. DR Bgee; ENSG00000104419; Expressed in olfactory bulb and 205 other cell types or tissues. DR ExpressionAtlas; Q92597; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IDA:UniProtKB. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0120212; C:sperm head-tail coupling apparatus; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0045296; F:cadherin binding; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0016151; F:nickel cation binding; IPI:DisProt. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEP:UniProtKB. DR GO; GO:0045576; P:mast cell activation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0010038; P:response to metal ion; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR DisProt; DP03990; -. DR FunFam; 3.40.50.1820:FF:000006; NDRG family member 3; 1. DR Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1. DR InterPro; IPR029058; AB_hydrolase_fold. DR InterPro; IPR004142; NDRG. DR PANTHER; PTHR11034; N-MYC DOWNSTREAM REGULATED; 1. DR Pfam; PF03096; Ndr; 1. DR SUPFAM; SSF53474; alpha/beta-Hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Charcot-Marie-Tooth disease; Cytoplasm; Cytoskeleton; KW Direct protein sequencing; Membrane; Microtubule; Neurodegeneration; KW Neuropathy; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..394 FT /note="Protein NDRG1" FT /id="PRO_0000159573" FT REPEAT 339..348 FT /note="1" FT REPEAT 349..358 FT /note="2" FT REPEAT 359..368 FT /note="3" FT REGION 325..394 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 339..368 FT /note="3 X 10 AA tandem repeats of G-T-R-S-R-S-H-T-S-E" FT COMPBIAS 327..339 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 345..371 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 328 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 330 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 335 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 336 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 340 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 342 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 346 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 356 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 362 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 364 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 366 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837, ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..81 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045037" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045038" FT VARIANT 67 FT /note="M -> V (in dbSNP:rs2233319)" FT /id="VAR_050234" FT VARIANT 111 FT /note="M -> L (in dbSNP:rs2233328)" FT /id="VAR_050235" FT CONFLICT 145 FT /note="I -> T (in Ref. 2; CAA63430)" FT /evidence="ECO:0000305" FT STRAND 33..39 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 42..48 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 58..62 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 69..72 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 74..77 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 80..82 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 83..88 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 115..120 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 141..152 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 157..164 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 187..195 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 209..217 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 221..232 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 255..260 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 266..274 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 278..280 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 298..311 FT /evidence="ECO:0007829|PDB:6ZMM" SQ SEQUENCE 394 AA; 42835 MW; 4C816B9C85E3756F CRC64; MSREMQDVDL AEVKPLVEKG ETITGLLQEF DVQEQDIETL HGSVHVTLCG TPKGNRPVIL TYHDIGMNHK TCYNPLFNYE DMQEITQHFA VCHVDAPGQQ DGAASFPAGY MYPSMDQLAE MLPGVLQQFG LKSIIGMGTG AGAYILTRFA LNNPEMVEGL VLINVNPCAE GWMDWAASKI SGWTQALPDM VVSHLFGKEE MQSNVEVVHT YRQHIVNDMN PGNLHLFINA YNSRRDLEIE RPMPGTHTVT LQCPALLVVG DSSPAVDAVV ECNSKLDPTK TTLLKMADCG GLPQISQPAK LAEAFKYFVQ GMGYMPSASM TRLMRSRTAS GSSVTSLDGT RSRSHTSEGT RSRSHTSEGT RSRSHTSEGA HLDITPNSGA AGNSAGPKSM EVSC // ID NOX5_HUMAN Reviewed; 765 AA. AC Q96PH1; B2RBJ4; Q08AN2; Q08AN3; Q8TEQ1; Q8TER4; Q96PH2; Q96PJ8; Q96PJ9; AC Q9H6E0; Q9HAM8; DT 07-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=NADPH oxidase 5; DE EC=1.-.-.- {ECO:0000269|PubMed:34784249}; DE EC=1.6.3.- {ECO:0000269|PubMed:12686516}; GN Name=NOX5 {ECO:0000312|HGNC:HGNC:14874}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS V1; V2; V3 AND V4), FUNCTION (ISOFORM RP V2), TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY (ISOFORM V2). RC TISSUE=Spleen, and Testis; RX PubMed=11483596; DOI=10.1074/jbc.m103034200; RA Banfi B., Molnar G., Maturana A., Steger K., Hegedus B., Demaurex N., RA Krause K.-H.; RT "A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes."; RL J. Biol. Chem. 276:37594-37601(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM V5), AND NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 98-765 (ISOFORMS V3/V4). RC TISSUE=Spleen; RA Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.; RT "The nucleotide sequence of a long cDNA clone isolated from human spleen."; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM V4), AND NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 159-765 (ISOFORMS V1/V2/V3/V4/V6). RC TISSUE=Kidney epithelium, and Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM V5). RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS V2 AND V6). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 177-765 (ISOFORMS V1/V2/V3/V4/V6). RC TISSUE=Spleen; RX PubMed=15994299; DOI=10.1074/jbc.m501882200; RA Kawahara T., Ritsick D., Cheng G., Lambeth J.D.; RT "Point mutations in the proline-rich region of p22phox are dominant RT inhibitors of Nox1- and Nox2-dependent reactive oxygen generation."; RL J. Biol. Chem. 280:31859-31869(2005). RN [9] RP TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=11376945; DOI=10.1016/s0378-1119(01)00449-8; RA Cheng G., Cao Z., Xu X., van Meir E.G., Lambeth J.D.; RT "Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and RT Nox5."; RL Gene 269:131-140(2001). RN [10] RP FUNCTION, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY. RX PubMed=12686516; DOI=10.1152/ajpcell.00525.2002; RA Brar S.S., Corbin Z., Kennedy T.P., Hemendinger R., Thornton L., RA Bommarius B., Arnold R.S., Whorton A.R., Sturrock A.B., Huecksteadt T.P., RA Quinn M.T., Krenitsky K., Ardie K.G., Lambeth J.D., Hoidal J.R.; RT "NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate RT cancer cells."; RL Am. J. Physiol. 285:C353-C369(2003). RN [11] RP ACTIVITY REGULATION (ISOFORM V2), COFACTOR (ISOFORM V2), MUTAGENESIS OF RP GLU-31 (ISOFORM V2), BIOPHYSICOCHEMICAL PROPERTIES (ISOFORM V2), FUNCTION RP (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), AND N-TERMINAL REGULATORY EF RP DOMAIN (ISOFORM V2). RX PubMed=14982937; DOI=10.1074/jbc.m310268200; RA Banfi B., Tirone F., Durussel I., Knisz J., Moskwa P., Molnar G.Z., RA Krause K.-H., Cox J.A.; RT "Mechanism of Ca2+ activation of the NADPH oxidase 5 (NOX5)."; RL J. Biol. Chem. 279:18583-18591(2004). RN [12] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=16179589; DOI=10.1161/01.res.0000187457.24338.3d; RA Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., RA Sorescu D.; RT "NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced RT differentiation of cardiac fibroblasts into myofibroblasts."; RL Circ. Res. 97:900-907(2005). RN [13] RP TISSUE SPECIFICITY. RX PubMed=16339585; DOI=10.4049/jimmunol.175.12.8424; RA Kamiguti A.S., Serrander L., Lin K., Harris R.J., Cawley J.C., Allsup D.J., RA Slupsky J.R., Krause K.-H., Zuzel M.; RT "Expression and activity of NOX5 in the circulating malignant B cells of RT hairy cell leukemia."; RL J. Immunol. 175:8424-8430(2005). RN [14] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), SUBCELLULAR RP LOCATION (ISOFORM V2), AND ACTIVITY REGULATION (ISOFORM V2). RX PubMed=17587483; DOI=10.1016/j.biochi.2007.05.004; RA Serrander L., Jaquet V., Bedard K., Plastre O., Hartley O., Arnaudeau S., RA Demaurex N., Schlegel W., Krause K.H.; RT "NOX5 is expressed at the plasma membrane and generates superoxide in RT response to protein kinase C activation."; RL Biochimie 89:1159-1167(2007). RN [15] RP FUNCTION (ISOFORMS V2 AND V5), TISSUE SPECIFICITY (ISOFORMS V1; V2; V3; V4 RP AND V5), SUBCELLULAR LOCATION (ISOFORMS V2 AND V5), AND CATALYTIC ACTIVITY RP (ISOFORMS V2 AND V5). RX PubMed=17275676; DOI=10.1016/j.freeradbiomed.2006.10.054; RA BelAiba R.S., Djordjevic T., Petry A., Diemer K., Bonello S., Banfi B., RA Hess J., Pogrebniak A., Bickel C., Gorlach A.; RT "NOX5 variants are functionally active in endothelial cells."; RL Free Radic. Biol. Med. 42:446-459(2007). RN [16] RP FUNCTION (ISOFORM V1), CATALYTIC ACTIVITY (ISOFORM V1), SUBUNIT (ISOFORM RP V1), AND MUTAGENESIS OF LEU-277; PRO-567 AND ASP-656 (ISOFORM V1). RX PubMed=21319793; DOI=10.1021/bi1020088; RA Kawahara T., Jackson H.M., Smith S.M., Simpson P.D., Lambeth J.D.; RT "Nox5 forms a functional oligomer mediated by self-association of its RT dehydrogenase domain."; RL Biochemistry 50:2013-2025(2011). RN [17] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), PHOSPHORYLATION AT RP SER-475; THR-494; SER-498; SER-502 AND SER-659 (ISOFORM V2), AND RP MUTAGENESIS OF SER-475; THR-494; SER-498; SER-502 AND SER-659 (ISOFORM V2). RX PubMed=21642394; DOI=10.1124/mol.110.070193; RA Pandey D., Gratton J.P., Rafikov R., Black S.M., Fulton D.J.; RT "Calcium/calmodulin-dependent kinase II mediates the phosphorylation and RT activation of NADPH oxidase 5."; RL Mol. Pharmacol. 80:407-415(2011). RN [18] RP FUNCTION (ISOFORMS V1 AND V2), CATALYTIC ACTIVITY (ISOFORMS V1 AND V2), RP ABSENCE OF CATALYTIC ACTIVITY (ISOFORMS V3; V4 AND V5), TISSUE SPECIFICITY RP (ISOFORMS V1 AND V2), AND DOMAIN. RX PubMed=22427510; DOI=10.1152/ajpheart.00910.2011; RA Pandey D., Patel A., Patel V., Chen F., Qian J., Wang Y., Barman S.A., RA Venema R.C., Stepp D.W., Rudic R.D., Fulton D.J.; RT "Expression and functional significance of NADPH oxidase 5 (Nox5) and its RT splice variants in human blood vessels."; RL Am. J. Physiol. 302:H1919-H1928(2012). RN [19] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), S-NITROSYLATION AT RP CYS-107; CYS-246; CYS-519 AND CYS-694 (ISOFORM V2), PHOSPHORYLATION AT RP SER-490; THR-494 AND SER-498 (ISOFORM V2), AND MUTAGENESIS OF CYS-107; RP CYS-519 AND CYS-694 (ISOFORM V2). RX PubMed=22387196; DOI=10.1016/j.freeradbiomed.2012.02.029; RA Qian J., Chen F., Kovalenkov Y., Pandey D., Moseley M.A., Foster M.W., RA Black S.M., Venema R.C., Stepp D.W., Fulton D.J.; RT "Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S- RT nitrosylation."; RL Free Radic. Biol. Med. 52:1806-1819(2012). RN [20] RP FUNCTION (ISOFORM V2), CATALYTIC ACTIVITY (ISOFORM V2), PHOSPHORYLATION AT RP SER-490; THR-494 AND SER-498 (ISOFORM V2), AND MUTAGENESIS OF SER-490; RP THR-494 AND SER-498 (ISOFORM V2). RX PubMed=24505490; DOI=10.1371/journal.pone.0088405; RA Chen F., Yu Y., Haigh S., Johnson J., Lucas R., Stepp D.W., Fulton D.J.; RT "Regulation of NADPH oxidase 5 by protein kinase C isoforms."; RL PLoS ONE 9:e88405-e88405(2014). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=34784249; DOI=10.1126/scisignal.abe3800; RA Gu F., Krueger A., Roggenkamp H.G., Alpers R., Lodygin D., Jaquet V., RA Moeckl F., Hernandez L.C., Winterberg K., Bauche A., Rosche A., RA Grasberger H., Kao J.Y., Schetelig D., Werner R., Schroeder K., Carty M., RA Bowie A.G., Huber S., Meier C., Mittruecker H.W., Heeren J., Krause K.H., RA Fluegel A., Diercks B.P., Guse A.H.; RT "Dual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for RT Ca2+ signaling during T cell activation."; RL Sci. Signal. 14:eabe3800-eabe3800(2021). RN [22] RP FUNCTION (ISOFORMS V2 AND V5), CATALYTIC ACTIVITY (ISOFORMS V2 AND V5), RP ACTIVITY REGULATION (ISOFORM V2), SUBCELLULAR LOCATION (ISOFORM V2), AND RP MUTAGENESIS OF GLU-110; SER-111; ALA-112; ILE-113; SER-114; LEU-115 AND RP PRO-116 (ISOFORM V2). RX PubMed=36653838; DOI=10.1002/1873-3468.14577; RA Miyano K., Kajikawa M.; RT "Ca2+ -binding-region-dependent cell surface localization of NADPH oxidase RT Nox5."; RL FEBS Lett. 597:702-713(2023). RN [23] {ECO:0007744|PDB:6SZ5} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 674-684 (ISOFORM V2) IN COMPLEX RP WITH CALMODULIN, AND N-TERMINAL REGULATORY EF DOMAIN (ISOFORM V2) AND RP C-TERMINAL CATALYTIC DEHYDROGENASE DOMAIN (ISOFORM V2). RX PubMed=31785178; DOI=10.1111/febs.15160; RA Millana Fananas E., Todesca S., Sicorello A., Masino L., Pompach P., RA Magnani F., Pastore A., Mattevi A.; RT "On the mechanism of calcium-dependent activation of NADPH oxidase 5 RT (NOX5)."; RL FEBS J. 287:2486-2503(2020). CC -!- FUNCTION: Calcium-dependent NADPH oxidase that catalyzes the generation CC of superoxide from molecular oxygen utilizing NADPH as an electron CC donor (PubMed:12686516). Also synthesizes NAADP from its reduced NAADPH CC form which promotes Ca(2+) signaling during T cell activation CC (PubMed:34784249). May play a role in cell growth and apoptosis CC (PubMed:12686516). {ECO:0000269|PubMed:12686516, CC ECO:0000269|PubMed:34784249}. CC -!- FUNCTION: [Isoform v2]: Calcium-dependent NADPH oxidase that catalyzes CC the generation of superoxide from molecular oxygen utilizing NADPH as CC an electron donor (PubMed:11483596, PubMed:14982937, PubMed:17275676, CC PubMed:17587483, PubMed:21642394, PubMed:22387196, PubMed:22427510, CC PubMed:24505490, PubMed:36653838). Involved in endothelial generation CC of reactive oxygen species (ROS), proliferation and angiogenesis and CC contributes to endothelial response to thrombin (PubMed:17275676). CC Regulates redox-dependent processes in lymphocytes and spermatozoa CC (PubMed:11483596). {ECO:0000269|PubMed:11483596, CC ECO:0000269|PubMed:14982937, ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:21642394, CC ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:22427510, CC ECO:0000269|PubMed:24505490, ECO:0000269|PubMed:36653838}. CC -!- FUNCTION: [Isoform v1]: Calcium-dependent NADPH oxidase that catalyzes CC the generation of superoxide from molecular oxygen utilizing NADPH as CC an electron donor. {ECO:0000269|PubMed:21319793, CC ECO:0000269|PubMed:22427510}. CC -!- FUNCTION: [Isoform v5]: This isoform lacks calcium-binding domains and CC was showed to present a NADPH oxidase activity in a calcium-independent CC manner (PubMed:17275676, PubMed:36653838). May be involved in CC endothelial generation of reactive oxygen species (ROS), proliferation CC and angiogenesis and contribute to endothelial response to thrombin CC (PubMed:17275676). However another study showed an absence of oxidase CC activity (PubMed:22427510). Subject to rapid degradation CC (PubMed:36653838). {ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:22427510, ECO:0000269|PubMed:36653838}. CC -!- FUNCTION: [Isoform v3]: Lacks calcium-dependent NADPH oxidase activity. CC {ECO:0000269|PubMed:22427510}. CC -!- FUNCTION: [Isoform v4]: Lacks calcium-dependent NADPH oxidase activity. CC {ECO:0000269|PubMed:22427510}. CC -!- CATALYTIC ACTIVITY: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:12686516}; CC -!- CATALYTIC ACTIVITY: [Isoform v2]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:14982937, CC ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:17587483, CC ECO:0000269|PubMed:21642394, ECO:0000269|PubMed:22387196, CC ECO:0000269|PubMed:22427510, ECO:0000269|PubMed:24505490, CC ECO:0000269|PubMed:36653838}; CC -!- CATALYTIC ACTIVITY: [Isoform v1]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:21319793, ECO:0000269|PubMed:22427510}; CC -!- CATALYTIC ACTIVITY: [Isoform v5]: CC Reaction=NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+); CC Xref=Rhea:RHEA:63180, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; CC Evidence={ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:36653838}; CC -!- CATALYTIC ACTIVITY: CC Reaction=NAADPH + 2 O2 = NAADP(+) + 2 superoxide + H(+); CC Xref=Rhea:RHEA:86239, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, CC ChEBI:CHEBI:18421, ChEBI:CHEBI:75967, ChEBI:CHEBI:235461; CC Evidence={ECO:0000269|PubMed:34784249}; CC -!- COFACTOR: [Isoform v2]: CC Name=FAD; Xref=ChEBI:CHEBI:57692; CC Evidence={ECO:0000269|PubMed:14982937}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14982937}; CC -!- ACTIVITY REGULATION: [Isoform v2]: Activated by calcium which induces CC conformational changes and interaction between the N-terminal CC regulatory region and the C-terminal catalytic region. Inhibited by CC diphenylene iodonium. {ECO:0000269|PubMed:14982937, CC ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:36653838}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: [Isoform v2]: CC Kinetic parameters: CC KM=1.06 uM for calcium {ECO:0000269|PubMed:14982937}; CC pH dependence: CC Optimum pH is 7.5 with NAADPH as substrate (PubMed:34784249). Optimum CC pH is between 8 and 9 with NADPH as substrate (PubMed:34784249). CC {ECO:0000269|PubMed:34784249}; CC -!- SUBUNIT: [Isoform v1]: Homooligomer. {ECO:0000269|PubMed:21319793}. CC -!- INTERACTION: CC Q96PH1-4; P62157: CALM; Xeno; NbExp=3; IntAct=EBI-7305642, EBI-397403; CC -!- SUBCELLULAR LOCATION: [Isoform v2]: Endoplasmic reticulum CC {ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:17587483}. Cell CC membrane {ECO:0000269|PubMed:17587483, ECO:0000269|PubMed:36653838}; CC Multi-pass membrane protein {ECO:0000255}. Note=Calcium-sensitive CC association and dissociation between the N- and C-terminal domains CC appears to facilitate its localization to the cell membrane. CC {ECO:0000269|PubMed:36653838}. CC -!- SUBCELLULAR LOCATION: [Isoform v5]: Endoplasmic reticulum CC {ECO:0000269|PubMed:17275676}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=v3; Synonyms=NOX5gamma; CC IsoId=Q96PH1-1; Sequence=Displayed; CC Name=v1; Synonyms=NOX5alpha; CC IsoId=Q96PH1-3; Sequence=VSP_017328; CC Name=v2; Synonyms=NOX5beta; CC IsoId=Q96PH1-4; Sequence=VSP_017327, VSP_017328; CC Name=v4; Synonyms=NOX5delta; CC IsoId=Q96PH1-2; Sequence=VSP_017327; CC Name=v5; Synonyms=NOX5epsilon, NOX5S; CC IsoId=Q96PH1-5; Sequence=VSP_017326; CC Name=v6; Synonyms=NOX5zeta; CC IsoId=Q96PH1-6; Sequence=VSP_041619, VSP_017328; CC -!- TISSUE SPECIFICITY: Mainly expressed in pachytene spermatocytes of CC testis and in lymphocyte-rich areas of spleen and lymph nodes. Also CC detected in ovary, placenta, pancreas, cardiac fibroblasts. Expressed CC in B-cells and prostate malignant cells. {ECO:0000269|PubMed:11376945, CC ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:12686516, CC ECO:0000269|PubMed:16179589, ECO:0000269|PubMed:16339585}. CC -!- TISSUE SPECIFICITY: [Isoform v1]: Expressed in spleen CC (PubMed:11483596). Expressed in endothelial cells, pulmonary artery CC smooth muscle cells and epithelial colorectal adenocarcinoma cells CC (PubMed:17275676, PubMed:22427510). {ECO:0000269|PubMed:11483596, CC ECO:0000269|PubMed:17275676, ECO:0000269|PubMed:22427510}. CC -!- TISSUE SPECIFICITY: [Isoform v2]: Expressed in microvascular CC endothelial cells (at protein level) (PubMed:17275676). Expressed in CC testis (PubMed:11483596). Expressed in endothelial cells and pulmonary CC artery smooth muscle cells (PubMed:17275676, PubMed:22427510). CC {ECO:0000269|PubMed:11483596, ECO:0000269|PubMed:17275676, CC ECO:0000269|PubMed:22427510}. CC -!- TISSUE SPECIFICITY: [Isoform v3]: Expressed in pulmonary artery smooth CC muscle cells and epithelial colorectal adenocarcinoma cells. CC {ECO:0000269|PubMed:17275676}. CC -!- TISSUE SPECIFICITY: [Isoform v4]: Expressed in endothelial cells and CC pulmonary artery smooth muscle cells. {ECO:0000269|PubMed:17275676}. CC -!- TISSUE SPECIFICITY: [Isoform v5]: Expressed in microvascular CC endothelial cells (at protein level). {ECO:0000269|PubMed:17275676}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal tissues. CC {ECO:0000269|PubMed:11376945}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:16179589}. CC -!- DOMAIN: [Isoform v2]: The C-lobe of the N-terminal calmodulin-like CC regulatory EF-domain acquires a folded and ordered structure upon CC calcium binding, and as a consequence, it is able to bind the C- CC terminal catalytic dehydrogenase domain, triggering enzyme activation. CC {ECO:0000269|PubMed:31785178}. CC -!- DOMAIN: [Isoform v1]: The C-terminal catalytic dehydrogenase domain CC mediates its homooligomerization. {ECO:0000269|PubMed:21319793}. CC -!- DOMAIN: [Isoform v3]: Absence of enzyme activity may be because the CC third EF-hand domain is interrupted by an insert. CC {ECO:0000305|PubMed:22427510}. CC -!- DOMAIN: [Isoform v4]: Absence of enzyme activity may be because the CC third EF-hand domain is interrupted by an insert. CC {ECO:0000305|PubMed:22427510}. CC -!- DOMAIN: [Isoform v5]: Absence of enzyme activity may be due to absence CC of EF-hand domains. {ECO:0000305|PubMed:22427510}. CC -!- PTM: [Isoform v2]: Phosphorylation at Ser-475 by CaMK2 and at Ser-490, CC Thr-494 and Ser-498 by PKC/PRKCA positively regulates its catalytic CC activity. {ECO:0000269|PubMed:21642394, ECO:0000269|PubMed:24505490}. CC -!- PTM: [Isoform v2]: S-nitrosylation in response to nitric oxide inhibits CC its catalytic activity. {ECO:0000269|PubMed:22387196}. CC -!- CAUTION: [Isoform v2]: This isoform was proposed to act as a calcium- CC dependent proton channel to compensate charge and pH alterations due to CC electron export; however the channel activity seems to lack strong CC experimental evidences. {ECO:0000305|PubMed:11483596}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG33638.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB15319.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB84897.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF325189; AAK57193.1; -; mRNA. DR EMBL; AF325190; AAK57194.1; -; mRNA. DR EMBL; AF353088; AAK57338.1; -; mRNA. DR EMBL; AF353089; AAK57339.1; -; mRNA. DR EMBL; AK074058; BAB84884.1; -; mRNA. DR EMBL; AK074071; BAB84897.1; ALT_INIT; mRNA. DR EMBL; AK026011; BAB15319.1; ALT_INIT; mRNA. DR EMBL; AK314689; BAG37241.1; -; mRNA. DR EMBL; DQ314884; ABC40743.1; -; Genomic_DNA. DR EMBL; AC027088; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087639; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471082; EAW77830.1; -; Genomic_DNA. DR EMBL; BC125097; AAI25098.1; -; mRNA. DR EMBL; BC125098; AAI25099.1; -; mRNA. DR EMBL; AF317889; AAG33638.1; ALT_INIT; mRNA. DR CCDS; CCDS32276.2; -. [Q96PH1-1] DR CCDS; CCDS53954.1; -. [Q96PH1-3] DR RefSeq; NP_001171708.1; NM_001184779.2. [Q96PH1-3] DR RefSeq; NP_001171709.1; NM_001184780.1. [Q96PH1-6] DR RefSeq; NP_078781.3; NM_024505.3. [Q96PH1-1] DR PDB; 6SZ5; X-ray; 2.23 A; B/C=19-765. DR PDB; 8U7Y; EM; 4.06 A; A/B=19-765. DR PDB; 8U85; EM; 3.20 A; A/C=19-765. DR PDB; 8U86; EM; 3.30 A; A/C=19-765. DR PDB; 8U87; EM; 3.86 A; A/C=19-765. DR PDBsum; 6SZ5; -. DR PDBsum; 8U7Y; -. DR PDBsum; 8U85; -. DR PDBsum; 8U86; -. DR PDBsum; 8U87; -. DR AlphaFoldDB; Q96PH1; -. DR EMDB; EMD-42013; -. DR EMDB; EMD-42014; -. DR EMDB; EMD-42015; -. DR EMDB; EMD-42016; -. DR EMDB; EMD-42345; -. DR EMDB; EMD-42348; -. DR SMR; Q96PH1; -. DR BioGRID; 122660; 47. DR FunCoup; Q96PH1; 206. DR IntAct; Q96PH1; 10. DR MINT; Q96PH1; -. DR STRING; 9606.ENSP00000373518; -. DR BindingDB; Q96PH1; -. DR ChEMBL; CHEMBL1926497; -. DR GuidetoPHARMACOLOGY; 3005; -. DR PeroxiBase; 6024; HsNOx05. DR TCDB; 5.B.1.1.5; the phagocyte (gp91(phox)) nadph oxidase family. DR iPTMnet; Q96PH1; -. DR PhosphoSitePlus; Q96PH1; -. DR BioMuta; NOX5; -. DR DMDM; 74717091; -. DR jPOST; Q96PH1; -. DR MassIVE; Q96PH1; -. DR PaxDb; 9606-ENSP00000373518; -. DR PeptideAtlas; Q96PH1; -. DR ProteomicsDB; 77694; -. [Q96PH1-1] DR ProteomicsDB; 77695; -. [Q96PH1-2] DR ProteomicsDB; 77696; -. [Q96PH1-3] DR ProteomicsDB; 77697; -. [Q96PH1-4] DR ProteomicsDB; 77698; -. [Q96PH1-5] DR ProteomicsDB; 77699; -. [Q96PH1-6] DR Antibodypedia; 57978; 240 antibodies from 30 providers. DR DNASU; 79400; -. DR Ensembl; ENST00000388866.8; ENSP00000373518.3; ENSG00000255346.11. [Q96PH1-1] DR Ensembl; ENST00000530406.7; ENSP00000432440.2; ENSG00000255346.11. [Q96PH1-3] DR GeneID; 79400; -. DR KEGG; hsa:134826889; -. DR KEGG; hsa:79400; -. DR MANE-Select; ENST00000388866.8; ENSP00000373518.3; NM_024505.4; NP_078781.3. DR UCSC; uc002arp.3; human. [Q96PH1-1] DR AGR; HGNC:14874; -. DR ClinPGx; PA31693; -. DR CTD; 79400; -. DR DisGeNET; 79400; -. DR GeneCards; NOX5; -. DR HGNC; HGNC:14874; NOX5. DR HPA; ENSG00000255346; Tissue enriched (lymphoid). DR HPA; ENSG00000290203; Not detected. DR MIM; 606572; gene. DR OpenTargets; ENSG00000255346; -. DR VEuPathDB; HostDB:ENSG00000255346; -. DR eggNOG; KOG0039; Eukaryota. DR GeneTree; ENSGT00940000162591; -. DR HOGENOM; CLU_009773_0_0_1; -. DR InParanoid; Q96PH1; -. DR OMA; WFVVPGC; -. DR OrthoDB; 167398at2759; -. DR PAN-GO; Q96PH1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PH1; -. DR PathwayCommons; Q96PH1; -. DR Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species. DR SABIO-RK; Q96PH1; -. DR SignaLink; Q96PH1; -. DR SIGNOR; Q96PH1; -. DR Agora; ENSG00000255346; -. DR BioGRID-ORCS; 79400; 14 hits in 1148 CRISPR screens. DR ChiTaRS; NOX5; human. DR GeneWiki; NOX5; -. DR GenomeRNAi; 79400; -. DR Pharos; Q96PH1; Tchem. DR PRO; PR:Q96PH1; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96PH1; protein. DR Bgee; ENSG00000255346; Expressed in oocyte and 141 other cell types or tissues. DR ExpressionAtlas; Q96PH1; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0043020; C:NADPH oxidase complex; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0050660; F:flavin adenine dinucleotide binding; NAS:UniProtKB. DR GO; GO:0020037; F:heme binding; NAS:UniProtKB. DR GO; GO:0050661; F:NADP binding; NAS:UniProtKB. DR GO; GO:0015252; F:proton channel activity; IDA:UniProtKB. DR GO; GO:0016175; F:superoxide-generating NAD(P)H oxidase activity; IDA:UniProtKB. DR GO; GO:0106292; F:superoxide-generating NADPH oxidase activity; IDA:FlyBase. DR GO; GO:0001525; P:angiogenesis; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; NAS:UniProtKB. DR GO; GO:0061640; P:cytoskeleton-dependent cytokinesis; NAS:UniProtKB. DR GO; GO:0006952; P:defense response; IBA:GO_Central. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; NAS:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB. DR GO; GO:1902600; P:proton transmembrane transport; IDA:UniProtKB. DR GO; GO:0043012; P:regulation of fusion of sperm to egg plasma membrane; NAS:UniProtKB. DR GO; GO:0042554; P:superoxide anion generation; IDA:UniProtKB. DR CDD; cd00051; EFh; 2. DR CDD; cd06186; NOX_Duox_like_FAD_NADP; 1. DR FunFam; 2.40.30.10:FF:000056; NADPH oxidase 5; 1. DR FunFam; 1.10.238.10:FF:000210; NADPH oxidase 5 isoform X2; 1. DR FunFam; 3.40.50.80:FF:000012; NADPH oxidase, isoform B; 1. DR Gene3D; 1.10.238.10; EF-hand; 1. DR Gene3D; 3.40.50.80; Nucleotide-binding domain of ferredoxin-NADP reductase (FNR) module; 1. DR Gene3D; 2.40.30.10; Translation factors; 1. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR018247; EF_Hand_1_Ca_BS. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR013112; FAD-bd_8. DR InterPro; IPR017927; FAD-bd_FR_type. DR InterPro; IPR013130; Fe3_Rdtase_TM_dom. DR InterPro; IPR013121; Fe_red_NAD-bd_6. DR InterPro; IPR039261; FNR_nucleotide-bd. DR InterPro; IPR050369; RBOH/FRE. DR InterPro; IPR017938; Riboflavin_synthase-like_b-brl. DR PANTHER; PTHR11972; NADPH OXIDASE; 1. DR PANTHER; PTHR11972:SF58; NADPH OXIDASE 5; 1. DR Pfam; PF13202; EF-hand_5; 1. DR Pfam; PF13405; EF-hand_6; 1. DR Pfam; PF08022; FAD_binding_8; 1. DR Pfam; PF01794; Ferric_reduct; 1. DR Pfam; PF08030; NAD_binding_6; 1. DR SFLD; SFLDS00052; Ferric_Reductase_Domain; 1. DR SFLD; SFLDG01168; Ferric_reductase_subgroup_(FRE; 1. DR SFLD; SFLDG01169; NADPH_oxidase_subgroup_(NOX); 1. DR SMART; SM00054; EFh; 2. DR SUPFAM; SSF47473; EF-hand; 1. DR SUPFAM; SSF52343; Ferredoxin reductase-like, C-terminal NADP-linked domain; 1. DR SUPFAM; SSF63380; Riboflavin synthase domain-like; 1. DR PROSITE; PS00018; EF_HAND_1; 2. DR PROSITE; PS50222; EF_HAND_2; 3. DR PROSITE; PS51384; FAD_FR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Calcium; Cell membrane; KW Electron transport; Endoplasmic reticulum; FAD; Flavoprotein; Ion channel; KW Ion transport; Membrane; Metal-binding; NADP; Oxidoreductase; KW Proteomics identification; Reference proteome; Repeat; Transmembrane; KW Transmembrane helix; Transport. FT CHAIN 1..765 FT /note="NADPH oxidase 5" FT /id="PRO_0000224995" FT TOPO_DOM 1..238 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 239..259 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 260..266 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 267..289 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 290..317 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 318..338 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 339..362 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 363..383 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 384..394 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 395..417 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 418..434 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 435..455 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 456..583 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 584..604 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 605..765 FT /note="Extracellular" FT /evidence="ECO:0000255" FT DOMAIN 26..56 FT /note="EF-hand 1" FT /evidence="ECO:0000305" FT DOMAIN 57..92 FT /note="EF-hand 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 93..156 FT /note="EF-hand 3; atypical; contains an insert of 28 FT residues" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 165..200 FT /note="EF-hand 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 293..440 FT /note="Ferric oxidoreductase" FT DOMAIN 441..577 FT /note="FAD-binding FR-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00716" FT REGION 122..141 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 42 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 44 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 49 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 70 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 72 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 74 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 76 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 81 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 106 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 108 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 138 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 140 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 145 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000305" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 180 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 182 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 189 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT VAR_SEQ 1..200 FT /note="Missing (in isoform v5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017326" FT VAR_SEQ 1..18 FT /note="Missing (in isoform v2 and isoform v4)" FT /evidence="ECO:0000303|PubMed:11483596, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334" FT /id="VSP_017327" FT VAR_SEQ 1..17 FT /note="MNTSGDPAQTGPEGCRG -> MAFVCAGLSD (in isoform v6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041619" FT VAR_SEQ 109..136 FT /note="Missing (in isoform v1, isoform v2 and isoform v6)" FT /evidence="ECO:0000303|PubMed:11483596, FT ECO:0000303|PubMed:15489334" FT /id="VSP_017328" FT VARIANT 576 FT /note="R -> H (in dbSNP:rs2277552)" FT /id="VAR_055820" FT VARIANT 759 FT /note="R -> G (in dbSNP:rs7168025)" FT /id="VAR_055821" FT CONFLICT 208 FT /note="A -> T (in Ref. 8; AAG33638)" FT /evidence="ECO:0000305" FT CONFLICT 272 FT /note="G -> S (in Ref. 7; AAI25099)" FT /evidence="ECO:0000305" FT CONFLICT 375 FT /note="L -> P (in Ref. 3; BAG37241)" FT /evidence="ECO:0000305" FT CONFLICT 380 FT /note="L -> F (in Ref. 2; BAB84884/BAB84897, 3; BAB15319/ FT BAG37241, 6; EAW77830 and 7; AAI25098/AAI25099)" FT /evidence="ECO:0000305" FT HELIX 23..35 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 47..53 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 60..69 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 79..90 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 94..105 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 143..152 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 187..196 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 200..203 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 229..259 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 267..286 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 290..292 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 307..309 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 310..340 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 369..383 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 387..391 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 397..402 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 405..413 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 419..436 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 441..444 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 447..454 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 455..457 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 458..464 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 476..479 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 482..484 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 490..494 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 502..509 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 513..524 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 567..571 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 576..579 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 580..589 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 590..593 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 594..609 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 611..613 FT /evidence="ECO:0007829|PDB:8U86" FT TURN 615..617 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 620..622 FT /evidence="ECO:0007829|PDB:8U86" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 647..659 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 664..666 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 670..675 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 682..685 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 686..695 FT /evidence="ECO:0007829|PDB:8U85" FT TURN 696..700 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 707..710 FT /evidence="ECO:0007829|PDB:8U85" FT STRAND 711..714 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 721..728 FT /evidence="ECO:0007829|PDB:6SZ5" FT STRAND 736..741 FT /evidence="ECO:0007829|PDB:8U85" FT HELIX 743..756 FT /evidence="ECO:0007829|PDB:8U85" FT REGION Q96PH1-3:416..737 FT /note="C-terminal catalytic dehydrogenase domain" FT /evidence="ECO:0000305|PubMed:21319793" FT MUTAGEN Q96PH1-3:277 FT /note="L->R: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT MUTAGEN Q96PH1-3:567 FT /note="P->H: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT MUTAGEN Q96PH1-3:656 FT /note="D->A: Loss of activity but no effect on protein FT levels." FT /evidence="ECO:0000269|PubMed:21319793" FT REGION Q96PH1-4:1..161 FT /note="N-terminal regulatory EF domain" FT /evidence="ECO:0000269|PubMed:14982937, FT ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:1..77 FT /note="N-terminal lobe of N-terminal regulatory EF domain" FT /evidence="ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:78..161 FT /note="C-terminal lobe of N-terminal regulatory EF domain" FT /evidence="ECO:0000305|PubMed:31785178" FT REGION Q96PH1-4:398..719 FT /note="C-terminal catalytic dehydrogenase domain" FT /evidence="ECO:0000305|PubMed:31785178" FT MOD_RES Q96PH1-4:107 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:246 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:475 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:490 FT /note="Phosphothreonine; by PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:22387196, FT ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:494 FT /note="Phosphothreonine; by CaMK2 and PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:498 FT /note="Phosphoserine; by CaMK2 and PKC/PRKCA" FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:22387196, ECO:0000269|PubMed:24505490" FT MOD_RES Q96PH1-4:502 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:519 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MOD_RES Q96PH1-4:659 FT /note="Phosphoserine; by CaMK2" FT /evidence="ECO:0000269|PubMed:21642394" FT MOD_RES Q96PH1-4:694 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:31 FT /note="E->Q: Loss of binding of 1 calcium molecule. No FT effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:14982937" FT MUTAGEN Q96PH1-4:107 FT /note="C->S: Substantial loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:110 FT /note="E->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:111 FT /note="S->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:112 FT /note="A->N: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:113 FT /note="I->N: Significant reduction in cell membrane FT localization and catalytic activity. Reduced calcium- FT dependent interaction between the N-terminal regulatory FT region and the C-terminal catalytic region." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:114 FT /note="S->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:115 FT /note="L->A: Significant reduction in cell membrane FT localization and catalytic activity. No effect on calcium- FT dependent interaction between the N-terminal regulatory FT region and the C-terminal catalytic region." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:116 FT /note="P->A: No effect on cell membrane localization and FT catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:475 FT /note="S->A: Loss of CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:490 FT /note="S->A: Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-494 and A-498." FT /evidence="ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:494 FT /note="T->A: No effect on CaMK2-mediated activation of its FT activity. Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-490 and A-498." FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:498 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity. Loss of PKC/PRKCA-mediated activation of its FT activity; when associated with A-490 and A-494." FT /evidence="ECO:0000269|PubMed:21642394, FT ECO:0000269|PubMed:24505490" FT MUTAGEN Q96PH1-4:502 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:519 FT /note="C->S: Very significant loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" FT MUTAGEN Q96PH1-4:549 FT /note="P->H: No effect on cell membrane localization but FT loss of catalytic activity." FT /evidence="ECO:0000269|PubMed:36653838" FT MUTAGEN Q96PH1-4:659 FT /note="S->A: No effect on CaMK2-mediated activation of its FT activity." FT /evidence="ECO:0000269|PubMed:21642394" FT MUTAGEN Q96PH1-4:694 FT /note="C->S: Reduced nitrosylation. Very significant loss FT of catalytic activity." FT /evidence="ECO:0000269|PubMed:22387196" SQ SEQUENCE 765 AA; 86439 MW; 96B57225BF919682 CRC64; MNTSGDPAQT GPEGCRGTMS AEEDARWLRW VTQQFKTIAG EDGEISLQEF KAALHVKESF FAERFFALFD SDRSGTITLQ ELQEALTLLI HGSPMDKLKF LFQVYDIDVC ARQGASAGTE WGAGAGPHWA SSPLGTGSGS IDPDELRTVL QSCLRESAIS LPDEKLDQLT LALFESADAD GNGAITFEEL RDELQRFPGV MENLTISAAH WLTAPAPRPR PRRPRQLTRA YWHNHRSQLF CLATYAGLHV LLFGLAASAH RDLGASVMVA KGCGQCLNFD CSFIAVLMLR RCLTWLRATW LAQVLPLDQN IQFHQLMGYV VVGLSLVHTV AHTVNFVLQA QAEASPFQFW ELLLTTRPGI GWVHGSASPT GVALLLLLLL MFICSSSCIR RSGHFEVFYW THLSYLLVWL LLIFHGPNFW KWLLVPGILF FLEKAIGLAV SRMAAVCIME VNLLPSKVTH LLIKRPPFFH YRPGDYLYLN IPTIARYEWH PFTISSAPEQ KDTIWLHIRS QGQWTNRLYE SFKASDPLGR GSKRLSRSVT MRKSQRSSKG SEILLEKHKF CNIKCYIDGP YGTPTRRIFA SEHAVLIGAG IGITPFASIL QSIMYRHQKR KHTCPSCQHS WIEGVQDNMK LHKVDFIWIN RDQRSFEWFV SLLTKLEMDQ AEEAQYGRFL ELHMYMTSAL GKNDMKAIGL QMALDLLANK EKKDSITGLQ TRTQPGRPDW SKVFQKVAAE KKGKVQVFFC GSPALAKVLK GHCEKFGFRF FQENF // ID NTRK2_HUMAN Reviewed; 822 AA. AC Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 249. DE RecName: Full=BDNF/NT-3 growth factors receptor; DE EC=2.7.10.1 {ECO:0000269|PubMed:15494731}; DE AltName: Full=GP145-TrkB; DE Short=Trk-B; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 2; DE AltName: Full=TrkB tyrosine kinase; DE AltName: Full=Tropomyosin-related kinase B; DE Flags: Precursor; GN Name=NTRK2; Synonyms=TRKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB). RC TISSUE=Hippocampus; RX PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q; RA Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J., RA Nycum L.M., Biegel J.A., Brodeur G.M.; RT "Cloning and chromosomal localization of the human TRK-B tyrosine kinase RT receptor gene (NTRK2)."; RL Genomics 25:538-546(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1). RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Hippocampus; RX PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x; RA Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M., RA Colebrook S.M., Feeney R., Macgowan S.H.; RT "Cloning of a non-catalytic form of human trkB and distribution of RT messenger RNA for trkB in human brain."; RL Neuroscience 60:825-834(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5), RP ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11798182; DOI=10.1006/bbrc.2001.6301; RA Stoilov P., Castren E., Stamm S.; RT "Analysis of the human TrkB gene genomic organization reveals novel TrkB RT isoforms, unusual gene length, and splicing mechanism."; RL Biochem. Biophys. Res. Commun. 290:1054-1065(2002). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309. RA Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J., RA Methner A.; RT "Full length truncated TrkB sequence identified in a screen for genes RT regulated by ischemic preconditioning."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121; RP ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412. RX PubMed=7574684; DOI=10.1006/abbi.1995.1460; RA Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.; RT "Extracellular domain of neurotrophin receptor trkB: disulfide structure, RT N-glycosylation sites, and ligand binding."; RL Arch. Biochem. Biophys. 322:256-264(1995). RN [12] RP INTERACTION WITH FRS2. RX PubMed=10092678; DOI=10.1074/jbc.274.14.9861; RA Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.; RT "The signaling adapter FRS-2 competes with Shc for binding to the nerve RT growth factor receptor TrkA. A model for discriminating proliferation and RT differentiation."; RL J. Biol. Chem. 274:9861-9870(1999). RN [13] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [14] RP ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1). RX PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x; RA Luberg K., Wong J., Weickert C.S., Timmusk T.; RT "Human TrkB gene: novel alternative transcripts, protein isoforms and RT expression pattern in the prefrontal cerebral cortex during postnatal RT development."; RL J. Neurochem. 113:952-964(2010). RN [15] {ECO:0007744|PDB:1WWB} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [16] {ECO:0007744|PDB:1HCF} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND RP DISULFIDE BONDS. RX PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5; RA Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., RA Brady R.L.; RT "Specificity in Trk receptor:neurotrophin interactions: the crystal RT structure of TrkB-d5 in complex with neurotrophin-4/5."; RL Structure 9:1191-1199(2001). RN [17] RP INTERACTION WITH SLITRK2. RX PubMed=35840571; DOI=10.1038/s41467-022-31566-z; RA El Chehadeh S., Han K.A., Kim D., Jang G., Bakhtiari S., Lim D., Kim H.Y., RA Kim J., Kim H., Wynn J., Chung W.K., Vitiello G., Cutcutache I., Page M., RA Gecz J., Harper K., Han A.R., Kim H.M., Wessels M., Bayat A., Jaen A.F., RA Selicorni A., Maitz S., de Brouwer A.P.M., Silfhout A.V., Armstrong M., RA Symonds J., Kuery S., Isidor B., Cogne B., Nizon M., Feger C., Muller J., RA Torti E., Grange D.K., Willems M., Kruer M.C., Ko J., Piton A., Um J.W.; RT "SLITRK2 variants associated with neurodevelopmental disorders impair RT excitatory synaptic function and cognition in mice."; RL Nat. Commun. 13:4112-4112(2022). RN [18] RP VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS RP A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=15494731; DOI=10.1038/nn1336; RA Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., RA Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.; RT "A de novo mutation affecting human TrkB associated with severe obesity and RT developmental delay."; RL Nat. Neurosci. 7:1187-1189(2004). RN [19] RP VARIANT [LARGE SCALE ANALYSIS] PHE-138. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP VARIANTS ILE-697; GLY-699 AND CYS-718. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). RN [21] RP VARIANT OBHD 444-GLY--GLY-822 DEL. RX PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215; RA Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L., RA Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J., RA Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M., RA van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A., RA Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.; RT "Diagnostic value of exome and whole genome sequencing in RT craniosynostosis."; RL J. Med. Genet. 54:260-268(2017). RN [22] RP VARIANT DEE58 CYS-434, VARIANT OBHD ILE-704, AND INVOLVEMENT IN DEE58. RX PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008; RG Deciphering Developmental Disorders Study; RA Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D., RA Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M., RA Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W., RA Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C., RA Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N., RA Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A., RA Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q., RA Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N., RA Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K., RA Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C., RA Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S., RA Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G., RA O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C., RA Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R., RA Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M., RA Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G., RA Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z., RA Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C., RA Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E., RA Minassian B.A., Michaud J.L.; RT "High rate of recurrent de novo mutations in developmental and epileptic RT encephalopathies."; RL Am. J. Hum. Genet. 101:664-685(2017). CC -!- FUNCTION: Receptor tyrosine kinase involved in the development and the CC maturation of the central and the peripheral nervous systems through CC regulation of neuron survival, proliferation, migration, CC differentiation, and synapse formation and plasticity (By similarity). CC Receptor for BDNF/brain-derived neurotrophic factor and CC NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 CC which is less efficient in activating the receptor but regulates neuron CC survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand- CC binding, undergoes homodimerization, autophosphorylation and activation CC (PubMed:15494731). Recruits, phosphorylates and/or activates several CC downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that CC regulate distinct overlapping signaling cascades. Through SHC1, FRS2, CC SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for CC instance neuronal differentiation including neurite outgrowth. Through CC the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade CC that mainly regulates growth and survival. Through PLCG1 and the CC downstream protein kinase C-regulated pathways controls synaptic CC plasticity. Thereby, plays a role in learning and memory by regulating CC both short term synaptic function and long-term potentiation. PLCG1 CC also leads to NF-Kappa-B activation and the transcription of genes CC involved in cell survival. Hence, it is able to suppress anoikis, the CC apoptosis resulting from loss of cell-matrix interactions. May also CC play a role in neutrophin-dependent calcium signaling in glial cells CC and mediate communication between neurons and glia. CC {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:7574684}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15494731}; CC -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium CC positively regulate the kinase activity and the internalization of the CC receptor which are both important for active signaling. Regulated by CC NGFR that may control the internalization of the receptor. NGFR may CC also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A CC inhibits the autophosphorylation of the receptor, and alters the CC recruitment and activation of downstream effectors and signaling CC cascades. The formation of active receptors dimers able to fully CC transduce the ligand-mediated signal, may be negatively regulated by CC the formation of inactive heterodimers with the non-catalytic isoforms CC (By similarity). {ECO:0000250|UniProtKB:P15209, CC ECO:0000250|UniProtKB:Q63604}. CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures. Interacts CC (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 CC phosphorylation and activation. Interacts (phosphorylated upon CC activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 CC phosphorylation and activation. Interacts with SH2B1 and SH2B2. CC Interacts with NGFR; may regulate the ligand specificity of the CC receptor (By similarity). Interacts with SORCS2; this interaction is CC important for normal targeting to post-synaptic densities in response CC to high-frequency stimulation (By similarity). Interacts CC (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. CC Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC (phosphorylated upon ligand-binding) with FRS2; activates the MAPK CC signaling pathway (PubMed:10092678). Interacts with APPL1 (By CC similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with CC KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with CC SORL1; this interaction facilitates NTRK2 trafficking between synaptic CC plasma membranes, postsynaptic densities and cell soma, hence CC positively regulates BDNF signaling (By similarity). Interacts with CC SLITRK2 (PubMed:35840571). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604, CC ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045, CC ECO:0000269|PubMed:35840571}. CC -!- INTERACTION: CC Q16620; P00533: EGFR; NbExp=3; IntAct=EBI-3904881, EBI-297353; CC Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704; CC Q16620; Q13485: SMAD4; NbExp=4; IntAct=EBI-3904881, EBI-347263; CC Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731}; CC Single-pass type I membrane protein {ECO:0000305}. Endosome membrane CC {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein CC {ECO:0000250|UniProtKB:P15209}. Early endosome membrane CC {ECO:0000250|UniProtKB:P15209}. Cell projection, axon CC {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region CC {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density CC {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon CC ligand-binding. {ECO:0000250|UniProtKB:P15209}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Comment=Additional isoforms seem to exist.; CC Name=TrkB; Synonyms=gp145-TrkB; CC IsoId=Q16620-1; Sequence=Displayed; CC Name=TrkB-T1; CC IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902; CC Name=TrkB-T-Shc; CC IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904; CC Name=4; CC IsoId=Q16620-4; Sequence=VSP_041942; CC Name=5; CC IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904; CC Name=TrkB-T-TK; CC IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179; CC Name=TrkB-N-T1; CC IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902; CC -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and CC peripheral nervous system. In the central nervous system (CNS), CC expression is observed in the cerebral cortex, hippocampus, thalamus, CC choroid plexus, granular layer of the cerebellum, brain stem, and CC spinal cord. In the peripheral nervous system, it is expressed in many CC cranial ganglia, the ophthalmic nerve, the vestibular system, multiple CC facial structures, the submaxillary glands, and dorsal root ganglia. CC Isoform TrkB-T1 is mainly expressed in the brain but also detected in CC other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc CC is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182, CC ECO:0000269|PubMed:7936202}. CC -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain. CC {ECO:0000269|PubMed:7936202}. CC -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that CC is required for interaction with SHC1 and PLCG1 and other downstream CC effectors. Isoform TrkB-T-Shc is not phosphorylated. CC {ECO:0000269|PubMed:15494731}. CC -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation; CC regulated by NGFR. Ubiquitination regulates the internalization of the CC receptor (By similarity). {ECO:0000250}. CC -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58) CC [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE58 is an autosomal dominant condition characterized CC by onset of refractory seizures in the first days or months of life. CC {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD) CC [MIM:613886]: A disorder characterized by early-onset obesity, CC hyperphagia, and severe developmental delay in motor function, speech, CC and language. {ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the CC first Trk was isolated as an oncogenic protein which was the result of CC a fusion between the tropomyosin gene TPM3 and NTRK1. CC -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41589/NTRK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U12140; AAC51371.1; -; mRNA. DR EMBL; S76473; AAB33109.1; -; mRNA. DR EMBL; S76474; AAB33110.1; -; mRNA. DR EMBL; X75958; CAA53571.1; -; mRNA. DR EMBL; AF410899; AAL67965.1; -; mRNA. DR EMBL; AF410900; AAL67966.1; -; mRNA. DR EMBL; AF410901; AAL67967.1; -; mRNA. DR EMBL; AF508964; AAM77876.1; -; mRNA. DR EMBL; AB209118; BAD92355.1; -; mRNA. DR EMBL; AK294285; BAG57570.1; -; mRNA. DR EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62688.1; -; Genomic_DNA. DR EMBL; BC031835; AAH31835.1; -; mRNA. DR CCDS; CCDS35050.1; -. [Q16620-1] DR CCDS; CCDS35051.1; -. [Q16620-5] DR CCDS; CCDS35052.1; -. [Q16620-3] DR CCDS; CCDS35053.1; -. [Q16620-2] DR CCDS; CCDS6671.1; -. [Q16620-4] DR CCDS; CCDS94429.1; -. [Q16620-7] DR PIR; A56853; A56853. DR PIR; I73631; I73631. DR RefSeq; NP_001007098.1; NM_001007097.3. [Q16620-2] DR RefSeq; NP_001018074.1; NM_001018064.3. [Q16620-1] DR RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5] DR RefSeq; NP_001018076.1; NM_001018066.3. [Q16620-3] DR RefSeq; NP_001356461.1; NM_001369532.1. [Q16620-1] DR RefSeq; NP_001356462.1; NM_001369533.1. [Q16620-1] DR RefSeq; NP_001356466.1; NM_001369537.1. [Q16620-5] DR RefSeq; NP_001356467.1; NM_001369538.1. [Q16620-3] DR RefSeq; NP_001356468.1; NM_001369539.1. [Q16620-2] DR RefSeq; NP_001356469.1; NM_001369540.1. [Q16620-2] DR RefSeq; NP_001356470.1; NM_001369541.1. [Q16620-2] DR RefSeq; NP_001356471.1; NM_001369542.1. [Q16620-2] DR RefSeq; NP_001356472.1; NM_001369543.1. [Q16620-2] DR RefSeq; NP_001356473.1; NM_001369544.1. [Q16620-2] DR RefSeq; NP_001356474.1; NM_001369545.1. [Q16620-2] DR RefSeq; NP_001356477.1; NM_001369548.1. [Q16620-2] DR RefSeq; NP_001356478.1; NM_001369549.1. [Q16620-2] DR RefSeq; NP_001356479.1; NM_001369550.1. [Q16620-7] DR RefSeq; NP_001356480.1; NM_001369551.1. [Q16620-7] DR RefSeq; NP_001356481.1; NM_001369552.1. [Q16620-7] DR RefSeq; NP_006171.2; NM_006180.4. [Q16620-4] DR RefSeq; XP_005252058.1; XM_005252001.4. [Q16620-4] DR RefSeq; XP_005252060.1; XM_005252003.4. [Q16620-4] DR RefSeq; XP_005252061.1; XM_005252004.3. [Q16620-4] DR RefSeq; XP_011517020.1; XM_011518718.4. [Q16620-1] DR RefSeq; XP_016870240.1; XM_017014751.3. [Q16620-4] DR RefSeq; XP_016870241.1; XM_017014752.2. [Q16620-1] DR RefSeq; XP_016870242.1; XM_017014753.3. [Q16620-1] DR RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5] DR RefSeq; XP_016870249.1; XM_017014760.3. [Q16620-2] DR RefSeq; XP_047279388.1; XM_047423432.1. [Q16620-4] DR RefSeq; XP_047279389.1; XM_047423433.1. [Q16620-4] DR RefSeq; XP_054218993.1; XM_054363018.1. [Q16620-4] DR RefSeq; XP_054218994.1; XM_054363019.1. [Q16620-4] DR RefSeq; XP_054218995.1; XM_054363020.1. [Q16620-4] DR RefSeq; XP_054218996.1; XM_054363021.1. [Q16620-4] DR RefSeq; XP_054218997.1; XM_054363022.1. [Q16620-4] DR RefSeq; XP_054218998.1; XM_054363023.1. [Q16620-4] DR RefSeq; XP_054218999.1; XM_054363024.1. [Q16620-1] DR RefSeq; XP_054219000.1; XM_054363025.1. [Q16620-1] DR RefSeq; XP_054219001.1; XM_054363026.1. [Q16620-1] DR RefSeq; XP_054219002.1; XM_054363027.1. [Q16620-5] DR RefSeq; XP_054219003.1; XM_054363028.1. [Q16620-2] DR PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383. DR PDB; 1WWB; X-ray; 2.10 A; X=283-385. DR PDB; 2MFQ; NMR; -; B=497-519. DR PDB; 4ASZ; X-ray; 1.70 A; A=527-822. DR PDB; 4AT3; X-ray; 1.77 A; A=527-822. DR PDB; 4AT4; X-ray; 2.36 A; A=527-822. DR PDB; 4AT5; X-ray; 1.71 A; A=527-822. DR PDB; 5MO9; X-ray; 2.59 A; X=278-426. DR PDB; 8OYD; NMR; -; A/B=422-466. DR PDBsum; 1HCF; -. DR PDBsum; 1WWB; -. DR PDBsum; 2MFQ; -. DR PDBsum; 4ASZ; -. DR PDBsum; 4AT3; -. DR PDBsum; 4AT4; -. DR PDBsum; 4AT5; -. DR PDBsum; 5MO9; -. DR PDBsum; 8OYD; -. DR AlphaFoldDB; Q16620; -. DR SMR; Q16620; -. DR BioGRID; 110970; 137. DR DIP; DIP-5720N; -. DR FunCoup; Q16620; 1218. DR IntAct; Q16620; 116. DR MINT; Q16620; -. DR STRING; 9606.ENSP00000277120; -. DR BindingDB; Q16620; -. DR ChEMBL; CHEMBL4898; -. DR DrugBank; DB00321; Amitriptyline. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB11823; Esketamine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16620; -. DR GuidetoPHARMACOLOGY; 1818; -. DR TCDB; 8.A.23.1.38; the basigin (basigin) family. DR GlyConnect; 1029; 12 N-Linked glycans (7 sites). DR GlyCosmos; Q16620; 13 sites, 14 glycans. DR GlyGen; Q16620; 13 sites, 21 N-linked glycans (8 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q16620; -. DR PhosphoSitePlus; Q16620; -. DR SwissPalm; Q16620; -. DR BioMuta; NTRK2; -. DR DMDM; 2497560; -. DR jPOST; Q16620; -. DR MassIVE; Q16620; -. DR PaxDb; 9606-ENSP00000277120; -. DR PeptideAtlas; Q16620; -. DR ProteomicsDB; 60955; -. [Q16620-1] DR ProteomicsDB; 60956; -. [Q16620-2] DR ProteomicsDB; 60957; -. [Q16620-3] DR ProteomicsDB; 60958; -. [Q16620-4] DR ProteomicsDB; 60959; -. [Q16620-5] DR ProteomicsDB; 60960; -. [Q16620-6] DR ProteomicsDB; 60961; -. [Q16620-7] DR ABCD; Q16620; 146 sequenced antibodies. DR Antibodypedia; 2081; 1498 antibodies from 49 providers. DR DNASU; 4915; -. DR Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.19. [Q16620-7] DR Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.19. [Q16620-5] DR GeneID; 4915; -. DR KEGG; hsa:4915; -. DR MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4] DR UCSC; uc004anz.1; human. [Q16620-1] DR AGR; HGNC:8032; -. DR CIViC; 4915; 5 evidence items across 2 molecular profiles. DR ClinPGx; PA31818; -. DR CTD; 4915; -. DR DisGeNET; 4915; -. DR GeneCards; NTRK2; -. DR HGNC; HGNC:8032; NTRK2. DR HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland). DR MalaCards; NTRK2; -. DR MIM; 600456; gene. DR MIM; 613886; phenotype. DR MIM; 617830; phenotype. DR OpenTargets; ENSG00000148053; -. DR Orphanet; 99704; Early-onset obesity-hyperphagia-severe developmental delay syndrome. DR Orphanet; 697160; Infantile epileptic spasms syndrome. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000148053; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155181; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16620; -. DR OMA; HIAMQIA; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16620; 16 GO annotations based on evolutionary models. DR PhylomeDB; Q16620; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16620; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-187024; NGF-independant TRKA activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1. DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN. DR Reactome; R-HSA-9032759; NTRK2 activates RAC1. DR Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5. DR SignaLink; Q16620; -. DR SIGNOR; Q16620; -. DR Agora; ENSG00000148053; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4915; 10 hits in 1188 CRISPR screens. DR ChiTaRS; NTRK2; human. DR EvolutionaryTrace; Q16620; -. DR GeneWiki; TrkB_receptor; -. DR GenomeRNAi; 4915; -. DR Pharos; Q16620; Tclin. DR PRO; PR:Q16620; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q16620; protein. DR Bgee; ENSG00000148053; Expressed in cranial nerve II and 196 other cell types or tissues. DR ExpressionAtlas; Q16620; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; ISS:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0043195; C:terminal bouton; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB. DR GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB. DR GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:ARUK-UCL. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central. DR GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0007631; P:feeding behavior; IEA:Ensembl. DR GO; GO:0014047; P:glutamate secretion; IEA:Ensembl. DR GO; GO:0007612; P:learning; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl. DR GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd05855; IgI_TrkB_d5; 1. DR CDD; cd05093; PTKc_TrkB; 1. DR DisProt; DP03945; -. DR FunFam; 2.60.40.10:FF:000239; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 3.80.10.10:FF:000048; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 1.10.510.10:FF:000034; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000486; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00672; -. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020455; NTRK2. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF136; BDNF_NT-3 GROWTH FACTORS RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01941; NTKRECEPTOR2. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Cytoplasm; Developmental protein; Differentiation; KW Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Obesity; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Synapse; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..31 FT CHAIN 32..822 FT /note="BDNF/NT-3 growth factors receptor" FT /id="PRO_0000016727" FT TOPO_DOM 32..430 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 431..454 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 455..822 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..61 FT /note="LRRNT" FT REPEAT 92..113 FT /note="LRR 1" FT REPEAT 116..137 FT /note="LRR 2" FT DOMAIN 148..196 FT /note="LRRCT" FT DOMAIN 197..282 FT /note="Ig-like C2-type 1" FT DOMAIN 295..365 FT /note="Ig-like C2-type 2" FT DOMAIN 538..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 455..466 FT /note="Interaction with MAPK8IP3/JIP3" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT REGION 475..498 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 485..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 676 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 706 FT /note="Interaction with SH2D1A" FT /evidence="ECO:0000250" FT SITE 817 FT /note="Interaction with PLCG1" FT /evidence="ECO:0000250" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P15209" FT MOD_RES 702 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 706 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 707 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 817 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 95 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 254 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 325 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 338 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT DISULFID 32..38 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 36..45 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 152..176 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 154..194 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 218..266 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 302..345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045, FT ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF, FT ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9" FT VAR_SEQ 1..156 FT /note="Missing (in isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042177" FT VAR_SEQ 465 FT /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_041942" FT VAR_SEQ 467..477 FT /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and FT isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002901" FT VAR_SEQ 478..822 FT /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002902" FT VAR_SEQ 529..537 FT /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002903" FT VAR_SEQ 538..822 FT /note="Missing (in isoform TrkB-T-Shc and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002904" FT VAR_SEQ 710..735 FT /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL FT LRLS (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042178" FT VAR_SEQ 736..822 FT /note="Missing (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042179" FT VARIANT 138 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041470" FT VARIANT 309 FT /note="G -> R" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_016320" FT VARIANT 338 FT /note="N -> Y (in dbSNP:rs1047856)" FT /id="VAR_011973" FT VARIANT 434 FT /note="Y -> C (in DEE58; uncertain significance; FT dbSNP:rs886041091)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080659" FT VARIANT 444..822 FT /note="Missing (in OBHD)" FT /evidence="ECO:0000269|PubMed:27884935" FT /id="VAR_080660" FT VARIANT 545 FT /note="G -> V (in dbSNP:rs1075108)" FT /id="VAR_049715" FT VARIANT 697 FT /note="M -> I (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046518" FT VARIANT 699 FT /note="R -> G (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046519" FT VARIANT 704 FT /note="T -> I (in OBHD; uncertain significance; FT dbSNP:rs1554774973)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080661" FT VARIANT 706 FT /note="Y -> C (in OBHD; expressed normally on the cell FT surface; results in markedly impaired ligand-induced FT phosphorylation as well as impaired downstream MAPK1 FT phosphorylation; dbSNP:rs121434633)" FT /evidence="ECO:0000269|PubMed:15494731" FT /id="VAR_065890" FT VARIANT 718 FT /note="R -> C (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs1324578301)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046520" FT STRAND 285..292 FT /evidence="ECO:0007829|PDB:5MO9" FT STRAND 300..308 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 328..337 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 339..350 FT /evidence="ECO:0007829|PDB:1WWB" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 357..364 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 369..376 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 380..382 FT /evidence="ECO:0007829|PDB:5MO9" FT HELIX 428..460 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 462..464 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:2MFQ" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:2MFQ" FT TURN 515..517 FT /evidence="ECO:0007829|PDB:2MFQ" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 538..545 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 552..557 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 567..574 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 579..592 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 634..638 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:4AT5" FT HELIX 650..669 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 679..681 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 682..684 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 686..688 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 690..692 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 698..701 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 713..715 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 722..727 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 732..747 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 748..750 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 753..756 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 759..768 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 780..789 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 794..796 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 800..813 FT /evidence="ECO:0007829|PDB:4ASZ" SQ SEQUENCE 822 AA; 91999 MW; 2FEB9159948F0D13 CRC64; MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG // ID NTRK3_HUMAN Reviewed; 839 AA. AC Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 06-MAR-2007, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=NT-3 growth factor receptor; DE EC=2.7.10.1; DE AltName: Full=GP145-TrkC; DE Short=Trk-C; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 3; DE AltName: Full=TrkC tyrosine kinase; DE Flags: Precursor; GN Name=NTRK3; Synonyms=TRKC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Fetal brain; RX PubMed=7806211; DOI=10.1006/geno.1994.1383; RA McGregor L.M., Baylin S.B., Griffin C.A., Hawkins A.L., Nelkin B.D.; RT "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal RT assignment, and evidence for a splice variant."; RL Genomics 22:267-272(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9778053; DOI=10.1038/sj.onc.1202100; RA Ichaso N., Rodriguez R.E., Martin-Zanca D., Gonzalez-Sarmiento R.; RT "Genomic characterization of the human trkC gene."; RL Oncogene 17:1871-1875(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [6] RP FUNCTION, PHOSPHORYLATION AT TYR-516, INVOLVEMENT IN CHD, VARIANTS PHE-21; RP VAL-71; MET-93; ILE-163; PHE-533 AND MET-817, CHARACTERIZATION OF VARIANTS RP MET-93; ILE-163; PHE-533 AND MET-817, AND MUTAGENESIS OF LYS-572. RX PubMed=25196463; DOI=10.1002/humu.22688; RA Werner P., Paluru P., Simpson A.M., Latney B., Iyer R., Brodeur G.M., RA Goldmuntz E.; RT "Mutations in NTRK3 suggest a novel signaling pathway in human congenital RT heart disease."; RL Hum. Mutat. 35:1459-1468(2014). RN [7] RP INTERACTION WITH PTPRS. RX PubMed=25385546; DOI=10.1038/ncomms6209; RA Coles C.H., Mitakidis N., Zhang P., Elegheert J., Lu W., Stoker A.W., RA Nakagawa T., Craig A.M., Jones E.Y., Aricescu A.R.; RT "Structural basis for extracellular cis and trans RPTPsigma signal RT competition in synaptogenesis."; RL Nat. Commun. 5:5209-5209(2014). RN [8] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 297-401, AND DISULFIDE BOND. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-149; CYS-306; LEU-307; GLN-336; RP TYR-677; GLN-678; ARG-768 AND LYS-781. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP VARIANTS SER-664; TYR-677; CYS-736; PRO-745 AND PHE-766. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). CC -!- FUNCTION: Receptor tyrosine kinase involved in nervous system and CC probably heart development. Upon binding of its ligand CC NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different CC signaling pathways, including the phosphatidylinositol 3-kinase/AKT and CC the MAPK pathways, that control cell survival and differentiation. CC {ECO:0000269|PubMed:25196463}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures (By similarity). Binds CC SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC with PTPRS (PubMed:25385546). Interacts with MAPK8IP3/JIP3 (By CC similarity). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:Q03351, ECO:0000269|PubMed:25385546}. CC -!- INTERACTION: CC Q16288; Q16832: DDR2; NbExp=2; IntAct=EBI-3936704, EBI-1381484; CC Q16288; Q6PKX4: DOK6; NbExp=3; IntAct=EBI-3936704, EBI-2880244; CC Q16288; Q15375: EPHA7; NbExp=2; IntAct=EBI-3936704, EBI-1383428; CC Q16288; P08581: MET; NbExp=2; IntAct=EBI-3936704, EBI-1039152; CC Q16288; P04629: NTRK1; NbExp=2; IntAct=EBI-3936704, EBI-1028226; CC Q16288; Q16620: NTRK2; NbExp=3; IntAct=EBI-3936704, EBI-3904881; CC Q16288; P18031: PTPN1; NbExp=2; IntAct=EBI-3936704, EBI-968788; CC Q16288; Q13332: PTPRS; NbExp=4; IntAct=EBI-3936704, EBI-711536; CC Q16288; P61619: SEC61A1; NbExp=2; IntAct=EBI-3936704, EBI-358919; CC Q16288; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-3936704, EBI-358766; CC Q16288; P31947: SFN; NbExp=2; IntAct=EBI-3936704, EBI-476295; CC Q16288; Q99523: SORT1; NbExp=2; IntAct=EBI-3936704, EBI-1057058; CC Q16288; P62258: YWHAE; NbExp=2; IntAct=EBI-3936704, EBI-356498; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=A; CC IsoId=Q16288-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=Q16288-2; Sequence=VSP_002925, VSP_002926; CC Name=3; Synonyms=C; CC IsoId=Q16288-3; Sequence=VSP_002927; CC Name=4; Synonyms=D; CC IsoId=Q16288-4; Sequence=VSP_002924; CC Name=5; Synonyms=E; CC IsoId=Q16288-5; Sequence=VSP_002924, VSP_002927; CC -!- TISSUE SPECIFICITY: Widely expressed but mainly in nervous tissue. CC Isoform 2 is expressed at higher levels in adult brain than in fetal CC brain. CC -!- PTM: Ligand-mediated auto-phosphorylation. CC -!- DISEASE: Note=Defects in NTRK3 are associated with susceptibility to CC congenital heart defects (CHD). A disease characterized by congenital CC developmental abnormalities involving structures of the heart. CHD are CC the most common major birth defects and the leading cause of death from CC congenital malformations. {ECO:0000269|PubMed:25196463}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/433/NTRK3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U05012; AAA75374.1; -; mRNA. DR EMBL; S76475; AAB33111.1; -; mRNA. DR EMBL; S76476; AAB33112.1; -; mRNA. DR EMBL; AJ224521; CAA12029.1; -; Genomic_DNA. DR EMBL; AJ224522; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224523; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224524; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224525; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224526; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224527; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224528; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224529; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224530; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224531; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224532; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224533; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224534; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224535; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AK297160; BAH12511.1; -; mRNA. DR EMBL; AC009711; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC021677; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS10340.1; -. [Q16288-3] DR CCDS; CCDS32322.1; -. [Q16288-1] DR CCDS; CCDS32323.1; -. [Q16288-2] DR CCDS; CCDS58399.1; -. [Q16288-5] DR PIR; A55178; A55178. DR PIR; I73632; I73632. DR PIR; I73633; I73633. DR RefSeq; NP_001007157.1; NM_001007156.3. [Q16288-2] DR RefSeq; NP_001012338.1; NM_001012338.3. [Q16288-1] DR RefSeq; NP_001230030.1; NM_001243101.2. [Q16288-5] DR RefSeq; NP_001307063.1; NM_001320134.1. DR RefSeq; NP_001307064.1; NM_001320135.1. DR RefSeq; NP_001362739.1; NM_001375810.1. [Q16288-1] DR RefSeq; NP_001362740.1; NM_001375811.1. [Q16288-3] DR RefSeq; NP_001362741.1; NM_001375812.1. [Q16288-5] DR RefSeq; NP_001362742.1; NM_001375813.1. [Q16288-2] DR RefSeq; NP_002521.2; NM_002530.4. [Q16288-3] DR RefSeq; XP_016877729.1; XM_017022240.2. [Q16288-3] DR RefSeq; XP_024305702.1; XM_024449934.2. [Q16288-2] DR RefSeq; XP_054234029.1; XM_054378054.1. [Q16288-3] DR RefSeq; XP_054234036.1; XM_054378061.1. [Q16288-2] DR PDB; 1WWC; X-ray; 1.90 A; A=297-422. DR PDB; 3V5Q; X-ray; 2.20 A; A/B=530-832. DR PDB; 4YMJ; X-ray; 2.00 A; A/B=530-839. DR PDB; 6KZC; X-ray; 2.00 A; A=528-839. DR PDB; 6KZD; X-ray; 1.71 A; A=528-839. DR PDBsum; 1WWC; -. DR PDBsum; 3V5Q; -. DR PDBsum; 4YMJ; -. DR PDBsum; 6KZC; -. DR PDBsum; 6KZD; -. DR AlphaFoldDB; Q16288; -. DR SMR; Q16288; -. DR BioGRID; 110971; 372. DR DIP; DIP-5723N; -. DR FunCoup; Q16288; 657. DR IntAct; Q16288; 355. DR MINT; Q16288; -. DR STRING; 9606.ENSP00000354207; -. DR BindingDB; Q16288; -. DR ChEMBL; CHEMBL5608; -. DR DrugBank; DB17191; Altiratinib. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB17140; JNJ-28312141. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16288; -. DR GuidetoPHARMACOLOGY; 1819; -. DR GlyCosmos; Q16288; 13 sites, No reported glycans. DR GlyGen; Q16288; 14 sites, 2 N-linked glycans (1 site). DR iPTMnet; Q16288; -. DR PhosphoSitePlus; Q16288; -. DR BioMuta; NTRK3; -. DR DMDM; 134035335; -. DR CPTAC; CPTAC-3001; -. DR CPTAC; CPTAC-3002; -. DR jPOST; Q16288; -. DR MassIVE; Q16288; -. DR PaxDb; 9606-ENSP00000354207; -. DR PeptideAtlas; Q16288; -. DR ProteomicsDB; 20249; -. DR ProteomicsDB; 40524; -. DR ProteomicsDB; 60850; -. [Q16288-1] DR ProteomicsDB; 60851; -. [Q16288-2] DR ProteomicsDB; 60852; -. [Q16288-3] DR ProteomicsDB; 60853; -. [Q16288-4] DR ABCD; Q16288; 8 sequenced antibodies. DR Antibodypedia; 3979; 851 antibodies from 42 providers. DR DNASU; 4916; -. DR Ensembl; ENST00000317501.9; ENSP00000318328.3; ENSG00000140538.18. [Q16288-2] DR Ensembl; ENST00000357724.6; ENSP00000350356.2; ENSG00000140538.18. [Q16288-4] DR Ensembl; ENST00000394480.6; ENSP00000377990.1; ENSG00000140538.18. [Q16288-3] DR Ensembl; ENST00000557856.5; ENSP00000453959.1; ENSG00000140538.18. [Q16288-5] DR Ensembl; ENST00000629765.3; ENSP00000485864.1; ENSG00000140538.18. [Q16288-1] DR Ensembl; ENST00000695462.1; ENSP00000511942.1; ENSG00000140538.18. [Q16288-1] DR GeneID; 4916; -. DR KEGG; hsa:4916; -. DR MANE-Select; ENST00000629765.3; ENSP00000485864.1; NM_001012338.3; NP_001012338.1. DR UCSC; uc059mwc.1; human. [Q16288-1] DR AGR; HGNC:8033; -. DR CIViC; 4916; 14 evidence items across 14 molecular profiles. DR ClinPGx; PA31819; -. DR CTD; 4916; -. DR DisGeNET; 4916; -. DR GeneCards; NTRK3; -. DR HGNC; HGNC:8033; NTRK3. DR HPA; ENSG00000140538; Tissue enhanced (brain). DR MalaCards; NTRK3; -. DR MIM; 191316; gene. DR OpenTargets; ENSG00000140538; -. DR Orphanet; 2665; Congenital mesoblastic nephroma. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2030; Fibrosarcoma. DR VEuPathDB; HostDB:ENSG00000140538; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155645; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16288; -. DR OMA; YREVTHP; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16288; 13 GO annotations based on evolutionary models. DR PhylomeDB; Q16288; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16288; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-388844; Receptor-type tyrosine-protein phosphatases. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9034013; NTF3 activates NTRK3 signaling. DR Reactome; R-HSA-9034015; Signaling by NTRK3 (TRKC). DR Reactome; R-HSA-9034793; Activated NTRK3 signals through PLCG1. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q16288; -. DR SIGNOR; Q16288; -. DR Agora; ENSG00000140538; -. DR BioGRID-ORCS; 4916; 12 hits in 1191 CRISPR screens. DR ChiTaRS; NTRK3; human. DR EvolutionaryTrace; Q16288; -. DR GeneWiki; TrkC_receptor; -. DR GenomeRNAi; 4916; -. DR Pharos; Q16288; Tclin. DR PRO; PR:Q16288; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q16288; protein. DR Bgee; ENSG00000140538; Expressed in Brodmann (1909) area 10 and 175 other cell types or tissues. DR ExpressionAtlas; Q16288; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl. DR GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central. DR GO; GO:0005030; F:neurotrophin receptor activity; IDA:BHF-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0048677; P:axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0090102; P:cochlea development; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IMP:UniProtKB. DR GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0048691; P:positive regulation of axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0010976; P:positive regulation of neuron projection development; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0097107; P:postsynaptic density assembly; IEA:Ensembl. DR GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl. DR GO; GO:1905606; P:regulation of presynapse assembly; IEA:Ensembl. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR CDD; cd04971; IgI_TrKABC_d5; 1. DR CDD; cd05094; PTKc_TrkC; 1. DR FunFam; 1.10.510.10:FF:000701; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000251; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000265; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.10.10:FF:000035; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020446; NTRK3. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF66; NT-3 GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01942; NTKRECEPTOR3. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Direct protein sequencing; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..31 FT CHAIN 32..839 FT /note="NT-3 growth factor receptor" FT /id="PRO_0000016731" FT TOPO_DOM 32..429 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 430..453 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 454..839 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 104..125 FT /note="LRR 1" FT REPEAT 128..149 FT /note="LRR 2" FT DOMAIN 160..209 FT /note="LRRCT" FT DOMAIN 210..300 FT /note="Ig-like C2-type 1" FT DOMAIN 309..382 FT /note="Ig-like C2-type 2" FT DOMAIN 538..839 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 679 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 834 FT /note="Interaction with PLC-gamma-1" FT /evidence="ECO:0000250" FT MOD_RES 493 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6VNS1" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:25196463" FT MOD_RES 705 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 709 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 710 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 72 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 79 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 133 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 163 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 218 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 232 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 267 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 272 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 294 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 375 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 388 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 32..38 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 36..45 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 164..189 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 166..207 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 231..284 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 320..362 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0007744|PDB:1WWC" FT VAR_SEQ 402..410 FT /note="ESTDNFILF -> V (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_002924" FT VAR_SEQ 529..612 FT /note="YVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLA FT ARKDFQREAELLTNLQHEHIVKFYGVCGDGDP -> WVFSNIDNHGILNLKDNRDHLVP FT STHYIYEEPEVQSGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVYFSKGRH FT GF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002925" FT VAR_SEQ 613..839 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002926" FT VAR_SEQ 712..725 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7806211, ECO:0000303|PubMed:7823156" FT /id="VSP_002927" FT VARIANT 21 FT /note="V -> F (in dbSNP:rs200822610)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074601" FT VARIANT 71 FT /note="I -> V (found in patients with CHD; uncertain FT significance; dbSNP:rs200923715)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074602" FT VARIANT 93 FT /note="T -> M (found in patients with congenital heart FT defects; uncertain significance; significantly reduced FT autophosphorylation; decreased NTRK3 signaling and FT decreased apoptosis in absence of NTF3; dbSNP:rs147992979)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074603" FT VARIANT 149 FT /note="T -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs368222977)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041471" FT VARIANT 163 FT /note="N -> I (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; no effect on NTRK3 signaling; FT dbSNP:rs547862658)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074604" FT VARIANT 306 FT /note="R -> C (in dbSNP:rs56386352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041472" FT VARIANT 307 FT /note="V -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1388363572)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041473" FT VARIANT 336 FT /note="L -> Q (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041474" FT VARIANT 533 FT /note="I -> F (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869112057)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074605" FT VARIANT 664 FT /note="A -> S (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046521" FT VARIANT 677 FT /note="H -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18293376" FT /id="VAR_041475" FT VARIANT 678 FT /note="R -> Q (in dbSNP:rs55890138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041476" FT VARIANT 735 FT /note="R -> F (in a lung large cell carcinoma sample; FT somatic mutation; requires 2 nucleotide substitutions)" FT /id="VAR_046770" FT VARIANT 736 FT /note="W -> C (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046522" FT VARIANT 745 FT /note="R -> P (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046523" FT VARIANT 766 FT /note="Y -> F (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046524" FT VARIANT 768 FT /note="K -> R (in dbSNP:rs55770052)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046771" FT VARIANT 781 FT /note="E -> K (in dbSNP:rs56393451)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046772" FT VARIANT 817 FT /note="I -> M (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869209165)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074606" FT MUTAGEN 572 FT /note="K->N: Loss of autophosphorylation and loss of NTRK3 FT signaling." FT /evidence="ECO:0000269|PubMed:25196463" FT CONFLICT 65 FT /note="S -> G (in Ref. 4; BAH12511)" FT /evidence="ECO:0000305" FT CONFLICT 70 FT /note="S -> N (in Ref. 2; AAB33111/AAB33112)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="D -> N (in Ref. 1; AAA75374)" FT /evidence="ECO:0000305" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 332..337 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 345..354 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 356..367 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 374..382 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 385..393 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 538..547 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 550..559 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 567..576 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 579..594 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 603..606 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 653..672 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 682..684 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 685..687 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 693..695 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 700..704 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:4YMJ" FT HELIX 734..736 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 739..744 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 749..764 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 765..767 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 770..773 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 776..784 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 797..806 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 811..813 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 817..827 FT /evidence="ECO:0007829|PDB:6KZD" SQ SEQUENCE 839 AA; 94428 MW; 7FE8846830083C08 CRC64; MDVSLCPAKC SFWRIFLLGS VWLDYVGSVL ACPANCVCSK TEINCRRPDD GNLFPLLEGQ DSGNSNGNAS INITDISRNI TSIHIENWRS LHTLNAVDME LYTGLQKLTI KNSGLRSIQP RAFAKNPHLR YINLSSNRLT TLSWQLFQTL SLRELQLEQN FFNCSCDIRW MQLWQEQGEA KLNSQNLYCI NADGSQLPLF RMNISQCDLP EISVSHVNLT VREGDNAVIT CNGSGSPLPD VDWIVTGLQS INTHQTNLNW TNVHAINLTL VNVTSEDNGF TLTCIAENVV GMSNASVALT VYYPPRVVSL EEPELRLEHC IEFVVRGNPP PTLHWLHNGQ PLRESKIIHV EYYQEGEISE GCLLFNKPTH YNNGNYTLIA KNPLGTANQT INGHFLKEPF PESTDNFILF DEVSPTPPIT VTHKPEEDTF GVSIAVGLAA FACVLLVVLF VMINKYGRRS KFGMKGPVAV ISGEEDSASP LHHINHGITT PSSLDAGPDT VVIGMTRIPV IENPQYFRQG HNCHKPDTYV QHIKRRDIVL KRELGEGAFG KVFLAECYNL SPTKDKMLVA VKALKDPTLA ARKDFQREAE LLTNLQHEHI VKFYGVCGDG DPLIMVFEYM KHGDLNKFLR AHGPDAMILV DGQPRQAKGE LGLSQMLHIA SQIASGMVYL ASQHFVHRDL ATRNCLVGAN LLVKIGDFGM SRDVYSTDYY RLFNPSGNDF CIWCEVGGHT MLPIRWMPPE SIMYRKFTTE SDVWSFGVIL WEIFTYGKQP WFQLSNTEVI ECITQGRVLE RPRVCPKEVY DVMLGCWQRE PQQRLNIKEI YKILHALGKA TPIYLDILG // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PIM1_HUMAN Reviewed; 313 AA. AC P11309; Q38RT9; Q5T7H7; Q96RG3; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 10-OCT-2018, sequence version 4. DT 28-JAN-2026, entry version 263. DE RecName: Full=Serine/threonine-protein kinase pim-1; DE EC=2.7.11.1 {ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054, ECO:0000269|PubMed:15808862, ECO:0000269|PubMed:31548394}; GN Name=PIM1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=2205533; DOI=10.1016/0378-1119(90)90195-w; RA Reeves R., Spies G.A., Kiefer M., Barr P.J., Power M.; RT "Primary structure of the putative human oncogene, pim-1."; RL Gene 90:303-307(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3475233; DOI=10.1016/0378-1119(87)90352-0; RA Zakut-Houri R., Hazum S., Givol D., Telerman A.; RT "The cDNA sequence and gene analysis of the human pim oncogene."; RL Gene 54:105-111(1987). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3329709; RA Domen J., von Lindern M., Hermans A., Breuer M., Grosveld G., Berns A.; RT "Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and RT immunological identification of the in vitro synthesized PIM-1 protein."; RL Oncogene Res. 1:103-112(1987). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3429489; DOI=10.1002/jcb.240350204; RA Meeker T.C., Nagarajan L., Ar-Rushdi A., Croce C.M.; RT "Cloning and characterization of the human PIM-1 gene: a putative oncogene RT related to the protein kinases."; RL J. Cell. Biochem. 35:105-112(1987). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE INITIATION, TISSUE RP SPECIFICITY, SUBCELLULAR LOCATION, INDUCTION, AND INTERACTION WITH BMX. RX PubMed=16186805; DOI=10.1038/sj.onc.1209058; RA Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., Qiu Y.; RT "The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX RT and protects human prostate cancer cells from apoptosis induced by RT chemotherapeutic drugs."; RL Oncogene 25:70-78(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-202 (ISOFORM 1). RX PubMed=11460166; DOI=10.1038/35085588; RA Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S.K., RA Kuppers R., Dalla-Favera R.; RT "Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell RT lymphomas."; RL Nature 412:341-346(2001). RN [10] RP CHARACTERIZATION. RX PubMed=2837645; DOI=10.1128/mcb.8.4.1498-1503.1988; RA Telerman A., Amson R., Zakut-Houri R., Givol D.; RT "Identification of the human pim-1 gene product as a 33-kilodalton RT cytoplasmic protein with tyrosine kinase activity."; RL Mol. Cell. Biol. 8:1498-1503(1988). RN [11] RP FUNCTION, AND ALTERNATIVE INITIATION. RX PubMed=1825810; DOI=10.1002/j.1460-2075.1991.tb07994.x; RA Saris C.J., Domen J., Berns A.; RT "The pim-1 oncogene encodes two related protein-serine/threonine kinases by RT alternative initiation at AUG and CUG."; RL EMBO J. 10:655-664(1991). RN [12] RP FUNCTION IN PHOSPHORYLATION OF CBX3. RX PubMed=10664448; DOI=10.1016/s0014-5793(00)01105-4; RA Koike N., Maita H., Taira T., Ariga H., Iguchi-Ariga S.M.M.; RT "Identification of heterochromatin protein 1 (HP1) as a phosphorylation RT target by Pim-1 kinase and the effect of phosphorylation on the RT transcriptional repression function of HP1."; RL FEBS Lett. 467:17-21(2000). RN [13] RP SUBCELLULAR LOCATION, AND FUNCTION IN PHOSPHORYLATION OF CDKN1A. RX PubMed=12431783; DOI=10.1016/s0167-4889(02)00347-6; RA Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S.; RT "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 RT kinase."; RL Biochim. Biophys. Acta 1593:45-55(2002). RN [14] RP SUBCELLULAR LOCATION. RX PubMed=12680209; RA Ionov Y., Le X., Tunquist B.J., Sweetenham J., Sachs T., Ryder J., RA Johnson T., Lilly M.B., Kraft A.S.; RT "Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear RT localization is necessary for its biologic effects."; RL Anticancer Res. 23:167-178(2003). RN [15] RP PHOSPHORYLATION, AND UBIQUITINATION. RX PubMed=12473674; DOI=10.1074/jbc.m208246200; RA Losman J.A., Chen X.P., Vuong B.Q., Fay S., Rothman P.B.; RT "Protein phosphatase 2A regulates the stability of Pim protein kinases."; RL J. Biol. Chem. 278:4800-4805(2003). RN [16] RP FUNCTION, AND INDUCTION. RX PubMed=15528381; DOI=10.4049/jimmunol.173.10.6409; RA Stout B.A., Bates M.E., Liu L.Y., Farrington N.N., Bertics P.J.; RT "IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 RT and STAT5 and promote Pim-1 and cyclin D3 protein expression in human RT eosinophils."; RL J. Immunol. 173:6409-6417(2004). RN [17] RP UBIQUITINATION, INTERACTION WITH HSP90AA1 AND HSP70, AND INDUCTION. RX PubMed=15798097; DOI=10.1158/1541-7786.mcr-04-0192; RA Shay K.P., Wang Z., Xing P.X., McKenzie I.F., Magnuson N.S.; RT "Pim-1 kinase stability is regulated by heat shock proteins and the RT ubiquitin-proteasome pathway."; RL Mol. Cancer Res. 3:170-181(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF CDC25C, AND INTERACTION WITH CDC25C. RX PubMed=16356754; DOI=10.1016/j.biocel.2005.10.010; RA Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T.; RT "The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and RT activates the G2/M specific phosphatase Cdc25C."; RL Int. J. Biochem. Cell Biol. 38:430-443(2006). RN [19] RP FUNCTION IN CELL CYCLE PROGRESSION, AND PHOSPHORYLATION OF CDKN1B AND RP FOXO3. RX PubMed=18593906; DOI=10.1158/0008-5472.can-08-0634; RA Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.; RT "Pim kinases promote cell cycle progression by phosphorylating and down- RT regulating p27Kip1 at the transcriptional and posttranscriptional levels."; RL Cancer Res. 68:5076-5085(2008). RN [20] RP FUNCTION. RX PubMed=18056989; DOI=10.1074/jbc.m707773200; RA Xie Y., Xu K., Linn D.E., Yang X., Guo Z., Shimelis H., Nakanishi T., RA Ross D.D., Chen H., Fazli L., Gleave M.E., Qiu Y.; RT "The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its RT multimerization and drug-resistant activity in human prostate cancer RT cells."; RL J. Biol. Chem. 283:3349-3356(2008). RN [21] RP FUNCTION IN PHOSPHORYLATION OF MAP3K5. RX PubMed=19749799; DOI=10.1038/onc.2009.276; RA Gu J.J., Wang Z., Reeves R., Magnuson N.S.; RT "PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis."; RL Oncogene 28:4261-4271(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP INTERACTION WITH EPSTEIN-BARR VIRUS EBNA6 (MICROBIAL INFECTION). RX PubMed=25121590; DOI=10.1371/journal.ppat.1004304; RA Banerjee S., Lu J., Cai Q., Sun Z., Jha H.C., Robertson E.S.; RT "EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to RT promote B-cell proliferation."; RL PLoS Pathog. 10:E1004304-E1004304(2014). RN [24] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31548394; DOI=10.1073/pnas.1904774116; RA Padi S.K.R., Singh N., Bearss J.J., Olive V., Song J.H., Cardo-Vila M., RA Kraft A.S., Okumura K.; RT "Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases RT inhibition of mTORC1 and promotes tumor growth."; RL Proc. Natl. Acad. Sci. U.S.A. 116:20505-20510(2019). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND MUTAGENESIS OF PRO-81. RX PubMed=37797010; DOI=10.1126/science.adg2253; RA Fisch D., Pfleiderer M.M., Anastasakou E., Mackie G.M., Wendt F., Liu X., RA Clough B., Lara-Reyna S., Encheva V., Snijders A.P., Bando H., Yamamoto M., RA Beggs A.D., Mercer J., Shenoy A.R., Wollscheid B., Maslowski K.M., RA Galej W.P., Frickel E.M.; RT "PIM1 controls GBP1 activity to limit self-damage and to guard against RT pathogen infection."; RL Science 382:eadg2253-eadg2253(2023). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 33-305 IN COMPLEXES WITH RP ADENOSINE AND INHIBITORS STAUROSPORINE AND LY294002, CATALYTIC ACTIVITY, RP COFACTOR, ACTIVITY REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION AT SER-8; THR-23; SER-98 AND SER-261. RX PubMed=15657054; DOI=10.1074/jbc.m413155200; RA Jacobs M.D., Black J., Futer O., Swenson L., Hare B., Fleming M., RA Saxena K.; RT "Pim-1 ligand-bound structures reveal the mechanism of serine/threonine RT kinase inhibition by LY294002."; RL J. Biol. Chem. 280:13728-13734(2005). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 14-313 OF APOPROTEIN AND IN RP COMPLEX WITH AMP-PNP, CATALYTIC ACTIVITY, COFACTOR, AND ACTIVITY RP REGULATION. RX PubMed=15525646; DOI=10.1074/jbc.m409123200; RA Qian K.C., Wang L., Hickey E.R., Studts J., Barringer K., Peng C., RA Kronkaitis A., Li J., White A., Mische S., Farmer B.; RT "Structural basis of constitutive activity and a unique nucleotide binding RT mode of human Pim-1 kinase."; RL J. Biol. Chem. 280:6130-6137(2005). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-313 OF APOPROTEIN AND IN RP COMPLEXES WITH AMP-PNP AND INHIBITORS, PARTIAL PROTEIN SEQUENCE, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, COFACTOR, AND MUTAGENESIS OF HIS-68; PRO-81; RP ASN-82 AND LEU-193. RX PubMed=15808862; DOI=10.1016/j.jmb.2005.02.039; RA Kumar A., Mandiyan V., Suzuki Y., Zhang C., Rice J., Tsai J., Artis D.R., RA Ibrahim P., Bremer R.; RT "Crystal structures of proto-oncogene kinase Pim1: a target of aberrant RT somatic hypermutations in diffuse large cell lymphoma."; RL J. Mol. Biol. 348:183-193(2005). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-53; GLN-124; LYS-135 AND ASP-142. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Proto-oncogene with serine/threonine kinase activity involved CC in cell survival and cell proliferation and thus providing a selective CC advantage in tumorigenesis (PubMed:15528381, PubMed:1825810, CC PubMed:31548394). Exerts its oncogenic activity through: the regulation CC of MYC transcriptional activity, the regulation of cell cycle CC progression and by phosphorylation and inhibition of proapoptotic CC proteins (BAD, MAP3K5, FOXO3) (PubMed:18593906). Phosphorylation of MYC CC leads to an increase of MYC protein stability and thereby an increase CC of transcriptional activity (By similarity). The stabilization of MYC CC exerted by PIM1 might explain partly the strong synergism between these CC two oncogenes in tumorigenesis (By similarity). Mediates survival CC signaling through phosphorylation of BAD, which induces release of the CC anti-apoptotic protein Bcl-X(L)/BCL2L1 (By similarity). Phosphorylation CC of MAP3K5, another proapoptotic protein, by PIM1, significantly CC decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated CC phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 CC activation and cell apoptosis (PubMed:19749799). Stimulates cell cycle CC progression at the G1-S and G2-M transitions by phosphorylation of CC CDC25A and CDC25C (PubMed:16356754). Phosphorylation of CDKN1A, a CC regulator of cell cycle progression at G1, results in the relocation of CC CDKN1A to the cytoplasm and enhanced CDKN1A protein stability CC (PubMed:12431783). Promotes cell cycle progression and tumorigenesis by CC down-regulating expression of a regulator of cell cycle progression, CC CDKN1B, at both transcriptional and post-translational levels CC (PubMed:18593906). Phosphorylation of CDKN1B, induces 14-3-3 proteins CC binding, nuclear export and proteasome-dependent degradation CC (PubMed:18593906). May affect the structure or silencing of chromatin CC by phosphorylating HP1 gamma/CBX3 (PubMed:10664448). Also acts as a CC regulator of homing and migration of bone marrow cells involving CC functional interaction with the CXCL12-CXCR4 signaling axis (By CC similarity). Acts as a positive regulator of mTORC1 signaling by CC mediating phosphorylation and inhibition of DEPDC5 component of the CC GATOR1 complex (PubMed:31548394). Acts as a negative regulator of CC innate immunity by mediating phosphorylation and inactivation of GBP1 CC in absence of infection: phosphorylation of GBP1 induces interaction CC with 14-3-3 protein sigma (SFN) and retention in the cytosol CC (PubMed:37797010). Also phosphorylates and activates the ATP-binding CC cassette transporter ABCG2, allowing resistance to drugs through their CC excretion from cells (PubMed:18056989). Promotes brown adipocyte CC differentiation (By similarity). {ECO:0000250|UniProtKB:P06803, CC ECO:0000269|PubMed:10664448, ECO:0000269|PubMed:12431783, CC ECO:0000269|PubMed:15528381, ECO:0000269|PubMed:16356754, CC ECO:0000269|PubMed:18056989, ECO:0000269|PubMed:1825810, CC ECO:0000269|PubMed:18593906, ECO:0000269|PubMed:19749799, CC ECO:0000269|PubMed:31548394, ECO:0000269|PubMed:37797010}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054, CC ECO:0000269|PubMed:15808862, ECO:0000269|PubMed:31548394, CC ECO:0000269|PubMed:37797010}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054, CC ECO:0000269|PubMed:15808862, ECO:0000269|PubMed:37797010}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:15525646, ECO:0000269|PubMed:15657054, CC ECO:0000269|PubMed:15808862}; CC -!- SUBUNIT: Interacts with RP9 (By similarity). Interacts with HSP90AA1, CC this interaction stabilizes PIM1 protein levels (PubMed:15798097). CC Interacts (ubiquitinated form) with HSP70 and promotes its proteasomal CC degradation (PubMed:15798097). {ECO:0000250|UniProtKB:P06803, CC ECO:0000269|PubMed:15798097}. CC -!- SUBUNIT: [Isoform 1]: Isoform 1 is isolated as a monomer whereas CC isoform 2 complexes with other proteins. CC {ECO:0000250|UniProtKB:P06803}. CC -!- SUBUNIT: [Isoform 2]: Isoform 2, but not isoform 1, binds BMX. CC {ECO:0000269|PubMed:16186805}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus EBNA6; CC this interaction upregulates and stabilizes PIM1 and induces cell CC proliferation by inhibiting the growth suppressive properties of p21. CC {ECO:0000269|PubMed:25121590}. CC -!- INTERACTION: CC P11309; Q8N9N5: BANP; NbExp=3; IntAct=EBI-696621, EBI-744695; CC P11309; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-696621, EBI-10181188; CC P11309; P51813: BMX; NbExp=2; IntAct=EBI-696621, EBI-696657; CC P11309; P07954: FH; NbExp=3; IntAct=EBI-696621, EBI-1050358; CC P11309; P51116: FXR2; NbExp=3; IntAct=EBI-696621, EBI-740459; CC P11309; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-696621, EBI-5460660; CC P11309; Q5T203: NHLH1; NbExp=3; IntAct=EBI-696621, EBI-10197511; CC P11309; P39019: RPS19; NbExp=7; IntAct=EBI-696621, EBI-354451; CC P11309; P0C1Z6-2: TFPT; NbExp=3; IntAct=EBI-696621, EBI-10178002; CC P11309; Q9Y2K1: ZBTB1; NbExp=3; IntAct=EBI-696621, EBI-2682961; CC P11309-1; P46527: CDKN1B; NbExp=2; IntAct=EBI-1018629, EBI-519280; CC P11309-1; O43524: FOXO3; NbExp=2; IntAct=EBI-1018629, EBI-1644164; CC P11309-1; Q9BZS1-1: FOXP3; NbExp=3; IntAct=EBI-1018629, EBI-9695448; CC P11309-2; Q9UNQ0: ABCG2; NbExp=5; IntAct=EBI-1018633, EBI-1569435; CC P11309-2; P51813: BMX; NbExp=6; IntAct=EBI-1018633, EBI-696657; CC P11309-2; P17252: PRKCA; NbExp=2; IntAct=EBI-1018633, EBI-1383528; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative initiation; Named isoforms=2; CC Name=1; Synonyms=Pim-1 {ECO:0000303|PubMed:18056989}; CC IsoId=P11309-1; Sequence=Displayed; CC Name=2; Synonyms=Pim-1L {ECO:0000303|PubMed:18056989}; CC IsoId=P11309-2; Sequence=VSP_059829; CC -!- TISSUE SPECIFICITY: Expressed primarily in cells of the hematopoietic CC and germline lineages. Isoform 1 and isoform 2 are both expressed in CC prostate cancer cell lines. {ECO:0000269|PubMed:16186805}. CC -!- INDUCTION: By interferon-gamma (IFNG) (PubMed:37797010). Strongly CC induced in leukocytes by the JAK/STAT pathway in response to cytokines. CC Induced by different cellular stresses, heat shock and cytotoxic agents CC (PubMed:15528381, PubMed:15798097, PubMed:16186805). CC {ECO:0000269|PubMed:15528381, ECO:0000269|PubMed:15798097, CC ECO:0000269|PubMed:16186805, ECO:0000269|PubMed:37797010}. CC -!- PTM: Autophosphorylated on both serine/threonine and tyrosine residues. CC Phosphorylated. Interaction with PPP2CA promotes dephosphorylation. CC {ECO:0000269|PubMed:12473674}. CC -!- PTM: Ubiquitinated, leading to proteasomal degradation. CC {ECO:0000269|PubMed:12473674, ECO:0000269|PubMed:15798097}. CC -!- MISCELLANEOUS: [Isoform 2]: Initiates from CTG codon. CC {ECO:0000269|PubMed:16186805, ECO:0000269|PubMed:1825810}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. PIM subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/261/PIM1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M27903; AAA60090.1; -; Genomic_DNA. DR EMBL; M16750; AAA60089.1; -; mRNA. DR EMBL; M54915; AAA36447.1; -; mRNA. DR EMBL; M24779; AAA81553.1; -; mRNA. DR EMBL; DQ022562; AAY87461.1; -; mRNA. DR EMBL; AL353579; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03934.1; -; Genomic_DNA. DR EMBL; BC020224; AAH20224.1; -; mRNA. DR EMBL; AF386792; AAK70871.1; -; Genomic_DNA. DR CCDS; CCDS4830.1; -. [P11309-1] DR PIR; JU0327; TVHUP1. DR RefSeq; NP_001230115.1; NM_001243186.2. [P11309-2] DR RefSeq; NP_002639.1; NM_002648.4. [P11309-1] DR PDB; 1XQZ; X-ray; 2.10 A; A=14-313. DR PDB; 1XR1; X-ray; 2.10 A; A=14-313. DR PDB; 1XWS; X-ray; 1.80 A; A=1-313. DR PDB; 1YHS; X-ray; 2.15 A; A=33-305. DR PDB; 1YI3; X-ray; 2.50 A; A=33-305. DR PDB; 1YI4; X-ray; 2.40 A; A=33-305. DR PDB; 1YWV; X-ray; 2.00 A; A=29-313. DR PDB; 1YXS; X-ray; 2.20 A; A=29-313. DR PDB; 1YXT; X-ray; 2.00 A; A=29-313. DR PDB; 1YXU; X-ray; 2.24 A; A/B/C/D=29-313. DR PDB; 1YXV; X-ray; 2.00 A; A=29-313. DR PDB; 1YXX; X-ray; 2.00 A; A=29-313. DR PDB; 2BIK; X-ray; 1.80 A; B=1-313. DR PDB; 2BIL; X-ray; 2.55 A; B=1-313. DR PDB; 2BZH; X-ray; 1.90 A; B=1-313. DR PDB; 2BZI; X-ray; 1.90 A; B=1-313. DR PDB; 2BZJ; X-ray; 2.05 A; A=1-313. DR PDB; 2BZK; X-ray; 2.45 A; B=1-313. DR PDB; 2C3I; X-ray; 1.90 A; B=1-313. DR PDB; 2J2I; X-ray; 1.90 A; B=1-312. DR PDB; 2O3P; X-ray; 2.24 A; A=29-313. DR PDB; 2O63; X-ray; 2.00 A; A=29-313. DR PDB; 2O64; X-ray; 2.44 A; A=29-313. DR PDB; 2O65; X-ray; 2.85 A; A=29-313. DR PDB; 2OBJ; X-ray; 2.50 A; A=1-313. DR PDB; 2OI4; X-ray; 2.20 A; X=1-313. DR PDB; 2XIX; X-ray; 2.40 A; A=14-313. DR PDB; 2XIY; X-ray; 2.20 A; A=14-313. DR PDB; 2XIZ; X-ray; 2.21 A; A=14-313. DR PDB; 2XJ0; X-ray; 3.10 A; A=14-313. DR PDB; 2XJ1; X-ray; 2.13 A; A=14-313. DR PDB; 2XJ2; X-ray; 2.20 A; A=14-313. DR PDB; 3A99; X-ray; 1.60 A; A=15-313. DR PDB; 3BGP; X-ray; 2.80 A; A=1-313. DR PDB; 3BGQ; X-ray; 2.00 A; A=1-313. DR PDB; 3BGZ; X-ray; 2.40 A; A=1-313. DR PDB; 3BWF; X-ray; 2.35 A; A=1-313. DR PDB; 3C4E; X-ray; 1.98 A; A/B/C/D=33-305. DR PDB; 3CXW; X-ray; 2.10 A; A=1-313. DR PDB; 3CY2; X-ray; 2.01 A; A=1-313. DR PDB; 3CY3; X-ray; 2.15 A; A=1-313. DR PDB; 3DCV; X-ray; 2.70 A; A=2-313. DR PDB; 3F2A; X-ray; 1.90 A; A=14-313. DR PDB; 3JPV; X-ray; 2.35 A; A=1-312. DR PDB; 3JXW; X-ray; 2.80 A; A=29-313. DR PDB; 3JY0; X-ray; 2.40 A; A=29-313. DR PDB; 3JYA; X-ray; 2.10 A; A=29-313. DR PDB; 3MA3; X-ray; 2.30 A; A=2-312. DR PDB; 3QF9; X-ray; 2.20 A; A=1-312. DR PDB; 3R00; X-ray; 2.10 A; A=29-313. DR PDB; 3R01; X-ray; 2.60 A; A=29-313. DR PDB; 3R02; X-ray; 1.95 A; A=29-313. DR PDB; 3R04; X-ray; 1.70 A; A=29-313. DR PDB; 3T9I; X-ray; 2.60 A; A=2-313. DR PDB; 3UIX; X-ray; 2.20 A; A=29-313. DR PDB; 3UMW; X-ray; 2.08 A; A=29-313. DR PDB; 3UMX; X-ray; 2.55 A; A=29-313. DR PDB; 3VBQ; X-ray; 1.85 A; A=29-313. DR PDB; 3VBT; X-ray; 2.23 A; A=29-313. DR PDB; 3VBV; X-ray; 2.08 A; A=29-313. DR PDB; 3VBW; X-ray; 2.48 A; A=29-313. DR PDB; 3VBX; X-ray; 2.03 A; A=29-313. DR PDB; 3VBY; X-ray; 2.27 A; A=29-313. DR PDB; 3VC4; X-ray; 2.23 A; A=29-313. DR PDB; 3WE8; X-ray; 1.95 A; A=33-305. DR PDB; 4A7C; X-ray; 2.30 A; A=30-313. DR PDB; 4ALU; X-ray; 2.60 A; A=2-313. DR PDB; 4ALV; X-ray; 2.59 A; A=2-313. DR PDB; 4ALW; X-ray; 1.92 A; A=2-313. DR PDB; 4AS0; X-ray; 2.30 A; A=33-305. DR PDB; 4BZN; X-ray; 1.90 A; A=2-313. DR PDB; 4BZO; X-ray; 2.10 A; A=2-313. DR PDB; 4DTK; X-ray; 1.86 A; A=30-305. DR PDB; 4ENX; X-ray; 2.80 A; A=29-313. DR PDB; 4ENY; X-ray; 2.80 A; A=29-313. DR PDB; 4GW8; X-ray; 2.00 A; A=1-312. DR PDB; 4I41; X-ray; 2.70 A; A=29-305. DR PDB; 4IAA; X-ray; 2.85 A; A=29-313. DR PDB; 4JX3; X-ray; 2.50 A; A=1-313. DR PDB; 4JX7; X-ray; 2.40 A; A=1-313. DR PDB; 4K0Y; X-ray; 1.95 A; A=33-306. DR PDB; 4K18; X-ray; 2.05 A; A=32-308. DR PDB; 4K1B; X-ray; 2.08 A; A=33-305. DR PDB; 4LL5; X-ray; 2.00 A; A=29-313. DR PDB; 4LM5; X-ray; 2.25 A; A=29-313. DR PDB; 4LMU; X-ray; 2.38 A; A=29-313. DR PDB; 4MBI; X-ray; 2.30 A; A=29-313. DR PDB; 4MBL; X-ray; 2.60 A; A=29-313. DR PDB; 4MTA; X-ray; 2.20 A; A=28-313. DR PDB; 4N6Y; X-ray; 2.60 A; A=2-313. DR PDB; 4N6Z; X-ray; 2.20 A; A=2-313. DR PDB; 4N70; X-ray; 2.10 A; A=2-313. DR PDB; 4RBL; X-ray; 2.55 A; A=29-313. DR PDB; 4RC2; X-ray; 2.10 A; A=29-313. DR PDB; 4RC3; X-ray; 2.34 A; A=29-313. DR PDB; 4RC4; X-ray; 2.65 A; A=29-313. DR PDB; 4RPV; X-ray; 3.05 A; A=1-313. DR PDB; 4TY1; X-ray; 2.70 A; A=33-305. DR PDB; 4WRS; X-ray; 2.20 A; A=33-305. DR PDB; 4WSY; X-ray; 2.30 A; A=33-305. DR PDB; 4WT6; X-ray; 2.30 A; A=33-305. DR PDB; 4XH6; X-ray; 2.04 A; A=29-313. DR PDB; 4XHK; X-ray; 1.90 A; B=1-313. DR PDB; 5C1Q; X-ray; 3.00 A; B=29-313. DR PDB; 5DGZ; X-ray; 2.50 A; A=29-313. DR PDB; 5DHJ; X-ray; 2.46 A; A=29-313. DR PDB; 5DIA; X-ray; 1.96 A; A=29-313. DR PDB; 5DWR; X-ray; 2.00 A; A=2-313. DR PDB; 5EOL; X-ray; 2.20 A; A=33-305. DR PDB; 5IIS; X-ray; 2.10 A; A=32-308. DR PDB; 5IPJ; X-ray; 2.10 A; A=33-305. DR PDB; 5KCX; X-ray; 2.20 A; A=29-313. DR PDB; 5KGD; X-ray; 1.98 A; A=30-305. DR PDB; 5KGE; X-ray; 2.23 A; A=30-305. DR PDB; 5KGG; X-ray; 1.95 A; A=30-305. DR PDB; 5KGI; X-ray; 2.13 A; A=30-305. DR PDB; 5KGK; X-ray; 2.66 A; A=30-305. DR PDB; 5KZI; X-ray; 2.10 A; A=33-305. DR PDB; 5MZL; X-ray; 1.96 A; A=1-313. DR PDB; 5N4N; X-ray; 2.09 A; A=1-313. DR PDB; 5N4O; X-ray; 2.22 A; A=1-313. DR PDB; 5N4R; X-ray; 2.13 A; A=1-313. DR PDB; 5N4U; X-ray; 2.20 A; A=1-313. DR PDB; 5N4V; X-ray; 1.85 A; A=1-313. DR PDB; 5N4X; X-ray; 2.20 A; A=1-313. DR PDB; 5N4Y; X-ray; 2.56 A; A=1-313. DR PDB; 5N4Z; X-ray; 2.26 A; A=1-313. DR PDB; 5N50; X-ray; 1.92 A; A=1-313. DR PDB; 5N51; X-ray; 2.12 A; A=1-313. DR PDB; 5N52; X-ray; 2.25 A; A=1-313. DR PDB; 5N5L; X-ray; 1.97 A; A=1-313. DR PDB; 5N5M; X-ray; 2.21 A; A=1-313. DR PDB; 5NDT; X-ray; 1.99 A; A=1-313. DR PDB; 5O11; X-ray; 2.40 A; A=29-313. DR PDB; 5O12; X-ray; 2.40 A; A=29-313. DR PDB; 5O13; X-ray; 2.44 A; A=29-313. DR PDB; 5TEL; X-ray; 2.21 A; A=33-306. DR PDB; 5TEX; X-ray; 2.15 A; A=33-306. DR PDB; 5TOE; X-ray; 2.30 A; A=34-306. DR PDB; 5TUR; X-ray; 2.95 A; A=1-313. DR PDB; 5V80; X-ray; 2.25 A; A=29-313. DR PDB; 5V82; X-ray; 1.89 A; A=29-313. DR PDB; 5VUA; X-ray; 2.20 A; B=29-313. DR PDB; 5VUB; X-ray; 2.00 A; B=29-313. DR PDB; 5VUC; X-ray; 2.00 A; B=29-313. DR PDB; 6AYD; X-ray; 3.00 A; A=1-312. DR PDB; 6BSK; X-ray; 2.57 A; A=30-305. DR PDB; 6KZI; X-ray; 2.80 A; A=29-313. DR PDB; 6L11; X-ray; 2.05 A; A=29-313. DR PDB; 6L12; X-ray; 1.87 A; A=29-313. DR PDB; 6L13; X-ray; 2.24 A; A=29-313. DR PDB; 6L14; X-ray; 1.95 A; A=29-313. DR PDB; 6L15; X-ray; 2.60 A; A=29-313. DR PDB; 6L16; X-ray; 2.10 A; A=29-313. DR PDB; 6L17; X-ray; 1.75 A; A=29-313. DR PDB; 6MT0; X-ray; 2.20 A; A=33-305. DR PDB; 6NO8; X-ray; 2.38 A; A=33-305. DR PDB; 6NO9; X-ray; 1.71 A; A=33-305. DR PDB; 6PCW; X-ray; 2.20 A; A=1-312. DR PDB; 6PDI; X-ray; 1.85 A; A=1-312. DR PDB; 6PDN; X-ray; 2.40 A; A=1-312. DR PDB; 6PDO; X-ray; 2.40 A; A=1-312. DR PDB; 6PDP; X-ray; 2.50 A; A=1-312. DR PDB; 6QXK; X-ray; 2.10 A; B=1-312. DR PDB; 6VRU; X-ray; 2.07 A; A=33-306. DR PDB; 6VRV; X-ray; 1.74 A; A=33-306. DR PDB; 6YKD; X-ray; 1.86 A; A=1-313. DR PDB; 7OOV; X-ray; 1.96 A; A=1-312. DR PDB; 7OOW; X-ray; 1.95 A; A=1-312. DR PDB; 7OOX; X-ray; 1.97 A; A=1-312. DR PDB; 7QB2; X-ray; 2.53 A; A=1-312. DR PDB; 7QFM; X-ray; 1.95 A; A=1-312. DR PDB; 7VSY; X-ray; 2.14 A; A=1-313. DR PDB; 7XSV; X-ray; 2.66 A; A=29-313. DR PDB; 7Z6U; X-ray; 2.28 A; A=1-313. DR PDB; 7ZUN; X-ray; 2.50 A; A=2-313. DR PDB; 8AFR; X-ray; 2.15 A; A=1-312. DR PDB; 8R0H; X-ray; 1.88 A; A=1-312. DR PDB; 8R0Q; X-ray; 1.70 A; A=1-312. DR PDB; 8R0W; X-ray; 1.95 A; A=1-312. DR PDB; 8R0Y; X-ray; 2.05 A; A=1-312. DR PDB; 8R10; X-ray; 2.20 A; A=1-312. DR PDB; 8R18; X-ray; 1.89 A; A=1-312. DR PDB; 8R1K; X-ray; 1.95 A; A=1-312. DR PDB; 8R1N; X-ray; 2.21 A; A=1-312. DR PDB; 8R1P; X-ray; 2.45 A; A=1-312. DR PDB; 8R1T; X-ray; 2.00 A; A=1-312. DR PDB; 8R1W; X-ray; 2.15 A; A=1-312. DR PDB; 8R25; X-ray; 2.10 A; A=1-312. DR PDB; 8R27; X-ray; 1.95 A; A=1-312. DR PDBsum; 1XQZ; -. DR PDBsum; 1XR1; -. DR PDBsum; 1XWS; -. DR PDBsum; 1YHS; -. DR PDBsum; 1YI3; -. DR PDBsum; 1YI4; -. DR PDBsum; 1YWV; -. DR PDBsum; 1YXS; -. DR PDBsum; 1YXT; -. DR PDBsum; 1YXU; -. DR PDBsum; 1YXV; -. DR PDBsum; 1YXX; -. DR PDBsum; 2BIK; -. DR PDBsum; 2BIL; -. DR PDBsum; 2BZH; -. DR PDBsum; 2BZI; -. DR PDBsum; 2BZJ; -. DR PDBsum; 2BZK; -. DR PDBsum; 2C3I; -. DR PDBsum; 2J2I; -. DR PDBsum; 2O3P; -. DR PDBsum; 2O63; -. DR PDBsum; 2O64; -. DR PDBsum; 2O65; -. DR PDBsum; 2OBJ; -. DR PDBsum; 2OI4; -. DR PDBsum; 2XIX; -. DR PDBsum; 2XIY; -. DR PDBsum; 2XIZ; -. DR PDBsum; 2XJ0; -. DR PDBsum; 2XJ1; -. DR PDBsum; 2XJ2; -. DR PDBsum; 3A99; -. DR PDBsum; 3BGP; -. DR PDBsum; 3BGQ; -. DR PDBsum; 3BGZ; -. DR PDBsum; 3BWF; -. DR PDBsum; 3C4E; -. DR PDBsum; 3CXW; -. DR PDBsum; 3CY2; -. DR PDBsum; 3CY3; -. DR PDBsum; 3DCV; -. DR PDBsum; 3F2A; -. DR PDBsum; 3JPV; -. DR PDBsum; 3JXW; -. DR PDBsum; 3JY0; -. DR PDBsum; 3JYA; -. DR PDBsum; 3MA3; -. DR PDBsum; 3QF9; -. DR PDBsum; 3R00; -. DR PDBsum; 3R01; -. DR PDBsum; 3R02; -. DR PDBsum; 3R04; -. DR PDBsum; 3T9I; -. DR PDBsum; 3UIX; -. DR PDBsum; 3UMW; -. DR PDBsum; 3UMX; -. DR PDBsum; 3VBQ; -. DR PDBsum; 3VBT; -. DR PDBsum; 3VBV; -. DR PDBsum; 3VBW; -. DR PDBsum; 3VBX; -. DR PDBsum; 3VBY; -. DR PDBsum; 3VC4; -. DR PDBsum; 3WE8; -. DR PDBsum; 4A7C; -. DR PDBsum; 4ALU; -. DR PDBsum; 4ALV; -. DR PDBsum; 4ALW; -. DR PDBsum; 4AS0; -. DR PDBsum; 4BZN; -. DR PDBsum; 4BZO; -. DR PDBsum; 4DTK; -. DR PDBsum; 4ENX; -. DR PDBsum; 4ENY; -. DR PDBsum; 4GW8; -. DR PDBsum; 4I41; -. DR PDBsum; 4IAA; -. DR PDBsum; 4JX3; -. DR PDBsum; 4JX7; -. DR PDBsum; 4K0Y; -. DR PDBsum; 4K18; -. DR PDBsum; 4K1B; -. DR PDBsum; 4LL5; -. DR PDBsum; 4LM5; -. DR PDBsum; 4LMU; -. DR PDBsum; 4MBI; -. DR PDBsum; 4MBL; -. DR PDBsum; 4MTA; -. DR PDBsum; 4N6Y; -. DR PDBsum; 4N6Z; -. DR PDBsum; 4N70; -. DR PDBsum; 4RBL; -. DR PDBsum; 4RC2; -. DR PDBsum; 4RC3; -. DR PDBsum; 4RC4; -. DR PDBsum; 4RPV; -. DR PDBsum; 4TY1; -. DR PDBsum; 4WRS; -. DR PDBsum; 4WSY; -. DR PDBsum; 4WT6; -. DR PDBsum; 4XH6; -. DR PDBsum; 4XHK; -. DR PDBsum; 5C1Q; -. DR PDBsum; 5DGZ; -. DR PDBsum; 5DHJ; -. DR PDBsum; 5DIA; -. DR PDBsum; 5DWR; -. DR PDBsum; 5EOL; -. DR PDBsum; 5IIS; -. DR PDBsum; 5IPJ; -. DR PDBsum; 5KCX; -. DR PDBsum; 5KGD; -. DR PDBsum; 5KGE; -. DR PDBsum; 5KGG; -. DR PDBsum; 5KGI; -. DR PDBsum; 5KGK; -. DR PDBsum; 5KZI; -. DR PDBsum; 5MZL; -. DR PDBsum; 5N4N; -. DR PDBsum; 5N4O; -. DR PDBsum; 5N4R; -. DR PDBsum; 5N4U; -. DR PDBsum; 5N4V; -. DR PDBsum; 5N4X; -. DR PDBsum; 5N4Y; -. DR PDBsum; 5N4Z; -. DR PDBsum; 5N50; -. DR PDBsum; 5N51; -. DR PDBsum; 5N52; -. DR PDBsum; 5N5L; -. DR PDBsum; 5N5M; -. DR PDBsum; 5NDT; -. DR PDBsum; 5O11; -. DR PDBsum; 5O12; -. DR PDBsum; 5O13; -. DR PDBsum; 5TEL; -. DR PDBsum; 5TEX; -. DR PDBsum; 5TOE; -. DR PDBsum; 5TUR; -. DR PDBsum; 5V80; -. DR PDBsum; 5V82; -. DR PDBsum; 5VUA; -. DR PDBsum; 5VUB; -. DR PDBsum; 5VUC; -. DR PDBsum; 6AYD; -. DR PDBsum; 6BSK; -. DR PDBsum; 6KZI; -. DR PDBsum; 6L11; -. DR PDBsum; 6L12; -. DR PDBsum; 6L13; -. DR PDBsum; 6L14; -. DR PDBsum; 6L15; -. DR PDBsum; 6L16; -. DR PDBsum; 6L17; -. DR PDBsum; 6MT0; -. DR PDBsum; 6NO8; -. DR PDBsum; 6NO9; -. DR PDBsum; 6PCW; -. DR PDBsum; 6PDI; -. DR PDBsum; 6PDN; -. DR PDBsum; 6PDO; -. DR PDBsum; 6PDP; -. DR PDBsum; 6QXK; -. DR PDBsum; 6VRU; -. DR PDBsum; 6VRV; -. DR PDBsum; 6YKD; -. DR PDBsum; 7OOV; -. DR PDBsum; 7OOW; -. DR PDBsum; 7OOX; -. DR PDBsum; 7QB2; -. DR PDBsum; 7QFM; -. DR PDBsum; 7VSY; -. DR PDBsum; 7XSV; -. DR PDBsum; 7Z6U; -. DR PDBsum; 7ZUN; -. DR PDBsum; 8AFR; -. DR PDBsum; 8R0H; -. DR PDBsum; 8R0Q; -. DR PDBsum; 8R0W; -. DR PDBsum; 8R0Y; -. DR PDBsum; 8R10; -. DR PDBsum; 8R18; -. DR PDBsum; 8R1K; -. DR PDBsum; 8R1N; -. DR PDBsum; 8R1P; -. DR PDBsum; 8R1T; -. DR PDBsum; 8R1W; -. DR PDBsum; 8R25; -. DR PDBsum; 8R27; -. DR AlphaFoldDB; P11309; -. DR SMR; P11309; -. DR BioGRID; 111310; 77. DR CORUM; P11309; -. DR FunCoup; P11309; 2834. DR IntAct; P11309; 86. DR MINT; P11309; -. DR STRING; 9606.ENSP00000362608; -. DR BindingDB; P11309; -. DR ChEMBL; CHEMBL2147; -. DR DrugBank; DB08022; (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile. DR DrugBank; DB03650; (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One. DR DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB08166; (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB08709; 2,3-diphenyl-1H-indole-7-carboxylic acid. DR DrugBank; DB01754; 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One. DR DrugBank; DB07151; 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one. DR DrugBank; DB08707; 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine. DR DrugBank; DB08705; 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB04522; Dexfosfoserine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB03366; Imidazole. DR DrugBank; DB04715; IMIDAZOPYRIDAZIN 1. DR DrugBank; DB02656; LY-294002. DR DrugBank; DB08708; N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine. DR DrugBank; DB07524; N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB04216; Quercetin. DR DrugBank; DB04530; S,S-(2-Hydroxyethyl)Thiocysteine. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB08230; Tricetin. DR DrugCentral; P11309; -. DR GuidetoPHARMACOLOGY; 2158; -. DR GlyGen; P11309; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P11309; -. DR PhosphoSitePlus; P11309; -. DR BioMuta; PIM1; -. DR DMDM; 83305339; -. DR jPOST; P11309; -. DR MassIVE; P11309; -. DR PaxDb; 9606-ENSP00000362608; -. DR PeptideAtlas; P11309; -. DR ProteomicsDB; 52741; -. [P11309-1] DR ProteomicsDB; 52742; -. [P11309-2] DR Pumba; P11309; -. DR Antibodypedia; 1207; 713 antibodies from 39 providers. DR DNASU; 5292; -. DR Ensembl; ENST00000373509.6; ENSP00000362608.5; ENSG00000137193.15. [P11309-1] DR GeneID; 5292; -. DR KEGG; hsa:5292; -. DR MANE-Select; ENST00000373509.6; ENSP00000362608.5; NM_002648.4; NP_002639.1. DR UCSC; uc003onk.4; human. [P11309-1] DR AGR; HGNC:8986; -. DR CIViC; 5292; 5 evidence items across 5 molecular profiles. DR ClinPGx; PA33318; -. DR CTD; 5292; -. DR DisGeNET; 5292; -. DR GeneCards; PIM1; -. DR HGNC; HGNC:8986; PIM1. DR HPA; ENSG00000137193; Tissue enhanced (bone). DR MalaCards; PIM1; -. DR MIM; 164960; gene. DR OpenTargets; ENSG00000137193; -. DR VEuPathDB; HostDB:ENSG00000137193; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000153394; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; P11309; -. DR OMA; IIRGQVY; -. DR OrthoDB; 10252171at2759; -. DR PAN-GO; P11309; 3 GO annotations based on evolutionary models. DR PhylomeDB; P11309; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P11309; -. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-9702518; STAT5 activation downstream of FLT3 ITD mutants. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR SignaLink; P11309; -. DR SIGNOR; P11309; -. DR Agora; ENSG00000137193; -. DR BioGRID-ORCS; 5292; 53 hits in 1206 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PIM1; human. DR EvolutionaryTrace; P11309; -. DR GeneWiki; PIM1; -. DR GenomeRNAi; 5292; -. DR Pharos; P11309; Tchem. DR PRO; PR:P11309; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; P11309; protein. DR Bgee; ENSG00000137193; Expressed in lower esophagus mucosa and 178 other cell types or tissues. DR ExpressionAtlas; P11309; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0043539; F:protein serine/threonine kinase activator activity; IMP:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0043024; F:ribosomal small subunit binding; IPI:UniProtKB. DR GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:1990748; P:cellular detoxification; IMP:UniProtKB. DR GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0045824; P:negative regulation of innate immune response; IDA:UniProtKB. DR GO; GO:0090336; P:positive regulation of brown fat cell differentiation; ISS:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IDA:BHF-UCL. DR GO; GO:1905062; P:positive regulation of cardioblast proliferation; IDA:BHF-UCL. DR GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; IEA:Ensembl. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0022898; P:regulation of transmembrane transporter activity; IMP:UniProtKB. DR GO; GO:0070561; P:vitamin D receptor signaling pathway; IMP:CACAO. DR CDD; cd14100; STKc_PIM1; 1. DR DisProt; DP00322; -. DR FunFam; 1.10.510.10:FF:000209; Serine/threonine-protein kinase pim-1; 1. DR FunFam; 3.30.200.20:FF:000232; Serine/threonine-protein kinase pim-1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017348; PIM1/2/3. DR InterPro; IPR051138; PIM_Ser/Thr_kinase. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22984; SERINE/THREONINE-PROTEIN KINASE PIM; 1. DR PANTHER; PTHR22984:SF29; SERINE_THREONINE-PROTEIN KINASE PIM-1; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF037993; STPK_Pim-1; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative initiation; Apoptosis; ATP-binding; Cell cycle; KW Cell membrane; Cytoplasm; Direct protein sequencing; KW Host-virus interaction; Kinase; Magnesium; Membrane; Metal-binding; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..313 FT /note="Serine/threonine-protein kinase pim-1" FT /id="PRO_0000043349" FT DOMAIN 38..290 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 167 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 44..52 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 67 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:15525646, FT ECO:0000305|PubMed:15657054, ECO:0000305|PubMed:15808862" FT BINDING 121 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:15525646, FT ECO:0000305|PubMed:15657054, ECO:0000305|PubMed:15808862" FT BINDING 128 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:15525646, FT ECO:0000305|PubMed:15657054, ECO:0000305|PubMed:15808862" FT MOD_RES 8 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15657054, FT ECO:0007744|PubMed:23186163" FT MOD_RES 23 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15657054" FT MOD_RES 98 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15657054" FT MOD_RES 261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15657054" FT VAR_SEQ 1 FT /note="M -> MPHEPHEPLTPPFSALPDPAGAPSRRQSRQRPQLSSDSPSAFRASRS FT HSRNATRSHSHSHSPRHSLRHSPGSGSCGSSSGHRPCADILEVGM (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:16186805" FT /id="VSP_059829" FT VARIANT 53 FT /note="Y -> H (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041004" FT VARIANT 124 FT /note="E -> Q (in dbSNP:rs35760989)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041005" FT VARIANT 135 FT /note="E -> K (in dbSNP:rs200523275)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041006" FT VARIANT 142 FT /note="E -> D (in dbSNP:rs33989191)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041007" FT MUTAGEN 68 FT /note="H->Y: Increased kinase activity." FT /evidence="ECO:0000269|PubMed:15808862" FT MUTAGEN 81 FT /note="P->S: Abolished kinase activity." FT /evidence="ECO:0000269|PubMed:15808862, FT ECO:0000269|PubMed:37797010" FT MUTAGEN 82 FT /note="N->K: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:15808862" FT MUTAGEN 193 FT /note="L->F: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:15808862" FT CONFLICT 15..16 FT /note="AP -> RA (in Ref. 2; AAA60089)" FT /evidence="ECO:0000305" FT TURN 6..9 FT /evidence="ECO:0007829|PDB:7OOX" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:7OOX" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 38..43 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 45..49 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 51..57 FT /evidence="ECO:0007829|PDB:3A99" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 63..70 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 71..73 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 77..79 FT /evidence="ECO:0007829|PDB:3A99" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:3C4E" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 88..96 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 98..100 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:3VBQ" FT STRAND 106..111 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 124..128 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 129..136 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 141..160 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 170..172 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 173..176 FT /evidence="ECO:0007829|PDB:3A99" FT TURN 177..180 FT /evidence="ECO:0007829|PDB:3A99" FT STRAND 181..184 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 187..189 FT /evidence="ECO:0007829|PDB:4ALW" FT HELIX 205..207 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 210..215 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 220..237 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 245..250 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 261..270 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 281..285 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:3A99" FT HELIX 296..303 FT /evidence="ECO:0007829|PDB:3A99" FT TURN 304..307 FT /evidence="ECO:0007829|PDB:3F2A" SQ SEQUENCE 313 AA; 35686 MW; 35BA76D3668E69A3 CRC64; MLLSKINSLA HLRAAPCNDL HATKLAPGKE KEPLESQYQV GPLLGSGGFG SVYSGIRVSD NLPVAIKHVE KDRISDWGEL PNGTRVPMEV VLLKKVSSGF SGVIRLLDWF ERPDSFVLIL ERPEPVQDLF DFITERGALQ EELARSFFWQ VLEAVRHCHN CGVLHRDIKD ENILIDLNRG ELKLIDFGSG ALLKDTVYTD FDGTRVYSPP EWIRYHRYHG RSAAVWSLGI LLYDMVCGDI PFEHDEEIIR GQVFFRQRVS SECQHLIRWC LALRPSDRPT FEEIQNHPWM QDVLLPQETA EIHLHSLSPG PSK // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PRAP1_HUMAN Reviewed; 151 AA. AC Q96NZ9; B7ZL57; B7ZL58; E9KL31; Q5VWY4; Q7Z4X5; Q8IWR3; Q8NCS2; DT 11-SEP-2007, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 153. DE RecName: Full=Proline-rich acidic protein 1; DE AltName: Full=Epididymis tissue protein Li 178; DE AltName: Full=Uterine-specific proline-rich acidic protein; DE Flags: Precursor; GN Name=PRAP1; Synonyms=UPA; ORFNames=UNQ608/PRO1195; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4), FUNCTION, INDUCTION, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND VARIANTS GLY-54; ARG-69 AND RP ARG-101. RX PubMed=14583459; RA Zhang J., Wong H., Ramanan S., Cheong D., Leong A., Hooi S.C.; RT "The proline-rich acidic protein is epigenetically regulated and inhibits RT growth of cancer cell lines."; RL Cancer Res. 63:6658-6665(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ARG-101, AND TISSUE RP SPECIFICITY. RC TISSUE=Epididymis; RX PubMed=20736409; DOI=10.1074/mcp.m110.001719; RA Li J., Liu F., Wang H., Liu X., Liu J., Li N., Wan F., Wang W., Zhang C., RA Jin S., Liu J., Zhu P., Liu Y.; RT "Systematic mapping and functional analysis of a family of human epididymal RT secretory sperm-located proteins."; RL Mol. Cell. Proteomics 9:2517-2528(2010). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-101. RA Zheng L.H., Yu L., Zhao S.Y.; RT "A novel human cDNA homologous to Mus musculus uterine-specific proline- RT rich acidic protein mRNA."; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-101. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-101. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4), NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 4-151 (ISOFORM 3), AND VARIANT ARG-101. RC TISSUE=Liver, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, AND INDUCTION. RX PubMed=23235459; DOI=10.1038/cddis.2012.180; RA Huang B.H., Zhuo J.L., Leung C.H., Lu G.D., Liu J.J., Yap C.T., Hooi S.C.; RT "PRAP1 is a novel executor of p53-dependent mechanisms in cell survival RT after DNA damage."; RL Cell Death Dis. 3:e442-e442(2012). RN [9] RP FUNCTION, INTERACTION WITH MAD1L1, AND TISSUE SPECIFICITY. RX PubMed=24374861; DOI=10.1002/path.4319; RA Sze K.M., Chu G.K., Mak Q.H., Lee J.M., Ng I.O.; RT "Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of RT MAD1 and has a suppressive role in mitotic checkpoint signalling in RT hepatocellular carcinoma."; RL J. Pathol. 233:51-60(2014). RN [10] RP TISSUE SPECIFICITY. RX PubMed=32629119; DOI=10.1016/j.jcmgh.2020.06.011; RA Wolfarth A.A., Liu X., Darby T.M., Boyer D.J., Spizman J.B., Owens J.A., RA Chandrasekharan B., Naudin C.R., Hanley K.Z., Robinson B.S., Ortlund E.A., RA Jones R.M., Neish A.S.; RT "Proline-Rich Acidic Protein 1 (PRAP1) Protects the Gastrointestinal RT Epithelium From Irradiation-Induced Apoptosis."; RL Cell. Mol. Gastroenterol. Hepatol. 10:713-727(2020). CC -!- FUNCTION: Lipid-binding protein which promotes lipid absorption by CC facilitating MTTP-mediated lipid transfer (mainly triglycerides and CC phospholipids) and MTTP-mediated apoB lipoprotein assembly and CC secretion (By similarity). Protects the gastrointestinal epithelium CC from irradiation-induced apoptosis (By similarity). May play an CC important role in maintaining normal growth homeostasis in epithelial CC cells (PubMed:14583459). Involved in p53/TP53-dependent cell survival CC after DNA damage (PubMed:23235459). May down-regulate the expression of CC MAD1L1 and exert a suppressive role in mitotic spindle assembly CC checkpoint in hepatocellular carcinomas (PubMed:24374861). CC {ECO:0000250|UniProtKB:Q80XD8, ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:23235459, ECO:0000269|PubMed:24374861}. CC -!- SUBUNIT: Interacts with isoform 1 and isoform 3 of MAD1L1 CC (PubMed:24374861). Interacts with MTTP (By similarity). CC {ECO:0000250|UniProtKB:Q80XD8, ECO:0000269|PubMed:24374861}. CC -!- INTERACTION: CC Q96NZ9; Q8IVF2-3: AHNAK2; NbExp=3; IntAct=EBI-2116102, EBI-12078468; CC Q96NZ9; Q12797-6: ASPH; NbExp=3; IntAct=EBI-2116102, EBI-12092171; CC Q96NZ9; Q96LK0: CEP19; NbExp=3; IntAct=EBI-2116102, EBI-741885; CC Q96NZ9; P17066: HSPA6; NbExp=3; IntAct=EBI-2116102, EBI-355106; CC Q96NZ9; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-2116102, EBI-16439278; CC Q96NZ9; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-2116102, EBI-995714; CC Q96NZ9; O43765: SGTA; NbExp=9; IntAct=EBI-2116102, EBI-347996; CC Q96NZ9; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-2116102, EBI-744081; CC Q96NZ9; Q9UMX0: UBQLN1; NbExp=6; IntAct=EBI-2116102, EBI-741480; CC Q96NZ9; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-2116102, EBI-10173939; CC Q96NZ9; Q9UHD9: UBQLN2; NbExp=6; IntAct=EBI-2116102, EBI-947187; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:14583459}. CC Endoplasmic reticulum {ECO:0000250|UniProtKB:Q80XD8}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=PRAP; CC IsoId=Q96NZ9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96NZ9-2; Sequence=VSP_027661, VSP_027662; CC Name=3; Synonyms=PRAPV1; CC IsoId=Q96NZ9-3; Sequence=VSP_027660; CC Name=4; Synonyms=PRAPV2; CC IsoId=Q96NZ9-4; Sequence=VSP_027661; CC -!- TISSUE SPECIFICITY: Highly expressed in the intestinal epithelial cells CC (at protein level) (PubMed:32629119). Abundantly expressed in the CC epithelial cells of the liver, kidney and cervix. Significantly down- CC regulated in hepatocellular carcinoma and right colon adenocarcinoma CC compared with the respective adjacent normal tissues. Expressed in CC epididymis (at protein level). {ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:20736409, ECO:0000269|PubMed:24374861, CC ECO:0000269|PubMed:32629119}. CC -!- INDUCTION: Up-regulated by butyrate, trichostatin A and 5'-aza-2' CC deoxycytidine (PubMed:14583459). Induced by DNA-damaging agents in a CC p53/TP53-dependent manner in HepG2 liver cancer cell line and HCT116 CC colon cancer cell line (PubMed:23235459). {ECO:0000269|PubMed:14583459, CC ECO:0000269|PubMed:23235459}. CC -!- SEQUENCE CAUTION: CC Sequence=AAP97247.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF421885; AAL16670.1; -; mRNA. DR EMBL; AY158074; AAN87018.1; -; mRNA. DR EMBL; AF123768; AAP97247.1; ALT_FRAME; mRNA. DR EMBL; AY358908; AAQ89267.1; -; mRNA. DR EMBL; GU727628; ADU87630.1; -; mRNA. DR EMBL; AL360181; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471211; EAW61336.1; -; Genomic_DNA. DR EMBL; BC029447; AAH29447.2; -; mRNA. DR EMBL; BC061643; AAH61643.1; -; mRNA. DR EMBL; BC071872; AAH71872.1; -; mRNA. DR EMBL; BC093853; AAH93853.1; -; mRNA. DR EMBL; BC101743; AAI01744.1; -; mRNA. DR EMBL; BC143590; AAI43591.1; -; mRNA. DR EMBL; BC143592; AAI43593.1; -; mRNA. DR EMBL; BC143591; AAI43592.1; -; mRNA. DR CCDS; CCDS44498.1; -. [Q96NZ9-4] DR CCDS; CCDS7679.1; -. [Q96NZ9-1] DR RefSeq; NP_001138673.1; NM_001145201.2. [Q96NZ9-4] DR RefSeq; NP_660203.3; NM_145202.4. [Q96NZ9-1] DR AlphaFoldDB; Q96NZ9; -. DR BioGRID; 125610; 18. DR FunCoup; Q96NZ9; 153. DR IntAct; Q96NZ9; 17. DR STRING; 9606.ENSP00000416126; -. DR BindingDB; Q96NZ9; -. DR ChEMBL; CHEMBL4879502; -. DR GlyCosmos; Q96NZ9; 1 site, 1 glycan. DR GlyGen; Q96NZ9; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q96NZ9; -. DR PhosphoSitePlus; Q96NZ9; -. DR BioMuta; PRAP1; -. DR DMDM; 317373269; -. DR jPOST; Q96NZ9; -. DR MassIVE; Q96NZ9; -. DR PaxDb; 9606-ENSP00000416126; -. DR PeptideAtlas; Q96NZ9; -. DR ProteomicsDB; 77584; -. [Q96NZ9-2] DR ProteomicsDB; 77585; -. [Q96NZ9-3] DR ProteomicsDB; 77586; -. [Q96NZ9-4] DR Antibodypedia; 48788; 69 antibodies from 18 providers. DR DNASU; 118471; -. DR Ensembl; ENST00000433452.6; ENSP00000416126.2; ENSG00000165828.16. [Q96NZ9-1] DR Ensembl; ENST00000463201.2; ENSP00000486265.1; ENSG00000165828.16. [Q96NZ9-4] DR GeneID; 118471; -. DR KEGG; hsa:118471; -. DR MANE-Select; ENST00000433452.6; ENSP00000416126.2; NM_145202.5; NP_660203.3. DR UCSC; uc001lmp.3; human. [Q96NZ9-1] DR AGR; HGNC:23304; -. DR ClinPGx; PA134981678; -. DR CTD; 118471; -. DR DisGeNET; 118471; -. DR GeneCards; PRAP1; -. DR HGNC; HGNC:23304; PRAP1. DR HPA; ENSG00000165828; Group enriched (intestine, liver). DR MIM; 609776; gene. DR OpenTargets; ENSG00000165828; -. DR VEuPathDB; HostDB:ENSG00000165828; -. DR eggNOG; ENOG502TDVH; Eukaryota. DR GeneTree; ENSGT00390000012626; -. DR InParanoid; Q96NZ9; -. DR OMA; WVETEDI; -. DR OrthoDB; 9938040at2759; -. DR PAN-GO; Q96NZ9; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q96NZ9; -. DR PathwayCommons; Q96NZ9; -. DR SignaLink; Q96NZ9; -. DR Agora; ENSG00000165828; -. DR BioGRID-ORCS; 118471; 9 hits in 1130 CRISPR screens. DR ChiTaRS; PRAP1; human. DR GenomeRNAi; 118471; -. DR Pharos; Q96NZ9; Tchem. DR PRO; PR:Q96NZ9; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q96NZ9; protein. DR Bgee; ENSG00000165828; Expressed in duodenum and 96 other cell types or tissues. DR ExpressionAtlas; Q96NZ9; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; ISS:UniProtKB. DR GO; GO:0017129; F:triglyceride binding; ISS:UniProtKB. DR GO; GO:0071481; P:cellular response to X-ray; ISS:UniProtKB. DR GO; GO:1902426; P:deactivation of mitotic spindle assembly checkpoint; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1904731; P:positive regulation of intestinal lipid absorption; ISS:UniProtKB. DR GO; GO:2001140; P:positive regulation of phospholipid transport; ISS:UniProtKB. DR GO; GO:1905885; P:positive regulation of triglyceride transport; ISS:UniProtKB. DR InterPro; IPR027922; PRAP. DR PANTHER; PTHR37861; PROLINE-RICH ACIDIC PROTEIN 1; 1. DR PANTHER; PTHR37861:SF1; PROLINE-RICH ACIDIC PROTEIN 1; 1. DR Pfam; PF15314; PRAP; 1. PE 1: Evidence at protein level; KW Alternative splicing; Endoplasmic reticulum; Lipid-binding; KW Proteomics identification; Reference proteome; Secreted; Signal. FT SIGNAL 1..20 FT /evidence="ECO:0000255" FT CHAIN 21..151 FT /note="Proline-rich acidic protein 1" FT /id="PRO_0000299416" FT REGION 71..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 43 FT /note="K -> NR (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_027660" FT VAR_SEQ 79..87 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14583459, FT ECO:0000303|PubMed:15489334" FT /id="VSP_027661" FT VAR_SEQ 95..151 FT /note="TEDTLGHVLSPEPDHDSLYHPPPEEDQGEERPRLWVMPNHQVLLGPEEDQDH FT IYHPQ -> SRARP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14583459" FT /id="VSP_027662" FT VARIANT 54 FT /note="E -> G (in dbSNP:rs1848687860)" FT /evidence="ECO:0000269|PubMed:14583459" FT /id="VAR_034815" FT VARIANT 69 FT /note="K -> R" FT /evidence="ECO:0000269|PubMed:14583459" FT /id="VAR_034816" FT VARIANT 81 FT /note="G -> S (in dbSNP:rs34780987)" FT /id="VAR_034817" FT VARIANT 101 FT /note="H -> R (in dbSNP:rs4369319)" FT /evidence="ECO:0000269|PubMed:12975309, FT ECO:0000269|PubMed:14583459, ECO:0000269|PubMed:15164054, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:20736409, FT ECO:0000269|Ref.3" FT /id="VAR_034818" SQ SEQUENCE 151 AA; 17208 MW; B751EDBFD24D08CA CRC64; MRRLLLVTSL VVVLLWEAGA VPAPKVPIKM QVKHWPSEQD PEKAWGARVV EPPEKDDQLV VLFPVQKPKL LTTEEKPRGQ GRGPILPGTK AWMETEDTLG HVLSPEPDHD SLYHPPPEED QGEERPRLWV MPNHQVLLGP EEDQDHIYHP Q // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID PTK6_HUMAN Reviewed; 451 AA. AC Q13882; B2RCR3; B4DW46; Q58F01; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Protein-tyrosine kinase 6; DE EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}; DE AltName: Full=Breast tumor kinase; DE AltName: Full=Tyrosine-protein kinase BRK; GN Name=PTK6; Synonyms=BRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary tumor; RX PubMed=8036022; RA Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., RA Page M.J., Gusterson B.A., Crompton M.R.; RT "Cloning and characterisation of cDNAs encoding a novel non-receptor RT tyrosine kinase, brk, expressed in human breast tumours."; RL Oncogene 9:2383-2390(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=9333026; DOI=10.1038/sj.onc.1201292; RA Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.; RT "Characterisation and chromosome mapping of the human non receptor tyrosine RT kinase gene, brk."; RL Oncogene 15:1497-1502(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Melanocyte; RX PubMed=9749526; RA Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.; RT "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 RT constitutes a distinct family of non-receptor tyrosine kinase."; RL Mol. Cells 8:401-407(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND RP TYR-447. RX PubMed=8940083; DOI=10.1074/jbc.271.48.30956; RA Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., RA Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.; RT "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, RT sensitizes mammary epithelial cells to epidermal growth factor."; RL J. Biol. Chem. 271:30956-30963(1996). RN [8] RP TISSUE SPECIFICITY. RX PubMed=9185712; RX DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f; RA Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., RA Bennett D.C.; RT "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK RT in metastatic melanoma."; RL Int. J. Cancer 71:1061-1065(1997). RN [9] RP FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66; RP ARG-105 AND LYS-219. RX PubMed=10980601; DOI=10.1038/sj.onc.1203775; RA Mitchell P.J., Sara E.A., Crompton M.R.; RT "A novel adaptor-like protein which is a substrate for the non-receptor RT tyrosine kinase, BRK."; RL Oncogene 19:4273-4282(2000). RN [10] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH RP KHDRBS1. RX PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000; RA Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., RA Cochrane A.W., Chen T., Tyner A.L.; RT "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RT RNA binding ability."; RL Mol. Cell. Biol. 20:6114-6126(2000). RN [11] RP PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 RP AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12121988; DOI=10.1074/jbc.m203877200; RA Qiu H., Miller W.T.; RT "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation RT and by autoinhibition."; RL J. Biol. Chem. 277:34634-34641(2002). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12833144; DOI=10.1038/sj.onc.1206465; RA Derry J.J., Prins G.S., Ray V., Tyner A.L.; RT "Altered localization and activity of the intracellular tyrosine kinase RT BRK/Sik in prostate tumor cells."; RL Oncogene 22:4212-4220(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND RP PHOSPHORYLATION. RX PubMed=15471878; DOI=10.1074/jbc.m409579200; RA Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.; RT "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA- RT binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2."; RL J. Biol. Chem. 279:54398-54404(2004). RN [14] RP FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR RP LOCATION, AND INTERACTION WITH PXN. RX PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004; RA Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.; RT "Brk activates rac1 and promotes cell migration and invasion by RT phosphorylating paxillin."; RL Mol. Cell. Biol. 24:10558-10572(2004). RN [15] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010; RA Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.; RT "Differential expression of the non-receptor tyrosine kinase BRK in oral RT squamous cell carcinoma and normal oral epithelium."; RL Oral Oncol. 40:1040-1047(2004). RN [16] RP FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK. RX PubMed=15539407; DOI=10.1074/jbc.m412038200; RA Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., RA Lange C.A.; RT "Regulated association of protein kinase B/Akt with breast tumor kinase."; RL J. Biol. Chem. 280:1982-1991(2005). RN [17] RP MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION. RX PubMed=15961400; DOI=10.1074/jbc.m504568200; RA Kim H.I.E., Lee S.T.; RT "An intramolecular interaction between SH2-kinase linker and kinase domain RT is essential for the catalytic activity of protein-tyrosine kinase-6."; RL J. Biol. Chem. 280:28973-28980(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KHDRBS1. RX PubMed=16179349; DOI=10.1074/jbc.m505802200; RA Lukong K.E., Larocque D., Tyner A.L., Richard S.; RT "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates RT intranuclear localization and cell cycle progression."; RL J. Biol. Chem. 280:38639-38647(2005). RN [19] RP INTERACTION WITH IRS4, AND ACTIVITY REGULATION. RX PubMed=15870689; DOI=10.1038/sj.onc.1208721; RA Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.; RT "Interaction between Brk kinase and insulin receptor substrate-4."; RL Oncogene 24:5656-5664(2005). RN [20] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16651629; DOI=10.2353/ajpath.2006.050521; RA Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., RA Marzec M., Gimotty P., Crompton M.R., Wasik M.A.; RT "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in RT lymphocytes."; RL Am. J. Pathol. 168:1631-1641(2006). RN [21] RP FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION. RX PubMed=16568091; DOI=10.1038/sj.onc.1209501; RA Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.; RT "Identification of STAT3 as a specific substrate of breast tumor kinase."; RL Oncogene 25:4904-4912(2006). RN [22] RP ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44. RX PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055; RA Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.; RT "Molecular dissection of the interaction between the SH3 domain and the RT SH2-Kinase Linker region in PTK6."; RL Biochem. Biophys. Res. Commun. 362:829-834(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF STAT5B. RX PubMed=17997837; DOI=10.1186/bcr1794; RA Weaver A.M., Silva C.M.; RT "Signal transducer and activator of transcription 5b: a new target of RT breast tumor kinase/protein tyrosine kinase 6."; RL Breast Cancer Res. 9:R79-R79(2007). RN [24] RP FUNCTION IN PHOSPHORYLATION OF ARHGAP35. RX PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997; RA Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., RA Settleman J., Chen R.H.; RT "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and RT promote breast carcinoma growth, migration, and invasion."; RL Cancer Res. 68:7779-7787(2008). RN [25] RP INTERACTION WITH ADAM15. RX PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028; RA Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., RA Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., RA Edwards D.R.; RT "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human RT mammary carcinoma."; RL Mol. Cancer Res. 6:383-394(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [27] RP INTERACTION WITH ERBB2. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [28] RP INTERACTION WITH SFPQ. RX PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008; RA Lukong K.E., Huot M.E., Richard S.; RT "BRK phosphorylates PSF promoting its cytoplasmic localization and cell RT cycle arrest."; RL Cell. Signal. 21:1415-1422(2009). RN [29] RP REVIEW ON FUNCTION. RX PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003; RA Brauer P.M., Tyner A.L.; RT "Building a better understanding of the intracellular tyrosine kinase PTK6 RT - BRK by BRK."; RL Biochim. Biophys. Acta 1806:66-73(2010). RN [30] RP FUNCTION, AND MUTAGENESIS OF ARG-105 AND LYS-219. RX PubMed=20554524; DOI=10.1074/jbc.m109.088971; RA Kang S.A., Lee E.S., Yoon H.Y., Randazzo P.A., Lee S.T.; RT "PTK6 inhibits down-regulation of EGF receptor through phosphorylation of RT ARAP1."; RL J. Biol. Chem. 285:26013-26021(2010). RN [31] RP PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [32] RP FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. RX PubMed=21479203; DOI=10.1371/journal.pone.0014789; RA Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., RA Tyner A.L.; RT "The alternative splice variant of protein tyrosine kinase 6 negatively RT regulates growth and enhances PTK6-mediated inhibition of beta-catenin."; RL PLoS ONE 6:E14789-E14789(2011). RN [33] RP STRUCTURE BY NMR OF 75-174. RX PubMed=15056653; DOI=10.1074/jbc.m313185200; RA Hong E., Shin J., Kim H.I., Lee S.T., Lee W.; RT "Solution structure and backbone dynamics of the non-receptor protein- RT tyrosine kinase-6 Src homology 2 domain."; RL J. Biol. Chem. 279:29700-29708(2004). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF LYS-219. RX PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121; RA Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.; RT "Crystal structure of the kinase domain of human protein tyrosine kinase 6 RT (PTK6) at 2.33 A resolution."; RL Biochem. Biophys. Res. Commun. 478:637-642(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH RP INHIBITORS, AND CATALYTIC ACTIVITY. RX PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030; RA Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S., RA Tyagi R., Gosu R.; RT "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel RT imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution."; RL Biochem. Biophys. Res. Commun. 482:1289-1295(2017). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the CC regulation of a variety of signaling pathways that control the CC differentiation and maintenance of normal epithelia, as well as tumor CC growth. Function seems to be context dependent and differ depending on CC cell type, as well as its intracellular localization. A number of CC potential nuclear and cytoplasmic substrates have been identified. CC These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, CC KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B CC and a variety of signaling molecules: ARHGAP35/p190RhoGAP, CC PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating CC protein ARAP1 following EGF stimulation which enhances EGFR signaling CC by delaying EGFR down-regulation (PubMed:20554524). Also associates CC with a variety of proteins that are likely upstream of PTK6 in various CC signaling pathways, or for which PTK6 may play an adapter-like role. CC These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal CC or non-tumorigenic tissues, PTK6 promotes cellular differentiation and CC apoptosis. In tumors PTK6 contributes to cancer progression by CC sensitizing cells to mitogenic signals and enhancing proliferation, CC anchorage-independent survival and migration/invasion. Association with CC EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and CC growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 CC kinase. Contributes to migration and proliferation by contributing to CC EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes CC association with RASA1/p120RasGAP, inactivating RhoA while activating CC RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by CC PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration CC and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. CC Nuclear PTK6 may be important for regulating growth in normal CC epithelia, while cytoplasmic PTK6 might activate oncogenic signaling CC pathways. {ECO:0000269|PubMed:20554524}. CC -!- FUNCTION: [Isoform 2]: Inhibits PTK6 phosphorylation and PTK6 CC association with other tyrosine-phosphorylated proteins. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, CC ECO:0000269|PubMed:27993680}; CC -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by CC SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an CC association between the SH3 domain and the SH2-TK linker region. CC Interaction between Trp-184 within SH2-TK linker region and the CC catalytic domain appears essential for positive regulation of kinase CC activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091, CC ECO:0000269|PubMed:17822667}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=83 uM for ATP {ECO:0000269|PubMed:12121988}; CC Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988}; CC -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3 CC and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with CC phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) CC with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. CC Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. CC Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193, CC ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407, CC ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:8940083}. CC -!- INTERACTION: CC Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652; CC Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093; CC Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027; CC Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634; CC Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012; CC Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258; CC Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927; CC Q13882; P00533: EGFR; NbExp=2; IntAct=EBI-1383632, EBI-297353; CC Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062; CC Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824; CC Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823; CC Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684; CC Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572; CC Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029; CC Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204; CC Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808; CC Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326; CC Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503; CC Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850; CC Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269; CC Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487; CC Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265; CC Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284; CC Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632; CC Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352; CC Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453; CC Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587; CC Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615; CC Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle. CC Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or CC KHDRBS3, within the nucleus. Nuclear localization in epithelial cells CC of normal prostate but cytoplasmic localization in cancer prostate. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13882-1; Sequence=Displayed; CC Name=2; Synonyms=ALT-PTK6, LambdaM5; CC IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067; CC -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and CC high levels in small intestine and prostate, and low levels in some CC fetal tissues. Not expressed in breast or ovarian tissue but expressed CC in high percentage of breast and ovarian cancers. Also overexpressed in CC some metastatic melanomas, lymphomas, colon cancers, squamous cell CC carcinomas and prostate cancers. Also found in melanocytes. Not CC expressed in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas. Isoform 2 is present in prostate epithelial cell CC lines derived from normal prostate and prostate adenocarcinomas, as CC well as in a variety of cell lines. {ECO:0000269|PubMed:12833144, CC ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629, CC ECO:0000269|PubMed:9185712}. CC -!- DOMAIN: The SH3 domain plays a major role in substrate interactions. CC The SH2 domain of PTK6 plays a role in protein-protein interactions, CC but is likely more important for the regulation of catalytic activity. CC -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an CC increase of kinase activity. Tyr-447 binds to the SH2 domain when CC phosphorylated and negatively regulates kinase activity. CC {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988, CC ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}. CC -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket. CC {ECO:0000269|PubMed:27993680}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X78549; CAA55295.1; -; mRNA. DR EMBL; U61412; AAC34935.1; -; Genomic_DNA. DR EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; AK315232; BAG37660.1; -; mRNA. DR EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA. DR EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC035843; AAH35843.1; -; mRNA. DR CCDS; CCDS13524.1; -. [Q13882-1] DR CCDS; CCDS74750.1; -. [Q13882-2] DR PIR; S49016; S49016. DR RefSeq; NP_001243287.1; NM_001256358.2. [Q13882-2] DR RefSeq; NP_005966.1; NM_005975.4. [Q13882-1] DR PDB; 1RJA; NMR; -; A=75-174. DR PDB; 2KGT; NMR; -; A=1-72. DR PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446. DR PDB; 5DA3; X-ray; 1.70 A; A=185-446. DR PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446. DR PDB; 6CZ2; X-ray; 2.50 A; A=182-443. DR PDB; 6CZ3; X-ray; 1.80 A; A=182-443. DR PDB; 6CZ4; X-ray; 1.50 A; A=182-443. DR PDB; 8S1C; X-ray; 1.75 A; A/B=11-72. DR PDBsum; 1RJA; -. DR PDBsum; 2KGT; -. DR PDBsum; 5D7V; -. DR PDBsum; 5DA3; -. DR PDBsum; 5H2U; -. DR PDBsum; 6CZ2; -. DR PDBsum; 6CZ3; -. DR PDBsum; 6CZ4; -. DR PDBsum; 8S1C; -. DR AlphaFoldDB; Q13882; -. DR BMRB; Q13882; -. DR SMR; Q13882; -. DR BioGRID; 111720; 103. DR DIP; DIP-39785N; -. DR FunCoup; Q13882; 312. DR IntAct; Q13882; 83. DR MINT; Q13882; -. DR STRING; 9606.ENSP00000442460; -. DR BindingDB; Q13882; -. DR ChEMBL; CHEMBL4601; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q13882; -. DR GuidetoPHARMACOLOGY; 2182; -. DR GlyGen; Q13882; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13882; -. DR PhosphoSitePlus; Q13882; -. DR BioMuta; PTK6; -. DR DMDM; 8928302; -. DR CPTAC; CPTAC-2842; -. DR CPTAC; CPTAC-2880; -. DR jPOST; Q13882; -. DR MassIVE; Q13882; -. DR PaxDb; 9606-ENSP00000442460; -. DR PeptideAtlas; Q13882; -. DR ProteomicsDB; 59709; -. [Q13882-1] DR ProteomicsDB; 59710; -. [Q13882-2] DR Antibodypedia; 29774; 545 antibodies from 39 providers. DR DNASU; 5753; -. DR Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.8. [Q13882-2] DR Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.8. [Q13882-1] DR GeneID; 5753; -. DR KEGG; hsa:5753; -. DR MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1. DR UCSC; uc002yfg.5; human. [Q13882-1] DR AGR; HGNC:9617; -. DR ClinPGx; PA33960; -. DR CTD; 5753; -. DR DisGeNET; 5753; -. DR GeneCards; PTK6; -. DR HGNC; HGNC:9617; PTK6. DR HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina). DR MIM; 602004; gene. DR OpenTargets; ENSG00000101213; -. DR VEuPathDB; HostDB:ENSG00000101213; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161218; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q13882; -. DR OMA; LWKGQVR; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q13882; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13882; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13882; -. DR Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8849472; PTK6 Down-Regulation. DR Reactome; R-HSA-8849473; PTK6 Expression. DR Reactome; R-HSA-8849474; PTK6 Activates STAT3. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR SABIO-RK; Q13882; -. DR SignaLink; Q13882; -. DR SIGNOR; Q13882; -. DR Agora; ENSG00000101213; -. DR BioGRID-ORCS; 5753; 17 hits in 1179 CRISPR screens. DR EvolutionaryTrace; Q13882; -. DR GeneWiki; PTK6; -. DR GenomeRNAi; 5753; -. DR Pharos; Q13882; Tchem. DR PRO; PR:Q13882; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13882; protein. DR Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0001726; C:ruffle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome. DR GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl. DR GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome. DR GO; GO:0045740; P:positive regulation of DNA replication; TAS:Reactome. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB. DR CDD; cd05148; PTKc_Srm_Brk; 1. DR CDD; cd10358; SH2_PTK6_Brk; 1. DR CDD; cd11847; SH3_Brk; 1. DR FunFam; 1.10.510.10:FF:000399; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000229; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000074; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR035846; PTK6_SH2. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase. FT CHAIN 1..451 FT /note="Protein-tyrosine kinase 6" FT /id="PRO_0000088133" FT DOMAIN 8..72 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 78..170 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 191..445 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 171..190 FT /note="Linker" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 197..205 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680" FT MOD_RES 13 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 61 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 66 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 114 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0007744|PubMed:18691976" FT MOD_RES 342 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 351 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 447 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:10913193" FT VAR_SEQ 78..134 FT /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI FT WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR FT ALPEARA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042066" FT VAR_SEQ 135..451 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042067" FT VARIANT 16 FT /note="L -> F (in a renal papillary sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041760" FT VARIANT 436 FT /note="A -> T (in dbSNP:rs56145017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041761" FT MUTAGEN 44 FT /note="W->A: Strong decrease in STAP2 phosphorylation. FT Markedly decreased interaction between SH3 domain the FT linker region." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:17822667" FT MUTAGEN 66 FT /note="Y->A: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 105 FT /note="R->A: Abolishes interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:20554524" FT MUTAGEN 105 FT /note="R->L: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 184 FT /note="W->A: Abrogates interaction between PTK6-domain FT kinase and PTK6-linker. Abrogates autophosphorylation and FT phosphorylation of KHDRBS1." FT /evidence="ECO:0000269|PubMed:15961400" FT MUTAGEN 219 FT /note="K->M: Abolishes kinase activity and cell FT transformation, and phosphorylation of STAP2. Reduces FT interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20554524, FT ECO:0000269|PubMed:8940083" FT MUTAGEN 219 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:27480927" FT MUTAGEN 342 FT /note="Y->A: 3-fold lower specific kinase activity. FT Decreased, but still significant, autophosphorylation. FT Decreased, but still significant, autophosphorylation; when FT associated with A-447." FT /evidence="ECO:0000269|PubMed:12121988" FT MUTAGEN 447 FT /note="Y->F: Decrease in transforming potential and FT increase in the kinase activity level. Decreased, but still FT significant, autophosphorylation; when associated with A- FT 342." FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 45..50 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2KGT" FT TURN 64..66 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 67..70 FT /evidence="ECO:0007829|PDB:2KGT" FT HELIX 85..92 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 102..106 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 125..131 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 143..147 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 148..157 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 162..164 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 188..190 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 229..240 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 256..264 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6CZ2" FT HELIX 272..278 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:5DA3" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 339..342 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 356..361 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 366..380 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 381..384 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 434..441 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 442..444 FT /evidence="ECO:0007829|PDB:5D7V" SQ SEQUENCE 451 AA; 51834 MW; CDCAC0EE242E1BD7 CRC64; MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM LTCWCRDPEQ RPCFKALRER LSSFTSYENP T // ID PTK7_HUMAN Reviewed; 1070 AA. AC Q13308; A8K974; B7Z477; E9PFZ5; Q13417; Q5T650; Q6IQ54; Q8NFA5; Q8NFA6; AC Q8NFA7; Q8NFA8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Inactive tyrosine-protein kinase 7; DE AltName: Full=Colon carcinoma kinase 4; DE Short=CCK-4; DE AltName: Full=Protein-tyrosine kinase 7; DE AltName: Full=Pseudo tyrosine kinase receptor 7; DE AltName: Full=Tyrosine-protein kinase-like 7; DE Flags: Precursor; GN Name=PTK7; Synonyms=CCK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon carcinoma, and Placenta; RX PubMed=7478540; RA Mossie K., Jallal B., Alves F., Sures I., Plowman G.D., Ullrich A.; RT "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine RT kinase family."; RL Oncogene 11:2179-2184(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fibroblast; RX PubMed=8882711; DOI=10.1093/oxfordjournals.jbchem.a021228; RA Park S.-K., Lee H.-S., Lee S.-T.; RT "Characterization of the human full-length PTK7 cDNA encoding a receptor RT protein tyrosine kinase-like molecule closely related to chick KLG."; RL J. Biochem. 119:235-239(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RP 1; 2; 3; 4 AND 5). RC TISSUE=Testis; RX PubMed=12427550; DOI=10.1016/s0167-4781(02)00536-5; RA Jung J.-W., Ji A.-R., Lee J., Kim U.-J., Lee S.-T.; RT "Organization of the human PTK7 gene encoding a receptor protein tyrosine RT kinase-like molecule and alternative splicing of its mRNA."; RL Biochim. Biophys. Acta 1579:153-163(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 6). RC TISSUE=Testis, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP GLYCOSYLATION AT ASN-646. RX PubMed=12754519; DOI=10.1038/nbt827; RA Zhang H., Li X.-J., Martin D.B., Aebersold R.; RT "Identification and quantification of N-linked glycoproteins using RT hydrazide chemistry, stable isotope labeling and mass spectrometry."; RL Nat. Biotechnol. 21:660-666(2003). RN [9] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-646. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [10] RP FUNCTION. RX PubMed=18471990; DOI=10.1016/j.bbrc.2008.04.168; RA Shin W.-S., Maeng Y.-S., Jung J.-W., Min J.-K., Kwon Y.-G., Lee S.-T.; RT "Soluble PTK7 inhibits tube formation, migration, and invasion of RT endothelial cells and angiogenesis."; RL Biochem. Biophys. Res. Commun. 371:793-798(2008). RN [11] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-116; ASN-175; ASN-268 AND RP ASN-283. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [12] RP FUNCTION. RX PubMed=20558616; DOI=10.1182/blood-2010-01-262352; RA Prebet T., Lhoumeau A.-C., Arnoulet C., Aulas A., Marchetto S., RA Audebert S., Puppo F., Chabannon C., Sainty D., Santoni M.-J., Sebbagh M., RA Summerour V., Huon Y., Shin W.-S., Lee S.-T., Esterni B., Vey N., RA Borg J.-P.; RT "The cell polarity PTK7 receptor acts as a modulator of the RT chemotherapeutic response in acute myeloid leukemia and impairs clinical RT outcome."; RL Blood 116:2315-2323(2010). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, INDUCTION, CLEAVAGE, AND MUTAGENESIS OF RP LEU-622; MET-641 AND MET-701. RX PubMed=20837484; DOI=10.1074/jbc.m110.165159; RA Golubkov V.S., Chekanov A.V., Cieplak P., Aleshin A.E., Chernov A.V., RA Zhu W., Radichev I.A., Zhang D., Dong P.D., Strongin A.Y.; RT "The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly RT efficient proteolytic target of membrane type-1 matrix metalloproteinase: RT implications in cancer and embryogenesis."; RL J. Biol. Chem. 285:35740-35749(2010). RN [14] RP FUNCTION. RX PubMed=21103379; DOI=10.1371/journal.pone.0014018; RA Meng L., Sefah K., O'Donoghue M.B., Zhu G., Shangguan D., Noorali A., RA Chen Y., Zhou L., Tan W.; RT "Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis RT via mitochondrial pathway."; RL PLoS ONE 5:E14018-E14018(2010). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP FUNCTION, INTERACTION WITH CTNNB1, AND REGION. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-276; SER-410; ASP-745; GLN-766; RP VAL-777; ARG-783; VAL-933; THR-1029 AND GLN-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Inactive tyrosine kinase involved in Wnt signaling pathway. CC Component of both the non-canonical (also known as the Wnt/planar cell CC polarity signaling) and the canonical Wnt signaling pathway. Functions CC in cell adhesion, cell migration, cell polarity, proliferation, actin CC cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, CC epithelial tissue organization and angiogenesis. CC {ECO:0000269|PubMed:18471990, ECO:0000269|PubMed:20558616, CC ECO:0000269|PubMed:20837484, ECO:0000269|PubMed:21103379, CC ECO:0000269|PubMed:21132015}. CC -!- SUBUNIT: Interacts with CTNNB1. {ECO:0000269|PubMed:21132015}. CC -!- INTERACTION: CC Q13308; P35222: CTNNB1; NbExp=5; IntAct=EBI-2803245, EBI-491549; CC Q13308; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-2803245, EBI-11749135; CC Q13308; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2803245, EBI-10171774; CC Q13308; Q99750: MDFI; NbExp=3; IntAct=EBI-2803245, EBI-724076; CC Q13308; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-2803245, EBI-11522433; CC Q13308; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2803245, EBI-22310682; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:20837484}; Single- CC pass type I membrane protein {ECO:0000269|PubMed:20837484}. Cell CC junction {ECO:0000269|PubMed:20837484}. Note=Colocalizes with MMP14 at CC cell junctions. Also localizes at the leading edge of migrating cells. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; Synonyms=PTK7-1; CC IsoId=Q13308-1; Sequence=Displayed; CC Name=2; Synonyms=PTK7-2; CC IsoId=Q13308-2; Sequence=VSP_037182; CC Name=3; Synonyms=PTK7-3; CC IsoId=Q13308-3; Sequence=VSP_037181; CC Name=4; Synonyms=PTK7-4; CC IsoId=Q13308-4; Sequence=VSP_037183; CC Name=5; Synonyms=PTK7-5; CC IsoId=Q13308-5; Sequence=VSP_037184, VSP_037185; CC Name=6; CC IsoId=Q13308-6; Sequence=VSP_044775; CC -!- TISSUE SPECIFICITY: Highly expressed in lung, liver, pancreas, kidney, CC placenta and melanocytes. Weakly expressed in thyroid gland, ovary, CC brain, heart and skeletal muscle. Also expressed in erythroleukemia CC cells. But not expressed in colon. CC -!- INDUCTION: Higher expression in cell lines established from normal non- CC tumorigenic tissues compared to cell lines established from highly CC metastatic invasive carcinomas (at protein level). CC {ECO:0000269|PubMed:20837484}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: MMP14 cleaves PTK7 between Pro-621 and Leu-622 generating an N- CC terminal soluble (70 kDa) fragment and a membrane C-terminal (50 kDa) CC fragment. Proteolysis by MMP14 regulates PTK7 function in non-canonical CC Wnt signaling pathway. {ECO:0000269|PubMed:20837484}. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41901/PTK7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33635; AAA87565.1; -; mRNA. DR EMBL; U40271; AAC50484.2; -; mRNA. DR EMBL; AF447176; AAL39062.1; -; Genomic_DNA. DR EMBL; AF447157; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447158; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447162; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447164; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447167; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447170; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447171; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447173; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447174; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447175; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF531868; AAN04862.1; -; mRNA. DR EMBL; AF531869; AAN04863.1; -; mRNA. DR EMBL; AF531870; AAN04864.1; -; mRNA. DR EMBL; AF531871; AAN04865.1; -; mRNA. DR EMBL; AF531872; AAN04866.1; -; mRNA. DR EMBL; AK291016; BAF83705.1; -; mRNA. DR EMBL; AK292589; BAF85278.1; -; mRNA. DR EMBL; AK296953; BAH12463.1; -; mRNA. DR EMBL; AL355385; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX04154.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04155.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04156.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04158.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04160.1; -; Genomic_DNA. DR EMBL; BC071557; AAH71557.1; -; mRNA. DR CCDS; CCDS4884.1; -. [Q13308-1] DR CCDS; CCDS4885.1; -. [Q13308-2] DR CCDS; CCDS4886.1; -. [Q13308-3] DR CCDS; CCDS4887.1; -. [Q13308-4] DR CCDS; CCDS59021.1; -. [Q13308-6] DR PIR; JC4593; JC4593. DR RefSeq; NP_001257327.1; NM_001270398.2. [Q13308-6] DR RefSeq; NP_002812.2; NM_002821.4. [Q13308-1] DR RefSeq; NP_690619.1; NM_152880.4. [Q13308-2] DR RefSeq; NP_690620.1; NM_152881.4. [Q13308-3] DR RefSeq; NP_690621.1; NM_152882.4. [Q13308-4] DR PDB; 6VG3; X-ray; 1.95 A; A/B/C=774-1069. DR PDBsum; 6VG3; -. DR AlphaFoldDB; Q13308; -. DR SMR; Q13308; -. DR BioGRID; 111721; 183. DR FunCoup; Q13308; 541. DR IntAct; Q13308; 121. DR MINT; Q13308; -. DR STRING; 9606.ENSP00000418754; -. DR GlyConnect; 655; 40 N-Linked glycans (6 sites). DR GlyCosmos; Q13308; 10 sites, 46 glycans. DR GlyGen; Q13308; 13 sites, 74 N-linked glycans (8 sites), 2 O-linked glycans (3 sites). DR iPTMnet; Q13308; -. DR MetOSite; Q13308; -. DR PhosphoSitePlus; Q13308; -. DR SwissPalm; Q13308; -. DR BioMuta; PTK7; -. DR DMDM; 116242736; -. DR jPOST; Q13308; -. DR MassIVE; Q13308; -. DR PaxDb; 9606-ENSP00000418754; -. DR PeptideAtlas; Q13308; -. DR ProteomicsDB; 20212; -. DR ProteomicsDB; 59293; -. [Q13308-1] DR ProteomicsDB; 59294; -. [Q13308-2] DR ProteomicsDB; 59295; -. [Q13308-3] DR ProteomicsDB; 59296; -. [Q13308-4] DR ProteomicsDB; 59297; -. [Q13308-5] DR Pumba; Q13308; -. DR TopDownProteomics; Q13308-3; -. [Q13308-3] DR ABCD; Q13308; 1 sequenced antibody. DR Antibodypedia; 1008; 616 antibodies from 38 providers. DR DNASU; 5754; -. DR Ensembl; ENST00000230418.8; ENSP00000230418.4; ENSG00000112655.17. [Q13308-5] DR Ensembl; ENST00000230419.9; ENSP00000230419.4; ENSG00000112655.17. [Q13308-1] DR Ensembl; ENST00000345201.6; ENSP00000325992.4; ENSG00000112655.17. [Q13308-2] DR Ensembl; ENST00000349241.6; ENSP00000325462.4; ENSG00000112655.17. [Q13308-3] DR Ensembl; ENST00000352931.6; ENSP00000326029.3; ENSG00000112655.17. [Q13308-4] DR Ensembl; ENST00000481273.5; ENSP00000418754.1; ENSG00000112655.17. [Q13308-6] DR GeneID; 5754; -. DR KEGG; hsa:5754; -. DR MANE-Select; ENST00000230419.9; ENSP00000230419.4; NM_002821.5; NP_002812.2. DR UCSC; uc003oub.3; human. [Q13308-1] DR AGR; HGNC:9618; -. DR ClinPGx; PA33961; -. DR CTD; 5754; -. DR DisGeNET; 5754; -. DR GeneCards; PTK7; -. DR HGNC; HGNC:9618; PTK7. DR HPA; ENSG00000112655; Low tissue specificity. DR MIM; 601890; gene. DR OpenTargets; ENSG00000112655; -. DR VEuPathDB; HostDB:ENSG00000112655; -. DR eggNOG; KOG1026; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT00940000157908; -. DR HOGENOM; CLU_012268_0_0_1; -. DR InParanoid; Q13308; -. DR OMA; HKILTSC; -. DR OrthoDB; 2413561at2759; -. DR PAN-GO; Q13308; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13308; -. DR PathwayCommons; Q13308; -. DR SignaLink; Q13308; -. DR SIGNOR; Q13308; -. DR Agora; ENSG00000112655; -. DR BioGRID-ORCS; 5754; 19 hits in 1197 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PTK7; human. DR GeneWiki; PTK7; -. DR GenomeRNAi; 5754; -. DR Pharos; Q13308; Tbio. DR PRO; PR:Q13308; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13308; protein. DR Bgee; ENSG00000112655; Expressed in stromal cell of endometrium and 127 other cell types or tissues. DR ExpressionAtlas; Q13308; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0043025; C:neuronal cell body; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0008046; F:axon guidance receptor activity; IBA:GO_Central. DR GO; GO:0015026; F:coreceptor activity; NAS:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0030036; P:actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0003401; P:axis elongation; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl. DR GO; GO:0060026; P:convergent extension; IEA:Ensembl. DR GO; GO:0060976; P:coronary vasculature development; IEA:Ensembl. DR GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IEA:Ensembl. DR GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IBA:GO_Central. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0001843; P:neural tube closure; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0050808; P:synapse organization; IBA:GO_Central. DR GO; GO:0003281; P:ventricular septum development; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR GO; GO:0042060; P:wound healing; IEA:Ensembl. DR CDD; cd00096; Ig; 2. DR CDD; cd05760; Ig2_PTK7; 1. DR CDD; cd05046; PTK_CCK4; 1. DR FunFam; 1.10.510.10:FF:000200; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000341; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000343; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000377; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000390; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000395; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000402; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000432; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 3.30.200.20:FF:000167; Putative inactive tyrosine-protein kinase 7; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050958; Cell_Adh-Cytoskel_Orgn. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR45080; CONTACTIN 5; 1. DR PANTHER; PTHR45080:SF21; INACTIVE TYROSINE-PROTEIN KINASE 7; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13927; Ig_3; 5. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 7. DR SMART; SM00408; IGc2; 7. DR SUPFAM; SSF48726; Immunoglobulin; 7. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 7. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell adhesion; Cell junction; KW Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transmembrane; Transmembrane helix; Wnt signaling pathway. FT SIGNAL 1..30 FT /evidence="ECO:0000255" FT CHAIN 31..1070 FT /note="Inactive tyrosine-protein kinase 7" FT /id="PRO_0000016748" FT TOPO_DOM 31..704 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 705..725 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 726..1070 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..120 FT /note="Ig-like C2-type 1" FT DOMAIN 128..218 FT /note="Ig-like C2-type 2" FT DOMAIN 225..317 FT /note="Ig-like C2-type 3" FT DOMAIN 309..407 FT /note="Ig-like C2-type 4" FT DOMAIN 412..497 FT /note="Ig-like C2-type 5" FT DOMAIN 503..586 FT /note="Ig-like C2-type 6" FT DOMAIN 578..680 FT /note="Ig-like C2-type 7" FT DOMAIN 796..1066 FT /note="Protein kinase; inactive" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 736..759 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 773..793 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 794..1070 FT /note="Interaction with CTNNB1" FT /evidence="ECO:0000269|PubMed:21132015" FT SITE 621..622 FT /note="Cleavage; by MMP14" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BKG3" FT CARBOHYD 116 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 214 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 268 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 405 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 463 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 567 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 646 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12754519, FT ECO:0000269|PubMed:19159218" FT DISULFID 53..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 150..200 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 246..301 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 343..391 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 433..481 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 524..570 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 613..664 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..26 FT /note="MGAARGSPARPRRLPLLSVLLLPLLG -> MGSFLSGEKRPSAPTVGSAMEK FT KEFPTPPGRVGP (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044775" FT VAR_SEQ 410..540 FT /note="TVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVF FT KNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEA FT TVPCSATGREKPTIKWERAD -> N (in isoform 3)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037181" FT VAR_SEQ 500..539 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12427550, FT ECO:0000303|PubMed:14702039" FT /id="VSP_037182" FT VAR_SEQ 627..682 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037183" FT VAR_SEQ 804..816 FT /note="KSEFGEVFLAKAQ -> RPQAVPEDFQEQG (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037184" FT VAR_SEQ 817..1070 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037185" FT VARIANT 276 FT /note="R -> H (in dbSNP:rs56188167)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041502" FT VARIANT 410 FT /note="T -> S (in dbSNP:rs34021075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041503" FT VARIANT 745 FT /note="E -> D (in dbSNP:rs9472017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041504" FT VARIANT 766 FT /note="E -> Q (in dbSNP:rs56216742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041505" FT VARIANT 777 FT /note="A -> V (in dbSNP:rs34764696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041506" FT VARIANT 783 FT /note="H -> R (in dbSNP:rs55820547)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041507" FT VARIANT 933 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041508" FT VARIANT 1029 FT /note="P -> T (in dbSNP:rs55755163)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041509" FT VARIANT 1038 FT /note="R -> Q (in dbSNP:rs34865794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041510" FT MUTAGEN 622 FT /note="L->D: Prevents proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 641 FT /note="M->R: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 701 FT /note="M->D: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT CONFLICT 87 FT /note="F -> L (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="R -> P (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 93 FT /note="L -> P (in Ref. 7; AAH71557)" FT /evidence="ECO:0000305" FT CONFLICT 147 FT /note="T -> K (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="G -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 495..496 FT /note="RV -> VL (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 515 FT /note="E -> G (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 755 FT /note="Q -> R (in Ref. 4; BAH12463)" FT /evidence="ECO:0000305" FT CONFLICT 799 FT /note="I -> F (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="G -> E (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 969 FT /note="P -> A (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 992 FT /note="F -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT HELIX 793..795 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 796..804 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 806..816 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 823..832 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 837..852 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 861..865 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 867..876 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 879..882 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 883..890 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 904..923 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 933..935 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 936..938 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 944..946 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 952..956 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 961..963 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 966..968 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 970..972 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 975..980 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 985..1000 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 1006..1009 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1012..1020 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1034..1043 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1048..1050 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1054..1062 FT /evidence="ECO:0007829|PDB:6VG3" SQ SEQUENCE 1070 AA; 118392 MW; 304926A1774EB5F4 CRC64; MGAARGSPAR PRRLPLLSVL LLPLLGGTQT AIVFIKQPSS QDALQGRRAL LRCEVEAPGP VHVYWLLDGA PVQDTERRFA QGSSLSFAAV DRLQDSGTFQ CVARDDVTGE EARSANASFN IKWIEAGPVV LKHPASEAEI QPQTQVTLRC HIDGHPRPTY QWFRDGTPLS DGQSNHTVSS KERNLTLRPA GPEHSGLYSC CAHSAFGQAC SSQNFTLSIA DESFARVVLA PQDVVVARYE EAMFHCQFSA QPPPSLQWLF EDETPITNRS RPPHLRRATV FANGSLLLTQ VRPRNAGIYR CIGQGQRGPP IILEATLHLA EIEDMPLFEP RVFTAGSEER VTCLPPKGLP EPSVWWEHAG VRLPTHGRVY QKGHELVLAN IAESDAGVYT CHAANLAGQR RQDVNITVAT VPSWLKKPQD SQLEEGKPGY LDCLTQATPK PTVVWYRNQM LISEDSRFEV FKNGTLRINS VEVYDGTWYR CMSSTPAGSI EAQARVQVLE KLKFTPPPQP QQCMEFDKEA TVPCSATGRE KPTIKWERAD GSSLPEWVTD NAGTLHFARV TRDDAGNYTC IASNGPQGQI RAHVQLTVAV FITFKVEPER TTVYQGHTAL LQCEAQGDPK PLIQWKGKDR ILDPTKLGPR MHIFQNGSLV IHDVAPEDSG RYTCIAGNSC NIKHTEAPLY VVDKPVPEES EGPGSPPPYK MIQTIGLSVG AAVAYIIAVL GLMFYCKKRC KAKRLQKQPE GEEPEMECLN GGPLQNGQPS AEIQEEVALT SLGSGPAATN KRHSTSDKMH FPRSSLQPIT TLGKSEFGEV FLAKAQGLEE GVAETLVLVK SLQSKDEQQQ LDFRRELEMF GKLNHANVVR LLGLCREAEP HYMVLEYVDL GDLKQFLRIS KSKDEKLKSQ PLSTKQKVAL CTQVALGMEH LSNNRFVHKD LAARNCLVSA QRQVKVSALG LSKDVYNSEY YHFRQAWVPL RWMSPEAILE GDFSTKSDVW AFGVLMWEVF THGEMPHGGQ ADDEVLADLQ AGKARLPQPE GCPSKLYRLM QRCWALSPKD RPSFSEIASA LGDSTVDSKP // ID RAF1_HUMAN Reviewed; 648 AA. AC P04049; B0LPH8; B2R5N3; Q15278; Q9UC20; DT 01-NOV-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1986, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:17603483}; DE AltName: Full=Proto-oncogene c-RAF; DE Short=cRaf; DE AltName: Full=Raf-1; GN Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003687; DOI=10.1093/nar/14.2.1009; RA Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A., RA Young A.C., Rapp U.R.; RT "The complete coding sequence of the human raf oncogene and the RT corresponding structure of the c-raf-1 gene."; RL Nucleic Acids Res. 14:1009-1015(1986). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308. RG NIEHS SNPs program; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648. RX PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985; RA Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.; RT "Structure and biological activity of human homologs of the raf/mil RT oncogene."; RL Mol. Cell. Biol. 5:1400-1407(1985). RN [7] RP PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH RP PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296; RP SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [8] RP PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269. RX PubMed=7477354; DOI=10.1038/378307a0; RA Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.; RT "Phosphorylation of Raf by ceramide-activated protein kinase."; RL Nature 378:307-310(1995). RN [9] RP PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=1886707; RA Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.; RT "An alternatively spliced c-mil/raf mRNA is predominantly expressed in RT chicken muscular tissues and conserved among vertebrate species."; RL Oncogene 6:1307-1311(1991). RN [10] RP PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621. RX PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x; RA Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.; RT "Identification of the major phosphorylation sites of the Raf-1 kinase."; RL J. Biol. Chem. 268:17309-17316(1993). RN [11] RP INTERACTION WITH YWHAZ, AND FUNCTION. RX PubMed=9360956; DOI=10.1074/jbc.272.46.28882; RA Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N., RA Moelling K., Aitken A.; RT "14-3-3 is phosphorylated by casein kinase I on residue 233. RT Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction."; RL J. Biol. Chem. 272:28882-28888(1997). RN [12] RP PHOSPHORYLATION. RX PubMed=9823899; DOI=10.1038/24184; RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RT "The protein kinase Pak3 positively regulates Raf-1 activity through RT phosphorylation of serine 338."; RL Nature 396:180-183(1998). RN [13] RP ERRATUM OF PUBMED:9823899. RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RL Nature 406:439-439(2000). RN [14] RP PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND RP INTERACTION WITH PKB/AKT1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43; RP SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND RP PPP2R1B. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [16] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494. RX PubMed=11447113; DOI=10.1093/emboj/20.14.3716; RA Chong H., Lee J., Guan K.L.; RT "Positive and negative regulation of Raf kinase activity and function by RT phosphorylation."; RL EMBO J. 20:3716-3727(2001). RN [17] RP FUNCTION, AND INTERACTION WITH MAP3K5/ASK1. RX PubMed=11427728; DOI=10.1073/pnas.141224398; RA Chen J., Fujii K., Zhang L., Roberts T., Fu H.; RT "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating RT kinase 1 through a MEK-ERK independent mechanism."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A. RX PubMed=11719507; DOI=10.1074/jbc.m106343200; RA Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.; RT "Phosphorylation of the myosin-binding subunit of myosin phosphatase by RT Raf-1 and inhibition of phosphatase activity."; RL J. Biol. Chem. 277:3053-3059(2002). RN [19] RP PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION RP WITH PAK1. RX PubMed=11733498; DOI=10.1074/jbc.m110000200; RA Zang M., Hayne C., Luo Z.; RT "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation RT and activation of Raf-1."; RL J. Biol. Chem. 277:4395-4405(2002). RN [20] RP PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR RP LOCATION. RX PubMed=11756411; DOI=10.1074/jbc.m108733200; RA Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.; RT "Dephosphorylation of Ser-259 regulates Raf-1 membrane association."; RL J. Biol. Chem. 277:7913-7919(2002). RN [21] RP COMPETITION WITH RIN1. RX PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001; RA Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., RA Colicelli J.; RT "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3- RT 3 proteins."; RL Mol. Cell. Biol. 22:916-926(2002). RN [22] RP ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4. RX PubMed=12717443; DOI=10.1038/ncb978; RA Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., RA Kuriyama M., Saito N., Shibuya M., Yoshimura A.; RT "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to RT Raf1."; RL Nat. Cell Biol. 5:427-432(2003). RN [23] RP PHOSPHORYLATION AT SER-259. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [24] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [25] RP FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH RP ADCY2; ADCY5 AND ADCY6. RX PubMed=15385642; DOI=10.1124/mol.66.4.921; RA Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.; RT "Raf kinase activation of adenylyl cyclases: isoform-selective RT regulation."; RL Mol. Pharmacol. 66:921-928(2004). RN [26] RP INTERACTION WITH STK3/MST2, AND FUNCTION. RX PubMed=15618521; DOI=10.1126/science.1103233; RA O'Neill E., Rushworth L., Baccarini M., Kolch W.; RT "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene RT product Raf-1."; RL Science 306:2267-2270(2004). RN [27] RP INTERACTION WITH RCAN1/DSCR1. RX PubMed=15935327; DOI=10.1016/j.abb.2005.05.002; RA Cho Y.J., Abe M., Kim S.Y., Sato Y.; RT "Raf-1 is a binding partner of DSCR1."; RL Arch. Biochem. Biophys. 439:121-128(2005). RN [28] RP REVIEW ON FUNCTION. RX PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024; RA Baccarini M.; RT "Second nature: biological functions of the Raf-1 'kinase'."; RL FEBS Lett. 579:3271-3277(2005). RN [29] RP FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339 RP BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2. RX PubMed=15849194; DOI=10.1074/jbc.m413374200; RA Jin S., Zhuo Y., Guo W., Field J.; RT "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates RT its mitochondrial localization, phosphorylation of BAD, and Bcl-2 RT association."; RL J. Biol. Chem. 280:24698-24705(2005). RN [30] RP PHOSPHORYLATION AT SER-471. RX PubMed=16093354; DOI=10.1091/mbc.e05-02-0090; RA Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z., RA Qin J., Avruch J., Tzivion G.; RT "Identification of Raf-1 S471 as a novel phosphorylation site critical for RT Raf-1 and B-Raf kinase activities and for MEK binding."; RL Mol. Biol. Cell 16:4733-4744(2005). RN [31] RP IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS, RP PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259. RX PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027; RA Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., RA McCormick F.; RT "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit RT of PP1 functions as an M-Ras effector to modulate Raf activity."; RL Mol. Cell 22:217-230(2006). RN [32] RP SUBUNIT. RX PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006; RA Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.; RT "Regulation and role of Raf-1/B-Raf heterodimerization."; RL Mol. Cell. Biol. 26:2262-2272(2006). RN [33] RP FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259; RP SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY RP PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND RP SER-494. RX PubMed=16892053; DOI=10.1038/ncb1465; RA von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.; RT "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5."; RL Nat. Cell Biol. 8:1011-1016(2006). RN [34] RP REVIEW ON REGULATION. RX PubMed=17218791; DOI=10.4161/cc.6.1.3593; RA Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.; RT "Phosphatase and feedback regulation of Raf-1 signaling."; RL Cell Cycle 6:3-7(2007). RN [35] RP FUNCTION. RX PubMed=16924233; DOI=10.1038/sj.onc.1209902; RA Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., RA Nusrat A.; RT "Raf 1 represses expression of the tight junction protein occludin via RT activation of the zinc-finger transcription factor slug."; RL Oncogene 26:1222-1230(2007). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [37] RP ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP. RX PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012; RA Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C., RA Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.; RT "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the RT phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated RT phosphorylation of MEK."; RL Cell. Signal. 20:935-941(2008). RN [38] RP PHOSPHORYLATION AT SER-338 BY PAK5. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP SUBCELLULAR LOCATION. RX PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004; RA Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.; RT "Retinoic acid induces nuclear accumulation of Raf1 during differentiation RT of HL-60 cells."; RL Exp. Cell Res. 315:2241-2248(2009). RN [43] RP ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH RP DGKH. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [45] RP REVIEW. RX PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092; RA Roskoski R. Jr.; RT "RAF protein-serine/threonine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 399:313-317(2010). RN [46] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [47] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [48] RP REVIEW. RX PubMed=21779496; DOI=10.1177/1947601911407323; RA Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., RA von Kriegsheim A., Kolch W.; RT "Raf family kinases: old dogs have learned new tricks."; RL Genes Cancer 2:232-260(2011). RN [49] RP MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1. RX PubMed=20956560; DOI=10.1128/mcb.00648-10; RA Moniz L.S., Stambolic V.; RT "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response RT to UV irradiation."; RL Mol. Cell. Biol. 31:30-42(2011). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [51] RP INTERACTION WITH FAM83B. RX PubMed=22886302; DOI=10.1172/jci60517; RA Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C., RA Scott S.A., Brown H.A., Stark G.R., Jackson M.W.; RT "FAM83B mediates EGFR- and RAS-driven oncogenic transformation."; RL J. Clin. Invest. 122:3197-3210(2012). RN [52] RP INTERACTION WITH GLS. RX PubMed=22538822; DOI=10.1073/pnas.1116573109; RA Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M., RA Suresh V., Schuler H., Low B.C., Sivaraman J.; RT "Structural basis for the allosteric inhibitory mechanism of human kidney- RT type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in RT cancer cell metabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012). RN [53] RP INTERACTION WITH MFHAS1. RX PubMed=23327923; DOI=10.1182/blood-2011-10-385252; RA Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R., RA Hsieh M.M., Tisdale J.F., Rodgers G.P.; RT "MASL1 induces erythroid differentiation in human erythropoietin-dependent RT CD34+ cells through the Raf/MEK/ERK pathway."; RL Blood 121:3216-3227(2013). RN [54] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [55] RP INTERACTION WITH PDE8A. RX PubMed=23509299; DOI=10.1073/pnas.1303004110; RA Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F., RA Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A., RA Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.; RT "Phosphodiesterase-8A binds to and regulates Raf-1 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [57] RP IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; RP AKT; CDK4 AND NR3C1. RX PubMed=29127155; DOI=10.15252/embj.201796700; RA Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., RA Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., RA Bourboulia D., Bratslavsky G., Wong M., Mollapour M.; RT "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding RT of kinase and non-kinase clients."; RL EMBO J. 36:3650-3665(2017). RN [58] RP INTERACTION WITH LZTR1. RX PubMed=30368668; DOI=10.1007/s00439-018-1951-7; RA Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S., RA Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y., RA Fujiwara I., Kure S., Aoki Y.; RT "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and RT identification of LZTR1 binding to RAF1-PPP1CB complexes."; RL Hum. Genet. 138:21-35(2019). RN [59] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [60] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [61] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [62] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131. RX PubMed=7791872; DOI=10.1038/375554a0; RA Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.; RT "The 2.2 A crystal structure of the Ras-binding domain of the RT serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue."; RL Nature 375:554-560(1995). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131. RX PubMed=8756332; DOI=10.1038/nsb0896-723; RA Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.; RT "Ras/Rap effector specificity determined by charge reversal."; RL Nat. Struct. Biol. 3:723-729(1996). RN [65] RP STRUCTURE BY NMR OF 55-132. RX PubMed=7766599; DOI=10.1021/bi00021a001; RA Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E., RA Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.; RT "Solution structure of the Ras-binding domain of c-Raf-1 and identification RT of its Ras interaction surface."; RL Biochemistry 34:6911-6918(1995). RN [66] RP STRUCTURE BY NMR OF 136-187. RX PubMed=8710867; DOI=10.1073/pnas.93.16.8312; RA Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.; RT "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and RT phospholipid binding site."; RL Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996). RN [67] RP VARIANTS NS5 SER-256; LEU-257; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; RP GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY RP ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, CHARACTERIZATION OF VARIANTS RP NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT LPRD2 RP VAL-613, AND CATALYTIC ACTIVITY. RX PubMed=17603483; DOI=10.1038/ng2073; RA Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., RA Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M., RA Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P., RA Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B., RA Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M., RA Gelb B.D.; RT "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with RT hypertrophic cardiomyopathy."; RL Nat. Genet. 39:1007-1012(2007). RN [68] RP VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND RP CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND RP VAL-613. RX PubMed=17603482; DOI=10.1038/ng2078; RA Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., RA Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y., RA Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J., RA Higashinakagawa T., Matsuoka R.; RT "Germline gain-of-function mutations in RAF1 cause Noonan syndrome."; RL Nat. Genet. 39:1013-1017(2007). RN [69] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [70] RP VARIANT NS5 SER-261. RX PubMed=20683980; DOI=10.1002/ajmg.a.33564; RA Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S., RA Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M., RA Riva P.; RT "Noonan syndrome associated with both a new Jnk-activating familial SOS1 RT and a de novo RAF1 mutations."; RL Am. J. Med. Genet. A 152:2176-2184(2010). RN [71] RP INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603; RP ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237; RP ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641. RX PubMed=24777450; DOI=10.1038/ng.2963; RA Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J., RA Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B., RA Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T., RA Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M., RA Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K., RA Gelb B.D.; RT "RAF1 mutations in childhood-onset dilated cardiomyopathy."; RL Nat. Genet. 46:635-639(2014). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory CC link between the membrane-associated Ras GTPases and the MAPK/ERK CC cascade, and this critical regulatory link functions as a switch CC determining cell fate decisions including proliferation, CC differentiation, apoptosis, survival and oncogenic transformation. RAF1 CC activation initiates a mitogen-activated protein kinase (MAPK) cascade CC that comprises a sequential phosphorylation of the dual-specific MAPK CC kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal- CC regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form CC of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates CC BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl CC cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. CC Phosphorylates PPP1R12A resulting in inhibition of the phosphatase CC activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote CC NF-kB activation and inhibit signal transducers involved in motility CC (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and CC angiogenesis (RB1). Can protect cells from apoptosis also by CC translocating to the mitochondria where it binds BCL2 and displaces CC BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and CC migration, and is required for normal wound healing. Plays a role in CC the oncogenic transformation of epithelial cells via repression of the CC TJ protein, occludin (OCLN) by inducing the up-regulation of a CC transcriptional repressor SNAI2/SLUG, which induces down-regulation of CC OCLN. Restricts caspase activation in response to selected stimuli, CC notably Fas stimulation, pathogen-mediated macrophage apoptosis, and CC erythroid differentiation. {ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, CC ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, CC ECO:0000269|PubMed:9360956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Regulation is a highly complex process involving CC membrane recruitment, protein-protein interactions, dimerization, and CC phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the CC membrane, thereby promoting its activation. The inactive conformation CC of RAF1 is maintained by autoinhibitory interactions occurring between CC the N-terminal regulatory and the C-terminal catalytic domains and by CC the binding of a 14-3-3 protein that contacts two phosphorylation CC sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A CC cooperate to release autoinhibition and the subsequent phosphorylation CC of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a CC fully active kinase. Through a negative feedback mechanism involving CC MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296, CC Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive, CC desensitized kinase. The signaling-competent conformation of RAF1 is CC finally re-established by the coordinated action of PIN1, a prolyl CC isomerase that converts pSer and pThr residues from the cis to the CC trans conformation, which is preferentially recognized and CC dephosphorylated by PPP2R1A. Activated by homodimerization and CC heterodimerization (with BRAF). Also regulated through association with CC other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin CC and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates CC MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the CC displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting CC cell membrane localization and phosphorylation of RAF1 at the CC activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras- CC dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1 CC activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873, CC ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}. CC -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this CC heterodimer possesses a highly increased kinase activity compared to CC the respective homodimers or monomers (PubMed:16508002). CC Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins CC (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback CC that promotes the dissociation of the heterodimer (PubMed:16508002). CC Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein CC phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts CC with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the CC interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts CC with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with BRAF, a CC ternary complex inhibited by GNAI1 (By similarity). Probably forms a CC complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, CC PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this CC complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 CC (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits CC its pro-apoptotic activity (PubMed:15618521). Interacts (when CC phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') CC (PubMed:31024343, PubMed:9360956). Interacts with MAP2K1/MEK1 and CC MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N- CC terminus) and this interaction inhibits the proapoptotic function of CC MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain) CC (PubMed:11733498). The phosphorylated form interacts with PIN1 (By CC similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1) CC interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and CC this interaction is enhanced if RAF1 is phosphorylated on residues Ser- CC 338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with CC ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA, CC PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin CC (PubMed:10576742, PubMed:10801873, PubMed:11719507, PubMed:12717443, CC PubMed:15385642, PubMed:15935327, PubMed:19710016). Interacts with CC ROCK2 (By similarity). In its active form, interacts with PRMT5 CC (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins CC from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A; CC the interaction promotes RAF1 activity (PubMed:23509299). Interacts CC with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822). CC Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10 CC and required for ERK1/2-signaling pathway activation in response to UV CC irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345, CC ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443, CC ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, CC ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327, CC ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714, CC ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302, CC ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299, CC ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668, CC ECO:0000269|PubMed:9360956}. CC -!- INTERACTION: CC P04049; P31749: AKT1; NbExp=3; IntAct=EBI-365996, EBI-296087; CC P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613; CC P04049; Q99933: BAG1; NbExp=2; IntAct=EBI-365996, EBI-1030678; CC P04049; O95816: BAG2; NbExp=12; IntAct=EBI-365996, EBI-355275; CC P04049; P15056: BRAF; NbExp=73; IntAct=EBI-365996, EBI-365980; CC P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060; CC P04049; P49368: CCT3; NbExp=8; IntAct=EBI-365996, EBI-356673; CC P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671; CC P04049; Q16543: CDC37; NbExp=20; IntAct=EBI-365996, EBI-295634; CC P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811; CC P04049; P00533: EGFR; NbExp=3; IntAct=EBI-365996, EBI-297353; CC P04049; O15371: EIF3D; NbExp=4; IntAct=EBI-365996, EBI-353818; CC P04049; O95714: HERC2; NbExp=6; IntAct=EBI-365996, EBI-1058922; CC P04049; P01112: HRAS; NbExp=30; IntAct=EBI-365996, EBI-350145; CC P04049; P07900: HSP90AA1; NbExp=15; IntAct=EBI-365996, EBI-296047; CC P04049; P08238: HSP90AB1; NbExp=17; IntAct=EBI-365996, EBI-352572; CC P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921; CC P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415; CC P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427; CC P04049; P05783: KRT18; NbExp=5; IntAct=EBI-365996, EBI-297888; CC P04049; P08727: KRT19; NbExp=2; IntAct=EBI-365996, EBI-742756; CC P04049; Q8IVT5: KSR1; NbExp=5; IntAct=EBI-365996, EBI-486984; CC P04049; Q02750: MAP2K1; NbExp=39; IntAct=EBI-365996, EBI-492564; CC P04049; P36507: MAP2K2; NbExp=7; IntAct=EBI-365996, EBI-1056930; CC P04049; Q15773: MLF2; NbExp=4; IntAct=EBI-365996, EBI-1051875; CC P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441; CC P04049; P01111: NRAS; NbExp=12; IntAct=EBI-365996, EBI-721993; CC P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879; CC P04049; Q13153: PAK1; NbExp=2; IntAct=EBI-365996, EBI-1307; CC P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887; CC P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365; CC P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384; CC P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667; CC P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158; CC P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408; CC P04049; P62136: PPP1CA; NbExp=2; IntAct=EBI-365996, EBI-357253; CC P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311; CC P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156; CC P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996; CC P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414; CC P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274; CC P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912; CC P04049; P31947: SFN; NbExp=9; IntAct=EBI-365996, EBI-476295; CC P04049; Q13485: SMAD4; NbExp=6; IntAct=EBI-365996, EBI-347263; CC P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580; CC P04049; Q9UNE7: STUB1; NbExp=8; IntAct=EBI-365996, EBI-357085; CC P04049; Q3ZCQ8: TIMM50; NbExp=7; IntAct=EBI-365996, EBI-355175; CC P04049; P31946: YWHAB; NbExp=39; IntAct=EBI-365996, EBI-359815; CC P04049; P62258: YWHAE; NbExp=24; IntAct=EBI-365996, EBI-356498; CC P04049; P61981: YWHAG; NbExp=25; IntAct=EBI-365996, EBI-359832; CC P04049; Q04917: YWHAH; NbExp=27; IntAct=EBI-365996, EBI-306940; CC P04049; P27348: YWHAQ; NbExp=25; IntAct=EBI-365996, EBI-359854; CC P04049; P63104: YWHAZ; NbExp=35; IntAct=EBI-365996, EBI-347088; CC P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267; CC P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911; CC P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291; CC P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993; CC P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711; CC P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus. CC Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and CC membranes. Phosphorylation at Ser-259 impairs its membrane CC accumulation. Recruited to the cell membrane by the active Ras protein. CC Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Retinoic acid-induced Ser-621 CC phosphorylated form of RAF1 is predominantly localized at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=6C; CC IsoId=P04049-1; Sequence=Displayed; CC Name=2; Synonyms=1A; CC IsoId=P04049-2; Sequence=VSP_034649; CC -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than CC isoform 2. {ECO:0000269|PubMed:1886707}. CC -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 CC results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, CC Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. CC Phosphorylation at Ser-259 induces the interaction with YWHAZ and CC inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2- CC MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and CC the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or CC PPP1CC); this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at CC Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Phosphorylation at Ser-621 in response to CC growth factor treatment stabilizes the protein, possibly by preventing CC proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, CC Ser-338 and Ser-621 are somehow linked to the methylation potential of CC cells. Treatment of cells with HGF in the presence of the methylation CC inhibitor 5'-methylthioadenosine (MTA) results in increased CC phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at CC Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C CC results in an activity decrease. {ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113, CC ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614, CC ECO:0000269|PubMed:9823899}. CC -!- PTM: Methylated at Arg-563 in response to EGF treatment. This CC modification leads to destabilization of the protein, possibly through CC proteasomal degradation. {ECO:0000269|PubMed:21917714}. CC -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:17603482, CC ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1NN (CMD1NN) [MIM:615916]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42032/RAF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03484; CAA27204.1; -; mRNA. DR EMBL; AY271661; AAP03432.1; -; Genomic_DNA. DR EMBL; AK312248; BAG35180.1; -; mRNA. DR EMBL; EU332868; ABY87557.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64134.1; -; Genomic_DNA. DR EMBL; BC018119; AAH18119.1; -; mRNA. DR EMBL; L00212; AAA60247.1; -; Genomic_DNA. DR EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2612.1; -. [P04049-1] DR CCDS; CCDS87047.1; -. [P04049-2] DR PIR; A00637; TVHUF6. DR PIR; S60341; S60341. DR RefSeq; NP_001341618.1; NM_001354689.3. [P04049-2] DR RefSeq; NP_001341619.1; NM_001354690.3. [P04049-1] DR RefSeq; NP_002871.1; NM_002880.4. [P04049-1] DR RefSeq; XP_011532276.1; XM_011533974.3. [P04049-1] DR RefSeq; XP_047304605.1; XM_047448649.1. [P04049-1] DR RefSeq; XP_047304606.1; XM_047448650.1. [P04049-1] DR RefSeq; XP_054203389.1; XM_054347414.1. [P04049-1] DR RefSeq; XP_054203390.1; XM_054347415.1. [P04049-1] DR RefSeq; XP_054203391.1; XM_054347416.1. [P04049-1] DR PDB; 1C1Y; X-ray; 1.90 A; B=55-131. DR PDB; 1FAQ; NMR; -; A=136-187. DR PDB; 1FAR; NMR; -; A=136-187. DR PDB; 1GUA; X-ray; 2.00 A; B=51-131. DR PDB; 1RFA; NMR; -; A=55-132. DR PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264. DR PDB; 3IQJ; X-ray; 1.15 A; P=255-264. DR PDB; 3IQU; X-ray; 1.05 A; P=255-260. DR PDB; 3IQV; X-ray; 1.20 A; P=255-260. DR PDB; 3KUC; X-ray; 1.92 A; B=51-131. DR PDB; 3KUD; X-ray; 2.15 A; B=51-131. DR PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264. DR PDB; 3O8I; X-ray; 2.00 A; B=255-264. DR PDB; 3OMV; X-ray; 4.00 A; A/B=323-618. DR PDB; 4FJ3; X-ray; 1.95 A; P=229-264. DR PDB; 4G0N; X-ray; 2.45 A; B=54-131. DR PDB; 4G3X; X-ray; 3.25 A; B=55-131. DR PDB; 4IEA; X-ray; 1.70 A; P=618-625. DR PDB; 4IHL; X-ray; 2.20 A; P=229-264. DR PDB; 6NTC; X-ray; 2.90 A; B=55-131. DR PDB; 6NTD; X-ray; 3.15 A; B=55-131. DR PDB; 6PTS; NMR; -; D=56-187. DR PDB; 6PTW; NMR; -; D=56-187. DR PDB; 6VJJ; X-ray; 1.40 A; B=52-131. DR PDB; 6XGU; X-ray; 2.70 A; B=52-188. DR PDB; 6XGV; X-ray; 2.11 A; B=52-188. DR PDB; 6XHA; X-ray; 2.87 A; B=52-188. DR PDB; 6XHB; X-ray; 2.50 A; B=52-188. DR PDB; 6XI7; X-ray; 1.95 A; B=52-188. DR PDB; 7JHP; X-ray; 2.77 A; C=55-187. DR PDB; 7Z37; EM; 3.67 A; CP1=1-648. DR PDB; 7Z38; EM; 3.16 A; C=1-648. DR PDB; 8A68; X-ray; 1.60 A; B=255-263. DR PDB; 8A6F; X-ray; 1.60 A; P=255-264. DR PDB; 8A6H; X-ray; 1.60 A; P=255-264. DR PDB; 8ATR; X-ray; 1.70 A; P=255-263. DR PDB; 8ATS; X-ray; 1.40 A; P=255-263. DR PDB; 8AV0; X-ray; 1.50 A; P=256-264. DR PDB; 8CHF; EM; 4.25 A; A/B=1-648. DR PDB; 8CPD; EM; 3.46 A; A/B=1-648. DR PDB; 8EPW; X-ray; 2.00 A; B=52-131. DR PDB; 8GAE; EM; 3.30 A; D=404-610. DR PDB; 8GFT; EM; 3.80 A; D=336-618. DR PDB; 8JOF; NMR; -; A=51-131. DR PDB; 8JOG; NMR; -; A=51-131. DR PDB; 8Q5C; X-ray; 2.00 A; P=255-264. DR PDB; 8S42; X-ray; 1.70 A; P=255-263. DR PDB; 8T74; X-ray; 1.65 A; B=52-131. DR PDB; 8T75; X-ray; 2.65 A; B/D/F/H=52-188. DR PDB; 8U1L; EM; 3.70 A; C=2-648. DR PDB; 9AXA; EM; 4.36 A; A/C=306-648. DR PDB; 9AXC; EM; 4.16 A; A/C=306-648. DR PDB; 9AY7; X-ray; 2.41 A; A=337-615. DR PDB; 9AYA; X-ray; 2.59 A; A/C=337-615. DR PDB; 9EW1; X-ray; 1.40 A; P=255-263. DR PDB; 9EW3; X-ray; 1.40 A; P=255-263. DR PDB; 9EW4; X-ray; 1.60 A; P=255-263. DR PDB; 9EW5; X-ray; 1.50 A; C/F=255-265. DR PDB; 9EW7; X-ray; 1.80 A; P=255-264. DR PDBsum; 1C1Y; -. DR PDBsum; 1FAQ; -. DR PDBsum; 1FAR; -. DR PDBsum; 1GUA; -. DR PDBsum; 1RFA; -. DR PDBsum; 3CU8; -. DR PDBsum; 3IQJ; -. DR PDBsum; 3IQU; -. DR PDBsum; 3IQV; -. DR PDBsum; 3KUC; -. DR PDBsum; 3KUD; -. DR PDBsum; 3NKX; -. DR PDBsum; 3O8I; -. DR PDBsum; 3OMV; -. DR PDBsum; 4FJ3; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4IEA; -. DR PDBsum; 4IHL; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6XI7; -. DR PDBsum; 7JHP; -. DR PDBsum; 7Z37; -. DR PDBsum; 7Z38; -. DR PDBsum; 8A68; -. DR PDBsum; 8A6F; -. DR PDBsum; 8A6H; -. DR PDBsum; 8ATR; -. DR PDBsum; 8ATS; -. DR PDBsum; 8AV0; -. DR PDBsum; 8CHF; -. DR PDBsum; 8CPD; -. DR PDBsum; 8EPW; -. DR PDBsum; 8GAE; -. DR PDBsum; 8GFT; -. DR PDBsum; 8JOF; -. DR PDBsum; 8JOG; -. DR PDBsum; 8Q5C; -. DR PDBsum; 8S42; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8U1L; -. DR PDBsum; 9AXA; -. DR PDBsum; 9AXC; -. DR PDBsum; 9AY7; -. DR PDBsum; 9AYA; -. DR PDBsum; 9EW1; -. DR PDBsum; 9EW3; -. DR PDBsum; 9EW4; -. DR PDBsum; 9EW5; -. DR PDBsum; 9EW7; -. DR AlphaFoldDB; P04049; -. DR BMRB; P04049; -. DR EMDB; EMD-14472; -. DR EMDB; EMD-14473; -. DR EMDB; EMD-16660; -. DR EMDB; EMD-16779; -. DR EMDB; EMD-29895; -. DR EMDB; EMD-29949; -. DR EMDB; EMD-29957; -. DR EMDB; EMD-29973; -. DR EMDB; EMD-29976; -. DR EMDB; EMD-29984; -. DR EMDB; EMD-41816; -. DR EMDB; EMD-43931; -. DR EMDB; EMD-43932; -. DR SMR; P04049; -. DR BioGRID; 111831; 1867. DR CORUM; P04049; -. DR DIP; DIP-1048N; -. DR FunCoup; P04049; 4763. DR IntAct; P04049; 435. DR MINT; P04049; -. DR STRING; 9606.ENSP00000401888; -. DR BindingDB; P04049; -. DR ChEMBL; CHEMBL1906; -. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB17568; Belvarafenib. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05268; iCo-007. DR DrugBank; DB04973; LErafAON. DR DrugBank; DB18865; Naporafenib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB12094; Semapimod. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P04049; -. DR GuidetoPHARMACOLOGY; 2184; -. DR MoonDB; P04049; Predicted. DR GlyCosmos; P04049; 1 site, 1 glycan. DR GlyGen; P04049; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P04049; -. DR PhosphoSitePlus; P04049; -. DR SwissPalm; P04049; -. DR BioMuta; RAF1; -. DR DMDM; 125651; -. DR CPTAC; CPTAC-1335; -. DR CPTAC; CPTAC-1336; -. DR CPTAC; CPTAC-1546; -. DR CPTAC; CPTAC-1762; -. DR CPTAC; CPTAC-5778; -. DR CPTAC; CPTAC-5779; -. DR CPTAC; CPTAC-5780; -. DR CPTAC; CPTAC-5828; -. DR CPTAC; CPTAC-5829; -. DR CPTAC; non-CPTAC-5431; -. DR CPTAC; non-CPTAC-5432; -. DR CPTAC; non-CPTAC-5433; -. DR CPTAC; non-CPTAC-5569; -. DR CPTAC; non-CPTAC-5570; -. DR CPTAC; non-CPTAC-5734; -. DR jPOST; P04049; -. DR MassIVE; P04049; -. DR PaxDb; 9606-ENSP00000251849; -. DR PeptideAtlas; P04049; -. DR ProteomicsDB; 51637; -. [P04049-1] DR ProteomicsDB; 51638; -. [P04049-2] DR Pumba; P04049; -. DR ABCD; P04049; 5 sequenced antibodies. DR Antibodypedia; 1131; 3127 antibodies from 52 providers. DR CPTC; P04049; 8 antibodies. DR DNASU; 5894; -. DR Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.15. [P04049-2] DR Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.15. [P04049-1] DR GeneID; 5894; -. DR KEGG; hsa:5894; -. DR MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1. DR UCSC; uc003bxf.5; human. [P04049-1] DR AGR; HGNC:9829; -. DR CIViC; 5894; 7 evidence items across 4 molecular profiles. DR ClinPGx; PA34183; -. DR CTD; 5894; -. DR DisGeNET; 5894; -. DR GeneCards; RAF1; -. DR GeneReviews; RAF1; -. DR HGNC; HGNC:9829; RAF1. DR HPA; ENSG00000132155; Low tissue specificity. DR MalaCards; RAF1; -. DR MIM; 164760; gene. DR MIM; 611553; phenotype. DR MIM; 611554; phenotype. DR MIM; 615916; phenotype. DR OpenTargets; ENSG00000132155; -. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000132155; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156084; -. DR InParanoid; P04049; -. DR OMA; SAYKRHA; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P04049; 5 GO annotations based on evolutionary models. DR PhylomeDB; P04049; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P04049; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR Reactome; R-HSA-392517; Rap1 signalling. DR Reactome; R-HSA-430116; GP1b-IX-V activation signalling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR Reactome; R-HSA-9732724; IFNG signaling activates MAPKs. DR SignaLink; P04049; -. DR SIGNOR; P04049; -. DR Agora; ENSG00000132155; -. DR BioGRID-ORCS; 5894; 99 hits in 1206 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; RAF1; human. DR EvolutionaryTrace; P04049; -. DR GeneWiki; C-Raf; -. DR GenomeRNAi; 5894; -. DR Pharos; P04049; Tclin. DR PRO; PR:P04049; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P04049; protein. DR Bgee; ENSG00000132155; Expressed in gastrocnemius and 214 other cell types or tissues. DR ExpressionAtlas; P04049; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IPI:MGI. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031143; C:pseudopodium; IEA:Ensembl. DR GO; GO:0010856; F:adenylate cyclase activator activity; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; EXP:Reactome. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; TAS:GO_Central. DR GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042060; P:wound healing; TAS:UniProtKB. DR CDD; cd20870; C1_A_C-Raf; 1. DR CDD; cd17135; RBD_CRAF; 1. DR CDD; cd14149; STKc_C-Raf; 1. DR DisProt; DP00171; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00292; -. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329:SF22; RAF PROTO-ONCOGENE SERINE_THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Kinase; Membrane; Metal-binding; Methylation; KW Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..648 FT /note="RAF proto-oncogene serine/threonine-protein kinase" FT /id="PRO_0000086596" FT DOMAIN 56..131 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 349..609 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..184 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 220..334 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 331..349 FT /note="Interaction with PEBP1/RKIP" FT COMPBIAS 239..271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 275..285 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 286..301 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 468 FT /note="Proton acceptor" FT BINDING 139 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 152 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 155 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 165 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 173 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 184 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 355..363 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 375 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 29 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000250|UniProtKB:Q99N57" FT MOD_RES 43 FT /note="Phosphoserine; by PKA and MAPK1" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 259 FT /note="Phosphoserine; by PKA, PKC and PKB/AKT1" FT /evidence="ECO:0000269|PubMed:10576742, FT ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614" FT MOD_RES 268 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 269 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000269|PubMed:7477354" FT MOD_RES 289 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332" FT MOD_RES 296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5" FT /evidence="ECO:0000269|PubMed:11733498, FT ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, FT ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714" FT MOD_RES 339 FT /note="Phosphoserine; by PAK1, PAK2 and PAK3" FT /evidence="ECO:0000269|PubMed:15849194" FT MOD_RES 340 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 341 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16093354" FT MOD_RES 491 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 499 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 563 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 621 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:10801873, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714, FT ECO:0000269|PubMed:8349614" FT MOD_RES 642 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 278 FT /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_034649" FT VARIANT 237 FT /note="A -> T (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777588)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071844" FT VARIANT 256 FT /note="R -> S (in NS5; dbSNP:rs397516826)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037807" FT VARIANT 257 FT /note="S -> L (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced ERK activation than wild-type; FT dbSNP:rs80338796)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037808" FT VARIANT 259 FT /note="S -> A (in an ovarian serous carcinoma sample; FT somatic mutation; increased ERK activation; FT dbSNP:rs3730271)" FT /evidence="ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041037" FT VARIANT 259 FT /note="S -> F (in NS5; dbSNP:rs397516827)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037809" FT VARIANT 260 FT /note="T -> I (in hypertrophic cardiomyopathy; uncertain FT significance; dbSNP:rs869025501)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037810" FT VARIANT 260 FT /note="T -> R (in NS5)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037811" FT VARIANT 261 FT /note="P -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037812" FT VARIANT 261 FT /note="P -> L (in NS5; shows greater kinase activity and FT enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516828)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037813" FT VARIANT 261 FT /note="P -> S (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980" FT /id="VAR_037814" FT VARIANT 263 FT /note="V -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516830)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037815" FT VARIANT 308 FT /note="P -> L (in dbSNP:rs5746220)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3" FT /id="VAR_018840" FT VARIANT 310 FT /note="T -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs778155315)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071845" FT VARIANT 332 FT /note="P -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1057403865)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071846" FT VARIANT 335 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041038" FT VARIANT 486 FT /note="D -> G (in NS5; dbSNP:rs397516815)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037816" FT VARIANT 486 FT /note="D -> N (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338798)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037817" FT VARIANT 491 FT /note="T -> I (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037818" FT VARIANT 491 FT /note="T -> R (in NS5; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037819" FT VARIANT 603 FT /note="L -> P (in CMD1NN; shows impaired kinase activity FT and reduced MAPK3 activation with this mutation; FT dbSNP:rs587777586)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071847" FT VARIANT 612 FT /note="S -> T (in NS5; dbSNP:rs1448392469)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037820" FT VARIANT 613 FT /note="L -> V (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced MAPK1 activation than wild- FT type; dbSNP:rs80338797)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037821" FT VARIANT 626 FT /note="H -> R (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1553609795)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071848" FT VARIANT 641 FT /note="T -> M (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777587)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071849" FT MUTAGEN 338..339 FT /note="SS->AA: Reduced kinase activity; when associated FT with 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 338..339 FT /note="SS->DE: Non-inhibited by PPP5C. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 340..341 FT /note="YY->DD: Constitutively active and highly FT phosphorylated on S-338, inhibited by PPP5C. Reduced kinase FT activity; when associated with 338-A-A-339. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 338-D-E-339." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 375 FT /note="K->W: Catalytically inactive." FT /evidence="ECO:0000269|PubMed:20956560" FT MUTAGEN 491 FT /note="T->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-494." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 494 FT /note="S->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-491." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 563 FT /note="R->K: Loss of methylation. Increased stability and FT catalytic activity in response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 240 FT /note="F -> L (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT CONFLICT 542 FT /note="M -> I (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:6VJJ" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:8T74" FT STRAND 67..71 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 78..88 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 96..100 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:8T74" FT HELIX 118..121 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:6PTW" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 153..155 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:7JHP" FT HELIX 174..179 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 182..185 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 350..353 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 363..376 FT /evidence="ECO:0007829|PDB:8CPD" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 418..422 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 434..437 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 442..461 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 478..480 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 481..484 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 514..518 FT /evidence="ECO:0007829|PDB:7Z38" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 527..542 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 547..550 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 554..563 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 593..595 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 612..614 FT /evidence="ECO:0007829|PDB:7Z38" SQ SEQUENCE 648 AA; 73052 MW; EF821B5349711BC3 CRC64; MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF // ID RB_HUMAN Reviewed; 928 AA. AC P06400; A8K5E3; P78499; Q5VW46; Q8IZL4; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1990, sequence version 2. DT 28-JAN-2026, entry version 286. DE RecName: Full=Retinoblastoma-associated protein; DE AltName: Full=p105-Rb; DE AltName: Full=p110-RB1 {ECO:0000303|PubMed:8336704}; DE AltName: Full=pRb; DE Short=Rb; DE AltName: Full=pp110; GN Name=RB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3657987; DOI=10.1038/329642a0; RA Lee W.-H., Shew J.-Y., Hong F.D., Sery T.W., Donoso L.A., Young L.-J.S., RA Bookstein R., Lee E.Y.-H.P.; RT "The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein RT associated with DNA binding activity."; RL Nature 329:642-645(1987). RN [2] RP SEQUENCE REVISION. RX PubMed=3823889; DOI=10.1126/science.3823889; RA Lee W.-H., Bookstein R., Hong F.D., Young L.-J., Shew J.-Y., Lee E.Y.-H.P.; RT "Human retinoblastoma susceptibility gene: cloning, identification, and RT sequence."; RL Science 235:1394-1399(1987). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3480530; DOI=10.1073/pnas.84.24.9059; RA Friend S.H., Horowitz J.M., Gerber M.R., Wang X.-F., Bogenmann E., Li F.P., RA Weinberg R.A.; RT "Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: RT organization of the sequence and its encoded protein."; RL Proc. Natl. Acad. Sci. U.S.A. 84:9059-9063(1987). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2701949; DOI=10.1016/0378-1119(89)90256-4; RA McGee T.L., Yandell D.W., Dryja T.P.; RT "Structure and partial genomic sequence of the human retinoblastoma RT susceptibility gene."; RL Gene 80:119-128(1989). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Carcinoma; RX PubMed=1352398; RA Hogg A., Onadim Z., Baird P.N., Cowell J.K.; RT "Detection of heterozygous mutations in the RB1 gene in retinoblastoma RT patients using single-strand conformation polymorphism analysis and RT polymerase chain reaction sequencing."; RL Oncogene 7:1445-1451(1992). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7902321; DOI=10.1006/geno.1993.1368; RA Toguchida J., McGee T.L., Paterson J.C., Eagle J.R., Tucker S., RA Yandell D.W., Dryja T.P.; RT "Complete genomic sequence of the human retinoblastoma susceptibility RT gene."; RL Genomics 17:535-543(1993). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-436 AND GLY-525. RG NIEHS SNPs program; RL Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cervix, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45. RX PubMed=2717184; RA T'Ang A., Wu K.J., Hashimoto T., Liu W.Y., Takahashi R., Shi X.H., RA Mihara K., Zhang F.H., Chen Y.Y., Du C., Qian J., Lin Y.G., Murphree A.L., RA Qiu W.R., Thompson T., Benedict W.F., Fung Y.K.T.; RT "Genomic organization of the human retinoblastoma gene."; RL Oncogene 4:401-407(1989). RN [13] RP PROTEIN SEQUENCE OF 47-65, AND INVOLVEMENT IN RETINOBLASTOMA. RX PubMed=7881418; DOI=10.1093/hmg/3.12.2187; RA Lohmann D.R., Brandt B., Hopping W., Passarge E., Horsthemke B.; RT "Spectrum of small length germline mutations in the RB1 gene."; RL Hum. Mol. Genet. 3:2187-2193(1994). RN [14] RP INTERACTION WITH SV40 LARGE T ANTIGEN AND HPV E7 PROTEIN (MICROBIAL RP INFECTION). RX PubMed=1316611; DOI=10.1073/pnas.89.10.4549; RA Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., RA Nevins J.R.; RT "Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 RT protein share the capacity to disrupt the interaction between transcription RT factor E2F and the retinoblastoma gene product."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4549-4553(1992). RN [15] RP INTERACTION WITH E2F1. RX PubMed=8336704; DOI=10.1128/mcb.13.8.4588-4599.1993; RA Zacksenhaus E., Bremner R., Phillips R.A., Gallie B.L.; RT "A bipartite nuclear localization signal in the retinoblastoma gene product RT and its importance for biological activity."; RL Mol. Cell. Biol. 13:4588-4599(1993). RN [16] RP PHOSPHORYLATION BY CDK6. RX PubMed=8114739; DOI=10.1128/mcb.14.3.2077-2086.1994; RA Meyerson M., Harlow E.; RT "Identification of G1 kinase activity for cdk6, a novel cyclin D partner."; RL Mol. Cell. Biol. 14:2077-2086(1994). RN [17] RP INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION). RX PubMed=2839300; DOI=10.1016/0092-8674(88)90559-4; RA Decaprio J.A., Ludlow J.W., Figge J., Shew J.-Y., Huang C.-M., Lee W.-H., RA Marsilio E., Paucha E., Livingston D.M.; RT "SV40 large tumor antigen forms a specific complex with the product of the RT retinoblastoma susceptibility gene."; RL Cell 54:275-283(1988). RN [18] RP INVOLVEMENT IN RETINOBLASTOMA. RX PubMed=3413073; DOI=10.1073/pnas.85.16.6017; RA Lee E.Y.-H.P., Bookstein R., Young L.-J., Lin C.-J., Rosenfeld M.G., RA Lee W.-H.; RT "Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma RT cell line Y79."; RL Proc. Natl. Acad. Sci. U.S.A. 85:6017-6021(1988). RN [19] RP PHOSPHORYLATION AT SER-249; THR-252; THR-373; SER-807 AND SER-811. RX PubMed=1756735; DOI=10.1002/j.1460-2075.1991.tb05006.x; RA Lees J.A., Buchkovich K.J., Marshak D.R., Anderson C.W., Harlow E.; RT "The retinoblastoma protein is phosphorylated on multiple sites by human RT cdc2."; RL EMBO J. 10:4279-4290(1991). RN [20] RP INTERACTION WITH KDM5A AND ARID4A. RX PubMed=8414517; RA Fattaey A.R., Helin K., Dembski M.S., Dyson N., Harlow E., Vuocolo G.A., RA Hanobik M.G., Haskell K.M., Oliff A., Defeo-Jones D., Jones R.E.; RT "Characterization of the retinoblastoma binding proteins RBP1 and RBP2."; RL Oncogene 8:3149-3156(1993). RN [21] RP INTERACTION WITH THOC1. RX PubMed=7525595; DOI=10.1083/jcb.127.3.609; RA Durfee T., Mancini M.A., Jones D., Elledge S.J., Lee W.H.; RT "The amino-terminal region of the retinoblastoma gene product binds a novel RT nuclear matrix protein that co-localizes to centers for RNA processing."; RL J. Cell Biol. 127:609-622(1994). RN [22] RP INTERACTION WITH KDM5A. RX PubMed=7935440; DOI=10.1128/mcb.14.11.7256-7264.1994; RA Kim Y.W., Otterson G.A., Kratzke R.A., Coxon A.B., Kaye F.J.; RT "Differential specificity for binding of retinoblastoma binding protein 2 RT to RB, p107, and TATA-binding protein."; RL Mol. Cell. Biol. 14:7256-7264(1994). RN [23] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=8892909; DOI=10.1128/jvi.70.11.7867-7877.1996; RA Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.S.; RT "The human cytomegalovirus IE1-72 protein interacts with the cellular p107 RT protein and relieves p107-mediated transcriptional repression of an E2F- RT responsive promoter."; RL J. Virol. 70:7867-7877(1996). RN [24] RP INTERACTION WITH ARID3B. RX PubMed=10446990; RA Numata S., Claudio P.P., Dean C., Giordano A., Croce C.M.; RT "Bdp, a new member of a family of DNA-binding proteins, associates with the RT retinoblastoma gene product."; RL Cancer Res. 59:3741-3747(1999). RN [25] RP FUNCTION, PHOSPHORYLATION AT SER-567 BY CDK2, AND PHOSPHORYLATION BY CDK4 RP AND CDK6. RX PubMed=10499802; DOI=10.1016/s0092-8674(00)81519-6; RA Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C.; RT "Cdk phosphorylation triggers sequential intramolecular interactions that RT progressively block Rb functions as cells move through G1."; RL Cell 98:859-869(1999). RN [26] RP INTERACTION WITH NDC80. RX PubMed=10409732; DOI=10.1128/mcb.19.8.5417; RA Zheng L., Chen Y., Lee W.-H.; RT "Hec1p, an evolutionarily conserved coiled-coil protein, modulates RT chromosome segregation through interaction with SMC proteins."; RL Mol. Cell. Biol. 19:5417-5428(1999). RN [27] RP INTERACTION WITH NDC80. RX PubMed=10779342; DOI=10.1128/mcb.20.10.3529-3537.2000; RA Zheng L., Chen Y., Riley D.J., Chen P.-L., Lee W.-H.; RT "Retinoblastoma protein enhances the fidelity of chromosome segregation RT mediated by hsHec1p."; RL Mol. Cell. Biol. 20:3529-3537(2000). RN [28] RP INTERACTION WITH TAF1. RX PubMed=9858607; DOI=10.1128/mcb.19.1.846; RA Siegert J.L., Robbins P.D.; RT "Rb inhibits the intrinsic kinase activity of TATA-binding protein- RT associated factor TAFII250."; RL Mol. Cell. Biol. 19:846-854(1999). RN [29] RP INTERACTION WITH PAX5. RX PubMed=10197586; RA Eberhard D., Busslinger M.; RT "The partial homeodomain of the transcription factor Pax-5 (BSAP) is an RT interaction motif for the retinoblastoma and TATA-binding proteins."; RL Cancer Res. 59:1716-1724(1999). RN [30] RP INTERACTION WITH E4F1. RX PubMed=10869426; DOI=10.1073/pnas.130198397; RA Fajas L., Paul C., Zugasti O., Le Cam L., Polanowska J., Fabbrizio E., RA Medema R., Vignais M.-L., Sardet C.; RT "pRB binds to and modulates the transrepressing activity of the E1A- RT regulated transcription factor p120E4F."; RL Proc. Natl. Acad. Sci. U.S.A. 97:7738-7743(2000). RN [31] RP INTERACTION WITH EID1. RX PubMed=11223246; DOI=10.1016/s0378-1119(00)00585-0; RA Wen H., Ao S.; RT "Identification and characterization of a novel human cDNA encoding a 21 RT kDa pRb-associated protein."; RL Gene 263:85-92(2001). RN [32] RP INTERACTION WITH DNMT1. RX PubMed=10888886; DOI=10.1038/77124; RA Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., RA Wolffe A.P.; RT "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription RT from E2F-responsive promoters."; RL Nat. Genet. 25:338-342(2000). RN [33] RP INTERACTION WITH SUV39H1. RX PubMed=11484059; DOI=10.1038/35087620; RA Nielsen S.J., Schneider R., Bauer U.-M., Bannister A.J., Morrison A., RA O'Carroll D., Firestein R., Cleary M.L., Jenuwein T., Herrera R.E., RA Kouzarides T.; RT "Rb targets histone H3 methylation and HP1 to promoters."; RL Nature 412:561-565(2001). RN [34] RP INTERACTION WITH USP4. RX PubMed=11571652; DOI=10.1038/sj.onc.1204824; RA DeSalle L.M., Latres E., Lin D., Graner E., Montagnoli A., Baker R.T., RA Pagano M., Loda M.; RT "The de-ubiquitinating enzyme Unp interacts with the retinoblastoma RT protein."; RL Oncogene 20:5538-5542(2001). RN [35] RP INTERACTION WITH AATF. RX PubMed=12450794; DOI=10.1016/s1535-6108(02)00182-4; RA Bruno T., De Angelis R., De Nicola F., Barbato C., Di Padova M., Corbi N., RA Libri V., Benassi B., Mattei E., Chersi A., Soddu S., Floridi A., RA Passananti C., Fanciulli M.; RT "Che-1 affects cell growth by interfering with the recruitment of HDAC1 by RT Rb."; RL Cancer Cell 2:387-399(2002). RN [36] RP INTERACTION WITH TMPO-ALPHA AND LMNA. RX PubMed=12475961; DOI=10.1091/mbc.e02-07-0450; RA Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J.; RT "Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of RT retinoblastoma protein."; RL Mol. Biol. Cell 13:4401-4413(2002). RN [37] RP INTERACTION WITH SNW1. RX PubMed=12466551; DOI=10.1093/nar/gkf658; RA Prathapam T., Kuhne C., Banks L.; RT "Skip interacts with the retinoblastoma tumor suppressor and inhibits its RT transcriptional repression activity."; RL Nucleic Acids Res. 30:5261-5268(2002). RN [38] RP INTERACTION WITH P-TEFB COMPLEX. RX PubMed=12037672; DOI=10.1038/sj.onc.1205511; RA Simone C., Bagella L., Bellan C., Giordano A.; RT "Physical interaction between pRb and cdk9/cyclinT2 complex."; RL Oncogene 21:4158-4165(2002). RN [39] RP INTERACTION WITH PELP1. RX PubMed=12682072; DOI=10.1074/jbc.m212822200; RA Balasenthil S., Vadlamudi R.K.; RT "Functional interactions between the estrogen receptor coactivator RT PELP1/MNAR and retinoblastoma protein."; RL J. Biol. Chem. 278:22119-22127(2003). RN [40] RP INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL82 (MICROBIAL INFECTION). RX PubMed=12626766; DOI=10.1073/pnas.0538058100; RA Kalejta R.F., Shenk T.; RT "Proteasome-dependent, ubiquitin-independent degradation of the Rb family RT of tumor suppressors by the human cytomegalovirus pp71 protein."; RL Proc. Natl. Acad. Sci. U.S.A. 100:3263-3268(2003). RN [41] RP FUNCTION IN G0-G1 TRANSITION, AND PHOSPHORYLATION AT SER-807 AND SER-811 BY RP CDK3. RX PubMed=15084261; DOI=10.1016/s0092-8674(04)00300-9; RA Ren S., Rollins B.J.; RT "Cyclin C/cdk3 promotes Rb-dependent G0 exit."; RL Cell 117:239-251(2004). RN [42] RP INTERACTION WITH LIN9. RX PubMed=15538385; DOI=10.1038/sj.emboj.7600470; RA Gagrica S., Hauser S., Kolfschoten I., Osterloh L., Agami R., Gaubatz S.; RT "Inhibition of oncogenic transformation by mammalian Lin-9, a pRB- RT associated protein."; RL EMBO J. 23:4627-4638(2004). RN [43] RP INTERACTION WITH CEBPA. RX PubMed=15107404; DOI=10.1101/gad.1183304; RA Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.; RT "Liver tumors escape negative control of proliferation via PI3K/Akt- RT mediated block of C/EBP alpha growth inhibitory activity."; RL Genes Dev. 18:912-925(2004). RN [44] RP INTERACTION WITH LIMD1. RX PubMed=15542589; DOI=10.1073/pnas.0407123101; RA Sharp T.V., Munoz F., Bourboulia D., Presneau N., Darai E., Wang H.-W., RA Cannon M., Butcher D.N., Nicholson A.G., Klein G., Imreh S., Boshoff C.; RT "LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at RT chromosome 3p21.3, binds pRB and represses E2F-driven transcription."; RL Proc. Natl. Acad. Sci. U.S.A. 101:16531-16536(2004). RN [45] RP PHOSPHORYLATION AT THR-821 AND THR-826. RX PubMed=15809340; DOI=10.1093/jb/mvi050; RA Takaki T., Fukasawa K., Suzuki-Takahashi I., Semba K., Kitagawa M., RA Taya Y., Hirai H.; RT "Preferences for phosphorylation sites in the retinoblastoma protein of D- RT type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro."; RL J. Biochem. 137:381-386(2005). RN [46] RP INTERACTION WITH KDM4A. RX PubMed=15927959; DOI=10.1074/jbc.m413687200; RA Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S., Jingu H., RA Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F.; RT "Functional characterization of JMJD2A, a histone deacetylase- and RT retinoblastoma-binding protein."; RL J. Biol. Chem. 280:28507-28518(2005). RN [47] RP INTERACTION WITH KDM5B. RX PubMed=15803180; DOI=10.1038/modpathol.3800413; RA Roesch A., Becker B., Meyer S., Wild P., Hafner C., Landthaler M., Vogt T.; RT "Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding RT protein downregulated in malignant melanomas."; RL Mod. Pathol. 18:1249-1257(2005). RN [48] RP INTERACTION WITH KDM5A. RX PubMed=15949438; DOI=10.1016/j.molcel.2005.05.012; RA Benevolenskaya E.V., Murray H.L., Branton P., Young R.A., Kaelin W.G. Jr.; RT "Binding of pRB to the PHD protein RBP2 promotes cellular RT differentiation."; RL Mol. Cell 18:623-635(2005). RN [49] RP INTERACTION WITH PSMA3. RX PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017; RA Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R., Allday M.J., RA Xiao Z.X.; RT "MDM2 promotes proteasome-dependent ubiquitin-independent degradation of RT retinoblastoma protein."; RL Mol. Cell 20:699-708(2005). RN [50] RP INTERACTION WITH ZUBR1. RX PubMed=16214886; DOI=10.1073/pnas.0507458102; RA Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K., Sawada J., RA Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.; RT "p600, a unique protein required for membrane morphogenesis and cell RT survival."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005). RN [51] RP INTERACTION WITH KDM5B. RX PubMed=16645588; DOI=10.1038/sj.jid.5700324; RA Roesch A., Becker B., Schneider-Brachert W., Hagen I., Landthaler M., RA Vogt T.; RT "Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals RT tumor-suppressive functions in highly metastatic melanoma cells."; RL J. Invest. Dermatol. 126:1850-1859(2006). RN [52] RP PHOSPHORYLATION AT SER-612 BY CHEK2, AND INTERACTION WITH CHEK2. RX PubMed=17380128; DOI=10.1038/sj.emboj.7601652; RA Inoue Y., Kitagawa M., Taya Y.; RT "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB RT and E2F-1 after DNA damage."; RL EMBO J. 26:2083-2093(2007). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252 AND THR-356, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [54] RP INTERACTION WITH MOLLUSCUM CONTAGIOSUM VIRUS PROTEIN MC007 (MICROBIAL RP FUNCTION). RX PubMed=18701596; DOI=10.1128/jvi.01187-08; RA Mohr S., Grandemange S., Massimi P., Darai G., Banks L., Martinou J.C., RA Zeier M., Muranyi W.; RT "Targeting the retinoblastoma protein by MC007L, gene product of the RT molluscum contagiosum virus: detection of a novel virus-cell interaction by RT a member of the poxviruses."; RL J. Virol. 82:10625-10633(2008). RN [55] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-252; RP SER-612; SER-807; SER-811; THR-823 AND THR-826, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [57] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-249; THR-373; SER-807 RP AND THR-841, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [59] RP METHYLATION AT LYS-860, INTERACTION WITH L3MBTL1, AND MUTAGENESIS OF RP LYS-860; LYS-870 AND 873-LYS-LYS-874. RX PubMed=20870719; DOI=10.1074/jbc.m110.137612; RA Saddic L.A., West L.E., Aslanian A., Yates J.R. III, Rubin S.M., Gozani O., RA Sage J.; RT "Methylation of the retinoblastoma tumor suppressor by SMYD2."; RL J. Biol. Chem. 285:37733-37740(2010). RN [60] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ACETYLATION AT LYS-873 AND RP LYS-874, AND MUTAGENESIS OF 873-LYS--LYS-874. RX PubMed=20940255; DOI=10.1242/jcs.068924; RA Pickard A., Wong P.P., McCance D.J.; RT "Acetylation of Rb by PCAF is required for nuclear localization and RT keratinocyte differentiation."; RL J. Cell Sci. 123:3718-3726(2010). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-821 AND THR-826, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [63] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [64] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [65] RP METHYLATION AT LYS-810 BY SMYD2. RX PubMed=22787429; DOI=10.1593/neo.12656; RA Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T., RA Dohmae N., Kogure M., Kang D., Neal D.E., Ponder B.A., Yamaue H., RA Nakamura Y., Hamamoto R.; RT "RB1 methylation by SMYD2 enhances cell cycle progression through an RT increase of RB1 phosphorylation."; RL Neoplasia 14:476-486(2012). RN [66] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; THR-252; THR-356; RP THR-373; SER-624; SER-780; SER-788; SER-795; SER-807; SER-811; THR-821; RP THR-823; THR-826 AND SER-855, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [67] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [68] RP INTERACTION WITH BLCAP. RX PubMed=26986503; DOI=10.3892/or.2016.4686; RA Zhao M., Zhang L., Qiu X., Zeng F., Chen W., An Y., Hu B., Wu X., Wu X.; RT "BLCAP arrests G(1)/S checkpoint and induces apoptosis through RT downregulation of pRb1 in HeLa cells."; RL Oncol. Rep. 35:3050-3058(2016). RN [69] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 378-562. RX PubMed=9145110; DOI=10.1038/nsb0597-390; RA Kim H.Y., Cho Y.; RT "Structural similarity between the pocket region of retinoblastoma tumour RT suppressor and the cyclin-box."; RL Nat. Struct. Biol. 4:390-395(1997). RN [70] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 380-785. RX PubMed=9495340; DOI=10.1038/36038; RA Lee J.O., Russo A.A., Pavletich N.P.; RT "Structure of the retinoblastoma tumour-suppressor pocket domain bound to a RT peptide from HPV E7."; RL Nature 391:859-865(1998). RN [71] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 860-876 IN COMPLEX WITH KPNA2. RX PubMed=12695505; DOI=10.1074/jbc.m303275200; RA Fontes M.R.M., Teh T., Jans D., Brinkworth R.I., Kobe B.; RT "Structural basis for the specificity of bipartite nuclear localization RT sequence binding by importin-alpha."; RL J. Biol. Chem. 278:27981-27987(2003). RN [72] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 829-874 IN COMPLEX WITH E2F1 AND RP TFDP1, INTERACTION WITH HETERODIMERIC COMPLEXES CONTAINING TFDP1 AND EITHER RP E2F1; E2F3; E2F4 OR E2F5, MUTAGENESIS OF THR-821 AND THR-826, AND RP PHOSPHORYLATION AT THR-821 AND THR-826. RX PubMed=16360038; DOI=10.1016/j.cell.2005.09.044; RA Rubin S.M., Gall A.-L., Zheng N., Pavletich N.P.; RT "Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for RT phosphorylation-induced E2F release."; RL Cell 123:1093-1106(2005). RN [73] RP X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 380-787 IN COMPLEX WITH HUMAN RP ADENOVIRUS E1A PROTEIN (MICROBIAL INFECTION). RX PubMed=17974914; DOI=10.1101/gad.1590607; RA Liu X., Marmorstein R.; RT "Structure of the retinoblastoma protein bound to adenovirus E1A reveals RT the molecular basis for viral oncoprotein inactivation of a tumor RT suppressor."; RL Genes Dev. 21:2711-2716(2007). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 52-355, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH THOC1 AND GRIP1, AND RP INTERACTION OF THE UNPHOSPHORYLATED PROTEIN WITH EID1. RX PubMed=17996702; DOI=10.1016/j.molcel.2007.08.023; RA Hassler M., Singh S., Yue W.W., Luczynski M., Lakbir R., RA Sanchez-Sanchez F., Bader T., Pearl L.H., Mittnacht S.; RT "Crystal structure of the retinoblastoma protein N domain provides insight RT into tumor suppression, ligand interaction, and holoprotein architecture."; RL Mol. Cell 28:371-385(2007). RN [75] RP VARIANT RB LEU-567. RX PubMed=2594029; DOI=10.1056/nejm198912213212501; RA Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D., RA Little J.B., McConkie-Rosell A., Buckley E., Dryja T.P.; RT "Oncogenic point mutations in the human retinoblastoma gene: their RT application to genetic counseling."; RL N. Engl. J. Med. 321:1689-1695(1989). RN [76] RP VARIANT RB TRP-661. RX PubMed=1352883; DOI=10.1073/pnas.89.13.6177; RA Onadim Z., Hogg A., Baird P.N., Cowell J.K.; RT "Oncogenic point mutations in exon 20 of the RB1 gene in families showing RT incomplete penetrance and mild expression of the retinoblastoma RT phenotype."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6177-6181(1992). RN [77] RP VARIANT RB ARG-457. RX PubMed=8346255; DOI=10.1073/pnas.90.15.7351; RA Hogg A., Bia B., Onadim Z., Cowell J.K.; RT "Molecular mechanisms of oncogenic mutations in tumors from patients with RT bilateral and unilateral retinoblastoma."; RL Proc. Natl. Acad. Sci. U.S.A. 90:7351-7355(1993). RN [78] RP VARIANT RB ARG-530. RX PubMed=7704558; DOI=10.1159/000472372; RA Cowell J.K., Smith T., Bia B.; RT "Frequent constitutional C to T mutations in CGA-arginine codons in the RB1 RT gene produce premature stop codons in patients with bilateral (hereditary) RT retinoblastoma."; RL Eur. J. Hum. Genet. 2:281-290(1994). RN [79] RP VARIANTS RB ASN-480 DEL AND TRP-661. RX PubMed=7927327; DOI=10.1007/bf00201591; RA Lohmann D.R., Brandt B., Hoepping W., Passarge E., Horsthemke B.; RT "Distinct RB1 gene mutations with low penetrance in hereditary RT retinoblastoma."; RL Hum. Genet. 94:349-354(1994). RN [80] RP VARIANT RB TYR-706. RX PubMed=8118465; DOI=10.1002/humu.1380030108; RA Kato M.V., Ishizaki K., Toguchida J., Kaneko A., Takayama J., Tanooka H., RA Kato T., Shimizu T., Sasaki M.S.; RT "Mutations in the retinoblastoma gene and their expression in somatic and RT tumor cells of patients with hereditary retinoblastoma."; RL Hum. Mutat. 3:44-51(1994). RN [81] RP VARIANTS RB GLN-72; TYR-549 AND LYS-803. RX PubMed=8605116; DOI=10.1002/gcc.2870140406; RA Liu Z., Song Y., Bia B., Cowell J.K.; RT "Germline mutations in the RB1 gene in patients with hereditary RT retinoblastoma."; RL Genes Chromosomes Cancer 14:277-284(1995). RN [82] RP VARIANTS RB THR-185; PRO-635; GLU-654 AND PRO-685. RX PubMed=7795591; DOI=10.1093/hmg/4.3.383; RA Blanquet V., Turleau C., Gross-Morand M.S., Senamaud-Beaufort C., Doz F., RA Besmond C.; RT "Spectrum of germline mutations in the RB1 gene: a study of 232 patients RT with hereditary and non hereditary retinoblastoma."; RL Hum. Mol. Genet. 4:383-388(1995). RN [83] RP VARIANTS RB GLY-358; PRO-657 AND TRP-661. RX PubMed=8776589; DOI=10.1093/hmg/5.6.755; RA Van Orsouw N.J., Li D., van der Vlies P., Scheffer H., Eng C., RA Buys C.H.C.M., Li F.P., Vijg J.; RT "Mutational scanning of large genes by extensive PCR multiplexing and two- RT dimensional electrophoresis: application to the RB1 gene."; RL Hum. Mol. Genet. 5:755-761(1996). RN [84] RP VARIANTS RB ASP-137 AND TRP-661. RX PubMed=9311732; DOI=10.1086/514845; RA Lohmann D.R., Gerick M., Brandt B., Oelschlaeger U., Lorenz B., RA Passarge E., Horsthemke B.; RT "Constitutional RB1-gene mutations in patients with isolated unilateral RT retinoblastoma."; RL Am. J. Hum. Genet. 61:282-294(1997). RN [85] RP VARIANT RB GLN-447. RX PubMed=9140452; DOI=10.1016/s0165-4608(96)00387-1; RA Mateu E., Sanchez F., Najera C., Beneyto M., Castell V., Hernandez M., RA Serra I., Prieto F.; RT "Genetics of retinoblastoma: a study."; RL Cancer Genet. Cytogenet. 95:40-50(1997). RN [86] RP VARIANTS RB LEU-567; PRO-662 AND ARG-712. RX PubMed=10671068; RX DOI=10.1002/(sici)1098-1004(1998)12:6<434::aid-humu16>3.0.co;2-7; RA Yilmaz S., Horsthemke B., Lohmann D.R.; RT "Twelve novel RB1 gene mutations in patients with hereditary RT retinoblastoma."; RL Hum. Mutat. 12:434-434(1998). RN [87] RP VARIANT RB GLU-310. RX PubMed=9973307; DOI=10.1086/302254; RA Klutz M., Horsthemke B., Lohmann D.R.; RT "RB1 gene mutations in peripheral blood DNA of patients with isolated RT unilateral retinoblastoma."; RL Am. J. Hum. Genet. 64:667-668(1999). RN [88] RP VARIANTS RB GLY-500 AND GLU-616. RX PubMed=11524739; DOI=10.1002/humu.1184; RA Yu Y.S., Kim I.-J., Ku J.-L., Park J.-G.; RT "Identification of four novel RB1 germline mutations in Korean RT retinoblastoma patients."; RL Hum. Mutat. 18:252-252(2001). RN [89] RP VARIANT HIS-173. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). CC -!- FUNCTION: Tumor suppressor that is a key regulator of the G1/S CC transition of the cell cycle (PubMed:10499802). The hypophosphorylated CC form binds transcription regulators of the E2F family, preventing CC transcription of E2F-responsive genes (PubMed:10499802). Both CC physically blocks E2Fs transactivating domain and recruits chromatin- CC modifying enzymes that actively repress transcription CC (PubMed:10499802). Cyclin and CDK-dependent phosphorylation of RB1 CC induces its dissociation from E2Fs, thereby activating transcription of CC E2F responsive genes and triggering entry into S phase CC (PubMed:10499802). RB1 also promotes the G0-G1 transition upon CC phosphorylation and activation by CDK3/cyclin-C (PubMed:15084261). CC Directly involved in heterochromatin formation by maintaining overall CC chromatin structure and, in particular, that of constitutive CC heterochromatin by stabilizing histone methylation. Recruits and CC targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to CC epigenetic transcriptional repression. Controls histone H4 'Lys-20' CC trimethylation. Inhibits the intrinsic kinase activity of TAF1. CC Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a CC histone deacetylase (HDAC) complex to the c-FOS promoter. In resting CC neurons, transcription of the c-FOS promoter is inhibited by BRG1- CC dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon CC calcium influx, RB1 is dephosphorylated by calcineurin, which leads to CC release of the repressor complex (By similarity). CC {ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568, CC ECO:0000269|PubMed:10499802, ECO:0000269|PubMed:15084261}. CC -!- FUNCTION: (Microbial infection) In case of viral infections, CC interactions with SV40 large T antigen, HPV E7 protein or adenovirus CC E1A protein induce the disassembly of RB1-E2F1 complex thereby CC disrupting RB1's activity. {ECO:0000269|PubMed:1316611, CC ECO:0000269|PubMed:17974914, ECO:0000269|PubMed:18701596, CC ECO:0000269|PubMed:2839300, ECO:0000269|PubMed:8892909}. CC -!- SUBUNIT: The hypophosphorylated form interacts with and sequesters the CC E2F1 transcription factor, thereby inhibiting E2F1 transcription CC (PubMed:20940255, PubMed:8336704). Interacts with heterodimeric E2F/DP CC transcription factor complexes containing TFDP1 and either E2F1, E2F3, CC E2F4 or E2F5, or TFDP2 and E2F4. Interacts (when hyperphosphorylated CC and hypophosphorylated) with PKP3; the interaction inhibits RB1 CC interaction with and repression of the transcription factor E2F1, CC potentially via sequestering RB1 to the cytoplasm (By similarity). The CC unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1, CC MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of TAF1. CC Interacts with SNW1, ATAD5, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C, CC PELP1, UHRF2 and TMPO-alpha. Interacts with GRIP1 and UBR4. Interacts CC with ARID4A and KDM5B. Interacts with E4F1 and LIMD1. Interacts with CC SMARCA4/BRG1 and HDAC1 (By similarity). Interacts with PSMA3 and USP4. CC Interacts (when methylated at Lys-860) with L3MBTL1. Interacts with CC CHEK2; phosphorylates RB1. Interacts with CDK1 and CDK2 (By CC similarity). Interacts with PRMT2. Interacts with CEBPA CC (PubMed:15107404). P-TEFB complex interacts with RB1; promotes CC phosphorylation of RB1 (PubMed:12037672). Interacts with RBBP9; the CC interaction disrupts RB1 binding to E2F1 (By similarity). Interacts CC with KAT2B/PCAF and EP300/P300 (By similarity). Interacts with PAX5 CC (PubMed:10197586). Interacts (phosphorylated and unphosphorylated) with CC BLCAP (PubMed:26986503). May interact with NDC80. CC {ECO:0000250|UniProtKB:P13405, ECO:0000250|UniProtKB:P33568, CC ECO:0000269|PubMed:10197586, ECO:0000269|PubMed:10409732, CC ECO:0000269|PubMed:10446990, ECO:0000269|PubMed:10779342, CC ECO:0000269|PubMed:10869426, ECO:0000269|PubMed:10888886, CC ECO:0000269|PubMed:11223246, ECO:0000269|PubMed:11484059, CC ECO:0000269|PubMed:11571652, ECO:0000269|PubMed:12037672, CC ECO:0000269|PubMed:12450794, ECO:0000269|PubMed:12466551, CC ECO:0000269|PubMed:12475961, ECO:0000269|PubMed:12682072, CC ECO:0000269|PubMed:12695505, ECO:0000269|PubMed:15107404, CC ECO:0000269|PubMed:15538385, ECO:0000269|PubMed:15542589, CC ECO:0000269|PubMed:15803180, ECO:0000269|PubMed:15927959, CC ECO:0000269|PubMed:15949438, ECO:0000269|PubMed:16214886, CC ECO:0000269|PubMed:16337594, ECO:0000269|PubMed:16360038, CC ECO:0000269|PubMed:16645588, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:17996702, ECO:0000269|PubMed:20870719, CC ECO:0000269|PubMed:20940255, ECO:0000269|PubMed:21952639, CC ECO:0000269|PubMed:26986503, ECO:0000269|PubMed:7525595, CC ECO:0000269|PubMed:7935440, ECO:0000269|PubMed:8336704, CC ECO:0000269|PubMed:8414517, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E1A protein. CC {ECO:0000269|PubMed:17974914}. CC -!- SUBUNIT: (Microbial infection) Interacts with HPV E7 protein. CC {ECO:0000269|PubMed:1316611}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 large T antigen. CC {ECO:0000269|PubMed:1316611, ECO:0000269|PubMed:2839300}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 proteins UL82 and UL123. CC {ECO:0000269|PubMed:12626766, ECO:0000269|PubMed:8892909}. CC -!- SUBUNIT: (Microbial infection) Interacts with molluscum contagiosum CC virus protein MC007. {ECO:0000269|PubMed:18701596}. CC -!- INTERACTION: CC P06400; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-491274, EBI-528269; CC P06400; P24863: CCNC; NbExp=4; IntAct=EBI-491274, EBI-395261; CC P06400; P24941: CDK2; NbExp=3; IntAct=EBI-491274, EBI-375096; CC P06400; O14757: CHEK1; NbExp=3; IntAct=EBI-491274, EBI-974488; CC P06400; O96017: CHEK2; NbExp=3; IntAct=EBI-491274, EBI-1180783; CC P06400; P39880: CUX1; NbExp=4; IntAct=EBI-491274, EBI-719064; CC P06400; Q13574-2: DGKZ; NbExp=6; IntAct=EBI-491274, EBI-715527; CC P06400; Q13627: DYRK1A; NbExp=4; IntAct=EBI-491274, EBI-1053596; CC P06400; Q9Y463: DYRK1B; NbExp=4; IntAct=EBI-491274, EBI-634187; CC P06400; Q01094: E2F1; NbExp=32; IntAct=EBI-491274, EBI-448924; CC P06400; Q14209: E2F2; NbExp=5; IntAct=EBI-491274, EBI-718476; CC P06400; O00716: E2F3; NbExp=5; IntAct=EBI-491274, EBI-765551; CC P06400; Q16254: E2F4; NbExp=6; IntAct=EBI-491274, EBI-448943; CC P06400; Q15329: E2F5; NbExp=2; IntAct=EBI-491274, EBI-1389773; CC P06400; O43524: FOXO3; NbExp=2; IntAct=EBI-491274, EBI-1644164; CC P06400; P42685: FRK; NbExp=3; IntAct=EBI-491274, EBI-1383583; CC P06400; P15976: GATA1; NbExp=2; IntAct=EBI-491274, EBI-3909284; CC P06400; P62993: GRB2; NbExp=4; IntAct=EBI-491274, EBI-401755; CC P06400; O60381: HBP1; NbExp=2; IntAct=EBI-491274, EBI-954175; CC P06400; Q13547: HDAC1; NbExp=19; IntAct=EBI-491274, EBI-301834; CC P06400; Q14653: IRF3; NbExp=2; IntAct=EBI-491274, EBI-2650369; CC P06400; P29375: KDM5A; NbExp=2; IntAct=EBI-491274, EBI-1560836; CC P06400; Q16539: MAPK14; NbExp=4; IntAct=EBI-491274, EBI-73946; CC P06400; Q00987: MDM2; NbExp=5; IntAct=EBI-491274, EBI-389668; CC P06400; O15151: MDM4; NbExp=4; IntAct=EBI-491274, EBI-398437; CC P06400; Q9Y676: MRPS18B; NbExp=2; IntAct=EBI-491274, EBI-750085; CC P06400; Q14686: NCOA6; NbExp=3; IntAct=EBI-491274, EBI-78670; CC P06400; P07197: NEFM; NbExp=2; IntAct=EBI-491274, EBI-1105035; CC P06400; Q9UQ80: PA2G4; NbExp=4; IntAct=EBI-491274, EBI-924893; CC P06400; P62136: PPP1CA; NbExp=5; IntAct=EBI-491274, EBI-357253; CC P06400; P55345: PRMT2; NbExp=3; IntAct=EBI-491274, EBI-78458; CC P06400; Q00577: PURA; NbExp=6; IntAct=EBI-491274, EBI-1045860; CC P06400; P04049: RAF1; NbExp=3; IntAct=EBI-491274, EBI-365996; CC P06400; P06400: RB1; NbExp=3; IntAct=EBI-491274, EBI-491274; CC P06400; Q99708: RBBP8; NbExp=2; IntAct=EBI-491274, EBI-745715; CC P06400; O75150: RNF40; NbExp=3; IntAct=EBI-491274, EBI-744408; CC P06400; Q8WTS6: SETD7; NbExp=4; IntAct=EBI-491274, EBI-1268586; CC P06400; Q96PU4: UHRF2; NbExp=4; IntAct=EBI-491274, EBI-625304; CC P06400; Q93009: USP7; NbExp=8; IntAct=EBI-491274, EBI-302474; CC P06400; P30285: Cdk4; Xeno; NbExp=2; IntAct=EBI-491274, EBI-847225; CC P06400; Q155P7: Cenpf; Xeno; NbExp=4; IntAct=EBI-491274, EBI-2211248; CC P06400; A0MPS7: E7; Xeno; NbExp=2; IntAct=EBI-491274, EBI-7014709; CC P06400; P03129: E7; Xeno; NbExp=30; IntAct=EBI-491274, EBI-866453; CC P06400; P04020: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-7005254; CC P06400; P06464: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-6944797; CC P06400; P06465: E7; Xeno; NbExp=3; IntAct=EBI-491274, EBI-963841; CC P06400; P06788: E7; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1776887; CC P06400; P52927: Hmga2; Xeno; NbExp=5; IntAct=EBI-491274, EBI-912574; CC P06400; Q9R002: Ifi202; Xeno; NbExp=5; IntAct=EBI-491274, EBI-3043899; CC P06400; Q8VSP9: ospF; Xeno; NbExp=2; IntAct=EBI-491274, EBI-6506625; CC P06400; Q9Z2X2: Psmd10; Xeno; NbExp=3; IntAct=EBI-491274, EBI-8377084; CC P06400; PRO_0000037321 [P0C6X7]: rep; Xeno; NbExp=3; IntAct=EBI-491274, EBI-25487301; CC P06400; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1802585; CC P06400; Q3TKT4: Smarca4; Xeno; NbExp=4; IntAct=EBI-491274, EBI-1210244; CC P06400; P03070; Xeno; NbExp=9; IntAct=EBI-491274, EBI-617698; CC P06400; P03254; Xeno; NbExp=3; IntAct=EBI-491274, EBI-8599077; CC P06400; P03255; Xeno; NbExp=10; IntAct=EBI-491274, EBI-2603114; CC P06400; P03255-1; Xeno; NbExp=2; IntAct=EBI-491274, EBI-6692439; CC P06400; P03255-2; Xeno; NbExp=3; IntAct=EBI-491274, EBI-6859460; CC P06400; PRO_0000041225 [Q86500]; Xeno; NbExp=3; IntAct=EBI-491274, EBI-2568719; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20940255}. Cytoplasm CC {ECO:0000250|UniProtKB:P13405}. Note=During keratinocyte CC differentiation, acetylation by KAT2B/PCAF is required for nuclear CC localization (PubMed:20940255). Localizes to the cytoplasm when CC hyperphosphorylated (By similarity). {ECO:0000250|UniProtKB:P13405, CC ECO:0000269|PubMed:20940255}. CC -!- TISSUE SPECIFICITY: Expressed in the retina. Expressed in foreskin CC keratinocytes (at protein level) (PubMed:20940255). CC {ECO:0000269|PubMed:20940255}. CC -!- DOMAIN: The Pocket domain binds to the threonine-phosphorylated domain CC C, thereby preventing interaction with heterodimeric E2F/DP CC transcription factor complexes. CC -!- PTM: Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at Ser- CC 567 in G1, thereby releasing E2F1 which is then able to activate cell CC growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV CC E7 and adenovirus E1A bind to the underphosphorylated, active form of CC pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction CC between the C-terminal domain C and the Pocket domain, and thereby CC inhibits interactions with heterodimeric E2F/DP transcription factor CC complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium CC stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser- CC 811 is required for G0-G1 transition. Phosphorylated by CDK1 and CDK2 CC upon TGFB1-mediated apoptosis. {ECO:0000269|PubMed:10499802, CC ECO:0000269|PubMed:8114739}. CC -!- PTM: N-terminus is methylated by METTL11A/NTM1 (By similarity). CC Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at Ser-807 CC and Ser-811, and promotes cell cycle progression. Monomethylation at CC Lys-860 by SMYD2 promotes interaction with L3MBTL1. {ECO:0000250, CC ECO:0000269|PubMed:15084261, ECO:0000269|PubMed:15809340, CC ECO:0000269|PubMed:16360038, ECO:0000269|PubMed:17380128, CC ECO:0000269|PubMed:1756735, ECO:0000269|PubMed:20870719, CC ECO:0000269|PubMed:22787429}. CC -!- PTM: Acetylated during keratinocyte differentiation. Acetylation at CC Lys-873 and Lys-874 regulates subcellular localization. Can be CC deacetylated by SIRT1. {ECO:0000269|PubMed:20940255}. CC -!- DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]: Congenital CC malignant tumor that arises from the nuclear layers of the retina. It CC occurs in about 1:20'000 live births and represents about 2% of CC childhood malignancies. It is bilateral in about 30% of cases. Although CC most RB appear sporadically, about 20% are transmitted as an autosomal CC dominant trait with incomplete penetrance. The diagnosis is usually CC made before the age of 2 years when strabismus or a gray to yellow CC reflex from pupil ('cat eye') is investigated. CC {ECO:0000269|PubMed:10671068, ECO:0000269|PubMed:11524739, CC ECO:0000269|PubMed:1352883, ECO:0000269|PubMed:2594029, CC ECO:0000269|PubMed:7704558, ECO:0000269|PubMed:7795591, CC ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8118465, CC ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116, CC ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452, CC ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating CC in bone-forming cells, affecting the ends of long bones. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the retinoblastoma protein (RB) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=RB1base; Note=RB1 mutation db; CC URL="http://rb1-lsdb.d-lohmann.de/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/90/RB1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Retinoblastoma protein entry; CC URL="https://en.wikipedia.org/wiki/Retinoblastoma_protein"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M15400; AAA69807.1; ALT_SEQ; mRNA. DR EMBL; M28419; AAA69808.1; -; mRNA. DR EMBL; M33647; AAA69806.1; -; mRNA. DR EMBL; L41870; AAB59465.1; -; mRNA. DR EMBL; M27866; AAA53484.1; -; Genomic_DNA. DR EMBL; M27845; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27846; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27847; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27849; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27850; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27851; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L35146; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27852; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27853; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27854; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27855; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27856; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27857; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27858; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27859; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27860; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L35147; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27862; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27863; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27864; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; M27865; AAA53484.1; JOINED; Genomic_DNA. DR EMBL; L41889; AAB59467.1; -; Genomic_DNA. DR EMBL; L41890; AAA65735.1; -; Genomic_DNA. DR EMBL; L41891; AAA65736.1; -; Genomic_DNA. DR EMBL; L41893; AAA65737.1; -; Genomic_DNA. DR EMBL; L41894; AAA65738.1; -; Genomic_DNA. DR EMBL; L41895; AAA65739.1; -; Genomic_DNA. DR EMBL; L41896; AAA65740.1; -; Genomic_DNA. DR EMBL; L41897; AAA65741.1; -; Genomic_DNA. DR EMBL; L41898; AAB59471.1; -; Genomic_DNA. DR EMBL; L41899; AAB59473.1; -; Genomic_DNA. DR EMBL; L41997; AAB59482.1; -; Genomic_DNA. DR EMBL; X16439; CAA34462.1; -; Genomic_DNA. DR EMBL; AF551763; AAN64133.1; -; Genomic_DNA. DR EMBL; AK291258; BAF83947.1; -; mRNA. DR EMBL; AL136960; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL392048; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08793.1; -; Genomic_DNA. DR EMBL; BC039060; AAH39060.1; -; mRNA. DR EMBL; BC040540; AAH40540.1; -; mRNA. DR EMBL; L11910; AAA53483.1; -; Genomic_DNA. DR CCDS; CCDS31973.1; -. DR PIR; JS0276; RBHU. DR RefSeq; NP_000312.2; NM_000321.3. DR PDB; 1AD6; X-ray; 2.30 A; A=378-562. DR PDB; 1GH6; X-ray; 3.20 A; B=379-577, B=645-772. DR PDB; 1GUX; X-ray; 1.85 A; A=372-589, B=636-787. DR PDB; 1H25; X-ray; 2.50 A; E=868-878. DR PDB; 1N4M; X-ray; 2.20 A; A/B=380-785. DR PDB; 1O9K; X-ray; 2.60 A; A/C/E/G=372-589, B/D/F/H=636-787. DR PDB; 1PJM; X-ray; 2.50 A; A=858-881. DR PDB; 2AZE; X-ray; 2.55 A; C=829-874. DR PDB; 2QDJ; X-ray; 2.00 A; A=52-355. DR PDB; 2R7G; X-ray; 1.67 A; A/C=380-787. DR PDB; 3N5U; X-ray; 3.20 A; C=870-882. DR PDB; 3POM; X-ray; 2.50 A; A/B=380-577, A/B=643-783. DR PDB; 4CRI; X-ray; 2.35 A; C/D=802-817. DR PDB; 4ELJ; X-ray; 2.70 A; A=53-787. DR PDB; 4ELL; X-ray; 1.98 A; A/B=380-787. DR PDB; 9DGK; X-ray; 2.38 A; A/B=380-793. DR PDB; 9DHC; X-ray; 2.32 A; A/B=380-793. DR PDB; 9DHF; X-ray; 2.26 A; A/B=380-793. DR PDB; 9DHU; X-ray; 2.16 A; A/B=380-786. DR PDBsum; 1AD6; -. DR PDBsum; 1GH6; -. DR PDBsum; 1GUX; -. DR PDBsum; 1H25; -. DR PDBsum; 1N4M; -. DR PDBsum; 1O9K; -. DR PDBsum; 1PJM; -. DR PDBsum; 2AZE; -. DR PDBsum; 2QDJ; -. DR PDBsum; 2R7G; -. DR PDBsum; 3N5U; -. DR PDBsum; 3POM; -. DR PDBsum; 4CRI; -. DR PDBsum; 4ELJ; -. DR PDBsum; 4ELL; -. DR PDBsum; 9DGK; -. DR PDBsum; 9DHC; -. DR PDBsum; 9DHF; -. DR PDBsum; 9DHU; -. DR AlphaFoldDB; P06400; -. DR SMR; P06400; -. DR BioGRID; 111860; 389. DR ComplexPortal; CPX-155; RB1-E2F1-DP1 transcriptional repressor complex. DR ComplexPortal; CPX-175; RB1-E2F2-DP1 transcriptional repressor complex. DR ComplexPortal; CPX-469; L3MBTL1 complex. DR ComplexPortal; CPX-7728; RB1-E2F3-DP1 transcriptional repressor complex. DR CORUM; P06400; -. DR DIP; DIP-582N; -. DR FunCoup; P06400; 3043. DR IntAct; P06400; 229. DR MINT; P06400; -. DR STRING; 9606.ENSP00000267163; -. DR BindingDB; P06400; -. DR ChEMBL; CHEMBL5288; -. DR GlyGen; P06400; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P06400; -. DR PhosphoSitePlus; P06400; -. DR BioMuta; RB1; -. DR DMDM; 132164; -. DR CPTAC; CPTAC-1328; -. DR CPTAC; CPTAC-3251; -. DR CPTAC; CPTAC-3288; -. DR CPTAC; CPTAC-898; -. DR CPTAC; CPTAC-941; -. DR CPTAC; CPTAC-942; -. DR jPOST; P06400; -. DR MassIVE; P06400; -. DR PaxDb; 9606-ENSP00000267163; -. DR PeptideAtlas; P06400; -. DR ProteomicsDB; 51900; -. DR Pumba; P06400; -. DR Antibodypedia; 3758; 3580 antibodies from 52 providers. DR CPTC; P06400; 6 antibodies. DR DNASU; 5925; -. DR Ensembl; ENST00000267163.6; ENSP00000267163.4; ENSG00000139687.18. DR GeneID; 5925; -. DR KEGG; hsa:5925; -. DR MANE-Select; ENST00000267163.6; ENSP00000267163.4; NM_000321.3; NP_000312.2. DR UCSC; uc001vcb.4; human. DR AGR; HGNC:9884; -. DR CIViC; 5925; 17 evidence items across 13 molecular profiles. DR ClinPGx; PA295; -. DR CTD; 5925; -. DR DisGeNET; 5925; -. DR GeneCards; RB1; -. DR GeneReviews; RB1; -. DR HGNC; HGNC:9884; RB1. DR HPA; ENSG00000139687; Low tissue specificity. DR MalaCards; RB1; -. DR MIM; 109800; phenotype. DR MIM; 180200; phenotype. DR MIM; 259500; phenotype. DR MIM; 614041; gene. DR OpenTargets; ENSG00000139687; -. DR Orphanet; 357027; Hereditary retinoblastoma. DR Orphanet; 1587; Monosomy 13q14 syndrome. DR Orphanet; 357034; Non-hereditary retinoblastoma. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000139687; -. DR eggNOG; KOG1010; Eukaryota. DR GeneTree; ENSGT00950000183202; -. DR HOGENOM; CLU_015754_0_0_1; -. DR InParanoid; P06400; -. DR OMA; VKDIGCI; -. DR OrthoDB; 844594at2759; -. DR PAN-GO; P06400; 7 GO annotations based on evolutionary models. DR PhylomeDB; P06400; -. DR PathwayCommons; P06400; -. DR Reactome; R-HSA-113501; Inhibition of replication initiation of damaged DNA by RB1/E2F1. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2299718; Condensation of Prophase Chromosomes. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-69200; Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes. DR Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry. DR Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation. DR Reactome; R-HSA-9661069; Defective binding of RB1 mutants to E2F1,(E2F2, E2F3). DR Reactome; R-HSA-9661070; Defective translocation of RB1 mutants to the nucleus. DR Reactome; R-HSA-9682706; Replication of the SARS-CoV-1 genome. DR Reactome; R-HSA-9687136; Aberrant regulation of mitotic exit in cancer due to RB1 defects. DR Reactome; R-HSA-9694686; Replication of the SARS-CoV-2 genome. DR Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer. DR Reactome; R-HSA-9764790; Positive Regulation of CDH1 Gene Transcription. DR Reactome; R-HSA-9841922; MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis. DR SignaLink; P06400; -. DR SIGNOR; P06400; -. DR Agora; ENSG00000139687; -. DR BioGRID-ORCS; 5925; 32 hits in 1194 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; RB1; human. DR EvolutionaryTrace; P06400; -. DR GeneWiki; Retinoblastoma_protein; -. DR GenomeRNAi; 5925; -. DR Pharos; P06400; Tchem. DR PRO; PR:P06400; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; P06400; protein. DR Bgee; ENSG00000139687; Expressed in epithelium of nasopharynx and 200 other cell types or tissues. DR ExpressionAtlas; P06400; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0061793; C:chromatin lock complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:CAFA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0035189; C:Rb-E2F complex; IDA:CAFA. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016514; C:SWI/SNF complex; TAS:BHF-UCL. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0061676; F:importin-alpha family protein binding; IPI:CAFA. DR GO; GO:0019900; F:kinase binding; IDA:UniProtKB. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IEA:Ensembl. DR GO; GO:0003714; F:transcription corepressor activity; TAS:ARUK-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0003180; P:aortic valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0051301; P:cell division; IEA:Ensembl. DR GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; IBA:GO_Central. DR GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0006338; P:chromatin remodeling; TAS:BHF-UCL. DR GO; GO:0051276; P:chromosome organization; IMP:BHF-UCL. DR GO; GO:0048565; P:digestive tract development; IEA:Ensembl. DR GO; GO:0043353; P:enucleate erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IEA:Ensembl. DR GO; GO:0034349; P:glial cell apoptotic process; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl. DR GO; GO:0031507; P:heterochromatin formation; IDA:ComplexPortal. DR GO; GO:0034088; P:maintenance of mitotic sister chromatid cohesion; IMP:BHF-UCL. DR GO; GO:0045445; P:myoblast differentiation; IMP:UniProtKB. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; ISS:ARUK-UCL. DR GO; GO:0045786; P:negative regulation of cell cycle; ISS:ARUK-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:MGI. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IEA:Ensembl. DR GO; GO:0050728; P:negative regulation of inflammatory response; ISS:BHF-UCL. DR GO; GO:1904761; P:negative regulation of myofibroblast differentiation; ISS:BHF-UCL. DR GO; GO:0006469; P:negative regulation of protein kinase activity; IPI:UniProtKB. DR GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:BHF-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0031175; P:neuron projection development; IBA:GO_Central. DR GO; GO:1904028; P:positive regulation of collagen fibril organization; ISS:BHF-UCL. DR GO; GO:1903055; P:positive regulation of extracellular matrix organization; ISS:BHF-UCL. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Ensembl. DR GO; GO:0045842; P:positive regulation of mitotic metaphase/anaphase transition; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IDA:MGI. DR GO; GO:0071459; P:protein localization to chromosome, centromeric region; IMP:BHF-UCL. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0051726; P:regulation of cell cycle; TAS:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0043550; P:regulation of lipid kinase activity; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0031134; P:sister chromatid biorientation; IMP:BHF-UCL. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd20599; CYCLIN_RB; 1. DR DisProt; DP01426; -. DR FunFam; 1.10.472.10:FF:000039; RB transcriptional corepressor 1; 1. DR FunFam; 1.10.472.140:FF:000002; RB transcriptional corepressor 1; 1. DR FunFam; 1.10.472.10:FF:000033; retinoblastoma-associated protein isoform X1; 1. DR Gene3D; 1.10.472.140; -; 1. DR Gene3D; 6.10.140.1380; -; 1. DR Gene3D; 6.10.250.530; -; 1. DR Gene3D; 1.10.472.10; Cyclin-like; 2. DR IDEAL; IID00017; -. DR InterPro; IPR013763; Cyclin-like_dom. DR InterPro; IPR036915; Cyclin-like_sf. DR InterPro; IPR002720; RB_A. DR InterPro; IPR002719; RB_B. DR InterPro; IPR015030; RB_C. DR InterPro; IPR028309; RB_fam. DR InterPro; IPR024599; RB_N. DR PANTHER; PTHR13742:SF36; RETINOBLASTOMA-ASSOCIATED PROTEIN; 1. DR PANTHER; PTHR13742; RETINOBLASTOMA-ASSOCIATED PROTEIN RB -RELATED; 1. DR Pfam; PF11934; DUF3452; 1. DR Pfam; PF01858; RB_A; 1. DR Pfam; PF01857; RB_B; 1. DR Pfam; PF08934; Rb_C; 1. DR SMART; SM00385; CYCLIN; 1. DR SMART; SM01367; DUF3452; 1. DR SMART; SM01368; RB_A; 1. DR SMART; SM01369; Rb_C; 1. DR SUPFAM; SSF47954; Cyclin-like; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Cell cycle; Chromatin regulator; Cytoplasm; KW Direct protein sequencing; Disease variant; DNA-binding; KW Host-virus interaction; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P13405" FT CHAIN 2..928 FT /note="Retinoblastoma-associated protein" FT /id="PRO_0000167836" FT REGION 1..42 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 373..771 FT /note="Pocket; binds T and E1A" FT REGION 373..579 FT /note="Domain A" FT REGION 580..639 FT /note="Spacer" FT REGION 610..632 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 640..771 FT /note="Domain B" FT REGION 763..928 FT /note="Interaction with LIMD1" FT /evidence="ECO:0000269|PubMed:15542589" FT REGION 771..928 FT /note="Domain C; mediates interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10869426" FT REGION 860..928 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 860..876 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000250|UniProtKB:P13405" FT COMPBIAS 8..19 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 29..39 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..632 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 915..928 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N,N-dimethylproline" FT /evidence="ECO:0000250|UniProtKB:P13405" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569" FT MOD_RES 249 FT /note="Phosphoserine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 252 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 356 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:1756735, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 567 FT /note="Phosphoserine; by CDK2" FT /evidence="ECO:0000269|PubMed:10499802" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P13405" FT MOD_RES 612 FT /note="Phosphoserine; by CHEK2 and CHEK1" FT /evidence="ECO:0000269|PubMed:17380128, FT ECO:0007744|PubMed:18669648" FT MOD_RES 624 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 788 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 795 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 807 FT /note="Phosphoserine; by CDK1 and CDK3" FT /evidence="ECO:0000269|PubMed:15084261, FT ECO:0000269|PubMed:1756735, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 810 FT /note="N6-methyllysine; by SMYD2" FT /evidence="ECO:0000269|PubMed:22787429" FT MOD_RES 811 FT /note="Phosphoserine; by CDK1 and CDK3" FT /evidence="ECO:0000269|PubMed:15084261, FT ECO:0000269|PubMed:1756735, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 821 FT /note="Phosphothreonine; by CDK6" FT /evidence="ECO:0000269|PubMed:15809340, FT ECO:0000269|PubMed:16360038, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 823 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 826 FT /note="Phosphothreonine; by CDK4" FT /evidence="ECO:0000269|PubMed:15809340, FT ECO:0000269|PubMed:16360038, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 841 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 855 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 860 FT /note="N6-methyllysine; by SMYD2" FT /evidence="ECO:0000269|PubMed:20870719" FT MOD_RES 873 FT /note="N6-acetyllysine; by PCAF" FT /evidence="ECO:0000269|PubMed:20940255" FT MOD_RES 874 FT /note="N6-acetyllysine; by PCAF" FT /evidence="ECO:0000269|PubMed:20940255" FT VARIANT 72 FT /note="E -> Q (in RB; dbSNP:rs369833913)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005572" FT VARIANT 133 FT /note="N -> H (in dbSNP:rs3092900)" FT /id="VAR_051909" FT VARIANT 137 FT /note="E -> D (in RB; unilateral form; dbSNP:rs3092902)" FT /evidence="ECO:0000269|PubMed:9311732" FT /id="VAR_005573" FT VARIANT 173 FT /note="Y -> H" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069376" FT VARIANT 185 FT /note="I -> T (in RB)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005574" FT VARIANT 310 FT /note="G -> E (in RB; uncertain significance; FT dbSNP:rs200844292)" FT /evidence="ECO:0000269|PubMed:9973307" FT /id="VAR_010045" FT VARIANT 358 FT /note="R -> G (in RB; dbSNP:rs121913301)" FT /evidence="ECO:0000269|PubMed:8776589" FT /id="VAR_010046" FT VARIANT 358 FT /note="R -> Q (in RB; dbSNP:rs767011440)" FT /id="VAR_005575" FT VARIANT 436 FT /note="Q -> K (in dbSNP:rs4151534)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019379" FT VARIANT 447 FT /note="K -> Q (in RB)" FT /evidence="ECO:0000269|PubMed:9140452" FT /id="VAR_010048" FT VARIANT 457 FT /note="M -> R (in RB)" FT /evidence="ECO:0000269|PubMed:8346255" FT /id="VAR_005576" FT VARIANT 480 FT /note="Missing (in RB; mild form)" FT /evidence="ECO:0000269|PubMed:7927327" FT /id="VAR_005577" FT VARIANT 500 FT /note="R -> G (in RB)" FT /evidence="ECO:0000269|PubMed:11524739" FT /id="VAR_011580" FT VARIANT 525 FT /note="A -> G (in dbSNP:rs4151539)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019380" FT VARIANT 530 FT /note="K -> R (in RB; dbSNP:rs1948534047)" FT /evidence="ECO:0000269|PubMed:7704558" FT /id="VAR_010049" FT VARIANT 549 FT /note="H -> Y (in RB; dbSNP:rs1050717570)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005578" FT VARIANT 567 FT /note="S -> L (in RB; dbSNP:rs137853292)" FT /evidence="ECO:0000269|PubMed:10671068, FT ECO:0000269|PubMed:2594029" FT /id="VAR_005579" FT VARIANT 569 FT /note="L -> F (in dbSNP:rs3092895)" FT /id="VAR_051910" FT VARIANT 616 FT /note="K -> E (in RB)" FT /evidence="ECO:0000269|PubMed:11524739" FT /id="VAR_011581" FT VARIANT 635 FT /note="A -> P (in RB; dbSNP:rs1949359622)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005580" FT VARIANT 654 FT /note="V -> E (in RB; dbSNP:rs769113950)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005581" FT VARIANT 657 FT /note="L -> P (in RB)" FT /evidence="ECO:0000269|PubMed:8776589" FT /id="VAR_010050" FT VARIANT 661 FT /note="R -> W (in RB; mild form; dbSNP:rs137853294)" FT /evidence="ECO:0000269|PubMed:1352883, FT ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8776589, FT ECO:0000269|PubMed:9311732" FT /id="VAR_005582" FT VARIANT 662 FT /note="L -> P (in RB)" FT /evidence="ECO:0000269|PubMed:10671068" FT /id="VAR_005583" FT VARIANT 673 FT /note="H -> P (in RB; dbSNP:rs2138336107)" FT /id="VAR_005584" FT VARIANT 685 FT /note="Q -> P (in RB)" FT /evidence="ECO:0000269|PubMed:7795591" FT /id="VAR_005585" FT VARIANT 697 FT /note="D -> E (in dbSNP:rs3092903)" FT /id="VAR_051911" FT VARIANT 706 FT /note="C -> Y (in RB; dbSNP:rs121913295)" FT /evidence="ECO:0000269|PubMed:8118465" FT /id="VAR_005586" FT VARIANT 712 FT /note="C -> R (in RB; dbSNP:rs137853296)" FT /evidence="ECO:0000269|PubMed:10671068" FT /id="VAR_005587" FT VARIANT 746 FT /note="E -> G (in dbSNP:rs3092905)" FT /id="VAR_034442" FT VARIANT 803 FT /note="N -> K (in RB; dbSNP:rs1379479714)" FT /evidence="ECO:0000269|PubMed:8605116" FT /id="VAR_005588" FT MUTAGEN 821 FT /note="T->A: Abolishes interaction with Pocket domain; when FT associated with A-826." FT /evidence="ECO:0000269|PubMed:16360038" FT MUTAGEN 826 FT /note="T->A: Abolishes interaction with Pocket domain; when FT associated with A-821." FT /evidence="ECO:0000269|PubMed:16360038" FT MUTAGEN 860 FT /note="K->R: Abolishes monomethylation by SMYD2 and FT subsequent interaction with L3MBTL1." FT /evidence="ECO:0000269|PubMed:20870719" FT MUTAGEN 870 FT /note="K->R: Does not affect the ability to be methylated FT by SMYD2; when associated with 873-R-R-874." FT /evidence="ECO:0000269|PubMed:20870719" FT MUTAGEN 873..874 FT /note="KK->R: Does not affect the ability to be methylated FT by SMYD2; when associated with 873-R-R-874." FT /evidence="ECO:0000269|PubMed:20870719, FT ECO:0000269|PubMed:20940255" FT MUTAGEN 873..874 FT /note="KK->RR: Does not alter Rb localization in cycling FT cells, but mislocalizes to the cytoplasm during FT keratinocyte differentiation. Does not affect the ability FT to arrest cell growth. Probable loss of acetylation by FT PCAF." FT /evidence="ECO:0000269|PubMed:20870719, FT ECO:0000269|PubMed:20940255" FT CONFLICT 500..501 FT /note="RS -> SN (in Ref. 7; AAN64133)" FT /evidence="ECO:0000305" FT HELIX 55..63 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 68..82 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 95..110 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 117..124 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 128..135 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 142..172 FT /evidence="ECO:0007829|PDB:2QDJ" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 188..204 FT /evidence="ECO:0007829|PDB:2QDJ" FT STRAND 207..209 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 212..228 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:2QDJ" FT TURN 237..240 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 241..243 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 272..281 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 285..294 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 296..299 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 302..306 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 314..328 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 333..338 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 341..343 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 347..353 FT /evidence="ECO:0007829|PDB:2QDJ" FT HELIX 382..391 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 398..405 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 407..409 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 412..434 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 439..468 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 474..477 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 480..501 FT /evidence="ECO:0007829|PDB:2R7G" FT TURN 504..506 FT /evidence="ECO:0007829|PDB:1N4M" FT STRAND 511..513 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 516..521 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 525..529 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 532..538 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 544..559 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 561..563 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:4ELJ" FT HELIX 569..577 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 582..586 FT /evidence="ECO:0007829|PDB:4ELL" FT HELIX 602..607 FT /evidence="ECO:0007829|PDB:4ELL" FT HELIX 645..669 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 676..690 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 692..695 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 700..714 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 721..728 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 731..733 FT /evidence="ECO:0007829|PDB:1N4M" FT HELIX 737..740 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 741..743 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 748..750 FT /evidence="ECO:0007829|PDB:9DHU" FT HELIX 752..758 FT /evidence="ECO:0007829|PDB:2R7G" FT HELIX 760..770 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 773..775 FT /evidence="ECO:0007829|PDB:2R7G" FT STRAND 830..836 FT /evidence="ECO:0007829|PDB:2AZE" FT TURN 838..840 FT /evidence="ECO:0007829|PDB:2AZE" FT HELIX 841..853 FT /evidence="ECO:0007829|PDB:2AZE" SQ SEQUENCE 928 AA; 106159 MW; C8E746111E19CC32 CRC64; MPPKTPRKTA ATAAAAAAEP PAPPPPPPPE EDPEQDSGPE DLPLVRLEFE ETEEPDFTAL CQKLKIPDHV RERAWLTWEK VSSVDGVLGG YIQKKKELWG ICIFIAAVDL DEMSFTFTEL QKNIEISVHK FFNLLKEIDT STKVDNAMSR LLKKYDVLFA LFSKLERTCE LIYLTQPSSS ISTEINSALV LKVSWITFLL AKGEVLQMED DLVISFQLML CVLDYFIKLS PPMLLKEPYK TAVIPINGSP RTPRRGQNRS ARIAKQLEND TRIIEVLCKE HECNIDEVKN VYFKNFIPFM NSLGLVTSNG LPEVENLSKR YEEIYLKNKD LDARLFLDHD KTLQTDSIDS FETQRTPRKS NLDEEVNVIP PHTPVRTVMN TIQQLMMILN SASDQPSENL ISYFNNCTVN PKESILKRVK DIGYIFKEKF AKAVGQGCVE IGSQRYKLGV RLYYRVMESM LKSEEERLSI QNFSKLLNDN IFHMSLLACA LEVVMATYSR STSQNLDSGT DLSFPWILNV LNLKAFDFYK VIESFIKAEG NLTREMIKHL ERCEHRIMES LAWLSDSPLF DLIKQSKDRE GPTDHLESAC PLNLPLQNNH TAADMYLSPV RSPKKKGSTT RVNSTANAET QATSAFQTQK PLKSTSLSLF YKKVYRLAYL RLNTLCERLL SEHPELEHII WTLFQHTLQN EYELMRDRHL DQIMMCSMYG ICKVKNIDLK FKIIVTAYKD LPHAVQETFK RVLIKEEEYD SIIVFYNSVF MQRLKTNILQ YASTRPPTLS PIPHIPRSPY KFPSSPLRIP GGNIYISPLK SPYKISEGLP TPTKMTPRSR ILVSIGESFG TSEKFQKINQ MVCNSDRVLK RSAEGSNPPK PLKKLRFDIE GSDEADGSKH LPGESKFQQK LAEMTSTRTR MQKQKMNDSM DTSNKEEK // ID RELB_HUMAN Reviewed; 579 AA. AC Q01201; Q6GTX7; Q9UEI7; DT 01-OCT-1993, integrated into UniProtKB/Swiss-Prot. DT 04-APR-2006, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Transcription factor RelB; DE AltName: Full=I-Rel; GN Name=RELB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=T-cell; RX PubMed=1577270; DOI=10.1101/gad.6.5.745; RA Ruben S.M., Klement J.F., Maher M., Coleman T.A., Chen C.H., Rosen C.A.; RT "I-Rel: a novel rel-related protein that inhibits NF-kappa B RT transcriptional activity."; RL Genes Dev. 6:745-760(1992). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Yoshiura K., Murray J.C.; RT "A transcriptional map in the region of 19q13 derived using direct RT sequencing and exon trapping."; RL Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION, AND IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX. RX PubMed=1732739; DOI=10.1128/mcb.12.2.674-684.1992; RA Ryseck R.P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., RA Bravo R.; RT "RelB, a new Rel family transcription activator that can interact with p50- RT NF-kappa B."; RL Mol. Cell. Biol. 12:674-684(1992). RN [6] RP FUNCTION. RX PubMed=8441398; DOI=10.1128/mcb.13.3.1572-1582.1993; RA Dobrzanski P., Ryseck R.P., Bravo R.; RT "Both N- and C-terminal domains of RelB are required for full RT transactivation: role of the N-terminal leucine zipper-like motif."; RL Mol. Cell. Biol. 13:1572-1582(1993). RN [7] RP FUNCTION, IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX, AND RP IDENTIFICATION IN THE NF-KAPPA-B RELB-P52 COMPLEX. RX PubMed=7925301; DOI=10.1002/j.1460-2075.1994.tb06782.x; RA Dobrzanski P., Ryseck R.P., Bravo R.; RT "Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha RT determine pools of constitutive and inducible NF-kappa B activity."; RL EMBO J. 13:4608-4616(1994). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37 AND SER-573, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [10] RP SUBCELLULAR LOCATION. RX PubMed=20873783; DOI=10.1021/pr100562w; RA Vaz Meirelles G., Ferreira Lanza D.C., da Silva J.C., Santana Bernachi J., RA Paes Leme A.F., Kobarg J.; RT "Characterization of hNek6 interactome reveals an important role for its RT short N-terminal domain and colocalization with proteins at the RT centrosome."; RL J. Proteome Res. 9:6298-6316(2010). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [12] RP FUNCTION, AND INDUCTION BY NUPR1. RX PubMed=22565310; DOI=10.1172/jci60144; RA Hamidi T., Algul H., Cano C.E., Sandi M.J., Molejon M.I., Riemann M., RA Calvo E.L., Lomberk G., Dagorn J.C., Weih F., Urrutia R., Schmid R.M., RA Iovanna J.L.; RT "Nuclear protein 1 promotes pancreatic cancer development and protects RT cells from stress by inhibiting apoptosis."; RL J. Clin. Invest. 122:2092-2103(2012). RN [13] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [14] RP FUNCTION, INVOLVEMENT IN IMD53, AND VARIANT IMD53 397-TYR--THR-579 DEL. RX PubMed=26385063; DOI=10.1016/j.jaut.2015.09.001; RA Sharfe N., Merico D., Karanxha A., Macdonald C., Dadi H., Ngan B., RA Herbrick J.A., Roifman C.M.; RT "The effects of RelB deficiency on lymphocyte development and function."; RL J. Autoimmun. 65:90-100(2015). CC -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor which is CC present in almost all cell types and is involved in many biological CC processed such as inflammation, immunity, differentiation, cell growth, CC tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric CC complex formed by the Rel-like domain-containing proteins RELA/p65, CC RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at CC kappa-B sites in the DNA of their target genes and the individual CC dimers have distinct preferences for different kappa-B sites that they CC can bind with distinguishable affinity and specificity. Different dimer CC combinations act as transcriptional activators or repressors, CC respectively. NF-kappa-B is controlled by various mechanisms of post- CC translational modification and subcellular compartmentalization as well CC as by interactions with other cofactors or corepressors. NF-kappa-B CC complexes are held in the cytoplasm in an inactive state complexed with CC members of the NF-kappa-B inhibitor (I-kappa-B) family. In a CC conventional activation pathway, I-kappa-B is phosphorylated by I- CC kappa-B kinases (IKKs) in response to different activators, CC subsequently degraded thus liberating the active NF-kappa-B complex CC which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 CC and RelB-p52 complexes are transcriptional activators. RELB neither CC associates with DNA nor with RELA/p65 or REL. Stimulates promoter CC activity in the presence of NFKB2/p49. As a member of the CC NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal CC adenocarcinoma with remarkable resistance to cell stress, such as CC starvation or gemcitabine treatment. Regulates the circadian clock by CC repressing the transcriptional activator activity of the CLOCK-BMAL1 CC heterodimer in a CRY1/CRY2 independent manner. Increased repression of CC the heterodimer is seen in the presence of NFKB2/p52. Is required for CC both T and B lymphocyte maturation and function (PubMed:26385063). CC {ECO:0000269|PubMed:1732739, ECO:0000269|PubMed:22565310, CC ECO:0000269|PubMed:26385063, ECO:0000269|PubMed:7925301, CC ECO:0000269|PubMed:8441398}. CC -!- SUBUNIT: Component of the NF-kappa-B RelB-p50 complex. Component of the CC NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to CC be transient and may prevent degradation allowing for heterodimer CC formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and CC NFKB2/p100. Interacts with NFKBID. Interacts with BMAL1 and the CC interaction is enhanced in the presence of CLOCK (By similarity). CC {ECO:0000250}. CC -!- INTERACTION: CC Q01201; Q8N668: COMMD1; NbExp=2; IntAct=EBI-357837, EBI-1550112; CC Q01201; P49841: GSK3B; NbExp=4; IntAct=EBI-357837, EBI-373586; CC Q01201; P19838: NFKB1; NbExp=8; IntAct=EBI-357837, EBI-300010; CC Q01201; Q00653: NFKB2; NbExp=6; IntAct=EBI-357837, EBI-307326; CC Q01201; Q00653-3: NFKB2; NbExp=2; IntAct=EBI-357837, EBI-50432018; CC Q01201; P25963: NFKBIA; NbExp=4; IntAct=EBI-357837, EBI-307386; CC Q01201; O00221: NFKBIE; NbExp=4; IntAct=EBI-357837, EBI-355098; CC Q01201; Q04206-2: RELA; NbExp=2; IntAct=EBI-357837, EBI-289947; CC Q01201; Q92922: SMARCC1; NbExp=2; IntAct=EBI-357837, EBI-355653; CC Q01201; Q96GM5: SMARCD1; NbExp=2; IntAct=EBI-357837, EBI-358489; CC Q01201; Q92925: SMARCD2; NbExp=2; IntAct=EBI-357837, EBI-358441; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20873783}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:20873783}. Note=Colocalizes with NEK6 in the CC centrosome. CC -!- INDUCTION: Up-regulated by mitogens and NUPR1. CC {ECO:0000269|PubMed:22565310}. CC -!- DOMAIN: Both N- and C-terminal domains are required for transcriptional CC activation. CC -!- PTM: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by CC proteasomal degradation. {ECO:0000250}. CC -!- DISEASE: Immunodeficiency 53 (IMD53) [MIM:617585]: An autosomal CC recessive primary immunodeficiency apparent from early infancy and CC resulting in recurrent infections, severe autoimmune skin disease CC rheumatoid arthritis, and failure to thrive. Immunologic workup shows CC increased CD4+/CD8+ ratio, impaired T-cell proliferative response to CC multiple antigen, T-cell developmental and functional defects, and CC impaired ability to produce specific immunoglobulins. CC {ECO:0000269|PubMed:26385063}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- CAUTION: Was originally thought to inhibit the transcriptional activity CC of nuclear factor NF-kappa-B. {ECO:0000305|PubMed:1577270}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/324/RELB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M83221; AAA36127.1; -; mRNA. DR EMBL; AF043463; AAC82346.1; -; Genomic_DNA. DR EMBL; AF043454; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043455; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043456; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043457; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043458; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043459; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043460; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043461; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043462; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; DQ314887; ABC40746.1; -; Genomic_DNA. DR EMBL; BC028013; AAH28013.1; -; mRNA. DR CCDS; CCDS46110.1; -. DR PIR; A42617; A42617. DR RefSeq; NP_006500.2; NM_006509.3. DR PDB; 8G8R; X-ray; 2.60 A; B=407-440. DR PDBsum; 8G8R; -. DR AlphaFoldDB; Q01201; -. DR SMR; Q01201; -. DR BioGRID; 111903; 77. DR ComplexPortal; CPX-5831; NF-kappaB DNA-binding transcription factor complex, p52/RelB. DR ComplexPortal; CPX-5833; NF-kappaB DNA-binding transcription factor complex, p50/RelB. DR CORUM; Q01201; -. DR DIP; DIP-27531N; -. DR FunCoup; Q01201; 727. DR IntAct; Q01201; 93. DR MINT; Q01201; -. DR STRING; 9606.ENSP00000221452; -. DR ChEMBL; CHEMBL4523273; -. DR DrugBank; DB01822; (4R,5R)-1,2-dithiane-4,5-diol. DR DrugBank; DB15010; Edasalonexent. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB06685; Laquinimod. DR DrugBank; DB13063; Parthenolide. DR DrugBank; DB12058; Recoflavone. DR DrugBank; DB15495; Rocaglamide. DR DrugBank; DB00795; Sulfasalazine. DR DrugBank; DB18804; Tepilamide fumarate. DR DrugBank; DB12025; Triptolide. DR DrugBank; DB06439; Tyloxapol. DR DrugBank; DB06235; Vadimezan. DR GlyGen; Q01201; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q01201; -. DR PhosphoSitePlus; Q01201; -. DR BioMuta; RELB; -. DR DMDM; 92090634; -. DR jPOST; Q01201; -. DR MassIVE; Q01201; -. DR PaxDb; 9606-ENSP00000221452; -. DR PeptideAtlas; Q01201; -. DR ProteomicsDB; 57938; -. DR Pumba; Q01201; -. DR Antibodypedia; 3573; 670 antibodies from 44 providers. DR DNASU; 5971; -. DR Ensembl; ENST00000221452.13; ENSP00000221452.7; ENSG00000104856.15. DR GeneID; 5971; -. DR KEGG; hsa:5971; -. DR MANE-Select; ENST00000221452.13; ENSP00000221452.7; NM_006509.4; NP_006500.2. DR UCSC; uc060zvi.1; human. DR AGR; HGNC:9956; -. DR ClinPGx; PA34322; -. DR CTD; 5971; -. DR DisGeNET; 5971; -. DR GeneCards; RELB; -. DR HGNC; HGNC:9956; RELB. DR HPA; ENSG00000104856; Low tissue specificity. DR MalaCards; RELB; -. DR MIM; 604758; gene. DR MIM; 617585; phenotype. DR OpenTargets; ENSG00000104856; -. DR Orphanet; 688594; Combined immunodeficiency due to RELB deficiency. DR VEuPathDB; HostDB:ENSG00000104856; -. DR eggNOG; ENOG502QV8A; Eukaryota. DR GeneTree; ENSGT00940000160230; -. DR InParanoid; Q01201; -. DR OMA; NQYREGA; -. DR OrthoDB; 7881762at2759; -. DR PAN-GO; Q01201; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q01201; -. DR PathwayCommons; Q01201; -. DR Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling. DR SignaLink; Q01201; -. DR SIGNOR; Q01201; -. DR Agora; ENSG00000104856; -. DR BioGRID-ORCS; 5971; 22 hits in 1173 CRISPR screens. DR ChiTaRS; RELB; human. DR GeneWiki; RELB; -. DR GenomeRNAi; 5971; -. DR Pharos; Q01201; Tbio. DR PRO; PR:Q01201; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q01201; protein. DR Bgee; ENSG00000104856; Expressed in granulocyte and 100 other cell types or tissues. DR ExpressionAtlas; Q01201; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000785; C:chromatin; IDA:ARUK-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0071159; C:NF-kappaB complex; NAS:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:CACAO. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:Ensembl. DR GO; GO:0017053; C:transcription repressor complex; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0019882; P:antigen processing and presentation; IEA:Ensembl. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IBA:GO_Central. DR GO; GO:0071470; P:cellular response to osmotic stress; IEA:Ensembl. DR GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IBA:GO_Central. DR GO; GO:0030098; P:lymphocyte differentiation; IMP:UniProtKB. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0032688; P:negative regulation of interferon-beta production; IMP:CACAO. DR GO; GO:0038061; P:non-canonical NF-kappaB signal transduction; IBA:GO_Central. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0034097; P:response to cytokine; IBA:GO_Central. DR GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl. DR CDD; cd01177; IPT_NFkappaB; 1. DR CDD; cd07886; RHD-n_RelB; 1. DR FunFam; 2.60.40.10:FF:000046; Nuclear factor NF-kappa-B p105 subunit; 1. DR FunFam; 2.60.40.340:FF:000005; RELB proto-oncogene, NF-kB subunit; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 2.60.40.340; Rel homology domain (RHD), DNA-binding domain; 1. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR014756; Ig_E-set. DR InterPro; IPR002909; IPT_dom. DR InterPro; IPR033926; IPT_NFkappaB. DR InterPro; IPR000451; NFkB/Dor. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR032399; RelB_leu_zip. DR InterPro; IPR030496; RelB_RHD_N. DR InterPro; IPR032400; RelB_transact. DR InterPro; IPR030492; RHD_CS. DR InterPro; IPR032397; RHD_dimer. DR InterPro; IPR011539; RHD_DNA_bind_dom. DR InterPro; IPR037059; RHD_DNA_bind_dom_sf. DR PANTHER; PTHR24169; NUCLEAR FACTOR NF-KAPPA-B PROTEIN; 1. DR PANTHER; PTHR24169:SF18; TRANSCRIPTION FACTOR RELB; 1. DR Pfam; PF16180; RelB_leu_zip; 1. DR Pfam; PF16181; RelB_transactiv; 1. DR Pfam; PF16179; RHD_dimer; 1. DR Pfam; PF00554; RHD_DNA_bind; 1. DR PRINTS; PR00057; NFKBTNSCPFCT. DR SMART; SM00429; IPT; 1. DR SUPFAM; SSF81296; E set domains; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS01204; REL_1; 1. DR PROSITE; PS50254; REL_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Biological rhythms; Cytoplasm; Cytoskeleton; KW Disease variant; DNA-binding; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation. FT CHAIN 1..579 FT /note="Transcription factor RelB" FT /id="PRO_0000205173" FT DOMAIN 125..440 FT /note="RHD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00265" FT REGION 1..39 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 40..68 FT /note="Leucine-zipper" FT MOTIF 433..438 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOD_RES 16 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT VARIANT 396 FT /note="T -> M (in dbSNP:rs770682728)" FT /id="VAR_051782" FT VARIANT 397..579 FT /note="Missing (in IMD53)" FT /evidence="ECO:0000269|PubMed:26385063" FT /id="VAR_079201" FT CONFLICT 139 FT /note="R -> P (in Ref. 1; AAA36127)" FT /evidence="ECO:0000305" FT CONFLICT 411 FT /note="R -> A (in Ref. 1; AAA36127)" FT /evidence="ECO:0000305" SQ SEQUENCE 579 AA; 62134 MW; C2C61C2C8640513E CRC64; MLRSGPASGP SVPTGRAMPS RRVARPPAAP ELGALGSPDL SSLSLAVSRS TDELEIIDEY IKENGFGLDG GQPGPGEGLP RLVSRGAASL STVTLGPVAP PATPPPWGCP LGRLVSPAPG PGPQPHLVIT EQPKQRGMRF RYECEGRSAG SILGESSTEA SKTLPAIELR DCGGLREVEV TACLVWKDWP HRVHPHSLVG KDCTDGICRV RLRPHVSPRH SFNNLGIQCV RKKEIEAAIE RKIQLGIDPY NAGSLKNHQE VDMNVVRICF QASYRDQQGQ MRRMDPVLSE PVYDKKSTNT SELRICRINK ESGPCTGGEE LYLLCDKVQK EDISVVFSRA SWEGRADFSQ ADVHRQIAIV FKTPPYEDLE IVEPVTVNVF LQRLTDGVCS EPLPFTYLPR DHDSYGVDKK RKRGMPDVLG ELNSSDPHGI ESKRRKKKPA ILDHFLPNHG SGPFLPPSAL LPDPDFFSGT VSLPGLEPPG GPDLLDDGFA YDPTAPTLFT MLDLLPPAPP HASAVVCSGG AGAVVGETPG PEPLTLDSYQ APGPGDGGTA SLVGSNMFPN HYREAAFGGG LLSPGPEAT // ID RET_HUMAN Reviewed; 1114 AA. AC P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 3. DT 28-JAN-2026, entry version 284. DE RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305}; DE EC=2.7.10.1 {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; DE AltName: Full=Cadherin family member 12; DE AltName: Full=Proto-oncogene c-Ret {ECO:0000303|PubMed:2660074}; DE Contains: DE RecName: Full=Soluble RET kinase fragment {ECO:0000305|PubMed:21357690}; DE Contains: DE RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment {ECO:0000305|PubMed:21357690}; DE Flags: Precursor; GN Name=RET {ECO:0000303|PubMed:2660074, ECO:0000312|HGNC:HGNC:9967}; GN Synonyms=CDHF12, CDHR16, PTC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Prostate; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2). RX PubMed=2660074; RA Takahashi M.; RT "Isolation of ret proto-oncogene cDNA with an amino-terminal signal RT sequence."; RL Oncogene 4:805-806(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1). RX PubMed=3078962; RA Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.; RT "Cloning and expression of the ret proto-oncogene encoding a tyrosine RT kinase with two potential transmembrane domains."; RL Oncogene 3:571-578(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL RP TRANSLOCATION WITH TRIM27. RX PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987; RA Takahashi M., Cooper G.M.; RT "ret transforming gene encodes a fusion protein homologous to tyrosine RT kinases."; RL Mol. Cell. Biol. 7:1378-1385(1987). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH GOLGA5. RC TISSUE=Fibroblast; RX PubMed=2734021; RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RT "Activation of the ret-II oncogene without a sequence encoding a RT transmembrane domain and transforming activity of two ret-II oncogene RT products differing in carboxy-termini due to alternative splicing."; RL Oncogene 4:789-794(1989). RN [8] RP ERRATUM OF PUBMED:2734021. RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RL Oncogene 4:1415-1415(1989). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CCDC6. RC TISSUE=Thyroid papillary carcinoma; RX PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3; RA Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., RA Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.; RT "PTC is a novel rearranged form of the ret proto-oncogene and is frequently RT detected in vivo in human thyroid papillary carcinomas."; RL Cell 60:557-563(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL RP TRANSLOCATION WITH PCM1. RX PubMed=10980597; DOI=10.1038/sj.onc.1203772; RA Corvi R., Berger N., Balczon R., Romeo G.; RT "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma."; RL Oncogene 19:4236-4242(2000). RN [11] RP SUBCELLULAR LOCATION, AND COFACTOR. RX PubMed=9575150; DOI=10.1074/jbc.273.20.12077; RA van Weering D.H., Moen T.C., Braakman I., Baas P.D., Bos J.L.; RT "Expression of the receptor tyrosine kinase Ret on the plasma membrane is RT dependent on calcium."; RL J. Biol. Chem. 273:12077-12081(1998). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24. RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [13] RP PHOSPHORYLATION AT TYR-1015 AND TYR-1062. RX PubMed=11061555; DOI=10.1210/jcem.85.10.6882; RA Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G., RA Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.; RT "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and RT ret-derived oncoproteins."; RL J. Clin. Endocrinol. Metab. 85:3898-3907(2000). RN [14] RP COFACTOR, AND MUTAGENESIS OF TYR-36; TYR-41 AND TRP-85. RX PubMed=11445581; DOI=10.1074/jbc.m104968200; RA Anders J., Kjar S., Ibanez C.F.; RT "Molecular modeling of the extracellular domain of the RET receptor RT tyrosine kinase reveals multiple cadherin-like domains and a calcium- RT binding site."; RL J. Biol. Chem. 276:35808-35817(2001). RN [15] RP PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015; RP TYR-1062; TYR-1090 AND TYR-1096. RX PubMed=14711813; DOI=10.1074/jbc.m312600200; RA Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M., RA Suzuki H., Takahashi M., Nakashima I.; RT "Identification of RET autophosphorylation sites by mass spectrometry."; RL J. Biol. Chem. 279:14213-14224(2004). RN [16] RP CHROMOSOMAL TRANSLOCATION WITH TRIM27. RX PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3; RA Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E., RA Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A., RA Namba H., Tsyb A., Yamashita S.; RT "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid RT carcinoma from externally irradiated patient."; RL Mutat. Res. 527:81-90(2003). RN [17] RP RETRACTED PAPER. RX PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RT "The receptor-type protein tyrosine phosphatase J antagonizes the RT biochemical and biological effects of RET-derived oncoproteins."; RL Cancer Res. 66:6280-6287(2006). RN [18] RP RETRACTION NOTICE OF PUBMED:16778204. RX PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RL Cancer Res. 78:6907-6907(2018). RN [19] RP ACTIVITY REGULATION. RX PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104; RA Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.; RT "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET RT kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 17:5886-5893(2007). RN [20] RP ACTIVITY REGULATION BY SORAFENIB. RX PubMed=17664273; DOI=10.1074/jbc.m703461200; RA Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., RA Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.; RT "Sorafenib functions to potently suppress RET tyrosine kinase activity by RT direct enzymatic inhibition and promoting RET lysosomal degradation RT independent of proteasomal targeting."; RL J. Biol. Chem. 282:29230-29240(2007). RN [21] RP ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES. RX PubMed=19053769; DOI=10.1021/jm8007823; RA Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L., RA Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.; RT "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and RT 4-substituted beta-carbolin-1-ones."; RL J. Med. Chem. 51:7777-7787(2008). RN [22] RP INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758. RX PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008; RA Tsui C.C., Pierchala B.A.; RT "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation RT of ret signal transduction."; RL J. Neurosci. 28:8789-8800(2008). RN [23] RP INTERACTION WITH AIP. RX PubMed=19366855; DOI=10.1210/jc.2008-1980; RA Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I., RA Melcarne A., Rimondini R., Romeo G., Bonora E.; RT "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon RT receptor-interacting protein to alter survivin availability."; RL J. Clin. Endocrinol. Metab. 94:2571-2578(2009). RN [24] RP INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3. RX PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055; RA Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H., RA Garcia-Barcelo M.M.; RT "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3."; RL J. Pediatr. Surg. 44:1904-1912(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS. RX PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014; RA Ma Q.; RT "RETouching upon mechanoreceptors."; RL Neuron 64:773-776(2009). RN [27] RP ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS. RX PubMed=20605972; DOI=10.1210/er.2009-0031; RA Ye L., Santarpia L., Gagel R.F.; RT "The evolving field of tyrosine kinase inhibitors in the treatment of RT endocrine tumors."; RL Endocr. Rev. 31:578-599(2010). RN [28] RP ACTIVITY REGULATION. RX PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017; RA Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C., RA Kunick C.; RT "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- RT thienyl)nicotinonitrile scaffold."; RL Eur. J. Med. Chem. 45:2919-2927(2010). RN [29] RP FUNCTION IN PITUITARY. RX PubMed=20616503; DOI=10.1159/000318502; RA Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E., RA Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.; RT "Functional role of the RET dependence receptor, GFRa co-receptors and RT ligands in the pituitary."; RL Front. Horm. Res. 38:127-138(2010). RN [30] RP FUNCTION IN CELL ADHESION/MIGRATION. RX PubMed=20702524; DOI=10.1210/jc.2010-0771; RA Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.; RT "RET-mediated cell adhesion and migration require multiple integrin RT subunits."; RL J. Clin. Endocrinol. Metab. 95:E342-E346(2010). RN [31] RP SUBCELLULAR LOCATION. RX PubMed=19823924; DOI=10.1007/s10895-009-0548-x; RA Richardson D.S., Mulligan L.M.; RT "Direct visualization of vesicle maturation and plasma membrane protein RT trafficking."; RL J. Fluoresc. 20:401-405(2010). RN [32] RP ACTIVITY REGULATION. RX PubMed=21134556; DOI=10.1016/j.surg.2010.09.026; RA Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.; RT "A novel RET inhibitor with potent efficacy against medullary thyroid RT cancer in vivo."; RL Surgery 148:1228-1236(2010). RN [33] RP FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY RP CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND RP 708-ALA--SER-1114, AND SUBUNIT. RX PubMed=21357690; DOI=10.1074/jbc.m110.195461; RA Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.; RT "RET modulates cell adhesion via its cleavage by caspase in sympathetic RT neurons."; RL J. Biol. Chem. 286:14628-14638(2011). RN [34] RP INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION. RX PubMed=21454698; DOI=10.1074/jbc.m110.168500; RA Plaza-Menacho I., Morandi A., Mologni L., Boender P., RA Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P., RA McDonald N.Q., Isacke C.M.; RT "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming RT a direct and reciprocal RET-FAK transactivation mechanism."; RL J. Biol. Chem. 286:17292-17302(2011). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21994944; DOI=10.1074/jbc.m111.246413; RA Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.; RT "Sorting protein-related receptor SorLA controls regulated secretion of RT glial cell line-derived neurotrophic factor."; RL J. Biol. Chem. 286:41871-41882(2011). RN [36] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011; RA Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C., RA Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P., RA Saarma M., Nykjaer A., Petersen C.M.; RT "SorLA controls neurotrophic activity by sorting of GDNF and its receptors RT GFRalpha1 and RET."; RL Cell Rep. 3:186-199(2013). RN [37] RP INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF RP TYR-1062. RX PubMed=28953886; DOI=10.1038/nature24042; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 550:255-259(2017). RN [38] RP ERRATUM OF PUBMED:28953886. RX PubMed=29144449; DOI=10.1038/nature24481; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 551:398-398(2017). RN [39] RP FUNCTION, AND INTERACTION WITH GFRAL. RX PubMed=28846097; DOI=10.1038/nm.4392; RA Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L., RA Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D., RA Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.; RT "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in RT mice and nonhuman primates."; RL Nat. Med. 23:1150-1157(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH GFRAL, AND PHOSPHORYLATION RP AT TYR-905 AND TYR-1062. RX PubMed=28846099; DOI=10.1038/nm.4394; RA Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X., RA Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B., RA Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M., RA Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.; RT "GFRAL is the receptor for GDF15 and is required for the anti-obesity RT effects of the ligand."; RL Nat. Med. 23:1158-1166(2017). RN [41] RP GLYCOSYLATION AT SER-688. RX PubMed=26237509; DOI=10.1038/nsmb.3063; RA Pathak S., Alonso J., Schimpl M., Rafie K., Blair D.E., Borodkin V.S., RA Albarbarawi O., van Aalten D.M.F.; RT "The active site of O-GlcNAc transferase imposes constraints on substrate RT sequence."; RL Nat. Struct. Mol. Biol. 22:744-750(2015). RN [42] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH RP INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT RP TYR-900 AND TYR-905. RX PubMed=16928683; DOI=10.1074/jbc.m605604200; RA Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., RA Santoro M., Ibanez C.F., McDonald N.Q.; RT "Structure and chemical inhibition of the RET tyrosine kinase domain."; RL J. Biol. Chem. 281:33577-33587(2006). RN [43] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905. RX PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011; RA Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S., RA Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q., RA Lucchini V., Gambacorti-Passerini C.; RT "Synthesis, structure-activity relationship and crystallographic studies of RT 3-substituted indolin-2-one RET inhibitors."; RL Bioorg. Med. Chem. 18:1482-1496(2010). RN [44] {ECO:0007744|PDB:2X2U} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151, RP AND DISULFIDE BONDS. RX PubMed=20473317; DOI=10.1038/nsmb.1808; RA Kjaer S., Hanrahan S., Totty N., McDonald N.Q.; RT "Mammal-restricted elements predispose human RET to folding impairment by RT HSCR mutations."; RL Nat. Struct. Mol. Biol. 17:726-731(2010). RN [45] {ECO:0007744|PDB:4UX8} RP STRUCTURE BY ELECTRON MICROSCOPY (24.00 ANGSTROMS) OF 29-635 IN COMPLEX RP WITH GFRA1; GDNF AND CALCIUM, FUNCTION, COFACTOR, AND DISULFIDE BONDS. RX PubMed=25242331; DOI=10.1016/j.celrep.2014.08.040; RA Goodman K.M., Kjaer S., Beuron F., Knowles P.P., Nawrotek A., Burns E.M., RA Purkiss A.G., George R., Santoro M., Morris E.P., McDonald N.Q.; RT "RET recognition of GDNF-GFRalpha1 ligand by a composite binding site RT promotes membrane-proximal self-association."; RL Cell Rep. 8:1894-1904(2014). RN [46] {ECO:0007744|PDB:4CKI, ECO:0007744|PDB:4CKJ} RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP ADENOSINE, FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-687; RP TYR-826; TYR-900; TYR-905; TYR-981; TYR-1015; TYR-1029 AND TYR-1062, RP MUTAGENESIS OF GLU-734; LYS-758; ARG-912 AND ILE-913, VARIANT MEN2B RP THR-918, CHARACTERIZATION OF VARIANT MEN2B THR-918, VARIANT MTC MET-804, RP AND CHARACTERIZATION OF VARIANT MTC MET-804. RX PubMed=24560924; DOI=10.1016/j.molcel.2014.01.015; RA Plaza-Menacho I., Barnouin K., Goodman K., Martinez-Torres R.J., Borg A., RA Murray-Rust J., Mouilleron S., Knowles P., McDonald N.Q.; RT "Oncogenic RET kinase domain mutations perturb the autophosphorylation RT trajectory by enhancing substrate presentation in trans."; RL Mol. Cell 53:738-751(2014). RN [47] {ECO:0007744|PDB:6NE7, ECO:0007744|PDB:6NEC, ECO:0007744|PDB:6NJA} RP X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) OF 705-1013, FUNCTION, ACTIVITY RP REGULATION, VARIANT MTC VAL-881, CHARACTERIZATION OF VARIANT MTC VAL-881, RP VARIANT ALA-810, AND CHARACTERIZATION OF VARIANT ALA-810. RX PubMed=31118272; DOI=10.1074/jbc.ra119.007682; RA Terzyan S.S., Shen T., Liu X., Huang Q., Teng P., Zhou M., Hilberg F., RA Cai J., Mooers B.H.M., Wu J.; RT "Structural basis of resistance of mutant RET protein-tyrosine kinase to RT its inhibitors nintedanib and vandetanib."; RL J. Biol. Chem. 294:10428-10437(2019). RN [48] {ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S} RP STRUCTURE BY ELECTRON MICROSCOPY (3.65 ANGSTROMS) OF 29-635 IN COMPLEX WITH RP CALCIUM; GDF15; GFRAL; GFRA1; GFRA2; GFRA3; GDNF; NRTN AND ARTN, COFACTOR, RP AND DISULFIDE BONDS. RX PubMed=31535977; DOI=10.7554/elife.47650; RA Li J., Shang G., Chen Y.J., Brautigam C.A., Liou J., Zhang X., Bai X.C.; RT "Cryo-EM analyses reveal the common mechanism and diversification in the RT activation of RET by different ligands."; RL Elife 8:0-0(2019). RN [49] RP REVIEW ON HSCR VARIANTS. RX PubMed=9359036; RA Hofstra R.M.W., Osinga J., Buys C.H.C.M.; RT "Mutations in Hirschsprung disease: when does a mutation contribute to the RT phenotype."; RL Eur. J. Hum. Genet. 5:180-185(1997). RN [50] RP VARIANTS MEN2A/MTC TYR-611; PHE-618; GLY-620 AND PHE-630. RX PubMed=9067749; RX DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m; RA Eng C., Mulligan L.M.; RT "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia RT type 2 syndromes, related sporadic tumours, and Hirschsprung disease."; RL Hum. Mutat. 9:97-109(1997). RN [51] RP VARIANTS MEN2A/MTC TRP-611; SER-618; TYR-618; ARG-620; TYR-620 AND ARG-634. RX PubMed=8103403; DOI=10.1093/hmg/2.7.851; RA Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., RA Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.; RT "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC."; RL Hum. Mol. Genet. 2:851-856(1993). RN [52] RP VARIANTS MEN2A GLY-618; 632-GLU--CYS-634 DELINS ASP-VAL-ARG; GLY-634; RP PHE-634; TYR-634 AND SER-634. RX PubMed=8099202; DOI=10.1038/363458a0; RA Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., RA Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., RA Tunnacliffe A., Ponder B.A.J.; RT "Germ-line mutations of the RET proto-oncogene in multiple endocrine RT neoplasia type 2A."; RL Nature 363:458-460(1993). RN [53] RP VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND RP LEU-973. RX PubMed=7704557; DOI=10.1159/000472371; RA Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I., RA Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M., RA Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M., RA Martucciello G., Romeo G.; RT "Heterogeneity and low detection rate of RET mutations in Hirschsprung RT disease."; RL Eur. J. Hum. Genet. 2:272-280(1994). RN [54] RP VARIANT MEN2B THR-918. RX PubMed=7911697; DOI=10.1093/hmg/3.2.237; RA Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A., RA Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.; RT "Point mutation within the tyrosine kinase domain of the RET proto-oncogene RT in multiple endocrine neoplasia type 2B and related sporadic tumours."; RL Hum. Mol. Genet. 3:237-241(1994). RN [55] RP VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND RP TYR-634. RX PubMed=7915165; DOI=10.1093/hmg/3.4.635; RA Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K., RA Browden D.W., Mao J.-I., Noll W.W.; RT "Germline RET mutations in MEN 2A and FMTC and their detection by simple RT DNA diagnostic tests."; RL Hum. Mol. Genet. 3:635-638(1994). RN [56] RP VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620. RX PubMed=7849720; DOI=10.1093/hmg/3.10.1895; RA Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B., RA Hruban R.H., Sidransky D.; RT "RET proto-oncogene mutations in inherited and sporadic medullary thyroid RT cancer."; RL Hum. Mol. Genet. 3:1895-1897(1994). RN [57] RP VARIANTS MTC, AND VARIANTS MEN2A. RX PubMed=7874109; DOI=10.1093/hmg/3.11.1939; RA Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N., RA Calmettes C., Modigliani E., Lenoir G.M.; RT "RET proto-oncogene mutations in French MEN 2A and FMTC families."; RL Hum. Mol. Genet. 3:1939-1943(1994). RN [58] RP VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND RP VARIANT MTC ARG-620. RX PubMed=7881414; DOI=10.1093/hmg/3.12.2163; RA Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J., RA Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J., RA Munnich A., Ponder B.A.J.; RT "Diverse phenotypes associated with exon 10 mutations of the RET proto- RT oncogene."; RL Hum. Mol. Genet. 3:2163-2167(1994). RN [59] RP VARIANT HSCR1 LYS-921. RX PubMed=7997019; DOI=10.1016/s0140-6736(94)92908-4; RA Pelet A., Attie T., Goulet O., Eng C., Ponder B.A., Munnich A., Lyonnet S.; RT "De-novo mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Lancet 344:1769-1770(1994). RN [60] RP VARIANT MEN2B THR-918. RX PubMed=7906866; DOI=10.1038/367375a0; RA Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., RA Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G., RA Lips C.J.M., Buys C.H.C.M.; RT "A mutation in the RET proto-oncogene associated with multiple endocrine RT neoplasia type 2B and sporadic medullary thyroid carcinoma."; RL Nature 367:375-376(1994). RN [61] RP VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972. RX PubMed=8114938; DOI=10.1038/367377a0; RA Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., RA Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.; RT "Point mutations affecting the tyrosine kinase domain of the RET proto- RT oncogene in Hirschsprung's disease."; RL Nature 367:377-378(1994). RN [62] RP VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393. RX PubMed=8114939; DOI=10.1038/367378a0; RA Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., RA Nihoul-Fkete C., Ponder B.A.J., Munnich A.; RT "Mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Nature 367:378-380(1994). RN [63] RP VARIANT MEN2B THR-918. RX PubMed=7906417; DOI=10.1073/pnas.91.4.1579; RA Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., RA Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.; RT "Single missense mutation in the tyrosine kinase catalytic domain of the RT RET protooncogene is associated with multiple endocrine neoplasia type RT 2B."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994). RN [64] RP VARIANTS MTC; MEN2A AND MEN2B. RX PubMed=8625130; RX DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m; RA Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., RA Colomer A., Roth J., Heitz P.U.; RT "Analysis of RET protooncogene point mutations distinguishes heritable from RT nonheritable medullary thyroid carcinomas."; RL Cancer 76:479-489(1995). RN [65] RP VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634. RX PubMed=7860065; DOI=10.1007/bf00209399; RA Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S., RA Takami H., Hikiji K., Nakamura Y.; RT "Germline mutations of the RET proto-oncogene in eight Japanese patients RT with multiple endocrine neoplasia type 2A (MEN2A)."; RL Hum. Genet. 95:187-190(1995). RN [66] RP VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT RP CYS-982. RC TISSUE=Blood; RX PubMed=7633441; DOI=10.1093/hmg/4.5.821; RA Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W., RA Buys C.H.C.M., Cass D.T., Chakravarti A.; RT "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung RT disease."; RL Hum. Mol. Genet. 4:821-830(1995). RN [67] RP VARIANTS HSCR1 HIS-231 AND LYS-251. RC TISSUE=Leukocyte; RX PubMed=7581377; DOI=10.1093/hmg/4.8.1381; RA Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L., RA Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.; RT "Diversity of RET proto-oncogene mutations in familial and sporadic RT Hirschsprung disease."; RL Hum. Mol. Genet. 4:1381-1386(1995). RN [68] RP VARIANT MEN2B THR-918, AND VARIANT TYR-922. RX PubMed=8595427; DOI=10.1093/hmg/4.10.1987; RA Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.; RT "Two maternally derived missense mutations in the tyrosine kinase domain of RT the RET protooncogene in a patient with de novo MEN 2B."; RL Hum. Mol. Genet. 4:1987-1988(1995). RN [69] RP VARIANT MTC ASP-768. RX PubMed=7845675; RA Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., RA Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.; RT "A novel point mutation in the tyrosine kinase domain of the RET proto- RT oncogene in sporadic medullary thyroid carcinoma and in a family with RT FMTC."; RL Oncogene 10:509-513(1995). RN [70] RP VARIANTS MTC ASP-768 AND LEU-804. RX PubMed=7784092; RA Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., RA Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J., RA Lenoir G.M., Romeo G.; RT "RET mutations in exons 13 and 14 of FMTC patients."; RL Oncogene 10:2415-2419(1995). RN [71] RP VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND RP PRO-1061. RA Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C., RA Buys C.H.C.M.; RT "Mutations in three genes are found associated with the development of RT Hirschsprung disease: RET, EDNRB and EDN3."; RL Am. J. Hum. Genet. 59:A263-A263(1996). RN [72] RP VARIANTS HSCR1 PRO-40 AND PRO-765. RX PubMed=9043870; DOI=10.1159/000472232; RA Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.; RT "Prevalence and parental origin of de novo RET mutations in Hirschsprung's RT disease."; RL Eur. J. Hum. Genet. 4:356-358(1996). RN [73] RP VARIANTS MTC/MEN2A. RX PubMed=8557249; DOI=10.1007/bf00218825; RA Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M., RA van Amstel H.K.P.; RT "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, RT MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A."; RL Hum. Genet. 97:11-14(1996). RN [74] RP VARIANT MTC ASP-768, VARIANTS MEN2A ARG-609; GLY-609; SER-611 AND ARG-611, RP AND VARIANT MEN2B THR-918. RX PubMed=8807338; RX DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p; RA Kambouris M., Jackson C.E., Feldman G.L.; RT "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial RT medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses RT of RET proto-oncogene mutations."; RL Hum. Mutat. 8:64-70(1996). RN [75] RP VARIANTS MEN2A. RX PubMed=8626834; DOI=10.1210/jcem.81.5.8626834; RA Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R., RA Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M., RA Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G., RA Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G., RA Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J., RA Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J., RA Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.; RT "Mutations of the ret protooncogene in German multiple endocrine neoplasia RT families: relation between genotype and phenotype."; RL J. Clin. Endocrinol. Metab. 81:1780-1783(1996). RN [76] RP VARIANT HSCR1 LEU-893. RX PubMed=9174404; DOI=10.1002/bies.950190506; RA Edery P., Eng C., Munnich A., Lyonnet S.; RT "RET in human development and oncogenesis."; RL Bioessays 19:389-395(1997). RN [77] RP VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS. RX PubMed=9097963; DOI=10.1093/hmg/6.4.587; RA Hoeppner W., Ritter M.M.; RT "A duplication of 12 bp in the critical cysteine rich domain of the RET RT proto-oncogene results in a distinct phenotype of multiple endocrine RT neoplasia type 2A."; RL Hum. Mol. Genet. 6:587-590(1997). RN [78] RP VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791. RX PubMed=9090527; RX DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8; RA Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B., RA Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M., RA Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I., RA Silengo M., Martucciello G., Romeo G.; RT "Frequency of RET mutations in long- and short-segment Hirschsprung RT disease."; RL Hum. Mutat. 9:243-249(1997). RN [79] RP VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618. RX PubMed=9259198; RX DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j; RA Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S., RA Grynberg E., Yakobson E., Graff E., Lapidot M.; RT "Cys 618 Arg mutation in the RET proto-oncogene associated with familial RT medullary thyroid carcinoma and maternally transmitted Hirschsprung's RT disease suggesting a role for imprinting."; RL Hum. Mutat. 10:155-159(1997). RN [80] RP VARIANT MEN2B PHE-883. RC TISSUE=Peripheral blood leukocyte; RX PubMed=9360560; DOI=10.1210/jcem.82.11.4508; RA Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., RA Zajac J.D., Robinson B.G., Eng C.; RT "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in RT multiple endocrine neoplasia type 2B without codon 918 mutation."; RL J. Clin. Endocrinol. Metab. 82:3902-3904(1997). RN [81] RP VARIANT MTC ALA-891. RX PubMed=9398735; DOI=10.1210/jcem.82.12.4439; RA Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U., RA Colantuoni V., Buys C.H.C.M.; RT "A novel point mutation in the intracellular domain of the ret RT protooncogene in a family with medullary thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 82:4176-4178(1997). RN [82] RP VARIANTS HSCR1 SER-174 AND TYR-197. RX PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3; RA Kusafuka T., Wang Y., Puri P.; RT "Mutation analysis of the RET, the endothelin-B receptor, and the RT endothelin-3 genes in sporadic cases of Hirschsprung's disease."; RL J. Pediatr. Surg. 32:501-504(1997). RN [83] RP VARIANTS MTC TYR-630 AND SER-630, AND VARIANT SER-691. RX PubMed=9223675; DOI=10.1038/sj.onc.1201102; RA Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W., RA Akasu H., Takami H., Tanaka S., Wells S.A. Jr.; RT "Novel germline RET proto-oncogene mutations associated with medullary RT thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC."; RL Oncogene 14:3103-3106(1997). RN [84] RP VARIANT MEN2B PHE-883. RX PubMed=9294615; DOI=10.1038/sj.onc.1201481; RA Smith D.P., Houghton C., Ponder B.A.J.; RT "Germline mutation of RET codon 883 in two cases of de novo MEN 2B."; RL Oncogene 15:1213-1217(1997). RN [85] RP VARIANT HSCR1 LEU-1039, AND VARIANT SER-691. RX PubMed=9497256; DOI=10.1086/301759; RA Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M., RA Gaultier C., Munnich A., Lyonnet S.; RT "Mutations of the RET-GDNF signaling pathway in Ondine's curse."; RL Am. J. Hum. Genet. 62:715-717(1998). RN [86] RP VARIANT MTC GLY-611. RX PubMed=9677065; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c; RA Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.; RT "Novel point mutation in exon 10 of the RET proto-oncogene in a family with RT medullary thyroid carcinoma."; RL Am. J. Med. Genet. 78:271-273(1998). RN [87] RP VARIANT CYS-982. RX PubMed=9760196; DOI=10.1007/s004390050797; RA Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.; RT "Phenotypic variation in a family with mutations in two Hirschsprung- RT related genes (RET and endothelin receptor B)."; RL Hum. Genet. 103:145-148(1998). RN [88] RP VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1 RP TYR-609; SER-618; ARG-620 AND TRP-620. RX PubMed=9384613; DOI=10.1093/hmg/7.1.129; RA Decker R.A., Peacock M.L., Watson P.; RT "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 RT genotypes and strong genotype-phenotype correlation."; RL Hum. Mol. Genet. 7:129-134(1998). RN [89] RP VARIANT MEN2A CYS-ARG-THR-636 INS. RX PubMed=9452064; DOI=10.1002/humu.1380110143; RA Hoeppner W., Dralle H., Brabant G.; RT "Duplication of 9 base pairs in the critical cysteine-rich domain of the RT RET proto-oncogene causes multiple endocrine neoplasia type 2A."; RL Hum. Mutat. Suppl. 1:S128-S130(1998). RN [90] RP VARIANT MTC MET-804. RX PubMed=9452077; DOI=10.1002/humu.1380110156; RA Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E., RA Colantuoni V.; RT "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET RT proto-oncogene in two families affected by familial medullary thyroid RT carcinoma."; RL Hum. Mutat. Suppl. 1:S167-S171(1998). RN [91] RP VARIANTS MTC/MEN2A PHE-790 AND PHE-791. RX PubMed=9506724; DOI=10.1210/jcem.83.3.4619; RA Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., RA Raue F., Ritter M.M., Hoeppner W.; RT "A new hot spot for mutations in the ret protooncogene causing familial RT medullary thyroid carcinoma and multiple endocrine neoplasia type 2A."; RL J. Clin. Endocrinol. Metab. 83:770-774(1998). RN [92] RP VARIANTS MTC AND MEN2A. RX PubMed=9621513; DOI=10.1007/s100380050048; RA Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A., RA Nakamura Y.; RT "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with RT medullary thyroid carcinoma."; RL J. Hum. Genet. 43:101-106(1998). RN [93] RP VARIANTS HSCR1 LYS-626 AND GLN-813. RX PubMed=10090908; DOI=10.1086/302329; RA Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A., RA Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A., RA Ceccherini I.; RT "Double heterozygosity for a RET substitution interfering with splicing and RT an EDNRB missense mutation in Hirschsprung disease."; RL Am. J. Hum. Genet. 64:1216-1221(1999). RN [94] RP VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061. RX PubMed=10484767; DOI=10.1093/hmg/8.11.1989; RA Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S., RA Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.; RT "Two distinct mutations of the RET receptor causing Hirschsprung's disease RT impair the binding of signalling effectors to a multifunctional docking RT site."; RL Hum. Mol. Genet. 8:1989-1999(1999). RN [95] RP VARIANT MTC GLU-GLU-CYS-531 INS. RX PubMed=10323403; DOI=10.1210/jcem.84.5.5665; RA Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P., RA Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.; RT "A novel 9-base pair duplication in RET exon 8 in familial medullary RT thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 84:1700-1704(1999). RN [96] RP VARIANT MEN2A GLY-640. RX PubMed=10522989; DOI=10.1210/jcem.84.10.6056; RA Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D., RA Bellastella A., Colantuoni V.; RT "A novel case of multiple endocrine neoplasia type 2A associated with two RT de novo mutations of the RET protooncogene."; RL J. Clin. Endocrinol. Metab. 84:3522-3527(1999). RN [97] RP VARIANTS HSCR1 GLN-287; PRO-690; ARG-767 AND GLN-873. RX PubMed=10664228; DOI=10.1007/s004310050043; RA Sakai T., Nirasawa Y., Itoh Y., Wakizaka A.; RT "Japanese patients with sporadic Hirschsprung: mutation analysis of the RT receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin- RT 3, glial cell line-derived neurotrophic factor and neurturin genes: a RT comparison with similar studies."; RL Eur. J. Pediatr. 159:160-167(2000). RN [98] RP VARIANTS MTC MET-804 AND LEU-844. RX PubMed=10826520; DOI=10.1055/s-2000-5806; RA Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.; RT "A RET double mutation in the germline of a kindred with FMTC."; RL Exp. Clin. Endocrinol. Diabetes 108:128-132(2000). RN [99] RP VARIANT GLN-600. RX PubMed=10612852; RX DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7; RA Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G., RA Borrego S.; RT "A new germline mutation, R600Q, within the coding region of RET proto- RT oncogene: a rare polymorphism or a MEN 2 causing mutation?"; RL Hum. Mutat. 15:122-122(2000). RN [100] RP VARIANT HSCR1 GLU-907. RX PubMed=10790203; RX DOI=10.1002/(sici)1098-1004(200005)15:5<418::aid-humu3>3.0.co;2-2; RA Hofstra R.M., Wu Y., Stulp R.P., Elfferich P., Osinga J., Maas S.M., RA Siderius L., Brooks A.S., vd Ende J.J., Heydendael V.M., Severijnen R.S., RA Bax K.M., Meijers C., Buys C.H.; RT "RET and GDNF gene scanning in Hirschsprung patients using two dual RT denaturing gel systems."; RL Hum. Mutat. 15:418-429(2000). RN [101] RP VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394. RX PubMed=10618407; DOI=10.1073/pnas.97.1.268; RA Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D., RA Buys C.H.C.M., Lyonnet S., Chakravarti A.; RT "A human model for multigenic inheritance: phenotypic expression in RT Hirschsprung disease requires both the RET gene and a new 9q31 locus."; RL Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000). RN [102] RP VARIANTS MTC GLY-639; GLY-641 AND PHE-922. RX PubMed=11692159; DOI=10.1007/s001090100250; RA Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B., RA Garkavtseva R.F., Izbicki J.R.; RT "Three novel mutations in the RET proto-oncogene."; RL J. Mol. Med. 79:609-612(2001). RN [103] RP VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634; RP TRP-634 AND PHE-791. RX PubMed=12000816; DOI=10.1056/nejmoa020152; RG The Freiburg-Warsaw-Columbus pheochromocytoma study group; RA Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., RA Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., RA Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., RA Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., RA Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., RA Eng C.; RT "Germ-line mutations in nonsyndromic pheochromocytoma."; RL N. Engl. J. Med. 346:1459-1466(2002). RN [104] RP VARIANT HIS-114. RX PubMed=12086152; DOI=10.1620/tjem.196.241; RA Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M., RA Hasegawa H., Shirasawa S., Hayasaka K.; RT "Congenital central hypoventilation syndrome: a novel mutation of the RET RT gene in an isolated case."; RL Tohoku J. Exp. Med. 196:241-246(2002). RN [105] RP VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982. RX PubMed=14566559; DOI=10.1007/s00439-003-1036-z; RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H., RA Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W., RA Nakamura T., Hayasaka K.; RT "Molecular analysis of congenital central hypoventilation syndrome."; RL Hum. Genet. 114:22-26(2003). RN [106] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [107] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489; RP SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [108] RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND RP SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND RP SER-1067. RX PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008; RA Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.; RT "Renal aplasia in humans is associated with RET mutations."; RL Am. J. Hum. Genet. 82:344-351(2008). RN [109] RP VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175; RP ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360; RP MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783; RP ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS RP HIS-114; ASN-278 AND MET-292. RX PubMed=22174939; DOI=10.1371/journal.pone.0028986; RA So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N., RA Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W., RA Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H., RA Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S., RA Tam P.K., Garcia-Barcelo M.M.; RT "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese RT patients."; RL PLoS ONE 6:E28986-E28986(2011). RN [110] RP ACTIVITY REGULATION, VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; RP VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998, CHARACTERIZATION OF RP VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; RP SER-810; ILE-871 AND VAL-998, VARIANTS MTC LEU-804; MET-804 AND THR-918, RP AND CHARACTERIZATION OF VARIANTS MTC LEU-804; MET-804 AND THR-918. RX PubMed=29908090; DOI=10.1111/bph.14395; RA Liu X., Shen T., Mooers B.H.M., Hilberg F., Wu J.; RT "Drug resistance profiles of mutations in the RET kinase domain."; RL Br. J. Pharmacol. 175:3504-3515(2018). CC -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous CC cellular mechanisms including cell proliferation, neuronal navigation, CC cell migration, and cell differentiation in response to glia cell line- CC derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) CC (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, CC PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, CC PubMed:28953886, PubMed:31118272). In contrast to most receptor CC tyrosine kinases, RET requires not only its cognate ligands but also CC coreceptors, for activation (PubMed:21994944, PubMed:23333276, CC PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, CC NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR CC coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), CC triggering RET autophosphorylation and activation, leading to CC activation of downstream signaling pathways, including the MAPK- and CC AKT-signaling pathways (PubMed:21994944, PubMed:23333276, CC PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, CC PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 CC signaling: in the presence of the ligand GDNF in somatotrophs within CC pituitary, promotes survival and down regulates growth hormone (GH) CC production, but triggers apoptosis in absence of GDNF (PubMed:20616503, CC PubMed:21994944). Required for the molecular mechanisms orchestration CC during intestine organogenesis via the ARTN-GFRA3 signaling: involved CC in the development of enteric nervous system and renal organogenesis CC during embryonic life, and promotes the formation of Peyer's patch-like CC structures, a major component of the gut-associated lymphoid tissue (By CC similarity). Mediates, through interaction with GDF15-receptor GFRAL, CC GDF15-induced cell-signaling in the brainstem which triggers an CC aversive response, characterized by nausea, vomiting, and/or loss of CC appetite in response to various stresses (PubMed:28846097, CC PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its CC cleavage by caspase in sympathetic neurons and mediates cell migration CC in an integrin (e.g. ITGB1 and ITGB3)-dependent manner CC (PubMed:20702524, PubMed:21357690). Also active in the absence of CC ligand, triggering apoptosis through a mechanism that requires receptor CC intracellular caspase cleavage (PubMed:21357690). Triggers the CC differentiation of rapidly adapting (RA) mechanoreceptors CC (PubMed:20064382). Involved in the development of the neural crest (By CC similarity). Regulates nociceptor survival and size (By similarity). CC Phosphorylates PTK2/FAK1 (PubMed:21454698). CC {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:20064382, CC ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:31118272}. CC -!- FUNCTION: [Isoform 1]: Isoform 1 in complex with GFRAL induces higher CC activation of MAPK-signaling pathway than isoform 2 in complex with CC GFRAL. {ECO:0000269|PubMed:28846099}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000269|PubMed:11445581, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:31535977, ECO:0000269|PubMed:9575150}; CC -!- ACTIVITY REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines CC derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl) CC nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones, CC vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184), CC lenvatinib, sunitinib, nintedanib, and withaferin A (WA) CC (PubMed:17664273, PubMed:17884497, PubMed:19053769, PubMed:20117004, CC PubMed:20409618, PubMed:20605972, PubMed:21134556, PubMed:29908090, CC PubMed:31118272). Inactivation by sorafenib both reduces kinase CC activity and promotes lysosomal degradation (PubMed:17664273). CC {ECO:0000269|PubMed:17664273, ECO:0000269|PubMed:17884497, CC ECO:0000269|PubMed:19053769, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:20409618, ECO:0000269|PubMed:20605972, CC ECO:0000269|PubMed:21134556, ECO:0000269|PubMed:29908090, CC ECO:0000269|PubMed:31118272}. CC -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2, CC DOK4 and DOK5 (By similarity). The phosphorylated form interacts with CC PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with CC PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell- CC membrane anchored RET cadherin fragments form complex in neurons with CC reduced trophic status, preferentially at the contact sites between CC somas (PubMed:21357690). Interacts with AIP in the pituitary gland; CC this interaction prevents the formation of the AIP-survivin complex CC (PubMed:19366855). Interacts (inactive) with CBLC and CD2AP; CC dissociates upon activation by GDNF which increases CBLC:CD2AP CC interaction (PubMed:18753381). {ECO:0000250|UniProtKB:P35546, CC ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:19366855, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}. CC -!- INTERACTION: CC P07949; Q9UM73: ALK; NbExp=2; IntAct=EBI-2480756, EBI-357361; CC P07949; P22681: CBL; NbExp=8; IntAct=EBI-2480756, EBI-518228; CC P07949; P62861: FAU; NbExp=4; IntAct=EBI-2480756, EBI-358093; CC P07949; P22455: FGFR4; NbExp=2; IntAct=EBI-2480756, EBI-6256193; CC P07949; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2480756, EBI-945833; CC P07949; P40763: STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675; CC P07949; Q9Y490: TLN1; NbExp=2; IntAct=EBI-2480756, EBI-2462036; CC P07949; Q62985: Sh2b1; Xeno; NbExp=3; IntAct=EBI-2480756, EBI-7395583; CC P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:9575150}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:19823924}. Endosome CC membrane {ECO:0000269|PubMed:19823924, ECO:0000269|PubMed:23333276}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}. CC Note=Predominantly located on the plasma membrane (PubMed:23333276, CC PubMed:9575150). In the presence of SORL1 and GFRA1, directed to CC endosomes (PubMed:23333276). {ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:9575150}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=RET51; CC IsoId=P07949-1; Sequence=Displayed; CC Name=2; Synonyms=RET9; CC IsoId=P07949-2; Sequence=VSP_040735; CC -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3. CC {ECO:0000269|PubMed:19853745}. CC -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon ligand CC stimulation. {ECO:0000269|PubMed:11061555, ECO:0000269|PubMed:14711813, CC ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}. CC -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase CC fragment is able to induce cell death. The extracellular cell-membrane CC anchored RET cadherin fragment accelerates cell adhesion in sympathetic CC neurons. {ECO:0000269|PubMed:21357690}. CC -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of CC neural crest development characterized by absence of enteric ganglia CC along a variable length of the intestine. It is the most common cause CC of congenital intestinal obstruction. Early symptoms range from CC complete acute neonatal obstruction, characterized by vomiting, CC abdominal distention and failure to pass stool, to chronic constipation CC in the older child. {ECO:0000269|PubMed:10090908, CC ECO:0000269|PubMed:10484767, ECO:0000269|PubMed:10618407, CC ECO:0000269|PubMed:10664228, ECO:0000269|PubMed:10790203, CC ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:7581377, CC ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7704557, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7997019, CC ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939, CC ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527, CC ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9174404, CC ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9384613, CC ECO:0000269|PubMed:9497256, ECO:0000269|Ref.71}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor CC derived from the C cells of the thyroid. Three hereditary forms are CC known, that are transmitted in an autosomal dominant fashion: (a) CC multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB CC (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC CC cases and where MTC is the only clinical manifestation. CC {ECO:0000269|PubMed:10323403, ECO:0000269|PubMed:10826520, CC ECO:0000269|PubMed:11692159, ECO:0000269|PubMed:24560924, CC ECO:0000269|PubMed:29908090, ECO:0000269|PubMed:31118272, CC ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675, CC ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249, CC ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198, CC ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077, CC ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513, CC ECO:0000269|PubMed:9677065}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited CC cancer syndrome characterized by predisposition to MTC and CC phaeochromocytoma which is associated with marfanoid habitus, mucosal CC neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of CC the intestine tract. Then the disease progresses rapidly with the CC development of metastatic MTC and a pheochromocytome in 50% of cases. CC {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:7906417, CC ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697, CC ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing CC tumor of chromaffin tissue of the adrenal medulla or sympathetic CC paraganglia. The cardinal symptom, reflecting the increased secretion CC of epinephrine and norepinephrine, is hypertension, which may be CC persistent or intermittent. {ECO:0000269|PubMed:12000816}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent CC form of medullary thyroid cancer (MTC). It is an inherited cancer CC syndrome characterized by MTC, phaeochromocytoma and/or CC hyperparathyroidism. {ECO:0000269|PubMed:10522989, CC ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403, CC ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9067749, ECO:0000269|PubMed:9097963, CC ECO:0000269|PubMed:9384613, ECO:0000269|PubMed:9452064}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Various chromosomal aberrations involving RET are known. CC Some of them have been found in papillary thyroid carcinomas (PTCs) CC (PubMed:10439047, PubMed:10980597, PubMed:12787916, PubMed:2406025). CC Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene CC (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the CC RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 CC generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). CC Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET CC fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with CC TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916). CC Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET CC (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with CC TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047). CC Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the CC TRIM27/RET oncogene (PubMed:3037315). {ECO:0000269|PubMed:10439047, CC ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916, CC ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021, CC ECO:0000269|PubMed:3037315}. CC -!- DISEASE: Note=Mutations in RET have been detected in patients with CC renal agenesis suggesting a possible involvement of this gene in CC disease pathogenesis. {ECO:0000269|PubMed:18252215}. CC -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor regression CC in medullary thyroid carcinomas (MTC). CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Original thought to be dephosphorylated by PTPRJ on Tyr-905, CC Tyr-1015 and Tyr-1062. However this paper was retracted due to CC manipulation of immunoblot data. {ECO:0000305|PubMed:16778204, CC ECO:0000305|PubMed:30552125}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA36524.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA36786.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA33787.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC14882.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/76/RET"; CC -!- WEB RESOURCE: Name=MEN2 RET database; CC URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK291807; BAF84496.1; -; mRNA. DR EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004257; AAH04257.1; -; mRNA. DR EMBL; X15262; CAA33333.1; -; mRNA. DR EMBL; X12949; CAA31408.1; -; mRNA. DR EMBL; M16029; AAA36786.1; ALT_INIT; mRNA. DR EMBL; X15786; CAA33787.1; ALT_INIT; mRNA. DR EMBL; M31213; AAA36524.1; ALT_INIT; mRNA. DR EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA. DR CCDS; CCDS53525.1; -. [P07949-2] DR CCDS; CCDS7200.1; -. [P07949-1] DR PIR; A27203; TVHURE. DR PIR; A34630; A34630. DR PIR; B34735; B34735. DR PIR; S05582; S05582. DR RefSeq; NP_001393672.1; NM_001406743.1. [P07949-1] DR RefSeq; NP_065681.1; NM_020630.7. [P07949-2] DR RefSeq; NP_066124.1; NM_020975.6. [P07949-1] DR PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013. DR PDB; 2IVT; X-ray; 2.60 A; A=705-1013. DR PDB; 2IVU; X-ray; 2.50 A; A=705-1013. DR PDB; 2IVV; X-ray; 2.25 A; A=705-1013. DR PDB; 2X2K; X-ray; 2.60 A; A=705-1013. DR PDB; 2X2L; X-ray; 2.00 A; A=705-1013. DR PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013. DR PDB; 2X2U; X-ray; 2.00 A; A=29-270. DR PDB; 4CKI; X-ray; 2.12 A; A=705-1013. DR PDB; 4CKJ; X-ray; 1.65 A; A=705-1013. DR PDB; 4UX8; EM; 24.00 A; A/B=29-635. DR PDB; 5AMN; X-ray; 2.57 A; A=705-1012. DR PDB; 5FM2; X-ray; 3.30 A; A=659-1013. DR PDB; 5FM3; X-ray; 2.95 A; A=659-1013. DR PDB; 6FEK; X-ray; 2.30 A; A=705-1013. DR PDB; 6GL7; EM; 6.30 A; E/F=29-635. DR PDB; 6I82; X-ray; 2.05 A; A/B=705-1013. DR PDB; 6I83; X-ray; 1.88 A; A=705-1013. DR PDB; 6NE7; X-ray; 1.99 A; A=705-1013. DR PDB; 6NEC; X-ray; 1.87 A; A/C=705-1013. DR PDB; 6NJA; X-ray; 1.92 A; A=705-1013. DR PDB; 6Q2J; EM; 4.10 A; E/F=29-635. DR PDB; 6Q2N; EM; 4.40 A; E/F=29-635. DR PDB; 6Q2O; EM; 3.65 A; E/F=29-635. DR PDB; 6Q2R; EM; 4.30 A; E/F/Y/Z=29-635. DR PDB; 6Q2S; EM; 3.80 A; E/F=29-635. DR PDB; 6VHG; X-ray; 2.30 A; A=705-1013. DR PDB; 7DU8; X-ray; 2.75 A; A/B=705-1013. DR PDB; 7DU9; X-ray; 2.31 A; A/B=705-1013. DR PDB; 7DUA; X-ray; 1.64 A; A/B=705-1013. DR PDB; 7JU5; X-ray; 1.90 A; A/B=705-1013. DR PDB; 7JU6; X-ray; 2.06 A; A/B=705-1013. DR PDB; 7NZN; X-ray; 2.39 A; A=705-1013. DR PDB; 7RUN; X-ray; 3.51 A; A/B=705-1013. DR PDBsum; 2IVS; -. DR PDBsum; 2IVT; -. DR PDBsum; 2IVU; -. DR PDBsum; 2IVV; -. DR PDBsum; 2X2K; -. DR PDBsum; 2X2L; -. DR PDBsum; 2X2M; -. DR PDBsum; 2X2U; -. DR PDBsum; 4CKI; -. DR PDBsum; 4CKJ; -. DR PDBsum; 4UX8; -. DR PDBsum; 5AMN; -. DR PDBsum; 5FM2; -. DR PDBsum; 5FM3; -. DR PDBsum; 6FEK; -. DR PDBsum; 6GL7; -. DR PDBsum; 6I82; -. DR PDBsum; 6I83; -. DR PDBsum; 6NE7; -. DR PDBsum; 6NEC; -. DR PDBsum; 6NJA; -. DR PDBsum; 6Q2J; -. DR PDBsum; 6Q2N; -. DR PDBsum; 6Q2O; -. DR PDBsum; 6Q2R; -. DR PDBsum; 6Q2S; -. DR PDBsum; 6VHG; -. DR PDBsum; 7DU8; -. DR PDBsum; 7DU9; -. DR PDBsum; 7DUA; -. DR PDBsum; 7JU5; -. DR PDBsum; 7JU6; -. DR PDBsum; 7NZN; -. DR PDBsum; 7RUN; -. DR AlphaFoldDB; P07949; -. DR EMDB; EMD-0026; -. DR EMDB; EMD-11777; -. DR EMDB; EMD-20572; -. DR EMDB; EMD-20575; -. DR EMDB; EMD-20576; -. DR EMDB; EMD-20578; -. DR EMDB; EMD-20579; -. DR EMDB; EMD-2712; -. DR SMR; P07949; -. DR BioGRID; 111911; 272. DR CORUM; P07949; -. DR DIP; DIP-41449N; -. DR FunCoup; P07949; 619. DR IntAct; P07949; 231. DR MINT; P07949; -. DR STRING; 9606.ENSP00000347942; -. DR BindingDB; P07949; -. DR ChEMBL; CHEMBL2041; -. DR DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB12742; Amuvatinib. DR DrugBank; DB08875; Cabozantinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB15036; Sitravatinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB07159; Tamatinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05014; XL999. DR DrugCentral; P07949; -. DR GuidetoPHARMACOLOGY; 2185; -. DR TCDB; 8.A.23.1.44; the basigin (basigin) family. DR GlyCosmos; P07949; 12 sites, No reported glycans. DR GlyGen; P07949; 19 sites, 4 N-linked glycans (4 sites). DR iPTMnet; P07949; -. DR PhosphoSitePlus; P07949; -. DR BioMuta; RET; -. DR DMDM; 547807; -. DR CPTAC; CPTAC-3059; -. DR jPOST; P07949; -. DR MassIVE; P07949; -. DR PaxDb; 9606-ENSP00000347942; -. DR PeptideAtlas; P07949; -. DR ProteomicsDB; 52047; -. [P07949-1] DR ProteomicsDB; 52048; -. [P07949-2] DR TopDownProteomics; P07949-2; -. [P07949-2] DR Antibodypedia; 1904; 1292 antibodies from 41 providers. DR DNASU; 5979; -. DR Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.23. [P07949-2] DR Ensembl; ENST00000355710.8; ENSP00000347942.3; ENSG00000165731.23. [P07949-1] DR GeneID; 5979; -. DR KEGG; hsa:5979; -. DR MANE-Select; ENST00000355710.8; ENSP00000347942.3; NM_020975.6; NP_066124.1. DR UCSC; uc001jak.2; human. [P07949-1] DR AGR; HGNC:9967; -. DR CIViC; 5979; 1 clinical assertion and 61 evidence items across 114 molecular profiles. DR ClinPGx; PA34335; -. DR CTD; 5979; -. DR DisGeNET; 5979; -. DR GeneCards; RET; -. DR GeneReviews; RET; -. DR HGNC; HGNC:9967; RET. DR HPA; ENSG00000165731; Tissue enhanced (adrenal gland, brain, parathyroid gland). DR MalaCards; RET; -. DR MIM; 114500; phenotype. DR MIM; 142623; phenotype. DR MIM; 155240; phenotype. DR MIM; 162300; phenotype. DR MIM; 164761; gene. DR MIM; 171300; phenotype. DR MIM; 171400; phenotype. DR OpenTargets; ENSG00000165731; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 99803; Haddad syndrome. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 99361; Isolated familial medullary thyroid carcinoma. DR Orphanet; 247698; Multiple endocrine neoplasia type 2A. DR Orphanet; 247709; Multiple endocrine neoplasia type 2B. DR Orphanet; 1848; Renal agenesis, bilateral. DR Orphanet; 93100; Renal agenesis, unilateral. DR Orphanet; 276621; Sporadic pheochromocytoma/secreting paraganglioma. DR VEuPathDB; HostDB:ENSG00000165731; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000158499; -. DR HOGENOM; CLU_009530_0_0_1; -. DR InParanoid; P07949; -. DR OMA; VENQDPH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P07949; 7 GO annotations based on evolutionary models. DR PhylomeDB; P07949; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P07949; -. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9830674; Formation of the ureteric bud. DR SignaLink; P07949; -. DR SIGNOR; P07949; -. DR Agora; ENSG00000165731; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5979; 18 hits in 1194 CRISPR screens. DR ChiTaRS; RET; human. DR EvolutionaryTrace; P07949; -. DR GeneWiki; RET_proto-oncogene; -. DR GenomeRNAi; 5979; -. DR Pharos; P07949; Tclin. DR PRO; PR:P07949; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P07949; protein. DR Bgee; ENSG00000165731; Expressed in substantia nigra pars reticulata and 130 other cell types or tissues. DR ExpressionAtlas; P07949; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl. DR GO; GO:0160144; P:GDF15-GFRAL signaling pathway; IDA:UniProt. DR GO; GO:0035860; P:glial cell-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro. DR GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl. DR GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB. DR GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0007497; P:posterior midgut development; TAS:ProtInc. DR GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB. DR GO; GO:0048265; P:response to pain; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035799; P:ureter maturation; IEA:Ensembl. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd11304; Cadherin_repeat; 1. DR CDD; cd05045; PTKc_RET; 1. DR FunFam; 1.10.510.10:FF:000190; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000132; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000205; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 3.30.200.20:FF:000234; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR Gene3D; 2.60.40.60; Cadherins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041163; Ret_CLD1. DR InterPro; IPR040667; Ret_CLD3. DR InterPro; IPR041317; RET_CLD4. DR InterPro; IPR055162; RET_CRD. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016249; Tyr_kinase_Ret_rcpt. DR PANTHER; PTHR24416:SF485; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00028; Cadherin; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF17756; RET_CLD1; 1. DR Pfam; PF17812; RET_CLD3; 1. DR Pfam; PF17813; RET_CLD4; 1. DR Pfam; PF22540; RET_CRD; 1. DR PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49313; Cadherin-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50268; CADHERIN_2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Chromosomal rearrangement; Disease variant; Disulfide bond; KW Endosome; Glycoprotein; Hirschsprung disease; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..28 FT /evidence="ECO:0000255" FT CHAIN 29..1114 FT /note="Proto-oncogene tyrosine-protein kinase receptor Ret" FT /id="PRO_0000024450" FT CHAIN 29..707 FT /note="Extracellular cell-membrane anchored RET cadherin FT 120 kDa fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415292" FT CHAIN 708..1017 FT /note="Soluble RET kinase fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415293" FT TOPO_DOM 29..635 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 636..657 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 658..1114 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 168..272 FT /note="Cadherin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 724..1016 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 29..153 FT /note="Cadherin-like region 1 (CLD1)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 265..379 FT /note="Cadherin-like region 3 (CLD3)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 405..506 FT /note="Cadherin-like region 4 (CLD4)" FT /evidence="ECO:0000305|PubMed:11445581" FT ACT_SITE 874 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 179 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 230 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 264 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 265 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 266 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 268 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 300 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 378 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 564 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 565 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 567 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 569 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 574 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 584 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 730..738 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924, ECO:0007744|PDB:4CKI" FT BINDING 758 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924" FT BINDING 805..807 FT /ligand="semaxanib" FT /ligand_id="ChEBI:CHEBI:91083" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:20117004, FT ECO:0007744|PDB:2X2M" FT SITE 587..588 FT /note="Breakpoint for translocation to form the TRIM27/RET FT oncogene" FT /evidence="ECO:0000269|PubMed:3037315" FT SITE 707..708 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT SITE 712..713 FT /note="Breakpoint for translocation to form PCM1-RET; RET- FT CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes" FT /evidence="ECO:0000269|PubMed:10439047, FT ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:2406025, FT ECO:0000269|PubMed:2734021" FT SITE 1017..1018 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT MOD_RES 687 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 696 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 806 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 809 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 826 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 900 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:24560924" FT MOD_RES 905 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1015 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1029 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 1062 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:24560924, FT ECO:0000269|PubMed:28846099" FT MOD_RES 1090 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 1096 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 151 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20473317" FT CARBOHYD 199 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 377 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 394 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 448 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 554 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 688 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:26237509" FT DISULFID 137..142 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 157..197 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 166..243 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 426..430 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 449..478 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 515..531 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 519..541 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 528..558 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 565..581 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 570..585 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 609..620 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 611..618 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 630..634 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT VAR_SEQ 1064..1114 FT /note="MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS FT -> RISHAFTRF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3037315" FT /id="VSP_040735" FT VARIANT 20 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1837067697)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_009459" FT VARIANT 32 FT /note="S -> L (in HSCR1; familial form; dbSNP:rs76764689)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006295" FT VARIANT 40 FT /note="L -> P (in HSCR1; dbSNP:rs2132657920)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:9043870" FT /id="VAR_009492" FT VARIANT 64 FT /note="P -> L (in HSCR1; familial form; dbSNP:rs77596424)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006296" FT VARIANT 67 FT /note="R -> H (in dbSNP:rs192489011)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018153" FT VARIANT 77 FT /note="R -> C (in HSCR1; dbSNP:rs1588862595)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009460" FT VARIANT 93 FT /note="G -> S (in HSCR1; uncertain significance; FT dbSNP:rs1477699803)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_006297" FT VARIANT 114 FT /note="R -> C (in HSCR1; uncertain significance; FT dbSNP:rs747483905)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067101" FT VARIANT 114 FT /note="R -> H (in dbSNP:rs76397662)" FT /evidence="ECO:0000269|PubMed:12086152, FT ECO:0000269|PubMed:14566559, ECO:0000269|PubMed:22174939" FT /id="VAR_018154" FT VARIANT 142 FT /note="C -> S (in HSCR1; sporadic form; FT dbSNP:rs2132680131)" FT /id="VAR_006298" FT VARIANT 145 FT /note="V -> G (in HSCR1; also in a colorectal cancer FT sample; somatic mutation; dbSNP:rs1588863999)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22174939" FT /id="VAR_035711" FT VARIANT 155 FT /note="P -> L (in HSCR1; dbSNP:rs999019810)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067102" FT VARIANT 157 FT /note="C -> Y (in HSCR1; uncertain significance; FT dbSNP:rs2132681401)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009461" FT VARIANT 163 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149403911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041762" FT VARIANT 174 FT /note="F -> S (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009462" FT VARIANT 175 FT /note="R -> P (in HSCR1; dbSNP:rs774097284)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067103" FT VARIANT 180 FT /note="R -> P (in HSCR1; sporadic form; dbSNP:rs370736139)" FT /evidence="ECO:0000269|PubMed:9090527" FT /id="VAR_009463" FT VARIANT 197 FT /note="C -> Y (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009464" FT VARIANT 198 FT /note="P -> T (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs76736111)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044392" FT VARIANT 231 FT /note="R -> H (in HSCR1; familial form; dbSNP:rs79661516)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006299" FT VARIANT 251 FT /note="E -> K (in HSCR1; familial form; dbSNP:rs562449603)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006300" FT VARIANT 278 FT /note="T -> A (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067104" FT VARIANT 278 FT /note="T -> N (found in two patients with Hirschsprung FT disease; dbSNP:rs35118262)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041763" FT VARIANT 278 FT /note="T -> P (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067105" FT VARIANT 287 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1564491460)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006301" FT VARIANT 292 FT /note="V -> M (found in patients with Hirschsprung disease; FT uncertain significance; dbSNP:rs34682185)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041764" FT VARIANT 300 FT /note="D -> N (in HSCR1; dbSNP:rs2132719351)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067106" FT VARIANT 313 FT /note="R -> Q (in HSCR1; dbSNP:rs77702891)" FT /evidence="ECO:0000269|PubMed:22174939, FT ECO:0000269|PubMed:9090527" FT /id="VAR_009465" FT VARIANT 316 FT /note="S -> I (in HSCR1; dbSNP:rs1060499894)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067107" FT VARIANT 330 FT /note="R -> Q (in HSCR1; dbSNP:rs80236571)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006302" FT VARIANT 339 FT /note="S -> L (in HSCR1; dbSNP:rs774829203)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067108" FT VARIANT 353 FT /note="D -> Y (in HSCR1; dbSNP:rs1837785429)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067109" FT VARIANT 359 FT /note="N -> K (in HSCR1; uncertain significance)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009466" FT VARIANT 360 FT /note="R -> Q (in HSCR1; dbSNP:rs762472027)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067110" FT VARIANT 360 FT /note="R -> W (in HSCR1; dbSNP:rs1424549058)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:16959974" FT /id="VAR_009467" FT VARIANT 376 FT /note="V -> A (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044393" FT VARIANT 393 FT /note="F -> L (in HSCR1; familial form; dbSNP:rs78098482)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006303" FT VARIANT 394 FT /note="N -> H (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to FT GDNF)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044394" FT VARIANT 394 FT /note="N -> K (in HSCR1; dbSNP:rs376465385)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009468" FT VARIANT 397 FT /note="V -> M (in HSCR1; dbSNP:rs183729115)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067111" FT VARIANT 399 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1554818362)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006304" FT VARIANT 412 FT /note="V -> M (in HSCR1; dbSNP:rs746970700)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067112" FT VARIANT 423 FT /note="G -> R (in HSCR1; dbSNP:rs767601598)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067113" FT VARIANT 432 FT /note="A -> E (found in a patient with congenital central FT hypoventilation syndrome; uncertain significance; FT dbSNP:rs552057730)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018155" FT VARIANT 475 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)" FT /id="VAR_006305" FT VARIANT 480 FT /note="E -> K (in HSCR1; dbSNP:rs537874538)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067114" FT VARIANT 489 FT /note="D -> N (in dbSNP:rs9282834)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018156" FT VARIANT 531 FT /note="C -> CEEC (in MTC; familial form)" FT /evidence="ECO:0000269|PubMed:10323403" FT /id="VAR_009469" FT VARIANT 549..550 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067115" FT VARIANT 593 FT /note="G -> E (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035712" FT VARIANT 595 FT /note="E -> Q (in HSCR1; dbSNP:rs1483605155)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067116" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs377767393)" FT /evidence="ECO:0000269|PubMed:10612852" FT /id="VAR_008966" FT VARIANT 609 FT /note="C -> G (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009470" FT VARIANT 609 FT /note="C -> R (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009471" FT VARIANT 609 FT /note="C -> W (in HSCR1; familial form; dbSNP:rs377767396)" FT /evidence="ECO:0000269|PubMed:7881414" FT /id="VAR_006307" FT VARIANT 609 FT /note="C -> Y (in MTC, MEN2A and HSCR1; familial and FT sporadic forms; dbSNP:rs77939446)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613, FT ECO:0000269|Ref.71" FT /id="VAR_006306" FT VARIANT 611 FT /note="C -> G (in MTC; familial form; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:9677065" FT /id="VAR_009472" FT VARIANT 611 FT /note="C -> R (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009473" FT VARIANT 611 FT /note="C -> S (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009474" FT VARIANT 611 FT /note="C -> W (in MEN2A and MTC; familial form; FT dbSNP:rs80069458)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006308" FT VARIANT 611 FT /note="C -> Y (in MEN2A; dbSNP:rs377767397)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006309" FT VARIANT 618 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006312" FT VARIANT 618 FT /note="C -> G (in MEN2A; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006310" FT VARIANT 618 FT /note="C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:9259198" FT /id="VAR_006311" FT VARIANT 618 FT /note="C -> S (in MEN2A, HSCR1 and MTC; familial and FT sporadic forms; dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613" FT /id="VAR_006313" FT VARIANT 618 FT /note="C -> Y (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006314" FT VARIANT 620 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7915165" FT /id="VAR_006318" FT VARIANT 620 FT /note="C -> G (in MEN2A and MTC; familial and sporadic FT forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006315" FT VARIANT 620 FT /note="C -> R (in MEN2A, MTC and HSCR1; familial and FT sporadic forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527, FT ECO:0000269|PubMed:9384613, ECO:0000269|Ref.71" FT /id="VAR_006316" FT VARIANT 620 FT /note="C -> S (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065" FT /id="VAR_006317" FT VARIANT 620 FT /note="C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)" FT /evidence="ECO:0000269|PubMed:9384613" FT /id="VAR_009475" FT VARIANT 620 FT /note="C -> Y (in MEN2A; dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006319" FT VARIANT 626 FT /note="Q -> K (in HSCR1; sporadic form; FT dbSNP:rs1255575160)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009476" FT VARIANT 630 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006320" FT VARIANT 630 FT /note="C -> S (in MTC; sporadic form; dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009477" FT VARIANT 630 FT /note="C -> Y (in MTC; familial and sporadic forms; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009478" FT VARIANT 631 FT /note="D -> G (in thyroid carcinoma; somatic mutation; FT dbSNP:rs121913308)" FT /id="VAR_006321" FT VARIANT 632..634 FT /note="ELC -> DVR (in MEN2A; dbSNP:rs377767408)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006322" FT VARIANT 634..635 FT /note="CR -> WG (in MEN2A)" FT /id="VAR_006329" FT VARIANT 634 FT /note="C -> CHELC (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9097963" FT /id="VAR_009479" FT VARIANT 634 FT /note="C -> F (in MEN2A and pheochromocytoma; FT dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006324" FT VARIANT 634 FT /note="C -> G (in MEN2A and pheochromocytoma; FT dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006323" FT VARIANT 634 FT /note="C -> R (in MEN2A, pheochromocytoma and MTC; familial FT form; also found as somatic mutation in a sporadic thyroid FT carcinoma; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403" FT /id="VAR_006326" FT VARIANT 634 FT /note="C -> S (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006327" FT VARIANT 634 FT /note="C -> W (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs77709286)" FT /evidence="ECO:0000269|PubMed:12000816" FT /id="VAR_006328" FT VARIANT 634 FT /note="C -> Y (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006325" FT VARIANT 636 FT /note="T -> TCRT (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9452064" FT /id="VAR_006330" FT VARIANT 639 FT /note="A -> G (in MTC; sporadic form; dbSNP:rs2132845622)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012743" FT VARIANT 640 FT /note="A -> G (in MEN2A; dbSNP:rs78935588)" FT /evidence="ECO:0000269|PubMed:10522989" FT /id="VAR_009480" FT VARIANT 641 FT /note="A -> G (in MTC; sporadic form)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012744" FT VARIANT 679 FT /note="P -> L (in HSCR1; dbSNP:rs2132851042)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067117" FT VARIANT 690 FT /note="S -> P (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006331" FT VARIANT 691 FT /note="G -> S (in dbSNP:rs1799939)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9223675, FT ECO:0000269|PubMed:9497256" FT /id="VAR_006332" FT VARIANT 694 FT /note="R -> Q (in HSCR1; dbSNP:rs141185224)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067118" FT VARIANT 730 FT /note="L -> I (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088874" FT VARIANT 730 FT /note="L -> V (confers resistance to vandetanib, FT cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088875" FT VARIANT 732 FT /note="E -> K (confers resistance to cabozantinib FT inhibitor)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088876" FT VARIANT 738 FT /note="V -> A (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs2132906265)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088877" FT VARIANT 749 FT /note="R -> T (in dbSNP:rs34288963)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041765" FT VARIANT 762 FT /note="E -> Q (in HSCR1; sporadic form; FT dbSNP:rs2132910256)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_009481" FT VARIANT 765 FT /note="S -> P (in HSCR1; dbSNP:rs75075748)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870" FT /id="VAR_009493" FT VARIANT 767 FT /note="S -> R (in HSCR1; sporadic form; FT dbSNP:rs2132928081)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006334" FT VARIANT 768 FT /note="E -> D (in MTC; familial and sporadic forms; FT dbSNP:rs78014899)" FT /evidence="ECO:0000269|PubMed:7784092, FT ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338" FT /id="VAR_006335" FT VARIANT 778 FT /note="V -> I (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; FT dbSNP:rs75686697)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044395" FT VARIANT 783 FT /note="N -> S (in HSCR1; dbSNP:rs587778656)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067119" FT VARIANT 790 FT /note="L -> F (in MEN2A and MTC; familial form; FT dbSNP:rs75030001)" FT /evidence="ECO:0000269|PubMed:9506724" FT /id="VAR_009482" FT VARIANT 791 FT /note="Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; FT familial form; dbSNP:rs77724903)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724" FT /id="VAR_009483" FT VARIANT 804 FT /note="V -> L (in MTC; familial form; confers resistance to FT vandetanib, lenvatinib, cabozantinib and nintedanib FT inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7784092" FT /id="VAR_006336" FT VARIANT 804 FT /note="V -> M (in MTC; familial form; faster FT autophosphorylation and activation, leading to enhanced FT activity; confers resistance to vandetanib, lenvatinib, FT cabozantinib and nintedanib inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:9452077" FT /id="VAR_006337" FT VARIANT 806 FT /note="Y -> N (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838154415)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088878" FT VARIANT 807 FT /note="A -> V (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs1554819523)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088879" FT VARIANT 810 FT /note="G -> A (found in a patient with lung adenocarcinoma; FT confers resistance to vandetanib inhibitor; FT dbSNP:rs2132943470)" FT /evidence="ECO:0000269|PubMed:31118272" FT /id="VAR_088880" FT VARIANT 810 FT /note="G -> S (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs764784013)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088881" FT VARIANT 813 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1318733775)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009484" FT VARIANT 826 FT /note="Y -> S (in dbSNP:rs34617196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041766" FT VARIANT 830 FT /note="G -> R (in HSCR1; dbSNP:rs200127630)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067120" FT VARIANT 844 FT /note="R -> L (in MTC; familial form; dbSNP:rs55947360)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:17344846" FT /id="VAR_011582" FT VARIANT 871 FT /note="V -> I (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs145170911)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088882" FT VARIANT 873 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1451004715)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006338" FT VARIANT 881 FT /note="L -> V (in MTC; confers resistance to nintedanib FT inhibitor; dbSNP:rs377767427)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:31118272" FT /id="VAR_088883" FT VARIANT 883 FT /note="A -> F (in MEN2B; somatic mutation in sporadic FT medullary thyroid carcinoma; requires 2 nucleotide FT substitutions; dbSNP:rs377767429)" FT /evidence="ECO:0000269|PubMed:9294615, FT ECO:0000269|PubMed:9360560" FT /id="VAR_009485" FT VARIANT 891 FT /note="S -> A (in MTC; familial form; dbSNP:rs75234356)" FT /evidence="ECO:0000269|PubMed:9398735" FT /id="VAR_009486" FT VARIANT 893 FT /note="F -> L (in HSCR1; sporadic form; dbSNP:rs768188546 FT and dbSNP:rs2132962164)" FT /evidence="ECO:0000269|PubMed:9174404" FT /id="VAR_006339" FT VARIANT 894 FT /note="G -> S (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form; dbSNP:rs2132962245)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044396" FT VARIANT 897 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006340" FT VARIANT 907 FT /note="K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)" FT /evidence="ECO:0000269|PubMed:10790203" FT /id="VAR_006341" FT VARIANT 907 FT /note="K -> T (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067121" FT VARIANT 918 FT /note="M -> T (in MEN2B and MTC; sporadic form; somatic FT mutation; also found in a patient with renal agenesis; FT faster autophosphorylation and activation, leading to FT enhanced activity; dbSNP:rs74799832)" FT /evidence="ECO:0000269|PubMed:18252215, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866, FT ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427, FT ECO:0000269|PubMed:8807338" FT /id="VAR_006342" FT VARIANT 921 FT /note="E -> K (in HSCR1; sporadic form; FT dbSNP:rs2132985306)" FT /evidence="ECO:0000269|PubMed:7997019" FT /id="VAR_006343" FT VARIANT 922 FT /note="S -> F (in MTC; sporadic form; dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012745" FT VARIANT 922 FT /note="S -> Y (in dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:8595427" FT /id="VAR_009487" FT VARIANT 946 FT /note="T -> M (in MEN2B and MTC; familial form)" FT /id="VAR_006345" FT VARIANT 961 FT /note="F -> L (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067122" FT VARIANT 972 FT /note="R -> G (in HSCR1; familial form; dbSNP:rs76534745)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006346" FT VARIANT 973 FT /note="P -> L (in HSCR1; familial form)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006347" FT VARIANT 980 FT /note="M -> T (in HSCR1; sporadic form)" FT /id="VAR_006348" FT VARIANT 982 FT /note="R -> C (in dbSNP:rs17158558)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:9760196" FT /id="VAR_006349" FT VARIANT 998 FT /note="F -> V (confers resistance to lenvatinib and FT cabozantinib inhibitors; dbSNP:rs2133017302)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088884" FT VARIANT 1039 FT /note="P -> L (in HSCR1; dbSNP:rs79853121)" FT /evidence="ECO:0000269|PubMed:9497256" FT /id="VAR_018157" FT VARIANT 1039 FT /note="P -> Q (in dbSNP:rs79853121)" FT /id="VAR_009488" FT VARIANT 1049 FT /note="P -> L (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs1490712863)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044397" FT VARIANT 1052 FT /note="L -> V (in HSCR1; dbSNP:rs1564501947)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067123" FT VARIANT 1059 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009489" FT VARIANT 1061 FT /note="L -> P (in HSCR1; dbSNP:rs536486113)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009490" FT VARIANT 1062 FT /note="Y -> C (in HSCR1; dbSNP:rs587778659)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067124" FT VARIANT 1064 FT /note="M -> T (in HSCR1; familial form; dbSNP:rs149513065)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_009491" FT VARIANT 1067 FT /note="P -> S (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs775583354)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044398" FT VARIANT 1112 FT /note="F -> Y (in a bladder transitional cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041767" FT MUTAGEN 36 FT /note="Y->S: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 41 FT /note="Y->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 85 FT /note="W->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 707 FT /note="D->N: Impaired cleavage by caspase-3 and loss of FT induced cell death." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 708..1114 FT /note="Missing: Loss of induced cell death, but increased FT cell aggregation." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 734 FT /note="E->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 758 FT /note="K->R,M: Loss of kinase activity. No effect on FT interaction with and dissociation from CBLC and CD2AP." FT /evidence="ECO:0000269|PubMed:18753381, FT ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:24560924" FT MUTAGEN 912 FT /note="R->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 913 FT /note="I->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 1062 FT /note="Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28953886" FT CONFLICT 647 FT /note="I -> V (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT CONFLICT 664 FT /note="A -> S (in Ref. 1; BAF84496)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="A -> G (in Ref. 9; AAA36524)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="S -> P (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT STRAND 30..32 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 49..52 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 70..73 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 90..92 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 103..111 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 139..141 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 142..152 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 162..166 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 184..187 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 191..196 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 202..208 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 235..245 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 252..263 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7DUA" FT TURN 715..717 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 721..723 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 724..733 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 736..744 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 746..748 FT /evidence="ECO:0007829|PDB:6NEC" FT STRAND 751..759 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 766..781 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 790..794 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 796..798 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 801..805 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 812..819 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 822..826 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 844..846 FT /evidence="ECO:0007829|PDB:6NJA" FT HELIX 848..867 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 880..883 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 887..890 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 893..895 FT /evidence="ECO:0007829|PDB:7JU5" FT TURN 900..902 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 915..917 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 920..925 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 930..945 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 978..987 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 992..994 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 998..1010 FT /evidence="ECO:0007829|PDB:7DUA" SQ SEQUENCE 1114 AA; 124319 MW; A3DA0CE01A19A441 CRC64; MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS // ID RIPK1_HUMAN Reviewed; 671 AA. AC Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 3. DT 28-JAN-2026, entry version 243. DE RecName: Full=Receptor-interacting serine/threonine-protein kinase 1; DE EC=2.7.11.1 {ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; DE AltName: Full=Cell death protein RIP {ECO:0000303|PubMed:8612133}; DE AltName: Full=Receptor-interacting protein 1 {ECO:0000303|PubMed:16603398}; DE Short=RIP-1 {ECO:0000303|PubMed:16603398}; GN Name=RIPK1 {ECO:0000312|HGNC:HGNC:10019}; GN Synonyms=RIP {ECO:0000303|PubMed:8612133}, GN RIP1 {ECO:0000303|PubMed:16603398}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1; RP TRAF2 AND TRAF3, AND VARIANT VAL-438. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8612133; DOI=10.1016/s1074-7613(00)80252-6; RA Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.; RT "TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 RT signaling complex."; RL Immunity 4:387-396(1996). RN [2] RP SEQUENCE REVISION TO 120. RA Huang J., Hsu H., Baichwal V.R., Goeddel D.V.; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2). RC TISSUE=Adrenal gland, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234. RG SeattleSNPs variation discovery resource; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-438. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438. RC TISSUE=Leukemic T-cell; RX PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1; RA Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.; RT "RIP: a novel protein containing a death domain that interacts with RT Fas/APO-1 (CD95) in yeast and causes cell death."; RL Cell 81:513-523(1995). RN [9] RP INTERACTION WITH CRADD, AND DOMAIN. RX PubMed=9044836; RA Ahmad M., Srinivasula S.M., Wang L., Talanian R.V., Litwack G., RA Fernandes-Alnemri T., Alnemri E.S.; RT "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and RT FasL/tumor necrosis factor receptor-interacting protein RIP."; RL Cancer Res. 57:615-619(1997). RN [10] RP CLEAVAGE BY CASP8, AND MUTAGENESIS OF ASP-324. RX PubMed=10521396; DOI=10.1101/gad.13.19.2514; RA Lin Y., Devin A., Rodriguez Y., Liu Z.-G.; RT "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced RT apoptosis."; RL Genes Dev. 13:2514-2526(1999). RN [11] RP INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN DEATH. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP INTERACTION WITH RIPK3. RX PubMed=10358032; DOI=10.1074/jbc.274.24.16871; RA Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.; RT "RIP3, a novel apoptosis-inducing kinase."; RL J. Biol. Chem. 274:16871-16875(1999). RN [13] RP INTERACTION WITH BNLF1. RX PubMed=10409763; DOI=10.1128/mcb.19.8.5759; RA Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B., Kieff E.D.; RT "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the RT tumor necrosis factor receptor-associated proteins TRADD and receptor- RT interacting protein (RIP) but does not induce apoptosis or require RIP for RT NF-kappaB activation."; RL Mol. Cell. Biol. 19:5759-5767(1999). RN [14] RP INTERACTION WITH IKBKG. RX PubMed=9927690; DOI=10.1073/pnas.96.3.1042; RA Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A., RA Wallach D., Horwitz M.S.; RT "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB RT activity and as a target of an adenovirus inhibitor of tumor necrosis RT factor alpha-induced apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999). RN [15] RP FUNCTION. RX PubMed=11101870; DOI=10.1038/82732; RA Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., RA Bodmer J.L., Schneider P., Seed B., Tschopp J.; RT "Fas triggers an alternative, caspase-8-independent cell death pathway RT using the kinase RIP as effector molecule."; RL Nat. Immunol. 1:489-495(2000). RN [16] RP INTERACTION WITH EGFR. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [17] RP INTERACTION WITH RNF216. RX PubMed=11854271; DOI=10.1074/jbc.m108675200; RA Chen D., Li X., Zhai Z., Shu H.-B.; RT "A novel zinc finger protein interacts with receptor-interacting protein RT (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B RT activation."; RL J. Biol. Chem. 277:15985-15991(2002). RN [18] RP RIP HOMOTYPIC INTERACTION MOTIF, AND INTERACTION WITH RIPK3. RX PubMed=11734559; DOI=10.1074/jbc.m109488200; RA Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M.; RT "Identification of a novel homotypic interaction motif required for the RT phosphorylation of receptor-interacting protein (RIP) by RIP3."; RL J. Biol. Chem. 277:9505-9511(2002). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [20] RP INTERACTION WITH ZFAND5. RX PubMed=14754897; DOI=10.1074/jbc.m309491200; RA Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z., RA Shu H.-B.; RT "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of RT NFkappaB activation."; RL J. Biol. Chem. 279:16847-16853(2004). RN [21] RP INTERACTION WITH DAB2IP. RX PubMed=15310755; DOI=10.1074/jbc.m407617200; RA Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.; RT "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2- RT induced ASK1-JNK activation."; RL J. Biol. Chem. 279:44955-44965(2004). RN [22] RP UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3. RX PubMed=15258597; DOI=10.1038/nature02794; RA Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., RA Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M.; RT "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF- RT kappaB signalling."; RL Nature 430:694-699(2004). RN [23] RP INTERACTION WITH MAVS. RX PubMed=16127453; DOI=10.1038/ni1243; RA Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., RA Takeuchi O., Akira S.; RT "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon RT induction."; RL Nat. Immunol. 6:981-988(2005). RN [24] RP UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377. RX PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026; RA Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.; RT "Activation of IKK by TNFalpha requires site-specific ubiquitination of RT RIP1 and polyubiquitin binding by NEMO."; RL Mol. Cell 22:245-257(2006). RN [25] RP INTERACTION WITH TAX1BP1, FUNCTION, AND UBIQUITINATION. RX PubMed=17703191; DOI=10.1038/sj.emboj.7601823; RA Shembade N., Harhaj N.S., Liebl D.J., Harhaj E.W.; RT "Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and RT LPS-mediated NF-kappaB and JNK signaling."; RL EMBO J. 26:3910-3922(2007). RN [26] RP REVIEW. RX PubMed=17301840; DOI=10.1038/sj.cdd.4402085; RA Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.; RT "RIP1, a kinase on the crossroads of a cell's decision to live or die."; RL Cell Death Differ. 14:400-410(2007). RN [27] RP FUNCTION IN PHOSPHORYLATION OF DAB2IP, AND INTERACTION WITH DAB2IP. RX PubMed=17389591; DOI=10.1074/jbc.m701148200; RA Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.; RT "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical RT for tumor necrosis factor-induced ASK1-JNK/p38 activation."; RL J. Biol. Chem. 282:14788-14796(2007). RN [28] RP INTERACTION WITH RBCK1. RX PubMed=17449468; DOI=10.1074/jbc.m701913200; RA Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M., RA Chen D.Y., Zhai Z.H., Shu H.B.; RT "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1- RT triggered NF-kappaB activation by targeting TAB2/3 for degradation."; RL J. Biol. Chem. 282:16776-16782(2007). RN [29] RP INTERACTION WITH RFFL, AND UBIQUITINATION BY RFFL. RX PubMed=18450452; DOI=10.1016/j.cub.2008.04.017; RA Liao W., Xiao Q., Tchikov V., Fujita K., Yang W., Wincovitch S., RA Garfield S., Conze D., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates RT TNF-induced NF-kappaB activation."; RL Curr. Biol. 18:641-649(2008). RN [30] RP MUTAGENESIS OF SER-161, INHIBITION BY NECROSTATIN-1, AND PHOSPHORYLATION AT RP SER-6; SER-20; SER-25; SER-161; SER-166; SER-303; SER-320 AND SER-333. RX PubMed=18408713; DOI=10.1038/nchembio.83; RA Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., RA Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A., RA Lugovskoy A., Yuan J.; RT "Identification of RIP1 kinase as a specific cellular target of RT necrostatins."; RL Nat. Chem. Biol. 4:313-321(2008). RN [31] RP INTERACTION WITH MURID HERPESVIRUS 1 PROTEIN RIR1. RX PubMed=18442983; DOI=10.1074/jbc.c800051200; RA Upton J.W., Kaiser W.J., Mocarski E.S.; RT "Cytomegalovirus M45 cell death suppression requires receptor-interacting RT protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RT RIP1."; RL J. Biol. Chem. 283:16966-16970(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, AND PHOSPHORYLATION. RX PubMed=19524513; DOI=10.1016/j.cell.2009.05.037; RA Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., RA Chan F.K.; RT "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates RT programmed necrosis and virus-induced inflammation."; RL Cell 137:1112-1123(2009). RN [34] RP FUNCTION, AND INTERACTION WITH RIPK3. RX PubMed=19524512; DOI=10.1016/j.cell.2009.05.021; RA He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X.; RT "Receptor interacting protein kinase-3 determines cellular necrotic RT response to TNF-alpha."; RL Cell 137:1100-1111(2009). RN [35] RP INTERACTION WITH RNF34, AND UBIQUITINATION BY RNF34. RX DOI=10.1016/j.cub.2008.11.041; RA Liao W., Fujita K., Xiao Q., Tchikov V., Yang W., Gunsor M., Garfield S., RA Goldsmith P., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "Response: CARP1 regulates induction of NF-kappaB by TNFalpha."; RL Curr. Biol. 19:R17-R19(2009). RN [36] RP REVIEW. RX PubMed=20354226; DOI=10.1126/scisignal.3115re4; RA Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T.; RT "The role of the kinases RIP1 and RIP3 in TNF-induced necrosis."; RL Sci. Signal. 3:RE4-RE4(2010). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP UBIQUITINATION BY THE LUBAC COMPLEX. RX PubMed=21455173; DOI=10.1038/nature09816; RA Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., RA Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U., RA Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H.; RT "Linear ubiquitination prevents inflammation and regulates immune RT signalling."; RL Nature 471:591-596(2011). RN [39] RP UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH RP BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4. RX PubMed=21931591; DOI=10.1371/journal.pone.0022356; RA Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J., RA Gevaert K., Declercq W., Vandenabeele P.; RT "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin RT chains to receptor interacting proteins kinases 1 to 4 (RIP1-4)."; RL PLoS ONE 6:E22356-E22356(2011). RN [40] RP IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK3 AND MLKL. RX PubMed=22265414; DOI=10.1016/j.cell.2011.11.030; RA Wang Z., Jiang H., Chen S., Du F., Wang X.; RT "The mitochondrial phosphatase PGAM5 functions at the convergence point of RT multiple necrotic death pathways."; RL Cell 148:228-243(2012). RN [41] RP INTERACTION WITH ARHGEF2. RX PubMed=21887730; DOI=10.1002/ibd.21851; RA Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B., RA Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.; RT "Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1."; RL Inflamm. Bowel Dis. 18:603-612(2012). RN [42] RP INTERACTION WITH DDX24. RX PubMed=24204270; DOI=10.1371/journal.ppat.1003721; RA Ma Z., Moore R., Xu X., Barber G.N.; RT "DDX24 negatively regulates cytosolic RNA-mediated innate immune RT signaling."; RL PLoS Pathog. 9:e1003721-e1003721(2013). RN [43] RP PROTEOLYTIC CLEAVAGE. RX PubMed=22858542; DOI=10.1038/cdd.2012.98; RA van Raam B.J., Ehrnhoefer D.E., Hayden M.R., Salvesen G.S.; RT "Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase- RT 6."; RL Cell Death Differ. 20:86-96(2013). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [45] RP FUNCTION, AND DEUBIQUITINATION BY USP7. RX PubMed=24144979; DOI=10.1128/mcb.00465-13; RA Zaman M.M., Nomura T., Takagi T., Okamura T., Jin W., Shinagawa T., RA Tanaka Y., Ishii S.; RT "Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor RT necrosis factor alpha-induced apoptosis."; RL Mol. Cell. Biol. 33:4971-4984(2013). RN [46] RP GLYCOSYLATION AT ARG-603 (MICROBIAL INFECTION). RX PubMed=23955153; DOI=10.1038/nature12436; RA Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L., RA Chen X., Chen S., Shao F.; RT "Pathogen blocks host death receptor signalling by arginine GlcNAcylation RT of death domains."; RL Nature 501:242-246(2013). RN [47] RP INTERACTION WITH TNFRSF1A. RX PubMed=24130170; DOI=10.1093/carcin/bgt338; RA Kim T.W., Kang Y.K., Park Z.Y., Kim Y.H., Hong S.W., Oh S.J., Sohn H.A., RA Yang S.J., Jang Y.J., Lee D.C., Kim S.Y., Yoo H.S., Kim E., Yeom Y.I., RA Park K.C.; RT "SH3RF2 functions as an oncogene by mediating PAK4 protein stability."; RL Carcinogenesis 35:624-634(2014). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [49] RP REVIEW. RX PubMed=25459879; DOI=10.1016/j.molcel.2014.11.001; RA Weinlich R., Green D.R.; RT "The two faces of receptor interacting protein kinase-1."; RL Mol. Cell 56:469-480(2014). RN [50] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [51] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 AND 2 PROTEIN RIR1 (MICROBIAL RP INFECTION). RX PubMed=25674983; DOI=10.1016/j.chom.2015.01.003; RA Guo H., Omoto S., Harris P.A., Finger J.N., Bertin J., Gough P.J., RA Kaiser W.J., Mocarski E.S.; RT "Herpes simplex virus suppresses necroptosis in human cells."; RL Cell Host Microbe 17:243-251(2015). RN [52] RP INTERACTION WITH MUMPS VIRUS PROTEIN SH (MICROBIAL INFECTION). RX PubMed=28659487; DOI=10.1128/jvi.01037-17; RA Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M., RA Finsterbusch T., Geyer H., Mankertz A., Friedrich N.; RT "Mumps virus SH protein inhibits NF-kappaB activation by interacting with RT tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like RT receptor 3 complexes."; RL J. Virol. 91:0-0(2017). RN [53] RP INTERACTION WITH PELI1 AND RIPK3, AND UBIQUITINATION BY PELI1. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [54] RP FUNCTION, SUBUNIT, MUTAGENESIS OF LYS-599, AND PHOSPHORYLATION AT SER-166. RX PubMed=29440439; DOI=10.1073/pnas.1722013115; RA Meng H., Liu Z., Li X., Wang H., Jin T., Wu G., Shan B., RA Christofferson D.E., Qi C., Yu Q., Li Y., Yuan J.; RT "Death-domain dimerization-mediated activation of RIPK1 controls RT necroptosis and RIPK1-dependent apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 115:E2001-E2009(2018). RN [55] RP INVOLVEMENT IN IMD57. RX PubMed=30026316; DOI=10.1126/science.aar2641; RA Cuchet-Lourenco D., Eletto D., Wu C., Plagnol V., Papapietro O., Curtis J., RA Ceron-Gutierrez L., Bacon C.M., Hackett S., Alsaleem B., Maes M., RA Gaspar M., Alisaac A., Goss E., AlIdrissi E., Siegmund D., Wajant H., RA Kumararatne D., AlZahrani M.S., Arkwright P.D., Abinun M., Doffinger R., RA Nejentsev S.; RT "Biallelic RIPK1 mutations in humans cause severe immunodeficiency, RT arthritis, and intestinal inflammation."; RL Science 361:810-813(2018). RN [56] RP REVIEW. RX PubMed=31457011; DOI=10.3389/fcell.2019.00163; RA Ang R.L., Chan M., Ting A.T.; RT "Ripoptocide - A Spark for Inflammation."; RL Front. Cell Dev. Biol. 7:163-163(2019). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-25, AND MUTAGENESIS OF RP SER-25 AND LYS-45. RX PubMed=30988283; DOI=10.1038/s41467-019-09690-0; RA Dondelinger Y., Delanghe T., Priem D., Wynosky-Dolfi M.A., Sorobetea D., RA Rojas-Rivera D., Giansanti P., Roelandt R., Gropengiesser J., RA Ruckdeschel K., Savvides S.N., Heck A.J.R., Vandenabeele P., Brodsky I.E., RA Bertrand M.J.M.; RT "Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in RT models of infection and inflammation."; RL Nat. Commun. 10:1729-1729(2019). RN [58] RP FUNCTION, PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF RP 539-ILE--GLY-542. RX PubMed=32657447; DOI=10.15252/embj.2020104469; RA Ashida H., Sasakawa C., Suzuki T.; RT "A unique bacterial tactic to circumvent the cell death crosstalk induced RT by blockade of caspase-8."; RL EMBO J. 39:e104469-e104469(2020). RN [59] RP FUNCTION, AND INTERACTION WITH GRB2. RX PubMed=35831301; DOI=10.1038/s41420-022-01106-1; RA Hou B., Huang H., Li Y., Liang J., Xi Z., Jiang X., Liu L., Li E.; RT "Grb2 interacts with necrosome components and is involved in rasfonin- RT induced necroptosis."; RL Cell. Death. Discov. 8:319-319(2022). RN [60] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-294 IN COMPLEXES WITH RP NECROSTATIN-TYPE INHIBITORS, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP AUTOPHOSPHORYLATION. RX PubMed=23473668; DOI=10.1016/j.str.2013.01.016; RA Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J., Shi Y.; RT "Structural basis of RIP1 inhibition by necrostatins."; RL Structure 21:493-499(2013). RN [61] {ECO:0007744|PDB:5V7Z} RP STRUCTURE BY NMR OF 532-549 IN COMPLEX WITH RIPK3, SUBUNIT, INTERACTION RP WITH RIPK3, DOMAIN, AND MUTAGENESIS OF SER-536. RX PubMed=29681455; DOI=10.1016/j.cell.2018.03.032; RA Mompean M., Li W., Li J., Laage S., Siemer A.B., Bozkurt G., Wu H., RA McDermott A.E.; RT "The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid RT signaling complex."; RL Cell 173:1244-1253(2018). RN [62] {ECO:0007744|PDB:6AC5} RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 561-671, GLYCOSYLATION AT ARG-603 RP (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-603. RX PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028; RA Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.; RT "Structural and functional insights into host death domains inactivation by RT the bacterial arginine GlcNAcyltransferase effector."; RL Mol. Cell 74:922-935(2019). RN [63] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404; VAL-443 RP AND VAL-569. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [64] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, RP CHARACTERIZATION OF VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, CLEAVAGE RP BY CASP8, AND FUNCTION. RX PubMed=31827281; DOI=10.1038/s41586-019-1828-5; RA Lalaoui N., Boyden S.E., Oda H., Wood G.M., Stone D.L., Chau D., Liu L., RA Stoffels M., Kratina T., Lawlor K.E., Zaal K.J.M., Hoffmann P.M., RA Etemadi N., Shield-Artin K., Biben C., Tsai W.L., Blake M.D., Kuehn H.S., RA Yang D., Anderton H., Silke N., Wachsmuth L., Zheng L., Moura N.S., RA Beck D.B., Gutierrez-Cruz G., Ombrello A.K., Pinto-Patarroyo G.P., RA Kueh A.J., Herold M.J., Hall C., Wang H., Chae J.J., Dmitrieva N.I., RA McKenzie M., Light A., Barham B.K., Jones A., Romeo T.M., Zhou Q., RA Aksentijevich I., Mullikin J.C., Gross A.J., Shum A.K., Hawkins E.D., RA Masters S.L., Lenardo M.J., Boehm M., Rosenzweig S.D., Pasparakis M., RA Voss A.K., Gadina M., Kastner D.L., Silke J.; RT "Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory RT disease."; RL Nature 577:103-108(2020). RN [65] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL HIS-324 AND VAL-324, CHARACTERIZATION RP OF VARIANTS AIEFL HIS-324 AND VAL-324, FUNCTION, CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-166, AND CLEAVAGE BY CASP8. RX PubMed=31827280; DOI=10.1038/s41586-019-1830-y; RA Tao P., Sun J., Wu Z., Wang S., Wang J., Li W., Pan H., Bai R., Zhang J., RA Wang Y., Lee P.Y., Ying W., Zhou Q., Hou J., Wang W., Sun B., Yang M., RA Liu D., Fang R., Han H., Yang Z., Huang X., Li H., Deuitch N., Zhang Y., RA Dissanayake D., Haude K., McWalter K., Roadhouse C., MacKenzie J.J., RA Laxer R.M., Aksentijevich I., Yu X., Wang X., Yuan J., Zhou Q.; RT "A dominant autoinflammatory disease caused by non-cleavable variants of RT RIPK1."; RL Nature 577:109-114(2020). CC -!- FUNCTION: Serine-threonine kinase which is a key regulator of TNF- CC mediated apoptosis, necroptosis and inflammatory pathways CC (PubMed:17703191, PubMed:24144979, PubMed:31827280, PubMed:31827281, CC PubMed:32657447, PubMed:35831301). Exhibits kinase activity-dependent CC functions that regulate cell death and kinase-independent scaffold CC functions regulating inflammatory signaling and cell survival CC (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, CC PubMed:30988283). Has kinase-independent scaffold functions: upon CC binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling CC complex (TNF-RSC also known as complex I) where it acts as a scaffold CC protein promoting cell survival, in part, by activating the canonical CC NF-kappa-B pathway (By similarity). Kinase activity is essential to CC regulate necroptosis and apoptosis, two parallel forms of cell death: CC upon activation of its protein kinase activity, regulates assembly of CC two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), CC which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which CC drives necroptosis (By similarity). RIPK1 is required to limit CASP8- CC dependent TNFR1-induced apoptosis (By similarity). In normal CC conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, CC a process mediated by RIPK3 component of complex IIb, which catalyzes CC phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3- CC mediated necroptosis via FADD-mediated recruitment of CASP8, which CC cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit CC apoptosis and necroptosis during embryonic development: acts by CC preventing the interaction of TRADD with FADD thereby limiting aberrant CC activation of CASP8 (By similarity). In addition to apoptosis and CC necroptosis, also involved in inflammatory response by promoting CC transcriptional production of pro-inflammatory cytokines, such as CC interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates CC RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans- CC phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' CC in a TNF-dependent manner, and thereby activates the MAP3K5-JNK CC apoptotic cascade (PubMed:15310755, PubMed:17389591). Required for CC ZBP1-induced NF-kappa-B activation in response to DNA damage (By CC similarity). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:15310755, CC ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513, CC ECO:0000269|PubMed:24144979, ECO:0000269|PubMed:29440439, CC ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281, ECO:0000269|PubMed:32657447, CC ECO:0000269|PubMed:35831301}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- ACTIVITY REGULATION: Serine-threonine kinase activity is inhibited by CC linear polyubiquitination ('Met-1'-linked) by the LUBAC complex (By CC similarity). Inhibited by necrostatins, including necrostatin-1, CC necrostatin-3 and necrostatin-4 (PubMed:23473668). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:23473668}. CC -!- SUBUNIT: Homodimer (PubMed:29440439, PubMed:29681455). Interacts (via CC RIP homotypic interaction motif) with RIPK3 (via RIP homotypic CC interaction motif); this interaction induces RIPK1 phosphorylation and CC formation of a RIPK1-RIPK3 necroptosis-inducing complex CC (PubMed:10358032, PubMed:11734559, PubMed:19524512, PubMed:29681455, CC PubMed:29883609). Upon TNF-induced necrosis, the RIPK1-RIPK3 dimer CC further interacts with PGAM5 and MLKL; the formation of this complex CC leads to PGAM5 phosphorylation and increase in PGAM5 phosphatase CC activity (PubMed:22265414). Interacts (via the death domain) with CC TNFRSF6 (via the death domain) and TRADD (via the death domain) CC (PubMed:8612133). Is recruited by TRADD to TNFRSF1A in a TNF-dependent CC process (PubMed:24130170). Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 and CC TRAF3 (PubMed:11116146, PubMed:11854271, PubMed:8612133, CC PubMed:9927690). Interacts with BNLF1 (PubMed:10409763). Interacts with CC SQSTM1 upon TNF stimulation (PubMed:10356400). May interact with CC MAVS/IPS1 (PubMed:16127453). Interacts with ZFAND5 (PubMed:14754897). CC Interacts with RBCK1 (PubMed:17449468). Interacts with ZBP1 (By CC similarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and XIAP/BIRC4 CC (PubMed:21931591). Interacts (via kinase domain) with DAB2IP (via Ras- CC GAP domain); the interaction occurs in a TNF-dependent manner CC (PubMed:15310755, PubMed:17389591). Interacts with ARHGEF2 CC (PubMed:21887730). Interacts (via protein kinase domain) with RFFL; CC involved in RIPK1 ubiquitination (PubMed:18450452). Interacts with CC RNF34; involved in RIPK1 ubiquitination (Ref.35). Interacts with TICAM1 CC and this interaction is enhanced in the presence of WDFY1 CC (PubMed:25736436). Interacts with PELI1 (PubMed:29883609). Interacts CC (via death domain) with CRADD (via death domain); the interaction is CC direct (PubMed:9044836). Component of complex IIa composed of at least CC RIPK1, FADD and CASP8 (By similarity). Component of the AIM2 CC PANoptosome complex, a multiprotein complex that drives inflammatory CC cell death (PANoptosis) (By similarity). Interacts with MAP3K7, CFLAR, CC CASP8, FADD and NEMO (By similarity). Interacts with TAX1BP1; this CC interaction negatively regulates RIPK1 ubiquitination CC (PubMed:17703191). Interacts with GRB2 (PubMed:35831301). Interacts CC with DDX24; this interaction disrupts RLR signaling activation of IFN- CC dependent transcription factor IRF7 (PubMed:24204270). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:10409763, CC ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11734559, CC ECO:0000269|PubMed:11854271, ECO:0000269|PubMed:14754897, CC ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:17389591, CC ECO:0000269|PubMed:17449468, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:19524512, CC ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:24130170, CC ECO:0000269|PubMed:24204270, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:29440439, ECO:0000269|PubMed:29681455, CC ECO:0000269|PubMed:29883609, ECO:0000269|PubMed:35831301, CC ECO:0000269|PubMed:8612133, ECO:0000269|PubMed:9044836, CC ECO:0000269|PubMed:9927690, ECO:0000269|Ref.35}. CC -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH; CC this interaction inhibits downstream NF-kappa-B pathway activation. CC {ECO:0000269|PubMed:28659487}. CC -!- SUBUNIT: (Microbial infection) Interacts with Murid herpesvirus 1 CC protein RIR1. {ECO:0000269|PubMed:18442983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 1/HHV-1 protein RIR1/ICP6 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 2/HHV-2 protein RIR1/ICP10 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- INTERACTION: CC Q13546; P04083: ANXA1; NbExp=5; IntAct=EBI-358507, EBI-354007; CC Q13546; Q13490: BIRC2; NbExp=10; IntAct=EBI-358507, EBI-514538; CC Q13546; Q13489: BIRC3; NbExp=3; IntAct=EBI-358507, EBI-517709; CC Q13546; Q92851: CASP10; NbExp=2; IntAct=EBI-358507, EBI-495095; CC Q13546; Q14790: CASP8; NbExp=30; IntAct=EBI-358507, EBI-78060; CC Q13546; Q8IVM0: CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996; CC Q13546; P48729: CSNK1A1; NbExp=5; IntAct=EBI-358507, EBI-1383726; CC Q13546; Q13158: FADD; NbExp=12; IntAct=EBI-358507, EBI-494804; CC Q13546; P08238: HSP90AB1; NbExp=2; IntAct=EBI-358507, EBI-352572; CC Q13546; Q9Y6K9: IKBKG; NbExp=9; IntAct=EBI-358507, EBI-81279; CC Q13546; Q96AB6: NTAN1; NbExp=2; IntAct=EBI-358507, EBI-12401218; CC Q13546; Q9ULZ3: PYCARD; NbExp=2; IntAct=EBI-358507, EBI-751215; CC Q13546; Q13546: RIPK1; NbExp=11; IntAct=EBI-358507, EBI-358507; CC Q13546; Q9Y572: RIPK3; NbExp=27; IntAct=EBI-358507, EBI-298250; CC Q13546; P19438: TNFRSF1A; NbExp=7; IntAct=EBI-358507, EBI-299451; CC Q13546; Q15628: TRADD; NbExp=3; IntAct=EBI-358507, EBI-359215; CC Q13546; Q13077: TRAF1; NbExp=8; IntAct=EBI-358507, EBI-359224; CC Q13546; Q12933: TRAF2; NbExp=10; IntAct=EBI-358507, EBI-355744; CC Q13546; Q13114: TRAF3; NbExp=5; IntAct=EBI-358507, EBI-357631; CC Q13546; O00635: TRIM38; NbExp=2; IntAct=EBI-358507, EBI-2130415; CC Q13546; Q13107: USP4; NbExp=4; IntAct=EBI-358507, EBI-723290; CC Q13546; B7UI21: nleB1; Xeno; NbExp=4; IntAct=EBI-358507, EBI-16070376; CC Q13546; PRO_0000449629 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-358507, EBI-25475885; CC Q13546; U5TQE9: UL39; Xeno; NbExp=3; IntAct=EBI-358507, EBI-11894787; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q60855}. Cell CC membrane {ECO:0000250|UniProtKB:Q9ZUF4}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13546-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13546-2; Sequence=VSP_037690; CC -!- DOMAIN: The RIP homotypic interaction motif (RHIM) mediates interaction CC with the RHIM motif of RIPK1. Both motifs form a hetero-amyloid CC serpentine fold, stabilized by hydrophobic packing and featuring an CC unusual Cys-Ser ladder of alternating Ser (from RIPK1) and Cys (from CC RIPK3). {ECO:0000269|PubMed:29681455}. CC -!- DOMAIN: The death domain mediates dimerization and activation of its CC kinase activity during necroptosis and apoptosis (PubMed:29440439). It CC engages other DD-containing proteins as well as a central CC (intermediate) region important for NF-kB activation and RHIM-dependent CC signaling (PubMed:10356400). {ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:29440439}. CC -!- PTM: (Microbial infection) Proteolytically cleaved by S.flexneri OspD3 CC within the RIP homotypic interaction motif (RHIM), leading to its CC degradation and inhibition of necroptosis. CC {ECO:0000269|PubMed:32657447}. CC -!- PTM: Proteolytically cleaved by CASP8 at Asp-324 (PubMed:10521396, CC PubMed:31827280, PubMed:31827281). Cleavage is crucial for limiting CC TNF-induced apoptosis, necroptosis and inflammatory response CC (PubMed:31827280, PubMed:31827281). Cleavage abolishes NF-kappa-B CC activation and enhances the interaction of TRADD with FADD CC (PubMed:10521396). Proteolytically cleaved by CASP6 during intrinsic CC apoptosis (PubMed:22858542). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:10521396, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281}. CC -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation CC (PubMed:18408713, PubMed:19524513, PubMed:31827280). Phosphorylation of CC Ser-161 by RIPK3 is necessary for the formation of the necroptosis- CC inducing complex (PubMed:18408713). Phosphorylation at Ser-25 represses CC its kinase activity and consequently prevents TNF-mediated RIPK1- CC dependent cell death (PubMed:30988283). Phosphorylated at Ser-320 by CC MAP3K7 which requires prior ubiquitination with 'Lys-63'-linked chains CC by BIRC2/c-IAP1 and BIRC3/c-IAP2 (By similarity). This phosphorylation CC positively regulates RIPK1 interaction with RIPK3 to promote CC necroptosis but negatively regulates RIPK1 kinase activity and its CC interaction with FADD to mediate apoptosis (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:18408713, CC ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280}. CC -!- PTM: Deubiquitinated by USP7; this modification is required for TNF- CC induced apoptosis. {ECO:0000269|PubMed:24144979}. CC -!- PTM: Ubiquitinated with 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear- CC linked type ubiquitin (PubMed:15258597, PubMed:16603398, CC PubMed:17703191, PubMed:18450452, PubMed:21455173, PubMed:21931591, CC PubMed:29883609, Ref.35). Polyubiquitination with 'Lys-63'-linked CC chains by TRAF2 induces association with the IKK complex CC (PubMed:15258597). Deubiquitination of 'Lys-63'-linked chains and CC polyubiquitination with 'Lys-48'-linked chains by TNFAIP3 leads to CC RIPK1 proteasomal degradation and consequently down-regulates TNF- CC induced NF-kappa-B signaling (PubMed:15258597). 'Lys-48'-linked CC polyubiquitination by RFFL or RNF34 also promotes proteasomal CC degradation and negatively regulates TNF-induced NF-kappa-B signaling CC (PubMed:18450452, Ref.35). Linear polyubiquitinated; the head-to-tail CC linear polyubiquitination ('Met-1'-linked) is mediated by the LUBAC CC complex and decreases protein kinase activity (PubMed:21455173). CC Deubiquitination of linear polyubiquitin by CYLD promotes the kinase CC activity (By similarity). Polyubiquitinated with 'Lys-48' and 'Lys-63'- CC linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation CC of NF-kappa-B (PubMed:21931591). Ubiquitinated with 'Lys-63'-linked CC chains by PELI1 (PubMed:29883609). Ubiquitination at Lys-377 with 'Lys- CC 63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2 is essential for its CC phosphorylation at Ser-320 mediated by MAP3K7 (By similarity). This CC ubiquitination is required for NF-kB activation, suppresses RIPK1 CC kinase activity and plays a critical role in preventing cell death CC during embryonic development (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:15258597, CC ECO:0000269|PubMed:16603398, ECO:0000269|PubMed:18450452, CC ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:29883609, ECO:0000269|Ref.35}. CC -!- PTM: (Microbial infection) Glycosylated at Arg-603 by enteropathogenic CC E.coli protein NleB1: arginine GlcNAcylation prevents CC homotypic/heterotypic death domain interactions. CC {ECO:0000305|PubMed:23955153}. CC -!- DISEASE: Immunodeficiency 57 with autoinflammation (IMD57) CC [MIM:618108]: An autosomal recessive primary immunodeficiency CC characterized by lymphopenia and recurrent viral, bacterial, and fungal CC infections. Patients exhibit early-onset inflammatory bowel disease CC involving the upper and lower gastrointestinal tract, and develop CC progressive polyarthritis. {ECO:0000269|PubMed:30026316}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. RIPK1-deficient immune cells from IMD57 patients have impaired CC proinflammatory signaling leading to dysregulated cytokine secretion CC and are prone to necroptosis. {ECO:0000269|PubMed:30026316}. CC -!- DISEASE: Autoinflammation with episodic fever and lymphadenopathy CC (AIEFL) [MIM:618852]: An autosomal dominant immunologic disorder CC characterized by early onset of recurrent episodes of unexplained CC fever, lymphadenopathy, hepatosplenomegaly, and increased levels of CC inflammatory cytokines and chemokines in patient serum. CC {ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65471.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U50062; AAC32232.1; -; mRNA. DR EMBL; AK314176; BAG36858.1; -; mRNA. DR EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA. DR EMBL; AY682848; AAT74626.1; -; Genomic_DNA. DR EMBL; AL031963; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC126254; AAI26255.1; -; mRNA. DR EMBL; BC126256; AAI26257.1; -; mRNA. DR EMBL; AB208926; BAD92163.1; -; mRNA. DR EMBL; U25994; AAC50137.1; -; mRNA. DR CCDS; CCDS4482.1; -. [Q13546-1] DR CCDS; CCDS93851.1; -. [Q13546-2] DR PIR; T09479; T09479. DR RefSeq; NP_001341859.1; NM_001354930.2. [Q13546-1] DR RefSeq; NP_001341860.1; NM_001354931.2. [Q13546-2] DR RefSeq; NP_003795.2; NM_003804.6. [Q13546-1] DR RefSeq; XP_047275403.1; XM_047419447.1. [Q13546-1] DR RefSeq; XP_047275404.1; XM_047419448.1. [Q13546-1] DR RefSeq; XP_054212622.1; XM_054356647.1. [Q13546-1] DR PDB; 4ITH; X-ray; 2.25 A; A/B=1-294. DR PDB; 4ITI; X-ray; 2.86 A; A/B=1-294. DR PDB; 4ITJ; X-ray; 1.80 A; A/B=1-294. DR PDB; 4NEU; X-ray; 2.57 A; A/B=1-324. DR PDB; 5HX6; X-ray; 2.23 A; A/B=1-294. DR PDB; 5TX5; X-ray; 2.56 A; A/B=1-294. DR PDB; 5V7Z; NMR; -; B/D/F/H=532-549. DR PDB; 6AC5; X-ray; 1.45 A; A=561-671. DR PDB; 6C3E; X-ray; 2.60 A; A/B=2-294. DR PDB; 6C4D; X-ray; 2.52 A; A/B/C/D=2-294. DR PDB; 6HHO; X-ray; 3.49 A; A/B=1-294. DR PDB; 6NW2; X-ray; 2.00 A; A/B=1-294. DR PDB; 6NYH; X-ray; 2.10 A; A/B=1-294. DR PDB; 6OCQ; X-ray; 2.79 A; A/B=1-294. DR PDB; 6R5F; X-ray; 3.25 A; A/B/C/D=1-294. DR PDB; 6RLN; X-ray; 2.87 A; A/B=1-294. DR PDB; 7CJB; X-ray; 2.80 A; D/H/L/P=189-203. DR PDB; 7FCZ; X-ray; 2.21 A; A/B=1-294. DR PDB; 7FD0; X-ray; 2.00 A; A/B=1-294. DR PDB; 7XMK; X-ray; 2.38 A; A/B=1-294. DR PDB; 7YDX; X-ray; 2.64 A; A/B=1-294. DR PDB; 8I2N; X-ray; 2.29 A; A/B=1-294. DR PDB; 8Z93; EM; 4.65 A; A/B/C=496-583. DR PDB; 9MZX; X-ray; 2.53 A; A/B=6-294. DR PDB; 9MZY; X-ray; 2.32 A; A/B=8-294. DR PDB; 9MZZ; X-ray; 2.68 A; A/B=7-294. DR PDBsum; 4ITH; -. DR PDBsum; 4ITI; -. DR PDBsum; 4ITJ; -. DR PDBsum; 4NEU; -. DR PDBsum; 5HX6; -. DR PDBsum; 5TX5; -. DR PDBsum; 5V7Z; -. DR PDBsum; 6AC5; -. DR PDBsum; 6C3E; -. DR PDBsum; 6C4D; -. DR PDBsum; 6HHO; -. DR PDBsum; 6NW2; -. DR PDBsum; 6NYH; -. DR PDBsum; 6OCQ; -. DR PDBsum; 6R5F; -. DR PDBsum; 6RLN; -. DR PDBsum; 7CJB; -. DR PDBsum; 7FCZ; -. DR PDBsum; 7FD0; -. DR PDBsum; 7XMK; -. DR PDBsum; 7YDX; -. DR PDBsum; 8I2N; -. DR PDBsum; 8Z93; -. DR PDBsum; 9MZX; -. DR PDBsum; 9MZY; -. DR PDBsum; 9MZZ; -. DR AlphaFoldDB; Q13546; -. DR BMRB; Q13546; -. DR EMDB; EMD-39853; -. DR SMR; Q13546; -. DR BioGRID; 114274; 207. DR ComplexPortal; CPX-1907; Ripoptosome. DR ComplexPortal; CPX-25723; sTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-25726; mTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-8828; sTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR ComplexPortal; CPX-8932; mTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR CORUM; Q13546; -. DR DIP; DIP-433N; -. DR FunCoup; Q13546; 1287. DR IntAct; Q13546; 138. DR MINT; Q13546; -. DR STRING; 9606.ENSP00000259808; -. DR BindingDB; Q13546; -. DR ChEMBL; CHEMBL5464; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16875; GSK-2982772. DR DrugBank; DB16492; SAR443122. DR DrugCentral; Q13546; -. DR GuidetoPHARMACOLOGY; 2189; -. DR GlyCosmos; Q13546; 3 sites, 1 glycan. DR GlyGen; Q13546; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q13546; -. DR MetOSite; Q13546; -. DR PhosphoSitePlus; Q13546; -. DR BioMuta; RIPK1; -. DR DMDM; 60393639; -. DR CPTAC; CPTAC-1053; -. DR CPTAC; CPTAC-900; -. DR CPTAC; CPTAC-901; -. DR CPTAC; CPTAC-902; -. DR jPOST; Q13546; -. DR MassIVE; Q13546; -. DR PaxDb; 9606-ENSP00000259808; -. DR PeptideAtlas; Q13546; -. DR ProteomicsDB; 59527; -. [Q13546-1] DR ProteomicsDB; 59528; -. [Q13546-2] DR Pumba; Q13546; -. DR Antibodypedia; 4145; 668 antibodies from 45 providers. DR DNASU; 8737; -. DR Ensembl; ENST00000259808.9; ENSP00000259808.3; ENSG00000137275.17. [Q13546-1] DR Ensembl; ENST00000380409.3; ENSP00000369773.3; ENSG00000137275.17. [Q13546-2] DR GeneID; 8737; -. DR KEGG; hsa:8737; -. DR MANE-Select; ENST00000259808.9; ENSP00000259808.3; NM_001354930.2; NP_001341859.1. DR UCSC; uc003mux.4; human. [Q13546-1] DR AGR; HGNC:10019; -. DR ClinPGx; PA34394; -. DR CTD; 8737; -. DR DisGeNET; 8737; -. DR GeneCards; RIPK1; -. DR HGNC; HGNC:10019; RIPK1. DR HPA; ENSG00000137275; Low tissue specificity. DR MalaCards; RIPK1; -. DR MIM; 603453; gene. DR MIM; 618108; phenotype. DR MIM; 618852; phenotype. DR OpenTargets; ENSG00000137275; -. DR Orphanet; 529977; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome. DR VEuPathDB; HostDB:ENSG00000137275; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000159347; -. DR HOGENOM; CLU_017229_0_0_1; -. DR InParanoid; Q13546; -. DR OrthoDB; 535509at2759; -. DR PAN-GO; Q13546; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13546; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13546; -. DR Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1. DR Reactome; R-HSA-2562578; TRIF-mediated programmed cell death. DR Reactome; R-HSA-3295583; TRP channels. DR Reactome; R-HSA-3371378; Regulation by c-FLIP. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5218900; CASP8 activity is inhibited. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-69416; Dimerization of procaspase-8. DR Reactome; R-HSA-75893; TNF signaling. DR Reactome; R-HSA-9013957; TLR3-mediated TICAM1-dependent programmed cell death. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-9692913; SARS-CoV-1-mediated effects on programmed cell death. DR Reactome; R-HSA-9693928; Defective RIPK1-mediated regulated necrosis. DR SignaLink; Q13546; -. DR SIGNOR; Q13546; -. DR Agora; ENSG00000137275; -. DR BioGRID-ORCS; 8737; 38 hits in 1199 CRISPR screens. DR ChiTaRS; RIPK1; human. DR EvolutionaryTrace; Q13546; -. DR GeneWiki; RIPK1; -. DR GenomeRNAi; 8737; -. DR Pharos; Q13546; Tchem. DR PRO; PR:Q13546; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13546; protein. DR Bgee; ENSG00000137275; Expressed in granulocyte and 154 other cell types or tissues. DR ExpressionAtlas; Q13546; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0070513; F:death domain binding; IPI:BHF-UCL. DR GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:DisProt. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0035591; F:signaling adaptor activity; IEA:Ensembl. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:1990000; P:amyloid fibril formation; IDA:DisProt. DR GO; GO:0006915; P:apoptotic process; IMP:UniProtKB. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:ARUK-UCL. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0060546; P:negative regulation of necroptotic process; ISS:UniProtKB. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0050729; P:positive regulation of inflammatory response; IMP:UniProtKB. DR GO; GO:0070105; P:positive regulation of interleukin-6-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; IMP:UniProtKB. DR GO; GO:1903800; P:positive regulation of miRNA processing; IDA:ARUK-UCL. DR GO; GO:0060545; P:positive regulation of necroptotic process; IMP:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0043068; P:positive regulation of programmed cell death; IMP:UniProtKB. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IMP:BHF-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL. DR GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0097300; P:programmed necrotic cell death; ISS:ARUK-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB. DR GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL. DR GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL. DR GO; GO:0097343; P:ripoptosome assembly; IMP:UniProtKB. DR GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IMP:DisProt. DR GO; GO:0070231; P:T cell apoptotic process; ISS:UniProtKB. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IC:BHF-UCL. DR CDD; cd08777; Death_RIP1; 1. DR CDD; cd14027; STKc_RIP1; 1. DR DisProt; DP04298; -. DR FunFam; 1.10.533.10:FF:000052; Putative receptor-interacting serine/threonine-protein kinase 1; 1. DR FunFam; 1.10.510.10:FF:000472; Receptor interacting serine/threonine kinase 1; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR037934; RIP1_Death. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329:SF6; RECEPTOR-INTERACTING SERINE_THREONINE-PROTEIN KINASE 1; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00005; DEATH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50017; DEATH_DOMAIN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Cytoplasm; Disease variant; Glycoprotein; Host-virus interaction; KW Inflammatory response; Isopeptide bond; Kinase; Membrane; Necrosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..671 FT /note="Receptor-interacting serine/threonine-protein kinase FT 1" FT /id="PRO_0000086606" FT DOMAIN 17..289 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 583..669 FT /note="Death" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00064" FT REGION 290..582 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000269|PubMed:10356400" FT REGION 331..354 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 389..455 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 531..547 FT /note="RIP homotypic interaction motif (RHIM)" FT /evidence="ECO:0000269|PubMed:11734559, FT ECO:0000269|PubMed:29681455" FT COMPBIAS 331..348 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 428..444 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 23..31 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 324..325 FT /note="Cleavage; by CASP8" FT /evidence="ECO:0000269|PubMed:10521396, FT ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281" FT MOD_RES 6 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 20 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 25 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0000269|PubMed:30988283" FT MOD_RES 161 FT /note="Phosphoserine; by RIPK3 and autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 166 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255, ECO:0000269|PubMed:29440439, FT ECO:0000269|PubMed:31827280" FT MOD_RES 303 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 320 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 331 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000250|UniProtKB:Q60855" FT MOD_RES 333 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 384 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:15144186" FT CARBOHYD 603 FT /note="(Microbial infection) N-beta-linked (GlcNAc) FT arginine" FT /evidence="ECO:0000269|PubMed:30979585, FT ECO:0000305|PubMed:23955153, ECO:0007744|PDB:6AC5" FT CROSSLNK 377 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16603398" FT VAR_SEQ 108..153 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037690" FT VARIANT 64 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs774996232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041039" FT VARIANT 81 FT /note="V -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs758268804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041040" FT VARIANT 220 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs759012409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041041" FT VARIANT 234 FT /note="E -> K (in dbSNP:rs17548383)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_021109" FT VARIANT 324 FT /note="D -> H (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827280, FT ECO:0000269|PubMed:31827281" FT /id="VAR_083518" FT VARIANT 324 FT /note="D -> N (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083519" FT VARIANT 324 FT /note="D -> V (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720924)" FT /evidence="ECO:0000269|PubMed:31827280" FT /id="VAR_084135" FT VARIANT 324 FT /note="D -> Y (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083520" FT VARIANT 404 FT /note="A -> S (in dbSNP:rs34872409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041042" FT VARIANT 438 FT /note="A -> V (in dbSNP:rs3173519)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:7538908, ECO:0000269|PubMed:8612133" FT /id="VAR_058285" FT VARIANT 443 FT /note="A -> V (in dbSNP:rs35722193)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041043" FT VARIANT 569 FT /note="A -> V (in dbSNP:rs55861377)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041044" FT MUTAGEN 25 FT /note="S->D: Phophomimetic mutant. Significant loss of FT kinase activity." FT /evidence="ECO:0000269|PubMed:30988283" FT MUTAGEN 45 FT /note="K->A: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:30988283, FT ECO:0000269|PubMed:8612133" FT MUTAGEN 161 FT /note="S->A: Decreases RIPK1 kinase activity." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 161 FT /note="S->E: No effect on RIPK1 autophosphorylation." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 324 FT /note="D->K: Abolishes cleavage by caspase-8." FT /evidence="ECO:0000269|PubMed:10521396" FT MUTAGEN 377 FT /note="K->R: Abolishes RIP-mediated NF-Kappa-B activation." FT /evidence="ECO:0000269|PubMed:16603398" FT MUTAGEN 536 FT /note="S->C: Strongly reduced homodimerization and FT interaction with RIPK3." FT /evidence="ECO:0000269|PubMed:29681455" FT MUTAGEN 539..542 FT /note="IQIG->AAAA: Abolished cleavage by S.flexneri OspD3." FT /evidence="ECO:0000269|PubMed:32657447" FT MUTAGEN 599 FT /note="K->R: Blocks homodimerization, necroptosis and FT apoptosis." FT /evidence="ECO:0000269|PubMed:29440439" FT MUTAGEN 603 FT /note="R->A: Abolished GlcNAcylation by E.coli NleB1." FT /evidence="ECO:0000269|PubMed:30979585" FT CONFLICT 258 FT /note="R -> I (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 286 FT /note="R -> S (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 514 FT /note="T -> S (in Ref. 8; AAC50137)" FT /evidence="ECO:0000305" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:7FD0" FT HELIX 14..16 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:5HX6" FT STRAND 20..22 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 26..28 FT /evidence="ECO:0007829|PDB:7FD0" FT STRAND 30..36 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 37..39 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 40..51 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 54..56 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 57..68 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 87..93 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 106..108 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 112..131 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 141..143 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 144..146 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 163..168 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:4ITH" FT HELIX 190..192 FT /evidence="ECO:0007829|PDB:6NW2" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 207..223 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:6C4D" FT HELIX 234..242 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 249..251 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 252..255 FT /evidence="ECO:0007829|PDB:6C3E" FT HELIX 258..267 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 278..292 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4NEU" FT HELIX 297..309 FT /evidence="ECO:0007829|PDB:4NEU" FT TURN 310..312 FT /evidence="ECO:0007829|PDB:4NEU" FT STRAND 533..542 FT /evidence="ECO:0007829|PDB:5V7Z" FT HELIX 575..577 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 584..593 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 599..604 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 609..618 FT /evidence="ECO:0007829|PDB:6AC5" FT TURN 619..622 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 624..643 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 659..668 FT /evidence="ECO:0007829|PDB:6AC5" SQ SEQUENCE 671 AA; 75931 MW; 976E2428D525A9B2 CRC64; MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID LLSSLIYVSQ N // ID RN5A_HUMAN Reviewed; 741 AA. AC Q05823; Q5W0L2; Q6AI46; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 2. DT 28-JAN-2026, entry version 218. DE RecName: Full=2-5A-dependent ribonuclease; DE Short=2-5A-dependent RNase; DE EC=3.1.26.-; DE AltName: Full=Ribonuclease 4; DE AltName: Full=Ribonuclease L; DE Short=RNase L; GN Name=RNASEL {ECO:0000303|PubMed:40010341}; Synonyms=RNS4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF LYS-240 AND LYS-274. RC TISSUE=Kidney; RX PubMed=7680958; DOI=10.1016/0092-8674(93)90403-d; RA Zhou A., Hassel B.A., Silverman R.H.; RT "Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator RT of interferon action."; RL Cell 72:753-765(1993). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=11063255; DOI=10.1007/s003350010194; RA Zhou A., Nie H., Silverman R.H.; RT "Analysis and origins of the human and mouse RNase L genes: mediators of RT interferon action."; RL Mamm. Genome 11:989-992(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Colon carcinoma; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION OF RNASEL ACTIVITY. RX PubMed=7514601; DOI=10.1016/s0021-9258(17)36767-4; RA Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F., RA Silverman R.H.; RT "Intrinsic molecular activities of the interferon-induced 2-5A-dependent RT RNase."; RL J. Biol. Chem. 269:14153-14158(1994). RN [8] RP INTERACTION WITH ABCE1. RX PubMed=7539425; DOI=10.1074/jbc.270.22.13308; RA Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.; RT "Cloning and characterization of a RNase L inhibitor. A new component of RT the interferon-regulated 2-5A pathway."; RL J. Biol. Chem. 270:13308-13317(1995). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11585831; DOI=10.1074/jbc.m107482200; RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RT "The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial RT mRNAs stability in interferon alpha-treated H9 cells."; RL J. Biol. Chem. 276:48473-48482(2001). RN [10] RP ERRATUM OF PUBMED:11585831. RA Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., Salehzada T.; RL J. Biol. Chem. 277:13354-13354(2002). RN [11] RP REVIEW. RX PubMed=9856285; DOI=10.1016/s0753-3322(99)80006-7; RA Castelli J., Wood K.A., Youle R.J.; RT "The 2-5A system in viral infection and apoptosis."; RL Biomed. Pharmacother. 52:386-390(1998). RN [12] RP MUTAGENESIS OF LYS-392. RX PubMed=9862963; DOI=10.1093/nar/27.2.439; RA Dong B., Silverman R.H.; RT "Alternative function of a protein kinase homology domain in 2', 5'- RT oligoadenylate dependent RNase L."; RL Nucleic Acids Res. 27:439-445(1999). RN [13] RP MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND HIS-672. RX PubMed=11333017; DOI=10.1017/s1355838201002230; RA Dong B., Niwa M., Walter P., Silverman R.H.; RT "Basis for regulated RNA cleavage by functional analysis of RNase L and RT Ire1p."; RL RNA 7:361-373(2001). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [15] RP FUNCTION. RX PubMed=26263979; DOI=10.3390/ijms160817611; RA Siddiqui M.A., Mukherjee S., Manivannan P., Malathi K.; RT "RNase L cleavage products promote switch from autophagy to apoptosis by RT caspase-mediated cleavage of beclin-1."; RL Int. J. Mol. Sci. 16:17611-17636(2015). RN [16] RP FUNCTION. RX PubMed=40010341; DOI=10.1016/j.immuni.2025.01.016; RA Huai W., Yang K., Xing C., Song K., Lyu H., Williams N.S., Wu J., Yan N.; RT "OAS cross-activates RNase L intercellularly through cell-to-cell transfer RT of 2-5A to spread innate immunity."; RL Immunity 58:797-810.e6(2025). RN [17] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE RP ACTIVATOR 2-5A. RX PubMed=15385955; DOI=10.1038/sj.emboj.7600420; RA Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y., Nakamura K.T.; RT "Structural basis for recognition of 2',5'-linked oligoadenylates by human RT ribonuclease L."; RL EMBO J. 23:3929-3938(2004). RN [18] RP VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541. RX PubMed=11941539; DOI=10.1086/340450; RA Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V., Mononen N., RA Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A., RA Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in RT patients and families with prostate cancer."; RL Am. J. Hum. Genet. 70:1299-1304(2002). RN [19] RP VARIANTS SER-59; GLN-462 AND GLU-541. RX PubMed=11799394; DOI=10.1038/ng823; RA Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M., RA Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I., RA Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K., Brownstein M., RA Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M., RA Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A., RA Papadopoulos N., Kallioniemi O.-P., Burk R., Meyers D., Groenberg H., RA Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., Trent J.; RT "Germline mutations in the ribonuclease L gene in families showing linkage RT with HPC1."; RL Nat. Genet. 30:181-184(2002). RN [20] RP CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541. RX PubMed=12415269; DOI=10.1038/ng1021; RA Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., RA Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., RA Witte J.S.; RT "RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer RT cases."; RL Nat. Genet. 32:581-583(2002). RN [21] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND RP HIS-592. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Endoribonuclease that functions in the interferon (IFN) CC antiviral response (PubMed:11585831, PubMed:26263979). In INF treated CC and virus infected cells, RNASEL probably mediates its antiviral CC effects through a combination of direct cleavage of single-stranded CC viral RNAs, inhibition of protein synthesis through the degradation of CC rRNA, induction of apoptosis, and induction of other antiviral genes CC (PubMed:11585831, PubMed:26263979). RNASEL mediated apoptosis is the CC result of a JNK-dependent stress-response pathway leading to cytochrome CC c release from mitochondria and caspase-dependent apoptosis CC (PubMed:11585831, PubMed:26263979). Therefore, activation of RNASEL CC could lead to elimination of virus infected cells under some CC circumstances (PubMed:11585831, PubMed:26263979). In the crosstalk CC between autophagy and apoptosis proposed to induce autophagy as an CC early stress response to small double-stranded RNA and at later stages CC of prolonged stress to activate caspase-dependent proteolytic cleavage CC of BECN1 to terminate autophagy and promote apoptosis CC (PubMed:26263979). Might play a central role in the regulation of mRNA CC turnover (PubMed:11585831). Cleaves 3' of UpNp dimers, with preference CC for UU and UA sequences, to sets of discrete products ranging from CC between 4 and 22 nucleotides in length. Involved in intercellular CC immune signaling (PubMed:40010341). Cross-activated by 2',5'- CC oligoadenylates (2-5A) previously generated in RNA virus-infected CC cells, triggers type I interferon signaling in uninfected neighboring CC cells to limit local spread of infection (PubMed:40010341). CC {ECO:0000269|PubMed:11585831, ECO:0000269|PubMed:26263979, CC ECO:0000269|PubMed:40010341}. CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Note=Manganese or magnesium. Required for optimal RNA cleavage rates.; CC -!- ACTIVITY REGULATION: After binding to 2-5A (5'-phosphorylated 2',5'- CC linked oligoadenylates) the homodimerization and subsequent activation CC occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a cytoplasmic member CC of the ATP-binding cassette (ABC) transporter family. CC -!- SUBUNIT: Monomer (inactive form) or homodimer. Interacts with ABCE1; CC this interaction inhibits the RNASEL. {ECO:0000269|PubMed:15385955, CC ECO:0000269|PubMed:7539425}. CC -!- INTERACTION: CC Q05823; P46940: IQGAP1; NbExp=2; IntAct=EBI-8390477, EBI-297509; CC Q05823-1; Q05823-1: RNASEL; NbExp=2; IntAct=EBI-16094551, EBI-16094551; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11585831}. CC Mitochondrion {ECO:0000269|PubMed:11585831}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q05823-1; Sequence=Displayed; CC Name=2; CC IsoId=Q05823-2; Sequence=VSP_056272, VSP_056273; CC -!- TISSUE SPECIFICITY: Highly expressed in spleen and thymus followed by CC prostate, testis, uterus, small intestine, colon and peripheral blood CC leukocytes. CC -!- INDUCTION: By interferons. Virus replication in higher vertebrates is CC restrained by IFNs that cause cells to transcribe genes encoding CC antiviral proteins, such as 2'-5' oligoadenylate synthetases (OASs). CC oligoadenylate synthetase is stimulated by dsRNA to produce 5'- CC phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is CC to activate RNASEL. CC -!- DOMAIN: The nine ankyrin repeats also called 2-5A sensor constitute the CC N-terminus 2-5A binding domain. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. It allows the homodimerization. CC -!- DOMAIN: The ribonuclease domain is located in the C-terminus. A single CC active nuclease domain in a dimer is sufficient for ribonuclease CC activity (By similarity). {ECO:0000250}. CC -!- DISEASE: Prostate cancer, hereditary, 1 (HPC1) [MIM:601518]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000305|PubMed:11799394, CC ECO:0000305|PubMed:11941539, ECO:0000305|PubMed:12415269, CC ECO:0000305|PubMed:17344846}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L10381; AAA18032.1; -; Genomic_DNA. DR EMBL; CR627369; CAH10468.1; -; mRNA. DR EMBL; AL138776; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471067; EAW91128.1; -; Genomic_DNA. DR EMBL; BC090934; AAH90934.1; -; mRNA. DR EMBL; BC114433; AAI14434.1; -; mRNA. DR CCDS; CCDS1347.1; -. [Q05823-1] DR PIR; A45771; A45771. DR RefSeq; NP_066956.1; NM_021133.4. [Q05823-1] DR RefSeq; XP_047283062.1; XM_047427106.1. [Q05823-2] DR RefSeq; XP_054194044.1; XM_054338069.1. [Q05823-2] DR PDB; 1WDY; X-ray; 1.80 A; A=21-305. DR PDB; 4G8K; X-ray; 2.40 A; A/B=1-337. DR PDB; 4G8L; X-ray; 2.80 A; A/B/C/D=1-337. DR PDB; 4OAU; X-ray; 2.60 A; C=21-719. DR PDB; 4OAV; X-ray; 2.10 A; B/D=21-719. DR PDBsum; 1WDY; -. DR PDBsum; 4G8K; -. DR PDBsum; 4G8L; -. DR PDBsum; 4OAU; -. DR PDBsum; 4OAV; -. DR AlphaFoldDB; Q05823; -. DR SMR; Q05823; -. DR BioGRID; 111969; 43. DR CORUM; Q05823; -. DR DIP; DIP-61367N; -. DR FunCoup; Q05823; 673. DR IntAct; Q05823; 42. DR MINT; Q05823; -. DR STRING; 9606.ENSP00000356530; -. DR BindingDB; Q05823; -. DR ChEMBL; CHEMBL3575; -. DR GlyGen; Q05823; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q05823; -. DR PhosphoSitePlus; Q05823; -. DR BioMuta; RNASEL; -. DR DMDM; 1350802; -. DR jPOST; Q05823; -. DR MassIVE; Q05823; -. DR PaxDb; 9606-ENSP00000356530; -. DR PeptideAtlas; Q05823; -. DR ProteomicsDB; 58353; -. [Q05823-1] DR ProteomicsDB; 66189; -. DR Pumba; Q05823; -. DR Antibodypedia; 1127; 232 antibodies from 30 providers. DR DNASU; 6041; -. DR Ensembl; ENST00000367559.7; ENSP00000356530.3; ENSG00000135828.12. [Q05823-1] DR Ensembl; ENST00000539397.1; ENSP00000440844.1; ENSG00000135828.12. [Q05823-2] DR GeneID; 6041; -. DR KEGG; hsa:6041; -. DR MANE-Select; ENST00000367559.7; ENSP00000356530.3; NM_021133.4; NP_066956.1. DR UCSC; uc001gpk.4; human. [Q05823-1] DR AGR; HGNC:10050; -. DR ClinPGx; PA34418; -. DR CTD; 6041; -. DR DisGeNET; 6041; -. DR GeneCards; RNASEL; -. DR HGNC; HGNC:10050; RNASEL. DR HPA; ENSG00000135828; Low tissue specificity. DR MalaCards; RNASEL; -. DR MIM; 176807; phenotype. DR MIM; 180435; gene. DR MIM; 601518; phenotype. DR OpenTargets; ENSG00000135828; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000135828; -. DR eggNOG; KOG1027; Eukaryota. DR eggNOG; KOG4177; Eukaryota. DR GeneTree; ENSGT00940000161114; -. DR HOGENOM; CLU_022542_0_0_1; -. DR InParanoid; Q05823; -. DR OMA; YGSESHK; -. DR OrthoDB; 194358at2759; -. DR PAN-GO; Q05823; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q05823; -. DR BioCyc; MetaCyc:HS06069-MONOMER; -. DR BRENDA; 4.6.1.19; 2681. DR PathwayCommons; Q05823; -. DR Reactome; R-HSA-8983711; OAS antiviral response. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR SignaLink; Q05823; -. DR SIGNOR; Q05823; -. DR Agora; ENSG00000135828; -. DR BioGRID-ORCS; 6041; 9 hits in 1192 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; RNASEL; human. DR EvolutionaryTrace; Q05823; -. DR GeneWiki; Ribonuclease_L; -. DR GeneWiki; RNASEL; -. DR GenomeRNAi; 6041; -. DR Pharos; Q05823; Tchem. DR PRO; PR:Q05823; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05823; protein. DR Bgee; ENSG00000135828; Expressed in amniotic fluid and 174 other cell types or tissues. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; NAS:UniProtKB. DR GO; GO:0004540; F:RNA nuclease activity; IDA:ARUK-UCL. DR GO; GO:0019843; F:rRNA binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl. DR GO; GO:0006397; P:mRNA processing; IEA:InterPro. DR GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; IEA:Ensembl. DR GO; GO:0006396; P:RNA processing; IBA:GO_Central. DR GO; GO:0006364; P:rRNA processing; IEA:Ensembl. DR CDD; cd10423; RNase_RNase-L; 1. DR FunFam; 1.25.40.20:FF:000231; 2-5A-dependent ribonuclease; 1. DR FunFam; 1.10.510.10:FF:000618; Ribonuclease L; 1. DR FunFam; 1.20.1440.180:FF:000003; Ribonuclease L; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR042745; RNase-L_RNase. DR PANTHER; PTHR24141; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR PANTHER; PTHR24141:SF1; 2-5A-DEPENDENT RIBONUCLEASE; 1. DR Pfam; PF12796; Ank_2; 3. DR Pfam; PF13857; Ank_5; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 8. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 6. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ANK repeat; KW Antiviral defense; ATP-binding; Cytoplasm; Endonuclease; Hydrolase; KW Immunity; Innate immunity; Metal-binding; Mitochondrion; Nuclease; KW Nucleotide-binding; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Zinc; Zinc-finger. FT CHAIN 1..741 FT /note="2-5A-dependent ribonuclease" FT /id="PRO_0000067051" FT REPEAT 24..53 FT /note="ANK 1" FT REPEAT 58..87 FT /note="ANK 2" FT REPEAT 91..120 FT /note="ANK 3" FT REPEAT 124..153 FT /note="ANK 4" FT REPEAT 167..197 FT /note="ANK 5" FT REPEAT 201..234 FT /note="ANK 6" FT REPEAT 238..268 FT /note="ANK 7" FT REPEAT 272..301 FT /note="ANK 8" FT REPEAT 303..329 FT /note="ANK 9" FT DOMAIN 365..586 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 589..723 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT ZN_FING 395..444 FT /note="C6-type; atypical" FT REGION 1..21 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 229..242 FT /note="2-5A binding (P-loop) 1" FT REGION 253..275 FT /note="2-5A binding (P-loop) 2" FT REGION 715..741 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9..18 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 684 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT VAR_SEQ 636..652 FT /note="INECVMKKMNKFYEKRG -> MSKLRHRQIIFPTTQNQ (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056272" FT VAR_SEQ 653..741 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_056273" FT VARIANT 59 FT /note="G -> S (in dbSNP:rs151296858)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539" FT /id="VAR_013509" FT VARIANT 97 FT /note="I -> L (in dbSNP:rs56250729)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042358" FT VARIANT 289 FT /note="A -> T (in dbSNP:rs35553278)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042359" FT VARIANT 406 FT /note="S -> F (in dbSNP:rs145787003)" FT /evidence="ECO:0000269|PubMed:11941539" FT /id="VAR_013510" FT VARIANT 462 FT /note="R -> Q (risk factor for prostate cancer; reduced FT enzymatic activity; dbSNP:rs486907)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012056" FT VARIANT 541 FT /note="D -> E (no change in enzymatic activity; FT dbSNP:rs627928)" FT /evidence="ECO:0000269|PubMed:11799394, FT ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269, FT ECO:0000269|PubMed:17344846" FT /id="VAR_012057" FT VARIANT 592 FT /note="R -> H (in dbSNP:rs35896902)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042360" FT MUTAGEN 240 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-274." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 274 FT /note="K->N: Reduced 2-5A binding activity; almost complete FT loss of 2-5A binding activity; when associated with N-240." FT /evidence="ECO:0000269|PubMed:7680958" FT MUTAGEN 392 FT /note="K->R: Complete loss of enzymatic activity and enzyme FT dimerization. No change in binding to 2-5A and RNA." FT /evidence="ECO:0000269|PubMed:9862963" FT MUTAGEN 583 FT /note="H->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 584 FT /note="P->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 632 FT /note="W->A: No change in enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 661 FT /note="D->A: Complete loss of enzymatic activity." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 667 FT /note="R->A: Complete loss of enzymatic activity. No change FT in 2-5A binding and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT MUTAGEN 672 FT /note="H->A: Complete loss of enzymatic activity. No change FT in 2-5A binding activity and enzyme dimerization." FT /evidence="ECO:0000269|PubMed:11333017" FT HELIX 22..34 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 56..58 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 62..68 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 72..80 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 95..102 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 105..113 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 128..134 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 138..146 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 159..163 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 171..178 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 181..189 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 205..211 FT /evidence="ECO:0007829|PDB:1WDY" FT TURN 215..217 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 218..227 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 237..239 FT /evidence="ECO:0007829|PDB:4G8K" FT HELIX 242..248 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 252..260 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:1WDY" FT HELIX 286..295 FT /evidence="ECO:0007829|PDB:1WDY" FT STRAND 301..303 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 304..310 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 314..322 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 341..344 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 361..363 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 370..374 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 377..395 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 399..409 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 420..425 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 427..435 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 441..445 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 459..477 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 488..490 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 491..493 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:4OAV" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 514..532 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 533..535 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 547..551 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 557..567 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 576..580 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 584..586 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 589..600 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 603..606 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 613..618 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 628..631 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 638..645 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:4OAV" FT TURN 649..652 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 659..672 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 681..685 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 688..695 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 699..707 FT /evidence="ECO:0007829|PDB:4OAV" FT HELIX 711..715 FT /evidence="ECO:0007829|PDB:4OAV" SQ SEQUENCE 741 AA; 83533 MW; 91385EA307E3CE1D CRC64; MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH SPNKPQCDGA GGASGLASPG C // ID SLK_HUMAN Reviewed; 1235 AA. AC Q9H2G2; D3DRA0; D3DRA1; O00211; Q6P1Z4; Q86WU7; Q86WW1; Q92603; Q9NQL0; AC Q9NQL1; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 206. DE RecName: Full=STE20-like serine/threonine-protein kinase; DE Short=STE20-like kinase; DE Short=hSLK; DE EC=2.7.11.1; DE AltName: Full=CTCL tumor antigen se20-9; DE AltName: Full=STE20-related serine/threonine-protein kinase; DE Short=STE20-related kinase; DE AltName: Full=Serine/threonine-protein kinase 2; GN Name=SLK; Synonyms=KIAA0204, STK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, RP PHOSPHORYLATION, AND MUTAGENESIS OF LYS-63. RC TISSUE=Lung carcinoma; RX PubMed=10699464; DOI=10.1016/s0167-4889(99)00164-0; RA Yamada E., Tsujikawa K., Itoh S., Kameda Y., Kohama Y., Yamamoto H.; RT "Molecular cloning and characterization of a novel human STE20-like kinase, RT hSLK."; RL Biochim. Biophys. Acta 1495:250-262(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=11149944; DOI=10.1073/pnas.98.2.629; RA Eichmueller S., Usener D., Dummer R., Stein A., Thiel D., Schadendorf D.; RT "Serological detection of cutaneous T-cell lymphoma-associated antigens."; RL Proc. Natl. Acad. Sci. U.S.A. 98:629-634(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RA Ohara O., Nagase T., Kikuno R., Nomura N.; RL Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-330; SER-565 AND RP SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-347; SER-348; RP SER-571; SER-777; SER-779 AND SER-818, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-344 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-779, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-571; SER-779 AND RP THR-1097, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-347; SER-348; SER-565 RP AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-189; SER-341; RP SER-518; SER-565; SER-571; SER-779; THR-814 AND SER-818, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-372; SER-518; SER-565; RP THR-569 AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-405; TYR-552; GLN-604; GLY-658; RP THR-679; ASN-683 AND ILE-697. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [18] RP VARIANT 472-GLU--SER-1235 DEL. RX PubMed=28940097; DOI=10.1007/s00439-017-1843-2; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Expanding the genetic heterogeneity of intellectual disability."; RL Hum. Genet. 136:1419-1429(2017). RN [19] RP ERRATUM OF PUBMED:28940097. RX PubMed=29288388; DOI=10.1007/s00439-017-1859-7; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Correction to: Expanding the genetic heterogeneity of intellectual RT disability."; RL Hum. Genet. 137:105-109(2018). CC -!- FUNCTION: Mediates apoptosis and actin stress fiber dissolution. CC {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC Q9H2G2; Q9H2G2: SLK; NbExp=3; IntAct=EBI-1022272, EBI-1022272; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9H2G2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H2G2-2; Sequence=VSP_018100; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highest expression is found CC in heart and in skeletal muscle. {ECO:0000269|PubMed:10699464}. CC -!- PTM: Proteolytically cleaved by caspase-3. CC -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:10699464}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47762.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 611.; Evidence={ECO:0000305}; CC Sequence=AAH47885.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 422.; Evidence={ECO:0000305}; CC Sequence=AAH64804.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 614.; Evidence={ECO:0000305}; CC Sequence=BAA13195.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002804; BAA19655.1; -; mRNA. DR EMBL; AF273048; AAG34908.1; -; mRNA. DR EMBL; D86959; BAA13195.2; ALT_SEQ; mRNA. DR EMBL; AL360170; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471066; EAW49615.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49616.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49617.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49618.1; -; Genomic_DNA. DR EMBL; BC047762; AAH47762.1; ALT_SEQ; mRNA. DR EMBL; BC047885; AAH47885.1; ALT_SEQ; mRNA. DR EMBL; BC064804; AAH64804.1; ALT_SEQ; mRNA. DR EMBL; BC111565; AAI11566.1; -; mRNA. DR CCDS; CCDS7553.1; -. [Q9H2G2-1] DR CCDS; CCDS76334.1; -. [Q9H2G2-2] DR RefSeq; NP_001291672.1; NM_001304743.2. [Q9H2G2-2] DR RefSeq; NP_055535.2; NM_014720.3. [Q9H2G2-1] DR PDB; 2J51; X-ray; 2.10 A; A=19-320. DR PDB; 2JFL; X-ray; 2.20 A; A=19-320. DR PDB; 2JFM; X-ray; 2.85 A; A=19-320. DR PDB; 2UV2; X-ray; 2.30 A; A=19-320. DR PDB; 4USF; X-ray; 1.75 A; A/B=19-320. DR PDB; 6HVD; X-ray; 1.63 A; A=19-320. DR PDB; 8BEM; X-ray; 2.60 A; A/B/D/G=19-319. DR PDBsum; 2J51; -. DR PDBsum; 2JFL; -. DR PDBsum; 2JFM; -. DR PDBsum; 2UV2; -. DR PDBsum; 4USF; -. DR PDBsum; 6HVD; -. DR PDBsum; 8BEM; -. DR AlphaFoldDB; Q9H2G2; -. DR PCDDB; Q9H2G2; -. DR SMR; Q9H2G2; -. DR BioGRID; 115096; 194. DR FunCoup; Q9H2G2; 2503. DR IntAct; Q9H2G2; 85. DR MINT; Q9H2G2; -. DR STRING; 9606.ENSP00000358770; -. DR BindingDB; Q9H2G2; -. DR ChEMBL; CHEMBL4202; -. DR DrugBank; DB07853; 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q9H2G2; -. DR GuidetoPHARMACOLOGY; 2200; -. DR GlyGen; Q9H2G2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9H2G2; -. DR MetOSite; Q9H2G2; -. DR PhosphoSitePlus; Q9H2G2; -. DR SwissPalm; Q9H2G2; -. DR BioMuta; SLK; -. DR DMDM; 74762732; -. DR CPTAC; CPTAC-2845; -. DR CPTAC; CPTAC-2948; -. DR jPOST; Q9H2G2; -. DR MassIVE; Q9H2G2; -. DR PaxDb; 9606-ENSP00000358770; -. DR PeptideAtlas; Q9H2G2; -. DR ProteomicsDB; 80544; -. [Q9H2G2-1] DR ProteomicsDB; 80545; -. [Q9H2G2-2] DR Pumba; Q9H2G2; -. DR Antibodypedia; 18194; 291 antibodies from 34 providers. DR DNASU; 9748; -. DR Ensembl; ENST00000335753.8; ENSP00000336824.4; ENSG00000065613.16. [Q9H2G2-2] DR Ensembl; ENST00000369755.4; ENSP00000358770.3; ENSG00000065613.16. [Q9H2G2-1] DR GeneID; 9748; -. DR KEGG; hsa:9748; -. DR MANE-Select; ENST00000369755.4; ENSP00000358770.3; NM_014720.4; NP_055535.2. DR UCSC; uc001kxo.2; human. [Q9H2G2-1] DR AGR; HGNC:11088; -. DR ClinPGx; PA35941; -. DR CTD; 9748; -. DR DisGeNET; 9748; -. DR GeneCards; SLK; -. DR HGNC; HGNC:11088; SLK. DR HPA; ENSG00000065613; Low tissue specificity. DR MalaCards; SLK; -. DR MIM; 616563; gene. DR OpenTargets; ENSG00000065613; -. DR VEuPathDB; HostDB:ENSG00000065613; -. DR eggNOG; KOG0579; Eukaryota. DR GeneTree; ENSGT00940000156184; -. DR HOGENOM; CLU_001965_3_0_1; -. DR InParanoid; Q9H2G2; -. DR OMA; DESCADS; -. DR OrthoDB; 10027016at2759; -. DR PAN-GO; Q9H2G2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9H2G2; -. DR PathwayCommons; Q9H2G2; -. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR SignaLink; Q9H2G2; -. DR SIGNOR; Q9H2G2; -. DR Agora; ENSG00000065613; -. DR BioGRID-ORCS; 9748; 24 hits in 1189 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; SLK; human. DR EvolutionaryTrace; Q9H2G2; -. DR GeneWiki; SLK_(gene); -. DR GenomeRNAi; 9748; -. DR Pharos; Q9H2G2; Tchem. DR PRO; PR:Q9H2G2; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q9H2G2; protein. DR Bgee; ENSG00000065613; Expressed in esophagus squamous epithelium and 213 other cell types or tissues. DR ExpressionAtlas; Q9H2G2; baseline and differential. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0031122; P:cytoplasmic microtubule organization; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR CDD; cd06643; STKc_SLK; 1. DR FunFam; 1.10.510.10:FF:000081; STE20-like serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000120; STE20-like serine/threonine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR022165; PKK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051585; STE20_Ser/Thr_Kinases. DR InterPro; IPR001943; UVR_dom. DR PANTHER; PTHR46538:SF1; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR46538; PROTEIN KINASE DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF12474; PKK; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50151; UVR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Coiled coil; KW Cytoplasm; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1235 FT /note="STE20-like serine/threonine-protein kinase" FT /id="PRO_0000233239" FT DOMAIN 34..292 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..910 FT /note="UVR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00217" FT REGION 309..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 363..393 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..441 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 519..539 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 613..760 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 826..1069 FT /evidence="ECO:0000255" FT COILED 1109..1183 FT /evidence="ECO:0000255" FT COMPBIAS 312..328 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 421..432 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 522..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 638..650 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 679..695 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 749..760 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 155 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 438..439 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 183 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 189 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08815" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 344 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 348 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 354 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 372 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 518 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 569 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 571 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 647 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 655 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 777 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 779 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 814 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 818 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1097 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT VAR_SEQ 929..959 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10699464, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9039502" FT /id="VSP_018100" FT VARIANT 405 FT /note="Q -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041080" FT VARIANT 472..1235 FT /note="Missing (found in a patient with global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28940097" FT /id="VAR_084656" FT VARIANT 552 FT /note="C -> Y (in dbSNP:rs805657)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041081" FT VARIANT 604 FT /note="E -> Q (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs190220654)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041082" FT VARIANT 658 FT /note="A -> G (in dbSNP:rs56400929)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041083" FT VARIANT 666 FT /note="G -> E (in dbSNP:rs7071400)" FT /id="VAR_051666" FT VARIANT 679 FT /note="I -> T (in dbSNP:rs34326537)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041084" FT VARIANT 683 FT /note="K -> N (in dbSNP:rs35389916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041085" FT VARIANT 697 FT /note="T -> I (in dbSNP:rs3740469)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041086" FT MUTAGEN 63 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:10699464" FT CONFLICT 5 FT /note="N -> S (in Ref. 3; BAA13195)" FT /evidence="ECO:0000305" FT STRAND 25..28 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 48..53 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 54..56 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 59..66 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 70..85 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 94..100 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 116..123 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 129..148 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 181..187 FT /evidence="ECO:0007829|PDB:2J51" FT HELIX 199..202 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 212..214 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 215..230 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 234..237 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 240..249 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 258..260 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 263..272 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 277..279 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 290..292 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 298..308 FT /evidence="ECO:0007829|PDB:6HVD" SQ SEQUENCE 1235 AA; 142695 MW; 53A43E7CA29B0ED3 CRC64; MSFFNFRKIF KLGSEKKKKQ YEHVKRDLNP EDFWEIIGEL GDGAFGKVYK AQNKETSVLA AAKVIDTKSE EELEDYMVEI DILASCDHPN IVKLLDAFYY ENNLWILIEF CAGGAVDAVM LELERPLTES QIQVVCKQTL DALNYLHDNK IIHRDLKAGN ILFTLDGDIK LADFGVSAKN TRTIQRRDSF IGTPYWMAPE VVMCETSKDR PYDYKADVWS LGITLIEMAE IEPPHHELNP MRVLLKIAKS EPPTLAQPSR WSSNFKDFLK KCLEKNVDAR WTTSQLLQHP FVTVDSNKPI RELIAEAKAE VTEEVEDGKE EDEEEETENS LPIPASKRAS SDLSIASSEE DKLSQNACIL ESVSEKTERS NSEDKLNSKI LNEKPTTDEP EKAVEDINEH ITDAQLEAMT ELHDRTAVIK ENEREKRPKL ENLPDTEDQE TVDINSVSEG KENNIMITLE TNIEHNLKSE EEKDQEKQQM FENKLIKSEE IKDTILQTVD LVSQETGEKE ANIQAVDSEV GLTKEDTQEK LGEDDKTQKD VISNTSDVIG TCEAADVAQK VDEDSAEDTQ SNDGKEVVEV GQKLINKPMV GPEAGGTKEV PIKEIVEMNE IEEGKNKEQA INSSENIMDI NEEPGTTEGE EITESSSTEE MEVRSVVADT DQKALGSEVQ DASKVTTQID KEKKEIPVSI KKEPEVTVVS QPTEPQPVLI PSININSDSG ENKEEIGSLS KTETILPPES ENPKENDNDS GTGSTADTSS IDLNLSISSF LSKTKDSGSI SLQETRRQKK TLKKTRKFIV DGVEVSVTTS KIVTDSDSKT EELRFLRRQE LRELRFLQKE EQRAQQQLNS KLQQQREQIF RRFEQEMMSK KRQYDQEIEN LEKQQKQTIE RLEQEHTNRL RDEAKRIKGE QEKELSKFQN MLKNRKKEVI NEVEKAPKEL RKELMKRRKE ELAQSQHAQE QEFVQKQQQE LDGSLKKIIQ QQKAELANIE RECLNNKQQL MRAREAAIWE LEERHLQEKH QLLKQQLKDQ YFMQRHQLLK RHEKETEQMQ RYNQRLIEEL KNRQTQERAR LPKIQRSEAK TRMAMFKKSL RINSTATPDQ DRDKIKQFAA QEEKRQKNER MAQHQKHENQ MRDLQLQCEA NVRELHQLQN EKCHLLVEHE TQKLKELDEE HSQELKEWRE KLRPRKKTLE EEFARKLQEQ EVFFKMTGES ECLNPSTQSR ISKFYPIPSL HSTGS // ID SP1_HUMAN Reviewed; 785 AA. AC P08047; E4Z9M7; G5E9M8; Q86TN8; Q9H3Q5; Q9NR51; Q9NY21; Q9NYE7; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 27-APR-2001, sequence version 3. DT 28-JAN-2026, entry version 268. DE RecName: Full=Transcription factor Sp1; GN Name=SP1; Synonyms=TSFP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=21798247; DOI=10.1016/j.bbrc.2011.07.047; RA Infantino V., Convertini P., Iacobazzi F., Pisano I., Scarcia P., RA Iacobazzi V.; RT "Identification of a novel Sp1 splice variant as a strong transcriptional RT activator."; RL Biochem. Biophys. Res. Commun. 412:86-91(2011). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 4-785 (ISOFORM 1). RC TISSUE=Cervix carcinoma; RA Haggart M.H., Ladurner A.G.; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-558 (ISOFORM 1), AND TRANS-SPLICING. RX PubMed=10973950; DOI=10.1074/jbc.m002010200; RA Takahara T., Kanazu S., Yanagisawa S., Akanuma H.; RT "Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of RT homotypic trans-splicing."; RL J. Biol. Chem. 275:38067-38072(2000). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 90-785 (ISOFORM 1/2), AND PROTEIN SEQUENCE OF RP 359-375 AND 670-675. RX PubMed=3319186; DOI=10.1016/0092-8674(87)90594-0; RA Kadonaga J.T., Carner K.R., Masiarz F.R., Tjian R.; RT "Isolation of cDNA encoding transcription factor Sp1 and functional RT analysis of the DNA binding domain."; RL Cell 51:1079-1090(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 1). RA Nicolas M., Noe V., Ciudad C.J.; RT "Expression of transcription factor Sp1 mRNA in mammalian cells."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-98 (ISOFORM 1). RA Handschug K., Huebner A.; RT "Sequencing of the 5' end of human transcription factor SP1 mRNA."; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [10] RP GLYCOSYLATION. RX PubMed=3139301; DOI=10.1016/0092-8674(88)90015-3; RA Jackson S.P., Tjian R.; RT "O-glycosylation of eukaryotic transcription factors: implications for RT mechanisms of transcriptional regulation."; RL Cell 55:125-133(1988). RN [11] RP TRANSACTIVATION DOMAINS. RX PubMed=3142690; DOI=10.1016/0092-8674(88)90144-4; RA Courey A.J., Tjian R.; RT "Analysis of Sp1 in vivo reveals multiple transcriptional domains, RT including a novel glutamine-rich activation motif."; RL Cell 55:887-898(1988). RN [12] RP INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION). RX PubMed=7592727; DOI=10.1074/jbc.270.43.25564; RA Wang L., Mukherjee S., Jia F., Narayan O., Zhao L.J.; RT "Interaction of virion protein Vpr of human immunodeficiency virus type 1 RT with cellular transcription factor Sp1 and trans-activation of viral long RT terminal repeat."; RL J. Biol. Chem. 270:25564-25569(1995). RN [13] RP IDENTIFICATION OF SEROTONIN 1A RECEPTOR PROMOTER BINDING SITES. RX PubMed=8626793; DOI=10.1074/jbc.271.8.4417; RA Parks C.L., Shenk T.; RT "The serotonin 1a receptor gene contains a TATA-less promoter that responds RT to MAZ and Sp1."; RL J. Biol. Chem. 271:4417-4430(1996). RN [14] RP GLYCOSYLATION AT SER-491, MUTAGENESIS OF SER-491, AND IDENTIFICATION BY RP MASS SPECTROMETRY. RX PubMed=9343410; DOI=10.1128/mcb.17.11.6472; RA Roos M.D., Su K., Baker J.R., Kudlow J.E.; RT "O glycosylation of an Sp1-derived peptide blocks known Sp1 protein RT interactions."; RL Mol. Cell. Biol. 17:6472-6480(1997). RN [15] RP INTERACTION WITH SV40 VP2/3 (MICROBIAL INFECTION). RX PubMed=9466902; DOI=10.1006/jmbi.1997.1461; RA Gordon-Shaag A., Ben-Nun-Shaul O., Kasamatsu H., Oppenheim A.B., RA Oppenheim A.; RT "The SV40 capsid protein VP3 cooperates with the cellular transcription RT factor Sp1 in DNA-binding and in regulating viral promoter activity."; RL J. Mol. Biol. 275:187-195(1998). RN [16] RP FUNCTION, AND INTERACTION WITH HLTF. RX PubMed=10391891; DOI=10.1074/jbc.274.28.19573; RA Ding H., Benotmane A.M., Suske G., Collen D., Belayew A.; RT "Functional interactions between Sp1 or Sp3 and the helicase-like RT transcription factor mediate basal expression from the human plasminogen RT activator inhibitor-1 gene."; RL J. Biol. Chem. 274:19573-19580(1999). RN [17] RP INTERACTION WITH ATF7IP; PHC2; POGZ AND HCFC1. RC TISSUE=Colon; RX PubMed=10976766; DOI=10.1023/a:1007177623283; RA Gunther M., Laithier M., Brison O.; RT "A set of proteins interacting with transcription factor Sp1 identified in RT a two-hybrid screening."; RL Mol. Cell. Biochem. 210:131-142(2000). RN [18] RP GLYCOSYLATION AT SER-491, FUNCTION, AND MUTAGENESIS OF SER-491. RX PubMed=11371615; DOI=10.1073/pnas.111099998; RA Yang X., Su K., Roos M.D., Chang Q., Paterson A.J., Kudlow J.E.; RT "O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its RT transcriptional capability."; RL Proc. Natl. Acad. Sci. U.S.A. 98:6611-6616(2001). RN [19] RP PHOSPHORYLATION AT THR-453 AND THR-739, FUNCTION, AND MUTAGENESIS OF RP THR-355; THR-453 AND THR-739. RX PubMed=11904305; DOI=10.1074/jbc.m201753200; RA Milanini-Mongiat J., Pouyssegur J., Pages G.; RT "Identification of two Sp1 phosphorylation sites for p42/p44 mitogen- RT activated protein kinases: their implication in vascular endothelial growth RT factor gene transcription."; RL J. Biol. Chem. 277:20631-20639(2002). RN [20] RP INTERACTION WITH ZBTB7A. RX PubMed=12004059; DOI=10.1074/jbc.m202078200; RA Lee D.K., Suh D., Edenberg H.J., Hur M.W.; RT "POZ domain transcription factor, FBI-1, represses transcription of RT ADH5/FDH by interacting with the zinc finger and interfering with DNA RT binding activity of Sp1."; RL J. Biol. Chem. 277:26761-26768(2002). RN [21] RP INTERACTION WITH SV40 VP1 (MICROBIAL INFECTION). RX PubMed=12021324; DOI=10.1128/jvi.76.12.5915-5924.2002; RA Gordon-Shaag A., Ben-Nun-Shaul O., Roitman V., Yosef Y., Oppenheim A.; RT "Cellular transcription factor Sp1 recruits simian virus 40 capsid proteins RT to the viral packaging signal, ses."; RL J. Virol. 76:5915-5924(2002). RN [22] RP INTERACTION WITH AATF. RX PubMed=12847090; DOI=10.1074/jbc.m306694200; RA Di Padova M., Bruno T., De Nicola F., Iezzi S., D'Angelo C., Gallo R., RA Nicosia D., Corbi N., Biroccio A., Floridi A., Passananti C., Fanciulli M.; RT "Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 RT from the p21WAF1/CIP1 promoter."; RL J. Biol. Chem. 278:36496-36504(2003). RN [23] RP INTERACTION WITH VARICELLA-ZOSTER VIRUS IE62 PROTEIN (MICROBIAL INFECTION). RX PubMed=12855699; DOI=10.1074/jbc.m302259200; RA Peng H., He H., Hay J., Ruyechan W.T.; RT "Interaction between the varicella zoster virus IE62 major transactivator RT and cellular transcription factor Sp1."; RL J. Biol. Chem. 278:38068-38075(2003). RN [24] RP PHOSPHORYLATION AT THR-453 AND THR-739, FUNCTION, AND MUTAGENESIS OF RP THR-453 AND THR-739. RX PubMed=14593115; DOI=10.1074/jbc.m308254200; RA Bonello M.R., Khachigian L.M.; RT "Fibroblast growth factor-2 represses platelet-derived growth factor RT receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 RT phosphorylation and an atypical cis-acting element in the proximal PDGFR- RT alpha promoter."; RL J. Biol. Chem. 279:2377-2382(2004). RN [25] RP INTERACTION WITH ATF7IP AND ATF7IP2. RX PubMed=15691849; DOI=10.1074/jbc.m413654200; RA Ichimura T., Watanabe S., Sakamoto Y., Aoto T., Fujita N., Nakao M.; RT "Transcriptional repression and heterochromatin formation by MBD1 and RT MCAF/AM family proteins."; RL J. Biol. Chem. 280:13928-13935(2005). RN [26] RP INTERACTION WITH DDX3X. RX PubMed=16818630; DOI=10.1158/0008-5472.can-05-2415; RA Chao C.H., Chen C.M., Cheng P.L., Shih J.W., Tsou A.P., Lee Y.H.; RT "DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and RT transcriptional regulation activity of the p21waf1/cip1 promoter, is a RT candidate tumor suppressor."; RL Cancer Res. 66:6579-6588(2006). RN [27] RP GLYCOSYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702, RP PHOSPHORYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702, RP INDUCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16332679; DOI=10.1074/jbc.m511223200; RA Majumdar G., Harrington A., Hungerford J., Martinez-Hernandez A., RA Gerling I.C., Raghow R., Solomon S.; RT "Insulin dynamically regulates calmodulin gene expression by sequential O- RT glycosylation and phosphorylation of SP1 and its subcellular RT compartmentalization in liver cells."; RL J. Biol. Chem. 281:3642-3650(2006). RN [28] RP PHOSPHORYLATION AT THR-453 AND THR-739, AND FUNCTION. RX PubMed=16377629; DOI=10.1074/jbc.m510937200; RA Hsu M.C., Chang H.C., Hung W.C.; RT "HER-2/neu represses the metastasis suppressor RECK via ERK and Sp RT transcription factors to promote cell invasion."; RL J. Biol. Chem. 281:4718-4725(2006). RN [29] RP SUMOYLATION AT LYS-16, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF LYS-16; RP GLU-18 AND LYS-19. RX PubMed=16407261; DOI=10.1074/jbc.m600035200; RA Spengler M.L., Brattain M.G.; RT "Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain RT and inhibits Sp1-dependent transcription."; RL J. Biol. Chem. 281:5567-5574(2006). RN [30] RP PHOSPHORYLATION AT SER-59 AND THR-681, DEPHOSPHORYLATION, GLYCOSYLATION, RP FUNCTION, AND MUTAGENESIS OF SER-59; SER-220; THR-355; THR-453; THR-651; RP THR-681 AND THR-739. RX PubMed=17049555; DOI=10.1016/j.jmb.2006.09.036; RA Vicart A., Lefebvre T., Imbert J., Fernandez A., Kahn-Perles B.; RT "Increased chromatin association of Sp1 in interphase cells by PP2A- RT mediated dephosphorylations."; RL J. Mol. Biol. 364:897-908(2006). RN [31] RP ACETYLATION AT LYS-703, INTERACTION WITH HDAC1; EP300 AND JUN, FUNCTION, RP AND MUTAGENESIS OF LYS-703. RX PubMed=16478997; DOI=10.1128/mcb.26.5.1770-1785.2006; RA Hung J.J., Wang Y.T., Chang W.C.; RT "Sp1 deacetylation induced by phorbol ester recruits p300 to activate RT 12(S)-lipoxygenase gene transcription."; RL Mol. Cell. Biol. 26:1770-1785(2006). RN [32] RP PHOSPHORYLATION AT SER-641, FUNCTION, AND MUTAGENESIS OF SER-641. RX PubMed=16943418; DOI=10.1128/mcb.00560-06; RA Zhang Y., Liao M., Dufau M.L.; RT "Phosphatidylinositol 3-kinase/protein kinase Czeta-induced phosphorylation RT of Sp1 and p107 repressor release have a critical role in histone RT deacetylase inhibitor-mediated derepression of transcription of the RT luteinizing hormone receptor gene."; RL Mol. Cell. Biol. 26:6748-6761(2006). RN [33] RP ERRATUM OF PUBMED:16943418. RA Zhang Y., Liao M., Dufau M.L.; RL Mol. Cell. Biol. 26:8214-8214(2006). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [35] RP PHOSPHORYLATION AT SER-101, FUNCTION, AND MUTAGENESIS OF SER-101. RX PubMed=18171990; DOI=10.1158/1541-7786.mcr-07-0374; RA Olofsson B.A., Kelly C.M., Kim J., Hornsby S.M., Azizkhan-Clifford J.; RT "Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia- RT mutated kinase."; RL Mol. Cancer Res. 5:1319-1330(2007). RN [36] RP GLYCOSYLATION, FUNCTION, AND MUTAGENESIS OF SER-612; THR-640; SER-641; RP SER-698 AND SER-702. RX PubMed=18513490; DOI=10.1016/j.bbrc.2008.05.096; RA Chung S.S., Kim J.H., Park H.S., Choi H.H., Lee K.W., Cho Y.M., Lee H.K., RA Park K.S.; RT "Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1."; RL Biochem. Biophys. Res. Commun. 372:713-718(2008). RN [37] RP PHOSPHORYLATION AT SER-7 AND SER-59, SUMOYLATION AT LYS-16, PROTEOLYTIC RP PROCESSING, UBIQUITINATION, FUNCTION, AND MUTAGENESIS OF SER-7; SER-59; RP SER-728 AND SER-732. RX PubMed=18239466; DOI=10.4161/cc.7.5.5402; RA Spengler M.L., Guo L.W., Brattain M.G.; RT "Phosphorylation mediates Sp1 coupled activities of proteolytic processing, RT desumoylation and degradation."; RL Cell Cycle 7:623-630(2008). RN [38] RP PHOSPHORYLATION AT SER-101, FUNCTION, AND MUTAGENESIS OF SER-36; SER-56; RP SER-81; SER-85; THR-98; SER-101; THR-250; SER-281; SER-291; SER-296; RP SER-313; SER-351; THR-394; THR-427 AND SER-431. RX PubMed=18619531; DOI=10.1016/j.cellsig.2008.06.007; RA Iwahori S., Yasui Y., Kudoh A., Sato Y., Nakayama S., Murata T., RA Isomura H., Tsurumi T.; RT "Identification of phosphorylation sites on transcription factor Sp1 in RT response to DNA damage and its accumulation at damaged sites."; RL Cell. Signal. 20:1795-1803(2008). RN [39] RP PHOSPHORYLATION AT THR-668; SER-670 AND THR-681, AND MUTAGENESIS OF RP THR-668; SER-670 AND THR-681. RX PubMed=18258854; DOI=10.1161/circresaha.107.167395; RA Tan N.Y., Midgley V.C., Kavurma M.M., Santiago F.S., Luo X., Peden R., RA Fahmy R.G., Berndt M.C., Molloy M.P., Khachigian L.M.; RT "Angiotensin II-inducible platelet-derived growth factor-D transcription RT requires specific Ser/Thr residues in the second zinc finger region of RT Sp1."; RL Circ. Res. 102:38-51(2008). RN [40] RP PHOSPHORYLATION AT SER-59 AND THR-278, FUNCTION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF SER-59; SER-73; THR-117; THR-278 AND THR-739. RX PubMed=18199680; DOI=10.1091/mbc.e07-09-0881; RA Chuang J.-Y., Wang Y.-T., Yeh S.-H., Liu Y.-W., Chang W.-C., Hung J.-J.; RT "Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of RT transcription factor Sp1 during mitosis."; RL Mol. Biol. Cell 19:1139-1151(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-651, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP GLYCOSYLATION, AND INTERACTION WITH ELF1. RX PubMed=19285002; DOI=10.1016/j.bbrc.2009.01.121; RA Lim K., Chang H.I.; RT "O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription RT factors."; RL Biochem. Biophys. Res. Commun. 380:569-574(2009). RN [43] RP GLYCOSYLATION, AND INTERACTION WITH NFYA. RX PubMed=19302979; DOI=10.1016/j.bbrc.2009.03.075; RA Lim K., Chang H.I.; RT "O-GlcNAcylation of Sp1 interrupts Sp1 interaction with NF-Y."; RL Biochem. Biophys. Res. Commun. 382:593-597(2009). RN [44] RP INTERACTION WITH ATF7IP AND TBP. RX PubMed=19106100; DOI=10.1074/jbc.m807098200; RA Liu L., Ishihara K., Ichimura T., Fujita N., Hino S., Tomita S., RA Watanabe S., Saitoh N., Ito T., Nakao M.; RT "MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated RT telomerase activity."; RL J. Biol. Chem. 284:5165-5174(2009). RN [45] RP GLYCOSYLATION, AND FUNCTION. RX PubMed=19193796; DOI=10.1128/jvi.01384-08; RA Jochmann R., Thurau M., Jung S., Hofmann C., Naschberger E., Kremmer E., RA Harrer T., Miller M., Schaft N., Stuerzl M.; RT "O-linked N-acetylglucosaminylation of Sp1 inhibits the human RT immunodeficiency virus type 1 promoter."; RL J. Virol. 83:3704-3718(2009). RN [46] RP INTERACTION WITH BAHD1. RX PubMed=19666599; DOI=10.1073/pnas.0901259106; RA Bierne H., Tham T.N., Batsche E., Dumay A., Leguillou M., RA Kerneis-Golsteyn S., Regnault B., Seeler J.S., Muchardt C., Feunteun J., RA Cossart P.; RT "Human BAHD1 promotes heterochromatic gene silencing."; RL Proc. Natl. Acad. Sci. U.S.A. 106:13826-13831(2009). RN [47] RP INTERACTION WITH EGR1. RX PubMed=20121949; DOI=10.1111/j.1742-4658.2009.07553.x; RA Hu C.T., Chang T.Y., Cheng C.C., Liu C.S., Wu J.R., Li M.C., Wu W.S.; RT "Snail associates with EGR-1 and SP-1 to upregulate transcriptional RT activation of p15INK4b."; RL FEBS J. 277:1202-1218(2010). RN [48] RP FUNCTION. RX PubMed=20091743; DOI=10.1002/jcb.22457; RA Yu H.T., Chan W.W., Chai K.H., Lee C.W., Chang R.C., Yu M.S., RA McLoughlin D.M., Miller C.C., Lau K.F.; RT "Transcriptional regulation of human FE65, a ligand of Alzheimer's disease RT amyloid precursor protein, by Sp1."; RL J. Cell. Biochem. 109:782-793(2010). RN [49] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2 AND SER-7, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [51] RP PHOSPHORYLATION AT SER-702. RX PubMed=20953893; DOI=10.1007/s00018-010-0541-1; RA Alemu E.A., Sjoettem E., Outzen H., Larsen K.B., Holm T., Bjoerkoey G., RA Johansen T.; RT "Transforming growth factor-beta-inducible early response gene 1 is a novel RT substrate for atypical protein kinase Cs."; RL Cell. Mol. Life Sci. 68:1953-1968(2011). RN [52] RP INTERACTION WITH MEIS2 AND PBX1. RX PubMed=21746878; DOI=10.1128/mcb.01456-10; RA Bjerke G.A., Hyman-Walsh C., Wotton D.; RT "Cooperative transcriptional activation by Klf4, Meis2, and Pbx1."; RL Mol. Cell. Biol. 31:3723-3733(2011). RN [53] RP FUNCTION. RX PubMed=21046154; DOI=10.1007/s00438-010-0586-8; RA Sachrajda I., Ratajewski M.; RT "Mithramycin A suppresses expression of the human melanoma-associated gene RT ABCB8."; RL Mol. Genet. Genomics 285:57-65(2011). RN [54] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-7, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [55] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-7 AND SER-59, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [56] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [57] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [58] RP 9AATAD MOTIF. RX PubMed=31375868; DOI=10.1007/s00018-019-03251-w; RA Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.; RT "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with RT valines and intron reservoirs."; RL Cell. Mol. Life Sci. 77:1793-1810(2020). RN [59] RP ACETYLATION, AND DEACETYLATION BY HDAC6. RX PubMed=38534334; DOI=10.3390/cells13060490; RA Sun C., Xie K., Yang L., Cai S., Wang M., Zhu Y., Tao B., Zhu Y.; RT "HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription RT Factor SP1, Potentiating BMP9-Induced Angiogenesis."; RL Cells 13:0-0(2024). RN [60] RP STRUCTURE BY NMR OF 654-684 AND 684-712. RX PubMed=9065444; DOI=10.1074/jbc.272.12.7801; RA Narayan V.A., Kriwacki R.W., Caradonna J.P.; RT "Structures of zinc finger domains from transcription factor Sp1. Insights RT into sequence-specific protein-DNA recognition."; RL J. Biol. Chem. 272:7801-7809(1997). CC -!- FUNCTION: Transcription factor that can activate or repress CC transcription in response to physiological and pathological stimuli. CC Binds with high affinity to GC-rich motifs and regulates the expression CC of a large number of genes involved in a variety of processes such as CC cell growth, apoptosis, differentiation and immune responses. Highly CC regulated by post-translational modifications (phosphorylations, CC sumoylation, proteolytic cleavage, glycosylation and acetylation). Also CC binds the PDGFR-alpha G-box promoter. May have a role in modulating the CC cellular response to DNA damage. Implicated in chromatin remodeling. CC Plays an essential role in the regulation of FE65 gene expression. In CC complex with ATF7IP, maintains telomerase activity in cancer cells by CC inducing TERT and TERC gene expression. Isoform 3 is a stronger CC activator of transcription than isoform 1. Positively regulates the CC transcription of the core clock component BMAL1 (PubMed:10391891, CC PubMed:11371615, PubMed:11904305, PubMed:14593115, PubMed:16377629, CC PubMed:16478997, PubMed:16943418, PubMed:17049555, PubMed:18171990, CC PubMed:18199680, PubMed:18239466, PubMed:18513490, PubMed:18619531, CC PubMed:19193796, PubMed:20091743, PubMed:21046154, PubMed:21798247). CC Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. CC Plays a role in protecting cells against oxidative stress following CC brain injury by regulating the expression of RNF112 (By similarity). CC {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:Q01714, CC ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:11371615, CC ECO:0000269|PubMed:11904305, ECO:0000269|PubMed:14593115, CC ECO:0000269|PubMed:16377629, ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:16943418, ECO:0000269|PubMed:17049555, CC ECO:0000269|PubMed:18171990, ECO:0000269|PubMed:18199680, CC ECO:0000269|PubMed:18239466, ECO:0000269|PubMed:18513490, CC ECO:0000269|PubMed:18619531, ECO:0000269|PubMed:19193796, CC ECO:0000269|PubMed:20091743, ECO:0000269|PubMed:21046154, CC ECO:0000269|PubMed:21798247}. CC -!- SUBUNIT: Interacts with ATF7IP, ATF7IP2, BAHD1, POGZ, HCFC1, AATF and CC PHC2. Interacts with HLTF; the interaction may be required for basal CC transcriptional activity of HLTF. Interacts (deacetylated form) with CC EP300; the interaction enhances gene expression. Interacts with HDAC1 CC and JUN. Interacts with ELF1; the interaction is inhibited by CC glycosylation of SP1. Interaction with NFYA; the interaction is CC inhibited by glycosylation of SP1. Interacts with ATF7IP and TBP. CC Interacts with MEIS2 isoform 4 and PBX1 isoform PBX1a. Interacts with CC EGR1 (PubMed:10391891, PubMed:10976766, PubMed:12021324, CC PubMed:12847090, PubMed:12855699, PubMed:15691849, PubMed:16478997, CC PubMed:19106100, PubMed:19285002, PubMed:19302979, PubMed:19666599, CC PubMed:20121949, PubMed:21746878, PubMed:7592727, PubMed:9466902). CC Interacts with SMARCA4/BRG1. Interacts with RNF112 in an oxidative CC stress-regulated manner (By similarity). Interacts with ZBTB7A; ZBTB7A CC prevents the binding to GC-rich motifs in promoters and represses the CC transcriptional activity of SP1 (PubMed:12004059). Interacts with CC DDX3X; this interaction potentiates SP1-induced CDKN1A/WAF1/CIP1 CC transcription (PubMed:16818630). Interacts with MSX1; the interaction CC may inhibit MSX1 autoinactivation (By similarity). CC {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:Q01714, CC ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:10976766, CC ECO:0000269|PubMed:12004059, ECO:0000269|PubMed:12847090, CC ECO:0000269|PubMed:15691849, ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:16818630, ECO:0000269|PubMed:19106100, CC ECO:0000269|PubMed:19285002, ECO:0000269|PubMed:19302979, CC ECO:0000269|PubMed:19666599, ECO:0000269|PubMed:20121949, CC ECO:0000269|PubMed:21746878}. CC -!- SUBUNIT: (Microbial infection) Interacts with varicella-zoster virus CC IE62 protein. {ECO:0000269|PubMed:12855699}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 VP2/3 proteins. CC Interacts with SV40 major capsid protein VP1; this interaction leads to CC a cooperativity between the 2 proteins in DNA binding. CC {ECO:0000269|PubMed:12021324, ECO:0000269|PubMed:9466902}. CC -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Vpr; the CC interaction is inhibited by SP1 O-glycosylation. CC {ECO:0000269|PubMed:7592727}. CC -!- INTERACTION: CC P08047; Q9NY61: AATF; NbExp=2; IntAct=EBI-298336, EBI-372428; CC P08047; Q8N726: CDKN2A; NbExp=4; IntAct=EBI-298336, EBI-625922; CC P08047; Q92988: DLX4; NbExp=4; IntAct=EBI-298336, EBI-1752755; CC P08047; Q01094: E2F1; NbExp=2; IntAct=EBI-298336, EBI-448924; CC P08047; P32519: ELF1; NbExp=2; IntAct=EBI-298336, EBI-765526; CC P08047; Q99814: EPAS1; NbExp=2; IntAct=EBI-298336, EBI-447470; CC P08047; P03372: ESR1; NbExp=2; IntAct=EBI-298336, EBI-78473; CC P08047; Q14192: FHL2; NbExp=3; IntAct=EBI-298336, EBI-701903; CC P08047; Q06546: GABPA; NbExp=2; IntAct=EBI-298336, EBI-638925; CC P08047; P51610: HCFC1; NbExp=4; IntAct=EBI-298336, EBI-396176; CC P08047; Q13547: HDAC1; NbExp=2; IntAct=EBI-298336, EBI-301834; CC P08047; Q16665: HIF1A; NbExp=3; IntAct=EBI-298336, EBI-447269; CC P08047; P17096: HMGA1; NbExp=4; IntAct=EBI-298336, EBI-746843; CC P08047; P42858: HTT; NbExp=2; IntAct=EBI-298336, EBI-466029; CC P08047; Q13118: KLF10; NbExp=2; IntAct=EBI-298336, EBI-1389509; CC P08047; P01106: MYC; NbExp=4; IntAct=EBI-298336, EBI-447544; CC P08047; P16333: NCK1; NbExp=2; IntAct=EBI-298336, EBI-389883; CC P08047; Q8IXK0: PHC2; NbExp=2; IntAct=EBI-298336, EBI-713786; CC P08047; Q7Z3K3: POGZ; NbExp=2; IntAct=EBI-298336, EBI-1389308; CC P08047; P14859: POU2F1; NbExp=7; IntAct=EBI-298336, EBI-624770; CC P08047; Q06455: RUNX1T1; NbExp=2; IntAct=EBI-298336, EBI-743342; CC P08047; Q15459: SF3A1; NbExp=2; IntAct=EBI-298336, EBI-1054743; CC P08047; Q13485: SMAD4; NbExp=2; IntAct=EBI-298336, EBI-347263; CC P08047; P08047: SP1; NbExp=2; IntAct=EBI-298336, EBI-298336; CC P08047; Q12772: SREBF2; NbExp=3; IntAct=EBI-298336, EBI-465059; CC P08047; P40763: STAT3; NbExp=4; IntAct=EBI-298336, EBI-518675; CC P08047; Q9UL17: TBX21; NbExp=4; IntAct=EBI-298336, EBI-3922312; CC P08047; P04637: TP53; NbExp=6; IntAct=EBI-298336, EBI-366083; CC P08047; Q8N680: ZBTB2; NbExp=4; IntAct=EBI-298336, EBI-2515601; CC P08047; P23708: Nfya; Xeno; NbExp=18; IntAct=EBI-298336, EBI-862337; CC P08047; O92837: vp3; Xeno; NbExp=2; IntAct=EBI-298336, EBI-7196689; CC P08047; P03070; Xeno; NbExp=2; IntAct=EBI-298336, EBI-617698; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear location is CC governed by glycosylated/phosphorylated states. Insulin promotes CC nuclear location, while glucagon favors cytoplasmic location. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Sp1a; CC IsoId=P08047-1; Sequence=Displayed; CC Name=2; Synonyms=Sp1b; CC IsoId=P08047-2; Sequence=VSP_053934; CC Name=3; Synonyms=Sp1c; CC IsoId=P08047-3; Sequence=VSP_053935; CC -!- TISSUE SPECIFICITY: Up-regulated in adenocarcinomas of the stomach (at CC protein level). Isoform 3 is ubiquitously expressed at low levels. CC {ECO:0000269|PubMed:21798247}. CC -!- INDUCTION: By insulin. {ECO:0000269|PubMed:16332679}. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:31375868}. CC -!- PTM: Phosphorylated on multiple serine and threonine residues. CC Phosphorylation is coupled to ubiquitination, sumoylation and CC proteolytic processing. Phosphorylation on Ser-59 enhances proteolytic CC cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein CC degradation. Hyperphosphorylation on Ser-101 in response to DNA damage CC has no effect on transcriptional activity. MAPK1/MAPK3-mediated CC phosphorylation on Thr-453 and Thr-739 enhances VEGF transcription but, CC represses FGF2-triggered PDGFR-alpha transcription. Also implicated in CC the repression of RECK by ERBB2. Hyperphosphorylated on Thr-278 and CC Thr-739 during mitosis by MAPK8 shielding SP1 from degradation by the CC ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain CC by calmodulin-activated PKCzeta. Phosphorylation on Ser-641 by PKCzeta CC is critical for TSA-activated LHR gene expression through release of CC its repressor, p107. Phosphorylation on Thr-668, Ser-670 and Thr-681 is CC stimulated by angiotensin II via the AT1 receptor inducing increased CC binding to the PDGF-D promoter. This phosphorylation is increased in CC injured artey wall. Ser-59 and Thr-681 can both be dephosphorylated by CC PP2A during cell-cycle interphase. Dephosphorylation on Ser-59 leads to CC increased chromatin association during interphase and increases the CC transcriptional activity. On insulin stimulation, sequentially CC glycosylated and phosphorylated on several C-terminal serine and CC threonine residues. {ECO:0000269|PubMed:11904305, CC ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16332679, CC ECO:0000269|PubMed:16377629, ECO:0000269|PubMed:16943418, CC ECO:0000269|PubMed:17049555, ECO:0000269|PubMed:18171990, CC ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466, CC ECO:0000269|PubMed:18258854, ECO:0000269|PubMed:18619531}. CC -!- PTM: Acetylated (PubMed:16478997, PubMed:38534334). CC Acetylation/deacetylation events affect transcriptional activity CC (PubMed:16478997, PubMed:38534334). Deacetylation leads to an increase CC in the expression of the 12(s)-lipooxygenase gene through recruitment CC of p300 to the promoter (PubMed:16478997). Deacetylated by HDAC6 which CC leads to increased expression of ENG and positive regulation of CC angiogenesis (PubMed:38534334). {ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:38534334}. CC -!- PTM: Ubiquitinated. Ubiquitination occurs on the C-terminal CC proteolytically-cleaved peptide and is triggered by phosphorylation. CC {ECO:0000269|PubMed:18239466}. CC -!- PTM: Sumoylated with SUMO1. Sumoylation modulates proteolytic cleavage CC of the N-terminal repressor domain. Sumoylation levels are attenuated CC during tumorigenesis. Phosphorylation mediates SP1 desumoylation. CC -!- PTM: Proteolytic cleavage in the N-terminal repressor domain is CC prevented by sumoylation. The C-terminal cleaved product is susceptible CC to degradation. CC -!- PTM: O-glycosylated; Contains 8 N-acetylglucosamine side chains. Levels CC are controlled by insulin and the SP1 phosphorylation states. Insulin- CC mediated O-glycosylation locates SP1 to the nucleus, where it is CC sequentially deglycosylated and phosphorylated. O-glycosylation affects CC transcriptional activity through disrupting the interaction with a CC number of transcription factors including ELF1 and NFYA. Also inhibits CC interaction with the HIV1 promoter. Inhibited by peroxisomome CC proliferator receptor gamma (PPARgamma). CC -!- MISCELLANEOUS: In the hepatoma cell line Hep-G2, SP1 precursor mRNA may CC undergo homotype trans-splicing leading to the duplication of exons 2 CC and 3. CC -!- SIMILARITY: Belongs to the Sp1 C2H2-type zinc-finger protein family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH43224.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; FN908228; CBM42955.1; -; mRNA. DR EMBL; AC068889; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC073611; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471054; EAW96699.1; -; Genomic_DNA. DR EMBL; BC043224; AAH43224.1; ALT_INIT; mRNA. DR EMBL; BC062539; AAH62539.1; -; mRNA. DR EMBL; AF252284; AAF67726.1; -; mRNA. DR EMBL; AB039286; BAB13476.1; -; Genomic_DNA. DR EMBL; J03133; AAA61154.1; -; mRNA. DR EMBL; AF255682; AAF78781.1; -; mRNA. DR EMBL; AJ272134; CAB75345.1; -; mRNA. DR CCDS; CCDS44898.1; -. [P08047-2] DR CCDS; CCDS8857.1; -. [P08047-1] DR PIR; A29635; A29635. DR RefSeq; NP_001238754.1; NM_001251825.2. [P08047-3] DR RefSeq; NP_003100.1; NM_003109.1. [P08047-2] DR RefSeq; NP_612482.2; NM_138473.2. [P08047-1] DR PDB; 1SP1; NMR; -; A=684-712. DR PDB; 1SP2; NMR; -; A=654-684. DR PDB; 1VA1; NMR; -; A=619-654. DR PDB; 1VA2; NMR; -; A=654-684. DR PDB; 1VA3; NMR; -; A=684-712. DR PDB; 6PV0; NMR; -; A=654-684. DR PDB; 6PV1; NMR; -; A=654-684. DR PDB; 6PV2; NMR; -; A=654-684. DR PDB; 6PV3; NMR; -; A=655-684. DR PDB; 6UCO; NMR; -; A=654-684. DR PDB; 6UCP; NMR; -; A=654-684. DR PDBsum; 1SP1; -. DR PDBsum; 1SP2; -. DR PDBsum; 1VA1; -. DR PDBsum; 1VA2; -. DR PDBsum; 1VA3; -. DR PDBsum; 6PV0; -. DR PDBsum; 6PV1; -. DR PDBsum; 6PV2; -. DR PDBsum; 6PV3; -. DR PDBsum; 6UCO; -. DR PDBsum; 6UCP; -. DR AlphaFoldDB; P08047; -. DR BMRB; P08047; -. DR SMR; P08047; -. DR BioGRID; 112550; 352. DR CORUM; P08047; -. DR DIP; DIP-36N; -. DR ELM; P08047; -. DR FunCoup; P08047; 4420. DR IntAct; P08047; 134. DR MINT; P08047; -. DR STRING; 9606.ENSP00000329357; -. DR BindingDB; P08047; -. DR ChEMBL; CHEMBL6103; -. DR DrugBank; DB12226; Terameprocol. DR GlyConnect; 605; 1 O-GlcNAc glycan. DR GlyCosmos; P08047; 25 sites, 2 glycans. DR GlyGen; P08047; 28 sites, 2 O-linked glycans (27 sites). DR iPTMnet; P08047; -. DR PhosphoSitePlus; P08047; -. DR BioMuta; SP1; -. DR DMDM; 13638437; -. DR jPOST; P08047; -. DR MassIVE; P08047; -. DR PaxDb; 9606-ENSP00000329357; -. DR PeptideAtlas; P08047; -. DR ProteomicsDB; 33987; -. DR ProteomicsDB; 52061; -. [P08047-1] DR Pumba; P08047; -. DR Antibodypedia; 892; 1093 antibodies from 47 providers. DR DNASU; 6667; -. DR Ensembl; ENST00000327443.9; ENSP00000329357.4; ENSG00000185591.11. [P08047-1] DR Ensembl; ENST00000426431.2; ENSP00000404263.2; ENSG00000185591.11. [P08047-2] DR GeneID; 6667; -. DR KEGG; hsa:6667; -. DR MANE-Select; ENST00000327443.9; ENSP00000329357.4; NM_138473.3; NP_612482.2. DR UCSC; uc001scw.4; human. [P08047-1] DR AGR; HGNC:11205; -. DR ClinPGx; PA36042; -. DR CTD; 6667; -. DR DisGeNET; 6667; -. DR GeneCards; SP1; -. DR HGNC; HGNC:11205; SP1. DR HPA; ENSG00000185591; Low tissue specificity. DR MIM; 189906; gene. DR OpenTargets; ENSG00000185591; -. DR VEuPathDB; HostDB:ENSG00000185591; -. DR eggNOG; KOG1721; Eukaryota. DR GeneTree; ENSGT00940000157804; -. DR HOGENOM; CLU_019688_2_0_1; -. DR InParanoid; P08047; -. DR OMA; IMNFAPS; -. DR OrthoDB; 6365676at2759; -. DR PAN-GO; P08047; 3 GO annotations based on evolutionary models. DR PhylomeDB; P08047; -. DR PathwayCommons; P08047; -. DR Reactome; R-HSA-1989781; PPARA activates gene expression. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9762293; Regulation of CDH11 gene transcription. DR Reactome; R-HSA-9764790; Positive Regulation of CDH1 Gene Transcription. DR Reactome; R-HSA-9818030; NFE2L2 regulating tumorigenic genes. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR SignaLink; P08047; -. DR SIGNOR; P08047; -. DR Agora; ENSG00000185591; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6667; 167 hits in 1197 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; SP1; human. DR EvolutionaryTrace; P08047; -. DR GeneWiki; Sp1_transcription_factor; -. DR GenomeRNAi; 6667; -. DR Pharos; P08047; Tbio. DR PRO; PR:P08047; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P08047; protein. DR Bgee; ENSG00000185591; Expressed in nipple and 188 other cell types or tissues. DR ExpressionAtlas; P08047; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0000791; C:euchromatin; IDA:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0032993; C:protein-DNA complex; ISS:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IDA:CAFA. DR GO; GO:0043425; F:bHLH transcription factor binding; ISS:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:BHF-UCL. DR GO; GO:0035035; F:histone acetyltransferase binding; IEA:Ensembl. DR GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISS:BHF-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:HGNC-UCL. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001221; F:transcription coregulator binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl. DR GO; GO:1904568; P:cellular response to wortmannin; IEA:Ensembl. DR GO; GO:0034224; P:cellular response to zinc ion starvation; IEA:Ensembl. DR GO; GO:0043923; P:host-mediated activation of viral transcription; IDA:UniProtKB. DR GO; GO:1902004; P:positive regulation of amyloid-beta formation; IMP:ARUK-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL. DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:1904828; P:positive regulation of hydrogen sulfide biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0033194; P:response to hydroperoxide; ISS:UniProtKB. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR CDD; cd22539; SP1_N; 1. DR DisProt; DP00378; -. DR FunFam; 3.30.160.60:FF:000014; Transcription factor Sp3; 1. DR FunFam; 3.30.160.60:FF:000026; Transcription factor Sp3; 1. DR FunFam; 3.30.160.60:FF:000061; Transcription factor Sp3; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 3. DR IDEAL; IID00266; -. DR InterPro; IPR036236; Znf_C2H2_sf. DR InterPro; IPR013087; Znf_C2H2_type. DR PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1. DR PANTHER; PTHR23235:SF16; TRANSCRIPTION FACTOR SP1; 1. DR Pfam; PF00096; zf-C2H2; 2. DR SMART; SM00355; ZnF_C2H2; 3. DR SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 1. DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3. DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Biological rhythms; Cytoplasm; Direct protein sequencing; DNA-binding; KW Glycoprotein; Host-virus interaction; Isopeptide bond; Metal-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Repressor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692" FT CHAIN 2..785 FT /note="Transcription factor Sp1" FT /id="PRO_0000047137" FT ZN_FING 626..650 FT /note="C2H2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 656..680 FT /note="C2H2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 686..708 FT /note="C2H2-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT REGION 1..93 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2..82 FT /note="Repressor domain" FT REGION 109..141 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 146..251 FT /note="Transactivation domain A (Gln-rich)" FT REGION 261..495 FT /note="Transactivation domain B (Gln-rich)" FT REGION 329..395 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 496..610 FT /note="Transactivation domain C (highly charged)" FT REGION 567..598 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 619..785 FT /note="VZV IE62-binding" FT REGION 708..785 FT /note="Domain D" FT MOTIF 462..470 FT /note="9aaTAD" FT /evidence="ECO:0000269|PubMed:31375868" FT COMPBIAS 20..34 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 72..85 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 109..123 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 124..136 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 342..357 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 358..379 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 381..395 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 63..64 FT /note="Cleavage" FT /evidence="ECO:0000305" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 7 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18239466, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 59 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:23186163" FT MOD_RES 101 FT /note="Phosphoserine; by ATM" FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MOD_RES 278 FT /note="Phosphothreonine; by MAPK8" FT /evidence="ECO:0000305|PubMed:18199680" FT MOD_RES 453 FT /note="Phosphothreonine; by MAPK1 and MAPK3" FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16377629" FT MOD_RES 612 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 640 FT /note="Phosphothreonine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 641 FT /note="Phosphoserine; by PKC/PRKCZ; alternate" FT /evidence="ECO:0000269|PubMed:16332679, FT ECO:0000269|PubMed:16943418" FT MOD_RES 651 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 668 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:18258854" FT MOD_RES 670 FT /note="Phosphoserine; by PKC/PRKCZ" FT /evidence="ECO:0000269|PubMed:18258854" FT MOD_RES 681 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18258854" FT MOD_RES 698 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 702 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679, FT ECO:0000305|PubMed:20953893" FT MOD_RES 703 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:16478997" FT MOD_RES 739 FT /note="Phosphothreonine; by MAPK1, MAPK3 and MAPK8" FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16377629" FT CARBOHYD 491 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:11371615, FT ECO:0000269|PubMed:9343410" FT CARBOHYD 612 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 640 FT /note="O-linked (GlcNAc) threonine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 641 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 698 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 702 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CROSSLNK 16 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO); alternate" FT CROSSLNK 16 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..7 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_053934" FT VAR_SEQ 54..101 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:21798247" FT /id="VSP_053935" FT VARIANT 737 FT /note="T -> A (in dbSNP:rs3741665)" FT /id="VAR_019971" FT MUTAGEN 7 FT /note="S->A: Increase in protein stability. No change in FT sumoylation." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 15 FT /note="V->R: Enhanced transcriptional activity." FT MUTAGEN 16 FT /note="K->R: Loss of sumoylation. No cleavage and reduced FT transcriptional activity." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 18 FT /note="E->A: Loss of sumoylation. Increased cleavage and FT enhanced transcriptional activity." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 19 FT /note="K->R: No effect on sumoylation nor on proteolytic FT cleavage." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 36 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 56 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 59 FT /note="S->A: Loss of phosphorylation. No effect on FT activated MAPK8-mediated phosphorylation. Similar loss of FT phosphorylation as by dephosphorylation by PP2AC. Reduced FT proteolytic processing." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466" FT MUTAGEN 59 FT /note="S->E: Some association with chromatin, increased FT phosphorylation levels and decreased glycosylation." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466" FT MUTAGEN 73 FT /note="S->A: Little effect on activated MAPK8-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 81 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 85 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 98 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 101 FT /note="S->A: Significant reduction of phosphorylation on FT DNA damage." FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MUTAGEN 101 FT /note="S->D: Increase in phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MUTAGEN 117 FT /note="T->A: No effect on activated MAPK8-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 220 FT /note="S->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:17049555" FT MUTAGEN 250 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 278 FT /note="T->A: Almost complete abolition of activated MAPK8- FT mediated phosphorylation and 40% reduction in protein FT levels during mitosis. Protein levels reduced by 70% during FT mitosis; when associated with A-739." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 278 FT /note="T->D: Increased protein stability during mitosis; FT when associated with D-739." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 281 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 291 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 296 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 313 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 351 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 355 FT /note="T->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:17049555" FT MUTAGEN 394 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 427 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 431 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 453 FT /note="T->A: Abolishes MAPK-mediated phosphorylation, 50% FT reduction in MAPK1/MAPK3-mediated activity on VEGF promoter FT and no effect on dephosphorylation by PP2A. Greatly reduced FT MAPK1-mediated activity on VEGF promoter; when associated FT with A-739." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555" FT MUTAGEN 491 FT /note="S->A: Loss of O-glycosylation. Increase in FT transcriptional activity." FT /evidence="ECO:0000269|PubMed:11371615, FT ECO:0000269|PubMed:9343410" FT MUTAGEN 612 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-640; A- FT 641; A-698 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 640 FT /note="T->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 641; A-698 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 641 FT /note="S->A: Abolishes PRKCzeta-mediated phosphorylation. FT Diminished glycosylation. Inhibits transcriptional FT activity; when associated with A-612; A-640; A-641 and A- FT 702." FT /evidence="ECO:0000269|PubMed:16943418, FT ECO:0000269|PubMed:18513490" FT MUTAGEN 651 FT /note="T->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:17049555" FT MUTAGEN 668 FT /note="T->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. No effect on DNA binding; when FT associated with A-670 and A-681." FT /evidence="ECO:0000269|PubMed:18258854" FT MUTAGEN 670 FT /note="S->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. No effect on DNA binding; when FT associated with A-668 and A-681." FT /evidence="ECO:0000269|PubMed:18258854" FT MUTAGEN 681 FT /note="T->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. Some effect on dephosphorylation FT by PP2A. No effect on DNA binding; when associated with A- FT 668 and A-681." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18258854" FT MUTAGEN 698 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 640; A-641 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 702 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 640; A-641 and A-698." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 703 FT /note="K->A: Abolishes acetylation. Increases recruitment FT of p300 to the promoter and enhances gene transcription." FT /evidence="ECO:0000269|PubMed:16478997" FT MUTAGEN 728 FT /note="S->A: Exhibits attenuated endoproteolytic cleavage; FT when associated with A-732." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 732 FT /note="S->A: Exhibits attenuated endoproteolytic cleavage; FT when associated with A-728." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 739 FT /note="T->A: Abolishes MAPK-mediated phosphorylation. 50% FT reduction in MAPK1/MAPK3-mediated activity on VEGF FT promoter, 40% reduction in protein levels during mitosis FT and no effect on dephosphorylation by PP2A. Greatly reduced FT MAPK1-mediated activity on VEGF promoter; when associated FT with A-453. Protein levels during mitosis reduced by 70%; FT when associated with A-278." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680" FT MUTAGEN 739 FT /note="T->D: Increased protein stability during mitosis; FT when associated with D-278." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680" FT CONFLICT 366 FT /note="D -> G (in Ref. 7; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 670 FT /note="S -> F (in Ref. 7; AA sequence)" FT /evidence="ECO:0000305" FT STRAND 620..622 FT /evidence="ECO:0007829|PDB:1VA1" FT STRAND 636..638 FT /evidence="ECO:0007829|PDB:1VA1" FT HELIX 640..651 FT /evidence="ECO:0007829|PDB:1VA1" FT STRAND 656..658 FT /evidence="ECO:0007829|PDB:6UCO" FT TURN 661..663 FT /evidence="ECO:0007829|PDB:1VA2" FT STRAND 666..668 FT /evidence="ECO:0007829|PDB:1VA2" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:1SP2" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:1SP2" FT TURN 681..683 FT /evidence="ECO:0007829|PDB:6PV0" FT TURN 689..692 FT /evidence="ECO:0007829|PDB:1SP1" FT HELIX 699..706 FT /evidence="ECO:0007829|PDB:1SP1" FT HELIX 707..709 FT /evidence="ECO:0007829|PDB:1SP1" SQ SEQUENCE 785 AA; 80693 MW; 43893DBF6518B9EA CRC64; MSDQDHSMDE MTAVVKIEKG VGGNNGGNGN GGGAFSQARS SSTGSSSSTG GGGQESQPSP LALLAATCSR IESPNENSNN SQGPSQSGGT GELDLTATQL SQGANGWQII SSSSGATPTS KEQSGSSTNG SNGSESSKNR TVSGGQYVVA AAPNLQNQQV LTGLPGVMPN IQYQVIPQFQ TVDGQQLQFA ATGAQVQQDG SGQIQIIPGA NQQIITNRGS GGNIIAAMPN LLQQAVPLQG LANNVLSGQT QYVTNVPVAL NGNITLLPVN SVSAATLTPS SQAVTISSSG SQESGSQPVT SGTTISSASL VSSQASSSSF FTNANSYSTT TTTSNMGIMN FTTSGSSGTN SQGQTPQRVS GLQGSDALNI QQNQTSGGSL QAGQQKEGEQ NQQTQQQQIL IQPQLVQGGQ ALQALQAAPL SGQTFTTQAI SQETLQNLQL QAVPNSGPII IRTPTVGPNG QVSWQTLQLQ NLQVQNPQAQ TITLAPMQGV SLGQTSSSNT TLTPIASAAS IPAGTVTVNA AQLSSMPGLQ TINLSALGTS GIQVHPIQGL PLAIANAPGD HGAQLGLHGA GGDGIHDDTA GGEEGENSPD AQPQAGRRTR REACTCPYCK DSEGRGSGDP GKKKQHICHI QGCGKVYGKT SHLRAHLRWH TGERPFMCTW SYCGKRFTRS DELQRHKRTH TGEKKFACPE CPKRFMRSDH LSKHIKTHQN KKGGPGVALS VGTLPLDSGA GSEGSGTATP SALITTNMVA MEAICPEGIA RLANSGINVM QVADLQSINI SGNGF // ID STK11_HUMAN Reviewed; 433 AA. AC Q15831; B2RBX7; E7EW76; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 245. DE RecName: Full=Serine/threonine-protein kinase STK11 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14976552}; DE AltName: Full=Liver kinase B1; DE Short=LKB1; DE Short=hLKB1; DE AltName: Full=Renal carcinoma antigen NY-REN-19; DE Flags: Precursor; GN Name=STK11 {ECO:0000312|HGNC:HGNC:11389}; Synonyms=LKB1, PJS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS. RC TISSUE=Liver; RX PubMed=9425897; DOI=10.1038/ng0198-38; RA Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R., RA Mueller O., Back W., Zimmer M.; RT "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine RT kinase."; RL Nat. Genet. 18:38-43(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9537235; RA Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R.; RT "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene RT in sporadic breast cancer."; RL Cancer Res. 58:1384-1386(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=11212897; DOI=10.1023/a:1006442024874; RA Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G.; RT "Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 RT mutations in human carcinoma metastases to the brain."; RL J. Neurooncol. 49:187-195(2000). RN [9] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND RP INTERACTION WITH SMAD4 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [10] RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF LYS-78 RP AND THR-189, AND PHOSPHORYLATION AT THR-189. RX PubMed=11430832; DOI=10.1016/s1097-2765(01)00258-1; RA Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., RA Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.; RT "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell RT death."; RL Mol. Cell 7:1307-1319(2001). RN [11] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=12097271; RA Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., RA Engles J.M., Westra W.H., Herman J.G., Sidransky D.; RT "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the RT lung."; RL Cancer Res. 62:3659-3662(2002). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA, PHOSPHORYLATION AT RP THR-336 AND THR-363, AND CHARACTERIZATION OF VARIANT SPORADIC CANCER RP TYR-176. RX PubMed=12805220; DOI=10.1093/emboj/cdg292; RA Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., RA Alessi D.R., Clevers H.C.; RT "Activation of the tumour suppressor kinase LKB1 by the STE20-like RT pseudokinase STRAD."; RL EMBO J. 22:3062-3072(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION IN A RP COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA; STRADB; CAB39 RP AND CAB39L. RX PubMed=14517248; DOI=10.1093/emboj/cdg490; RA Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., RA Prescott A.R., Clevers H.C., Alessi D.R.; RT "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to RT bind, activate and localize LKB1 in the cytoplasm."; RL EMBO J. 22:5102-5114(2003). RN [14] RP FUNCTION IN CELL POLARITY. RX PubMed=15016379; DOI=10.1016/s0092-8674(04)00114-x; RA Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., RA Peters P.J., Clevers H.C.; RT "Complete polarization of single intestinal epithelial cells upon RT activation of LKB1 by STRAD."; RL Cell 116:457-466(2004). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [16] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=15021901; DOI=10.1038/sj.onc.1207502; RA Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M.; RT "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor RT suppressor gene."; RL Oncogene 23:4037-4040(2004). RN [17] RP FUNCTION. RX PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042; RA Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., RA Alessi D.R.; RT "Identification of the sucrose non-fermenting related kinase SNRK, as a RT novel LKB1 substrate."; RL FEBS Lett. 579:1417-1423(2005). RN [18] RP FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND CHARACTERIZATION RP OF VARIANT PJS ASN-176. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [20] RP INTERACTION WITH WDR6. RX PubMed=17216128; DOI=10.1007/s11010-006-9402-5; RA Xie X., Wang Z., Chen Y.; RT "Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell RT growth arrest and p27(Kip1) induction."; RL Mol. Cell. Biochem. 301:115-122(2007). RN [21] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x; RA Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., RA Mitsudomi T.; RT "LKB1 gene mutations in Japanese lung cancer patients."; RL Cancer Sci. 98:1747-1751(2007). RN [22] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17676035; DOI=10.1038/nature06030; RA Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., RA Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., RA Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., RA Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., RA Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., RA Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., RA Sharpless N.E., Wong K.K.; RT "LKB1 modulates lung cancer differentiation and metastasis."; RL Nature 448:807-810(2007). RN [23] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17384680; DOI=10.1038/sj.onc.1210418; RA Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., RA Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.; RT "Prevalence and specificity of LKB1 genetic alterations in lung cancers."; RL Oncogene 26:5911-5918(2007). RN [24] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=18594528; DOI=10.1038/sj.bjc.6604469; RA Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., RA Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., RA Sugarbaker D.J., Johnson B.E., Janne P.A.; RT "Mutations in the LKB1 tumour suppressor are frequently detected in tumours RT from Caucasian but not Asian lung cancer patients."; RL Br. J. Cancer 99:245-252(2008). RN [25] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [26] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [27] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97; RP LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF LYS-44; RP LYS-48; LYS-96 AND LYS-97. RX PubMed=18687677; DOI=10.1074/jbc.m805711200; RA Lan F., Cacicedo J.M., Ruderman N., Ido Y.; RT "SIRT1 modulation of the acetylation status, cytosolic localization, and RT activity of LKB1. Possible role in AMP-activated protein kinase RT activation."; RL J. Biol. Chem. 283:27628-27635(2008). RN [28] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, RP PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428. RX PubMed=18854309; DOI=10.1074/jbc.m806153200; RA Denison F.C., Hiscock N.J., Carling D., Woods A.; RT "Characterization of an alternative splice variant of LKB1."; RL J. Biol. Chem. 284:67-76(2009). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=20559149; DOI=10.1097/jto.0b013e3181e05016; RA Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., RA Pao W., Chen H., Ji H.; RT "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung RT adenocarcinomas."; RL J. Thorac. Oncol. 5:1130-1135(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP FUNCTION. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [33] RP REVIEW ON FUNCTION. RX PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010; RA Alexander A., Walker C.L.; RT "The role of LKB1 and AMPK in cellular responses to stress and damage."; RL FEBS Lett. 585:952-957(2011). RN [34] RP REVIEW ON INVOLVEMENT IN LUNG CANCER. RX PubMed=21380642; DOI=10.1007/s13238-011-1021-6; RA Gao Y., Ge G., Ji H.; RT "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor RT suppressor."; RL Protein Cell 2:99-107(2011). RN [35] RP ACTIVITY REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION. RX PubMed=22983157; DOI=10.1038/nchembio.1069; RA Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z., Zhang L.R., RA Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C., Yang K., Li A.Z., RA Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D., Lin S.C., Chang C., RA Huang P.Q., Lin T., Wu Q.; RT "The orphan nuclear receptor Nur77 regulates LKB1 localization and RT activates AMPK."; RL Nat. Chem. Biol. 8:897-904(2012). RN [36] RP INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION. RX PubMed=23572524; DOI=10.1074/jbc.m112.418103; RA Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A., RA Alahari S.K.; RT "Integrin-binding protein nischarin interacts with tumor suppressor liver RT kinase B1 (LKB1) to regulate cell migration of breast epithelial cells."; RL J. Biol. Chem. 288:15495-15509(2013). RN [37] RP SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION AT SER-399 (ISOFORM RP 2). RX PubMed=23612973; DOI=10.1074/jbc.m112.443580; RA Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.; RT "Phosphorylation of serine 399 in LKB1 protein short form by protein kinase RT Czeta is required for its nucleocytoplasmic transport and consequent AMP- RT activated protein kinase (AMPK) activation."; RL J. Biol. Chem. 288:16495-16505(2013). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [40] RP FUNCTION, AND INTERACTION WITH CDKN1A. RX PubMed=25329316; DOI=10.1371/journal.pgen.1004721; RA Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J., RA Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B., RA Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A., RA Garcia-Patos V., Recio J.A.; RT "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating RT CDKN1A (p21WAF1/CIP1) degradation."; RL PLoS Genet. 10:E1004721-E1004721(2014). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH STRADA AND RP CAB39, ACTIVITY REGULATION, CHARACTERIZATION OF VARIANTS SPORADIC CANCER RP MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170; SER-171; ARG-174; RP TYR-176; ASN-177; GLU-181; GLN-199; THR-205; PHE-216; VAL-223; PRO-230; RP PRO-232; ARG-245; PRO-250; HIS-272; TYR-277; GLN-285 AND SER-315, AND RP MUTAGENESIS OF ARG-74; ASP-194 AND PHE-204. RX PubMed=19892943; DOI=10.1126/science.1178377; RA Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.; RT "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism RT of kinase activation."; RL Science 326:1707-1711(2009). RN [42] RP VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION OF RP VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF LYS-78. RX PubMed=9837816; DOI=10.1086/302159; RA Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., RA Blouin J.L., Scott H.S., Antonarakis S.E.; RT "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for RT allelic and locus heterogeneity."; RL Am. J. Hum. Genet. 63:1641-1650(1998). RN [43] RP VARIANT TGCT ASP-163. RX PubMed=9605748; RA Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., RA Fossaa S.D., Salovaara R., Aaltonen L.A.; RT "Somatic mutations in LKB1 are rare in sporadic colorectal and testicular RT tumors."; RL Cancer Res. 58:2087-2090(1998). RN [44] RP VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354 AND RP MET-367. RX PubMed=9731485; RA Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., RA Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y., Yang Y.M., Kim S.H., RA Kim C.S., Lee J.Y.; RT "Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers RT syndrome gene in left-sided colon cancer."; RL Cancer Res. 58:3787-3790(1998). RN [45] RP VARIANT COLORECTAL CANCER HIS-314. RX PubMed=9809980; RA Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., RA Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., RA Rossini F.P., Tenconi R., Guanti G.; RT "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer."; RL Cancer Res. 58:4799-4801(1998). RN [46] RP VARIANT PJS ASN-247 DEL. RX PubMed=9760200; DOI=10.1007/s004390050801; RA Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M., RA Yasutomi M., Matsuura N., Monden M., Nakamura Y.; RT "Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers RT syndrome."; RL Hum. Genet. 103:168-172(1998). RN [47] RP VARIANT GASTRIC CARCINOMA LEU-324. RX PubMed=9683800; RA Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., RA Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.; RT "Mutations of the STK11 gene in sporadic gastric carcinoma."; RL Int. J. Oncol. 13:601-604(1998). RN [48] RP VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN. RX PubMed=9428765; DOI=10.1038/34432; RA Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., RA Bignell G., Warren W., Aminoff M., Hoeglund P., Jaervinen H., Kristo P., RA Pelin K., Ridanpaeae M., Salovaara R., Toro T., Bodmer W., Olschwang S., RA Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A.; RT "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome."; RL Nature 391:184-187(1998). RN [49] RP VARIANT LUNG CANCER VAL-194. RX PubMed=10079245; DOI=10.1016/s0002-9440(10)65314-x; RA Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., RA Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., RA Jarvinen H., Aaltonen L.A.; RT "LKB1 somatic mutations in sporadic cancers."; RL Am. J. Pathol. 154:677-681(1999). RN [50] RP VARIANTS PJS 162-ASP--LEU-164 DELINS ASN-ASP-MET; ASN-194 AND LYS-297. RX PubMed=10408777; RX DOI=10.1002/(sici)1098-1004(1999)13:6<476::aid-humu7>3.0.co;2-2; RA Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E., RA Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J., de Rooij F.W.M., RA Wilson J.H.P.; RT "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families."; RL Hum. Mutat. 13:476-481(1999). RN [51] RP CHARACTERIZATION OF VARIANT TGCT ASP-163. RX PubMed=9887330; DOI=10.1093/hmg/8.1.45; RA Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., RA Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., RA Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H., Maekelae T.P., RA Aaltonen L.A.; RT "Mutations and impaired function of LKB1 in familial and non-familial RT Peutz-Jeghers syndrome and a sporadic testicular cancer."; RL Hum. Mol. Genet. 8:45-51(1999). RN [52] RP VARIANT OVARIAN CARCINOMA LEU-281. RX PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x; RA Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of STK11 gene in ovarian carcinomas."; RL Jpn. J. Cancer Res. 90:629-632(1999). RN [53] RP VARIANTS MELANOMA ASP-49 AND ARG-135. RX PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x; RA Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., RA Tomlinson I.; RT "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic RT malignant melanomas."; RL J. Invest. Dermatol. 112:509-511(1999). RN [54] RP VARIANT MELANOMA TYR-194. RX PubMed=10208439; DOI=10.1038/sj.onc.1202486; RA Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., RA Zeuthen J.; RT "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in RT malignant melanoma."; RL Oncogene 18:1777-1780(1999). RN [55] RP VARIANTS PJS CYS-239 AND SER-315. RX PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x; RA Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A., Mowat D., RA McPhillips M., Spigelman A.D.; RT "Mutation analysis of the STK11/LKB1 gene and clinical characteristics of RT an Australian series of Peutz-Jeghers syndrome patients."; RL Clin. Genet. 62:282-287(2002). RN [56] RP VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT CERVICAL RP CARCINOMA MET-66. RX PubMed=12533684; DOI=10.1097/01.lab.0000049821.16698.d0; RA Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R., Ueda Y., RA Wada H., Murata Y., Toki T., Konishi I., Fujii S.; RT "Mutations in the STK11 gene characterize minimal deviation adenocarcinoma RT of the uterine cervix."; RL Lab. Invest. 83:35-45(2003). RN [57] RP VARIANT [LARGE SCALE ANALYSIS] LYS-87. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP VARIANT PJS GLY-16. RX PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008; RA Liu L., Du X., Nie J.; RT "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome RT patient significantly diminished p53 activity."; RL Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that CC controls the activity of AMP-activated protein kinase (AMPK) family CC members, thereby playing a role in various processes such as cell CC metabolism, cell polarity, apoptosis and DNA damage response. Acts by CC phosphorylating the T-loop of AMPK family proteins, thus promoting CC their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, CC MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not CC MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN CC and possibly p53/TP53. Acts as a key upstream regulator of AMPK by CC mediating phosphorylation and activation of AMPK catalytic subunits CC PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition CC of signaling pathways that promote cell growth and proliferation when CC energy levels are low, glucose homeostasis in liver, activation of CC autophagy when cells undergo nutrient deprivation, and B-cell CC differentiation in the germinal center in response to DNA damage. Also CC acts as a regulator of cellular polarity by remodeling the actin CC cytoskeleton. Required for cortical neuron polarization by mediating CC phosphorylation and activation of BRSK1 and BRSK2, leading to axon CC initiation and specification. Involved in DNA damage response: CC interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to CC participate in transcription activation. Able to phosphorylate CC p53/TP53; the relevance of such result in vivo is however unclear and CC phosphorylation may be indirect and mediated by downstream STK11/LKB1 CC kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis CC via interaction with p53/TP53: translocates to the mitochondrion during CC apoptosis and regulates p53/TP53-dependent apoptosis pathways. CC Regulates UV radiation-induced DNA damage response mediated by CDKN1A. CC In association with NUAK1, phosphorylates CDKN1A in response to UV CC radiation and contributes to its degradation which is necessary for CC optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, CC ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:25329316}. CC -!- FUNCTION: [Isoform 2]: Has a role in spermiogenesis. {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC -!- ACTIVITY REGULATION: Activated by forming a complex with STRAD (STRADA CC or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): STRADA CC (or STRADB)-binding promotes a conformational change of STK11/LKB1 in CC an active conformation, which is stabilized by CAB39/MO25alpha (or CC CAB39L/MO25beta) interacting with the STK11/LKB1 activation loop. CC Sequestration in the nucleus by NR4A1 prevents it from phosphorylating CC and activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157}. CC -!- SUBUNIT: Catalytic component of a trimeric complex composed of CC STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CC CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and CC stimulates its catalytic activity. Found in a ternary complex composed CC of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, CC STK11IP and WDR6. Interacts with NR4A1. Interacts with NISCH; this CC interaction may increase STK11 activity. Interacts with PTEN; leading CC to PTEN phosphorylation. Interacts with SIRT1; the interaction CC deacetylates STK11. Interacts with CDKN1A. CC {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220, CC ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128, CC ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524, CC ECO:0000269|PubMed:25329316}. CC -!- INTERACTION: CC Q15831; Q9Y376: CAB39; NbExp=23; IntAct=EBI-306838, EBI-306905; CC Q15831; Q16543: CDC37; NbExp=6; IntAct=EBI-306838, EBI-295634; CC Q15831; Q9BT78: COPS4; NbExp=5; IntAct=EBI-306838, EBI-742413; CC Q15831; Q13451: FKBP5; NbExp=11; IntAct=EBI-306838, EBI-306914; CC Q15831; P07900: HSP90AA1; NbExp=6; IntAct=EBI-306838, EBI-296047; CC Q15831; P08238: HSP90AB1; NbExp=8; IntAct=EBI-306838, EBI-352572; CC Q15831; O95835: LATS1; NbExp=2; IntAct=EBI-306838, EBI-444209; CC Q15831; Q96L34: MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319; CC Q15831; P26927: MST1; NbExp=2; IntAct=EBI-306838, EBI-6929133; CC Q15831; P54646: PRKAA2; NbExp=3; IntAct=EBI-306838, EBI-1383852; CC Q15831; Q7RTN6: STRADA; NbExp=23; IntAct=EBI-306838, EBI-1109114; CC Q15831; Q7RTN6-1: STRADA; NbExp=3; IntAct=EBI-306838, EBI-15787241; CC Q15831; Q9C0K7: STRADB; NbExp=14; IntAct=EBI-306838, EBI-306893; CC Q15831; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372; CC Q15831; Q9NNW5: WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315; CC Q15831; P63104: YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}. CC Mitochondrion. Note=A small fraction localizes at membranes (By CC similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or CC STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta). CC Translocates to the mitochondrion during apoptosis. PTEN promotes CC cytoplasmic localization. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:23612973}. Cytoplasm {ECO:0000269|PubMed:23612973}. CC Note=Predominantly nuclear, but translocates to the cytoplasm in CC response to metformin or peroxynitrite treatment. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LKB1(L); CC IsoId=Q15831-1; Sequence=Displayed; CC Name=2; Synonyms=LKB1(S); CC IsoId=Q15831-2; Sequence=VSP_041746; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression in CC testis and fetal liver. CC -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation CC (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is required CC to inhibit cell growth. Phosphorylation at Ser-428 is also required CC during neuronal polarization to mediate phosphorylation of BRSK1 and CC BRSK2 (By similarity). Phosphorylation by PKC/PRKCZ at Ser-399 in CC isoform 2 promotes metformin (or peroxynitrite)-induced nuclear export CC of STK11 and activation of AMPK. UV radiation-induced phosphorylation CC at Thr-363 mediates CDKN1A degradation (By similarity). CC {ECO:0000250|UniProtKB:Q9WTK7, ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:18854309}. CC -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic CC localization and kinase activity in vitro. CC {ECO:0000269|PubMed:18687677}. CC -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal CC dominant disorder characterized by melanocytic macules of the lips, CC multiple gastrointestinal hamartomatous polyps and an increased risk CC for various neoplasms, including gastrointestinal cancer. CC {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, CC ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, CC ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, CC ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Defects in STK11 are associated with some sporadic CC cancers, especially lung cancers. Frequently mutated and inactivated in CC non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis CC process, especially lung cancer progression and metastasis. Confers CC lung adenocarcinoma the ability to trans-differentiate into squamous CC cell carcinoma. Also able to promote lung cancer metastasis, via both CC cancer-cell autonomous and non-cancer-cell autonomous mechanisms. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. LKB1 subfamily. {ECO:0000305}. CC -!- CAUTION: Its phosphorylation by PKC/PRKCZ at Ser-428 is reported to CC promote peroxynitrite-induced nuclear export of STK11, leading to PTEN CC activation and subsequent inhibition of PI3K/AKT signaling and CC induction of apoptosis in vein endothelial cells (PubMed:18321849). CC However this paper was withdrawn by the authors due to concerns of CC image duplication in the figures. Its phosphorylation by PKC/PRKCZ has CC been confirmed in other studies (PubMed:18854309, PubMed:23612973). CC {ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309, CC ECO:0000269|PubMed:23612973, ECO:0000305|PubMed:31519760}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/292/STK11"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry; CC URL="https://en.wikipedia.org/wiki/PJS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63333; AAB05809.1; -; mRNA. DR EMBL; AF035625; AAC39527.1; -; mRNA. DR EMBL; AF032984; AAB97833.1; -; Genomic_DNA. DR EMBL; AF055327; AAC15742.1; -; Genomic_DNA. DR EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AK314858; BAG37374.1; -; mRNA. DR EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471139; EAW69540.1; -; Genomic_DNA. DR EMBL; BC007981; AAH07981.1; -; mRNA. DR EMBL; BC019334; AAH19334.1; -; mRNA. DR CCDS; CCDS45896.1; -. [Q15831-1] DR RefSeq; NP_000446.1; NM_000455.5. [Q15831-1] DR RefSeq; NP_001394184.1; NM_001407255.1. [Q15831-2] DR PDB; 2WTK; X-ray; 2.65 A; C/F=43-347. DR PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340. DR PDB; 5WXN; X-ray; 2.93 A; C/D=331-343. DR PDB; 8VSU; EM; 2.86 A; C=1-433. DR PDBsum; 2WTK; -. DR PDBsum; 4ZDR; -. DR PDBsum; 5WXN; -. DR PDBsum; 8VSU; -. DR AlphaFoldDB; Q15831; -. DR EMDB; EMD-43506; -. DR SMR; Q15831; -. DR BioGRID; 112670; 322. DR ComplexPortal; CPX-2431; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADA variant. DR ComplexPortal; CPX-2845; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADA variant. DR ComplexPortal; CPX-2868; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADB variant. DR ComplexPortal; CPX-2869; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADB variant. DR CORUM; Q15831; -. DR DIP; DIP-31317N; -. DR FunCoup; Q15831; 3083. DR IntAct; Q15831; 222. DR MINT; Q15831; -. DR STRING; 9606.ENSP00000324856; -. DR BindingDB; Q15831; -. DR ChEMBL; CHEMBL5606; -. DR DrugCentral; Q15831; -. DR GlyGen; Q15831; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q15831; -. DR PhosphoSitePlus; Q15831; -. DR BioMuta; STK11; -. DR DMDM; 3024670; -. DR CPTAC; CPTAC-2999; -. DR CPTAC; CPTAC-3000; -. DR jPOST; Q15831; -. DR MassIVE; Q15831; -. DR PaxDb; 9606-ENSP00000324856; -. DR PeptideAtlas; Q15831; -. DR ProteomicsDB; 60780; -. [Q15831-1] DR ProteomicsDB; 60781; -. [Q15831-2] DR Pumba; Q15831; -. DR Antibodypedia; 2048; 1357 antibodies from 44 providers. DR CPTC; Q15831; 1 antibody. DR DNASU; 6794; -. DR Ensembl; ENST00000326873.12; ENSP00000324856.6; ENSG00000118046.19. [Q15831-1] DR Ensembl; ENST00000585465.3; ENSP00000490268.2; ENSG00000118046.19. [Q15831-2] DR Ensembl; ENST00000652231.1; ENSP00000498804.1; ENSG00000118046.19. [Q15831-2] DR GeneID; 6794; -. DR KEGG; hsa:6794; -. DR MANE-Select; ENST00000326873.12; ENSP00000324856.6; NM_000455.5; NP_000446.1. DR UCSC; uc002lrl.2; human. [Q15831-1] DR AGR; HGNC:11389; -. DR CIViC; 6794; 20 evidence items across 8 molecular profiles. DR ClinPGx; PA36198; -. DR CTD; 6794; -. DR DisGeNET; 6794; -. DR GeneCards; STK11; -. DR GeneReviews; STK11; -. DR HGNC; HGNC:11389; STK11. DR HPA; ENSG00000118046; Low tissue specificity. DR MalaCards; STK11; -. DR MIM; 175200; phenotype. DR MIM; 273300; phenotype. DR MIM; 602216; gene. DR OpenTargets; ENSG00000118046; -. DR Orphanet; 2869; Peutz-Jeghers syndrome. DR VEuPathDB; HostDB:ENSG00000118046; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000158050; -. DR HOGENOM; CLU_000288_1_2_1; -. DR InParanoid; Q15831; -. DR OMA; AYHYGSE; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q15831; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q15831; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15831; -. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes. DR SignaLink; Q15831; -. DR SIGNOR; Q15831; -. DR Agora; ENSG00000118046; -. DR BioGRID-ORCS; 6794; 153 hits in 1229 CRISPR screens. DR ChiTaRS; STK11; human. DR EvolutionaryTrace; Q15831; -. DR GeneWiki; STK11; -. DR GenomeRNAi; 6794; -. DR Pharos; Q15831; Tchem. DR PRO; PR:Q15831; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q15831; protein. DR Bgee; ENSG00000118046; Expressed in left testis and 156 other cell types or tissues. DR ExpressionAtlas; Q15831; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0140535; C:intracellular protein-containing complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:1902554; C:serine/threonine protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI. DR GO; GO:0043276; P:anoikis; IMP:BHF-UCL. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; IEA:Ensembl. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0097484; P:dendrite extension; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0030010; P:establishment of cell polarity; IMP:UniProtKB. DR GO; GO:0070314; P:G1 to G0 transition; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0051645; P:Golgi localization; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:1901610; P:positive regulation of vesicle transport along microtubule; IMP:UniProtKB. DR GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006470; P:protein dephosphorylation; IMP:UniProtKB. DR GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome. DR GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0001944; P:vasculature development; ISS:UniProtKB. DR CDD; cd14119; STKc_LKB1; 1. DR FunFam; 1.10.510.10:FF:000245; serine/threonine-protein kinase STK11; 1. DR FunFam; 3.30.200.20:FF:000235; serine/threonine-protein kinase STK11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00613; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR039154; LKB1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF94; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Autophagy; Cell cycle; Cytoplasm; Differentiation; Disease variant; KW DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane; KW Metal-binding; Methylation; Mitochondrion; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Prenylation; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Spermatogenesis; KW Transferase; Tumor suppressor. FT CHAIN 1..430 FT /note="Serine/threonine-protein kinase STK11" FT /id="PRO_0000086699" FT PROPEP 431..433 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000422300" FT DOMAIN 49..309 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 45..90 FT /note="Sufficient for interaction with SIRT1" FT /evidence="ECO:0000269|PubMed:18687677" FT REGION 312..331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 397..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..326 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..433 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 176 FT /note="Proton acceptor" FT BINDING 55..63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 78 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 31 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 44 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 48 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 96 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 97 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 189 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11430832" FT MOD_RES 296 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 311 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9WTK7" FT MOD_RES 336 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 363 FT /note="Phosphothreonine; by ATM and autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 401 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 416 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 423 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 428 FT /note="Phosphoserine; by autocatalysis, PKA, PKC/PRKCZ and FT RPS6KA1" FT /evidence="ECO:0000269|PubMed:18854309" FT MOD_RES 430 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000250" FT MOD_RES 431 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT LIPID 418 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000250" FT LIPID 430 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000250" FT VAR_SEQ 371..433 FT /note="QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASS FT KIRRLSACKQQ -> GEEASEAGLRAERGLQKSEGSDLSGEEASRPAPQ (in FT isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041746" FT VARIANT 14 FT /note="E -> K (in cervical cancer; somatic mutation; FT dbSNP:rs2145404557)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065627" FT VARIANT 16 FT /note="E -> G (in PJS; dbSNP:rs2145404592)" FT /evidence="ECO:0000269|PubMed:21411391" FT /id="VAR_065628" FT VARIANT 49 FT /note="Y -> D (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853080)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033138" FT VARIANT 50..53 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071057" FT VARIANT 66 FT /note="V -> M (in cervical carcinoma; somatic mutation; FT dbSNP:rs1599915144)" FT /evidence="ECO:0000269|PubMed:12533684, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065629" FT VARIANT 67 FT /note="L -> P (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs137853077)" FT /evidence="ECO:0000269|PubMed:9428765, FT ECO:0000269|PubMed:9837816" FT /id="VAR_006202" FT VARIANT 86 FT /note="R -> G (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1057520039)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065630" FT VARIANT 87 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1568690463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041139" FT VARIANT 123 FT /note="Q -> R (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs764449808)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065631" FT VARIANT 135 FT /note="G -> R (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853081)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033139" FT VARIANT 157 FT /note="F -> S (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145424124)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065632" FT VARIANT 160 FT /note="L -> P (in cervical cancer; somatic mutation; FT dbSNP:rs2145424155)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065633" FT VARIANT 162..164 FT /note="DGL -> NDM (in PJS)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007920" FT VARIANT 163 FT /note="G -> D (in TGCT; a tumor with seminoma and teratoma FT components; somatic mutation; severely impaired but FT detectable kinase activity; impairs heterotrimeric complex FT assembly with STRADA and CAB39; predominantly nuclear FT localization; dbSNP:rs137853078)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330" FT /id="VAR_033140" FT VARIANT 170 FT /note="Q -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs876659972)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065634" FT VARIANT 171 FT /note="G -> S (in colorectal cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1599926499)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9731485" FT /id="VAR_065635" FT VARIANT 174 FT /note="H -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065636" FT VARIANT 176 FT /note="D -> N (in PJS; loss of kinase activity, leading to FT greatly reduced autophosphorylation; fails to phosphorylate FT PTEN in vitro; no significant effect on nucleocytoplasmic FT localization; dbSNP:rs730881979)" FT /evidence="ECO:0000269|PubMed:15987703, FT ECO:0000269|PubMed:9837816" FT /id="VAR_071058" FT VARIANT 176 FT /note="D -> Y (in sporadic cancer; somatic mutation; Loss FT of kinase activity)" FT /evidence="ECO:0000269|PubMed:12805220, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065637" FT VARIANT 177 FT /note="I -> N (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520041)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065638" FT VARIANT 181 FT /note="N -> E (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; requires 2 nucleotide substitutions; FT dbSNP:rs1568707668)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065639" FT VARIANT 194 FT /note="D -> N (in PJS; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007921" FT VARIANT 194 FT /note="D -> V (in lung cancer; somatic mutation; FT dbSNP:rs121913316)" FT /evidence="ECO:0000269|PubMed:10079245" FT /id="VAR_065640" FT VARIANT 194 FT /note="D -> Y (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10208439" FT /id="VAR_033141" FT VARIANT 199 FT /note="E -> K (in colorectal cancer; somatic mutation; FT impaired kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065641" FT VARIANT 199 FT /note="E -> Q (in sporadic cancer; somatic mutation; does FT not affect kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065642" FT VARIANT 205 FT /note="A -> T (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs730881981)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065643" FT VARIANT 208 FT /note="D -> N (in colorectal cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738372)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065644" FT VARIANT 215 FT /note="G -> D (in colorectal cancer; somatic mutation; FT dbSNP:rs1057520038)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065645" FT VARIANT 216 FT /note="S -> F (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520017)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065646" FT VARIANT 223 FT /note="E -> V (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2080776621)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065647" FT VARIANT 230 FT /note="T -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425367)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065648" FT VARIANT 231 FT /note="F -> L (in cervical cancer; somatic mutation; FT dbSNP:rs929783669)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065649" FT VARIANT 232 FT /note="S -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425398)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065650" FT VARIANT 239 FT /note="W -> C (in PJS; late onset suggests reduced FT penetrance; dbSNP:rs137853082)" FT /evidence="ECO:0000269|PubMed:12372054" FT /id="VAR_033142" FT VARIANT 245 FT /note="L -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065651" FT VARIANT 247 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9760200" FT /id="VAR_006203" FT VARIANT 250 FT /note="T -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1568709142)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065652" FT VARIANT 272 FT /note="Y -> H (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs2145427076)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065653" FT VARIANT 277 FT /note="D -> Y (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1555738692)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065654" FT VARIANT 281 FT /note="P -> L (in ovarian carcinoma; somatic mutation; FT dbSNP:rs121913322)" FT /evidence="ECO:0000269|PubMed:10429654" FT /id="VAR_065655" FT VARIANT 285 FT /note="L -> Q (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738724)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065656" FT VARIANT 297 FT /note="R -> K (in PJS; dbSNP:rs1568710381)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007922" FT VARIANT 303..306 FT /note="IRQH -> N (in PJS)" FT /id="VAR_033143" FT VARIANT 308 FT /note="W -> C (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs1057520042)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071059" FT VARIANT 314 FT /note="P -> H (in colorectal cancer; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs1064795752)" FT /evidence="ECO:0000269|PubMed:9809980" FT /id="VAR_065657" FT VARIANT 315 FT /note="P -> S (in PJS; uncertain significance; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs786202431)" FT /evidence="ECO:0000269|PubMed:12372054, FT ECO:0000269|PubMed:19892943" FT /id="VAR_033144" FT VARIANT 324 FT /note="P -> L (in gastric carcinoma; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs367807476)" FT /evidence="ECO:0000269|PubMed:9683800" FT /id="VAR_065658" FT VARIANT 354 FT /note="F -> L (in colorectal cancer; somatic mutation; FT dbSNP:rs59912467)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065659" FT VARIANT 367 FT /note="T -> M (in colorectal cancer; somatic mutation; FT dbSNP:rs587782835)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065660" FT MUTAGEN 44 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->Q: No effect on basal nucleocytoplasmic FT localization, but fails to translocate to the cytoplasm FT when coexpressed with SIRT1." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->R: Enhanced phosphorylation at Thr-336 and Ser- FT 428, enhanced cytoplasmic localization and increased kinase FT activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 74 FT /note="R->A: Impaired formation of a heterotrimeric complex FT with STRADA and CAB39; when associated with A-204." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 78 FT /note="K->I: Loss of kinase activity, leading to greatly FT reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 78 FT /note="K->M: Loss of kinase activity, leading to reduced FT autophosphorylation and acting as a dominant-negative FT mutant." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 96 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 97 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 189 FT /note="T->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:11430832" FT MUTAGEN 194 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14517248, FT ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943" FT MUTAGEN 204 FT /note="F->A: No effect. Impaired formation of a FT heterotrimeric complex with STRADA and CAB39; when FT associated with A-74." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 428 FT /note="S->A,E: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18854309" FT STRAND 54..57 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 69..71 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 74..80 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 82..87 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 91..102 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 120..123 FT /evidence="ECO:0007829|PDB:8VSU" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 136..142 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 150..169 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 231..233 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 234..250 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 260..269 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 280..289 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 294..296 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 307..310 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 326..328 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4ZDR" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:2WTK" FT MOD_RES Q15831-2:399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:23612973" SQ SEQUENCE 433 AA; 48636 MW; 6DF4C37AB7A89569 CRC64; MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA SSKIRRLSAC KQQ // ID STK26_HUMAN Reviewed; 416 AA. AC Q9P289; B2RAU2; Q3ZB77; Q8NC04; Q9BXC3; Q9BXC4; DT 16-AUG-2005, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=Serine/threonine-protein kinase 26 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:29232556}; DE AltName: Full=MST3 and SOK1-related kinase {ECO:0000303|PubMed:11741893}; DE AltName: Full=Mammalian STE20-like protein kinase 4 {ECO:0000303|PubMed:11641781}; DE Short=MST-4 {ECO:0000305}; DE Short=STE20-like kinase MST4 {ECO:0000305}; DE AltName: Full=Serine/threonine-protein kinase MASK {ECO:0000305}; GN Name=STK26 {ECO:0000312|HGNC:HGNC:18174}; GN Synonyms=MASK {ECO:0000303|PubMed:11741893}, GN MST4 {ECO:0000303|PubMed:11641781}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=11641781; DOI=10.1038/sj.onc.1204818; RA Lin J.-L., Chen H.-C., Fang H.-I., Robinson D., Kung H.-J., Shih H.-M.; RT "MST4, a new Ste20-related kinase that mediates cell growth and RT transformation via modulating ERK pathway."; RL Oncogene 20:6559-6569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Fetal brain; RX PubMed=11306563; DOI=10.1074/jbc.m009323200; RA Qian Z., Lin C., Espinosa R., LeBeau M., Rosner M.R.; RT "Cloning and characterization of MST4, a novel Ste20-like kinase."; RL J. Biol. Chem. 276:22439-22445(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=11741893; DOI=10.1074/jbc.m110882200; RA Dan I., Ong S.E., Watanabe N.M., Blagoev B., Nielsen M.M., Kajikawa E., RA Kristiansen T.Z., Mann M., Pandey A.; RT "Cloning of MASK, a novel member of the mammalian germinal center kinase RT III subfamily, with apoptosis-inducing properties."; RL J. Biol. Chem. 277:5929-5939(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-178, INTERACTION WITH GOLGA2, RP AND ACTIVITY REGULATION. RX PubMed=15037601; DOI=10.1083/jcb.200310061; RA Preisinger C., Short B., De Corte V., Bruyneel E., Haas A., Kopajtich R., RA Gettemans J., Barr F.A.; RT "YSK1 is activated by the Golgi matrix protein GM130 and plays a role in RT cell migration through its substrate 14-3-3zeta."; RL J. Cell Biol. 164:1009-1020(2004). RN [10] RP INTERACTION WITH PDCD10, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17360971; DOI=10.1091/mbc.e06-07-0608; RA Ma X., Zhao H., Shan J., Long F., Chen Y., Chen Y., Zhang Y., Han X., RA Ma D.; RT "PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and RT transformation via modulation of the ERK pathway."; RL Mol. Biol. Cell 18:1965-1978(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4 AND THR-178, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-300; SER-304 AND SER-306, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP INTERACTION WITH PDCD10. RX PubMed=19370760; DOI=10.1002/humu.20996; RA Voss K., Stahl S., Hogan B.M., Reinders J., Schleider E., RA Schulte-Merker S., Felbor U.; RT "Functional analyses of human and zebrafish 18-amino acid in-frame deletion RT pave the way for domain mapping of the cerebral cavernous malformation 3 RT protein."; RL Hum. Mutat. 30:1003-1011(2009). RN [14] RP INTERACTION WITH CTTNBP2NL, IDENTIFICATION IN STRIPAK COMPLEX, AND RP FUNCTION. RX PubMed=18782753; DOI=10.1074/mcp.m800266-mcp200; RA Goudreault M., D'Ambrosio L.M., Kean M.J., Mullin M.J., Larsen B.G., RA Sanchez A., Chaudhry S., Chen G.I., Sicheri F., Nesvizhskii A.I., RA Aebersold R., Raught B., Gingras A.C.; RT "A PP2A phosphatase high density interaction network identifies a novel RT striatin-interacting phosphatase and kinase complex linked to the cerebral RT cavernous malformation 3 (CCM3) protein."; RL Mol. Cell. Proteomics 8:157-171(2009). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4; THR-178 AND SER-300, CLEAVAGE OF INITIATOR METHIONINE RP [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE RP SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-178, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [17] RP INTERACTION WITH PDCD10 AND GOLGA2, AND SUBCELLULAR LOCATION. RX PubMed=20332113; DOI=10.1242/jcs.061341; RA Fidalgo M., Fraile M., Pires A., Force T., Pombo C., Zalvide J.; RT "CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell RT orientation."; RL J. Cell Sci. 123:1274-1284(2010). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-4; SER-300; SER-304 AND SER-306, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4; THR-178; SER-325; THR-327 RP AND THR-328, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [24] RP FUNCTION, INTERACTION WITH RIPOR1, AND SUBCELLULAR LOCATION. RX PubMed=27807006; DOI=10.1242/jcs.198614; RA Mardakheh F.K., Self A., Marshall C.J.; RT "RHO binding to FAM65A regulates Golgi reorientation during cell RT migration."; RL J. Cell Sci. 129:4466-4479(2016). RN [25] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-53. RX PubMed=29232556; DOI=10.1016/j.ccell.2017.11.005; RA Huang T., Kim C.K., Alvarez A.A., Pangeni R.P., Wan X., Song X., Shi T., RA Yang Y., Sastry N., Horbinski C.M., Lu S., Stupp R., Kessler J.A., RA Nishikawa R., Nakano I., Sulman E.P., Lu X., James C.D., Yin X.M., Hu B., RA Cheng S.Y.; RT "MST4 phosphorylation of ATG4B regulates autophagic activity, RT tumorigenicity, and radioresistance in glioblastoma."; RL Cancer Cell 32:840-855(2017). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 1-300 IN COMPLEX WITH QUINAZOLIN RP INHIBITOR, AND SUBUNIT. RX PubMed=20730082; DOI=10.1371/journal.pone.0011905; RA Record C.J., Chaikuad A., Rellos P., Das S., Pike A.C., Fedorov O., RA Marsden B.D., Knapp S., Lee W.H.; RT "Structural comparison of human mammalian ste20-like kinases."; RL PLoS ONE 5:E11905-E11905(2010). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-9; TRP-36 AND CYS-45. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a mediator of CC cell growth (PubMed:11641781, PubMed:17360971). Modulates apoptosis CC (PubMed:11641781, PubMed:17360971). In association with STK24 CC negatively regulates Golgi reorientation in polarized cell migration CC upon RHO activation (PubMed:27807006). Phosphorylates ATG4B at 'Ser- CC 383', thereby increasing autophagic flux (PubMed:29232556). Part of the CC striatin-interacting phosphatase and kinase (STRIPAK) complexes. CC STRIPAK complexes have critical roles in protein (de)phosphorylation CC and are regulators of multiple signaling pathways including Hippo, CC MAPK, nuclear receptor and cytoskeleton remodeling. Different types of CC STRIPAK complexes are involved in a variety of biological processes CC such as cell growth, differentiation, apoptosis, metabolism and immune CC regulation (PubMed:18782753). {ECO:0000269|PubMed:11641781, CC ECO:0000269|PubMed:17360971, ECO:0000269|PubMed:18782753, CC ECO:0000269|PubMed:27807006, ECO:0000269|PubMed:29232556}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:11641781, ECO:0000269|PubMed:29232556}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:11641781}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9Y4P1}; CC -!- ACTIVITY REGULATION: Interaction with Golgi matrix protein GOLGA2 leads CC to autophosphorylation on Thr-178, possibly as a consequence of CC stabilization of dimer formation. May also be activated by C-terminal CC cleavage. {ECO:0000269|PubMed:15037601}. CC -!- SUBUNIT: Homodimer (PubMed:20730082). Interacts with PDCD10 CC (PubMed:17360971, PubMed:19370760, PubMed:20332113). Interacts with CC GOLGA2 (PubMed:15037601, PubMed:20332113). Interacts with CTTNBP2NL CC (PubMed:18782753). Interacts with RIPOR1 (via C-terminus); this CC interaction occurs in a PDCD10-dependent and Rho-independent manner CC (PubMed:27807006). Interacts with PDCD10; this interaction is required CC for the association of STK26 with RIPOR1 (PubMed:27807006). Part of the CC core of STRIPAK complexes composed of PP2A catalytic and scaffolding CC subunits, the striatins (PP2A regulatory subunits), the striatin- CC associated proteins MOB4, STRIP1 and STRIP2, PDCD10 and members of the CC STE20 kinases, such as STK24 and STK26 (PubMed:18782753). CC {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:17360971, CC ECO:0000269|PubMed:18782753, ECO:0000269|PubMed:19370760, CC ECO:0000269|PubMed:20332113, ECO:0000269|PubMed:20730082, CC ECO:0000269|PubMed:27807006}. CC -!- INTERACTION: CC Q9P289; Q9Y376: CAB39; NbExp=6; IntAct=EBI-618239, EBI-306905; CC Q9P289; P13569: CFTR; NbExp=6; IntAct=EBI-618239, EBI-349854; CC Q9P289; Q9P2B4: CTTNBP2NL; NbExp=6; IntAct=EBI-618239, EBI-1774273; CC Q9P289; Q08379: GOLGA2; NbExp=7; IntAct=EBI-618239, EBI-618309; CC Q9P289; Q9BUL8: PDCD10; NbExp=11; IntAct=EBI-618239, EBI-740195; CC Q9P289; Q9P289: STK26; NbExp=4; IntAct=EBI-618239, EBI-618239; CC Q9P289; Q5VSL9: STRIP1; NbExp=4; IntAct=EBI-618239, EBI-1773588; CC Q9P289-1; Q9Y376: CAB39; NbExp=10; IntAct=EBI-15996971, EBI-306905; CC Q9P289-1; Q9BUL8: PDCD10; NbExp=10; IntAct=EBI-15996971, EBI-740195; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17360971, CC ECO:0000269|PubMed:27807006}. Golgi apparatus CC {ECO:0000269|PubMed:15037601, ECO:0000269|PubMed:27807006}. CC Note=Colocalized with RIPOR1 in the Golgi of serum-starved cells and CC relocated to cytoplasmic punctae, probably vesicular compartments, CC along with RIPOR1 upon serum stimulation in a Rho- and PDCD10-dependent CC manner (PubMed:27807006). {ECO:0000269|PubMed:27807006}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P289-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9P289-2; Sequence=VSP_041469; CC Name=3; Synonyms=MST4a; CC IsoId=Q9P289-3; Sequence=VSP_041470; CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF231012; AAK38484.1; -; mRNA. DR EMBL; AF344882; AAK29620.1; -; mRNA. DR EMBL; AF344883; AAK29621.1; -; mRNA. DR EMBL; AB040057; BAA92785.2; -; mRNA. DR EMBL; BT020099; AAV38902.1; -; mRNA. DR EMBL; AK075107; BAC11406.1; -; mRNA. DR EMBL; AK314356; BAG36989.1; -; mRNA. DR EMBL; AL109749; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471107; EAX11786.1; -; Genomic_DNA. DR EMBL; CH471107; EAX11787.1; -; Genomic_DNA. DR EMBL; BC098315; AAH98315.1; -; mRNA. DR EMBL; BC103503; AAI03504.1; -; mRNA. DR CCDS; CCDS14631.1; -. [Q9P289-1] DR CCDS; CCDS43995.1; -. [Q9P289-3] DR CCDS; CCDS48168.1; -. [Q9P289-2] DR RefSeq; NP_001035917.1; NM_001042452.2. [Q9P289-3] DR RefSeq; NP_001035918.1; NM_001042453.2. [Q9P289-2] DR RefSeq; NP_057626.2; NM_016542.3. [Q9P289-1] DR PDB; 3GGF; X-ray; 2.35 A; A/B=1-300. DR PDB; 3W8I; X-ray; 2.40 A; B=346-416. DR PDB; 4FZA; X-ray; 3.15 A; B=18-297. DR PDB; 4FZD; X-ray; 3.25 A; B=18-297, C=323-327. DR PDB; 4FZF; X-ray; 3.64 A; B=18-297. DR PDB; 4GEH; X-ray; 1.95 A; B/D=325-413. DR PDB; 5XY9; X-ray; 2.30 A; C/D=314-325. DR PDB; 5YF4; X-ray; 1.90 A; B=320-335. DR PDB; 7B36; X-ray; 2.11 A; A/C=1-300. DR PDBsum; 3GGF; -. DR PDBsum; 3W8I; -. DR PDBsum; 4FZA; -. DR PDBsum; 4FZD; -. DR PDBsum; 4FZF; -. DR PDBsum; 4GEH; -. DR PDBsum; 5XY9; -. DR PDBsum; 5YF4; -. DR PDBsum; 7B36; -. DR AlphaFoldDB; Q9P289; -. DR SMR; Q9P289; -. DR BioGRID; 119722; 244. DR CORUM; Q9P289; -. DR DIP; DIP-34049N; -. DR FunCoup; Q9P289; 1696. DR IntAct; Q9P289; 111. DR MINT; Q9P289; -. DR STRING; 9606.ENSP00000377867; -. DR BindingDB; Q9P289; -. DR ChEMBL; CHEMBL5941; -. DR DrugBank; DB07853; 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P289; -. DR GlyGen; Q9P289; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9P289; -. DR PhosphoSitePlus; Q9P289; -. DR SwissPalm; Q9P289; -. DR BioMuta; STK26; -. DR DMDM; 73621232; -. DR jPOST; Q9P289; -. DR MassIVE; Q9P289; -. DR PaxDb; 9606-ENSP00000377867; -. DR PeptideAtlas; Q9P289; -. DR ProteomicsDB; 83756; -. [Q9P289-1] DR ProteomicsDB; 83757; -. [Q9P289-2] DR ProteomicsDB; 83758; -. [Q9P289-3] DR Pumba; Q9P289; -. DR Antibodypedia; 30220; 299 antibodies from 38 providers. DR DNASU; 51765; -. DR Ensembl; ENST00000394334.7; ENSP00000377867.2; ENSG00000134602.17. [Q9P289-1] DR Ensembl; ENST00000394335.6; ENSP00000377868.2; ENSG00000134602.17. [Q9P289-2] DR Ensembl; ENST00000496850.1; ENSP00000419702.1; ENSG00000134602.17. [Q9P289-3] DR GeneID; 51765; -. DR KEGG; hsa:51765; -. DR MANE-Select; ENST00000394334.7; ENSP00000377867.2; NM_016542.4; NP_057626.2. DR UCSC; uc004ewk.2; human. [Q9P289-1] DR AGR; HGNC:18174; -. DR CTD; 51765; -. DR DisGeNET; 51765; -. DR GeneCards; STK26; -. DR HGNC; HGNC:18174; STK26. DR HPA; ENSG00000134602; Tissue enhanced (bone marrow, epididymis). DR MIM; 300547; gene. DR OpenTargets; ENSG00000134602; -. DR VEuPathDB; HostDB:ENSG00000134602; -. DR eggNOG; KOG0201; Eukaryota. DR GeneTree; ENSGT00940000157904; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; Q9P289; -. DR OrthoDB; 8693905at2759; -. DR PAN-GO; Q9P289; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P289; -. DR PathwayCommons; Q9P289; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR SignaLink; Q9P289; -. DR SIGNOR; Q9P289; -. DR Agora; ENSG00000134602; -. DR BioGRID-ORCS; 51765; 18 hits in 777 CRISPR screens. DR ChiTaRS; STK26; human. DR EvolutionaryTrace; Q9P289; -. DR GeneWiki; MST4; -. DR GenomeRNAi; 51765; -. DR Pharos; Q9P289; Tchem. DR PRO; PR:Q9P289; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9P289; protein. DR Bgee; ENSG00000134602; Expressed in germinal epithelium of ovary and 175 other cell types or tissues. DR ExpressionAtlas; Q9P289; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0071944; C:cell periphery; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0090443; C:FAR/SIN/STRIPAK complex; IDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005798; C:Golgi-associated vesicle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0012506; C:vesicle membrane; TAS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IMP:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:1903698; P:positive regulation of microvillus assembly; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR CDD; cd06640; STKc_MST4; 1. DR FunFam; 1.10.510.10:FF:000411; Probable Ste20-like kinase Don3; 1. DR FunFam; 1.10.12.70:FF:000004; Serine/threonine-protein kinase 26; 1. DR FunFam; 3.30.200.20:FF:000252; Serine/threonine-protein kinase 26; 1. DR Gene3D; 1.10.12.70; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR046409; PDC10_dimerisation_sf. DR InterPro; IPR048288; PDCD10_N. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050629; STE20/SPS1-PAK. DR InterPro; IPR035056; STK_MST4. DR PANTHER; PTHR48012:SF7; SERINE_THREONINE-PROTEIN KINASE 26; 1. DR PANTHER; PTHR48012; STERILE20-LIKE KINASE, ISOFORM B-RELATED; 1. DR Pfam; PF20929; PDCD10_N; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Golgi apparatus; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT CHAIN 2..416 FT /note="Serine/threonine-protein kinase 26" FT /id="PRO_0000086404" FT DOMAIN 24..274 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 297..340 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 144 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:29232556" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 4 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 178 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15037601, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 300 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692" FT MOD_RES 304 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 306 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 309 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99JT2" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 327 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 328 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 15..91 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041469" FT VAR_SEQ 200..261 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11306563" FT /id="VSP_041470" FT VARIANT 9 FT /note="Q -> R (in dbSNP:rs56035648)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040844" FT VARIANT 36 FT /note="G -> W (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040845" FT VARIANT 45 FT /note="R -> C (in dbSNP:rs56044451)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040846" FT MUTAGEN 53 FT /note="K->E: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:29232556" FT HELIX 20..23 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 24..31 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 32..34 FT /evidence="ECO:0007829|PDB:4FZD" FT STRAND 36..43 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 44..46 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 49..56 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:4FZD" FT HELIX 61..63 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 64..76 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 85..91 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 94..100 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:3GGF" FT HELIX 107..111 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 118..137 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 138..142 FT /evidence="ECO:0007829|PDB:3GGF" FT HELIX 147..149 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 158..160 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:4FZD" FT TURN 172..174 FT /evidence="ECO:0007829|PDB:4FZA" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:4FZA" FT HELIX 188..191 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 199..214 FT /evidence="ECO:0007829|PDB:7B36" FT TURN 218..221 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 224..233 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 241..243 FT /evidence="ECO:0007829|PDB:4FZA" FT HELIX 245..254 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 265..268 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 272..277 FT /evidence="ECO:0007829|PDB:7B36" FT HELIX 282..296 FT /evidence="ECO:0007829|PDB:7B36" FT STRAND 329..331 FT /evidence="ECO:0007829|PDB:5YF4" FT HELIX 346..350 FT /evidence="ECO:0007829|PDB:3W8I" FT HELIX 352..355 FT /evidence="ECO:0007829|PDB:4GEH" FT HELIX 357..366 FT /evidence="ECO:0007829|PDB:4GEH" FT TURN 367..370 FT /evidence="ECO:0007829|PDB:3W8I" FT HELIX 372..391 FT /evidence="ECO:0007829|PDB:4GEH" FT HELIX 395..409 FT /evidence="ECO:0007829|PDB:4GEH" SQ SEQUENCE 416 AA; 46529 MW; 3E31B7E3CBDA5768 CRC64; MAHSPVAVQV PGMQNNIADP EELFTKLERI GKGSFGEVFK GIDNRTQQVV AIKIIDLEEA EDEIEDIQQE ITVLSQCDSS YVTKYYGSYL KGSKLWIIME YLGGGSALDL LRAGPFDEFQ IATMLKEILK GLDYLHSEKK IHRDIKAANV LLSEQGDVKL ADFGVAGQLT DTQIKRNTFV GTPFWMAPEV IQQSAYDSKA DIWSLGITAI ELAKGEPPNS DMHPMRVLFL IPKNNPPTLV GDFTKSFKEF IDACLNKDPS FRPTAKELLK HKFIVKNSKK TSYLTELIDR FKRWKAEGHS DDESDSEGSD SESTSRENNT HPEWSFTTVR KKPDPKKVQN GAEQDLVQTL SCLSMIITPA FAELKQQDEN NASRNQAIEE LEKSIAVAEA ACPGITDKMV KKLIEKFQKC SADESP // ID TOPRS_HUMAN Reviewed; 1045 AA. AC Q9NS56; O43273; Q6P987; Q9NS55; Q9UNR9; DT 18-APR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=E3 ubiquitin-protein ligase Topors; DE EC=2.3.2.27; DE AltName: Full=RING-type E3 ubiquitin transferase Topors {ECO:0000305}; DE AltName: Full=SUMO1-protein E3 ligase Topors; DE AltName: Full=Topoisomerase I-binding RING finger protein; DE AltName: Full=Topoisomerase I-binding arginine/serine-rich protein; DE AltName: Full=Tumor suppressor p53-binding protein 3; DE Short=p53-binding protein 3; DE Short=p53BP3; GN Name=TOPORS; Synonyms=LUN, TP53BPL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH TOP1, AND RP SUBCELLULAR LOCATION. RX PubMed=10352183; DOI=10.1093/nar/27.12.2538; RA Haluska P. Jr., Saleem A., Rasheed Z., Ahmed F., Su E.W., Liu L.F., RA Rubin E.H.; RT "Interaction between human topoisomerase I and a novel RING RT finger/arginine-serine protein."; RL Nucleic Acids Res. 27:2538-2544(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PUTATIVE DNA-BINDING, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=11278651; DOI=10.1074/jbc.m010262200; RA Chu D., Kakazu N., Gorrin-Rivas M.J., Lu H.P., Kawata M., Abe T., Ueda K., RA Adachi Y.; RT "Cloning and characterization of LUN, a novel RING-finger protein that is RT highly expressed in lung and specifically binds to a palindromic RT sequence."; RL J. Biol. Chem. 276:14004-14013(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS THR-154; RP LYS-517 AND ASP-749. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 51-1045 (ISOFORM 1), INTERACTION WITH TP53, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10415337; DOI=10.1016/s0378-1119(99)00203-6; RA Zhou R., Wen H., Ao S.-Z.; RT "Identification of a novel gene encoding a p53-associated protein."; RL Gene 235:93-101(1999). RN [6] RP SUBCELLULAR LOCATION. RX PubMed=12083797; DOI=10.1006/excr.2002.5550; RA Rasheed Z.A., Saleem A., Ravee Y., Pandolfi P.P., Rubin E.H.; RT "The topoisomerase I-binding RING protein, topors, is associated with RT promyelocytic leukemia nuclear bodies."; RL Exp. Cell Res. 277:152-160(2002). RN [7] RP INTERACTION WITH SUMO1 AND UBE2I, SUBCELLULAR LOCATION, SUMOYLATION, AND RP MUTAGENESIS OF LYS-76; LYS-301; LYS-485; LYS-560 AND LYS-921. RX PubMed=14516784; DOI=10.1016/s0014-4827(03)00292-1; RA Weger S., Hammer E., Engstler M.; RT "The DNA topoisomerase I binding protein topors as a novel cellular target RT for SUMO-1 modification: characterization of domains necessary for RT subcellular localization and sumolation."; RL Exp. Cell Res. 290:13-27(2003). RN [8] RP FUNCTION, AND MUTAGENESIS OF TRP-131. RX PubMed=15247280; DOI=10.1074/jbc.c400300200; RA Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z., RA Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H.; RT "Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and RT ubiquitinates p53."; RL J. Biol. Chem. 279:36440-36444(2004). RN [9] RP REDUCED EXPRESSION IN LUNG CANCERS. RX PubMed=15364129; DOI=10.1016/j.lungcan.2004.03.009; RA Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K., RA Wada H., Tanaka F.; RT "Expression of LUN gene that encodes a novel RING finger protein is RT correlated with development and progression of non-small cell lung RT cancer."; RL Lung Cancer 46:21-28(2004). RN [10] RP TISSUE SPECIFICITY, AND REDUCED EXPRESSION IN COLON CANCERS. RX PubMed=15107820; DOI=10.1038/sj.onc.1207700; RA Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., RA Marshall H., Luo M., Li H., Rubin E.H.; RT "The topoisomerase I- and p53-binding protein topors is differentially RT expressed in normal and malignant human tissues and may function as a tumor RT suppressor."; RL Oncogene 23:5293-5300(2004). RN [11] RP FUNCTION, AND SUMOYLATION. RX PubMed=16122737; DOI=10.1016/j.febslet.2005.07.088; RA Weger S., Hammer E., Heilbronn R.; RT "Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo."; RL FEBS Lett. 579:5007-5012(2005). RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=15735665; DOI=10.1038/sj.onc.1208554; RA Lin L., Ozaki T., Takada Y., Kageyama H., Nakamura Y., Hata A., Zhang J.H., RA Simonds W.F., Nakagawara A., Koseki H.; RT "Topors, a p53 and topoisomerase I-binding RING finger protein, is a RT coactivator of p53 in growth suppression induced by DNA damage."; RL Oncogene 24:3385-3396(2005). RN [13] RP INVOLVEMENT IN RP31. RX PubMed=17924349; DOI=10.1086/521953; RA Chakarova C.F., Papaioannou M.G., Khanna H., Lopez I., Waseem N., Shah A., RA Theis T., Friedman J., Maubaret C., Bujakowska K., Veraitch B., RA El-Aziz M.M.A., Prescott de Q., Parapuram S.K., Bickmore W.A., RA Munro P.M.G., Gal A., Hamel C.P., Marigo V., Ponting C.P., Wissinger B., RA Zrenner E., Matter K., Swaroop A., Koenekoop R.K., Bhattacharya S.S.; RT "Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with RT perivascular retinal pigment epithelium atrophy."; RL Am. J. Hum. Genet. 81:1098-1103(2007). RN [14] RP FUNCTION, AND INTERACTION WITH SIN3A. RX PubMed=17803295; DOI=10.1021/pr0703674; RA Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H., Lackland H., RA Saleem A., Rubin E.H.; RT "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins."; RL J. Proteome Res. 6:3918-3923(2007). RN [15] RP PHOSPHORYLATION AT SER-98; SER-499; SER-585 AND SER-866, MUTAGENESIS OF RP SER-98, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19053840; DOI=10.1021/bi801904q; RA Park H.J., Zheng H., Kulkarni D., Kerrigan J., Pungaliya P., Saleem A., RA Rubin E.H.; RT "Identification of phosphorylation sites of TOPORS and a role for serine 98 RT in the regulation of ubiquitin but not SUMO E3 ligase activity."; RL Biochemistry 47:13887-13896(2008). RN [16] RP FUNCTION, INTERACTION WITH NKX3-1, AND SUBCELLULAR LOCATION. RX PubMed=18077445; DOI=10.1074/jbc.m708630200; RA Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H., RA Bieberich C.J.; RT "Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1."; RL J. Biol. Chem. 283:4834-4840(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP FUNCTION, INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-718 BY PLK1, RP MUTAGENESIS OF SER-718, AND SUBCELLULAR LOCATION. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [21] RP FUNCTION, INTERACTION WITH IKBKE, AND SUBCELLULAR LOCATION. RX PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018; RA Renner F., Moreno R., Schmitz M.L.; RT "SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is RT essential for protection against DNA-damage-triggered cell death."; RL Mol. Cell 37:503-515(2010). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-194; SER-585 AND RP SER-734, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76; LYS-83; LYS-249 AND LYS-701, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [27] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [29] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-73; LYS-76; LYS-83; LYS-88; RP LYS-159; LYS-249; LYS-701; LYS-819 AND LYS-837, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Functions as an E3 ubiquitin-protein ligase and as an E3 CC SUMO1-protein ligase. Probable tumor suppressor involved in cell CC growth, cell proliferation and apoptosis that regulates p53/TP53 CC stability through ubiquitin-dependent degradation. May regulate CC chromatin modification through sumoylation of several chromatin CC modification-associated proteins. May be involved in DNA damage-induced CC cell death through IKBKE sumoylation. {ECO:0000269|PubMed:15247280, CC ECO:0000269|PubMed:15735665, ECO:0000269|PubMed:16122737, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- SUBUNIT: Interacts with PARK7/DJ-1 (By similarity). Interacts with CC TOP1. Interacts with p53/TP53; can both ubiquitinate and sumoylate CC p53/TP53. Interacts with the SUMO1 conjugating enzyme UBE2I. Interacts CC with SUMO1. Interacts with NKX3-1; polyubiquitinates NKX3-1 and induces CC its proteasomal degradation. Interacts with SIN3A; sumoylates SIN3A. CC Interacts with IKBKE; induced by DNA damage. CC {ECO:0000250|UniProtKB:Q80Z37, ECO:0000269|PubMed:10352183, CC ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- INTERACTION: CC Q9NS56; P03132: Rep68; Xeno; NbExp=3; IntAct=EBI-1996473, EBI-7387242; CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Localizes to CC discrete nuclear foci which partly overlap with PML nuclear bodies. CC Targeted to PML nuclear bodies upon DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LUN-1; CC IsoId=Q9NS56-1; Sequence=Displayed; CC Name=2; Synonyms=LUN-2; CC IsoId=Q9NS56-2; Sequence=VSP_017916, VSP_017917; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in testis and at lower CC levels in adrenal gland, bone marrow, brain, colon, heart, kidney, CC liver, muscle, ovary, pancreas, placenta, prostate, skeletal muscle, CC skin, small intestine, spleen, stomach, testis, thymus, thyroid and CC uterus. Expressed in the alveolar epithelium of the lung. Expression is CC commonly decreased in colon adenocarcinomas and lung cancers. CC {ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:11278651, CC ECO:0000269|PubMed:15107820}. CC -!- INDUCTION: By genotoxic agents such as cisplatin and camptothecin. CC {ECO:0000269|PubMed:15735665}. CC -!- PTM: Phosphorylation at Ser-98 regulates the E3 ubiquitin-protein CC ligase activity but not the SUMO1-protein ligase activity. CC Phosphorylation at Ser-718 increases the E3 ubiquitin-protein ligase CC activity versus the SUMO1-protein ligase activity resulting in CC increased p53/TP53 ubiquitination and degradation. CC {ECO:0000269|PubMed:19053840, ECO:0000269|PubMed:19473992}. CC -!- PTM: Sumoylated. {ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:16122737}. CC -!- DISEASE: Retinitis pigmentosa 31 (RP31) [MIM:609923]: A retinal CC dystrophy belonging to the group of pigmentary retinopathies. Retinitis CC pigmentosa is characterized by retinal pigment deposits visible on CC fundus examination and primary loss of rod photoreceptor cells followed CC by secondary loss of cone photoreceptors. Patients typically have night CC vision blindness and loss of midperipheral visual field. As their CC condition progresses, they lose their far peripheral visual field and CC eventually central vision as well. {ECO:0000269|PubMed:17924349}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- CAUTION: Was originally thought to bind to the palindromic consensus CC sequence 5'-TCCCAGCACTTTGGGA-3' and to regulate the transcription of CC numerous genes in the lung. {ECO:0000305|PubMed:11278651}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC98530.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42663/TOPORS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098300; AAD23379.1; -; mRNA. DR EMBL; AB045732; BAB03714.1; -; mRNA. DR EMBL; AB045733; BAB03715.1; -; mRNA. DR EMBL; AL353671; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC060884; AAH60884.1; -; mRNA. DR EMBL; U82939; AAC98530.1; ALT_INIT; mRNA. DR CCDS; CCDS56566.1; -. [Q9NS56-2] DR CCDS; CCDS6527.1; -. [Q9NS56-1] DR RefSeq; NP_001182551.1; NM_001195622.2. [Q9NS56-2] DR RefSeq; NP_005793.2; NM_005802.4. [Q9NS56-1] DR AlphaFoldDB; Q9NS56; -. DR SMR; Q9NS56; -. DR BioGRID; 115505; 99. DR FunCoup; Q9NS56; 1905. DR IntAct; Q9NS56; 49. DR MINT; Q9NS56; -. DR STRING; 9606.ENSP00000353735; -. DR GlyGen; Q9NS56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9NS56; -. DR PhosphoSitePlus; Q9NS56; -. DR BioMuta; TOPORS; -. DR DMDM; 74752935; -. DR jPOST; Q9NS56; -. DR MassIVE; Q9NS56; -. DR PaxDb; 9606-ENSP00000353735; -. DR PeptideAtlas; Q9NS56; -. DR ProteomicsDB; 82481; -. [Q9NS56-1] DR ProteomicsDB; 82482; -. [Q9NS56-2] DR Pumba; Q9NS56; -. DR Antibodypedia; 25068; 220 antibodies from 25 providers. DR DNASU; 10210; -. DR Ensembl; ENST00000360538.7; ENSP00000353735.2; ENSG00000197579.9. [Q9NS56-1] DR Ensembl; ENST00000379858.1; ENSP00000369187.1; ENSG00000197579.9. [Q9NS56-2] DR GeneID; 10210; -. DR KEGG; hsa:10210; -. DR MANE-Select; ENST00000360538.7; ENSP00000353735.2; NM_005802.5; NP_005793.2. DR UCSC; uc003zrb.4; human. [Q9NS56-1] DR AGR; HGNC:21653; -. DR ClinPGx; PA134979531; -. DR CTD; 10210; -. DR DisGeNET; 10210; -. DR GeneCards; TOPORS; -. DR GeneReviews; TOPORS; -. DR HGNC; HGNC:21653; TOPORS. DR HPA; ENSG00000197579; Low tissue specificity. DR MalaCards; TOPORS; -. DR MIM; 609507; gene. DR MIM; 609923; phenotype. DR OpenTargets; ENSG00000197579; -. DR Orphanet; 2754; Orofaciodigital syndrome type 6. DR Orphanet; 791; Retinitis pigmentosa. DR VEuPathDB; HostDB:ENSG00000197579; -. DR eggNOG; KOG4430; Eukaryota. DR GeneTree; ENSGT00530000064170; -. DR HOGENOM; CLU_012046_0_0_1; -. DR InParanoid; Q9NS56; -. DR OMA; DCVIVGF; -. DR OrthoDB; 21204at2759; -. DR PAN-GO; Q9NS56; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9NS56; -. DR PathwayCommons; Q9NS56; -. DR Reactome; R-HSA-3899300; SUMOylation of transcription cofactors. DR Reactome; R-HSA-4085377; SUMOylation of SUMOylation proteins. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR SignaLink; Q9NS56; -. DR SIGNOR; Q9NS56; -. DR Agora; ENSG00000197579; -. DR BioGRID-ORCS; 10210; 13 hits in 1201 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; TOPORS; human. DR GeneWiki; TOPORS; -. DR GenomeRNAi; 10210; -. DR Pharos; Q9NS56; Tbio. DR PRO; PR:Q9NS56; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9NS56; protein. DR Bgee; ENSG00000197579; Expressed in secondary oocyte and 207 other cell types or tissues. DR GO; GO:0005814; C:centriole; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:BHF-UCL. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:BHF-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032391; C:photoreceptor connecting cilium; IDA:BHF-UCL. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0000922; C:spindle pole; IDA:BHF-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:BHF-UCL. DR GO; GO:0003823; F:antigen binding; IPI:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0044547; F:DNA topoisomerase binding; IPI:UniProtKB. DR GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006351; P:DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:BHF-UCL. DR GO; GO:0035845; P:photoreceptor cell outer segment organization; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL. DR GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB. DR GO; GO:0006513; P:protein monoubiquitination; IDA:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL. DR GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0010842; P:retina layer formation; ISS:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR CDD; cd16574; RING-HC_Topors; 1. DR FunFam; 3.30.40.10:FF:000136; E3 ubiquitin-protein ligase Topors; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR058745; PWI_Topors. DR InterPro; IPR018957; Znf_C3HC4_RING-type. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR058746; Znf_RING-type_Topors. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR46077; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR PANTHER; PTHR46077:SF2; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR Pfam; PF26084; PWI_Topors; 1. DR Pfam; PF00097; zf-C3HC4; 1. DR SMART; SM00184; RING; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW Alternative splicing; DNA damage; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Retinitis pigmentosa; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..1045 FT /note="E3 ubiquitin-protein ligase Topors" FT /id="PRO_0000232626" FT ZN_FING 103..142 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..195 FT /note="E3 ubiquitin-protein ligase activity" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 51..374 FT /note="Required for DNA-binding" FT REGION 437..654 FT /note="Interaction with SUMO1" FT /evidence="ECO:0000269|PubMed:14516784" FT REGION 437..574 FT /note="Required for sumoylation and localization to FT discrete nuclear foci" FT REGION 442..475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 456..882 FT /note="Interaction with TOP1" FT /evidence="ECO:0000269|PubMed:10352183" FT REGION 456..731 FT /note="Interaction with p53/TP53" FT /evidence="ECO:0000269|PubMed:10415337" FT REGION 511..692 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..936 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 854..917 FT /note="Interaction with UBE2I" FT /evidence="ECO:0000269|PubMed:14516784" FT COMPBIAS 453..463 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..534 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 539..565 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..578 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 588..597 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 613..630 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..647 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..669 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 721..730 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 731..747 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 755..766 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 816..825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..863 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 880..897 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 913..923 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 98 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 194 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 499 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:23186163" FT MOD_RES 718 FT /note="Phosphoserine; by PLK1" FT /evidence="ECO:0000269|PubMed:19473992" FT MOD_RES 734 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:21406692" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692" FT MOD_RES 912 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 914 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 1028 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT CROSSLNK 73 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 76 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 83 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 88 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 249 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 560 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT CROSSLNK 701 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 819 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 837 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..65 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017916" FT VAR_SEQ 66 FT /note="E -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017917" FT VARIANT 154 FT /note="A -> T (in dbSNP:rs17855104)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037629" FT VARIANT 517 FT /note="E -> K (in dbSNP:rs17855103)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037630" FT VARIANT 749 FT /note="N -> D (in dbSNP:rs17857515)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037631" FT VARIANT 812 FT /note="P -> R (in dbSNP:rs36034138)" FT /id="VAR_037632" FT MUTAGEN 76 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 98 FT /note="S->A: Loss of phosphorylation but no effect on E3 FT ubiquitin-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 98 FT /note="S->D: Increase in E3 ubiquitin-protein ligase FT activity and increased binding to UBE2D1. No effect on FT SUMO1-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 131 FT /note="W->A: Abrogates E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:15247280" FT MUTAGEN 301 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 485 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 560 FT /note="K->R: Strongly reduces sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 718 FT /note="S->A: Loss of phosphorylation by PLK1 and increases FT in p53/TP53 stability." FT /evidence="ECO:0000269|PubMed:19473992" FT MUTAGEN 921 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT CONFLICT 124..125 FT /note="CF -> K (in Ref. 5; AAC98530)" FT /evidence="ECO:0000305" FT CONFLICT 257 FT /note="N -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="F -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 922 FT /note="E -> G (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 1040 FT /note="R -> K (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" SQ SEQUENCE 1045 AA; 119198 MW; 3DA635FDB5C83B77 CRC64; MGSQPPLGSP LSREEGEAPP PAPASEGRRR SRRVRLRGSC RHRPSFLGCR ELAASAPARP APASSEIMAS AAKEFKMDNF SPKAGTSKLQ QTVPADASPD SKCPICLDRF DNVSYLDRCL HKFCFRCVQE WSKNKAECPL CKQPFDSIFH SVRAEDDFKE YVLRPSYNGS FVTPDRRFRY RTTLTRERNA SVYSPSGPVN RRTTTPPDSG VLFEGLGIST RPRDVEIPQF MRQIAVRRPT TADERSLRKI QEQDIINFRR TLYRAGARVR NIEDGGRYRD ISAEFFRRNP ACLHRLVPWL KRELTVLFGA HGSLVNIVQH IIMSNVTRYD LESQAFVSDL RPFLLNRTEH FIHEFISFAR SPFNMAAFDQ HANYDCPAPS YEEGSHSDSS VITISPDEAE TQELDINVAT VSQAPWDDET PGPSYSSSEQ VHVTMSSLLN TSDSSDEELV TGGATSQIQG VQTNDDLNND SDDSSDNCVI VGFVKPLAER TPELVELSSD SEDLGSYEKM ETVKTQEQEQ SYSSGDSDVS RCSSPHSVLG KDEQINKGHC DSSTRIKSKK EEKRSTSLSS PRNLNSSVRG DRVYSPYNHR HRKRGRSRSS DSRSQSRSGH DQKNHRKHHG KKRMKSKRSR SRESSRPRGR RDKKRSRTRD SSWSRRSQTL SLSSESTSRS RSRSSDHGKR RSRSRNRDRY YLRNNYGSRY KWEYTYYSRN KDRDGYESSY RRRTLSRAHY SRQSSSPEFR VQSFSERTNA RKKNNHSERK YYYYERHRSR SLSSNRSRTA STGTDRVRNE KPGGKRKYKT RHLEGTNEVA QPSREFASKA KDSHYQKSSS KLDGNYKNES DTFSDSRSSD RETKHKRRKR KTRSLSVEIV YEGKATDTTK HHKKKKKKHK KKHKKHHGDN ASRSPVVITI DSDSDKDSEV KEDTECDNSG PQDPLQNEFL APSLEPFETK DVVTIEAEFG VLDKECDIAT LSNNLNNANK TVDNIPPLAA SVEQTLDVRE ESTFVSDLEN QPSNIVSLQT EPSRQLPSPR TSLMSVCLGR DCDMS // ID TRRAP_HUMAN Reviewed; 3859 AA. AC Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 226. DE RecName: Full=Transformation/transcription domain-associated protein; DE AltName: Full=350/400 kDa PCAF-associated factor; DE Short=PAF350/400; DE AltName: Full=STAF40; DE AltName: Full=Tra1 homolog; GN Name=TRRAP; Synonyms=PAF400; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1. RC TISSUE=Cervix carcinoma; RX PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8; RA McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.; RT "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc RT and E2F oncoproteins."; RL Cell 94:363-374(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344; RP 369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820; RP 1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726; RP 2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND RP IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L; RP TAF10; SUPT3H; TAF12 AND TAF9. RC TISSUE=Fetal heart; RX PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9; RA Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., RA Nakatani Y.; RT "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the RT ATM superfamily."; RL Mol. Cell 2:869-875(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [6] RP SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H; RP GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [7] RP IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H; RP TAF2; TAF4; TAF5; GCN5L2 AND TAF10. RX PubMed=10373431; DOI=10.1074/jbc.274.26.18285; RA Brand M., Yamamoto K., Staub A., Tora L.; RT "Identification of TATA-binding protein-free TAFII-containing complex RT subunits suggests a role in nucleosome acetylation and signal RT transduction."; RL J. Biol. Chem. 274:18285-18289(1999). RN [8] RP IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2. RX PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9; RA Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., RA Scully R., Qin J., Nakatani Y.; RT "Involvement of the TIP60 histone acetylase complex in DNA repair and RT apoptosis."; RL Cell 102:463-473(2000). RN [9] RP INTERACTION WITH GCN5L2. RX PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000; RA McMahon S.B., Wood M.A., Cole M.D.; RT "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 RT to c-Myc."; RL Mol. Cell. Biol. 20:556-562(2000). RN [10] RP INTERACTION WITH E2F1 AND E2F4, AND FUNCTION. RX PubMed=11418595; DOI=10.1074/jbc.m102067200; RA Lang S.E., McMahon S.B., Cole M.D., Hearing P.; RT "E2F transcriptional activation requires TRRAP and GCN5 cofactors."; RL J. Biol. Chem. 276:32627-32634(2001). RN [11] RP DOMAIN. RX PubMed=11445536; DOI=10.1101/gad.900101; RA Park J., Kunjibettu S., McMahon S.B., Cole M.D.; RT "The ATM-related domain of TRRAP is required for histone acetyltransferase RT recruitment and Myc-dependent oncogenesis."; RL Genes Dev. 15:1619-1624(2001). RN [12] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002; RA Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., RA McMahon S.B.; RT "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP RT acetyltransferase complexes."; RL Mol. Cell. Biol. 22:5650-5661(2002). RN [13] RP IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4. RX PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002; RA Park J., Wood M.A., Cole M.D.; RT "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc- RT interacting nuclear cofactor for oncogenic transformation."; RL Mol. Cell. Biol. 22:1307-1316(2002). RN [14] RP FUNCTION. RX PubMed=12743606; DOI=10.1038/sj.onc.1206376; RA Lang S.E., Hearing P.; RT "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone RT acetyltransferase complex."; RL Oncogene 22:2836-2841(2003). RN [15] RP FUNCTION. RX PubMed=12660246; DOI=10.1074/jbc.m211795200; RA Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.; RT "c-Myc transformation domain recruits the human STAGA complex and requires RT TRRAP and GCN5 acetylase activity for transcription activation."; RL J. Biol. Chem. 278:20405-20412(2003). RN [16] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE RP NUA4 COMPLEX. RX PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004; RA Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.; RT "Structural and functional conservation of the NuA4 histone RT acetyltransferase complex from yeast to humans."; RL Mol. Cell. Biol. 24:1884-1896(2004). RN [17] RP IDENTIFICATION IN STAGA COMPLEX. RX PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011; RA Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., RA Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G., RA Schuele R., Takeyama K., Kato S., Tora L., Devys D.; RT "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, RT coactivates nuclear receptors, and counteracts heterochromatin silencing."; RL Mol. Cell 29:92-101(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT. RX PubMed=17967892; DOI=10.1128/mcb.00607-07; RA DeRan M., Pulvino M., Greene E., Su C., Zhao J.; RT "Transcriptional activation of histone genes requires NPAT-dependent RT recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S RT phase transition."; RL Mol. Cell. Biol. 28:435-447(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [22] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF RP VARIANT PHE-722. RX PubMed=21499247; DOI=10.1038/ng.810; RA Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., RA Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S., RA Rosenberg S.A., Samuels Y.; RT "Exome sequencing identifies GRIN2A as frequently mutated in melanoma."; RL Nat. Genet. 43:442-446(2011). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [29] RP FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX. RX PubMed=24463511; DOI=10.1038/nature12922; RA Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., RA Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C., RA Hamiche A.; RT "ANP32E is a histone chaperone that removes H2A.Z from chromatin."; RL Nature 505:648-653(2014). RN [30] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724; RP VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690; RP ASP-2750; GLU-2801 AND MET-2931. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [32] RP INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004. RX PubMed=30424743; DOI=10.1186/s12881-018-0711-9; RA Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S., RA Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J., RA Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.; RT "De novo variant of TRRAP in a patient with very early onset psychosis in RT the context of non-verbal learning disability and obsessive-compulsive RT disorder: a case report."; RL BMC Med. Genet. 19:197-197(2018). RN [33] RP VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037; RP THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866; RP ARG-1866; ARG-1883; LEU-1932 AND GLN-3757. RX PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010; RG CAUSES Study; RG Deciphering Developmental Disorders study; RA Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T., RA Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R., RA Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A., RA Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T., RA Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M., RA Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H., RA Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P., RA Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J., RA Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A., RA Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E., RA Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R., RA Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N., RA Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A., RA Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X., RA Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K., RA Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R., RA Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S., RA Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S., RA Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B., RA Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y., RA Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S., RA Campeau P.M.; RT "Missense Variants in the Histone Acetyltransferase Complex Component Gene RT TRRAP Cause Autism and Syndromic Intellectual Disability."; RL Am. J. Hum. Genet. 104:530-541(2019). RN [34] RP VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN RP DFNA75. RX PubMed=31231791; DOI=10.1111/cge.13590; RA Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.; RT "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing RT loss."; RL Clin. Genet. 96:300-308(2019). CC -!- FUNCTION: Adapter protein, which is found in various multiprotein CC chromatin complexes with histone acetyltransferase activity (HAT), CC which gives a specific tag for epigenetic transcription activation. CC Component of the NuA4 histone acetyltransferase complex which is CC responsible for acetylation of nucleosomal histones H4 and H2A. Plays a CC central role in MYC transcription activation, and also participates in CC cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4- CC mediated transcription activation. Also involved in transcription CC activation mediated by the adenovirus E1A, a viral oncoprotein that CC deregulates transcription of key genes. Probably acts by linking CC transcription factors such as E1A, MYC or E2F1 to HAT complexes such as CC STAGA thereby allowing transcription activation. Probably not required CC in the steps following histone acetylation in processes of CC transcription activation. May be required for the mitotic checkpoint CC and normal cell cycle progression. Component of a SWR1-like complex CC that specifically mediates the removal of histone H2A.Z/H2AZ1 from the CC nucleosome. May play a role in the formation and maintenance of the CC auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}. CC -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors. CC Interacts directly with p53/TP53. Interacts with GCN5L2. Component of CC various HAT complexes. Component of the PCAF complex, at least composed CC of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65- CC alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component CC of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, CC SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, CC TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase CC complex which contains the catalytic subunit KAT5/TIP60 and the CC subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, CC RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, CC MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of CC the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, CC TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core CC complex is associated with a subcomplex required for histone CC deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the CC BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and CC TRRAP, which preferentially acetylates histone H4 (and H2A) within CC nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. CC Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431, CC ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738, CC ECO:0000269|PubMed:9885574}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:9708738}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9Y4A5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103; CC -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT CC complexes, and the MYC-dependent transactivation. Although it is CC strongly related to the PI3/PI4-kinase family, it lacks the typical CC motifs that constitute the catalytic site of PI3/PI4-kinase proteins, CC and lacks such activity. {ECO:0000269|PubMed:11445536}. CC -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in CC cutaneous malignant melanoma, suggesting that TRRAP may play a role in CC the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}. CC -!- DISEASE: Developmental delay with or without dysmorphic facies and CC autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental CC disorder apparent from infancy or early childhood. Some patients CC present with intellectual disability and renal, cardiac, genitourinary CC systems, as well as structural brain abnormalities. In some cases, the CC phenotype is less severe, has no systemic involvement and is CC characterized by autism spectrum disorder and/or intellectual CC disability, sometimes associated with epilepsy. Affected individuals CC manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743, CC ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form CC of non-syndromic deafness characterized by late-onset hearing loss that CC involves mid and high frequencies, and progresses to encompass all CC frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF076974; AAD09420.1; -; mRNA. DR EMBL; AF110377; AAD04629.1; -; mRNA. DR EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA. DR EMBL; AC004991; AAC27675.2; -; Genomic_DNA. DR EMBL; CH471091; EAW76694.1; -; Genomic_DNA. DR EMBL; CH236956; EAL23887.1; -; Genomic_DNA. DR CCDS; CCDS5659.1; -. [Q9Y4A5-2] DR CCDS; CCDS59066.1; -. [Q9Y4A5-1] DR PIR; T02632; T02632. DR RefSeq; NP_001231509.1; NM_001244580.2. [Q9Y4A5-1] DR RefSeq; NP_003487.1; NM_003496.4. [Q9Y4A5-2] DR PDB; 7KTR; EM; 2.93 A; A=369-3859. DR PDB; 8H7G; EM; 3.70 A; C=1-3859. DR PDB; 8QRI; EM; 3.50 A; C=1-3859. DR PDB; 8XVG; EM; 9.40 A; L=1-3859. DR PDB; 8XVV; EM; 3.20 A; L=1-3859. DR PDB; 9C47; EM; 3.40 A; C=1-3859. DR PDB; 9CAD; EM; 3.05 A; D=1-3859. DR PDB; 9CAF; EM; 2.35 A; D=1-3859. DR PDBsum; 7KTR; -. DR PDBsum; 8H7G; -. DR PDBsum; 8QRI; -. DR PDBsum; 8XVG; -. DR PDBsum; 8XVV; -. DR PDBsum; 9C47; -. DR PDBsum; 9CAD; -. DR PDBsum; 9CAF; -. DR EMDB; EMD-18612; -. DR EMDB; EMD-18613; -. DR EMDB; EMD-18618; -. DR EMDB; EMD-18619; -. DR EMDB; EMD-34520; -. DR EMDB; EMD-38703; -. DR EMDB; EMD-38720; -. DR EMDB; EMD-45176; -. DR EMDB; EMD-45387; -. DR EMDB; EMD-45389; -. DR SMR; Q9Y4A5; -. DR BioGRID; 113900; 797. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR ComplexPortal; CPX-903; TFTC histone acetylation complex. DR ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex. DR ComplexPortal; CPX-989; PCAF histone acetylase complex. DR CORUM; Q9Y4A5; -. DR DIP; DIP-28149N; -. DR FunCoup; Q9Y4A5; 1798. DR MINT; Q9Y4A5; -. DR STRING; 9606.ENSP00000352925; -. DR GlyGen; Q9Y4A5; 9 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (5 sites). DR iPTMnet; Q9Y4A5; -. DR MetOSite; Q9Y4A5; -. DR PhosphoSitePlus; Q9Y4A5; -. DR SwissPalm; Q9Y4A5; -. DR BioMuta; TRRAP; -. DR DMDM; 116242829; -. DR jPOST; Q9Y4A5; -. DR MassIVE; Q9Y4A5; -. DR PaxDb; 9606-ENSP00000352925; -. DR PeptideAtlas; Q9Y4A5; -. DR ProteomicsDB; 86142; -. [Q9Y4A5-1] DR ProteomicsDB; 86143; -. [Q9Y4A5-2] DR Pumba; Q9Y4A5; -. DR Antibodypedia; 16027; 189 antibodies from 23 providers. DR DNASU; 8295; -. DR Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.15. [Q9Y4A5-2] DR Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.15. [Q9Y4A5-1] DR GeneID; 8295; -. DR KEGG; hsa:8295; -. DR UCSC; uc003upp.3; human. [Q9Y4A5-1] DR AGR; HGNC:12347; -. DR ClinPGx; PA37020; -. DR CTD; 8295; -. DR DisGeNET; 8295; -. DR GeneCards; TRRAP; -. DR HGNC; HGNC:12347; TRRAP. DR HPA; ENSG00000196367; Low tissue specificity. DR MalaCards; TRRAP; -. DR MIM; 603015; gene. DR MIM; 618454; phenotype. DR MIM; 618778; phenotype. DR OpenTargets; ENSG00000196367; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000196367; -. DR eggNOG; KOG0889; Eukaryota. DR GeneTree; ENSGT00390000017961; -. DR InParanoid; Q9Y4A5; -. DR OrthoDB; 5570127at2759; -. DR PAN-GO; Q9Y4A5; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y4A5; -. DR PathwayCommons; Q9Y4A5; -. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q9Y4A5; -. DR SIGNOR; Q9Y4A5; -. DR Agora; ENSG00000196367; -. DR BioGRID-ORCS; 8295; 773 hits in 1197 CRISPR screens. DR ChiTaRS; TRRAP; human. DR GenomeRNAi; 8295; -. DR Pharos; Q9Y4A5; Tbio. DR PRO; PR:Q9Y4A5; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9Y4A5; protein. DR Bgee; ENSG00000196367; Expressed in ventricular zone and 156 other cell types or tissues. DR ExpressionAtlas; Q9Y4A5; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000786; C:nucleosome; IDA:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB. DR GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB. DR GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IBA:GO_Central. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal. DR GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd05163; PIKK_TRRAP; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR046807; Tra1_central. DR InterPro; IPR046805; Tra1_ring. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF1; TRANSFORMATION_TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF20175; Tra1_central; 1. DR Pfam; PF20206; Tra1_ring; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Autism spectrum disorder; Chromatin regulator; Deafness; KW Direct protein sequencing; Disease variant; Intellectual disability; KW Isopeptide bond; Non-syndromic deafness; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3859 FT /note="Transformation/transcription domain-associated FT protein" FT /id="PRO_0000088851" FT DOMAIN 2692..3275 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 3500..3823 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3827..3859 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 491..541 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2010..2388 FT /note="Interaction with TP53" FT /evidence="ECO:0000269|PubMed:12138177" FT REGION 2023..2044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2543..2578 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3506..3512 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3687..3695 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3707..3732 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 2047..2062 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 491..526 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 529..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2033..2044 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2543..2554 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 1628 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2051 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163" FT MOD_RES 2077 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3078 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 2543 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1492..1509 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009102" FT VAR_SEQ 3001..3012 FT /note="GKPTWSGMHSSS -> A (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009103" FT VARIANT 171 FT /note="R -> C (in DFNA75; uncertain significance; FT dbSNP:rs200157211)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083794" FT VARIANT 394 FT /note="D -> N (in DFNA75; uncertain significance; FT dbSNP:rs1554407965)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083795" FT VARIANT 722 FT /note="S -> F (found in a cutaneous malignant melanoma FT sample; somatic mutation; induces cell transformation and FT confers resistance to apoptosis; dbSNP:rs147405090)" FT /evidence="ECO:0000269|PubMed:21499247" FT /id="VAR_067754" FT VARIANT 805 FT /note="L -> F (in DEDDFA; uncertain significance; FT dbSNP:rs1562940289)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082969" FT VARIANT 860 FT /note="F -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082970" FT VARIANT 878 FT /note="R -> L (in dbSNP:rs17161510)" FT /id="VAR_028359" FT VARIANT 893 FT /note="R -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041658" FT VARIANT 893 FT /note="R -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082971" FT VARIANT 1031 FT /note="I -> M (in DEDDFA; dbSNP:rs1187165148)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082972" FT VARIANT 1035 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs2116495143)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082973" FT VARIANT 1037 FT /note="S -> R (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082974" FT VARIANT 1043 FT /note="A -> T (in DEDDFA; dbSNP:rs1562945106)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082975" FT VARIANT 1070 FT /note="S -> G (in dbSNP:rs55920979)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041659" FT VARIANT 1104 FT /note="E -> G (in DEDDFA; dbSNP:rs1790257064)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082976" FT VARIANT 1106 FT /note="E -> K (in DEDDFA; dbSNP:rs1584324956)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082977" FT VARIANT 1111 FT /note="G -> W (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082978" FT VARIANT 1159 FT /note="G -> R (in DEDDFA; dbSNP:rs1790288810)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082979" FT VARIANT 1669 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373632999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041660" FT VARIANT 1724 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs782203759)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041661" FT VARIANT 1859 FT /note="R -> C (in DEDDFA; dbSNP:rs1791432323)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082980" FT VARIANT 1866 FT /note="W -> C (in DEDDFA; uncertain significance; FT dbSNP:rs1562957576)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082981" FT VARIANT 1866 FT /note="W -> R (in DEDDFA; dbSNP:rs1562957569)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082982" FT VARIANT 1883 FT /note="G -> R (in DEDDFA)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082983" FT VARIANT 1925 FT /note="A -> V (in dbSNP:rs56197298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041662" FT VARIANT 1932 FT /note="P -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:30827496" FT /id="VAR_041663" FT VARIANT 1947 FT /note="R -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041664" FT VARIANT 2004 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs1562959030)" FT /evidence="ECO:0000269|PubMed:30424743" FT /id="VAR_082984" FT VARIANT 2139 FT /note="W -> G (in dbSNP:rs34185633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041665" FT VARIANT 2302 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs528967912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041666" FT VARIANT 2433 FT /note="S -> G (in dbSNP:rs35634065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041667" FT VARIANT 2690 FT /note="P -> L (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs753661271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041668" FT VARIANT 2750 FT /note="E -> D (in dbSNP:rs55755466)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:31231791" FT /id="VAR_041669" FT VARIANT 2801 FT /note="K -> E (in dbSNP:rs56341061)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041670" FT VARIANT 2931 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1294404368)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041671" FT VARIANT 3757 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs987263983)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082985" FT CONFLICT 660 FT /note="E -> D (in Ref. 2; AAD04629)" FT /evidence="ECO:0000305" FT HELIX 20..26 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 30..33 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 37..50 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 55..57 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 59..74 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 80..84 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 85..99 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 128..139 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 148..171 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 214..227 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 244..254 FT /evidence="ECO:0007829|PDB:9C47" FT TURN 255..259 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 276..293 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 294..298 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 307..319 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 325..338 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 342..345 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 347..351 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 365..367 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 371..385 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 387..389 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 392..406 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 413..434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 442..469 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 535..564 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 583..599 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 600..604 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 605..607 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 613..615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 627..639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 657..664 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 669..677 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 679..681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 682..695 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 698..702 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 704..723 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 725..732 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 736..747 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 774..779 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 780..782 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 783..795 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 821..827 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 828..835 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 839..855 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 858..865 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 869..879 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 885..898 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 899..903 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 923..927 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 934..938 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 940..951 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 952..955 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 957..973 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 981..988 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 992..995 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1005..1007 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1013..1029 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1032..1034 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1035..1057 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1058..1061 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1064..1066 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1067..1069 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1074..1076 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1080..1082 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1085..1087 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1091..1101 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1102..1104 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1107..1126 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1129..1132 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1136..1146 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1147..1150 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1151..1153 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1154..1170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1173..1193 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1194..1196 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1199..1201 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1202..1218 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1223..1225 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1228..1248 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1254..1271 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1280..1285 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1287..1289 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1297..1299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1302..1315 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1317..1320 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1327..1329 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1330..1344 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1347..1351 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1354..1357 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1360..1362 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1363..1375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1376..1378 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1380..1382 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1383..1394 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1399..1413 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1415..1418 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1420..1431 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1435..1437 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1442..1454 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1456..1458 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1461..1484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1511..1523 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1524..1526 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1529..1531 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1532..1546 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1549..1551 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1555..1562 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1576..1579 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1582..1592 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1594..1596 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1598..1605 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1609..1612 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1613..1615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1638..1653 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1657..1659 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1661..1672 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1674..1681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1692..1706 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1707..1709 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1710..1715 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1716..1718 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1723..1725 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1728..1738 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1740..1743 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1746..1748 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1749..1758 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1760..1766 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1770..1773 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1774..1776 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1777..1786 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1804..1813 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1818..1820 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1828..1841 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1846..1853 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1854..1859 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1861..1870 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1877..1893 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1900..1911 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1913..1915 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1921..1925 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1928..1931 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1950..1964 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1966..1970 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1972..1974 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1976..1985 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1990..2000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2003..2016 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2021..2026 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2031..2042 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2045..2060 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2064..2073 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2077..2088 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2096..2099 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2105..2111 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2114..2118 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2120..2133 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2139..2141 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2146..2154 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2155..2157 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2158..2161 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2165..2182 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2184..2189 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2191..2200 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 2201..2203 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2205..2207 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 2212..2219 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2226..2232 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2233..2235 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2240..2251 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2257..2273 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2278..2286 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2287..2290 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2292..2294 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2295..2299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2301..2312 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2320..2331 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2340..2357 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2361..2375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2382..2384 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2389..2406 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2411..2426 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2429..2434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2435..2439 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2440..2448 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2452..2464 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2470..2478 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2483..2486 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2492..2500 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2506..2508 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2514..2516 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2523..2527 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2530..2538 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2586..2602 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2607..2618 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2622..2639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2642..2656 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2659..2666 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2671..2679 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2682..2684 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2690..2699 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2703..2714 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2718..2720 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2728..2730 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2742..2755 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2758..2768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2772..2781 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2782..2784 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2786..2806 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2811..2813 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2814..2830 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2834..2841 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2844..2847 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2849..2856 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2857..2859 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2862..2872 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2873..2875 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2878..2880 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2881..2894 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2904..2919 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2928..2930 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2931..2952 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2955..2957 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2961..2976 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2985..3000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3012..3020 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3028..3051 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3054..3062 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3063..3066 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3072..3089 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3090..3092 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3095..3106 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3115..3131 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3132..3134 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3135..3148 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3153..3170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3173..3186 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3192..3195 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3196..3205 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3206..3208 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3214..3222 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3224..3226 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 3228..3234 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3235..3242 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3247..3260 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3262..3283 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3284..3286 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3295..3310 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3312..3324 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3325..3328 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3332..3354 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3355..3358 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3365..3376 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3396..3407 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3411..3423 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3429..3432 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3434..3452 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3457..3460 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3461..3463 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3466..3470 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3473..3475 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3481..3484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3489..3491 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3495..3499 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3501..3507 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3509..3520 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3525..3531 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3536..3552 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3553..3557 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3562..3565 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3574..3578 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3581..3585 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3588..3592 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3593..3604 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3610..3625 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3631..3644 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3650..3658 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3662..3685 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3693..3695 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3696..3699 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3700..3702 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3705..3708 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3716..3718 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3719..3721 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3726..3729 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3733..3739 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3741..3745 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3747..3759 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3762..3764 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3766..3789 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3798..3800 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3804..3826 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3829..3831 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3834..3842 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3845..3848 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3853..3855 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 3859 AA; 437600 MW; 391E467C0047B00B CRC64; MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA AANSLDNLCR MDPAWHPWL // ID UBX2A_HUMAN Reviewed; 259 AA. AC P68543; A8K577; B7ZKP8; Q569G8; DT 23-NOV-2004, integrated into UniProtKB/Swiss-Prot. DT 23-NOV-2004, sequence version 1. DT 28-JAN-2026, entry version 154. DE RecName: Full=UBX domain-containing protein 2A {ECO:0000305}; DE AltName: Full=UBX domain-containing protein 4 {ECO:0000312|HGNC:HGNC:27265}; GN Name=UBXN2A {ECO:0000312|HGNC:HGNC:27265}; GN Synonyms=UBXD4 {ECO:0000303|PubMed:26265139}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Adipose tissue; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Liver, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION, INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [6] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH STUB1; VCP AND CHRNA3, AND RP INTERACTION WITH CHRNA3. RX PubMed=26265139; DOI=10.1016/j.bcp.2015.08.084; RA Teng Y., Rezvani K., De Biasi M.; RT "UBXN2A regulates nicotinic receptor degradation by modulating the E3 RT ligase activity of CHIP."; RL Biochem. Pharmacol. 97:518-530(2015). RN [7] RP FUNCTION, AND INTERACTION WITH HSPA9. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [8] RP FUNCTION, INTERACTION WITH RICTOR, AND TISSUE SPECIFICITY. RX PubMed=37037900; DOI=10.1038/s41388-023-02686-7; RA Sane S., Srinivasan R., Potts R.A., Eikanger M., Zagirova D., Freeling J., RA Reihe C.A., Antony R.M., Gupta B.K., Lynch D., Bleeker J., Turaihi H., RA Pillatzki A., Zhou W., Luo X., Linnebacher M., Agany D., Zohim E.G., RA Humphrey L.E., Black A.R., Rezvani K.; RT "UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established RT tumorigenic pathway in human colorectal cancer."; RL Oncogene 42:1763-1776(2023). CC -!- FUNCTION: Acts to repress the ubiquitination and subsequent endoplasmic CC reticulum-associated degradation of CHRNA3 by the STUB1-VCP-UBXN2A CC complex in cortical neurons (PubMed:26265139). Also acts to promote the CC translocation of CHRNA3 to the plasma membrane and subsequently CC increases plasma membrane acetylcholine-gated ion-channel activation CC (By similarity). Plays a role in the inhibition of STUB1-mediated TP53 CC degradation, via its interaction with HSPA9 which acts to inhibit TP53 CC binding to HSPA9 (PubMed:24625977, PubMed:26634371). Positively CC mediates the ubiquitination and proteosomal degradation of RICTOR, may CC thereby act as a negative regulator of the mTORC2 pathway CC (PubMed:37037900). {ECO:0000250|UniProtKB:Q99KJ0, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:26265139, CC ECO:0000269|PubMed:26634371, ECO:0000269|PubMed:37037900}. CC -!- SUBUNIT: Part of a complex composed of STUB1/CHIP, VCP/p97, CHRNA3, and CC UBXN2A that modulates the ubiquitination and endoplasmic reticulum- CC associated degradation (ERAD) of CHRNA3 (PubMed:26265139). Within the CC complex UBXN2A acts as a scaffold protein required for the interaction CC of CHRNA3 with VCP/p97, this interaction also inhibits CHRNA3 CC ubiquitination by STUB1/CHIP and subsequently ERAD (PubMed:26265139). CC Interacts (via SEP domain) with CHRNA3 and interacts (via UBX domain) CC with VCP/P97; these interactions are required for the interaction of CC CHRNA3 with the STUB1-VCP-UBXN2A complex (PubMed:26265139). Interacts CC with HSPA9/MOT-2 (via SBD domain); the interaction inhibits HSPA9/MOT-2 CC interaction with and degradation of p53, thereby promotes p53 CC translocation to the nucleus (PubMed:24625977, PubMed:26634371). CC Interacts with RICTOR (PubMed:37037900). {ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26265139, ECO:0000269|PubMed:26634371, CC ECO:0000269|PubMed:37037900}. CC -!- INTERACTION: CC P68543; Q96IM9: DYDC2; NbExp=3; IntAct=EBI-1993668, EBI-749277; CC P68543; Q9BZV1: UBXN6; NbExp=5; IntAct=EBI-1993668, EBI-1993899; CC P68543; P55072: VCP; NbExp=20; IntAct=EBI-1993668, EBI-355164; CC -!- SUBCELLULAR LOCATION: Golgi apparatus {ECO:0000250|UniProtKB:Q99KJ0}. CC Endoplasmic reticulum {ECO:0000250|UniProtKB:Q99KJ0}. Perikaryon CC {ECO:0000250|UniProtKB:Q99KJ0}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q99KJ0}. Nucleus {ECO:0000269|PubMed:24625977}. CC Cytoplasm {ECO:0000269|PubMed:24625977}. Note=Expressed at the axon CC initial segment. {ECO:0000250|UniProtKB:Q99KJ0}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P68543-1; Sequence=Displayed; CC Name=2; CC IsoId=P68543-2; Sequence=VSP_056306; CC -!- TISSUE SPECIFICITY: Expressed in the colon (at protein level). CC {ECO:0000269|PubMed:37037900}. CC -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q99KJ0}. CC -!- MISCELLANEOUS: Acts as a tumor suppressor in cancer cells via CC stabilization of TP53 and subsequent promotion of TP53-mediated CC apoptosis (PubMed:24625977). Acts as a tumor suppressor in colorectal CC cancer by repressing cell migration, growth, tumor dedifferentiation CC and cancer stem cell populations (PubMed:37037900). May act as a CC biomarker of positive survival outcome in both colon and rectal CC adenocarcinoma patients (PubMed:37037900). CC {ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:37037900}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK291192; BAF83881.1; -; mRNA. DR EMBL; AL832079; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC066692; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC092484; AAH92484.1; -; mRNA. DR EMBL; BC093681; AAH93681.1; -; mRNA. DR EMBL; BC111997; AAI11998.1; -; mRNA. DR EMBL; BC143298; AAI43299.1; -; mRNA. DR CCDS; CCDS1704.1; -. [P68543-1] DR RefSeq; NP_859064.2; NM_181713.3. [P68543-1] DR RefSeq; XP_005264223.1; XM_005264166.6. [P68543-1] DR RefSeq; XP_005264224.1; XM_005264167.6. [P68543-1] DR RefSeq; XP_005264225.1; XM_005264168.6. [P68543-1] DR RefSeq; XP_005264226.1; XM_005264169.5. [P68543-1] DR RefSeq; XP_011530935.1; XM_011532633.4. [P68543-1] DR RefSeq; XP_047299535.1; XM_047443579.1. [P68543-1] DR RefSeq; XP_047299536.1; XM_047443580.1. [P68543-1] DR RefSeq; XP_054196839.1; XM_054340864.1. [P68543-1] DR RefSeq; XP_054196840.1; XM_054340865.1. [P68543-1] DR RefSeq; XP_054196841.1; XM_054340866.1. [P68543-1] DR RefSeq; XP_054196842.1; XM_054340867.1. [P68543-1] DR RefSeq; XP_054196843.1; XM_054340868.1. [P68543-1] DR RefSeq; XP_054196844.1; XM_054340869.1. [P68543-1] DR RefSeq; XP_054196845.1; XM_054340870.1. [P68543-1] DR AlphaFoldDB; P68543; -. DR SMR; P68543; -. DR BioGRID; 127913; 28. DR ComplexPortal; CPX-8124; VCP-UBXN2A AAA ATPase complex. DR FunCoup; P68543; 1705. DR IntAct; P68543; 19. DR MINT; P68543; -. DR STRING; 9606.ENSP00000312107; -. DR iPTMnet; P68543; -. DR PhosphoSitePlus; P68543; -. DR BioMuta; UBXN2A; -. DR DMDM; 55976658; -. DR jPOST; P68543; -. DR MassIVE; P68543; -. DR PaxDb; 9606-ENSP00000312107; -. DR PeptideAtlas; P68543; -. DR ProteomicsDB; 57542; -. [P68543-1] DR ProteomicsDB; 7186; -. DR Pumba; P68543; -. DR Antibodypedia; 58573; 98 antibodies from 18 providers. DR DNASU; 165324; -. DR Ensembl; ENST00000309033.5; ENSP00000312107.4; ENSG00000173960.15. [P68543-1] DR Ensembl; ENST00000404924.5; ENSP00000385525.1; ENSG00000173960.15. [P68543-1] DR GeneID; 165324; -. DR KEGG; hsa:165324; -. DR MANE-Select; ENST00000309033.5; ENSP00000312107.4; NM_181713.4; NP_859064.2. DR UCSC; uc002ren.4; human. [P68543-1] DR AGR; HGNC:27265; -. DR ClinPGx; PA162408375; -. DR CTD; 165324; -. DR DisGeNET; 165324; -. DR GeneCards; UBXN2A; -. DR HGNC; HGNC:27265; UBXN2A. DR HPA; ENSG00000173960; Low tissue specificity. DR OpenTargets; ENSG00000173960; -. DR VEuPathDB; HostDB:ENSG00000173960; -. DR eggNOG; KOG2086; Eukaryota. DR GeneTree; ENSGT00520000055567; -. DR HOGENOM; CLU_029402_3_1_1; -. DR InParanoid; P68543; -. DR OMA; SRCQRSC; -. DR OrthoDB; 25887at2759; -. DR PAN-GO; P68543; 8 GO annotations based on evolutionary models. DR PhylomeDB; P68543; -. DR PathwayCommons; P68543; -. DR SignaLink; P68543; -. DR Agora; ENSG00000173960; -. DR BioGRID-ORCS; 165324; 13 hits in 1151 CRISPR screens. DR ChiTaRS; UBXN2A; human. DR GenomeRNAi; 165324; -. DR Pharos; P68543; Tbio. DR PRO; PR:P68543; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P68543; protein. DR Bgee; ENSG00000173960; Expressed in buccal mucosa cell and 197 other cell types or tissues. DR GO; GO:0005801; C:cis-Golgi network; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell. DR GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell. DR GO; GO:0033130; F:acetylcholine receptor binding; IEA:Ensembl. DR GO; GO:0043130; F:ubiquitin binding; IBA:GO_Central. DR GO; GO:0000045; P:autophagosome assembly; IBA:GO_Central. DR GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl. DR GO; GO:0007030; P:Golgi organization; IBA:GO_Central. DR GO; GO:0061025; P:membrane fusion; IBA:GO_Central. DR GO; GO:1904293; P:negative regulation of ERAD pathway; IMP:UniProtKB. DR GO; GO:0045861; P:negative regulation of proteolysis; IMP:UniProtKB. DR GO; GO:0031468; P:nuclear membrane reassembly; IBA:GO_Central. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:UniProtKB. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central. DR GO; GO:0031396; P:regulation of protein ubiquitination; IEA:Ensembl. DR CDD; cd17160; UBX_UBXN2A; 1. DR FunFam; 3.10.20.90:FF:000164; UBX domain-containing protein 2A; 1. DR FunFam; 3.30.420.210:FF:000004; UBX domain-containing protein 2A; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.420.210; SEP domain; 1. DR InterPro; IPR036241; NSFL1C_SEP_dom_sf. DR InterPro; IPR012989; SEP_domain. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR InterPro; IPR001012; UBX_dom. DR PANTHER; PTHR23333; UBX DOMAIN CONTAINING PROTEIN; 1. DR PANTHER; PTHR23333:SF16; UBX DOMAIN-CONTAINING PROTEIN 2A; 1. DR Pfam; PF08059; SEP; 1. DR Pfam; PF00789; UBX; 1. DR SMART; SM00553; SEP; 1. DR SMART; SM00166; UBX; 1. DR SUPFAM; SSF102848; NSFL1 (p97 ATPase) cofactor p47, SEP domain; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS51399; SEP; 1. DR PROSITE; PS50033; UBX; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell projection; Cytoplasm; Endoplasmic reticulum; KW Golgi apparatus; Nucleus; Proteomics identification; Reference proteome; KW Ubl conjugation. FT CHAIN 1..259 FT /note="UBX domain-containing protein 2A" FT /id="PRO_0000211031" FT DOMAIN 60..124 FT /note="SEP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00732" FT DOMAIN 169..246 FT /note="UBX" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00215" FT REGION 1..164 FT /note="Required for inhibition of CHRNA3 ubiquitination and FT translocation of CHRNA3 to the plasma membrane resulting in FT an increase in acetylcholine-gated nicotinic acetylcholine FT receptor currents" FT /evidence="ECO:0000250|UniProtKB:Q99KJ0" FT REGION 1..151 FT /note="Required for interaction with CHRNA3" FT /evidence="ECO:0000269|PubMed:26265139" FT REGION 167..259 FT /note="Required for interaction with VCP" FT /evidence="ECO:0000269|PubMed:26265139" FT VAR_SEQ 142..194 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_056306" SQ SEQUENCE 259 AA; 29278 MW; 4B2CD68375A0BABD CRC64; MKDVDNLKSI KEEWVCETGS DNQPLGNNQQ SNCEYFVDSL FEEAQKVSSK CVSPAEQKKQ VDVNIKLWKN GFTVNDDFRS YSDGASQQFL NSIKKGELPS ELQGIFDKEE VDVKVEDKKN EICLSTKPVF QPFSGQGHRL GSATPKIVSK AKNIEVENKN NLSAVPLNNL EPITNIQIWL ANGKRIVQKF NITHRVSHIK DFIEKYQGSQ RSPPFSLATA LPVLRLLDET LTLEEADLQN AVIIQRLQKT ASFRELSEH // ID UFO_HUMAN Reviewed; 894 AA. AC P30530; Q8N5L2; Q9UD27; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 4. DT 28-JAN-2026, entry version 241. DE RecName: Full=Tyrosine-protein kinase receptor UFO; DE EC=2.7.10.1 {ECO:0000269|PubMed:28076778}; DE AltName: Full=AXL oncogene; DE Flags: Precursor; GN Name=AXL; Synonyms=UFO; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA. RC TISSUE=Fibroblast; RX PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991; RA O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., RA Espinosa R., le Beau M.M., Earp H., Liu E.T.; RT "AXL, a transforming gene isolated from primary human myeloid leukemia RT cells, encodes a novel receptor tyrosine kinase."; RL Mol. Cell. Biol. 11:5016-5031(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RX PubMed=1834974; RA Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M., RA Strehl S., Ambros P., Bartram C.R.; RT "A novel putative tyrosine kinase receptor with oncogenic potential."; RL Oncogene 6:2113-2120(1991). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 674-730. RX PubMed=8247543; RA Lee S.-T., Strunk K.M., Spritz R.A.; RT "A survey of protein tyrosine kinase mRNAs expressed in normal human RT melanocytes."; RL Oncogene 8:3403-3410(1993). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Colon tumor; RX PubMed=7896447; DOI=10.1002/ijc.2910600611; RA Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S., RA Varnum B., Liu E.T., Cance W.G.; RT "Receptor tyrosine kinases expressed in metastatic colon cancer."; RL Int. J. Cancer 60:791-797(1995). RN [8] RP INTERACTION WITH LIGAND GAS6. RX PubMed=7854420; DOI=10.1038/373623a0; RA Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W., RA Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L., RA Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.; RT "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein RT encoded by growth-arrest-specific gene 6."; RL Nature 373:623-626(1995). RN [9] RP INTERACTION WITH GAS6, AND ACTIVITY REGULATION. RX PubMed=8621659; DOI=10.1074/jbc.271.16.9785; RA Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.; RT "Characterization of Gas6, a member of the superfamily of G domain- RT containing proteins, as a ligand for Rse and Axl."; RL J. Biol. Chem. 271:9785-9789(1996). RN [10] RP PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2; RP LCK; PIK3R1; PIK3R2 AND PLCG1. RX PubMed=9178760; DOI=10.1038/sj.onc.1201123; RA Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R., RA Ullrich A., Bartram C.R., Janssen J.W.; RT "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is RT mediated mainly by a multi-substrate docking-site."; RL Oncogene 14:2619-2631(1997). RN [11] RP ROLE IN PROSTATIC CARCINOMA. RX PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x; RA Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N., RA Prashar Y., Kandpal R.P.; RT "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a RT modified differential display PCR are overexpressed in metastatic prostatic RT carcinoma cell line DU145."; RL Cancer Detect. Prev. 23:325-332(1999). RN [12] RP ROLE IN BREAST CANCER. RX PubMed=11484958; DOI=10.1023/a:1011126330233; RA Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E., RA Andres A.C.; RT "Estrogen dependent expression of the receptor tyrosine kinase axl in RT normal and malignant human breast."; RL Ann. Oncol. 12:819-824(2001). RN [13] RP INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2. RX PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3; RA Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.; RT "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 RT domain-containing protein with homology to tensin."; RL Biochem. Biophys. Res. Commun. 299:793-800(2002). RN [14] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9; RA D'Arcangelo D., Gaetano C., Capogrossi M.C.; RT "Acidification prevents endothelial cell apoptosis by Axl activation."; RL Circ. Res. 91:E4-12(2002). RN [15] RP ROLE IN THYROID CARCINOMAS. RX PubMed=12490074; DOI=10.1089/105072502320908303; RA Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N., RA Demedchik E.P., Sekine I., Yamashita S.; RT "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in RT pediatric thyroid carcinomas around Chernobyl."; RL Thyroid 12:971-975(2002). RN [16] RP INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION. RX PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086; RA Valverde P.; RT "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and RT downregulation."; RL Biochem. Biophys. Res. Commun. 333:180-185(2005). RN [17] RP ACTIVITY REGULATION, AND FUNCTION. RX PubMed=15507525; DOI=10.1182/blood-2004-04-1469; RA Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., RA Avanzi G.C., Bussolino F.; RT "Inhibition of vascular endothelial growth factor receptor 2-mediated RT endothelial cell activation by Axl tyrosine kinase receptor."; RL Blood 105:1970-1976(2005). RN [18] RP FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION. RX PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x; RA Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J., RA Peterson J.T., Perrin L.A.; RT "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate RT thrombotic responses."; RL J. Thromb. Haemost. 3:733-741(2005). RN [19] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=17005688; DOI=10.1128/jvi.01157-06; RA Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., RA Jones S., Feldmann H., Kawaoka Y.; RT "Tyro3 family-mediated cell entry of Ebola and Marburg viruses."; RL J. Virol. 80:10109-10116(2006). RN [20] RP INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779; RP TYR-821 AND TYR-866. RX PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x; RA Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.; RT "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; RT in vitro mutagenesis defines the requisite binding sites for downstream Akt RT activation."; RL J. Neurochem. 106:134-146(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=18840707; DOI=10.1182/blood-2008-05-157073; RA Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.; RT "The Axl/Gas6 pathway is required for optimal cytokine signaling during RT human natural killer cell development."; RL Blood 113:2470-2477(2009). RN [23] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [24] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21501828; DOI=10.1016/j.chom.2011.03.012; RA Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.; RT "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine RT to the TAM receptor tyrosine kinase Axl to mediate viral entry."; RL Cell Host Microbe 9:286-298(2011). RN [25] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22156524; DOI=10.1128/jvi.06451-11; RA Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.; RT "Identification of cell surface molecules involved in dystroglycan- RT independent Lassa virus cell entry."; RL J. Virol. 86:2067-2078(2012). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22673088; DOI=10.1292/jvms.12-0176; RA Shimojima M., Kawaoka Y.; RT "Cell surface molecules involved in infection mediated by lymphocytic RT choriomeningitis virus glycoprotein."; RL J. Vet. Med. Sci. 74:1363-1366(2012). RN [27] RP FUNCTION (MICROBIAL INFECTION), AND REVIEW. RX PubMed=25277499; DOI=10.1016/j.virol.2014.09.009; RA Moller-Tank S., Maury W.; RT "Phosphatidylserine receptors: enhancers of enveloped virus entry and RT infection."; RL Virology 468:565-580(2014). RN [28] RP FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY, RP AND SUBCELLULAR LOCATION. RX PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045; RA Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L., RA Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A., RA Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R., RA Gressens P., Schwartz O., Amara A.; RT "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate RT Immune Responses."; RL Cell Rep. 18:324-333(2017). RN [29] RP INDUCTION BY MOSQUITO LYMPHOTOXIN BETA RECEPTOR INHIBITOR DURING ZIKA VIRUS RP INFECTION (MICROBIAL INFECTION). RX PubMed=29507355; DOI=10.1038/s41590-018-0063-9; RA Jin L., Guo X., Shen C., Hao X., Sun P., Li P., Xu T., Hu C., Rose O., RA Zhou H., Yang M., Qin C.F., Guo J., Peng H., Zhu M., Cheng G., Qi X., RA Lai R.; RT "Salivary factor LTRIN from Aedes aegypti facilitates the transmission of RT Zika virus by interfering with the lymphotoxin-beta receptor."; RL Nat. Immunol. 19:342-353(2018). RN [30] RP FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=29379210; DOI=10.1038/s41564-017-0092-4; RA Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R., RA Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.; RT "AXL promotes Zika virus infection in astrocytes by antagonizing type I RT interferon signalling."; RL Nat. Microbiol. 3:302-309(2018). RN [31] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=31311882; DOI=10.1128/mbio.01372-19; RA Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C., RA Sadri-Ardekani H., Shi P.Y., Verma S.; RT "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human RT Sertoli Cells."; RL MBio 10:0-0(2019). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6, RP MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT. RX PubMed=16362042; DOI=10.1038/sj.emboj.7600912; RA Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A., RA Timpl R., Hohenester E.; RT "Structural basis for Gas6-Axl signalling."; RL EMBO J. 25:80-87(2006). RN [33] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding growth factor GAS6 CC and which is thus regulating many physiological processes including CC cell survival, cell proliferation, migration and differentiation. CC Ligand binding at the cell surface induces dimerization and CC autophosphorylation of AXL. Following activation by ligand, AXL binds CC and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, CC PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other CC downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. CC Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory CC subunits by AXL leads to the downstream activation of the AKT kinase. CC GAS6/AXL signaling plays a role in various processes such as CC endothelial cell survival during acidification by preventing apoptosis, CC optimal cytokine signaling during human natural killer cell CC development, hepatic regeneration, gonadotropin-releasing hormone CC neuron survival and migration, platelet activation, or regulation of CC thrombotic responses. Also plays an important role in inhibition of CC Toll-like receptors (TLRs)-mediated innate immune response. CC {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, CC ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, CC ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, CC ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and CC lymphocytic choriomeningitis virus, possibly through GAS6 binding to CC phosphatidyl-serine at the surface of virion envelope. CC {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, CC ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, CC possibly through GAS6 binding to phosphatidyl-serine at the surface of CC virion envelope. {ECO:0000269|PubMed:22673088}. CC -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial CC cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, CC PubMed:31311882). Additionally, Zika virus potentiates AXL kinase CC activity to antagonize type I interferon signaling and thereby promotes CC infection (PubMed:28076778). Interferon signaling inhibition occurs via CC an SOCS1-dependent mechanism (PubMed:29379210). CC {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, CC ECO:0000269|PubMed:31311882}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:28076778}; CC -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent CC autophosphorylation. {ECO:0000269|PubMed:15507525, CC ECO:0000269|PubMed:8621659}. CC -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts CC with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and CC TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2 CC promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648, CC ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042, CC ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557, CC ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659, CC ECO:0000269|PubMed:9178760}. CC -!- INTERACTION: CC P30530; P00533: EGFR; NbExp=5; IntAct=EBI-2850927, EBI-297353; CC P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104; CC P30530; Q14393-2: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-21517417; CC P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755; CC P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572; CC P30530; Q01638: IL1RL1; NbExp=2; IntAct=EBI-2850927, EBI-993762; CC P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464; CC P30530; O43791: SPOP; NbExp=5; IntAct=EBI-2850927, EBI-743549; CC P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778, CC ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:7896447}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; CC IsoId=P30530-1; Sequence=Displayed; CC Name=Short; CC IsoId=P30530-2; Sequence=VSP_005017; CC -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors. CC Expressed in primary colon tumors. Weakly expressed in normal colon CC tissue. {ECO:0000269|PubMed:7896447}. CC -!- INDUCTION: (Microbial infection) Up-regulated by Aedes aegypti CC lymphotoxin beta receptor inhibitor during Zika virus infection. CC {ECO:0000269|PubMed:29507355}. CC -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of CC the receptor could be subjected to polyubiquitination in a very CC transient fashion. {ECO:0000269|PubMed:15958209}. CC -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which CC activates kinase activity. {ECO:0000269|PubMed:18346204, CC ECO:0000269|PubMed:9178760}. CC -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid CC carcinoma tissues, and might thus be involved in thyroid tumorigenesis. CC Overexpression of AXL and its ligand was also detected in many other CC cancers such as myeloproliferative disorders, prostatic carcinoma CC cells, or breast cancer. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/733/AXL"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M76125; AAA61243.1; -; mRNA. DR EMBL; S65125; AAB20305.1; -; mRNA. DR EMBL; X57019; CAA40338.1; -; mRNA. DR EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032229; AAH32229.1; -; mRNA. DR CCDS; CCDS12574.1; -. [P30530-2] DR CCDS; CCDS12575.1; -. [P30530-1] DR PIR; A41527; A41527. DR RefSeq; NP_001690.2; NM_001699.5. [P30530-2] DR RefSeq; NP_068713.2; NM_021913.4. [P30530-1] DR PDB; 2C5D; X-ray; 3.30 A; C/D=33-227. DR PDB; 4RA0; X-ray; 3.07 A; C/D=33-227. DR PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818. DR PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135. DR PDBsum; 2C5D; -. DR PDBsum; 4RA0; -. DR PDBsum; 5U6B; -. DR PDBsum; 5VXZ; -. DR AlphaFoldDB; P30530; -. DR SMR; P30530; -. DR BioGRID; 107036; 404. DR CORUM; P30530; -. DR FunCoup; P30530; 354. DR IntAct; P30530; 298. DR MINT; P30530; -. DR STRING; 9606.ENSP00000301178; -. DR BindingDB; P30530; -. DR ChEMBL; CHEMBL4895; -. DR DrugBank; DB12411; Bemcentinib. DR DrugBank; DB15187; Dubermatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12141; Gilteritinib. DR DrugBank; DB19201; Tamnorzatinib. DR DrugCentral; P30530; -. DR GuidetoPHARMACOLOGY; 1835; -. DR GlyConnect; 1983; 12 N-Linked glycans (4 sites). DR GlyCosmos; P30530; 8 sites, 12 glycans. DR GlyGen; P30530; 10 sites, 13 N-linked glycans (4 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P30530; -. DR PhosphoSitePlus; P30530; -. DR BioMuta; AXL; -. DR DMDM; 239938818; -. DR CPTAC; CPTAC-1766; -. DR CPTAC; CPTAC-2791; -. DR jPOST; P30530; -. DR MassIVE; P30530; -. DR PaxDb; 9606-ENSP00000301178; -. DR PeptideAtlas; P30530; -. DR ProteomicsDB; 54712; -. [P30530-1] DR ProteomicsDB; 54713; -. [P30530-2] DR Pumba; P30530; -. DR ABCD; P30530; 23 sequenced antibodies. DR Antibodypedia; 30709; 1302 antibodies from 46 providers. DR CPTC; P30530; 2 antibodies. DR DNASU; 558; -. DR Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.13. [P30530-1] DR Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.13. [P30530-2] DR GeneID; 558; -. DR KEGG; hsa:558; -. DR MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2. DR UCSC; uc010ehj.5; human. [P30530-1] DR AGR; HGNC:905; -. DR CIViC; 558; 1 evidence item across 1 molecular profile. DR ClinPGx; PA25197; -. DR CTD; 558; -. DR DisGeNET; 558; -. DR GeneCards; AXL; -. DR GeneReviews; AXL; -. DR HGNC; HGNC:905; AXL. DR HPA; ENSG00000167601; Low tissue specificity. DR MalaCards; AXL; -. DR MIM; 109135; gene. DR OpenTargets; ENSG00000167601; -. DR VEuPathDB; HostDB:ENSG00000167601; -. DR eggNOG; ENOG502QQQ3; Eukaryota. DR GeneTree; ENSGT00940000160232; -. DR InParanoid; P30530; -. DR OMA; WTIMSTL; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P30530; 13 GO annotations based on evolutionary models. DR PhylomeDB; P30530; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P30530; -. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR SignaLink; P30530; -. DR SIGNOR; P30530; -. DR Agora; ENSG00000167601; -. DR BioGRID-ORCS; 558; 17 hits in 1198 CRISPR screens. DR ChiTaRS; AXL; human. DR EvolutionaryTrace; P30530; -. DR GeneWiki; AXL_receptor_tyrosine_kinase; -. DR GenomeRNAi; 558; -. DR Pharos; P30530; Tchem. DR PRO; PR:P30530; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P30530; protein. DR Bgee; ENSG00000167601; Expressed in synovial joint and 206 other cell types or tissues. DR ExpressionAtlas; P30530; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IDA:FlyBase. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEP:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB. DR GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB. DR GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB. DR GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl. DR GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl. DR GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl. DR GO; GO:0042698; P:ovulation cycle; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IDA:UniProtKB. DR GO; GO:0030168; P:platelet activation; IBA:GO_Central. DR GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO. DR GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase. DR GO; GO:0032940; P:secretion by cell; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:CACAO. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome. DR CDD; cd00063; FN3; 2. DR CDD; cd20966; IgI_1_Axl_like; 1. DR CDD; cd05749; IgI_2_Axl_Tyro3_like; 1. DR CDD; cd05075; PTKc_Axl; 1. DR FunFam; 2.60.40.10:FF:000865; AXL receptor tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:000089; Tyrosine-protein kinase receptor TYRO3; 1. DR FunFam; 2.60.40.10:FF:000662; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000810; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 3.30.200.20:FF:000509; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000696; tyrosine-protein kinase receptor UFO isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF323; TYROSINE-PROTEIN KINASE RECEPTOR UFO; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Differentiation; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Immunity; KW Immunoglobulin domain; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Oncogene; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..894 FT /note="Tyrosine-protein kinase receptor UFO" FT /id="PRO_0000024481" FT TOPO_DOM 26..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 452..472 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 473..894 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..128 FT /note="Ig-like C2-type 1" FT DOMAIN 139..222 FT /note="Ig-like C2-type 2" FT DOMAIN 227..331 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 336..428 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 536..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 26..92 FT /note="Interaction with GAS6" FT REGION 823..853 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 672 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 542..550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 821 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 866 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 884 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 339 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 401 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 56..117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 160..205 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 429..437 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1656220" FT /id="VSP_005017" FT VARIANT 112 FT /note="T -> M (in dbSNP:rs35202236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045596" FT VARIANT 266 FT /note="D -> N (in dbSNP:rs7249222)" FT /id="VAR_057990" FT VARIANT 295 FT /note="R -> W (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs751738506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045597" FT VARIANT 499 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs747576071)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041877" FT VARIANT 515 FT /note="S -> G (in dbSNP:rs1240393707)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041878" FT MUTAGEN 63 FT /note="E->R: Slightly reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 66 FT /note="E->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 84 FT /note="T->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 567 FT /note="K->M: Catalytically inactive mutant." FT /evidence="ECO:0000269|PubMed:28076778" FT CONFLICT 303 FT /note="T -> P (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 338 FT /note="E -> K (in Ref. 2; AAA61243)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="Q -> E (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 696 FT /note="K -> I (in Ref. 7; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 764 FT /note="Q -> R (in Ref. 5; AAH32229)" FT /evidence="ECO:0000305" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 44..46 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 52..63 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 68..71 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 80..87 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 94..106 FT /evidence="ECO:0007829|PDB:5VXZ" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 156..159 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 178..187 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 190..194 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 219..223 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 536..544 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 546..556 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 558..571 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 576..590 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 602..605 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 628..637 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 638..640 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 646..665 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 678..680 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 686..688 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 713..715 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 718..723 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 728..743 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 755..763 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 796..809 FT /evidence="ECO:0007829|PDB:5U6B" SQ SEQUENCE 894 AA; 98337 MW; 262D3659218E3202 CRC64; MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA // ID WWOX_HUMAN Reviewed; 414 AA. AC Q9NZC7; A8K323; Q5MYT5; Q96KM3; Q96RF2; Q9BTT8; Q9NPC9; Q9NRF4; Q9NRF5; AC Q9NRF6; Q9NRK1; Q9NZC5; DT 22-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 210. DE RecName: Full=WW domain-containing oxidoreductase; DE EC=1.1.1.-; DE AltName: Full=Fragile site FRA16D oxidoreductase; DE AltName: Full=Short chain dehydrogenase/reductase family 41C member 1; GN Name=WWOX; Synonyms=FOR, SDR41C1, WOX1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [GENOMIC DNA] RP OF 1-35, AND TISSUE SPECIFICITY. RC TISSUE=Placenta; RX PubMed=10786676; RA Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., Aldaz C.M.; RT "WWOX, a novel WW domain-containing protein mapping to human chromosome RT 16q23.3-24.1, a region frequently affected in breast cancer."; RL Cancer Res. 60:2140-2145(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 173-414, AND CHROMOSOMAL REARRANGEMENT. RX PubMed=10861292; DOI=10.1093/hmg/9.11.1651; RA Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., RA Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., RA Richards R.I.; RT "Common chromosomal fragile site FRA16D sequence: identification of the FOR RT gene spanning FRA16D and homozygous deletions and translocation breakpoints RT in cancer cells."; RL Hum. Mol. Genet. 9:1651-1663(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=11719429; RA Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., RA Bergsagel P.L., Kiguchi K., Brenner A.J., Aldaz C.M.; RT "WWOX, the FRA16D gene, behaves as a suppressor of tumor growth."; RL Cancer Res. 61:8068-8073(2001). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 3 AND RP 7), VARIANTS LEU-98; SER-111; TRP-120; THR-179; PHE-272; ALA-282 AND RP HIS-314, AND INVOLVEMENT IN CANCERS. RX PubMed=11572989; DOI=10.1073/pnas.191175898; RA Paige A.J.W., Taylor K.J., Taylor C., Hillier S.G., Farrington S., RA Scott D., Porteous D.J., Smyth J.F., Gabra H., Watson J.E.V.; RT "WWOX: a candidate tumor suppressor gene involved in multiple tumor RT types."; RL Proc. Natl. Acad. Sci. U.S.A. 98:11417-11422(2001). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-179. RC TISSUE=Colon adenocarcinoma; RA Chang N.-S.; RT "Cloning of human WOX8 (WWOX v8)."; RL Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=14695174; RA Watanabe A., Hippo Y., Taniguchi H., Iwanari H., Yashiro M., Hirakawa K., RA Kodama T., Aburatani H.; RT "An opposing view on WWOX protein function as a tumor suppressor."; RL Cancer Res. 63:8629-8633(2003). RN [10] RP INTERACTION WITH MAPK8 AND TP53, AND MUTAGENESIS OF LYS-28; ASP-29 AND RP TYR-33. RX PubMed=12514174; DOI=10.1074/jbc.m208373200; RA Chang N.-S., Doherty J., Ensign A.; RT "JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) RT and inhibits WOX1-mediated apoptosis."; RL J. Biol. Chem. 278:9195-9202(2003). RN [11] RP INVOLVEMENT IN CANCERS. RX PubMed=15266310; DOI=10.1038/sj.bjc.6602023; RA Park S.-W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., RA Aldaz C.M.; RT "Frequent downregulation and loss of WWOX gene expression in human RT hepatocellular carcinoma."; RL Br. J. Cancer 91:753-759(2004). RN [12] RP FUNCTION, INTERACTION WITH TFAP2C AND TFAP2A, AND DOMAIN. RX PubMed=15548692; DOI=10.1158/0008-5472.can-04-2055; RA Aqeilan R.I., Palamarchuk A., Weigel R.J., Herrero J.J., Pekarsky Y., RA Croce C.M.; RT "Physical and functional interactions between the Wwox tumor suppressor RT protein and the AP-2gamma transcription factor."; RL Cancer Res. 64:8256-8261(2004). RN [13] RP INVOLVEMENT IN CANCERS. RX PubMed=15073125; DOI=10.1158/1078-0432.ccr-03-0096; RA Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., RA Rattan S., Cesari R., Nolli M.L., Williams N.N., Mori M., Kanematsu T., RA Croce C.M.; RT "The tumor suppressor gene WWOX at FRA16D is involved in pancreatic RT carcinogenesis."; RL Clin. Cancer Res. 10:2459-2465(2004). RN [14] RP INVOLVEMENT IN CANCERS. RX PubMed=15131042; DOI=10.1158/1078-0432.ccr-03-0594; RA Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., RA Huebner K., Edmonds P., Croce C.M.; RT "Loss of WWOX expression in gastric carcinoma."; RL Clin. Cancer Res. 10:3053-3058(2004). RN [15] RP INTERACTION WITH LITAF; WBP1; FAM189B AND SCOTIN, MUTAGENESIS OF RP 44-TRP--PRO-47 AND 85-TYR--PRO-88, DOMAIN, AND SUBCELLULAR LOCATION. RX PubMed=15064722; DOI=10.1038/sj.onc.1207680; RA Ludes-Meyers J.H., Kil H., Bednarek A.K., Drake J., Bedford M.T., RA Aldaz C.M.; RT "WWOX binds the specific proline-rich ligand PPXY: identification of RT candidate interacting proteins."; RL Oncogene 23:5049-5055(2004). RN [16] RP FUNCTION, INTERACTION WITH TP73, DOMAIN, MUTAGENESIS OF TYR-33 AND TYR-61, RP PHOSPHORYLATION AT TYR-33, AND SUBCELLULAR LOCATION. RX PubMed=15070730; DOI=10.1073/pnas.0400805101; RA Aqeilan R.I., Pekarsky Y., Herrero J.J., Palamarchuk A., Letofsky J., RA Druck T., Trapasso F., Han S.-Y., Melino G., Huebner K., Croce C.M.; RT "Functional association between Wwox tumor suppressor protein and p73, a RT p53 homolog."; RL Proc. Natl. Acad. Sci. U.S.A. 101:4401-4406(2004). RN [17] RP FUNCTION, AND INTERACTION WITH ERBB4. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [18] RP PHOSPHORYLATION AT TYR-287 BY TNK2, UBIQUITINATION, MUTAGENESIS OF TYR-287, RP AND INTERACTION WITH TNK2. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [19] RP FUNCTION, INTERACTION WITH MDM2 AND TP53, PHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [20] RP DISEASE. RX PubMed=16223882; DOI=10.1073/pnas.0505485102; RA Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., RA Yendamuri S., Han S.-Y., Amadori D., Huebner K., Croce C.M.; RT "WWOX gene restoration prevents lung cancer growth in vitro and in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15611-15616(2005). RN [21] RP FUNCTION, PHOSPHORYLATION AT TYR-33, SUBCELLULAR LOCATION, AND INTERACTION RP WITH HYAL2. RX PubMed=19366691; DOI=10.1074/jbc.m806688200; RA Hsu L.-J., Schultz L., Hong Q., Van Moer K., Heath J., Li M.-Y., Lai F.-J., RA Lin S.-R., Lee M.-H., Lo C.-P., Lin Y.-S., Chen S.-T., Chang N.-S.; RT "Transforming growth factor beta1 signaling via interaction with cell RT surface Hyal-2 and recruitment of WWOX/WOX1."; RL J. Biol. Chem. 284:16049-16059(2009). RN [22] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DVL1; DVL2 AND DVL3. RX PubMed=19465938; DOI=10.1038/onc.2009.120; RA Bouteille N., Driouch K., Hage P.E., Sin S., Formstecher E., Camonis J., RA Lidereau R., Lallemand F.; RT "Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor RT protein."; RL Oncogene 28:2569-2580(2009). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-12 AND SER-14, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH TMEM207. RX PubMed=22226915; DOI=10.1093/carcin/bgs001; RA Takeuchi T., Adachi Y., Nagayama T.; RT "A WWOX-binding molecule, transmembrane protein 207, is related to the RT invasiveness of gastric signet-ring cell carcinoma."; RL Carcinogenesis 33:548-554(2012). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION, INTERACTION WITH VOPP1, AND MUTAGENESIS OF TYR-33. RX PubMed=30285739; DOI=10.1186/s12915-018-0576-6; RA Bonin F., Taouis K., Azorin P., Petitalot A., Tariq Z., Nola S., RA Bouteille N., Tury S., Vacher S., Bieche I., Rais K.A., Pierron G., RA Fuhrmann L., Vincent-Salomon A., Formstecher E., Camonis J., Lidereau R., RA Lallemand F., Driouch K.; RT "VOPP1 promotes breast tumorigenesis by interacting with the tumor RT suppressor WWOX."; RL BMC Biol. 16:109-109(2018). RN [27] RP INVOLVEMENT IN SCAR12. RX PubMed=24456803; DOI=10.1186/1750-1172-9-12; RA Abdel-Salam G., Thoenes M., Afifi H.H., Koerber F., Swan D., Bolz H.J.; RT "The supposed tumor suppressor gene WWOX is mutated in an early lethal RT microcephaly syndrome with epilepsy, growth retardation and retinal RT degeneration."; RL Orphanet J. Rare Dis. 9:12-12(2014). RN [28] RP INVOLVEMENT IN DEE28, AND VARIANT DEE28 ARG-47. RX PubMed=25411445; DOI=10.1136/jmedgenet-2014-102748; RA Mignot C., Lambert L., Pasquier L., Bienvenu T., Delahaye-Duriez A., RA Keren B., Lefranc J., Saunier A., Allou L., Roth V., Valduga M., RA Moustaine A., Auvin S., Barrey C., Chantot-Bastaraud S., Lebrun N., RA Moutard M.L., Nougues M.C., Vermersch A.I., Heron B., Pipiras E., Heron D., RA Olivier-Faivre L., Gueant J.L., Jonveaux P., Philippe C.; RT "WWOX-related encephalopathies: delineation of the phenotypical spectrum RT and emerging genotype-phenotype correlation."; RL J. Med. Genet. 52:61-70(2015). RN [29] RP STRUCTURE BY NMR OF 51-101. RA Kowalski K., Merkel A.L., Colella A., Richards R.I., Booker G.W.; RT "Solution structure of the second WW domain of WWOX."; RL Submitted (FEB-2009) to the PDB data bank. RN [30] RP VARIANT PRO-291, AND INVOLVEMENT IN ESCR. RX PubMed=11956080; RA Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M., RA Croce C.M.; RT "Genetic alterations of the tumor suppressor gene WWOX in esophageal RT squamous cell carcinoma."; RL Cancer Res. 62:2258-2260(2002). RN [31] RP VARIANTS SCAR12 THR-47 AND ARG-372. RX PubMed=24369382; DOI=10.1093/brain/awt338; RA Mallaret M., Synofzik M., Lee J., Sagum C.A., Mahajnah M., Sharkia R., RA Drouot N., Renaud M., Klein F.A., Anheim M., Tranchant C., Mignot C., RA Mandel J.L., Bedford M., Bauer P., Salih M.A., Schuele R., Schoels L., RA Aldaz C.M., Koenig M.; RT "The tumour suppressor gene WWOX is mutated in autosomal recessive RT cerebellar ataxia with epilepsy and mental retardation."; RL Brain 137:411-419(2014). CC -!- FUNCTION: Putative oxidoreductase. Acts as a tumor suppressor and plays CC a role in apoptosis. Required for normal bone development (By CC similarity). May function synergistically with p53/TP53 to control CC genotoxic stress-induced cell death. Plays a role in TGFB1 signaling CC and TGFB1-mediated cell death. May also play a role in tumor necrosis CC factor (TNF)-mediated cell death. Inhibits Wnt signaling, probably by CC sequestering DVL2 in the cytoplasm. {ECO:0000250, CC ECO:0000269|PubMed:11719429, ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:15548692, ECO:0000269|PubMed:16061658, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:19366691, CC ECO:0000269|PubMed:19465938}. CC -!- SUBUNIT: Interacts with TP53, p73/TP73 and MAPK8. Interacts with CC MAPT/TAU, RUNX2 and HYAL2 (By similarity). Forms a ternary complex with CC TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. Interacts with CC DVL1, DVL2 and DVL3. May interact with FAM189B and SCOTIN. Interacts CC with TNK2. Interacts with TMEM207. Interacts (via WW domain) with VOPP1 CC (PubMed:30285739). {ECO:0000250, ECO:0000269|PubMed:12514174, CC ECO:0000269|PubMed:15064722, ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:15548692, ECO:0000269|PubMed:16061658, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16288044, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938, CC ECO:0000269|PubMed:22226915, ECO:0000269|PubMed:30285739}. CC -!- INTERACTION: CC Q9NZC7; O14641: DVL2; NbExp=2; IntAct=EBI-4320739, EBI-740850; CC Q9NZC7; P81408: ENTREP3; NbExp=6; IntAct=EBI-4320739, EBI-6366314; CC Q9NZC7; Q99732: LITAF; NbExp=5; IntAct=EBI-4320739, EBI-725647; CC Q9NZC7; Q8N114: SHISA5; NbExp=2; IntAct=EBI-4320739, EBI-2115556; CC Q9NZC7; P04637: TP53; NbExp=2; IntAct=EBI-4320739, EBI-366083; CC Q9NZC7; O15350: TP73; NbExp=4; IntAct=EBI-4320739, EBI-389606; CC Q9NZC7; O15350-1: TP73; NbExp=3; IntAct=EBI-4320739, EBI-389619; CC Q9NZC7; O15350-2: TP73; NbExp=5; IntAct=EBI-4320739, EBI-389623; CC Q9NZC7; Q96AW1: VOPP1; NbExp=7; IntAct=EBI-4320739, EBI-715058; CC Q9NZC7; Q96G27: WBP1; NbExp=4; IntAct=EBI-4320739, EBI-3867685; CC Q9NZC7; Q67FY2: Bcl9l; Xeno; NbExp=3; IntAct=EBI-4320739, EBI-5234367; CC Q9NZC7; Q60838: Dvl2; Xeno; NbExp=2; IntAct=EBI-4320739, EBI-641940; CC Q9NZC7; Q61527: Erbb4; Xeno; NbExp=3; IntAct=EBI-4320739, EBI-4398741; CC Q9NZC7-5; Q8NFV4-4: ABHD11; NbExp=3; IntAct=EBI-12040603, EBI-12318443; CC Q9NZC7-5; Q9NYB9-2: ABI2; NbExp=5; IntAct=EBI-12040603, EBI-11096309; CC Q9NZC7-5; Q9BWD1: ACAT2; NbExp=3; IntAct=EBI-12040603, EBI-1047273; CC Q9NZC7-5; Q5BKX5-3: ACTMAP; NbExp=3; IntAct=EBI-12040603, EBI-11976299; CC Q9NZC7-5; Q03154: ACY1; NbExp=3; IntAct=EBI-12040603, EBI-742064; CC Q9NZC7-5; P18825: ADRA2C; NbExp=3; IntAct=EBI-12040603, EBI-12015266; CC Q9NZC7-5; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-12040603, EBI-12224467; CC Q9NZC7-5; P50995: ANXA11; NbExp=3; IntAct=EBI-12040603, EBI-715243; CC Q9NZC7-5; Q96B67: ARRDC3; NbExp=8; IntAct=EBI-12040603, EBI-2875665; CC Q9NZC7-5; Q86V38: ATN1; NbExp=3; IntAct=EBI-12040603, EBI-11954292; CC Q9NZC7-5; Q7L5A3: ATOSB; NbExp=3; IntAct=EBI-12040603, EBI-745689; CC Q9NZC7-5; Q5SWW7: C10orf55; NbExp=3; IntAct=EBI-12040603, EBI-12809220; CC Q9NZC7-5; Q6NUJ2: C11orf87; NbExp=3; IntAct=EBI-12040603, EBI-6660291; CC Q9NZC7-5; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-12040603, EBI-1104933; CC Q9NZC7-5; P40199: CEACAM6; NbExp=3; IntAct=EBI-12040603, EBI-4314501; CC Q9NZC7-5; Q8NE01: CNNM3; NbExp=3; IntAct=EBI-12040603, EBI-741032; CC Q9NZC7-5; Q16630-2: CPSF6; NbExp=3; IntAct=EBI-12040603, EBI-11088043; CC Q9NZC7-5; Q02930-3: CREB5; NbExp=3; IntAct=EBI-12040603, EBI-10192698; CC Q9NZC7-5; P02489: CRYAA; NbExp=3; IntAct=EBI-12040603, EBI-6875961; CC Q9NZC7-5; P67870: CSNK2B; NbExp=3; IntAct=EBI-12040603, EBI-348169; CC Q9NZC7-5; P78358: CTAG1B; NbExp=3; IntAct=EBI-12040603, EBI-1188472; CC Q9NZC7-5; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-12040603, EBI-751587; CC Q9NZC7-5; Q15038: DAZAP2; NbExp=6; IntAct=EBI-12040603, EBI-724310; CC Q9NZC7-5; Q9NQL9: DMRT3; NbExp=3; IntAct=EBI-12040603, EBI-9679045; CC Q9NZC7-5; G5E9A7: DMWD; NbExp=3; IntAct=EBI-12040603, EBI-10976677; CC Q9NZC7-5; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-12040603, EBI-744099; CC Q9NZC7-5; P00488: F13A1; NbExp=3; IntAct=EBI-12040603, EBI-2565863; CC Q9NZC7-5; Q8WU58: FAM222B; NbExp=5; IntAct=EBI-12040603, EBI-2807642; CC Q9NZC7-5; Q9BSK4: FEM1A; NbExp=3; IntAct=EBI-12040603, EBI-2515349; CC Q9NZC7-5; Q9NU39: FOXD4L1; NbExp=3; IntAct=EBI-12040603, EBI-11320806; CC Q9NZC7-5; Q12951-2: FOXI1; NbExp=3; IntAct=EBI-12040603, EBI-12018822; CC Q9NZC7-5; O43559: FRS3; NbExp=3; IntAct=EBI-12040603, EBI-725515; CC Q9NZC7-5; O75603: GCM2; NbExp=3; IntAct=EBI-12040603, EBI-10188645; CC Q9NZC7-5; P55040: GEM; NbExp=3; IntAct=EBI-12040603, EBI-744104; CC Q9NZC7-5; P14136: GFAP; NbExp=3; IntAct=EBI-12040603, EBI-744302; CC Q9NZC7-5; Q9BZE0: GLIS2; NbExp=3; IntAct=EBI-12040603, EBI-7251368; CC Q9NZC7-5; Q9Y223-2: GNE; NbExp=3; IntAct=EBI-12040603, EBI-11975289; CC Q9NZC7-5; P28799: GRN; NbExp=3; IntAct=EBI-12040603, EBI-747754; CC Q9NZC7-5; P49639: HOXA1; NbExp=3; IntAct=EBI-12040603, EBI-740785; CC Q9NZC7-5; P31273: HOXC8; NbExp=3; IntAct=EBI-12040603, EBI-1752118; CC Q9NZC7-5; P04792: HSPB1; NbExp=3; IntAct=EBI-12040603, EBI-352682; CC Q9NZC7-5; Q16082: HSPB2; NbExp=3; IntAct=EBI-12040603, EBI-739395; CC Q9NZC7-5; Q8IZ03: IFIT2; NbExp=3; IntAct=EBI-12040603, EBI-746217; CC Q9NZC7-5; Q0VD86: INCA1; NbExp=3; IntAct=EBI-12040603, EBI-6509505; CC Q9NZC7-5; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-12040603, EBI-1055254; CC Q9NZC7-5; Q92993: KAT5; NbExp=3; IntAct=EBI-12040603, EBI-399080; CC Q9NZC7-5; O60333-2: KIF1B; NbExp=3; IntAct=EBI-12040603, EBI-10975473; CC Q9NZC7-5; Q96G42: KLHDC7B; NbExp=3; IntAct=EBI-12040603, EBI-9478422; CC Q9NZC7-5; Q2WGJ6: KLHL38; NbExp=3; IntAct=EBI-12040603, EBI-6426443; CC Q9NZC7-5; Q92876: KLK6; NbExp=3; IntAct=EBI-12040603, EBI-2432309; CC Q9NZC7-5; P12035: KRT3; NbExp=3; IntAct=EBI-12040603, EBI-2430095; CC Q9NZC7-5; O76011: KRT34; NbExp=3; IntAct=EBI-12040603, EBI-1047093; CC Q9NZC7-5; O95678: KRT75; NbExp=3; IntAct=EBI-12040603, EBI-2949715; CC Q9NZC7-5; Q8IUC1: KRTAP11-1; NbExp=3; IntAct=EBI-12040603, EBI-1052037; CC Q9NZC7-5; Q14847-2: LASP1; NbExp=3; IntAct=EBI-12040603, EBI-9088686; CC Q9NZC7-5; Q99732: LITAF; NbExp=3; IntAct=EBI-12040603, EBI-725647; CC Q9NZC7-5; Q8TAP4-4: LMO3; NbExp=6; IntAct=EBI-12040603, EBI-11742507; CC Q9NZC7-5; Q71SY5: MED25; NbExp=3; IntAct=EBI-12040603, EBI-394558; CC Q9NZC7-5; Q13064: MKRN3; NbExp=3; IntAct=EBI-12040603, EBI-2340269; CC Q9NZC7-5; Q9HB07: MYG1; NbExp=3; IntAct=EBI-12040603, EBI-709754; CC Q9NZC7-5; Q9NP98: MYOZ1; NbExp=3; IntAct=EBI-12040603, EBI-744402; CC Q9NZC7-5; Q9NPC6: MYOZ2; NbExp=3; IntAct=EBI-12040603, EBI-746712; CC Q9NZC7-5; P19404: NDUFV2; NbExp=3; IntAct=EBI-12040603, EBI-713665; CC Q9NZC7-5; Q14511-2: NEDD9; NbExp=3; IntAct=EBI-12040603, EBI-11746523; CC Q9NZC7-5; P29474: NOS3; NbExp=3; IntAct=EBI-12040603, EBI-1391623; CC Q9NZC7-5; Q7RTU3: OLIG3; NbExp=3; IntAct=EBI-12040603, EBI-10225049; CC Q9NZC7-5; P32242: OTX1; NbExp=3; IntAct=EBI-12040603, EBI-740446; CC Q9NZC7-5; Q86TB9: PATL1; NbExp=5; IntAct=EBI-12040603, EBI-2562092; CC Q9NZC7-5; Q9HBE1-4: PATZ1; NbExp=5; IntAct=EBI-12040603, EBI-11022007; CC Q9NZC7-5; P55771: PAX9; NbExp=3; IntAct=EBI-12040603, EBI-12111000; CC Q9NZC7-5; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-12040603, EBI-10302990; CC Q9NZC7-5; Q9UBV8: PEF1; NbExp=3; IntAct=EBI-12040603, EBI-724639; CC Q9NZC7-5; Q99697-2: PITX2; NbExp=3; IntAct=EBI-12040603, EBI-12138495; CC Q9NZC7-5; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-12040603, EBI-12014286; CC Q9NZC7-5; Q9NRY6: PLSCR3; NbExp=3; IntAct=EBI-12040603, EBI-750734; CC Q9NZC7-5; P62937-2: PPIA; NbExp=3; IntAct=EBI-12040603, EBI-25884072; CC Q9NZC7-5; P23284: PPIB; NbExp=3; IntAct=EBI-12040603, EBI-359252; CC Q9NZC7-5; P17252: PRKCA; NbExp=3; IntAct=EBI-12040603, EBI-1383528; CC Q9NZC7-5; P60891: PRPS1; NbExp=3; IntAct=EBI-12040603, EBI-749195; CC Q9NZC7-5; P28062-2: PSMB8; NbExp=3; IntAct=EBI-12040603, EBI-372312; CC Q9NZC7-5; Q9BTL3: RAMAC; NbExp=3; IntAct=EBI-12040603, EBI-744023; CC Q9NZC7-5; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-12040603, EBI-396669; CC Q9NZC7-5; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-12040603, EBI-6257312; CC Q9NZC7-5; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-12040603, EBI-3957636; CC Q9NZC7-5; Q7Z5V6-2: SAXO4; NbExp=3; IntAct=EBI-12040603, EBI-12000762; CC Q9NZC7-5; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-12040603, EBI-9090795; CC Q9NZC7-5; Q9H788: SH2D4A; NbExp=5; IntAct=EBI-12040603, EBI-747035; CC Q9NZC7-5; Q92529: SHC3; NbExp=5; IntAct=EBI-12040603, EBI-79084; CC Q9NZC7-5; Q16348: SLC15A2; NbExp=3; IntAct=EBI-12040603, EBI-12806032; CC Q9NZC7-5; Q99954: SMR3A; NbExp=3; IntAct=EBI-12040603, EBI-12067698; CC Q9NZC7-5; P09234: SNRPC; NbExp=3; IntAct=EBI-12040603, EBI-766589; CC Q9NZC7-5; Q96LM6: SPMIP9; NbExp=3; IntAct=EBI-12040603, EBI-743976; CC Q9NZC7-5; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-12040603, EBI-5235340; CC Q9NZC7-5; Q9BT92: TCHP; NbExp=3; IntAct=EBI-12040603, EBI-740781; CC Q9NZC7-5; Q9BXF9: TEKT3; NbExp=3; IntAct=EBI-12040603, EBI-8644516; CC Q9NZC7-5; Q92734: TFG; NbExp=3; IntAct=EBI-12040603, EBI-357061; CC Q9NZC7-5; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-12040603, EBI-11525489; CC Q9NZC7-5; Q3SY00: TSGA10IP; NbExp=5; IntAct=EBI-12040603, EBI-10241197; CC Q9NZC7-5; Q6NVU6: UFSP1; NbExp=3; IntAct=EBI-12040603, EBI-12068150; CC Q9NZC7-5; O95231: VENTX; NbExp=5; IntAct=EBI-12040603, EBI-10191303; CC Q9NZC7-5; Q14119: VEZF1; NbExp=3; IntAct=EBI-12040603, EBI-11980193; CC Q9NZC7-5; A5D8V6: VPS37C; NbExp=3; IntAct=EBI-12040603, EBI-2559305; CC Q9NZC7-5; O76024: WFS1; NbExp=3; IntAct=EBI-12040603, EBI-720609; CC Q9NZC7-5; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-12040603, EBI-12040603; CC Q9NZC7-5; P61981: YWHAG; NbExp=3; IntAct=EBI-12040603, EBI-359832; CC Q9NZC7-5; A0A0C4DGF1: ZBTB32; NbExp=6; IntAct=EBI-12040603, EBI-10188476; CC Q9NZC7-5; Q15915: ZIC1; NbExp=3; IntAct=EBI-12040603, EBI-11963196; CC Q9NZC7-5; P52742: ZNF135; NbExp=3; IntAct=EBI-12040603, EBI-7101455; CC Q9NZC7-5; Q96IQ9: ZNF414; NbExp=3; IntAct=EBI-12040603, EBI-744257; CC Q9NZC7-5; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-12040603, EBI-745520; CC Q9NZC7-5; Q96EJ4; NbExp=3; IntAct=EBI-12040603, EBI-750454; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14695174, CC ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938}. Nucleus CC {ECO:0000269|PubMed:14695174, ECO:0000269|PubMed:15064722, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:19366691}. CC Mitochondrion {ECO:0000269|PubMed:14695174}. Golgi apparatus CC {ECO:0000269|PubMed:30285739}. Lysosome {ECO:0000269|PubMed:30285739}. CC Note=Partially localizes to the mitochondria (PubMed:14695174). CC Translocates to the nucleus upon genotoxic stress or TNF stimulation CC (By similarity). Translocates to the nucleus in response to TGFB1 CC (PubMed:19366691). Isoform 5 and isoform 6 may localize in the nucleus. CC Localized to the lysosome probably upon binding to VOPP1 CC (PubMed:30285739). {ECO:0000250, ECO:0000269|PubMed:14695174, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:30285739}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=FOR II, FOR2, WWOXv1, WWOX v8; CC IsoId=Q9NZC7-1; Sequence=Displayed; CC Name=2; Synonyms=FOR I, FOR1, WOX2, WWOXv2; CC IsoId=Q9NZC7-2; Sequence=VSP_016367, VSP_016369; CC Name=3; Synonyms=FOR III, FOR3, WOX3; CC IsoId=Q9NZC7-3; Sequence=VSP_016364, VSP_016365; CC Name=4; Synonyms=FOR IV; CC IsoId=Q9NZC7-4; Sequence=VSP_016358, VSP_016359; CC Name=5; Synonyms=WWOXdelta6-8, WWOXv4; CC IsoId=Q9NZC7-5; Sequence=VSP_016363; CC Name=6; Synonyms=WWOXdelta5-8, WWOXv3; CC IsoId=Q9NZC7-6; Sequence=VSP_016360; CC Name=7; CC IsoId=Q9NZC7-7; Sequence=VSP_016362, VSP_016366; CC -!- TISSUE SPECIFICITY: Widely expressed. Strongly expressed in testis, CC prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and CC isoform 6 may only be expressed in tumor cell lines. CC {ECO:0000269|PubMed:10786676, ECO:0000269|PubMed:11719429}. CC -!- DOMAIN: The WW 1 domain mediates interaction with TP53, and probably CC TP73, TFAP2C, LITAF and WBP1. {ECO:0000269|PubMed:15064722, CC ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:15548692}. CC -!- PTM: Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 CC regulates interaction with TP53, TP73 and MAPK8. May also regulate CC proapoptotic activity. Phosphorylation by TNK2 is associated with CC polyubiquitination and degradation. {ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:19366691}. CC -!- PTM: Ubiquitinated when phosphorylated by TNK2, leading to its CC degradation. {ECO:0000269|PubMed:16288044}. CC -!- DISEASE: Note=Defects in WWOX may be involved in several cancer types. CC The gene spans the second most common chromosomal fragile site (FRA16D) CC which is frequently altered in cancers (PubMed:10861292). Alteration of CC the expression and expression of some isoforms is associated with CC cancers. However, it is still unclear if alteration of WWOX is directly CC implicated in cancerogenesis or if it corresponds to a secondary effect CC (PubMed:10861292, PubMed:11572989, PubMed:15073125, PubMed:15131042, CC PubMed:15266310). {ECO:0000269|PubMed:10861292, CC ECO:0000269|PubMed:11572989, ECO:0000269|PubMed:15073125, CC ECO:0000269|PubMed:15131042, ECO:0000269|PubMed:15266310}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:11956080}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. CC -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 12 (SCAR12) CC [MIM:614322]: A form of spinocerebellar ataxia, a clinically and CC genetically heterogeneous group of cerebellar disorders. Patients show CC progressive incoordination of gait and often poor coordination of CC hands, speech and eye movements, due to degeneration of the cerebellum CC with variable involvement of the brainstem and spinal cord. SCAR12 is CC additionally characterized by onset of generalized seizures in infancy, CC and delayed psychomotor development with intellectual disability. Some CC patients may also show spasticity. {ECO:0000269|PubMed:24369382, CC ECO:0000269|PubMed:24456803}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Developmental and epileptic encephalopathy 28 (DEE28) CC [MIM:616211]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. {ECO:0000269|PubMed:25411445}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR) CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAP94227.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/508/WWOX"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF211943; AAF27049.1; -; mRNA. DR EMBL; AF212843; AAF27050.1; -; Genomic_DNA. DR EMBL; AH009490; AAF78197.1; -; Genomic_DNA. DR EMBL; AF227526; AAF82053.1; -; mRNA. DR EMBL; AF227527; AAF82054.1; -; mRNA. DR EMBL; AF227528; AAF82055.1; -; mRNA. DR EMBL; AF227529; AAF82056.1; -; mRNA. DR EMBL; AF395123; AAK81727.1; -; mRNA. DR EMBL; AF395124; AAK81728.1; -; mRNA. DR EMBL; AF325432; AAL05449.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325427; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325428; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325430; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325431; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325429; AAL05450.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325427; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325432; AAL05451.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325433; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AY256821; AAP94227.1; ALT_FRAME; mRNA. DR EMBL; AK290438; BAF83127.1; -; mRNA. DR EMBL; BT007445; AAP36113.1; -; mRNA. DR EMBL; BC003184; AAH03184.1; -; mRNA. DR CCDS; CCDS42196.1; -. [Q9NZC7-1] DR CCDS; CCDS42197.1; -. [Q9NZC7-3] DR RefSeq; NP_001278926.1; NM_001291997.1. DR RefSeq; NP_057457.1; NM_016373.4. [Q9NZC7-1] DR RefSeq; NP_570607.1; NM_130791.5. [Q9NZC7-3] DR PDB; 1WMV; NMR; -; A=51-101. DR PDBsum; 1WMV; -. DR AlphaFoldDB; Q9NZC7; -. DR SMR; Q9NZC7; -. DR BioGRID; 119707; 636. DR CORUM; Q9NZC7; -. DR FunCoup; Q9NZC7; 1428. DR IntAct; Q9NZC7; 194. DR MINT; Q9NZC7; -. DR STRING; 9606.ENSP00000457230; -. DR iPTMnet; Q9NZC7; -. DR PhosphoSitePlus; Q9NZC7; -. DR BioMuta; WWOX; -. DR DMDM; 74725363; -. DR jPOST; Q9NZC7; -. DR MassIVE; Q9NZC7; -. DR PaxDb; 9606-ENSP00000457230; -. DR PeptideAtlas; Q9NZC7; -. DR ProteomicsDB; 83364; -. [Q9NZC7-1] DR ProteomicsDB; 83365; -. [Q9NZC7-2] DR ProteomicsDB; 83366; -. [Q9NZC7-3] DR ProteomicsDB; 83367; -. [Q9NZC7-4] DR ProteomicsDB; 83368; -. [Q9NZC7-5] DR ProteomicsDB; 83369; -. [Q9NZC7-6] DR ProteomicsDB; 83370; -. [Q9NZC7-7] DR Pumba; Q9NZC7; -. DR Antibodypedia; 8291; 399 antibodies from 43 providers. DR DNASU; 51741; -. DR Ensembl; ENST00000355860.7; ENSP00000348119.3; ENSG00000186153.19. [Q9NZC7-3] DR Ensembl; ENST00000402655.6; ENSP00000384238.2; ENSG00000186153.19. [Q9NZC7-6] DR Ensembl; ENST00000406884.6; ENSP00000384495.2; ENSG00000186153.19. [Q9NZC7-5] DR Ensembl; ENST00000408984.7; ENSP00000386161.3; ENSG00000186153.19. [Q9NZC7-2] DR Ensembl; ENST00000566780.6; ENSP00000457230.1; ENSG00000186153.19. [Q9NZC7-1] DR Ensembl; ENST00000569818.1; ENSP00000454485.1; ENSG00000186153.19. [Q9NZC7-4] DR GeneID; 51741; -. DR KEGG; hsa:51741; -. DR MANE-Select; ENST00000566780.6; ENSP00000457230.1; NM_016373.4; NP_057457.1. DR UCSC; uc002ffi.3; human. [Q9NZC7-1] DR AGR; HGNC:12799; -. DR ClinPGx; PA37398; -. DR CTD; 51741; -. DR DisGeNET; 51741; -. DR GeneCards; WWOX; -. DR HGNC; HGNC:12799; WWOX. DR HPA; ENSG00000186153; Low tissue specificity. DR MalaCards; WWOX; -. DR MIM; 133239; phenotype. DR MIM; 605131; gene. DR MIM; 614322; phenotype. DR MIM; 616211; phenotype. DR OpenTargets; ENSG00000186153; -. DR Orphanet; 251510; 46,XY partial gonadal dysgenesis. DR Orphanet; 284282; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency. DR Orphanet; 708171; Facial dysmorphism-corpus callosum hypoplasia-infantile epileptic encephalopathy. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000186153; -. DR eggNOG; KOG1208; Eukaryota. DR GeneTree; ENSGT00940000157389; -. DR HOGENOM; CLU_010194_44_0_1; -. DR InParanoid; Q9NZC7; -. DR OMA; PPAEKYW; -. DR OrthoDB; 9989144at2759; -. DR PAN-GO; Q9NZC7; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q9NZC7; -. DR PathwayCommons; Q9NZC7; -. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-8866904; Negative regulation of activity of TFAP2 (AP-2) family transcription factors. DR Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors. DR SignaLink; Q9NZC7; -. DR SIGNOR; Q9NZC7; -. DR Agora; ENSG00000186153; -. DR BioGRID-ORCS; 51741; 12 hits in 1160 CRISPR screens. DR ChiTaRS; WWOX; human. DR EvolutionaryTrace; Q9NZC7; -. DR GeneWiki; WWOX; -. DR GenomeRNAi; 51741; -. DR Pharos; Q9NZC7; Tbio. DR PRO; PR:Q9NZC7; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q9NZC7; protein. DR Bgee; ENSG00000186153; Expressed in parotid gland and 201 other cell types or tissues. DR ExpressionAtlas; Q9NZC7; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:BHF-UCL. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; ISS:BHF-UCL. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016491; F:oxidoreductase activity; NAS:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:BHF-UCL. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL. DR GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd09809; human_WWOX_like_SDR_c-like; 1. DR CDD; cd00201; WW; 2. DR FunFam; 2.20.70.10:FF:000032; WW domain containing oxidoreductase; 1. DR FunFam; 2.20.70.10:FF:000040; WW domain containing oxidoreductase; 1. DR FunFam; 3.40.50.720:FF:000353; WW domain-containing oxidoreductase; 1. DR Gene3D; 2.20.70.10; -; 2. DR Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1. DR InterPro; IPR036291; NAD(P)-bd_dom_sf. DR InterPro; IPR002347; SDR_fam. DR InterPro; IPR001202; WW_dom. DR InterPro; IPR036020; WW_dom_sf. DR InterPro; IPR042732; WWOX_SDR_c-like. DR PANTHER; PTHR24320; RETINOL DEHYDROGENASE; 1. DR PANTHER; PTHR24320:SF282; WW DOMAIN-CONTAINING OXIDOREDUCTASE; 1. DR Pfam; PF00106; adh_short; 1. DR Pfam; PF00397; WW; 2. DR PRINTS; PR00081; GDHRDH. DR SMART; SM00456; WW; 2. DR SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1. DR SUPFAM; SSF51045; WW domain; 2. DR PROSITE; PS01159; WW_DOMAIN_1; 2. DR PROSITE; PS50020; WW_DOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; Cytoplasm; Disease variant; KW Epilepsy; Golgi apparatus; Lysosome; Mitochondrion; NADP; KW Neurodegeneration; Nucleus; Oxidoreductase; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Tumor suppressor; KW Ubl conjugation; Wnt signaling pathway. FT CHAIN 1..414 FT /note="WW domain-containing oxidoreductase" FT /id="PRO_0000054815" FT DOMAIN 16..49 FT /note="WW 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00224" FT DOMAIN 57..90 FT /note="WW 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00224" FT REGION 1..23 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 125..414 FT /note="Interaction with MAPT" FT /evidence="ECO:0000250" FT REGION 209..273 FT /note="Mediates targeting to the mitochondria" FT /evidence="ECO:0000250" FT MOTIF 50..55 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250" FT ACT_SITE 293 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 131..137 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000250" FT BINDING 260 FT /ligand="substrate" FT /evidence="ECO:0000250" FT MOD_RES 12 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 33 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:15070730, FT ECO:0000269|PubMed:19366691" FT MOD_RES 287 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:16288044" FT VAR_SEQ 36 FT /note="N -> K (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016358" FT VAR_SEQ 37..414 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016359" FT VAR_SEQ 137..414 FT /note="GFETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKVEAMTLDLALLR FT SVQHFAEAFKAKNVPLHVLVCNAATFALPWSLTKDGLETTFQVNHLGHFYLVQLLQDVL FT CRSAPARVIVVSSESHRFTDINDSLGKLDFSRLSPTKNDYWAMLAYNRSKLCNILFSNE FT LHRRLSPRGVTSNAVHPGNMMYSNIHRSWWVYTLLFTLARPFTKSMQQGAATTVYCAAV FT PELEGLGGMYFNNCCRCMPSPEAQSEETARTLWALSERLIQERLGSQSG -> ATGSCH FT HRVLCCCPRTGGSGRDVLQQLLPLHALTRSSERRDGPDPVGAQREADPRTAWQPVRLSG FT AQSGWAHTPALCVSPHASARAGPLPNVPPTQIRKSKGNKSSHNRVKNLKYQWEAGNSWG FT KVSLFWGWARHRSLCFLVVACLKVKTCLVCRFRISLEKHQQFSFFYCYRIA (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:11719429" FT /id="VSP_016360" FT VAR_SEQ 138..213 FT /note="FETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKVEAMTLDLALLRS FT VQHFAEAFKAKNVPLHVLVCNAAT -> KASCHVGRTLKHTRVEELSLLPTAINRELPP FT PCTVLLSQNWRVWEGCTSTTAAAACPHQKLRAKRRPGPCGRSARG (in isoform FT 7)" FT /evidence="ECO:0000305" FT /id="VSP_016362" FT VAR_SEQ 173..352 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:11719429, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.7" FT /id="VSP_016363" FT VAR_SEQ 173..189 FT /note="HKAKVEAMTLDLALLRS -> KTKYHPPPEKCRIKIFH (in isoform FT 3)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016364" FT VAR_SEQ 190..414 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016365" FT VAR_SEQ 214..414 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_016366" FT VAR_SEQ 353..363 FT /note="QQGAATTVYCA -> VSDCLVEGGHF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016367" FT VAR_SEQ 364..414 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016369" FT VARIANT 47 FT /note="P -> R (in DEE28; dbSNP:rs730880292)" FT /evidence="ECO:0000269|PubMed:25411445" FT /id="VAR_072351" FT VARIANT 47 FT /note="P -> T (in SCAR12; dbSNP:rs587777128)" FT /evidence="ECO:0000269|PubMed:24369382" FT /id="VAR_070992" FT VARIANT 98 FT /note="P -> L (in dbSNP:rs144601717)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023916" FT VARIANT 111 FT /note="T -> S (in a Burkitt lymphoma cell line; FT dbSNP:rs114755364)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023917" FT VARIANT 120 FT /note="R -> W (in a primary colorectal tumor and a FT histiocytic lymphoma cell line; dbSNP:rs141361080)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023918" FT VARIANT 179 FT /note="A -> T (in dbSNP:rs11545029)" FT /evidence="ECO:0000269|PubMed:11572989, ECO:0000269|Ref.5" FT /id="VAR_023919" FT VARIANT 216 FT /note="L -> V (in dbSNP:rs7201683)" FT /id="VAR_052323" FT VARIANT 272 FT /note="L -> F (in dbSNP:rs186745328)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023920" FT VARIANT 282 FT /note="P -> A (in dbSNP:rs3764340)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023921" FT VARIANT 291 FT /note="L -> P (found in a esophageal cancer sample; somatic FT mutation; dbSNP:rs119487098)" FT /evidence="ECO:0000269|PubMed:11956080" FT /id="VAR_023922" FT VARIANT 314 FT /note="R -> H (in dbSNP:rs73572838)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023923" FT VARIANT 372 FT /note="G -> R (in SCAR12; dbSNP:rs587777127)" FT /evidence="ECO:0000269|PubMed:24369382" FT /id="VAR_070993" FT MUTAGEN 28 FT /note="K->T: No effect on interaction with TP53. Abolishes FT interaction with MAPK8; when associated with V-29." FT /evidence="ECO:0000269|PubMed:12514174" FT MUTAGEN 29 FT /note="D->V: No effect on interaction with TP53. Abolishes FT interaction with MAPK8; when associated with T-28." FT /evidence="ECO:0000269|PubMed:12514174" FT MUTAGEN 33 FT /note="Y->F: Loss of phosphorylation." FT /evidence="ECO:0000269|PubMed:12514174, FT ECO:0000269|PubMed:15070730" FT MUTAGEN 33 FT /note="Y->R: Abolishes interaction with TP53, TP73, MAPK8 FT and ERBB4. Partial loss of interaction with TFAP2C. Loss of FT phosphorylation. Loss of the proapoptotic activity. FT Abolishes binding to VOPP1." FT /evidence="ECO:0000269|PubMed:12514174, FT ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:30285739" FT MUTAGEN 44..47 FT /note="WEHP->FEHA: Abolishes interaction with LITAF." FT /evidence="ECO:0000269|PubMed:15064722" FT MUTAGEN 61 FT /note="Y->R: No effect on interaction with TP73." FT /evidence="ECO:0000269|PubMed:15070730" FT MUTAGEN 85..88 FT /note="YLDP->ALDA: No effect on interaction with LITAF." FT /evidence="ECO:0000269|PubMed:15064722" FT MUTAGEN 287 FT /note="Y->A: Loss of phosphorylation by TNK2." FT /evidence="ECO:0000269|PubMed:16288044" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:1WMV" FT STRAND 73..80 FT /evidence="ECO:0007829|PDB:1WMV" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:1WMV" FT VARIANT Q9NZC7-3:182 FT /note="K -> E (found in a primary colorectal tumor and FT tumor cells; dbSNP:rs77067228)" FT /evidence="ECO:0000305" FT /id="VAR_082915" SQ SEQUENCE 414 AA; 46677 MW; E4D9A649E6CB05DF CRC64; MAALRYAGLD DTDSEDELPP GWEERTTKDG WVYYANHTEE KTQWEHPKTG KRKRVAGDLP YGWEQETDEN GQVFFVDHIN KRTTYLDPRL AFTVDDNPTK PTTRQRYDGS TTAMEILQGR DFTGKVVVVT GANSGIGFET AKSFALHGAH VILACRNMAR ASEAVSRILE EWHKAKVEAM TLDLALLRSV QHFAEAFKAK NVPLHVLVCN AATFALPWSL TKDGLETTFQ VNHLGHFYLV QLLQDVLCRS APARVIVVSS ESHRFTDIND SLGKLDFSRL SPTKNDYWAM LAYNRSKLCN ILFSNELHRR LSPRGVTSNA VHPGNMMYSN IHRSWWVYTL LFTLARPFTK SMQQGAATTV YCAAVPELEG LGGMYFNNCC RCMPSPEAQS EETARTLWAL SERLIQERLG SQSG //